PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lawe, DC; Chawla, A; Merithew, E; Dumas, J; Carrington, W; Fogarty, K; Lifshitz, L; Tuft, R; Lambright, D; Corvera, S				Lawe, DC; Chawla, A; Merithew, E; Dumas, J; Carrington, W; Fogarty, K; Lifshitz, L; Tuft, R; Lambright, D; Corvera, S			Sequential roles for phosphatidylinositol 3-phosphate and Rab5 in tethering and fusion of early endosomes via their interaction with EEA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EFFECTOR EEA1; FYVE FINGER; IN-VITRO; BINDING; PROTEIN; CELLS; LOCALIZATION; ENDOCYTOSIS; REGULATOR; TRANSPORT	DEarly endosome antigen 1 (EEA1) is a 170-kDa polypeptide required for endosome fusion in mammalian cells. The COOH terminus of EEA1 contains a FYVE domain that interacts specifically with phosphatidylinositol 3-phosphate (PtdIns-3-P) and a Rab5 GTPase binding region adjacent to the FYVE domain. The dual interaction of EEA1 with both Ptdlns-3-P and Rab5 has been hypothesized to provide the specificity required to target EEA1 to early endosomes. To test this hypothesis, we generated truncated (amino acids 1277-1411) and full-length EEA1 constructs containing point mutations in the COOH terminus that impair Rab5 but not Ptdlns3-P binding. These constructs localized to endosomes in intact cells as efficiently as their wild-type counterparts. Furthermore, overexpression of the truncated constructs, both wild-type and mutated, impaired the function of endogenous EEA1 resulting in the accumulation of small, untethered endosomes. These results suggest that association with Rab5 is not necessary for the initial binding and tethering functions of EEA1. A role for Rab5 binding was revealed, however, upon comparison of endosomes in cells expressing full-length wild-type or mutated EEA1 The mutant full-length EEA1 caused the accumulation of endosome clusters and suppressed the enlargement of endosomes caused by a persistently active form of Rab5 (Rab5Q79L). In contrast, expression of wild-type EEA1 with Rab5Q79L enhanced this enlargement. Thus, endosome tethering depends on the interaction of EEA1 with Ptdlns-3-P, and its interaction with Rab5 appears to regulate subsequent fusion.	Univ Massachusetts, Sch Med, Dept Biochem & Pharmacol, Worcester, MA 01615 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01615 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01615 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Corvera, S (corresponding author), 373 Plantat St, Worcester, MA 01615 USA.				NIDDK NIH HHS [DK54479] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Burd CG, 1996, MOL CELL BIOL, V16, P2369; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gerrard SR, 2000, MOL BIOL CELL, V11, P613, DOI 10.1091/mbc.11.2.613; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; Isenberg G, 1996, P NATL ACAD SCI USA, V93, P5413, DOI 10.1073/pnas.93.11.5413; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Paemeleire K, 2000, MOL BIOL CELL, V11, P1815, DOI 10.1091/mbc.11.5.1815; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657; ZhuGe RH, 1999, J GEN PHYSIOL, V113, P215, DOI 10.1085/jgp.113.2.215	28	97	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8611	8617		10.1074/jbc.M109239200	http://dx.doi.org/10.1074/jbc.M109239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11602609	hybrid			2022-12-25	WOS:000174268000126
J	Aguirre, V; Werner, ED; Giraud, J; Lee, YH; Shoelson, SE; White, MF				Aguirre, V; Werner, ED; Giraud, J; Lee, YH; Shoelson, SE; White, MF			Phosphorylation of Ser(307) in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOTYROSINE-DEPENDENT INTERACTION; STIMULATED TYROSINE PHOSPHORYLATION; GROWTH-FACTOR-I; PLECKSTRIN HOMOLOGY; SERINE/THREONINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; YMXM MOTIFS; NPEY MOTIF; IRS-1	Serine phosphorylation of insulin receptor substrate-1 (IRS-1) inhibits insulin signal transduction in a variety of cell backgrounds, which might contribute to peripheral insulin resistance. However, because of the large number of potential phosphorylation sites, the mechanism of inhibition has been difficult to determine. One serine residue located near the phosphotyrosine-binding (PTB) domain in IRS-1 (Ser(307) in rat IRS-1 or Ser(312) in human IRS-1) is phosphorylated via several mechanisms, including insulin-stimulated kinases or stress-activated kinases like JNK1. During a yeast trihybrid assay, phosphorylation of Ser(307) by JNK1 disrupted the interaction between the catalytic domain of the insulin receptor and the PTB domain of IRS-1. In 32D myeloid progenitor cells, phosphorylation of Ser(307) inhibited insulin stimulation of the phosphatidylinositol 3-kinase and MAPK cascades. These results suggest that inhibition of PTB domain function in IRS-1 by phosphorylation of Ser(307) (Ser(312) in human IRS-1) might be a general mechanism to regulate insulin signaling.	Harvard Univ, Howard Hughes Med Inst, Joslin Diabet Ctr, Sch Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	White, MF (corresponding author), Harvard Univ, Howard Hughes Med Inst, Joslin Diabet Ctr, Sch Med, 1 Joslin Pl, Boston, MA 02215 USA.	morris.white@joslin.harvard.edu	Sancheti, Harsh/H-3538-2012					Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CARBONI JM, 1995, ONCOGENE, V10, P1905; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; COMB DG, 1958, J BIOL CHEM, V232, P807; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Loddick SA, 1999, P NATL ACAD SCI USA, V96, P9449, DOI 10.1073/pnas.96.17.9449; Maezono K, 1998, DIABETES, V47, pA333; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1995, DIABETES, V44, pA49; Myers MG, 1996, MOL CELL BIOL, V16, P4147; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; PONS S, 1995, MOL CELL BIOL, V15, P4453; RICHARDSON JM, 1993, J BIOL CHEM, V268, P21021; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; Vaxillaire M, 1997, HUM MOL GENET, V6, P583, DOI 10.1093/hmg/6.4.583; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 2001, ENDOCRINOLOGY, V1; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yoshikawa T, 1999, BIOCHEM BIOPH RES CO, V256, P676, DOI 10.1006/bbrc.1999.0394; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	54	735	776	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1531	1537		10.1074/jbc.M101521200	http://dx.doi.org/10.1074/jbc.M101521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11606564	hybrid			2022-12-25	WOS:000173166800086
J	Jee, JG; Ikegami, T; Hashimoto, M; Kawabata, T; Ikeguchi, M; Watanabe, T; Shirakawa, M				Jee, JG; Ikegami, T; Hashimoto, M; Kawabata, T; Ikeguchi, M; Watanabe, T; Shirakawa, M			Solution structure of the fibronectin type III domain from Bacillus circulans WL-12 chitinase A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOSE-BINDING DOMAIN; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; ANTIFREEZE PROTEIN; HEPARIN-BINDING; NMR STRUCTURE; GENE-TRANSFER; 2.0 ANGSTROM; RESOLUTION	Growing evidence suggests that horizontal gene transfer plays an integral role in the evolution of bacterial genomes. One of the debated examples of horizontal gene transfer from animal to prokaryote is the fibronectin type III domain (FnIIID). Certain extracellular proteins of soil bacteria contain an unusual cluster of FnHIDs, which show sequence similarity to those of animals and are likely to have been acquired horizontally from animals. Here we report the solution structure of the FnIIID of chitinase A1 from Bacillus circulans WL-12. To the best of our knowledge, this is the first tertiary structure to be reported for an FnIIID from a bacterial protein. The structure of the domain shows significant similarity to FnIIIDs from animal proteins. Sequence comparisons with FnIIIDs from other soil bacteria proteins show that the core-forming residues are highly conserved and, thus, are under strong evolutionary pressure. Striking similarities in the tertiary structures of bacterial FnIlIDs and their mammalian counterparts may support the hypothesis that the evolution of the FnIIID in bacterial carbohydrases occurred horizontally. The total lack of surface-exposed aromatic residues also suggests that the role of this FnIIID is different from those of other bacterial beta-sandwich domains, which function as carbohydrate-binding modules.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Niigata Univ, Fac Agr, Dept Appl Biol Chem, Niigata 95021891, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Shizuoka 2300045, Japan; Natl Inst Genet, Lab Gene Prod Informat, Shizuoka 411, Japan	Nara Institute of Science & Technology; Niigata University; Yokohama City University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Shirakawa, M (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		Ikegami, Takahisa/I-9626-2017	Ikegami, Takahisa/0000-0002-1429-1844				Alam MM, 1996, J FERMENT BIOENG, V82, P28, DOI 10.1016/0922-338X(96)89450-5; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bateman A, 1996, CURR BIOL, V6, P1544, DOI 10.1016/S0960-9822(02)70765-3; Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; Bisig D, 1999, ACTA CRYSTALLOGR D, V55, P1069, DOI 10.1107/S090744499900284X; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Copie V, 1998, J MOL BIOL, V277, P663; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1999, J AM CHEM SOC, V121, P2949, DOI 10.1021/ja9902221; de Pereda JM, 1999, EMBO J, V18, P4087, DOI 10.1093/emboj/18.15.4087; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Fattorusso R, 1999, STRUCTURE, V7, P381, DOI 10.1016/S0969-2126(99)80051-3; Goll CM, 1998, STRUCTURE, V6, P1291, DOI 10.1016/S0969-2126(98)00129-4; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; Graether SP, 2000, NATURE, V406, P325, DOI 10.1038/35018610; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Ikegami T, 2000, J BIOL CHEM, V275, P13654, DOI 10.1074/jbc.275.18.13654; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Koide A, 1998, J MOL BIOL, V284, P1141, DOI 10.1006/jmbi.1998.2238; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lawrence JG, 1999, CURR OPIN MICROBIOL, V2, P519, DOI 10.1016/S1369-5274(99)00010-7; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Li W. H, 1997, MOL EVOLUTION; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Liou YC, 2000, NATURE, V406, P322, DOI 10.1038/35018604; LITTLE E, 1994, J MOL EVOL, V39, P631, DOI 10.1007/BF00160409; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Matsumoto T, 1999, P JPN ACAD B-PHYS, V75, P269, DOI 10.2183/pjab.75.269; Mikami B, 1999, BIOCHEMISTRY-US, V38, P7050, DOI 10.1021/bi9829377; MuhleGoll C, 1997, J BIOMOL NMR, V9, P2, DOI 10.1023/A:1018611316059; Nei M., 1987, MOL EVOLUTIONARY GEN; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Simpson PJ, 1999, STRUCTURE, V7, P853, DOI 10.1016/S0969-2126(99)80108-7; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; Suzuki K, 1999, BIOCHEM J, V343, P587, DOI 10.1042/0264-6021:3430587; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsyguelnaia I, 1998, J MOL EVOL, V46, P612, DOI 10.1007/PL00013148; Uchiyama T, 2001, J BIOL CHEM, V276, P41343, DOI 10.1074/jbc.M103610200; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; WATANABE T, 1990, J BACTERIOL, V172, P4017, DOI 10.1128/jb.172.7.4017-4022.1990; WATANABE T, 1990, J BIOL CHEM, V265, P15659; Whittam Thomas S., 1992, Current Biology, V2, P676, DOI 10.1016/0960-9822(92)90140-6; WOOTTON JC, 1994, CURR OPIN STRUC BIOL, V4, P413, DOI 10.1016/S0959-440X(94)90111-2; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	60	51	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1388	1397		10.1074/jbc.M109726200	http://dx.doi.org/10.1074/jbc.M109726200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11600504	hybrid			2022-12-25	WOS:000173166800069
J	Dai, GX; Carmicle, S; Steede, NK; Landry, SJ				Dai, GX; Carmicle, S; Steede, NK; Landry, SJ			Structural basis for helper T-cell and antibody epitope immunodominance in bacteriophage T4 Hsp10 - Role of disordered loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; MHC CLASS-II; MYCOBACTERIUM-LEPRAE; LEPROSY PATIENTS; CO-CHAPERONIN; PROTEIN; ANTIGEN; VIRUS; DETERMINANTS; RECOGNITION	Antigen three-dimensional structure potentially limits the access of endoproteolytic processing enzymes to cleavage sites and of class 11 major histocompatibility antigen-presenting proteins to helper T-cell epitopes. Helper T-cell epitopes in bacteriophage T4 Hsp10 have been mapped by restimulation of splenocytes from CBA/J and C57BL/6J mice immunized in conjunction with mutant (R192G) heat-labile enterotoxin from Escherichia coli. Promiscuously immunogenic sequences were associated with unstable loops in the three-dimensional structure of T4 Hsp10. The immunodominant sequence lies on the N-terminal flank of the 22-residue mobile loop, which is sensitive to proteolysis in divergent Hsp10s. Several mobile loop deletions that inhibited proteolysis in vitro caused global changes in the helper T-cell epitope map. A mobile loop deletion that strongly stabilized the protein dramatically reduced the immunogenicity of the flanking immunodominant helper T-cell epitope, although the protein retained good overall immunogenicity. Antisera against the mobile loop deletion variants exhibited increased cross-reactivity, most especially the antisera against the strongly stabilized variant. The results support the hypothesis that unstable loops promote the presentation of flanking epitopes and suggest that loop deletion could be a general strategy to increase the breadth and strength of an immune response.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA	Tulane University	Landry, SJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.		Landry, Samuel/AAK-5778-2020	Landry, Samuel/0000-0002-4082-0543	NIAID NIH HHS [R01-AI42350] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042350] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALL JM, 1992, J VIROL, V66, P732, DOI 10.1128/JVI.66.2.732-742.1992; Bouhdoud L, 2000, J VIROL, V74, P2121, DOI 10.1128/JVI.74.5.2121-2130.2000; Cardenas-Freytag L, 1999, INFECT IMMUN, V67, P826; Carmicle S, 2002, J BIOL CHEM, V277, P155, DOI 10.1074/jbc.M107624200; Castellino F, 1998, J IMMUNOL, V161, P4048; Chua-Intra B, 1998, INFECT IMMUN, V66, P4903, DOI 10.1128/IAI.66.10.4903-4909.1998; Chua-Intra B, 1998, IMMUNOLOGY, V93, P64, DOI 10.1046/j.1365-2567.1998.00400.x; COHEN IR, 1996, STRESS PROTEINS MED, P93; DAI G, 2001, IN PRESS J BIOL CHEM; DLETHELMOKITA BM, 2000, J INFECT DIS, V181, P1001; Gapin L, 1998, J IMMUNOL, V160, P1555; Hubbard SJ, 1998, PROTEIN ENG, V11, P349, DOI 10.1093/protein/11.5.349; Hunt JF, 1997, CELL, V90, P361, DOI 10.1016/S0092-8674(00)80343-8; Hussain R, 1998, CLIN EXP IMMUNOL, V114, P204; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; Kim J, 1997, J IMMUNOL, V159, P335; Landry SJ, 1997, IMMUNOL TODAY, V18, P527, DOI 10.1016/S0167-5699(97)01152-3; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Landry SJ, 2000, J THEOR BIOL, V203, P189, DOI 10.1006/jtbi.1999.1056; Landry SJ, 1997, BIOCHEMISTRY-US, V36, P10975, DOI 10.1021/bi971141p; Lu S, 1998, AIDS RES HUM RETROV, V14, P151, DOI 10.1089/aid.1998.14.151; MAMULA MJ, 1993, IMMUNOL TODAY, V14, P151, DOI 10.1016/0167-5699(93)90274-O; MILLER MA, 1992, AIDS RES HUM RETROV, V8, P1153, DOI 10.1089/aid.1992.8.1153; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; Moudgil KD, 1998, J IMMUNOL, V161, P6046; Moudgil KD, 1996, J AUTOIMMUN, V9, P227, DOI 10.1006/jaut.1996.0028; OZAKI S, 1987, J IMMUNOL, V138, P4133; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Richardson A, 1999, J BIOL CHEM, V274, P52, DOI 10.1074/jbc.274.1.52; Ringe D, 1986, Methods Enzymol, V131, P389; SIMITSEK PD, 1995, J EXP MED, V181, P1957, DOI 10.1084/jem.181.6.1957; Srivastava PK, 2001, VACCINE, V19, P2590, DOI 10.1016/S0264-410X(00)00492-8; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; Wang H, 1999, J IMMUNOL, V162, P4177	36	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					161	168		10.1074/jbc.M102259200	http://dx.doi.org/10.1074/jbc.M102259200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11602571	hybrid			2022-12-25	WOS:000173087900023
J	Perez-Jannotti, RM; Klein, SM; Bogenhagen, DF				Perez-Jannotti, RM; Klein, SM; Bogenhagen, DF			Two forms of mitochondrial DNA ligase III are produced in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; GREEN FLUORESCENT PROTEIN; TRANSFER-RNA SYNTHETASES; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; CATALYTIC SUBUNIT; MOLECULAR-CLONING; POLYMERASE-GAMMA; GENE ENCODES	Full-length cDNAs for DNA ligase IV and the alpha and beta isoforms of DNA ligase III were cloned from Xenopus laevis to permit study of the genes encoding mitochondrial DNA ligase. DNA ligase IIIa and IIIbeta share a common NH2, terminus that encodes a mitochondrial localization signal capable of targeting green fluorescent protein to mitochondria while the NH2 terminus of DNA ligase IV does not. Reverse transcriptase-polymerase chain reaction analyses with adult frog tissues demonstrate that while DNA ligase IIIalpha and DNA ligase IV are ubiquitously expressed, DNA ligase HIP expression is restricted to testis and ovary. Mitochondrial lysates from X. laevis oocytes contain both DNA ligase IIIalpha and IIIbeta but no detectable DNA ligase IV. Gel filtration, sedimentation, native gel electrophoresis, and in vitro cross-linking experiments demonstrate that mtDNA ligase IIIa exists as a high molecular weight complex. We discuss the possibility that DNA ligase IIIalpha exists in mitochondria in association with novel mitochondrial protein partners or as a homodimer.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bogenhagen, DF (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.				NIGMS NIH HHS [R01GM29681] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2910, DOI 10.1128/MCB.8.7.2910; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; CAPELLI E, 1997, J BIOL CHEM, V272, P23970; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN JW, 1995, MOL CELL BIOL, V15, P5412; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; Dulic A, 2001, BIOCHEMISTRY-US, V40, P5906, DOI 10.1021/bi002701e; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; HUSAIN I, 1995, J BIOL CHEM, V270, P9683, DOI 10.1074/jbc.270.16.9683; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakshmipathy U, 2000, NUCLEIC ACIDS RES, V28, P3880, DOI 10.1093/nar/28.20.3880; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; Lakshmipathy U, 2001, NUCLEIC ACIDS RES, V29, P668, DOI 10.1093/nar/29.3.668; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; Mackey ZB, 1997, MOL CELL BIOL, V17, P989, DOI 10.1128/MCB.17.2.989; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; Sambrook J., 2002, MOL CLONING LAB MANU; Sawyer DE, 1999, MUTAT RES-DNA REPAIR, V434, P161, DOI 10.1016/S0921-8777(99)00027-0; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; WAGA S, 1994, J BIOL CHEM, V269, P10923; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; Willer M, 1999, CURR BIOL, V9, P1085, DOI 10.1016/S0960-9822(99)80477-1; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; WU GJ, 1972, BIOCHEMISTRY-US, V11, P3589, DOI 10.1021/bi00769a015; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	61	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48978	48987		10.1074/jbc.M107177200	http://dx.doi.org/10.1074/jbc.M107177200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598119	hybrid			2022-12-25	WOS:000173922100049
J	Boll, M; Fuchs, G; Meier, C; Trautwein, A; El Kasmi, A; Ragsdale, SW; Buchanan, G; Lowe, DJ				Boll, M; Fuchs, G; Meier, C; Trautwein, A; El Kasmi, A; Ragsdale, SW; Buchanan, G; Lowe, DJ			Redox centers of 4-hydroxybenzoyl-CoA reductase, a member of the xanthine oxidase family of molybdenum-containing enzymes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC METABOLISM; THAUERA-AROMATICA; RHODOPSEUDOMONAS-PALUSTRIS; ALDEHYDE OXIDOREDUCTASE; PHENOLIC-COMPOUNDS; PROSTHETIC GROUPS; CRYSTAL-STRUCTURE; ELECTRON-DONOR; KEY ENZYME; FERREDOXIN	4-Hydroxybenzoyl-CoA reductase (4-HBCR) is a key enzyme in the anaerobic metabolism of phenolic compounds. It catalyzes the reductive removal of the hydroxyl group from the aromatic ring yielding benzoyl-CoA and water. The subunit architecture, amino acid sequence, and the cofactor/metal content indicate that it belongs to the xanthine oxidase (XO) family of molybdenum cofactor-containing enzymes. 4-HBCR is an unusual XO family member as it catalyzes the irreversible reduction of a CoA-thioester substrate. A radical mechanism has been proposed for the enzymatic removal of phenolic hydroxyl groups. In this work we studied the spectroscopic and electrochemical properties of 4-HBCR by EPR and Mossbauer spectroscopy and identified the pterin cofactor as molybdopterin mononucleotide. In addition to two different [2Fe-2S] clusters, one FAD and one molybdenum species per monomer, we also identified a [4Fe-4S] cluster/monomer, which is unique among members of the XO family. The reduced [4Fe-4S] cluster interacted magnetically with the Mo(V) species, suggesting that the centers are in close proximity, (< 15 A apart). Additionally, reduction of the [4Fe-4S] cluster resulted in a loss of the EPR signals of the [2Fe-2S] clusters probably because of magnetic interactions between the Fe-S clusters as evidenced in power saturation studies. The Mo(V) EPR signals of 4-HBCR were typical for XO family members. Under steady-state conditions of substrate reduction, in the presence of excess dithionite, the [4Fe-4S] clusters were in the fully oxidized state while the [2Fe-2S] clusters remained reduced. The redox potentials of the redox cofactors were determined to be: [2Fe-2S](+1/+2) I, -205 mV, [2Fe-2S](+1/+2) II, -255 mV, FAD/FADH(.)/FADH, -250 mV/-470 mV; [4Fe-4S](+1/+2), -465 mV and Mo(VI)/(V)/(VI), -380 mV/-500 mV. A catalytic cycle is proposed that takes into account the common properties of molybdenum cofactor enzymes and the special one-electron chemistry of dehydroxylation of phenolic compounds.	Inst Biol 2, D-79104 Freiburg, Germany; Med Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany; Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	University of Lubeck; University of Nebraska System; University of Nebraska Lincoln; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Boll, M (corresponding author), Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	boll@uni-freiburg.de						ANDERS HJ, 1995, INT J SYST BACTERIOL, V45, P327, DOI 10.1099/00207713-45-2-327; BARATA BAS, 1993, BIOCHEMISTRY-US, V32, P11559, DOI 10.1021/bi00094a012; BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P3561, DOI 10.1021/bi00258a006; BIEGERT T, 1993, EUR J BIOCHEM, V213, P555, DOI 10.1111/j.1432-1033.1993.tb17794.x; Boll M, 1995, EUR J BIOCHEM, V234, P921, DOI 10.1111/j.1432-1033.1995.921_a.x; Boll M, 2000, BIOCHEMISTRY-US, V39, P4929, DOI 10.1021/bi9927890; Boll M, 1998, EUR J BIOCHEM, V251, P946, DOI 10.1046/j.1432-1327.1998.2510946.x; Boll M, 2000, J BIOL CHEM, V275, P31857, DOI 10.1074/jbc.M001508200; BRACKMANN R, 1993, EUR J BIOCHEM, V213, P563, DOI 10.1111/j.1432-1033.1993.tb17795.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; Breese K, 1998, EUR J BIOCHEM, V251, P916, DOI 10.1046/j.1432-1327.1998.2510916.x; Buckel W., 1995, ANGEW CHEM, V107, P1595; Caldeira J, 2000, BIOCHEMISTRY-US, V39, P2700, DOI 10.1021/bi9921485; Canne C, 1997, BIOCHEMISTRY-US, V36, P9780, DOI 10.1021/bi970581d; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; Gibson J, 1997, J BACTERIOL, V179, P634, DOI 10.1128/jb.179.3.634-642.1997; GIBSON J, 1994, J BACTERIOL, V176, P634, DOI 10.1128/jb.176.3.634-641.1994; GROSS GG, 1966, Z NATURFORSCH PT B, VB 21, P683; Heider J, 1997, EUR J BIOCHEM, V243, P577, DOI 10.1111/j.1432-1033.1997.00577.x; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; KASMI AE, 1995, BIOCHEMISTRY-US, V34, P11668; Kisker C, 1998, FEMS MICROBIOL REV, V22, P503, DOI 10.1016/S0168-6445(98)00040-0; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laempe D, 2001, J BACTERIOL, V183, P968, DOI 10.1128/JB.183.3.968-979.2001; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Lloyd SG, 1996, J AM CHEM SOC, V118, P9892, DOI 10.1021/ja954000o; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; Mulliez E, 1999, J BIOL INORG CHEM, V4, P614, DOI 10.1007/s007750050385; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; THOMPSON CL, 1974, BIOCHEM J, V139, P97, DOI 10.1042/bj1390097; TSCHECH A, 1987, ARCH MICROBIOL, V148, P213, DOI 10.1007/BF00414814; ZEHR BD, 1989, ANAL BIOCHEM, V182, P157, DOI 10.1016/0003-2697(89)90734-3	38	30	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47853	47862		10.1074/jbc.M106766200	http://dx.doi.org/10.1074/jbc.M106766200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602591	hybrid			2022-12-25	WOS:000172927000019
J	Hu, YY; Szente, B; Kiely, JM; Gimbrone, MA				Hu, YY; Szente, B; Kiely, JM; Gimbrone, MA			Molecular events in transmembrane signaling via E-selectin - SHP2 association, adaptor protein complex formation and ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHPTP2; FOCAL ADHESION KINASE; VASCULAR ENDOTHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; P-SELECTIN; MAP KINASE; TRANSDUCTION PATHWAYS; LEUKOCYTE ADHESION; HUMAN NEUTROPHILS; BETA-RECEPTOR	E-selectin is a cytoldne-inducible adhesion molecule that is expressed by activated endothelial cells at sites of inflammation. In addition to supporting rolling and stable arrest of leukocytes, there is increasing evidence that E-selectin functions in transmembrane signaling into endothelial cells during these adhesive interactions. We have previously shown that adhesion of HL-60 cells (which express ligands for E-selectin), or antibody-mediated cross-linking of E-selectin, results in formation of a Ras/Raf-1/phospho-MEK macrocomplex, extracellular signal-regulated protein kinase (ERK1/2) activation, and c-fos up-regulation. All of these downstream signaling events appear to require an intact cytoplasmic domain of E-selectin. Here we demonstrate that tyrosine 603 in the cytoplasmic domain of E-selectin is required for the E-selectin-dependent ERK1/2 activation. Tyrosine 603 plays an important role in mediating the association of E-selectin with SHP2, and the catalytic domain of SHP2 is, in turn, critical for E-selectin-dependent ERK1/2 activation. An adapter protein complex consisting of She-Grb2.Sos bridges between SHP2 and the Ras-Raf-phospho-MEK macrocomplex. These molecular events thus outline a mechanism by which cross-linking of E-selectin by engagement of ligands on adherent leukocytes can initiate a multifunctional signaling pathway in the activated endothelial cell at sites of inflammation.	Harvard Univ, Dept Pathol, Div Vasc Res, Brigham & Womens Hosp,Sch Med, Boston, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Gimbrone, MA (corresponding author), Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, 221 Longwood Ave,LMRC-401, Boston, MA 02115 USA.				NHLBI NIH HHS [P01-HL36028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Artcanuthurry Valerie, 1996, Seminars in Thrombosis and Hemostasis, V22, P317, DOI 10.1055/s-2007-999026; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BEVILACQUA MP, 1987, SEMIN THROMB HEMOST, V13, P425, DOI 10.1055/s-2007-1003519; Brenner B, 1997, BIOCHEM BIOPH RES CO, V231, P802, DOI 10.1006/bbrc.1997.6191; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Brenner B, 1998, EXP CELL RES, V243, P123, DOI 10.1006/excr.1998.4146; CASE RD, 1994, J BIOL CHEM, V269, P10467; CrockettTorabi E, 1997, AM J PHYSIOL-HEART C, V272, pH1302, DOI 10.1152/ajpheart.1997.272.3.H1302; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Haller H, 1997, J IMMUNOL, V158, P1061; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; KUMAR G, 1995, BIOCHEM J, V307, P215, DOI 10.1042/bj3070215; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Lorenzon P, 1998, J CELL BIOL, V142, P1381, DOI 10.1083/jcb.142.5.1381; Manes S, 1999, MOL CELL BIOL, V19, P3125; Masuda M, 1997, FEBS LETT, V408, P331, DOI 10.1016/S0014-5793(97)00457-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Milstone DS, 1998, MICROCIRCULATION-LON, V5, P153, DOI 10.1080/713773857; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Steeber DA, 1997, J IMMUNOL, V159, P952; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yoshida M, 1998, J IMMUNOL, V161, P933; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	39	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48549	48553		10.1074/jbc.M105513200	http://dx.doi.org/10.1074/jbc.M105513200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602579	hybrid			2022-12-25	WOS:000172927000109
J	Borggrefe, T; Davis, R; Bareket-Samish, A; Kornberg, RD				Borggrefe, T; Davis, R; Bareket-Samish, A; Kornberg, RD			Quantitation of the RNA polymerase II transcription machinery in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; IDENTIFICATION; MEDIATOR; PROTEINS; DOMAIN; GENOME	TAP tags and dot blot analysis have been used to measure the amounts of RNA polymerase II transcription proteins in crude yeast extracts. The measurements showed comparable amounts of RNA polymerase II, TFIIE, and TFIIF, lower levels of TBP and TFIIB, and still lower levels of Mediator and TFIIH. These findings are consistent with the presumed roles of the transcription proteins, but do not support the idea of their recruitment in a single large complex to RNA polymerase II promoters. The approach employed here can be readily extended to quantitative analysis of the entire yeast proteome.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu			NIGMS NIH HHS [GM 36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Kornberg RD, 1998, COLD SPRING HARB SYM, V63, P229, DOI 10.1101/sqb.1998.63.229; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Puig O, 1998, YEAST, V14, P1139; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315	24	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47150	47153		10.1074/jbc.M109581200	http://dx.doi.org/10.1074/jbc.M109581200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591727	hybrid			2022-12-25	WOS:000172768500065
J	Musgrove, EA; Hunter, LJK; Lee, CSL; Swarbrick, A; Hui, R; Sutherland, RL				Musgrove, EA; Hunter, LJK; Lee, CSL; Swarbrick, A; Hui, R; Sutherland, RL			Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(KP1) association with cyclin E-Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; C-MYC; TRANSCRIPTION FACTOR; ECTOPIC EXPRESSION; DEPENDENT KINASES; S-PHASE; PROGRESSION; ACTIVATION; P27(KIP1); GROWTH	Long-term growth inhibition, arrest in G(1) phase and reduced activity of both cyclin D1-Cdk4 and cyclin E-Cdk2 are elicited by progestin treatment of breast cancer cells in culture. Decreased cyclin expression, induction of p18(INK4c) and increased association of the CDK inhibitors p21(WAF1/Cip1) and p27(Kip1) with cyclin E-Cdk2 have been implicated in these responses. To determine the role of decreased cyclin expression, T-47D human breast cancer cells constitutively expressing cyclin D1 or cyclin E were treated with the progestin ORG 2058. Overexpression of cyclin E had only a modest effect on growth inhibition. Although cyclin E expression was maintained during progestin treatment, cyclin E-Cdk2 activity decreased by similar to 60%. This was accompanied by p27(Kip1) association with cyclin E-Cdk2, indicating that both cyclin E down-regulation and p27(Kip1) recruitment contribute to the decrease in activity. In contrast, overexpression of cyclin D1 induced progestin resistance and cell proliferation continued despite decreased cyclin E-Cdk2 activity. Progestin treatment of cyclin overexpressing cells was associated with increased p27(Kip1) association with cyclin E-Cdk2. Thus the ability of cyclin D1 to confer progestin resistance does not depend on sequestration of p27(Kip1) away from cyclin E-Cdk2, providing evidence for a critical function of cyclin D1 other than as a high-capacity "sink" for p27(Kip1). These data indicate that regulation of cyclin D1 is a critical element of progestin inhibition in breast cancer cells and suggest that breast cancers overexpressing cyclin D1 may respond poorly to progestin therapy.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Musgrove, EA (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	e.musgrove@garvan.org.au	Swarbrick, Alexander/E-6107-2010; Sutherland, Robert L/A-8378-2008	Swarbrick, Alexander/0000-0002-3051-5676; 				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; HARLOW E, 1986, ANTIBODIES LAB MANUA; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; JIANG W, 1993, ONCOGENE, V8, P3447; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; KEYOMARSI K, 1994, CANCER RES, V54, P380; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen KE, 1999, CANCER RES, V59, P2297; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Pacilio C, 1998, CANCER RES, V58, P871; Pelosio P, 1996, ANN ONCOL, V7, P695; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rose PG, 1996, NEW ENGL J MED, V335, P640, DOI 10.1056/NEJM199608293350907; Scott KA, 1997, BRIT J CANCER, V76, P1288, DOI 10.1038/bjc.1997.550; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soni R, 2001, JNCI-J NATL CANCER I, V93, P436, DOI 10.1093/jnci/93.6.436; SUTHERLAND RL, 1988, CANCER RES, V48, P5084; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; vanDiest PJ, 1997, AM J PATHOL, V150, P705; Veronesi U, 1995, OXFORD TXB ONCOLOGY, P1243; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	53	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47675	47683		10.1074/jbc.M106371200	http://dx.doi.org/10.1074/jbc.M106371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590147	hybrid			2022-12-25	WOS:000172768500130
J	Scaffidi, P; Bianchi, ME				Scaffidi, P; Bianchi, ME			Spatially precise DNA bending is an essential activity of the Sox2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG DOMAIN; SRY; PROTEIN; BINDING; ENHANCER; ACTIVATION; DEPENDS; COMPLEX; OCT-3; GENES	Sox proteins, a subclass of high mobility group box proteins, govern cell fate decisions by acting both as classical transcription factors and architectural components of chromatin. We aimed to demonstrate that the DNA bending activity of Sox proteins is essential to regulate gene expression. We focused on mouse Sox2, which participates in the transactivation of the Fgf4 (fibroblast growth factor (4) under bar) gene in the inner cell mass of the blastocyst. We generated six substitutions in the high mobility group box of Sox2. One mutant showed a reduced DNA bending activity on the Fgf4 enhancer (46 degrees instead of 80 degrees), which resulted in more powerful transactivation compared with the wild type protein. We then selected two single-base mutations in the Fgf4 enhancer that make the DNA less bendable by the Sox2 protein. Again, a different DNA bend (0 degrees and 42 degrees instead of 80 degrees) resulted in a different activation of transcription, but in this case reduced bending corresponded to decreased transcription. We found that the opposite effect on transcription of similar DNA bending angles is due to a 20 degrees difference in the relative orientation of the DNA bends, proving that a correct three-dimensional geometry of enhanceosome complexes is necessary to promote transcription.	San Raffaele Sci Inst, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, Fac Med, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Bianchi, ME (corresponding author), San Raffaele Sci Inst, Via Olgettina 58, I-20132 Milan, Italy.		Bianchi, Marco Emilio/K-3417-2018; Scaffidi, Paola/GRS-9019-2022	Bianchi, Marco Emilio/0000-0002-5329-6445; Scaffidi, Paola/0000-0002-3642-4193				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; Collignon J, 1996, DEVELOPMENT, V122, P509; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; Engelhorn M, 1998, MOL MICROBIOL, V30, P431, DOI 10.1046/j.1365-2958.1998.01078.x; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	26	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47296	47302		10.1074/jbc.M107619200	http://dx.doi.org/10.1074/jbc.M107619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584012	hybrid			2022-12-25	WOS:000172768500084
J	Summa, V; Mordasini, D; Roger, F; Bens, M; Martin, PY; Vandewalle, A; Verrey, F; Feraille, E				Summa, V; Mordasini, D; Roger, F; Bens, M; Martin, PY; Vandewalle, A; Verrey, F; Feraille, E			Short term effect of aldosterone on Na,K-ATPase cell surface expression in kidney collecting duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; EPITHELIAL SODIUM-CHANNELS; RABBIT NEPHRON; TRANSPORT; RECEPTOR; SGK; STEROIDS; SUBUNIT; KINASE; TUBULE	Aldosterone controls extracellular volume and blood pressure by regulating Na+ reabsorption, in particular by epithelia of the distal nephron. A main regulatory site of this transcellular transport is the epithelial sodium channel (ENaC) that mediates luminal Na+ influx. The Na,K-ATPase (Na+ pump) that coordinately extrudes Na+ across the basolateral membrane is known to be regulated by short term aldosterone as well. We now show that in the cortical collecting duct (CCD) from adrenalectomized rats, the increase in Na,K-ATPase activity (approximately 3-fold in 3 h), induced by a single aldosterone injection, can be fully accounted by the increase in Na,K-ATPase cell surface expression (+ 497 +/- 35%). The short term aldosterone action was further investigated in cultured mouse collecting duct principal cells mpkCCD(c14). Within 2 h, maximal Na,K-ATPase function assessed by Na+ pump current (I-p) measurements and Na,K-ATPase cell surface expression were increased by 20-50%. Aldosterone did not modify the Na+ dependence of the Na+ pumps and induced transcription and translation-dependent actions on pump surface expression and current independently of ENaC-mediated Na+ influx. In summary, short term aldosterone directly increases the cell surface expression of preexisting Na+ pumps in kidney CCD target cells. Thus, aldosterone controls Na+ reabsorption in the short term not only by regulating the apical cell surface expression of ENaC (Loffing, J., Zecevic, M., Feraille, E., Kaissling, B., Asher, C., Rossier, B. C., Firestone, G. L., Pearce, D., and Verrey, F. (2001) Ant. J. Physiol. 280, F675-F682) but also by coordinately acting on the basolateral cell surface expression of the Na,K-ATPase.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Geneva, Div Nephrol, CH-1211 Geneva, Switzerland; Univ Geneva, Dept Pathol, CH-1211 Geneva, Switzerland; Univ Paris 07, INSERM Unite 478, F-75870 Paris 18, France	University of Zurich; University of Geneva; University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Verrey, F (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	verrey@physiol.unizh.ch		Verrey, Francois/0000-0003-3250-9824; Feraille, Eric/0000-0003-1656-8365				Bachmann S, 1999, ANAT EMBRYOL, V200, P447, DOI 10.1007/s004290050294; BARLETBAS C, 1990, AM J PHYSIOL, V259, pF246, DOI 10.1152/ajprenal.1990.259.2.F246; BARLETBAS C, 1990, J BIOL CHEM, V265, P7799; BARLETBAS C, 1988, P NATL ACAD SCI USA, V85, P1707, DOI 10.1073/pnas.85.5.1707; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Berger S, 2000, KIDNEY INT, V57, P1295, DOI 10.1046/j.1523-1755.2000.00965.x; BERON J, 1994, AM J PHYSIOL, V266, pC1278, DOI 10.1152/ajpcell.1994.266.5.C1278; BERON J, 1995, MOL BIOL CELL, V6, P261, DOI 10.1091/mbc.6.3.261; BLOTCHABAUD M, 1990, J BIOL CHEM, V265, P11676; BLOTCHABAUD M, 1988, AM J PHYSIOL, V255, pF605, DOI 10.1152/ajprenal.1988.255.4.F605; Carranza ML, 1996, AM J PHYSIOL-CELL PH, V271, pC136, DOI 10.1152/ajpcell.1996.271.1.C136; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; de Weer P., 1992, KIDNEY PHYSL PATHOPH, P93, DOI The Kidney:Physiology and Physiopathology; Dechenes G, 2000, J AM SOC NEPHROL, V11, P604, DOI 10.1681/ASN.V114604; DESCHENES G, 2001, IN PRESS J AM SOC NE; ELMERNISSI G, 1983, PFLUG ARCH EUR J PHY, V399, P147; ELMERNISSI G, 1984, PFLUG ARCH EUR J PHY, V402, P258; ELMERNISSI G, 1983, PFLUGERS ARCH, V339, P139; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1994, AM J PHYSIOL, V266, pF108, DOI 10.1152/ajprenal.1994.266.1.F108; GEERING K, 1985, AM J PHYSIOL, V248, pC102, DOI 10.1152/ajpcell.1985.248.1.C102; Gonin S, 2001, MOL BIOL CELL, V12, P255, DOI 10.1091/mbc.12.2.255; HORISBERGER JD, 1983, AM J PHYSIOL, V245, pF89, DOI 10.1152/ajprenal.1983.245.1.F89; HORSTER M, 1980, PFLUG ARCH EUR J PHY, V384, P203, DOI 10.1007/BF00584554; LAPLACE JR, 1992, J CLIN INVEST, V90, P1370, DOI 10.1172/JCI116003; Loffing J, 2001, CURR OPIN NEPHROL HY, V10, P667, DOI 10.1097/00041552-200109000-00019; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; PETTY KJ, 1981, J CLIN INVEST, V68, P1514, DOI 10.1172/JCI110405; Pfeiffer R, 1999, J PHYSIOL-LONDON, V516, P647, DOI 10.1111/j.1469-7793.1999.0647u.x; Reilly RF, 2000, PHYSIOL REV, V80, P277, DOI 10.1152/physrev.2000.80.1.277; SCHULTZ SG, 1981, AM J PHYSIOL, V241, pF579, DOI 10.1152/ajprenal.1981.241.6.F579; Shi HK, 2001, AM J PHYSIOL-RENAL, V280, pF505, DOI 10.1152/ajprenal.2001.280.3.F505; SILVER RB, 1993, AM J PHYSIOL, V264, pF557, DOI 10.1152/ajprenal.1993.264.3.F557; VERREY F, 1989, MOL ENDOCRINOL, V3, P1369, DOI 10.1210/mend-3-9-1369; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; Verrey F., 2000, KIDNEY PHYSL PATHOPH, P1441; WELLING PA, 1993, J BIOL CHEM, V268, P23469	42	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47087	47093		10.1074/jbc.M107165200	http://dx.doi.org/10.1074/jbc.M107165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598118	hybrid			2022-12-25	WOS:000172768500056
J	Volpicelli, LA; Lah, JJ; Levey, AI				Volpicelli, LA; Lah, JJ; Levey, AI			Rab5-dependent trafficking of the m4 muscarinic acetylcholine receptor to the plasma membrane, early endosomes, and multivesicular bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; RAB GTPASES; CELL LINE; ENDOCYTOSIS; INTERNALIZATION; SUBTYPE; STIMULATION; COMPLEXES; NEURONS; STORAGE	The m4 subtype of muscarinic acetylcholine receptor regulates many physiological processes and is a novel therapeutic target for neurologic and psychiatric disorders. However, little is known about m4 regulation because of the lack of pharmacologically selective ligands. A crucial component of G protein-coupled receptor regulation is intracellular trafficking. We thus used subtype-specific antibodies and quantitative immunocytochemistry to characterize the intracellular trafficking of m4. We show that following carbachol stimulation, m4 co-localizes with transferrin, and the selective marker of early endosomes, EEA1. In addition, m4 intracellular localization depends on Rab5 activity. The dominant negative Rab5S34N inhibits m4 endocytosis initially following carbachol stimulation, and reduces the size of m4 containing vesicles. The constitutively active Rab5Q79L enhances m4 intracellular distribution, even in unstimulated cells. Rab5Q79L also produces strikingly enlarged vacuoles, which by electron microscopy contain internal vesicles, suggesting that they are multivesicular bodies. m4 localizes both to the perimeter and interior of these vacuoles. In contrast, transferrin localizes only to the vacuole perimeter, demonstrating divergence of m4 trafficking from the pathway followed by constitutively endocytosed transferrin. We thus suggest a novel model by which multivesicular bodies sort G protein-coupled receptors from a transferrin-positive recycling pathway to a nonrecycling, possibly degradative pathway.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University	Levey, AI (corresponding author), Emory Univ, Sch Med, Dept Neurol, Woodruff Mem Res Bldg, Atlanta, GA 30322 USA.		Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030454] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30454] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berkeley JL, 2000, J NEUROCHEM, V75, P487, DOI 10.1046/j.1471-4159.2000.0750487.x; Bernard V, 1999, J NEUROSCI, V19, P10237; BERNHEIM L, 1992, P NATL ACAD SCI USA, V89, P9544, DOI 10.1073/pnas.89.20.9544; BURRY RW, 1993, J NEUROSCI RES, V36, P241, DOI 10.1002/jnr.490360302; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Felder CC, 2001, LIFE SCI, V68, P2605, DOI 10.1016/S0024-3205(01)01059-1; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FLYNN DD, 1995, J NEUROCHEM, V64, P1888; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GHOSH RN, 1994, J CELL SCI, V107, P2177; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P10483, DOI 10.1073/pnas.96.18.10483; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Koenig JA, 1996, MOL PHARMACOL, V49, P351; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krudewig R, 2000, J NEUROCHEM, V74, P1721, DOI 10.1046/j.1471-4159.2000.0741721.x; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Rodman JS, 2000, J CELL SCI, V113, P183; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P5184, DOI 10.1073/pnas.74.11.5184; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Szekeres PG, 1998, J NEUROCHEM, V70, P1694; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155	31	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47590	47598		10.1074/jbc.M106535200	http://dx.doi.org/10.1074/jbc.M106535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590149	hybrid			2022-12-25	WOS:000172768500119
J	Girardi, ACC; Degray, BC; Nagy, T; Biemesderfer, D; Aronson, PS				Girardi, ACC; Degray, BC; Nagy, T; Biemesderfer, D; Aronson, PS			Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase TV in the renal proximal tubule.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; BRUSH-BORDER; REGULATORY PROTEIN; APICAL MEMBRANE; SODIUM-CHANNEL; CELL; EZRIN; CD26; PHOSPHORYLATION; EXPRESSION	In an attempt to identify proteins that assemble with the apical membrane Na+-H+ exchanger isoform NHE3, we generated monoclonal antibodies (in-Abs) against affinity-purified NHE3 protein complexes isolated from solubilized renal microvillus membrane vesicles. Hybridomas were selected based on their ability to immunoprecipitate NHE3. We have characterized in detail one of the m-Abs (1D11) that specifically co-precipitated NHE3 but not villin or NaPi-2. Western blot analyses of microvillus membranes and immunoelectron microscopy of kidney sections showed that mAb 1D11 recognizes a 110-kDa protein highly expressed on the apical membrane of proximal tubule cells. Immunoaffinity chromatography was used to isolate the antigen against which mAb 1D11 is directed. N-terminal sequencing of the purified protein identified it as dipeptidyl peptidase IV (DPPIV) (EC 3.4.14.15), which was confirmed by assays of DPPIV enzyme activity. We also evaluated the distribution of the NHE3-DPPIV complex in microdomains of rabbit renal brush border. In contrast to the previously described NHE3-megalin complex, which principally resides in a dense membrane population (coated pits) in which NHE3 is inactive, the NHE3-DPPIV complex was predominantly in the microvillar fraction in which NHE3 is active. Serial precipitation experiments confirmed that anti-megalin and anti-DPPIV antibodies co-precipitate different pools of NHE3. Taken together, these studies revealed an unexpected association of the brush border Na+-H+ exchanger NHE3 with dipeptidyl peptidase IV in the proximal tubule. These findings raise the possibility that association with DPPIV may affect NHE3 surface expression and/or activity.	Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Aronson, PS (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, 333 Cedar St,LMP 2073,POB 208029, New Haven, CT 06520 USA.		Girardi, Adriana/C-4827-2012; Girardi, Adriana C. C./B-4334-2014	Girardi, Adriana/0000-0003-3715-6917; Girardi, Adriana C. C./0000-0003-3715-6917	NIDDK NIH HHS [DK-33793] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033793, R01DK033793] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2001, J AM SOC NEPHROL, V12, P1114, DOI 10.1681/ASN.V1261114; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; ALPERN RJ, 1993, J LAB CLIN MED, V122, P137; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; Bertog M, 1999, J PHYSIOL-LONDON, V521, P3, DOI 10.1111/j.1469-7793.1999.00003.x; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 2001, J BIOL CHEM, V276, P10161, DOI 10.1074/jbc.M008098200; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; BIEMESDERFER D, 1997, AM J PHYSIOL, V273, P289; Choi JY, 2000, J CLIN INVEST, V105, P1141, DOI 10.1172/JCI9260; Girardi Adriana C. C., 2000, Journal of the American Society of Nephrology, V11, p4A; HINO M, 1976, CLIN CHEM, V22, P1256; HONG WJ, 1989, EXP CELL RES, V182, P256, DOI 10.1016/0014-4827(89)90296-6; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Ohtsuki T, 2000, J DERMATOL SCI, V22, P152, DOI 10.1016/S0923-1811(99)00081-X; Paillard M, 1997, EXP NEPHROL, V5, P277; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RODMAN JS, 1986, J CELL BIOL, V102, P77, DOI 10.1083/jcb.102.1.77; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SZASZ G, 1969, CLIN CHEM, V15, P124; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; Wang T, 1999, AM J PHYSIOL-RENAL, V277, pF298, DOI 10.1152/ajprenal.1999.277.2.F298; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	42	97	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46671	46677		10.1074/jbc.M106897200	http://dx.doi.org/10.1074/jbc.M106897200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590171	hybrid			2022-12-25	WOS:000172573100155
J	Kashima, Y; Miki, T; Shibasaki, T; Ozaki, N; Miyazaki, M; Yano, H; Seino, S				Kashima, Y; Miki, T; Shibasaki, T; Ozaki, N; Miyazaki, M; Yano, H; Seino, S			Critical role of cAMP-GEFII.Rim2 complex in incretin-potentiated insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; GLUCAGON-LIKE PEPTIDE-1; PANCREATIC BETA-CELLS; INHIBITORY POLYPEPTIDE RECEPTOR; K-ATP CHANNEL; GLUCOSE-INTOLERANCE; B-CELL; CAMP; EXPRESSION; PHOSPHORYLATION	Incretins such as glucagon-like peptide-1 and gastric inhibitory polypeptide/glucose-dependent insulinotropic peptide are known to potentiate insulin secretion mainly through a cAMP/protein kinase A (PKA) signaling pathway in pancreatic beta -cells, but the mechanism is not clear. We recently found that the cAMP-binding protein eAMP-GEFII (or Epae 2), interacting with Rim2, a target of the small G protein Rab3, mediates cAMP-dependent, PKA-independent exocytosis in a reconstituted system. In the present study, we investigated the role of the cAMP-GEFII.Rim2 pathway in incretin-potentiated insulin secretion in native pancreatic beta -cells. Treatment of pancreatic islets with antisense oligodeoxynucleotides (ODNs) against cAMP-GEFII alone or with the PKA inhibitor H-89 alone inhibited incretin-potentiated insulin secretion similar to 50%, while a combination of antisense ODNs and H-89 inhibited the secretion similar to 80-90% The effect of cAMP-GEFII on insulin secretion is mediated by Rim2 and depends on intracellular calcium as well as on cAMP. Treatment of the islets with antisense ODNs attenuated both the first and second phases of insulin secretion potentiated by the cAMP analog 8-bromo-cAMP. These results indicate that the PKA-independent mechanism involving the cAMP-GEFII.Rim2 pathway is critical in the potentiation of insulin secretion by incretins.	Chiba Univ, Dept Cellular & Mol Med, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Dept Gen Surg, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan	Chiba University; Chiba University	Seino, S (corresponding author), Chiba Univ, Dept Cellular & Mol Med, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		MIKI, Takashi/ABD-3995-2020	MIKI, Takashi/0000-0001-5741-1626				Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; Bode HP, 1999, ENDOCRINOLOGY, V140, P3919, DOI 10.1210/en.140.9.3919; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brown J C, 1975, Recent Prog Horm Res, V31, P487; BROWN JC, 1978, DIABETES, V27, P782, DOI 10.2337/diab.27.7.782; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Ding WG, 1997, DIABETES, V46, P615, DOI 10.2337/diabetes.46.4.615; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; ELRICK H, 1964, J CLIN ENDOCR METAB, V24, P1076, DOI 10.1210/jcem-24-10-1076; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GARCIA MC, 1988, BIOCHEM J, V254, P211, DOI 10.1042/bj2540211; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; HOLZ GG, 2001, MOL BASIS PANCREAS D, P109; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; KATADA T, 1979, J BIOL CHEM, V254, P469; Kawaki J, 1999, DIABETES, V48, P2001, DOI 10.2337/diabetes.48.10.2001; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kleppisch T, 1995, P NATL ACAD SCI USA, V92, P12441, DOI 10.1073/pnas.92.26.12441; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LIPPE C, 1991, COMP BIOCHEM PHYS C, V99, P209, DOI 10.1016/0742-8413(91)90101-X; MALAISSE WJ, 1967, J CLIN INVEST, V46, P1724, DOI 10.1172/JCI105663; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; MONTAGUE W, 1971, BIOCHEM J, V122, P115, DOI 10.1042/bj1220115; MONTAGUE W, 1972, BIOCHEM J, V129, P551, DOI 10.1042/bj1290551; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; PERLEY MJ, 1967, J CLIN INVEST, V46, P1954, DOI 10.1172/JCI105685; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; SCHUIT FC, 1985, ENDOCRINOLOGY, V117, P834, DOI 10.1210/endo-117-3-834; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Skoglund G, 2000, DIABETES, V49, P1156, DOI 10.2337/diabetes.49.7.1156; STEINER DF, 1969, NEW ENGL J MED, V280, P1106, DOI 10.1056/NEJM196905152802008; SUGDEN MC, 1979, BIOCHEM J, V180, P219, DOI 10.1042/bj1800219; Takahashi N, 1999, P NATL ACAD SCI USA, V96, P760, DOI 10.1073/pnas.96.2.760; Thorens B, 1996, J BIOL CHEM, V271, P8075, DOI 10.1074/jbc.271.14.8075; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; YASUDA K, 1994, BIOCHEM BIOPH RES CO, V205, P1556, DOI 10.1006/bbrc.1994.2844; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X	54	280	294	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46046	46053		10.1074/jbc.M108378200	http://dx.doi.org/10.1074/jbc.M108378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11598134	hybrid			2022-12-25	WOS:000172573100076
J	Ruiz, FA; Marchesini, N; Seufferheld, M; Govindjee; Docampo, R				Ruiz, FA; Marchesini, N; Seufferheld, M; Govindjee; Docampo, R			The polyphosphate bodies of Chlamydomonas reinhardtii possess a proton-pumping pyrophosphatase and axe similar to acidocalcisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-PYROPHOSPHATASE; CONTRACTILE VACUOLE; INORGANIC POLYPHOSPHATE; PLASMA-MEMBRANE; ATPASE; PLANT; FRACTIONATION; REVERSIBILITY; LOCALIZATION; GRANULES	Acidocalcisomes are acidic calcium storage compartments described initially in trypanosomatid and apicomplexan parasites. In this work, we describe organelles with properties similar to acidocalcisomes in the green alga Chlamydomonas reinhardtii. Nigericin and NH4Cl released Ca-45(2+) from preloaded permeabilized cells, suggesting the incorporation of a significant amount of this cation into an acidic compartment. X-ray microanalysis of the electron-dense vacuoles or polyphosphate bodies of C. reinhardtii showed large amounts of phosphorus, magnesium, calcium, and zinc. Immunofluorescence microscopy, using antisera raised against a peptide sequence of the vacuolar type proton pyrophosphatase (H+-PPase) of Arabidopsis thaliana which is conserved in the C. reinhardtii enzyme, indicated localization in the plasma membrane, in intracellular vacuoles, and the contractile vacuole where it colocalized with the vacuolar proton ATPase (V-H+-ATPase). Purification of the electron-dense vacuoles using iodixanol density gradients indicated a preferential localization of the H+-PPase and the V-H+-ATPase activities in addition to high concentrations of PPi and short and long chain polyphosphate, but lack of markers for mitochondria and chloroplasts. In isolated electron-dense vacuoles, PPi-driven proton translocation was stimulated by potassium ions and inhibited by the PPi analog aminomethylenediphosphonate. Potassium fluoride, imidodiphosphate, N,N'-dicyclohexylcarbodiimide, and N-ethylmaleimide also inhibited PPi hydrolysis in the isolated organelles in a dose-dependent manner. These results indicate that the electron-dense vacuoles of C. reinhardtii are very similar to acidocalcisomes with regard to their chemical composition and the presence of proton pumps. Polyphosphate was also localized to the contractile vacuole by 4',6-diamidino-2-phenylindole staining, suggesting, with the immunochemical data, a link between these organelles and the acidocalcisomes.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Dept Plant Biol, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Govindjee, Govindjee/ABF-3362-2021; Ruiz, Felix A./B-1032-2008	Ruiz, Felix A./0000-0003-0748-5015	NIAID NIH HHS [AI-23259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN RA, 1980, CAN J MICROBIOL, V26, P912, DOI 10.1139/m80-158; Ault-Riche D, 1998, J BACTERIOL, V180, P1841; CLARK TB, 1959, J PROTOZOOL, V6, P227, DOI 10.1111/j.1550-7408.1959.tb04362.x; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Facanha AR, 1998, PLANT PHYSIOL, V116, P1487, DOI 10.1104/pp.116.4.1487; FOK AK, 1993, J CELL SCI, V106, P1103; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; HARRIS EH, 1988, CHLAMYDOMONAS SOURCE, P25; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; Hirata T, 2000, J BIOL CHEM, V275, P386, DOI 10.1074/jbc.275.1.386; KLEIN U, 1983, PLANT PHYSIOL, V72, P481, DOI 10.1104/pp.72.2.481; Komine Y, 1996, J PHOTOCH PHOTOBIO B, V36, P301, DOI 10.1016/S1011-1344(96)07386-1; Komine Y, 2000, PLANTA, V210, P897, DOI 10.1007/s004250050695; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KREUZBERG K, 1987, PHYSIOL PLANTARUM, V69, P481, DOI 10.1111/j.1399-3054.1987.tb09229.x; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LINDER JC, 1979, J CELL BIOL, V83, P371, DOI 10.1083/jcb.83.2.371; LONG AR, 1995, J PLANT PHYSIOL, V146, P629, DOI 10.1016/S0176-1617(11)81925-5; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; Meyer A., 1904, BOT Z, V62, P113; Moniakis J, 1999, J CELL SCI, V112, P405; NIYOGI KK, 1977, PLANT CELL, V4, P1369; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; PEREZCATINEIRA JR, 2001, NEW TRENDS INORGANIC, P129; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; Robinson DG, 1996, PLANTA, V198, P95, DOI 10.1007/BF00197591; Robinson DG, 1998, BOT ACTA, V111, P108, DOI 10.1111/j.1438-8677.1998.tb00685.x; Rodrigues CO, 2000, BIOCHEM J, V349, P737, DOI 10.1042/bj3490737; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; Siderius M, 1996, J PHYCOL, V32, P402, DOI 10.1111/j.0022-3646.1996.00402.x; WIAME JM, 1947, BIOCHIM BIOPHYS ACTA, V1, P234, DOI 10.1016/0006-3002(47)90137-6; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	40	145	151	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46196	46203		10.1074/jbc.M105268200	http://dx.doi.org/10.1074/jbc.M105268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579086	hybrid			2022-12-25	WOS:000172573100096
J	Um, JH; Kang, CD; Lee, BG; Kim, DW; Chung, BS; Kim, SH				Um, JH; Kang, CD; Lee, BG; Kim, DW; Chung, BS; Kim, SH			Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance	ONCOGENE			English	Article						multidrug resistance; NF-kappa B; Ku autoantigen; PKA inhibitor; anticancer drug	DEPENDENT PROTEIN-KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; INDUCED APOPTOSIS; CYCLIC-AMP; CROSS-RESISTANCE; GENE-EXPRESSION; CANCER-THERAPY; DNA-DAMAGE; CELL-DEATH; INDUCIBLE CHEMORESISTANCE	In this study, we investigated possible engagement of NF-kappaB and Ku autoantigen (Ku) activation in development of multidrug resistance (MDR) and circumvention of MDR by modulation of NF-kappaB and Ku. The NF-kappaB activity and NF-kappaB p65 subunit level were constitutively higher in MDR cells than in drug-sensitive parental cells. Interestingly, a faster running NF-kappaB DNA binding complex was identified as Ku, a DNA damage sensor and a key double strand break repair protein, and was positively correlated with the NF-kappaB activity in MDR cells and Ku- or both subunits of NF-kappaB-transfected cells. Also both NF-kappaB and Ku activities were activated or inhibited by treatment with etoposide (VP-16) or MG-132 (a proteasome inhibitor), respectively. Furthermore, PKA inhibitor suppressed markedly the constitutive and drug-induced activities of NF-kappaB and Ku in MDR cells and subsequently potentiated the cytotoxic activity of anticancer drugs. Our results proposed that the NF-kappaB and Ku activation could be one of multi-factorial MDR mechanism, and PKA inhibitor, likely via inhibition of NF-kappaB and Ku activities, could enhance the effectiveness of anticancer drugs against MDR cells with high activities of NF-kappaB and Ku.	Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 602739, South Korea; Pusan Natl Univ, Coll Med, Res Ctr Mol Med, Pusan 602739, South Korea; Chang Won Natl Univ, Coll Nat Sci, Dept Microbiol, Chang Won 641773, South Korea	Pusan National University; Pusan National University; Changwon National University	Kim, SH (corresponding author), Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 602739, South Korea.							ALBERT DA, 1995, J CLIN INVEST, V95, P1490, DOI 10.1172/JCI117820; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bjork-Eriksson T, 1999, INT J RADIAT ONCOL, V45, P1005, DOI 10.1016/S0360-3016(99)00268-0; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Chao CCK, 1996, EUR J PHARMACOL, V305, P213, DOI 10.1016/0014-2999(96)00168-9; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; Christodoulopoulos G, 1998, CANCER RES, V58, P1789; Cusack JC, 2000, CANCER RES, V60, P2323; Cvijic ME, 1997, CELL GROWTH DIFFER, V8, P1243; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kang CD, 2000, EXP CELL RES, V256, P300, DOI 10.1006/excr.2000.4807; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIM SH, 1993, CANCER LETT, V74, P37, DOI 10.1016/0304-3835(93)90041-7; Kim SH, 1999, CANCER RES, V59, P4012; Kim SH, 2000, LEUKEMIA RES, V24, P917, DOI 10.1016/S0145-2126(00)00061-8; Lee HJ, 2001, J NEUROCHEM, V76, P602, DOI 10.1046/j.1471-4159.2001.00076.x; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; McKenna SL, 1997, BRIT J HAEMATOL, V96, P659, DOI 10.1046/j.1365-2141.1997.d01-2095.x; MICKISCH G, 1991, UROL RES, V19, P99, DOI 10.1007/BF00368184; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; NEUMANN M, 1992, ANTICANCER RES, V12, P2297; Nueda A, 1999, J BIOL CHEM, V274, P14988, DOI 10.1074/jbc.274.21.14988; Pae HO, 1999, IMMUNOPHARM IMMUNOT, V21, P233, DOI 10.3109/08923979909052760; Pajonk F, 2000, INT J RADIAT ONCOL, V47, P1025, DOI 10.1016/S0360-3016(00)00516-2; Palissot V, 1998, BIOCHEM BIOPH RES CO, V245, P918, DOI 10.1006/bbrc.1998.8550; Pernin D, 2000, B CANCER, V87, P635; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; SATTA T, 1992, CANCER, V69, P941, DOI 10.1002/1097-0142(19920215)69:4<941::AID-CNCR2820690418>3.0.CO;2-H; Shackelford DA, 1999, J NEUROSCI, V19, P4727; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stavrovskaya AA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P95; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; Watanabe K, 2000, BIOCHEM PHARMACOL, V60, P823, DOI 10.1016/S0006-2952(00)00387-7; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhou DC, 1996, INT J CANCER, V65, P365, DOI 10.1002/(SICI)1097-0215(19960126)65:3<365::AID-IJC15>3.0.CO;2-9; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	61	46	52	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6048	6056		10.1038/sj.onc.1204732	http://dx.doi.org/10.1038/sj.onc.1204732			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593412				2022-12-25	WOS:000171056300012
J	Hoover, RR; Gerlach, MJ; Koh, EY; Daley, GQ				Hoover, RR; Gerlach, MJ; Koh, EY; Daley, GQ			Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells	ONCOGENE			English	Article						BCR/ABL; signal transduction; STAT5; Ras; apoptosis; DNA damage	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; BCR-ABL; INHIBITS APOPTOSIS; ACTIVATION; RECEPTOR; P210; SURVIVAL; GROWTH	The Akt, Ras and STAT5 signaling pathways have each been linked to transformation of hematopoietic cells by BCR/ABL. However the relative contributions of these signaling pathways to BCR/ABL mediated cytokine-independent survival, proliferation and resistance to DNA damage-induced apoptosis have not been systematically defined. Here we report that activation of either Akt, Ras or STAT5 confers cytokine-independent survival to IL-3 dependent BaF3 cells. Ras or STAT5, but not Akt, also drives cytokine-independent proliferation and imparts sustained resistance to DNA damage-induced apoptosis. We also show that dominant negative (DN) inhibition of STAT5, but not Ras or Akt, significantly reduces resistance to DNA damage-induced apoptosis in BCR/ABL transformed BaF3 cells. Whereas inhibition of STAT5 or Ras alone does not compromise cytokine-independent proliferation of BaF3-BCR/ABL cells, simultaneous blockade of both STAT5 and Ras reduces proliferation and maximally sensitizes BaF3-BCR/ABL cells to DNA damage induced by gamma -irradiation, suggesting a cooperative role for these two signaling pathways in BCR/ABL transformation. The anti-apoptotic properties of BCR/ABL can be partly explained by an increase in the expression of Pim-1 and Bcl-XL, as ectopic expression of these STAT5 target genes imparts both cytokine-independent survival and partial gamma -radiation resistance. These data illustrate both cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed cells, with STAT5 playing a dominant role in resistance to DNA damage-induced apoptosis.	Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Daley, GQ (corresponding author), Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.	daley@wi.mit.edu			NATIONAL CANCER INSTITUTE [R29CA076418, R01CA086991] Funding Source: NIH RePORTER; NCI NIH HHS [CA 86991, CA 76418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Cortez D, 1996, ONCOGENE, V13, P2589; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lilly M, 1997, CANCER RES, V57, P5348; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SKORSKI T, 1995, CANCER RES, V55, P2275; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WilsonRawls J, 1996, CANCER RES, V56, P3426	47	70	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5826	5835		10.1038/sj.onc.1204549	http://dx.doi.org/10.1038/sj.onc.1204549			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593388				2022-12-25	WOS:000171037200006
J	Kotsonis, P; Frohlich, LG; Raman, CS; Li, HY; Berg, M; Gerwig, R; Groehn, V; Kang, YH; Al-Masoudi, N; Taghavi-Moghadam, S; Mohr, D; Munch, U; Schnabel, J; Martasek, P; Masters, BSS; Strobel, H; Poulos, T; Matter, H; Pfleiderer, W; Schmidt, HHHW				Kotsonis, P; Frohlich, LG; Raman, CS; Li, HY; Berg, M; Gerwig, R; Groehn, V; Kang, YH; Al-Masoudi, N; Taghavi-Moghadam, S; Mohr, D; Munch, U; Schnabel, J; Martasek, P; Masters, BSS; Strobel, H; Poulos, T; Matter, H; Pfleiderer, W; Schmidt, HHHW			Structural basis for pterin antagonism in nitric-oxide synthase - Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC PHYSICOCHEMICAL PARAMETERS; DIRECTED QUANTITATIVE STRUCTURE; MICE LACKING; L-ARGININE; HOMOLOGOUS PROTEINS; L-THIOCITRULLINE; TETRAHYDROBIOPTERIN; INHIBITOR; NO; POTENT	Pathological nitric oxide (NO) generation in sepsis, inflammation, and stroke may be therapeutically controlled by inhibiting NO synthases (NOS). Here we targeted the (6R)-5,6,7,8-tetrahydro-L-biopterin (H(4)Bip)binding site of NOS, which, upon cofactor binding, maximally increases enzyme activity and NO production from substrate L-arginine. The first generation of H(4)Bip-based NOS inhibitors employed a 4-amino pharmacophore of H(4)Bip analogous to antifolates such as methotrexate. We developed a novel series of 4-oxo-pteridine derivatives that were screened for inhibition against neuronal NOS (NOS-I) and a structure-activity relationship was determined. To understand the structural basis for pterin antagonism, selected derivatives were docked into the NOS pterin binding cavity. Using a reduced 4-oxo-pteridine scaffold, derivatives with certain modifications such as electron-rich aromatic phenyl or benzoyl groups at the 5- and 6-positions, were discovered to markedly inhibit NOS-I, possibly due to hydrophobic and electrostatic interactions with Phe(462) and Ser(104), respectively, within the pterin binding pocket. One of the most effective 4-oxo compounds and, for comparisons an active 4-amino derivative, were then co-crystallized with the endothelial NOS (NOS-III) oxygenase domain and this structure solved to confirm the hypothetical binding modes. Collectively, these findings suggest (i) that, unlike the antifolate principle, the 4-amino substituent is not essential for developing pterin-based NOS inhibitors and (ii), provide a steric and electrostatic basis for their rational design.	Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Texas, Sch Med, Struct Biol Ctr MSB 6 128, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Program Macromol Struct, Irvine, CA 92697 USA; Univ Konstanz, Fac Chem, D-78434 Constance, Germany; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Aventis Pharma, Res Chem Frankfurt, D-65926 Frankfurt, Germany	University of Wurzburg; University of Texas System; University of California System; University of California Irvine; University of Konstanz; University of Texas System; University of Texas Health San Antonio; Sanofi-Aventis	Kotsonis, P (corresponding author), Novartis Inst Med Sci, 5 Gower Pl, London WC1E 6BS, England.	peter.kotsonis@pharma.novartis.com; Harald.Schmidt@pharma.med.uni-giessen.de	Martásek, Pavel/G-6622-2017; Schmidt, Harald HHW/B-1549-2008	Martásek, Pavel/0000-0001-6165-4444; Schmidt, Harald HHW/0000-0003-0419-5549; Raman, C. S./0000-0002-1036-3193; Prof.Dr. Al-Masoudi, Najim/0000-0001-6811-191X				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAUGH CM, 1964, J ORG CHEM, V29, P3610, DOI 10.1021/jo01035a042; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; BOYLE PH, 1980, CHEM BER-RECL, V113, P1514, DOI 10.1002/cber.19801130431; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brickmann J., 1987, TAGUNGSBER VORTRAGST, P93; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FREY C, 1994, J BIOL CHEM, V269, P26083; Frohlich LG, 1999, J MED CHEM, V42, P4108, DOI 10.1021/jm981129a; FURCHGOTT R F, 1988, P401; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GHOSE AK, 1986, J COMPUT CHEM, V7, P565, DOI 10.1002/jcc.540070419; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Griffith O. W., 1996, METHODS NITRIC OXIDE, P187; HEIDEN W, 1993, J COMPUT AID MOL DES, V7, P503, DOI 10.1007/BF00124359; HEIDEN W, 1993, J COMPUT CHEM, V14, P246, DOI 10.1002/jcc.540140212; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; Huang H, 1999, J MED CHEM, V42, P3147, DOI 10.1021/jm990111c; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KATO K, 1996, Patent No. 737671; KATSURA Y, 1997, Patent No. 9702254; KEIL M, 1988, J MOL MODEL, V4, P335; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Komarov AM, 2000, FREE RADICAL BIO MED, V28, P739, DOI 10.1016/S0891-5849(00)00156-8; Kotsonis P, 1999, BIOCHEM J, V340, P745, DOI 10.1042/0264-6021:3400745; KWON NS, 1989, J BIOL CHEM, V264, P20496; MACDONALD JE, 1996, Patent No. 0624588; MACDONALD JE, 1996, Patent No. 9601817; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; NARAYANAN K, 1995, J BIOL CHEM, V270, P11103, DOI 10.1074/jbc.270.19.11103; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; SRINIVASAN N, 1993, PROTEIN ENG, V6, P501, DOI 10.1093/protein/6.5.501; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P385, DOI 10.1093/protein/1.5.385; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; *SYBYL, 1999, MOL MOD PACK VERS 6; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Traub H, 1999, PTERIDINES, V10, P79; VISWANADHAN VN, 1989, J CHEM INF COMP SCI, V29, P163, DOI 10.1021/ci00063a006; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Werner ER, 2000, HANDB EXP PHARMACOL, V143, P137	72	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49133	49141		10.1074/jbc.M011469200	http://dx.doi.org/10.1074/jbc.M011469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11590164	hybrid			2022-12-25	WOS:000173922100068
J	Rashid, T; Banerjee, M; Nikolic, M				Rashid, T; Banerjee, M; Nikolic, M			Phosphorylation of Pak1 by the p35/Cdk5 kinase affects neuronal morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; SITE-SPECIFIC PHOSPHORYLATION; FAMILY PROTEIN-KINASES; P21-ACTIVATED KINASE; NEURITE OUTGROWTH; CORTICAL DEVELOPMENT; STRUCTURAL BASIS; NERVOUS-SYSTEM; ACTIVATOR P35; BOVINE BRAIN	The small GTPase Rac and its effectors, the Pak1 and p35/Cdk5 kinases, have been assigned important roles in regulating cytoskeletal dynamics in neurons. Our previous work revealed that the neuronal p35/Cdk5 kinase associates with Pak1 in a RacGTP-dependent manner, causing hyperphosphorylation and down-regulation of Pak1 kinase activity. We have now demonstrated direct phosphorylation of Pak1 on threonine 212 by the p35/Cdk5 kinase. In neuronal growth cones, Pak1 phosphorylated on Thr-212 localized to actin and tubulin-rich areas, suggesting a role in regulating growth cone dynamics. The expression of a non-phosphorylatable Pak1 mutant (Pak1A212) induced dramatic neurite disorganization. We also observed a strong association between p35/Cdk5 and the Pak1 C-terminal kinase domain. Overall, our data show that in neurons, membrane-associated, active Pak1 is regulated by the p35/Cdk5 kinase both by association and phosphorylation, which is essential for the proper regulation of the cytoskeleton during neurite outgrowth and remodeling.	Kings Coll London, MRC, Mol & Dev Neurobiol Ctr, London SE1 1UL, England	University of London; King's College London	Nikolic, M (corresponding author), Kings Coll London, MRC, Mol & Dev Neurobiol Ctr, New Hunts House, London SE1 1UL, England.	margareta.nikolic@kcl.ac.uk						Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Connell-Crowley L, 2000, CURR BIOL, V10, P599, DOI 10.1016/S0960-9822(00)00487-5; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Gilmore EC, 1998, J NEUROSCI, V18, P6370; Gleeson JG, 2000, TRENDS NEUROSCI, V23, P352, DOI 10.1016/S0166-2236(00)01607-6; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Humbert S, 2000, NEUROREPORT, V11, P2213, DOI 10.1097/00001756-200007140-00030; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Kwon YT, 2000, RES PRO CEL, V30, P241; Leberer E, 2000, BIOL CHEM, V381, P427, DOI 10.1515/BC.2000.055; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Oehlen LJWM, 1998, J BIOL CHEM, V273, P25089, DOI 10.1074/jbc.273.39.25089; Ohshima T, 1999, J NEUROSCI, V19, P6017, DOI 10.1523/JNEUROSCI.19-14-06017.1999; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 1998, J NEUROSCI, V18, P9858; Paglini G, 2001, EUR J BIOCHEM, V268, P1528, DOI 10.1046/j.1432-1033.2001.02023.x; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Philpott A, 1999, DEV BIOL, V207, P119, DOI 10.1006/dbio.1998.9146; Pigino G, 1997, J CELL SCI, V110, P257; Redmond L, 2001, CURR OPIN NEUROBIOL, V11, P111, DOI 10.1016/S0959-4388(00)00181-1; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Sharma P, 1998, BIOCHEMISTRY-US, V37, P4759, DOI 10.1021/bi972746o; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Symons M, 2000, CURR BIOL, V10, pR535, DOI 10.1016/S0960-9822(00)00588-1; Tomizawa K, 1996, NEUROSCIENCE, V74, P519, DOI 10.1016/0306-4522(96)00136-4; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Tu H, 1999, MOL CELL BIOL, V19, P602; Wu CL, 1998, J BIOL CHEM, V273, P28107, DOI 10.1074/jbc.273.43.28107; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	61	115	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49043	49052		10.1074/jbc.M105599200	http://dx.doi.org/10.1074/jbc.M105599200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11604394	hybrid			2022-12-25	WOS:000173922100057
J	Izumi, M; Yatagai, F; Hanaoka, F				Izumi, M; Yatagai, F; Hanaoka, F			Cell cycle-dependent proteolysis and phosphorylation of human Mcm10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT NUCLEAR-STRUCTURES; ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; S-PHASE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CHROMATIN; XENOPUS; PROTEIN; CDK	Mcm10 (Dna43) is an essential protein for chromosomal DNA replication in Saccharomyces cerevisiae. Recently, we identified a human Mcm10 homolog that interacts with the mammalian Orc2 and Mcm2-7 complex. We additionally demonstrated that human Mcm10 binds nuclease-resistant nuclear structures during S phase and dissociates from them in G(2) phase. In this study, we have further characterized the subcellular localization, modification, and expression levels of human Mcm10 protein throughout the cell cycle. Human Mcm10 protein decreased in late M phase, remained low during G(1) phase, started to accumulate, and bound chromatin at the onset of S phase. Proteasome inhibitors stabilized Mcm10 levels, suggesting that proteolysis is involved in the down-regulation of the protein in late M/G(1) phase. Dissociation of Mcm10 from chromatin in G(2)/M phase was concomitant with alterations in the electrophoretic mobility of the protein. Treatment with A phosphatase revealed that mobility shifts were due to hyperphosphorylation. These results indicate that human Mcm10 is regulated by proteolysis and phosphorylation in a cell cycle-dependent manner. It is further suggested at mammalian Mcm10 is involved in S phase progression, and not the formation of a prereplicative comp as previously proposed from data on the S. cervisiae protein.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Osaka Univ, JSTC, CREST, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Div Radioisotope Technol, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Cellular Physiol Lab, Wako, Saitama 3510198, Japan	Osaka University; Japan Science & Technology Agency (JST); Osaka University; RIKEN; RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.							Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Homesley L, 2000, GENE DEV, V14, P913; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Izumi M, 2000, MOL BIOL CELL, V11, P4323, DOI 10.1091/mbc.11.12.4323; Jares P, 2000, GENE DEV, V14, P1528; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lei M, 2001, J CELL SCI, V114, P1447; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2000, GENE DEV, V14, P655; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rowles A, 1999, J CELL SCI, V112, P2011; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	43	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48526	48531		10.1074/jbc.M107190200	http://dx.doi.org/10.1074/jbc.M107190200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602595	hybrid			2022-12-25	WOS:000172927000106
J	Skinner, MA; Wildeman, AG				Skinner, MA; Wildeman, AG			Suppression of tumor-related glycosylation of cell surface receptors by the 16-kDa membrane subunit of vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; GROWTH-FACTOR RECEPTOR; BETA-1-6 BRANCHED OLIGOSACCHARIDES; LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; PROTEOLIPID SUBUNIT; PAPILLOMAVIRUS E5; PROGNOSTIC VALUE; POOR-PROGNOSIS; PROTON PUMP	The glycosylation of integrins and other cell surface receptors is altered in many transformed cells. Notably, an increase in the number of beta1,6-branched N-linked oligosaccharides correlates strongly with invasive growth of cells. An ectopic expression of the Golgi enzyme N-acetylglucosaminyltransferase V (GlcNAc-TV), which forms beta1,6 linkages, promotes metastasis of a number of cell types. It is shown here that the 16-kDa transmembrane subunit (16K) of vacuolar H+-ATPase suppresses beta1,6 branching of beta (1) integrin and the epidermal growth factor receptor. Overexpression of 16K inhibits cell adhesion and invasion. 16K contains four hydrophobic membrane-spanning a-helices, and its ability to influence glycosylation is localized primarily within the second and fourth membrane-spanning alpha -helices. 16K also interacts directly with the transmembrane domain of beta (1) integrin, but its effects on glycosylation were independent of its binding to beta (1) integrin. These data link cell surface tumor-related glycosylation to a component of the enzyme responsible for acidification of the exocytic pathway.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Skinner, MA (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.							ALBINI A, 1989, CLIN EXP METASTAS, V7, P437, DOI 10.1007/BF01753664; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Arao S, 2000, PANCREAS, V20, P129, DOI 10.1097/00006676-200003000-00004; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bartlett JMS, 1996, BRIT J CANCER, V73, P301, DOI 10.1038/bjc.1996.53; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; Braut-Boucher F, 1998, LEUKEMIA RES, V22, P947, DOI 10.1016/S0145-2126(98)00094-0; BROCHIER G, 1993, NEUROCHEM INT, V23, P525, DOI 10.1016/0197-0186(93)90100-J; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; Chen L, 1998, ONCOGENE, V17, P2087, DOI 10.1038/sj.onc.1202124; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DO KY, 1994, J BIOL CHEM, V269, P23456; FENG Y, 1992, J BIOL CHEM, V267, P19769; FERNANDES B, 1991, CANCER RES, V51, P718; FINBOW ME, 1993, EXP CELL RES, V207, P261, DOI 10.1006/excr.1993.1192; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; FINBOW ME, 1994, J CELL SCI, V107, P1817; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; Fishman DA, 1998, INVAS METAST, V18, P15, DOI 10.1159/000024495; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; Granovsky M, 2000, NAT MED, V6, P306; Guo HB, 2000, J CELL BIOCHEM, V79, P370, DOI 10.1002/1097-4644(20001201)79:3<370::AID-JCB30>3.0.CO;2-Z; Hauri HP, 2000, J CELL SCI, V113, P587; Huang SM, 1999, INVEST NEW DRUG, V17, P259, DOI 10.1023/A:1006384521198; Jasiulionis MG, 1996, CANCER RES, V56, P1682; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Litynska A, 2000, ACTA BIOCHIM POL, V47, P427; MACLAREN LA, 1995, BIOL REPROD, V53, P153, DOI 10.1095/biolreprod53.1.153; MALEKHEDAYAT S, 1995, GENE, V158, P287, DOI 10.1016/0378-1119(94)00911-B; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Murata K, 2000, CLIN CANCER RES, V6, P1772; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON N, 1992, J EXP BIOL, V172, P149; Nishimura S, 1996, BRIT J CANCER, V74, P1406, DOI 10.1038/bjc.1996.556; Park HR, 1996, CANCER LETT, V106, P227, DOI 10.1016/0304-3835(96)04330-3; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Seberger PJ, 1999, GLYCOBIOLOGY, V9, P235, DOI 10.1093/glycob/9.3.235; Seelentag WKF, 1998, CANCER RES, V58, P5559; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Shao DM, 1999, J EXP CLIN CANC RES, V18, P331; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Smith KD, 1996, GROWTH FACTORS, V13, P121, DOI 10.3109/08977199609034572; Stroeken PJM, 2000, ONCOGENE, V19, P1232, DOI 10.1038/sj.onc.1203423; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; ULRICH A, 1984, NATURE, V309, P418; Zuzarte PC, 2000, BBA-GENE STRUCT EXPR, V1517, P82, DOI 10.1016/S0167-4781(00)00261-X	61	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48451	48457		10.1074/jbc.M103569200	http://dx.doi.org/10.1074/jbc.M103569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604389	hybrid			2022-12-25	WOS:000172927000097
J	Bhowmick, NA; Zent, R; Ghiassi, M; McDonnell, M; Moses, HL				Bhowmick, NA; Zent, R; Ghiassi, M; McDonnell, M; Moses, HL			Integrin beta(1) signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTOR; CELLS; PROTEIN; BINDING; TRANSDIFFERENTIATION; TRANSCRIPTION; TRANSDUCTION; FIBRONECTIN; REQUIREMENT; MEDIATOR	Transforming growth factor-beta (TGF-beta) can induce epithelial to mesenchymal transdifferentiation (EMT) in mammary epithelial cells. TGF-beta -meditated EMT involves the stimulation of a number of signaling path. ways by the sequential binding of the type II and type I serine/threonine kinase receptors, respectively. Integrins comprise a family of heterodimeric extracellular matrix receptors that mediate cell adhesion and intracellular signaling, hence making them crucial for EMT progression. In light of substantial evidence indicating TGF-beta regulation of various beta (1), integrins and their extracellular matrix ligands, we examined the cross-talk between the TGF-P and integrin signal transduction pathways. Using an inducible system for the expression of a cytoplasmically truncated dominant negative TGF-beta type II receptor, we blocked TGF-beta -mediated growth inhibition, transcriptional activation, and EMT progression. Dominant negative TGF-beta type II receptor expression inhibited TGF-P signaling to the SMAD and AKT pathways, but did not block TGF-beta -mediated p38MAPK activation. Interestingly, blocking integrin beta (1) function inhibited TGF-p-mediated p383LAPK activation and EMT progression. Limiting p38MAPK activity through the expression of a dominant negative-p38MAPK also blocked TGF-p-mediated EMT. In summary, TGF-beta -mediated p38MAPK activation is dependent on functional integrin beta (1), and p38MAPK activity is required but is not sufficient to induce EMT.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA.	hal.moses@mcmail.vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	NATIONAL CANCER INSTITUTE [R35CA042572, R01CA085492, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85492, CA 68485, CA 42572] Funding Source: Medline; NIDDK NIH HHS [DK 20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Brown LA, 1999, ONCOGENE, V18, P7985, DOI 10.1038/sj.onc.1203197; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chin BY, 2001, AM J PHYSIOL-RENAL, V280, pF495, DOI 10.1152/ajprenal.2001.280.3.F495; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; KUMAR NM, 1995, EXP CELL RES, V221, P385, DOI 10.1006/excr.1995.1389; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MOSES HL, 1981, CANCER RES, V41, P2842; Piek E, 1999, J CELL SCI, V112, P4557; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; Tafazoli F, 2000, INFECT IMMUN, V68, P5335, DOI 10.1128/IAI.68.9.5335-5343.2000; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	36	316	331	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46707	46713		10.1074/jbc.M106176200	http://dx.doi.org/10.1074/jbc.M106176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590169	hybrid			2022-12-25	WOS:000172768500006
J	Pham, N; Rotin, D				Pham, N; Rotin, D			Nedd4 regulates ubiquitination and stability of the guanine-nucleotide exchange factor CNrasGEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; PLASMA-MEMBRANE PROTEINS; LIDDLES-SYNDROME; SURFACE EXPRESSION; LIGASE NEDD4; WW DOMAINS; PY MOTIF; RAS; FAMILY; ACTIVATION	Cyclic nucleotide ras GEF (CNrasGEF) is a guanine-nucleotide exchange factor previously isolated in a screen for Nedd4-WW domain interacting proteins (Pham, N., Cheglakov, I, Koch, C. A., de Hoog, C. L., Moran, M. F., and Rotin, D. (2000) Curr. Biol. 10, 555-558). It activates Ras in a cAMP-dependent manner and Rap-1 independent of cAMP. Here we show that CNrasGEF is a likely substrate of the ubiquitin protein ligase Nedd4. CNrasGEF possesses two PY motifs at its C terminus that are responsible for binding to Nedd4 in vitro. Moreover, Nedd4 and CNrasGEF co-immunoprecipitate from 293T cells expressing ectopic CNrasGEF and endogenous Nedd4, and this co-immunoprecipitation is abrogated in PY motif-mutated CNrasGEF (CNrasGEF Delta 2PY). CNrasGEF is ubiquitinated in cells, and this ubiquitination is augmented upon overexpression of wt-Nedd4 but is inhibited in cells overexpressing a catalytically inactive Nedd4 (Nedd4(CS)) or in cells expressing CNrasGEF Delta 2PY, which cannot bind Nedd4. Moreover, pulse-chase experiments have demonstrated that the half-life of CNrasGEF is reduced 5-fold (from similar to 10 to similar to2 h) in cells co-expressing Nedd4 with CNrasGEF but not with CNrasGEF Delta 2PY (t(0.5) similar to 14 h). CNrasGEF is also stabilized in cells co-expressing Nedd4(CS) or following treatment with lactacystin, indicating proteasomal degradation of this protein. Deletion/mutation of the CDC25 domain to abrogate Ras (or Rap-1) binding leads to impaired ubiquitination of CNrasGEF, suggesting that such binding is critical for ubiquitination. Treatment of cells with the cAMP analogue 8-bromo-cAMP does not affect the ability of CNrasGEF to bind Nedd4 nor its level of ubiquitination, suggesting that Ras binding per se and not its activation is the critical step in triggering ubiquitination of CNrasGEF. These results suggest that CNrasGEF is a substrate for Nedd4, which regulates its ubiquitination and stability in cells.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bonny O, 2000, KIDNEY INT, V57, P1313, DOI 10.1046/j.1523-1755.2000.00968.x; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; de Hoog CL, 2001, MOL CELL BIOL, V21, P2107, DOI 10.1128/MCB.21.6.2107-2117.2001; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; KAPLON T, 1995, J BIOL CHEM, V270, P20742, DOI 10.1074/jbc.270.35.20742; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1156; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Mastroberardino L, 1998, MOL BIOL CELL, V9, P3417, DOI 10.1091/mbc.9.12.3417; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	34	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46995	47003		10.1074/jbc.M108373200	http://dx.doi.org/10.1074/jbc.M108373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598133	hybrid			2022-12-25	WOS:000172768500045
J	Zhang, T; Wolfe, MW; Roberson, MS				Zhang, T; Wolfe, MW; Roberson, MS			An early growth response protein (Egr) 1 cis-element is required for gonadotropin-releasing hormone-induced mitogen-activated protein kinase phosphatase 2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; ALPHA-T3-1 CELL-LINE; SIGNAL-REGULATED KINASE; NGFI-A EGR-1; TYROSINE-PHOSPHATASE; MAP KINASE; BETA-GENE; CATALYTIC ACTIVATION; TRANSCRIPTION FACTOR; SUBUNIT GENE	In pituitary gonadotropes, gonadotropin-releasing hormone (GnRH) activates all three major mitogen-activated protein kinase (MAPK) cascades. The MAPKs play key roles in transcriptional activation of GnRH-responsive genes. MAPK phosphatases (MKPs) are dual specificity protein phosphatases involved in feedback regulation of MAPK activity. Previous studies indicate that GnRH activates MKP-2 expression in gonadotropes, dependent upon activation of multiple MAPKs and discrete Ca2+ signals. To further understand the transcriptional mechanism(s) of MKP-2 induction by GnRH, we studied the activity of a 198-nucleotide MKP-2 proximal promoter region that supports GnRH responsiveness in reporter gene assays. Functional analysis of the MKP-2 promoter confirmed a requirement for the protein kinase C-extracellular signal-regulated kinase (ERK) pathway and VGCC-derived Ca2+ signals in transcriptional activation of the MKP-2 gene. However, the inhibitory effect of thapsigargin on MKP-2 protein expression previously identified was not mediated at the level of promoter activation, suggesting a distinct mechanism for the action of thapsigargin-sensitive Ca2+ signals. MGRE (MKP-2 GnRH response element) within the MKP-2 promoter mediated promoter activation through the protein kinase C-ERK pathway. The zinc finger transcription factor Egr-1 was identified in the MGRE-binding complex. Egr-1/MGRE binding was induced by GnRH in an ERK-dependent manner. Transcriptional activity of Egr-1 protein was enhanced by GnRH treatment. In addition, overexpression of the Egr-interacting protein, NAB1, resulted in increased GnRH-stimulated MKP-2 gene transcription. Consistent with the putative role of Egr-1 in MKP-2 promoter regulation, Egr-1 protein expression closely correlated with the expression of MKP-2 protein in alpha T3-1 cells. Together, these data suggest that Egr-1 may be a key factor in mediating GnRH-dependent transcriptional activation of the MKP-2 gene.	Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA	Cornell University; University of Kansas; University of Kansas Medical Center	Roberson, MS (corresponding author), Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034722] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034722] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34722] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Bokemeyer D, 1997, J AM SOC NEPHROL, V8, P40; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Call GB, 1999, BIOL REPROD, V61, P715, DOI 10.1095/biolreprod61.3.715; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; CESNJAJ M, 1994, ENDOCRINOLOGY, V135, P692, DOI 10.1210/en.135.2.692; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Coulon V, 1999, J BIOL CHEM, V274, P30439, DOI 10.1074/jbc.274.43.30439; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Dowd S, 1998, J CELL SCI, V111, P3389; Fukada T, 2001, J BIOL CHEM, V276, P25512, DOI 10.1074/jbc.M101354200; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Halvorson LM, 1999, MOL ENDOCRINOL, V13, P106, DOI 10.1210/me.13.1.106; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Harris D, 1997, J BIOL CHEM, V272, P13534, DOI 10.1074/jbc.272.21.13534; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Johnson MS, 1996, MOL CELL BIOCHEM, V165, P65; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; King AG, 1995, ONCOGENE, V11, P2553; Kratzmeier M, 1996, MOL CELL ENDOCRINOL, V118, P103, DOI 10.1016/0303-7207(96)03788-4; KWAK SP, 1994, J BIOL CHEM, V269, P3596; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MITCHELL R, 1994, J ENDOCRINOL, V140, pR15, DOI 10.1677/joe.0.140R015; Muda M, 1996, J BIOL CHEM, V271, P4319; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; Roberson MS, 2000, MOL CELL BIOL, V20, P3331, DOI 10.1128/MCB.20.10.3331-3344.2000; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Ryser S, 2001, J BIOL CHEM, V276, P33319, DOI 10.1074/jbc.M102326200; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Stanislaus D, 1998, ENDOCRINOLOGY, V139, P2710, DOI 10.1210/en.139.6.2710; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; WERLEN G, 1993, J BIOL CHEM, V268, P16596; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P752, DOI 10.1210/me.13.5.752; Zhang T, 2001, MOL CELL ENDOCRINOL, V172, P79, DOI 10.1016/S0303-7207(00)00378-6; Zhang T, 2001, GENE, V273, P71, DOI 10.1016/S0378-1119(01)00574-1; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526	76	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45604	45613		10.1074/jbc.M107075200	http://dx.doi.org/10.1074/jbc.M107075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591707	hybrid			2022-12-25	WOS:000172573100017
J	Skabkin, MA; Evdokimova, V; Thomas, AAM; Ovchinnikov, LP				Skabkin, MA; Evdokimova, V; Thomas, AAM; Ovchinnikov, LP			The major messenger ribonucleoprotein particle protein p50 (YB-1) promotes nucleic acid strand annealing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y-BOX PROTEINS; RNA-BINDING-PROTEINS; TYPE-1 NUCLEOCAPSID PROTEIN; COMPLEMENTARY-DNA STRANDS; MURINE LEUKEMIA-VIRUS; COLD-SHOCK DOMAIN; ESCHERICHIA-COLI; CYTOPLASMIC MRNP; CORE PROTEIN; TRANSCRIPTION FACTOR	p50, a member of the Y-box binding transcription factor family, is tightly associated with eukaryotic mRNAs and is responsible for general translational regulation. Here we show that p50, in addition to its previously described ability to melt mRNA secondary structure, is capable of promoting rapid annealing of complementary nucleic acid strands. p50 accelerates annealing of RNA and DNA duplexes up to 1500-fold within a wide range of salt concentrations and temperatures. Phosphorylation of p50 selectively inhibits DNA annealing. Moreover, p50 catalyzes strand exchange between double-stranded and single-stranded RNAs yielding a product bearing a more extended double-stranded structure. Strikingly, p50 displays both RNA-melting and -annealing activities in a dose-dependent manner; a relatively low amount of p50 promotes formation of RNA duplexes, whereas an excess of p50 causes unwinding of double-stranded forms. Our results suggest that the alteration of nucleic acid conformation is a basic mechanism of the p50-dependent regulation of gene expression.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia; Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands	Russian Academy of Sciences; Utrecht University	Ovchinnikov, LP (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	ovchinn@vega.protres.ru	Ovchinnikov, Lev/L-2397-2015					BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BLOBEL G, 1972, BIOCHEM BIOPH RES CO, V47, P88, DOI 10.1016/S0006-291X(72)80014-7; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; Chansky HA, 2001, CANCER RES, V61, P3586; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Graumann P, 1996, BIOESSAYS, V18, P309, DOI 10.1002/bies.950180409; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HERRICK G, 1976, J BIOL CHEM, V251, P2133; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hitti E, 1998, NUCLEIC ACIDS RES, V26, P4382, DOI 10.1093/nar/26.19.4382; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Jiang WN, 1997, J BIOL CHEM, V272, P196; KARPEL RL, 1980, BIOCHEMISTRY-US, V19, P4674, DOI 10.1021/bi00561a021; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LEE CG, 1993, J BIOL CHEM, V268, P13472; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Manival X, 2001, NUCLEIC ACIDS RES, V29, P2223, DOI 10.1093/nar/29.11.2223; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MINICH WB, 1990, MOL BIOL REP, V14, P65, DOI 10.1007/BF00360418; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; SABATH DE, 1990, J BIOL CHEM, V265, P12671; SAMARINA OP, 1968, J MOL BIOL, V33, P251, DOI 10.1016/0022-2836(68)90292-1; Shibao K, 1999, INT J CANCER, V83, P732; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Ustinov VA, 1996, BIOCHEMISTRY-MOSCOW+, V61, P414; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VANVENROOIJ WJ, 1977, NATURE, V270, P189, DOI 10.1038/270189a0; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8	64	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44841	44847		10.1074/jbc.M107581200	http://dx.doi.org/10.1074/jbc.M107581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11585833	hybrid			2022-12-25	WOS:000172406700069
J	Weiss, JL; Burgoyne, RD				Weiss, JL; Burgoyne, RD			Voltage-independent inhibition of P/Q-type Ca2+ channels in adrenal chromaffin cells via a neuronal Ca2+ sensor-1-dependent pathway involves Src family tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNELS; G-PROTEIN; BINDING-PROTEINS; SENSOR 1; MODULATION; CURRENTS; STIMULATION; ACTIVATION; EXOCYTOSIS; FREQUENIN	In common with many neurons, adrenal chromaffin cells possess distinct voltage-dependent and voltage-independent pathways for Ca2+ channel regulation. In this study, the voltage-independent pathway was revealed by addition of naloxone and suramin to remove tonic blockade of Ca2+ currents via opioid and purinergic receptors due to autocrine feedback inhibition. This pathway requires the Ca2+-binding protein neuronal calcium sensor-1 (NCS-1). The voltage-dependent pathway was pertussis toxin-sensitive, whereas the voltage-independent pathway was largely pertussis toxin-insensitive. Characterization of the voltage-independent inhibition of Ca2+ currents revealed that it did not involve protein kinase C-dependent signaling pathways but did require the activity of a Src family tyrosine kinase. Two structurally distinct Src kinase inhibitors, 4-amino-5-(4-methylphenyl)7-(t-butyl)pyrazolo[3,4-d] pyrimidine (PP1) and a Src inhibitory peptide, increased the Ca2+ currents, and no further increase in Ca2+ currents was elicited by addition of naloxone and suramin. In addition, the Src-like kinase appeared to act in the same pathway as NCS-1. In contrast, addition of PP1 did not prevent a voltage-dependent facilitation elicited by a strong pre-pulse depolarization indicating that this pathway was independent of Src kinase activity. PPI no longer increased Ca2+ currents after addition of the P/Q-type channel blocker omega -agatoxin TK. The alpha (1A) subunit of P/Q-type Ca2+ channels was immunoprecipitated from chromaffin cell extracts and found to be phosphorylated in a PP1-sensitive manner by endogenous kinases in the immunoprecipitate. A high molecular mass (around 220 kDa) form of the alpha (1A) subunit was detected by anti-phosphotyrosine, suggesting a possible target for Src family kinase action. These data demonstrate a voltage-independent mechanism for autocrine inhibition of P/Q-type Ca2+ channel currents in chromaffin cells that requires Src family kinase activity and suggests that this may be a widely distributed pathway for Ca2+ channel regulation.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Burgoyne, Robert/C-6706-2008; Weiss, Jamie/HHS-2536-2022; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387; Weiss, Jamie L/0000-0001-6784-5831				ALBILLOS A, 1993, FEBS LETT, V336, P259, DOI 10.1016/0014-5793(93)80815-C; Albillos A, 1996, J PHYSIOL-LONDON, V494, P687, DOI 10.1113/jphysiol.1996.sp021524; Allen CM, 1996, J NEUROSCI RES, V44, P421, DOI 10.1002/(SICI)1097-4547(19960601)44:5<421::AID-JNR2>3.0.CO;2-H; BEECH DJ, 1991, P NATL ACAD SCI USA, V88, P652, DOI 10.1073/pnas.88.2.652; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; Burgoyne RD, 2001, BIOCHEM J, V353, P1; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Carabelli V, 1998, NEURON, V20, P1255, DOI 10.1016/S0896-6273(00)80505-X; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CENA V, 1991, J MEMBRANE BIOL, V122, P23, DOI 10.1007/BF01872736; Currie KPM, 2000, J NEUROPHYSIOL, V83, P1435, DOI 10.1152/jn.2000.83.3.1435; Currie KPM, 1997, J NEUROSCI, V17, P4570; Currie KPM, 1996, NEURON, V16, P1027, DOI 10.1016/S0896-6273(00)80126-9; Delmas P, 1998, EUR J NEUROSCI, V10, P1654, DOI 10.1046/j.1460-9568.1998.00170.x; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; DIVERSEPIERLUISSI M, 1991, P NATL ACAD SCI USA, V88, P1261, DOI 10.1073/pnas.88.4.1261; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; DOUPNIK CA, 1994, J MEMBRANE BIOL, V140, P47; Dunlap KL, 1998, SEMIN NEUROSCI, V9, P198, DOI 10.1006/smns.1997.0119; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Evans GJO, 1999, EUR J NEUROSCI, V11, P279, DOI 10.1046/j.1460-9568.1999.00427.x; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Kammermeier PJ, 2000, J NEUROSCI, V20, P5623, DOI 10.1523/JNEUROSCI.20-15-05623.2000; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; Perroy J, 2000, J NEUROSCI, V20, P7896; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Powell AD, 2000, J NEUROSCI, V20, P606, DOI 10.1523/JNEUROSCI.20-02-00606.2000; RANE SG, 1986, P NATL ACAD SCI USA, V83, P184, DOI 10.1073/pnas.83.1.184; SAKURAI T, 1995, J BIOL CHEM, V270, P21234, DOI 10.1074/jbc.270.36.21234; SATO K, 1990, BIOCHEM BIOPH RES CO, V171, P1152, DOI 10.1016/0006-291X(90)90805-W; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Shapiro MS, 1999, P NATL ACAD SCI USA, V96, P10899, DOI 10.1073/pnas.96.19.10899; TERAMOTO T, 1993, BIOCHEM BIOPH RES CO, V196, P134, DOI 10.1006/bbrc.1993.2225; TWITCHELL WA, 1993, NEURON, V10, P701, DOI 10.1016/0896-6273(93)90171-M; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Wijetunge S, 2000, BRIT J PHARMACOL, V129, P1347, DOI 10.1038/sj.bjp.0703186; Winkler H, 1998, CELL MOL NEUROBIOL, V18, P193, DOI 10.1023/A:1022516919932; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	55	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44804	44811		10.1074/jbc.M103262200	http://dx.doi.org/10.1074/jbc.M103262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11583988	hybrid			2022-12-25	WOS:000172406700064
J	Yu, CJ; Kim, SH; Ikeuchi, T; Xu, HX; Gasparini, L; Wang, R; Sisodia, SS				Yu, CJ; Kim, SH; Ikeuchi, T; Xu, HX; Gasparini, L; Wang, R; Sisodia, SS			Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma - Evidence for distinct mechanisms involved in gamma-secretase processing or the APP and Notch1 transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; INTRACELLULAR DOMAIN; CLEAVAGE; ENDOPROTEOLYSIS; MEMBRANE; RELEASE; CELLS; COMPARTMENTS; PROTEOLYSIS; DEFICIENCY	A variety of investigations have led to the conclusion that presenilins (PS) play a critical role in intramembranous, gamma -secretase proteolysis of selected type I membrane proteins, including Notch1 and amyloid precursor protein (APP). We now show that the generation of the S3/Notch intracellular domain and APP-carboxyl-terminal fragment gamma (CTF gamma) derivatives are dependent on PS expression and inhibited by a highly selective and potent gamma -secretase inhibitor. Unexpectedly, the APP-CTF-gamma derivative is generated by processing between Leu-645 and Val-646 (of APP(695)), several amino acids carboxyl-terminal to the scissile bonds for production of amyloid beta protein peptides. Although the relationship of APP-CTF gamma to the production of amyloid beta protein peptides is not known, we conclude that in contrast to the highly selective PS-dependent processing of Notch, the PS-dependent gamma -secretase processing of APP is largely nonselective and occurs at multiple sites within the APP transmembrane domain.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Rockefeller Univ, Dept Mol & Cellular Neurosci, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry, New York, NY 10021 USA	University of Chicago; Rockefeller University; Rockefeller University	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.		Xu, Huaxi/AAV-7177-2021; Wang, Rong/A-8721-2009; Yu, Chunjiang/E-9419-2012; Gasparini, Laura/G-7711-2011	Gasparini, Laura/0000-0003-3894-9898	NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG14248, P01 AG014248] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lamb BT, 1999, NAT NEUROSCI, V2, P695, DOI 10.1038/11154; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; McLendon C, 2000, FASEB J, V14, P2383; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	38	190	196	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43756	43760		10.1074/jbc.C100410200	http://dx.doi.org/10.1074/jbc.C100410200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11583985	hybrid			2022-12-25	WOS:000172297700037
J	Pavey, S; Russell, T; Gabrielli, B				Pavey, S; Russell, T; Gabrielli, B			G2 phase cell cycle arrest in human skin following UV irradiation	ONCOGENE			English	Article						p16; UV; skin; G2 checkpoint	ULTRAVIOLET-RADIATION; HUMAN MELANOCYTES; G(1) ARREST; HUMAN KERATINOCYTES; MSH RECEPTORS; GROWTH-FACTOR; DNA-DAMAGE; EXPRESSION; KINASE; MELANOGENESIS	The contribution of the short wavelength ultraviolet (UV) component of sunlight to the aetiology of skin cancer has been widely acknowledged, although its direct contribution to tumour initiation or progression is still poorly understood. The loss of normal cell cycle controls, particularly checkpoint controls, are a common feature of cancer. UV radiation causes both GI and G2 phase checkpoint arrest in vitro cultured cells. In this study we have investigated the cell cycle responses to suberythemal doses of UV on skin. We have utilized short-term whole organ skin cultures, and multi parameter immunohistochemical and biochemical analysis to demonstrate that basal and suprabasal layer melanocytes and keratinocytes undergo a G2 phase cell cycle arrest for up to 48 h following irradiation. The arrest is associated with increased p16 expression but no apparent p53 involvement. This type of organ culture provides a very useful model system, combining the ease of in vitro manipulation with the ability to perform detailed molecular analysis in a normal tissue environment.	Univ Queensland, Sch Med, Dept Pathol, Joint Expt Oncol Program, Brisbane, Qld 4006, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Joint Expt Oncol Program, Herston Rd, Brisbane, Qld 4006, Australia.		Pavey, Sandra/B-3662-2011; Gabrielli, Brian G/B-3655-2011	Pavey, Sandra/0000-0003-4519-5932; Gabrielli, Brian G/0000-0003-3933-1651				CAMPBELL C, 1993, CANCER RES, V53, P2697; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; CHAKRABORTY A, 1993, J CELL PHYSIOL, V157, P344, DOI 10.1002/jcp.1041570218; Chakraborty AK, 1999, ANN NY ACAD SCI, V885, P100; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; FREEMAN SE, 1987, J INVEST DERMATOL, V88, P430, DOI 10.1111/1523-1747.ep12469778; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; Haddad MM, 1999, EXP CELL RES, V253, P561, DOI 10.1006/excr.1999.4688; HERZINGER T, 1995, ONCOGENE, V11, P2151; HONIGSMANN H, 1987, J PHOTOCH PHOTOBIO B, V1, P33, DOI 10.1016/1011-1344(87)80004-0; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Im SB, 1998, CANCER RES, V58, P47; IYENGAR B, 1994, MELANOMA RES, V4, P293; LEY KD, 1992, CARCINOGENESIS, V13, P183, DOI 10.1093/carcin/13.2.183; LIBOW LF, 1988, PIGM CELL RES, V1, P397, DOI 10.1111/j.1600-0749.1988.tb00142.x; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCLANE JA, 1988, BIOCHEMISTRY-US, V27, P3743, DOI 10.1021/bi00410a033; MEDRANO EE, 1995, CANCER RES, V55, P4047; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Pavey S, 1999, CANCER RES, V59, P4185; Petrocelli T, 1996, ONCOGENE, V12, P1387; QUEVEDO WC, 1969, AM ZOOL, V9, P531; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; TAM SW, 1994, CANCER RES, V54, P5816; Thody AJ, 1998, PIGM CELL RES, V11, P265, DOI 10.1111/j.1600-0749.1998.tb00735.x; Wang XQ, 1996, CANCER RES, V56, P2510; Watters D, 1998, BIOCHEM PHARMACOL, V55, P1691, DOI 10.1016/S0006-2952(97)00680-1; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	40	56	59	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6103	6110		10.1038/sj.onc.1204707	http://dx.doi.org/10.1038/sj.onc.1204707			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593418				2022-12-25	WOS:000171206300001
J	Ishima, R; Ghirlando, R; Tozser, J; Gronenborn, AM; Torchia, DA; Louis, JM				Ishima, R; Ghirlando, R; Tozser, J; Gronenborn, AM; Torchia, DA; Louis, JM			Folded monomer of HIV-1 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-RESONANCE NMR; RETROVIRAL PROTEASES; HUMAN-IMMUNODEFICIENCY; DRUG-RESISTANCE; INHIBITORS; KINETICS; SPECTROSCOPY; PROTEINASES; FLEXIBILITY; RELAXATION	The mature human immunodeficiency virus type 1 protease rapidly folds into an enzymatically active stable dimer, exhibiting an intricate interplay between structure formation and dimerization. We now show by NMR and sedimentation equilibrium studies that a mutant protease containing the R87K substitution (PRR87K) within the highly conserved Gly(86)-Arg(87)-Asn(88) sequence forms a monomer with a fold similar to a single subunit of the dimer. However, binding of the inhibitor DMP323 to PRR87K produces a stable dimer complex. Based on the crystal structure and our NMR results, we postulate that loss of specific interactions involving the side chain of Arg(87) destabilizes PRR87K by perturbing the inner C-terminal beta-sheet (residues 96-99 from each monomer), a region that is sandwiched between the two beta-strands formed by the N-terminal residues (residues 1-4) in the mature protease. We systematically examined the folding, dimerization, and catalytic activities of mutant proteases comprising deletions of either one of the terminal regions (residues 1-4 or 96-99) or both. Although both N- and C-terminal P-strands were found to contribute to dimer stability, our results indicate that the inner C-terminal strands are absolutely essential for dimer formation. Knowledge of the monomer fold and regions critical for dimerization may aid in the rational design of novel inhibitors of the protease to overcome the problem of drug resistance.	NIDDK, Phys Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Struct Mol Biol Unit, NIH, Bethesda, MD 20892 USA; Univ Debrecen, Fac Med, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Debrecen	Louis, JM (corresponding author), NIDDK, Phys Chem Lab, NIH, Rm 411,Bldg 5, Bethesda, MD 20892 USA.	jmlouis@helix.nih.gov	Tozser, Jozsef/A-7840-2008; Ghirlando, Rodolfo/A-8880-2009	Tozser, Jozsef/0000-0003-0274-0056; Tozser, Jozsef/0000-0001-5076-8729; Gronenborn, Angela M/0000-0001-9072-3525; Louis, John M/0000-0002-0052-1899	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029022, Z01DK029025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ala PJ, 1997, BIOCHEMISTRY-US, V36, P1573, DOI 10.1021/bi962234u; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erickson JW, 1999, AIDS, V13, pS189; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5; Ishima R, 2001, J MOL BIOL, V305, P515, DOI 10.1006/jmbi.2000.4321; Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; Louis JM, 1999, NAT STRUCT BIOL, V6, P868; LOUIS JM, 1989, BIOCHEM BIOPH RES CO, V159, P87, DOI 10.1016/0006-291X(89)92408-X; Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437; Mahalingam B, 1999, EUR J BIOCHEM, V263, P238, DOI 10.1046/j.1432-1327.1999.00514.x; MILDNER AM, 1994, BIOCHEMISTRY-US, V33, P9405, DOI 10.1021/bi00198a005; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PARIKH U, 2000, 2000 HIV SEQUENCE CO, P125; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RAO JKM, 1991, BIOCHEMISTRY-US, V30, P4663, DOI 10.1021/bi00233a005; Rose RB, 1998, BIOCHEMISTRY-US, V37, P2607, DOI 10.1021/bi9716074; Schatz GW, 2001, J VIROL, V75, P4761, DOI 10.1128/JVI.75.10.4761-4770.2001; Shultz MD, 1999, BIOORG MED CHEM LETT, V9, P2431, DOI 10.1016/S0960-894X(99)00400-X; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176; Yamazaki T, 1996, PROTEIN SCI, V5, P495; Zutshi R, 2000, BIOORG MED CHEM LETT, V10, P1901, DOI 10.1016/S0960-894X(00)00369-3	34	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49110	49116		10.1074/jbc.M108136200	http://dx.doi.org/10.1074/jbc.M108136200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598128	hybrid			2022-12-25	WOS:000173922100065
J	Truty, J; Malpe, R; Linder, MC				Truty, J; Malpe, R; Linder, MC			Iron prevents ferritin turnover in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DEGRADATION; LIVER; EXPRESSION; MECHANISM; PROTEINS	It has long been assumed that iron regulates the turnover of ferritin, but evidence for or against this idea has been lacking. This issue was addressed using rat hepatoma cells with characteristics of hepatocytes subjected to a continuous influx of iron. Iron-pretreated cells were pulsed with [S-35]Met for 60 min or with Fe-59 overnight and harvested up to 30 h thereafter, during which they were/were not cultured with ferric ammonium citrate (FAC; 180 muM). Radioactivity in ferritin/ferritin subunits of cell heat supernatants was determined by autoradiography of rockets obtained by immunoelectrophoresis or after precipitation with ferritin antibody and SDS-PAGE. Both methods gave similar results. During the +FAC chase, the concentration of ferritin in the cells increased linearly with time. Without FAC, the half-life of S-35-ferritin was 19-20 h; with FAC there was no turnover. Without FAC, the iron in ferritin had an apparent half-life of 20 h; in the presence of FAC there was no loss of Fe-59. Without FAC, concentrations of ferritin iron and protein also decreased in parallel. We conclude that a continuous influx of excess iron can completely inhibit the degradation of ferritin protein and that the iron and protein portions of ferritin molecules may be coordinately degraded.	Calif State Univ Fullerton, Dept Chem & Biochem, Fullerton, CA 92834 USA; Calif State Univ Fullerton, Inst Mol Biol, Fullerton, CA 92834 USA	California State University System; California State University Fullerton; California State University System; California State University Fullerton	Linder, MC (corresponding author), Calif State Univ Fullerton, Dept Chem & Biochem, Fullerton, CA 92834 USA.	mlinder@fullerton.edu			NIDDK NIH HHS [R01 DK 53080, DK53080] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053080] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLBERG J, 1985, J BIOL CHEM, V260, P5847; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Cerveza PJ, 2000, ARCH BIOCHEM BIOPHYS, V373, P451, DOI 10.1006/abbi.1999.1572; Cuervo AM, 2000, EXP GERONTOL, V35, P119, DOI 10.1016/S0531-5565(00)00075-9; Cuervo Ana Maria, 1998, Frontiers in Bioscience, V3, pD25; DRYSDALE JW, 1966, J BIOL CHEM, V241, P3630; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Haile DJ, 1999, AM J MED SCI, V318, P230, DOI 10.1097/00000441-199910000-00003; James W., 1958, AM J CLIN PATHOL, V29, P590; Kakhlon O, 2001, BLOOD, V97, P2863, DOI 10.1182/blood.V97.9.2863; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOHGO Y, 1980, J BIOL CHEM, V255, P5195; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LINDER MC, 1973, BIOCHIM BIOPHYS ACTA, V297, P70, DOI 10.1016/0304-4165(73)90050-0; MORTIMORE GE, 1988, J BIOL CHEM, V263, P2506; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; OVE P, 1972, BIOCHIM BIOPHYS ACTA, V277, P211, DOI 10.1016/0005-2787(72)90367-X; Ponka P, 1999, KIDNEY INT, V55, pS2, DOI 10.1046/j.1523-1755.1999.055Suppl.69002.x; Radisky DC, 1998, BIOCHEM J, V336, P201, DOI 10.1042/bj3360201; RITTLING SR, 1984, J BIOL CHEM, V259, P5561; ROBERTS S, 1988, J BIOL CHEM, V263, P19181; SCHIMKE RT, 1964, J BIOL CHEM, V239, P3808; SCHIMKE RT, 1965, J BIOL CHEM, V240, P322; THEIL EC, 1993, BIOFACTORS, V4, P87; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Theil EC, 2000, BIOCHEM PHARMACOL, V59, P87, DOI 10.1016/S0006-2952(99)00300-7; Tran TN, 1997, BLOOD, V90, P4979, DOI 10.1182/blood.V90.12.4979.4979_4979_4986; TREFFRY A, 1984, BIOCHEM J, V220, P857, DOI 10.1042/bj2200857; TREFFRY A, 1984, FEBS LETT, V165, P243, DOI 10.1016/0014-5793(84)80177-5; Vaisman B, 2000, BRIT J HAEMATOL, V110, P394, DOI 10.1046/j.1365-2141.2000.02167.x; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857	32	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48775	48780		10.1074/jbc.M105392200	http://dx.doi.org/10.1074/jbc.M105392200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11606570	hybrid			2022-12-25	WOS:000173922100022
J	Yuan, Y; Shen, ZY				Yuan, Y; Shen, ZY			Interaction with BRCA2 suggests a role for filamin-1 (hsFLNa) in DNA damage response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN-280; MITOTIC CHECKPOINT; CANCER; BREAST; RAD51; RADIATION; ABP-280; MICE; HYPERSENSITIVITY; PHOSPHORYLATION	The BRCA2 tumor suppressor plays significant roles in DNA damage response. The human actin binding protein filamin-1 (hsFLNa, also known as ABP-280) participates in orthogonal actin network, cellular stress responses, signal transduction, and cell migration. Through a yeast two-hybrid system, an in vitro binding assay, and in vivo co-immunoprecipitations, we identified an interaction between BRCA2 and hsFLNa. The hsFLNa binding domain of BRCA2 was mapped to an internal conserved region, and the BRCA2-interacting domain of hsFLNa was mapped to its C terminus. Although hsFLNa is known for its cytoplasmic functions in cell migration and signal transduction, some hsFLNa resides in the nucleus, raising the possibility that it participates in DNA damage response through a nuclear interaction with BRCA2. Lack of hsFLNa renders a human melanoma cell line (M2) more sensitive to several genotoxic agents including gamma irradiation, bleomycin, and ultraviolet-c light. These results suggest that BRCA2/hsFLNa interaction may serve to connect cytoskeletal signal transduction to DNA damage response pathways.	Univ New Mexico, Sch Med, Dept Mol Biol & Microbiol, Albuquerque, NM 87131 USA; Univ Illinois, Sch Med, Dept Mol Genet, Grad Program, Chicago, IL 60607 USA	University of New Mexico; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Shen, ZY (corresponding author), Univ New Mexico, Sch Med, Dept Mol Biol & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.	zshen@salud.unm.edu		Shen, Zhiyuan/0000-0003-2834-0309	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008353, R29ES008353] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES08353] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bertwistle D, 1997, CANCER RES, V57, P5485; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Friedman LS, 1998, CANCER RES, V58, P1338; Futamura M, 2000, CANCER RES, V60, P1531; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Jantti J, 1999, P NATL ACAD SCI USA, V96, P909, DOI 10.1073/pnas.96.3.909; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marscher AP, 1999, ASTROPART PHYS, V11, P19, DOI 10.1016/S0927-6505(99)00019-5; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; McAllister KA, 1997, CANCER RES, V57, P3121; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Morimatsu M, 1998, CANCER RES, V58, P3441; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Ohta Y, 1996, J BIOL CHEM, V271, P11858, DOI 10.1074/jbc.271.20.11858; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Shen ZY, 1996, MUTAT RES-DNA REPAIR, V364, P81, DOI 10.1016/0921-8777(96)00025-0; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Stossel TP, 1999, BIOCHEM SOC SYMP, V65, P267; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 1999, SCIENCE, V286, P1100, DOI 10.1126/science.286.5442.1100; Vidal M, 1997, ADV MOLEC BIOL, P109; Wang HC, 2001, CANCER RES, V61, P270; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	46	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48318	48324		10.1074/jbc.M102557200	http://dx.doi.org/10.1074/jbc.M102557200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602572	hybrid			2022-12-25	WOS:000172927000078
J	Zilka, A; Garlapati, S; Dahan, E; Yaolsky, V; Shapira, M				Zilka, A; Garlapati, S; Dahan, E; Yaolsky, V; Shapira, M			Developmental regulation of heat shock protein 83 in Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP70 MESSENGER-RNA; 3'-UNTRANSLATED REGION; MEXICANA-AMAZONENSIS; TRYPANOSOMA-BRUCEI; GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; STAR PROTEIN; TRANSLATION; DISRUPTION; LEADER	Developmental gene regulation in trypanosomatids proceeds exclusively by post-transcriptional mechanisms. Stability and abundance of heat shock protein (HSP)70 and HSP83 transcripts in Leishmania increase at mammalian-like temperatures, and their translation is enhanced. Here we report that the W-untranslated region (UTR) of HSP83 (886 nucleotides) confers the temperature-dependent pattern of regulation on a chloramphenicol acetyltransferase (CAT) reporter transcript. We also show that the majority of the 3'-UTR sequences are required for increasing mRNA stability during heat shock. Processing of the HSP70 and HSP83 primary transcripts to poly(A)(+) mRNA was more efficient during heat shock, therefore, even when stability at 33 degreesC was reduced by deletions in the 3'-UTR, transcripts still accumulated to comparable and even higher levels. Translation of heat shock transcripts in Leishmania increases dramatically upon temperature elevation. Unlike in other eukaryotes in which the 5'-UTR confers preferential translation on heat shock transcripts, we show that translational control of HSP83 in Leishmania originates from its 3'-UTR. The 5'-UTR alone cannot induce translation during heat shock, but it has a minor contribution when combined with the HSP83 3'-UTR. We identified an element located between positions 201 and 472 of the 3'-UTR which is essential for increasing translation of the CAT-HSP83 reporter RNA at 33-37 degreesC. This region confers preferential translation during heat shock even in transcripts that were less stable. Thus, investigating the traditionally conserved heat shock response reveals that Leishmania parasites use unique pathways for translational control.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Shapira, M (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.			Shapira, Michal/0000-0002-6164-7874				ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; ALY R, 1993, GENE, V127, P155, DOI 10.1016/0378-1119(93)90714-E; ALY R, 1995, EXP PARASITOL, V80, P159; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; BOND U, 1988, EMBO J, V7, P3509, DOI 10.1002/j.1460-2075.1988.tb03227.x; Bracken AP, 1999, RNA, V5, P1586, DOI 10.1017/S1355838299991203; BRANDAU S, 1995, BIOCHEM J, V310, P225, DOI 10.1042/bj3100225; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; Dalgleish G, 2001, J BIOL CHEM, V276, P13593, DOI 10.1074/jbc.M001141200; DELLAVALLE RP, 1994, MOL CELL BIOL, V14, P3646, DOI 10.1128/MCB.14.6.3646; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Garlapati S, 1999, MOL BIOCHEM PARASIT, V100, P95, DOI 10.1016/S0166-6851(99)00037-7; HESS MA, 1994, J BIOL CHEM, V269, P10913; Hotz HR, 1998, MOL BIOCHEM PARASIT, V91, P131, DOI 10.1016/S0166-6851(97)00196-5; Jan E, 1999, EMBO J, V18, P258, DOI 10.1093/emboj/18.1.258; KAPOTAS N, 1993, NUCLEIC ACIDS RES, V21, P4067, DOI 10.1093/nar/21.17.4067; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Lee MGS, 1998, NUCLEIC ACIDS RES, V26, P4025, DOI 10.1093/nar/26.17.4025; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MUHICH ML, 1989, GENE, V82, P169, DOI 10.1016/0378-1119(89)90042-5; MUHICH ML, 1989, J BIOL CHEM, V264, P7107; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PETERSEN R, 1988, GENE, V72, P161, DOI 10.1016/0378-1119(88)90138-2; PINELLI E, 1990, EUR J BIOCHEM, V194, P685, DOI 10.1111/j.1432-1033.1990.tb15669.x; Quijada L, 2000, MOL BIOCHEM PARASIT, V110, P79, DOI 10.1016/S0166-6851(00)00258-9; Saccomanno L, 1999, P NATL ACAD SCI USA, V96, P12605, DOI 10.1073/pnas.96.22.12605; SAMARAS N, 1987, MOL BIOCHEM PARASIT, V25, P279, DOI 10.1016/0166-6851(87)90092-2; SHAPIRA M, 1990, MOL BIOCHEM PARASIT, V42, P247, DOI 10.1016/0166-6851(90)90168-L; SHAPIRA M, 1988, EMBO J, V7, P2895, DOI 10.1002/j.1460-2075.1988.tb03147.x; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; Vivinus S, 2001, EUR J BIOCHEM, V268, P1908, DOI 10.1046/j.1432-1327.2001.02064.x; Wharton RP, 1998, MOL CELL, V1, P863, DOI 10.1016/S1097-2765(00)80085-4; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; YOST HJ, 1991, MOL CELL BIOL, V11, P1062, DOI 10.1128/MCB.11.2.1062	43	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47922	47929		10.1074/jbc.M108271200	http://dx.doi.org/10.1074/jbc.M108271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11598129	hybrid			2022-12-25	WOS:000172927000028
J	Hullinger, TG; Panek, RL; Xu, XY; Karathanasis, SK				Hullinger, TG; Panek, RL; Xu, XY; Karathanasis, SK			p21-activated kinase-1 (PAK1) inhibition of the human scavenger receptor class B, type I promoter in macrophages is independent of PAK1 kinase activity, but requires the GTPase-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ACTIVATED PROTEIN-KINASE; NUCLEOTIDE EXCHANGE FACTORS; SR-BI; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; HUMAN MONOCYTES; HUMAN HOMOLOG; EXPRESSION; CDC42	Scavenger receptor class B, type I (SR-BI), is a high density lipoprotein receptor that mediates the flux of cholesterol between high density lipoprotein and cells. Recent evidence suggests that SR-Bl plays a role in atherosclerosis and that inflammatory mediators downregulate SR-BI in the macrophage. The purpose of this study was to evaluate the ability of lipopolysaccharide (LPS) to down-regulate the activity of the human SR-BI promoter in the macrophage and to delineate the mechanisms involved. Experiments with cultured cells and in vivo derived macrophages showed that LPS has a powerful suppressive effect on SR-BI expression both in vitro and in vivo. Transient transfection studies demonstrated that LPS represses SR-Bl promoter activity in the macrophage cell line RAW 264.7. Cotransfection with either a constitutively active p21-activated protein kinase-1 (PAK1) construct (T423E) or a kinase-deficient PAR1 construct (K299R) resulted in repression of the SR-BI promoter, similar to LPS. These results demonstrate that PAK1-mediated down-regulation of the SR-BI promoter is independent of PAKI kinase activity and suggest that PAKI mediates the LPS-induced decrease in promoter activity. Cotransfection with constitutively active Cdc42 or Rac expression constructs also resulted in down-regulation of the promoter; whereas the dominant-negative Cdc42 and Rac constructs elevated basal promoter activity and blunted the LPS response. Cotransfection of PAK1 constructs containing mutations in both the kinase domain and the Cdc42/Rac-binding domain attenuated the PAR1-mediated downregulation of the promoter, suggesting that Rac and Cdc42 are required for PAK1-mediated decreases in SR-Bl promoter activity. 5'-Deletion analysis and gel shift data suggest that LPS inhibits binding of a novel transcription factor to a myeloid zing finger protein-1-like element (-476 to -456) in the human SR-BI promoter. These results demonstrate that the PAK1 pathway down-regulates the SR-BI promoter and suggest that activation of this pathway may play an important role in cholesterol trafficking in the vessel wall.	Pfizer Global Res & Dev, Dept Cardiovasc Pharmacol, Ann Arbor, MI 48105 USA	Pfizer	Hullinger, TG (corresponding author), Pfizer Global Res & Dev, Cardiovasc Therapeut Dept, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.							Abraham LA, 1998, J BONE MINER RES, V13, P818, DOI 10.1359/jbmr.1998.13.5.818; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Azim AC, 2000, BLOOD, V95, P959, DOI 10.1182/blood.V95.3.959.003k22_959_964; Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buechler C, 1999, BIOCHEM BIOPH RES CO, V262, P251, DOI 10.1006/bbrc.1999.1193; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Fluiter K, 1998, J BIOL CHEM, V273, P8434, DOI 10.1074/jbc.273.14.8434; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Haeffner A, 1997, J IMMUNOL, V158, P1310; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hirano K, 1999, CIRC RES, V85, P108; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Liu JQ, 1997, J CLIN ENDOCR METAB, V82, P2522, DOI 10.1210/jc.82.8.2522; Lopez D, 1999, ENDOCRINOLOGY, V140, P5669, DOI 10.1210/en.140.12.5669; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mizutani T, 2000, J BIOL CHEM, V275, P22512, DOI 10.1074/jbc.M001631200; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782; Zhu W, 2000, J IMMUNOL, V164, P6349, DOI 10.4049/jimmunol.164.12.6349	49	13	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46807	46814		10.1074/jbc.M103176200	http://dx.doi.org/10.1074/jbc.M103176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585816	hybrid			2022-12-25	WOS:000172768500019
J	Kawasaki-Nishi, S; Bowers, K; Nishi, T; Forgac, M; Stevens, TH				Kawasaki-Nishi, S; Bowers, K; Nishi, T; Forgac, M; Stevens, TH			The amino-terminal domain of the vacuolar proton-translocating ATPase a subunit controls targeting and in vivo dissociation, and the carboxyl-terminal domain affects coupling of proton transport and ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST V-ATPASE; H+-ATPASE; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; SORTING RECEPTOR; PREVACUOLAR COMPARTMENT; LUMINAL ACIDIFICATION; CARBOXYPEPTIDASE-Y; STRUCTURAL-CHANGES; CDNA SEQUENCE	The 100-kDa "a" subunit of the vacuolar proton-translocating ATPase (V-ATPase) is encoded by two genes in yeast, VPII1 and STV1. The Vph1p-containing complex localizes to the vacuole, whereas the Stv1p-containing complex resides in some other intracellular compartment, suggesting that the a subunit contains information necessary for the correct targeting of the V-ATPase. We show that Stv1p localizes to a late Golgi compartment at steady state and cycles continuously via a prevacuolar endosome back to the Golgi. V-ATPase complexes containing Vph1p and Stv1p also differ in their assembly properties, coupling of proton transport to ATP hydrolysis, and dissociation in response to glucose depletion. To identify the regions of the a subunit that specify these different properties, chimeras were constructed containing the cytosolic amino-terminal domain of one isoform and the integral membrane, carboxyl-terminal domain from the other isoform. Like the Stv1p-containing complex, the V-ATPase complex containing the chimera with the amino-terminal domain of Stv1p localized to the Golgi and the complex did not dissociate in response to glucose depletion. Like the Vph1p-containing complex, the V-ATPase complex containing the chimera with the amino-terminal domain of Vph1p localized to the vacuole and the complex exhibited normal dissociation upon glucose withdrawal. Interestingly, the V-ATPase complex containing the chimera with the carboxyl-terminal domain of Vph1p exhibited a higher coupling of proton transport to ATP hydrolysis than the chimera containing the carboxyl-terminal domain of Stv1p. Our results suggest that whereas targeting and in vivo dissociation are controlled by sequences located in the amino-terminal domains of the subunit a isoforms, coupling efficiency is controlled by the carboxyl-terminal region.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	Tufts University; University of Oregon	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu	Bowers, Katherine/U-2013-2019	Bowers, Katherine/0000-0001-5085-5208; Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006, R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [GM 38006, GM 34478, R01 GM034478, R37 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brickner JH, 1997, J CELL BIOL, V139, P23, DOI 10.1083/jcb.139.1.23; Brown D, 2000, J EXP BIOL, V203, P137; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; Bryant NJ, 1998, J CELL BIOL, V142, P651, DOI 10.1083/jcb.142.3.651; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; Gerrard SR, 2000, TRAFFIC, V1, P45, DOI 10.1034/j.1600-0854.2000.010108.x; Graham LA, 2000, J EXP BIOL, V203, P61; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MORANO KA, 1994, J CELL SCI, V107, P2813; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rossanese OW, 2001, J CELL BIOL, V153, P47, DOI 10.1083/jcb.153.1.47; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wieczorek H, 2000, J EXP BIOL, V203, P127; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	68	192	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47411	47420		10.1074/jbc.M108310200	http://dx.doi.org/10.1074/jbc.M108310200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592965	hybrid			2022-12-25	WOS:000172768500097
J	Lam, M; Oleinick, NL; Nieminen, AL				Lam, M; Oleinick, NL; Nieminen, AL			Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells - Reactive oxygen species and mitochondrial inner membrane permeabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; TRANSITION PORE; CYCLOSPORINE-A; LETHAL INJURY; RELEASE; LOCALIZATION; HEPATOCYTES; DEATH; ACTIVATION; INHIBITION	Photodynamic therapy (PDT), a novel and promising cancer treatment that employs a combination of a photosensitizing chemical and visible light, induces apoptosis in human epidermoid carcinoma A431 cells. However, the precise mechanism of PDT-induced apoptosis is not well characterized. To dissect the pathways of PDT-induced apoptosis, we investigated the involvement of mitochondrial damage by examining a second generation photosensitizer, the silicon phthalocyanine 4 (Pc 4). By using laser-scanning confocal microscopy, we found that Pc 4 localized to cytosolic membranes primarily, but not exclusively, in mitochondria. Formation of mitochondrial reactive oxygen species (ROS) was detected within minutes when cells were exposed to Pc 4 and 670-675 nm light. This was followed by mitochondrial inner membrane permeabilization, depolarization and swelling, cytochrome c release, and apoptotic death. Desferrioxamine prevented mitochondrial ROS production and the events thereafter. Cyclosporin A plus trifluoperazine, blockers of the mitochondrial permeability transition, inhibited mitochondrial inner membrane permeabilization and depolarization without affecting mitochondrial ROS generation. These data indicate that the mitochondrial ROS are critical in initiating mitochondrial inner membrane permeabilization, which leads to mitochondrial swelling, cytochrome c release to the cytosol, and apoptotic death during PDT with Pc 4.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Nieminen, AL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Anat, W520,10900 Euclid Ave, Cleveland, OH 44106 USA.	axn25@po.cwru.edu			NCI NIH HHS [T32 CA 59366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; BERG K, 1994, INT J CANCER, V59, P814, DOI 10.1002/ijc.2910590618; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Chen JY, 2000, PHOTOCHEM PHOTOBIOL, V72, P541, DOI 10.1562/0031-8655(2000)072<0541:TBCAIL>2.0.CO;2; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Chiu SM, 2001, CANCER LETT, V165, P51, DOI 10.1016/S0304-3835(01)00422-0; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; DOUGHERTY TJ, 1992, EUR J CANCER, V28A, P1734, DOI 10.1016/0959-8049(92)90080-L; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; He J, 1997, PHOTOCHEM PHOTOBIOL, V65, P581; HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lam M, 1998, J BIOL CHEM, V273, P17307, DOI 10.1074/jbc.273.28.17307; Lemasters JJ, 1999, BIOCHEM SOC SYMP, V66, P205, DOI 10.1042/bss0660205; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; POHFITZPATRICK MB, 1986, PHOTODERMATOLOGY, V3, P148; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RICCHELLI F, 1995, EUR J BIOCHEM, V233, P165, DOI 10.1111/j.1432-1033.1995.165_1.x; Ricchelli F, 1999, BIOCHEMISTRY-US, V38, P9295, DOI 10.1021/bi9900828; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Taguchi H, 1996, INVEST OPHTH VIS SCI, V37, P1444; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	58	258	281	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47379	47386		10.1074/jbc.M107678200	http://dx.doi.org/10.1074/jbc.M107678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579101	hybrid			2022-12-25	WOS:000172768500093
J	Pudota, BN; Hommema, EL; Hallgren, KW; McNally, BA; Lee, S; Berkner, KL				Pudota, BN; Hommema, EL; Hallgren, KW; McNally, BA; Lee, S; Berkner, KL			Identification of sequences within the gamma-carboxylase that represent a novel contact site with vitamin K-dependent proteins and that are required for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMATIC MUTATIONAL ANALYSIS; BLOOD-COAGULATION FACTORS; PROPEPTIDE BINDING-SITE; GLUTAMYL CARBOXYLASE; FACTOR-IX; CARBOXYGLUTAMIC-ACID; MAMMALIAN-CELLS; PARTIAL-PURIFICATION; COMBINED DEFICIENCY; RECOGNITION SITE	The vitamin K-dependent (VKD) carboxylase converts clusters of Glu residues to gamma -carboxylated Glu residues (Glas) in VKD proteins, which is required for their activity. VKD precursors are targeted to the carboxylase by their carboxylase recognition site, which in most cases is a propeptide. We have identified a second tethering site for carboxylase and VKD proteins that is required for carboxylase activity, called the vitamin K-dependent protein site of interaction (VKS). Several VKD proteins specifically bound an immobilized peptide comprising amino acids 343-355 of the human carboxylase (CVYKRSRGKSGQK) but not a scrambled peptide containing the same residues in a different order. Association with the 343-355 peptide was independent of propeptide binding, because the VKD proteins lacked the propeptide and because the 343-355 peptide did not disrupt association of a propeptide factor IX-carboxylase complex, Analysis with peptides that overlapped amino acids 343-355 indicated that the 343-345 CVY residues were necessary but not sufficient for prothrombin binding. Ionic interactions were also suggested because peptide-VKD protein binding could be disrupted by changes in ionic strength or pH. Mutagenesis Of Cys(343) to Ser and Tyr(345) to Phe resulted in 7-11-fold decreases in vitamin K epoxidation and peptide (EEL) substrate and carboxylase carboxylation, and kinetic analysis showed 5-6-fold increases in K-m values for the Glusubstrate. These results suggest that Cys(343) and Tyr(345) are near the catalytic center and affect the active site conformation required for correct positioning of the Glu substrate. The 343-355 VKS peptide had a higher affinity for carboxylated prothrombin (K-d = 5 mum) than uncarboxylated prothrombin (K-d = 60 mum), and the basic VKS region may also facilitate exiting of the Gla product from the catalytic center by ionic attraction. Tethering of VKD proteins to the carboxylase via the propeptide-binding site and the VKS region has important implications for the mechanism of VKD protein carboxylation, and a model is proposed for how the carboxylase VKS region may be required for efficient and processive VKD protein carboxylation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Berkner, KL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.			Berkner, Kathleen/0000-0001-8054-8081	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055666] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 55666] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; BANFIELD DK, 1994, J MOL EVOL, V38, P177, DOI 10.1007/BF00166164; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; Begley GS, 2000, J BIOL CHEM, V275, P36245, DOI 10.1074/jbc.M003944200; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; Berkner KL, 2000, J NUTR, V130, P1877, DOI 10.1093/jn/130.8.1877; Berkner KL, 1997, METHOD ENZYMOL, V282, P313; BERKNER KL, 1993, METHOD ENZYMOL, V222, P450; Berkner KL, 1998, P NATL ACAD SCI USA, V95, P466, DOI 10.1073/pnas.95.2.466; Brenner B, 1998, BLOOD, V92, P4554, DOI 10.1182/blood.V92.12.4554.424k42_4554_4559; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; CANFIELD LM, 1987, BIOCHEM BIOPH RES CO, V148, P184, DOI 10.1016/0006-291X(87)91093-X; Chu K, 1996, J CLIN INVEST, V98, P1619, DOI 10.1172/JCI118956; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DEMETZ M, 1981, FEBS LETT, V123, P215, DOI 10.1016/0014-5793(81)80290-6; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HARBECK MC, 1989, THROMB RES, V56, P317, DOI 10.1016/0049-3848(89)90173-4; Houben RJTJ, 1999, BIOCHEM J, V341, P265, DOI 10.1042/0264-6021:3410265; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; Lingenfelter SE, 1996, BIOCHEMISTRY-US, V35, P8234, DOI 10.1021/bi9523318; Lirazan MB, 2000, BIOCHEMISTRY-US, V39, P1583, DOI 10.1021/bi9923712; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; PRICE PA, 1984, ANAL BIOCHEM, V136, P119, DOI 10.1016/0003-2697(84)90313-0; Pudota BN, 2000, P NATL ACAD SCI USA, V97, P13033, DOI 10.1073/pnas.97.24.13033; Romero EE, 1998, BIOCHEM BIOPH RES CO, V248, P783, DOI 10.1006/bbrc.1998.8987; ROTH DA, 1993, P NATL ACAD SCI USA, V90, P8372, DOI 10.1073/pnas.90.18.8372; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V251, P22, DOI 10.1006/bbrc.1998.9410; Spronk HMH, 2000, BLOOD, V96, P3650; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; Stenina O, 2001, BIOCHEMISTRY-US, V40, P10301, DOI 10.1021/bi0107039; Sugiura I, 1996, J BIOL CHEM, V271, P17837, DOI 10.1074/jbc.271.30.17837; SWANSON JC, 1982, BIOCHEMISTRY-US, V21, P6011, DOI 10.1021/bi00266a044; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; Walker CS, 2001, J BIOL CHEM, V276, P7769, DOI 10.1074/jbc.M009576200; WERTMAN KF, 1992, GENETICS, V132, P337; Wu SM, 1997, J BIOL CHEM, V272, P11718, DOI 10.1074/jbc.272.18.11718; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P481, DOI 10.1021/bi00002a012; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009	51	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46878	46886		10.1074/jbc.M108696200	http://dx.doi.org/10.1074/jbc.M108696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591726	hybrid			2022-12-25	WOS:000172768500029
J	Chen, YB; Yoo, B; Lee, JB; Weng, GZ; Iyengar, R				Chen, YB; Yoo, B; Lee, JB; Weng, GZ; Iyengar, R			The signal transfer regions of G alpha(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; CRYSTAL-STRUCTURE; IDENTIFICATION; RESIDUES; ALPHA(S); DOMAINS	The crystal structure of soluble functional fragments of adenylyl cyclase complexed with G alpha (s) and forskolin, shows three regions of G alpha (s) in direct contact with adenylyl cyclase. The functions of these three regions are not known. We tested synthetic peptides encoding these regions of G alpha (s) on the activities of full-length adenylyl cyclases 2 and 6. A peptide encoding the Switch II region (amino acids 222-247) stimulated both adenylyl cyclases 2- to 3-fold. Forskolin synergized the stimulation. Addition of peptides in the presence of activated Ga. partially inhibited G alpha (s) stimulation. Corresponding Switch II region peptides from G alpha (q) and G alpha (i) did not stimulate adenylyl cyclase. A peptide encoding the Switch I region (amino acids 199-216) also stimulated AC2 and AC6. The stimulatory effects of the two peptides at saturating concentrations were non-additive. A peptide encoding the third contact region (amino acids 268-286) located in the alpha3-beta5 region, inhibits basal, forskolin, and G alpha (s)-stimulated enzymatic activities. Since this region in G alpha (s) interacts with both the central cytoplasmic loop and C-terminal tail of adenylyl cyclases this peptide may be involved in blocking interactions between these two domains. These functional data in conjunction with the available structural information suggest that G alpha (s) activation of adenylyl cyclase is a complex event where the alpha3-beta5 loop of G alpha (s) may bring together the central cytoplasmic loop and C-terminal tail of adenylyl cyclase thus allowing the Switch I and Switch II regions to function as signal transfer regions to activate adenylyl cyclase.	Mt Sinai Med Ctr, Sch Med, Dept Pharmacol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Iyengar, R (corresponding author), Mt Sinai Med Ctr, Sch Med, Dept Pharmacol, 1 Gustave Levy,Box 1215, New York, NY 10029 USA.	ravi.iyengar@mssm.edu			NIDDK NIH HHS [DK-38761] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Buck E, 2001, J BIOL CHEM, V276, P36014, DOI 10.1074/jbc.M103228200; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; Harry A, 1997, J BIOL CHEM, V272, P19017, DOI 10.1074/jbc.272.30.19017; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968	17	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45751	45754		10.1074/jbc.M107191200	http://dx.doi.org/10.1074/jbc.M107191200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579096	hybrid			2022-12-25	WOS:000172573100035
J	Muyderman, H; Angehagen, M; Sandberg, M; Bjorklund, U; Olsson, T; Hansson, E; Nilsson, M				Muyderman, H; Angehagen, M; Sandberg, M; Bjorklund, U; Olsson, T; Hansson, E; Nilsson, M			alpha(1)-Adrenergic modulation of metabotropic glutamate receptor-induced calcium oscillations and glutamate release in astrocytes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CA-2+ RESPONSES; IN-SITU RESPOND; CULTURED ASTROCYTES; GLIAL-CELLS; NEUROTRANSMITTER RECEPTORS; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; CORTICAL ASTROCYTES; ASTROGLIAL CELLS; ARACHIDONIC-ACID	Astrocytic responses to activation of metabotropic glutamate receptors group I (mGluRs I) and alpha (1)-adrenoreceptors in cultured cells have been assessed using spectral analyzes and calcium imaging. Concentration-dependent changes were observed after stimulation with the mGluR I agonist (S)-3,5-dihydroxyphenylglycine (DHPG). These responses changed from a regular low frequency signal with sharp peaks at 1 muM to a pronounced stage of irregularity at 10 muM. After stimulation with 100 muM the signal was again homogenous in shape and regularity but occurred at a higher frequency. In contrast, the spectral properties after stimulation with the alpha (1)-adrenoreceptor agonist phenylephrine, exhibited considerable variation for all investigated concentrations. DHPG-induced increases in [Ca2+](i) were also associated with astroglial glutamate release, whereas no release was observed after noradrenergic stimulation. Both DHPG-mediated calcium signaling and glutamate release were inhibited by preincubation with 10 or 100 muM phenylephrine. Collectively, the present investigation provides new information about the spatial-temporal characteristics of astroglial intracellular calcium responses and demonstrates distinct differences between noradrenergic and glutamatergic receptors regarding intracellular calcium signaling and coupling to glutamate release. The noradrenergic modulation of DHPG-induced responses indicates that intracellular astroglial processes can be regulated in a bi-directional feedback loop between closely connected astrocytes and neurons in the central nervous system.	Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Dept Med Biophys, SE-41345 Gothenburg, Sweden; Chalmers Univ Technol, Dept Signals & Syst, SE-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg; University of Gothenburg; Chalmers University of Technology	Muyderman, H (corresponding author), Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden.		NILSSON, MICHAEL/ABE-7821-2020	NILSSON, MICHAEL/0000-0002-8826-1621				Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 1999, CAN J PHYSIOL PHARM, V77, P699, DOI 10.1139/cjpp-77-9-699; Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; Balazs R, 1998, J NEUROCHEM, V70, P2446; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Condorelli DF, 1999, ADV EXP MED BIOL, V468, P49; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DANI JW, 1995, CIBA F SYMP, V188, P195; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUFFY S, 1995, J NEUROSCI, V15, P5535; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HANSSON E, 1988, PROG NEUROBIOL, V30, P369, DOI 10.1016/0301-0082(88)90008-1; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; HERTZ L, 1984, PROG NEURO-PSYCHOPH, V8, P521, DOI 10.1016/0278-5846(84)90010-1; Hosli E, 2000, NEUROCHEM INT, V36, P301, DOI 10.1016/S0197-0186(99)00138-2; Innocenti B, 2000, J NEUROSCI, V20, P1800; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kulik A, 1999, J NEUROSCI, V19, P8401; LONGO EA, 1991, J BIOL CHEM, V266, P9314; Manolakis D, 1996, DIGITAL SIGNAL PROCE; MASON WT, 1988, J EXP BIOL, V139, P287; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; Muyderman H, 1998, BRAIN RES, V793, P127, DOI 10.1016/S0006-8993(98)00151-6; Muyderman H, 1997, NEUROSCI LETT, V238, P33, DOI 10.1016/S0304-3940(97)00838-0; Nakahara K, 1997, J NEUROCHEM, V69, P1467; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NILSSON M, 1991, LIFE SCI, V49, P1339, DOI 10.1016/0024-3205(91)90198-K; NILSSON M, 1991, DEV BRAIN RES, V63, P33, DOI 10.1016/0165-3806(91)90064-P; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PASTI L, 1995, J BIOL CHEM, V270, P15203, DOI 10.1074/jbc.270.25.15203; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Pasti L, 1997, J NEUROSCI, V17, P7817; PEARCE B, 1986, EUR J PHARMACOL, V121, P231, DOI 10.1016/0014-2999(86)90494-2; PEARCE B, 1985, J NEUROCHEM, V45, P1534, DOI 10.1111/j.1471-4159.1985.tb07224.x; Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8; Porter JT, 1996, J NEUROSCI, V16, P5073; PORTER JT, 1995, GLIA, V13, P101, DOI 10.1002/glia.440130204; Ruan Y, 1998, J PHARMACOL EXP THER, V284, P576; Sanzgiri RP, 1999, J NEUROBIOL, V41, P221, DOI 10.1002/(SICI)1097-4695(19991105)41:2<221::AID-NEU5>3.3.CO;2-1; Schafer C, 1998, NATURE, V392, P239, DOI 10.1038/32567; Schools GP, 1999, J NEUROSCI RES, V58, P533, DOI 10.1002/(SICI)1097-4547(19991115)58:4<533::AID-JNR6>3.0.CO;2-G; Simpson PB, 1998, J NEUROSCI RES, V52, P672; Simpson PB, 1997, BIOCHEM J, V325, P239, DOI 10.1042/bj3250239; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; Soen Y, 1999, PHYS REV LETT, V82, P3556, DOI 10.1103/PhysRevLett.82.3556; STELLA N, 1994, J NEUROSCI, V14, P568; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Tass P, 1998, PHYS REV LETT, V81, P3291, DOI 10.1103/PhysRevLett.81.3291; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Thorlin T, 1998, J NEUROSCI RES, V54, P390, DOI 10.1002/(SICI)1097-4547(19981101)54:3<390::AID-JNR10>3.0.CO;2-#; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Wallin C, 1999, J NEUROCHEM, V73, P1566, DOI 10.1046/j.1471-4159.1999.0731566.x; Winder DG, 1996, J PHYSIOL-LONDON, V494, P743, DOI 10.1113/jphysiol.1996.sp021529; YAGODIN S, 1995, MOL CELL BIOCHEM, V149, P137, DOI 10.1007/BF01076572; Yuan LL, 1999, SCIENCE, V283, P1343, DOI 10.1126/science.283.5406.1343	61	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46504	46514		10.1074/jbc.M103849200	http://dx.doi.org/10.1074/jbc.M103849200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579082	hybrid			2022-12-25	WOS:000172573100136
J	Somwar, R; Niu, W; Kim, DY; Sweeney, G; Randhawa, VK; Huang, C; Ramlal, T; Klip, A				Somwar, R; Niu, W; Kim, DY; Sweeney, G; Randhawa, VK; Huang, C; Ramlal, T; Klip, A			Differential effects of phosphatidylinositol 3-kinase inhibition on intracellular signals regulating GLUT4 translocation and glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; AMINO-ACID-TRANSPORT; RAT SKELETAL-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; INSULIN STIMULATION; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANES; POTENTIAL ROLE; CELL-SURFACE; MAP KINASE	Phosphatidylinositol (PI) 3-kinase is required for insulin-stimulated translocation of GLUT4 to the surface of muscle and fat cells. Recent evidence suggests that the full stimulation of glucose uptake by insulin also requires activation of GLUT4, possibly via a p38 mitogen-activated protein kinase (p38 MAPK)-dependent pathway. Here we used L6 myotubes expressing Myc-tagged GLUT4 to examine at what level the signals regulating GLUT4 translocation and activation bifurcate. We compared the sensitivity of each process, as well as of signals leading to GLUT4 translocation (Akt and atypical protein kinase C) to PI 3-kinase inhibition. Wortmannin inhibited insulin-stimulated glucose uptake with an IC50 of 3 nM. In contrast, GLUT4myc appearance at the cell surface was less sensitive to inhibition (IC50 = 43 nm). This dissociation between insulin-stimulated glucose uptake and GLUT4myc translocation was not observed with LY294002 (IC50 = 8 and 10 mum, respectively). The sensitivity of insulin-stimulated activation of PKC xi/gimel, Akt1, Akt2, and Akt3 to wortmannin (IC50 = 24, 30, 35, and 60 nm, respectively) correlated closely with inhibition of GLUT4 translocation. In contrast, insulin-dependent p38 MAPK phosphorylation was efficiently reduced in cells pretreated with wortmannin, with an IC50 of 7 nM. Insulin-dependent p38 alpha and p38 beta MAPK activities were also markedly reduced by wortmannin (IC50 = 6 and 2 nm, respectively). LY294002 or transient expression of a dominant inhibitory PI 3-kinase construct (Delta p85), however, did not affect p38 MAPK phosphorylation. These results uncover a striking correlation between PI 3-kinase, Akt, PKC xi/gimel, and GLUT4 translocation on one hand and their segregation from glucose uptake and p38 MAPK activation on the other, based on their wortmannin sensitivity. We propose that a distinct, high affinity target of wortmannin, other than PI 3-kinase, may be necessary for activation of p38 MA and GLUT4 in response to insulin.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	amira@sickkids.ca						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hansen PA, 1998, J BIOL CHEM, V273, P18173, DOI 10.1074/jbc.273.29.18173; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; Haruta T, 1998, ENDOCRINOLOGY, V139, P358, DOI 10.1210/en.139.1.358; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; KANAI F, 1993, J BIOL CHEM, V268, P14523; KING PA, 1992, J CLIN INVEST, V90, P1568, DOI 10.1172/JCI116025; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Lee-Kwon W, 1998, BIOCHEMISTRY-US, V37, P15747, DOI 10.1021/bi9805947; Lund S, 1998, FEBS LETT, V425, P472, DOI 10.1016/S0014-5793(98)00293-2; Malide D, 2000, J CELL SCI, V113, P4203; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; OKADA T, 1994, J BIOL CHEM, V269, P3568; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 2000, DIABETES, V49, pA245; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; SOMWAR R, 2001, 8 INT S INS REC INS; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Sweeney G, 2001, ENDOCRINOLOGY, V142, P4806, DOI 10.1210/en.142.11.4806; Sweeney G, 2001, DIABETES, V50, pA19; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; VanEppsFung M, 1997, ENDOCRINOLOGY, V138, P5170, DOI 10.1210/en.138.12.5170; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	58	71	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46079	46087		10.1074/jbc.M109093200	http://dx.doi.org/10.1074/jbc.M109093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11598141	hybrid			2022-12-25	WOS:000172573100080
J	Makowski, AM; Dutnall, RN; Annunziato, AT				Makowski, AM; Dutnall, RN; Annunziato, AT			Effects of acetylation of histone H4 at lysines 8 and 16 on activity of the Hat1 histone acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED HISTONES; ASSEMBLY FACTOR-I; DNA-REPLICATION; CHROMATIN; YEAST; H3; PHOSPHORYLATION; PURIFICATION; ASSOCIATION; TETRAHYMENA	During nucleosome assembly in vivo, newly synthesized histone H4 is specifically diacetylated. on lysines 5 and 12 within the H4 NH2-terminal tail domain. The highly conserved "K5/K12" deposition pattern of acetylation is thought to be generated by the Hat1 histone acetyltransferase, which in vivo is found in the HAT-B complex. In the following report, the activity and substrate specificity of the human HAT-B complex and of recombinant yeast Hat1p have been examined, using synthetic H4 NH2-terminal peptides as substrates. As expected, the unacetylated H4 peptide was a good substrate for acetylation by yeast Hat1p and human RAT-B, while the K5/K12-diacetylated peptide was not significantly acetylated. Notably, an H4 peptide previously diacetylated on lysines 8 and 16 was a very poor substrate for acetylation by either yeast Hat1p or human RAT-B. Treating the K8/KI6-diacetylated peptide with histone deacetylase prior to the HAT-B reaction raised acetylation at K5/K12 to 70-80% of control levels. These results present strong support for the model of H4-Hat1p interaction proposed by Dutnall et al. (Dutnall, R. N., Tafrov, S. T., Sternglanz, R., and Ramakrishnan, V. (1998) Cell 94, 427-438) and provide evidence for the first time that site-specific acetylation of histones can regulate the acetylation of other substrate sites.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	Boston College; University of California System; University of California San Diego	Annunziato, AT (corresponding author), Boston Coll, Dept Biol, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035837] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35837] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; ANNUNZIATO AT, 1982, J BIOL CHEM, V257, P8507; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Dutnall RN, 1998, COLD SPRING HARB SYM, V63, P501, DOI 10.1101/sqb.1998.63.501; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; Imhof A, 1999, BIOCHEMISTRY-US, V38, P13085, DOI 10.1021/bi9912490; INOUE A, 1970, BIOCHIM BIOPHYS ACTA, V220, P307, DOI 10.1016/0005-2744(70)90015-X; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; JACKSON V, 1981, CELL, V23, P121, DOI 10.1016/0092-8674(81)90277-4; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kolle D, 1998, FEBS LETT, V421, P109, DOI 10.1016/S0014-5793(97)01544-5; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lusser A, 1999, NUCLEIC ACIDS RES, V27, P4427, DOI 10.1093/nar/27.22.4427; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; PERRY CA, 1989, NUCLEIC ACIDS RES, V17, P4275, DOI 10.1093/nar/17.11.4275; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; VANHOLDE KE, 1988, CHROMATIN SPRINGER S; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 2000, GENE DEV, V14, P1430; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wolffe A. P., 1999, CHROMATIN STRUCTURE; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	40	37	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43499	43502		10.1074/jbc.C100549200	http://dx.doi.org/10.1074/jbc.C100549200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11585814	hybrid			2022-12-25	WOS:000172297700004
J	Zhou, H; Chen, WD; Qin, XS; Lee, K; Liu, LL; Markowitz, SD; Gerson, SL				Zhou, H; Chen, WD; Qin, XS; Lee, K; Liu, LL; Markowitz, SD; Gerson, SL			MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice	ONCOGENE			English	Article						c-neu transgenic mice; mammary tumor; DNA hypomethylation; MNU; MMTV promoter	METHYL-N-NITROSOUREA; DE-NOVO METHYLATION; HUMAN-BREAST-CANCER; DNA METHYLATION; FOREIGN DNA; HUMAN MGMT; RAS ONCOGENE; INDUCTION; TUMORS; ALKYLTRANSFERASE	The erbB family of receptor tyrosine kinases is frequently implicated in neoplasia. Amplification and overexpression of erbB2/neu has been found in 20 to 40% of human breast cancers. Previous studies using MMTV/c-neu transgenic mice have linked rat neu overexpression to mammary tumor development. In this study, we provide evidence that rat neu overexpression in mammary tumors of MMTV/c-neu transgenic mice is always associated with demethylation of the MMTV promoter, whereas the normal mammary glands of these transgenic mice always contain specific methylated regions of the MMTV promoter. In addition, after exposure to N-methyl-N-nitrosourea (MNU), the latency of mammary tumor development is significantly reduced and again is also associated with MMTV promoter demethylation. Thus, the transition from methylation to hypomethylation of the MMTV promoter induces high-level expression of c-neu and appears to be a prerequisite for transformation from normal to malignant mammary epithelium, either spontaneously or after carcinogen exposure. Expression of transgenic c-neu from the demethylated MMTV promoter appears to be an early event that allows outgrowth of mammary epithelium predisposed to malignant transformation.	Case Western Reserve Univ, Univ Hosp, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Howard Hughes Medical Institute	Gerson, SL (corresponding author), Case Western Reserve Univ, Univ Hosp, Div Hematol Oncol, BRB-3W,10900 Euclid Ave, Cleveland, OH 44106 USA.	slg5@po.cwru.edu	CHEN, WEI-DONG/F-4521-2014	CHEN, WEI-DONG/0000-0003-2264-5515	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NIEHS NIH HHS [5R01 ES 06288] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Asamoto M, 2000, CARCINOGENESIS, V21, P243, DOI 10.1093/carcin/21.2.243; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Betzl G, 1996, BIOL CHEM, V377, P711, DOI 10.1515/bchm3.1996.377.11.711; BOEHM TLJ, 1983, RECENT RES CANCER, V84, P212; BOEHM TLJ, 1981, CARCINOGENESIS, V2, P39, DOI 10.1093/carcin/2.1.39; BOEHM TLJ, 1983, J NATL CANCER I, V71, P429; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Cervoni N, 1999, J BIOL CHEM, V274, P8363, DOI 10.1074/jbc.274.13.8363; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; Doerfler W, 1997, TRENDS BIOTECHNOL, V15, P297, DOI 10.1016/S0167-7799(97)01061-5; DOERFLER W, 1995, GENE, V157, P241, DOI 10.1016/0378-1119(95)00080-P; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FONG LYY, 1990, CARCINOGENESIS, V11, P411, DOI 10.1093/carcin/11.3.411; FREI JV, 1980, J NATL CANCER I, V64, P845; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GERSON SL, 1985, J CLIN INVEST, V76, P2106, DOI 10.1172/JCI112215; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HANADA M, 1993, BLOOD, V82, P1820; Hung MC, 1999, SEMIN ONCOL, V26, P51; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; LU SJ, 1992, MOL CARCINOGEN, V6, P260, DOI 10.1002/mc.2940060407; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OREND G, 1995, J VIROL, V69, P1226, DOI 10.1128/JVI.69.2.1226-1242.1995; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; RAO PM, 1989, CARCINOGENESIS, V10, P933, DOI 10.1093/carcin/10.5.933; Robertson G, 1996, NUCLEIC ACIDS RES, V24, P1465, DOI 10.1093/nar/24.8.1465; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Young LH, 1996, MOL CARCINOGEN, V15, P251, DOI 10.1002/(SICI)1098-2744(199604)15:4<251::AID-MC2>3.0.CO;2-J; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	44	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6009	6017		10.1038/sj.onc.1204830	http://dx.doi.org/10.1038/sj.onc.1204830			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593408				2022-12-25	WOS:000171056300008
J	Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Cheng, WF; Chang, MC; Su, JL; Hsieh, CY				Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Cheng, WF; Chang, MC; Su, JL; Hsieh, CY			The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway	ONCOGENE			English	Article						cervical cancer; interleukin-6; apoptosis; Mcl-1; PI3-K/Akt	AUTOCRINE GROWTH-FACTOR; HUMAN MYELOMA CELLS; IMMUNOHISTOCHEMICAL ANALYSIS; BCL-2 FAMILY; IN-VITRO; IL-6 FUNCTIONS; BONE-MARROW; EXPRESSION; GENE; DIFFERENTIATION	Interleukin-6 (IL-6), a multifunctional cytokine, has recently been implicated in human cervical cancer, though the mechanism remains elusive. This study demonstrates that the anti-apoptotic protein Mcl-1 and IL-6 was concomitantly expressed in human cervical cancer tissues and cell lines, but not in normal cervix tissues. Upon IL-6 treatment, Mcl-1, but not other Bcl-2 family members, was rapidly up-regulated peaking at 4-8 h in human cervical cancer C33A cells. Supporting this observation, using anti-IL-6 or anti-IL-6 receptor antibody to interrupt the IL-6 autocrine loop in SiHa cells significantly reduced cellular level of Mcl-1. This study hypothesizes that the expression of Mcl-1 in cervical cancer cells is regulated by IL-6. The matter of which signaling pathways transduced by IL-6 is responsible for the Mcl-1 up-regulation is further investigated herein. Blocking the STAT3 or MAPK pathway with dominant-negative mutant STAT3F or the MEK inhibitor PD98059 failed to inhibit IL-6-mediated Mcl-1 expression. Meanwhile, the IL-6-induced Mcl-1 up-regulation was effectively abolished by treatment with PI 3-K inhibitors, LY294002. Additionally, overexpression of dominant-negative (dn) Akt in C33A cells could inhibit the IL-6-induced increase of Mcl-1. Finally, overexpression of IL-6 in C33A cells caused a markable resistance to apoptosis induced by doxorubicin or cisplatin. Transient transfection of IL-6-overexpressed cells with a mcl-1 antisense vector, leading to the attenuation of their apoptosis-resistant activity. In conclusion, the data herein suggest that IL-6 regulated the mcl-1 expression via a PI 3-K/Akt-dependent pathway that may facilitate the oncogenesis of human cervical cancer by modulating the apoptosis threshold.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei, Taiwan.		Wei, Lin-Hung/B-1188-2008; Kuo, Min-Liang/C-4872-2009	CHENG, WEN-FANG/0000-0002-3282-6304; Wei, Lin-Hung/0000-0001-8789-0859; KUO, MIN-LIANG/0000-0002-7139-0144; CHEN, CHI-AN/0000-0001-6670-7939				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cervero C, 1999, AM J HEMATOL, V60, P191, DOI 10.1002/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHOI SS, 1995, ONCOGENE, V11, P1693; Crawford RAF, 1998, BRIT J CANCER, V78, P210, DOI 10.1038/bjc.1998.466; DOLE MG, 1995, CANCER RES, V55, P2576; Elder DJE, 1996, CANCER RES, V56, P2273; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, J NEUROSCI, V19, P5429; Ogata A, 1997, J IMMUNOL, V159, P2212; Okamoto M, 1997, CANCER RES, V57, P141; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Richter HE, 1999, AM J OBSTET GYNECOL, V181, P940, DOI 10.1016/S0002-9378(99)70329-7; ROBERT ME, 1990, SEMIN DIAGN PATHOL, V7, P173; SCHLAIFER D, 1995, BLOOD, V85, P2671, DOI 10.1182/blood.V85.10.2671.bloodjournal85102671; Tartour E, 1999, CANCER RES, V59, P3698; TARTOUR E, 1994, CANCER RES, V54, P6243; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tjiong MY, 1999, GYNECOL ONCOL, V73, P285, DOI 10.1006/gyno.1999.5358; Tlsty TD, 1999, NAT GENET, V21, P64, DOI 10.1038/4998; Wei LH, 2001, GYNECOL ONCOL, V82, P49, DOI 10.1006/gyno.2001.6235; WU S, 1992, AM J OBSTET GYNECOL, V166, P997, DOI 10.1016/0002-9378(92)91379-O; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	47	139	155	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5799	5809		10.1038/sj.onc.1204733	http://dx.doi.org/10.1038/sj.onc.1204733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593385				2022-12-25	WOS:000171037200003
J	Yang, RJ; Cao, LW; Gasa, R; Brady, MJ; Sherry, AD; Newgard, CB				Yang, RJ; Cao, LW; Gasa, R; Brady, MJ; Sherry, AD; Newgard, CB			Glycogen-targeting subunits and glucokinase differentially affect pathways of glycogen metabolism and their regulation in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT; ADENOVIRUS-MEDIATED TRANSFER; HEPATIC GLUCOSE-METABOLISM; AMINO-ACID-SEQUENCE; PROTEIN PHOSPHATASE-1; HEXOKINASE-I; MAGNETIC-RESONANCE; DIABETES-MELLITUS; SKELETAL-MUSCLE; OVEREXPRESSION	Overexpression of the glucose-phosphorylating enzyme glucokinase (GK) or members of the family of glycogen-targeting subunits of protein phosphatase-1 increases hepatic glucose disposal and glycogen synthesis. This study was undertaken to evaluate the functional properties of a novel, truncated glycogen-targeting subunit derived from the skeletal muscle isoform G(M)/R-GI and to compare pathways of glycogen metabolism and their regulation in cells with overexpressed targeting subunits and GK. When overexpressed in hepatocytes, truncated G(M)/R-GI (G(M)DeltaC) was approximately twice as potent as full-length G(M)/R-GI in stimulation of glycogen synthesis, but clearly less potent than GK or two other native glycogen-targeting subunits, G(L) and PTG. We also found that cells with overexpressed G(M)DeltaC are unique in that glycogen was efficiently degraded in response to lowering of media glucose concentrations, stimulation with forskolin, or a combination of both maneuvers, whereas cells with overexpressed G(L), PTG, or GK exhibited impairment in one or both of these glycogenolytic signaling pathways. H-2 NMR analysis of purified glycogen revealed that hepatocytes with overexpressed GK synthesized a larger portion of their glycogen from triose phosphates and a smaller portion from tricarboxylic acid cycle intermediates than cells with overexpressed glycogen-targeting subunits. Additional evidence for activation of distinct pathways of glycogen synthesis by GK and targeting subunits is provided by the additive effect of co-overexpression of the two types of proteins upon glycogen synthesis and a much larger stimulation of glucose utilization, glucose transport, and lactate production elicited by GK. We conclude that overexpression of the novel targeting subunit G(M)DeltaC confers unique regulation of glycogen metabolism. Furthermore, targeting subunits and GK stimulate glycogen synthesis by distinct pathways.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Rogers NMR Ctr, Dallas, TX 75390 USA; Univ Chicago, Dept Internal Med, Endocrinol Sect, Chicago, IL 60637 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Chicago	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Rm Y8-212,5323 Harry Hines Blvd, Dallas, TX 75290 USA.		Sherry, Dean/P-2348-2018	Sherry, Dean/0000-0001-7150-8301	NCRR NIH HHS [P41-RR02584] Funding Source: Medline; NIDDK NIH HHS [P01-DK58398] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An J, 2001, J BIOL CHEM, V276, P10722, DOI 10.1074/jbc.M009525200; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUBBARD MJ, 1990, FEBS LETT, V189, P245; JONES JG, 2001, AM J PHYSIOL, V281, pE484; Landau BR, 1996, J CLIN INVEST, V98, P378, DOI 10.1172/JCI118803; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; TANG PM, 1991, J BIOL CHEM, V266, P15782; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000	36	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 11	2002	277	2					1514	1523		10.1074/jbc.M107001200	http://dx.doi.org/10.1074/jbc.M107001200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	509TY	11600496	hybrid			2022-12-25	WOS:000173166800084
J	Lin, MT; Lee, RC; Yang, PC; Ho, FM; Kuo, ML				Lin, MT; Lee, RC; Yang, PC; Ho, FM; Kuo, ML			Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells - Involvement of phosphatidylinositol 3-kinase/Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; INDUCED APOPTOSIS; CANCER CELLS; EXPRESSION; MCL-1; GENE; CARCINOMA; BCL-2; TUMORIGENESIS; ACTIVATORS	Cyclooxygenase 2 (COX-2) has been reported to be commonly expressed in advanced stages of human lung adenocarcinoma. In this study, the COX-2 constitutive expression vector was transfected into a human lung adenocarcinoma cell line CL1.0 and several clones were obtained which stably expressed COX-2. These COX-2-overexpressed clones demonstrated remarkable resistance to apoptosis induced by Ultraviolet B (UVB) irradiation, vinblastine B (VBL) cell lymphoma-2 (Bcl-2), or other anti-cancer drugs. To understand how COX-2 prevents apoptosis, the investigators examined the expression level of Bcl-2 family members. Mcl-1, but not other Bcl-2 members, was significantly up-regulated by COX-2 transfection or prostaglandin E, (PGE(2)) treatment. Treatment of COX-2-overexpressed cells (cox-2/cl.4) with two specific COX-2 inhibitors, NS-398 and celecoxib, caused an effective reduction of the increased level of Mcl-1. These data suggest that the expression level of Mcl-1 is tightly regulated by COX-2. Moreover, transfection of cox-2/cl.4 cells with antisense Mcl-1 enhanced apoptosis induced by UVB irradiation, revealing that Mcl-1 plays a crucial role in cell survival activity mediated by COX-2. Furthermore, COX-2 transfection or PGE(2), treatment evidently activated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Inhibition of the PI3K pathway by LY294002 or wortmannin effectively attenuated the increased level of Mcl-1 induced by COX-2 or PGE(2). Blocking the PI3K activity with a dominant-negative vector, DN-p85, also greatly diminished the level of Mcl-1 and enhanced UVB-elicited cell death in cells transfected by COX-2. In a similar way, LY294002 inhibited cell survival and Mcl-1 level in PGE(2)-treated CL1.0 cells. These findings suggest that COX-2 promotes cell survival by up-regulating the level of Mcl-1 by activating the PI3K/Akt-dependent pathway.	Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Tao Yuan Gen Hosp, Tao Yuan 330, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Kuo, ML (corresponding author), Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, 1 Sec 1 Jen Ai Rd, Taipei 100, Taiwan.		Kuo, Min-Liang/C-4872-2009; Yang, Pan-Chyr/B-8808-2009	YANG, PAN-CHYR/0000-0001-6330-6048; LIN, MING-TSAN/0000-0001-7313-7057; KUO, MIN-LIANG/0000-0002-7139-0144				Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hida T, 1998, CANCER RES, V58, P3761; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KELLEY RJ, 1998, AM J PHYSIOL, V274, pL990; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; Noel A, 1997, INVAS METAST, V17, P221; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rioux N, 1998, CANCER RES, V58, P5354; Ristimaki A, 1997, CANCER RES, V57, P1276; SANO H, 1995, CANCER RES, V55, P3785; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wolff H, 1998, CANCER RES, V58, P4997; Zimmermann KC, 1999, CANCER RES, V59, P198	34	159	174	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48997	49002		10.1074/jbc.M107829200	http://dx.doi.org/10.1074/jbc.M107829200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11585835	hybrid			2022-12-25	WOS:000173922100051
J	Scott, BR; McManus, DC; Franklin, V; McKenzie, AG; Neville, T; Sparks, DL; Mercel, YL				Scott, BR; McManus, DC; Franklin, V; McKenzie, AG; Neville, T; Sparks, DL; Mercel, YL			The N-terminal globular domain and the first class A amphipathic helix of apolipoprotein A-I important for Lecithin : Cholesterol acyltransferase activation and the maturation of high density lipoprotein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-FREE STRUCTURE; RECONSTITUTED LPA-I; CELLULAR CHOLESTEROL; SYSTEMIC AMYLOIDOSIS; TRANSGENIC MICE; ALPHA-HELIX; PRE-BETA; APOA-I; EFFLUX; BINDING	To investigate the role of the N terminus of apolipoprotein A-I (apoA-I) in the maturation of high density lipoproteins (HDL), two N-terminal mutants with deletions of residues 1-43 and 1-65 (referred to as Delta1-43 and Delta1-65 apoA-I) were studied. In vitro, these deletions had little effect on cellular cholesterol efflux from macrophages but LCAT activation was reduced by 50 and 70% for the Delta1-43 and Delta1-65 apoA-I mutants, respectively, relative to wild-type (Wt) apoA-I. To further define the role of the N terminus of apoA-I in HDL maturation, we constructed recombinant adenoviruses containing Wt apoA-I and two similar mutants with deletions of residues 7-43 and 7-65 (referred to as Delta7-43 and Delta7-65 apoA-I, respectively). Residues 1-6 were not removed in these mutants to allow proper cleavage of the pro-sequence in vivo. Following injection of these adenoviruses into apoA-I-deficient mice, plasma concentrations of both Delta7-43 and A,7-65 apoA-I were reduced 4-fold relative to Wt apoA-I. The N-terminal deletion mutants, in particular Delta7-65 apoA-I, were associated with greater proportions of prebeta-HDL and accumulated fewer HDL cholesteryl esters relative to Wt apoA-I. Wt and Delta7-43 apoA-I formed predominantly alpha-migrating and spherical HDL, whereas Delta7-65 apoA-I formed only prebeta-HDL of discoidal morphology. This demonstrates that deletion of the first class A amphipathic alpha-helix has a profound additive effect in vivo over the deletion of the globular domain alone (amino acids 1-43) indicating its important role in the production of mature alpha-migrating HDL. In summary, the combined in vitro and in vivo studies demonstrate a role for the N terminus of apoA-I in lecithin:cholesterol acyltransferase activation and the requirement of the first class A amphipathic alpha-helix for the maturation of HDL in vivo.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Mercel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Rm H460,40 Ruskin Ave, Ottawa, ON K1Y 4W7, Canada.			Scott, Brian/0000-0002-7012-4696				Albers J J, 1986, Methods Enzymol, V129, P763; ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; Barrans A, 1996, BBA-LIPID LIPID MET, V1300, P73, DOI 10.1016/0005-2760(95)00236-7; Bergeron J, 1997, BBA-LIPID LIPID MET, V1344, P139, DOI 10.1016/S0005-2760(96)00136-1; BOOTH DR, 1995, QJM-INT J MED, V88, P695; Booth DR, 1996, J CLIN INVEST, V97, P2714, DOI 10.1172/JCI118725; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; DAVIDSON WS, 1994, J BIOL CHEM, V269, P8959; Ehnholm S, 1998, J LIPID RES, V39, P1248; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FORTE TM, 1984, ARTERIOSCLEROSIS, V4, P130, DOI 10.1161/01.ATV.4.2.130; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; Fournier N, 2000, ARTERIOSCL THROM VAS, V20, P1283, DOI 10.1161/01.ATV.20.5.1283; Frank PG, 2000, J LIPID RES, V41, P853; Genschel J, 1998, FEBS LETT, V430, P145, DOI 10.1016/S0014-5793(98)00668-1; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GLOMSET JA, 1968, J LIPID RES, V9, P155; Huang W, 2000, ARTERIOSCL THROM VAS, V20, P210, DOI 10.1161/01.ATV.20.1.210; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; McManus DC, 2001, J BIOL CHEM, V276, P21292, DOI 10.1074/jbc.M100463200; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; Moriyama K, 1996, J Atheroscler Thromb, V3, P12; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PALGUNACHARI M, 1996, TROMB VASC BIOL, V16, P328; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Pyle LE, 2001, BIOCHEMISTRY-US, V40, P3101, DOI 10.1021/bi002025g; Qin SC, 2000, J LIPID RES, V41, P269; RADER DJ, 1992, J LIPID RES, V33, P755; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Roosbeek S, 2001, J LIPID RES, V42, P31; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCHMIDT HHJ, 1995, J BIOL CHEM, V270, P5469, DOI 10.1074/jbc.270.10.5469; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Sorci-Thomas MG, 2000, J BIOL CHEM, V275, P12156, DOI 10.1074/jbc.275.16.12156; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SOUTAR AK, 1982, J LIPID RES, V23, P380; SOUTAR AK, 1992, P NATL ACAD SCI USA, V89, P7389, DOI 10.1073/pnas.89.16.7389; Sparks DL, 1998, BBA-LIPID LIPID MET, V1390, P160, DOI 10.1016/S0005-2760(97)00172-0; SPARKS DL, 1995, J BIOL CHEM, V270, P5151, DOI 10.1074/jbc.270.10.5151; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; STOFFEL W, 1984, J LIPID RES, V25, P1586; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; SWANEY JB, 1976, BIOCHEM BIOPH RES CO, V71, P636, DOI 10.1016/0006-291X(76)90835-4; VANALLEN MW, 1969, NEUROLOGY, V19, P10, DOI 10.1212/WNL.19.1.10; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200	54	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48716	48724		10.1074/jbc.M106265200	http://dx.doi.org/10.1074/jbc.M106265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11602583	hybrid			2022-12-25	WOS:000173922100015
J	Le Roy, F; Bisbal, C; Silhol, M; Martinand, C; Lebleu, B; Salehzada, T				Le Roy, F; Bisbal, C; Silhol, M; Martinand, C; Lebleu, B; Salehzada, T			The 2-5A/RNase L/RNase L inhibitor (RNI) pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; APOPTOSIS; ACTIVATION; CLONING; IMPORT; LOCALIZATION; EXPRESSION; MEMBRANE; CLEAVAGE; SIGNAL	Interferon alpha (IFN alpha) belongs to a cytokine family that exhibits antiviral properties, immuno-modulating effects, and antiproliferative activity on normal and neoplasic cells in vitro and in vivo. IFN alpha exerts antitumor action by inducing direct cytotoxicity against tumor cells. This toxicity is at least partly due to induction of apoptosis. Although the molecular basis of the inhibition of cell growth by IFN alpha is only partially understood, there is a direct correlation between the sensitivity of cells to the antiproliferative action of IFN alpha and the down-regulation of their mitochondrial mRNAs. Here, we studied the role of the 2-5A/RNase L system and its inhibitor RLI in this regulation of the mitochondrial mRNAs by IFNa. We found that a fraction of cellular RNase L and RLI is localized in the mitochondria. Thus, we down-regulated RNase L activity in human H9 cells by stably transfecting (i) RNase L antisense cDNA or (ii) RLI sense cDNA constructions. In contrast to control cells, no post-transcriptional down-regulation of mitochondrial mRNAs and no cell growth inhibition were observed after IFN alpha treatment in these transfectants. These results demonstrate that IFNa exerts its antiproliferative effect on H9 cells at least in part via the degradation of mitochondrial mRNAs by RNase L.	Inst Genet Mol, EP2030 CNRS, F-34293 Montpellier, France	Universite de Montpellier	Bisbal, C (corresponding author), Inst Human Genet, UPR CNRS 1142, 141 Rue Cardonille, F-34396 Montpellier, France.	Catherine.Bisbal@igh.cnrs.fr	Le Roy, florence/J-7455-2013; Bisbal, Catherine/I-6984-2016	Bisbal, Catherine/0000-0003-1086-020X				BAYARD B, 1984, EUR J BIOCHEM, V142, P291, DOI 10.1111/j.1432-1033.1984.tb08284.x; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Besse S, 1998, EXP CELL RES, V239, P379, DOI 10.1006/excr.1997.3908; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; BONNIEU A, 1989, ONCOGENE, V4, P881; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Enriquez J A, 1996, Methods Enzymol, V264, P50, DOI 10.1016/S0076-6879(96)64008-7; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KELLY JM, 1986, EMBO J, V5, P1601, DOI 10.1002/j.1460-2075.1986.tb04402.x; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Lewis JA, 1996, J BIOL CHEM, V271, P13184, DOI 10.1074/jbc.271.22.13184; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOU J, 1994, J INTERFERON RES, V14, P33, DOI 10.1089/jir.1994.14.33; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martinand C, 1998, EUR J BIOCHEM, V254, P248, DOI 10.1046/j.1432-1327.1998.2540248.x; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; Ni L, 1999, J BIOL CHEM, V274, P12685, DOI 10.1074/jbc.274.18.12685; Pelicano L, 1998, B CANCER, V85, P313; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; REID GA, 1982, J BIOL CHEM, V257, P3056; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; Rusch L, 2000, J INTERF CYTOK RES, V20, P1091, DOI 10.1089/107999000750053762; Sambrook J., 1989, MOL CLONING LAB MANU, P3; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VON HG, 1989, EUR J BIOCHEM, V180, P535; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Waterhouse NJ, 1999, J CLIN IMMUNOL, V19, P378, DOI 10.1023/A:1020550716138; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; Yanase N, 2000, J INTERF CYTOK RES, V20, P1121, DOI 10.1089/107999000750053799; Zhou AM, 1998, J INTERF CYTOK RES, V18, P953, DOI 10.1089/jir.1998.18.953; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	67	64	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48473	48482		10.1074/jbc.M107482200	http://dx.doi.org/10.1074/jbc.M107482200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11585831	hybrid, Green Published			2022-12-25	WOS:000172927000100
J	Merlos-Suarez, A; Ruiz-Paz, S; Baselga, J; Arribas, J				Merlos-Suarez, A; Ruiz-Paz, S; Baselga, J; Arribas, J			Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CELL-SURFACE; INTRACELLULAR MATURATION; PROTGF-ALPHA; DISINTEGRIN-METALLOPROTEASE; SECRETASE CLEAVAGE; ALZHEIMERS-DISEASE; TGF-ALPHA; LOCALIZATION; MATRIX	Zinc-dependent metalloproteases can mediate the shedding of the extracellular domain of many unrelated transmembrane proteins from the cell surface. In most instances, this process, also known as ectodomain shedding, is regulated via protein kinase C (PKC). The tumor necrosis factor a-converting enzyme (TACE) was the first protease involved in regulated protein ectodomain shedding identified. Although TACE belongs to the family of metalloprotease-disintegrins, few members of this family have been shown to participate in regulated ectodomain shedding. In fact, the phenotype of tace-/- cells and that of Chinese hamster ovary cell mutants defective in ectodomain shedding points to the existence of a common PKC-activated ectodomain shedding system, whose proteolytic component is TACE, that acts on a variety of transmembrane proteins. Examples of these proteins include the Alzheimer's disease-related protein beta -amyloid precursor protein (beta APP) and the transmembrane growth factors protransforming growth factor-a (pro-TGF-a) and, as shown in this report, pro-heparin-binding epidermal growth factor-like growth factor (pro-HB-EGF). Here we show that the mercurial compound 4-aminophenylmercuric acetate (APMA), frequently used to activate in vitro recombinant matrix metalloproteases, is an activator of the shedding of beta APP, pro-HB-EGF, and pro-TGF-a. Treatment of tace-/- cells or Chinese hamster ovary shedding-defective mutants with APMA activates the cleavage of pro-TGF-alpha but not that of pro-HB-EGF or beta APP, indicating that APMA activates TACE and also a previously unacknowledged proteolytic activity specific for pro-TGF-a. Characterization of this proteolytic activity indicates that it acts on pro-TGF-alpha located at the cell surface and that it is a metalloprotease active in cells defective in furin activity. In summary, treatment of shedding-defective cell lines with APMA unveils the existence of a metalloprotease activity alternative to TACE with the ability to specifically shed the ectodomain of pro-TGF-alpha.	Hosp Univ Vall dHebron, Serv Oncol Med, Lab Recerca Oncol, Barcelona 08035, Spain	Hospital Universitari Vall d'Hebron	Arribas, J (corresponding author), Hosp Univ Vall dHebron, Serv Oncol Med, Lab Recerca Oncol, Psg Vall dHebron 119-129, Barcelona 08035, Spain.		Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664				Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kiessling LL, 1998, CHEM BIOL, V5, pR49, DOI 10.1016/S1074-5521(98)90056-4; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; McCulloch DR, 2000, MOL CELL ENDOCRINOL, V167, P11, DOI 10.1016/S0303-7207(00)00305-1; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Urena JM, 1999, J CELL SCI, V112, P773; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	37	112	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48510	48517		10.1074/jbc.M103488200	http://dx.doi.org/10.1074/jbc.M103488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11600492	hybrid			2022-12-25	WOS:000172927000104
J	Thyagarajan, B; Poteser, M; Romanin, C; Kahr, H; Zhu, MX; Groschner, K				Thyagarajan, B; Poteser, M; Romanin, C; Kahr, H; Zhu, MX; Groschner, K			Expression of Trp3 determines sensitivity of capacitative Ca2+ entry to nitric oxide and mitochondrial Ca2+ handling - Evidence for a role of Trp3 as a subunit of capacitative Ca2+ entry channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ENTRY; INFLUX; RECEPTOR; CELLS; REQUIREMENT; ACTIVATION; PROTEINS; STORES	The role of Trp3 in cellular regulation of Ca2+ entry by NO was studied in human embryonic kidney (HEK) 293 cells. In vector-transfected HEK293 cells (controls), thapsigargin (TG)-induced (capacitative Ca2+ entry (CCE)-mediated) intracellular Ca2+ signals and Mn2+ entry were markedly suppressed by the NO donor 2-(N,N-diethylamino)diazenolate-2-oxide sodium salt (3 muM) or by authentic NO (100 muM). In cells overexpressing Trp3 (T3-9), TG-induced intracellular Ca2+ signals exhibited an amplitude similar to that of controls but lacked sensitivity to inhibition by NO. Consistently, NO inhibited TG-induced Mn2+ entry in controls but not in T3-9 cells. Moreover, CCE-mediated Mn2+ entry into T3-9 cells exhibited a striking sensitivity to inhibition by extracellular Ca2+, which was not detectable in controls. Suppression of mitochondrial Ca2+ handling with the uncouplers carbonyl cyanide m-chlorophenyl hydrazone (300 nM) or antimycin A(1) (-AA(1)) mimicked the inhibitory effect of NO on CCE in controls but barely affected CCE in T3-9 cells. T3-9 cells exhibited enhanced carbachol-stimulated Ca2+ entry and clearly detectable cation currents through Trp3 cation channels. NO as well as carbonyl cyanide m-chlorophenyl hydrazone slightly promoted carbachol-induced Ca2+ entry into T3-9 cells. Simultaneous measurement of cytoplasmic Ca2+ and membrane currents revealed that Trp3 cation currents are inhibited during Ca2+ entry-induced elevation of cytoplasmic Ca2+, and that this negative feedback regulation is blunted by NO. Our results demonstrate that overexpression of Trp3 generates phospholipase C-regulated cation channels, which exhibit regulatory properties different from those of endogenous CCE channels. Moreover, we show for the first time that Trp3 expression determines biophysical properties as well as regulation of CCE channels by NO and mitochondrial Ca2+ handling. Thus, we propose Trp3 as a subunit of CCE channels.	Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, A-8010 Graz, Austria; Johannes Kepler Univ, Dept Biophys, A-4040 Linz, Austria; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA	University of Graz; Johannes Kepler University Linz; University System of Ohio; Ohio State University	Groschner, K (corresponding author), Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.		Romanin, Christoph/D-5399-2009; Groschner, Klaus/A-2550-2010	Romanin, Christoph/0000-0003-3756-4136; Groschner, Klaus/0000-0002-8659-377X; Poteser, Michael/0000-0002-9962-1098				Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Collins TJ, 2000, BIOCHEM J, V347, P593, DOI 10.1042/0264-6021:3470593; David G, 2000, J NEUROSCI, V20, P7290; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Poteser M, 2001, J BIOL CHEM, V276, P14797, DOI 10.1074/jbc.M008244200; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rustenbeck I, 1997, DIABETES, V46, P1305, DOI 10.2337/diabetes.46.8.1305; SCHAEFER G, 1998, DIABETOLOGIA, V41, P1; Smaili SS, 2001, J BIOL CHEM, V276, P23329, DOI 10.1074/jbc.M100989200; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Watson EL, 1999, AM J PHYSIOL-CELL PH, V277, pC262, DOI 10.1152/ajpcell.1999.277.2.C262; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	28	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48149	48158		10.1074/jbc.M103977200	http://dx.doi.org/10.1074/jbc.M103977200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11600493	hybrid			2022-12-25	WOS:000172927000056
J	Ablooglu, AJ; Frankel, M; Rusinova, E; Ross, JBA; Kohanski, RA				Ablooglu, AJ; Frankel, M; Rusinova, E; Ross, JBA; Kohanski, RA			Multiple activation loop conformations and their regulatory properties in the insulin receptor's kinase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TYROSINE KINASE; CRYSTAL-STRUCTURE; AUTOINHIBITORY MECHANISM; INTRASTERIC REGULATION; PEPTIDE SUBSTRATE; C-SRC; AUTOPHOSPHORYLATION; PHOSPHORYLATION; EXPRESSION	Low catalytic efficiency of protein kinases often results from intrasteric inhibition caused by the activation loop blocking the active site. In the insulin receptor's kinase domain, Asp-1161 and Tyr-1162 in the peptide substrate-like sequence of the unphosphorylated activation loop can interact with four invariant residues in the active site: Lys-1085, Asp-1132, Arg-1136, and Gln-1208. Contributions of these six residues to intrasteric inhibition were tested by mutagenesis, and the unphosphorylated kinase domains were characterized. The mutations Q1208S, K1085N, and Y1162F each relieved intrasteric inhibition, increasing catalytic efficiency but without changing the rate-limiting step of the reaction. The mutants R1136Q and D1132N were virtually inactive. Steric accessibility of the active site was ranked by relative changes in iodide quenching of intrinsic fluorescence, and A-loop conformation was ranked by limited tryptic cleavage. Together these ranked the openness of the active site cleft as R1136Q approximate to D1132N greater than or equal to D1161A > Y1162F approximate to K1085N > Q1208S greater than or equal to wildtype. These findings demonstrate the importance of specific invariant residues for intrasteric inhibition and show that diverse activation loop conformations can produce similar steady-state kinetic properties. This suggests a broader range of regulatory properties for the activation loop than expected from a simple off-versus-on switch for kinase activation.	CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Kohanski, RA (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, Box 1020,1 Gustave Levy Pl, New York, NY 10029 USA.				NIDDK NIH HHS [R01 DK059522, DK 59522] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059522] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ablooglu AJ, 2001, BIOCHEMISTRY-US, V40, P504, DOI 10.1021/bi002292m; ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Bishop SM, 1999, BIOCHEMISTRY-US, V38, P3079, DOI 10.1021/bi982546s; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Frankel M, 2001, MOL CELL BIOL, V21, P4197, DOI 10.1128/MCB.21.13.4197-4207.2001; Frankel M, 1999, PROTEIN SCI, V8, P2158, DOI 10.1110/ps.8.10.2158; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kobe B, 1997, ADV SEC MESS PHOSPH, V31, P29; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Parang K, 2001, NAT STRUCT BIOL, V8, P37; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Williams DM, 2000, J BIOL CHEM, V275, P38127, DOI 10.1074/jbc.C000606200; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	40	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46933	46940		10.1074/jbc.M107236200	http://dx.doi.org/10.1074/jbc.M107236200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598120	hybrid			2022-12-25	WOS:000172768500036
J	Bultynck, G; Rossi, D; Callewaert, G; Missiaen, L; Sorrentino, V; Parys, JB; De Smedt, H				Bultynck, G; Rossi, D; Callewaert, G; Missiaen, L; Sorrentino, V; Parys, JB; De Smedt, H			The conserved sites for the FK506-binding proteins in ryanodine receptors and inositol 1,4,5-trisphosphate receptors are structurally and functionally different	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; CYCLIC ADP-RIBOSE; SECONDARY STRUCTURE PREDICTION; FK506 BINDING-PROTEIN; BASOPHILIC LEUKEMIA-CELLS; CA2+ RELEASE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; CA2+-RELEASE CHANNEL; SELECTIVE BINDING	We compared the interaction of the FK506-binding protein (FKBP) with the type 3 ryanodine receptor (RyR3) and with the type 1 and type 3 inositol 1,4,5-trisphosphate receptor (IP(3)R1 and IP3R3), using a quantitative GST-FIKBP12 and GST-FKBP12.6 affinity assay. We first characterized and mapped the interaction of the FKBPs with the RyR3. GST-FKBP12 as well as GST-FKBP12.6 were able to bind similar to 30% of the solubilized RyR3. The interaction was completely abolished by FK506, strengthened by the addition of Mg2+, and weakened in the absence of Ca2+ but was not affected by the addition of cyclic ADP-ribose. By using proteolytic mapping and site-directed mutagenesis, we pinpointed Val(2322), located in the central modulatory domain of the RyR3, as a critical residue for the interaction of RyR3 with FKBPs. Substitution of Val(2322) for leucine (as in IP(3)R1) or isoleucine (as in RyR2) decreased the binding efficiency and shifted the selectivity to FKBP12.6; substitution of Val(2322) for aspartate completely abolished the FKBP interaction. Importantly, the occurrence of the valylprolyl residue as alpha -helix breaker was an important determinant of FKBP binding. This secondary structure is conserved among the different RyR isoforms but not in the IP3R isoforms. A chimeric RyR3/IP(3)R1, containing the core of the FKBP12-binding site of IP(3)R1 in the RyR3 context, retained this secondary structure and was able to interact with FKBPs. In contrast, IP(3)Rs did not interact with the FKBP isoforms. This indicates that the primary sequence in combination with the local structural environment plays an important role in targeting the FKBPs to the intracellular Ca2+-release channels. Structural differences in the FKBP-binding site of RyRs and IP(3)Rs may contribute to the occurrence of a stable interaction between RyR isoforms and FKBPs and to the absence of such interaction with IP(3)Rs.	Katholieke Univ Leuven, Physiol Lab, D-3000 Hannover, Germany; Univ Siena, Dept Neurosci, Sect Mol Med, I-53100 Siena, Italy; San Raffaele Sci Inst, DIBIT, I-20132 Milan, Italy	KU Leuven; University of Siena	De Smedt, H (corresponding author), Katholieke Univ Leuven, Physiol Lab, Campus Gasthuisberg O-N,Herestr 49, D-3000 Hannover, Germany.		Rossi, Daniela/G-7764-2012; Sorrentino, Vincenzo/A-4793-2014	Rossi, Daniela/0000-0003-0463-7327; Sorrentino, Vincenzo/0000-0002-8573-8631; Bultynck, Geert/0000-0002-5968-4828; Parys, Jan/0000-0002-3591-4967	Telethon [1151] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; Barg S, 1997, AM J PHYSIOL-CELL PH, V272, pC1726, DOI 10.1152/ajpcell.1997.272.5.C1726; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bultynck G, 2000, J PHYSIOL-LONDON, V525, P681, DOI 10.1111/j.1469-7793.2000.t01-1-00681.x; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; BULTYNCK G, 1999, CURR T BIOCHEM RES, V1, P193; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; DeSmedt H, 1997, BIOCHEM J, V322, P575; DiFrancesco V, 1996, PROTEIN SCI, V5, P106; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jeyakumar LH, 2001, BIOCHEM BIOPH RES CO, V281, P979, DOI 10.1006/bbrc.2001.4444; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kanoh S, 1999, AM J PHYSIOL-LUNG C, V276, pL891, DOI 10.1152/ajplung.1999.276.6.L891; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Manunta M, 2000, FEBS LETT, V471, P256, DOI 10.1016/S0014-5793(00)01385-5; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Ogawa Y, 2000, TRENDS CARDIOVAS MED, V10, P65, DOI 10.1016/S1050-1738(00)00050-5; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Poirier SN, 2001, BIOCHEMISTRY-US, V40, P6486, DOI 10.1021/bi010207k; Qi Y, 1998, J BIOL CHEM, V273, P34813, DOI 10.1074/jbc.273.52.34813; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Sienaert I, 1998, PFLUG ARCH EUR J PHY, V436, P40, DOI 10.1007/s004240050602; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; SITSAPESAN R, 1995, AM J PHYSIOL-CELL PH, V268, pC1235, DOI 10.1152/ajpcell.1995.268.5.C1235; SITSAPESAN R, 1995, J MEMBRANE BIOL, V146, P133, DOI 10.1007/BF00238004; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; Sorrentino V, 1999, TRENDS CARDIOVAS MED, V9, P54, DOI 10.1016/S1050-1738(99)00003-1; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; Valdivia HH, 2001, CIRC RES, V88, P134; Vanlingen S, 1997, CELL CALCIUM, V22, P475, DOI 10.1016/S0143-4160(97)90075-0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Xin HB, 1999, J BIOL CHEM, V274, P15315, DOI 10.1074/jbc.274.22.15315; XIN HB, 1995, BIOCHEM BIOPH RES CO, V214, P263, DOI 10.1006/bbrc.1995.2283; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613	65	59	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47715	47724		10.1074/jbc.M106573200	http://dx.doi.org/10.1074/jbc.M106573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598113	hybrid			2022-12-25	WOS:000172768500136
J	Iko, Y; Sambongi, Y; Tanabe, M; Iwamoto-Kihara, A; Saito, K; Ueda, I; Wada, Y; Futai, M				Iko, Y; Sambongi, Y; Tanabe, M; Iwamoto-Kihara, A; Saito, K; Ueda, I; Wada, Y; Futai, M			ATP synthase F-1 sector rotation - Defective torque generation in the beta subunit Ser-174 to Phe mutant and its suppression by second mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL REGION; GLYCINE-RICH SEQUENCE; ESCHERICHIA-COLI; H+-ATPASE; GAMMA-SUBUNIT; CATALYTIC SITE; F-TYPE; F1-ATPASE; F-1-ATPASE; OLIGOMER	Subunit gamma of the ATP synthase F-1 sector is located at the center of the alpha (3)beta (3), hexamer and rotates unidirectionally during ATP hydrolysis, generating the rotational torque of similar to 45 pN.nm. A mutant F-1 with the beta Ser-174 to Phe substitution (beta S174F) in the beta subunit generated lower torque (similar to 17 pN.nm), indicating that beta S174F is mechanically defective, the first such mutant reported. The defective rotation of beta S174F was suppressed by a second-site mutation, beta Gly-149 to Ala, beta Ile-163 to Ala, or beta Ile-166 to Ala in the same subunit, but not by beta Leu-238 to Ala. These results suggest that the region between beta Gly-149 and beta Ser-174 plays an important role in the coupling between ATP hydrolysis and mechanical work.	Osaka Univ, Div Biol Sci, Inst Sci & Ind Res, CREST,Japan Sci & Technol Corp, Ibaraki, Osaka 5670047, Japan; Univ Tokyo, Dept Life Sci, Grad Sch Arts & Sci, Tokyo 1538902, Japan; Kanazawa Univ, Dept Phys, Kanazawa, Ishikawa 9201192, Japan	Japan Science & Technology Agency (JST); Osaka University; University of Tokyo; Kanazawa University	Futai, M (corresponding author), Osaka Univ, Div Biol Sci, Inst Sci & Ind Res, CREST,Japan Sci & Technol Corp, Ibaraki, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; IDA K, 1991, J BIOL CHEM, V266, P5424; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; NOUMI T, 1984, J BIOL CHEM, V259, P71; OMOTE H, 1992, J BIOL CHEM, V267, P20571; OMOTE H, 1994, J BIOL CHEM, V269, P10265; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Sambongi Y, 2000, J BIOENERG BIOMEMBR, V32, P441, DOI 10.1023/A:1005656706248; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SHIN K, 1992, J BIOL CHEM, V267, P20835; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	25	25	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47508	47511		10.1074/jbc.M108803200	http://dx.doi.org/10.1074/jbc.M108803200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590180	hybrid			2022-12-25	WOS:000172768500108
J	Ishiguro, K; Kadomatsu, K; Kojima, T; Muramatsu, H; Iwase, M; Yoshikai, Y; Yanada, M; Yamamoto, K; Matsushita, T; Nishimura, M; Kusugami, K; Saito, H; Muramatsu, T				Ishiguro, K; Kadomatsu, K; Kojima, T; Muramatsu, H; Iwase, M; Yoshikai, Y; Yanada, M; Yamamoto, K; Matsushita, T; Nishimura, M; Kusugami, K; Saito, H; Muramatsu, T			Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GROWTH-FACTOR; ENDOTOXIC-SHOCK; EXPRESSION; PATHOGENESIS; ENDOTHELIUM; ACTIVATION; CYTOKINES; RESPONSES; IMPAIRS	Syndecan-4 is a transmembrane heparan sulfate proteoglycan belonging to the syndecan family. Following intraperitoneal injection of lipopolysaccharide (LPS), syndecan-4-deficient mice exhibited high mortality compared with wild-type controls. Severe endotoxin shock was observed in the deficient mice: systolic blood pressure and left ventricular fractional shortening were lower in the deficient mice than in the wild-type controls 9 h after LPS injection. Although histological examinations revealed no apparent differences between two groups, the plasma level of interleukin (IL)-1 beta was higher in the deficient mice than in the wild-type controls 9 h after LPS injection. Consistent with the regulatory roles of syndecan-4, its expression in monocytes and endothelial cells of microvasculature increased in the wild-type mice after LPS administration. Although IL-1 beta was produced to the same extent by macrophages from syndecan-4-deficient and wild-type mice after LPS stimulation, inhibition of its production by transforming growth factor-beta1 was impaired in the syndecan-4-deficient macropbages. These results indicate that syndecan-4 could be involved in prevention of endotoxin shock, at least partly through the inhibitory action of transforming growth factor-beta1 on IL-1 beta production.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med,Res Inst Dis Mechanism & Control, Lab Host Def & Germfree Life, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Inst Lab Anim Res, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Nagoya Natl Hosp, Naka Ku, Nagoya, Aichi 4600001, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University; Nagoya University	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tmurama@med.nagoya-u.ac.jp	Yanada, Masamitsu/B-5146-2012; Kojima, Tetsuhito/I-6271-2014; Yanada, Masamitsu/AAX-1343-2021; Matsushita, Tadadshi/I-7349-2014; Kadomatsu, Kenji/G-8083-2012	Kojima, Tetsuhito/0000-0002-1905-1065; Yanada, Masamitsu/0000-0003-1602-9775; Ishiguro, Kazuhiro/0000-0003-1776-2805				Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Amiot F, 1997, MOL MED, V3, P864, DOI 10.1007/BF03401722; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Dinarello CA, 1997, CHEST, V112, p321S, DOI 10.1378/chest.112.6_Supplement.321S; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; GALANOS C, 1993, IMMUNOBIOLOGY, V187, P346, DOI 10.1016/S0171-2985(11)80349-9; Imai K, 2000, INFECT IMMUN, V68, P2418, DOI 10.1128/IAI.68.5.2418-2423.2000; Ishiguro K, 2000, DEV DYNAM, V219, P539, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1081>3.0.CO;2-K; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; Ishiguro K, 1999, HISTOCHEM CELL BIOL, V112, P25, DOI 10.1007/s004180050388; Ishiguro K, 2001, LAB INVEST, V81, P509, DOI 10.1038/labinvest.3780259; Kaisho T, 2000, CRIT REV IMMUNOL, V20, P393; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; Krishnaswamy G, 1999, J INTERF CYTOK RES, V19, P91, DOI 10.1089/107999099314234; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; Marsh CB, 1996, CLIN CHEST MED, V17, P183, DOI 10.1016/S0272-5231(05)70308-7; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MIOSSEC P, 1986, J IMMUNOL, V136, P2486; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Tanaka Y, 1998, P ASSOC AM PHYSICIAN, V110, P118; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Yamamoto K, 1996, J CLIN INVEST, V97, P2440, DOI 10.1172/JCI118691; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786	35	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47483	47488		10.1074/jbc.M106268200	http://dx.doi.org/10.1074/jbc.M106268200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585825	hybrid			2022-12-25	WOS:000172768500105
J	Lundqvist, ML; Middleton, DL; Hazard, S; Warr, GW				Lundqvist, ML; Middleton, DL; Hazard, S; Warr, GW			The immunoglobulin heavy chain locus of the duck - Genomic organization and expression of D, J, and C region genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE THIOESTERASE; CONSTANT-REGION; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; ANAS-PLATYRHYNCHOS; GERMINAL-CENTERS; DNA-SEQUENCES; CLASS SWITCH; B-CELLS; IGA	The region of the duck IgH locus extending from upstream of the proximal diversity (D) segment to downstream of the constant gene cluster has been cloned and mapped. A sequence contig of 48,796 base pairs established that the organization of the genes is D-J(H)-mu-alpha-upsilon. No evidence for a functional homologue (or remnant) of a delta gene was found. The a gene is in inverted transcriptional orientation; class switch to IgA expression thus requires inversion of the similar to 27-kilobase pair region that includes both mu and alpha genes. The secreted forms of duck alpha and mu are each encoded by 4 constant region exons, and the hydrophobic C-terminal regions of the membrane receptor forms of a and tx are encoded by one and two transmembrane exons, respectively. Putative switch (S) regions were identified for duck mu and upsilon by comparison with chicken S mu and S upsilon sequences and for duck alpha by comparison with mouse S alpha. The duck IgH locus is rich in complex variable number tandem repeats, which occupy similar to 60% of the sequenced region, and occur at a much higher frequency in the IgH locus than in other sequenced regions of the duck genome.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Biomol Comp Resource, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Warr, GW (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045111] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 45111] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arakawa H, 1996, EMBO J, V15, P2540, DOI 10.1002/j.1460-2075.1996.tb00611.x; Arakawa H, 1998, J IMMUNOL, V160, P4232; BARKER WC, 1972, ATLAS PROTEIN SEQUEN, V5, P31; Bengten E, 2000, CURR TOP MICROBIOL, V248, P189; BRUGGEMANN M, 1987, MOL GENETICS IMMUNOG, P51; Brusco A, 1999, J IMMUNOL, V163, P4392; Campbell K S, 1994, Semin Immunol, V6, P393, DOI 10.1006/smim.1994.1049; Coyle JH, 2000, J IMMUNOL, V164, P3659, DOI 10.4049/jimmunol.164.7.3659; DAHAN A, 1983, NUCLEIC ACIDS RES, V11, P5381, DOI 10.1093/nar/11.16.5381; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; Du Pasquier L, 2000, CURR TOP MICROBIOL, V248, P159; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HIGGINS DA, 1993, AVIAN PATHOL, V22, P211, DOI 10.1080/03079459308418916; JACK HM, 1988, P NATL ACAD SCI USA, V85, P1581, DOI 10.1073/pnas.85.5.1581; Kitao H, 2000, INT IMMUNOL, V12, P959, DOI 10.1093/intimm/12.7.959; LESLIE GA, 1976, INT ARCH ALLER A IMM, V51, P175, DOI 10.1159/000231590; LI X, 1995, BBA-GENE STRUCT EXPR, V1261, P25, DOI 10.1016/0167-4781(94)00211-K; Longmire JL, 1999, J HERED, V90, P574, DOI 10.1093/jhered/90.5.574; Magor KE, 1999, IMMUNOGENETICS, V49, P692, DOI 10.1007/s002510050666; Magor KE, 1998, EUR J IMMUNOL, V28, P1063, DOI 10.1002/(SICI)1521-4141(199803)28:03&lt;1063::AID-IMMU1063&gt;3.0.CO;2-O; MAGOR KE, 1994, J IMMUNOL, V153, P5549; MAGOR KE, 1992, J IMMUNOL, V149, P2627; MANSIKKA A, 1992, J IMMUNOL, V149, P855; MCCORMACK WT, 1991, ANNU REV IMMUNOL, V9, P219; NG PLK, 1986, IMMUNOLOGY, V58, P323; PARVARI R, 1988, EMBO J, V7, P739, DOI 10.1002/j.1460-2075.1988.tb02870.x; Primmer CR, 1997, GENOME RES, V7, P471, DOI 10.1101/gr.7.5.471; REYNAUD CA, 1994, ADV IMMUNOL, V57, P353, DOI 10.1016/S0065-2776(08)60676-8; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROSE TM, 1994, DNA CELL BIOL, V13, P669, DOI 10.1089/dna.1994.13.669; Ross DA, 1998, IMMUNOL REV, V166, P143, DOI 10.1111/j.1600-065X.1998.tb01259.x; SASAKI GC, 1988, DNA-J MOLEC CELL BIO, V7, P449, DOI 10.1089/dna.1.1988.7.449; SEIPELT RL, 1995, MOL IMMUNOL, V32, P277, DOI 10.1016/0161-5890(94)00141-M; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; TUCKER PW, 1981, P NATL ACAD SCI-BIOL, V78, P7684, DOI 10.1073/pnas.78.12.7684; van Tuinen M, 2000, MOL BIOL EVOL, V17, P451, DOI 10.1093/oxfordjournals.molbev.a026324; Vergnaud G, 2000, GENOME RES, V10, P899, DOI 10.1101/gr.10.7.899; WACHTEL SS, 1993, COMP BIOCHEM PHYS B, V104, P207, DOI 10.1016/0305-0491(93)90360-H; WARR GW, 1995, IMMUNOL TODAY, V16, P392, DOI 10.1016/0167-5699(95)80008-5; WHITE MB, 1985, SCIENCE, V228, P733, DOI 10.1126/science.3922054; Wilson M, 1997, P NATL ACAD SCI USA, V94, P4593, DOI 10.1073/pnas.94.9.4593; YU LM, 1990, J IMMUNOL, V145, P3932; Zhao Y, 2000, IMMUNOLOGY, V101, P348, DOI 10.1046/j.1365-2567.2000.00106.x	46	70	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46729	46736		10.1074/jbc.M106221200	http://dx.doi.org/10.1074/jbc.M106221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592961	hybrid			2022-12-25	WOS:000172768500009
J	Androutsellis-Theotokis, A; Ghassemi, F; Rudnick, G				Androutsellis-Theotokis, A; Ghassemi, F; Rudnick, G			A conformationally sensitive residue on the cytoplasmic surface of serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; TRANSMEMBRANE DOMAIN; PLATELET 5-HYDROXYTRYPTAMINE; SCANNING MUTAGENESIS; EXPRESSION CLONING; GABA TRANSPORTER; COCAINE BINDING; BETA-ALANINE	Serotonin transporter (SERT) contains a single reactive external cysteine residue at position 109 (Chen, J. G., Liu-Chen, S., and Rudnick, G. (1997) Biochemistry 36, 1479-1486) and seven predicted cytoplasmic cysteines. A mutant of rat SERT (X8C) in which those eight cysteine residues were replaced by other amino acids retained similar to 32% of wild type transport activity and similar to 56% of wild type binding activity. In contrast to wild-type SERT or the C109A mutant, X8C was resistant to inhibition of high affinity cocaine analog binding by the cysteine reagent 2-(aminoethyl)methanethiosulfonate hydrobromide (MTSEA) in membrane preparations from transfected cells. Each predicted cytoplasmic cysteine residue was reintroduced, one at a time, into the X8C template. Reintroduction of Cys-357, located in the third intracellular loop, restored MTSEA sensitivity similar to that of C109A. Replacement of only Cys-109 and Cys-357 was sufficient to prevent MTSEA sensitivity. Thus, Cys-357 was the sole cytoplasmic determinant of MTSEA sensitivity in SERT. Both serotonin and cocaine protected SERT from inactivation by MTSEA at Cys-357. This protection was apparently mediated through a conformational change following ligand binding. Although both ligands bind in the absence of Na+ and at 4 degreesC, their ability to protect Cys-357 required Na+ and was prevented at 4 degreesC. The accessibility of Cys-357 to MTSEA inactivation was increased by monovalent cations. The K+ ion, which is believed to serve as a countertransport substrate for SERT, was the most effective ion for increasing Cys-357 reactivity.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,POB 3333, New Haven, CT 06510 USA.			Androutsellis-Theotokis, Andreas/0000-0002-1985-4589				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BOYER WF, 1992, INT CLIN PSYCHOPHARM, V6, P5, DOI 10.1097/00004850-199206005-00001; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; MAYSER W, 1991, FEBS LETT, V295, P203, DOI 10.1016/0014-5793(91)81418-8; Nelson N, 1998, J NEUROCHEM, V71, P1785; NELSON PJ, 1979, J BIOL CHEM, V254, P84; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Smicun Y, 1999, J BIOL CHEM, V274, P36058, DOI 10.1074/jbc.274.51.36058; SMITH KE, 1992, MOL PHARMACOL, V42, P563; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; TATE CG, 1994, J BIOL CHEM, V269, P26303; UHL GR, 1994, J EXP BIOL, V196, P229; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; WALL SC, 1993, MOL PHARMACOL, V43, P264; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	41	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45933	45938		10.1074/jbc.M107462200	http://dx.doi.org/10.1074/jbc.M107462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11592963	hybrid			2022-12-25	WOS:000172573100061
J	Blanchard-Fillion, B; Souza, JM; Friel, T; Jiang, GCT; Vrana, K; Sharov, V; Barron, L; Schoneich, C; Quijano, C; Alvarez, B; Radi, R; Przedborski, S; Fernando, GS; Horwitz, J; Ischiropoulos, H				Blanchard-Fillion, B; Souza, JM; Friel, T; Jiang, GCT; Vrana, K; Sharov, V; Barron, L; Schoneich, C; Quijano, C; Alvarez, B; Radi, R; Przedborski, S; Fernando, GS; Horwitz, J; Ischiropoulos, H			Nitration and inactivation of tyrosine hydroxylase by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; TRYPTOPHAN-HYDROXYLASE; OXIDATIVE STRESS; PROTEIN; IDENTIFICATION; MICE; INHIBITION; METHIONINE; SUBSTRATE	Tyrosine hydroxylase (TH) is modified by nitration after exposure of mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydrophenylpyridine. The temporal association of tyrosine nitration with inactivation of TH activity in vitro suggests that this covalent post-translational modification is responsible for the in vivo loss of TH function (Ara, J., Przedborski, S., Naini, A. B., Jackson-Lewis, V., Trifiletti, R. R., Horwitz, J., and Ischiropoulos, H. (1998) Proc. Natl. Acad Sci. U. S. A. 95, 7659 -7663). Recent data showed that cysteine oxidation rather than tyrosine nitration is responsible for TH inactivation after peroxynitrite exposure in vitro (Kuhn, D. M., Aretha, C. W., and Geddes, T. J. (1999) J. Neurosci. 19, 10289-10294). However, re-examination of the reaction of peroxynitrite with purified TH failed to produce cysteine oxidation but resulted in a concentration-dependent increase in tyrosine nitration and inactivation. Cysteine oxidation is only observed after partial unfolding of the protein. Tyrosine residue 423 and to lesser extent tyrosine residues 428 and 432 are modified by nitration. Mutation of Tyr(423) to Phe resulted in decreased nitration as compared with wild type protein without loss of activity. Stopped-flow experiments reveal a second order rate constant of (3.8 +/- 0.9) X 10(3) M-1 s(-1) at pH 7.4 and 25 degreesC for the reaction of peroxynitrite with TH. Collectively, the data indicate that peroxynitrite reacts with the metal center of the protein and results primarily in the nitration of tyrosine residue 423, which is responsible for the inactivation of TH.	Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27106 USA; Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Univ Republica, Fac Ciencas, Lab Enzimol, Montevideo 11800, Uruguay; Univ Republica, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Columbia Univ, Dept Neurol, Movement Disorder Div, New York, NY 10032 USA; Columbia Univ, Dept Pathol, Movement Disorder Div, New York, NY 10032 USA; MCP Hahnemann Sch Med, Dept Physiol & Pharmacol, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Wake Forest University; University of Kansas; Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Columbia University; Columbia University; Drexel University	Ischiropoulos, H (corresponding author), Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ischirop@mial.med.upenn.edu		Alvarez, Beatriz/0000-0001-6911-3132; Vrana, Kent/0000-0003-4902-7733	NIA NIH HHS [AG13966] Funding Source: Medline; NINDS NIH HHS [NS38370, NS38586, NS37345] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038370, R29NS037345, R01NS038586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013966] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Ellis HR, 2000, BIOCHEMISTRY-US, V39, P4174, DOI 10.1021/bi9928546; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Fahn S., 2000, MERRITTS NEUROLOGY, P679; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; Kaufman S, 1995, Adv Enzymol Relat Areas Mol Biol, V70, P103; Kuhn DM, 1999, J NEUROSCI, V19, P10289; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; Minetti M, 2000, BIOCHEMISTRY-US, V39, P6689, DOI 10.1021/bi9927991; NAGATSU T, 1990, NEUROCHEM RES, V15, P425, DOI 10.1007/BF00969928; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Perl DP, 1998, ANN NEUROL, V44, pS19, DOI 10.1002/ana.410440705; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Quijano C, 2001, J BIOL CHEM, V276, P11631, DOI 10.1074/jbc.M009429200; Quinsey NS, 1996, J NEUROCHEM, V66, P908; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; RIBEIRO P, 1991, J BIOL CHEM, V266, P16207; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; VRANA KE, 1994, LIFE SCI, V55, P1045, DOI 10.1016/0024-3205(94)00639-3; WALKER SJ, 1994, BBA-PROTEIN STRUCT M, V1206, P113, DOI 10.1016/0167-4838(94)90079-5; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Yohrling GJ, 1999, J MOL NEUROSCI, V12, P23, DOI 10.1385/JMN:12:1:23; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	47	131	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46017	46023		10.1074/jbc.M105564200	http://dx.doi.org/10.1074/jbc.M105564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590168	hybrid			2022-12-25	WOS:000172573100072
J	Dow, R; Hendley, J; Pirkmaier, A; Musgrove, EA; Germain, D				Dow, R; Hendley, J; Pirkmaier, A; Musgrove, EA; Germain, D			Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT PROTEOLYSIS; BREAST-CARCINOMA CELLS; CYCLIN D1; EXPRESSION; P27(KIP1); COMPLEX; DIFFERENTIATION; SUPPRESSION; PHOSPHORYLATION; CHEMOPREVENTION	The mechanism by which all-trans retinoic acid (ATRA) leads to a Gi arrest of the cell cycle remains unclear. We show here that the decrease in D-type cyclin levels observed following ATRA treatment correlates with an increase in the rate of cyclin D1 ubiquitylation in both T-47D and MCF-7 breast cancer cell lines. However, MCF-7 cells are more resistant to ATRA than T-47D cells indicating that cyclin DI degradation is not sufficient for ATRA-mediated arrest. We found a striking difference between these cells in that while ATRA induces an elevation in the cdk inhibitor p27 in T-47D cells, this is not observed in the ATRA-resistant MCF-7 cells. Furthermore, we demonstrate that ATRA promotes the ubiquitylation of Skp2, an F-box protein that targets p27 for degradation. Moreover, overexpression of Skp2 in T-47D cells prevents accumulation of p27 and promotes resistance to ATRA In addition, overexpression of cyclin DI in T-47D cells also promotes ATRA resistance. We found that the mechanism of ATRA-induced ubiquitylation of cyclin D1 and Skp2 is independent of CUL-1 expression and that ATRA can rescue cyclin DI degradation in the uterine cell line SK-UT-1, where D-type cyclins are stabilized due to a specific defect in proteolysis. These data suggest that ATRA induces a novel pathway of ubiquitylation and that the degradation of the F-box protein Skp2 is the mechanism underlying p27 accumulation and cyclin E-cdk2 inactivation following ATRA treatment.	Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, Sydney, NSW 2010, Australia	Peter Maccallum Cancer Center; University of Melbourne; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Germain, D (corresponding author), Peter MacCallum Canc Inst, St Andrews Pl, Melbourne, Vic 3002, Australia.	d.germain@pmei.unimelb.edu.au						Ahn MJ, 1995, ONCOGENE, V11, P2357; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; COBLEIGH MA, 1994, LEUKEMIA, V8, pS59; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Green A, 1999, CARCINOGENESIS, V20, P1535, DOI 10.1093/carcin/20.8.1535; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Welcker M, 1996, ONCOGENE, V13, P419; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zajac-Kaye M, 2000, BIOCHEM J, V345, P535, DOI 10.1042/0264-6021:3450535; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	39	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45945	45951		10.1074/jbc.M103593200	http://dx.doi.org/10.1074/jbc.M103593200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11595732	hybrid			2022-12-25	WOS:000172573100063
J	Emrick, MA; Hoofnagle, AN; Miller, AS; Ten Eyck, LF; Ahn, NG				Emrick, MA; Hoofnagle, AN; Miller, AS; Ten Eyck, LF; Ahn, NG			Constitutive activation of extracellular signal-regulated kinase 2 by synergistic point mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OF-FUNCTION MUTATION; PROTEIN-KINASE; PHOSPHORYLATION SITES; CATALYTIC ACTIVATION; MAP KINASES; ERK2; AUTOPHOSPHORYLATION; TRANSFORMATION; IDENTIFICATION; TYROSINE	Constitutively active mutant forms of signaling enzymes provide insight into mechanisms of activation as well as useful molecular tools for probing downstream targets. In this study, point mutations in ERK2 at conserved residues L73P and S151D were identified that individually led to 8-12-fold increased specific activity and in combination reached 50-fold, indicating synergistic interactions between these residues. Examination by mass spectrometry, phosphatase sensitivity, and Western blotting revealed that the mutations enhanced ERK2 activity by facilitating intramolecular autophosphorylation predominantly at Tyr-185 and to a lesser extent at Thr-183 and that phosphorylation at both sites is required for activation. A set of short molecular dynamics simulations were carried out using different random seeds to sample locally accessible configurations. Simulations of the active mutant showed potential hydrogen bonding interactions between the phosphoryl acceptor and catalytic nucleophile, which could account for enhanced intramolecular autophosphorylation. In intact cells, the ERK2 mutants were functionally active in phosphorylating Elk-1 and RSK1 and activating the e-fos promoter. This activity was only partially reduced upon treatment of cells with the MKK1/2 inhibitor, U0126, indicating that in vivo the mechanism of ERK2 activation occurs substantially through autophosphorylation and partially through phosphorylation by MKK1/2.	Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA; Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of California System; University of California San Diego	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Campus Box 215, Boulder, CO 80309 USA.				NIGMS NIH HHS [T32 GM008759, GM48521, T32 GM142607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048521, T32GM008759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; BRUNET A, 1994, ONCOGENE, V9, P3379; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CASE D, 1997, AMBER 5 0; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hall JP, 1996, MOL CELL BIOL, V16, P6715; Ikeda H, 1997, P NATL ACAD SCI USA, V94, P6375, DOI 10.1073/pnas.94.12.6375; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; Resing KA, 1997, METHOD ENZYMOL, V283, P29; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5778; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	34	61	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46469	46479		10.1074/jbc.M107708200	http://dx.doi.org/10.1074/jbc.M107708200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591711	hybrid			2022-12-25	WOS:000172573100132
J	Jho, SH; Radoja, N; Im, MJ; Tomic-Canic, M				Jho, SH; Radoja, N; Im, MJ; Tomic-Canic, M			Negative response elements in keratin genes mediate transcriptional repression and the cross-talk among nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID; BINDING-SPECIFICITY; DNA; IDENTIFICATION; EXPRESSION; POSITION; HETERODIMERIZATION; DIFFERENTIATION; TRANSFECTION	Very little is known about the mechanisms responsible for the findings that binding of nuclear receptors (NR) to some promoter elements leads to transcriptional activation, whereas binding to others leads to repression. Case in point is the group of epidermal keratin genes and their DNA sequences responsible for repression by NR. Keratin response elements (KREs) interact with receptors for retinoic acid, thyroid hormone, and glucocorticoids. KREs, by their structure and sequence, direct the binding of retinoic acid and thyroid hormone as homodimers and glucocorticoids as monomers. Such specific DNA-receptor interactions are crucial for the repression signal of transcription. In this paper we have analyzed the interactions between the KREs and NR that lead to such repression. We have found that KREs are promoter-independent. They not only provide a docking platform for the receptors, but also play a key role in directing the receptors to bind into particular configurations and coordinating the interactions among different receptors. Both an intact KRE and an intact receptor DNA-binding domain are necessary for the regulation to occur, which emphasizes the importance of interaction between the DNA and NR. for proper signaling. Furthermore, KREs allow simultaneous binding of multiple receptors, thus providing fine-tuning of transcriptional regulation. The DNA/DNA-binding domain interactions in keratin promoters exemplify tissue and gene specificity of hormone action.	NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA; Inst Vinca, YU-11000 Belgrade, Yugoslavia	New York University; University of Belgrade	Tomic-Canic, M (corresponding author), NYU, Sch Med, Ronald O Perelman Dept Dermatol, 550 1St Ave, New York, NY 10016 USA.	tomicm01@med.nyu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045974] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLUMENBERG M, 1997, FORMATION STRUCTURE; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CARR FE, 1992, J BIOL CHEM, V267, P18689; CARR FE, 1994, J BIOL CHEM, V269, P4175; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; FISHER C, 1995, CRIT REV ORAL BIOL M, V6, P284, DOI 10.1177/10454411950060040201; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; Hagerty T, 2001, J NEUROCHEM, V76, P825, DOI 10.1046/j.1471-4159.2001.00072.x; Hanley K, 1997, J CLIN INVEST, V100, P705, DOI 10.1172/JCI119583; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; Komuves LG, 1998, J INVEST DERMATOL, V111, P429, DOI 10.1046/j.1523-1747.1998.00296.x; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2000, J STEROID BIOCHEM, V74, P351, DOI 10.1016/S0960-0760(00)00112-6; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; PONEC M, 1981, J INVEST DERMATOL, V76, P211, DOI 10.1111/1523-1747.ep12525761; PUNNONEN R, 1980, J ENDOCRINOL INVEST, V3, P217, DOI 10.1007/BF03348266; QI JS, 1995, MOL CELL BIOL, V15, P1817; Radoja N, 1997, J INVEST DERMATOL, V109, P566, DOI 10.1111/1523-1747.ep12337483; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Randolph RK, 1997, J LIPID RES, V38, P1374; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; Reginato MJ, 1996, J BIOL CHEM, V271, P28199, DOI 10.1074/jbc.271.45.28199; Reichardt HM, 2000, Z RHEUMATOL, V59, P1; Rivier M, 1998, J INVEST DERMATOL, V111, P1116, DOI 10.1046/j.1523-1747.1998.00439.x; SLOAN KB, 1996, CUTANEOUS MED SURG, V1, P160; Slominski A, 2000, BBA-GEN SUBJECTS, V1474, P1, DOI 10.1016/S0304-4165(99)00215-9; Taylor AH, 1996, BIOCHEMISTRY-US, V35, P8281, DOI 10.1021/bi960269o; TOMIC M, 1990, CELL REGUL, V1, P965, DOI 10.1091/mbc.1.12.965; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; Tomic-Canic M, 1996, Methods Mol Biol, V57, P249; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; TOMICCANIC M, 1992, J INVEST DERMATOL, V99, P842, DOI 10.1111/1523-1747.ep12614806; Tzameli I, 1996, J BIOL CHEM, V271, P8402, DOI 10.1074/jbc.271.14.8402; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; WU Y, 2001, J BIOL CHEM, V276, P3939; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	42	24	26	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45914	45920		10.1074/jbc.M103144200	http://dx.doi.org/10.1074/jbc.M103144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591699	Green Published, hybrid			2022-12-25	WOS:000172573100058
J	San, AK; Tribble, GD; Grainge, I; Frohlich, RF; Knudsen, BR; Jayaram, M				San, AK; Tribble, GD; Grainge, I; Frohlich, RF; Knudsen, BR; Jayaram, M			Biochemical and kinetic analysis of the RNase active sites of the integrase/tyrosine family site-specific DNA recombinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-MU-M CIRCLE PLASMID; FLP RECOMBINASE; RIBONUCLEASE-ACTIVITIES; CRYSTAL-STRUCTURE; INT FAMILY; TOPOISOMERASE; CLEAVAGE; MODEL; AMPLIFICATION; SIMILARITIES	In this study, we have used multiple strategies to characterize the mechanisms of the type I and type II RNA cleavage activities harbored by the Flp (pronounced here as "flip") site-specific DNA recombinase (Flp-RNase I and II, respectively). Reactions using half-sites prebound by step-arrest mutants of Flp agree with a "shared active site" being responsible for the type I reaction (as is the case with normal DNA recombination). In a "pre-cleaved" type I substrate containing a 3'-phosphotyrosyl bond, the Flp-RNase I activity can be elicited by either wild type Flp or by Flp(Y343F). Kinetic analyses of the type I reaction are consistent with the above observations and support the notion that the DNA recombinase and type I RNase active sites are identical. The type II RNase activity is expressed by Flp(Y343F) in a half-site substrate and is unaffected by the catalytic constitution of a Flp monomer present on a partner half-site. Reaction conditions that proscribe the assembly of a DNA bound Flp dimer have no effect on Flp-RNase II. These biochemical results, together with kinetic data, are consistent with the reaction being performed from a "non-shared active site" contained within a single Flp monomer. The Flp-related recombinase Cre, which utilizes a non-shared recombination active site, exhibits the type I RNA cleavage reaction. So far, we have failed to detect the type II RNase activity in Cre. Despite their differences in active site assembly, Cre functionally mimics Flp in being able to provide two functional active sites from a trimer of Cre bound to a three-armed (Y-shaped) substrate.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark	University of Texas System; University of Texas Austin; Aarhus University	Jayaram, M (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.	Jayaram@icmb.utexas.edu	Grainge, Ian RF/A-9031-2010; Tribble, Gena/A-8755-2011	Grainge, Ian RF/0000-0001-8268-583X; Tribble, Gena/0000-0002-6468-2851; Knudsen, Birgitta Ruth/0000-0002-3484-3802	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019687] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM019687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROACH JR, 1991, MOL CELLULAR BIOL YE, V1, P297; Burgin AB, 1997, CELL, V91, P873, DOI 10.1016/S0092-8674(00)80478-X; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; FUTCHER B, 1988, GENETICS, V118, P411; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; Grainge I, 2000, J MOL BIOL, V298, P749, DOI 10.1006/jmbi.2000.3679; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; JAYARAM M, 2000, IN PRESS MOBILE DN 2; Knudsen BR, 1997, J MOL BIOL, V266, P93, DOI 10.1006/jmbi.1996.0767; Knudsen BR, 1998, J BIOL CHEM, V273, P22028, DOI 10.1074/jbc.273.34.22028; LEE J, 1993, J BIOL CHEM, V268, P17564; Lee J, 1996, J MOL BIOL, V257, P532, DOI 10.1006/jmbi.1996.0183; Lee J, 2000, J MOL BIOL, V296, P403, DOI 10.1006/jmbi.1999.3472; Lee J, 1997, GENE DEV, V11, P3061, DOI 10.1101/gad.11.22.3061; Lee J, 1997, GENE DEV, V11, P2438, DOI 10.1101/gad.11.18.2438; Lee J, 1999, EMBO J, V18, P784, DOI 10.1093/emboj/18.3.784; LUETKE KH, 1995, J MOL BIOL, V251, P493, DOI 10.1006/jmbi.1995.0451; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PAN GH, 1992, J BIOL CHEM, V267, P12397; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; Tribble G, 2000, J BIOL CHEM, V275, P22255, DOI 10.1074/jbc.M908261199; VOLKERT FC, 1986, CELL, V46, P541, DOI 10.1016/0092-8674(86)90879-2; Voziyanov Y, 1996, J MOL BIOL, V256, P720, DOI 10.1006/jmbi.1996.0120; Voziyanov Y, 1999, NUCLEIC ACIDS RES, V27, P930, DOI 10.1093/nar/27.4.930; Woods KC, 2001, J MOL BIOL, V313, P49, DOI 10.1006/jmbi.2001.5012; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6; Xu CJ, 1998, J BIOL CHEM, V273, P30591, DOI 10.1074/jbc.273.46.30591	37	5	6	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46612	46623		10.1074/jbc.M106492200	http://dx.doi.org/10.1074/jbc.M106492200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585826	hybrid			2022-12-25	WOS:000172573100148
J	Yarmola, EG; Parikh, S; Bubb, MR				Yarmola, EG; Parikh, S; Bubb, MR			Formation and implications of a ternary complex of profilin, thymosin beta(4), and actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE ACTIN; F-ACTIN; FILAMENT DYNAMICS; POLYMORPHONUCLEAR LEUKOCYTES; PROTEIN-STRUCTURE; MONOMERIC ACTIN; PLANT PROFILIN; BARBED-END; BINDING; BETA-4	Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that profilin, thymosin beta (4), and actin form a ternary complex. In contrast, steady-state assays measuring F-actin concentration are insensitive to the formation of such a complex. Experiments using a peptide that corresponds to the N terminus of thymosin beta (4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta (4), and explain why thymosin beta (4) and profilin can bind simultaneously to actin. Surprisingly, despite much lower affinity, the N-terminal thymosin beta (4) peptide has a very slow dissociation rate constant relative to the intact protein, consistent with a catalytic effect of the C terminus on conformational change occurring at the N terminus of thymosin beta (4). Intracellular concentrations of thymosin beta (4) and profilin may greatly exceed the equilibrium dissociation constant of the ternary complex, inconsistent with models showing sequential formation of complexes of profilin-actin or thymosin beta (4)-actin during dynamic remodeling of the actin cytoskeleton. The formation of a ternary complex results in a very large amplification mechanism by which profilin and thymosin beta (4) can sequester much more actin than is possible for either protein acting alone, providing an explanation for significant sequestration even if molecular crowding results in a very low critical concentration of actin in vivo.	Univ Florida, Dept Med, Gainesville, FL 32610 USA; Vet Affairs Med Ctr, Malcom Randall Dept, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bubb, MR (corresponding author), Univ Florida, Dept Med, Box 100277, Gainesville, FL 32610 USA.							Ballweber E, 1998, FEBS LETT, V425, P251, DOI 10.1016/S0014-5793(98)00240-3; Bonnet D, 1996, EXP HEMATOL, V24, P776; BUBB MR, 1991, J BIOL CHEM, V266, P3820; CARLIER MF, 1991, J BIOL CHEM, V266, P1; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; CZISCH M, 1993, EUR J BIOCHEM, V218, P335, DOI 10.1111/j.1432-1033.1993.tb18382.x; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; Feinberg J, 1996, BIOCHEM BIOPH RES CO, V222, P127, DOI 10.1006/bbrc.1996.0709; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Huff T, 1997, FEBS LETT, V414, P39, DOI 10.1016/S0014-5793(97)00946-0; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Selden LA, 1999, BIOCHEMISTRY-US, V38, P2769, DOI 10.1021/bi981543c; Simenel C, 2000, EUR J BIOCHEM, V267, P3530, DOI 10.1046/j.1432-1327.2000.01380.x; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STROMQVIST M, 1984, J MUSCLE RES CELL M, V5, P443, DOI 10.1007/BF00818262; Tarachandani A, 1996, CELL MOTIL CYTOSKEL, V34, P313, DOI 10.1002/(SICI)1097-0169(1996)34:4<313::AID-CM6>3.0.CO;2-8; TELLAM RL, 1983, BIOCHEM J, V213, P651, DOI 10.1042/bj2130651; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; Young JD, 1999, NAT MED, V5, P1424; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	45	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45555	45563		10.1074/jbc.M105723200	http://dx.doi.org/10.1074/jbc.M105723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579089	hybrid			2022-12-25	WOS:000172573100011
J	Chen, Q; Nussbaum-Shochat, A; Amster-Choder, O				Chen, Q; Nussbaum-Shochat, A; Amster-Choder, O			A novel sugar-stimulated covalent switch in a sugar sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; BETA-GLUCOSIDE PERMEASE; OXYR TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; BGL SYSTEM; ANTITERMINATOR PROTEIN; PHOSPHORYLATION; DOMAIN; DIMERIZATION; REQUIREMENTS	The bgl sensory system is composed of a membrane-bound sugar sensor, BglF, and a transcriptional regulator, BglG. The sensor BglF has several enzymatic activities: in its nonstimulated state, it acts as BglG phosphorylase; in the presence of beta -glucoside in the growth medium, it acts as BglG dephosphorylase and as the beta -glucoside phosphotransferase. The same active site on BglF, Cys-24, is responsible for the phosphorylation of both the stimulating sugar and the BglG protein. BglF is composed of three domains, two hydrophilic and one hydrophobic. Our previous results suggested that catalysis of the sugar-stimulated functions depends on specific interactions between the B domain, which contains the active site cysteine, and the integral membrane C domain. We report here that the stimulating sugar triggers the formation of a disulfide bond between the active site cysteine and another cysteine in the membrane-embedded domain of BglF. Inability of a mutant BglF protein to form the disulfide bridge between the B and C domains correlates with its inability to catalyze the sugar-stimulated functions. The ability of the cysteine residue in BglF to bind covalently either to a phosphoryl group or to another cysteine residue, depending on the protein stimulation state, suggests a novel way to control signaling by alternative bond formation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Amster-Choder, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.							AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Chen Q, 1998, BIOCHEMISTRY-US, V37, P17040, DOI 10.1021/bi980067n; Chen Q, 1999, J BACTERIOL, V181, P462, DOI 10.1128/JB.181.2.462-468.1999; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Chen Q, 2000, J BACTERIOL, V182, P2033, DOI 10.1128/JB.182.7.2033-2036.2000; Chen Q, 1998, BIOCHEMISTRY-US, V37, P8714, DOI 10.1021/bi9731652; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; Meijberg W, 1998, J BIOL CHEM, V273, P7949, DOI 10.1074/jbc.273.14.7949; Paget MSB, 1998, EMBO J, V17, P5776, DOI 10.1093/emboj/17.19.5776; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; ROBILLARD GT, 1986, BIOCHEMISTRY-US, V25, P1346, DOI 10.1021/bi00354a024; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; van Montfort BA, 2001, J BIOL CHEM, V276, P12756, DOI 10.1074/jbc.M010728200; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	25	6	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44751	44756		10.1074/jbc.M108729200	http://dx.doi.org/10.1074/jbc.M108729200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579106	hybrid			2022-12-25	WOS:000172406700056
J	Hall, C; Brown, M; Jacobs, T; Ferrari, G; Cann, N; Teo, M; Monfries, C; Lim, L				Hall, C; Brown, M; Jacobs, T; Ferrari, G; Cann, N; Teo, M; Monfries, C; Lim, L			Collapsin response mediator protein switches RhoA and Rac1 morphology in N1E-115 neuroblastoma cells and is regulated by Rho kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-CONE COLLAPSE; ACTIN STRESS FIBERS; LYSOPHOSPHATIDIC ACID; FOCAL COMPLEXES; NERVOUS-SYSTEM; ACTIVATING RHO; AXON OUTGROWTH; SEMAPHORIN 3A; SMALL GTPASES; PC12 CELLS	The formation and directional guidance of neurites involves dynamic regulation of Rho family GTPases. Rac and Cdc42 promote neurite outgrowth, whereas Rho activation causes neurite retraction. Here we describe a role for collapsin response mediator protein (Crmp-2), a neuronal protein implicated in axonal outgrowth and a component of the semaphorin 3A pathway, in switching GTPase signaling when expressed in combination with either dominant active Rac or Rho. In neuroblastoma N1E-115 cells, co-expression of Crmp-2 with dominant active RhoA V14 induced Rac morphology, cell spreading and ruffling (and the formation of neurites). Conversely, co-expression of Crmp-2 with dominant active Rac1 V12 inhibited Rac morphology, and in cells already expressing Rac1 V12, Crmp-2 caused localized peripheral collapse, involving pivotal Rho (and Cdc42) activation. Rho kinase was a regulator of Crmp-2; Crmp-2 phosphorylation was required for Crmp-2/Rac1 V12 inhibition, but not Crmp2/RhoA V14 induction, of Rac morphology. Thus Crmp-2, regulated by Rho kinase, promotes outgrowth and collapse in response to active Rho and Rac, respectively, reversing their usual morphological effects and providing a mechanism for dynamic modulation of growth cone guidance.	UCL, Inst Neurol, Dept Neurochem, London WC1N 1PJ, England; Inst Mol & Cell Biol, Glaxo IMCB Grp, Singapore 117609, Singapore	University of London; University College London; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline	Hall, C (corresponding author), UCL, Inst Neurol, Dept Neurochem, 1 Wakefield St, London WC1N 1PJ, England.	C.Hall@ion.ucl.ac.uk	Hall, Christine/C-8390-2009					Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hall C, 2001, J NEUROSCI, V21, P5191, DOI 10.1523/JNEUROSCI.21-14-05191.2001; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Jin Z, 1997, J NEUROSCI, V17, P6256; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuhn TB, 1999, J NEUROSCI, V19, P1965; LI W, 1992, GENETICS, V132, P675; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohm B, 2000, FEBS LETT, V486, P68, DOI 10.1016/S0014-5793(00)02240-7; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tigyi G, 1996, J NEUROCHEM, V66, P549; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Wong WT, 2000, CURR OPIN NEUROBIOL, V10, P118, DOI 10.1016/S0959-4388(99)00059-8; Yuan G, 1999, J BIOL CHEM, V274, P8175, DOI 10.1074/jbc.274.12.8175	38	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43482	43486		10.1074/jbc.C100455200	http://dx.doi.org/10.1074/jbc.C100455200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11583986	hybrid			2022-12-25	WOS:000172169300109
J	Falk, K; Lau, JM; Santambrogio, L; Esteban, VM; Puentes, F; Rotzschke, O; Strominger, JL				Falk, K; Lau, JM; Santambrogio, L; Esteban, VM; Puentes, F; Rotzschke, O; Strominger, JL			Ligand exchange of major histocompatibility complex class II proteins is triggered by H-bond donor groups of small molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE DENDRITIC CELLS; MYELIN BASIC-PROTEIN; HLA-DR MOLECULES; IN-VIVO; ANTIGEN PRESENTATION; ENCEPHALITOGENIC DETERMINANT; INFLUENZA HEMAGGLUTININ; PROTEOLIPID PROTEIN; CRYSTAL-STRUCTURE; PEPTIDE EXCHANGE	Hydrogen bonds (H-bonds) are crucial for the stability of the peptide-major histocompatibility complex (MHC) complex. In particular, the H-bonds formed between the peptide ligand and the MHC class 11 binding site appear to have a great influence on the half-life of the complex. Here we show that functional groups with the capacity to disrupt hydrogen bonds (e.g. -OH) can efficiently catalyze ligand exchange reactions on HLA-DR molecules. In conjunction with simple carrier molecules (such as propyl or benzyl residues), they trigger the release of low affinity ligands, which permits the rapid binding of peptides with higher affinity. Similar to HLA-DM, these compounds are able to influence the MHC class 11 ligand repertoire. In contrast to HLA-DM, however, these simple small molecules are still active at neutral pH. Under physiological conditions, they increase the number of "peptide-receptive" MHC class 11 molecules and facilitate exogenous peptide loading of dendritic cells. The drastic acceleration of the ligand exchange on these antigen presenting cells suggests that, in general, availability of H-bond donors in the extracellular milieu controls the rate of MHC class II ligand exchange reactions on the cell surface. These molecules may therefore be extremely useful for the loading of antigens onto dendritic cells for therapeutic purposes.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Dana Farber Canc Inst, Dept Canc Immunol AIDS, Boston, MA 02115 USA	Harvard University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Harvard University; Dana-Farber Cancer Institute	Strominger, JL (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.		Marin-Esteban, Viviana/A-8856-2014; Roetzschke, Olaf/GXH-0012-2022		NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045198] Funding Source: NIH RePORTER; NCI NIH HHS [5R35-CA47554] Funding Source: Medline; NIAID NIH HHS [N01-AI-45198] Funding Source: Medline; PHS HHS [R01-48832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arndt SO, 2000, EMBO J, V19, P1241, DOI 10.1093/emboj/19.6.1241; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; Ceman S, 1998, J EXP MED, V188, P2139, DOI 10.1084/jem.188.11.2139; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Chou CL, 2000, J EXP MED, V192, P1697, DOI 10.1084/jem.192.12.1697; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; Crews FT, 1996, INT REV NEUROBIOL, V39, P283, DOI 10.1016/S0074-7742(08)60670-4; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; Falk K, 2000, J EXP MED, V191, P717, DOI 10.1084/jem.191.4.717; Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245; Ghumman B, 1998, J IMMUNOL, V161, P3262; GREER JM, 1992, J IMMUNOL, V149, P783; JANEWAY J, 1999, IMMUNOBIOLOGY IMMUNE, P491; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; LAPAN KE, 1992, HYBRIDOMA, V11, P217, DOI 10.1089/hyb.1992.11.217; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; McFarland BJ, 1999, J IMMUNOL, V163, P3567; Min YH, 2000, BRIT J HAEMATOL, V110, P385, DOI 10.1046/j.1365-2141.2000.02180.x; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; Natarajan SK, 1999, J IMMUNOL, V162, P4030; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Peoples RW, 1996, ANNU REV PHARMACOL, V36, P185, DOI 10.1146/annurev.pa.36.040196.001153; Perrin CL, 1997, ANNU REV PHYS CHEM, V48, P511, DOI 10.1146/annurev.physchem.48.1.511; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; Roche PA, 1996, SCIENCE, V274, P526, DOI 10.1126/science.274.5287.526; ROOF RW, 1990, P NATL ACAD SCI USA, V87, P1735, DOI 10.1073/pnas.87.5.1735; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; Sant AJ, 1999, IMMUNOL REV, V172, P239, DOI 10.1111/j.1600-065X.1999.tb01369.x; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15050, DOI 10.1073/pnas.96.26.15050; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15056, DOI 10.1073/pnas.96.26.15056; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; TUOHY VK, 1989, J IMMUNOL, V142, P1523; Vergelli M, 1997, EUR J IMMUNOL, V27, P941, DOI 10.1002/eji.1830270421; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; WEDDERBURN LR, 1995, EUR J IMMUNOL, V25, P1654, DOI 10.1002/eji.1830250627; Wilson N, 2001, IMMUNITY, V14, P513, DOI 10.1016/S1074-7613(01)00140-6; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	45	39	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2709	2715		10.1074/jbc.M109098200	http://dx.doi.org/10.1074/jbc.M109098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11602608	hybrid			2022-12-25	WOS:000173421500045
J	Verhagen, AM; Silke, J; Ekert, PG; Pakusch, M; Kaufmann, H; Connolly, LM; Day, CL; Tikoo, A; Burke, R; Wrobel, C; Moritz, RL; Simpson, RJ; Vaux, DL				Verhagen, AM; Silke, J; Ekert, PG; Pakusch, M; Kaufmann, H; Connolly, LM; Day, CL; Tikoo, A; Burke, R; Wrobel, C; Moritz, RL; Simpson, RJ; Vaux, DL			HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA CASPASE DRONC; STRUCTURAL BASIS; IAP; SMAC/DIABLO; GENE; SURVIVAL; SEQUENCE; BINDING; FAMILY; DIAP1	Inhibitor of apoptosis (IAP) proteins inhibit caspases, a function counteracted by IAP antagonists, insect Grim, HID, and Reaper and mammalian DIABLO/Smac. We now demonstrate that HtrA2, a mammalian homologue of the Escherichia coli heat shock-inducible protein HtrA, can bind to MIHA/XIAP, MIHB, and baculoviral OpIAP but not survivin. Although produced as a 50-kDa protein, HtrA2 is processed to yield an active serine protease with an N terminus similar to that of Grim, Reaper, HID, and DIABLO/Smac that mediates its interaction with XIAP. HtrA2 is largely membrane-associated in healthy cells, with a significant proportion observed within the mitochondria, but in response to UV irradiation, HtrA2 shifts into the cytosol, where it can interact with IAPs. HtrA2 can, like DLABLO/Smac, prevent XIAP inhibition of active caspase 3 in vitro and is able to counteract XIAP protection of mammalian NT2 cells against UV-indueed cell death. The proapoptotic activity of HtrA2 in vivo involves both IAP binding and serine protease activity. Mutations of either the N-terminal alanine of mature HtrA2 essential for LAP interaction or the catalytic serine residue reduces the ability of HtrA2 to promote cell death, whereas a complete loss in proapoptotic activity is observed when both sites are mutated.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; PO Royal Melbourne Hosp, Ludwig Inst Canc Res, Joint Prot Struct Lab, Melbourne, Vic 3050, Australia; Univ Otago, Dept Biochem, Dunedin, New Zealand; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Otago; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Verhagen, AM (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Vaux, David L/C-7249-2013; Ekert, Paul/Q-1842-2015; Moritz, Robert L/B-9222-2011; Ekert, Paul G/C-7247-2013; Silke, John/B-7622-2008	Vaux, David L/0000-0003-2703-1651; Ekert, Paul/0000-0002-2976-8617; Ekert, Paul G/0000-0002-2976-8617; Silke, John/0000-0002-7611-5774; Burke, Richard/0000-0003-0086-0767; Simpson, Richard/0000-0002-9834-0796; Day, Catherine/0000-0003-1571-4367				BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Ji H, 1997, ELECTROPHORESIS, V18, P605, DOI 10.1002/elps.1150180344; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; MORITZ RL, 1992, J CHROMATOGR, V599, P119; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Savopoulos JW, 2000, PROTEIN EXPRES PURIF, V19, P227, DOI 10.1006/prep.2000.1240; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; SKORKOGLONEK J, 1995, GENE, V163, P47, DOI 10.1016/0378-1119(95)00406-V; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	35	428	462	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					445	454		10.1074/jbc.M109891200	http://dx.doi.org/10.1074/jbc.M109891200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11604410	hybrid			2022-12-25	WOS:000173087900060
J	Dutoya, S; Gibert, S; Lemercier, G; Santarelli, X; Baltz, D; Baltz, T; Bakalara, N				Dutoya, S; Gibert, S; Lemercier, G; Santarelli, X; Baltz, D; Baltz, T; Bakalara, N			A novel C-terminal kinesin is essential for maintaining functional acidocalcisomes in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE MOTOR; AFRICAN TRYPANOSOMES; ACIDIC COMPARTMENT; MEMBRANE-TRANSPORT; CYTOPLASMIC PH; POINT MUTATION; CA2+ STORAGE; PROTEIN; PURIFICATION; BINDING	Kinesins are cytoskeletal motor proteins that play roles in a variety of fundamental cellular processes including cell division and the anterograde transport of vesicles and organelles. We purified, cloned, and functionally characterized in Trypanosoma brucei a new member of the C-terminal kinesin family, TbKIFC1. Kinetic constants of the recombinant motor domain of TbKIFC1 were estimated at 0.56 muM for the microtubule dissociation constant (K-d) with a k(cat) of 0.2 s(-1). Immunolocalization analysis showed an association of TbKIFC1 with punctate structures. Because they were rapidly transported to the negative pole of the microtubule after NH4Cl treatment, these structures were considered to be associated with acidic vesicles. To determine the role of the kinesin in vivo, we produced an inducible kinesin-deficient strain by double-stranded RNA interference methodology. Mutant cells were loaded with the fluorescent reagent fura2/acetoxymethylester to measure intracellular free calcium ([Ca2+](i)). The resting [Ca2+](i) was unchanged in mutant cells; how. ever, alkalinization of acidic vesicles induced by NH4Cl or nigericin was not followed by release of Ca2+. These data and the relative importance of the ionomycin-releasable and the ionomycin-plus-NH4Cl-releasable Ca2+ pools suggest a lower Ca2+ content in acidocalcisomes and dysfunctional Ca2+ release.	Univ Bordeaux 2, Lab Immunol & Parasitol Mol, Ecole Super Technol & Biomol, F-33076 Bordeaux, France; Univ Victor Segalen, CNRS, UMR 5016, Mol Parasitol Lab, F-33076 Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bakalara, N (corresponding author), Univ Bordeaux 2, Lab Immunol & Parasitol Mol, Ecole Super Technol & Biomol, BP 12,146 Rue Leo Saignat, F-33076 Bordeaux, France.			SANTARELLI, Xavier/0000-0003-1530-4632				Bakalara N, 2000, J BIOL CHEM, V275, P8863, DOI 10.1074/jbc.275.12.8863; Bakalara N, 1995, EUR J BIOCHEM, V234, P871, DOI 10.1111/j.1432-1033.1995.871_a.x; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKMAN MJ, 1995, J CELL SCI, V108, P3611; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P458, DOI 10.1093/nar/17.1.458; CHANDRA R, 1993, J CELL SCI, V104, P899; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; FAZEKAS S, 1980, J IMMUNOL METHODS, V35, P1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FraserLhostis C, 1997, BIOL CHEM, V378, P1039, DOI 10.1515/bchm.1997.378.9.1039; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; GOODSON HV, 1994, J CELL SCI, V107, P1875; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; HOLDER AA, 1981, MOL BIOCHEM PARASIT, V2, P135, DOI 10.1016/0166-6851(81)90095-5; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Hurd DD, 1996, GENETICS, V142, P195; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Lingnau A, 1999, J CELL SCI, V112, P3061; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; MACRAE TH, 1990, BIOCHEM J, V265, P87, DOI 10.1042/bj2650087; Marszalek JR, 2000, BBA-MOL CELL RES, V1496, P142, DOI 10.1016/S0167-4889(00)00015-X; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MITSUI H, 1994, PLANT MOL BIOL, V25, P865, DOI 10.1007/BF00028881; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PAMER EG, 1989, MOL BIOCHEM PARASIT, V33, P27, DOI 10.1016/0166-6851(89)90038-8; Parsons M, 2000, PARASITOL TODAY, V16, P56, DOI 10.1016/S0169-4758(99)01590-2; Piperno G, 1997, P NATL ACAD SCI USA, V94, P4457, DOI 10.1073/pnas.94.9.4457; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROSS CA, 1987, ACTA TROP, V44, P293; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; Scott DA, 1998, BIOCHEM J, V331, P583, DOI 10.1042/bj3310583; SEYFANG A, 1993, EUR J BIOCHEM, V214, P593, DOI 10.1111/j.1432-1033.1993.tb17958.x; Sheetz MP, 1999, EUR J BIOCHEM, V262, P19, DOI 10.1046/j.1432-1327.1999.00340.x; Sloboda Roger D., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P5447, DOI 10.1093/emboj/18.20.5447; Song HB, 1998, NATURE, V396, P587, DOI 10.1038/25153; STIEGER J, 1984, J BIOL CHEM, V259, P4596; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vannier-Santos MA, 1999, MICROBIOL-UK, V145, P3213, DOI 10.1099/00221287-145-11-3213; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Xiong ZH, 1997, J BIOL CHEM, V272, P31022, DOI 10.1074/jbc.272.49.31022	64	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49117	49124		10.1074/jbc.M105962200	http://dx.doi.org/10.1074/jbc.M105962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11581257	hybrid			2022-12-25	WOS:000173922100066
J	Hicke, BJ; Marion, C; Chang, YF; Gould, T; Lynott, CK; Parma, D; Schmidt, PG; Warren, S				Hicke, BJ; Marion, C; Chang, YF; Gould, T; Lynott, CK; Parma, D; Schmidt, PG; Warren, S			Tenascin-C aptamers are generated using tumor cells and purified protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMON RESONANCE BIOSENSORS; ENDOTHELIAL GROWTH-FACTOR; EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; HUMAN BREAST; PHASE-I; OLIGONUCLEOTIDE INHIBITORS; VASCULAR-PERMEABILITY; PROSTATIC HYPERPLASIA; MONOCLONAL-ANTIBODIES	Tenascin-C (TN-C) is an extracellular matrix protein that is overexpressed during tissue remodeling processes, including tumor growth. To identify an aptamer for testing as a tumor-selective ligand, SELEX (systematic evolution of ligands by exponential enrichment) procedures were performed using both TN-C and TN-C-expressing U251 glioblastoma cells. The different selection techniques yielded TN-C aptamers that are related in sequence. In addition, a crossover procedure that switched from tumor cell to purified protein selections was effective in isolating two high-affinity TN-C aptamers. When targeting tumor cells in vitro, the observed propensity of naive oligonucleotide pools to evolve TN-C aptamers may be due to the abundance of this protein. In vivo, TN-C abundance may also be well suited for aptamer accumulation in the tumor milieu. A size-minimized and nuclease-stabilized aptamer, TTA1, binds to the fibrinogen-like domain of TN-C with an equilibrium dissociation constant (K-d) of 5 x 10(-9) M. At 13 kDa, this aptamer is intermediate in size between peptides and single chain antibody fragments, both of which are superior to antibodies for tumor targeting because of their smaller size. TTA1 defines a new class of ligands that are intended for targeted delivery of radioisotopes or chemical agents to diseased tissues.	SomaLog, Boulder, CO 80301 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Novus Biol, Littleton, CO 80160 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; PR Pharmaceut Inc, Ft Collins, CO 80524 USA; IOMED Inc, Salt Lake City, UT 84120 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder	Hicke, BJ (corresponding author), SomaLog, Boulder, CO 80301 USA.							AUKHIL I, 1993, J BIOL CHEM, V268, P2542; Bigner DD, 1998, J CLIN ONCOL, V16, P2202, DOI 10.1200/JCO.1998.16.6.2202; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; Charlton J, 1999, RNA, V5, P1326, DOI 10.1017/S1355838299991021; Drolet DW, 1999, COMB CHEM HIGH T SCR, V2, P271; Dueck M, 1999, INT J CANCER, V82, P477, DOI 10.1002/(SICI)1097-0215(19990812)82:4<477::AID-IJC2>3.0.CO;2-5; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; Famulok M, 1999, CURR TOP MICROBIOL, V243, P123; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; HAUPTMANN S, 1995, LAB INVEST, V73, P172; Hicke BJ, 2000, J CLIN INVEST, V106, P923, DOI 10.1172/JCI11324; Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006; HOWEEDY AA, 1990, LAB INVEST, V63, P798; IBRAHIM SN, 1993, HUM PATHOL, V24, P982, DOI 10.1016/0046-8177(93)90112-T; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; Ishihara A, 1995, CLIN CANCER RES, V1, P1035; Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714; Jahkola T, 1998, EUR J CANCER, V34, P1687, DOI 10.1016/S0959-8049(98)00215-9; Jenison RD, 1998, ANTISENSE NUCLEIC A, V8, P265, DOI 10.1089/oli.1.1998.8.265; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kostianovsky M, 1997, ULTRASTRUCT PATHOL, V21, P537, DOI 10.3109/01913129709016370; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LIGHTNER VA, 1990, ANN NY ACAD SCI, V580, P260, DOI 10.1111/j.1749-6632.1990.tb17935.x; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0; Riedl S, 1998, DIS COLON RECTUM, V41, P86, DOI 10.1007/BF02236901; Ringquist S, 1998, CYTOMETRY, V33, P394, DOI 10.1002/(SICI)1097-0320(19981201)33:4<394::AID-CYTO2>3.0.CO;2-0; Riva P, 1999, CLIN CANCER RES, V5, p3275S; Riva P, 1999, ACTA ONCOL, V38, P351; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; SAKAI T, 1993, BRIT J CANCER, V67, P1058, DOI 10.1038/bjc.1993.194; SCHALKWIJK J, 1991, AM J PATHOL, V139, P1143; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SOINI Y, 1993, AM J CLIN PATHOL, V100, P145, DOI 10.1093/ajcp/100.2.145; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; Tokes AM, 1999, PATHOL RES PRACT, V195, P821; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Vacca A, 1996, LEUKEMIA LYMPHOMA, V22, P473, DOI 10.3109/10428199609054786; Vant-Hull B, 1998, J MOL BIOL, V278, P579, DOI 10.1006/jmbi.1998.1727; VENTIMIGLIA JB, 1992, J NEUROIMMUNOL, V36, P41, DOI 10.1016/0165-5728(92)90029-K; Wallner K, 1999, CIRCULATION, V99, P1284, DOI 10.1161/01.CIR.99.10.1284; Watson SR, 2000, ANTISENSE NUCLEIC A, V10, P63, DOI 10.1089/oli.1.2000.10.63; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Xue Y, 1998, BRIT J UROL, V81, P844; YARUS M, 1970, ANAL BIOCHEM, V35, P450, DOI 10.1016/0003-2697(70)90207-1; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200; Zagzag D, 1996, CANCER RES, V56, P182; ZAGZAG D, 1995, CANCER RES, V55, P907; Zuker M., 1999, V70, P11	56	255	296	5	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48644	48654		10.1074/jbc.M104651200	http://dx.doi.org/10.1074/jbc.M104651200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11590140	hybrid			2022-12-25	WOS:000173922100007
J	Szabo, L; Jamal, S; Xie, HF; Charnock, SJ; Bolam, DN; Gilbert, HJ; Davies, GJ				Szabo, L; Jamal, S; Xie, HF; Charnock, SJ; Bolam, DN; Gilbert, HJ; Davies, GJ			Structure of a family 15 carbohydrate-binding module in complex with xylopentaose - Evidence that xylan binds in an approximate 3-fold helical conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI CENC; MANNAN-BINDING; DOMAIN; PROTEIN; SPECIFICITY; EXPRESSION; IDENTIFICATION; REFINEMENT; MEDIATE; CLONING	The recycling of photosynthetically fixed carbon by the action of microbial glycoside hydrolases is a key biological process. The consortium of degradative enzymes involved in this process frequently display catalytic modules appended to one or more noncatalytic carbohydrate-binding modules (CBMs). CBMs play a central role in the optimization of the catalytic activity of plant cell wall hydrolases through their binding to specific plant structural polysaccharides. Despite their pivotal role in the biodegradation of plant biomass, the mechanism by which these proteins recognize their target ligands is unclear. This report describes the structure of a xylan-binding CBM (CBM15) in complex with its ligand. This module, derived from Pseudomonas cellulosa xylanase Xyn10C, binds to both soluble xylan and xylooligosaccharides. The three-dimensional crystal structure of CBM15 bound to xylopentaose has been solved by x-ray crystallography to a resolution of 1.6 Angstrom. The protein displays a similar p-jelly roll fold to that observed in many other families of binding-modules. A groove, 20-25 Angstrom in length, on the concave surface of one of the beta-sheets presents two tryptophan residues, the faces of which are orientated at similar to240degrees to one another. These form-stacking interactions with the n and n+2 sugars of xylopentaose complementing the approximate 3-fold helical structure of this ligand in the binding cleft of CBM15. In four of the five observed binding subsites, the 2' and 3' hydroxyls of the bound ligand are solvent-exposed, providing an explanation for the capacity of this xylan-binding CBM to accommodate the highly decorated xylans found in the plant cell wall.	Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Struct Biol Lab, Dept Chem, York YO10 5DD, N Yorkshire, England	Newcastle University - UK; University of York - UK		davies@ysbl.york.ac.uk	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Bolam, David/0000-0003-0314-3122				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; ATKINS EDT, 1992, PROGR BIOTECHNOL, V7, P39; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; COUGHLAN MP, 1985, BIOTECHNOL GENET ENG, V3, P39, DOI 10.1080/02648725.1985.10647809; Coutinho PM, 1999, ROY SOC CH, P3; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Freelove ACJ, 2001, J BIOL CHEM, V276, P43010, DOI 10.1074/jbc.M107143200; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; GHANGAS GS, 1989, J BACTERIOL, V171, P2963, DOI 10.1128/jb.171.6.2963-2969.1989; Johnson PE, 1998, BIOCHEMISTRY-US, V37, P12772, DOI 10.1021/bi980978x; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P14381, DOI 10.1021/bi961612s; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Michel G, 2001, STRUCTURE, V9, P513, DOI 10.1016/S0969-2126(01)00612-8; MILLWARDSADLER SJ, 1995, BIOCHEM J, V312, P39, DOI 10.1042/bj3120039; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy T, 1998, FEBS LETT, V429, P312, DOI 10.1016/S0014-5793(98)00625-5; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Simpson PJ, 1999, STRUCTURE, V7, P853, DOI 10.1016/S0969-2126(99)80108-7; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Stoll D, 2000, FEMS MICROBIOL LETT, V183, P265, DOI 10.1111/j.1574-6968.2000.tb08969.x; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P16032, DOI 10.1021/bi972407v; Sunna A, 2001, BIOCHEM J, V356, P791, DOI 10.1042/0264-6021:3560791; Tomme P, 1996, BIOCHEMISTRY-US, V35, P13885, DOI 10.1021/bi961185i; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	39	85	88	1	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49061	49065		10.1074/jbc.M109558200	http://dx.doi.org/10.1074/jbc.M109558200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598143	hybrid			2022-12-25	WOS:000173922100059
J	Takahashi, Y; Kahyo, T; Toh-e, A; Yasuda, H; Kikuchi, Y				Takahashi, Y; Kahyo, T; Toh-e, A; Yasuda, H; Kikuchi, Y			Yeast Ull1/Siz1 is a novel SUM01/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SMT3P; UBIQUITIN; SUMO-1; NUCLEOLUS; HOMOLOG; RINGS; GENE; E2	SUMO1/Smt3, a ubiquitin-like protein modifier, is known to conjugate to other proteins and modulate their functions in various important processes. Similar to the ubiquitin conjugation system, SUMO/Smt3 is transferred to substrate lysine residues through the thioester cascade of El (activating enzyme) and E2 (conjugating enzyme). In our previous report (Takahashi, Y., Toh-e, A., and Kikuchi, Y. (2001) Gene 275, 223-231), we showed that Siz1/Ull1 (YDR409w) of budding yeast, a member of the human PLAS family containing a RING-like domain, is a strong candidate for SUMO1/Smt3 ligase because the SUMO1/Smt3 modification of septin components was abolished in the ull1 mutant and Ull1 associated with E2 (Ubc9) and the substrates (septin components) in immunoprecipitation experiments. Here we have developed an in vitro Smt3 conjugation system for a septin component (Cdc3) using purified recombinant proteins. In this system, Ull1 is additionally required as well as El (Sua1(.)Uba2 complex), E2 (Ubc9), and ATP. A cysteine residue of the RING-like domain was essential for the conjugation both in vivo and in vitro. Furthermore, a region containing the RING-like domain directly interacted with Ubc9 and Cdc3. Thus, this SUMO/Smt3 ligase functions as an adaptor between E2 and the target proteins.	Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Kikuchi, Y (corresponding author), Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; James P, 1996, GENETICS, V144, P1425; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kaiser C., 1994, METHODS YEAST GENETI; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	24	156	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48973	48977		10.1074/jbc.M109295200	http://dx.doi.org/10.1074/jbc.M109295200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11577116	hybrid			2022-12-25	WOS:000173922100048
J	Bash, RC; Yodh, J; Lyubchenko, Y; Woodbury, N; Lohr, D				Bash, RC; Yodh, J; Lyubchenko, Y; Woodbury, N; Lohr, D			Population analysis of subsaturated 172-12 nucleosomal arrays by atomic force microscopy detects nonrandom behavior that is favored by histone acetylation and short repeat length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST CHROMATIN STRUCTURE; HIGHER-ORDER STRUCTURE; RNA-POLYMERASE-III; MICROCOCCAL NUCLEASE; ACTIVE CHROMATIN; GENE-EXPRESSION; DNA-SEQUENCES; TRANSCRIPTION; ORGANIZATION; DISRUPTION	Concatameric 5 S rDNA templates reconstituted in vitro into nueleosomal arrays provide very popular chromatin models for many kinds of studies. Here, atomic force microscopy is used to determine the population distributions for one such nucleosomal array, the 172-12, reconstituted to various subsaturated levels with nonacetylated or hyperacetylated HeLa histones. This array is a model for short linker length genomes and transcriptionally active and newly replicated chromatins. The analysis shows that as input histone levels increase, template occupation increases progressively as discrete population distributions. The distributions are random at (n(av) < 4) and high (n(av) > 8) loadings but display specific nonrandom features, such as a deficit of molecules with one nucleosome more or less than the peak species in the distribution and enhanced distribution breadths, in the mid-range (n(av) = 4-8). Thus, the mid-range of occupation on polynucleosomal arrays may be a special range for chromatin structure and/or assembly. The mid-range nonrandom. features are enhanced in distributions from short repeat (172-12) arrays, particularly for unacetylated chromatin, and in distributions from hyperacetylated chromatin, particularly for long repeat (208-12) arrays. Thus, short repeat length and acetylation can affect basic chromatin properties, like population tendencies, in very similar ways and therefore may cause similar changes in chromatin structure. Some possible effects are suggested. The data also indicate that it is thermodynamically more difficult for hyperacetylated nucleosomes to assemble onto the 172-12 templates, a result having implications for in vivo chromatin assembly.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Midwestern Univ, Arizona Coll Osteopath Med, Div Basic Sci, Glendale, AZ 85308 USA; Arizona State Univ, Dept Microbiol, Tempe, AZ 85287 USA; Arizona State Univ, Dept Biol, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Midwestern University; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Lohr, D (corresponding author), Arizona State Univ, Dept Chem & Biochem, POB 871604, Tempe, AZ 85287 USA.	dlohr@asu.edu			NCI NIH HHS [CA85990] Funding Source: Medline; NIGMS NIH HHS [GM54991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM054991, R44GM054991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MJ, 1993, BIOCHEMISTRY-US, V32, P8390, DOI 10.1021/bi00084a002; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; BERKOWITZ EM, 1981, BIOCHEMISTRY-US, V20, P7284, DOI 10.1021/bi00528a036; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BURGOYNE LA, 1981, BIOCHEM BIOPH RES CO, V99, P893, DOI 10.1016/0006-291X(81)91247-X; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; COMPTON JL, 1976, P NATL ACAD SCI USA, V73, P4382, DOI 10.1073/pnas.73.12.4382; DAVIE JR, 1981, J BIOL CHEM, V256, P2574; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; FRITZSCHE W, 1997, SCANNING, P1942; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; LOHR D, 1986, J BIOL CHEM, V261, P9904; Lohr D, 1997, J BIOL CHEM, V272, P26795, DOI 10.1074/jbc.272.43.26795; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LOHR D, 1977, P NATL ACAD SCI USA, V74, P79, DOI 10.1073/pnas.74.1.79; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; LYUBCHENKO YL, 1992, J BIOMOL STRUCT DYN, V10, P589, DOI 10.1080/07391102.1992.10508670; Lyubchenko YL, 1996, SCANNING MICROSCOPY SUPPLEMENT 10, 1996, P97; LYUBCHENKO YL, 1995, SCANNING MICROSCOPY, V9, P705; LYUHCHENKO YL, 2001, METHOD MOL BIOL, V147, P569; MARTIN LD, 1995, BIOCHEMISTRY-US, V34, P4610, DOI 10.1021/bi00014a014; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Sato MH, 1999, FEBS LETT, V452, P267, DOI 10.1016/S0014-5793(99)00644-4; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Staynov DZ, 2000, NUCLEIC ACIDS RES, V28, P3092, DOI 10.1093/nar/28.16.3092; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thastrom A, 1999, J MOL BIOL, V288, P213, DOI 10.1006/jmbi.1999.2686; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; van Holde K.E., 1988, CHROMATIN; VILLEPONTEAU B, 1992, BIOCHEMISTRY-US, V31, P1554, DOI 10.1021/bi00120a037; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Widlund HR, 2000, BIOCHEMISTRY-US, V39, P3835, DOI 10.1021/bi991957l; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yodh JG, 1999, BIOCHEMISTRY-US, V38, P15756, DOI 10.1021/bi991034q	57	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48362	48370		10.1074/jbc.M104916200	http://dx.doi.org/10.1074/jbc.M104916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11583994	hybrid			2022-12-25	WOS:000172927000085
J	Ermilov, AN; Olshevskaya, EV; Dizhoor, AM				Ermilov, AN; Olshevskaya, EV; Dizhoor, AM			Instead of binding calcium, one of the EF-hand structures in guanylyl cyclase activating protein-2 is required for targeting photoreceptor guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEINS; MAMMALIAN RETINAS; EXPRESSION; GCAP-2; LIGHT; RODS; PHOTOTRANSDUCTION; LOCALIZATION; DIMERIZATION; NEUROCALCIN	Guanylyl cyclase activator proteins (GCAPs) are calcium-binding proteins closely related to recoverin, neurocalcin, and many other neuronal Ca2+-sensor proteins of the EF-hand superfamily. GCAP-1 and GCAP-2 interact with the intracellular portion of photoreceptor membrane guanylyl cyclase and stimulate its activity by promoting tight dimerization of the cyclase subunits. At low free Ca2+ concentrations, the activator form of GCAP-2 associates into a dimer, which dissociates when GCAP-2 binds Ca2+ and becomes inhibitor of the cyclase. GCAP-2 is known to have three active EF-hands and one additional EF-hand-like structure, EF-1, that deviates form the EF-hand consensus sequence. We have found that various point mutations within the EF-1 domain can specifically affect the ability of GCAP-2 to interact with the target cyclase but do not hamper the ability of GCAP-2 to undergo reversible Ca2+-sensitive dimerization. Point mutations within the EF-1 region can interfere with both the activation of the cyclase by the Ca2+. free form of GCAP-2 and the inhibition of retGC basal activity by the Ca2+-loaded GCAP-2. Our results strongly indicate that evolutionary conserved and GCAP-specific amino acid residues within the EF-1 can create a contact surface for binding GCAP-2 to the cyclase. Apparently, in the course of evolution GCAP-2 exchanged the ability of its first EF-hand motif to bind Ca2+ for the ability to interact with the target enzyme.	Wayne State Univ, Sch Med, Dept Ophthalmol, Kresge Eye Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol Anat & Cell Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Dizhoor, AM (corresponding author), Wayne State Univ, Ophthalmol Kresge Eye Inst, K-456,4717 St Antoine Blvd, Detroit, MI 48201 USA.			Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY11522] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Celio MR, 1996, GUIDEBOOK CALCIUM BI, P15; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Hurley JB, 2000, METHOD ENZYMOL, V315, P708; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; Krylov DM, 2001, J BIOL CHEM, V276, P30648, DOI 10.1074/jbc.M104121200; LADANT D, 1995, J BIOL CHEM, V270, P3179; Lange C, 1999, FEBS LETT, V460, P27, DOI 10.1016/S0014-5793(99)01312-5; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998; NEF P, 1996, GUIDEBOOK CALCIUM BI, P15; Olshevskaya EV, 1999, J BIOL CHEM, V274, P25583, DOI 10.1074/jbc.274.36.25583; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Ramamurthy V, 2001, J BIOL CHEM, V276, P26218, DOI 10.1074/jbc.M010495200; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sampath AP, 1999, J GEN PHYSIOL, V113, P267, DOI 10.1085/jgp.113.2.267; Sokal I, 1999, BIOCHEMISTRY-US, V38, P1387, DOI 10.1021/bi982512k; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; Yu H, 1999, J BIOL CHEM, V274, P15547, DOI 10.1074/jbc.274.22.15547	45	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48143	48148		10.1074/jbc.M107539200	http://dx.doi.org/10.1074/jbc.M107539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11584009	hybrid			2022-12-25	WOS:000172927000055
J	Lu, ZH; Solioz, M				Lu, ZH; Solioz, M			Copper-induced proteolysis of the CopZ copper chaperone of Enterococcus hirae.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; ESCHERICHIA-COLI; ATX1 GENE; HOMEOSTASIS; TRANSPORT; PROTEIN; DEGRADATION; RESISTANCE; ENDOCYTOSIS; EXPRESSION	The cop operon is a key element of copper homeostasis in Enterococcus hirae. It encodes two copper ATPases, CopA and CopB, the Copy repressor, and the CopZ metallochaperone. It was previously shown that the transcription of the operon is induced by copper. The concomitant increase in the levels of Cop proteins, particularly the CopB copper export ATPase, allows uncompromised growth of E. hirae in up to 5 mm ambient copper. We here show by Western blotting that the steady-state level of CopZ was increased only up to 0.5 mm copper. At higher copper concentrations, the level of CopZ was decreased and became undetectable at 5 mm media copper. When CopZ was overexpressed from a plasmid, the cells exhibited increased sensitivity to copper and oxidative stress, suggesting that high CopZ expression could become toxic to cells. In wild-type cells, the level of mRNA transcripts from the cop operon remained high in up to 5 mm copper, suggesting that CopZ was proteolyzed. Cell extracts were found to contain a copper-activated proteolytic activity that degraded CopZ in vitro. In this assay, Cu-CopZ was more susceptible to degradation than apo-CopZ. The growth of E. hirae in copper increased the copper-inducible proteolytic activity in extracts. Zymographic studies showed the presence of a copper-dependent protease in crude cell lysates. Thus, copper-stimulated proteolysis plays an important role in the regulation of copper homeostasis in E. hirae.	Univ Bern, Dept Clin Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Solioz, M (corresponding author), Univ Bern, Dept Clin Pharmacol, Murtenstr 35, CH-3010 Bern, Switzerland.		Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721; Lu, Zen H./0000-0002-9408-0579				Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; Cobine P, 1999, FEBS LETT, V445, P27, DOI 10.1016/S0014-5793(99)00091-5; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Horn N, 1999, J TRACE ELEM EXP MED, V12, P297; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Kelner GS, 2000, J BIOL CHEM, V275, P580, DOI 10.1074/jbc.275.1.580; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Multhaup G, 2001, BIOCHEM BIOPH RES CO, V288, P172, DOI 10.1006/bbrc.2001.5757; Naeve GS, 1999, NEUROSCIENCE, V93, P1179, DOI 10.1016/S0306-4522(99)00175-X; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; ODERMATT A, 1994, BIOCHEM BIOPH RES CO, V202, P44, DOI 10.1006/bbrc.1994.1891; ODERMATT A, 1995, J BIOL CHEM, V270, P4349, DOI 10.1074/jbc.270.9.4349; ODERMATT A, 1992, ANN NY ACAD SCI, V671, P484, DOI 10.1111/j.1749-6632.1992.tb43836.x; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; SILVER S, 1993, MOL MICROBIOL, V10, P7, DOI 10.1111/j.1365-2958.1993.tb00898.x; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Strausak D, 1997, J BIOL CHEM, V272, P8932; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Willett WS, 1996, BIOCHEMISTRY-US, V35, P5992, DOI 10.1021/bi9530191; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; Wunderli-Ye H, 1999, BIOCHEM BIOPH RES CO, V259, P443, DOI 10.1006/bbrc.1999.0807; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	43	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47822	47827		10.1074/jbc.M106218200	http://dx.doi.org/10.1074/jbc.M106218200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11585824	hybrid			2022-12-25	WOS:000172927000014
J	Sterling, D; Reithmeier, RAF; Casey, JR				Sterling, D; Reithmeier, RAF; Casey, JR			A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; ERYTHROCYTE ANION-EXCHANGER; INTRACELLULAR PH; BAND-3 PROTEIN; HUMAN KIDNEY; CHROMOSOMAL LOCALIZATION; PROTEOLYTIC DISSECTION; CL-/HCO3 EXCHANGER; CARBOXYL-TERMINUS; CYTOPLASMIC SIDE	The cytoplasmic carboxyl-terminal domain of AE1, the plasma membrane chloride/bicarbonate exchanger of erythrocytes, contains a binding site for carbonic anhydrase II (CAII). To examine the physiological role of the AE1/CAII interaction, anion exchange activity of transfected HEK293 cells was monitored by following the changes in intracellular pH associated with AE1-mediated bicarbonate transport. AE1-mediated chloride/bicarbonate exchange was reduced 50-60% by inhibition of endogenous carbonic anhydrase with acetazolamide, which indicates that CAH activity is required for fun anion transport activity. AE1 mutants, unable to bind CAR, had significantly lower transport activity than wild-type AE1 (10% of wild-type activity), suggesting that a direct interaction was required. To determine the effect of displacement of endogenous wild-type CAII from its binding site on AE1, AE1-transfected HEK293 cells were co-transfected with cDNA for a functionally inactive CAR mutant, V143Y. AE1 activity was maximally inhibited 61 +/- 4% in the presence of V143Y CAH. A similar effect of V143Y CAII was found for AE2 and AE3cardiac anion exchanger isoforms. We conclude that the binding of CAH to the AE1 carboxyl-terminus potentiates anion transport activity and allows for maximal transport. The interaction of CAII with AE1 forms a transport metabolon, a membrane protein complex involved in regulation of bicarbonate metabolism and transport.	Univ Alberta, Membrane Transport Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Inst, Hlth Res Grp Mol Biol Membrane Prot, Dept Physiol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Toronto, Canadian Inst, Res Grp Membrane Biol, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Alberta; University of Alberta; University of Alberta; University of Toronto; University of Toronto	Casey, JR (corresponding author), Univ Alberta, Membrane Transport Grp, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				ALPER SL, 1988, J BIOL CHEM, V263, P17092; BALDWIN CT, 1995, HUM MOL GENET, V4, P1637, DOI 10.1093/hmg/4.9.1637; BORON WF, 1989, KIDNEY INT, V36, P392, DOI 10.1038/ki.1989.208; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; COUSIN JL, 1976, J PHYSIOL-LONDON, V256, P61, DOI 10.1113/jphysiol.1976.sp011311; COUSIN JL, 1975, J PHYSIOL-LONDON, V253, P385, DOI 10.1113/jphysiol.1975.sp011195; Everett LA, 1999, P NATL ACAD SCI USA, V96, P9727, DOI 10.1073/pnas.96.17.9727; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; GEHRIG H, 1992, BIOCHIM BIOPHYS ACTA, V1130, P326, DOI 10.1016/0167-4781(92)90446-7; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grichtchenko II, 2001, J BIOL CHEM, V276, P8358, DOI 10.1074/jbc.C000716200; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; JACOBS M. H., 1942, JOUR GEN PHYSIOL, V25, P539, DOI 10.1085/jgp.25.4.539; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; Keilin D, 1941, NATURE, V148, P493, DOI 10.1038/148493a0; KIFOR G, 1993, J MEMBRANE BIOL, V134, P169; Kivela A, 2000, AM J PATHOL, V156, P577, DOI 10.1016/S0002-9440(10)64762-1; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LODISH H, 2000, MOL CELL BIOL, P600; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; MAREN TH, 1976, SCIENCE, V191, P469; MAREN TH, 1970, MOL PHARMACOL, V6, P430; MAREN TH, 1967, PHYSIOL REV, V47, P595, DOI 10.1152/physrev.1967.47.4.595; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Minetti G, 1998, BIOCHEM J, V335, P305, DOI 10.1042/bj3350305; Mori K, 1999, J BIOL CHEM, V274, P15701, DOI 10.1074/jbc.274.22.15701; PARKES JL, 1989, ARCH BIOCHEM BIOPHYS, V275, P459, DOI 10.1016/0003-9861(89)90392-5; Pilas B, 1997, CYTOMETRY, V28, P316, DOI 10.1002/(SICI)1097-0320(19970801)28:4<316::AID-CYTO7>3.3.CO;2-J; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; Rajendran VM, 2000, AM J PHYSIOL-GASTR L, V279, pG931, DOI 10.1152/ajpgi.2000.279.5.G931; RANDALL RF, 1972, BIOCHIM BIOPHYS ACTA, V268, P730, DOI 10.1016/0005-2744(72)90277-X; Reithmeier RAF, 2001, BLOOD CELL MOL DIS, V27, P85, DOI 10.1006/bcmd.2000.0353; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; SHIP S, 1977, J MEMBRANE BIOL, V33, P311, DOI 10.1007/BF01869522; Soleimani M, 2001, AM J PHYSIOL-RENAL, V280, pF356, DOI 10.1152/ajprenal.2001.280.2.F356; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STECK TL, 1971, BIOCHEMISTRY-US, V10, P2617, DOI 10.1021/bi00789a031; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; Sterling D, 1999, BIOCHEM J, V344, P221, DOI 10.1042/0264-6021:3440221; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; Tanner MJA, 1997, MOL MEMBR BIOL, V14, P155, DOI 10.3109/09687689709048178; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; Tashian R E, 1976, Adv Hum Genet, V7, P1; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuganezawa H, 2001, J BIOL CHEM, V276, P8180, DOI 10.1074/jbc.M004513200; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P70, DOI 10.1016/0005-2736(91)90252-4; YANNOUKAKOS D, 1994, CIRC RES, V75, P603, DOI 10.1161/01.RES.75.4.603; ZEIDEL ML, 1986, J CLIN INVEST, V77, P1682, DOI 10.1172/JCI112486	65	285	290	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47886	47894		10.1074/jbc.M105959200	http://dx.doi.org/10.1074/jbc.M105959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606574	hybrid			2022-12-25	WOS:000172927000023
J	Szafer, E; Rotman, M; Cassel, D				Szafer, E; Rotman, M; Cassel, D			Regulation of GTP hydrolysis on ADP-ribosylation factor-1 at the Golgi membrane.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PUTATIVE CARGO RECEPTORS; ACTIVATING PROTEIN; ARF-GAP; ENDOPLASMIC-RETICULUM; BINDING PROTEIN; COATED VESICLES; PHOSPHOLIPASE-D; SACCHAROMYCES-CEREVISIAE; COATOMER BINDING	The interaction of the coatomer coat complex with the Golgi membrane is initiated by the active, GTP-bound state of the small GTPase ADP-ribosylation factor I (ARF1), whereas GTP hydrolysis triggers coatomer dissociation. The hydrolysis of GTP on ARF1 depends on the action of members of a family of ARF1-directed GTPase-activating proteins (GAPs). Previous studies in well defined systems indicated that the activity of a mammalian Golgi membrane-localized ARF GAP (GAP1) might be subjected to regulation by membrane lipids as well as by the coatomer complex. Coatomer was found to strongly stimulate GAP-dependent GTP hydrolysis on a membrane-independent mutant of ARF1, whereas we reported that GTP hydrolysis on wild type, myristoylated ARF1 loaded with GTP in the presence of phospholipid vesicles was coatomer-independent. To investigate the regulation of ARF1 GAPs under more physiological conditions, we studied GTP hydrolysis on Golgi membrane-associated ARF1. The activities at the Golgi of recombinant GAP1 as well as coatomer-depleted fractions from rat brain cytosol resembled those observed in the presence of liposomes; however, unlike in liposomes, GAP activities on Golgi membranes were approximately doubled upon addition of coatomer. By contrast, endogenous GAP activity in Golgi membrane preparations was unaffected by coatomer. Cytosolic GAP activity was partially reduced following immunodepletion of GAP1, indicating that GAP1 plays a significant although not exclusive role in the regulation of GTP hydrolysis at the Golgi. Unlike the activities of the mammalian proteins, the Saccharomyces cerevisiae Glo3 ARF GAP displayed activity at the Golgi that was highly dependent on coatomer. We conclude that ARF GAPs in themselves can efficiently stimulate GTP hydrolysis on ARF1 at the Golgi, and that coatomer may play an auxiliary role in this reaction, which would lead to an increased cycling rate of ARF1 in COPI-coated regions of the Golgi membrane.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Cassel, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.							Andreev J, 1999, MOL CELL BIOL, V19, P2338; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Dogic D, 1999, EUR J CELL BIOL, V78, P305, DOI 10.1016/S0171-9335(99)80064-8; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Eugster A, 2000, EMBO J, V19, P3905, DOI 10.1093/emboj/19.15.3905; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Goldberg J, 2000, CELL, V100, P671, DOI 10.1016/S0092-8674(00)80703-5; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; Huber I, 2001, METHOD ENZYMOL, V329, P307; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Liu XQ, 2001, FEBS LETT, V490, P79, DOI 10.1016/S0014-5793(01)02134-2; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; Nickel W, 1998, SEMIN CELL DEV BIOL, V9, P493, DOI 10.1006/scdb.1998.0256; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Poon PP, 1999, EMBO J, V18, P555, DOI 10.1093/emboj/18.3.555; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Poon PP, 2001, METHOD ENZYMOL, V329, P317; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Szafer E, 2000, J BIOL CHEM, V275, P23615, DOI 10.1074/jbc.M003171200; TABAS I, 1979, J BIOL CHEM, V254, P1655; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Uchida H, 2001, J EXP MED, V193, P955, DOI 10.1084/jem.193.8.955; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; WEISS O, 1989, J BIOL CHEM, V264, P21066; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198	65	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47834	47839		10.1074/jbc.M106000200	http://dx.doi.org/10.1074/jbc.M106000200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11592960	hybrid			2022-12-25	WOS:000172927000016
J	Zhang, XT; Moye-Rowley, WS				Zhang, XT; Moye-Rowley, WS			Saccharomyces cerevisiae multidrug resistance gene expression inversely correlates with the status of the F-0 component of the mitochondrial ATPase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; PLEIOTROPIC DRUG-RESISTANCE; CYTOCHROME-C-OXIDASE; YEAST ABC PROTEINS; PLASMA-MEMBRANE; NUCLEAR GENE; TRANSCRIPTIONAL CONTROL; NULL MUTATION; SUBUNIT; PDR5	Loss of the mitochondrial genome (rho (0) cell) or elimination of the mitochondrial inner membrane protein Oxa1p causes a dramatic increase in expression of the ATP binding cassette transporter-encoding gene PDR5 in the yeast Saccharomyces cerevisiae. This increase in gene expression occurs via activation of the function of the Cys(6)-Zn(II)(2) cluster transcription factor Pdr3p, which in turn autoregulates expression of its structural gene. Surprisingly, the acquisition of PDR5-dependent multidrug resistance occurs at a very high frequency, consistent with the appearance of rho (-) cells in a fermentatively growing culture (similar to2%). The degree of activation of Pdr3p target genes was found to vary considerably and to be influenced by the presence of the homologous protein, Pdr1p. Mutagenesis and overexpression studies provided evidence that the control of Pdr3p expression was the major control point of this transcription factor by mitochondrial retrograde signaling. Because both JP and oxa1 mutant cells have multiple defects including loss of normal respiratory chain function and oxidative phosphorylation, a series of mutant strains with more selective defects in mitochondrial function was employed to identify the molecular signal that triggers PDR5 transcriptional activation. Only mutations that influenced the functional status of the F-0 subunit of the mitochondrial ATPase were found to lead to activation of PDR5 expression.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Mol Biol PhD Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-612 Bown Sci Bldg, Iowa City, IA 52242 USA.		Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; Delahodde A, 2001, MOL MICROBIOL, V39, P304, DOI 10.1046/j.1365-2958.2001.02182.x; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEVRIES S, 1992, EUR J BIOCHEM, V203, P587; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; EGNER R, 1995, MOL CELL BIOL, V15, P5879; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hamel P, 1998, GENETICS, V150, P601; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; Michaelis S, 1995, COLD SPRING HARB SYM, V60, P291, DOI 10.1101/SQB.1995.060.01.034; Miyazaki H, 1998, ANTIMICROB AGENTS CH, V42, P1695, DOI 10.1128/AAC.42.7.1695; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paul MF, 2000, J BIOL CHEM, V275, P29238, DOI 10.1074/jbc.M004546200; POON WW, 1997, MOL ASPECTS MED, V18, P121; Robert J, 1999, EUR J CLIN INVEST, V29, P536, DOI 10.1046/j.1365-2362.1999.00495.x; RONINSON IB, 1992, MUTAT RES, V276, P151, DOI 10.1016/0165-1110(92)90005-T; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; Sanglard D, 2001, ANTIMICROB AGENTS CH, V45, P1174, DOI 10.1128/AAC.45.4.1174-1183.2001; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH M, 1979, CELL, V16, P753, DOI 10.1016/0092-8674(79)90091-6; Soubannier V, 1999, BIOCHEMISTRY-US, V38, P15017, DOI 10.1021/bi9916067; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	70	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47844	47852		10.1074/jbc.M106285200	http://dx.doi.org/10.1074/jbc.M106285200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602584	hybrid			2022-12-25	WOS:000172927000018
J	Buslepp, J; Zhao, R; Donnini, D; Loftus, D; Saad, M; Appella, E; Collins, EJ				Buslepp, J; Zhao, R; Donnini, D; Loftus, D; Saad, M; Appella, E; Collins, EJ			T cell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; MAXIMUM-LIKELIHOOD; ANTAGONIST LIGANDS; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; TCR; MOLECULES; REFINEMENT; ACTIVATION; ANTIGEN	Recognition of virally infected cells by CD8(+) T cells requires differentiation between self and nonself peptide-class I major histocompatibility complexes (pMHC). Recognition of foreign pMHC by host T cells is a major factor in the rejection of transplanted organs from the same species (allotransplant) or different species (xenotransplant). AHIII12.2 is a murine T cell clone that recognizes the xenogeneic (human) class I NMC HLA-A2.1 molecule (A2) and the syngeneic murine class I MHC H-2 D-b molecule (D-b). Recognition of both A2 and D-b are peptide-dependent, and the sequences of the peptides recognized have been determined. Alterations in the antigenic peptides bound to A2 cause large changes in AHIII12.2 T cell responsiveness. Crystal structures of three representative peptides (agonist, null, and antagonist) bound to A2 partially explain the changes in AHIII12.2 responsiveness. Using class I pMHC octamers, a strong correlation is seen between T cell activity and the affinity of pMHC complexes for the T cell receptor. However, contrary to previous studies, we see similar half-lives for the pMHC multimers bound to the AHIII12.2 cell surface.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Collins, EJ (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, CB 7290,804 ME Jones Bldg, Chapel Hill, NC 27599 USA.			SAAD, Mohamed/0000-0003-0458-5942				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; Batalia MA, 1997, BIOPOLYMERS, V43, P281, DOI 10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R; Batalia MA, 2000, BIOCHEMISTRY-US, V39, P9030, DOI 10.1021/bi000442n; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1997, DOI 10.1002/eji.1830210905; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; Hennecke J, 2000, EMBO J, V19, P5611, DOI 10.1093/emboj/19.21.5611; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalergis AM, 2001, NAT IMMUNOL, V2, P229, DOI 10.1038/85286; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Loftus DJ, 1996, J EXP MED, V184, P647, DOI 10.1084/jem.184.2.647; Loftus DJ, 1998, CANCER RES, V58, P2433; Loftus DJ, 1997, J IMMUNOL, V158, P3651; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; POGUE RR, 1995, P NATL ACAD SCI USA, V92, P8166, DOI 10.1073/pnas.92.18.8166; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Reid SW, 1996, J EXP MED, V184, P2279, DOI 10.1084/jem.184.6.2279; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Sharma AK, 2001, J BIOL CHEM, V276, P21443, DOI 10.1074/jbc.M010791200; SILVERMAN T, 1988, J IMMUNOL, V140, P4378; Sykulev Y, 1998, IMMUNITY, V9, P475, DOI 10.1016/S1074-7613(00)80631-7; Zhao R, 1999, J EXP MED, V189, P359, DOI 10.1084/jem.189.2.359	47	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47320	47328		10.1074/jbc.M109231200	http://dx.doi.org/10.1074/jbc.M109231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584024	hybrid			2022-12-25	WOS:000172768500087
J	Jiang, DM; Sullivan, PG; Sensi, SL; Steward, O; Weiss, JH				Jiang, DM; Sullivan, PG; Sensi, SL; Steward, O; Weiss, JH			Zn2+ induces permeability transition pore opening and release of pro-apoptotic peptides from neuronal mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; GLUTAMATE NEUROTOXICITY; ZINC; DEATH; BRAIN; INHIBITION; NECROSIS; ACCUMULATION; SUPEROXIDE; CULTURES	Rapid entry of Ca2+ or Zn2+ kills neurons. Mitochondria are major sites of Ca2+-dependent toxicity. This study examines Zn2+-initiated mitochondrial cell death signaling. 10 nm Zn2+ induced acute swelling of isolated mitochondria, which was much greater than that induced by higher Ca2+ levels. Zn2+ entry into mitochondria was dependent upon the Ca2+ uniporter, and the consequent swelling resulted from opening of the mitochondrial permeability transition pore. Confocal imaging of intact neurons revealed entry of Zn2+ (with Ca2+) to cause pronounced mitochondrial swelling, which was far greater than that induced by Ca2+ entry alone. Further experiments compared the abilities of Zn2+ and Ca2+ to induce mitochondrial release of cytochrome c (Cyt-c) or apoptosis-inducing factor. In isolated mitochondria, 10 nm Zn2+ exposures induced Cyt-c release. Induction of Zn2+ entry into cortical neurons resulted in distinct increases in cytosolic Cyt-c immunolabeling and in cytosolic and nuclear apoptosis-inducing factor labeling within 60 min. In comparison, higher absolute [Ca2+](i) rises were less effective in inducing release of these factors. Addition of the mitochondrial permeability transition pore inhibitors cyclosporin A and bongkrekic acid decreased Zn2+-dependent release of the factors and attenuated neuronal cell death as assessed by trypan blue staining 5-6 h after the exposures.	Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92697 USA; Univ G DAnnunzio, Dept Neurol, I-66013 Chieti, Italy	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; G d'Annunzio University of Chieti-Pescara	Weiss, JH (corresponding author), Univ Calif Irvine, Dept Neurol, 2101 Gillespie Neurosci Facil, Irvine, CA 92697 USA.	jweiss@uci.edu	Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019; weiss, john/B-4283-2008	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; weiss, john/0000-0001-9323-7813; Steward, Oswald/0000-0001-7069-8756	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032280, R01NS030884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000096] Funding Source: NIH RePORTER; NIA NIH HHS [2T32 AG 00096, AG 00836, AG 00919] Funding Source: Medline; NINDS NIH HHS [NS 32280, NS 30884] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brand IA, 1996, J BIOL CHEM, V271, P1941, DOI 10.1074/jbc.271.4.1941; BRIERLEY GP, 1967, BIOCHEMISTRY-US, V6, P3892, DOI 10.1021/bi00864a035; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buckman JF, 2001, J NEUROSCI METH, V104, P165, DOI 10.1016/S0165-0270(00)00340-X; Canzoniero LMT, 1999, J NEUROSCI, V19; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Hyrc K, 1997, J NEUROSCI, V17, P6669; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Lobner D, 2000, CELL MOL BIOL, V46, P797; Manev H, 1997, EXP NEUROL, V146, P171, DOI 10.1006/exnr.1997.6510; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nicotera P, 1999, J CEREBR BLOOD F MET, V19, P583, DOI 10.1097/00004647-199906000-00001; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; SARIS NEL, 1994, FEBS LETT, V356, P195, DOI 10.1016/0014-5793(94)01256-3; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; SKULACHE.VP, 1967, BIOCHEM BIOPH RES CO, V26, P1, DOI 10.1016/0006-291X(67)90242-2; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Wudarczyk J, 1999, ARCH BIOCHEM BIOPHYS, V363, P1, DOI 10.1006/abbi.1998.1058; Yin HZ, 1998, BRAIN RES, V781, P45, DOI 10.1016/S0006-8993(97)01208-0	34	224	232	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47524	47529		10.1074/jbc.M108834200	http://dx.doi.org/10.1074/jbc.M108834200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595748	hybrid			2022-12-25	WOS:000172768500111
J	Jiang, JL; Zhou, Q; Yu, MK; Ho, LS; Chen, ZN; Chan, HC				Jiang, JL; Zhou, Q; Yu, MK; Ho, LS; Chen, ZN; Chan, HC			The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 MATRIX-METALLOPROTEINASE; INHIBITOR CARBOXYAMIDO-TRIAZOLE; VASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL-TRANSDUCTION; MEDIATED MOTILITY; MOUSE BASIGIN; GELATINASE-A; CA2+ ENTRY	The present study examined the effect of hepatoma. associated antigen HAb18G (homologous to CD147) expression on the NO/cGMP-regulated Ca2+ mobilization and metastatic process of human hepatoma cells. HAb18G/CD147 cDNA was transfected into human 7721 hepatoma cells to obtain a cell line stably expressing HAb18G/CD147, T7721, as demonstrated by Northern blot and immunocytochemical studies. 8-Bromo-cGMP (cGMP) inhibited the thapsigargin-induced Ca2+ entry in a concentration-dependent manner in 7721 cells. The cGMP-induced inhibition was abolished by an inhibitor of protein kinase G, KT5823 (1 mum). However, expression of HAb18G/CD147 in T7721 cells decreased the inhibitory response to cGMP. A similar concentration-dependent inhibitory effect on the Ca2+ entry was observed in 7721 cells in response to a NO donor, (+/-)-S-nitroso-N-acetylpenicillamine (SNAP). The inhibitory effect of SNAP on the thapsigargin-induced Ca2+ entry was significantly reduced in HAb18G/CD147-expressing T7721 cells, indicating a role for HAb18G/CD147 in NO/cGMP-regulated Ca2+ entry. Experiments investigating metastatic potentials demonstrated that HAb18G/CD147-expressing T7721 cells attached to the Matrigel-coated culture plates and invaded through Matrigel-coated permeable filters at the rate significantly greater than that observed in 7721 cells. Both the attachment and invasion rates could be suppressed by SNAP, and the inhibitory effect of SNA-P could be reversed by NO inhibitor, NI-nitro-L-arginine methyl ester. The sensitivity of the attachment and invasion rates to cGMP was significantly reduced in T7721 cells as compared with 7721 cells when cells were pretreated with thapsigargin. The difference in the sensitivity between the two cells could be abolished by a Ca2+ channel blocker, Ni2+ (3 mm). These results suggest that HAb18G/CD147 enhances metastatic potentials in human hepatoma cells by disrupting the regulation of store-operated Ca2+ entry by NO/cGMP.	Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; Fourth Mil Med Univ, Cell Engn Res Ctr, Xian 710032, Peoples R China	Chinese University of Hong Kong; Air Force Military Medical University	Chan, HC (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China.		Chan, Hsiao Chang/E-1507-2016					Alessandro R, 1996, IN VIVO, V10, P153; Arii S, 1996, HEPATOLOGY, V24, P316; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Bauer KS, 2000, J PHARMACOL EXP THER, V292, P31; BISCHOF G, 1995, CELL CALCIUM, V17, P250, DOI 10.1016/0143-4160(95)90071-3; BISWAS C, 1982, BIOCHEM BIOPH RES CO, V109, P1026, DOI 10.1016/0006-291X(82)92042-3; BISWAS C, 1995, CANCER RES, V55, P434; Chen ZN, 1999, J CELL MOL IMMUNOL, V15, P34; CHEN ZN, 1989, REPORTS MONOCLONAL A, V27, P33; CHEN ZN, 1992, CHINESE J ONCOL, V14, P9; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLE K, 1994, CANCER METAST REV, V13, P31, DOI 10.1007/BF00690417; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Farias EF, 1998, INT J CANCER, V78, P727, DOI 10.1002/(SICI)1097-0215(19981209)78:6<727::AID-IJC10>3.0.CO;2-A; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; George SJ, 1997, ARTERIOSCL THROM VAS, V17, P2500, DOI 10.1161/01.ATV.17.11.2500; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; HAUANG AJ, 1993, J CELL BIOL, V120, P1371; JI Y, 1991, CHIN MED J, V71, P369; Jiang JL, 2001, CELL BIOL INT, V25, P993, DOI 10.1006/cbir.2001.0751; Jurasz P, 2001, CANCER RES, V61, P376; KANEKURA T, 1991, CELL STRUCT FUNCT, V16, P23, DOI 10.1247/csf.16.23; KASINRERK W, 1992, J IMMUNOL, V149, P847; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOHN EC, 1994, CANCER RES, V54, P935; Kwan HY, 2000, J BIOL CHEM, V275, P6758, DOI 10.1074/jbc.275.10.6758; Lala PK, 1998, CANCER METAST REV, V17, P1, DOI 10.1023/A:1005963400984; LESTER BR, 1989, CANCER RES, V49, P5940; LESTER BR, 1991, INT J CANCER, V48, P113; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; LIU Y, 1991, CHIN MED J, V71, P362; Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749-6632.1999.tb07690.x; MAMACHI T, 1986, BIOOCH BIOPHYS ACTA, V889, P136; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; MENSING H, 1984, INT J CANCER, V33, P43, DOI 10.1002/ijc.2910330109; MIYAUCHI T, 1991, J BIOCHEM-TOKYO, V110, P770, DOI 10.1093/oxfordjournals.jbchem.a123657; MONCADA S, 1991, PHARMACOL REV, V43, P109; Ogata R, 1999, HUM PATHOL, V30, P443, DOI 10.1016/S0046-8177(99)90121-1; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; Sameshima T, 2000, INT J CANCER, V88, P21, DOI 10.1002/1097-0215(20001001)88:1<21::AID-IJC4>3.0.CO;2-S; SAVARESE DMF, 1992, J BIOL CHEM, V267, P21928; SEULBERGER H, 1992, NEUROSCI LETT, V140, P93, DOI 10.1016/0304-3940(92)90690-9; STOCKINGER H, 1997, LEUKOCYTE TYPING, V6, P760; Sun JJ, 2000, J CANCER RES CLIN, V126, P595, DOI 10.1007/PL00008470; Sun JX, 2001, CANCER RES, V61, P2276; Theret N, 2001, HEPATOLOGY, V34, P82, DOI 10.1053/jhep.2001.25758; Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4; WINEGAR BD, 1991, J GEN PHYSIOL, V97, P351, DOI 10.1085/jgp.97.2.351; Wu YG, 1997, CLIN CANCER RES, V3, P1915; XU X, 1994, J BIOL CHEM, V269, P12645; Yao X, 2000, FASEB J, V14, P932, DOI 10.1096/fasebj.14.7.932; Zabrenetzky V., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P33; Zeng L, 1996, J BIOL CHEM, V271, P27744, DOI 10.1074/jbc.271.44.27744; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	58	111	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46870	46877		10.1074/jbc.M108291200	http://dx.doi.org/10.1074/jbc.M108291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591720	hybrid			2022-12-25	WOS:000172768500028
J	Tam, A; Schmidt, WK; Michaelis, S				Tam, A; Schmidt, WK; Michaelis, S			The multispanning membrane protein Ste24p catalyzes CAAX proteolysis and NH2-terminal processing of the yeast a-factor precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FARNESYLTRANSFERASE; METHYLTRANSFERASE; RAS; PREDICTION; IDENTIFICATION; MECHANISMS; INHIBITORS; MATURATION	Saccharomyces cerevisiae Ste24p is a multispanning membrane protein implicated in the CAAX proteolysis step that occurs during biogenesis of the prenylated a-factor mating pheromone. Whether Ste24p acts directly as a CAAX protease or indirectly to activate a downstream protease has not yet been established. In this study, we demonstrate that purified, detergent-solubilized Ste24p directly mediates CAAX proteolysis in a zinc-dependent manner. We also show that Ste24p mediates a separate proteolytic step, the first NH2-terminal cleavage in a-factor maturation. These results establish that Ste24p functions both as a bona fide COOH-terminal CAAX protease and as an a-factor NH2-terminal protease. Importantly, this study is the first to directly demonstrate that a eukaryotic multispanning membrane protein can possess intrinsic proteolytic activity.	Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA	Johns Hopkins University	Michaelis, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA.	michaelis@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041223] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Ambroziak P., 2001, ENZYMES, P155; ANSORGE S, 1984, BIOMED BIOCHIM ACTA, V43, P39; ASHBY MN, 1995, METHOD ENZYMOL, V250, P235; AULD DS, 1995, METHOD ENZYMOL, V248, P228; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen P, 1997, J CELL BIOL, V136, P251, DOI 10.1083/jcb.136.2.251; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dekker N, 2001, BIOCHEMISTRY-US, V40, P1694, DOI 10.1021/bi0014195; Desrosiers RR, 1999, BIOCHEM BIOPH RES CO, V261, P790, DOI 10.1006/bbrc.1999.0936; Dolence JM, 2000, BIOCHEMISTRY-US, V39, P4096, DOI 10.1021/bi9923611; Freije JMP, 1999, GENOMICS, V58, P270, DOI 10.1006/geno.1999.5834; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HRYCYNA CA, 1995, METHOD ENZYMOL, V250, P251; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Juretic D, 1998, COMPUT CHEM, V22, P279, DOI 10.1016/S0097-8485(97)00070-3; Kumagai H, 1999, BBA-GEN SUBJECTS, V1426, P468, DOI 10.1016/S0304-4165(98)00170-6; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Nijbroek GL, 1998, METHOD ENZYMOL, V292, P193; Omer CA, 1997, TRENDS PHARMACOL SCI, V18, P437, DOI 10.1016/S0165-6147(97)90677-5; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Persson B, 1997, J PROTEIN CHEM, V16, P453, DOI 10.1023/A:1026353225758; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; REISS Y, 1992, J BIOL CHEM, V267, P6403; RINE J, 1990, New Biologist, V2, P219; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; SIKORSKI RS, 1989, GENETICS, V122, P19; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	49	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46798	46806		10.1074/jbc.M106150200	http://dx.doi.org/10.1074/jbc.M106150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581258	hybrid			2022-12-25	WOS:000172768500018
J	Zhang, XY; Bi, EF; Novick, P; Du, LL; Kozminski, KG; Lipschutz, JH; Guo, W				Zhang, XY; Bi, EF; Novick, P; Du, LL; Kozminski, KG; Lipschutz, JH; Guo, W			Cdc42 interacts with the exocyst and regulates polarized secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL POLARITY; BUDDING YEAST; SEC6/8 COMPLEX; GTPASE; ACTIN; EXOCYTOSIS; DELIVERY; VESICLES; ESTABLISHMENT	Polarized delivery and incorporation of proteins and lipids to specific domains of the plasma membrane is fundamental to a wide range of biological processes such as neuronal synaptogenesis and epithelial cell polarization. The exocyst complex is specifically localized to sites of active exocytosis and plays essential roles in secretory vesicle targeting and docking at the plasma membrane. Sec3p, a component of the exocyst, is thought to be a spatial landmark for polarized exocytosis. In a search for proteins that regulate the localization of the exocyst in the budding yeast Saccharomyces cerevisiae, we found that certain cdc42 mutants affect the polarized localization of the exocyst proteins. In addition, we found that these mutant cells have a randomized protein secretion pattern on the cell surface. Biochemical experiments indicated that Sec3p directly interacts with Cdc42 in its GTP-bound form. Genetic studies demonstrated synthetically lethal interactions between cdc42 and several exocyst mutants. These results have revealed a role for Cdc42 in exocytosis. We propose that Cdc42 coordinates the vesicle docking machinery and the actin cytoskeleton for polarized secretion.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Yale University; University of California System; University of California Berkeley	Guo, W (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	guowei@sas.upenn.edu		Du, Li-Lin/0000-0002-1028-7397	NIGMS NIH HHS [GM 59216, GM 35370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059216, R37GM035370, R01GM035370] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bi EF, 1996, MOL CELL BIOL, V16, P5264; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; CHANG LW, 1995, BIOMED ENG-APP BAS C, V7, P1; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Finger FP, 2000, GENETICS, V156, P943; Finger FP, 1998, J CELL BIOL, V142, P609, DOI 10.1083/jcb.142.3.609; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Gladfelter AS, 2001, MOL BIOL CELL, V12, P1239, DOI 10.1091/mbc.12.5.1239; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Karpova TS, 2000, MOL BIOL CELL, V11, P1727, DOI 10.1091/mbc.11.5.1727; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Moskow JJ, 2000, MOL CELL BIOL, V20, P7559, DOI 10.1128/MCB.20.20.7559-7571.2000; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Richman TJ, 2000, MOL CELL BIOL, V20, P8548, DOI 10.1128/MCB.20.22.8548-8559.2000; Richman TJ, 1999, J BIOL CHEM, V274, P16861, DOI 10.1074/jbc.274.24.16861; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	38	273	279	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46745	46750		10.1074/jbc.M107464200	http://dx.doi.org/10.1074/jbc.M107464200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595741	hybrid			2022-12-25	WOS:000172768500011
J	Guo, YL; Guettouche, T; Fenna, M; Boellmann, F; Pratt, WB; Toft, DO; Smith, DF; Voellmy, R				Guo, YL; Guettouche, T; Fenna, M; Boellmann, F; Pratt, WB; Toft, DO; Smith, DF; Voellmy, R			Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MOLECULAR CHAPERONES; FACTOR HSF1; FACTOR-I; PHOSPHORYLATION; HSP90; RECEPTOR; GELDANAMYCIN; SALICYLATE; OXIDATION	In the absence of stress, human heat shock factor I (hHSF1) is in its unactivated form. hHSF1 polypeptide is in a dynamic heterocomplex with Hsp90 and is incapable of specifically binding DNA. When cells are stressed, heterocomplex assembly is disrupted. Unbound hHSF1 homotrimerizes, acquires DNA binding activity, and concentrates in the nucleus, but remains transcriptionally inactive. A subsequent reaction converts this inactive, trimeric form into the active, hyperphosphorylated transcription factor. Subsequent to the stressful event, hHSF1 is deactivated and eventually returned to its unactivated form. Evidence is presented herein that trimeric hHSF1 has the propensity to dynamically associate with an Hsp90-immunophilin-p23 complex through its regulatory domain. Formation of this heterocomplex results in repression of the transcriptional activity of trimeric hHSF1. Stress-denatured proteins effectively compete with trimeric hHSF1 for Hsp90-immunophilin-p23 complex, counteracting assembly of the heterocomplex and repression of hHSF1 transcriptional activity. This repression mechanism may be required for a proportional transcriptional response to stress. Formation of the heterocomplex may also represent the first step toward returning the hHSF1 to its unactivated form.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Biol, Scottsdale, AZ 85259 USA	University of Miami; University of Michigan System; University of Michigan; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix	Voellmy, R (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, 1011 NW 15th St, Miami, FL 33136 USA.	rvoellmy@molbio.med.miami.edu			NIGMS NIH HHS [GM31125] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRUCE JL, 1993, CANCER RES, V53, P12; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; FOWDEN L, 1967, ADV ENZYMOL RAMB, V29, P89; FOWDEN L, 1963, BIOCHIM BIOPHYS ACTA, V71, P459, DOI 10.1016/0006-3002(63)91104-1; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Freeman ML, 1999, FREE RADICAL BIO MED, V26, P737, DOI 10.1016/S0891-5849(98)00258-5; GREEN M, 1995, MOL CELL BIOL, V15, P3354; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LEPOCK JR, 1988, J CELL PHYSIOL, V137, P14, DOI 10.1002/jcp.1041370103; Liu JM, 1999, MOL ENDOCRINOL, V13, P355, DOI 10.1210/me.13.3.355; MIVECHI NF, 1995, CANCER RES, V55, P5512; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Ohnishi K, 1999, MOL CELL BIOCHEM, V197, P129, DOI 10.1023/A:1006937513154; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; Voellmy R, 1996, EXS, V77, P121; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; Xiao NQ, 1997, MOL ENDOCRINOL, V11, P1365, DOI 10.1210/me.11.9.1365; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zou JY, 1998, CELL STRESS CHAPERON, V3, P130, DOI 10.1379/1466-1268(1998)003<0130:CBGOAT>2.3.CO;2; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	47	161	176	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45791	45799		10.1074/jbc.M105931200	http://dx.doi.org/10.1074/jbc.M105931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583998	hybrid			2022-12-25	WOS:000172573100040
J	Imai, S; Tezuka, H; Furuhashi, Y; Muto, R; Fujita, K				Imai, S; Tezuka, H; Furuhashi, Y; Muto, R; Fujita, K			A factor of inducing IgE from a filarial parasite is an agonist of human CD40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; B-CELL PROLIFERATION; HELMINTH INFECTION; DENDRITIC CELLS; ABA-1 ALLERGEN; T-CELLS; LIGAND; EXPRESSION; CYTOKINES; RESPONSES	Immune responses to parasitic helminth are usually characterized by quite mysterious phenomena: dominance of Th2-like immunity and antigen-nonspecific IgE secretion. We previously purified a factor from Dirofilaria immitis that induces antigen-nonspecific IgE in rats and named it DiAg. In the presence of IL-4, DiAg induces mouse B cells to secrete IgE, which is antigen-nonspecific polyclonal antibody. We investigated the biochemical characteristics of DiAg as a factor of inducing IgE in this study. Recombinant DiAg (rDiAg) with interleukin (IL)-4 induced IgE synthesis in highly purified human normal B cells in vitro cell culture systems. The addition of recombinant human soluble CD40 IgG fusion protein (rsCD40-Ig) inhibited induction of IgE synthesis by rDiAg with IL-4. Monocyte cells were stimulated with rDiAg and recombinant human soluble CD40L (rsCD40L); IL-12 and TNF-alpha were induced. The addition of rsCD40-Ig to THP-1 cells activated with rDiAg and rsCD40L inhibited the production of IL-12. rDiAg bound to the monocyte cell membrane fraction and recombinant human soluble CD40; this binding of rDiAg was competitively inhibited by addition of rsCD40L. Moreover, in CD40-deficient mice, IgE production and MLN-B cell proliferation by rDiAg were completely absent. Based on these results, we concluded that DiAg is an agonist of CD40.	Tokyo Med & Dent Univ, Sect Environm Parasitol, Dept Int Hlth Dev, Div Publ Hlth,Grad Sch,Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Imai, S (corresponding author), Tokyo Med & Dent Univ, Sect Environm Parasitol, Dept Int Hlth Dev, Div Publ Hlth,Grad Sch,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							AJUH PM, 1995, EXP PARASITOL, V81, P145, DOI 10.1006/expr.1995.1103; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; BRITTON C, 1995, MOL BIOCHEM PARASIT, V72, P77, DOI 10.1016/0166-6851(95)00088-I; Buelens C, 1997, EUR J IMMUNOL, V27, P1848, DOI 10.1002/eji.1830270805; CLARK EA, 1990, TISSUE ANTIGENS, V36, P33, DOI 10.1111/j.1399-0039.1990.tb01795.x; DUNLAP NE, 1989, LEUCOCYTE TYPING, V4, P487; Else KJ, 1998, INT J PARASITOL, V28, P1145, DOI 10.1016/S0020-7519(98)00087-3; FANSLOW WC, 1992, J IMMUNOL, V149, P655; Furuhashi Y, 2001, INT ARCH ALLERGY IMM, V125, P144, DOI 10.1159/000053808; GALY AHM, 1992, J IMMUNOL, V149, P775; HORII Y, 1986, J PARASITOL, V72, P315, DOI 10.2307/3281611; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; INDZHIIA LV, 1992, J CLIN IMMUNOL, V12, P225, DOI 10.1007/BF00918093; ISHIZAKA T, 1976, J ALLERGY CLIN IMMUN, V58, P523, DOI 10.1016/0091-6749(76)90196-2; Jabara HH, 1996, INT IMMUNOL, V8, P1503, DOI 10.1093/intimm/8.10.1503; JARRETT EEE, 1982, PROG ALLERGY, V31, P178; Kato T, 1997, CELL IMMUNOL, V181, P59, DOI 10.1006/cimm.1997.1196; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; LEE TDG, 1993, INT ARCH ALLERGY IMM, V102, P185, DOI 10.1159/000236570; LEE TDG, 1995, J ALLERGY CLIN IMMUN, V95, P1247; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MALISZEWSKI CR, 1993, EUR J IMMUNOL, V23, P1044, DOI 10.1002/eji.1830230510; Ning ZQ, 1996, EUR J IMMUNOL, V26, P2356, DOI 10.1002/eji.1830261013; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OWHASHI M, 1993, MOL IMMUNOL, V30, P1315, DOI 10.1016/0161-5890(93)90048-G; PRITCHARD DI, 1993, PARASITE IMMUNOL, V15, P5, DOI 10.1111/j.1365-3024.1993.tb00566.x; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SPENCE HJ, 1993, MOL BIOCHEM PARASIT, V57, P339, DOI 10.1016/0166-6851(93)90210-O; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TWEEDIE S, 1993, EXP PARASITOL, V76, P156, DOI 10.1006/expr.1993.1018; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; WARE CF, 1991, J IMMUNOL, V147, P4229; Wynn TA, 1997, MEM I OSWALDO CRUZ, V92, P105, DOI 10.1590/S0074-02761997000800014; Xia Y, 2000, PARASITOLOGY, V120, P211, DOI 10.1017/S0031182099005363; YAMAOKA KA, 1994, IMMUNOLOGY, V81, P507; Yoshimoto T, 1997, EUR J IMMUNOL, V27, P3461, DOI 10.1002/eji.1830271247	40	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46118	46124		10.1074/jbc.M104581200	http://dx.doi.org/10.1074/jbc.M104581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591702	hybrid			2022-12-25	WOS:000172573100086
J	Iwamoto, T; Fukumoto, S; Kanaoka, K; Sakai, E; Shibata, M; Fukumoto, E; Inokuchi, J; Takamiya, K; Furukawa, K; Furukawa, K; Kato, Y; Mizuno, A				Iwamoto, T; Fukumoto, S; Kanaoka, K; Sakai, E; Shibata, M; Fukumoto, E; Inokuchi, J; Takamiya, K; Furukawa, K; Furukawa, K; Kato, Y; Mizuno, A			Lactosylceramide is essential for the osteoclastogenesis mediated by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappa B ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; NEURITE OUTGROWTH; BONE-RESORPTION; CELL-ADHESION; GLUCOSYLCERAMIDE SYNTHASE; SIGNAL-TRANSDUCTION; GLYCOSPHINGOLIPID SYNTHESIS; COMPLEX GANGLIOSIDES	Glycosphingolipids and their metabolites play important roles in a variety of biological processes. Several signal molecules are localized in a glycolipid-enriched microdomain on the cell surface, and their signals are regulated by the glycolipid composition. However, the function of glycolipids in osteoclastogenesis has not been clearly understood. We found that D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanoI (D-PDMP), a glucosylceramide synthase inhibitor, completely inhibits the osteoclast formation induced by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappaB ligand (RANKL) in a dose-dependent manner. Expression of RANK, the receptor of RANKL, induced by macrophage colony-stimulating factor, was reduced markedly in D-PDMP-treated cells. D-PDMP also inhibited the phosphorylation. of the inhibitor of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2 induced by RANKL. In several experiments with the addition of glycolipids to D-PDMP-treated purified bone marrow cells, lactosylceramide (LacCer) strongly affected the differentiation into tartrate-resistant acid phosphatase mononucleated cells, but not positive multinucleated cells. GM3 and GM1 also recovered, but less effectively compared with LacCer. Moreover, exogenous LacCer recovered the reduced expression of RANK and the phosphorylation of inhibitor of NF-kappaB and extracellular signal-regulated kinase 1/2 after stimulation by RANKL at the same level of cells without D-PDMP treatment. Our data suggest that glycosphingolipids, especially LacCer, are necessary for the initiation step of RANKL-induced osteoclastogenesis.	Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Dent, Dept Oral & Maxillofacial Surg 1, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Dent, Dept Prevent Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Dent, Dept Pharmacol, Nagasaki 8528588, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Sapporo, Hokkaido 0600812, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Hokkaido University; Nagoya University	Fukumoto, S (corresponding author), Nagasaki Univ, Sch Dent, Dept Pediat Dent, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	satoshi@dh.nagasaki-u.ac.jp	Inokuchi, Jin-ichi/AAW-9964-2020; Iwamoto, Tsutomu/AAA-6597-2019; Iwamoto, Tsutomu/AAI-8952-2021	Inokuchi, Jin-ichi/0000-0002-0703-5746; Iwamoto, Tsutomu/0000-0001-8472-605X; Fukumoto, Satoshi/0000-0002-5046-6891; sakai, eiko/0000-0002-6776-6540; Takamiya, Kogo/0000-0001-7240-6307				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; CHAMBERS TJ, 1984, J CELL SCI, V66, P383; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CLOVER J, 1992, J CELL SCI, V103, P267; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; FURUKAWA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P70, DOI 10.1016/0003-9861(90)90414-T; Harada H, 1998, ENDOCRINOLOGY, V139, P3967, DOI 10.1210/en.139.9.3967; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; Hynds DL, 1997, J NEUROSCI RES, V47, P617, DOI 10.1002/(SICI)1097-4547(19970315)47:6<617::AID-JNR7>3.0.CO;2-G; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; KATO H, 1993, J BIOL CHEM, V268, P2655; KOIKE T, 1993, IMMUNOL LETT, V35, P207, DOI 10.1016/0165-2478(93)90184-4; KRUPPA G, 1992, J IMMUNOL, V148, P3152; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Probstmeier R, 1999, EUR J NEUROSCI, V11, P2474, DOI 10.1046/j.1460-9568.1999.00670.x; Probstmeier R, 1999, GLYCOBIOLOGY, V9, P101, DOI 10.1093/glycob/9.2.101; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Sakai H, 2000, BIOCHEM BIOPH RES CO, V270, P550, DOI 10.1006/bbrc.2000.2485; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SHINAR DM, 1993, J BONE MINER RES, V8, P403; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; Takeda H, 1998, FEBS LETT, V422, P255, DOI 10.1016/S0014-5793(98)00005-2; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tsurukai T, 1998, J CELL PHYSIOL, V177, P26, DOI 10.1002/(SICI)1097-4652(199810)177:1<26::AID-JCP3>3.0.CO;2-G; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; Usuki S, 1996, J NEUROCHEM, V67, P1821; VANDERPLUIJM G, 1994, J BONE MINER RES, V9, P1021; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhao JM, 1999, J BIOL CHEM, V274, P13744, DOI 10.1074/jbc.274.20.13744	64	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46031	46038		10.1074/jbc.M104464200	http://dx.doi.org/10.1074/jbc.M104464200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11592959	hybrid			2022-12-25	WOS:000172573100074
J	Satou, A; Taira, T; Iguchi-Ariga, SMM; Ariga, H				Satou, A; Taira, T; Iguchi-Ariga, SMM; Ariga, H			A novel transrepression pathway of c-Myc. Recruitment of a transcriptional corepressor complex to c-Myc by MM-1, a c-Myc-binding protein.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; ESSENTIAL COFACTOR; REPRESSOR DOMAIN; SWI/SNF COMPLEX; CELL-GROWTH; TIF1 BETA; HETEROCHROMATIN; INTERACTS; KAP-1; MAD	The protooncogene product c-Myc plays a role in transcription regulation both for activation and repression. While transactivation pathways of c-Myc either from the N-proximal or the C-proximal region that is linked to the chromatin remodeling complex have been identified, a transrepression pathway had been identified only from the C-proximal region via Max and Mad that recruit the histone deacetylase (HDAC) complex. We have reported that a novel c-Myc-binding protein, MM-1, repressed the E-box-dependent transcription activity of c-Myc (Mori, K., Maeda, Y., Kitaura, H., Taira, T., Iguchi-Ariga, S. M. M., and Ariga, H. (1998) J. Biol. Chem. 273, 29794-29800). To clarify the molecular mechanisms of MM-1 toward c-Myc, cDNAs encoding MM-l-binding proteins were screened by the two-hybrid method with MM-1 as a bait using a human HeLa cDNA library, and a cDNA encoding TIF1 beta /KAP1, a transcriptional corepressor, was obtained. MM-1 was found to bind to the central portion of TIF1 beta in vitro and in vivo, and these proteins were found to be colocalized in the nucleus. MM-1 and TIF1 beta complex in human HeLa cells was found to also contain c-Myc, mSin3, and HDAC1. Introduction of the C-terminal half of TIF1 beta as a dominant negative form abrogated the inhibitory activity of MM-1 toward c-Myc and greatly stimulated the transcription activity of c-Myc. Moreover, the inhibitory activity of MM-1 toward c-Myc was canceled by trichostatin A, an inhibitor of HDAC1. These results indicate that MM-1 is a connecting factor that forms a novel transcription repression pathway of c-Myc.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 060, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Sanae/H-9647-2013; Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guo QM, 2000, CANCER RES, V60, P5922; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; NEGISHI Y, 1994, ONCOGENE, V9, P1133; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Prendergast GC, 1999, ONCOGENE, V18, P2914, DOI 10.1038/sj.onc.1202784; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; SINGH PB, 1994, J CELL SCI, V107, P2653; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; Takayama M, 2000, GENES CELLS, V5, P481, DOI 10.1046/j.1365-2443.2000.00338.x; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X	38	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46562	46567		10.1074/jbc.M104937200	http://dx.doi.org/10.1074/jbc.M104937200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585818	hybrid			2022-12-25	WOS:000172573100142
J	Yuan, X; Lu, ML; Li, T; Balk, SP				Yuan, X; Lu, ML; Li, T; Balk, SP			SRY interacts with and negatively regulates androgen receptor transcriptional activity.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL HYPOPLASIA CONGENITA; PROSTATE-SPECIFIC ANTIGEN; LIGAND-BINDING DOMAIN; ESTROGEN RESPONSE ELEMENT; INHIBITING SUBSTANCE GENE; TESTIS-DETERMINING FACTOR; AUTOSOMAL SEX REVERSAL; AMINO-TERMINAL DOMAIN; Y-CHROMOSOME GENES; NUCLEAR-RECEPTOR	This study investigated interactions between SRY, the Y chromosome encoded male sex determining factor, and the androgen receptor (AR). Coexpression of AR and SRY caused marked repression of AR transcriptional activity on a series of androgen-responsive reporter genes. Mammalian one- and two-hybrid experiments demonstrated an AR-SRY interaction mediated by the AR DNA binding domain. Precipitations with glutathione S-transferase fusion proteins indicated that AR-SRY interactions were direct and mediated by the AR DNA binding domain and the SRY high mobility group box DNA binding domain. Transient expression of SRY in LNCaP prostate cancer cells repressed expression of an androgen-dependent prostate-specific antigen (PSA) reporter gene and stable SRY expression repressed the endogenous PSA gene. SRY protein expression was increased by proteosome inhibitors and by the androgen-liganded AR in transient and stable transfectants. AR transcriptional activity was also repressed by DAX1, and the effects of SRY and DAX1 on the AR were additive. These findings indicate that interactions between the AR, SRY, and DAX1 contribute to normal male development and function and suggest a general role for protein-protein interactions between high mobility group box proteins and steroid hormone receptors in regulating tissue-specific gene expression.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Dept Med, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Urol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Yuan, X (corresponding author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Dept Med, Canc Biol Program, 330 Brookline Ave, Boston, MA 02215 USA.	xyuan@caregroup.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA065647] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA65647] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bowles J, 1999, NAT GENET, V22, P405, DOI 10.1038/11981; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Dasari VK, 2001, J UROLOGY, V165, P1335, DOI 10.1016/S0022-5347(01)69895-1; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Gottlieb B, 1999, AM J MED GENET, V89, P210, DOI 10.1002/(SICI)1096-8628(19991229)89:4<210::AID-AJMG5>3.0.CO;2-P; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUO WW, 1995, BIOCHEM MOL MED, V56, P8, DOI 10.1006/bmme.1995.1049; Habiby RL, 1996, J CLIN INVEST, V98, P1055, DOI 10.1172/JCI118866; HACKER A, 1995, DEVELOPMENT, V121, P1603; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Harley VR, 1996, FEBS LETT, V391, P24, DOI 10.1016/0014-5793(96)00694-1; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Lau YFC, 2000, MOL CARCINOGEN, V27, P308, DOI 10.1002/(SICI)1098-2744(200004)27:4<308::AID-MC9>3.0.CO;2-R; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; McElreavey K, 1999, AM J MED GENET, V89, P176, DOI 10.1002/(SICI)1096-8628(19991229)89:4<176::AID-AJMG2>3.0.CO;2-B; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Melvin VS, 1999, STEROIDS, V64, P576, DOI 10.1016/S0039-128X(99)00036-7; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; ONATE SA, 1995, SCIENCE, V270, P1354; Perinchery G, 2000, J UROLOGY, V163, P1339, DOI 10.1016/S0022-5347(05)67774-9; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Romine LE, 1998, MOL ENDOCRINOL, V12, P664, DOI 10.1210/me.12.5.664; Salas-Cortes L, 1999, INT J DEV BIOL, V43, P135; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRICOLI JV, 1993, GENE CHROMOSOME CANC, V8, P28, DOI 10.1002/gcc.2870080106; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Weiss MA, 2001, MOL ENDOCRINOL, V15, P353, DOI 10.1210/me.15.3.353; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WONG CI, 1993, J BIOL CHEM, V268, P19004; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	78	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46647	46654		10.1074/jbc.M108404200	http://dx.doi.org/10.1074/jbc.M108404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585838	hybrid			2022-12-25	WOS:000172573100152
J	Rani, MRS; Asthagiri, AR; Singh, A; Sizemore, N; Sathe, SS; Li, XX; DiDonato, JD; Stark, GR; Ransohoff, RM				Rani, MRS; Asthagiri, AR; Singh, A; Sizemore, N; Sathe, SS; Li, XX; DiDonato, JD; Stark, GR; Ransohoff, RM			A role for NF-kappa B in the induction of beta-R1 by interferon-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; DNA-BINDING; MEDIATED PHOSPHORYLATION; DEPENDENT TRANSCRIPTION; P65 SUBUNIT; IFN-GAMMA; ACTIVATION; GENE; PROTEIN; INTERLEUKIN-1	Previous experiments have suggested that induction of the beta3-R1 gene by interferon (IFN)-beta required transcription factor ISGF-3 (IFN-stimulated gene factor-3) and an additional component. We now provide evidence that nuclear factor-kappaB (NF-kappaB) can serve as this component. Site-directed mutagenesis of an NF-kappaB binding site in the beta -R1 promoter or over-expression of an I kappaB alpha super-repressor abrogated IFN-beta -mediated induction of a beta -R1 promoter-reporter. IFN-beta treatment did not augment abundance of NF-kappaB but did lead to phosphorylation of the p65 NF-kappaB subunit. It is proposed that IFN-beta -mediated enhancement of the transactivation competence of NF-kappaB components is required for inducible transcription of the beta -R1 promoter. These results provide a novel insight into the role of NF-kappaB in the transcriptional response to IFN-beta.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, NC30, Cleveland, OH 44195 USA.	ransohr@ccf.org			NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [2PO1 CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GRESSER I, 1990, J INVEST DERMATOL, V95, pS66, DOI 10.1111/1523-1747.ep12874776; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Li XX, 1999, MOL CELL BIOL, V19, P4643; Majumder S, 1998, J IMMUNOL, V161, P4736; Moitreyee CK, 1998, MOL CELL BIOCHEM, V178, P103, DOI 10.1023/A:1006816806138; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Rani MRS, 1999, J BIOL CHEM, V274, P32507, DOI 10.1074/jbc.274.45.32507; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; Rani MRS, 1999, J BIOL CHEM, V274, P1891, DOI 10.1074/jbc.274.4.1891; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WIEST JS, 1994, ONCOGENE, V9, P2449; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	27	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44365	44368		10.1074/jbc.C100417200	http://dx.doi.org/10.1074/jbc.C100417200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11591697	hybrid			2022-12-25	WOS:000172406700002
J	Johnson, AJ; Upshaw, J; Pavelko, KD; Rodriguez, M; Pease, LR				Johnson, AJ; Upshaw, J; Pavelko, KD; Rodriguez, M; Pease, LR			Preservation of motor function by inhibition of CD8+virus peptide-specific T cells in Theiler's virus infection	FASEB JOURNAL			English	Article						class I molecules; multiple sclerosis; immunodominant peptide; neurological deficit; central nervous system	CENTRAL-NERVOUS-SYSTEM; PERFORIN-DEFICIENT MICE; INDUCED DEMYELINATION; MULTIPLE-SCLEROSIS; LYMPHOCYTIC CHORIOMENINGITIS; INTERFERON-ALPHA/BETA; PERSISTENT INFECTION; MURINE MODEL; VIRAL MODEL; EPITOPE	Central nervous system-infiltrating CD8+ T cells are potential mediators of neuropathology in models of multiple sclerosis induced by Theiler's murine encephalomyelitis virus (TMEV) infection. C57BL/6 mice mount a vigorous cytotoxic T lymphocyte (CTL) response against the immunodominant virus peptide VP2(121-130) and clear TMEV infection. Interferon-gamma (IFN-gamma )R-/- mice also mount a strong CTL response against the VP2(121-130) epitope, but because of genetic deficiencies in critical IFN-gamma signaling pathways, they do not clear TMEV infection and develop prominent neurological deficits within 6 wk. This pronounced disease process, coupled with a defined CTL response, provides an ideal model for evaluating the importance of antiviral CTL activity in the development of severe demyelination and loss of motor neuron function. By administering the VP2(121-130) peptide before and during TMEV infection, 99% of the VP2(121-130)-specific CD8+ T cell response was inhibited. No decrease in virus infection was observed. Peptide treatment did result in significantly less motor dysfunction, even when no differences in levels of demyelination were observed. Although most investigators focus on the role of CD4+ T cells in demyelinating disease, these studies are the first to demonstrate a clear contribution of antiviral CD8+ T cells in neurological injury in a chronic-progressive model of multiple sclerosis.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Pease, LR (corresponding author), Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	pease.larry@mayo.edu	Pavelko, Kevin D/K-7072-2019	Pavelko, Kevin D/0000-0001-7555-1315; Rodriguez, Moses/0000-0001-6328-6497				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ATLINTAS A, 1993, J IMMUNOL, V151, P2803; Aubagnac S, 1999, J VIROL, V73, P7965, DOI 10.1128/JVI.73.10.7965-7971.1999; Borson ND, 1997, J VIROL, V71, P5244, DOI 10.1128/JVI.71.7.5244-5250.1997; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Carter RJ, 1999, J NEUROSCI, V19, P3248; CASTRO RF, 1995, J VIROL, V69, P8127, DOI 10.1128/JVI.69.12.8127-8131.1995; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1988, CELL IMMUNOL, V116, P475, DOI 10.1016/0008-8749(88)90246-8; FIETTE L, 1995, J EXP MED, V181, P2069, DOI 10.1084/jem.181.6.2069; FIETTE L, 1993, J VIROL, V67, P589, DOI 10.1128/JVI.67.1.589-592.1993; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Katz-Levy Y, 1999, J CLIN INVEST, V104, P599, DOI 10.1172/JCI7292; LarssonSciard EL, 1997, J VIROL, V71, P797, DOI 10.1128/JVI.71.1.797-799.1997; LECH K, 1987, CURRENT PROTOCOLS MO; LINDSLEY MD, 1989, J IMMUNOL, V142, P2677; LINDSLEY MD, 1992, MAYO CLIN PROC, V67, P829, DOI 10.1016/S0025-6196(12)60820-9; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; McGavern DB, 1999, EXP NEUROL, V158, P171, DOI 10.1006/exnr.1999.7082; Melero I, 1997, J VIROL, V71, P3998, DOI 10.1128/JVI.71.5.3998-4004.1997; Miller DJ, 1995, J NEUROSCI, V15, P8345; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Murray PD, 1998, J NEUROSCI, V18, P7306; Murray PD, 1998, J VIROL, V72, P7320, DOI 10.1128/JVI.72.9.7320-7329.1998; Njenga MK, 1997, LAB INVEST, V77, P71; Njenga MK, 1997, J VIROL, V71, P8592, DOI 10.1128/JVI.71.11.8592-8601.1997; PEWE L, 1996, IMMUNITY, V5, P352; PIERCE M, 1989, J HISTOTECHNOL, V12, P35; PULLEN LC, 1993, EUR J IMMUNOL, V23, P2287, DOI 10.1002/eji.1830230935; Rivera-Quinones C, 1998, NAT MED, V4, P187, DOI 10.1038/nm0298-187; RODRIGUEZ M, 1993, J IMMUNOL, V151, P266; RODRIGUEZ M, 1988, J IMMUNOL, V140, P2950; RODRIGUEZ M, 1991, J IMMUNOL, V146, P2596; RODRIGUEZ M, 1985, J IMMUNOL, V135, P2145; RODRIGUEZ M, 1983, ANN NEUROL, V13, P426, DOI 10.1002/ana.410130409; Rodriguez M, 1996, J IMMUNOL, V157, P5699; RODRIGUEZ M, 1986, IMMUNOL TODAY, V7, P9; Rolland J, 1998, CURR OPIN IMMUNOL, V10, P640, DOI 10.1016/S0952-7915(98)80082-4; Rossi CP, 1998, J VIROL, V72, P4515; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Vanderlugt CL, 1998, IMMUNOL REV, V164, P63, DOI 10.1111/j.1600-065X.1998.tb01208.x; Velders MP, 1998, CRIT REV IMMUNOL, V18, P7, DOI 10.1615/CritRevImmunol.v18.i1-2.30; Wu GF, 2000, J IMMUNOL, V165, P2278, DOI 10.4049/jimmunol.165.4.2278	47	58	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2760	+		10.1096/fj.01-0373fje	http://dx.doi.org/10.1096/fj.01-0373fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606479				2022-12-25	WOS:000171920400014
J	de Leeuw, WJF; van Puijenbroek, M; Merx, R; Wijnen, JT; Brocker-Vriends, AHJT; Tops, C; Vasen, H; Cornelisse, CJ; Morreau, H				de Leeuw, WJF; van Puijenbroek, M; Merx, R; Wijnen, JT; Brocker-Vriends, AHJT; Tops, C; Vasen, H; Cornelisse, CJ; Morreau, H			Bias in detection of instability of the (C)8 mononucleotide repeat of MSH6 in tumours from HNPCC patients	ONCOGENE			English	Article						HNPCC; MSI; MSH6; repeat; microsatellite	NONPOLYPOSIS COLORECTAL-CANCER; II RECEPTOR GENE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATIONS; CARCINOMAS; TUMORS	Recently, we and others reported instability in the (C)8 repeat in exon 5 of MSH6 as a preferential target for somatic mutations in tumours from MSH6 germline mutation carriers. Here, we report that in 45% of tumours from MLH1, MSH2 and MSH6 germline mutation carriers no sequence change in the (C)8 repeat of MSH6 was found upon DNA sequencing analysis of PCR products with a shift in electrophoresis mobility. Using 'standard' PCR primers a high frequency of instability (50-86%) of the (C)8 repeat was found, but using a modified PCR reverse primer, accomplishing modulation of non-templated addition of adenine during in vitro PCR amplification by the Taq polymerase, a markedly lower frequency of instability was found in turnours from MLH1, MSH2 and MSH6 mutation carriers (6, 13 and 40%, respectively). Furthermore, a significant difference of the frequency of instability of the (C)8 repeat in tumours from MSH6 mutation carriers was found compared to MLH1, MSH2 mutation carriers. These results might have important implications for the detection of instability of other short mononucleotide repeats, e.g. TGF beta RII, BAX, IGFRII, PTEN, BRCA2.	Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human & Clin Genet, MGC, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Fdt Detect Hereditary Tumours, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Leeuw, WJF (corresponding author), Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands.			Vasen, Hans/0000-0003-2682-2603				Akiyama Y, 1996, CANCER-AM CANCER SOC, V78, P2478, DOI 10.1002/(SICI)1097-0142(19961215)78:12<2478::AID-CNCR5>3.0.CO;2-G; Akiyama Y, 1997, CANCER RES, V57, P3920; Boland CR, 1998, CANCER RES, V58, P5248; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; de Leeuw WJF, 2000, J PATHOL, V192, P328, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO;2-2; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kolodner RD, 1999, CANCER RES, V59, P5068; Koul A, 1999, GENE CHROMOSOME CANC, V24, P207, DOI 10.1002/(SICI)1098-2264(199903)24:3<207::AID-GCC5>3.0.CO;2-3; Magnuson VL, 1996, BIOTECHNIQUES, V21, P700, DOI 10.2144/96214rr03; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; PARSONS R, 1995, CANCER RES, V55, P5548; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Planck M, 2000, GENE CHROMOSOME CANC, V29, P33, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1004>3.0.CO;2-R; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SMITH JR, 1995, GENOME RES, V5, P312, DOI 10.1101/gr.5.3.312; SOUZA RF, 1996, NAT GENET, V14, P2255; Togo G, 1996, CANCER RES, V56, P5620; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612	23	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6241	6244		10.1038/sj.onc.1204795	http://dx.doi.org/10.1038/sj.onc.1204795			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593433				2022-12-25	WOS:000171206300016
J	Schmidt, M; Koller, R; Haviernik, P; Bies, J; Maciag, K; Wolff, L				Schmidt, M; Koller, R; Haviernik, P; Bies, J; Maciag, K; Wolff, L			Deregulated c-Myb expression in murine myeloid leukemias prevents the up-regulation of p15(INK4b) normally associated with differentiation	ONCOGENE			English	Article						c-Myb; p15(INK4b); myeloid leukemia	CELL-CYCLE INHIBITORS; TERMINAL DIFFERENTIATION; GENE FAMILY; BALB/C MICE; APOPTOSIS; INACTIVATION; METHYLATION; P16(INK4A); INDUCTION; PROTEIN	Deregulated expression of the proto-oncogene c-myb, which results from provirus integration, is thought to be responsible for transformation in a set of murine leukemia virus (MuLV)-induced myeloid leukemias (MML). We reported recently that this transcription factor promotes proliferation by directly transactivating c-myc and inhibits cell death through its up-regulation of Bcl-2 (Schmidt et al., 2000). To understand more about how these cells become transformed we looked at how they deal with cellular pathways inducing growth arrest. Specifically, we were interested in the expression of the tumor suppressor gene Cdkn2b (p15(INK4b)) in MML because this gene is expressed during myeloid differentiation and its inactivation by methylation has been shown to be important for the development of human acute myeloid leukemia. mRNA levels for p15(INK4b) and another INK4 gene p16(INK4b) were examined in monocytic Myb tumors and were compared with expression of the same genes in c-myc transformed monocytic tumors that do not express c-Myb. The Cdkn2a (p16(INK4b)) gene was generally not expressed in either tumor type, an observation explained by methylation or deletion in the promoter region. Although Cdkn2b (p15(INK4b)) mRNA was expressed in the Myc tumors, many transcripts were aberrant in size and contained only exon 1. Surprisingly, in the majority of the Myb tumors there was no p15(INK4b) transcription and neither deletion nor methylation could explain this result. Additional experiments demonstrated that, in the presence of constitutive c-Myb expression, the induction of p15(INK4b) mRNA that accompanies differentiation of MI cells to monocytes does not occur. Therefore, the transcriptional regulator c-Myb appears to prevent activation of a growth arrest pathway that normally accompanies monocyte maturation.	NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA; Canc Res Inst, Mol Virol Lab, Bratislava, Slovakia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Slovak Academy of Sciences	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA.	LWOLFF@helix.nih.gov		/0000-0003-0803-4312				Amanullah A, 2000, BLOOD, V96, P475; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; Batova A, 1997, CANCER RES, V57, P832; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DellaRagione F, 1997, LEUKEMIA LYMPHOMA, V25, P23, DOI 10.3109/10428199709042493; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, CANCER RES, V56, P722; HIRAMA T, 1995, BLOOD, V86, P841; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; QUELLE DE, 1995, ONCOGENE, V11, P635; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; Siebert R, 1996, LEUKEMIA LYMPHOMA, V23, P505, DOI 10.3109/10428199609054859; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Teofili L, 1998, EXP HEMATOL, V26, P1133; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Wolff L, 1996, CURR TOP MICROBIOL, V211, P191; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; WOLFF L, 1988, J IMMUNOL, V141, P681; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; Zhang B, 2000, J MOL BIOL, V299, P1121, DOI 10.1006/jmbi.2000.3803; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	45	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6205	6214		10.1038/sj.onc.1204821	http://dx.doi.org/10.1038/sj.onc.1204821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593429				2022-12-25	WOS:000171206300012
J	Bannasch, D; Madge, B; Schwab, M				Bannasch, D; Madge, B; Schwab, M			Functional interaction of Yaf2 with the central region of MycN	ONCOGENE			English	Article						expression; immunofluorescence; MycN; protein-protein interactions; Yaf2; yeast two-hybrid	TRANSCRIPTION FACTOR YY1; C-MYC; NEUROBLASTOMA-CELLS; BINDING-PROTEIN; TRANSFORMATION; COMPLEX; GROWTH; NETWORK; VECTOR; NMI	MYCN is often amplified in advanced-stage neuroblastomas with the consequence of enhanced MycN protein expression. By employing the yeast two-hybrid system we found that Yaf2 binds to the central region of MycN. Binding was also seen in vitro and in vivo. Ectopically expressed Yaf2, like MycN, is localized in the nuclei of neuroblastoma cells. Endogenous Yaf2 is expressed in all three tested neuroblastoma cell lines, all of which also express MycN. Yaf2 was able to enhance MycN-mediated transactivation from an E-box promoter, deletion of the Yaf2 binding region in MycN abrogates this effect. Thus, the binding of Yaf2 to the central region of MycN is functional in mammalian cells.	Deutsch Krebsforschungszentrum, Div Cytogenet H0400, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Cytogenet H0400, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			Madge, Britta/0000-0002-5948-8552				Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bannasch D, 1999, PLASMID, V42, P139, DOI 10.1006/plas.1999.1413; Bao JX, 1996, ONCOGENE, V12, P2171; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; CHATTON B, 1995, BIOTECHNIQUES, V18, P5527; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Dang CV, 1999, MOL CELL BIOL, V19, P1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Lutz W, 1996, ONCOGENE, V13, P803; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SCHWAB M, 2000, PATHOLOGY GENETICS T, P153; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X	24	15	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5913	5919		10.1038/sj.onc.1204747	http://dx.doi.org/10.1038/sj.onc.1204747			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593398				2022-12-25	WOS:000171037200016
J	Liu, YZ; Hiraiwa, Y; Liu, EB; Kurata, H; Thant, AA; Matsuda, S; Hamaguchi, M				Liu, YZ; Hiraiwa, Y; Liu, EB; Kurata, H; Thant, AA; Matsuda, S; Hamaguchi, M			Suppression of cell spreading by v-Crk requires Ras-MPK-MAP kinase signaling	ONCOGENE			English	Article						v-Crk; Ras; MAP kinase; cell spreading; integrin	PROTEIN; TRANSFORMATION; PATHWAY; ACTIVATION; TRANSDUCTION; FIBROBLASTS; INTEGRINS; ADHESION	We investigated the attachment and spreading of v-Crk-transformed cells, v-Crk3Y1, on fibronectin. Transformation-by v-Crk virtually suppressed the spreading, but not the attachment, of cells on fibronectin. This suppression of cell spreading was not correlated with the suppression of integrin alpha5 and beta1 expression. However, the spreading of v-Crk3Y1 on fibronectin was dramatically restored by either expression of dominant-negative Ras or treatment with manumycin A, a Ras farnesyltransferase inhibitor. Moreover, both expression of dominant-negative MEK1 and treatment of cells with U0126, a MEK1 inhibitor, restored the cell spreading of v-Crk3Y1. In contrast, neither treatment with LY294002, a PI3K inhibitor, nor expression of dominant-negative C3G showed no effect on cell spreading on fibronectin. Taken together, our results suggest that, among multiple signaling pathways activated by v-Crk, the Ras-MEK1-MAP kinase cascade plays a pivotal role in the suppression of cell spreading on fibronectin, but C3G and the PI3 kinase do not.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.							ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Liu EB, 2000, CANCER RES, V60, P2361; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356	21	5	5	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5908	5912		10.1038/sj.onc.1204738	http://dx.doi.org/10.1038/sj.onc.1204738			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593397				2022-12-25	WOS:000171037200015
J	Harris, TJC; Ravandi, A; Siu, CH				Harris, TJC; Ravandi, A; Siu, CH			Assembly of glycoprotein-80 adhesion complexes in Dictyostelium - Receptor compartmentalization and oligomerization in membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; CELL-CELL ADHESION; PLASMA-MEMBRANE; LIPID RAFTS; SURFACE GLYCOPROTEIN; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; DISCOIDEUM; DOMAINS; DDCAD-1	The phospholipid-anchored membrane glycoprotein (gp)-80 mediates cell-cell adhesion through a homophilic trans-interaction mechanism during Dictyostelium development and is enriched in a Triton X-100-insoluble floating fraction. To elucidate how gp80 adhesion complexes assemble in the plasma membrane, gp80-gp80 and gp80-raft interactions were investigated. A low density raft-like membrane fraction was isolated using a detergent-free method. It was enriched in sterols, the phospholipid-anchored proteins gp80, gp138, and ponticulin, as well as DdCD36 and actin, corresponding to components found in the Triton X-100-insoluble floating fraction. Chemical cross-linking revealed that gp80 oligomers were enriched in the raft-like membrane fraction, implicating stable oligomer-raft interactions. However, gp80 oligomers resisted sterol sequestration and were partially dissociated with Triton X-100, suggesting that compartmentalization in rafts was not solely responsible for their formation. The trans-dimer known to mediate adhesion was identified, but cis-oligomerization predominated and displayed greater accumulation during development. In fact, oligomerization was dependent on the level of gp80 expression and occurred among isolated gp80 extracellular domains, indicating that it was mediated by direct gp80-gp80 interactions. Rafts existed in gp80-null cells and such pre-existent membrane domains may provide optimal microenvironments for gp80 cis-oligomerization and the assembly of adhesion complexes.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Siu, CH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Ravandi, Amir/O-7552-2019					AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; BRAR SK, 1993, J BIOL CHEM, V268, P24902; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BRUNETTE DM, 1971, J MEMBRANE BIOL, V5, P215, DOI 10.1007/BF01870550; DASILVA AM, 1989, EXP CELL RES, V185, P464, DOI 10.1016/0014-4827(89)90315-7; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; Esni F, 1999, J CELL BIOL, V144, P325, DOI 10.1083/jcb.144.2.325; FANG H, 1993, DEV BIOL, V156, P201, DOI 10.1006/dbio.1993.1070; FECHHEIMER M, 1994, J CELL SCI, V107, P2393; FONTANA DR, 1993, DIFFERENTIATION, V53, P139, DOI 10.1111/j.1432-0436.1993.tb00702.x; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Funatsu N, 1999, J BIOL CHEM, V274, P8224, DOI 10.1074/jbc.274.12.8224; GAO EN, 1992, J BIOL CHEM, V267, P9409; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HARLOFF C, 1989, GENE DEV, V3, P2011, DOI 10.1101/gad.3.12a.2011; Harris TJC, 2001, J BIOL CHEM, V276, P18640, DOI 10.1074/jbc.M010016200; HITT AL, 1994, J CELL BIOL, V126, P1433, DOI 10.1083/jcb.126.6.1433; HITT AL, 1994, J CELL BIOL, V126, P1421, DOI 10.1083/jcb.126.6.1421; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; Janssen KP, 2001, BBA-GEN SUBJECTS, V1525, P228, DOI 10.1016/S0304-4165(01)00108-8; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; Kloboucek A, 1999, BIOPHYS J, V77, P2311, DOI 10.1016/S0006-3495(99)77070-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loomis WF., 1975, DICTYOSTELIUM DISCOI; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; OCHIAI H, 1982, CELL DIFFER DEV, V11, P1, DOI 10.1016/0045-6039(82)90011-2; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Ponte E, 1998, P NATL ACAD SCI USA, V95, P9360, DOI 10.1073/pnas.95.16.9360; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SADEGHI H, 1988, P NATL ACAD SCI USA, V85, P5512, DOI 10.1073/pnas.85.15.5512; Sandig M, 1997, CELL MOTIL CYTOSKEL, V36, P149, DOI 10.1002/(SICI)1097-0169(1997)36:2<149::AID-CM5>3.3.CO;2-#; Schreiner G F, 1976, Adv Immunol, V24, P37, DOI 10.1016/S0065-2776(08)60329-6; Sesaki H, 1997, J CELL BIOL, V138, P939, DOI 10.1083/jcb.138.4.939; Sesaki H, 1996, DEV BIOL, V177, P504, DOI 10.1006/dbio.1996.0181; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SIU CH, 1988, BIOCHIM BIOPHYS ACTA, V968, P283, DOI 10.1016/0167-4889(88)90019-5; SIU CH, 1997, DICTYOSTELIUM MODEL, P69; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wang J, 2000, DEV BIOL, V227, P734, DOI 10.1006/dbio.2000.9881; Wong EFS, 1996, J BIOL CHEM, V271, P16399, DOI 10.1074/jbc.271.27.16399; Xiao Z, 1997, MOL BIOL CELL, V8, P855, DOI 10.1091/mbc.8.5.855	56	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48764	48774		10.1074/jbc.M108030200	http://dx.doi.org/10.1074/jbc.M108030200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11604403	hybrid			2022-12-25	WOS:000173922100021
J	Dourdin, N; Bhatt, AK; Dutt, P; Greer, PA; Arthur, JSC; Elce, JS; Huttenlocher, A				Dourdin, N; Bhatt, AK; Dutt, P; Greer, PA; Arthur, JSC; Elce, JS; Huttenlocher, A			Reduced cell migration and disruption of the actin cytoskeleton in calpain-deficient embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; PLATELET ACTIVATION; MYOBLAST FUSION; STEM-CELLS; TALIN; INTEGRIN; GENE; EXPRESSION; INHIBITOR; ISCHEMIA	The physiological functions and substrates of the calcium-dependent protease calpain remain only partly understood. The mu- and m-calpains consist of a mu- or m-80-kDa large subunit (genes Capn1 and Capn2), and a common 28-kDa small subunit (Capn4). To assess the role of calpain in migration, we used fibroblasts obtained from Capn4(-/-) mouse embryos. The cells lacked calpain activity on casein zymography and did not generate the characteristic calpain-generated spectrin breakdown product that is observed in wild-type cells. Capn4(-/-) cells had decreased migration rates and abnormal organization of the actin cytoskeleton with a loss of central stress fibers. Interestingly, these cells extended numerous thin projections and displayed delayed retraction of membrane protrusions and filopodia. The number of focal adhesions was decreased in Capn4(-/-) cells, but the cells had prominent vinculin-containing focal complexes at the cell periphery. The levels of the focal adhesion proteins, a-actinin, focal adhesion kinase (FAK), spectrin, talin, and vinculin, were the same in Capn4(+/+) and Capn4(-/-) cells. FAK, a-actinin, and vinculin were not cleaved in either cell type plated on fibronectin. However, proteolysis of the focal complex component, talin, was detected in the wild-type cells but not in the Capn4(-/-) cells, suggesting that calpain cleavage of talin is important during cell migration. Moreover, talin cleavage was again observed when calpain activity was partially restored in Capn4(-/-) embryonic fibroblasts by stable transfection with a vector expressing the rat 28-kDa calpain small subunit. The results demonstrate unequivocally that calpain is a critical regulator of cell migration and of the organization of the act-in cytoskeleton and focal adhesions.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Queens University - Canada; Queens University - Canada; University of Dundee	Huttenlocher, A (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA.		Arthur, J. Simon/B-8058-2010	Arthur, J. Simon/0000-0002-8135-1958	NCI NIH HHS [R01 CA85862-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Arthur JSC, 2000, METH MOL B, V144, P109; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; BALCERZAK D, 1995, J CELL SCI, V108, P2077; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; Dourdin N, 1999, EXP CELL RES, V246, P433, DOI 10.1006/excr.1998.4325; GREZ M, 1990, P NATL ACAD SCI USA, V87, P9202, DOI 10.1073/pnas.87.23.9202; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; Hayashi M, 1999, ARCH BIOCHEM BIOPHYS, V371, P133, DOI 10.1006/abbi.1999.1427; HIRAMATSU K, 1993, STROKE, V24, P1725, DOI 10.1161/01.STR.24.11.1725; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; MELLGREN RL, 1999, CALPAIN PHARM TOXICO, P161; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; OHALLORAN T, 1985, NATURE, V317, P449, DOI 10.1038/317449a0; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Palecek SP, 1998, J CELL SCI, V111, P929; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Raptis L, 1997, CELL GROWTH DIFFER, V8, P891; RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SAMIS JA, 1991, BIOCHEM J, V276, P293, DOI 10.1042/bj2760293; Shiraha H, 1999, J CELL BIOL, V146, P243; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; Towbin H, 1992, Biotechnology, V24, P145; TRANQUI L, 1995, EXP CELL RES, V217, P149, DOI 10.1006/excr.1995.1074; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	51	206	216	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48382	48388		10.1074/jbc.M108893200	http://dx.doi.org/10.1074/jbc.M108893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602605	hybrid			2022-12-25	WOS:000172927000088
J	Duan, JM; Zhang, ZY; Tong, TJ				Duan, JM; Zhang, ZY; Tong, TJ			Senescence delay of human diploid fibroblast induced by anti-sense p16(INK4a) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; BROKEN CHROMOSOME ENDS; LIFE-SPAN; REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; TELOMERASE ACTIVITY; GROWTH-FACTOR; ARREST; P53; PATHWAY	p16(INK4a), a tumor suppressor gene that inhibits cyclin-dependent kinase 4 and cyclin-dependent kinase 6, is also implicated in the mechanisms underlying replicative senescence, because its RNA and protein accumulate as cells approach their finite number of population doublings in tissue culture. To further explore the involvement of p16(INK4a), in replicative senescence, we constructed a retroviral vector containing antisense p16(INK4a), pDOR-ASp16, and introduced it into early passages of human diploid fibroblasts. The introduction of this construct significantly suppressed the expression of wild-type p16(INK4a). It also imposed a finite increase in proliferative life span and significant delay of several other cell senescent features, such as cell flattening, cell cycle arrest, and senescence-associated beta -galactosidase positivity. Moreover, telomere shortening and decline in DNA repair capacity, which normally accompany cell senescence, are also postponed by the ASp16 transfection. The life span of fibroblasts was significantly extended, but the onset of replicative senescence could not be totally prevented. Telomerase could not be activated even though telomere shortening was slowed. These observations suggest that the telomere pathway of senescence cannot be bypassed by ASp16 expression. These data not only strongly support a role for p16(INK4a) in replicative senescence but also raise the possibility of using the antisense p16(INK4a) therapeutically.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University	Tong, TJ (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	ttjzzy@public.gb.com.cn						Baylin SB, 1998, ADV CANCER RES, V72, P141; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BIESSMANN H, 1992, MOL CELL BIOL, V12, P3910, DOI 10.1128/MCB.12.9.3910; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; BONDAR AG, 1998, SCIENCE, V279, P349; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Campisi Judith, 1996, P121; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; HARD E, 1991, BIOCHEM BIOPH RES CO, V179, P528; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Henderson YC, 2000, HEAD NECK-J SCI SPEC, V22, P347, DOI 10.1002/1097-0347(200007)22:4<347::AID-HED6>3.0.CO;2-J; Huschtscha LI, 1998, CANCER RES, V58, P3508; Huschtscha LI, 1999, CARCINOGENESIS, V20, P921, DOI 10.1093/carcin/20.6.921; Jarrard DF, 1999, CANCER RES, V59, P2957; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; LI JH, 1995, MECH AGEING DEV, V80, P25, DOI 10.1016/0047-6374(94)01557-3; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Liu Y, 1999, ONCOL REP, V6, P445; Lloyd AC, 2000, NAT CELL BIOL, V2, pE48, DOI 10.1038/35004078; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Noble JR, 1996, ONCOGENE, V13, P1259; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Sandhu C, 2000, CANCER RES, V60, P2616; Sawa H, 1999, J NEURO-ONCOL, V42, P45, DOI 10.1023/A:1006176708928; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shay JW, 2001, SCIENCE, V291, P839, DOI 10.1126/science.1058546; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wadhwa R, 2000, Prog Mol Subcell Biol, V24, P191; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; Wang XD, 1999, PROG NAT SCI-MATER, V9, P432; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1996, CELLULAR AGING CELL, P153; You YO, 2000, BIOCHEM BIOPH RES CO, V268, P268, DOI 10.1006/bbrc.2000.2101; Zeng ZH, 1999, J CELL BIOCHEM, V73, P545, DOI 10.1002/(SICI)1097-4644(19990615)73:4<545::AID-JCB12>3.3.CO;2-H	49	55	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48325	48331		10.1074/jbc.M104814200	http://dx.doi.org/10.1074/jbc.M104814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606567	hybrid			2022-12-25	WOS:000172927000079
J	Kiger, L; Marden, MC				Kiger, L; Marden, MC			Electron transfer kinetics between hemoglobin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALENCY HYBRID HEMOGLOBIN; BETA-CHAINS; METHEMOGLOBIN REDUCTION; ALPHA; HEME; STABILITY; GLOBIN	The kinetics for electron transfer have been measured for samples of hemoglobin valency hybrids with initially one type of subunit, alpha or beta, in the oxidized state. Incubation of these samples under anaerobic conditions tends to randomize the type of subunit that is oxidized. With a time coefficient of a few hours at pH 7, 25 degreesC, the Hb solution (0.1 mm heme) approaches a form with about 60% of beta chains reduced, indicating a faster transfer rate in the direction alpha to beta. There was no observable electron transfer for samples saturated with oxygen. The electron transfer occurs predominantly between deoxy and aquo-met subunits, both high spin species. Furthermore, electron transfer does not depend on the quaternary state of hemoglobin. Incubation of oxidized crosslinked tetramer Hb A with deoxy Hb S also displayed electron transfer, implying a mechanism via inter-tetramer collisions. A dependence on the overall Hb concentration confirms this mechanism, although a small contribution of transfer between subunits of the same tetramer cannot be ruled out. These results suggest that in vivo collisions between the Hb tetramers will be involved in the relative distribution of the methemoglobin between subunits in association with the reductase system present in the erythrocyte.	INSERM, U473, F-94276 Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Marden, MC (corresponding author), INSERM, U473, 84 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	marden@kb.inserm.fr	Marden, Michael C/G-3139-2012; Marden, Michael/AAA-5923-2020; Kiger, Laurent/Q-1686-2018	Marden, Michael C/0000-0002-5254-6385; 				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P47; BANERJEE R, 1969, J MOL BIOL, V42, P337, DOI 10.1016/0022-2836(69)90047-3; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; BULL C, 1981, J BIOL CHEM, V256, P2673; BUNN HF, 1968, J BIOL CHEM, V243, P465; Cassoly R, 1981, Methods Enzymol, V76, P106; EDELSTEIN SJ, 1975, J BIOL CHEM, V250, P961; ENGLANDER SW, 1987, ANAL BIOCHEM, V161, P300, DOI 10.1016/0003-2697(87)90454-4; GIBSON QH, 1974, J BIOL CHEM, V249, P7255; GIBSON QH, 1964, J BIOL CHEM, V239, P3282; GIBSON QH, 1969, J BIOL CHEM, V244, P4668; GIBSON QH, 1963, J BIOL CHEM, V238, P1384; Granel B, 2001, HAEMATOLOGICA, V86, P105; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; KISTER J, 1987, J BIOL CHEM, V262, P12085; KUMA F, 1981, J BIOL CHEM, V256, P5518; MAWATARI K, 1983, BIOCHIM BIOPHYS ACTA, V748, P381, DOI 10.1016/0167-4838(83)90183-8; MUKERJI I, 1984, BIOCHEMISTRY-US, V33, P13132; Nagababu E, 2000, BIOCHEMISTRY-US, V39, P12503, DOI 10.1021/bi992170y; PARKHURST KM, 1992, INT J BIOCHEM, V24, P993, DOI 10.1016/0020-711X(92)90109-E; RIFKIND JM, 1991, FREE RADICAL RES COM, V12-3, P645; Shibayama N, 1998, BIOCHEMISTRY-US, V37, P6221, DOI 10.1021/bi980134d; Shibayama N, 1997, BIOCHEMISTRY-US, V36, P4375, DOI 10.1021/bi970009m; TOMODA A, 1979, J BIOL CHEM, V254, P3119; TOMODA A, 1978, J BIOL CHEM, V253, P7415; TOMODA A, 1981, ANAL BIOCHEM, V110, P431, DOI 10.1016/0003-2697(81)90215-3; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WINTERHALTER KH, 1971, BIOCHEMISTRY-US, V10, P621, DOI 10.1021/bi00780a012	29	1	1	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47937	47943		10.1074/jbc.M106807200	http://dx.doi.org/10.1074/jbc.M106807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602592	hybrid			2022-12-25	WOS:000172927000030
J	Raghavan, A; Robison, RL; McNabb, J; Miller, CR; Williams, DA; Bohjanen, PR				Raghavan, A; Robison, RL; McNabb, J; Miller, CR; Williams, DA; Bohjanen, PR			HuA and tristetraprolin are induced following T cell activation and display distinct but overlapping RNA binding specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOKINE MESSENGER-RNA; 3' UNTRANSLATED REGION; AU-RICH ELEMENTS; ELAV PROTEIN; IN-VIVO; GM-CSF; IDENTIFICATION; DEGRADATION; STABILITY; TUMOR	AU-rich elements found in the 3 ' -untranslated regions of cytokine and proto-oncogene transcripts regulate mRNA degradation and function as binding sites for the mRNA-stabilizing protein HuA and the mRNA-destabilizing protein tristetraprolin. Experiments were performed to evaluate the expression of HuA and tristetraprolin in purified human T lymphocytes and to evaluate the ability of these proteins to recognize specific AU-rich sequences. HuA is a predominantly nuclear protein that can also be found in the cytoplasm of resting T lymphocytes. Within I h after stimulation of T lymphocytes with anti-T cell receptor antibodies or a combination of a phorbol myristate acetate and ionomycin, an increase in cytoplasmic HuA RNA-binding activity was observed. Although absent in resting cells, cytoplasmic tristetraprolin protein was detected 3-6 h following activation. HuA recognized specific AU-rich sequences found in c-jun or c-myc mRNA that were poorly recognized by tristetraprolin. In contrast, tristetraprolin recognized an AU-rich sequence in interleukin-2 mRNA that was poorly recognized by HuA. Both HuA and tristetraprolin, however, recognized AU-rich sequences from ic-fos, interleukin-3, tumor necrosis factor-alpha, and granulocyte/macrophage colony-stimulating factor mRNA. HuA may transiently stabilize a subset of AU-rich element-containing transcripts following T lymphocyte activation, and tristetraprolin may subsequently mediate their degradation.	Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Microbiol Immunol & Canc Biol Grad Program, Minneapolis, MN 55455 USA; Duke Univ, Med Ctr, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27710 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Duke University	Bohjanen, PR (corresponding author), Univ Minnesota, Dept Microbiol, Mayo Mail Code 196,420 Delaware St SE, Minneapolis, MN 55455 USA.		Bohjanen, Paul/B-2329-2015	Bohjanen, Paul/0000-0002-2772-3597; Raghavan, Arvind/0000-0002-2959-3626	NIAID NIH HHS [R01 AI049494, 1R01AI49494, 7K08AI01517] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049494, K08AI001517] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Atasoy U, 1998, J CELL SCI, V111, P3145; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Malter JS, 1998, ADV IMMUNOL, V68, P1, DOI 10.1016/S0065-2776(08)60557-X; Merup M, 1998, MED ONCOL, V15, P79, DOI 10.1007/BF02989584; MONDINO A, 1995, J BIOL CHEM, V270, P26593, DOI 10.1074/jbc.270.44.26593; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; Pearson PL, 1998, J INTERN MED, V243, P413; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	114	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47958	47965		10.1074/jbc.M109511200	http://dx.doi.org/10.1074/jbc.M109511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602610	hybrid			2022-12-25	WOS:000172927000033
J	Bunemann, M; Bucheler, MM; Philipp, M; Lohse, MJ; Hein, L				Bunemann, M; Bucheler, MM; Philipp, M; Lohse, MJ; Hein, L			Activation and deactivation kinetics of alpha(2A)- and alpha(2C)-adrenergic receptor-activated G protein-activated inwardly rectifying K+ channel currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(2A)-ADRENERGIC RECEPTOR; ALPHA-2-ADRENERGIC RECEPTORS; HUMAN ALPHA(2)-ADRENOCEPTORS; CALCIUM-CHANNELS; MODULATION; G(I); INHIBITION; POTASSIUM; DESENSITIZATION; IDENTIFICATION	Although G protein-coupled receptor-mediated signaling is one of the best studied biological events, little is known about the kinetics of these processes in intact cells. Experiments with neurons from alpha (2A)-adrenergic receptor knockout mice suggested that the alpha (2A)-receptor subtype inhibits neurotransmitter release with higher speed and at higher action potential frequencies than the a,c-adrenergic receptor. Here we investigated whether these functional differences between presynaptic alpha (2)-adrenergic receptor subtypes are the result of distinct signal transduction kinetics of these two receptors and their coupling to G proteins. alpha (2A)- and alpha (2C)-receptors were stably expressed in HEK293 cells at moderate (similar to2 pmol/mg) or high (17-24 pmol/mg) levels. Activation of G protein-activated inwardly rectifying K+ (GIRK) channels was similar in extent and kinetics for alpha (2A)- and alpha (2C)-receptors at both expression levels. However, the two receptors differed significantly in their deactivation kinetics after removal of the agonist norepinephrine. alpha (2C)-Receptor-activated GIRK currents returned much more slowly to base line than did alpha (2A)-stimulated currents. This observation correlated with a higher affinity of norepinephrine at the murine alpha (2C)- than at the alpha (2A)-receptor subtype and may explain why alpha (2C)-adrenergic receptors are especially suited to control sympathetic neurotransmission at low action potential frequencies in contrast to the alpha (2A)-receptor subtype.	Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany	University of Wurzburg	Hein, L (corresponding author), Univ Wurzburg, Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.	hein@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012; Philipp, Melanie/B-5198-2016	Lohse, Martin J/0000-0002-0599-3510; Philipp, Melanie/0000-0003-2714-965X				Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; BYLUND DB, 1994, PHARMACOL REV, V46, P121; CERESA BP, 1994, J BIOL CHEM, V269, P29557; CHRUSCINSKI AJ, 1992, BIOCHEM BIOPH RES CO, V186, P1280, DOI 10.1016/S0006-291X(05)81544-X; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; Docherty JR, 1998, EUR J PHARMACOL, V361, P1, DOI 10.1016/S0014-2999(98)00682-7; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; EASON MG, 1992, J BIOL CHEM, V267, P25473; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; Hein L, 2001, REV PHYSIOL BIOCH P, V142, P161, DOI 10.1007/BFb0117493; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hurt CM, 2000, J BIOL CHEM, V275, P35424, DOI 10.1074/jbc.M006241200; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; LANGER SZ, 1974, BIOCHEM PHARMACOL, V23, P1793, DOI 10.1016/0006-2952(74)90187-7; MacDonald E, 1997, TRENDS PHARMACOL SCI, V18, P211; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; Olli-Lahdesmaki T, 1999, J NEUROSCI, V19, P9281; Pihlavisto M, 1998, BBA-MOL CELL RES, V1448, P135, DOI 10.1016/S0167-4889(98)00118-9; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Shekter LR, 1997, MOL PHARMACOL, V52, P282, DOI 10.1124/mol.52.2.282; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; STARKE K, 1975, NATURE, V254, P440, DOI 10.1038/254440a0; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; Trendelenburg AU, 2001, N-S ARCH PHARMACOL, V364, P117, DOI 10.1007/s002100100423; VON ZM, 1993, J BIOL CHEM, V268, P763	33	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47512	47517		10.1074/jbc.M108652200	http://dx.doi.org/10.1074/jbc.M108652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591725	hybrid			2022-12-25	WOS:000172768500109
J	Chen, NY; Ma, WY; She, QB; Wu, E; Liu, GM; Bode, AM; Dong, ZG				Chen, NY; Ma, WY; She, QB; Wu, E; Liu, GM; Bode, AM; Dong, ZG			Transactivation of the epidermal growth factor receptor is involved in 12-O-tetradecanoylphorbol-13-acetate-induced signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACID RESPONSE ELEMENT; TUMOR PROMOTION; METALLOPROTEINASE CLEAVAGE; INDUCED TRANSFORMATION; RETINOIC ACID; AP-1 ACTIVITY; EGF RECEPTOR; FACTOR-ALPHA; SKIN TUMORS	The mechanism of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced tumor promotion is still not well understood even though it is thought to be related to the protein kinase C/mitogen-activated protein kinase/AP-1 pathway. Recently, TPA was also found to induce epidermal growth factor receptor (EGFR) activity. Here, we investigated whether the EGFR is a necessary component for TPA-induced signal transduction associated with tumor promotion. We demonstrated that potent inhibitors of the EGFR, PD153035 and AG1478, blocked TPA-induced phosphorylation of extracellular signal-regulated kinases (ERKs), AP-1 activity, and cell transformation. Egfr gene deficiency blocked TPA-induced ERK activity and AP-1 binding activity. The blocking of the ectodomain of the EGFR by a monoclonal antibody depressed TPA-induced ERK activity and AP-1 DNA binding activity. The use of a neutralizing antibody for heparin-binding EGF, one of the ligands of EGFR, blocked TPA-induced phosphorylation of ERKs. BB-94, a potent inhibitor of matrix metalloproteinases, which are activators of ectodomain shedding of EGFR ligands, also blocked TPA-induced ERK activity, AP-1 DNA binding, and cell transformation but had no effect on EGF-induced signal transduction. Anti-EGFR, anti-heparin-binding EGF, and BB-94 each blocked TPA-induced EGFR phosphorylation, but only anti-EGFR could block EGF-induced EGFR phosphorylation. Based on these results, we conclude that the EGFR is required for mediating TPA-induced signal transduction. EGFR transactivation induced by TPA is a mechanism by which the EGFR mediates TPA-induced tumor promotion-relate signal transduction.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	University of Minnesota System; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Wu, Erxi/0000-0002-1680-3639; She, Qing-Bai/0000-0002-7207-0599	NATIONAL CANCER INSTITUTE [R37CA081064, R01CA081064, R29CA074916, R01CA077646] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74916, CA 81064, CA 77646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Angel J M, 1999, Prog Exp Tumor Res, V35, P143; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; DIGIOVANNI J, 1995, SKIN CANC MECH HUMAN, P181; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 1997, CANCER RES, V57, P4414; DONG ZG, 1994, CARCINOGENESIS, V15, P1001, DOI 10.1093/carcin/15.5.1001; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HOSHI M, 1988, J BIOL CHEM, V263, P5396; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L; Li JJ, 1996, CANCER RES, V56, P483; LOO D, 1994, CELL BIOL LAB HDB, P45; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; WU EX, 1999, NATO SCI SERIES, P263; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	43	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46722	46728		10.1074/jbc.M107156200	http://dx.doi.org/10.1074/jbc.M107156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592962	hybrid			2022-12-25	WOS:000172768500008
J	Sinal, CJ; Yoon, M; Gonzalez, FJ				Sinal, CJ; Yoon, M; Gonzalez, FJ			Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; ORPHAN NUCLEAR RECEPTOR; RESPONSIVE ELEMENT UPSTREAM; FATTY-ACIDS; PPAR-ALPHA; HORMONE-RECEPTOR; LIPOPROTEIN METABOLISM; TARGETED DISRUPTION; ADAPTIVE RESPONSE; LIPID-METABOLISM	The peroxisome proliferator-activated receptor-a (PPAR alpha) is a ligand-activated transcription factor that regulates the expression of a number of genes critical for fatty acid beta -oxidation. Because a number of substrates and intermediates of this metabolic pathway serve as ligand activators of this receptor, homeostatic control of fatty acid metabolism is achieved. Evidence also exists for PPAR alpha -dependent regulation of genes encoding critical enzymes of bile acid biosynthesis. To determine whether the primary products of bile acid biosynthesis, cholic acid and chenodeoxycholic acid, were capable of modulating PPAR alpha function, a variety of in vivo and in vitro approaches were utilized. Feeding a bile acid-enriched diet significantly reduced the degree of hepatomegaly and induction of target genes encoding enzymes of fatty acid beta -oxidation caused by treatment with the potent PPAR alpha ligand Wyeth-14,643. Convergent data from mechanistic studies indicate that bile acids interfere with transactivation by PPAR alpha at least in part by impairing the recruitment of transcriptional coactivators. The results of this study provide the first evidence in favor of the existence of compounds, normally found within the body, that are capable of antagonizing the physiological actions of PPAR alpha. The impact of PPAR alpha antagonism by endogenous bile acids is likely to be limited under normal conditions and to have only minimal effects on bile acid homeostasis. However, during certain pathophysiological states where intracellular bile acid concentrations are elevated, meaningful effects on PPAR alpha -dependent target gene regulation are possible.	NCI, Div Basic Sci, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gonzalez, FJ (corresponding author), NCI, Div Basic Sci, Lab Metab, NIH, Bldg 10,Rm 3E24, Bethesda, MD 20892 USA.			Sinal, Christopher/0000-0001-8301-3349				ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; BERTOLOTTI M, 1995, ARTERIOSCL THROM VAS, V15, P1064, DOI 10.1161/01.ATV.15.8.1064; Cheema SK, 2000, J BIOL CHEM, V275, P12530, DOI 10.1074/jbc.275.17.12530; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; Corton JC, 2000, MUTAT RES-FUND MOL M, V448, P139, DOI 10.1016/S0027-5107(99)00232-8; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; Gervois P, 2000, CLIN CHEM LAB MED, V38, P3, DOI 10.1515/CCLM.2000.002; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hunt MC, 2000, J BIOL CHEM, V275, P28947, DOI 10.1074/jbc.M002782200; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; Kassam A, 2001, MOL CELL ENDOCRINOL, V176, P49, DOI 10.1016/S0303-7207(01)00475-0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LAKE BG, 1995, ANNU REV PHARMACOL, V35, P483, DOI 10.1146/annurev.pa.35.040195.002411; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEWIS DFV, 1993, XENOBIOTICA, V23, P79, DOI 10.3109/00498259309059364; LI YC, 1990, J BIOL CHEM, V265, P12012; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Marrapodi M, 2000, J LIPID RES, V41, P514; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; ONATE SA, 1995, SCIENCE, V270, P1354; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Patel DD, 2000, BIOCHEM J, V351, P747, DOI 10.1042/0264-6021:3510747; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Post SM, 1999, BIOCHEM J, V341, P339, DOI 10.1042/0264-6021:3410339; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; STAHLBERG D, 1995, HEPATOLOGY, V21, P1025, DOI 10.1016/0270-9139(95)90250-3; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200	66	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47154	47162		10.1074/jbc.M107000200	http://dx.doi.org/10.1074/jbc.M107000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11606578	hybrid			2022-12-25	WOS:000172768500066
J	Zvereva, MI; Ivanov, PV; Teraoka, Y; Topilina, NI; Dontsova, OA; Bogdanov, AA; Kalkum, M; Nierhaus, KH; Shpanchenko, OV				Zvereva, MI; Ivanov, PV; Teraoka, Y; Topilina, NI; Dontsova, OA; Bogdanov, AA; Kalkum, M; Nierhaus, KH; Shpanchenko, OV			Complex of transfer-messenger RNA and elongation factor Tu - Unexpected modes of interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; DIRECTED CROSS-LINKING; 10SA RNA; ANGSTROM RESOLUTION; TERNARY COMPLEX; LOOP-IV; 23S RNA; EF-TU; TMRNA; PROTEINS	Transfer-messenger RNA (tmRNA) is a stable RNA in bacteria of 360 +/- 40 nucleotides that can be charged with alanine and can function as both tRNA and mRNA. Ribosomes that are stalled either in a coding region of mRNA or at the 3 ' end of an mRNA fragment lacking a stop codon are rescued by replacing their mRNA for tmRNA. Here we demonstrate that the interaction of tmRNA with the elongation factor Tu shows unexpected features. Deacylated tmRNA can form a complex with either EF-Tu-GDP or EF-Tu-GTP, the association constants are about one order of magnitude smaller than that of an Ala-tRNA(.)EF-Tu(.)GTP complex. tmRNA as well as Ala-tmRNA can be efficiently cross-linked with EF-Tu(.)GDP using a zero-length cross-link. The efficiency of cross-linking in the case of deacylated tmRNA does not depend on an intact CCA-3 ' end and is about the same, regardless whether protein mixtures such as the post-ribosomal supernatant (S100 enzymes) or purified EF-Tu are present. Two cross-linking sites with EF-Tu(.)GDP have been identified that are located outside the tRNA part of tmRNA, indicating an unusual interaction of tmRNA with EF-Tu-GDP.	Max Planck Inst Mol Genet, AG Ribosomen, D-14195 Berlin, Germany; Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia	Max Planck Society; Lomonosov Moscow State University	Nierhaus, KH (corresponding author), Max Planck Inst Mol Genet, AG Ribosomen, Ihnestr 73, D-14195 Berlin, Germany.	Nierhaus@molgen.mpg.de	Shpanchenko, Olga/C-7813-2015; Zvereva, Maria Imilievna/J-9724-2013; Dontsova, Olga/T-6072-2019; Bogdanov, Alexey A/L-1407-2013; Ivanov, Pavel/AAZ-9197-2021; Ivanov, Pavel/F-3339-2016	Zvereva, Maria Imilievna/0000-0002-7432-1574; Ivanov, Pavel/0000-0002-7986-7760; Ivanov, Pavel/0000-0002-7986-7760; Kalkum, Markus/0000-0002-9506-671X				Alexeeva EV, 1996, NUCLEIC ACIDS RES, V24, P2228, DOI 10.1093/nar/24.12.2228; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BOMMER U, 1996, SUBCELLULAR FRACTION, P271; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; Dokudovskaya S, 1996, RNA, V2, P146; DONTSOVA O, 1994, P NATL ACAD SCI USA, V91, P4125, DOI 10.1073/pnas.91.10.4125; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DRAPER DE, 1988, METHOD ENZYMOL, V164, P203; Felden B, 1996, BIOCHIMIE, V78, P979, DOI 10.1016/S0300-9084(97)86720-X; Felden B, 1997, RNA, V3, P89; Felden B, 1999, BBA-GENE STRUCT EXPR, V1446, P145, DOI 10.1016/S0167-4781(99)00085-8; Felden B, 1998, EMBO J, V17, P3188, DOI 10.1093/emboj/17.11.3188; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Karzai AW, 2001, P NATL ACAD SCI USA, V98, P3040, DOI 10.1073/pnas.051628298; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller D L, 1974, Methods Enzymol, V30, P219; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; Nierhaus KH, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P319; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; Petrushenko ZM, 1997, FEBS LETT, V407, P13, DOI 10.1016/S0014-5793(97)00242-1; RINKEAPPEL J, 1991, EMBO J, V10, P2195, DOI 10.1002/j.1460-2075.1991.tb07755.x; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; SERGIEV P, 2001, IN PRESS MOL BIOL MO, V35; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; Stelzl U, 2000, P NATL ACAD SCI USA, V97, P4597, DOI 10.1073/pnas.090009297; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Williams KP, 1998, NUCLEIC ACIDS RES, V26, P163, DOI 10.1093/nar/26.1.163; Williams KP, 1996, RNA, V2, P1306; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; YOKOSAWA H, 1973, J BIOL CHEM, V248, P375; Zwieb C, 1999, NUCLEIC ACIDS RES, V27, P2063, DOI 10.1093/nar/27.10.2063	45	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47702	47708		10.1074/jbc.M106786200	http://dx.doi.org/10.1074/jbc.M106786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595738	hybrid			2022-12-25	WOS:000172768500134
J	Artemenko, IP; Zhao, D; Hales, DB; Hales, KH; Jefcoate, CR				Artemenko, IP; Zhao, D; Hales, DB; Hales, KH; Jefcoate, CR			Mitochondrial processing of newly synthesized steroidogenic acute regulatory protein (StAR), but not total StAR, mediates cholesterol transfer to cytochrome P450 side chain cleavage enzyme in adrenal cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; DIAZEPAM-BINDING INHIBITOR; BENZODIAZEPINE-RECEPTOR; TARGETED DISRUPTION; HORMONE STIMULATION; RAPID ACCUMULATION; ACTH REGULATION; GENE; BIOSYNTHESIS; MECHANISM	The metabolism of cholesterol by cytochrome P450 side chain cleavage enzyme is hormonally regulated in steroidogenic tissues via intramitochondrial cholesterol transport. The mediating steroidogenic acute regulatory protein (StAR) is synthesized as a 37-kDa (p37) precursor that is phosphorylated by protein kinase A and cleaved within the mitochondria to generate 30-kDa forms (p30, pp30). The effectiveness of modified recombinant StAR forms in COS-1 cells without mitochondrial import has led to a prevailing view that cholesterol transport is mediated by p37 StAR via activity on the outer mitochondrial membrane. The present study of the activation of cholesterol metabolism by bromo-cAMP in adrenal cells in relation to S-35-StAR turnover indicates that targeting of pp30 to the inner membrane provides the dominant cholesterol transport mechanism. We show that 1) only newly synthesized StAR is functional, 2) phosphorylation and processing of p37 to pp30 occurs rapidly and stoichiometrically, 3) both steps are necessary for optimum transport, and 4) newly synthesized pp30 exhibits very high activity (400 molecules of cholesterol/StAR/min). Segregation of cAMP activation and synthesis of StAR from cholesterol metabolism showed that very low levels of newly synthesized StAR (1 fmol/min/10(6) cells) sustained activated cholesterol metabolism (0.4 pmol/min/10(6) cells, t(1/2) = 70 min) long after complete removal of p37 (t(1/2) = 5 min). This activity was highly sensitive to inhibition of processing by CCCP only until sufficient pp30 was formed. Maximum activation preceded bromo-cAMP-induced StAR expression, indicating other limiting steps in cholesterol metabolism.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Jefcoate, CR (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	jefcoate@facstaff.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009090, R01ES009827] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18585] Funding Source: Medline; NIEHS NIH HHS [ES09827, ES09090] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAHAM GE, 1973, J CLIN ENDOCR METAB, V37, P40, DOI 10.1210/jcem-37-1-40; ALBERTA JA, 1989, J BIOL CHEM, V264, P20467; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; BRAKE PB, 1995, ENDOCRINOLOGY, V136, P5034, DOI 10.1210/en.136.11.5034; BROWNIE AC, 1973, ANN NY ACAD SCI, V212, P344, DOI 10.1111/j.1749-6632.1973.tb47606.x; BRUNNER M, 1995, METHOD ENZYMOL, V248, P717; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; CHURCHILL PF, 1979, J BIOL CHEM, V254, P443; Clark BJ, 1996, TRENDS ENDOCRIN MET, V7, P227, DOI 10.1016/S1043-2760(96)00114-2; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CRIVELLO JF, 1978, BIOCHIM BIOPHYS ACTA, V542, P315, DOI 10.1016/0304-4165(78)90027-2; DIBARTOLOMEIS MJ, 1984, J BIOL CHEM, V259, P159; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Finkielstein C, 1998, EUR J BIOCHEM, V256, P60, DOI 10.1046/j.1432-1327.1998.2560060.x; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Garren L D, 1971, Recent Prog Horm Res, V27, P433; HALL PF, 1984, CAN J BIOCHEM CELL B, V62, P653, DOI 10.1139/o84-087; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; ISAYA G, 1995, METHOD ENZYMOL, V248, P556; JEFCOATE CR, 1974, EUR J BIOCHEM, V42, P539, DOI 10.1111/j.1432-1033.1974.tb03369.x; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; King SR, 2000, MOL CELL ENDOCRINOL, V166, P147, DOI 10.1016/S0303-7207(00)00280-X; King SR, 1999, J STEROID BIOCHEM, V69, P143, DOI 10.1016/S0960-0760(98)00152-6; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; KNUDSEN J, 1990, BIOCHEM J, V265, P927, DOI 10.1042/bj2650927; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Maloberti P, 2000, ENDOCR RES, V26, P653, DOI 10.3109/07435800009048585; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAPADOPOULOS V, 1991, J BIOL CHEM, V266, P3682; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; PON LA, 1986, J BIOL CHEM, V261, P3309; PON LA, 1986, ENDOCR RES, V12, P429, DOI 10.3109/07435808609035449; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; SAENGER P, 1995, J CLIN ENDOCR METAB, V80, P200, DOI 10.1210/jc.80.1.200; SIMPSON ER, 1972, EUR J BIOCHEM, V28, P442, DOI 10.1111/j.1432-1033.1972.tb01931.x; STOCCO DM, 1993, J STEROID BIOCHEM, V46, P337, DOI 10.1016/0960-0760(93)90223-J; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Watari H, 2000, EXP CELL RES, V255, P56, DOI 10.1006/excr.1999.4774	57	168	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46583	46596		10.1074/jbc.M107815200	http://dx.doi.org/10.1074/jbc.M107815200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579102	hybrid			2022-12-25	WOS:000172573100145
J	Stannard, AK; Riddell, DR; Sacre, SM; Tagalakis, AD; Langer, C; von Eckardstein, A; Cullen, P; Athanasopoulos, T; Dickson, G; Owen, JS				Stannard, AK; Riddell, DR; Sacre, SM; Tagalakis, AD; Langer, C; von Eckardstein, A; Cullen, P; Athanasopoulos, T; Dickson, G; Owen, JS			Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD-PLATELETS; NITRIC-OXIDE; LIPOPROTEIN METABOLISM; GENE-EXPRESSION; DEFICIENT MICE; VLDL RECEPTOR; ATHEROSCLEROSIS; MACROPHAGES; CHOLESTEROL; AGGREGATION	Sub-endothelial infiltration of monocytes occurs early in atherogenesis and is facilitated by cell adhesion molecules that are up-regulated on activated endothelium. Apolipoprotein E (apoE) helps protect against atherosclerosis, in part, because apoE particles secreted by macrophages have local beneficial effects at lesion sites. Here, we hypothesize that such protection includes antiinflammatory actions and investigate whether cell-derived apoE can inhibit tumor necrosis factor-a-mediated up-regulation of vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HuVECs). Two models were used to mimic endothelial exposure to macrophage-derived apoE. In the first, HUVECs were transiently transfected to secrete apoE; VCAM-1 induction inversely correlated with secretion of apoE into the media (r = -0.76, p < 0.001). In the second, incubation of HUVECs with media from recombinant Chinese hamster ovary (CHO) cells expressing apoE (CHO(apoE)) also reduced VCAM-1 in a dose-dependent manner (r = -0.70, p < 0.001). Characterization of CHO(apoE) cell-derived apoE revealed several similarities to apoE particles secreted by human blood monocyte-derived macrophages. The suppression of endothelial activation by apoE most likely occurs via stimulation of endothelial nitric oxide synthase; apoE increased levels of intracellular nitric oxide and its surrogate marker, cyclic guanosine monophosphate, while the nitric oxide synthase inhibitor, ethyl-isothiourea, blocked its effect. We propose that apoE secreted locally at lesion sites by macrophages may be anti-inflammatory by stimulating endothelium to release NO and suppress VCAM-1 expression.	UCL, Dept Med, Royal Free & Univ Coll, Sch Med, London NW3 2PF, England; Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of London; University College London; UCL Medical School; University of Munster; University of Munster; University of London; Royal Holloway University London	Owen, JS (corresponding author), UCL, Dept Med, Royal Free & Univ Coll, Sch Med, Rowland Hill St, London NW3 2PF, England.	j.owen@rfc.ucl.ac.uk	Owen, James/C-5908-2009; Tagalakis, Aristides/E-8883-2011; Athanasopoulos, Takis/C-5739-2009; Owen, James S./AAP-8628-2020; Sacre, Sandra/AAE-2297-2020	Athanasopoulos, Takis/0000-0003-2620-4952; Sacre, Sandra/0000-0003-1665-1142				Chia MC, 1998, CRIT REV CL LAB SCI, V35, P573, DOI 10.1080/10408369891234282; Cioffi L, 1999, GENE THER, V6, P1153, DOI 10.1038/sj.gt.3300890; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; DE CR, 1995, J CLIN INVEST, V96, P60; DESAI K, 1989, J LIPID RES, V30, P831; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Korschineck I, 2001, J BIOL CHEM, V276, P13192, DOI 10.1074/jbc.M011795200; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LINCOLN J, 1997, NITRIC OXIDE HLTH DI; Linton MF, 1999, CURR OPIN LIPIDOL, V10, P97, DOI 10.1097/00041433-199904000-00003; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; Nilsson L, 1999, J LIPID RES, V40, P913; Paka L, 1999, J BIOL CHEM, V274, P4816, DOI 10.1074/jbc.274.8.4816; Pitas RE, 1998, BIOCHEM SOC T, V26, P257, DOI 10.1042/bst0260257; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; Riddell DR, 1999, VITAM HORM, V57, P25; Riddell DR, 2001, J LIPID RES, V42, P998; Riddell DR, 1997, J BIOL CHEM, V272, P89; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saxena Uday, 1994, Current Opinion in Lipidology, V5, P316, DOI 10.1097/00041433-199410000-00002; SOUTHAN GJ, 1995, BRIT J PHARMACOL, V114, P510, DOI 10.1111/j.1476-5381.1995.tb13256.x; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; Stannard AK, 1998, ATHEROSCLEROSIS, V139, P57, DOI 10.1016/S0021-9150(98)00052-5; Tagalakis AD, 2001, J BIOL CHEM, V276, P13226, DOI 10.1074/jbc.C000883200; Takahashi S, 1996, FEBS LETT, V386, P197, DOI 10.1016/0014-5793(96)00439-5; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Truskey GA, 1999, ARTERIOSCL THROM VAS, V19, P393, DOI 10.1161/01.ATV.19.2.393; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Wolle J, 1996, ARTERIOSCL THROM VAS, V16, P1501, DOI 10.1161/01.ATV.16.12.1501	42	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46011	46016		10.1074/jbc.M104812200	http://dx.doi.org/10.1074/jbc.M104812200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590165	hybrid			2022-12-25	WOS:000172573100071
J	Zhang, Z; Yu, Y; Musser, JM; Palzkill, T				Zhang, Z; Yu, Y; Musser, JM; Palzkill, T			Amino acid sequence determinants of extended spectrum cephalosporin hydrolysis by the class CP99 beta-lactamase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; KLEBSIELLA-PNEUMONIAE; SUBSTRATE-SPECIFICITY; PSEUDOMONAS-AERUGINOSA; AMPC CEPHALOSPORINASE; MOLECULAR EVOLUTION; AEROMONAS-SOBRIA	Class C beta -lactamases are commonly encoded on the chromosome of Gram-negative bacterial species. Mutations leading to increased expression of these enzymes are a common cause of resistance to many cephalosporins including extended spectrum cephalosporins. Recent reports of plasmid- and integrin-encoded class C beta -lactamases are a cause for concern because these enzymes are likely to spread horizontally to susceptible strains. Because of their increasing clinical significance, it is critical to identify the determinants of catalysis and substrate specificity of these enzymes. For this purpose, the codons of a set of 21 amino acid residues that encompass the active site region of the P99 beta -lactamase were individually randomized to create libraries containing all possible amino acid substitutions. The amino acid sequence requirements for the hydrolysis of ceftazidime, an extended spectrum cephalosporin commonly used to treat serious infections, were determined by selecting resistant mutants from each of the 21 libraries. DNA sequencing identified the residue positions that are critical for ceftazidime hydrolysis. In addition, it was found that certain amino acid substitutions in the omega -loop region of the P99 enzyme result in increased ceftazidime hydrolysis suggesting the loop is an important determinant of substrate specificity.	Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; NIAID, Rocky Mt Labs, Lab Human Bacterial Pathogenesis, NIH, Hamilton, MT 59840 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Palzkill, T (corresponding author), Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32956] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; Barnaud G, 1997, FEMS MICROBIOL LETT, V148, P15, DOI 10.1016/S0378-1097(97)00006-2; Bauernfeind A, 1996, ANTIMICROB AGENTS CH, V40, P1926, DOI 10.1128/AAC.40.8.1926; Bauernfeind A, 1999, ANTIMICROB AGENTS CH, V43, P1924, DOI 10.1128/AAC.43.8.1924; Bou G, 2000, ANTIMICROB AGENTS CH, V44, P428, DOI 10.1128/AAC.44.2.428-432.2000; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Bulychev A, 1999, ANTIMICROB AGENTS CH, V43, P1743, DOI 10.1128/AAC.43.7.1743; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1998, J BIOL CHEM, V273, P26603, DOI 10.1074/jbc.273.41.26603; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Caselli E, 2001, CHEM BIOL, V8, P17, DOI 10.1016/S1074-5521(00)00052-1; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Crichlow GV, 1999, BIOCHEMISTRY-US, V38, P10256, DOI 10.1021/bi9908787; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Dubus A, 1996, PROTEINS, V25, P473, DOI 10.1002/prot.7; DUBUS A, 1994, BIOCHEM J, V301, P485, DOI 10.1042/bj3010485; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; GALLENI M, 1988, BIOCHEM J, V250, P753, DOI 10.1042/bj2500753; Gazouli M, 1996, ANTIMICROB AGENTS CH, V40, P1736, DOI 10.1128/AAC.40.7.1736; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gonzalez Leiza M, 1994, Antimicrob Agents Chemother, V38, P2150; HORII T, 1993, ANTIMICROB AGENTS CH, V37, P984, DOI 10.1128/AAC.37.5.984; HUANG W, 2000, J BIOL CHEM, V275, P14984; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JAURIN B, 1981, P NATL ACAD SCI-BIOL, V78, P4897, DOI 10.1073/pnas.78.8.4897; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LOBKOVSKY E, 1993, P NATL ACAD SCI USA, V90, P11257, DOI 10.1073/pnas.90.23.11257; LODGE JM, 1990, BIOCHEM J, V272, P627, DOI 10.1042/bj2720627; Marchese A, 1998, ANTIMICROB AGENTS CH, V42, P464; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; MAZZELLA LJ, 1989, BIOCHEM J, V259, P255, DOI 10.1042/bj2590255; MONNAIE D, 1994, BIOCHEM J, V302, P1; MONNAIE D, 1994, BIOCHEMISTRY-US, V33, P5193, DOI 10.1021/bi00183a024; NOMURA K, 1990, FEMS MICROBIOL LETT, V70, P295, DOI 10.1016/S0378-1097(05)80011-4; NUKAGA M, 1995, J BIOL CHEM, V270, P5729, DOI 10.1074/jbc.270.11.5729; NUKAGA M, 1993, FEBS LETT, V332, P93, DOI 10.1016/0014-5793(93)80491-C; Nukaga M, 1998, BIOCHEMISTRY-US, V37, P10461, DOI 10.1021/bi980184i; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PAPANICOLAOU GA, 1990, ANTIMICROB AGENTS CH, V34, P2200, DOI 10.1128/AAC.34.11.2200; Patera A, 2000, J AM CHEM SOC, V122, P10504, DOI 10.1021/ja001676x; Petrosino J, 1998, TRENDS MICROBIOL, V6, P323, DOI 10.1016/S0966-842X(98)01317-1; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Preston KE, 2000, ANTIMICROB AGENTS CH, V44, P3158, DOI 10.1128/AAC.44.11.3158-3162.2000; RASMUSSEN BA, 1994, ANTIMICROB AGENTS CH, V38, P2078, DOI 10.1128/AAC.38.9.2078; SEOANE A, 1992, ANTIMICROB AGENTS CH, V36, P1049, DOI 10.1128/AAC.36.5.1049; Tenover FC, 1996, JAMA-J AM MED ASSOC, V275, P300, DOI 10.1001/jama.275.4.300; Trepanier S, 1999, ANTIMICROB AGENTS CH, V43, P543, DOI 10.1128/AAC.43.3.543; TZOUVELEKIS LS, 1994, ANTIMICROB AGENTS CH, V38, P2207, DOI 10.1128/AAC.38.9.2207; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Usher KC, 1998, BIOCHEMISTRY-US, V37, P16082, DOI 10.1021/bi981210f; WALSH TR, 1995, J ANTIMICROB CHEMOTH, V36, P41, DOI 10.1093/jac/36.1.41; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	59	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46568	46574		10.1074/jbc.M102757200	http://dx.doi.org/10.1074/jbc.M102757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591698	hybrid			2022-12-25	WOS:000172573100143
J	Sohda, M; Misumi, Y; Yamamoto, A; Yano, A; Nakamura, N; Ikehara, Y				Sohda, M; Misumi, Y; Yamamoto, A; Yano, A; Nakamura, N; Ikehara, Y			Identification and characterization of a novel Golgi protein, GCP60, that interacts with the integral membrane protein giantin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; COILED-COIL PROTEINS; BREFELDIN-A; MOLECULAR CHARACTERIZATION; BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; GUANINE-NUCLEOTIDE; SECRETORY PROTEINS; MATRIX PROTEIN; DOMAIN	We demonstrated previously that the integral membrane protein giantin has the Golgi localization signal at the COOH-terminal cytoplasmic domain (Misumi, Y., Sohda, M., Tashiro, A., Sato, H., and Ikehara, Y. (2001) J Biol. Chem. 276, 6867-6873). In the present study, using this domain as bait in the yeast two-hybrid screening system, we identified a novel protein interacting with giantin. The 3.6-kilobase mRNA encoding a 528-amino acid protein of 60 kDa designated GCP60 was ubiquitously expressed and was especially abundant in the testis and ovary. Immunofluorescence and immunoelectron microscopy confirmed that GCP60 was co-localized with giantin in the Golgi complex. GCP60 was found to be a peripheral protein associated with the Golgi membrane, where a COOH-terminal domain of GCP60 interacts with the COOH-terminal cytoplasmic domain of giantin. Overexpression of the COON-terminal domain of GCP60 caused disassembly of the Golgi structure and blocked protein transport from the endoplasmic reticulum to the Golgi. Taken together, these results suggest that GCP60 is involved in the maintenance of the Golgi structure by interacting with giantin, affecting protein transport between the endoplasmic reticulum and the Golgi.	Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140180, Japan; Fukuoka Univ, Adv Mat Inst, Jonan Ku, Fukuoka 8140180, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan; Kanazawa Univ, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan	Fukuoka University; Fukuoka University; Kansai Medical University; Kanazawa University	Ikehara, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140180, Japan.		Nakamura, Nobuhiro/F-7811-2011	Nakamura, Nobuhiro/0000-0002-8836-6714				Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Kragelund BB, 1999, BIOCHEMISTRY-US, V38, P2386, DOI 10.1021/bi982427c; LEE SC, 1993, J BIOL CHEM, V268, P12164; Lesa GM, 2000, J BIOL CHEM, V275, P2831, DOI 10.1074/jbc.275.4.2831; Linstedt AD, 2000, J BIOL CHEM, V275, P10196, DOI 10.1074/jbc.275.14.10196; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Miller J.H., 1992, SHORT COURSE BACTERI, P74; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Misumi Y, 2001, J BIOL CHEM, V276, P6867, DOI 10.1074/jbc.M010121200; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Sohda M, 1998, J BIOL CHEM, V273, P5385, DOI 10.1074/jbc.273.9.5385; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Toki C, 1997, CELL STRUCT FUNCT, V22, P565, DOI 10.1247/csf.22.565; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; WEUDLER F, 2001, TRAFFIC, V2, P606; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	58	101	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45298	45306		10.1074/jbc.M108961200	http://dx.doi.org/10.1074/jbc.M108961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11590181	hybrid			2022-12-25	WOS:000172406700125
J	Sun, P; Loh, HH				Sun, P; Loh, HH			Transcriptional regulation of mouse delta-opioid receptor gene - Role of Ets-1 in the transcriptional activation of mouse delta-opioid receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROENKEPHALIN MESSENGER-RNA; DNA-BINDING MOTIF; FACTOR USF; AUTO-INHIBITION; NG108-15 CELLS; CORE PROMOTER; MURINE ETS-1; ADULT-RAT; T-CELLS; EXPRESSION	Previously, we identified a minimum core promoter of the mouse delta -opioid receptor (DOR) gene. The DOR promoter contains an E-box that binds upstream stimulatory factor and is crucial for the DOR promoter activity in NS20Y cells, a mouse neuronal cell line that constitutively expresses DOR. In the present study, we further analyzed the DOR promoter in NS20Y cells and have demonstrated that transcription factor Ets-1 binds to an Ets-1-binding site overlapping the E-box and trans-activates the DOR promoter by synergizing with upstream stimulatory factor in specific DNA binding. In addition, the Ets-1 DNA-binding domain is sufficient to play the functional role of Ets-1 in trans-activating the DOR promoter. Furthermore, through in vivo cross-linking assays and Northern blot analyses, we have demonstrated that Ets-1 binds to the DOR promoter in the neonatal mouse brain and that overexpressed Ets-1 can significantly enhance the expression of DOR mRNA in primary neonatal mouse neuronal cells. Collectively, our data suggest that Ets-1 functions as a trans-activator of the DOR promoter in the neonatal mouse brain and thus may contribute to the development of the mouse brain DOR system.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Sun, P (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NIDA NIH HHS [DA-01583, DA-11806, DA-00546, KO5-DA-70554] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, K05DA070554, R37DA001583, R01DA001583] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABOOD ME, 1995, J PHARMACOL EXP THER, V274, P1566; Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Beczkowska IW, 1996, BRAIN RES BULL, V39, P193, DOI 10.1016/0361-9230(95)02104-3; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRANN A W JR, 1977, Clinics in Perinatology, V4, P149; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHARNESS ME, 1993, MOL PHARMACOL, V44, P1119; Cowley DO, 2000, GENE DEV, V14, P366; Dang W, 1998, MOL CELL BIOL, V18, P1477, DOI 10.1128/MCB.18.3.1477; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; El-Khodor BF, 2000, BEHAV BRAIN RES, V107, P171, DOI 10.1016/S0166-4328(99)00119-9; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Gylys KH, 1997, NEUROREPORT, V8, P2369, DOI 10.1097/00001756-199707070-00053; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOSEN MD, 1996, MOL CELL BIOL, V16, P2065; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIMBERLY P, 1994, J PHARMACOL EXP THER, V268, P683; KIMBERLY P, 1994, J PHARMACOL EXP THER, V268, P74; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1689; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; Liu HC, 1999, J BIOL CHEM, V274, P23617, DOI 10.1074/jbc.274.33.23617; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Mayfield KP, 1996, NEUROSCIENCE, V72, P785, DOI 10.1016/0306-4522(95)00585-4; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; SACCHI N, 1991, ONCOGENE, V6, P2149; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SMIRNOV D, 1993, MOL PHARMACOL, V60, P331; Thorlin T, 1999, GLIA, V25, P370, DOI 10.1002/(SICI)1098-1136(19990215)25:4<370::AID-GLIA6>3.0.CO;2-J; Tian G, 1999, MOL CELL BIOL, V19, P2946; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON DK, 1990, ONCOGENESIS; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; YAVIN Z, 1977, EXP BRAIN RES, V29, P137; ZAGON IS, 1983, SCIENCE, V221, P1179, DOI 10.1126/science.6612331; ZAGON IS, 1994, MOL BRAIN RES, V21, P85, DOI 10.1016/0169-328X(94)90381-6; ZAGON IS, 1995, MOL BRAIN RES, V33, P111, DOI 10.1016/0169-328X(95)00119-D; Zawia NH, 1998, DEV BRAIN RES, V107, P291, DOI 10.1016/S0165-3806(98)00023-6; Zhu YX, 1998, J NEUROSCI, V18, P2538	59	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45462	45469		10.1074/jbc.M104793200	http://dx.doi.org/10.1074/jbc.M104793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11583993	hybrid			2022-12-25	WOS:000172406700144
J	Hofer, T; Desbaillets, I; Hopfl, G; Gassmann, M; Wenger, RH				Hofer, T; Desbaillets, I; Hopfl, G; Gassmann, M; Wenger, RH			Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1 alpha activation cascade: implications for HIF-1 alpha gene therapy	FASEB JOURNAL			English	Article						oxygen; VEGF; therapeutic angiogenesis; inducible gene expression; MAP kinase	INDUCIBLE FACTOR 1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; FACTOR-I HIF-1; TRANSCRIPTION FACTOR; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; EXPRESSION; CELLS	The heterodimeric hypoxia-inducible factor (HIF)-1 is a master transcriptional regulator of oxygen homeostasis and a possible target for gene therapy of ischemic disease. Although the role of oxygen concentration in HIF-1 alpha protein stabilization is well established, it is less clear whether and how oxygen-regulated mechanisms contribute to HIF-1 alpha protein modifications, nuclear translocation, heterodimerization with the beta -subunit, recruitment of cofactors, and gene trans-activation. Because the HIF-1 alpha protein is proteolytically degraded under normoxic conditions, we established two HeLa Tet-Off cell lines (HT42 and HT43), which inducibly overexpress high levels of HIF-1 alpha under normoxic conditions, allowing to distinguish hypoxia-dependent from hypoxia-independent activation mechanisms. Using these cells, we found that normoxically induced HIF-1 alpha is localized to the nucleus, binds DNA, and trans-activates reporter and endogenous target genes. The levels of p53 expression remained unaffected. The MAP kinase inhibitor PD98059 attenuated HIF-1 alpha protein modifications and trans-activation ability but not protein stabilization and DNA-binding activity. Because overexpressed HIF-1 alpha is fully localized to the nucleus but displays only partial DNA-binding and trans-activation activity, mitogen-activated protein kinase-dependent phosphorylation might be required for full HIF-1 activation. HIF-1 alpha protein was also overexpressed in vivo, following the transplantation of HT42 cells into nude mice, demonstrating the feasibility of HIF-1 alpha gene transfer.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Zurich; University of Zurich; University of Lubeck	Gassmann, M (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	maxg@access.unizh.ch	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen EY, 2001, CANCER RES, V61, P2429; Chilov D, 1999, J CELL SCI, V112, P1203; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kim CY, 1997, CANCER RES, V57, P4200; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 1998, CANCER RES, V58, P5678; Xia GB, 2001, CANCER-AM CANCER SOC, V91, P1429, DOI 10.1002/1097-0142(20010415)91:8<1429::AID-CNCR1149>3.0.CO;2-V; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	50	69	74	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2715	+		10.1096/fj.01-0546fje	http://dx.doi.org/10.1096/fj.01-0546fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606485				2022-12-25	WOS:000171920400008
J	Marotta, A; Tan, C; Gray, V; Malik, S; Gallinger, S; Sanghera, J; Dupuis, B; Owen, D; Dedhar, S; Salh, B				Marotta, A; Tan, C; Gray, V; Malik, S; Gallinger, S; Sanghera, J; Dupuis, B; Owen, D; Dedhar, S; Salh, B			Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis	ONCOGENE			English	Article						intestinal polyposis; integrin-linked kinase (ILK); non-steroidal anti-inflammatory drugs (NSAIDs); adenomatous polyposis coli (APC); beta-catenin	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTATE-CANCER CELLS; CYCLIN D1 GENE; BETA-CATENIN; PROTEIN-KINASE; CYCLOOXYGENASE-2 INHIBITOR; ANTICANCER AGENTS; SULINDAC SULFIDE; UP-REGULATION; APC	Mutation of the adenomatous polyposis coli (APC) gene and the subsequent dysregulation of beta -catenin are well-documented abnormalities in familial adenomatous polyposis (FAP), as well as sporadic polyposis. Intriguingly, overexpression of the integrin-linked kinase (ILK) has been shown to modulate beta -catenin subcellular localization and function. However, the significance of this finding for human carcinogenesis remains unclear. Here, we report the increased biochemical activity and expression of ILK protein in polyps from FAP patients. Furthermore, dramatic increases in ILK immunoreactivity were observed in all abnormal crypts from sporadic polyps, when compared with the normal appearing crypts within the same resected specimens. As sulindac and aspirin are the two most important therapeutic/chemopreventative agents demonstrated in colorectal carcinogenesis, in both humans and animals, further investigation revealed that these non-steroidal antiinflammatory drugs (NSAIDs) target ILK and ILK-mediated events in vivo. These include inhibition of, both the biochemical activation of ILK, inhibition of serine 9 GSK3 beta phosphorylation and the enhancement of TCF-4 transcriptional activity. In conclusion, ILK protein hyperexpression appears to be an early event in colonic polyposis. Additionally, ILK signaling is shown to undergo modulation by sulindac (and aspirin) for the first time, indicating that it is likely to be one of the targets affected by these agents in vivo.	Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Thunderbay Reg Hosp, Thunder Bay, ON P7E 1G6, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6PA, Canada; Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of British Columbia	Salh, B (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Gallinger, Steven/E-4575-2013	Dedhar, Shoukat/0000-0003-4355-1657				Akashi H, 2000, INT J CANCER, V88, P873, DOI 10.1002/1097-0215(20001215)88:6<873::AID-IJC6>3.0.CO;2-B; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Barker N, 2000, ADV CANCER RES, V77, P1; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chiu CH, 1997, CANCER RES, V57, P4267; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OConnor PM, 1997, CANCER RES, V57, P4285; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Reddy BS, 1996, CANCER RES, V56, P4566; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salh B, 1999, ANTICANCER RES, V19, P731; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sparks AB, 1998, CANCER RES, V58, P1130; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	45	68	74	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6250	6257		10.1038/sj.onc.1204791	http://dx.doi.org/10.1038/sj.onc.1204791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593435				2022-12-25	WOS:000171206300018
J	Bartkova, J; Falck, J; Rajpert-De Meyts, E; Skakkebaek, NE; Lukas, J; Bartek, J				Bartkova, J; Falck, J; Rajpert-De Meyts, E; Skakkebaek, NE; Lukas, J; Bartek, J			Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours	ONCOGENE			English	Article						cell cycle checkpoints; Chk2; spermatogenesis; carcinoma in situ; testicular germ-cell tumours	DNA-DAMAGE RESPONSE; P53 PROTEIN; MEIOTIC CHROMOSOMES; ATM; CHECKPOINT; CANCER; KINASE; LINE; MICE; DIFFERENTIATION	Chk2 is a transducer of DNA damage signals and a tumour suppressor whose germ-line mutations predispose to diverse tumour types. Unlike its downstream targets such as the p53 tumour suppressor, the expression patterns of Chk2 in tissues and tumours remain unknown. As DNA breaks occur commonly during gametogenesis, and p53 is wild-type and overexpressed in testicular cancer, we examined abundance and localisation of the Chk2 protein during normal development of human testes, and at various stages of germ-cell tumour (GCT) pathogenesis. Our results show that Chk2 is abundant in foetal germ cells and adult spermatogonia, yet only weakly expressed or lacking during the meiotic and later stages of spermatogenesis. High levels of Chk2 are detected in the majority of GCTs including all preinvasive carcinoma-in-situ lesions, contrary to variable expression and even lack of Chk2 in subsets of invasive GCTs and some teratoma structures, respectively. Together with our analyses of cell culture models, these results indicate that downmodulation or lack of Chk2 is not simply attributable to quiescence or differentiation, they suggest a role for Chk2 in mitotic rather than meiotic divisions, support the concept of foetal origin of GCTs, and have implications for protein-based screening for tumour-associated aberrations of Chk2.	Inst Canc Biol, Danish Canc Soc, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Rigshospitalet; University of Copenhagen	Bartek, J (corresponding author), Inst Canc Biol, Danish Canc Soc, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014; Rajpert-De Meyts, Ewa/H-6526-2019	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Lukas, Jiri/0000-0001-9087-506X				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Bartkova J, 2000, ONCOGENE, V19, P4146, DOI 10.1038/sj.onc.1203769; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chehab NH, 2000, GENE DEV, V14, P278; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; Grigor KM, 1998, APMIS, V106, P221, DOI 10.1111/j.1699-0463.1998.tb01339.x; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Shieh SY, 2000, GENE DEV, V14, P289; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	30	57	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5897	5902		10.1038/sj.onc.1204746	http://dx.doi.org/10.1038/sj.onc.1204746			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593395				2022-12-25	WOS:000171037200013
J	Suzuki, H; Nakayama, T; Yonekura-Sakakibara, K; Fukui, Y; Nakamura, N; Nakao, M; Tanaka, Y; Yamaguchi, M; Kusumi, T; Nishino, T				Suzuki, H; Nakayama, T; Yonekura-Sakakibara, K; Fukui, Y; Nakamura, N; Nakao, M; Tanaka, Y; Yamaguchi, M; Kusumi, T; Nishino, T			Malonyl-CoA : anthocyanin 5-O-glucoside-6 '''-O-malonyltransferase from scarlet sage (Salvia splendens) flowers - Enzyme purification, gene cloning, expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BIOCHEMICAL-CHARACTERIZATION; FUNCTIONAL EXPRESSION; TRANSFERASE CDNA; IDENTIFICATION; ACETYLTRANSFERASE; ACYLTRANSFERASE; BIOSYNTHESIS; PROTEINS; TAXUS	The orange to blue coloration of flowers in nature is, in most cases, provided by anthocyanins, a class of plant flavonoids, many of which are modified by malonyl group(s). However, the identity of the enzyme catalyzing the malonylation reaction remains to be established. Here, we describe for the first time the purification, characterization, and cDNA cloning of an anthocyanin malonyltransferase from scarlet sage (Salvia splendens) flowers. The purified enzyme (termed Ss5MaT1) was a monomeric 50-kDa protein catalyzing the regiospecific transfer of the malonyl group from malonyl-CoA to the 6"'-hydroxyl group of the 5-glucosyl moiety of anthocyanins. Ss5MaT1 showed a k(cat) value of 7.8 s(-1) at 30 degreesC and pH 7.0 for the malonylation of bisdemalonylsalvianin (pelargonidin 3-(6"-O-caffeyl-beta-glueopyranoside)-5-beta-glucopyranoside) and K-m values of 101 gm and 57 mum for bisdemalonylsalvianin and malonyl-CoA, respectively. p-Coumaric acid, which mimics an aromatic acyl group linked to the 3-glucosidic moiety of an anthocyanin substrate, was a competitive inhibitor with respect to the substrate. This strongly suggests that the presence of an aromatic acyl group at the 3-glucosidic moiety of anthocyanin is important for substrate recognition by the enzyme. On the basis of the partial amino acid sequences of the purified enzyme, we isolated a cDNA encoding Ss5MaT1. Ss5MaT1 consisted of 462 amino acids and shared motifs that are commonly found among members of a versatile plant acyltransferase family, which was recently shown to include numerous homologs of unknown biochemical functions. Northern blot analysis revealed that the transcripts of Ss5MaT1 were detected in petals, sepals, bracts, and red stems, in accordance with the pigment accumulation patterns. Phylogenetic analysis suggests that the aliphatic and aromatic acylations of anthocyanins are generally catalyzed by subfamily members of the plant acyltransferase family.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Suntory Ltd, Inst Fundamental Res, Shimamoto, Osaka 6188503, Japan; Minami Kyushu Univ, Dept Food Sci & Technol, Miyazaki 8840003, Japan	Tohoku University; Suntory Holdings Ltd	Nishino, T (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aobayama 07, Sendai, Miyagi 9808579, Japan.	nishino@mail.cc.tohoku.ac.jp	Suzuki, Hirokazu/AAG-2285-2020; Yonekura-Sakakibara, Keiko/J-8749-2014	Suzuki, Hirokazu/0000-0002-9507-6467; Yonekura-Sakakibara, Keiko/0000-0002-0409-1523				Aggelis A, 1997, PLANT MOL BIOL, V33, P313, DOI 10.1023/A:1005701730598; Aharoni A, 2000, PLANT CELL, V12, P647, DOI 10.1105/tpc.12.5.647; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brouillard R., 1994, FLAVONOIDS ADV RES 1, P565, DOI DOI 10.1007/978-1-4899-2911-2_13; Dudareva N, 2000, PLANT PHYSIOL, V122, P627, DOI 10.1104/pp.122.3.627; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; Fujiwara H, 1998, PLANT SCI, V137, P87, DOI 10.1016/S0168-9452(98)00119-8; GOTO T, 1991, ANGEW CHEM INT EDIT, V30, P17, DOI 10.1002/anie.199100171; Grothe T, 2001, J BIOL CHEM, V276, P30717, DOI 10.1074/jbc.M102688200; Heller W., 1993, ADV RES 1986, P499; ISEGAWA Y, 1992, MOL CELL PROBE, V6, P467, DOI 10.1016/0890-8508(92)90043-W; Kimura M, 1998, J BIOL CHEM, V273, P1654, DOI 10.1074/jbc.273.3.1654; KONDO T, 1989, TETRAHEDRON LETT, V30, P6729, DOI 10.1016/S0040-4039(00)70662-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; MCGOOKIN R, 1984, METHOD MOL BIOL, V2, P113; Nakayama M, 1997, BIOSCI BIOTECH BIOCH, V61, P1607, DOI 10.1271/bbb.61.1607; Neuhaus JM, 1998, PLANT MOL BIOL, V38, P127, DOI 10.1023/A:1006032627036; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; Strack D., 1994, FLAVONOIDS ADV RES 1, P1; SUZUKI H, UNPUB; TAKEDA K, 1986, PHYTOCHEMISTRY, V25, P2191, DOI 10.1016/0031-9422(86)80089-9; Tanaka Y, 1998, PLANT CELL PHYSIOL, V39, P1119, DOI 10.1093/oxfordjournals.pcp.a029312; Walker K, 2000, P NATL ACAD SCI USA, V97, P583, DOI 10.1073/pnas.97.2.583; Walker K, 2000, ARCH BIOCHEM BIOPHYS, V374, P371, DOI 10.1006/abbi.1999.1609; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405; Yonekura-Sakakibara K, 2000, PLANT CELL PHYSIOL, V41, P495, DOI 10.1093/pcp/41.4.495	29	52	61	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49013	49019		10.1074/jbc.M108444200	http://dx.doi.org/10.1074/jbc.M108444200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598135	hybrid			2022-12-25	WOS:000173922100053
J	Biederer, T; Sudhof, TC				Biederer, T; Sudhof, TC			CASK and protein 4.1 support F-actin nucleation on neurexins.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; ALPHA-LATROTOXIN; GLYCOPHORIN-C; 4.1 FAMILY; SUBCELLULAR-LOCALIZATION; BASOLATERAL MEMBRANE; BINDING INTERFACE; PDZ DOMAINS; DISCS-LARGE; HOMOLOG	Rearrangements of the actin cytoskeleton are involved in a variety of cellular processes from locomotion of cells to morphological alterations of the cell surface. One important question is how local interactions of cells with the extracellular space are translated into alterations of their membrane organization. To address this problem, we studied CASK, a member of the membrane-associated guanylate kinase homologues family of adaptor proteins. CASK has been shown to bind the erythrocyte isoform of protein 4.1, a class of proteins that promote formation of actin/spectrin microfilaments. In neurons, CASK also interacts via its PDZ domain with the cytosolic C termini of neurexins, neuron-specific cell-surface proteins. We now show that CASK binds a brain-enriched isoform of protein 4.1, and nucleates local assembly of actin/spectrin filaments. These interactions can be reconstituted on the cytosolic tail of neurexins. Furthermore, CASK can be recovered with actin filaments prepared from rat brain extracts, and neurexins are recruited together with CASK and protein 4.1 into these actin filaments. Thus, analogous to the PDZ-domain protein p55 and glycophorin C at the erythrocyte membrane, a similar complex comprising CASK and neurexins exists in neurons. Our data suggest that intercellular junctions formed by neurexins, such as junctions initiated by beta -neurexins with neuroligins, are at least partially coupled to the actin cytoskeleton via an interaction with CASK and protein 4.1.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Biederer, T (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA.	thomas.biederer@utsouthwestern.edu	Biederer, Thomas/AAZ-6133-2021	Biederer, Thomas/0000-0003-0912-1514	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; BIEDERER T, 2000, J BIOL CHEM; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bredt DS, 2000, NATURE, V404, P241, DOI 10.1038/35005208; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; CORREAS I, 1986, J BIOL CHEM, V261, P3310; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; Hata Y, 1996, J NEUROSCI, V16, P2488; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; Honda M, 1999, J MOL BIOL, V287, P293, DOI 10.1006/jmbi.1999.2592; Hoover KB, 2000, CURR OPIN CELL BIOL, V12, P229, DOI 10.1016/S0955-0674(99)00080-0; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Knust E, 2000, CURR OPIN GENET DEV, V10, P471, DOI 10.1016/S0959-437X(00)00115-5; LING E, 1988, J BIOL CHEM, V263, P2209; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Missler M, 1998, J NEUROCHEM, V71, P1339; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; MORRIS MB, 1995, EUR J BIOCHEM, V231, P644, DOI 10.1111/j.1432-1033.1995.tb20743.x; Ohara R, 1999, DEV BRAIN RES, V117, P127, DOI 10.1016/S0165-3806(99)00110-8; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shen L, 2000, J NEUROSCI, V20, P7932; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; STOKES DL, 1991, BIOPHYS J, V59, P456, DOI 10.1016/S0006-3495(91)82239-1; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Thomas U, 2000, CURR BIOL, V10, P1108, DOI 10.1016/S0960-9822(00)00696-5; Tseng TC, 2001, BBA-GENE STRUCT EXPR, V1518, P249, DOI 10.1016/S0167-4781(01)00191-9; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Walensky LD, 1999, J NEUROSCI, V19, P6457; Workman RF, 1998, J BIOL CHEM, V273, P6171, DOI 10.1074/jbc.273.11.6171; Yamakawa H, 1999, MOL BRAIN RES, V70, P197, DOI 10.1016/S0169-328X(99)00139-4; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1	57	124	130	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47869	47876		10.1074/jbc.M105287200	http://dx.doi.org/10.1074/jbc.M105287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604393	hybrid			2022-12-25	WOS:000172927000021
J	Harbers, M; Nomura, T; Ohno, S; Ishii, S				Harbers, M; Nomura, T; Ohno, S; Ishii, S			Intracellular localization of the Ret finger protein depends on a functional nuclear export signal and protein kinase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; PML-RAR-ALPHA; LEPTOMYCIN B; TRANSFORMING GENE; MAP-KINASE; TRANSPORT; RECEPTOR; INTERACTS; BINDING; IMPORT	The Ret finger protein (RFP) was identified initially as an oncogene product and belongs to a family of proteins that contain a tripartite motif consisting of a RING finger, a B box, and a coiled-coil domain. RFP represses transcription by interacting with Enhancer of Polycomb and is localized to the cytoplasm or nucleus depending on the cell type. Here, we have identified the nuclear export signal (NES) located in the coiled-coil region of RFP. Mutation of this NES or treatment with leptomycin B abrogated the nuclear export of RFP in NIH3T3 cells. In addition, fusion of this NES to other nuclear proteins, such as yeast transcription factor Gal4, resulted in their release into the cytoplasm of NIH3T3 cells. Although the NES function of RFP in HepG2 cells is masked by another domain in RFP or by another protein, 12-O-tetradecanoylphorbol-13-acetate treatment or overexpression of constitutively active protein kinase C alpha (PKC alpha) abrogated masking, leading to the cytoplasmic localization of RFP. Furthermore, treatment of NIH3T3 cells with PKC inhibitors blocked the function of NES, resulting in nuclear localization of RFP. Thus, the nuclear export of RFP is regulated positively by PKC activation. However, RFP was not a direct substrate of PKC, and additional signaling pathways may be involved in the regulation of nuclear export of RFP.	RIKEN Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Corp, CREST Project, Tsukuba, Ibaraki 3050074, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan	RIKEN; Japan Science & Technology Agency (JST); Yokohama City University	Ishii, S (corresponding author), RIKEN Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ohno, Shigeo/B-1768-2010; Ishii, Shunsuke/A-5271-2016	Ohno, Shigeo/0000-0002-1294-5269; Ishii, Shunsuke/0000-0002-6530-2478; Harbers, Matthias/0000-0002-5613-7220				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BORNER C, 1992, J BIOL CHEM, V267, P12900; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; Cao TY, 1996, DEV GENET, V19, P309, DOI 10.1002/(SICI)1520-6408(1996)19:4<309::AID-DVG4>3.3.CO;2-1; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Douarin BL, 1996, EMBO J, V15, P6701; DOUARIN BL, 1995, EMBO J, V14, P2020; DOUARIN BL, 1995, NUCLEIC ACIDS RES, V23, P876; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FANDREY J, 1994, EUR J BIOCHEM, V226, P335, DOI 10.1111/j.1432-1033.1994.tb20057.x; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; HALLER H, 1994, HYPERTENSION, V23, P848, DOI 10.1161/01.HYP.23.6.848; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hasegawa N, 1996, BIOCHEM BIOPH RES CO, V225, P627, DOI 10.1006/bbrc.1996.1221; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schmalz D, 1998, J CELL SCI, V111, P1823; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; STUNNENBERG HG, 1998, BIOCHIM BIOPHYS ACTA, V1423, pF15; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; THE H, 1991, CELL, V66, P675; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zini N, 1997, EUR J CELL BIOL, V72, P142	64	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48596	48607		10.1074/jbc.M108077200	http://dx.doi.org/10.1074/jbc.M108077200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11591718	hybrid			2022-12-25	WOS:000172927000115
J	Basak, S; Nagaraja, V				Basak, S; Nagaraja, V			DNA unwinding mechanism for the transcriptional activation of momP1 promoter by the transactivator protein C of bacteriophage Mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; MERR HOMOLOG; -35 REGIONS; GENE; RECOGNITION; BINDING; SIGMA(70)-SUBUNIT; EXPRESSION	Transcription factor-induced conformational changes in DNA are one of the mechanisms of transcription activation. C protein of bacteriophage Mu appears to transactivate the inom gene of the phage by this mode. DNA binding by C to its site leads to torsional changes that seem to compensate for a weak momP1 promoter having a suboptimal spacing of 19 bp between the poor -35 and -10 elements. The C-mediated unwinding could realign the promoter elements for RNA polymerase recruitment to the reoriented promoter. In this study, the model has been tested by mutational analysis of the spacer region of momP1 and by assessing the strength of the mutant promoters. The response to C-mediated transactivation was dependent on the spacer length of the promoters. Mutants with 17-bp spacing between the two promoter elements showed reduced activity in the presence of the transactivator as compared with their basal level. A synthetic promoter with near consensus promoter elements and optimal 17-bp spacing was also tested to evaluate the model. The results imply a role for C-mediated unwinding in mom transcription activation.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Nagaraja, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.							ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ANSARI AZ, 1995, NATURE, V374, P371; AUBLE DT, 1986, J BIOL CHEM, V261, P1202; AUBLE DT, 1988, J MOL BIOL, V202, P471, DOI 10.1016/0022-2836(88)90279-3; BALKE V, 1992, NUCLEIC ACIDS RES, V20, P2777, DOI 10.1093/nar/20.11.2777; Basak S, 1998, J MOL BIOL, V284, P893, DOI 10.1006/jmbi.1998.2213; Basak S, 2001, J BIOL CHEM, V276, P19836, DOI 10.1074/jbc.M011790200; BOLKER M, 1989, J BACTERIOL, V171, P2019; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Dai X, 1999, CURR OPIN MICROBIOL, V2, P126, DOI 10.1016/S1369-5274(99)80022-8; De A, 1997, PROTEIN ENG, V10, P935, DOI 10.1093/protein/10.8.935; De A, 1998, BIOCHEMISTRY-US, V37, P3831, DOI 10.1021/bi972171v; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DUTTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GINDLESPERGER TL, 1994, J BACTERIOL, V176, P2885, DOI 10.1128/JB.176.10.2885-2891.1994; Hattman S, 1999, PHARMACOL THERAPEUT, V84, P367, DOI 10.1016/S0163-7258(99)00042-X; Hidalgo E, 1997, EMBO J, V16, P1056, DOI 10.1093/emboj/16.5.1056; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; Hochschild A, 1998, CELL, V92, P597, DOI 10.1016/S0092-8674(00)81126-5; Ishihama A., 1997, NUCL ACIDS MOL BIOL, V11, P53; Kahmann R., 1987, PHAGE MU, P93; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Kulkarni RD, 1999, BIOCHEMISTRY-US, V38, P3362, DOI 10.1021/bi982814m; LOZINSKI T, 1991, NUCLEIC ACIDS RES, V19, P2947, DOI 10.1093/nar/19.11.2947; Miller JH., 1992, SHORT COURSE BACTERI, P72; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; RAMESH V, 1994, PROTEIN ENG, V7, P1053, DOI 10.1093/protein/7.8.1053; Ramesh V, 1996, J MOL BIOL, V260, P22, DOI 10.1006/jmbi.1996.0379; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; Sambrook J., 2002, MOL CLONING LAB MANU; Sun WY, 1998, J MOL BIOL, V284, P885, DOI 10.1006/jmbi.1998.2228; Sun WY, 1998, J BACTERIOL, V180, P3257, DOI 10.1128/JB.180.12.3257-3259.1998; Sun WY, 1997, J MOL BIOL, V273, P765, DOI 10.1006/jmbi.1997.1349	36	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46941	46945		10.1074/jbc.M107476200	http://dx.doi.org/10.1074/jbc.M107476200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598122	hybrid			2022-12-25	WOS:000172768500037
J	Gregson, HC; Schmiesing, JA; Kim, JS; Kobayashi, T; Zhou, S; Yokomori, K				Gregson, HC; Schmiesing, JA; Kim, JS; Kobayashi, T; Zhou, S; Yokomori, K			A potential role for human cohesin in mitotic spindle aster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; NUCLEAR MATRIX; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; YEAST COHESIN; SMC PROTEINS; CELL-CYCLE; COMPLEX; NUMA; IDENTIFICATION	The cohesin multiprotein complex containing SMC1, SMC3, Scc3 (SA), and Scc1 (1Rad2l) is required for sister chromatid cohesion in eukaryotes. Although metazoan cohesin associates with chromosomes and was shown to function in the establishment of sister chromatid cohesion during interphase, the majority of cohesin was found to be off chromosomes and reside in the cytoplasm in metaphase. Despite its dissociation from chromosomes, however, microinjection of an antibody against human SMC1 led to disorganization of the metaphase plate and cell cycle arrest, indicating that human cohesin still plays an important role in metaphase. To address the mitotic function of human cohesin, the subcellular localization of cohesin components was reexamined in human cells. Interestingly, we found that cohesin localizes to the spindle poles during mitosis and interacts with NuMA, a spindle pole-associated factor required for mitotic spindle organization. The interaction with NuMA persists during interphase. Similar to NuMA, a significant amount of cohesin was found to associate with the nuclear matrix. Furthermore, in the absence of cohesin, mitotic spindle asters failed to form in vitro. Our results raise the intriguing possibility that in addition to its well demonstrated function in sister chromatid cohesion, cohesin may be involved in spindle assembly during mitosis.	Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Irvine; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Yokomori, K (corresponding author), Univ Calif Irvine, Coll Med, Dept Biol Chem, 240D Mod Sci 1, Irvine, CA 92697 USA.			Kobayashi, Toshiki/0000-0001-6158-9670	NIGMS NIH HHS [GM 59150] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059150] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; COMPTON DA, 1995, J CELL SCI, V108, P621; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Hsu HL, 1996, J CELL SCI, V109, P277; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; SUMARA I, 2000, J CELL BIOL; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zheng L, 1999, MOL CELL BIOL, V19, P5417	38	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47575	47582		10.1074/jbc.M103364200	http://dx.doi.org/10.1074/jbc.M103364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590136	hybrid			2022-12-25	WOS:000172768500117
J	Troyano, A; Fernandez, C; Sancho, P; de Blas, E; Aller, P				Troyano, A; Fernandez, C; Sancho, P; de Blas, E; Aller, P			Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells - The role of intracellular oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; BUTHIONINE SULFOXIMINE; SUPEROXIDE ANION; DEATH; SENSITIVITY; INHIBITION; INDUCTION; STRESS; CYTOTOXICITY; ACTIVATION	Treatment with the DNA topoisomerase inhibitors etoposide, doxorubicin, and camptothecin, and with the alkylating agents cisplatin and melphalan, caused peroxide accumulation and apoptosis in U-937 human promonocytic cells. Preincubation with the reduced glutathione (GSH) synthesis inhibitor L-buthionine-(SR)sulfoximine (BSO) always potentiated peroxide accumulation. However, although GSH depletion potentiated the toxicity of cisplatin and melphalan, occasionally switching the mode of death from apoptosis to necrosis, it did not affect the toxicity of the other antitumor drugs. Hypoxia or preincubation with antioxidant agents attenuated death induction, apoptotic and necrotic, by alkylating drugs. The generation of necrosis by cisplatin could not be mimicked by addition of exogenous H2O2 instead of BSO and was not adequately explained by caspase inactivation nor by a selective fall in ATP content. Treatment with cisplatin and melphalan caused a late decrease in mitochondrial transmembrane potential (Delta Psim), which was much greater during necrosis than during apoptosis. The administration of the antioxidant agents N-acetyl-L-cysteine and butylated hydroxyanisole after pulse treatment with cisplatin or melphalan did not affect apoptosis but attenuated necrosis. Under these conditions, both antioxidants attenuated the necrosis-associated Delta Psim decrease. These results indicate that oxidation-mediated alterations in mitochondrial function regulate the selection between apoptosis and necrosis in alkylating drug-treated human promonocytic cells.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Univ Alcala de Henares, Dept Biol Celular & Genet, Madrid 28006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Alcala	Aller, P (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.	aller@cib.csic.es	Sancho, Patricia/ABH-5258-2020	Sancho, Patricia/0000-0002-1092-5395				ALBINA JE, 1993, J IMMUNOL, V150, P5080; Anderson M E, 1997, Adv Pharmacol, V38, P65; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; BENCHEKROUN MN, 1993, EUR J BIOCHEM, V211, P141, DOI 10.1111/j.1432-1033.1993.tb19880.x; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BONNER JA, 1992, INT J RADIAT ONCOL, V22, P519, DOI 10.1016/0360-3016(92)90866-G; BUJA LM, 1993, ARCH PATHOL LAB MED, V117, P1208; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Ceruti S, 1997, J NEUROSCI RES, V47, P372, DOI 10.1002/(SICI)1097-4547(19970215)47:4<372::AID-JNR2>3.0.CO;2-B; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Ciolino HP, 1997, FREE RADICAL BIO MED, V22, P1277, DOI 10.1016/S0891-5849(96)00495-9; Comelli M, 1998, FREE RADICAL BIO MED, V24, P924, DOI 10.1016/S0891-5849(97)00373-0; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; CRESCIMANNO M, 1994, J CHEMOTHERAPY, V6, P343; Del Bello B, 1999, FASEB J, V13, P69; Eguchi Y, 1997, CANCER RES, V57, P1835; Evans RM, 1998, EXP CELL RES, V245, P69, DOI 10.1006/excr.1998.4250; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Franek WR, 2001, J BIOL CHEM, V276, P569, DOI 10.1074/jbc.M004716200; Galan A, 2001, EUR J CELL BIOL, V80, P312, DOI 10.1078/0171-9335-00159; Gantchev TG, 1997, ANTI-CANCER DRUG, V8, P164, DOI 10.1097/00001813-199702000-00007; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ikeda K, 1999, BIOCHEM PHARMACOL, V57, P1361, DOI 10.1016/S0006-2952(99)00055-6; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; LEE FYF, 1988, NATL CANCER I MONOGR, V6, P211; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Lee YJ, 2000, FREE RADICAL BIO MED, V29, P684, DOI 10.1016/S0891-5849(00)00366-X; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Liang BC, 1998, CELL DEATH DIFFER, V5, P694, DOI 10.1038/sj.cdd.4400401; MAJNO G, 1995, AM J PATHOL, V146, P3; MANS DRA, 1992, EUR J CANCER, V28A, P1447, DOI 10.1016/0959-8049(92)90541-9; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363; MUSCHEL RJ, 1995, CANCER RES, V55, P995; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Sawyer TE, 1996, BRIT J CANCER, V74, pS109; Shacter E, 2000, BLOOD, V96, P307, DOI 10.1182/blood.V96.1.307.013k47_307_313; Shinoura N, 1999, ONCOGENE, V18, P5703, DOI 10.1038/sj.onc.1202966; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; Sugimoto C, 1996, ANTICANCER RES, V16, P675; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TEW KD, 1994, CANCER RES, V54, P4313; Ueda S, 1998, J IMMUNOL, V161, P6689; USLU R, 1996, CANCER, V15, P725; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vilaboa NE, 1997, J CELL SCI, V110, P201; Virag L, 1998, J IMMUNOL, V161, P3753; Wyllie A H, 1980, Int Rev Cytol, V68, P251	64	141	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47107	47115		10.1074/jbc.M104516200	http://dx.doi.org/10.1074/jbc.M104516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11602574	hybrid			2022-12-25	WOS:000172768500059
J	Appa, RS; Shin, CG; Lee, P; Chow, SA				Appa, RS; Shin, CG; Lee, P; Chow, SA			Role of the nonspecific DNA-binding region and alpha helices within the core domain of retroviral integrase in selecting target DNA sites for integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AVIAN-SARCOMA VIRUS; PHOTO-CROSS-LINKING; N-TERMINAL DOMAIN; HIV-1 INTEGRASE; TYPE-1 INTEGRASE; VIRAL-DNA; IN-VITRO; ESCHERICHIA-COLI; RESTRICTION ENDONUCLEASES	Retroviral integrase plays an import-ant role in choosing host chromosomal sites for integration of the cDNA copy of the viral genome. The domain responsible for target site selection has been previously mapped to the central core of the protein (amino acid residues 49-238). Chimeric integrases between human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus (FIV) were prepared to examine the involvement of a nonspecific DNA-binding region (residues 213-266) and certain a helices within the core domain in target site selection. Determination of the distribution and frequency of integration events of the chimeric integrases narrowed the target site-specifying motif to within residues 49-187 and showed that alpha3 and alpha4 helices (residues 123-166) were not involved in target site selection. Furthermore, the chimera with the alpha2 helix (residues 118-121) of FIV identity displayed characteristic integration events from both HIV-1 and FIV integrases. The results indicate that the alpha2 helix plays a role in target site preference as either part of a larger or multiple target site-specifying motif.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, AIDS Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chow, SA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Inst Mol Biol, 23-133 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R01CA068859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA68859] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRAKE MD, 1995, J BIOL CHEM, V270, P29299, DOI 10.1074/jbc.270.49.29299; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; Bor YC, 1996, VIROLOGY, V222, P283, DOI 10.1006/viro.1996.0422; Brannvall M, 1999, J MOL BIOL, V292, P53, DOI 10.1006/jmbi.1999.3048; Brown P.O., 1997, INTEGRATION RETROVIR, P161; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; Dorner LF, 1999, J MOL BIOL, V285, P1515, DOI 10.1006/jmbi.1998.2408; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Gerton JL, 1999, J BIOL CHEM, V274, P33480, DOI 10.1074/jbc.274.47.33480; Gerton JL, 1997, J BIOL CHEM, V272, P25809, DOI 10.1074/jbc.272.41.25809; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Goulaouic H, 1996, J VIROL, V70, P37, DOI 10.1128/JVI.70.1.37-46.1996; Harper AL, 2001, J VIROL, V75, P7756, DOI 10.1128/JVI.75.16.7756-7762.2001; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; Holmes-Son M L, 2001, Adv Genet, V43, P33, DOI 10.1016/S0065-2660(01)43003-3; HUGHES SH, 1978, CELL, V15, P1397, DOI 10.1016/0092-8674(78)90064-8; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; Katzman M, 1998, J VIROL, V72, P1744, DOI 10.1128/JVI.72.3.1744-1753.1998; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KRUGER DH, 1995, GENE, V157, P165, DOI 10.1016/0378-1119(95)00699-7; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Lukacs CM, 2000, NAT STRUCT BIOL, V7, P134; Lutzke RAP, 1998, J VIROL, V72, P4841, DOI 10.1128/JVI.72.6.4841-4848.1998; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; PRUSS D, 1994, J BIOL CHEM, V269, P25031; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, P NATL ACAD SCI USA, V89, P9237, DOI 10.1073/pnas.89.19.9237; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Rhodes D, 1996, PHILOS T ROY SOC B, V351, P501, DOI 10.1098/rstb.1996.0048; Shibagaki Y, 1997, J BIOL CHEM, V272, P8361, DOI 10.1074/jbc.272.13.8361; Shibagaki Y, 1997, VIROLOGY, V230, P1, DOI 10.1006/viro.1997.8466; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; Skinner LM, 1998, J ACQ IMMUN DEF SYND, V19, P99, DOI 10.1097/00042560-199810010-00001; Su LHJ, 2001, J MOL BIOL, V306, P655, DOI 10.1006/jmbi.2000.4323; van den Ent FMI, 1999, J VIROL, V73, P3176, DOI 10.1128/JVI.73.4.3176-3183.1999; VENCLOVAS C, 1995, NAT STRUCT BIOL, V2, P838, DOI 10.1038/nsb1095-838; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P2433; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659; Zhou HB, 2001, J VIROL, V75, P1359, DOI 10.1128/JVI.75.3.1359-1370.2001	75	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45848	45855		10.1074/jbc.M107365200	http://dx.doi.org/10.1074/jbc.M107365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585830	hybrid			2022-12-25	WOS:000172573100048
J	Kamitani, T; Kito, K; Fukuda-Kamitani, T; Yeh, ETH				Kamitani, T; Kito, K; Fukuda-Kamitani, T; Yeh, ETH			Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CUL-1; UBIQUITIN; IDENTIFICATION; PROTEINS; SUBUNIT; DOMAIN	NEDD8 is a ubiquitin-like protein that controls vital biological events through its conjugation to cullin family members. Recently, we identified a negative regulator of the NEDD8 conjugation system, NUB1, which interacts with NEDD8 and down-regulates NEDD8 expression post-transcriptionally (Kito, K., Yeh, E. T. H., and Kamitani, T. (2001) J. Biol. Chem. 276, 20603-20609). Here, we show that NUB1 possesses a ubiquitin-like domain at the N-terminal region and binds to S5a of the 19 S proteasome activator (PA700). A GST pull-down assay revealed that the overexpression of NUB1 leads to a greater precipitation of NEDD8 conjugates with GST-S5a, suggesting that NUB1 might have an adaptor function between S5a and NEDD8. Furthermore, proteasome inhibitors completely block NUB1-mediated down-regulation of NEDD8 expression. These results suggest that NUB1 recruits NEDD8 and its conjugates to the proteasome for degradation, providing a direct functional link between the NEDD8 conjugation system and the proteasomal degradation pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Mol Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Kamitani, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, 1515 Holcombe Blvd,Box 449, Houston, TX 77030 USA.	tkamitani@mdanderson.org	Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056298] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK56298] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Wada H, 2000, J BIOL CHEM, V275, P17008, DOI 10.1074/jbc.275.22.17008; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	25	111	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46655	46660		10.1074/jbc.M108636200	http://dx.doi.org/10.1074/jbc.M108636200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585840	hybrid			2022-12-25	WOS:000172573100153
J	Kischkel, FC; Lawrence, DA; Tinel, A; LeBlanc, H; Virmani, A; Schow, P; Gazdar, A; Blenis, J; Arnott, D; Ashkenazi, A				Kischkel, FC; Lawrence, DA; Tinel, A; LeBlanc, H; Virmani, A; Schow, P; Gazdar, A; Blenis, J; Arnott, D; Ashkenazi, A			Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; TNF RECEPTOR; CELL-DEATH; MEDIATED APOPTOSIS; SIGNALING COMPLEX; DECOY RECEPTORS; DOMAIN; FAS; FADD; PROTEIN	Caspase-8 is believed to play an obligatory role in apoptosis initiation by death receptors, but the role of its structural relative, caspase-10, remains controversial. Although earlier evidence implicated caspase-10 in apoptosis signaling by CD95L and Apo2L/TRAIL, recent studies indicated that these death receptor ligands recruit caspase-8 but not caspase-10 to their death-inducing signaling complex (DISC) even in presence of abundant caspase-10. We characterized a series of caspase-10-specific antibodies and found that certain commercially available antibodies cross-react with HSP60, shedding new light on previous results. The majority of 55 lung and breast carcinoma cell lines expressed mRNA for both caspase-8 and -10; however, immunoblot analysis revealed that caspase-10 protein expression was more frequently absent than that of caspase-8, suggesting a possible selective pressure against caspase-10 production in cancer cells. In nontransfected cells expressing both caspases, CD95L and Apo2L/TRAIL recruited endogenous caspase-10 as well as caspase-8 to their DISC, where both enzymes were proteolytically processed with similar kinetics. Caspase-10 recruitment required the adaptor FADD/ Mort1, and caspase-10 cleavage in vitro required DISC assembly, consistent with the processing of an apoptosis initiator. Cells expressing only one of the caspases underwent ligand-induced apoptosis, indicating that each caspase can initiate apoptosis independently of the other. Thus, apoptosis signaling by death receptors involves not only caspase-8 but also caspase-10, and both caspases may have equally important roles in apoptosis initiation.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Cell Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Univ Texas, SW Med Sch, Dallas, TX 75390 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; French LE, 1999, J EXP MED, V190, P891, DOI 10.1084/jem.190.7.891; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gelmini S, 1997, CLIN CHEM, V43, P752; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Gronbaek K, 2000, BLOOD, V95, P2184; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; ITOH N, 1993, J BIOL CHEM, V268, P10932; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 1998, CYTOGENET CELL GENET, V82, P95, DOI 10.1159/000015073; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Phelps RM, 1996, J CELL BIOCHEM, P32; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733	43	394	412	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46639	46646		10.1074/jbc.M105102200	http://dx.doi.org/10.1074/jbc.M105102200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583996	hybrid			2022-12-25	WOS:000172573100151
J	Lau, PP; Villanueva, H; Kobayashi, K; Nakamuta, M; Chang, BHJ; Chan, L				Lau, PP; Villanueva, H; Kobayashi, K; Nakamuta, M; Chang, BHJ; Chan, L			A DnaJ protein, apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; MESSENGER-RNA; J-DOMAIN; MOLECULAR CHAPERONES; SECONDARY STRUCTURE; 40-KDA PROTEIN; NMR STRUCTURE; RICH REGION; CLONING	Mammalian homologues of DnaJ proteins, also known as Hsp40 proteins, are co-chaperonins that complement Hsp70 chaperone function. Using the yeast two-hybrid system, we cloned an apolipoprotein (apo) B mRNA editing complementation protein, called apobec-1-binding protein-2 (ABBP-2), and found that it is a Class II DnaJ homologue. ABBP-2 binds to apobec-1, the mammalian apoB mRNA editase, via its J domain and neighboring G/F domain. It is a ubiquitously expressed protein, and, by transfection analysis of GFP-ABBP-2, we found that the protein is located in both the nucleus and cytosol of transfected cells, with predominance in the nucleus. Down-regulation of ABBP-2 expression in cultured cells inhibits endogenous apobec-1-mediated apoB mRNA editing. Like other Hsp40 proteins, ABBP-2 binds to Hsp70 and has ATPase-stimulating activity. Apobec-1-mediated apoB mRNA editing activity of in vitro tissue extracts requires the presence of Hsp70/ABBP-2. Although exogenously added ATP is not required for editing activity, removal of the endogenous ATP present in these extracts, which disrupts ABBP-2-Hsp70 interaction, completely inhibits editing. ABBP-2 differs from previously described auxiliary proteins (ABBP-1, ACF, and GRY-RBP) in that it does not contain any RNA recognition motifs. Not only is ABBP-2 required for efficient apoB mRNA editing, this newly discovered apobec-1-binding protein may help determine the subcellular distribution and trafficking of apobec-1 via its interaction with the chaperonin Hsp70.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.	lchan@bcm.tmc.edu	Villanueva, Helena/AAB-7911-2019; Kobayashi, Kunihisa/V-9554-2019	Kobayashi, Kunihisa/0000-0002-7741-846X	NHLBI NIH HHS [HL-56668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056668] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Chan L, 2000, RECENT PROG HORM RES, V55, P93; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CRAIG E, 1990, ANTON LEEUW INT J G, V58, P137, DOI 10.1007/BF00548924; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; HARPER JW, 1993, CELL, V75, P805; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; Hirano H, 1997, J LIPID RES, V38, P847; Huang K, 1999, PROTEIN SCI, V8, P203; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; Lau PP, 2001, BIOCHEM BIOPH RES CO, V282, P977, DOI 10.1006/bbrc.2001.4679; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Mallouk Y, 1999, INT J MOL MED, V4, P463; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; OHTSUKA K, 1990, BIOCHEM BIOPH RES CO, V166, P642, DOI 10.1016/0006-291X(90)90857-J; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Teng BB, 1999, J LIPID RES, V40, P623; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Yan W, 1999, MOL CELL BIOL, V19, P7751; Yang Y, 2001, EXP CELL RES, V267, P153, DOI 10.1006/excr.2001.5255; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	47	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46445	46452		10.1074/jbc.M109215200	http://dx.doi.org/10.1074/jbc.M109215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584023	hybrid			2022-12-25	WOS:000172573100129
J	Liu, CJ; Dib-Hajj, SD; Black, JA; Greenwood, J; Lian, Z; Waxman, SG				Liu, CJ; Dib-Hajj, SD; Black, JA; Greenwood, J; Lian, Z; Waxman, SG			Direct interaction with contactin targets voltage-gated sodium channel Na(v)1.9/NaN to the cell membrane.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; PROMOTES NEURITE OUTGROWTH; RECOGNITION MOLECULE F11; FIBRONECTIN TYPE-III; TENASCIN-R; SENSORY NEURONS; PROTEIN CASPR; FUNCTIONAL EXPRESSION; TRANSCRIPTION FACTOR; PARANODAL JUNCTIONS	The mechanisms that target various sodium channels within different regions of the neuronal membrane, which they endow with different physiological properties, are not yet understood. To examine this issue we studied the voltage-gated sodium channel Na(v)1.9/NaN, which is preferentially expressed in small sensory neurons of dorsal root ganglia and trigeminal ganglia and the nonmyelinated axons that arise from them. Our results show that the cell adhesion molecule contactin binds directly to Na(v)1.9/NaN and recruits tenascin to the protein complex in vitro. Na(v)1.9/NaN and contactin coimmunoprecipitate from dorsal root ganglia and transfected Chinese hamster ovary cell line, and co-localize in the C-type neuron soma and along nonmyelinated C-fibers and at nerve endings in the skin. Co-transfection of Chinese hamster ovary cells with Na(v)1.9/NaN and contactin enhances the surface expression of the sodium channel over that of Na,1.9/NaN alone. Thus contactin binds directly to Na(v)1.9/NaN and participates in the surface localization of this channel along nonmyelinated axons.	Yale Univ, Sch Med, Dept Neurol, Neurosci Res Ctr,, New Haven, CT 06510 USA; Yale Univ, Sch Med, Paralyzed Vet Amer,Eastern Paralysed Vet Assoc, Neurosci Res Ctr, New Haven, CT 06510 USA; Transmol Inc, Birmingham, AL 35243 USA; Vet Affairs Connecticut Healthcare Syst, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06536 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Waxman, SG (corresponding author), Yale Univ, Sch Med, Dept Neurol, Neurosci Res Ctr,, 333 Cedar St,LCI 707, New Haven, CT 06510 USA.		Waxman, Stephen/Z-2507-2019	Waxman, Stephen/0000-0001-5718-7177; liu, chuanju/0000-0002-7181-8032				Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Amaya F, 2000, MOL CELL NEUROSCI, V15, P331, DOI 10.1006/mcne.1999.0828; Berglund EO, 1999, NEURON, V24, P739, DOI 10.1016/S0896-6273(00)81126-5; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Black JA, 1996, MOL BRAIN RES, V43, P117, DOI 10.1016/S0169-328X(96)00163-5; BLACK JA, 1988, PROC R SOC SER B-BIO, V233, P45, DOI 10.1098/rspb.1988.0011; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; BRUMMENDORF T, 1993, NEURON, V10, P711; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; CUNNINGHAM TP, 1993, GENE, V124, P93, DOI 10.1016/0378-1119(93)90766-V; Dib-Hajj SD, 1999, FEBS LETT, V462, P117, DOI 10.1016/S0014-5793(99)01519-7; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; DURBEC P, 1992, J CELL BIOL, V117, P877, DOI 10.1083/jcb.117.4.877; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; Fjell J, 1999, MOL BRAIN RES, V67, P267, DOI 10.1016/S0169-328X(99)00070-4; Fjell J, 2000, NEUROREPORT, V11, P199, DOI 10.1097/00001756-200001170-00039; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Herzog RI, 2001, J NEUROPHYSIOL, V86, P1351, DOI 10.1152/jn.2001.86.3.1351; HONMOU O, 1994, J NEUROPHYSIOL, V71, P1627, DOI 10.1152/jn.1994.71.5.1627; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; McCormick KA, 1999, J BIOL CHEM, V274, P32638, DOI 10.1074/jbc.274.46.32638; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PATTON DE, 1994, J BIOL CHEM, V269, P17649; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PELLEGRINO RG, 1984, BRAIN RES, V305, P357, DOI 10.1016/0006-8993(84)90442-6; Perrin FE, 2001, NEURON, V30, P707, DOI 10.1016/S0896-6273(01)00315-4; Pesheva P, 2000, PROG NEUROBIOL, V61, P465, DOI 10.1016/S0301-0082(99)00061-1; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; Qu YS, 1999, J BIOL CHEM, V274, P32647, DOI 10.1074/jbc.274.46.32647; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; RITCHIE JM, 1977, P NATL ACAD SCI USA, V74, P211, DOI 10.1073/pnas.74.1.211; RIZZO MA, 1994, J NEUROPHYSIOL, V72, P2796, DOI 10.1152/jn.1994.72.6.2796; ROY ML, 1992, J NEUROSCI, V12, P2104; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; Sleeper AA, 2000, J NEUROSCI, V20, P7279; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; UNDROVINAS AI, 1995, AM J PHYSIOL-HEART C, V269, pH203, DOI 10.1152/ajpheart.1995.269.1.H203; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; Volkmer H, 1998, J CELL BIOL, V142, P1083, DOI 10.1083/jcb.142.4.1083; Wang H, 2000, J BIOL CHEM, V275, P27377; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	70	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46553	46561		10.1074/jbc.M108699200	http://dx.doi.org/10.1074/jbc.M108699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581273	hybrid			2022-12-25	WOS:000172573100141
J	Maag, D; Castro, C; Hong, Z; Cameron, CE				Maag, D; Castro, C; Hong, Z; Cameron, CE			Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MECHANISM	Ribavirin is administered in combination with interferon-a for treatment of hepatitis C virus (HCV) infection. Recently, we demonstrated that the antiviral activity of ribavirin can result from the ability of a viral RNA polymerase to utilize ribavirin triphosphate and to incorporate this nucleotide with reduced specificity, thereby mutagenizing the genome and decreasing the yield of infectious virus (Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y., Hong, Z., Andino, R., and Cameron, C. E. (2000) Nat. Med. 6, 1375-1379). In this study, we performed a quantitative analysis of a novel HCV RNA polymerase derivative that is capable of utilizing stably annealed primer-template substrates and exploited this derivative to evaluate whether lethal mutagenesis of the HCV genome is a possible mechanism for the anti-HCV activity of ribavirin. These studies demonstrate HCV RNA polymerase-catalyzed incorporation of ribavirin opposite cytidine and uridine. In addition, we demonstrate that templates containing ribavirin support CMP and UMP incorporation with equivalent efficiency. Surprisingly, templates containing ribavirin can also cause a significant block to RNA elongation. Together, these data suggest that ribavirin can exert a direct effect on HCV replication, which is mediated by the HCV RNA polymerase. We discuss the implications of this work on the development of nucleoside analogs for treatment of HCV infection.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; ICN Pharmaceut, Drug Discovery, Costa Mesa, CA 92626 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	cec9@psu.edu			NCI NIH HHS [CA75118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598; Davis G L, 1999, Clin Liver Dis, V3, P811, DOI 10.1016/S1089-3261(05)70240-3; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; HOUGHTON M, 1996, FIELDS VIROLOGY, V1, P1035; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1998, VIROLOGY, V249, P108, DOI 10.1006/viro.1998.9311; MILLER JP, 1977, ANN NY ACAD SCI, V284, P211, DOI 10.1111/j.1749-6632.1977.tb21953.x; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; VILEEK J, 1996, FIELDS VIROLOGY, V1, P375; WRAY SK, ANTIVIRAL RES, V5, P29; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000; Zoulim F, 1998, J VIRAL HEPATITIS, V5, P193, DOI 10.1046/j.1365-2893.1998.00099.x	17	225	238	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46094	46098		10.1074/jbc.C100349200	http://dx.doi.org/10.1074/jbc.C100349200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11602568	Green Published, hybrid			2022-12-25	WOS:000172573100082
J	Perroy, J; Gutierrez, GJ; Coulon, V; Bockaert, J; Pin, JP; Fagni, L				Perroy, J; Gutierrez, GJ; Coulon, V; Bockaert, J; Pin, JP; Fagni, L			The C terminus of the metabotropic glutamate receptor subtypes 2 and 7 specifies the receptor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; CALCIUM-CHANNELS; GAMMA-SUBUNITS; CA2+ CHANNELS; MODULATION; PHOSPHORYLATION; ACTIVATION; EXPRESSION; NEURONS; INHIBITION	There is accumulating evidence that the specificity of the transduction cascades activated by G protein-coupled receptors cannot solely depend on the nature of the coupled G protein. To identify additional structural determinants, we studied two metabotropic glutamate (mGlu) receptors, the mGlu2 and mGlu7 receptors, that are both coupled to G. proteins but are known to affect different effectors in neurons. Thus, the mGlu2 receptor selectively blocks N- and L-type Ca2+ channels via a protein kinase C-independent pathway, whereas the mGlu7 receptor selectively blocks P/Q-type Ca2+ channels via a protein kinase C-dependent pathway, and both effects are pertussis toxin-sensitive. We examined the role of the C-terminal domain of these receptors in this coupling. Chimeras were constructed by exchanging the C terminus of these receptors and transfected into neurons. Different chimeric receptors bearing the C terminus of mGlu7 receptor blocked selectively P/Q-type Ca2+ channels, whereas chimeras bearing the C terminus of mGlu2 receptor selectively blocked N- and L-type Ca2+ channels. These results show that the C terminus of mGlu2 and mGlu7 receptors is a key structural determinant that allows these receptors to select a specific signaling pathway in neurons.	CNRS, UPR 9032, CCIPE, F-34000 Montpellier, France; EMBL, D-69117 Heidelberg, Germany; CNRS, UMR 5535, Inst Genet Mol Montpellier, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Fagni, L (corresponding author), CNRS, UPR 9032, CCIPE, 141 Rue Cardonille, F-34000 Montpellier, France.	fagni@bacchus.montp.inserm.fr	Coulon, Vincent/B-2437-2009; Pin, Jean-Philippe/Y-6668-2019; Gutierrez, Gustavo/AAO-9957-2021; Gutierrez, Gustavo/B-6771-2013; Coulon, Vincent/AFF-7934-2022	Coulon, Vincent/0000-0002-3168-8755; Pin, Jean-Philippe/0000-0002-1423-345X; Gutierrez, Gustavo/0000-0001-8652-972X; Gutierrez, Gustavo/0000-0003-4133-5002; Coulon, Vincent/0000-0002-3168-8755; perroy, julie/0000-0001-6199-0448				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; BOSS V, 1992, J NEUROCHEM, V59, P2340; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; CHAVIS P, 1994, J NEUROSCI, V14, P7067; CHAVIS P, 1995, NEUROPHARMACOLOGY, V34, P929, DOI 10.1016/0028-3908(95)00082-H; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Corti C, 1998, EUR J NEUROSCI, V10, P3629, DOI 10.1046/j.1460-9568.1998.00371.x; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; Dev KK, 2001, TRENDS PHARMACOL SCI, V22, P355, DOI 10.1016/S0165-6147(00)01684-9; Dev KK, 2000, J NEUROSCI, V20, P7252; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Ferraguti F, 1999, EUR J NEUROSCI, V11, P2073, DOI 10.1046/j.1460-9568.1999.00626.x; Flor PJ, 1997, NEUROPHARMACOLOGY, V36, P153, DOI 10.1016/S0028-3908(96)00176-1; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Garcia DE, 1998, J NEUROSCI, V18, P9163; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA SR, 1995, NEURON, V14, P1029, DOI 10.1016/0896-6273(95)90341-0; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Jeong SW, 2000, P NATL ACAD SCI USA, V97, P907, DOI 10.1073/pnas.97.2.907; Jeong SW, 1999, J NEUROSCI, V19, P4755; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; Perroy J, 2000, J NEUROSCI, V20, P7896; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; PREZEAU L, 1994, MOL PHARMACOL, V45, P570; SAHARA Y, 1993, J NEUROSCI, V13, P3041; Shapiro MS, 1999, P NATL ACAD SCI USA, V96, P10899, DOI 10.1073/pnas.96.19.10899; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229	46	23	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45800	45805		10.1074/jbc.M106876200	http://dx.doi.org/10.1074/jbc.M106876200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584003	Green Published, hybrid			2022-12-25	WOS:000172573100041
J	Fujimoto, M; Poe, JC; Hasegawa, M; Tedder, TF				Fujimoto, M; Poe, JC; Hasegawa, M; Tedder, TF			CD19 amplification of B lymphocyte Ca2+ responses - A role for Lyn sequestration in extinguishing negative regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION MOLECULE; CYTOPLASMIC DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED ACTIVATION; CD22-DEFICIENT MICE; PHOSPHATASE 1C; CD22; COMPLEX	B lymphocyte antigen receptor (BCR) signals are regulated by CD19, with BCR-induced intracellular calcium ([Ca2+](i)) responses enhanced by CD19 co-ligation. In this study, CD19 engagement using a dimeric anti-CD19 antibody induced [Ca2+](i) mobilization and significantly enhanced BCR-induced [Ca2+](i) responses without a requirement for CD19/BCR co-ligation. Although simultaneous CD19 and BCR engagement significantly enhanced CD19/Lyn complex formation and [Ca2+](i) responses, downstream tyrosine phosphorylation of CD22 and multiple other cellular proteins was inhibited, as teas SHP1 recruitment to phosphorylated CD22. CD19 overexpression also enhanced BCR-induced [Ca2+](i) responses, but down-regulated tyrosine phosphorylation of CD22 and multiple other cellular proteins following BCR ligation. Because CD19 and Lyn expression are genetically titrated in B cells, CD19 engagement may augment BCR-induced [Ca2+](i) responses by sequestering the available pool of functional Lyn away from downstream negative regulatory proteins such as CD22. Consistent with this, simultaneous CD19 engagement did not further enhance the BCR-induced [Ca2+](i) responses of Lyn- or CD22-deficient B cells. Thus, CD19 recruitment of Lyn may preferentially activate selective signaling pathways downstream of the CD19/Lyn complex to the exclusion of other downstream regulatory and effector pathways. Other receptors may also utilize a similar strategy to regulate kinase availability and downstream intermolecular signaling.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Tedder, TF (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Box 3010, Durham, NC 27710 USA.			Poe, Jonathan/0000-0002-7789-1564; Fujimoto, Manabu/0000-0002-3062-4872	NATIONAL CANCER INSTITUTE [R55CA054464, R01CA054464, R01CA081776] Funding Source: NIH RePORTER; NCI NIH HHS [CA54464, CA81776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT TB, 1990, EUR J IMMUNOL, V20, P1053, DOI 10.1002/eji.1830200516; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; Buhl AM, 1999, J IMMUNOL, V162, P4438; Buhl AM, 1997, IMMUNOL REV, V160, P127, DOI 10.1111/j.1600-065X.1997.tb01033.x; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cherukuri A, 2001, IMMUNITY, V14, P169; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; de Fougerolles AR, 2001, EUR J IMMUNOL, V31, P2189, DOI 10.1002/1521-4141(200107)31:7<2189::AID-IMMU2189>3.0.CO;2-V; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Fujimoto M, 1998, SEMIN IMMUNOL, V10, P267, DOI 10.1006/smim.1998.9999; Hasegawa M, 2001, J IMMUNOL, V167, P3190, DOI 10.4049/jimmunol.167.6.3190; Hasegawa M, 2001, J IMMUNOL, V167, P2469, DOI 10.4049/jimmunol.167.5.2469; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Li XL, 1998, J IMMUNOL, V161, P5901; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; Poe JC, 2000, J BIOL CHEM, V275, P17420, DOI 10.1074/jbc.M001892200; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; RIGLEY KP, 1991, EUR J IMMUNOL, V21, P535, DOI 10.1002/eji.1830210302; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; Sato S, 2000, J IMMUNOL, V165, P6635, DOI 10.4049/jimmunol.165.11.6635; SATO S, 1995, P NATL ACAD SCI USA, V92, P11558, DOI 10.1073/pnas.92.25.11558; Sato S, 1997, J IMMUNOL, V159, P3278; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1997, J IMMUNOL, V158, P4662; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Sato T, 1996, SUPRAMOL CHEM, V7, P157, DOI 10.1080/10610279608035192; Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Somani AK, 2001, J BIOL CHEM, V276, P1938, DOI 10.1074/jbc.M006820200; Tedder TF, 1998, SEMIN IMMUNOL, V10, P259, DOI 10.1006/smim.1998.0118; TEDDER TF, 1989, J IMMUNOL, V143, P712; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; WENG WK, 1994, J BIOL CHEM, V269, P32514; ZHOU LJ, 1991, J IMMUNOL, V147, P1424; ZHOU LJ, 1994, MOL CELL BIOL, V14, P3884, DOI 10.1128/MCB.14.6.3884; Zipfel PA, 2000, J IMMUNOL, V165, P6872, DOI 10.4049/jimmunol.165.12.6872	66	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44820	44827		10.1074/jbc.M107559200	http://dx.doi.org/10.1074/jbc.M107559200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584010	hybrid			2022-12-25	WOS:000172406700066
J	Perez-Ferreiro, CM; Luque, CM; Correas, I				Perez-Ferreiro, CM; Luque, CM; Correas, I			4.1R proteins associate with interphase microtubules in human T cells - A 4.1R constitutive region is involved in tubulin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; MEMBRANE SKELETAL PROTEIN-4.1; SPECTRIN-ACTIN BINDING; ERYTHROCYTE PROTEIN-4.1; STRUCTURAL PROTEIN-4.1; NONERYTHROID ISOFORM; MULTIPLE ISOFORMS; LEUCINE-ZIPPER; DOMAIN; INTERACTS	Red blood cell protein 4.1 (4.1R) is an 80-kDa protein that stabilizes the spectrin-actin network and anchors it to the plasma membrane. To contribute to the characterization of functional roles and partners of specific nonerythroid 4.1R isoforms, we analyzed 4.1R in human T cells and found that endogenous 4.1R was distributed to the microtubule network. Transfection experiments of T cell 4.1R cDNAs in conjunction with confocal microscopy analysis revealed the colocalization of exogenous 4.1R isoforms with the tubulin skeleton. Biochemical analyses using Taxol(R) (paclitaxel)-polymerized microtubules from stably transfected T cells confirmed the association of the exogenous 4.1R proteins with microtubules. Consistent with this, endogenous 4.1R immunoreactive proteins were also detected in the microtubule-containing fraction. In vitro binding assays using glutathione S-transferase-4.1R fusion proteins showed that a constitutive domain of the 4.1R molecule, one that is therefore present in all 4.1R isoforms, is responsible for the association with tubulin. A 22-amino acid sequence comprised in this domain and containing heptad repeats of leucine residues was essential for tubulin binding. Furthermore, ectopic expression of 4.1R in COS-7 cells provoked microtubule disorganization. Our results suggest an involvement of 4.1R in interphase microtubule architecture and support the hypothesis that some 4.1R functional activities are cell type-regulated.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Correas, I (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain.		Luque, Carlos M./Q-6043-2019; Luque, Carlos/H-6810-2015; Correas, Isabel/O-4061-2018	Luque, Carlos M./0000-0002-2993-4152; Luque, Carlos/0000-0002-2993-4152; Correas, Isabel/0000-0002-2286-186X				ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Charrasse S, 1998, J CELL SCI, V111, P1371; COHEN CM, 1982, NATURE, V299, P648, DOI 10.1038/299648a0; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; CORREAS I, 1988, BIOCHEM J, V255, P217; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DELAUNAY J, 1995, CRIT REV ONCOL HEMAT, V19, P79, DOI 10.1016/1040-8428(94)00139-K; DOMINGUEZ JE, 1994, J CELL SCI, V107, P601; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gascard P, 1998, BLOOD, V92, P4404, DOI 10.1182/blood.V92.11.4404.423k50_4404_4414; GRANGER BL, 1984, CELL, V37, P595, DOI 10.1016/0092-8674(84)90390-8; Han BG, 2000, NAT STRUCT BIOL, V7, P871; HORNE WC, 1993, BLOOD, V82, P2558; Hou CL, 2000, BLOOD, V96, P747; HUANG JP, 1993, J BIOL CHEM, V268, P3758; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Kontrogianni-Konstantopoulos A, 2000, MOL BIOL CELL, V11, P3805, DOI 10.1091/mbc.11.11.3805; Kontrogianni-Konstantopoulos A, 2001, J BIOL CHEM, V276, P20679, DOI 10.1074/jbc.M010581200; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallena MJ, 1997, J CELL SCI, V110, P239; Lallena MJ, 1998, J CELL SCI, V111, P1963; LEE JK, 1988, CELL, V55, P807, DOI 10.1016/0092-8674(88)90136-5; Luque CM, 1998, J BIOL CHEM, V273, P11643, DOI 10.1074/jbc.273.19.11643; Luque CM, 1999, P NATL ACAD SCI USA, V96, P14925, DOI 10.1073/pnas.96.26.14925; Luque CM, 2000, J CELL SCI, V113, P2485; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PASTERNACK GR, 1989, P NATL ACAD SCI USA, V86, P9712, DOI 10.1073/pnas.86.24.9712; Pu WT, 1999, MOL CELL BIOL, V19, P4113; Ratner S, 1997, J IMMUNOL, V159, P1063; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Schischmanoff PO, 1997, J BIOL CHEM, V272, P10254, DOI 10.1074/jbc.272.15.10254; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Tang CJC, 1998, BLOOD, V92, P1442, DOI 10.1182/blood.V92.4.1442.416k14_1442_1447; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673	52	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44785	44791		10.1074/jbc.M107369200	http://dx.doi.org/10.1074/jbc.M107369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579097	hybrid			2022-12-25	WOS:000172406700061
J	Jung, MS; Yun, J; Chae, HD; Kim, JM; Kim, SC; Choi, TS; Shin, DY				Jung, MS; Yun, J; Chae, HD; Kim, JM; Kim, SC; Choi, TS; Shin, DY			p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor	ONCOGENE			English	Article						p53; p63; p73; cdk1; cyclin B; NF-Y; senescence	WILD-TYPE P53; TATA-BINDING PROTEIN; MAMMALIAN-CELLS; ONCOGENIC RAS; TUMOR-CELLS; IN-VIVO; PREMATURE SENESCENCE; GENE-EXPRESSION; PROMOTER; REPRESSION	Recent studies have identified two p53 homologues, p63 and p73. They activate p53-responsive promoters and induce apoptosis when overexpressed in certain human tumors. Here, we report that p63, like p53 and p73, induces replicative senescence when expressed in a tetracycline-regulated manner in EJ cells lacking a functional p53. In addition to transcription activation of p53-responsive genes, we found that p63 and p73 repress transcription of the cdk1 and cyclin B genes, both of which are irreversibly repressed in senescent human fibroblast. In transient transfection assay, p63 and p73 repress the cdk1 promoter regardless of the presence of a dominant negative mutant form of p53. Furthermore, we found that DNA binding activity of NF-Y transcription factor, which is essential for transcription of the cdk1 and cyclin B genes and inactivated in senescent fibroblast, is significantly decreased by expression of either of p53, p63, or p73. Since NF-Y binds to many promoters besides the cdk1 and cyclin B promoters, inactivation of NF-Y by p53 family genes may be a general mechanism for transcription repression in replicative senescence.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab Cell Cycle Regulat, Cheonan 330714, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Jongro Gu, Seoul 10300, South Korea; Korea Adv Inst Sci & Technol, Taejon 305333, South Korea; LG Chem LTD, Biotech Res Inst, Taejon 305380, South Korea	Dankook University; Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST); LG Chem	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab Cell Cycle Regulat, Cheonan 330714, South Korea.		Kim, Sun Chang/C-2026-2011; Kim, Sun/GSN-4867-2022; Chae, Hee-Don/D-2620-2011					AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; Chen Kuang Yu, 1997, Frontiers in Bioscience (online), V2, pD417; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Deb D, 1999, INT J ONCOL, V15, P413; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Ferbeyre G, 2000, GENE DEV, V14, P2015; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Good LF, 1996, BIOL SIGNAL, V5, P163; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park M, 2000, CANCER RES, V60, P542; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Shimada A, 1999, CANCER RES, V59, P2781; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	58	79	81	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5818	5825		10.1038/sj.onc.1204748	http://dx.doi.org/10.1038/sj.onc.1204748			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593387				2022-12-25	WOS:000171037200005
J	Ducoux, M; Urbach, S; Baldacci, G; Hubscher, U; Koundrioukoff, S; Christensen, J; Hughes, P				Ducoux, M; Urbach, S; Baldacci, G; Hubscher, U; Koundrioukoff, S; Christensen, J; Hughes, P			Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA replication through a conserved p21(Cip1)-like PCNA-binding motif present in the third subunit of human DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; IN-VITRO; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL INTERACTION; CATALYTIC SUBUNIT; P21; INHIBITOR	The subunit that mediates binding of proliferating cell nuclear antigen (PCNA) to human DNA polymerase delta has not been clearly defined. We show that the third subunit of human DNA polymerase delta, p66, interacts with PCNA through a canonical PCNA-binding sequence located in its C terminus. Conversely, p66 interacts with the domain-interconnecting loop of PCNA, a region previously shown to be important for DNA polymerase delta activity and for binding of the cell cycle inhibitor P21(CiP1). In accordance with this, a peptide containing the PCNA-binding domain of p21(CiP1) inhibited p66 binding to PCNA and the activity of native three-subunit DNA polymerase delta. Furthermore, pull-down assays showed that DNA polymerase delta requires p66 for interaction with PCNA. More importantly, only reconstituted three-subunit DNA polymerase delta displayed PCNA-dependent DNA replication that could be inhibited by the PCNA-binding domain of p21(CiP1). Direct participation of p66 in PCNA-dependent DNA replication in vivo is demonstrated by co-localization of p66 with PCNA and DNA polymerase 8 within DNA replication foci. Finally, in vitro phosphorylation of p66 by cyclin-dependent kinases suggests that p66 activity may be subject to cell cycle-dependent regulation. These results suggest that p66 is the chief mediator of PCNA-dependent DNA synthesis by DNA polymerase delta.	Ctr Univ Orsay, CNRS, UMR 2027, Inst Curie, F-91405 Orsay, France; Univ Zurich Irchel, Dept Vet Biochem, CH-8057 Zurich, Switzerland; Univ Copenhagen, Dept Immunol & Microbiol, DK-2200 Copenhagen, Denmark	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Zurich; University of Copenhagen	Hughes, P (corresponding author), Ctr Univ Orsay, CNRS, UMR 2027, Inst Curie, Batiment 110, F-91405 Orsay, France.	hughes@curie.u-psud.fr		Ducoux-Petit, Manuelle/0000-0002-5346-2044				Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARPER JW, 1993, CELL, V75, P805; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Huang ME, 2000, CURR GENET, V38, P178, DOI 10.1007/s002940000149; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; HUGHES DA, 1992, MOL GEN GENET, V231, P401, DOI 10.1007/BF00292709; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MacNeill SA, 2001, TRENDS BIOCHEM SCI, V26, P16, DOI 10.1016/S0968-0004(00)01709-6; Marians KJ, 1998, J BIOL CHEM, V273, P2452, DOI 10.1074/jbc.273.4.2452; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Perderiset M, 1998, BIOCHEM J, V335, P581, DOI 10.1042/bj3350581; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Roos G, 1996, EXP CELL RES, V226, P208, DOI 10.1006/excr.1996.0220; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Suzuki S, 2000, Nagoya J Med Sci, V63, P99; Tratner I, 1997, BIOCHEM BIOPH RES CO, V231, P321, DOI 10.1006/bbrc.1997.6082; Waga S, 2001, P NATL ACAD SCI USA, V98, P4978, DOI 10.1073/pnas.081088798; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	53	84	88	15	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49258	49266		10.1074/jbc.M106990200	http://dx.doi.org/10.1074/jbc.M106990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11595739	hybrid, Green Accepted			2022-12-25	WOS:000173922100084
J	Shimizu, N; Guo, J; Gardella, TJ				Shimizu, N; Guo, J; Gardella, TJ			Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL REGION; CROSS-LINKING; PROTEIN; FRAGMENTS; SITE; MUTAGENESIS; SELECTIVITY; PEPTIDES; RESIDUES; CONTACT	The N-terminal portion of parathyroid hormone is critical for PTH-1 receptor (P1R) activation and has been postulated to be a-helical when bound to the receptor. We investigated whether substitution of the sterically hindered and helix-promoting amino acid a-aminoisobutyric acid (Aib) in N-terminal PTH oligopeptides would improve the capacity of the peptide to activate the P1R. Analysis of the effects of individual Aib substitutions at each position in [Ala 3,12 Gln(10), Har(11),Trp(14)]PTH(1-14)NH2, ([M]PTH(1-14)) on cAMP-stimulating potency in HKRK-B28 cells revealed that Aib at most positions diminished potency; however, Aib at positions 1 and 3 enhanced potency. Thus [Aib(1,3)M]PTH(1-14) was similar to100-fold more potent than [M]PTH(1-14) (EC50 = 1.1 +/- 0.1 and 100 +/- 20 rim, respectively), similar to100,000-fold more potent than native PTH(1-14), and 2-fold more potent than PTH(1-34). The shorter peptide, [Aib(1,) M-3]PTH(1-11), was also fully efficacious and 1,000-fold more potent than [M]PTH(1-11) (EC50 4 +/- 1 nM versus 3 +/- 1 mum). In cAMP stimulation assays performed in COS-7 cells expressing P1R-delNt, a receptor that lacks most of the N-terminal extracellular domain, [Aib(1,3)M]PTH(1-14) was 50-fold more potent than [M]PTH(1-14) (EC50 = 0.7 +/- 0.2 versus 40 +/- 2 nm) and 1,000-fold more potent than PTH(1-34) (EC50 = 700 rim). [Aib(1,3),M]PTH(1-14), but not PTH(1-34), inhibited the binding of I-125[Aib(1),(3),Nle(8),Gln(10),Har(11),Ala(12) Trp(14),Arg(19),Tyr(21)]PTH(1-21)NH2 to hP1R-delNt (IC50 = 1,600 200 nm). The Aib(1),(3) substitutions in otherwise unmodified PTH(1-34) enhanced potency and binding affinity on hP1R-delNt, but they had no effect for this peptide on hP1R-WT. Circular dichroism spectroscopy demonstrated that the Aib-1,3 substitutions increased helicity in all peptides tested, including PTH(1-34). The overall data thus suggest that the N-terminal residues of PTH are intrinsically disordered but become conformationally constrained, possibly as an a-helix, upon interaction with the activation domain of the PTH-1 receptor.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.	Gardella@helix.MGH.Harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Barden JA, 1996, BIOCHEM BIOPH RES CO, V220, P431, DOI 10.1006/bbrc.1996.0390; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Bowen WP, 1995, TRENDS PHARMACOL SCI, V16, P413, DOI 10.1016/S0165-6147(00)89091-4; Carter PH, 1999, J BIOL CHEM, V274, P31955, DOI 10.1074/jbc.274.45.31955; Carter PH, 2001, BBA-MOL CELL RES, V1538, P290, DOI 10.1016/S0167-4889(01)00080-5; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; Chen ZG, 2000, BIOCHEMISTRY-US, V39, P12766, DOI 10.1021/bi000882e; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; FUKAYAMA S, 1994, J CELL PHYSIOL, V158, P391, DOI 10.1002/jcp.1041580302; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; Gronwald W, 1996, BIOL CHEM H-S, V377, P175, DOI 10.1515/bchm3.1996.377.3.175; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; Inooka H, 2001, NAT STRUCT BIOL, V8, P161, DOI 10.1038/84159; Jin L, 2000, J BIOL CHEM, V275, P27238; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; Kaul R, 1999, BIOORGAN MED CHEM, V7, P105, DOI 10.1016/S0968-0896(98)00221-1; Kronenberg HM, 1998, RECENT PROG HORM RES, V53, P283; KRONENBERG HM, 1993, HDB EXPT PHARM, P185; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Marx UC, 1998, J BIOL CHEM, V273, P4308, DOI 10.1074/jbc.273.8.4308; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; Marx UC, 2000, BIOCHEM BIOPH RES CO, V267, P213, DOI 10.1006/bbrc.1999.1958; NEUGEBAUER W, 1992, BIOCHEMISTRY-US, V31, P2056, DOI 10.1021/bi00122a023; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; PRASAD BVV, 1979, BIOPOLYMERS, V18, P1635, DOI 10.1002/bip.1979.360180704; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; SARGENT DF, 1986, P NATL ACAD SCI USA, V83, P5774, DOI 10.1073/pnas.83.16.5774; Schievano E, 2000, BIOPOLYMERS, V54, P429, DOI 10.1002/1097-0282(200011)54:6<429::AID-BIP70>3.0.CO;2-W; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Shimizu M, 2000, J BIOL CHEM, V275, P19456, DOI 10.1074/jbc.M001596200; Shimizu M, 2001, ENDOCRINOLOGY, V142, P3068, DOI 10.1210/en.142.7.3068; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; Takasu H, 1999, J BONE MINER RES, V14, P11, DOI 10.1359/jbmr.1999.14.1.11; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; YANG JT, 1986, METHOD ENZYMOL, V130, P208	46	77	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49003	49012		10.1074/jbc.M106827200	http://dx.doi.org/10.1074/jbc.M106827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11604398	hybrid			2022-12-25	WOS:000173922100052
J	Vassiliou, G; Benoist, F; Lau, P; Kavaslar, GN; McPherson, R				Vassiliou, G; Benoist, F; Lau, P; Kavaslar, GN; McPherson, R			The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MOUSE ADRENOCORTICAL-CELLS; LIPASE IN-VITRO; APOPROTEIN-A-I; SCAVENGER RECEPTOR; CLASS-B; APOLIPOPROTEIN-E; HEPATIC LIPASE; ALPHA-2-MACROGLOBULIN RECEPTOR; SURFACE PROTEOGLYCANS	The concept that selective transfer of high density lipoprotein (HDL)-derived cholesteryl esters (CE) does not require lipoprotein internalization has been challenged recently by evidence that implicates HDL recycling during the selective uptake process. This has prompted us to examine the role of the low density lipoprotein receptor-related protein (LRP) in selective uptake. LRP is an endocytic receptor for lipoprotein lipase (LpL) and apolipoprotein E (apoE) ligands that are able to mediate selective uptake. We report that molecules that interfere with ligand binding to LRP, such as the receptor-associated protein (RAP), suramin, alpha(2)-macroglobulin, or lactoferrin, inhibit HDL-CE selective uptake by human primary adipocytes and SW872 liposarcoma cells by 35-50%. This partial inhibition of selective uptake from total HDL was not due to preferential inhibition of the HDL3 or HDL3 subfractions. Selective uptake by the scavenger receptor BI was not inhibited by RAP, excluding its involvement. Furthermore, in SW872 cells in which LRP was reduced to 14% of control levels by stable antisense expression, selective uptake was attenuated by at least 33%, confirming a role for LRP in this process. RAP, alpha(2)-macroglobulin, lactoferrin, and suramin (individually or in paired combinations) also attenuated selective uptake of HDL-CE by primary human adipocytes by about 40%. On the other hand, human skin fibroblasts express LRP abundantly but lack the capacity for selective uptake, demonstrating that other molecules are required. In SW872 cells, exogenous apoE or LpL can facilitate selective uptake but only the apoE-enhanced uptake can be inhibited by RA-P, implicating apoE as a likely co-mediator. We discuss the possible mechanisms by which the endocytic receptor, LRP, can mediate selective uptake.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; University of Ottawa Heart Institute	Vassiliou, G (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4E9, Canada.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Benoist F, 1997, J BIOL CHEM, V272, P23572, DOI 10.1074/jbc.272.38.23572; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; Collet X, 1999, J LIPID RES, V40, P1185; DESPRES JP, 1988, AM J PHYSIOL, V254, pE667, DOI 10.1152/ajpendo.1988.254.5.E667; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Fazio S, 2000, TRENDS CARDIOVAS MED, V10, P23, DOI 10.1016/S1050-1738(00)00033-5; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; Gliemann J, 1998, BIOL CHEM, V379, P951; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; GREEN SR, 1991, J LIPID RES, V32, P667; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HERZ J, 1991, J BIOL CHEM, V266, P21232; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; JI ZS, 1993, J BIOL CHEM, V268, P10160; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MISRA UK, 1994, J BIOL CHEM, V269, P12541; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RALL SC, 1986, METHOD ENZYMOL, V128, P273; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RINNINGER F, 1988, J LIPID RES, V29, P1179; Rinninger F, 1998, ATHEROSCLEROSIS, V141, P273, DOI 10.1016/S0021-9150(98)00181-6; RINNINGER F, 1987, J LIPID RES, V28, P1313; Rinninger F, 1998, J LIPID RES, V39, P1335; RISKE F, 1991, J BIOL CHEM, V266, P11245; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Schorsch F, 1997, FEBS LETT, V414, P507, DOI 10.1016/S0014-5793(97)01061-2; Seo T, 2000, J BIOL CHEM, V275, P30355, DOI 10.1074/jbc.M910327199; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vassiliou G, 1997, EUR J BIOCHEM, V250, P320, DOI 10.1111/j.1432-1033.1997.0320a.x; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	61	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48823	48830		10.1074/jbc.M103954200	http://dx.doi.org/10.1074/jbc.M103954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11604390	hybrid			2022-12-25	WOS:000173922100028
J	Jian, XY; Clark, WA; Kowalak, J; Markey, SP; Simonds, WF; Northup, JK				Jian, XY; Clark, WA; Kowalak, J; Markey, SP; Simonds, WF; Northup, JK			GB gamma affinity for bovine rhodopsin is determined by the carboxyl-terminal sequences of the gamma subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; G-PROTEIN; ALPHA(2A)-ADRENERGIC RECEPTOR; ALPHA-SUBUNITS; INTRACELLULAR LOOP; SF9 CELLS; BINDING; TRANSDUCIN; MEMBRANES; PRENYLATION	Two native beta gamma dimers, beta (1)gamma (1), and beta (1)gamma (2), display very different affinities for receptors. Since these gamma subunits differ in both primary structure and isoprenoid modification, we examined the relative contributions of each to G beta gamma interaction with receptors. We constructed baculoviruses encoding gamma (1) and gamma (2) subunits with altered CAAX (where A is an aliphatic amino acid) motifs to direct alternate or no prenylation of they chains and a set of gamma (1) and gamma (2) chimeras with the gamma (2) CAAX motif at the carboxyl terminus. All they constructs coexpressed with beta (1) in Sf9 cells yielded beta (1)gamma dimers, which were purified to near homogeneity, and their affinities for receptors and Ga were quantitatively determined. Whereas alteration of the isoprenoid of gamma (1) from farnesyl to geranylgeranyl and of gamma (2) from geranylgeranyl to farnesyl had no impact on the affinities of beta (1)gamma dimers for Gat, the non-prenylated beta (1)gamma (2) dimer had significantly diminished affinity. Altered prenylation resulted in a <2-fold decrease in affinity of the beta (1)gamma (2) dimer for rhodopsin and a <3-fold change for the beta (1)gamma (1), dimer. In each case with identical isoprenylation, the beta (1)gamma (2) dimer displayed significantly greater affinity for rhodopsin compared with the beta (1)gamma (1), dimer. Furthermore, dimers containing chimeric G gamma chains with identical geranylgeranyl modification displayed rhodopsin affinities largely determined by the carboxyl-terminal one-third of the protein. These results indicate that isoprenoid modification of the G gamma subunit is essential for binding to both G alpha and receptors. The isoprenoid type influences the binding affinity for receptors, but not for G alpha. Finally, the primary structure of the G gamma subunit provides a major contribution to receptor binding of G beta gamma, with the carboxyl-terminal sequence conferring receptor selectivity.	NIDCD, Lab Cellular Biol, NIH, Bethesda, MD 20892 USA; NIMH, Lab Neurotoxicol, NIH, Bethesda, MD 20892 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Northup, JK (corresponding author), NIDCD, Lab Cellular Biol, NIH, Rm 2A-11,5 Res Ct, Rockville, MD 20850 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043304, Z01DK043304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH000274, Z01MH000274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000047, Z01DC000047] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ASANO T, 1993, J BIOL CHEM, V268, P20512; Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHABRE O, 1994, J BIOL CHEM, V269, P5730; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Clark WA, 2001, BIOCHEM J, V358, P389, DOI 10.1042/0264-6021:3580389; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; KALMAN VK, 1995, J BIOL CHEM, V270, P14835, DOI 10.1074/jbc.270.24.14835; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; McIntire WE, 2001, J BIOL CHEM, V276, P15801, DOI 10.1074/jbc.M011233200; MITCHELL J, 1992, P NATL ACAD SCI USA, V89, P8933, DOI 10.1073/pnas.89.19.8933; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Nasman J, 1997, J BIOL CHEM, V272, P9703; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; REMAURY A, 1993, BIOCHEM J, V292, P283, DOI 10.1042/bj2920283; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; Rosenberg SJ, 1998, CELL SIGNAL, V10, P131, DOI 10.1016/S0898-6568(97)00117-4; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Small KM, 2000, J BIOL CHEM, V275, P38518, DOI 10.1074/jbc.M004550200; STRULOVICI B, 1984, SCIENCE, V225, P837, DOI 10.1126/science.6089331; Taylor JM, 1996, J BIOL CHEM, V271, P3336; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	45	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48518	48525		10.1074/jbc.M107129200	http://dx.doi.org/10.1074/jbc.M107129200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602594	hybrid			2022-12-25	WOS:000172927000105
J	Bag, J				Bag, J			Feedback inhibition of poly(A)-binding protein mRNA translation - A possible mechanism of translation arrest by stalled 40 S ribosomal subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYADENYLATE-BINDING-PROTEIN; MESSENGER-RNA; XENOPUS-LAEVIS; IN-VITRO; DEPENDENT TRANSLATION; EXPRESSION; INITIATION; YEAST; IDENTIFICATION; SEQUENCE	An adenine-rich cis element at the 5'-untranslated region (UTR) of Pabp1 mRNA is able to inhibit translation of its own mRNA. Similar inhibition of translation of a reporter beta -galactosidase mRNA is observed when the adenine-rich auto regulatory sequence (ARS) is placed within the 5'-UTR of this mRNA. For this translational control the distance of the ARS from the 5' cap is not important. However, it determines the number of 40 S ribosomal subunits bound to the translationally arrested mRNA. Inhibition of mRNA translation by this regulatory sequence occurs at the step of joining of the 60 S ribosomal subunit to the pre-initiation complex. Translational arrest of the ARS containing mRNA in a rabbit reticulocyte lysate cell-free system in the presence of exogenous Pabp1 protects the 5'-flanking region of the ARS from nuclease digestion. This protection depends on the binding of the 40 S ribosomal subunit to the mRNA. The size and the sequence of the nucleotide-protected fragment depends on the location of the ARS within the 5'-UTR. When the ARS is located at a distance of about 78 nucleotides from the 5' cap, a 40-nucleotide-long region adjacent to the ARS is protected. On the other hand, when the ARS is moved further away from the 5' cap to a distance of similar to 267 nucleotides, a 100-nucleotide- long region adjacent to the ARS is protected from nuclease digestion. Nuclease protection is attributed to the presence of one or more stalled 40 S ribosomal subunits near the Pabp1-bound ARS.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Bag, J (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	jbag@uoguelph.ca						ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ADAMOU J, 1992, EUR J BIOCHEM, V209, P803, DOI 10.1111/j.1432-1033.1992.tb17351.x; Amrani N, 1997, MOL CELL BIOL, V17, P3694, DOI 10.1128/MCB.17.7.3694; Bag J, 1996, EUR J BIOCHEM, V237, P143, DOI 10.1111/j.1432-1033.1996.0143n.x; BAG J, 1991, TRANSLATION EUKARYOT, P71; BELOSTOTSKY DA, 1993, P NATL ACAD SCI USA, V90, P6686, DOI 10.1073/pnas.90.14.6686; BERGER LC, 1992, EUR J BIOCHEM, V204, P733, DOI 10.1111/j.1432-1033.1992.tb16688.x; BERGER LC, 1992, BIOCHEM CELL BIOL, V70, P770, DOI 10.1139/o92-117; Biberman Y, 1999, FEBS LETT, V456, P357, DOI 10.1016/S0014-5793(99)00983-7; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Cao JH, 1996, MOL CELL BIOL, V16, P603; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CARDINATI B, 1993, NUCLEIC ACIDS RES, V21, P2300; Cherkasova V, 2000, J MOL BIOL, V300, P433, DOI 10.1006/jmbi.2000.3880; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Deardorff JA, 1997, J MOL BIOL, V269, P67, DOI 10.1006/jmbi.1997.1013; Deo RC, 2001, P NATL ACAD SCI USA, V98, P4414, DOI 10.1073/pnas.071552198; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ERNSTEIN P, 1989, MOL CELL BIOL, V9, P659; Fraser CS, 1999, J BIOL CHEM, V274, P196, DOI 10.1074/jbc.274.1.196; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; GREENBERG JR, 1981, P NATL ACAD SCI-BIOL, V78, P2923, DOI 10.1073/pnas.78.5.2923; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; KASPAR RL, 1992, J BIOL CHEM, V267, P508; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; Kolupaeva VG, 2000, J VIROL, V74, P6242, DOI 10.1128/JVI.74.14.6242-6250.2000; Korner CG, 1997, J BIOL CHEM, V272, P10448; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; MAUNDRELL K, 1983, J BIOL CHEM, V258, P1387; MERCER WE, 1989, EXP CELL RES, V181, P531, DOI 10.1016/0014-4827(89)90109-2; Mohr E, 2001, P NATL ACAD SCI USA, V98, P7072, DOI 10.1073/pnas.111146598; NETO OPD, 1995, NUCLEIC ACIDS RES, V23, P2198, DOI 10.1093/nar/23.12.2198; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; Pellizzoni L, 1996, J MOL BIOL, V259, P904, DOI 10.1006/jmbi.1996.0368; Pellizzoni L, 1997, J MOL BIOL, V267, P264, DOI 10.1006/jmbi.1996.0888; Pellizzoni L, 1998, J MOL BIOL, V281, P593, DOI 10.1006/jmbi.1998.1961; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SEVERSON WE, 1995, EUR J BIOCHEM, V229, P426, DOI 10.1111/j.1432-1033.1995.tb20483.x; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; ULRICH SJ, 1986, EXP CELL RES, V178, P273; VAZQUEZ D, 1979, INHIBITIONS PROTEIN, P10; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; Wu J, 1998, J BIOL CHEM, V273, P34535, DOI 10.1074/jbc.273.51.34535; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	64	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47352	47360		10.1074/jbc.M107676200	http://dx.doi.org/10.1074/jbc.M107676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590158	hybrid			2022-12-25	WOS:000172768500090
J	Klezovitch, O; Edelstein, C; Scanu, AM				Klezovitch, O; Edelstein, C; Scanu, AM			Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a) Evidence for a critical involvement of elements in its C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-1; HUMAN ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; LP(A) LIPOPROTEIN; RISK FACTOR; PLASMINOGEN-ACTIVATOR; GENE-EXPRESSION; ATHEROSCLEROSIS; PROTEIN; FRAGMENTS	In the vessel wall, macrophages are among the cells that upon activation contribute to the atherosclerotic process. Low density lipoproteins (LDL) can mediate this activation but only after enzymatic or oxidative modification. Lipoprotein(a) (Lp(a)) is an LDL variant that has been shown to have an atherogenic potential by no clearly established mechanisms. In the present study we examined whether native Lp(a) can activate macrophages and, if so, identify the structural elements involved in this action. For this purpose, we utilized human THP-1 macrophages, prepared by treating THP-1 monocytes with phorbol ester, and we exposed them to Lp(a) and its two derivatives, apo(a)-free LDL (Lp(a-)) and free apo(a). We also studied apo(a) fragments, F1 (N terminus) and F2 (C terminus) and subfragments thereof, obtained by leukocyte elastase digestion. By Northern blot analyses, Lp(a), but not Lp(a-), caused up to a 12-fold increase in interleukin 8 (IL-8) mRNA as compared with untreated cells. Free apo(a) also induced the production of IL-8 mRNA; however, the effect was 3-4-fold higher than that of Lp (a). The increase in mRNA was associated with the accumulation of IL-8 protein in the culture medium. F1 had only a minimal effect, whereas F2 was 1.5-2-fold more potent than apo(a), an activity mostly contained in the Kringle V-protease region. A monoclonal antibody specific for Kringle V inhibited the apo(a)-mediated effect on IL-8. We conclude that Lp(a) via elements contained in the C-terminal domain of apo(a) causes in THP-1 macrophages an increased production of IL-8, a chemokine with pro-inflammatory properties, an event that may be relevant to the process of atherosclerosis.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Scanu, AM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC5041, Chicago, IL 60637 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577, R01HL063115] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63115, HL 18577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen S, 1998, FASEB J, V12, P1765, DOI 10.1096/fasebj.12.15.1765; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BANDELLO F, 1994, THROMB HAEMOSTASIS, V72, P39; Berge KE, 1997, CLIN GENET, V52, P314; Boisvert WA, 2000, IMMUNOL RES, V21, P129, DOI 10.1385/IR:21:2-3:129; BOLGER C, 1995, NEUROSURGERY, V37, P241, DOI 10.1227/00006123-199508000-00008; BUDDE T, 1994, ARTERIOSCLER THROMB, V14, P1730, DOI 10.1161/01.ATV.14.11.1730; COLDITZ IG, 1990, J LEUKOCYTE BIOL, V48, P129, DOI 10.1002/jlb.48.2.129; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 1995, BIOCHEMISTRY-US, V34, P16483, DOI 10.1021/bi00050a032; Edelstein C, 1997, J BIOL CHEM, V272, P11079; Edelstein C, 1999, J BIOL CHEM, V274, P10019, DOI 10.1074/jbc.274.15.10019; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; Fortunato JE, 2000, J VASC SURG, V32, P555, DOI 10.1067/mva.2000.107757; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Grenett HE, 1998, ARTERIOSCL THROM VAS, V18, P1803, DOI 10.1161/01.ATV.18.11.1803; GROVES P, 1993, BRIT HEART J, V69, P26; Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786; Klezovitch O, 1996, J CLIN INVEST, V98, P185, DOI 10.1172/JCI118765; Klezovitch O, 1998, J BIOL CHEM, V273, P23856, DOI 10.1074/jbc.273.37.23856; KOCH AE, 1992, SCIENCE, V268, P447; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEVIN EG, 1994, ARTERIOSCLER THROMB, V14, P438, DOI 10.1161/01.ATV.14.3.438; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; NAGAYAMA M, 1994, STROKE, V25, P74, DOI 10.1161/01.STR.25.1.74; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; SATTLER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P65, DOI 10.1016/0005-2760(91)90251-C; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; SCHMIDT J, 1994, IMMUNOPHARMACOLOGY, V27, P173, DOI 10.1016/0162-3109(94)90013-2; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VALENTINE RJ, 1994, ARCH INTERN MED, V154, P801, DOI 10.1001/archinte.154.7.801; VIA DP, 1989, J LIPID RES, V30, P1515; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; WILSON L, 1993, FEBS LETT, V325, P295, DOI 10.1016/0014-5793(93)81092-E; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1; YUE TL, 1993, EUR J PHARMACOL, V240, P81	45	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46864	46869		10.1074/jbc.M107943200	http://dx.doi.org/10.1074/jbc.M107943200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591715	hybrid			2022-12-25	WOS:000172768500027
J	Morrison, CJ; Butler, GS; Bigg, HF; Roberts, CR; Soloway, PD; Overall, CM				Morrison, CJ; Butler, GS; Bigg, HF; Roberts, CR; Soloway, PD; Overall, CM			Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-3 MATRIX METALLOPROTEINASES; HEMOPEXIN-LIKE DOMAIN; C-TERMINAL DOMAIN; TISSUE INHIBITOR; PROGELATINASE-A; 72-KDA GELATINASE; CATALYTIC DOMAIN; EFFICIENT ACTIVATION; BRAIN-TUMORS; CDNA LIBRARY	The role of membrane-type (AIT) 2-matrix metalloproteinase (MMP) in the cellular activation of MMP-2 and the tissue inhibitor of matrix metalloproteinase (TIMP) requirements for this process have not been clearly established. To address these issues a TIMP-2-free cell line derived from a Timp2-/- mouse was transfected for stable cell surface expression of hMT2-MMP. Untransfected cells did not activate endogenous or exogenous TIMP-2-free MMP-2 unless both TIMP-2 and concanavalin A (ConA) were added. Transfected cells expressing hMT2-MMP efficiently activated both endogenous and exogenous MMP-2 (within 4 h) via the 68-kDa intermediate in the absence of TIMP-2 and ConA. In contrast, activation of MMP-2 by Timp2-/- cells expressing recombinant hMT1-MMP occurred more slowly (12 h) and required the addition of 0.3-27 nM TIMP-2. Addition of TIMP-2 or TIMP-4 did not enhance MMP-2 activation by MT2-MMP at any concentration tested; furthermore, activation was inhibited by both TIMPs at concentrations >9 ml, consistent with the similar association rate constants (k(on)) calculated for the binding of TIMP-4 and TIMP-2 to MT2-MMP (3.56 x 10(5) M-1 s(-1) and 6.52 x 10(5) M-1 s(-1), respectively). MT2-MMP-mediated activation involved cell surface association of the MMP-2 in a hemopexin carboxyl-terminal domain (C domain)-dependent manner: Exogenous MMP-2 hemopexin C domain blocked activation, and cells expressing hMT2-MMP did not bind or activate a truncated form of MMP-2 lacking the hemopexin C domain. These studies demonstrate the existence of an alternative TIMP-2-independent pathway for MMP-2 activation involving MT2-MMP, which may be important in mediating MMP-2 activation in specific tissues or pathologies where MT2-MMP is expressed.	Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY USA	University of British Columbia; University of British Columbia; Roswell Park Cancer Institute	Overall, CM (corresponding author), Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, 2199 Wesbrook Mall,JB Macdonald Bldg, Vancouver, BC V6T 1Z3, Canada.		Butler, Georgina/GQP-7553-2022; Soloway, Paul/T-8243-2019	Butler, Georgina/0000-0003-1172-1578; Soloway, Paul/0000-0003-1967-0437				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kinoshita T, 1996, CANCER RES, V56, P2535; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Llano E, 1999, CANCER RES, V59, P2570; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Mitas M, 2001, INT J CANCER, V93, P162, DOI 10.1002/ijc.1312; Mitsiades N, 2001, CANCER RES, V61, P577; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morrison CJ, 1997, BIOTECHNOL BIOENG, V53, P594, DOI 10.1002/(SICI)1097-0290(19970320)53:6<594::AID-BIT7>3.3.CO;2-M; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; OVERALL CM, 1987, J DENT RES, V66, P1271, DOI 10.1177/00220345870660071201; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Ueno H, 1997, CANCER RES, V57, P2055; Velasco G, 2000, CANCER RES, V60, P877; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	60	152	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47402	47410		10.1074/jbc.M108643200	http://dx.doi.org/10.1074/jbc.M108643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584019	hybrid			2022-12-25	WOS:000172768500096
J	Santhoshkumar, P; Sharma, KK				Santhoshkumar, P; Sharma, KK			Phe(71) is essential for chaperone-like function in alpha A-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SITE-DIRECTED MUTATIONS; B-CRYSTALLIN; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; QUATERNARY STRUCTURE; BINDING-SITES; DOMAIN; IDENTIFICATION; SECONDARY; FAMILY	Experiments with mini-alphaA-crystallin (KFVIFLD. VKHFSPEDLTVK) showed that Phe(71) in alphaA-crystallin could be essential for the chaperone-like action of the protein (Sharma, K. K., Kumar, R. S., Kumar, G. S., and Quinn, P. T. (2000) J. BioL Chem. 275, 3767-3771). In the present study we replaced Phe(71) in rat alphaA-crystallin with Gly by site-directed mutagenesis and then compared the structural and functional properties of the mutant protein with the wild-type protein. There were no differences in molecular size or intrinsic tryptophan fluorescence between the proteins. However, 1,1'-bi(4-anilino)naphthalene-5,5'-disulfonic acid interaction indicated a higher hydrophobicity for the mutant protein. Both wild-type and mutant proteins displayed similar secondary structure during far UV CD experiments, Near UV CD signal showed a slight difference in the tertiary structure around the 285-295 region for the two proteins. The mutant protein was totally inactive in suppressing the aggregation of reduced insulin, heat-denatured citrate synthase, and alcohol dehydrogenase. However, a marginal suppression of beta (L)-crystallin aggregation was observed when mutant alphaA-crystallin was included. These results suggest that Phe (71) contributes to the chaperone-like action of alphaA-crystallin. Therefore we conclude that the 70-88-region in alphaA-crystallin, identified by us earlier, is the functional chaperone site in alphaA-crystallin.	Univ Missouri, Mason Eye Inst, Dept Ophthalmol, Columbia, MO 65212 USA; Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sharma, KK (corresponding author), Univ Missouri, Mason Eye Inst, Dept Ophthalmol, 1 Hosp Dr, Columbia, MO 65212 USA.	Sharmak@health.missouri.edu	Santhoshkumar, Puttur/G-1798-2010	Santhoshkumar, Puttur/0000-0002-6897-7278	NEI NIH HHS [EY 11981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agius MA, 1999, ACTA NEUROL SCAND, V100, P139; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; AUGUSTEYN RC, 1992, EXP EYE RES, V54, P219, DOI 10.1016/S0014-4835(05)80211-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bhattacharyya J, 2001, J PEPT RES, V57, P428, DOI 10.1034/j.1399-3011.2001.00871.x; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Celet B, 2000, J NEUROL, V247, P935, DOI 10.1007/s004150070049; Cobb BA, 2000, BIOCHEMISTRY-US, V39, P15791, DOI 10.1021/bi001453j; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Derham BK, 2001, EUR J BIOCHEM, V268, P713, DOI 10.1046/j.1432-1327.2001.01929.x; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; GOPALAKRISHNAN S, 1994, INVEST OPHTH VIS SCI, V35, P382; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HARDING JJ, 1984, EYE, P207; Hepburne-Scott HW, 1999, MOL VIS, V5; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, INT J BIOL MACROMOL, V22, P263, DOI 10.1016/S0141-8130(98)00024-5; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P525, DOI 10.1073/pnas.79.2.525; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; Kumar LVS, 2000, J BIOL CHEM, V275, P22009, DOI 10.1074/jbc.M003307200; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Lee JS, 1997, BIOCHEM BIOPH RES CO, V237, P277, DOI 10.1006/bbrc.1997.7131; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Santhoshkumar P, 2001, MOL VIS, V7, P172; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Shroff NP, 2000, BIOCHEMISTRY-US, V39, P1420, DOI 10.1021/bi991656b; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; Srinivas V, 2001, MOL VIS, V7, P114; TAKEMOTO L, 1994, ARCH BIOCHEM BIOPHYS, V315, P133, DOI 10.1006/abbi.1994.1481; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; van Rijk AF, 2000, FEBS LETT, V480, P79, DOI 10.1016/S0014-5793(00)01908-6; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; WANG KY, 1994, J BIOL CHEM, V269, P13601	53	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47094	47099		10.1074/jbc.M107737200	http://dx.doi.org/10.1074/jbc.M107737200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598124	hybrid			2022-12-25	WOS:000172768500057
J	Wurmbach, E; Yuen, T; Ebersole, BJ; Sealfon, SC				Wurmbach, E; Yuen, T; Ebersole, BJ; Sealfon, SC			Gonadotropin-releasing hormone receptor-coupled gene network organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; BETA-GENE; GNRH RECEPTOR; FOS PROTEIN; EXPRESSION; ACTIVATION; PROMOTER; TRANSCRIPTION; MICROARRAYS; DIVERGENT	An early gene cDNA microarray was developed to study genes that are regulated immediately following gonadotropin-releasing hormone (GnRH) receptor activation. 956 selected candidate genes were printed in triplicate, a t statistic-based regulation algorithm was used for data analysis, and the response to GnRH in a time course from 1 to 6 h was determined. Measurements were highly reproducible within arrays, between arrays, and between experiments. Accuracy and algorithm reliability were established by real-time polymerase chain reaction assays of 60 genes. Gene changes ranging from 1.3- to 31 -fold on the microarray were confirmed by real-time polymerase chain reaction. Many of the genes were found to be highly regulated. The regulated genes identified were all elevated at 1 h of treatment and returned nearly or completely to baseline levels of expression by 3 h of treatment. This broad, robust and transient transcriptional response to constant GnRH exposure includes modulators of signal transduction (e.g. Rgs2 and I kappaB), cytoskeletal proteins (e.g. gamma -actin), and transcription factors (e.g. c-Fos, Egr1, and LRG21). The interplay of the activators, repressors, and feedback inhibitors identified embodies a combinatorial code to direct the activity of specific downstream secondary genes.	Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Sealfon, SC (corresponding author), Mt Sinai Sch Med, Dept Neurol, Box 1137, New York, NY 10029 USA.	Stuart.Sealfon@mssm.edu		SEALFON, Stuart/0000-0001-5791-1217	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046943] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 46943] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas MM, 2000, NEUROENDOCRINOLOGY, V71, P292, DOI 10.1159/000054549; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Box G.E.P., 1978, STAT EXPT INTRO DESI, P165; Cheng KW, 2000, ENDOCRINOLOGY, V141, P3611, DOI 10.1210/en.141.10.3611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALKIN AC, 1989, ENDOCRINOLOGY, V125, P917, DOI 10.1210/endo-125-2-917; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; Klein C, 2000, ANN NEUROL, V47, P369, DOI 10.1002/1531-8249(200003)47:3<369::AID-ANA14>3.3.CO;2-0; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; Taylor E, 2001, BIOTECHNIQUES, V31, P62, DOI 10.2144/01311st01; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Venables W., 2013, MODERN APPL STAT S, V53, P86; Weck J, 2000, MOL ENDOCRINOL, V14, P472, DOI 10.1210/me.14.4.472; WEISS J, 1990, MOL ENDOCRINOL, V4, P557, DOI 10.1210/mend-4-4-557; Yokoi T, 2000, J BIOL CHEM, V275, P21639, DOI 10.1074/jbc.M910252199; Yuen T, 2002, METHOD ENZYMOL, V345, P556	33	151	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47195	47201		10.1074/jbc.M108716200	http://dx.doi.org/10.1074/jbc.M108716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581274	hybrid			2022-12-25	WOS:000172768500071
J	Bilej, M; De Baetselier, P; Van Dijck, E; Stijlemans, B; Colige, A; Beschin, A				Bilej, M; De Baetselier, P; Van Dijck, E; Stijlemans, B; Colige, A; Beschin, A			Distinct carbohydrate recognition domains of an invertebrate defense molecule recognize Gram-negative and Gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPHENOLOXIDASE-ACTIVATING SYSTEM; EISENIA-FOETIDA; BOMBYX-MORI; BINDING PROTEIN; CELOMIC FLUID; LUMBRICUS-TERRESTRIS; GLUCAN-BINDING; CDNA CLONING; PEPTIDOGLYCAN; SILKWORM	Coelomic fluid of Eisenia foetida earthworms (Oligochaeta, Annelida) contains a 42-kDa defense molecule named CCF for coelomic cytolytic factor. By binding microbial antigens, namely the O-antigen of lipopolysaccharide (LPS), beta -1,3-glucans, or N,N'-diacetylchitobiose present, respectively, on Gram-negative bacteria or yeast cell walls, CCF triggers the prophenoloxidase activating pathway. We report that CCF recognizes lysozyme-predigested Gram-positive bacteria or the peptidoglycan constituent muramyl dipeptide as well as muramic acid. To identify the pattern recognition domains of CCF, deletion mutants were tested for their ability to reconstitute the prophenoloxidase cascade in E. foetida coelomic fluid depleted of endogenous CCF in the presence of LPS, beta -1,3-glucans, N,N'-diacetylchitobiose, and muramic acid. In addition, affinity chromatography of CCF peptides was performed on immobilized beta -1,3-glucans or N,N'-diacetylchitobiose. We found that the broad specificity of CCF for pathogen-associated molecular patterns results from the presence of two distinct pattern recognition domains. One domain, which shows homology with the polysaccharide and glucanase motifs of beta -1,3-glucanases and invertebrate defense molecules located in the central part of the CCF polypeptide chain, interacts with LPS and beta -1,3-glucans. The C-terminal tryptophan-rich domain mediates interactions of CCF with N,N'-diacetylchitobiose and muramic acid. These data provide evidence for the presence of spatially distinct carbohydrate recognition domains within this invertebrate defense molecule.	Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, B-1640 Rhode St Genese, Belgium; Acad Sci Czech Republ, Inst Microbiol, Dept Immunol, Prague 4, Czech Republic; Univ Liege, Lab Connect Tissue Biol, B-4000 Liege, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Liege	Beschin, A (corresponding author), Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, 65 Paardenstr,St Genesius Rode, B-1640 Rhode St Genese, Belgium.	abeschin@vub.ac.be	Beschin, Alain/L-2154-2014; Bilej, Martin/I-4564-2014; De Baetselier, Patrick/D-3866-2014; Stijlemans, Benoit/AAD-9122-2021	Beschin, Alain/0000-0001-8478-6941; Stijlemans, Benoit/0000-0003-0082-9751				Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; Beschin A, 1999, NATURE, V400, P627, DOI 10.1038/23164; Bianchet MA, 2000, PROTEINS, V40, P378, DOI 10.1002/1097-0134(20000815)40:3<378::AID-PROT40>3.0.CO;2-7; BILEJ M, 1995, IMMUNOL LETT, V45, P123, DOI 10.1016/0165-2478(94)00248-P; Bilej M, 1998, IMMUNOL LETT, V60, P23, DOI 10.1016/S0165-2478(97)00127-2; Bilej M, 2000, FOLIA MICROBIOL, V45, P283, DOI 10.1007/BF02817549; COTUK A, 1984, COMP BIOCHEM PHYS A, V78, P469, DOI 10.1016/0300-9629(84)90580-2; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Iketani M, 1999, INSECT BIOCHEM MOLEC, V29, P19, DOI 10.1016/S0965-1748(98)00099-X; Ito Y, 1999, EUR J BIOCHEM, V259, P456, DOI 10.1046/j.1432-1327.1999.00064.x; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Johansson M.W., 1996, Progress in Molecular and Subcellular Biology, V15, P46; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim YS, 2000, J BIOL CHEM, V275, P2071, DOI 10.1074/jbc.275.3.2071; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEIPNER C, 1993, COMP BIOCHEM PHYS B, V105, P637, DOI 10.1016/0305-0491(93)90099-Q; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; SEKI N, 1994, J BIOL CHEM, V269, P1370; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Smith V.J., 1996, Advances in Comparative and Environmental Physiology, V23, P75; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; TUCKOVA L, 1986, DEV COMP IMMUNOL, V10, P181, DOI 10.1016/0145-305X(86)90002-9; Valembois P., 1986, P74; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; YAMAMOTO M, 1993, BIOSCI BIOTECH BIOCH, V57, P1518, DOI 10.1271/bbb.57.1518; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	37	63	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45840	45847		10.1074/jbc.M107220200	http://dx.doi.org/10.1074/jbc.M107220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585829	hybrid			2022-12-25	WOS:000172573100047
J	Leung, D; Schroder, K; White, H; Fang, NX; Stoermer, MJ; Abbenante, G; Martin, JL; Young, PR; Fairlie, DP				Leung, D; Schroder, K; White, H; Fang, NX; Stoermer, MJ; Abbenante, G; Martin, JL; Young, PR; Fairlie, DP			Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; SERINE-PROTEASE; DRUG-DESIGN; IN-VITRO; NONSTRUCTURAL PROTEINS; STRUCTURAL PROTEINS; DELETION ANALYSIS; CRYSTAL-STRUCTURE; AMINO-ACIDS; FLAVIVIRUS	Recombinant forms of the dengue 2 virus NS3 protease linked to a 40-residue co-factor, corresponding to part of NS2B, have been expressed in Escherichia coli and shown to be active against para-nitroanilide substrates comprising the P6-P1 residues of four substrate cleavage sequences. The enzyme is inactive alone or after the addition of a putative 13-residue co-factor peptide but is active when fused to the 40-residue co-factor, by either a cleavable or a noncleavable glycine linker. The NS4B/NS5 cleavage site was processed most readily, with optimal processing conditions being pH 9, I = 10 mm, 1 mm CHAPS, 20% glycerol. A longer 10-residue peptide corresponding to the NS2B/NS3 cleavage site (P6-P4') was a poorer substrate than the hexapeptide (P6-P1) para-nitroanilide substrate under these conditions, suggesting that the prime side substrate residues did not contribute significantly to protease binding. We also report the first inhibitors of a co-factor-complexed, catalytically active flavivirus NS3 protease. Aprotinin was the only standard serine protease inhibitor to be active, whereas a number of peptide substrate analogues were found to be competitive inhibitors at micromolar concentrations.	Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Fairlie, DP (corresponding author), Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.		Young, Paul R/A-6176-2010; Stoermer, Martin J/E-2317-2012; Schroder, Kate/C-6132-2008; Fairlie, David P/F-8865-2014; Martin, Jennifer L./A-6039-2010	Young, Paul R/0000-0002-2040-5190; Stoermer, Martin J/0000-0003-3445-2104; Schroder, Kate/0000-0001-9261-3805; Fairlie, David P/0000-0002-7856-8566; Martin, Jennifer L./0000-0002-9225-8863				ABBENANTE G, 2001, IN PRESS LETT PEPT S; Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; BAZAN JF, 1990, SEMIN VIROL, V1, P311; Bennett JM, 2001, BIOORG MED CHEM LETT, V11, P355, DOI 10.1016/S0960-894X(00)00654-5; Brinkworth RI, 1999, J GEN VIROL, V80, P1167, DOI 10.1099/0022-1317-80-5-1167; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; Droll DA, 2000, VIROLOGY, V275, P335, DOI 10.1006/viro.2000.0488; EDWARDS PD, 1994, MED RES REV, V14, P127, DOI 10.1002/med.2610140202; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; Han W, 2000, BIOORG MED CHEM LETT, V10, P711, DOI 10.1016/S0960-894X(00)00074-3; Jacobs MG, 1998, CURR OPIN INFECT DIS, V11, P319, DOI 10.1097/00001432-199806000-00009; Kempf DJ, 1996, CURR PHARM DESIGN, V2, P225; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; LEUNG D, 2001, THESIS U QUEENSLAND; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; PREUGSCHAT F, 1991, J VIROL, V65, P4749, DOI 10.1128/JVI.65.9.4749-4758.1991; Ripka AS, 1998, CURR OPIN CHEM BIOL, V2, P441, DOI 10.1016/S1367-5931(98)80119-1; RIPKA WC, 1998, Patent No. 5731413; Seife C, 1997, SCIENCE, V277, P1602, DOI 10.1126/science.277.5332.1602; Semple JE, 1997, BIOORG MED CHEM LETT, V7, P2421, DOI 10.1016/S0960-894X(97)00446-0; SPEIGHT G, 1988, J GEN VIROL, V69, P23, DOI 10.1099/0022-1317-69-1-23; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; Steinkuhler C, 1996, J BIOL CHEM, V271, P6367, DOI 10.1074/jbc.271.11.6367; Steinkuhler C, 1996, J VIROL, V70, P6694; Tamura SY, 1996, TETRAHEDRON LETT, V37, P4109, DOI 10.1016/0040-4039(96)00777-0; WEBB TR, 1996, Patent No. 5514777; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; WEST ML, 1995, TRENDS PHARMACOL SCI, V16, P67, DOI 10.1016/S0165-6147(00)88980-4; Yusof R, 2000, J BIOL CHEM, V275, P9963, DOI 10.1074/jbc.275.14.9963	39	246	259	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45762	45771		10.1074/jbc.M107360200	http://dx.doi.org/10.1074/jbc.M107360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581268	hybrid, Green Published			2022-12-25	WOS:000172573100037
J	Pucar, D; Dzeja, PP; Bast, P; Juranic, N; Macura, S; Terzic, A				Pucar, D; Dzeja, PP; Bast, P; Juranic, N; Macura, S; Terzic, A			Cellular energetics in the preconditioned state - Protective role for phosphotransfer reactions captured by O-18-assisted P-31 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-CATALYZED PHOSPHOTRANSFER; ACTIVATED PROTEIN-KINASE; SENSITIVE K+ CHANNELS; CREATINE-KINASE; ADENYLATE KINASE; PHOSPHORYL TRANSFER; SKELETAL-MUSCLE; ENERGY-METABOLISM; HEART-FAILURE; ATP SYNTHESIS	Cell survival is critically dependent on the preservation of cellular bioenergetics. However, the metabolic mechanisms that confer resistance to injury are poorly understood. Phosphotransfer reactions integrate ATP-consuming with ATP-producing processes and could thereby contribute to the generation of a protective phenotype. Here, we used ischemic preconditioning to induce a stress-tolerant state and O-18-assisted P-31 nuclear magnetic resonance spectroscopy to capture intracellular phosphotransfer dynamics. Preconditioning of isolated perfused hearts triggered a redistribution in phosphotransfer flux with significant increase in creatine kinase and glycolytic rates. High energy phosphoryl fluxes through creatine kinase, adenylate kinase, and glycolysis in preconditioned hearts correlated tightly with post-ischemic functional recovery. This was associated with enhanced metabolite exchange between subcellular compartments, manifested by augmented transfer of inorganic phosphate from cellular ATPases to mitochondrial ATP synthase. Preconditioning-induced energetic remodeling protected cellular ATP synthesis and ATP consumption, improving contractile performance following ischemia-reperfusion insult. Thus, the plasticity of phosphotransfer networks contributes to the effective functioning of the cellular energetic system, providing a mechanism for increased tolerance toward injury.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Div Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Guggenheim 7, Rochester, MN 55905 USA.	terzic.andre@mayo.edu			NHLBI NIH HHS [HL-64822] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barany M., 1984, PHOSPHORUS 31 NMR PR, P511; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Cohen MV, 2000, ANNU REV PHYSIOL, V62, P79, DOI 10.1146/annurev.physiol.62.1.79; De Sousa E, 1999, CIRC RES, V85, P68; Dzeja P P, 2000, Curr Cardiol Rep, V2, P212, DOI 10.1007/s11886-000-0071-9; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Garnier A, 1996, J MOL CELL CARDIOL, V28, P1671, DOI 10.1006/jmcc.1996.0157; Gibbs CL, 1998, ADV EXP MED BIOL, V453, P527; Govindaraju V, 2000, NMR BIOMED, V13, P129, DOI 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V; Gross GJ, 2000, BASIC RES CARDIOL, V95, P280, DOI 10.1007/s003950050004; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hassinen IE, 1998, MOL CELL BIOCHEM, V184, P393, DOI 10.1023/A:1006818708565; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Hochachka PW, 1999, P NATL ACAD SCI USA, V96, P12233, DOI 10.1073/pnas.96.22.12233; JANIER MF, 1994, AM J PHYSIOL-HEART C, V267, pH1353, DOI 10.1152/ajpheart.1994.267.4.H1353; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Jennings R B, 1995, Monogr Pathol, V37, P47; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; KINGSLEYHICKMAN PB, 1987, BIOCHEMISTRY-US, V26, P7501, DOI 10.1021/bi00397a045; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; SAKO EY, 1988, J BIOL CHEM, V263, P10600; Saks VA, 1996, MOL CELL BIOCHEM, V161, P195, DOI 10.1007/BF00240050; Saupe KW, 1998, CIRC RES, V82, P898; Saupe KW, 2000, J BIOL CHEM, V275, P19742, DOI 10.1074/jbc.M001932200; Shen WQ, 1999, CIRCULATION, V100, P2113, DOI 10.1161/01.CIR.100.20.2113; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; TAEGTMEYER H, 1994, CURR PROB CARDIOLOGY, V19, P61, DOI 10.1016/0146-2806(94)90008-6; Takeo S, 1999, CARDIOVASC RES, V43, P32, DOI 10.1016/S0008-6363(99)00079-6; Terzic A, 1999, CLIN PHARMACOL THER, V66, P105, DOI 10.1053/cp.1999.v66.99991; Terzic A, 2000, J MOL CELL CARDIOL, V32, P1911, DOI 10.1006/jmcc.2000.1256; Tian R, 1997, J CLIN INVEST, V99, P745, DOI 10.1172/JCI119220; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Weiss RG, 1996, CIRC RES, V79, P435, DOI 10.1161/01.RES.79.3.435; WEVERS RA, 1995, CLIN CHEM, V41, P744; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	56	86	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44812	44819		10.1074/jbc.M104425200	http://dx.doi.org/10.1074/jbc.M104425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11583991	hybrid			2022-12-25	WOS:000172406700065
J	Kamohara, H; Yamashiro, S; Galligan, C; Yoshimura, T				Kamohara, H; Yamashiro, S; Galligan, C; Yoshimura, T			Discoidin domain receptor 1 isoform-a (DDR1a) promotes migration of leukocytes in three-dimensional collagen lattices	FASEB JOURNAL			English	Article						receptor tyrosine kinase; cell migration; adherence; extracellular matrix; inflammation	TYROSINE KINASE; FOCAL ADHESIONS; MESSENGER-RNA; CELLS; INTEGRINS; EXPRESSION; MATRIX; NEUTROPHILS; ACTIVATION; STRATEGIES	Although integrins are crucial for migration of leukocytes through endothelium, integrin-independent mechanisms appear to take over and mediate the migration of leukocytes through extracellular matrix (ECM) in a three-dimensional tissue microenvironment. Discoidin domain receptor (DDR) 1 is a receptor tyrosine kinase activated by collagen, the most abundant ECM protein. In the present study, we detected that peripheral blood mononuclear cells (PBMC) and polymorphonuclear neutrophils were induced to express DDR1 after incubation in RPMI 1640. The expression level of DDR1 in PBMC was increased further by stimulation with tumor necrosis factor-alpha, interleukin-1 beta, granulocyte-macrophage colony-stimulating factor, lipopolysaccharide, or phytohemagglutinin, but not with interferon-gamma. In vivo, DDR1 mRNA was detectable in mononuclear leukocytes infiltrating human renal tumor tissue. Among three DDR1 isoforms, DDR1a was the major transcript in leukocytes. Functionally, overexpression of either DDR1a or DDR1b in THP-1 cells resulted in increased adherence to collagen-coated plates in a beta1-integrin independent manner. However, only DDR1a-, but not DDR1b-, overexpressing cells exhibited marked pseudopod extension and migrated successfully through three-dimensional collagen lattices. Consequently, we propose that the interaction of DDR1a with collagen of the ECM results in a requisite intracellular signaling that enables leukocytes to migrate in a tissue microenvironment and participate in host defense.	NCI, Mol Immunoregulat Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yoshimura, T (corresponding author), NCI, Mol Immunoregulat Lab, Bldg 559,Room 9, Frederick, MD 21702 USA.	yoshimur@mail.ncifcrf.gov		Yoshimura, Teizo/0000-0002-3853-2075				ABERCROMBIE M, 1970, EXP CELL RES, V60, P437, DOI 10.1016/0014-4827(70)90537-9; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; ALVES F, 1995, ONCOGENE, V10, P609; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Foehr ED, 2000, FASEB J, V14, P973, DOI 10.1096/fasebj.14.7.973; Friedl P, 1998, EUR J IMMUNOL, V28, P2331, DOI 10.1002/(SICI)1521-4141(199808)28:08<2331::AID-IMMU2331>3.0.CO;2-C; Friedl P, 1998, CELL ADHES COMMUN, V6, P225, DOI 10.3109/15419069809004478; Goebeler M, 1996, J CELL SCI, V109, P1957; GUILFORD WH, 1995, AM J PHYSIOL-CELL PH, V268, pC1308, DOI 10.1152/ajpcell.1995.268.5.C1308; Gunzer M, 1997, ADV EXP MED BIOL, V417, P97; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; HUNTTENLOCHER A, 1996, J CELL BIOL, V134, P1551; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Mandeville JTH, 1997, J LEUKOCYTE BIOL, V61, P188, DOI 10.1002/jlb.61.2.188; NOBLE PB, 1987, J CELL SCI, V81, P241; Perez JL, 1996, ONCOGENE, V12, P1469; Playford MP, 1996, GENOME RES, V6, P620, DOI 10.1101/gr.6.7.620; Sakuma S, 1996, FEBS LETT, V398, P165, DOI 10.1016/S0014-5793(96)01234-3; SAKUMA S, 1995, RADIAT RES, V143, P1, DOI 10.2307/3578919; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Werr J, 1998, J EXP MED, V187, P2091, DOI 10.1084/jem.187.12.2091; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yamashiro S, 1999, J LEUKOCYTE BIOL, V65, P671, DOI 10.1002/jlb.65.5.671; YOSHIMURA T, 1993, J IMMUNOL, V150, P5025	36	99	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2724	+		10.1096/fj.01-0359fje	http://dx.doi.org/10.1096/fj.01-0359fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606478				2022-12-25	WOS:000171920400015
J	Wu, CJ; O'Rourke, DM; Feng, GS; Johnson, GR; Wang, Q; Greene, MI				Wu, CJ; O'Rourke, DM; Feng, GS; Johnson, GR; Wang, Q; Greene, MI			The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors	ONCOGENE			English	Article						SHP-2; phosphatidylinositol 3-kinase (PI3K); Akt; growth factors; signaling	HUMAN GLIOBLASTOMA CELLS; FACTOR RECEPTOR; PHOSPHOINOSITIDE-3-OH KINASE; PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; FOCAL ADHESION; SH2 DOMAINS; ERBB FAMILY; PROTEIN	SHP-2 is a ubiquitously expressed non-transmembrane tyrosine phosphatase with two SH2 domains. Multiple reverse-genetic studies have indicated that SHP-2 is a required component for organ and animal development. SHP-2 wild-type and homozygous mutant mouse fibroblast cells in which the N-terminal SH2 domain was target-deleted were used to examine the function of SHP-2 in regulating Phosphatidylinositol 3-Kinase (PI3K) activation by growth factors. In addition, SHP-2 and various mutants were introduced into human glioblastoma cells as well as SHP-2(-/-) mouse fibroblasts. We found that EGF stimulation and EGFR oncoprotein (Delta EGFR) expression independently induced the co-immunoprecipitation of the p85 subunit of PI3K with SHP-2. Targeted deletion of the N-terminal SH2 domain of SHP-2 severely impaired PDGF- and IGF-induced Akt phosphorylation. Ectopic expression of SHP-2 in U87MG gliobastoma cells elevated EGF-induced Akt phosphorylation, and the effect was abolished by mutation of its N-terminal SH2 domain. Likewise, the reconstitution of SHP-2 expression in the SHP-2(-/-) cells enhanced Akt phosphorylation induced by EGF while rescuing that induced by PDGF and IGF. Further lipid kinase activity assays confirmed that SHP-2 modulation of Akt phosphorylation correlated with its regulation of PI3K activation. Based on these results, we conclude that SHP-2 is required for mediating PI3K/Akt activation, and the N-terminal SH2 domain is critically important for a 'positive' role of SHP-2 in regulating PI3K pathway activation.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Burnham Inst, La Jolla, CA 92037 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Sanford Burnham Prebys Medical Discovery Institute; US Food & Drug Administration (FDA)	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	O'Rourke, Donald/AAC-3376-2021; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; O'Rourke, Donald/0000-0002-8479-7314				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Allard JD, 1996, DEVELOPMENT, V122, P1137; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Manes S, 1999, MOL CELL BIOL, V19, P3125; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; Oh ES, 1999, MOL CELL BIOL, V19, P3205; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Takahashi Y, 1999, J CELL PHYSIOL, V178, P69, DOI 10.1002/(SICI)1097-4652(199901)178:1<69::AID-JCP9>3.0.CO;2-Z; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	39	119	120	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6018	6025		10.1038/sj.onc.1204699	http://dx.doi.org/10.1038/sj.onc.1204699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593409				2022-12-25	WOS:000171056300009
J	Aouacheria, A; Arnaud, E; Venet, S; Lalle, P; Gouy, M; Rigal, D; Gillet, G				Aouacheria, A; Arnaud, E; Venet, S; Lalle, P; Gouy, M; Rigal, D; Gillet, G			Nrh, a human homologue of Nr-13 associates with Bcl-Xs and is an inhibitor of apoptosis	ONCOGENE			English	Article						apoptosis; molecular cloning; Bcl-2 family; phylogeny	CYTOCHROME-C; BH3 DOMAIN; CELL-DEATH; BCL-2-RELATED GENE; ION-CHANNEL; BAX; FAMILY; EXPRESSION; PROTEINS; RELEASE	In search of human homologues of the anti-apoptotic protein Nr-13, we have characterized a human EST clone that potentially encodes a protein, which is the closest homologue of Nr-13 among the Bcl-2 family members, to date known, in humans. Phylogenetic analyses suggest Human nrh, Mouse diva/boo and Quail nr-13 to be orthologous genes. The nrh gene has the same overall organization as nr-13 and diva/boo with one single intron interrupting the ORF at the level of the Bcl-2-homology domain BH2. RT-PCR-based analysis of nrh expression indicated that this gene is preferentially expressed in the lungs, the liver and the kidneys. Interestingly, two in frame ATG codons can lead potentially to the synthesis of two products, one of them lacking 10 aminoacids at the N-terminal end. Sequence alignment with nr-13 and Diva/Boo in addition to secondary structure prediction of the nrh transcript suggested that the shortest protein will be preferentially synthetized. Immunohistochemical analyses have revealed that Nrh is associated with mitochondria and the nuclear envelope. Moreover, Nrh preferentially associates with the apoptosis accelerator Bcl-Xs and behaves as an inhibitor of apoptosis both in yeast and vertebrate cells.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Univ Lyon 1, CNRS, UMR 5558, F-67622 Villeurbanne, France; Etablissement Transfus Sanguine, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup	Gillet, G (corresponding author), Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	g.gillet@ibcp.fr	gillet, germain/A-9095-2013; LALLE, Philippe/G-7734-2018	GILLET, Germain/0000-0002-1514-327X				Afonso CL, 2001, J VIROL, V75, P971, DOI 10.1128/JVI.75.2.971-978.2001; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; DONALDSON JG, 1998, CURRENT PROTOCOLS CE, V1; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Espanel X, 1998, ONCOGENE, V17, P585, DOI 10.1038/sj.onc.1201962; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOLEMIS EA, 1999, CURRENT PROTOCOLS MO, V4; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Mangeney M, 1996, ONCOGENE, V13, P1441; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Otter I, 1998, J BIOL CHEM, V273, P6110, DOI 10.1074/jbc.273.11.6110; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SAMBROOK J, 1989, MOL CLONING, V2, P9; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Simonen M, 1997, EUR J BIOCHEM, V249, P85, DOI 10.1111/j.1432-1033.1997.t01-1-00085.x; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Walczak H, 2000, CANCER RES, V60, P3051; WANG HG, 1994, ONCOGENE, V9, P2751; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang QF, 2000, BREAST CANCER RES TR, V61, P211, DOI 10.1023/A:1006474307180; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930	52	33	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5846	5855		10.1038/sj.onc.1204740	http://dx.doi.org/10.1038/sj.onc.1204740			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593390				2022-12-25	WOS:000171037200008
J	Fernandez-Fernandez, MR; Camafeita, E; Bonay, P; Mendez, E; Albar, JP; Garcia, JA				Fernandez-Fernandez, MR; Camafeita, E; Bonay, P; Mendez, E; Albar, JP; Garcia, JA			The capsid protein of a plant single-stranded RNA virus is modified by O-linked N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAT PROTEIN; SIGNAL-TRANSDUCTION; MOSAIC-VIRUS; NUCLEAR; PHOSPHORYLATION; GLYCOSYLATION; POTYVIRUS; SEQUENCE; CONTAINS; TRANSMISSIBILITY	Plum pox virus (PPV) is a member of the Potyvirus genus of plant viruses. Labeling with UDP-[H-3]galactose and galactosyltransferase indicated that the capsid protein (CP) of PPV is a glycoprotein with N-acetylglucosamine terminal residues. Mass spectrometry analysis of different PPV isolates and mutants revealed O-linked N-acetylglucosamination, a modification barely studied in plant proteins, of serine and/or threonine residues near the amino end of PPV CP. CP of PPV virions is also modified by serine and threonine phosphorylation, as shown by Western blot analysis with anti-phosphoserine and anti-phosphothreonine antibodies. Thus, "yin-yang" glycosylation and phosphorylation may play an important role in the regulation of the different functions in which the potyviral CP is involved.	CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Garcia, JA (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, E-28049 Madrid, Spain.	jagarcia@cnb.uam.es	Garcia, Juan Antonio/N-3723-2014	Garcia, Juan Antonio/0000-0002-4861-9609; Fernandez-Fernandez, Maria Rosario/0000-0002-9128-5296				Altmann F, 2000, J GEN VIROL, V81, P1111, DOI 10.1099/0022-1317-81-4-1111; Atabekov JG, 2001, VIROLOGY, V286, P466, DOI 10.1006/viro.2001.1013; ATREYA CD, 1990, VIROLOGY, V178, P161, DOI 10.1016/0042-6822(90)90389-9; ATREYA PL, 1991, P NATL ACAD SCI USA, V88, P7887, DOI 10.1073/pnas.88.17.7887; BENKO DM, 1988, P NATL ACAD SCI USA, V85, P2573, DOI 10.1073/pnas.85.8.2573; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Dolja V V, 1995, Virology, V206, P1007, DOI 10.1006/viro.1995.1023; DOLJA VV, 1994, EMBO J, V13, P1482, DOI 10.1002/j.1460-2075.1994.tb06403.x; Fernandez-Fernandez MR, 1998, FEBS LETT, V427, P229, DOI 10.1016/S0014-5793(98)00429-3; FERNANDEZFERNAN.MR, 1999, THESIS UNIVERSIDAD A; GONZALEZ SA, 1991, VIROLOGY, V182, P8, DOI 10.1016/0042-6822(91)90642-O; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Heese-Peck A, 1998, PLANT CELL, V10, P599, DOI 10.1105/tpc.10.4.599; HEESEPECK A, 1995, PLANT CELL, V7, P1459, DOI 10.1105/tpc.7.9.1459; Ivanov KI, 2001, J BIOL CHEM, V276, P13530, DOI 10.1074/jbc.M009551200; Karpova OV, 1999, VIROLOGY, V261, P20, DOI 10.1006/viro.1999.9842; LAIN S, 1988, VIRUS RES, V10, P325, DOI 10.1016/0168-1702(88)90074-3; LOPEZMOYA JJ, 1995, J GEN VIROL, V76, P2293, DOI 10.1099/0022-1317-76-9-2293; MAISS E, 1992, J GEN VIROL, V73, P709, DOI 10.1099/0022-1317-73-3-709; MARTIN MT, 1990, VIRUS RES, V15, P97, DOI 10.1016/0168-1702(90)90001-R; MULLIS KG, 1990, J VIROL, V64, P5317, DOI 10.1128/JVI.64.11.5317-5323.1990; PARTRIDGE JE, 1974, NATURE, V247, P391, DOI 10.1038/247391a0; RATKA M, 1989, J VIROL, V63, P3954, DOI 10.1128/JVI.63.9.3954-3960.1989; Revers F, 1999, MOL PLANT MICROBE IN, V12, P367, DOI 10.1094/MPMI.1999.12.5.367; RIECHMANN JL, 1992, J GEN VIROL, V73, P1, DOI 10.1099/0022-1317-73-1-1; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SHUKLA DD, 1988, J GEN VIROL, V69, P1497, DOI 10.1099/0022-1317-69-7-1497; SHUKLA DD, 1994, POLYVIRIDAE; Thornton TM, 1999, TRENDS PLANT SCI, V4, P424, DOI 10.1016/S1360-1385(99)01485-5; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TOZZINI AC, 1994, VIROLOGY, V202, P651, DOI 10.1006/viro.1994.1386; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WHITFORD M, 1992, J VIROL, V66, P3324, DOI 10.1128/JVI.66.6.3324-3329.1992	36	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					135	140		10.1074/jbc.M106883200	http://dx.doi.org/10.1074/jbc.M106883200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11606576	hybrid			2022-12-25	WOS:000173087900019
J	Bechard, D; Gentina, T; Delehedde, M; Scherpereel, A; Lyon, M; Aumercier, M; Vazeux, R; Richet, C; Degand, P; Jude, B; Janin, A; Fernig, DG; Tonnel, AB; Lassalle, P				Bechard, D; Gentina, T; Delehedde, M; Scherpereel, A; Lyon, M; Aumercier, M; Vazeux, R; Richet, C; Degand, P; Jude, B; Janin, A; Fernig, DG; Tonnel, AB; Lassalle, P			Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-SCATTER FACTOR; CELL-SPECIFIC MOLECULE-1; HEPARAN-SULFATE; C-MET; DERMATAN SULFATE; TYROSINE KINASE; HIGH-AFFINITY; FIBROBLAST-GROWTH; FACTOR ISOFORMS; IN-VITRO	Proteoglycans that modulate the activities of growth factors, chemokines, and coagulation factors regulate in turn the vascular endothelium with respect to processes such as inflammation, hemostasis, and angiogenesis. Endothelial cell-specific molecule-1 is mainly expressed by endothelial cells and regulated by pro-inflammatory cytokines (Lassalle, P., Molet, S., Janin, A., Heyden, J. V., Tavernier, J., Fiers, W., Devos, R., and Tonnel, A. B. (1996) J. Biol. Chem. 271, 20458-20464). We demonstrate that this molecule is secreted as a soluble dermatan sulfate (DS) proteoglycan. This proteoglycan represents the major form either secreted by cell lines or circulating in the human bloodstream. Because this proteoglycan is specifically secreted by endothelial cells, we propose to nam it endocan. The glycosaminoglycan component of endocan consists of a single DS chain covalently attached to serine 137. Endocan dose-dependently increased the hepatocyte growth factor/scatter factor (HGF/SF)-mediated proliferation of human embryonic kidney cells, whereas the nonglycanated form of endocan did not. Moreover, DS chains purified from endocan mimicked the endocan-mediated increase of cell proliferation in the presence of HGF/SF. Overall, our results demonstrate that endocan is a novel soluble dermatan sulfate proteoglycan produced by endothelial cells. Endocan regulates HGF/SF-mediated mitogenic activity and may support the function of HGF/SF not only in embryogenesis and tissue repair after injury but also in tumor progression.	Inst Pasteur, INSERM, U416, F-59019 Lille, France; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Christie Hosp NHS Trust, Canc Res Campaign, Dept Med Oncol, Manchester M20 4BX, Lancs, England; CNRS, UMR 8526, Inst Biol Lille, F-75700 Paris, France; CHRU, Hop Cardiol, Lab Hematol A, F-59019 Lille, France; ICOS Corp, Bothell, WA 98021 USA; INSERM, U377, F-59019 Lille, France; Hop St Louis, Serv Anat Pathol, F-75475 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Liverpool; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; CHU Lille; Icos Corporation; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Lassalle, P (corresponding author), Inst Pasteur, INSERM, U416, 1 Rue Pr A Calmette,BP 245, F-59019 Lille, France.	philippe.lassalle@pasteur-lille.fr	Lassalle, Philippe/L-6705-2018; Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Lyon, Malcolm/0000-0001-9575-6879; Aumercier, Marc/0000-0002-0370-3452; lassalle, philippe/0000-0001-6434-0344; DELEHEDDE, Maryse/0000-0003-2724-143X				Bechard D, 2000, J VASC RES, V37, P417, DOI 10.1159/000025758; Bechard D, 2001, J IMMUNOL, V167, P3099, DOI 10.4049/jimmunol.167.6.3099; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Borghesi LA, 1999, BLOOD, V93, P140, DOI 10.1182/blood.V93.1.140.401k40_140_148; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; Deakin JA, 1999, J CELL SCI, V112, P1999; Delorme MA, 1996, THROMB HAEMOSTASIS, V75, P747; Fernig D G, 2001, Methods Mol Biol, V171, P505; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Hammerman MR, 1998, CURR OPIN NEPHROL HY, V7, P419, DOI 10.1097/00041552-199807000-00012; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Lassalle P, 1996, J BIOL CHEM, V271, P20458, DOI 10.1074/jbc.271.34.20458; LASSALLE P, 1992, EUR J IMMUNOL, V22, P425, DOI 10.1002/eji.1830220221; Leygue E, 2000, J PATHOL, V192, P313; Leygue E, 1998, CANCER RES, V58, P1348; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; Matsumoto K, 1996, CANCER CHEMOTH PHARM, V38, pS42, DOI 10.1007/s002800051037; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Nelimarkka L, 1997, J BIOL CHEM, V272, P12730, DOI 10.1074/jbc.272.19.12730; Okada M, 1999, BIOCHEM BIOPH RES CO, V255, P80, DOI 10.1006/bbrc.1999.0150; Otsuka T, 1998, CANCER RES, V58, P5157; Penc SF, 1998, J LEUKOCYTE BIOL, V64, P351, DOI 10.1002/jlb.64.3.351; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Sakata H, 1997, J BIOL CHEM, V272, P9457; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; Sergeant N, 2000, J BIOL CHEM, V275, P17094, DOI 10.1074/jbc.M000237200; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; Siegfried JM, 1998, ANN THORAC SURG, V66, P1915, DOI 10.1016/S0003-4975(98)01165-5; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; TAKEBAYASHI T, 1995, J CELL BIOL, V129, P1411, DOI 10.1083/jcb.129.5.1411; Takigawa N, 1997, LUNG CANCER-J IASLC, V17, P211, DOI 10.1016/S0169-5002(97)00651-X; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	66	178	186	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48341	48349		10.1074/jbc.M108395200	http://dx.doi.org/10.1074/jbc.M108395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11590178	hybrid			2022-12-25	WOS:000172927000082
J	Bembenek, J; Yu, HT				Bembenek, J; Yu, HT			Regulation of the anaphase-promoting complex by the dual specificity phosphatase human Cdc14a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CYCLIN DESTRUCTION; CELL-DIVISION; MITOSIS; PROTEIN; EXIT; APC; FAMILY; CDC20; YEAST	Two forms of the anaphase-promoting complex (APC) mediate the degradation of critical cell cycle regulators. APC(Cdc20) promotes sister-chromatid separation by ubiquitinating securin, whereas APC(Cdh1) ubiquitinates mitotic cyclins, allowing the exit from mitosis. Here we show that phosphorylation of human Cdh1 (hCdh1) by cyclin B-Cdc2 alters the conformation of hCdh1 and prevents it from activating APC. A human homologue of yeast Cdc14, human Cdc14a (hCdc14a), dephosphorylates hCdh1 and activates APC(Cdh1). In contrast, hCdc14a does not affect the activity of APC(Cdc20). hCdc14a is a major phosphatase for hCdh1 and localizes to centrosomes in HeLa cells. Therefore, hCdc14a may promote the activation of APC(Cdh1) and exit from mitosis in mam. malian cells.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, HT (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Yu, Hongtao/0000-0002-8861-049X; Bembenek, Joshua/0000-0002-0966-2268	NIGMS NIH HHS [GM61542] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061542] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bloecher A, 2000, NAT CELL BIOL, V2, P556, DOI 10.1038/35019601; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Frenz LM, 2000, J CELL SCI, V113, P3399; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; KENG T, 1994, YEAST, V10, P953, DOI 10.1002/yea.320100710; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Menssen R, 2001, CURR BIOL, V11, P345, DOI 10.1016/S0960-9822(01)00095-1; Moreno CS, 2001, J BIOL CHEM, V276, P24253, DOI 10.1074/jbc.M102398200; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	39	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48237	48242		10.1074/jbc.M108126200	http://dx.doi.org/10.1074/jbc.M108126200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11598127	hybrid			2022-12-25	WOS:000172927000067
J	Brzeska, H; Young, R; Tan, C; Szczepanowska, J; Korn, ED				Brzeska, H; Young, R; Tan, C; Szczepanowska, J; Korn, ED			Calmodulin-binding and autoinhibitory domains of Acanthamoeba myosin I heavy chain kinase, a p21-activated kinase (PAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CATALYTIC DOMAIN; SUBSTRATE-SPECIFICITY; RAC GTPASES; ACTIVATION; CDC42; PHOSPHORYLATION; IDENTIFICATION; SEQUENCE; FAMILY	The sequence homology between Acanthamoeba myosin I heavy chain kinase (MIHCK) and other p21-activated kinases (PAKs) is relatively low, including only the catalytic domain and a short PAK N-terminal motif (PAN), and even these regions are not highly homologous. In this paper, we report the expression in insect cells of full-length, fully regulated Acanthamoeba MIHCK and further characterize the regulation of this PAK by Rac, calmodulin, and autoinhibition. We map the autoinhibitory region of MIHCK to its PAN region and show that the PAN region inhibits autophosphorylation and kinase activity of unphosphorylated full-length MIHCK and its expressed catalytic domain but has very little effect on either when they are phosphorylated. These properties are similar to those reported for mammalian PAK1. Unlike PAK1, MIHCK is activated by Rac only in the presence of phospholipid. However, peptides containing the PAN region of MIHCK bind Rac in the absence of lipid, and Rac binding reverses the inhibition of the MIHCK catalytic domain by PAN peptides. Our data suggest that a region N-terminal to PAN is required for optimal binding of Rac. Also unlike mammalian PAK, phospholipid stimulation of Acanthamoeba MIHCK and Dictyostelium MIHCK) (which is also a PAK) is inhibited by Ca2+-calmodulin. In contrast to Dictyostelium MIHCK, however, Ca2+-calmodulin also inhibits Rac-induced activity of Acanthamoeba MIHCK. The basic region N-terminal to PAN is essential for calmodulin binding.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Korn, ED (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 50,Rm 2517,9000 Rockville Pike, Bethesda, MD 20892 USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295; Szczepanowska, Joanna/0000-0002-0434-1262	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000506, Z01HL000506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; Brzeska H, 1996, J BIOL CHEM, V271, P27049, DOI 10.1074/jbc.271.43.27049; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Gizachew D, 2000, BIOCHEMISTRY-US, V39, P3963, DOI 10.1021/bi992646d; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee SF, 1998, J BIOL CHEM, V273, P27911, DOI 10.1074/jbc.273.43.27911; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Stevens WK, 1999, BIOCHEMISTRY-US, V38, P5968, DOI 10.1021/bi990426u; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	41	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47468	47473		10.1074/jbc.M108957200	http://dx.doi.org/10.1074/jbc.M108957200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579107	hybrid			2022-12-25	WOS:000172768500103
J	Inokuchi, A; Hinoshita, E; Iwamoto, Y; Kohno, K; Kuwano, M; Uchiumi, T				Inokuchi, A; Hinoshita, E; Iwamoto, Y; Kohno, K; Kuwano, M; Uchiumi, T			Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes - A transcriptional control of a plausible bile acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; EXPORT PUMP; HUMAN ILEAL; CMOAT GENE; CELL LINE; CHOLESTEROL; MUTATIONS; MRP3; IDENTIFICATION; LIGANDS	The enterohepatic circulation is essential for the maintenance of bile acids and cholesterol homeostasis. The ileal bile acid transporter on the apical membrane of enterocytes mediates the intestinal uptake of bile salts, but little is known about the bile salt secretion from the basolateral membrane of enterocytes into blood. In the basolateral membrane of enterocytes, an ATP-binding cassette transporter, multidrug resistance protein 3 (MRP3), is expressed, which has the ability to transport bile salts. We hypothesized that MRP3 might play a role in the enterohepatic circulation of bile salts by transporting them from enterocytes into circulating blood through the up-regulation of MRP3 expression, so we investigated the transcriptional control of MRP3 in response to bile salts. MRP3 mRNA levels were increased about 3-fold in human colon cells by chenodeoxycholic acid (CDCA), in a dose- and time-dependent manner. In the promoter assay, the promoter activity of MRP3 was increased about 3-fold over the basal promoter activity when treated with CDCA, and the putative bile salt-responsive elements exist in the region -229/-138 including two alpha -1 fetoprotein transcription factor (FTF)-like elements. Constructs with a specific mutation in the consensus sequence of FTF elements showed no increase in basal transcriptional activity following CDCA treatment. In electrophoretic mobility shift assay with nuclear extracts, specific binding of FTF to FTF-like elements was observed when treated with CDCA. The expression of FTF mRNA levels were also markedly enhanced in response to CDCA, and overexpression of FTF specifically activated the MRP3 promoter activity about 4-fold over the basal promoter activity. FTF thus might play a key role not only in the bile salt synthetic pathway in hepatocytes but also in the bile salt excretion pathway in enterocytes through the regulation of MRP3 expression. MRP3 may contribute as a plausible bile salt-exporting transporter to the enterohepatic circulation of bile salts.	Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Higashi Ku, Fukuoka 8128582, Japan; Univ Occupat & Environm Hlth, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	Kyushu University; Kyushu University; University of Occupational & Environmental Health - Japan	Uchiumi, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	uchiumi@biochem1.med.kyushu-u.ac.jp						Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chen WL, 2001, J LIPID RES, V42, P1402; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hirohashi T, 2000, J PHARMACOL EXP THER, V292, P265; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; Keppler D, 1998, METHOD ENZYMOL, V292, P607; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1997, CANCER RES, V57, P3537; KUIPERS F, 1988, J CLIN INVEST, V81, P1593, DOI 10.1172/JCI113493; Lee J, 2000, SEMIN LIVER DIS, V20, P373, DOI 10.1055/s-2000-9390; Lee JM, 2000, GASTROENTEROLOGY, V118, P163, DOI 10.1016/S0016-5085(00)70425-2; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MEUNIER V, 1995, CELL BIOL TOXICOL, V11, P187, DOI 10.1007/BF00756522; Nies AT, 1998, HEPATOLOGY, V28, P1332, DOI 10.1002/hep.510280523; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; OELKERS P, 1995, BBA-LIPID LIPID MET, V1257, P199, DOI 10.1016/0005-2760(95)00098-W; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Ortiz DF, 1999, AM J PHYSIOL-GASTR L, V276, pG1493, DOI 10.1152/ajpgi.1999.276.6.G1493; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stravitz RT, 1997, GASTROENTEROLOGY, V113, P1599, DOI 10.1053/gast.1997.v113.pm9352862; Tanaka T, 1999, HEPATOLOGY, V30, P1507, DOI 10.1002/hep.510300617; Taniguchi K, 1996, CANCER RES, V56, P4124; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Tsujii H, 1999, GASTROENTEROLOGY, V117, P653, DOI 10.1016/S0016-5085(99)70459-2; Uchiumi T, 1998, BIOCHEM BIOPH RES CO, V252, P103, DOI 10.1006/bbrc.1998.9546; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; Walters JRF, 2000, GUT, V46, P308, DOI 10.1136/gut.46.3.308; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228	48	96	101	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46822	46829		10.1074/jbc.M104612200	http://dx.doi.org/10.1074/jbc.M104612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590139	hybrid			2022-12-25	WOS:000172768500021
J	Rousse, S; Lallemand, F; Montarras, D; Pinset, C; Mazars, A; Prunier, C; Atfi, A; Dubois, C				Rousse, S; Lallemand, F; Montarras, D; Pinset, C; Mazars, A; Prunier, C; Atfi, A; Dubois, C			Transforming growth factor-beta inhibition of insulin-like growth factor-binding protein-5 synthesis in skeletal muscle cells involves a c-Jun N-terminal kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOGENIC DIFFERENTIATION; MYOBLAST DIFFERENTIATION; SIGNAL-TRANSDUCTION; EXPRESSION; ACTIVATION; INDUCTION; PROLIFERATION; TRANSCRIPTION; TGF-BETA-2; SECRETION	Transforming growth factor-beta (TGF-beta) and insulin-like growth factors (IGFs) play critical roles in the control of myogenesis. Insulin-like growth factor-binding protein-5 (IGFBP-5), by regulating the bioavailability of IGFs, is involved in controlling IGF-dependent differentiation. We investigated the effects of TGF-13 on the IGFBP-5 production induced by IGFs in mouse myoblasts. TGF-beta leads to a decrease in IGFBP-5 synthesis at both transcript and protein levels, and blocked muscle differentiation. The Smad proteins and the e-Jun N-terminal kinase (JNK) have been shown to be involved in TGF-beta signaling pathways. We provide evidence that the JNK pathway, rather than Smad proteins, is involved in the response of muscle cells to TGF-beta. This factor failed to stimulate the GAL4-Smad 2/3 transcriptional activities of the constructs used to transfect myoblasts. Moreover, stable expression of the antagonistic Smad7 did not abolish the inhibitory effect of TGF-beta on IGFBP-5 production whereas expression of a dominant-negative version of MKK4, an upstream activator of JNK, did. We also showed, using a specific inhibitor, that the p38 mitogen-activated protein kinase (p38 MAPK) was not involved in the inhibition of IGFBP-5 production. Thus, TGF-beta -mediated IGFBP-5 inhibition is independent of Smads and requires activation of the JNK signaling pathway.	Hop St Antoine, INSERM U482, F-75571 Paris 12, France; INSERM U515, F-75571 Paris 12, France; Inst Pasteur, Lab Dev Cellulaire, URA CNRS 1947, F-75724 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Dubois, C (corresponding author), Hop St Antoine, INSERM U482, F-75571 Paris 12, France.	dubois@st-antoine.inserm.fr	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BOSCHE WJ, 1995, J CELL PHYSIOL, V164, P324, DOI 10.1002/jcp.1041640213; CARONI P, 1994, J NEUROSCI, V14, P3378; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; EWTON DZ, 1995, J ENDOCRINOL, V144, P539, DOI 10.1677/joe.0.1440539; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; Frey RS, 1997, CANCER RES, V57, P628; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HEINO J, 1990, J BIOL CHEM, V265, P10181; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; LAFYATIS R, 1991, MOL CELL BIOL, V11, P3795, DOI 10.1128/MCB.11.7.3795; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; LANDSTROM M, 2000, CELL, V87, P565; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; MCCUSKER RH, 1989, J BIOL CHEM, V264, P7795; MCCUSKER RH, 1994, ENDOCRINOLOGY, V134, P2095, DOI 10.1210/en.134.5.2095; McLennan IS, 1997, DEV DYNAM, V208, P278, DOI 10.1002/(SICI)1097-0177(199702)208:2<278::AID-AJA14>3.0.CO;2-#; Montarras D, 1996, J CELL SCI, V109, P551; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; ROTWEIN P, 1995, MOL ENDOCRINOL, V9, P913, DOI 10.1210/me.9.7.913; Rousse S, 1998, ENDOCRINOLOGY, V139, P1487, DOI 10.1210/en.139.4.1487; SCHOFIELD JN, 1990, EXP CELL RES, V191, P144, DOI 10.1016/0014-4827(90)90048-F; SCHULLER AGP, 1994, MOL CELL ENDOCRINOL, V104, P57, DOI 10.1016/0303-7207(94)90051-5; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	51	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46961	46967		10.1074/jbc.M104440200	http://dx.doi.org/10.1074/jbc.M104440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598109	hybrid			2022-12-25	WOS:000172768500040
J	Sengupta, S; Wehbe, C; Majors, AK; Ketterer, ME; DiBello, PM; Jacobsen, DW				Sengupta, S; Wehbe, C; Majors, AK; Ketterer, ME; DiBello, PM; Jacobsen, DW			Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; REDOX STATUS; CATALYZED OXIDATION; PROTEIN-BINDING; IN-VIVO; PLASMA; COPPER; HYPERHOMOCYSTEINEMIA; ATHEROSCLEROSIS; AMINOTHIOLS	Disulfide forms of homocysteine account for > 98% of total homocysteine in plasma from healthy individuals. We recently reported that homocysteine reacts with albumin-Cys(34)-S-S-cysteine to form homocysteine-cysteine mixed disulfide and albumin-Cys(34) thiolate anion. The latter then reacts with homocystine or homocysteine-cysteine mixed disulfide to form albumin-bound homocysteine (Sengupta, S., Chen, H., Togawa, T., DiBello, P. M., Majors, A. K, Budy, B., Ketterer, M. E., and Jacobsen, D. W. (2001) J. Biol. Chem. 276, 30111-30117). We now extend these studies to show that human albumin, but not ceruloplasmin, mediates the conversion of homocysteine to its low molecular weight disulfide forms (homocystine and homocysteine-cysteine mixed disulfide) by thiol/disulfide exchange reactions. Only a small fraction of homocystine is formed by an oxidative process in which copper bound to albumin, but not ceruloplasmin, mediates the reaction. When copper is removed from albumin by chelation, the overall conversion of homocysteine to its disulfide forms is reduced by only 20%. Ceruloplasmin was an ineffective catalyst of homocysteine oxidation, and immunoprecipitation of ceruloplasmin from human plasma did not inhibit the capacity of plasma to mediate the conversion of homocysteine to its disulfide forms. In contrast, ceruloplasmin was a highly efficient catalyst for the oxidation of cysteine and cysteinylglycine to cystine and bis(-S-cysteinylglycine), respectively. However, when thiols (cysteine and homocysteine) that are disulfide-bonded to albumin-Cys(34) are removed by treatment with dithiothreitol to form albumin-Cys(34)-SH (mercaptalbumin), the conversion of homocysteine to its disulfide forms is completely blocked. In conclusion, albumin mediates the formation of disulfide forms of homocysteine by thiol/disulfide exchange, whereas ceruloplasmin converts cysteine to cystine by copper-dependent autooxidation.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; No Arizona Univ, Dept Chem, Flagstaff, AZ 86011 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Northern Arizona University	Jacobsen, DW (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	jacobsd@ccf.org						BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; Bescond A, 1999, BIOCHEM BIOPH RES CO, V263, P498, DOI 10.1006/bbrc.1999.1391; CAVALLINI D, 1969, ARCH BIOCHEM BIOPHYS, V130, P354, DOI 10.1016/0003-9861(69)90044-7; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; DUDMAN NPB, 1983, CLIN CHIM ACTA, V127, P105, DOI 10.1016/0009-8981(83)90080-3; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FELDMAN SL, 1985, J INORG BIOCHEM, V17, P51; FRIEDMAN M, 1965, J AM CHEM SOC, V87, P3672, DOI 10.1021/ja01094a025; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; HOUK RS, 1994, ACCOUNTS CHEM RES, V27, P333, DOI 10.1021/ar00047a003; JACOBSEN DW, 1984, BIOCHEMISTRY-US, V23, P2017, DOI 10.1021/bi00304a021; Jacobsen DW, 2000, ARTERIOSCL THROM VAS, V20, P1182, DOI 10.1161/01.ATV.20.5.1182; JACOBSEN DW, 1993, J INORG BIOCHEM, V50, P47, DOI 10.1016/0162-0134(93)80013-Y; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Jacobsen DW, 1998, CLIN CHEM, V44, P1833; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JOCELYN PC, 1972, BIOCH SH GROUP, P54; JOYCE DA, 1991, J PHARM SCI, V80, P1370; Kachur AV, 1999, FREE RADICAL RES, V31, P23, DOI 10.1080/10715769900300571; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; MANSOOR MA, 1993, CLIN CHEM, V39, P980; MANSOOR MA, 1993, METABOLISM, V42, P1481, DOI 10.1016/0026-0495(93)90202-Y; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; McCaddon A, 1998, INT J GERIATR PSYCH, V13, P235, DOI 10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; Miller JW, 2000, NUTRITION, V16, P675, DOI 10.1016/S0899-9007(00)00307-5; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Muniz P, 2001, FREE RADICAL BIO MED, V30, P354, DOI 10.1016/S0891-5849(00)00480-9; Nygard O, 1999, J INTERN MED, V246, P425, DOI 10.1046/j.1365-2796.1999.00512.x; Peters T, 1996, ALL ALBUMIN BIOCH GE, P51; Poddar R, 2001, CIRCULATION, V103, P2717; REFSUM H, 1985, CLIN CHEM, V31, P624; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; Sengupta S, 2001, J BIOL CHEM, V276, P30111, DOI 10.1074/jbc.M104324200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOGAMI M, 1984, INT J PEPT PROT RES, V24, P96; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; SUZUKI KT, 1989, ARCH BIOCHEM BIOPHYS, V273, P572, DOI 10.1016/0003-9861(89)90517-1; TIETZ NW, 1983, CLIN GUIDE LAB TESTS, P168; TRAVIS J, 1976, BIOCHEM J, V157, P301, DOI 10.1042/bj1570301; Ueland PM, 2000, AM J CLIN NUTR, V72, P324; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380; Welch GN, 1997, ANN NY ACAD SCI, V811, P48, DOI 10.1111/j.1749-6632.1997.tb51988.x; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YOSHIDA Y, 1992, ACTA NEUROL SCAND, V86, P490, DOI 10.1111/j.1600-0404.1992.tb05130.x; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582	55	111	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46896	46904		10.1074/jbc.M108451200	http://dx.doi.org/10.1074/jbc.M108451200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592966	hybrid			2022-12-25	WOS:000172768500031
J	Curat, CA; Eck, M; Dervillez, X; Vogel, WF				Curat, CA; Eck, M; Dervillez, X; Vogel, WF			Mapping of epitopes in discoidin domain receptor 1 critical for collagen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED JUVENILE RETINOSCHISIS; COAGULATION-FACTOR-V; TYROSINE KINASE; BRAIN-TUMORS; I-DOMAIN; EXPRESSION; PROTEIN; IDENTIFICATION; C2-DOMAIN; INTEGRIN	The binding and activation of the discoidin domain receptor I by collagen has led to the conclusion that proteins from the extracellular matrix can directly induce receptor tyrosine kinase-mediated signaling cascades. A region in the extracellular domain of DDR1 homologous to the Dictyostelium discoideum protein discoidin-I is also present in the secreted human protein RS1. Mutations in RS1 cause retinoschisis, a genetic disorder characterized by ablation of the retina. By introducing point mutations into the discoidin domain of DDR1 at positions homologous to the retinoschisis mutations, ligand binding epitopes in the discoidin domain of DDR1 were mapped. Surprisingly, some residues only affected receptor phosphorylation, whereas others influenced both collagen-binding and receptor activation. Furthermore, two truncated DDR1 variants, lacking either the discoidin domain or the stalk region between the discoidin and transmembrane domain, were generated. We showed that (i) the discoidin domain was necessary and sufficient for collagen binding, (ii) only the region between discoidin and transmembrane domain was glycosylated, and (iii) the entire extracellular domain was essential for transmembrane signaling. Using these results, we were able to predict key sites in the collagen-binding epitope of DDR1 and to suggest a potential mechanism of signaling.	Goethe Univ Frankfurt, Georg Speyer Haus Inst Biomed Res, Lab Extracellular Matrix Signaling & Tumor Invas, D-60596 Frankfurt, Germany; Goethe Univ Frankfurt, Georg Speyer Haus Inst Biomed Res, Dept Infect Dis, D-60596 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Vogel, WF (corresponding author), Goethe Univ Frankfurt, Georg Speyer Haus Inst Biomed Res, Lab Extracellular Matrix Signaling & Tumor Invas, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	Wolfgangfvogel@hotmail.com	Dervillez, Xavier/AAB-4798-2020					ALEXANDER S, 1992, DIFFERENTIATION, V51, P149, DOI 10.1111/j.1432-0436.1992.tb00691.x; ALVES F, 1995, ONCOGENE, V10, P609; Alves F, 2001, FASEB J, V15, P1321, DOI 10.1096/fj.00-0626fje; BARKER KT, 1995, ONCOGENE, V10, P569; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; Chin GS, 2000, PLAST RECONSTR SURG, V106, P1532, DOI 10.1097/00006534-200012000-00014; den Dunnen JT, 1998, HUM MOL GENET, V7, P1185; Dervillez X, 1997, IMMUNOPHARMACOLOGY, V38, P129, DOI 10.1016/S0162-3109(97)00066-0; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Foehr ED, 2000, FASEB J, V14, P973, DOI 10.1096/fasebj.14.7.973; George NDL, 1996, ARCH OPHTHALMOL-CHIC, V114, P274, DOI 10.1001/archopht.1996.01100130270007; Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873; Hiriyanna KT, 1999, HUM MUTAT, V14, P423, DOI 10.1002/(SICI)1098-1004(199911)14:5<423::AID-HUMU8>3.0.CO;2-D; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; Jansson M, 2001, J CELL SCI, V114, P2043; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; Kim SW, 2000, BIOCHEMISTRY-US, V39, P1951, DOI 10.1021/bi992256r; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Layne MD, 2001, MOL CELL BIOL, V21, P5256, DOI 10.1128/MCB.21.15.5256-5261.2001; Leitinger B, 2000, NAT STRUCT BIOL, V7, P614, DOI 10.1038/77895; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Mohan RR, 2001, EXP EYE RES, V72, P87, DOI 10.1006/exer.2000.0932; Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Nicolaes GAF, 2000, BLOOD COAGUL FIBRIN, V11, P89, DOI 10.1097/00001721-200011010-00010; PEREZ JL, 1994, ONCOGENE, V9, P211; Perez JL, 1996, ONCOGENE, V12, P1469; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Reid SNM, 1999, GENE, V227, P257, DOI 10.1016/S0378-1119(98)00578-2; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; Sakamoto O, 2001, EUR RESPIR J, V17, P969, DOI 10.1183/09031936.01.17509690; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; ZERLIN M, 1993, ONCOGENE, V8, P2731	50	59	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45952	45958		10.1074/jbc.M104360200	http://dx.doi.org/10.1074/jbc.M104360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11598108	hybrid			2022-12-25	WOS:000172573100064
J	Gurezka, R; Langosch, D				Gurezka, R; Langosch, D			In vitro selection of membrane-spanning leucine zipper protein-protein interaction motifs using POSSYCCAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE ALPHA-HELICES; ESCHERICHIA-COLI; ERYTHROPOIETIN RECEPTOR; GXXXG MOTIF; ASSOCIATION; DIMERIZATION; TRANSCRIPTION; GLYCOPHORIN; ACTIVATION; RESIDUES	A membrane-spanning heptad repeat motif mediates interaction between transmembrane segments. This motif was randomized with three different sets of mostly hydrophobic residues in the context of POSSYCCAT, a modified ToxR transcription activator system. The resulting combinatorial libraries were subjected to different levels of selective pressure to obtain groups of transmembrane segments that are distinguished by their ability to self-interact in bacterial membranes. Upon relating self-interaction to amino acid composition, the following conclusions were made. First, randomization with only Leu, Ile, Val, Met, and Phe resulted in unexpected robust self-interaction with little sequence specificity. Second, with more complex amino acid mixtures that represent natural transmembrane segments more closely, self-interaction critically depended on amino acid composition of the interface. Whereas the contents of Ile and Leu residues increased with the ability to self-interact, the contents of Pro and Arg residues decreased. Third, heptad repeat motifs composed of Leu, Ile, Val, Met, and Phe were similar to 40-fold over-represented in transmembrane segments of single-span membrane proteins as compared with motifs composed of the more complex amino acid mixtures. This suggests that heptad motifs composed of the smaller subset of amino acids were enriched in the course of natural single-span membrane protein evolution.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Langosch, D (corresponding author), Tech Univ Munich, Lehrstuhl Chem Biopolymere, Weihenstephaner Berg 3, D-85354 Freising Weihenstephan, Germany.							Arkin IT, 1998, BBA-PROTEIN STRUCT M, V1429, P113, DOI 10.1016/S0167-4838(98)00225-8; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Bowie JU, 2000, NAT STRUCT BIOL, V7, P91, DOI 10.1038/72454; Brosig B, 1998, PROTEIN SCI, V7, P1052; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dieckmann GR, 1997, CURR OPIN STRUC BIOL, V7, P486, DOI 10.1016/S0959-440X(97)80111-X; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Huber O, 1999, J CELL SCI, V112, P4415; KOLMAR H, 1995, EMBO J, V14, P3895, DOI 10.1002/j.1460-2075.1995.tb00061.x; KOLMAR H, 1994, BIOL CHEM H-S, V375, P61; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MCGINNES L, 1993, VIROLOGY, V196, P101, DOI 10.1006/viro.1993.1458; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; Niland P, 1996, J MOL BIOL, V264, P667, DOI 10.1006/jmbi.1996.0668; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shapiro L, 1998, CURR OPIN NEUROBIOL, V8, P593, DOI 10.1016/S0959-4388(98)80086-X; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SKERRA A, 1994, GENE, V151, P131, DOI 10.1016/0378-1119(94)90643-2; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	35	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45580	45587		10.1074/jbc.M105362200	http://dx.doi.org/10.1074/jbc.M105362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585820	hybrid			2022-12-25	WOS:000172573100014
J	Lindemann, RK; Ballsehmieter, P; Nordheim, A; Dittmer, J				Lindemann, RK; Ballsehmieter, P; Nordheim, A; Dittmer, J			Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS TRANSCRIPTION FACTORS; GENE-EXPRESSION; DNA-BINDING; PTHRP GENE; C-JUN; ACTIVATION; PROMOTER; RECEPTOR; RAS; SP1	The majority of breast cancers metastasizing to bone secrete parathyroid hormone-related protein (PTHrP). PTHrP induces local osteolysis that leads to activation of bone matrix-borne transforming growth factor beta (TGF beta). In turn, TGF beta stimulates PTHrP expression and, thereby, accelerates bone destruction. We studied the mechanism by which TGF beta activates PTHrP in invasive MDA-MB-231 breast cancer cells. We demonstrate that TGF beta1 up-regulates specifically the level of PTHrP P3 promoter-derived RNA in an actinomycin D-sensitive fashion. Transient transfection studies revealed that TGF beta1 and its effector Smad3 are able to activate the P3 promoter. This effect depended upon an AGAC box and a previously described Ets binding site. Addition of Etsl greatly enhanced the Smad3/TGF beta -mediated activation. Ets2 had also some effect, whereas other Ets proteins, Elf-1, Ese-1, and Erf-1, failed to cooperate with Smad3. In comparison, Ets1 did not increase Smad3/TGF beta -induced stimulation of the TGF beta -responsive plasminogen activator inhibitor 1 (PAI-1) promoter. Smad3 and Smad4 were able to specifically interact with the PTHrP P3-AGAC box and to bind to the P3 promoter together with Etsl. Inhibition of endogenous Etsl expression by calphostin C abrogated TGF beta -induced up-regulation of the P3 transcript, whereas it did not affect the TGF beta effect on PAI expression. In TGF beta receptor II- and Ets1-deficient, noninvasive MCF-7 breast cancer cells, TGF beta1 neither influenced endogenous PTHrP expression nor stimulated the PTHrP P3 promoter. These data suggest that TGF beta activates PTHrP expression by specifically up-regulating transcription from the PTHrP P3 promoter through a novel Smad3/Ets1 synergism.	Univ Tubingen, Inst Zellbiol, Abt Mol Biol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Dittmer, J (corresponding author), Univ Tubingen, Inst Zellbiol, Abt Mol Biol, Morgenstelle 15, D-72076 Tubingen, Germany.	juergen.dittmer@uni-tuebingen.de	Dittmer, Juergen/G-1160-2011					Aklilu F, 1997, CANCER RES, V57, P4517; Benitez-Verguizas J, 1999, LIFE SCI, V65, P1807, DOI 10.1016/S0024-3205(99)00437-3; BIRCH MA, 1995, BRIT J CANCER, V72, P90, DOI 10.1038/bjc.1995.282; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bouizar Z, 1999, J BONE MINER RES, V14, P406, DOI 10.1359/jbmr.1999.14.3.406; Carron JA, 1997, BRIT J CANCER, V76, P1095, DOI 10.1038/bjc.1997.513; CASEY ML, 1993, J CLIN ENDOCR METAB, V77, P188, DOI 10.1210/jc.77.1.188; Chen ZQ, 1997, CANCER RES, V57, P2013; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Cowley DO, 2000, GENE DEV, V14, P366; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Farina AR, 1998, INT J CANCER, V75, P721; Foley J, 1999, MOL CELL ENDOCRINOL, V156, P13, DOI 10.1016/S0303-7207(99)00151-3; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; Grill V, 1998, EUR J CANCER, V34, P222, DOI 10.1016/S0959-8049(97)10130-7; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Guise TA, 1997, CANCER-AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.3.CO;2-D; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karperien M, 1997, MOL ENDOCRINOL, V11, P1435, DOI 10.1210/me.11.10.1435; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KIRIYAMA T, 1993, MOL CELL ENDOCRINOL, V92, P55, DOI 10.1016/0303-7207(93)90074-T; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; LI X, 1994, J BIOL CHEM, V269, P6263; LIAPIS H, 1993, AM J PATHOL, V143, P1169; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Naito S, 1998, AM J PHYSIOL-CELL PH, V274, pC472, DOI 10.1152/ajpcell.1998.274.2.C472; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Pouliot F, 1999, INT J CANCER, V81, P98, DOI 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SOUTHBY J, 1995, BRIT J CANCER, V72, P702, DOI 10.1038/bjc.1995.397; Strewler GJ, 2000, ENDOCRIN METAB CLIN, V29, P629, DOI 10.1016/S0889-8529(05)70154-7; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Tian G, 1999, MOL CELL BIOL, V19, P2946; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Werkmeister JR, 1998, ENDOCRINE, V8, P291, DOI 10.1385/ENDO:8:3:291; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431; WYSOLMERSKI JJ, 1994, ANNU REV MED, V45, P189, DOI 10.1146/annurev.med.45.1.189; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou JN, 1998, MOL CARCINOGEN, V21, P234, DOI 10.1002/(SICI)1098-2744(199804)21:4<234::AID-MC2>3.0.CO;2-K	72	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46661	46670		10.1074/jbc.M105816200	http://dx.doi.org/10.1074/jbc.M105816200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590145	hybrid			2022-12-25	WOS:000172573100154
J	Wain, R; Pertinhez, TA; Tomlinson, EJ; Hong, L; Dobson, CM; Ferguson, SJ; Smith, LJ				Wain, R; Pertinhez, TA; Tomlinson, EJ; Hong, L; Dobson, CM; Ferguson, SJ; Smith, LJ			The cytochrome c fold can be attained from a compact apo state by occupancy of a nascent heme binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE INTERMEDIATE; X-RAY-SCATTERING; APOCYTOCHROME-C; STRUCTURAL-ANALYSIS; DENATURED STATE; NMR; PROTEINS; BIOGENESIS; STABILITY; C(552)	NMR techniques and 8-anilino-1-napthalenesulphonate (ANS) binding studies have been used to characterize the apo state of a variant of cytochrome C-552 from Hydrogenobacter thermophilus. In this variant the two cysteines that form covalent thioether linkages to the heme group have been replaced by alanine residues (C11A/C14A). CD studies show that the apo state contains similar to 14% helical secondary structure, and measurements of hydrodynamic radii using pulse field gradient NAM methods show that it is compact (R-h, 16.6 Angstrom). The apo state binds 1 mol of ANS/mol of protein, and a linear reduction in fluorescence enhancement is observed on adding aliquots of hemin to a solution of apo C11A/C14A cytochrome c(552) with ANS bound. These results suggest that the bound ANS is located in the heme binding pocket, which would therefore be at least partially formed in the apo state. Consistent with these characteristics, the formation of the holo state of the variant cytochrome c(552) from the apo state on the addition of heme has been demonstrated using NMR techniques. The properties of the apo state of C11A/C14A cytochrome c(552) reported here contrast strongly with those of mitochondrial cytochrome c whose apo state resembles a random coil under similar conditions.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Cent Chem Lab, Oxford OX1 3QU, England; Natl Synchrotron Light Lab, Ctr Mol & Struct Biol, BR-13084971 Campinas, Brazil	University of Oxford; University of Oxford; Laboratorio Nacional de Luz Sincrotron (LNLS)	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	ferguson@bioch.ox.ac.uk; lorna.smith@chem.ox.ac.uk						BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; DAMASCHUN G, 1991, BIOCHIM BIOPHYS ACTA, V1078, P289, DOI 10.1016/0167-4838(91)90571-G; DEJONGH HHJ, 1992, BIOCHEMISTRY-US, V31, P1636, DOI 10.1021/bi00121a008; Dobson CM., 1992, CURR OPIN STRUC BIOL, V2, P6; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; EDEN D, 1982, P NATL ACAD SCI-BIOL, V79, P815, DOI 10.1073/pnas.79.3.815; Englander SW, 1998, ACCOUNTS CHEM RES, V31, P737, DOI 10.1021/ar970085h; FENG YQ, 1994, NAT STRUCT BIOL, V1, P30, DOI 10.1038/nsb0194-30; FENG YQ, 1991, BIOCHEMISTRY-US, V30, P7711, DOI 10.1021/bi00245a007; FENG YQ, 1990, BIOCHEMISTRY-US, V29, P3505, DOI 10.1021/bi00466a012; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Gillespie JR, 1997, J MOL BIOL, V268, P170, DOI 10.1006/jmbi.1997.0953; GOTO Y, 1994, METHOD ENZYMOL, V232, P3; HAMADA D, 1993, BIOCHEMISTRY-US, V32, P10351, DOI 10.1021/bi00090a010; Hasegawa J, 2000, J BIOL CHEM, V275, P37824, DOI 10.1074/jbc.M005861200; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895; Kortemme T, 2000, J MOL BIOL, V297, P1217, DOI 10.1006/jmbi.2000.3618; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; MOORE CD, 1991, BIOCHEMISTRY-US, V30, P8357, DOI 10.1021/bi00098a012; MOORE CD, 1993, BIOCHEMISTRY-US, V32, P199, DOI 10.1021/bi00052a026; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Pan H, 1997, PROTEIN SCI, V6, P1985, DOI 10.1002/pro.5560060919; Pettigrew G.W., 1990, CYTOCHROMES C EVOLUT; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rankin SE, 1999, PROTEIN SCI, V8, P381; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SAMBONGI Y, 1994, FEBS LETT, V344, P207, DOI 10.1016/0014-5793(94)00399-8; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; Schwalbe H, 1997, BIOCHEMISTRY-US, V36, P8977, DOI 10.1021/bi970049q; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Shastry MCR, 1998, ACCOUNTS CHEM RES, V31, P717; Shortle DR, 1996, CURR OPIN STRUC BIOL, V6, P24, DOI 10.1016/S0959-440X(96)80091-1; Sinha A, 2000, BIOCHEM J, V345, P711, DOI 10.1042/0264-6021:3450711; Sinha N, 1998, FEMS MICROBIOL LETT, V161, P1; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; TREWHELLA J, 1988, BIOCHEMISTRY-US, V27, P1121, DOI 10.1021/bi00404a007; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Yeh SR, 1998, ACCOUNTS CHEM RES, V31, P727, DOI 10.1021/ar970084p	43	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45813	45817		10.1074/jbc.M107572200	http://dx.doi.org/10.1074/jbc.M107572200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584011	hybrid			2022-12-25	WOS:000172573100043
J	Westendorf, JJ				Westendorf, JJ			The formin/diaphanous-related protein, FHOS, interacts with Rac1 and activates transcription from the serum response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMB DEFORMITY GENE; GTP-BINDING PROTEIN; RHO-FAMILY; SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; TERNARY COMPLEX; HUMAN HOMOLOG; DROSOPHILA; GTPASES; FORMINS	FHOS is a member of the formin homology (FH) family of proteins and is expressed at high levels in splenic cells. FH proteins link cellular signaling pathways to the actin cytoskeleton and serum response factor-dependent transcription. In these studies, the role of FHOS in Rho family GTPase signaling pathways was analyzed. FHOS interacted with the polybasic domain in the Rac1 C terminus in a guanine nucleotide-independent manner but did not interact with RhoA, Cdc42Hs, Rac2, or Rac3. Intramolecular autoinhibitory interactions between the C terminus of FHOS and an N-terminal region partially overlapping the Rac1 interaction domain were also identified. FHOS truncation mutants lacking the N- or C-terminal autoregulatory domains stimulated transcription of a c-fos serum response element (SRE)-driven reporter. Overexpression of wild-type and mutant (N17 and V12) Rac1 proteins repressed SRE induction by the N-terminal FHOS deletion mutant but not by the C-terminal FHOS deletion mutant. Immunofluorescence studies indicated that the localization of the mutant FHOS proteins might contribute to their differential responses to Rac1. Wild-type FHOS and the N-terminal deletion mutant localized to the perinuclear region and membrane edges. In contrast, the C-terminal FHOS mutants were diffusely localized. These data suggest that FHOS induces transcription from SREs by multiple pathways and that Rac1 may influence the course of some FHOS-induced signaling events.	Univ Minnesota, Dept Orthopaed Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Univ Minnesota Canc Ctr, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Westendorf, JJ (corresponding author), Univ Minnesota, Dept Orthopaed Surg, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.				NATIONAL CANCER INSTITUTE [F32CA077167] Funding Source: NIH RePORTER; NCI NIH HHS [F32-CA77167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 2000, J BIOL CHEM, V16, P16; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P209; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Norris PS, 1998, J VIROL METHODS, V75, P161, DOI 10.1016/S0166-0934(98)00108-6; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Treisman R, 1990, Semin Cancer Biol, V1, P47; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uetz P, 1996, J BIOL CHEM, V271, P33525, DOI 10.1074/jbc.271.52.33525; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000; Zhang BL, 2001, J BIOL CHEM, V276, P8958, DOI 10.1074/jbc.M008720200	47	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46453	46459		10.1074/jbc.M105162200	http://dx.doi.org/10.1074/jbc.M105162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590143	hybrid			2022-12-25	WOS:000172573100130
J	Greenberg, AS; Shen, WJ; Muliro, K; Patel, S; Souza, SC; Roth, RA; Kraemer, FB				Greenberg, AS; Shen, WJ; Muliro, K; Patel, S; Souza, SC; Roth, RA; Kraemer, FB			Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LIPID STORAGE DROPLETS; SEQUENCE SIMILARITY; 3T3-L1 ADIPOCYTES; COUPLED RECEPTORS; BROWN ADIPOCYTES; RAT ADIPOCYTES; PERILIPIN-A; IN-VITRO; PHOSPHORYLATION	Hormonally stimulated lipolysis occurs by activation of cyclic AMP-dependent protein kinase (PKA) which phosphorylates hormone-sensitive lipase (HSL) and increases adipocyte lipolysis. Evidence suggests that catecholamines not only can activate PKA, but also the mitogen-activated protein kinase pathway and extracellular signal-regulated kinase (ERK). We now demonstrate that two different inhibitors of MEK, the upstream activator of ERK, block catecholamine- and beta (3)-stimulated lipolysis by similar to 30%. Furthermore, treatment of adipocytes with dioctanoylglycerol, which activates ERK, increases lipolysis, although MEK inhibitors decrease dioctanoylglycerol-stimulated activation of lipolysis. Using a tamoxifen regulatable Raf system expressed in 3T3-L1 preadipocytes, exposure to tamoxifen causes a 14-fold activation of ERK within 15-30 min and results in similar to2-fold increase in HSL activity. In addition, when differentiated 3T3-L1 cells expressing the regulatable Raf were exposed to tamoxifen, a 2-fold increase in lipolysis is observed. HSL is a substrate of activated ERK and site-directed mutagenesis of putative ERK consensus phosphorylation sites in HSL identified Ser(600) as the site phosphorylated by active ERK. When S600A HSL was expressed in 3T3-L1 cells expressing the regulatable Raf, tamoxifen treatment fails to increase its activity. Thus, activation of the ERK pathway appears to be able to regulate adipocyte lipolysis by phosphorylating HSL on Ser(600) and increasing the activity of HSL.	Stanford Univ, Dept Med, Div Endocrinol, Stanford, CA 94305 USA; Tufts Univ New England Med Ctr, Dept Med, Boston, MA 02111 USA; Tufts Univ, USDA, Jean Meyer Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Kraemer, FB (corresponding author), Stanford Univ, Dept Med, Div Endocrinol, S-005, Stanford, CA 94305 USA.		Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807; Shen, Wen-Jun/0000-0001-5150-1698	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050647, R01DK049705, R01DK046942] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50647, DK 49705, DK 46942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Choo DW, 1998, APPL ENVIRON MICROB, V64, P486; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; DAVIS RJ, 1985, J BIOL CHEM, V260, P1562; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GARTON AJ, 1988, FEBS LETT, V229, P68, DOI 10.1016/0014-5793(88)80799-3; GARTON AJ, 1990, EUR J BIOCHEM, V191, P245, DOI 10.1111/j.1432-1033.1990.tb19116.x; GORDON RS, 1956, J CLIN INVEST, V35, P206, DOI 10.1172/JCI103265; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KRAEMER FB, 1993, J LIPID RES, V34, P663; Lindquist JM, 2000, J BIOL CHEM, V275, P22670, DOI 10.1074/jbc.M909093199; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Manco G, 1998, BIOCHEM J, V332, P203, DOI 10.1042/bj3320203; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mizuno K, 1999, EUR J PHARMACOL, V385, P63, DOI 10.1016/S0014-2999(99)00733-5; Morimoto C, 2001, J LIPID RES, V42, P120; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osterlund T, 1999, J BIOL CHEM, V274, P15382, DOI 10.1074/jbc.274.22.15382; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; PROBST MR, 1994, J BIOL CHEM, V269, P21650; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 1998, BIOCHEMISTRY-US, V37, P8973, DOI 10.1021/bi980545u; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; SZTALRYD C, 1994, AM J PHYSIOL, V266, pE179, DOI 10.1152/ajpendo.1994.266.2.E179; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wei YY, 1999, NAT STRUCT BIOL, V6, P340	57	271	285	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45456	45461		10.1074/jbc.M104436200	http://dx.doi.org/10.1074/jbc.M104436200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581251	hybrid			2022-12-25	WOS:000172406700143
J	Pisarchik, A; Slominski, AT				Pisarchik, A; Slominski, AT			Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression	FASEB JOURNAL			English	Article						CRH receptors; mammalian skin; stress	CORTICOTROPIN-RELEASING-FACTOR; CUTANEOUS EXPRESSION; HORMONE-RECEPTOR; FACTOR CRF; CLONING; MELANOGENESIS; DOMAIN; DETERMINANTS; MELANOCYTES; SAUVAGINE	We identified four new isoforms of human CRH-R1 (e-h) and three of mouse (mCRH-R1c, e, and f). In all new forms exon 6 was missing. Human CRH-R1e was characterized by the deletion of exons 3 and 4; exon 12 from CRH-R1f; exon 11, 27 base pairs (bp) of exon 10 and 28 bp of exon 12 from CRH-R1g and CRH-R1h by the addition of a cryptic exon. In mouse CRH-R1c exon 3 was spliced out; in mCRH-R1e exons 3 and 4 and in mCRH-R1f exon 11 were spliced from mRNA. CRH-R1 was expressed in all skin specimens in patterns dependent on the cell type, physiological status, and presence of pathology. CRH-R1, the most prevalent form, was detected in almost all samples. Ultraviolet radiation (UV) changed the splicing pattern and induced or increased expression of CRH-R1 in cultured skin cells. Continuing UV treatment of succeeding generations of cells resulted in a progressive increase in the number of CRH-R1 isoforms, which suggests that receptor heterogeneity might favor cell survival. TPA (phorbol 12-myristate 13-acetate), forskolin, dbcAMP (N6, 2'-O-dibutyryladenosine 3':5'-cyclic monophospate sodium), and IBMX (3-isobutyl-1-methylxanthine) also changed the splicing pattern. We suggest that a polymorphism of CRH-R1 expression is related to anatomic location, skin physiological or pathologic status, specific cell type, and external stress (UV), and that cAMP-dependent pathways and TPA may regulate CRH-R1.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Slominski, AT (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 899 Madison Ave,Room 576 BMH, Memphis, TN 38163 USA.	aslominski@utmem.edu		Pisarchik, Alexander/0000-0002-8991-919X; Slominski, Andrzej/0000-0001-8963-3995				ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Arai M, 2001, ENDOCRINOLOGY, V142, P446, DOI 10.1210/en.142.1.446; ARTS E, 2000, HUM MOL GENET, V9, P237; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640; Grammatopoulos DK, 1999, MOL ENDOCRINOL, V13, P2189, DOI 10.1210/me.13.12.2189; HINUMA K, 1997, Patent No. 1997070289; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liaw CW, 1997, MOL ENDOCRINOL, V11, P980, DOI 10.1210/me.11.7.980; Liaw CW, 1996, ENDOCRINOLOGY, V137, P72, DOI 10.1210/en.137.1.72; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; NABHAN C, 1995, BIOCHEM BIOPH RES CO, V212, P1015, DOI 10.1006/bbrc.1995.2071; Owens AH, 1982, TUMOR CELL HETEROGEN; PAWELEK JM, 1992, PIGM CELL RES, V5, P348, DOI 10.1111/j.1600-0749.1992.tb00561.x; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P836; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; ROBBINS M, 1992, MOL BRAIN RES, V13, P83, DOI 10.1016/0169-328X(92)90047-F; ROSS PC, 1994, BIOCHEM BIOPH RES CO, V205, P1836, DOI 10.1006/bbrc.1994.2884; SAKAI RR, 1998, PERSPECT ANTISEN SCI, V1, P125; SLOMINSKI A, 1992, LIFE SCI, V50, P1103, DOI 10.1016/0024-3205(92)90347-R; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P815, DOI 10.1210/jc.85.2.815; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 1996, BBA-GEN SUBJECTS, V1289, P247, DOI 10.1016/0304-4165(95)00159-X; Slominski A, 1999, IN VITRO CELL DEV-AN, V35, P564; Slominski A, 1998, CLIN DERMATOL, V16, P503, DOI 10.1016/S0738-081X(98)00023-6; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Slominski A, 1996, FEBS LETT, V399, P175, DOI 10.1016/S0014-5793(96)01315-4; Slominski A, 2000, J CLIN ENDOCR METAB, V85, P3582, DOI 10.1210/jc.85.10.3582; Slominski AT, 2000, IN VITRO CELL DEV-AN, V36, P211; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sorek R, 2001, NAT BIOTECHNOL, V19, P196, DOI 10.1038/85613; Spiess J, 1998, TRENDS ENDOCRIN MET, V9, P140, DOI 10.1016/S1043-2760(98)00037-X; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; TsaiMorris CH, 1996, J BIOL CHEM, V271, P14519, DOI 10.1074/jbc.271.24.14519; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x	46	151	154	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2754	+		10.1096/fj.01-0487fje	http://dx.doi.org/10.1096/fj.01-0487fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606483				2022-12-25	WOS:000171920400010
J	Sugai, T; Habano, W; Uesugi, N; Jiao, YF; Nakamura, S; Yoshida, T; Higuchi, T				Sugai, T; Habano, W; Uesugi, N; Jiao, YF; Nakamura, S; Yoshida, T; Higuchi, T			Frequent allelic imbalance at the ATM locus in DNA multiploid colorectal carcinomas	ONCOGENE			English	Article						allelic imbalance; ATM; colorectal carcinogenesis; DNA multiploidy; PCR	CRYPT-ISOLATION TECHNIQUE; ATAXIA-TELANGIECTASIA GENE; TUMOR-SUPPRESSOR GENES; CHROMOSOME 11Q23; HETEROZYGOSITY; CANCER; REGION; DAMAGE; IDENTIFICATION; ANEUPLOIDY	DNA multiploidy may involve specific DNA ploidy states with respect to genetic alterations such as oncogenes, tumor suppressor gene mutation and microsatellite instability. To clarify the role of DNA multiploidy in colorectal cancer, we analysed allelic imbalance involving the ATM gene, localized to chromosome 11q22-23 and thought to be involved in genetic stability, in a series of multiploid colorectal carcinomas. In addition, p53 gene mutation (exons 5 - 8) and allelic imbalance at 11q24 loci distal to the ATM locus were also examined. The crypt isolation technique coupled with DNA cytometric sorting and polymerase chain reaction assay using 10 microsatellite markers tightly linked to the ATM gene were used to study ATM allelic imbalance in 55 colorectal carcinomas (15 diploid, 13 aneuploid, 27 multiploid). While allelic imbalance at the ATM locus was rarely observed in diploid and aneuploid carcinomas, multiploid carcinomas exhibited a high frequency of ATM allelic imbalance. In multiploid carcinoma samples, diploid subpopulations showed a smaller range of allelic imbalance at the loci tested compared to aneuploid subpopulations that demonstrated allelic imbalance over a relatively large region. Also, the frequency of AI at 11q24 showed a similar tendency to that at the ATM locus for each DNA ploidy state. An association between p53 gene mutation and ATM allelic imbalance in multiploid carcinoma was also observed. Our results suggest that ATM allelic imbalance and p53 gene mutations occur during the progression from diploid to aneuploid cell populations in multiploid colorectal carcinomas.	Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, Morioka, Iwate 0208505, Japan; Iwate Med Univ, Sch Med, Dept Surg 1, Morioka, Iwate 0208505, Japan	Iwate Medical University; Iwate Medical University	Sugai, T (corresponding author), Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, 19-1 Morioka, Morioka, Iwate 0208505, Japan.							BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; CARDER PJ, 1995, BRIT J CANCER, V71, P215, DOI 10.1038/bjc.1995.46; CARTER SL, 1994, CANCER RES, V54, P6270; Connolly KC, 1999, CANCER RES, V59, P2806; Davis M, 1996, CANCER RES, V56, P741; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; Japanese Society for Cancer of the Colon and Rectum, 1997, JAP CLASS COL CARC, P30; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; LANGE E, 1995, AM J HUM GENET, V57, P112; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1995, CANCER RES, V55, P5991; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; NAKAMURA S, 1994, GASTROENTEROLOGY, V106, P100, DOI 10.1016/S0016-5085(94)94651-5; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; RASIO D, 1995, CANCER RES, V55, P6053; RASIO D, 1995, CANCER RES, V55, P3988; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sugai T, 2000, INT J CANCER, V88, P614, DOI 10.1002/1097-0215(20001115)88:4<614::AID-IJC15>3.3.CO;2-S; Sugai T, 2000, HUM PATHOL, V31, P925, DOI 10.1053/hupa.2000.9087; Sugai T, 2000, ARCH PATHOL LAB MED, V124, P382; Sugai T, 2000, PATHOL RES PRACT, V196, P145, DOI 10.1016/S0344-0338(00)80094-1; Takagi M, 1998, CANCER RES, V58, P4923; TURNBULL RB, 1967, ANN SURG, V166, P420; Uhrhammer N, 1999, ONCOL REP, V6, P655; VANAGAITE L, 1995, HUM GENET, V95, P451; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; ZBIERANOWSKI I, 1993, ANAL CELL PATHOL, V5, P69	33	21	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6095	6101		10.1038/sj.onc.1204731	http://dx.doi.org/10.1038/sj.onc.1204731			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593417				2022-12-25	WOS:000171056300017
J	Kuwasako, K; Kitamura, K; Ito, K; Uemura, T; Yanagita, Y; Kato, J; Sakata, T; Eto, T				Kuwasako, K; Kitamura, K; Ito, K; Uemura, T; Yanagita, Y; Kato, J; Sakata, T; Eto, T			The seven amino acids of human RAMP2 (86-92) and RAMP3 (59-65) are critical for agonist binding to human adrenomedullin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; ACTIVITY-MODIFYING PROTEINS; CALCITONIN; CELLS	When co-expressed with a receptor activity-modifying protein (RAMP) accessory protein, calcitonin receptor-like receptor (CRLR) can function as a calcitonin gene-related peptide receptor (CRLR-RAMP1) or an adrenomedullin (AM) receptor (CRLR-RAMP2/3). Here we report on the structural domain(s) involved in selective AM binding that were examined using various RAMP chimeras and deletion mutants. Co-expression of chimeric RAMPS and CRLR in HEK293 cells revealed that residues 77-101, situated in the extracellular N-terminal domain of human RAMP2 (hRAMP2), were crucial for selective AM-evoked cAMP production. More detailed analysis showed that deletion of hRAMP2 residues 86-92 significantly attenuated high-affinity I-125-AM binding and AM-evoked cAMP production despite full cell surface expression of the receptor heterodimer and that deletion of hRAMP3 residues 59-65 had a similar effect. There is little sequence identity between hRAMP3 residues 59-65 and hRAMP2 residues 86-92; moreover, substituting alanine for Trp(86) (Ala(87)), Met(88), Ile(89), Ser(90), Arg(91), or Pro(92) of hRAMP2 had no effect on AM-evoked cAMP production. It thus seems unlikely that any one amino acid residue is responsible for determining selective AM binding or that AM binds directly to these peptide segments. Instead these findings suggest that the respective seven-amino acid sequences confer selectivity either by directly contributing to the structure of ligand binding pocket or by allosteric modulation of the conformation of CRLR.	Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan; Shionogi & Co Ltd, Shionogi Res Labs, Osaka 5660022, Japan	University of Miyazaki; Shionogi & Company Limited	Kuwasako, K (corresponding author), Miyazaki Med Coll, Dept Internal Med 1, 5200 Kihara, Miyazaki 8891692, Japan.		Kuwasako, Kenji/H-8065-2016					Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Aldecoa A, 2000, FEBS LETT, V471, P156, DOI 10.1016/S0014-5793(00)01387-9; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; EGUCHI S, 1994, ENDOCRINOLOGY, V135, P2454, DOI 10.1210/en.135.6.2454; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; GUON XM, 1992, J BIOL CHEM, V267, P21995; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Husmann K, 2000, MOL CELL ENDOCRINOL, V162, P35, DOI 10.1016/S0303-7207(00)00212-4; Kitamura K, 1997, CURR OPIN NEPHROL HY, V6, P80, DOI 10.1097/00041552-199701000-00015; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Muff R, 1998, FEBS LETT, V441, P366, DOI 10.1016/S0014-5793(98)01587-7; Samson WK, 1998, FRONT NEUROENDOCRIN, V19, P100, DOI 10.1006/frne.1998.0164; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	20	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49459	49465		10.1074/jbc.M108369200	http://dx.doi.org/10.1074/jbc.M108369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11591721	hybrid			2022-12-25	WOS:000173922100108
J	Clare, PM; Poorman, RA; Kelley, LC; Watenpaugh, KD; Bannow, CA; Leach, KL				Clare, PM; Poorman, RA; Kelley, LC; Watenpaugh, KD; Bannow, CA; Leach, KL			The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-CYCLE; CATALYTIC SUBUNIT; NEURONAL DIFFERENTIATION; SUBSTRATE-SPECIFICITY; CLINICAL DEVELOPMENT; TYROSINE KINASE; MAP KINASE; INHIBITORS; PHOSPHORYLATION	cdk2-cyclin E and cdk5-p25 are two members of the cyclin-dependent kinase family that are potential therapeutic targets for oncology and Alzheimer's disease, respectively. In this study we have investigated the mechanism for these enzymes. Kinases catalyze the transfer of phosphate from ATP to a protein acceptor, thus utilizing two substrates, ATP and the target protein. For a two-substrate reaction, possible kinetic mechanisms include: ping-pong, sequential random, or sequential ordered. To determine the kinetic mechanism of cdk2-GST-cyclin E and cdk5-GST-p25, kinase activity was measured in experiments in which concentrations of peptide and ATP substrates were varied in the presence of dead-end inhibitors. A peptide identical to the peptide substrate, but with a substitution of valine for the phosphoacceptor threonine, competed with substrate with a K-i value of 0.6 mM. An aminopyrimidine, PNU 112455A, was identified in a screen for inhibitors of cdk2. Nonlinear least squares and Lineweaver-Burk analyses demonstrated that the inhibitor PNU 112455A was competitive with ATP with a K-i value of 2 muM. In addition, a co-crystal of PNU 112455A with cdk2 showed that the inhibitor binds in the ATP binding pocket of the enzyme. Analysis of the inhibitor data demonstrated that both kinases use a sequential random mechanism, in which either ATP or peptide may bind first to the enzyme active site. For both kinases, the binding of the second substrate was shown to be anticooperative, in that the binding of the first substrate decreases the affinity of the second substrate. For cdk2-GST-cyclin E the kinetic parameters were determined to be K-m,K-ATP = 3.6 +/- 1.0 muM, K-m,K-peptide = 4.6 +/- 1.4 muM, and the anticooperativity factor, alpha = 130 +/- 44. For cdk5(.)GST-p25, the K-m,K-ATP = 3.2 +/- 0.7 muM, K-m,K-peptide = 1.6 +/- 0.3 muM, and alpha = 7.2 +/- 1.8.	Pharmacia Corp, Dept Cell & Mol Biol, Kalamazoo, MI 49007 USA; Pharmacia Corp, Dept Prot Sci, Kalamazoo, MI 49007 USA; Pharmacia Corp, Dept Operat Res, Kalamazoo, MI 49007 USA; Pharmacia Corp, Dept Struct Analyt & Med Chem, Kalamazoo, MI 49007 USA	Pfizer; Pfizer; Pfizer; Pfizer	Leach, KL (corresponding author), Pharmacia Corp, Cell & Mol Biol, 7252-267-306,301 Henrietta St, Kalamazoo, MI 49007 USA.	karen.1.leach@pharmacia.com						AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Ando S, 1997, J BIOCHEM, V122, P409; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Buolamwini JK, 2000, CURR PHARM DESIGN, V6, P379, DOI 10.2174/1381612003400948; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cohen P, 1999, CURR OPIN CHEM BIOL, V3, P459, DOI 10.1016/S1367-5931(99)80067-2; COLE PA, 1994, J BIOL CHEM, V269, P30880; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; Fromm H J, 1979, Methods Enzymol, V63, P467; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; HIGASHI H, 1995, BIOCHEM BIOPH RES CO, V216, P520, DOI 10.1006/bbrc.1995.2653; Horiuchi KY, 1998, BIOCHEMISTRY-US, V37, P8879, DOI 10.1021/bi972731q; Hudkins RL, 1999, CURR MED CHEM, V6, pU2; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kaubisch A, 2000, CANCER J, V6, P192; Konstantinidis AK, 1998, J BIOL CHEM, V273, P26506, DOI 10.1074/jbc.273.41.26506; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee KY, 1997, INT J BIOCHEM CELL B, V29, P951, DOI 10.1016/S1357-2725(97)00048-4; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Martin-Castellanos C, 1997, TRENDS CELL BIOL, V7, P95, DOI 10.1016/S0962-8924(96)10055-6; Meijer L, 2000, DRUG RESIST UPDATE, V3, P83, DOI 10.1054/drup.2000.0129; MEIJER L, 2000, PROGR CELL CYCLE RES, V4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Parast CV, 1998, BIOCHEMISTRY-US, V37, P16788, DOI 10.1021/bi981291f; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pei JJ, 1998, BRAIN RES, V797, P267, DOI 10.1016/S0006-8993(98)00296-0; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; POSNER I, 1992, J BIOL CHEM, V267, P20638; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; Sandhu C, 2000, CANCER DETECT PREV, V24, P107; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; Segel, 1975, ENZYME KINETICS BEHA, P274; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sielecki TM, 2000, J MED CHEM, V43, P1, DOI 10.1021/jm990256j; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Tang D, 1996, Prog Cell Cycle Res, V2, P205; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WONG TW, 1984, J BIOL CHEM, V259, P3127; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	64	43	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48292	48299		10.1074/jbc.M102034200	http://dx.doi.org/10.1074/jbc.M102034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604388	hybrid			2022-12-25	WOS:000172927000075
J	Emanuelli, B; Peraldi, P; Filloux, C; Chavey, C; Freidinger, K; Hilton, DJ; Hotamisligil, GS; Van Obberghen, E				Emanuelli, B; Peraldi, P; Filloux, C; Chavey, C; Freidinger, K; Hilton, DJ; Hotamisligil, GS; Van Obberghen, E			SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PROTEIN-KINASE-C; TNF-ALPHA; LACKING SUPPRESSOR; STAT 5B; RECEPTOR; RESISTANCE; PATHWAY; IRS-1; PHOSPHORYLATION	SOCS (suppressor of cytokine signaling) proteins are inhibitors of cytokine signaling involved in negative feedback loops. We have recently shown that insulin increases SOCS-3 mRNA expression in 3T3-L1 adipocytes. When expressed, SOCS-3 binds to phosphorylated Tyr(960) of the insulin receptor and prevents Stat 5B activation by insulin. Here we show that in COS-7 cells SOCS-3 decreases insulin-induced insulin receptor substrate I (IRS-1) tyrosine phosphorylation and its association with p85, a regulatory subunit of phosphatidylinositol-3 kinase. This mechanism points to a function of SOCS-3 in insulin resistance. Interestingly, SOCS-3 expression was found to be increased in the adipose tissue of obese mice, but not in the liver and muscle of these animals. Two polypeptides known to be elevated during obesity, insulin and tumor necrosis factor-alpha (TNF-alpha), induce SOCS-3 mRNA expression in mice. Insulin induces a transient expression of SOCS-3 in the liver, muscle, and the white adipose tissue (WAT). Strikingly, TNF-alpha induced a sustained SOCS-3 expression, essentially in the WAT. Moreover, transgenic ob/ob mice lacking both TNF receptors have a pronounced decrease in SOCS-3 expression in the WAT compared with ob/ob mice, providing genetic evidence for a function of this cytokine in obesity-induced SOCS-3 expression. As SOCS-3 appears as a TNF-alpha target gene that is elevated during obesity, and as SOCS-3 antagonizes insulin-induced IRS-1 tyrosine phosphorylation, we suggest that it is a player in the development of insulin resistance.	Fac Med, INSERM U145, IFR 50, F-06107 Nice 2, France; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Div Biol Sci, Boston, MA 02115 USA; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Walter & Eliza Hall Institute	Peraldi, P (corresponding author), Fac Med, INSERM U145, IFR 50, F-06107 Nice 2, France.	peraldi@unice.fr	Emanuelli, Brice/M-2097-2016; Peraldi, Pascal/O-4592-2016; Hilton, Douglas J/C-7250-2013	Emanuelli, Brice/0000-0001-5795-5666; Peraldi, Pascal/0000-0003-0205-9252; Hilton, Douglas J/0000-0002-7698-2392; Chavey, Carine/0000-0002-5267-5638	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Emilsson V, 1999, FEBS LETT, V455, P170, DOI 10.1016/S0014-5793(99)00874-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Guo DQ, 1998, J IMMUNOL, V160, P2742; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hong F, 2001, FASEB J, V15, P1595, DOI 10.1096/fj.00-0908fje; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Itani SI, 2000, DIABETES, V49, P1353, DOI 10.2337/diabetes.49.8.1353; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Krebs DL, 2000, J CELL SCI, V113, P2813; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sadowski CL, 2001, J BIOL CHEM, V276, P20703, DOI 10.1074/jbc.M101014200; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sawka-Verhelle D, 2000, ENDOCRINOLOGY, V141, P1977, DOI 10.1210/en.141.6.1977; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Sethi JK, 1999, SEMIN CELL DEV BIOL, V10, P19, DOI 10.1006/scdb.1998.0273; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Uysal KT, 1998, ENDOCRINOLOGY, V139, P4832, DOI 10.1210/en.139.12.4832; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wang ZW, 2000, BIOCHEM BIOPH RES CO, V277, P20, DOI 10.1006/bbrc.2000.3615; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	49	356	370	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47944	47949		10.1074/jbc.M104602200	http://dx.doi.org/10.1074/jbc.M104602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604392	hybrid			2022-12-25	WOS:000172927000031
J	Lonigro, R; Donnini, D; Zappia, E; Damante, G; Bianchi, ME; Guazzi, S				Lonigro, R; Donnini, D; Zappia, E; Damante, G; Bianchi, ME; Guazzi, S			Nestin is a neuroepithelial target gene of thyroid transcription factor-1, a homeoprotein required for forebrain organogenesis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; FACTOR-I TTF-1; ENHANCER-BINDING PROTEIN; CNS STEM-CELL; B GENE; EXPRESSION; PROMOTER; HOMEODOMAIN; SEQUENCE; LUNG	Thyroid transcription factor-1 (TTF-1, also known as NKX2.1 and T/EBP), a transcription factor belonging to the NKX-2 family of homeodomain-containing genes, plays an essential role in the organogenesis of the thyroid gland, lung, and ventral forebrain. Nestin is an intermediate filament protein strongly expressed in multipotential neuroepithelial stem cells and rapidly down-regulated during postnatal life. Here we show that stable fibroblastic clones expressing TTF-1 acquire a phenotype reminiscent of neuroepithelial cells in culture and up-regulate the endogenous nestin gene. TTF-1 transactivates in HeLa and NIH3T3 cells a reporter gene driven by a central nervous system-specific enhancer element from the second intron of the rat nestin gene, where it recognizes a DNA-binding site (NestBS) whose sequence resembles a nuclear hormone/cAMP-responsive element very different from canonical TTF-1 binding sites. Nuclear extracts from the head of mouse embryos form a retarded complex with NestBS of the same mobility of the extracts obtained from TTF1-expressing clones, which is either abolished or supershifted in the presence of two different antibodies recognizing the TTF-1 protein. Thus, the neuroepithelial marker nestin is a direct central nervous system-specific target gene of TTF-1, leading to the hypothesis that it might be the effector through which TTF-1 plays its role in the organogenesis of the forebrain.	San Raffaele Sci Inst, Dept Biol & Biotechnol, DNA Prot Interact Unit, I-20132 Milan, Italy; Univ Udine, Dept Biol Sci & Technol, I-33100 Udine, Italy; Univ Udine, Dept Expt & Clin Pathol & Med, I-33100 Udine, Italy; Univ Genoa, Dept Expt Med, Human Anat Sect, I-16132 Genoa, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Udine; University of Udine; University of Genoa	Guazzi, S (corresponding author), San Raffaele Sci Inst, Dept Biol & Biotechnol, DNA Prot Interact Unit, Via Olgettina 58, I-20132 Milan, Italy.		Bianchi, Marco Emilio/K-3417-2018; Damante, Giuseppe/AAC-5200-2022	Bianchi, Marco Emilio/0000-0002-5329-6445; Damante, Giuseppe/0000-0003-2312-4009	Telethon [E.0601] Funding Source: Medline	Telethon(Fondazione Telethon)		BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; FABBRO D, 1995, BIOCHEM BIOPH RES CO, V213, P781, DOI 10.1006/bbrc.1995.2198; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FROIMAN K, 1997, DIFFERENTIATION, V61, P243; Guazzi S, 1998, J BIOL CHEM, V273, P11092, DOI 10.1074/jbc.273.18.11092; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Hackett BP, 1996, ANNU REV PHYSIOL, V58, P51, DOI 10.1146/annurev.physiol.58.1.51; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Josephson R, 1998, DEVELOPMENT, V125, P3087; KACHINSKY AM, 1994, DEV BIOL, V165, P216, DOI 10.1006/dbio.1994.1248; KACHINSKY AM, 1995, J HISTOCHEM CYTOCHEM, V43, P843, DOI 10.1177/43.8.7542682; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LAZZARO D, 2001, DEVELOPMENT, V17, P107; Lee BJ, 2001, MOL CELL NEUROSCI, V17, P107, DOI 10.1006/mcne.2000.0933; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lothian C, 1999, EXP CELL RES, V248, P509, DOI 10.1006/excr.1999.4417; Marin O, 2000, J NEUROSCI, V20, P6063; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Oguchi H, 1998, ENDOCRINOLOGY, V139, P1999, DOI 10.1210/en.139.4.1999; Pleasure SJ, 2000, NEURON, V28, P727, DOI 10.1016/S0896-6273(00)00149-5; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; Ramirez MI, 1997, J BIOL CHEM, V272, P26285, DOI 10.1074/jbc.272.42.26285; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; Saji M, 1997, J BIOL CHEM, V272, P20096, DOI 10.1074/jbc.272.32.20096; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; Sussel L, 1999, DEVELOPMENT, V126, P3359; Suzuki K, 1998, MOL CELL BIOL, V18, P7410, DOI 10.1128/MCB.18.12.7410; Suzuki K, 1998, ENDOCRINOLOGY, V139, P3014, DOI 10.1210/en.139.6.3014; Terling C, 1995, INT J DEV BIOL, V39, P947; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zhang LQ, 1997, BBA-GENE STRUCT EXPR, V1350, P359, DOI 10.1016/S0167-4781(96)00180-7	41	22	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47807	47813		10.1074/jbc.M107692200	http://dx.doi.org/10.1074/jbc.M107692200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11584016	hybrid			2022-12-25	WOS:000172927000012
J	Trevillyan, JM; Chiou, XG; Chen, YW; Ballaron, SJ; Sheets, MP; Smith, ML; Wiedeman, PE; Warrior, U; Wilkins, J; Gubbins, EJ; Gagne, GD; Fagerland, J; Carter, GW; Luly, JR; Mollison, KW; Djuric, SW				Trevillyan, JM; Chiou, XG; Chen, YW; Ballaron, SJ; Sheets, MP; Smith, ML; Wiedeman, PE; Warrior, U; Wilkins, J; Gubbins, EJ; Gagne, GD; Fagerland, J; Carter, GW; Luly, JR; Mollison, KW; Djuric, SW			Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; CALCINEURIN; INDUCTION; SIGNAL; IMMUNOSUPPRESSANT; DEPHOSPHORYLATION; KINASES; PATHWAY; BINDING; FK-506	NFAT (nuclear factor of activated T cell) proteins are expressed in most immune system cells and regulate the transcription of cytokine genes critical for the immune response. The activity of NFAT proteins is tightly regulated by the Ca2+/calmodulin-dependent protein phosphatase 2B/calcineurin (CaN). Dephosphorylation of NFAT by CaN is required for NFAT nuclear localization. Current immunosuppressive drugs such as cyclosporin A and FK506 block CaN activity thus inhibiting nuclear translocation of NFAT and consequent cytokine gene transcription. The inhibition of CaN in cells outside of the immune system may contribute to the toxicities associated with cyclosporin A therapy. In a search for safer immunosuppressive drugs, we identified a series of 3,5-bistrifluoromethyl pyrazole (BTP) derivatives that block Th1 and Th2 cytokine gene transcription. The BTP compounds block the activation-dependent nuclear localization of NFAT as determined by electrophoretic mobility shift assays. Confocal microscopy of cells expressing fluorescent-tagged NFAT confirmed that the BTP compounds block calcium-induced movement of NFAT from the cytosol. to the nucleus. Inhibition of NFAT was selective because the BTP compounds did not affect the activation of NF-kappaB and AP-1 transcription factors. Treatment of intact T cells with the BTP compounds prior to calcium ionophore-induced activation of CaN caused NFAT to remain in a highly phosphorylated state. However, the BTP compounds did not directly inhibit the dephosphorylation of NFAT by CaN in vitro, nor did the drugs block the dephosphorylation of other CaN substrates including the type II regulatory subunit of protein kinase A and the transcription factor Elk-1. The data suggest that the BTP compounds cause NFAT to be maintained in the cytosol in a phosphorylated state and block the nuclear import of NFAT and, hence, NFAT-dependent cytokine gene transcription by a mechanism other than direct inhibition of CaN phosphatase activity. The novel inhibitors described herein will be useful in better defining the cellular regulation of NFAT activation and may lead to identification of new therapeutic targets for the treatment of autoimmune disease and transplant rejection.	Abbott Labs, Global Pharmaceut Prod Div, Abbott Pk, IL 60064 USA	Abbott Laboratories	Trevillyan, JM (corresponding author), D-47R,AP10-103,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	james.m.trevillyan@abbott.com						Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; Djuric SW, 2000, J MED CHEM, V43, P2975, DOI 10.1021/jm990615a; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FERRARI JR, 1997, J PREVENTION INTERVE, V15, P83; FLANAGAN WM, 1992, J BIOL CHEM, V267, P399; FUNG JJ, 1991, TRANSPLANT P, V23, P3105; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JUNE CH, 1989, J IMMUNOL, V143, P153; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu WF, 2001, FEBS LETT, V496, P105, DOI 10.1016/S0014-5793(01)02411-5; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; Matsuda S, 2000, EMBO REP, V1, P428, DOI 10.1093/embo-reports/kvd090; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORRIS RE, 1995, TRANSPLANTATION LIVE, P760; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; THOMSON AW, 1993, SPRINGER SEMIN IMMUN, V14, P323, DOI 10.1007/BF00192307; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TSUCHIDA T, 1988, J IMMUNOL, V140, P3446; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	39	84	97	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48118	48126		10.1074/jbc.M107919200	http://dx.doi.org/10.1074/jbc.M107919200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11592964	hybrid			2022-12-25	WOS:000172927000052
J	Chelli, M; Alizon, M				Chelli, M; Alizon, M			Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-SURFACE EXPRESSION; HIV-1 INFECTION; EXTRACELLULAR CYSTEINES; CORECEPTOR; OLIGOMERIZATION; INHIBITION; ENTRY; DIMERIZATION	The human immunodeficiency virus, type 1 (HIV-1) entry process is triggered by interaction between the viral envelope and a seven membrane-spanning domain receptor at the cell surface, usually the CCR5 chemokine receptor. Different naturally occurring mutations in the CCR5 gene abolish receptor function, the most frequent being a 32-nucleotide deletion resulting in a truncated protein (Delta 32) lacking the last three transmembrane domains (TM5-7). This mutant is retained in the endoplasmic reticulum and exerts a trans-dominant negative (TDN) effect on the wild type, preventing its exit from this compartment. This TDN effect is often considered as evidence for the oligomerization of CCR5 during transport to the cell surface. Here we use a genetic approach to define the structural determinants of the TDN effect of the Delta 32 mutant. It was abolished by certain deletions and by mutations of cysteine residues preventing formation of a disulfide link between the first and second extracellular loops, suggesting that conformation of Delta 32 is important for its interaction with CCR5. To circumvent this problem, we used chimeric forms of the Delta 32 and wild type CCR5, consisting in substitutions with homologous domains from the mouse CCR5. All chimeric full-length receptors were expressed at the cell surface and were functional for interaction with HIV-1 or with a chemokine ligand, when assayed. The TDN effect was only observed if both the TM3 domain in CCR5 and the TM4 domain in Delta 32 were from human origin, whereas the rest of the proteins could be from either origin, This suggests that the TDN effect involves some form of interaction between these transmembrane domains. Alternatively, but less likely to us, substitutions in TM4 could affect the conformation of CCR5 in the endoplasmic reticulum. but not at the cell surface. However that may be, it seems that the TDN effect of the Delta 32 mutant has no bearing to the issue of CCR5 dimerization and to its possible role in the processing of the receptor to the cell surface.	Inst Cochin Genet Mol, INSERM U332, F-75014 Paris, France; Inst Cochin Genet Mol, Dept Cell Biol, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Alizon, M (corresponding author), Inst Cochin Genet Mol, INSERM U332, 22 Rue Mechain, F-75014 Paris, France.	alizon@cochin.inserm.fr	Chelli, Mario/L-7389-2015	Chelli, Mario/0000-0003-2939-6961				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BOULAY F, 1988, J CELL BIOL, V106, P629, DOI 10.1083/jcb.106.3.629; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Doms RW, 2000, J CELL BIOL, V151, pF9, DOI 10.1083/jcb.151.2.F9; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Heiken H, 1999, AIDS, V13, P529, DOI 10.1097/00002030-199903110-00017; Heymann JAW, 1997, P NATL ACAD SCI USA, V94, P4966, DOI 10.1073/pnas.94.10.4966; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Kuipers H, 1999, AIDS, V13, P433, DOI 10.1097/00002030-199902250-00025; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lee SP, 2000, NEUROPSYCHOPHARMACOL, V23, pS32, DOI 10.1016/S0893-133X(00)00155-X; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Mellado M, 1999, NATURE, V400, P723, DOI 10.1038/23382; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; Milligan G, 2001, J CELL SCI, V114, P1265; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Ng GYK, 1997, ENDOCRINOLOGY, V138, P4199, DOI 10.1210/en.138.10.4199; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rosenberg AR, 1999, J CELL BIOL, V145, P57, DOI 10.1083/jcb.145.1.57; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042; Shimizu N, 2000, J VIROL, V74, P619, DOI 10.1128/JVI.74.2.619-626.2000; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x; Tarasova NI, 1999, J BIOL CHEM, V274, P34911, DOI 10.1074/jbc.274.49.34911; van Rij RP, 1999, J INFECT DIS, V180, P854, DOI 10.1086/314940; Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	61	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46975	46982		10.1074/jbc.M106432200	http://dx.doi.org/10.1074/jbc.M106432200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11600494	hybrid			2022-12-25	WOS:000172768500042
J	Fey, J; Balleininger, M; Borissenko, LV; Schmidt, B; von Figura, K; Dierks, T				Fey, J; Balleininger, M; Borissenko, LV; Schmidt, B; von Figura, K; Dierks, T			Characterization of posttranslational formylglycine formation by luminal components of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MODIFICATION; ARYLSULFATASE-A; EUKARYOTIC SULFATASES; CATALYTIC ACTIVITY; CYSTEINE; CONVERSION; BINDING; MECHANISM; SERINE; SITE	C-alpha-formylglycine is the key catalytic residue in the active site of sulfatases. In eukaryotes formylglycine is generated during or immediately after sulfatase translocation into the endoplasmic reticulum by oxidation of a specific cysteine residue. We established an in vitro assay that allowed us to measure formylglycine modification independent of protein translocation. The modifying enzyme was recovered in a microsomal detergent extract. As a substrate we used ribosome-associated nascent chain complexes comprising in vitro synthesized sulfatase fragments that were released from the ribosomes by puromycin. Formylglycine modification was highly efficient and did not require a signal sequence in the substrate polypeptide. Ribosome association helped to maintain the modification competence of nascent chains but only after their release efficient modification occurred. The modifying machinery consists of soluble components of the endoplasmic reticulum lumen, as shown by differential extraction of microsomes. The in vitro assay can be performed under kinetically controlled conditions. The activation energy for formylglycine formation is 61 kJ/mol, and the pH optimum is approximate to 10. The activity is sensitive to the SH/SS equilibrium and is stimulated by Ca2+. Formylglycine formation is efficiently inhibited by a synthetic sulfatase peptide representing the sequence directing formylglycine modification. The established assay system should make possible the biochemical identification of the modifying enzyme.	Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	University of Gottingen	Dierks, T (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	tdierks@gwdg.de	Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; KENDALL RL, 1990, METHOD ENZYMOL, V185, P398; Knaust A, 1998, BIOCHEMISTRY-US, V37, P13941, DOI 10.1021/bi9810205; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Meyer HA, 2000, J BIOL CHEM, V275, P14550, DOI 10.1074/jbc.275.19.14550; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Recksiek R, 1998, J BIOL CHEM, V273, P6096, DOI 10.1074/jbc.273.11.6096; Schirmer A, 1998, CHEM BIOL, V5, pR181, DOI 10.1016/S1074-5521(98)90154-5; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; Suh JK, 1999, P NATL ACAD SCI USA, V96, P2687, DOI 10.1073/pnas.96.6.2687; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; Waldow A, 1999, J BIOL CHEM, V274, P12284, DOI 10.1074/jbc.274.18.12284; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809	25	24	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47021	47028		10.1074/jbc.M108943200	http://dx.doi.org/10.1074/jbc.M108943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11600503	hybrid			2022-12-25	WOS:000172768500048
J	Godsey, MH; Baranova, NN; Neyfakh, AA; Brennan, RG				Godsey, MH; Baranova, NN; Neyfakh, AA; Brennan, RG			Crystal structure of MtaN, a global multidrug transporter gene activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINGED HELIX PROTEIN; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; COILED-COILS; TRANSCRIPTIONAL ACTIVATION; ANOMALOUS DIFFRACTION; SEQUENCE ALIGNMENTS; MUTANTS IMPLICATE; MERR HOMOLOG; DNA	MtaN (Multidrug Transporter Activation, N terminus) is a constitutive, transcriptionally active 109-residue truncation mutant, which contains only the N-terminal DNA-binding and dimerization domains of MerR family member Mta. The 2.75 Angstrom resolution crystal structure of apo-MtaN reveals a winged helix-turn-helix protein with a protruding 8-turn helix (alpha5) that is involved in dimerization by the formation of an antiparallel coiled-coil. The hydrophobic core and helices al through alpha4 are structurally homologous to MerR family member BmrR bound to DNA, whereas one wing (Wing 1) is shifted. Differences between the orientation of alpha5 with respect to the core and the revolution of the antiparallel coiled-coil lead to significantly altered conformations of MtaN and BmrR dimers. These shifts result in a conformation of MtaN that appears to be incompatible with the transcription activation mechanism of BmrR and suggest that additional DNA-induced structural changes are necessary.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA	Oregon Health & Science University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Brennan, RG (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	brennanr@ohsu.edu		Godsey, Michael/0000-0003-1006-7084; Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048593] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 48593] Funding Source: Medline; NIGMS NIH HHS [GM 08617-05] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED M, 1995, J BACTERIOL, V177, P3904, DOI 10.1128/jb.177.14.3904-3910.1995; AHMED M, 1994, J BIOL CHEM, V269, P28506; Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; Baranova NN, 1999, MOL MICROBIOL, V31, P1549, DOI 10.1046/j.1365-2958.1999.01301.x; Barbosa TM, 2000, J BACTERIOL, V182, P3467, DOI 10.1128/JB.182.12.3467-3474.2000; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caguiat JJ, 1999, J BACTERIOL, V181, P3462, DOI 10.1128/JB.181.11.3462-3471.1999; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Godsey MH, 2000, ACTA CRYSTALLOGR D, V56, P1456, DOI 10.1107/S0907444900010295; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Grkovic S, 2001, SEMIN CELL DEV BIOL, V12, P225, DOI 10.1006/scdb.2000.0248; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; Jin CW, 1999, J MOL BIOL, V292, P641, DOI 10.1006/jmbi.1999.3106; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 PLUS ESF, V26; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LOMOVSKAYA O, 1995, J BACTERIOL, V177, P2328, DOI 10.1128/jb.177.9.2328-2334.1995; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; NISHIKAWA K, 1976, MACROMOLECULES, V9, P395, DOI 10.1021/ma60051a004; Noll M, 1998, J BIOL CHEM, V273, P21393, DOI 10.1074/jbc.273.33.21393; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2340, DOI 10.1021/bi00431a053; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Veen HW, 1999, BBA-BIOMEMBRANES, V1461, P201, DOI 10.1016/S0005-2736(99)00172-8; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zeng QD, 1998, BIOCHEMISTRY-US, V37, P15885, DOI 10.1021/bi9817562; ZHELEZNOVAHELDW.EE, 2001, NATURE, V409, P378; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250	49	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47178	47184		10.1074/jbc.M105819200	http://dx.doi.org/10.1074/jbc.M105819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581256	hybrid			2022-12-25	WOS:000172768500069
J	Shohat, G; Spivak-Kroizman, T; Cohen, O; Bialik, S; Shani, G; Berrisi, H; Eisenstein, M; Kimchi, A				Shohat, G; Spivak-Kroizman, T; Cohen, O; Bialik, S; Shani, G; Berrisi, H; Eisenstein, M; Kimchi, A			The pro-apoptotic function of death-associated protein kinase is controlled by a unique inhibitory autophosphorylation-based mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CELL LUNG-CANCER; DAP-KINASE; PROMOTER HYPERMETHYLATION; INTRASTERIC REGULATION; STRUCTURAL BASIS; SMOOTH-MUSCLE; CPG ISLAND; CALMODULIN; PHOSPHORYLATION	Death-associated protein kinase is a calcium/calmodulin serine/threonine kinase, which positively mediates programmed cell death in a variety of systems. Here we addressed its mode of regulation and identified a mechanism that restrains its apoptotic function in growing cells and enables its activation during cell death. It involves autophosphorylation of Ser(308) within the calmodulin (CaM)-regulatory domain, which occurs at basal state, in the absence of Ca2+/CaM, and is inversely correlated with substrate phosphorylation. This type of phosphorylation takes place in growing cells and is strongly reduced upon their exposure to the apoptotic stimulus of C-6-ceramide. The substitution of Ser(308) to alanine, which mimics the ceramide-induced dephosphorylation at this site, increases Ca2+/CaM-independent substrate phosphorylation as well as binding and overall sensitivity of the kinase to CaM. At the cellular level, it strongly enhances the death-promoting activity of the kinase. Conversely, mutation to aspartic acid reduces the binding of the protein to CaM and abrogates almost completely the death-promoting function of the protein. These results are consistent with a molecular model in which phosphorylation on Ser(308) stabilizes a locked conformation of the CaM-regulatory domain within the catalytic cleft and simultaneously also interferes with CaM binding. We propose that this unique mechanism of auto-inhibition evolved to impose a locking device, which keeps death-associated protein kinase silent in healthy cells and ensures its activation only in response to apoptotic signals.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Chem Serv, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.							Abe M, 1996, CELL STRUCT FUNCT, V21, P183, DOI 10.1247/csf.21.183; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Esteller M, 1999, CANCER RES, V59, P67; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; LOU LL, 1989, J NEUROSCI, V9, P2020; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; Nakatsuka S, 2000, LAB INVEST, V80, P1651, DOI 10.1038/labinvest.3780175; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Shani G, 2001, EMBO J, V20, P1099, DOI 10.1093/emboj/20.5.1099; SITKOFF D, 1994, BIOPHYS CHEM, V51, P397, DOI 10.1016/0301-4622(94)00062-X; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031	37	125	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47460	47467		10.1074/jbc.M105133200	http://dx.doi.org/10.1074/jbc.M105133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579085	hybrid			2022-12-25	WOS:000172768500102
J	Estepa, AM; Rocha, AI; Mas, V; Perez, L; Encinar, JA; Nunez, E; Fernandez, A; Ros, JMG; Gavilanes, F; Coll, JM				Estepa, AM; Rocha, AI; Mas, V; Perez, L; Encinar, JA; Nunez, E; Fernandez, A; Ros, JMG; Gavilanes, F; Coll, JM			A protein G fragment from the Salmonid viral hemorrhagic septicemia rhabdovirus induces cell-to-cell fusion and membrane phosphatidylserine translocation at low pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS GLYCOPROTEIN-G; VESICULAR STOMATITIS; FISH RHABDOVIRUS; CONFORMATIONAL-CHANGES; SYNTHETIC PEPTIDES; RABIES; MUTATIONS; BINDING; DOMAIN; VHSV	The fusion-related properties of segments p9, p3, p4, and p9 + p2 surrounding the p2 phospholipid-binding domain of the protein G (pG) of the salmonid rhabdovirus of viral hemorrhagic septicemia (VHS) (Nunez, E., Fernandez, A. M., Estepa, A., Gonzalez-Ros, J. M., Gavilanes, F., and Coll, J. M. (1998) Virology 243,322-330; Estepa, A., and Coll, J. M. (1996) Virology 216, 60-70), have been studied at neutral and fusion (low) pH values by using its derived peptides. Cell-to-cell fusion, translocation of phosphatidylserine, and inhibition of fusion of pG-transfected cells defined the p9 + p2 (fragment 11, sequence 56-110) as a fragment with higher specific activity for anionic phospholipid aggregation than the previously reported p2. While fragment 11, p2, and p3 showed interactions with anionic phospholipids, p9 and p4 showed no interactions with any phospholipids. When added to a cell monolayer model at low pH, fragment 11 induced pH-dependent cell-to-cell fusion and translocated phosphatidylserine from the inner to the outer leaflet of the membrane. At low pH and in the presence of anionic phospholipids, fragment 11 showed more than 80% beta -sheet conformation (IR and CD spectroscopies). Finally, anti-fragment 11 antibodies inhibited low pH-dependent pG-transfected cell-to-cell fusion. All of the data support the conclusion that fragment 11 is a primary determinant of some of the viral cell fusion events in VHSV.	Inst Nacl Invest Agrarias & Alimentar, Subdirecc Gen Invest & Tecnol, Dept Biotecnol, Madrid 28040, Spain; Univ Miguel Hernandez, Ctr Biol Mol & Celular, Elche 03202, Spain; Univ Complutense Madrid, Dept Bioquim, Madrid 28028, Spain	Universidad Miguel Hernandez de Elche; Complutense University of Madrid	Coll, JM (corresponding author), Inst Nacl Invest Agrarias & Alimentar, Subdirecc Gen Invest & Tecnol, Dept Biotecnol, Crt Coruna Km 7, Madrid 28040, Spain.	coll@inia.es	Encinar, José Antonio/AAE-9141-2020; Coll, julio/M-6071-2019; Encinar, José A/F-2946-2013; Coll, Julio M/G-4533-2010; Carvajal, Asia Fernandez/G-8877-2015; Mas, Vicente/M-4776-2015; Gavilanes, Francisco/K-9903-2014	Encinar, José Antonio/0000-0002-7219-3863; Coll, julio/0000-0001-8496-3493; Encinar, José A/0000-0002-7219-3863; Coll, Julio M/0000-0001-8496-3493; Mas, Vicente/0000-0002-0887-0743; Gavilanes, Francisco/0000-0003-1047-2362; Gonzalez Ros, Jose Manuel/0000-0002-4804-6855; Perez Garcia-Estan, Luis/0000-0003-4078-8763; Fernandez-Carvajal, Asia/0000-0003-2741-1427				BASURCO B, 1991, ARCH VIROL, V119, P153, DOI 10.1007/BF01310666; BEARZOTTI M, 1995, VET RES, V26, P413; Bearzotti M, 1999, J VIROL, V73, P7703, DOI 10.1128/JVI.73.9.7703-7709.1999; Budker V, 1996, NAT BIOTECHNOL, V14, P760, DOI 10.1038/nbt0696-760; Carneiro FA, 2001, J BIOL CHEM, V276, P62, DOI 10.1074/jbc.M008753200; COLL JM, 1987, J IMMUNOL METHODS, V104, P219, DOI 10.1016/0022-1759(87)90507-2; COLL JM, 1995, ARCH VIROL, V140, P827, DOI 10.1007/BF01314961; Coll JM, 1997, ARCH VIROL, V142, P2089, DOI 10.1007/s007050050227; COLL JM, 1995, VIRUS GENES, V10, P107, DOI 10.1007/BF01702591; COLL JM, 1999, RRD VIROLOGY 1, V1, P75; Delos SE, 2000, J VIROL, V74, P1686, DOI 10.1128/JVI.74.4.1686-1693.2000; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; Einer-Jensen K, 1998, J VIROL, V72, P10189, DOI 10.1128/JVI.72.12.10189-10196.1998; Estepa A, 1996, VIROLOGY, V216, P60, DOI 10.1006/viro.1996.0034; Estepa A, 1997, DIS AQUAT ORGAN, V28, P185, DOI 10.3354/dao028185; Estepa A, 1996, J VIROL METHODS, V61, P37, DOI 10.1016/0166-0934(96)02067-8; Estepa A, 1999, VIRUS RES, V63, P27, DOI 10.1016/S0168-1702(99)00055-6; Fernandez-Alonso M, 1999, J FISH DIS, V22, P237, DOI 10.1046/j.1365-2761.1999.00161.x; FLAMAND A, 1993, VIROLOGY, V194, P302, DOI 10.1006/viro.1993.1261; Fredericksen BL, 1996, VIROLOGY, V217, P49, DOI 10.1006/viro.1996.0092; Gaudin Y, 1999, J GEN VIROL, V80, P1221, DOI 10.1099/0022-1317-80-5-1221; Gaudin Y, 1999, MOL MEMBR BIOL, V16, P21, DOI 10.1080/096876899294724; GAUDIN Y, 1993, J VIROL, V67, P1365, DOI 10.1128/JVI.67.3.1365-1372.1993; le Berre M, 1977, Bulletin Off int Epizoot, V87, P391; LECOCQXHONNEUX F, 1994, J GEN VIROL, V75, P1579, DOI 10.1099/0022-1317-75-7-1579; LENARD J, 1993, VIRAL FUSION MECHANI, P425; Lopez A, 2001, BIOTECHNOL LETT, V23, P481, DOI 10.1023/A:1010393723002; Lorenzo G, 1996, J VIROL METHODS, V58, P1, DOI 10.1016/0166-0934(95)01972-3; Nunez E, 1998, VIROLOGY, V243, P322, DOI 10.1006/viro.1998.9076; Odell D, 1997, J VIROL, V71, P7996, DOI 10.1128/JVI.71.10.7996-8000.1997; Perez L, 1998, J VIROL METHODS, V76, P1, DOI 10.1016/S0166-0934(98)00028-7; SANZ FA, 1992, AM J VET RES, V53, P897; SCHULZ GE, 1984, PRINCIPLES PROTEIN S, P2; Shokralla S, 1998, VIROLOGY, V242, P39, DOI 10.1006/viro.1997.8986; THIRY M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P345, DOI 10.1016/0167-4781(91)90200-6; Walker PJ, 1999, J GEN VIROL, V80, P1211, DOI 10.1099/0022-1317-80-5-1211; ZHANG L, 1994, J VIROL, V68, P2186, DOI 10.1128/JVI.68.4.2186-2193.1994	37	30	32	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46268	46275		10.1074/jbc.M108682200	http://dx.doi.org/10.1074/jbc.M108682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590161	hybrid, Green Published			2022-12-25	WOS:000172573100106
J	Kelly, A; Lynch, A; Vereker, E; Nolan, Y; Queeman, P; Whittaker, E; O'Neill, LAJ; Lynch, MA				Kelly, A; Lynch, A; Vereker, E; Nolan, Y; Queeman, P; Whittaker, E; O'Neill, LAJ; Lynch, MA			The anti-inflammatory cytokine, interleukin (IL)-10, blocks the inhibitory effect of IL-1 beta on long term potentiation - A role for JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED ACTIVATION; CENTRAL-NERVOUS-SYSTEM; SUPEROXIDE-DISMUTASE; ARACHIDONIC-ACID; GLUTAMATE RELEASE; DENTATE GYRUS; IL-10; RAT	Several effects of the proinflammatory cytokine, interleukin-1 beta (IL-1 beta), have been described in the central nervous system, and one area of the brain where marked changes have been reported is the hippocampus. Among these changes are an IL-1 beta -induced inhibition of long term potentiation (LTP) in perforant path-granule cell synapses and an attenuation of glutamate release in synaptosomes prepared from the hippocampus. Evidence suggests that, at least in circulating cells, the anti-inflammatory cytokine, IL-10, antagonizes certain effects of IL-1. We investigated the effect of IL-10 on IL-1 beta -induced inhibition of LTP and glutamate release. The evidence presented indicates that IL-1 beta stimulates the stress-activated protein kinase, c-Jun-activated protein kinase (JNK), and IL-1 receptor-associated kinase, which may explain its inhibitory effect on release and LTP, and that IL-10 reversed the IL-10-induced stimulation of JNK activity and inhibition of release and LTP. We observed that IL-10 abrogated the stimulatory effect of IL-1 beta on superoxide dismutase activity and reactive oxygen species production, whereas the H2O2-induced inhibition of LTP was also blocked by IL-10. We present evidence that suggests that the action of IL-10 may be mediated by its ability to induce shedding of the IL-1 type I receptor.	Univ Dublin Trinity Coll, Inst Neurosci, Dept Physiol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	Lynch, MA (corresponding author), Univ Dublin Trinity Coll, Inst Neurosci, Dept Physiol, Dublin 2, Ireland.	lynchma@tcd.ie		Kelly, Aine/0000-0002-9255-0848; Whittaker, Elizabeth/0000-0002-7944-8793; Nolan, Yvonne/0000-0003-2426-234X; Lynch, Marina/0000-0002-4631-0499; O'Neill, Luke/0000-0002-4333-2748				AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; Bluthe RM, 1999, PSYCHONEUROENDOCRINO, V24, P301, DOI 10.1016/S0306-4530(98)00077-8; BORG LAH, 1992, ENDOCRINOLOGY, V130, P2851, DOI 10.1210/en.130.5.2851; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chou YK, 1998, CELL IMMUNOL, V188, P125, DOI 10.1006/cimm.1998.1342; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; CUNNINGHAM ET, 1992, J NEUROSCI, V12, P1101; Dandona P, 1999, CLIN PHARMACOL THER, V66, P58, DOI 10.1016/S0009-9236(99)70054-8; Delgado M, 2000, J NEUROIMMUNOL, V110, P97, DOI 10.1016/S0165-5728(00)00359-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUREZ P, 1993, J EXP MED, V177, P551, DOI 10.1084/jem.177.2.551; Ericsson A., 1993, Society for Neuroscience Abstracts, V19, P95; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Gunnett CA, 2000, AM J PHYSIOL-HEART C, V279, pH1555, DOI 10.1152/ajpheart.2000.279.4.H1555; Hu SX, 1999, J LEUKOCYTE BIOL, V65, P815, DOI 10.1002/jlb.65.6.815; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; Leon LR, 1998, ANN NY ACAD SCI, V856, P69, DOI 10.1111/j.1749-6632.1998.tb08314.x; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; Maroney AC, 1998, J NEUROSCI, V18, P104; McGahon B, 1996, NEUROSCIENCE, V72, P847, DOI 10.1016/0306-4522(95)00579-X; McGahon B, 1999, NEUROSCIENCE, V90, P1167, DOI 10.1016/S0306-4522(98)00528-4; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Murray CA, 1997, NEUROBIOL AGING, V18, P343, DOI 10.1016/S0197-4580(97)80317-X; Murray CA, 1998, J NEUROSCI, V18, P2974; Niiro H, 1998, BIOCHEM BIOPH RES CO, V250, P200, DOI 10.1006/bbrc.1998.9287; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OPP MR, 1995, J NEUROIMMUNOL, V60, P165, DOI 10.1016/0165-5728(95)00066-B; ORDRONNEAU P, 1991, J IMMUNOL METHODS, V142, P169, DOI 10.1016/0022-1759(91)90103-M; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; PARNET P, 1994, MOL BRAIN RES, V27, P63, DOI 10.1016/0169-328X(94)90185-6; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; PLATASALAMAN CR, 1994, EUR J PHARM-MOLEC PH, V266, P1, DOI 10.1016/0922-4106(94)90202-X; Pousset F, 1999, GLIA, V26, P12, DOI 10.1002/(SICI)1098-1136(199903)26:1<12::AID-GLIA2>3.0.CO;2-S; Qin SF, 1999, BIOCHEM BIOPH RES CO, V262, P231, DOI 10.1006/bbrc.1999.1079; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; RADY PL, 1995, CELL MOL NEUROBIOL, V15, P289, DOI 10.1007/BF02073335; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Sato K, 1999, J IMMUNOL, V162, P3865; SHOHAM S, 1987, AM J PHYSIOL, V253, pR142, DOI 10.1152/ajpregu.1987.253.1.R142; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; VANDERPOLL T, 1994, J EXP MED, V180, P1985, DOI 10.1084/jem.180.5.1985; Vannier E, 1999, EUR CYTOKINE NETW, V10, P37; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200	54	112	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45564	45572		10.1074/jbc.M108757200	http://dx.doi.org/10.1074/jbc.M108757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581275	Green Published, hybrid			2022-12-25	WOS:000172573100012
J	Leung, KW; Liaw, YC; Chan, SC; Lo, HY; Musayev, FN; Chen, JZW; Fang, HJ; Chen, HM				Leung, KW; Liaw, YC; Chan, SC; Lo, HY; Musayev, FN; Chen, JZW; Fang, HJ; Chen, HM			Significance of local electrostatic interactions in staphylococcal nuclease studied by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENATURED STATE; PROTEINS; THERMODYNAMICS; STABILITY; DYNAMICS; COMPLEX; MODEL	In this paper, we show that amino acids Glu(73) and Asp(77) of staphylococcal nuclease cooperate unequally with Glu(75) to stabilize its structure located between the C-terminal helix and beta -barrel of the protein. Amino acid substitutions E73G and D77G cause losses of the catalytic efficiency of 24 and 16% and cause thermal stability losses of 22 and 26%, respectively, in comparison with the wild type (WT) protein. However, these changes do not significantly change global and local secondary structures, based on measurements of fluorescence and CD222nm. Furthermore, x-ray diffraction analysis of the E75G protein shows that the overall structure of mutant and WT proteins is similar. However, this mutation does cause a loss of essential hydrogen bonding and charge interactions between Glu(75) and Lyg(9), Tyr(93), and HiS(121). In experiments using double point mutations, E73G/ D77G, E73G/E75G, and E75G/D77G, significant changes are seen in all mutants in comparison with WT protein as measured by fluorescence and CD spectroscopy. The losses of thermal stability are 47, 59, and 58%, for E73G/ D77G, E73G/E75G, and E75G/D77G, respectively. The triple mutant, E73G/E75G/D77G, results in fluorescence intensity and CD222nm close to those of the denatured state and in a thermal stability loss of 65% relative to the WT protein. Based on these results, we propose a model in which significant electrostatic interactions result in the formation of a locally stable structure in staphylococcal nuclease.	Acad Sinica, Inst Bioagr Sci, Taipei 115, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Academia Sinica - Taiwan; Academia Sinica - Taiwan; Hong Kong University of Science & Technology	Chen, HM (corresponding author), Acad Sinica, Inst Bioagr Sci, Taipei 115, Taiwan.		Musayev, Faik/AAY-2010-2020					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Baskakov IV, 1998, BIOCHEMISTRY-US, V37, P18010, DOI 10.1021/bi981849j; BRUNGER AT, 1987, SCIENCE, V235, P348; Carra JH, 1996, FASEB J, V10, P67, DOI 10.1096/fasebj.10.1.8566550; CARRA JH, 1994, BIOCHEMISTRY-US, V28, P204; Chen HM, 1999, EUR J BIOCHEM, V261, P599, DOI 10.1046/j.1432-1327.1999.00317.x; CHEN HM, 1992, BIOCHEMISTRY-US, V31, P12369, DOI 10.1021/bi00164a011; CHEN HM, 1992, BIOCHEMISTRY-US, V31, P1483, DOI 10.1021/bi00120a027; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GITTIS AG, 1993, J MOL BIOL, V232, P718, DOI 10.1006/jmbi.1993.1425; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; KARPLUS M, 1994, PROTEIN SCI, V3, P650; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; Rock RS, 1996, J ORG CHEM, V61, P1526, DOI 10.1021/jo950822s; Rock RS, 1998, J AM CHEM SOC, V120, P10766, DOI 10.1021/ja980551d; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sinclair JF, 1999, PROTEIN SCI, V8, P991, DOI 10.1110/ps.8.5.991; SKOOG DA, 1969, FUNDAMENTALS ANAL CH, P37; Su ZD, 1996, P NATL ACAD SCI USA, V93, P2539, DOI 10.1073/pnas.93.6.2539; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5	31	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46039	46045		10.1074/jbc.M106620200	http://dx.doi.org/10.1074/jbc.M106620200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11598114	hybrid			2022-12-25	WOS:000172573100075
J	Misenheimer, TM; Hahr, AJ; Harms, AC; Annis, DS; Mosher, DF				Misenheimer, TM; Hahr, AJ; Harms, AC; Annis, DS; Mosher, DF			Disulfide connectivity of recombinant C-terminal region of human thrombospondin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; BINDING COMPETITIVE INHIBITOR; HUMAN-PLATELET THROMBOSPONDIN; GENE FAMILY; MONOCLONAL-ANTIBODIES; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; TYPE-3 REPEATS; PSEUDOACHONDROPLASIA	The thrombospondin (TSP) family of extracellular glycoproteins consists of five members in vertebrates, TSP1 to -4 and TSP5/cartilage oligomeric matrix protein, and a single member in Drosophila. TSPs are modular multimeric proteins. The C-terminal end of a monomer consists of 3-6 EGF-like modules; seven tandem 23-, 36-, or 38-residne aspartate-rich, Ca2+-binding repeats; and an similar to 230-residue C-terminal sequence. The Ca2+-binding repeats and C-terminal sequence are spaced almost exactly the same in different TSPs and share many blocks of identical residues. We studied the C-terminal portion of human TSP2 from the third EGF-like module through the end of the protein (E3CaG2). E3CaG2, CaG2 lacking the EGF module, and Ca2 composed of only the Ca2+. binding repeats were expressed using recombinant baculoviruses and purified from conditioned media of insect cells. As previously described for intact TSP1, E3CaG2 bound Ca2+ in a cooperative manner as assessed by equilibrium dialysis, and its circular dichroism spectrum was sensitive to the presence of Ca2+. Mass spectrometry of the recombinant proteins digested with endoproteinase Asp-N revealed that disulfide pairing of the IS cysteines in the Ca2+-binding repeats and C-terminal sequence is sequential, i.e. a 1-2, 3-4, 5-6, etc., pattern.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Misenheimer, TM (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.			Harms, Amy/0000-0002-2931-4295	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V188, P190; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adolph KW, 2001, GENE, V269, P177, DOI 10.1016/S0378-1119(01)00441-3; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; CHEN H, 1994, J BIOL CHEM, V269, P32226; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Deere M, 1999, AM J MED GENET, V85, P486, DOI 10.1002/(SICI)1096-8628(19990827)85:5<486::AID-AJMG10>3.0.CO;2-O; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Hecht JT, 1998, MATRIX BIOL, V17, P625, DOI 10.1016/S0945-053X(98)90113-5; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HOGG PJ, 1993, J BIOL CHEM, V268, P7139; HOGG PJ, 1993, J BIOL CHEM, V268, P21811; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; OLDBERG A, 1992, J BIOL CHEM, V267, P346; QABAR A, 1995, J BIOL CHEM, V270, P12725, DOI 10.1074/jbc.270.21.12725; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Tooney PA, 1998, MATRIX BIOL, V17, P131, DOI 10.1016/S0945-053X(98)90026-9; TUCKER RP, 1995, DEV DYNAM, V203, P477, DOI 10.1002/aja.1002030410; VOS HL, 1992, J BIOL CHEM, V267, P12192	49	23	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45882	45887		10.1074/jbc.M104218200	http://dx.doi.org/10.1074/jbc.M104218200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590138	hybrid			2022-12-25	WOS:000172573100053
J	Zhang, H; Gallo, KA				Zhang, H; Gallo, KA			Autoinhibition of mixed lineage kinase 3 through its Src homology 3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; PROTEIN-KINASE; LEUCINE-ZIPPER; SH3 DOMAINS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BINDING MOTIF; JNK PATHWAY; HUMAN BRAIN; ACTIVATION	Mixed lineage kinase 3 (MLK3) is a serine/threonine protein kinase that functions as a mitogen-activated protein kinase kinase kinase to activate the c-Jun NH2-terminal kinase pathway. MLK3 has also been implicated as an I kappaB kinase kinase in the activation of NF-kappaB. Amino-terminal to its catalytic domain, MLK3 contains a Src homology 3 (SH3) domain. SH3 domains harbor three highly conserved aromatic amino acids that are important for ligand binding. In this study, we mutated one of these corresponding residues within MLK3 to deliberately disrupt the function of its SH3 domain. This SH3-defective mutant of MLK3 exhibited increased catalytic activity compared with wild type MLK3 suggesting that the SH3 domain negatively regulates MLK3 activity. We report herein that the SH3 domain of MLK3 interacts with full-length MLK3, and we have mapped the site of interaction to a region between the zipper and the Cdc42/Rac interactive binding motif. Interestingly, the SH3-binding region contains not a proline-rich sequence but, rather, a single proline residue. Mutation of this sole proline abrogates SH3 binding and increases MLK3 catalytic activity. Taken together, these data demonstrate that MLK3 is autoinhibited through its SH3 domain. The critical proline residue in the SH3 binding site of MLK3 is conserved in the closely related family members, MLK1 and MLK2, suggesting a common autoinhibitory mechanism among these kinases. Our study has revealed the first example of SH3 domain-mediated autoinhibition of a serine/threonine kinase and provides insight into the regulation of the mixed lineage family of protein kinases.	Michigan State Univ, Dept Physiol, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, Cell & Mol Biol Program, 108 Giltner Hall, E Lansing, MI 48824 USA.				NATIONAL CANCER INSTITUTE [R29CA076306] Funding Source: NIH RePORTER; NCI NIH HHS [CA76306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hubbard SR, 1999, NAT STRUCT BIOL, V6, P711, DOI 10.1038/11468; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KATOH M, 1995, ONCOGENE, V10, P1447; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; Liu TC, 2000, BIOCHEM BIOPH RES CO, V274, P811, DOI 10.1006/bbrc.2000.3236; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	43	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45598	45603		10.1074/jbc.M107176200	http://dx.doi.org/10.1074/jbc.M107176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590155	hybrid			2022-12-25	WOS:000172573100016
J	Guzman-Verri, C; Chaves-Olarte, E; von Eichel-Streiber, C; Lopez-Goni, I; Thelestam, M; Arvidson, S; Gorvel, JP; Moreno, E				Guzman-Verri, C; Chaves-Olarte, E; von Eichel-Streiber, C; Lopez-Goni, I; Thelestam, M; Arvidson, S; Gorvel, JP; Moreno, E			GTPases of the Rho subfamily are required for Brucella abortus internalization in nonprofessional phagocytes - Direct activation of Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN EPITHELIAL-CELLS; KINASE INHIBITORS BLOCK; HUMAN-ENDOTHELIAL-CELLS; TISSUE-CULTURE CELLS; LISTERIA-MONOCYTOGENES; SALMONELLA-TYPHIMURIUM; BACTERIAL INVASION; SHIGELLA-FLEXNERI; PHOSPHATIDYLINOSITOL 3-KINASE; CLOSTRIDIUM-DIFFICILE	Members of the genus Brucella are intracellular a-Proteobacteria responsible for brucellosis, a chronic disease of humans and animals. Little is known about Brucella virulence mechanisms, but the abilities of these bacteria to invade and to survive within cells are decisive factors for causing disease. Transmission electron and fluorescence microscopy of infected nonprofessional phagocytic HeLa cells revealed minor membrane changes accompanied by discrete recruitment of F-actin at the site of Brucella abortus entry. Cell uptake of B. abortus was negatively affected to various degrees by actin, actin-myosin, and microtubule chemical inhibitors. Modulators of MAPKs and protein-tyrosine kinases hampered Brucella cell internalization. Inactivation of Rho small GTPases using clostridial toxins TcdB-10463, TcdB-1470, TcsL-1522, and TcdA significantly reduced the uptake of B. abortus by HeLa cells. In contrast, cytotoxic necrotizing factor from Escherichia coli, known to activate Rho, Rac, and Cdc42 small GTPases, increased the internalization of both virulent and non-virulent B. abortus. Expression of dominant-positive Rho, Rac, and Cdc42 forms in HeLa cells promoted the uptake of B. abortus, whereas expression of dominant-negative forms of these GTPases in HeLa cells hampered Brucella uptake. Cdc42 was activated upon cell contact by virulent B. abortus, but not by a noninvasive isogenic strain, as proven by affinity precipitation of active Rho, Rac, and Cdc42. The polyphasic approach used to discern the molecular events leading to Brucella internalization provides new alternatives for exploring the complexity of the signals required by intracellular pathogens for cell invasion.	Univ Nacl, Escuela Med Vet, Programa Invest Enfermedades Trop, Heredia 3000, Costa Rica; Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Univ Costa Rica, Fac Microbiol, Ctr Invest Enfermedades Trop, San Jose 1000, Costa Rica; Univ Mainz, Inst Med Mikrobiol & Hyg, Verfugungsgebaude Forsch & Entwicklung, D-55101 Mainz, Germany; Univ Navarra, Dept Microbiol, E-31080 Pamplona, Spain; CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France	Universidad Nacional Costa Rica; Karolinska Institutet; Universidad Costa Rica; Johannes Gutenberg University of Mainz; University of Navarra; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Moreno, E (corresponding author), Univ Nacl, Escuela Med Vet, Programa Invest Enfermedades Trop, POB 304, Heredia 3000, Costa Rica.		López-Goñi, Ignacio/K-2572-2017; Gorvel, Jean-Pierre/O-1332-2018; Guzman-Verri, Caterina/AAP-3074-2020	López-Goñi, Ignacio/0000-0002-3873-8743; Gorvel, Jean-Pierre/0000-0002-2829-9804; Guzman-Verri, Caterina/0000-0003-1036-920X				ACKERMANN MR, 1988, VET PATHOL, V25, P28, DOI 10.1177/030098588802500104; ADAM T, 1995, J CELL BIOL, V129, P367, DOI 10.1083/jcb.129.2.367; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON TD, 1986, AM J PATHOL, V124, P226; ANDERSON TD, 1986, VET PATHOL, V23, P227, DOI 10.1177/030098588602300302; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BERMUDEZ LE, 1994, INFECT IMMUN, V62, P2021, DOI 10.1128/IAI.62.5.2021-2026.1994; CAMPBELL GA, 1994, VET IMMUNOL IMMUNOP, V41, P295, DOI 10.1016/0165-2427(94)90103-1; Celli J, 2000, CELL MICROBIOL, V2, P1, DOI 10.1046/j.1462-5822.2000.00033.x; Chaves-Olarte E, 1999, J BIOL CHEM, V274, P11046, DOI 10.1074/jbc.274.16.11046; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; Comerci DJ, 1998, INFECT IMMUN, V66, P3862, DOI 10.1128/IAI.66.8.3862-3866.1998; Comerci DJ, 2001, CELL MICROBIOL, V3, P159, DOI 10.1046/j.1462-5822.2001.00102.x; Corbel MJ, 1997, J MED MICROBIOL, V46, P101, DOI 10.1099/00222615-46-2-101; Corbel MJ, 1984, BERGEYS MANUAL SYSTE, P377; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Coxon PY, 1998, INFECT IMMUN, V66, P2905, DOI 10.1128/IAI.66.6.2905-2913.1998; DETEJADA GM, 1995, INFECT IMMUN, V63, P3054; DETILLEUX PG, 1991, AM J VET RES, V52, P1658; DETILLEUX PG, 1990, INFECT IMMUN, V58, P2320, DOI 10.1128/IAI.58.7.2320-2328.1990; DETILLEUX PG, 1990, VET PATHOL, V27, P317, DOI 10.1177/030098589002700503; Drevets DA, 1998, INFECT IMMUN, V66, P232, DOI 10.1128/IAI.66.1.232-238.1998; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; FRANCIS CL, 1991, J INFECT DIS, V164, P693, DOI 10.1093/infdis/164.4.693; Freer E, 1996, J BACTERIOL, V178, P5867, DOI 10.1128/jb.178.20.5867-5876.1996; Freer E, 1999, INFECT IMMUN, V67, P6181, DOI 10.1128/IAI.67.11.6181-6186.1999; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; GARCIADELPORTILLO F, 1994, J CELL SCI, V107, P2005; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; HARMON BG, 1988, AM J VET RES, V49, P1092; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; HERRMANN C, 1992, BIOCHEMISTRY-US, V31, P12227, DOI 10.1021/bi00163a036; Hu L, 1999, INFECT IMMUN, V67, P4171, DOI 10.1128/IAI.67.8.4171-4182.1999; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; JANDA JM, 1991, INFECT IMMUN, V59, P154, DOI 10.1128/IAI.59.1.154-161.1991; Jerse AE, 1997, TRENDS MICROBIOL, V5, P217, DOI 10.1016/S0966-842X(97)01056-1; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kazmierczak BI, 2001, CELL MICROBIOL, V3, P85, DOI 10.1046/j.1462-5822.2001.00091.x; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kespichayawattana W, 2000, INFECT IMMUN, V68, P5377, DOI 10.1128/IAI.68.9.5377-5384.2000; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Krendel M, 1998, CELL MOTIL CYTOSKEL, V40, P368, DOI 10.1002/(SICI)1097-0169(1998)40:4<368::AID-CM5>3.3.CO;2-R; Kugler S, 1997, FEMS MICROBIOL LETT, V157, P131; Kuhn M, 1998, FEMS MICROBIOL LETT, V160, P87, DOI 10.1016/S0378-1097(98)00017-2; Kusumawati A, 2000, MICROB PATHOGENESIS, V28, P343, DOI 10.1006/mpat.2000.0354; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMONT RJ, 1995, INFECT IMMUN, V63, P3878, DOI 10.1128/IAI.63.10.3878-3885.1995; Linder S, 2001, INFECT IMMUN, V69, P1739, DOI 10.1128/IAI.69.3.1739-1746.2001; Meier C, 1996, INFECT IMMUN, V64, P2391, DOI 10.1128/IAI.64.7.2391-2399.1996; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Meyer DH, 1999, INFECT IMMUN, V67, P6518; MILIOTIS MD, 1995, INFECT IMMUN, V63, P4959, DOI 10.1128/IAI.63.12.4959-4963.1995; MOUNIER J, 1992, INFECT IMMUN, V60, P237, DOI 10.1128/IAI.60.1.237-248.1992; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Nhieu GTV, 2000, CELL MICROBIOL, V2, P187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OELSCHLAEGER TA, 1993, P NATL ACAD SCI USA, V90, P6884, DOI 10.1073/pnas.90.14.6884; Oelschlaeger TA, 1997, INFECT IMMUN, V65, P2950, DOI 10.1128/IAI.65.7.2950-2958.1997; Pizarro-Cerda J, 1999, ADV CELL MOL BIOL ME, V6, P201, DOI 10.1016/S1874-5172(99)80013-3; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P5711; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P2387; Pizarro-Cerda J, 2000, MICROBES INFECT, V2, P829, DOI 10.1016/S1286-4579(00)90368-X; PIZON V, 1994, J CELL SCI, V107, P1661; PLOTKOWSKI MC, 1994, INFECT IMMUN, V62, P5456, DOI 10.1128/IAI.62.12.5456-5463.1994; Porte F, 1999, INFECT IMMUN, V67, P4041, DOI 10.1128/IAI.67.8.4041-4047.1999; Procyk KJ, 1999, INFECT IMMUN, V67, P1011, DOI 10.1128/IAI.67.3.1011-1017.1999; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RICHARDSON WP, 1988, INFECT IMMUN, V56, P2512, DOI 10.1128/IAI.56.9.2512-2514.1988; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROBINSON DG, 1987, METHODS PREPARATION, P69; Rochlin MW, 1999, MOL BIOL CELL, V10, P2309, DOI 10.1091/mbc.10.7.2309; ROJAS N, 1994, CLIN DIAGN LAB IMMUN, V1, P206, DOI 10.1128/CDLI.1.2.206-213.1994; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; ROSENSHINE I, 1994, METHOD ENZYMOL, V236, P467; SALYERS AA, 1994, BACTERIAL PATHOGENES; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SANGARI F, 1991, MICROB PATHOGENESIS, V11, P443, DOI 10.1016/0882-4010(91)90040-H; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; Sola-Landa A, 1998, MOL MICROBIOL, V29, P125, DOI 10.1046/j.1365-2958.1998.00913.x; STEVENS MG, 1994, INFECT IMMUN, V62, P3206, DOI 10.1128/IAI.62.8.3206-3212.1994; STGEME JW, 1990, INFECT IMMUN, V58, P4036, DOI 10.1128/IAI.58.12.4036-4044.1990; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tang P, 1998, INFECT IMMUN, V66, P1106, DOI 10.1128/IAI.66.3.1106-1112.1998; TANG P, 1994, MOL BIOL CELL, V5, P455, DOI 10.1091/mbc.5.4.455; Thelestam M, 2000, CURR TOP MICROBIOL, V250, P85; Ugalde RA, 1999, MICROBES INFECT, V1, P1211, DOI 10.1016/S1286-4579(99)00240-3; VASSELON T, 1991, INFECT IMMUN, V59, P1723, DOI 10.1128/IAI.59.5.1723-1732.1991; VELGE P, 1994, MICROB PATHOGENESIS, V17, P37, DOI 10.1006/mpat.1994.1050; Velge P, 1997, J MED MICROBIOL, V46, P681, DOI 10.1099/00222615-46-8-681; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WALKER RL, 1999, VET MICROBIOL, P196; WALKER TS, 1984, INFECT IMMUN, V44, P205, DOI 10.1128/IAI.44.2.205-210.1984; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wells CL, 1998, INFECT IMMUN, V66, P2410, DOI 10.1128/IAI.66.6.2410-2419.1998; Wells CL, 1999, J NUTR, V129, P634, DOI 10.1093/jn/129.3.634; Wilson SL, 1998, J INFECT DIS, V178, P1658, DOI 10.1086/314490; YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283	114	86	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44435	44443		10.1074/jbc.M105606200	http://dx.doi.org/10.1074/jbc.M105606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579087	hybrid			2022-12-25	WOS:000172406700013
J	Tanner, JA; Abowath, A; Miller, AD				Tanner, JA; Abowath, A; Miller, AD			Isothermal titration calorimetry reveals a zinc ion as an atomic switch in the diadenosine polyphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; 5',5'''-P-1,P-4-TETRAPHOSPHATE AP(4)A ANALOGS; STRESS PROTEIN LYSU; SERYL-TRANSFER RNA; ESCHERICHIA-COLI; DINUCLEOSIDE POLYPHOSPHATES; HEAT-SHOCK; ENZYMATIC-SYNTHESIS; 5',5'''-P1,P4-TETRAPHOSPHATE; CELLS	Diadenosine polyphosphates (diadenosine 5',5'''-P-1,P-n-polyphosphate (Ap(n)A)) are 5'-5'''-phosphate-bridged dinucleosides that have been proposed to act as signaling molecules in a variety of biological systems. Isothermal titration calorimetry was used to measure the affinities of a variety of metal cations for ATP, diadenosine 5',5'''-P-1,P-3-triphosphate (Ap(3)A), diadenosine 5',5'''-P-1,P-4- tetraphosphate (Ap(4)A), and diadenosine 5',5'''-P-1,P-5-pentaphosphate (Ap(5)A). The binding of Me2+, Ca2+, and Mn2+ to ATP is shown to take place with the beta,gamma-phosphates (primary site) and be endothermic in character. The binding of Ni2+, Cd2+, and Zn2+ to ATP is found to take place at both the primary site and at a secondary site identified as N-7 of the adenine ring. Binding to this second site is exothermic in character. Generally, the binding of metal cations to diadenosine polyphosphates involves a similar primary site to ATP. No exothermic binding events are identified. Critically, the binding of Zn2+ to diadenosine polyphosphates proves to be exceptional. This appears to involve a very high affinity association involving the N-7 atoms of both adenine rings in each Ap(n)A, as well as the more usual endothermic association with the phosphate chain. The high affinity association is also endothermic in character. A combination of NMR and CD evidence is provided in support of the calorimetry data demonstrating chemical shift changes and base stacking disruptions entirely consistent with N-7 bridging interactions. N-7 bridging interactions are entirely reversible, as demonstrated by EDTA titration. Considering the effects of Zn2+ on a wide variety of dinucleoside polyphosphate-metabolizing enzymes, we examine the possibility of Zn2+ acting as an atomic switch to control the biological function of the diadenosine polyphosphates.	Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, London SW7 2AZ, England	Imperial College London	Miller, AD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, Flowers Bldg,Armstrong Rd, London SW7 2AZ, England.		Tanner, Julian A./C-4412-2009; Miller, Andrew/G-8291-2019	Tanner, Julian A./0000-0002-5459-1526; Miller, Andrew/0000-0003-0661-249X				Aschner M, 1996, FASEB J, V10, P1129, DOI 10.1096/fasebj.10.10.8751715; BLANQUET S, 1983, MOL CELL BIOCHEM, V52, P3; BREVET A, 1991, J BACTERIOL, V173, P5275, DOI 10.1128/jb.173.17.5275-5279.1991; CAMESELLE JC, 1983, BIOCHEM BIOPH RES CO, V113, P717, DOI 10.1016/0006-291X(83)91785-0; DANG CV, 1989, J BIOL CHEM, V264, P5861; Desogus G, 2000, BIOCHEMISTRY-US, V39, P8418, DOI 10.1021/bi0006722; FEDER J, 1983, TOP PHOSPHORUS CHEM, V11, P1; FUGE EK, 1993, J BACTERIOL, V175, P2321, DOI 10.1128/JB.175.8.2321-2326.1993; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; GRUMMT F, 1986, EXP CELL RES, V163, P191, DOI 10.1016/0014-4827(86)90572-0; Guranowski A, 2000, PHARMACOL THERAPEUT, V87, P117, DOI 10.1016/S0163-7258(00)00046-2; HARNES LD, 1996, BIOCHEMISTRY-US, V35, P11529; Hilderman RH, 1998, FEBS LETT, V427, P320, DOI 10.1016/S0014-5793(98)00454-2; HOLLER E, 1983, BIOCHEMISTRY-US, V22, P4924, DOI 10.1021/bi00290a008; HOLLER E, 1984, BIOCHEM BIOPH RES CO, V120, P1037, DOI 10.1016/S0006-291X(84)80211-9; HOYLE CHV, 1990, GEN PHARMACOL-VASC S, V21, P827, DOI 10.1016/0306-3623(90)90440-W; HURTADO C, 1987, J BACTERIOL, V169, P1718, DOI 10.1128/jb.169.4.1718-1723.1987; JAKUBOWSKI H, 1983, ACTA BIOCHIM POL, V30, P51; JOHNSTONE DB, 1991, EMBO J, V10, P3897, DOI 10.1002/j.1460-2075.1991.tb04959.x; KATAYAMA T, 1996, Patent No. 0721955; Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7; KOLODNY NH, 1986, J BIOL CHEM, V261, P4571; KOLODNY NH, 1979, FEBS LETT, V107, P121, DOI 10.1016/0014-5793(79)80477-9; LED JJ, 1983, EUR J BIOCHEM, V136, P469, DOI 10.1111/j.1432-1033.1983.tb07765.x; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; LEE PC, 1983, J BIOL CHEM, V258, P6827; MAYO KH, 1990, FEBS LETT, V265, P97, DOI 10.1016/0014-5793(90)80892-M; McLennan AG, 2000, PHARMACOL THERAPEUT, V87, P73, DOI 10.1016/S0163-7258(00)00041-3; Miras-Portugal MT, 1998, FEBS LETT, V430, P78, DOI 10.1016/S0014-5793(98)00560-2; MORIOKA M, 1987, EXP CELL RES, V169, P57, DOI 10.1016/0014-4827(87)90224-2; Nishimura A, 1997, GENES CELLS, V2, P401, DOI 10.1046/j.1365-2443.1997.1300328.x; OGILVIE A, 1983, J BIOL CHEM, V258, P4105; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Pintor J, 2000, PHARMACOL THERAPEUT, V87, P103, DOI 10.1016/S0163-7258(00)00049-8; PLATEAU P, 1981, BIOCHIMIE, V63, P827; PLATEAU P, 1981, BIOCHEMISTRY-US, V20, P4654, DOI 10.1021/bi00519a021; PRESCOTT M, 1992, INT J BIOCHEM, V24, P565, DOI 10.1016/0020-711X(92)90328-X; RAMOS A, 1995, BBA-PROTEIN STRUCT M, V1253, P103, DOI 10.1016/0167-4838(95)00154-M; RAPAPORT E, 1976, P NATL ACAD SCI USA, V73, P3984, DOI 10.1073/pnas.73.11.3984; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; Schluter H, 1996, J AUTON PHARMACOL, V16, P357, DOI 10.1111/j.1474-8673.1996.tb00053.x; SCOTT JF, 1969, P NATL ACAD SCI USA, V64, P1308, DOI 10.1073/pnas.64.4.1308; SEGAL E, 1984, BIOPOLYMERS, V23, P1623, DOI 10.1002/bip.360230902; Sillero A, 2000, PHARMACOL THERAPEUT, V87, P91, DOI 10.1016/S0163-7258(00)00047-4; TANAKA Y, 1981, BIOCHEM BIOPH RES CO, V99, P837, DOI 10.1016/0006-291X(81)91240-7; THEOCLITOU ME, 1994, J CHEM SOC CHEM COMM, P659, DOI 10.1039/c39940000659; Theoclitou ME, 1996, J CHEM SOC PERK T 1, P2009, DOI 10.1039/p19960002009; VALLEJO CG, 1989, INT J BIOCHEM, V21, P1223, DOI 10.1016/0020-711X(89)90007-4; WILSON JE, 1991, ANAL BIOCHEM, V193, P16, DOI 10.1016/0003-2697(91)90036-S; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	51	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3073	3078		10.1074/jbc.M106588200	http://dx.doi.org/10.1074/jbc.M106588200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11604396	hybrid			2022-12-25	WOS:000173688000004
J	Garault, P; Le Bars, D; Besset, C; Monnet, V				Garault, P; Le Bars, D; Besset, C; Monnet, V			Three oligopeptide-binding proteins are involved in the oligopeptide transport of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOCOCCUS-LACTIS; NUTRITIONAL-REQUIREMENTS; LISTERIA-MONOCYTOGENES; PEPTIDE-TRANSPORT; SYSTEM; LIPOPROTEINS; PERMEASE; GROWTH; MILK; OPPA	The functions necessary for bacterial growth strongly depend on the features of the bacteria and the components of the growth media. Our objective was to identify the functions essential to the optimum growth of Streptococcus thermophilus in milk. Using random insertional mutagenesis on a S. thermophilus strain chosen for its ability to grow rapidly in milk, we obtained several mutants incapable of rapid growth in milk. We isolated and characterized one of these mutants in which an amiA1 gene encoding an oligopeptide-binding protein (OBP) was interrupted. This gene was a part of an operon containing all the components of an ATP binding cassette transporter. Three highly homologous amiA genes encoding OBPs work with the same components of the ATP transport system. Their simultaneous inactivation led to a drastic diminution in the growth rate in milk and the absence of growth in chemically defined medium containing peptides as the nitrogen source. We constructed single and multiple negative mutants for AmiAs and cell wall proteinase (PrtS), the only proteinase capable of hydrolyzing casein oligopeptides outside the cell. Growth experiments in chemically defined medium containing peptides indicated that AmiA1, AmiA2, and AmiA3 exhibited overlapping substrate specificities, and that the whole system allows the transport of peptides containing from 3 to 23 residues.	INRA, Unite Biochim & Struct Prot, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Monnet, V (corresponding author), INRA, Unite Biochim & Struct Prot, F-78352 Jouy En Josas, France.	monnet@jouy.inra.fr	Monnet, Veronique/E-9022-2014	Monnet, Veronique/0000-0001-7438-5618; Garault, Peggy/0000-0001-9105-2831				ALLOING G, 1994, J MOL BIOL, V241, P44, DOI 10.1006/jmbi.1994.1472; Alloing G, 1996, MOL MICROBIOL, V21, P471; BISWAS I, 1993, J BACTERIOL, V175, P3628, DOI 10.1128/JB.175.11.3628-3635.1993; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; Bono JL, 1998, MICROBIOL-UK, V144, P1033, DOI 10.1099/00221287-144-4-1033; Borezee E, 2000, INFECT IMMUN, V68, P7069, DOI 10.1128/IAI.68.12.7069-7077.2000; COGAINBOUSQUET M, 1995, J APPL BACTERIOL, V79, P108; COWMAN RA, 1990, J DENT RES, V69, P1847, DOI 10.1177/00220345900690121101; DEGUCHI Y, 1992, BIOSCI BIOTECH BIOCH, V56, P913, DOI 10.1271/bbb.56.913; DESMAZEAUD MJ, 1972, EUR J BIOCHEM, V28, P190, DOI 10.1111/j.1432-1033.1972.tb01902.x; Detmers FJM, 2000, P NATL ACAD SCI USA, V97, P12487, DOI 10.1073/pnas.220308797; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERNANDEZESPLA MD, 1999, EUR J BIOCHEM, V66, P4772; FOUCAUD C, 1995, J BACTERIOL, V177, P4652, DOI 10.1128/jb.177.16.4652-4657.1995; Garault P, 2000, APPL ENVIRON MICROB, V66, P5128, DOI 10.1128/AEM.66.12.5128-5133.2000; Garault P, 2001, LAIT, V81, P83, DOI 10.1051/lait:2001114; HAGTING A, 1994, J BIOL CHEM, V269, P11391; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUGGINS AR, 1984, J DAIRY SCI, V67, P1674, DOI 10.3168/jds.S0022-0302(84)81491-5; Jenkinson HF, 1996, J BACTERIOL, V178, P68, DOI 10.1128/jb.178.1.68-77.1996; Juarez ZE, 1999, INFECT IMMUN, V67, P271, DOI 10.1128/IAI.67.1.271-278.1999; Juillard V, 1998, APPL ENVIRON MICROB, V64, P1230; Kornacki JA, 1998, INFECT IMMUN, V66, P4115; Kunji ERS, 1998, MOL MICROBIOL, V27, P1107, DOI 10.1046/j.1365-2958.1998.00769.x; KUNJI ERS, 1993, J BACTERIOL, V175, P2052, DOI 10.1128/JB.175.7.2052-2059.1993; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lanfermeijer FC, 1999, BIOCHEMISTRY-US, V38, P14440, DOI 10.1021/bi9914715; Letort C, 2001, J APPL MICROBIOL, V91, P1023, DOI 10.1046/j.1365-2672.2001.01469.x; Maguin E, 1996, J BACTERIOL, V178, P931, DOI 10.1128/jb.178.3.931-935.1996; MILLS OE, 1981, NEW ZEAL J DAIRY SCI, V16, P43; MORISHITA T, 1981, J BACTERIOL, V148, P64, DOI 10.1128/JB.148.1.64-71.1981; PAYNE JW, 1994, ADV MICROB PHYSIOL, V36, P1, DOI 10.1016/S0065-2911(08)60176-9; Podbielski A, 1996, MOL MICROBIOL, V21, P1087, DOI 10.1046/j.1365-2958.1996.661421.x; RAUCH PJG, 1990, NUCLEIC ACIDS RES, V18, P4253, DOI 10.1093/nar/18.14.4253; Rul F, 1997, J APPL MICROBIOL, V82, P695, DOI 10.1046/j.1365-2672.1997.00185.x; Sambrook J, 2001, MOL CLONING LAB MANU; SANZ Y, 2001, BIOCH, V39, P4855; SMID EJ, 1989, J BACTERIOL, V171, P292, DOI 10.1128/jb.171.1.292-298.1989; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; THOMAE H, 1998, PSYCHOSOZIALE GERONT, V1, P35; Thomas T. D., 1977, New Zealand Journal of Dairy Science and Technology, V12, P15; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; Verheul A, 1998, APPL ENVIRON MICROB, V64, P1059	45	54	55	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					32	39		10.1074/jbc.M107002200	http://dx.doi.org/10.1074/jbc.M107002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11602593	Green Published, hybrid			2022-12-25	WOS:000173087900006
J	Remaut, H; Safarov, N; Ciurli, S; Van Beeumen, J				Remaut, H; Safarov, N; Ciurli, S; Van Beeumen, J			Structural basis for Ni2+ transport and assembly of the urease active site by the metallochaperone UreE from Bacillus pasteurii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY DATA; IN-VIVO; NICKEL METALLOCHAPERONE; CRYSTAL-STRUCTURE; METAL-BINDING; PROTEIN; ACTIVATION; APOPROTEIN; COMPLEX; PURIFICATION	Bacillus pasteurii UreE (BpUreE) is a putative chaperone assisting the insertion of Ni2+ ions in the active site of urease. The x-ray structure of the protein has been determined for two crystal forms, at 1.7 and 1.85 Angstrom resolution, using SIRAS phases derived from a Hg2+ derivative. BpUreE is composed of distinct N- and C-terminal domains, connected by a short flexible linker. The structure reveals the topology of an elongated homodimer, formed by interaction of the two C-terminal domains through hydrophobic interactions. A single Zn2+ ion bound to four conserved His-100 residues, one from each monomer, connects two dimers resulting in a tetrameric BpUreE known to be formed in concentrated solutions. The Zn2+ ion can be replaced by Ni2+ as shown by anomalous difference maps obtained on a crystal of BpUreE soaked in a solution containing NiCl2. A large hydrophobic patch surrounding the metal ion site is surface-exposed in the biologically relevant dimer. The BpUreE structure represents the first for this class of proteins and suggests a possible role for UreE in the urease nickel-center assembly.	Univ Bologna, Dept Agroenvironm Sci & Technol, I-40127 Bologna, Italy; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	University of Bologna; Ghent University	Ciurli, S (corresponding author), Univ Bologna, Dept Agroenvironm Sci & Technol, Via Filippo Re 8, I-40127 Bologna, Italy.	sciurli@agrsci.unibo.it; jozef.vanbeeumen@rug.ac.be	SAFAROV, NIYAZ/S-1375-2016; Safarov, Niyaz/AAS-5884-2020; Safarov, Niyaz/AAN-3206-2020; Ciurli, Stefano/K-4355-2014	SAFAROV, NIYAZ/0000-0002-9293-4921; Safarov, Niyaz/0000-0002-9293-4921; Safarov, Niyaz/0000-0002-9293-4921; Ciurli, Stefano/0000-0001-9557-926X; Remaut, Han/0000-0002-9775-4102				Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Benini S, 2001, J BIOL INORG CHEM, V6, P778, DOI 10.1007/s007750100254; Benini S, 1998, J BIOL INORG CHEM, V3, P268, DOI 10.1007/s007750050231; Benini S, 2000, J BIOL INORG CHEM, V5, P110, DOI 10.1007/s007750050014; Brayman TG, 1996, J BACTERIOL, V178, P5410, DOI 10.1128/jb.178.18.5410-5416.1996; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ciurli S, 2001, HANDBOOK ON METALLOPROTEINS, P669; Colpas GJ, 1998, J BIOL INORG CHEM, V3, P150, DOI 10.1007/s007750050216; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; Colpas GJ, 2000, J BIOL CHEM, V275, P10731, DOI 10.1074/jbc.275.15.10731; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; Ha NC, 2001, NAT STRUCT BIOL, V8, P505, DOI 10.1038/88563; Hausinger RP, 1997, J BIOL INORG CHEM, V2, P279, DOI 10.1007/s007750050133; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; Kim SS, 2000, J BIOL CHEM, V275, P31245, DOI 10.1074/jbc.M004541200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; LEE MH, 1990, J BACTERIOL, V172, P4427, DOI 10.1128/jb.172.8.4427-4431.1990; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; Musiani F, 2001, J BIOL INORG CHEM, V6, P300, DOI 10.1007/s007750000204; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; PARK IS, 1995, J BACTERIOL, V177, P1947, DOI 10.1128/jb.177.8.1947-1951.1995; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o	38	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49365	49370		10.1074/jbc.M108304200	http://dx.doi.org/10.1074/jbc.M108304200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11602602	hybrid			2022-12-25	WOS:000173922100097
J	Li, F; Zhang, D; Fujise, K				Li, F; Zhang, D; Fujise, K			Characterization of fortilin, a novel antiapoptotic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR PROTEIN; CYTOCHROME-C; CELL-DEATH; DNA FRAGMENTATION; BCL-2 PROTEIN; IN-VIVO; APOPTOSIS; INHIBITOR; FAMILY; GENE	Apoptosis is meticulously controlled in living organisms. Its dysregulation has been shown to play a key role in a number of human diseases, including neoplastic, cardiovascular, and degenerative disorders. Bcl-2 family member proteins and inhibitors of apoptosis proteins are two major negative regulators of apoptosis. We report here the characterization of novel antiapoptotic protein, fortilin, which we identified through yeast two-hybrid library screening. Sequence analysis of fortilin revealed it to be a 172-amino acid polypeptide highly conserved from mammals to plants. Fortilin is structurally unrelated to either Bcl-2 family member proteins or inhibitors of apoptosis proteins. Northern blot analysis showed the fortilin message to be ubiquitous in normal tissue but especially abundant in the liver, kidney, and small intestine. Western blot analysis using anti-fortilin antibody showed more extensive expression in cancerous cell lines (H1299, MCF-7, and A549) than in cell lines derived from normal tissue (HEK293). Immunocytochemistry using HeLa cells transiently expressing FLAG-tagged fortilin and immunohistochemistry using human breast ductal carcinoma tissue and anti-fortilin antibody both showed that fortilin is predominantly localized in the nucleus. Functionally, the transient overexpression of fortilin in HeLa cells prevented them, in a dose-dependent fashion, from undergoing etoposide-induced apoptosis. Consistently, U2OS cells stably expressing fortilin protected the cells from cell death induced by etoposide over various concentrations and durations of exposure. In addition, fortilin overexpression inhibited caspase-3-like activity as assessed by the cleavage of fluorogenic substrate benzyloxycarbonyl-DEVD-7-amido-4-(trifluoromethyl)coumarin. Furthermore, the antisense depletion of fortilin from breast cancer cell line MCF-7 was associated with massive cell death. These data suggest that fortilin represents a novel antiapoptotic protein involved in cell survival and apoptosis regulation.	Univ Texas, Sch Med, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Cardiol, Dept Internal Med, Houston, TX 77030 USA	University of Texas System; University of Texas System	Fujise, K (corresponding author), Univ Texas, Sch Med, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, 6431 Fannin St, Suite 1-246, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 68024, HL 04015] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GROSS B, 1989, NUCLEIC ACIDS RES, V17, P8367, DOI 10.1093/nar/17.20.8367; HAGHIGHAT NG, 1992, MOL BIOCHEM PARASIT, V51, P99, DOI 10.1016/0166-6851(92)90205-X; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; Maki CG, 1996, CANCER RES, V56, P2649; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rheaume E, 1997, EMBO J, V16, P6346, DOI 10.1093/emboj/16.21.6346; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SATO M, 1975, BIOCHIM BIOPHYS ACTA, V397, P179, DOI 10.1016/0005-2744(75)90191-6; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sturzenbaum SR, 1998, BBA-GENE STRUCT EXPR, V1398, P294, DOI 10.1016/S0167-4781(98)00077-3; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Thiele H, 1998, EUR J BIOCHEM, V257, P62, DOI 10.1046/j.1432-1327.1998.2570062.x; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; WANG HG, 1994, ONCOGENE, V9, P2751; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	56	215	239	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47542	47549		10.1074/jbc.M108954200	http://dx.doi.org/10.1074/jbc.M108954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598139	hybrid			2022-12-25	WOS:000172768500113
J	Negrerie, M; Bouzhir, L; Martin, JL; Liebl, U				Negrerie, M; Bouzhir, L; Martin, JL; Liebl, U			Control of nitric oxide dynamics by guanylate cyclase in its activated state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; GEMINATE RECOMBINATION; PROXIMAL LIGAND; HEME-PROTEINS; MUTANT; IRON; HEMOGLOBIN; BINDING; NO; IDENTIFICATION	Soluble guanylate cyclase (sGC) is the target of nitric oxide (NO) released by nitric-oxide synthase in endothelial cells, inducing an increase of cGMP synthesis in response. This heterodimeric protein possesses a regulatory subunit carrying a heme where NO binding occurs, while the second subunit harbors the catalytic site. The binding of NO and the subsequent breaking of the bond between the proximal histidine and the heme-Fe2+ are assumed to induce conformational changes, which are the origin of the catalytic activation. At the molecular level, the activation and deactivation mechanisms are unknown, as is the dynamics of NO once in the heme pocket. Using ultrafast time-resolved absorption spectroscopy, we measured the kinetics of NO rebinding to sGC after photodissociation. The main spectral transient in the Soret band does not match the equilibrium difference spectrum of NO-liganded minus unliganded sGC, and the geminate rebinding was found to be monoexponential and ultrafast (tau = 7.5 ps), with a relative amplitude close to unity (0.97). These characteristics, so far not observed in other hemoproteins, indicate that NO encounters a high energy barrier for escaping from the heme pocket once the His-Fe2+ bond has been cleaved; this bond does not reform before NO recombination. The deactivation of isolated sGC cannot occur by only simple diffusion of NO from the heme; therefore, several allosteric states may be inferred, including a desensitized one, to induce NO release. Thus, besides the structural change leading to activation, a consequence of the decoupling of the proximal histidine may also be to induce a change of the heme pocket distal geometry, which raises the energy barrier for NO escape, optimizing the efficiency of NO trapping. The non-single exponential character of the NO picosecond rebinding coexists only with the presence of the protein structure surrounding the heme, and the single exponential rate observed in sGC is very likely to be due to a closed conformation of the heme pocket. Our results emphasize the physiological importance of NO geminate recombination in hemoproteins like nitric-oxide synthase and sGC and show that the protein structure controls NO dynamics in a manner adapted to their function. This control of ligand dynamics provides a regulation at molecular level in the function of these enzymes.	Ecole Polytech, Lab Opt & Biosci, INSERM, U451, F-91128 Palaiseau, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris	Negrerie, M (corresponding author), Ecole Polytech, Lab Opt & Biosci, INSERM, U451, F-91128 Palaiseau, France.	negrerie@enstay.ensta.fr	Negrerie, Michel/L-2283-2018	Negrerie, Michel/0000-0001-9918-031X; LIEBL, Ursula/0000-0003-0869-4388				BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Das TK, 1999, INORG CHEM, V38, P1952, DOI 10.1021/ic990049+; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P4939, DOI 10.1021/bi951661p; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DEPILLIS GD, 1994, J AM CHEM SOC, V116, P6981, DOI 10.1021/ja00094a081; DUPRAT AF, 1995, BIOCHEMISTRY-US, V34, P2634, DOI 10.1021/bi00008a030; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Friebe A, 1997, BIOCHEMISTRY-US, V36, P1194, DOI 10.1021/bi962047w; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Hurley JH, 1998, CURR OPIN STRUC BIOL, V8, P770, DOI 10.1016/S0959-440X(98)80097-3; JONES CM, 1992, BIOCHEMISTRY-US, V31, P6692, DOI 10.1021/bi00144a008; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; KIM TD, 1994, J BIOL CHEM, V269, P15540; LeclercLHostis E, 1996, BBA-PROTEIN STRUCT M, V1293, P140, DOI 10.1016/0167-4838(95)00237-5; Margulis A, 2000, BIOCHEMISTRY-US, V39, P1034, DOI 10.1021/bi992040p; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; MULSCH A, 1991, METHOD ENZYMOL, V195, P377; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PRESS WH, 1988, NUMERICAL RECIPES, P59; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rohlfs RJ, 1998, J BIOL CHEM, V273, P12128, DOI 10.1074/jbc.273.20.12128; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Tomita T, 1997, BIOCHEMISTRY-US, V36, P10155, DOI 10.1021/bi9710131; Vos MH, 2000, J CHIN CHEM SOC-TAIP, V47, P765; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; Zhao YD, 1998, BIOCHEMISTRY-US, V37, P12458, DOI 10.1021/bi9811563	39	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46815	46821		10.1074/jbc.M102224200	http://dx.doi.org/10.1074/jbc.M102224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590135	hybrid			2022-12-25	WOS:000172768500020
J	Xing, YN; Lin, W; Jiang, M; Myers, RV; Cao, DH; Bernard, MP; Moyle, WR				Xing, YN; Lin, W; Jiang, M; Myers, RV; Cao, DH; Bernard, MP; Moyle, WR			Alternatively folded choriogonadotropin analogs - Implications for hormone folding and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LEUCINE-RICH REPEATS; ALPHA-SUBUNIT; BETA-SUBUNIT; GLYCOPROTEIN HORMONES; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; DISULFIDE BONDS; LH ACTIVITY	Most heterodimeric proteins are stabilized by intersubunit contacts or disulfide bonds. In contrast, human chorionic gonadotropin (hCG) and other glycoprotein hormones are secured by a strand of their beta -subunits that is wrapped around alpha -subunit loop 2 "like a seatbelt." During studies of hCG synthesis in COS-7 cells, we found that, when the seatbelt was prevented from forming the disulfide that normally "latches" it to the beta -subunit, its carboxyl-terminal end can "scan" the surface of the heterodimer and become latched by a disulfide to cysteines substituted for residues in the a-subunit. Analogs in which the seatbelt was latched to residues 35, 37,41-43, and 56 of alpha -subunit loop 2 had similar lutropin activities to those of hCG; that in which it was latched to residue 92 at the carboxyl terminus had 10-20% the activity of hCG. Attachment of the seatbelt to a-subunit residues 45-51, 86, 88, 90, and 91 reduced lutropin activity substantially. These findings show that the heterodimer can form before the beta -subunit has folded completely and support the notions that the carboxyl-terminal end of the seatbelt, portions of alpha -subunit loop 2, and the end of the alpha -subunit carboxyl terminus do not participate in lutropin receptor interactions. They suggest also that several different architectures could have been sampled without disrupting hormone activity as the glycoprotein hormones diverged from other cysteine knot proteins.	Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Obstet & Gynecol, 675 Hoes Lane, Piscataway, NJ 08854 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014907, R01HD014907, R01HD038547] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 14907, HD 38547] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAHL OP, 1969, J BIOL CHEM, V244, P567; BenMenahem D, 1997, J BIOL CHEM, V272, P6827, DOI 10.1074/jbc.272.11.6827; Bernard MP, 1998, BIOCHEM J, V335, P611, DOI 10.1042/bj3350611; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; Campbell RK, 1997, NAT BIOTECHNOL, V15, P439, DOI 10.1038/nbt0597-439; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P54, DOI 10.1210/me.9.1.54; Galet C, 2000, J ENDOCRINOL, V167, P117, DOI 10.1677/joe.0.1670117; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Han Y, 1996, MOL CELL ENDOCRINOL, V124, P151, DOI 10.1016/S0303-7207(96)03936-6; Heikoop JC, 1997, EUR J BIOCHEM, V245, P656, DOI 10.1111/j.1432-1033.1997.00656.x; Jackson AM, 1999, MOL ENDOCRINOL, V13, P2175, DOI 10.1210/me.13.12.2175; JI I, 1993, J BIOL CHEM, V268, P20851; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LI CH, 1964, NATURE, V202, P291; Li MD, 1998, J ENDOCRINOL, V156, P529, DOI 10.1677/joe.0.1560529; Lin W, 1999, MOL CELL ENDOCRINOL, V152, P91, DOI 10.1016/S0303-7207(99)00056-8; Marichatou H, 2000, EUR J ENDOCRINOL, V142, P402, DOI 10.1530/eje.0.1420402; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; Moyle WR, 1998, CHEM BIOL, V5, P241, DOI 10.1016/S1074-5521(98)90617-2; Myers RV, 2000, BBA-GEN SUBJECTS, V1475, P390, DOI 10.1016/S0304-4165(00)00097-0; PANTEL J, 1993, BIOCHEM BIOPH RES CO, V195, P588, DOI 10.1006/bbrc.1993.2086; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Remy JJ, 1996, MOL CELL ENDOCRINOL, V125, P79, DOI 10.1016/S0303-7207(96)03955-X; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Wang YH, 2000, MOL CELL ENDOCRINOL, V170, P67, DOI 10.1016/S0303-7207(00)00331-2; WOODRUFF TK, 1995, ANNU REV PHYSIOL, V57, P219; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2001, PROTEIN SCI, V10, P226, DOI 10.1110/ps.25901	41	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46953	46960		10.1074/jbc.M108374200	http://dx.doi.org/10.1074/jbc.M108374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591722	hybrid			2022-12-25	WOS:000172768500039
J	Nakanishi, M; Yatome, C; Ishida, N; Kitade, Y				Nakanishi, M; Yatome, C; Ishida, N; Kitade, Y			Putative ACP phosphodiesterase gene (acpD) encodes an azoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; NAD(P)H-QUINONE REDUCTASE; PROTEIN; PNEUMONIAE; CLONING; MAP	An FMN-dependent NADH-azoreductase of Escherichia coli was purified and analyzed for identification of the gene responsible for azo reduction by microorganisms. The N-terminal sequence of the azoreductase conformed to that of the acpD gene product, acyl carrier protein phosphodiesterase. Overexpression of the acpD gene provided the E. coli with a large amount of the 23-kDa protein and more than 800 times higher azoreductase activity. The purified gene product exhibited activity corresponding to that of the native azoreductase. The reaction followed a ping-pong mechanism requiring 2 mol of NADH to reduce I mol of methyl red (4 ' -dimethylaminoazobenzene-2-carboxylic acid) into 2-aminobenzoic acid and N,N ' -dimethyl-p-phenylenediamine. On the other hand, the gene product could not convert holo-acyl carrier protein into the apo form under either in vitro or in vivo conditions. These data indicate that the acpD gene product is not acyl carrier protein phosphodiesterase but an azoreductase.	Gifu Univ, Fac Engn, Dept Biomol Sci, Lab Mol Biochem, Gifu 5011193, Japan	Gifu University	Kitade, Y (corresponding author), Gifu Univ, Fac Engn, Dept Biomol Sci, Lab Mol Biochem, 1-1 Yanagido, Gifu 5011193, Japan.	kitade@biomol.gifu-u.ac.jp						BAYNEY RM, 1987, J BIOL CHEM, V262, P572; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CRONAN JE, 1980, J BACTERIOL, V141, P1291, DOI 10.1128/JB.141.3.1291-1297.1980; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Ghosh Dilip K., 1993, Indian Journal of Experimental Biology, V31, P951; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Holme I., 1984, ECOLOGICAL ASPECTS C, P111; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; MORRIS SA, 1993, BIOCHEM J, V294, P521, DOI 10.1042/bj2940521; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Suzuki Y, 2001, J BIOL CHEM, V276, P9059, DOI 10.1074/jbc.M008083200; Takami H, 1999, EXTREMOPHILES, V3, P21, DOI 10.1007/s007920050095; THERISOD H, 1986, P NATL ACAD SCI USA, V83, P7236, DOI 10.1073/pnas.83.19.7236; VANDENBOOM T, 1989, ANNU REV MICROBIOL, V43, P317, DOI 10.1146/annurev.micro.43.1.317; Wong PK, 1996, WATER RES, V30, P1736, DOI 10.1016/0043-1354(96)00067-X; ZIMMERMANN T, 1984, ARCH MICROBIOL, V138, P37, DOI 10.1007/BF00425404; ZIMMERMANN T, 1982, EUR J BIOCHEM, V129, P197, DOI 10.1111/j.1432-1033.1982.tb07040.x	27	131	145	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46394	46399		10.1074/jbc.M104483200	http://dx.doi.org/10.1074/jbc.M104483200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583992	hybrid			2022-12-25	WOS:000172573100122
J	Nogueira, V; Rigoulet, M; Piquet, MA; Devin, A; Fontaine, E; Leverve, XM				Nogueira, V; Rigoulet, M; Piquet, MA; Devin, A; Fontaine, E; Leverve, XM			Mitochondrial respiratory chain adjustment to cellular energy demand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; RAT-LIVER MITOCHONDRIA; FATTY-ACID DEFICIENCY; OXIDATIVE-PHOSPHORYLATION; THYROID-HORMONE; THERMODYNAMIC CONTROL; H+/E STOICHIOMETRY; BOVINE HEART; HYPERTHYROIDISM; HEPATOCYTES	Because adaptation to physiological changes in cellular energy demand is a crucial imperative for life, mitochondrial oxidative phosphorylation is tightly controlled by ATP consumption. Nevertheless, the mechanisms permitting such large variations in ATP synthesis capacity, as well as the consequence on the overall efficiency of oxidative phosphorylation, are not known. By investigating several physiological models in vivo in rats (hyper- and hypothyroidism, polyunsaturated fatty acid deficiency, and chronic ethanol intoxication) we found that the increase in hepatocyte respiration (from 9.8 to 22.7 nmol of O-2/min/mg dry cells) was tightly correlated with total mitochondrial cytochrome content, expressed both per mg dry cells or per mg mitochondrial protein. Moreover, this increase in total cytochrome content was accompanied by an increase in the respective proportion of cytochrome oxidase; while total cytochrome content increased 2-fold (from 0.341 +/- 0.021 to 0.821 +/- 0.024 nmol/mg protein), cytochrome oxidase increased 10-fold (from 0.020 +/- 0.002 to 0.224 +/- 0.006 nmol/mg protein). This modification was associated with a decrease in the overall efficiency of the respiratory chain. Since cytochrome oxidase is well recognized for slippage between redox reactions and proton pumping, we suggest that this dramatic increase in cytochrome oxidase is responsible for the decrease in the overall efficiency of respiratory chain and, in turn, of ATP synthesis yield, linked to the adaptive increase in oxidative phosphorylation capacity.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble, France; Univ Bordeaux 2, Inst Biochim & Genet Cellulaire, CNRS, F-33077 Bordeaux, France; CHU Cote Nacre, Serv Hepatogastroenterol & Nutr, F-14033 Caen, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; CHU de Caen NORMANDIE; Universite de Caen Normandie	Leverve, XM (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, BP 53X, F-38041 Grenoble, France.		Fontaine, Eric/ABA-8853-2020	Fontaine, Eric/0000-0002-5204-9477				AKERBOOM TPM, 1979, TECH METAB RES B, V105, P1; AZZONE GF, 1985, J INORG BIOCHEM, V23, P349, DOI 10.1016/0162-0134(85)85045-5; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Bobyleva V, 1998, FEBS LETT, V430, P409, DOI 10.1016/S0014-5793(98)00700-5; BRAND MD, 1992, EUR J BIOCHEM, V206, P775, DOI 10.1111/j.1432-1033.1992.tb16984.x; CAPITANIO N, 1991, FEBS LETT, V288, P179, DOI 10.1016/0014-5793(91)81029-8; CHEN YDI, 1977, ARCH BIOCHEM BIOPHYS, V181, P470, DOI 10.1016/0003-9861(77)90253-3; DEAVER OE, 1986, J NUTR, V116, P1148, DOI 10.1093/jn/116.7.1148; DIVAKARAN P, 1978, EXPERIENTIA, V34, P1540, DOI 10.1007/BF02034659; DIVAKARAN P, 1977, J NUTR, V107, P1621, DOI 10.1093/jn/107.9.1621; ESPIE P, 1995, BBA-BIOENERGETICS, V1230, P139, DOI 10.1016/0005-2728(95)00045-K; FITTON V, 1994, BIOCHEMISTRY-US, V33, P9692, DOI 10.1021/bi00198a039; Fontaine EM, 1996, BBA-BIOENERGETICS, V1276, P181, DOI 10.1016/0005-2728(96)00075-8; Frank V, 1996, FEBS LETT, V382, P121, DOI 10.1016/0014-5793(96)00096-8; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; GREGORY RB, 1991, BIOCHIM BIOPHYS ACTA, V1098, P61; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HOCH FL, 1988, PROG LIPID RES, V27, P199, DOI 10.1016/0163-7827(88)90013-6; HOLNESS M, 1984, FEBS LETT, V177, P231, DOI 10.1016/0014-5793(84)81289-2; HORRUM MA, 1991, MOL CELL BIOCHEM, V103, P9; HULBERT AJ, 1976, BIOCHIM BIOPHYS ACTA, V455, P597, DOI 10.1016/0005-2736(76)90328-X; Huttemann M, 2000, EUR J BIOCHEM, V267, P2098, DOI 10.1046/j.1432-1327.2000.01216.x; KLINGENBERG M, 1959, BIOCHEM Z, V331, P486; LUVISETTO S, 1991, J BIOL CHEM, V266, P1034; LUVISETTO S, 1991, FEBS LETT, V291, P17, DOI 10.1016/0014-5793(91)81093-N; LUVISETTO S, 1992, J BIOL CHEM, V267, P15348; MADDAIAH VT, 1981, ARCH BIOCHEM BIOPHYS, V210, P666, DOI 10.1016/0003-9861(81)90234-4; MURPHY MP, 1992, BIOCHEM PHARMACOL, V43, P2663, DOI 10.1016/0006-2952(92)90158-F; Nogueira V, 2001, J BIOENERG BIOMEMBR, V33, P53, DOI 10.1023/A:1005624707780; OHNISHI T, 1966, J BIOL CHEM, V241, P797; OUHABI R, 1989, FEBS LETT, V254, P199, DOI 10.1016/0014-5793(89)81038-5; PAPA S, 1991, FEBS LETT, V288, P183, DOI 10.1016/0014-5793(91)81030-C; PAPA S, 1987, EUR J BIOCHEM, V164, P507, DOI 10.1111/j.1432-1033.1987.tb11156.x; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Piquet MA, 1996, BIOCHEM J, V317, P667, DOI 10.1042/bj3170667; Piquet MA, 2000, FEBS LETT, V468, P239, DOI 10.1016/S0014-5793(00)01225-4; RAFAEL J, 1984, J NUTR, V114, P255, DOI 10.1093/jn/114.2.255; Rigoulet M, 1998, MOL CELL BIOCHEM, V184, P35, DOI 10.1023/A:1006858104988; Rigoulet M, 1998, BBA-BIOENERGETICS, V1365, P117, DOI 10.1016/S0005-2728(98)00051-6; ROHDICH F, 1993, BIOCHEMISTRY-US, V32, P8499, DOI 10.1021/bi00084a015; SARTI P, 1985, P NATL ACAD SCI USA, V82, P4876, DOI 10.1073/pnas.82.15.4876; SCHMEHL I, 1995, FEBS LETT, V375, P206, DOI 10.1016/0014-5793(95)01211-V; SHEARS SB, 1979, BIOCHEM J, V178, P505, DOI 10.1042/bj1780505; SOBOLL S, 1992, BIOCHEM J, V281, P171, DOI 10.1042/bj2810171; SOBOLL S, 1993, BIOCHIM BIOPHYS ACTA, V1144, P1, DOI 10.1016/0005-2728(93)90024-A; SONE N, 1984, BIOCHEMISTRY-US, V23, P6550, DOI 10.1021/bi00321a042; STEVERDING D, 1990, BIOCHEMISTRY-US, V29, P2945, DOI 10.1021/bi00464a009; STONER CD, 1987, J BIOL CHEM, V262, P10445; SUMMER JB, 1944, SCIENCE, V100, P413; VANNESTE WH, 1966, BIOCHIM BIOPHYS ACTA, V113, P175, DOI 10.1016/S0926-6593(66)80132-7; VERHOEVEN AJ, 1985, BIOCHEM J, V226, P183, DOI 10.1042/bj2260183; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514	54	51	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46104	46110		10.1074/jbc.M107425200	http://dx.doi.org/10.1074/jbc.M107425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579099	hybrid			2022-12-25	WOS:000172573100084
J	Mullan, PB; Quinn, JE; Gilmore, PM; McWilliams, S; Andrews, H; Gervin, C; McCabe, N; McKenna, S; White, P; Song, YH; Maheswaran, S; Liu, E; Haber, DA; Johnston, PG; Harkin, DP				Mullan, PB; Quinn, JE; Gilmore, PM; McWilliams, S; Andrews, H; Gervin, C; McCabe, N; McKenna, S; White, P; Song, YH; Maheswaran, S; Liu, E; Haber, DA; Johnston, PG; Harkin, DP			BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents	ONCOGENE			English	Article						BRCA1; GADD45; antimicrotubule agents; G2/M arrest; cell death	TRANSCRIPTION-COUPLED REPAIR; RETRACTED ARTICLE. SEE; DNA-DAMAGE RESPONSE; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; INDUCTION; INSTABILITY; CENTROSOME; CHECKPOINT	BRCA1 is a tumour suppressor gene implicated in the predisposition to early onset breast and ovarian cancer. We have generated cell lines with inducible expression of BRCA1 to evaluate its role in mediating the cellular response to various chemotherapeutic drugs commonly used in the treatment of breast and ovarian cancer. Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45. A proportion of the arrested cells were blocked in mitosis suggesting activation of both a G2 and a mitotic spindle checkpoint. In contrast, no specific interaction was observed between BRCA1 induction and treatment of cells with a range of DNA damaging agents including Cisplatin and Adriamycin. Inducible expression of GADD45 in the presence of Taxol induced both G2 and mitotic arrest in these cells consistent with a role for GADD45 in contributing to these effects. Our results support a role for both BRCA1 and GADD45 in selectively regulating a G2/M checkpoint in response to antimicrotubule agents and raise the possibility that their expression levels in cells may contribute to the toxicity observed with these compounds.	Queens Univ Belfast, Canc Res Ctr, Dept Oncol, Belfast BT9 7AB, Antrim, North Ireland; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; NIH, Div Clin Sci, Bethesda, MD 20892 USA	Queens University Belfast; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA	Harkin, DP (corresponding author), Queens Univ Belfast, Belfast City Hosp, Canc Res Ctr, Dept Oncol, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk	Liu, Edison/C-4141-2008	Song, Young-Han/0000-0002-0758-3654	Breast Cancer Now [2000:119] Funding Source: Medline	Breast Cancer Now		Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Futamura M, 2000, CANCER RES, V60, P1531; GAYTHER SA, 1998, NEOPLASIA, V4, P365; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber D, 2000, LANCET, V355, P2090, DOI 10.1016/S0140-6736(00)02371-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Larson JS, 1997, CANCER RES, V57, P3351; Leadon SA, 1997, CANCER RES, V57, P3784; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang Y, 2000, GENE DEV, V14, P927; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	40	131	141	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6123	6131		10.1038/sj.onc.1204712	http://dx.doi.org/10.1038/sj.onc.1204712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593420				2022-12-25	WOS:000171206300003
J	Terakita, A; Yamashita, T; Nimbari, N; Kojima, D; Shichida, Y				Terakita, A; Yamashita, T; Nimbari, N; Kojima, D; Shichida, Y			Functional interaction between bovine rhodopsin and G protein transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4TH CYTOPLASMIC LOOP; ALPHA-SUBUNITS; AMINO-ACIDS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; COUPLED RECEPTOR; RETINAL ROD; ACTIVATION; BINDING; CELLS	To elucidate the mechanisms of specific coupling of bovine rhodopsin with the G protein transducin (G(t)), we have constructed the bovine rhodopsin mutants whose second or third cytoplasmic loop (loop 2 or 3) was replaced with the corresponding loop of the G(o)-coupled scallop rhodopsin and investigated the difference in the activation abilities for G(t), G(o), and G(i) among these mutants and wild type. We have also prepared the Galpha(i) mutants whose C-terminal 11 or 5 amino acids were replaced with those of Galpha(t), Galpha(o), and Galpha(q) to evaluate the role of the C-terminal tail of the a-subunit on the specific coupling of bovine rhodopsin with G(t). Replacement of loop 2 of bovine rhodopsin with that of the scallop rhodopsin caused about a 40% loss of G(t) and G(o) activation, whereas that of loop 3 enhanced the Go activation four times with a 60% decrease in the G(t) activation. These results indicated that loop 3 of bovine rhodopsin is one of the regions responsible for the specific coupling with G(t), Loop 3 of bovine rhodopsin discriminates the difference of the 6-amino acid sequence (region A) at a position adjacent to the C-terminal 5 amino acids of the G protein, resulting in the different activation efficiency between G(t) and G(o). In addition, the binding of region A to loop 3 of bovine rhodopsin is essential for activation of G(t) but not G(i), even though the sequence of the region A is almost identical between Galpha(t) and Galpha(i). These results suggest that the binding of loop 3 of bovine rhodopsin to region A in Galpha(t) is one of the mechanisms of specific G(t) activation by bovine rhodopsin.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Japan Technol Corp, CREST, Kyoto 6068502, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Shichida, Y (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan.		Kojima, Daisuke/G-4958-2014	Kojima, Daisuke/0000-0003-2658-780X; Terakita, Akihisa/0000-0002-8379-8913				Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Bae H, 1999, J BIOL CHEM, V274, P14963, DOI 10.1074/jbc.274.21.14963; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Han M, 1997, J BIOL CHEM, V272, P23081, DOI 10.1074/jbc.272.37.23081; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1994, METHOD ENZYMOL, V237, P131; Kazmi MA, 2000, BIOCHEMISTRY-US, V39, P3734, DOI 10.1021/bi992354c; Kojima D, 1997, J BIOL CHEM, V272, P22979, DOI 10.1074/jbc.272.37.22979; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Nagata T, 1997, BIOCHEMISTRY-US, V36, P6164, DOI 10.1021/bi962920t; Natochin M, 2000, J BIOL CHEM, V275, P2669, DOI 10.1074/jbc.275.4.2669; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; Seibert C, 1999, EUR J BIOCHEM, V266, P911, DOI 10.1046/j.1432-1327.1999.00927.x; Shi W, 1998, BIOCHEMISTRY-US, V37, P4869, DOI 10.1021/bi9731100; Shichida Y, 2000, METHOD ENZYMOL, V315, P347; Shichida Y, 1998, CELL MOL LIFE SCI, V54, P1299, DOI 10.1007/s000180050256; Simonet J, 1999, ELECTROCHEM COMMUN, V1, P252, DOI 10.1016/S1388-2481(99)00050-8; Tachibanaki S, 1997, BIOCHEMISTRY-US, V36, P14173, DOI 10.1021/bi970932o; Terakita A, 1998, FEBS LETT, V439, P110, DOI 10.1016/S0014-5793(98)01340-4; Varga EV, 2000, J PHARMACOL EXP THER, V292, P209; WEISS ER, 1988, FASEB J, V2, P2841, DOI 10.1096/fasebj.2.13.3139484; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; Yamaguchi I, 1997, J BIOL CHEM, V272, P16599, DOI 10.1074/jbc.272.26.16599; Yamashita T, 2000, J BIOL CHEM, V275, P34272, DOI 10.1074/jbc.M002954200; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t	48	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					40	46		10.1074/jbc.M104960200	http://dx.doi.org/10.1074/jbc.M104960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11606568	hybrid			2022-12-25	WOS:000173087900007
J	Andersen, PS; Menne, C; Mariuzza, RA; Geisler, C; Karjalainen, K				Andersen, PS; Menne, C; Mariuzza, RA; Geisler, C; Karjalainen, K			A response calculus for immobilized T cell receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; ANTIGEN RECOGNITION; PEPTIDE COMPLEXES; CRYSTAL-STRUCTURE; LOW-AFFINITY; BETA-CHAIN; TCR; ACTIVATION; ADHESION; MOLECULES	To address the molecular mechanism of T cell receptor (TCR) signaling, we have formulated a model for T cell activation, termed the 2D-affinity model, in which the density of TCR on the T cell surface, the density of ligand on the presenting surface, and their corresponding two-dimensional affinity determine the level of T cell activation. When fitted to T cell responses against purified ligands immobilized on plastic surfaces, the 2D-affinity model adequately simulated changes in cellular activation as a result of varying ligand affinity and ligand density. These observations further demonstrated the importance of receptor cross-linking density in determining TCR signaling. Moreover, it was found that the functional two-dimensional affinity of TCR ligands was affected by the chemical composition of the ligand-presenting surface. This makes it possible that cell. bound TCR ligands, despite their low affinity in solution, are of optimal two-dimensional affinity thereby allowing effective TCR binding under physiological conditions, i.e. at low ligand densities in cellular interfaces.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark; Univ Maryland, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Basel Inst Immunol, CH-4005 Basel, Switzerland	University of Copenhagen	Andersen, PS (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Bldg 24-2,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.	psa@symphogen.com	Geisler, Carsten/A-7056-2012; Karjalainen, Klaus/A-2206-2011	Geisler, Carsten/0000-0002-8472-0771; Bonefeld, Charlotte Menne/0000-0002-0523-6229				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Andersen PS, 1999, IMMUNITY, V10, P473, DOI 10.1016/S1074-7613(00)80047-3; Andersen PS, 2001, J BIOL CHEM, V276, P33452, DOI 10.1074/jbc.M103750200; Bachmann MF, 1998, EUR J IMMUNOL, V28, P2571, DOI 10.1002/(SICI)1521-4141(199808)28:08<2571::AID-IMMU2571>3.0.CO;2-T; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Bot A, 1996, J IMMUNOL, V157, P3436; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Gett AV, 2000, NAT IMMUNOL, V1, P239, DOI 10.1038/79782; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; Kalergis AM, 2001, NAT IMMUNOL, V2, P229, DOI 10.1038/85286; KARJALAINEN K, 1994, CURR OPIN IMMUNOL, V6, P9, DOI 10.1016/0952-7915(94)90027-2; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Pecorari F, 1999, J MOL BIOL, V285, P1831, DOI 10.1006/jmbi.1998.2422; Pierres A, 1996, P NATL ACAD SCI USA, V93, P15114, DOI 10.1073/pnas.93.26.15114; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Redpath S, 1999, J IMMUNOL, V163, P6; Riper JW, 1998, BIOPHYS J, V74, P492, DOI 10.1016/S0006-3495(98)77807-5; Schodin BA, 1996, IMMUNITY, V5, P137, DOI 10.1016/S1074-7613(00)80490-2; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Sykulev Y, 1995, P NATL ACAD SCI USA, V92, P11990, DOI 10.1073/pnas.92.26.11990; Sykulev Y, 1998, IMMUNITY, V9, P475, DOI 10.1016/S1074-7613(00)80631-7; Tissot AC, 2000, J MOL BIOL, V302, P873, DOI 10.1006/jmbi.2000.4501; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; van der Merwe PA, 2000, NAT IMMUNOL, V1, P194, DOI 10.1038/79729; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; WALLNY HJ, 1995, EUR J IMMUNOL, V25, P1262, DOI 10.1002/eji.1830250520; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Williams TE, 2001, J BIOL CHEM, V276, P13283, DOI 10.1074/jbc.M010427200	51	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49125	49132		10.1074/jbc.M109396200	http://dx.doi.org/10.1074/jbc.M109396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11592972	hybrid			2022-12-25	WOS:000173922100067
J	Hin, S; Bianco, A; Zabel, C; Jung, G; Walden, P				Hin, S; Bianco, A; Zabel, C; Jung, G; Walden, P			Mimetics of a T cell epitope based on poly-N-acylated amine backbone structures induce T cells in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; COMPLEX; BINDING; RECOGNITION; STABILITY; POTENT	Peptidomimetics of the major histocompatibility complex (MHC) class I-restricted ovalbumin-derived T cell epitope SIINFEKL were generated by replacing parts of the peptide backbone by a poly-N-acylated amine (PAA) backbone with aromatic, heteroaromatic, and pseudoaromatic side chains that branch off of the main chain at the amine nitrogen. The structure of the PAAs was designed to position this side chain in the central epitope anchor pocket of the MHC molecule. A number of biologically active PAAs were found that induced cytolysis by the mouse cytotoxic T cell clone 4G3. Competition experiments with independent peptides that are known to bind to the restricting MHC molecule H-2K(b) suggest that the PAAs are bound by the MHC molecules at the same site as conventional peptide epitopes. The PAAs were active also in vivo and induced primary cytotoxic T cell responses in mice.	Humboldt Univ, Med Ctr, Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen	Walden, P (corresponding author), Humboldt Univ, Med Ctr, Charite, Dept Dermatol & Allergy, Schumannstr 20-21, D-10117 Berlin, Germany.	peter.walden@charite.de						Aramori I, 1999, IMMUNOPHARMACOLOGY, V45, P185, DOI 10.1016/S0162-3109(99)00144-7; AUBRY A, 1989, BIOPOLYMERS, V28, P27, DOI 10.1002/bip.360280106; BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163; Beeley NRA, 2000, DRUG DISCOV TODAY, V5, P354, DOI 10.1016/S1359-6446(00)01528-2; Bianco A, 1998, J BIOL CHEM, V273, P28759, DOI 10.1074/jbc.273.44.28759; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BORGES E, 1994, J IMMUNOL METHODS, V173, P253, DOI 10.1016/0022-1759(94)90304-2; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; Brock R, 1996, P NATL ACAD SCI USA, V93, P13108, DOI 10.1073/pnas.93.23.13108; EVANS BE, 1988, J MED CHEM, V31, P2235, DOI 10.1021/jm00120a002; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; Falcioni F, 1999, NAT BIOTECHNOL, V17, P562, DOI 10.1038/9865; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; Gundlach BR, 1996, J IMMUNOL, V156, P3645; Hin S, 1999, J IMMUNOL, V163, P2363; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; PATCHETT AA, 1995, P NATL ACAD SCI USA, V92, P7001, DOI 10.1073/pnas.92.15.7001; PERLMAN S, 1995, J BIOL CHEM, V270, P1493, DOI 10.1074/jbc.270.4.1493; Pridzun L, 1996, EUR J BIOCHEM, V236, P249, DOI 10.1111/j.1432-1033.1996.00249.x; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; UDAKA K, 1995, J BIOL CHEM, V270, P24130, DOI 10.1074/jbc.270.41.24130; UDAKA K, 1995, J EXP MED, V181, P2097, DOI 10.1084/jem.181.6.2097; VANBLEEK GM, 1990, NATURE, V348, P213; WALDEN P, 1995, BIOCHEM SOC T, V23, P678, DOI 10.1042/bst0230678	28	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48790	48796		10.1074/jbc.M107552200	http://dx.doi.org/10.1074/jbc.M107552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11600499	hybrid			2022-12-25	WOS:000173922100024
J	Ridsdale, R; Tseu, I; Wang, JX; Post, M				Ridsdale, R; Tseu, I; Wang, JX; Post, M			CTP : phosphocholine cytidylyltransferase alpha is a cytosolic protein in pulmonary epithelial cells and tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT LUNG; NUCLEAR-LOCALIZATION; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; MEMBRANE INTERACTIONS; II CELLS; SURFACTANT; IDENTIFICATION; PHOSPHATIDYLGLYCEROL; DIACYLGLYCEROL	CTP:phosphocholine cytidylyltransferase (CCT) is a rate-determining enzyme in de novo synthesis of phosphatidylcholine (PC). The lung requires a steady synthesis of PC for lung surfactant of which disaturated PC is the essential active agent. Surfactant synthesis occurs in alveolar type II cells. Studies with non-pulmonary cells have suggested that COT is both a nuclear and cytoplasmic protein. The unusual requirements of the lung for PC synthesis and, therefore, COT activity suggest a unique mechanism of regulation and possibly localization of COT. The localization of CCTalpha in lung epithelial cells and, of greater consequence, lung tissues are yet unknown. Three isoforms of COT have been identified. Herein we investigated the localization of the ubiquitously expressed CCTalpha isoform. To ascertain CCTalpha localization in lungs and lung-related epithelial cells, we employed a number of localization methods. Immunogold electron microscopy using polyclonal antibodies raised to either the carboxyl terminus, catalytic domain, or amino terminus of CCTalpha localized CCTalpha mostly to the exterior plasma membrane or regions of the endoplasmic reticulum (ER) in both A549 and MLE-15 epithelial lung cell lines and primary cultures of fetal rat lung epithelial cells. In contrast to other studies, little or no nuclear labeling was observed. Indirect immunofluorescence of these cells with anti-CCTalpha antibodies resulted in a similar distribution. Indirect visualization of both hemagglutinin- and FLAG-tagged CCTalpha as well as direct visualization of enhanced green fluorescence protein-CCTalpha fusion protein corroborated a cytoplasmic localization of CCTalpha in pulmonary cells. Moreover, analysis of lung tissue from fetal and adult mouse by either immunogold electron microscopy or indirect immunofluorescence yielded a strong cytoplasmic CCTalpha signal with virtually no nuclear localization in epithelial cells lining the airways. The cytoplasmic localization of CCTalpha in type II cells was further substantiated with transgenic mice overexpressing FLAG-tagged CCTalpha using the lung-specific human surfactant protein C (SP-C) promoter. We conclude that CCTa does not localize to the nucleus in pulmonary tissues, and, therefore, nuclear localization of CCTalpha is not a universal event.	Univ Toronto, Hosp Sick Children, Res Inst,Canadian Inst,Hlth Res Grp, Inst Med Sci,Programme Lung Biol Res, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Post, M (corresponding author), Univ Toronto, Hosp Sick Children, Res Inst,Canadian Inst,Hlth Res Grp, Inst Med Sci,Programme Lung Biol Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; DeLong CJ, 2000, J BIOL CHEM, V275, P32325, DOI 10.1074/jbc.M004644200; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; HALLMAN M, 1985, PEDIATR RES, V19, P286, DOI 10.1203/00006450-198503000-00006; HOGAN M, 1994, AM J PHYSIOL, V267, pL25, DOI 10.1152/ajplung.1994.267.1.L25; Houweling M, 1996, EUR J CELL BIOL, V69, P55; JASSAL D, 1991, IN VITRO CELL DEV B, V27, P625; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; POST M, 1988, BIOCHIM BIOPHYS ACTA, V947, P249, DOI 10.1016/0304-4157(88)90011-1; SCHLAME M, 1986, BIOCHEM J, V240, P247, DOI 10.1042/bj2400247; SCHLAME M, 1988, BIOCHEM J, V253, P209, DOI 10.1042/bj2530209; TADERERA JV, 1967, DEV BIOL, V16, P489, DOI 10.1016/0012-1606(67)90061-9; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615; Yang JL, 1997, BIOCHEM J, V325, P29, DOI 10.1042/bj3250029; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; ZIMMERMANN LJ, 1994, BBA-LIPID LIPID MET, V1211, P44, DOI 10.1016/0005-2760(94)90137-6; ZIMMERMANN LJ, 1993, AM J PHYSIOL, V264, pF575	36	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49148	49155		10.1074/jbc.M103566200	http://dx.doi.org/10.1074/jbc.M103566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11583989	hybrid			2022-12-25	WOS:000173922100070
J	Gerrish, K; Cissell, AA; Stein, R				Gerrish, K; Cissell, AA; Stein, R			The role of hepatic nuclear factor 1 alpha and PDX-1 in transcriptional regulation of the pdx-1 gene.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC TRANSCRIPTION; HUMAN INSULIN GENE; HOMEODOMAIN PROTEIN; FACTOR-I; DIABETES-MELLITUS; HOMEOBOX FACTOR; BETA-CELLS; PANCREAS DEVELOPMENT; FACTOR 3-BETA; ISLET CELLS	The PDX-1 homeodomain transcription factor regulates pancreatic development and adult islet beta cell function. Expression of the pdx-1 gene is almost exclusively localized to beta cells within the adult endocrine pancreas. Islet beta cell-selective transcription is controlled by evolutionarily conserved subdomain sequences (termed Areas I (-2839 to -2520 base pairs (bp)), II (-2252 to -2023 bp), and III (-1939 to -1664 bp)) found within the 5'-flanking region of the pdx-1 gene. Areas I and II are independently capable of directing beta cell-selective reporter gene activity in transfection assays, with Area I-mediated stimulation dependent upon binding of hepatic nuclear factor 3 beta (HN-F3 beta), a key regulator of islet beta cell function. To identify other transactivators of Area I, highly conserved sequence segments within this subdomain were mutagenized, and their effect on activation was determined. Several of the sensitive sites were found by transcription factor data base analysis to potentially bind endodermally expressed transcription factors, including HNF1 alpha (-2758 to -2746 bp, Segment 2), HNF4 (-2742 to -2730 bp, Segment 4; -2683 to -2671 bp, Segment 7-8), and HNF6 (-2727 to -2715 bp, Segment 5). HNF1 alpha, but not HNF4 and HNF6, binds specifically to Area I sequences in vitro. HNF1 alpha was also shown to specifically activate Area I-driven transcription through Segment 2. In addition, PDX-1 itself was found to stimulate Area I activation. The chromatin immunoprecipitation assay performed with PDX-1 antisera also demonstrated that this factor bound to Area I within the endogenous pdx-1 gene in beta cells. Our results indicate that regulatory factors binding to Area I conserved sequences contribute to the selective transcription pattern of the pdx-1 gene and that control is mediated by endodermal regulators like HNF1 alpha, HNF3 beta, and PDX-1.	Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37215 USA	Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37215 USA.	roland.stein@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050203, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK50203, P60 DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; BrethertonWatt D, 1996, BIOCHEM J, V313, P495, DOI 10.1042/bj3130495; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Crane-Robinson C, 1998, TRENDS GENET, V14, P477, DOI 10.1016/S0168-9525(98)01621-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DiMattia GE, 1997, DEV BIOL, V182, P180, DOI 10.1006/dbio.1996.8472; Drewes T, 1996, MOL CELL BIOL, V16, P925; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; GUZ Y, 1995, DEVELOPMENT, V121, P11; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jiang GQ, 1997, J BIOL CHEM, V272, P1218, DOI 10.1074/jbc.272.2.1218; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jorgensen MC, 1999, FEBS LETT, V461, P287, DOI 10.1016/S0014-5793(99)01436-2; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Oka T, 1997, HEART VESSELS, P10; Okita K, 1999, BIOCHEM BIOPH RES CO, V263, P566, DOI 10.1006/bbrc.1999.1412; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Packer AI, 1998, DEVELOPMENT, V125, P1991; Pankratova EV, 1998, FEBS LETT, V426, P81, DOI 10.1016/S0014-5793(98)00316-0; Parrizas M, 2001, MOL CELL BIOL, V21, P3234, DOI 10.1128/MCB.21.9.3234-3243.2001; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Poitout V, 1996, ANNU REV MED, V47, P69; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; St-Onge L, 1999, CURR OPIN GENET DEV, V9, P295, DOI 10.1016/S0959-437X(99)80044-6; STEIN R, 2001, HDB PHYSL 7, V2, P25; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Tronche F, 1997, J MOL BIOL, V266, P231, DOI 10.1006/jmbi.1996.0760; TRONCHE F, 1994, LIVER GENE EXPRESSIO, P207; Velho G, 1998, EUR J ENDOCRINOL, V138, P233, DOI 10.1530/eje.0.1380233; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Watada H, 1996, BIOCHEM BIOPH RES CO, V229, P746, DOI 10.1006/bbrc.1996.1875; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Xu FH, 1999, J BIOL CHEM, V274, P34310, DOI 10.1074/jbc.274.48.34310; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	78	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47775	47784		10.1074/jbc.M109244200	http://dx.doi.org/10.1074/jbc.M109244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11590182	hybrid			2022-12-25	WOS:000172927000008
J	Kalivendi, SV; Kotamraju, S; Zhao, H; Joseph, J; Kalyanaraman, B				Kalivendi, SV; Kotamraju, S; Zhao, H; Joseph, J; Kalyanaraman, B			Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase - Effect of antiapoptotic antioxidants and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL FORMATION; OXIDATIVE STRESS MEASUREMENTS; REACTIVE OXYGEN; HORSERADISH-PEROXIDASE; INDUCED CARDIOMYOPATHY; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; APAF-1 APOPTOSOME; HYDROGEN-PEROXIDE; ADRIAMYCIN	The clinical efficacy of the antitumor antibiotic drug doxorubicin (DOX) is severely limited by its dose-limiting cardiotoxicity in cancer patients. DOX-induced generation of reactive oxygen species was proposed to be a major mechanism of its cardiotoxicity. Previously, we showed that DOX undergoes a reductive activation at the reductase domain of endothelial nitric-oxide synthase (eNOS) forming the semiquinone and superoxide (Vasquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, K. A., Jr., and Kalyanaraman, B. (1997) Biochemistry 36, 11293-11297). In this report, we provide evidence for DOX-induced increase in eNOS transcription and protein expression in bovine aortic endothelial cells (BAEC). We propose that DOX-induced hydrogen peroxide formation is responsible for the increased transcription of eNOS. BAEC treated with antisense eNOS oligonucleotide inhibits DOX-induced endothelial apoptosis. Treatment with antioxidants restored the levels of antiapoptotic proteins (Hsp70 and Bcl-2) in DOX-treated BAEC. DOX-induced intracellular oxidative stress, as measured by oxidation of dichlorodihydrofluorescein diacetate to dichlorofluorescein and hydroethidium to ethidium, was inhibited by antisense eNOS oligonucleotide and antioxidant treatment. Furthermore, antiapoptotic antioxidants (e.g. FeTBAP, ebselen, and alpha -phenyl-tert-butyl nitrone) inhibited DOX-induced eNOS transcription. We conclude that DOX-induced apoptosis is linked to the redox activation of DOX by eNOS.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NATIONAL CANCER INSTITUTE [R01CA077822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77822] Funding Source: Medline; NCRR NIH HHS [RR 01008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aoyama M, 1998, BIOCHEM J, V336, P727, DOI 10.1042/bj3360727; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BALLA GH, 1991, ARTERIOSCLER THROMB, V111, P1700; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; BUZDAR AU, 1985, CANCER, V55, P2761, DOI 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Garner AP, 1999, CANCER RES, V59, P1929; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Gorodeski GI, 2000, AM J PHYSIOL-CELL PH, V279, pC1495, DOI 10.1152/ajpcell.2000.279.5.C1495; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANDA K, 1976, GANN, V67, P523; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Hensley K, 1998, J NEUROCHEM, V71, P2549; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Ito H, 1999, LIFE SCI, V64, P755, DOI 10.1016/S0024-3205(98)00617-1; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Katusic ZS, 2001, AM J PHYSIOL-HEART C, V281, pH981, DOI 10.1152/ajpheart.2001.281.3.H981; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; KUSUOKA H, 1991, J CARDIOVASC PHARM, V18, P437, DOI 10.1097/00005344-199109000-00017; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Mortensen K, 1999, J BIOL CHEM, V274, P37679, DOI 10.1074/jbc.274.53.37679; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS C, 1986, FASEB J, V45, P2792; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; Nakamura T, 2000, CIRCULATION, V102, P572; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Sen CK, 2000, ANTIOXIDANT REDOX RE; Shi Y, 2000, FREE RADICAL BIO MED, V29, P695, DOI 10.1016/S0891-5849(00)00364-6; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SVINGEN BA, 1981, ARCH BIOCHEM BIOPHYS, V209, P119, DOI 10.1016/0003-9861(81)90263-0; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; UBEZIO P, 1994, FREE RADICAL BIO MED, V16, P509, DOI 10.1016/0891-5849(94)90129-5; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Volk T, 1997, MOL CELL BIOCHEM, V171, P11, DOI 10.1023/A:1006886215193; Xiao ZS, 1997, J CELL PHYSIOL, V171, P205, DOI 10.1002/(SICI)1097-4652(199705)171:2<205::AID-JCP11>3.3.CO;2-3; Zhao HT, 2001, FREE RADICAL BIO MED, V31, P599, DOI 10.1016/S0891-5849(01)00619-0	57	167	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47266	47276		10.1074/jbc.M106829200	http://dx.doi.org/10.1074/jbc.M106829200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579094	hybrid			2022-12-25	WOS:000172768500080
J	Wagner, MJ; Gogela-Spehar, M; Skirrow, RC; Johnston, RN; Riabowol, K; Helbing, CC				Wagner, MJ; Gogela-Spehar, M; Skirrow, RC; Johnston, RN; Riabowol, K; Helbing, CC			Expression of novel ING variants is regulated by thyroid hormone in the Xenopus laevis tadpole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE TUMOR-SUPPRESSOR; RANA-CATESBEIANA TADPOLES; GENE-EXPRESSION; HISTONE DEACETYLASE; ALTERNATIVE TRANSCRIPTS; NEGATIVE REGULATOR; MESSENGER-RNA; PHD FINGER; A GENE; N-COR	The candidate tumor suppressor gene, ING1, encodes several protein isoforms as a result of alternative splicing that may possess agonistic and antagonistic roles in the control of cell proliferation and apoptosis. Recently a related gene, ING2, was isolated in human whose expression is increased in adenocarcinomas. Little is known about the cellular function and regulation of these ING family members, but the fact that ING proteins contain a plant homeodomain finger suggests that these proteins may modulate transcription factor-mediated pathways. To elucidate how ING may interact in different tissues to modulate function, we used amphibian metamorphosis as a model system in which a single stimulus, thyroid hormone (TH), initiates tissue-specific proliferation, differentiation, and apoptosis. We have isolated the first Xenopus laevis ING2 and demonstrate that transcript levels increase in response to TH treatment. We provide evidence for the existence of splice variants that are differentially expressed in tissues with different TH-induced fates. Western blots using an anti. body directed against the highly conserved C-terminal end of ING proteins reveal a tissue-specific pattern of ING isoform expression in adult Xenopus tissues. Analyses of premetamorphic tadpole tissues show a TH-induced accumulation of ING proteins in tail, whereas the levels in the leg are not affected. This TH-induced accumulation is also observed in serum-free tail organ cultures and is prevented by inhibitors of tail apoptosis. Therefore, this work presents the first link between ING expression and a hormonally regulated nuclear transcription factor-mediated apoptotic response opening the possibility that ING family members may be involved in transducing the signal initiated by TH that determines cell fate.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Victoria; University of Calgary	Helbing, CC (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055,STN CSC, Victoria, BC V8W 3P6, Canada.	chelbing@uvic.ca	Johnston, Randal/B-9247-2009	Helbing, Caren/0000-0002-8861-1070				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Barrera-Hernandez G, 1998, DNA CELL BIOL, V17, P743, DOI 10.1089/dna.1998.17.743; BERGER R, 1989, GENE CHROMOSOME CANC, V1, P115, DOI 10.1002/gcc.2870010202; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; BRENT G A, 1989, New Biologist, V1, P329; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; Chen LS, 2001, CANCER RES, V61, P4345; Cheung KJ, 2001, EXP CELL RES, V268, P1, DOI 10.1006/excr.2001.5258; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; Denver RJ, 1997, J BIOL CHEM, V272, P8179, DOI 10.1074/jbc.272.13.8179; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; Garkavtsev I, 1998, EXP GERONTOL, V33, P81, DOI 10.1016/S0531-5565(97)00086-7; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Garkavtsev I, 1999, NAT GENET, V23, P373, DOI 10.1038/15566; Gunduz M, 2000, CANCER RES, V60, P3143; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HELBING C, 1992, DEV GENET, V13, P289, DOI 10.1002/dvg.1020130406; Helbing C, 1996, DEV GENET, V18, P223, DOI 10.1002/(SICI)1520-6408(1996)18:3<223::AID-DVG3>3.3.CO;2-T; Helbing C., 1996, METAMORPHOSIS, P539; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; Helbing CC, 1997, CANCER RES, V57, P1255; HELBING CC, 1994, J BIOL CHEM, V269, P11743; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; Jager D, 1999, CANCER RES, V59, P6197; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; MOTOMURA K, 1988, Genomics, V2, P180, DOI 10.1016/0888-7543(88)90101-2; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohmori M, 1999, AM J HEMATOL, V62, P118; OOFUSA K, 1991, DEV GROWTH DIFFER, V33, P329; PHILLIPS ME, 1994, GEN COMP ENDOCR, V95, P409, DOI 10.1006/gcen.1994.1140; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; REGARD E, 1978, ENDOCRINOLOGY, V102, P674, DOI 10.1210/endo-102-3-674; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; Sachs LM, 1997, FASEB J, V11, P801, DOI 10.1096/fasebj.11.10.9271365; Sachs LM, 2000, COMP BIOCHEM PHYS B, V126, P199, DOI 10.1016/S0305-0491(00)00198-X; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Shi Y-B., 1996, METAMORPHOSIS POSTEM, P505; Shi YB, 1996, BIOESSAYS, V18, P391, DOI 10.1002/bies.950180509; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Shinoura N, 1999, CANCER RES, V59, P5521; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Su Y, 1999, HISTOL HISTOPATHOL, V14, P175, DOI 10.14670/HH-14.175; Szelci J, 2000, J STEROID BIOCHEM, V72, P89, DOI 10.1016/S0960-0760(00)00025-X; TATA JR, 1991, DEV BIOL, V146, P72, DOI 10.1016/0012-1606(91)90447-B; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; WANG Z, 1993, J BIOL CHEM, V268, P16270; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zhang JC, 1999, MOL ENDOCRINOL, V13, P1130, DOI 10.1210/me.13.7.1130	73	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47013	47020		10.1074/jbc.M106965200	http://dx.doi.org/10.1074/jbc.M106965200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11600495	hybrid			2022-12-25	WOS:000172768500047
J	Galea, MA; Eleftheriou, A; Henderson, BR				Galea, MA; Eleftheriou, A; Henderson, BR			ARM domain-dependent nuclear import of adenomatous polyposis coli protein is stimulated by the B56 alpha subunit of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-LINE MUTATIONS; BETA-CATENIN; APC GENE; TUMOR-SUPPRESSOR; EXPORT SIGNALS; WILD-TYPE; CANCER; PHOSPHORYLATION; LOCALIZATION; CYTOPLASM	Inactivating mutations in the adenomatous polyposis coli (APC) gene correlate with progression of colon cancer and familial adenomatous polyposis. The APC tumor suppressor contributes to chromosome segregation and turnover of the oncogenic transcriptional activator beta -catenin, and these activities are impaired by truncating cancer mutations. APC was recently identified as a shuttling protein whose subcellular distribution is regulated by two nuclear localization signals (NLSs) and multiple nuclear export signals (NESs). Here, we show that mutant disease-linked truncated forms of APC, most of which lack the two central NLSs and certain NES sequences, retain nuclear-cytoplasmic shuttling activity. Nuclear export of truncated APC is mediated by a dominant N-terminal NES. Nuclear import of NLS-deficient APC mutants is facilitated by the N-terminal ARM domain. Furthermore, co-expression of the ARM-binding protein, B56 alpha, increased the nuclear localization of mutant and wild-type APC. The minimal B56 alpha -responsive sequence mapped to APC amino acids 302-625. B56 alpha is a regulatory subunit of protein phosphatase 2A, however, its ability to shift APC to the nucleus was independent of phosphatase activity. We conclude that APC nuclear import is regulated by the ARM domain through its interaction with B56 alpha and postulate that APC/B56 alpha complexes target the dephosphorylation of specific proteins within the nucleus.	Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.		Galea, Melanie A/I-2236-2014					Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAGASE H, 1992, CANCER RES, V52, P4055; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2000, EMBO REP, V1, P519; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Polakis P, 2000, GENE DEV, V14, P1837; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, CANCER RES, V53, P2728; SU LK, 1995, CANCER RES, V55, P2972; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	37	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45833	45839		10.1074/jbc.M107149200	http://dx.doi.org/10.1074/jbc.M107149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585828	hybrid			2022-12-25	WOS:000172573100046
J	Pfeffer, LM; Yang, CH; Murti, A; McCormack, SA; Viar, MJ; Ray, RM; Johnson, LR				Pfeffer, LM; Yang, CH; Murti, A; McCormack, SA; Viar, MJ; Ray, RM; Johnson, LR			Polyamine depletion induces rapid NF-kappa B activation in IEC-6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; P65 SUBUNIT; INTERFERON; APOPTOSIS; TRANSCRIPTION; INFLAMMATION; INHIBITION; STAT3; MICE; LINE	The proliferation of the rat intestinal mucosal IEC-6 cell line requires polyamines, whose synthesis is catalyzed by the enzyme ornithine decarboxylase (ODC). ODC inhibition leads to polyamine depletion, as well as inhibition of both cell proliferation and apoptosis by regulating gene expression. The NF-kappaB transcription factor regulates genes involved in apoptotic, immune, and inflammatory responses. In the present study we tested the hypothesis that NF-KB is activated following ODC inhibition. We found that the inhibition of ODC by a-difluoromethylornithine (DFMO) resulted in a similar to 50% decrease in intracellular putrescine levels within Ih. NF-KB is activated by DFMO through the degradation of the inhibitory protein I kappaB alpha that sequesters NF-kappaB in the cytoplasm. The DFMO-induced NF-KB complexes contain the p65 and p50 members of the Rel protein family. DFMO-induced NF-kappaB activation was accompanied by the translocation of p65 from the cytoplasm into the nucleus. DFMO selectively inhibited a gene reporter construct dependent on the kappaB site present in the HLA-B7 gene. In contrast, DFMO had no effect on a gene reporter construct dependent on the kappaB site present in the interleukin-8 gene. Thus, we report that ODC inhibition activates the NF-KB transcription factor, which may mediate the altered physiological state of intestinal cells that occurs following polyamine depletion.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pfeffer, LM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 899 Madison Ave, Memphis, TN 38163 USA.			Pfeffer, Lawrence/0000-0003-2809-1234	NCI NIH HHS [CA73753] Funding Source: Medline; NIDDK NIH HHS [DK-16505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016505, R01DK016505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CELANO P, 1989, J BIOL CHEM, V264, P8922; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; MCCORMACK SA, 1993, AM J PHYSIOL, V264, pG367, DOI 10.1152/ajpgi.1993.264.2.G367; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; PEGG AE, 1982, AM J PHYSIOL, V243, P212; POULIN R, 1995, BIOCHEM J, V311, P723, DOI 10.1042/bj3110723; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ray RM, 2000, AM J PHYSIOL-CELL PH, V278, pC480, DOI 10.1152/ajpcell.2000.278.3.C480; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Schmid RM, 2000, GASTROENTEROLOGY, V118, P1208, DOI 10.1016/S0016-5085(00)70374-X; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; Shah N, 2001, ONCOGENE, V20, P1715, DOI 10.1038/sj.onc.1204247; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOBIAS KE, 1995, CELL GROWTH DIFFER, V6, P1279; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG JY, 1993, AM J PHYSIOL, V265, pG331, DOI 10.1152/ajpgi.1993.265.2.G331; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057	28	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45909	45913		10.1074/jbc.M108097200	http://dx.doi.org/10.1074/jbc.M108097200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590175	hybrid			2022-12-25	WOS:000172573100057
J	Vielhaber, EL; Duricka, D; Ullman, KS; Virshup, DM				Vielhaber, EL; Duricka, D; Ullman, KS; Virshup, DM			Nuclear export of mammalian PERIOD proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; CIRCADIAN CLOCK; MOUSE SCN; MPER1; ENTRY; MECHANISMS; EXPRESSION	The timing of mammalian circadian rhythm is determined by interlocking negative and positive transcriptional feedback loops that govern the cyclic expression of both clock regulators and output genes. In mammals, nuclear localization of the circadian regulators PER1-3 is controlled by multiple mechanisms, including multimerization with PER and CRY proteins. In addition, nuclear entry of mammalian PER1 (mPER1) can be regulated by a phosphorylation-dependent masking of its nuclear localization signal. Here we present evidence suggesting that nuclear localization of PER proteins is a dynamic process determined by both nuclear import and previously unrecognized nuclear export pathways. Examination of the subcellular localization of a series of truncated mPER1 proteins demonstrated that cytoplasmic localization is mediated by an I IL-amino acid region with homology to leucine-rich nuclear export signals (NESs). Similar sequences were identified in mPER2 and mPER3 as well as in several insect PER proteins. The putative NESs from mPER1 and mPER2 were able to direct cytoplasmic accumulation when fused to a heterologous protein. Mutations in conserved NES residues and the nuclear export inhibitor leptomycin B each blocked the function of the NES. Full-length mPER1 was also exported from microinjected Xenopus laevis oocyte nuclei in an NES-dependent manner. The presence of a functional NES in mPER1 and mPER2 as well as related sequences in a variety of other PER proteins suggests that nuclear export may be a conserved and important feature of circadian regulators.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Div Hematol Oncol, Dept Pediat, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA.	david.virshup@hci.utah.edu	Virshup, David M/C-1449-2009; Duricka, Deborah/AAA-2671-2022	Virshup, David M/0000-0001-6976-850X; Duricka, Deborah/0000-0002-5057-6361; Ullman, Katharine/0000-0003-3693-2830	NCI NIH HHS [R01 CA71074, P30 CA042014, 3P30 CA42014] Funding Source: Medline; NIGMS NIH HHS [R01 GM060387-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Yagita K, 2000, GENE DEV, V14, P1353; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	29	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45921	45927		10.1074/jbc.M107726200	http://dx.doi.org/10.1074/jbc.M107726200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591712	Green Accepted, hybrid			2022-12-25	WOS:000172573100059
J	Sundaram, M; Yao, SYM; Ingram, JC; Berry, ZA; Abidi, F; Cass, CE; Baldwin, SA; Young, JD				Sundaram, M; Yao, SYM; Ingram, JC; Berry, ZA; Abidi, F; Cass, CE; Baldwin, SA; Young, JD			Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PROTEINS; MEMBRANE; EI; IDENTIFICATION; PREDICTION; CLEAVAGE; SEGMENTS; BINDING; RENT1	The human equilibrative nucleoside transporter hENT1, the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for the cellular uptake of physiologic nucleosides, including adenosine, and many anti-cancer nucleoside drugs. We have produced recombinant hENT1 in Xenopus oocytes and used native and engineered N-glycosylation sites in combination with immunological approaches to experimentally define the membrane architecture of this prototypic nucleoside transporter. hENT1 (456 amino acid residues) is shown to contain 11 transmembrane helical segments with an amino terminus that is intracellular and a carboxyl terminus that is extracellular. Transmembrane helices are linked by short hydrophilic regions, except for a large glycosylated extracellular loop between transmembrane helices 1 and 2 and a large central cytoplasmic loop between transmembrane helices 6 and 7. Sequence analyses suggest that this membrane topology is common to all mammalian, insect, nematode, protozoan, yeast, and plant members of the ENT protein family.	Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada; Cross Canc Inst, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	james.young@ualberta.ca	Cass, Carol E/F-5861-2010					Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; DAVIES A, 1990, BIOCHEM J, V266, P799; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Osses N, 1996, BIOCHEM J, V317, P843, DOI 10.1042/bj3170843; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PLAGEMANN PGW, 1987, BIOCHIM BIOPHYS ACTA, V899, P295, DOI 10.1016/0005-2736(87)90411-1; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; SIVAPRASADARAO A, 1994, BIOCHEM J, V300, P437, DOI 10.1042/bj3000437; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; Yao SYM, 2000, PRACT APPROACH SER, P47; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Young JD, 2001, CURR TOP MEMBR, V50, P329	32	113	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45270	45275		10.1074/jbc.M107169200	http://dx.doi.org/10.1074/jbc.M107169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584005	hybrid			2022-12-25	WOS:000172406700121
J	Layne, MD; Patel, A; Chen, YH; Rebel, VI; Carvajal, IM; Pellacani, A; Ith, B; Zhao, DZ; Schreiber, BM; Yet, SF; Lee, ME; Storch, J; Perrella, MA				Layne, MD; Patel, A; Chen, YH; Rebel, VI; Carvajal, IM; Pellacani, A; Ith, B; Zhao, DZ; Schreiber, BM; Yet, SF; Lee, ME; Storch, J; Perrella, MA			Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice	FASEB JOURNAL			English	Article						atheroma; inflammatory cytokines; chemokines	COLONY-STIMULATING FACTOR; E-DEFICIENT MICE; APOLIPOPROTEIN-E; AP2(-/-) MICE; CELLS; ARTERIOSCLEROSIS; CHEMOKINES; RECEPTOR; DISEASE; LESIONS	Atherosclerosis is an inflammatory disease process associated with elevated levels of plasma cholesterol, especially low-density lipoproteins. The latter become trapped within the arterial wall and are oxidized and taken up by macrophages to form foam cells. This process is an initiating event for atherosclerosis. Fatty acid binding proteins (FABP) are involved in fatty acid metabolism and cellular lipid transport, and adipocyte FABP (aP2) is also expressed in macrophages. We recently generated mice lacking both apolipoprotein (Apo) E and aP2 (ApoE(-/-) aP2(-/-)) and found that these mice, compared with ApoE(-/-) mice, developed markedly smaller atherosclerotic lesions that contained fewer macrophages. Here we investigated the mechanism(s) responsible for this prevention of atherosclerotic lesion formation. Bone marrow transplantations were performed in ApoE(-/-) mice, receiving cells from either ApoE(-/-) or ApoE(-/-) aP2(-/-) mice. The lack of aP2 in donor marrow cells led to the development of smaller (5.5-fold) atherosclerotic lesions in the recipient mice. No differences were found in plasma cholesterol, glucose, or insulin levels between recipients of bone marrow cells from ApoE(-/-) or ApoE(-/-) aP2(-/-) mice. However, the expression of chemoattractant and inflammatory cytokines was decreased in macrophages from ApoE(-/-) aP2(-/-) mice compared with ApoE(-/-) mice, which may contribute to the decrease in atherosclerotic lesion formation. Taken together, we demonstrate the importance of macrophage aP2 in the development of atherosclerotic lesions.	Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08903 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Boston University; Rutgers State University New Brunswick	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu	Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Schreiber, Barbara/0000-0001-8560-4249; Yet, Shaw-Fang/0000-0001-9097-3962; Rebel, Vivienne/0000-0002-3862-3903; Layne, Matthew/0000-0003-0007-4870; Storch, Judith/0000-0001-5482-1777	NIDDK NIH HHS [R01 DK038389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello RJ, 1999, ARTERIOSCL THROM VAS, V19, P1518, DOI 10.1161/01.ATV.19.6.1518; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CATALA A, 1986, ACTA PHYSIOL PHARM L, V36, P19; Gerszten RE, 2000, J LAB CLIN MED, V136, P87, DOI 10.1067/mlc.2000.108154; Glasser SP, 1996, AM HEART J, V131, P379, DOI 10.1016/S0002-8703(96)90370-1; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; OCKNER RK, 1976, J CLIN INVEST, V58, P632, DOI 10.1172/JCI108510; Orford JL, 2001, J LAB CLIN MED, V137, P82, DOI 10.1067/mlc.2001.110970; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; PERRELLA MA, 2001, FASEB J         0608; Perrow C., 1994, TECHNOLOGY STUDIES, V1, P1; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Qiao JH, 1997, AM J PATHOL, V150, P1687; Rebel VI, 1999, J EXP MED, V190, P1493, DOI 10.1084/jem.190.10.1493; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossberg R., 1995, Microsystem Technologies, V2, P11, DOI 10.1007/BF02739522; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; Shaughnessy S, 2000, DIABETES, V49, P904, DOI 10.2337/diabetes.49.6.904; SHI CW, 1994, CIRC RES, V75, P199, DOI 10.1161/01.RES.75.2.199; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; THIELE DL, 1989, J CLIN INVEST, V84, P1947, DOI 10.1172/JCI114383; Wilcox J N, 1994, J Atheroscler Thromb, V1 Suppl 1, pS10; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	32	53	62	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2733	+		10.1096/fj.01-0374fje	http://dx.doi.org/10.1096/fj.01-0374fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606480				2022-12-25	WOS:000171920400013
J	Suzuki, H; Tomida, A; Tsuruo, T				Suzuki, H; Tomida, A; Tsuruo, T			Dephosphorylated hypoxia-inducible factor 1 alpha as a mediator of p53-dependent apoptosis during hypoxia	ONCOGENE			English	Article						apoptosis; HIF-1 alpha; hypoxia; p53; phosphorylation	RING-FINGER DOMAIN; TRANSCRIPTION FACTOR; TUMOR ANGIOGENESIS; NUCLEAR EXPORT; SOLID TUMORS; IN-VIVO; P53; PROTEIN; MITOCHONDRIA; HIF-1-ALPHA	Under hypoxia, HIF-1 alpha binds to aryl hydrocarbon receptor nuclear translocator (ARNT, also called HIF-1 alpha) to activate expression of genes important for cell survival. Alternatively, HIF-1 alpha can bind to the tumor suppressor p53 and promote p53-dependent apoptosis. Here we show that the opposite functions of HIF-1 alpha are distinguished by its phosphorylation status. Two distinguishable forms of HIF-1 alpha, phosphorylated and dephosphorylated, were induced during hypoxia-induced apoptosis. The phosphorylated HIF-1 alpha was the major form that bound to ARNT. Ectopically expressed ARNT was consistently able to enhance HIF-1 alpha phosphorylation in a binding-dependent manner. In contrast, the dephosphorylated HIF-1 alpha was the major form that bound to p53. Depletion of the dephosphorylated HIF-1 alpha, by using the Hsp90 inhibitor geldanamycin A that had little effect on the phosphorylated HIF-1 alpha expression, suppressed p53 induction and subsequent apoptosis. Depletion of dephosphorylated HIF-1 alpha also prevented hypoxia-induced nuclear accumulation of HDM2, a negative regulator of p53. Our results indicate that the functions of HIF-1 alpha varied with its phosphorylation status and that dephosphorylated HIF-1 alpha mediated apoptosis by binding to and stabilizing p53.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chavany C, 1996, J BIOL CHEM, V271, P4974; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shimizu S, 1996, CANCER RES, V56, P2161; Tomida A, 1996, ONCOGENE, V13, P2699; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaupel PW, 1997, KLIN PADIATR, V209, P243, DOI 10.1055/s-2008-1043957; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 1997, BIOL CHEM, V378, P609	38	186	212	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5779	5788		10.1038/sj.onc.1204742	http://dx.doi.org/10.1038/sj.onc.1204742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593383				2022-12-25	WOS:000171037200001
J	Xia, CZ; Ma, WB; Wang, F; Hua, SB; Liu, MY				Xia, CZ; Ma, WB; Wang, F; Hua, SB; Liu, MY			Identification of a prostate-specific G-protein coupled receptor in prostate cancer	ONCOGENE			English	Article						G-protein coupled receptor; GPCRs; prostate cancer; Galpha12; PSGR	TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; CELL-GROWTH; P115 RHOGEF; G-ALPHA-12; KINASE; PATHWAY; EXPRESSION; ONCOGENES	Membrane receptors coupled to heterotrimeric G-proteins play an essential role in the transmission of signals from the extracellular environment to the cytoplasm of the cell. A wide variety of external stimuli, including neurotransmitters, hormones, phospholipids, photons, odorants, taste ligands, and growth factors, can activate specific members of the G-protein coupled receptors (GPCRs). Besides essential functions in fully differentiated cells and tissues, GPCRs are also involved in embryogenesis, tissue regeneration, cell growth stimulation, and cell proliferation. In this study, we identified a novel prostate-specific G-protein coupled receptor that interacts with G alpha (12) in our yeast two-hybrid assays. The expression of the receptor protein is highly restricted to human prostate tissues using multiple-tissue Northern blot analysis, and tissue expression array. Furthermore, the expression of prostate-specific receptor is increased significantly in prostate tumors in comparison with the matched normal prostate tissues using PCR and Southern blot analysis, suggesting a potential role of this tissue-specific G-protein coupled receptor in prostate cancer development.	Inst Biosci & Technol Houston, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, Houston, TX 77030 USA; Genetastix Corp, San Jose, CA 95131 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Liu, MY (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamu.edu						ABE K, 1993, J BIOL CHEM, V268, P12033; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dermott JM, 1999, ONCOGENE, V18, P7185, DOI 10.1038/sj.onc.1203345; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Xu LL, 2000, CANCER RES, V60, P6568; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	34	60	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5903	5907		10.1038/sj.onc.1204803	http://dx.doi.org/10.1038/sj.onc.1204803			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593396				2022-12-25	WOS:000171037200014
J	Brosius, U; Dehmel, T; Gartner, J				Brosius, U; Dehmel, T; Gartner, J			Two different targeting signals direct human peroxisomal membrane protein 22 to peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; PICHIA-PASTORIS; SACCHAROMYCES-CEREVISIAE; ZELLWEGER-SYNDROME; CANDIDA-BOIDINII; PEX19P INTERACTS; BIOGENESIS; GENE; IMPORT; PEX3P	The 22-kDa peroxisomal membrane protein (PMP22) is a major component of peroxisomal membranes in mammals. Although its precise role in peroxisome function is poorly understood, it seems to be involved in pore forming activity and may contribute to the unspecific permeability of the organelle membrane. PMP22 is synthesized on free cytosolic ribosomes and then directed to the peroxisome membrane by specific targeting information. Previous studies in rats revealed that PMP22 contains one distinct peroxisomal membrane targeting signal in the amino-terminal cytoplasmic tail. We cloned and characterized the targeting signal of human PMP22 and compared it with the already described characteristics of the corresponding rat protein. Amino acid sequence alignment of rat and human protein revealed 77% identity including a high conservation of several protein motifs. We expressed various deletion constructs of PMP22 in fusion with the green fluorescent protein in COS-7 cells and determined their intracellular localization. In contrast to previous studies on rat PMP22 and most other peroxisomal membrane proteins, we showed that human as well as rat PMP22 contains two distinct and nonoverlapping peroxisomal membrane targeting signals, one in the amino-terminal and the other in the carboxyl-terminal protein region. They consist of two transmembrane domains and adjacent protein loops with almost identical basic clusters. Both of these peroxisomal targeting regions interact with PEX19, a factor required for peroxisome membrane synthesis. In addition, we observed that fusing the green fluorescent protein immediately adjacent to the targeting region completely abolishes targeting function and mislocalizes PMP22 to the cytosol.	Univ Dusseldorf, Zentrum Kinderheilkunde, Dept Pediat, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Gartner, J (corresponding author), Univ Dusseldorf, Zentrum Kinderheilkunde, Dept Pediat, Moorenstr 5, D-40225 Dusseldorf, Germany.							ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Gotte K, 1998, MOL CELL BIOL, V18, P616; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ., 2001, METABOLIC MOL BASES, P3181; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; KALDI K, 1993, FEBS LETT, V315, P217, DOI 10.1016/0014-5793(93)81167-X; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MORENO M, 1994, YEAST, V10, P1447, DOI 10.1002/yea.320101108; Pause B, 2000, FEBS LETT, V471, P23, DOI 10.1016/S0014-5793(00)01332-6; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUZUKI Y, 1987, J BIOCHEM-TOKYO, V101, P491, DOI 10.1093/oxfordjournals.jbchem.a121935; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Tugal HB, 1999, PLANT PHYSIOL, V120, P309, DOI 10.1104/pp.120.1.309; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Wylin T, 1998, EUR J BIOCHEM, V258, P332, DOI 10.1046/j.1432-1327.1998.2580332.x	44	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					774	784		10.1074/jbc.M108155200	http://dx.doi.org/10.1074/jbc.M108155200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11590176	hybrid			2022-12-25	WOS:000173087900100
J	Chen, GP; Paka, L; Kako, Y; Singhal, P; Duan, WL; Pillarisetti, S				Chen, GP; Paka, L; Kako, Y; Singhal, P; Duan, WL; Pillarisetti, S			A protective role for kidney apolipoprotein E - Regulation of mesangial cell proliferation and matrix expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE-CELLS; DIABETIC-NEPHROPATHY; DENSITY-LIPOPROTEIN; TRANSGENIC MICE; ATHEROSCLEROSIS; EXPRESSION; PERLECAN; DISEASE; ALLELE	Mesangial expansion is a key feature in the pathogenesis of numerous renal diseases involving the glomerulus. Studies indicate that mutations in apolipoprotein E (apoE) might independently contribute to kidney dysfunction. Although the role of apoE as an atheroprotective molecule is well established, its role in kidney is unclear. In this study, we sought to explore whether apoE has a protective function in kidney. Northern blotting and reverse transcriptase-polymerase chain reaction showed apoE expression in kidney, and mesangial cell is a major source of apoE in kidney. In the kidneys of 14-16-month-old apoE-null mice, hematoxylin-eosin (HE) staining revealed increased mesangial cell proliferation and matrix formation compared with wild type mice or apoB-overexpressing mice, which have elevated plasma cholesterol and triglycerides. These data suggest that lack of apoE, rather than hyperlipidemia, contributes to increased mesangial expansion. We isolated mesangial cells from mouse kidney and determined the effect of apoE on cell growth. ApoE (E3, 10 mug/ml) completely inhibited serum, platelet-derived growth factor (10 ng/ml), as well as low density lipoprotein-induced mesangial cell proliferation. Among the three isoforms, E3 was found to be most effective in inhibiting mesangial cell proliferation. ApoE did not show any cytotoxic effect, and moreover, inhibited mesangial cell apoptosis induced by oxidized low density lipoprotein. These data suggest that apoE regulates growth as well as survival of mesangial cells. We previously showed that apoE induces matrix heparan sulfate proteoglycan (HSPG) in vascular cells, which has an antiproliferative effect. Similarly, apoE induced the mesangial matrix HSPG. Perlecan is the major HSPG of mesangial matrix and subendothelial space, and consistent with this, blockade of perlecan reversed the antiproliferative effect of apoE. Immunohistochemistry revealed reduced staining of perlecan in kidney from apoE-null mice. Because the loss of anionic HSPG in the basement membrane and mesangial matrix is associated with disruption of filtration barrier, these data suggest a novel role for kidney apoE in preserving the filtration barrier. In summary, apoE has a protective function in kidney as an autocrine regulator of mesangial expansion and kidney function.	Reddy US Therapeut, Norcross, GA 30071 USA; N Shore Long Isl Jewish Hlth Syst, Dept Radiat Oncol, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Hlth Syst, Dept Med, Manhasset, NY 11030 USA; Columbia Univ, Dept Med, Div Prevent Med, New York, NY 10032 USA	Northwell Health; Northwell Health; Columbia University	Pillarisetti, S (corresponding author), Reddy US Therapeut, 3065 Northwoods Circle, Norcross, GA 30071 USA.	Ram@reddyus.com		Singhal, Pravin/0000-0002-6898-358X				Araki S, 2000, DIABETES, V49, P2190, DOI 10.2337/diabetes.49.12.2190; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; CASTELLOT JJ, 1985, AM J PATHOL, V120, P427; Chowdhury TA, 1998, DIABETES, V47, P278, DOI 10.2337/diab.47.2.278; COUSER WG, 1994, AM J KIDNEY DIS, V23, P193, DOI 10.1016/S0272-6386(12)80971-1; Eitner F, 1997, KIDNEY INT, V51, P69, DOI 10.1038/ki.1997.9; Eto M, 1995, CLIN GENET, V48, P288; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Groffen AJA, 1999, NEPHROL DIAL TRANSPL, V14, P2119, DOI 10.1093/ndt/14.9.2119; GROND J, 1990, CONTRIB NEPHROL, V81, P229; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Jensen T, 1997, DIABETES, V46, pS98, DOI 10.2337/diab.46.2.S98; Kako Y, 1999, J LIPID RES, V40, P2185; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAKINO H, 1992, NEPHRON, V61, P415, DOI 10.1159/000186959; Makino H, 2000, KIDNEY INT, V58, pS67, DOI 10.1046/j.1523-1755.2000.07711.x; Mamputu JC, 2000, ARTERIOSCL THROM VAS, V20, P2212, DOI 10.1161/01.ATV.20.10.2212; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Obunike JC, 2000, ARTERIOSCL THROM VAS, V20, P111, DOI 10.1161/01.ATV.20.1.111; Onuma T, 1996, J AM SOC NEPHROL, V7, P1075; Paka L, 1999, J BIOL CHEM, V274, P4816, DOI 10.1074/jbc.274.8.4816; Paka L, 1999, J BIOL CHEM, V274, P36403, DOI 10.1074/jbc.274.51.36403; Pillarisetti S, 2000, TRENDS CARDIOVAS MED, V10, P60, DOI 10.1016/S1050-1738(00)00048-7; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RAIJ L, 1984, KIDNEY INT, V26, P137, DOI 10.1038/ki.1984.147; Rossert J, 2000, DIABETES METAB, V26, P16; Saleh H, 2000, KIDNEY INT, V58, P1876, DOI 10.1046/j.1523-1755.2000.00359.x; Schocklmann HO, 1999, KIDNEY INT, V56, P1199, DOI 10.1046/j.1523-1755.1999.00710.x; Sharma K, 2000, CYTOKINE GROWTH F R, V11, P115, DOI 10.1016/S1359-6101(99)00035-0; Sharma P, 1996, KIDNEY INT, V50, P1604, DOI 10.1038/ki.1996.476; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Stevenson FT, 2001, KIDNEY INT, V59, P2062, DOI 10.1046/j.1523-1755.2001.0590062062.x; Stockand JD, 1997, AM J KIDNEY DIS, V29, P971, DOI 10.1016/S0272-6386(97)90476-5; TAMSMA JT, 1994, DIABETOLOGIA, V37, P313, DOI 10.1007/BF00398060; van der Woude FJ, 1999, HAEMOSTASIS, V29, P61; VANDENBORN J, 1995, DIABETOLOGIA, V38, P1169, DOI 10.1007/BF00422365; WALLIS SC, 1983, EMBO J, V2, P2369, DOI 10.1002/j.1460-2075.1983.tb01748.x; Werle E, 1998, DIABETES CARE, V21, P994, DOI 10.2337/diacare.21.6.994; WOLF G, 1992, AM J PATHOL, V140, P95; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	44	66	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49142	49147		10.1074/jbc.M104879200	http://dx.doi.org/10.1074/jbc.M104879200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11579084	hybrid			2022-12-25	WOS:000173922100069
J	Thoma, NH; Niculae, A; Goody, RS; Alexandrov, K				Thoma, NH; Niculae, A; Goody, RS; Alexandrov, K			Double prenylation by RabGGTase can proceed without dissociation of the mono-prenylated intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE TYPE-II; RAB ESCORT PROTEIN; TERNARY COMPLEX; BINDING; TRANSFERASE; MECHANISM; PEPTIDE; ENZYME; TOOLS; REP-1	Rab geranylgeranyltransferase (RabGGTase) catalyzes the prenylation of Rab proteins. Despite possessing a single active site, RabGGTase is able to add geranylgeranyl moieties onto each of the two C-terminal cysteine residues of Rab. We have studied the kinetics of Rab double prenylation employing a combination of a novel high pressure liquid chromatography (HPLC)-based in vitro prenylation assay and fluorescence spectroscopy. Transfer of the first geranylgeranyl group proceeds with a k(1) = 0.16 s(-1), while the conversion from singly to double prenylated Rab is 4-fold slower (k(2) = 0.039 s(-1)). We found that following the first transfer reaction, the conjugated lipid is removed from the active site of RabGGTase but mono-prenylated Rab.REP complex remains bound to RabGGTase with a K-d < 1nM. In contrast to the doubly prenylated Rab7.REP dissociation of the mono-prenylated species from RabGGTase was only weakly stimulated by phosphoisoprenoid. Based on the obtained rate constants we calculated that at least 72% of mono-prenylated Rab molecules proceed to double prenylation without dissociating from RabGGTase. The obtained data provides an explanation of how RabGGTase discriminates between mono-prenylated intermediate and double prenylated reaction product. It also indicates that the phosphoisoprenoid acts both as a substrate and as a sensor governing the kinetics of protein-protein interactions in the double prenylation reaction.	Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany	Max Planck Society	Alexandrov, K (corresponding author), Max Planck Inst Mol Physiol, Dept Phys Biochem, Otto Hahn Str 11, D-44227 Dortmund, Germany.	kirill.alexandrov@mpi-dortmund.mpg.de	Alexandrov, Kirill/A-5830-2013; Goody, Roger S/J-8845-2014	Alexandrov, Kirill/0000-0002-0957-6511; Goody, Roger S/0000-0002-0772-0444				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; Alexandrov K, 1999, EUR J BIOCHEM, V265, P160, DOI 10.1046/j.1432-1327.1999.00699.x; Alexandrov K, 1998, FEBS LETT, V425, P460, DOI 10.1016/S0014-5793(98)00290-7; Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; Cane DE, 1999, CHEM BIOL, V6, pR319, DOI 10.1016/S1074-5521(00)80001-0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Desnoyers L, 1998, P NATL ACAD SCI USA, V95, P12266, DOI 10.1073/pnas.95.21.12266; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Hightower KE, 1998, BIOCHEMISTRY-US, V37, P15555, DOI 10.1021/bi981525v; Iakovenko A, 2000, FEBS LETT, V468, P155, DOI 10.1016/S0014-5793(00)01143-1; Kalinin A, 2001, PROTEIN EXPRES PURIF, V22, P84, DOI 10.1006/prep.2001.1423; Owen DJ, 1999, ANGEW CHEM INT EDIT, V38, P509, DOI 10.1002/(SICI)1521-3773(19990215)38:4<509::AID-ANIE509>3.0.CO;2-3; PETER M, 1992, J CELL SCI, V102, P857; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Shen F, 1996, J BIOL CHEM, V271, P3692; Stenmark H, 2001, GENOME BIOL, V2; Thoma NH, 2000, BIOCHEMISTRY-US, V39, P12043, DOI 10.1021/bi000835m; Thoma NH, 2001, BIOCHEMISTRY-US, V40, P268, DOI 10.1021/bi002034p; Wilson AL, 1998, BIOCHEM J, V333, P497, DOI 10.1042/bj3330497; Witter DJ, 1996, BIOCHEMISTRY-US, V35, P10454, DOI 10.1021/bi960500y; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7	23	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48631	48636		10.1074/jbc.M106470200	http://dx.doi.org/10.1074/jbc.M106470200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11591706	hybrid			2022-12-25	WOS:000173922100005
J	Onda, T; Hashimoto, Y; Nagai, M; Kuramochi, H; Saito, S; Yamazaki, H; Toya, Y; Sakai, I; Homcy, CJ; Nishikawa, K; Ishikawa, Y				Onda, T; Hashimoto, Y; Nagai, M; Kuramochi, H; Saito, S; Yamazaki, H; Toya, Y; Sakai, I; Homcy, CJ; Nishikawa, K; Ishikawa, Y			Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; CYCLIC-AMP; HEART-FAILURE; CATALYTIC MECHANISM; MOLECULAR-CLONING; RAT-BRAIN; FORSKOLIN; ACTIVATION; DERIVATIVES; BINDING	Crystallographic studies have elucidated the binding mechanism of forskolin and P-site inhibitors to adenylyl cyclase. Accordingly, computer-assisted drug design has enabled us to identify isoform-selective regulators of adenylyl cyclase. After examining more than 200 newly synthesized derivatives of forskolin, we found that the modification at the positions of C6 and C7, in general, enhances isoform selectivity. The 6-(3-dimethylaminopropionyl) modification led to an enhanced selectivity for type V, whereas 6-[N-(2-isothiocyanatoethyl) aminocarbonyl] and 6-(4-acrylbutyryl) modification led to an enhanced selectivity for type II. In contrast, 2'-deoxyadenosine 3'-monophosphate, a classical and 3'-phosphate-substituted P-site inhibitor, demonstrated a 27-fold selectivity for inhibiting type V relative to type II, whereas 9-(tetrahydro-2-furyl) adenine, a ribose-substituted P-site ligand, showed a markedly increased, 130-fold selectivity for inhibiting type V. Consequently, on the basis of the pharmacophore analysis of 9-(tetrahydro-2-furyl) adenine and adenylyl cyclase, a novel nonnucleoside inhibitor, 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone (NKY80), was identified after virtual screening of more than 850,000 compounds. NKY80 demonstrated a 210-fold selectivity for inhibiting type V relative to type II. More importantly, the combination of a type III-selective forskolin derivative and 9-(tetrahydro-2-furyl) adenine or NKY80 demonstrated a further enhanced selectivity for type III stimulation over other isoforms. Our data suggest the feasibility of adenylyl cyclase isoform-targeted regulation of cyclic AMP signaling by pharmacological reagents, either alone or in combination.	Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Med, Newark, NJ 07103 USA; Nippon Kayaku Co Ltd, Pharmaceut Grp, Div Res & Dev, Tokyo 1158588, Japan; COR Therapeut Inc, San Francisco, CA 94080 USA; Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Med, Yokohama, Kanagawa 2360004, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Nippon Kayaku Co., Ltd.; Yokohama City University; Yokohama City University	Ishikawa, Y (corresponding author), Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Med, 185 S Orange Ave, Newark, NJ 07103 USA.				NHLBI NIH HHS [HL38070, HL54895] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; Asai T, 1996, MOL PHARMACOL, V50, P1262; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BRISTOW MR, 1984, J CLIN INVEST, V74, P212, DOI 10.1172/JCI111404; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Chaudhry A, 1997, AM J PHYSIOL-REG I, V273, pR762, DOI 10.1152/ajpregu.1997.273.2.R762; Defer N, 1998, FEBS LETT, V424, P216, DOI 10.1016/S0014-5793(98)00178-1; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FELDMAN MD, 1987, CIRCULATION, V75, P331, DOI 10.1161/01.CIR.75.2.331; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; HO RJ, 1984, J BIOL CHEM, V259, P7630; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; HOSONO M, 1992, J CARDIOVASC PHARM, V19, P625, DOI 10.1097/00005344-199204000-00021; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; Ishikawa Y, 2000, MOL CELL ENDOCRINOL, V162, P107, DOI 10.1016/S0303-7207(00)00210-0; ISHIKAWA Y, 1994, J CLIN INVEST, V93, P2224, DOI 10.1172/JCI117219; Ishikawa Y, 1997, CIRC RES, V80, P297, DOI 10.1161/01.RES.80.3.297; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; KAWABE J, 1994, J BIOL CHEM, V269, P24906; LIPPE C, 1991, COMP BIOCHEM PHYS C, V99, P209, DOI 10.1016/0742-8413(91)90101-X; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; Robbins JD, 1996, J MED CHEM, V39, P2745, DOI 10.1021/jm960191+; ROBBINS JD, 1992, BRAIN RES, V581, P148, DOI 10.1016/0006-8993(92)90354-C; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SANBE A, 1995, J PHARMACOL EXP THER, V274, P120; SEAMON KB, 1983, J MED CHEM, V26, P436, DOI 10.1021/jm00357a021; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHAFIQ J, 1992, CIRC RES, V71, P70, DOI 10.1161/01.RES.71.1.70; Shoshani I, 1999, J BIOL CHEM, V274, P34742, DOI 10.1074/jbc.274.49.34742; STUBNER D, 1989, FEBS LETT, V248, P155, DOI 10.1016/0014-5793(89)80452-1; Sutkowski EM, 1996, MOL PHARMACOL, V50, P299; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Toya Y, 1998, J MOL CELL CARDIOL, V30, P97, DOI 10.1006/jmcc.1997.0575; WATSON PA, 1994, J BIOL CHEM, V269, P28893; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	42	90	97	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47785	47793		10.1074/jbc.M107233200	http://dx.doi.org/10.1074/jbc.M107233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602596	hybrid			2022-12-25	WOS:000172927000009
J	Park, DS; Lee, H; Riedel, C; Hulit, J; Scherer, PE; Pestell, RG; Lisanti, MP				Park, DS; Lee, H; Riedel, C; Hulit, J; Scherer, PE; Pestell, RG; Lisanti, MP			Prolactin negatively regulates caveolin-1 gene expression in the mammary gland during lactation, via a Ras-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; MAP KINASE CASCADE; IN-VIVO; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; GROWTH-HORMONE; RECEPTOR; ACTIVATION; TRANSCRIPTION; PATHWAYS	Caveolin-1 is a 22-kDa integral membrane protein that has been suggested to function as a negative regulator of mitogen-stimulated proliferation in a variety of cell types, including mammary epithelial cells. Because much of our insight into caveolin-1 function has come from the study of hum an breast tumor-derived cell lines in culture, the normal physiological regulators of caveolin-1 expression in the mammary gland remain unknown. Here, we examine caveolin-1 expression in mice at different stages of mammary gland development. We show that caveolin-1 expression is significantly downregulated during late pregnancy and lactation. Upon weaning, mammary gland expression of caveolin-1 rap. idly returns to non-pregnant "steady-state" levels. Injection of virgin mice with a battery of hormones normally up-regulated during lactation demonstrates that prolactin is the main mediator of caveolin-1 down-regulation. Virtually identical results were obtained with human mammary epithelial cells (hTERT-HME1) in culture. In addition, we demonstrate that prolactin-mediated down-regulation of caveolin-1 expression occurs at the level of transcriptional control and via a Ras-dependent mechanism. Interestingly, in the mammary gland, both mammary epithelial cells and the surrounding mammary adipocytes show prolactin-mediated down-regulation of caveolin-1. This hormone-dependent regulation of caveolin-1 expression is specific to the mammary fat pad. Finally, we employed HC11 cells, a well-established model of mammary epithelial cell differentiation, to study the possible functional effects of caveolin-1 expression. In the presence of lactogenic hormones, recombinant expression of caveolin-1 in HC11 cells dramatically suppresses the induction of the promoter activity and the synthesis of P-casein, an established reporter of lactogenic differentiation and milk production. These findings may explain why caveolin-1 levels are normally down-regulated during lactation. This report is the first demonstration that caveolin-1 levels are down-regulated during a normal physiological event in vivo, i.e. lactation, because previous reports have only documented that down-regulation of caveolin-1 occurs during cell transformation and tumorigenesis.	Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Mol Pharmacol, Bronx, NY 10416 USA; Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10416 USA; Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Med, Bronx, NY 10416 USA; Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Cell Biol, Bronx, NY 10416 USA; Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Div Hormone Dependent Tumor Biol, Bronx, NY 10416 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10416 USA.		Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Riedel, Claudia/0000-0001-6168-8601	NATIONAL CANCER INSTITUTE [R01CA070897, T32CA009475, R01CA075503, R01CA086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758] Funding Source: NIH RePORTER; NCI NIH HHS [TG-CA09475, R01-CA75503, R01-CA70897, R01-CA86072] Funding Source: Medline; NIDDK NIH HHS [R01-DK55758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BONNETERRE J, 1988, EUR J CANCER CLIN ON, V24, P1851, DOI 10.1016/0277-5379(88)90097-1; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; *CLON INC, 2000, CLONTECHNIQUES, V15, P1; *CLONT INC, 2000, CLONTECHNIQUES, V14, P2; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gallego MI, 2001, DEV BIOL, V229, P163, DOI 10.1006/dbio.2000.9961; Hayashi K, 2001, CANCER RES, V61, P2361; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; HIGUCHI T, 1983, ENDOCRINOL JAPON, V30, P353; KURTZ A, 1993, BIOL REPROD, V48, P1095, DOI 10.1095/biolreprod48.5.1095; KWA HG, 1974, LANCET, V1, P433; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MANNI A, 1989, BREAST CANCER RES TR, V14, P289, DOI 10.1007/BF01806300; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MURPHY LJ, 1984, CANCER RES, V44, P1963; NEDERGAARD J, 2001, ADIPOSE TISSUE PROTO, P203; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SHIU RPC, 1979, CANCER RES, V39, P4381; SUBRAMANIAM A, 1990, J BIOL CHEM, V265, P13986; Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630; VANGILDER JC, 1975, ARCH SURG-CHICAGO, V110, P293; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; WOOD WM, 1989, J BIOL CHEM, V264, P14840; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	44	31	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48389	48397		10.1074/jbc.M108210200	http://dx.doi.org/10.1074/jbc.M108210200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602600	hybrid			2022-12-25	WOS:000172927000089
J	Degraeve, F; Bolla, M; Blaie, S; Creminon, C; Quere, I; Boquet, P; Levy-Toledano, S; Bertoglio, J; Habib, A				Degraeve, F; Bolla, M; Blaie, S; Creminon, C; Quere, I; Boquet, P; Levy-Toledano, S; Bertoglio, J; Habib, A			Modulation of COX-2 expression by statins in human aortic smooth muscle cells - Involvement of geranylgeranylated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; COENZYME-A REDUCTASE; ENDOTHELIAL-CELLS; CYCLOOXYGENASE-2 EXPRESSION; NECROTIZING FACTOR-1; CEREBRAL-ISCHEMIA; ONCOGENIC RAS; RHO GTPASES; K-RAS; INHIBITION	Cyclooxygenase (COX)-2 and COX-1 play an important role in prostacyclin production in vessels and participate in maintaining vascular homeostasis. Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which is crucial in cholesterol biosynthesis. Recently, cholesterol-independent effects of statins have been described. In this study, we evaluated the effect of two inhibitors of HMG CoA reductase, mevastatin and lovastatin, on the production of prostacyclin and the expression of COX in human aortic smooth muscle cells. Treatment of cells with 25 muM mevastatin or lovastatin resulted in the induction of COX-2 and increase in prostacyclin production. Mevalonate, the direct metabolite of HMG CoA reductase, and geranylgeranyl-pyrophosphate reversed this effect. GGTI-286, a selective inhibitor of geranylgeranyltransferases, increased COX-2 expression and prostacyclin formation, thus indicating the involvement of geranylgeranylated proteins in the down-regulation of COX-2. Furthermore, Clostridium difficile toxin B, an inhibitor of the Rho GTP-binding protein family, the Rho selective inhibitor C3 transferase, and Y-27632, a selective inhibitor of the Rho-associated kinases, targets of Rho A, increased COX-2 expression whereas the activator of the Rho GTPase, the cytotoxic necrotizing factor 1, blocked interlukin-1 alpha -dependent COX-2 induction. These results demonstrate that statins up-regulate COX-2 expression and subsequent prostacyclin formation in human aortic smooth muscle cells in part through inhibition of Rho.	CEA, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; St Eloi Hosp, Dept Internal Med B, F-34295 Montpellier, France; INSERM, U452, F-06107 Nice, France; INSERM, U461, F-92296 Chatenay Malabry, France; Hop Lariboisiere, INSERM, U348, Inst Federat Circulat Paris 6 7, F-75010 Paris, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Habib, A (corresponding author), INSERM, U348, 8 Rue Guy Patin, F-75475 Paris 10, France.	aida.habib@inserm.lrb.ap-hop-paris.fr	Habib, Aida/H-8647-2019; Quere, Isabelle/AAB-8519-2020	Habib, Aida/0000-0001-6027-0043; Quere, Isabelle/0000-0002-1492-9764				Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Bellosta S, 1998, ATHEROSCLEROSIS, V137, pS101, DOI 10.1016/S0021-9150(97)00319-5; Bernard C, 1999, CIRC RES, V85, P1124; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bishop-Bailey D, 1999, INT J MOL MED, V3, P41; Bishop-Bailey D, 1998, BIOCHEM BIOPH RES CO, V249, P44, DOI 10.1006/bbrc.1998.8966; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Chen H, 2000, HYPERTENSION, V36, P923, DOI 10.1161/01.HYP.36.6.923; Colli S, 1997, ARTERIOSCL THROM VAS, V17, P265, DOI 10.1161/01.ATV.17.2.265; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; FALKE P, 1989, PHARMACOL TOXICOL, V64, P173, DOI 10.1111/j.1600-0773.1989.tb00624.x; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; FitzGerald GA, 1998, LANCET, V351, P1206, DOI 10.1016/S0140-6736(05)79155-8; Fujita M, 2000, J GASTROEN HEPATOL, V15, P1277, DOI 10.1046/j.1440-1746.2000.02399.x; GERSON RJ, 1989, AM J MED, V87, pS28, DOI 10.1016/S0002-9343(89)80596-0; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Habib A, 1997, J IMMUNOL, V158, P3845; HABIB A, 1993, J BIOL CHEM, V268, P23448; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; JONES DA, 1993, J BIOL CHEM, V268, P9049; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Knapp AC, 2000, ATHEROSCLEROSIS, V152, P217, DOI 10.1016/S0021-9150(99)00462-1; Koh KK, 2000, CARDIOVASC RES, V47, P648, DOI 10.1016/S0008-6363(00)00146-2; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laufs U, 2000, CIRC RES, V87, P526, DOI 10.1161/01.RES.87.7.526; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 2000, TRENDS CARDIOVAS MED, V10, P143, DOI 10.1016/S1050-1738(00)00044-X; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; Muniyappa R, 2000, AM J PHYSIOL-HEART C, V278, pH1762, DOI 10.1152/ajpheart.2000.278.6.H1762; NOTARBARTOLO A, 1995, ARTERIOSCL THROM VAS, V15, P247, DOI 10.1161/01.ATV.15.2.247; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; Park HJ, 1999, P NATL ACAD SCI USA, V96, P11525, DOI 10.1073/pnas.96.20.11525; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; Pratico D, 2000, BLOOD, V96, P3823, DOI 10.1182/blood.V96.12.3823.h8003823_3823_3826; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Shibata R, 2001, CIRCULATION, V103, P284; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; ZHANG SZ, 1990, CELL BIOL TOXICOL, V6, P219	73	90	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46849	46855		10.1074/jbc.M104197200	http://dx.doi.org/10.1074/jbc.M104197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591701	hybrid			2022-12-25	WOS:000172768500025
J	Dimitroff, CJ; Lee, JY; Schor, KS; Sandmaier, BM; Sackstein, R				Dimitroff, CJ; Lee, JY; Schor, KS; Sandmaier, BM; Sackstein, R			Differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTANEOUS LYMPHOCYTE ANTIGEN; P-SELECTIN; GLYCOPROTEIN LIGAND-1; PROGENITOR CELLS; EXPRESSION CLONING; PLATELET RECOVERY; CD34(+) CELLS; ADHESION; EXPANSION; STEM	Expression of L-selectin on human hematopoietic cells (HC) is associated with a higher proliferative activity and a more rapid engraftment after hematopoietic stem cell transplantation. Two L-selectin ligands are expressed on human HCs, P-selectin glycoprotein ligand-1 (PSGL-1) and a specialized glycoform of CD44 (hematopoietic cell E- and L-selectin ligand, HCELL). Although the structural biochemistry of HCELL and PSGL-1 is well characterized, the relative capacity of these molecules to mediate L-selectin-dependent adhesion has not been explored. In this study, we examined under shear stress conditions L-selectin-dependent leukocyte adhesive interactions mediated by HCELL and PSGL-1, both as naturally expressed on human HC membranes and as purified molecules. By utilizing both Stamper-Woodruff and parallel-plate flow chamber assays, we found that HCELL displayed a 5-fold greater capacity to support L-selectin-dependent leukocyte adherence across a broad range of shear stresses compared with that of PSGL-1. Moreover, L-selectin-mediated leukocyte binding to immunopurified HCELL was consistently > 5-fold higher than leukocyte binding to equivalent amounts of PSGL-1. Taken together, these data indicate that HCELL is a more avid L-selectin ligand than PSGL-1 and may be the preferential mediator of L-selectin-dependent adhesive interactions among human HCs in the bone marrow.	Harvard Univ, Brigham & Womens Hosp, Dept Dermatol, Skin Dis Res Ctr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Med, Skin Dis Res Ctr, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Clin Res, Seattle, WA 98109 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Sackstein, R (corresponding author), Harvard Univ, Inst Med, Skin Dis Res Ctr, Dept Dermatol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	rsackstein@rics.bwh.harvard.edu		Lee, Jack/0000-0002-4543-4000	NCI NIH HHS [R01 CA 84156] Funding Source: Medline; NHLBI NIH HHS [R01 HL 60528, HL 36444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060528, P01HL036444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; DERCKSEN MW, 1995, BLOOD, V85, P3313, DOI 10.1182/blood.V85.11.3313.bloodjournal85113313; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; GOELZ S, 1994, J BIOL CHEM, V269, P1033; Greenberg AW, 2000, BLOOD, V95, P478, DOI 10.1182/blood.V95.2.478; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; Koenig JM, 1999, PEDIATR RES, V45, P867, DOI 10.1203/00006450-199906000-00015; KOLLER MR, 1993, BIO-TECHNOL, V11, P358, DOI 10.1038/nbt0393-358; KOLLER MR, 1993, BLOOD, V82, P378; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LAWRENCE MB, 1987, BLOOD, V70, P1284; LEON WM, 1993, BLOOD, V82, P109; Levesque JP, 1999, IMMUNITY, V11, P369, DOI 10.1016/S1074-7613(00)80112-0; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; OXLEY SM, 1994, BLOOD, V84, P3299; PALSSON BO, 1993, BIO-TECHNOL, V11, P368, DOI 10.1038/nbt0393-368; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramos CL, 1998, BLOOD, V91, P1067, DOI 10.1182/blood.V91.3.1067.1067_1067_1075; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Sackstein R, 2000, BLOOD, V96, P2765, DOI 10.1182/blood.V96.8.2765.h8002765_2765_2774; Sackstein R, 1997, BLOOD, V89, P2773, DOI 10.1182/blood.V89.8.2773; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI K, 1993, J BIOL CHEM, V268, P22782; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Tu LL, 1999, J IMMUNOL, V163, P5070; Tu LL, 1996, J IMMUNOL, V157, P3995; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; VANZANT G, 1994, BLOOD CELLS, V20, P482; Watanabe T, 1998, EXP HEMATOL, V26, P10; ZANDSTRA PW, 1994, BIO-TECHNOL, V12, P909, DOI 10.1038/nbt0994-909; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	38	41	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47623	47631		10.1074/jbc.M105997200	http://dx.doi.org/10.1074/jbc.M105997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591704	hybrid			2022-12-25	WOS:000172768500123
J	Jakobsen, SN; Hardie, DG; Morrice, N; Tornqvist, HE				Jakobsen, SN; Hardie, DG; Morrice, N; Tornqvist, HE			5 '-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4carboxamide riboside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; ACETYL-COA CARBOXYLASE; SKELETAL-MUSCLE; GLUCOSE-UPTAKE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; RAT MUSCLE; CONTRACTION; TRANSPORT; EXERCISE	Exercise is known to increase insulin sensitivity and is an effective form of treatment for the hyperglycemia observed in type 2 diabetes. Activation of 5'-AMP-activated protein kinase (AMPK) by 5-aminoimidazole-4-carboxamide riboside (AICAR), exercise, or electrically stimulated contraction leads to increased glucose transport in skeletal muscle. Here we report the first evidence of a direct interaction between AMPK and the most upstream component of the insulin-signaling cascade, insulin receptor substrate-1 (IRS-1). We find that AMPK rapidly phosphorylates IRS-1 on Ser-789 in cell-free assays as well as in mouse C2C12 myotubes incubated with AICAR. In the C2C12 myotubes activation of AMPK by AICAR matched the phosphorylation of IRS-1 on Ser-789. This phosphorylation correlates with a 65% increase in insulin-stimulated IRS-1-associated phosphatidylinositol 3-kinase activity in C2C12 myotubes preincubated with AICAR. The binding of phosphatidylinositol 3-kinase to IRS-1 was not affected by AICAR. These results demonstrate the existence of an interaction between AMPK and early insulin signaling that could be of importance to our understanding of the potentiating effects of exercise on insulin signaling.	Novo Nordisk AS, Diabet Biol, DK-2880 Bagsvaerd, Denmark; Univ Dundee, Wellcome Trust Bioctr, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, MRC,Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	Novo Nordisk; University of Dundee; University of Dundee	Jakobsen, SN (corresponding author), Novo Nordisk AS, Diabet Biol, Novo Alle, DK-2880 Bagsvaerd, Denmark.	snyj@novonordisk.com	Hardie, David/Z-1979-2019	jakobsen, soren nyboe/0000-0002-2227-8615; Hardie, Grahame/0000-0002-8373-7379				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DEFRONZO RA, 1981, J CLIN INVEST, V68, P1468, DOI 10.1172/JCI110399; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; PLOUG T, 1984, AM J PHYSIOL, V247, pE726, DOI 10.1152/ajpendo.1984.247.6.E726; PLOUG T, 1987, AM J PHYSIOL, V253, pE12, DOI 10.1152/ajpendo.1987.253.1.E12; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; VRANIC M, 1976, J CLIN INVEST, V57, P245, DOI 10.1172/JCI108275; Whitehead JP, 2000, BIOCHEM J, V349, P775, DOI 10.1042/bj3490775; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wojtaszewski JFP, 1996, J APPL PHYSIOL, V81, P1501, DOI 10.1152/jappl.1996.81.4.1501; Wojtaszewski JFP, 1997, DIABETES, V46, P1775, DOI 10.2337/diabetes.46.11.1775; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	39	201	216	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46912	46916		10.1074/jbc.C100483200	http://dx.doi.org/10.1074/jbc.C100483200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598104	hybrid			2022-12-25	WOS:000172768500033
J	Schumann, D; Chen, CJ; Kaplan, B; Shively, JE				Schumann, D; Chen, CJ; Kaplan, B; Shively, JE			Carcinoembryonic antigen cell adhesion molecule 1 directly associates with cytoskeleton proteins actin and tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY GLYCOPROTEIN CD66A; PHOSPHOTYROSINE-CONTAINING PROTEIN; C-CAM CELL-CAM-105; GENE FAMILY MEMBER; EPITHELIAL-CELLS; CYTOPLASMIC DOMAIN; ECTO-ATPASE; IMMUNOGLOBULIN SUPERFAMILY; TYROSINE PHOSPHORYLATION; COLORECTAL CARCINOMAS	CEA cell adhesion molecule 1 (CEACAM1), a type I transmembrane and homotypic cell adhesion protein belonging to the carcinoembryonic antigen (CEA) gene family and expressed on epithelial cells, is alternatively spliced to produce four major isoforms with three or four Ig-like ectodomains and either long (CEACAM1-L) or short (CEACAM1-S) cytoplasmic domains. When murine MC38 (methylcholanthrene-induced adenocarcinoma 38) cells were transfected with human CEACAM1-L and stimulated with sodium pervanadate, actin was found to co-localize with CEACAM1-L at cell-cell boundaries but not in untreated cells. When CEACAM1-L was immunoprecipitated from pervanadate-treated MC38/CEACAM1-L cells and the associated proteins were analyzed by two-dimensional get analysis and mass spectrometry, actin and tropomyosin, among other proteins, were identified. Whereas a glutathione S-transferase (GST) fusion protein containing the L-isoform. (GST-Cyto-L) bound poorly to F-actin in a cosedimentation assay, the S-isoform fusion protein (GST-Cyto-S) co-sedimented with F-actin, especially when incubated with G-actin during polymerization (K-D = 7.0 muM). Both GST-Cyto-S and GST-Cyto-L fusion proteins bind G-actin and tropomyosin by surface plasmon resonance studies with binding constants of 0.7 x 10(-8) and 1.0 x 10(-7) M for GST-Cyto-L to G-actin and tropomyosin, respectively, and 3.1 x 10(-8) and 1.3 x 10(-7) M for GST-Cyto-S to G-actin and tropomyosin, respectively. Calmodulin or EDTA inhibited binding of the GST-Cyto-L fusion protein to G-actin, whereas calmodulin and G-actin, but not EDTA, stimulated binding to tropomyosin. A biotinylated 14-amino acid peptide derived from the juxtamembrane portion of the cytoplasmic domain of CEACAM1-L associated with both G-actin and tropomyosin with KD values of 1.3 x 10(-5) and 1.8 x 10(-5) M, respectively. These studies demonstrate the direct interaction of CEACAM1 isoforms with G-actin and tropomyosin and the direct interaction of CEACAM1-S with F-actin.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA.				NATIONAL CANCER INSTITUTE [R01CA084202] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BLIKSTAD I, 1992, FEBS LETT, V302, P26, DOI 10.1016/0014-5793(92)80276-M; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; BRUMMER J, 1995, ONCOGENE, V11, P1649; Chen CJ, 1996, J BIOL CHEM, V271, P28181, DOI 10.1074/jbc.271.45.28181; Da Silva-Azevedo L, 1999, BIOCHEM BIOPH RES CO, V256, P404, DOI 10.1006/bbrc.1999.0351; Davis MT, 1998, J AM SOC MASS SPECTR, V9, P194, DOI 10.1016/S1044-0305(97)00282-1; DVESKSLER GS, 1993, J VIROL, V67, P1; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; Griffiths Gillian M., 1997, P1251; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; Hnath EJ, 1996, BIOPHYS J, V71, P1920, DOI 10.1016/S0006-3495(96)79391-8; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIS JF, 1982, P NATL ACAD SCI-BIOL, V79, P6507, DOI 10.1073/pnas.79.21.6507; LEUSCH HG, 1990, FEBS LETT, V261, P405, DOI 10.1016/0014-5793(90)80603-G; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SKUBITZ KM, 1992, J IMMUNOL, V148, P852; SKUBITZ KM, 1993, FEBS LETT, V318, P200, DOI 10.1016/0014-5793(93)80021-L; Steinmetz MO, 1997, J STRUCT BIOL, V119, P295, DOI 10.1006/jsbi.1997.3873; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Temm-Grove CJ, 1998, CELL MOTIL CYTOSKEL, V40, P393, DOI 10.1002/(SICI)1097-0169(1998)40:4<393::AID-CM7>3.0.CO;2-C; THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Turbide C, 1997, CANCER RES, V57, P2781; TURBIDE C, 1991, J BIOL CHEM, V266, P309; TYNAN K, 1992, NUCLEIC ACIDS RES, V20, P1629, DOI 10.1093/nar/20.7.1629; WAGENER C, 1983, J IMMUNOL, V130, P2302; Wang FL, 1996, CANCER RES, V56, P3634; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	61	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47421	47433		10.1074/jbc.M109110200	http://dx.doi.org/10.1074/jbc.M109110200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595750	hybrid			2022-12-25	WOS:000172768500098
J	Qureshi, MH; Yeung, JC; Wu, SC; Wong, SL				Qureshi, MH; Yeung, JC; Wu, SC; Wong, SL			Development and characterization of a series of soluble tetrameric and monomeric streptavidin muteins with differential biotin binding affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR INTERACTIONS; SUBUNIT ASSOCIATION; BACILLUS-SUBTILIS; AVIDIN; COMPLEX; TRYPTOPHAN; SYSTEM; EQUILIBRIUM; CONTACTS; PROTEINS	The strong biotin-streptavidin interaction limits the application of streptavidin as a reversible affinity matrix for purification of biotinylated biomolecules. To address this concern, a series of single, double, and triple streptavidin muteins with different affinities to biotin were designed. The strategy involves mutating one to three strategically positioned residues (Ser-45, Thr-90, and Asp-128) that interact with biotin and other framework structure-maintaining residues of streptavidin. The muteins were produced in soluble forms via secretion from Bacillus subtilis. The impact of individual residues on the overall structure of streptavidin is reflected by the formation of monomeric streptavidin to different extents. Of the three targeted residues, Asp-128 has the most dramatic effect (Asp-128 > Thr-90 > Ser-45). Conversion of all three targeted residues to alanine results in a soluble biotin binding mutein that exists 100% in the monomeric state. Both wild-type and mutated (monomeric and tetrameric) streptavidin proteins were purified, and their kinetic parameters (on- and off-rates) were determined using a BIAcore biosensor with biotin-conjugated bovine serum albumin immobilized to the sensor chip. This series of muteins shows a wide spectrum of affinity toward biotin (K-d from 10(-6) to 10(-11) M). Some of them have the potential to serve as reversible biotin binding agents.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada	University of Calgary	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.			Yeung, Jonathan/0000-0001-5759-3028				Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; Chu V, 1998, PROTEIN SCI, V7, P848; Ewalt KL, 2001, ANAL BIOCHEM, V289, P162, DOI 10.1006/abio.2000.4927; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Freitag S, 1998, J MOL BIOL, V279, P211, DOI 10.1006/jmbi.1998.1735; Freitag S, 1999, BIOMOL ENG, V16, P13, DOI 10.1016/S1050-3862(99)00048-0; Freitag S, 1999, P NATL ACAD SCI USA, V96, P8384, DOI 10.1073/pnas.96.15.8384; Freitag S, 1997, PROTEIN SCI, V6, P1157, DOI 10.1002/pro.5560060604; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gonzalez M, 1999, BIOMOL ENG, V16, P67, DOI 10.1016/S1050-3862(99)00041-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENRIKSON KP, 1979, ANAL BIOCHEM, V94, P366, DOI 10.1016/0003-2697(79)90374-9; HOFMANN K, 1980, P NATL ACAD SCI-BIOL, V77, P4666, DOI 10.1073/pnas.77.8.4666; Hyre DE, 2000, PROTEIN SCI, V9, P878, DOI 10.1110/ps.9.5.878; Klumb LA, 1998, BIOCHEMISTRY-US, V37, P7657, DOI 10.1021/bi9803123; KOHANSKI RA, 1990, METHOD ENZYMOL, V184, P194; Kurihara A, 1999, BIOCONJUGATE CHEM, V10, P502, DOI 10.1021/bc980123x; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200; Maraveyas A, 1998, INT J CANCER, V78, P610, DOI 10.1002/(SICI)1097-0215(19981123)78:5<610::AID-IJC14>3.3.CO;2-K; MUZYKANTOV VR, 1994, J NUCL MED, V35, P1358; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; Rosebrough SF, 1996, J PHARMACOL EXP THER, V276, P770; Sano T, 1997, P NATL ACAD SCI USA, V94, P6153, DOI 10.1073/pnas.94.12.6153; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; Schechter B, 1999, J DRUG TARGET, V6, P337, DOI 10.3109/10611869908996841; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; Wong J, 1999, BIOMOL ENG, V16, P45, DOI 10.1016/S1050-3862(99)00035-2; Wu SC, 1998, J BACTERIOL, V180, P2830, DOI 10.1128/JB.180.11.2830-2835.1998; WU SC, 2000, 11 INT C ANT ENG SAN; WU XC, 1990, J BIOL CHEM, V265, P6845; YAO ZS, 1995, J NUCL MED, V36, P837; Zhang ML, 1998, NUCL MED BIOL, V25, P101, DOI 10.1016/S0969-8051(97)00157-1	40	76	86	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46422	46428		10.1074/jbc.M107398200	http://dx.doi.org/10.1074/jbc.M107398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584006	hybrid			2022-12-25	WOS:000172573100126
J	Thibeault, D; Maurice, R; Pilote, L; Lamarre, D; Pause, A				Thibeault, D; Maurice, R; Pilote, L; Lamarre, D; Pause, A			In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE ACTIVITIES; NS2-3 PROTEASE; NON-A; NS3; NS4A; POLYPROTEIN; INHIBITION; PRODUCTS; REGION	The cleavage of the hepatitis C virus polyprotein between the nonstructural proteins NS2 and NS3 is mediated by the NS2/3 protease, whereas the NS3 protease is responsible for the cleavage of the downstream proteins. Purification and in vitro characterization of the NS2/3 protease has been hampered by its hydrophobic nature. NS2/3 protease activity could only be detected in cells or in in vitro translation assays with the addition of microsomal membranes or detergent. To facilitate purification of this poorly characterized protease, we truncated the N-terminal hydrophobic domain, resulting in an active enzyme with improved biophysical properties. We define a minimal catalytic region of NS2/3 protease retaining autocleavage activity that spans residues 904-1206 and includes the C-terminal half of NS2 and the N-terminal NS3 protease domain. The NS2/3 (904-1206) variant was purified from Escherichia coli inclusion bodies and refolded by gel filtration chromatography. The purified inactive form of NS2/3 (904-1206) was activated by the addition of glycerol and detergent to induce autocleavage at the predicted site between Leu(1026) and Ala(1027). NS2/3 (904-1206) activity was dependent on zinc ions and could be inhibited by NS4A peptides, peptides that span the cleavage site, or an N-terminal peptidic cleavage product. This NS2/3 variant will facilitate the development of an assay suitable for identifying inhibitors of HCV replication.	Boehringer Ingelheim Canada Ltd, Dept Sci Biol, Res & Dev, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim	Thibeault, D (corresponding author), Boehringer Ingelheim Canada Ltd, Dept Sci Biol, Res & Dev, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.	dthibeault@lav.boehringer-ingelheim.com						BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; BODANSKY M, 1993, PEPTIDE CHEM; Buchanan SK, 1999, CURR OPIN STRUC BIOL, V9, P455, DOI 10.1016/S0959-440X(99)80064-5; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Darke PL, 1999, J BIOL CHEM, V274, P34511, DOI 10.1074/jbc.274.49.34511; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Dymock BW, 2000, ANTIVIR CHEM CHEMOTH, V11, P79, DOI 10.1177/095632020001100201; Gorbalenya AE, 1996, PERSPECT DRUG DISCOV, V6, P64, DOI 10.1007/BF02174046; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIROWATARI Y, 1993, ARCH VIROL, V133, P349, DOI 10.1007/BF01313774; Hong Z, 2000, ACTA GASTRO-ENT BELG, V63, P210; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; KOMODA Y, 1994, GENE, V145, P221; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lin TY, 1996, PROTEIN SCI, V5, P372; Liu QY, 1999, BIOCHEM BIOPH RES CO, V254, P572, DOI 10.1006/bbrc.1998.9986; Liu X, 1998, J VIROL, V72, P4463, DOI 10.1128/JVI.72.5.4463-4466.1998; Liu X, 2000, J VIROL, V74, P5949, DOI 10.1128/JVI.74.13.5949-5956.2000; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P1713, DOI 10.1016/S0960-894X(98)00299-6; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MIZUSHIMA H, 1994, J VIROL, V68, P6215, DOI 10.1128/JVI.68.10.6215-6222.1994; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; REED KE, 1995, J VIROL, V69, P4127, DOI 10.1128/JVI.69.7.4127-4136.1995; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SANTOLINI E, 1995, J VIROL, V69, P7461, DOI 10.1128/JVI.69.12.7461-7471.1995; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Steinkuhler C, 1996, J VIROL, V70, P6694; Tijms MA, 2001, P NATL ACAD SCI USA, V98, P1889, DOI 10.1073/pnas.041390398; Walker MA, 1999, DRUG DISCOV TODAY, V4, P518, DOI 10.1016/S1359-6446(99)01414-2; Yan YW, 1998, PROTEIN SCI, V7, P837; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	36	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46678	46684		10.1074/jbc.M108266200	http://dx.doi.org/10.1074/jbc.M108266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591719	hybrid			2022-12-25	WOS:000172573100156
J	Tuo, J; Muftuoglu, M; Chen, C; Jaruga, P; Selzer, RR; Brosh, RM; Rodriguez, H; Dizdaroglu, M; Bohr, VA				Tuo, J; Muftuoglu, M; Chen, C; Jaruga, P; Selzer, RR; Brosh, RM; Rodriguez, H; Dizdaroglu, M; Bohr, VA			The Cockayne Syndrome group B gene product is involved in general genome base excision repair of 8-hydroxyguanine in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; SITE-DIRECTED MUTAGENESIS; AQUEOUS-SOLUTION; SYNDROME CELLS; ACTIVE GENES; XERODERMA-PIGMENTOSUM; PREFERENTIAL REPAIR; PUTATIVE HELICASES; DEFECTIVE REPAIR	Cockayne Syndrome (CS) is a human genetic disorder with two complementation groups, CS-A and CS-B. The CSB gene product is involved in transcription-coupled repair of DNA damage but may participate in other pathways of DNA metabolism. The present study investigated the role of different conserved helicase motifs of CSB in base excision repair. Stably transformed human cell lines with site-directed CSB mutations in different motifs within its putative helicase domain were established. We find that CSB null and helicase motif V and VI mutants had greater sensitivity than wild type cells to gamma -radiation. Whole cell extracts from CSB null and motif V/VI mutants had lower activity of 8-hydroxyguanie incision in DNA than wild type cells. Also, 8-hydroxyguanine accumulated more in CSB null and motif VI mutant cells than in wild type cells after exposure to gamma -radiation. We conclude that a deficiency in general genome base excision repair of selective modified DNA base(s) might contribute to CS pathogenesis. Furthermore, whereas the disruption of helicase motifs V or VI results in a CSB phenotype, mutations in other helicase motifs do not cause this effect. The biological functions of CSB in different DNA repair pathways may be mediated by distinct functional motifs of the protein.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; NIST, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institute of Standards & Technology (NIST) - USA	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Jaruga, Pawel/M-4378-2015; Muftuoglu, Meltem/AAG-5004-2019; Bohr, Vilhelm/AAP-5931-2020	Muftuoglu, Meltem/0000-0001-5372-4780; Jaruga, Pawel/0000-0001-9192-6084	NATIONAL INSTITUTE ON AGING [Z01AG000737, ZIAAG000727, Z01AG000727, Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; Balajee AS, 2000, ONCOGENE, V19, P477, DOI 10.1038/sj.onc.1203372; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; Citterio E, 2000, CELL, V101, P447, DOI 10.1016/S0092-8674(00)80854-5; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; COOPER PK, 1994, ANN NY ACAD SCI, V726, P330, DOI 10.1111/j.1749-6632.1994.tb52842.x; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIANOV G, 1991, NUCLEIC ACIDS RES, V19, P3829, DOI 10.1093/nar/19.14.3829; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; DIZDAROGLU M, 1985, BIOCHEMISTRY-US, V24, P4476, DOI 10.1021/bi00337a032; Douki T, 1997, CARCINOGENESIS, V18, P2385, DOI 10.1093/carcin/18.12.2385; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; Mallery DL, 1998, AM J HUM GENET, V62, P77, DOI 10.1086/301686; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; May A, 2000, BIOCHEM BIOPH RES CO, V269, P433, DOI 10.1006/bbrc.2000.2264; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Ohshima H, 1996, J RADIAT RES, V37, P199, DOI 10.1269/jrr.37.199; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Piekoszewski W, 2000, POL J PHARMACOL, V52, P389; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; Sunesen M, 2000, NUCLEIC ACIDS RES, V28, P3151, DOI 10.1093/nar/28.16.3151; Tabocchini MA, 2000, MUTAT RES-DNA REPAIR, V461, P71, DOI 10.1016/S0921-8777(00)00041-0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	55	126	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45772	45779		10.1074/jbc.M107888200	http://dx.doi.org/10.1074/jbc.M107888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581270	hybrid			2022-12-25	WOS:000172573100038
J	Vila, R; Ponte, I; Collado, M; Arrondo, JLR; Jimenez, MA; Rico, M; Suau, P				Vila, R; Ponte, I; Collado, M; Arrondo, JLR; Jimenez, MA; Rico, M; Suau, P			DNA-induced alpha-helical structure in the NH2-terminal domain of histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRANSCRIPTION IN-VIVO; C-TERMINAL DOMAIN; SECONDARY STRUCTURE; INFRARED-SPECTROSCOPY; GENE-EXPRESSION; LINKER HISTONES; GLOBULAR DOMAIN; PROTEINS; CHROMATIN	It is important to establish the structural properties of linker histones to understand the role they play in chromatin higher order structure and gene regulation. Here, we use CD, NAM, and IR spectroscopy to study the conformation of the amino-terminal domain of histone H1 degrees, free in solution and bound to the DNA. The NH2-terminal domain has little structure in aqueous solution, but it acquires a substantial amount of a-helical structure in the presence of trifluoroethanol (TFE). As in other H1 subtypes, the basic residues of the NH2-terminal domain of histone H1 degrees are clustered in its COOH-terminal half. According to the NMR results, the helical region comprises the basic cluster (Lys(11)-Lys(20)) and extends until Asp(23). The fractional helicity of this region in 90% TFE is about 50%. His(24) together with Pro(25) constitute the joint between the NH2-terminal helix and helix I of the globular domain. Infrared spectroscopy shows that interaction with the DNA induces an amount of a-helical structure equivalent to that observed in TFE. As coulombic interactions are involved in complex formation, it is highly likely in the complexes with DNA that the minimal region with a-helical structure is that containing the basic cluster. In chromatin, the high positive charge density of the inducible NH2-terminal helical element may contribute to the binding stability of the globular domain.	Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; CSIC, Inst Estructura Mat, E-28006 Madrid, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); University of Basque Country	Suau, P (corresponding author), Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain.	pere.suau@uab.es	Suau, Pedro/D-2695-2009; Ponte, Inma/AGN-5337-2022; Jimenez, M. Angeles/C-7193-2008; Vila, Roger/A-1817-2012; Ponte, Inma/E-6848-2015	Suau, Pedro/0000-0001-6673-8209; Jimenez, M. Angeles/0000-0001-6835-5850; Vila, Roger/0000-0002-2447-4388; Ponte, Inma/0000-0002-9448-6915				ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOHM L, 1985, FEBS LETT, V193, P1, DOI 10.1016/0014-5793(85)80067-3; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; Howe L, 1998, BIOCHEMISTRY-US, V37, P7077, DOI 10.1021/bi980410o; JIMENEZ MA, 1993, EUR J BIOCHEM, V211, P569, DOI 10.1111/j.1432-1033.1993.tb17584.x; JOHNSON NP, 1994, P NATL ACAD SCI USA, V91, P4840, DOI 10.1073/pnas.91.11.4840; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MIRZABEKOV AD, 1990, J MOL BIOL, V211, P479, DOI 10.1016/0022-2836(90)90366-T; Padmanabhan S, 1997, BIOCHEMISTRY-US, V36, P5193, DOI 10.1021/bi962927a; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REISDORF WC, 1996, BIOCHEMISTRY-US, V35, P1386; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SUZUKI M, 1993, PROTEIN ENG, V6, P565, DOI 10.1093/protein/6.6.565; TORII H, 1992, J CHEM PHYS, V96, P3379, DOI 10.1063/1.461939; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Vila R, 2000, PROTEIN SCI, V9, P627; Vila R, 2001, J BIOL CHEM, V276, P30898, DOI 10.1074/jbc.M104189200; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; ZLATANOVA J, 1992, J CELL SCI, V103, P889	38	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46429	46435		10.1074/jbc.M106952200	http://dx.doi.org/10.1074/jbc.M106952200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584004	hybrid			2022-12-25	WOS:000172573100127
J	Lim, SR; Hertel, KJ				Lim, SR; Hertel, KJ			Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3 ' splice site pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; ANTISENSE OLIGONUCLEOTIDES; SINGLE NUCLEOTIDE; DETERMINING GENE; FACTOR U2AF(35); SMN; ENHANCER; PROTEIN; IDENTIFICATION; BINDING	Spinal muscular atrophy is caused by the loss of functional survival motor neuron (SMN1) alleles. A translationally silent nucleotide transition in the duplicated copy of the gene (SMN2) leads to exon 7 skipping and expression of a nonfunctional gene product. It has been suggested that differential SMN2 splicing is caused by the disruption of an exonic splicing enhancer. Here we show that the single nucleotide difference reduces the intrinsic strength of the 3' splice site of exon 7 2-fold, whereas the strength of the 5' splice site of the exon 7 is not affected. Thus, a decrease in splice site strength is magnified in the context of competing exons. These data suggest that lower levels of exon 7 definition not only reduce intron 6 removal but, more importantly, increase the efficiency of the competing exon 7 skipping pathway. Antisense oligonucleotides were tested to modulate exon 7 inclusion, which contains the authentic translation stop codon. Oligonucleotides directed toward the 3' splice site of exon 8 were shown to alter SMN2 splicing in favor of exon 7 inclusion. These results suggest that antisense oligonucleotides could be used as a therapeutic strategy to counteract the progression of SMA.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine	Hertel, KJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.			Hertel, Klemens/0000-0002-7560-9529	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062287] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062287] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; COBBEN JM, 1995, AM J HUM GENET, V57, P805; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; Friedman KJ, 1999, J BIOL CHEM, V274, P36193, DOI 10.1074/jbc.274.51.36193; FU XD, 1995, RNA, V1, P663; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Lynch KW, 2001, J BIOL CHEM, V276, P24341, DOI 10.1074/jbc.M102175200; McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Rio Donald C., 1992, Gene Expression, V2, P1; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; WANG Z, 1995, RNA, V1, P21; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	35	131	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45476	45483		10.1074/jbc.M107632200	http://dx.doi.org/10.1074/jbc.M107632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584013	hybrid, Green Published			2022-12-25	WOS:000172406700146
J	Yammani, RR; Seetharam, S; Seetharam, B				Yammani, RR; Seetharam, S; Seetharam, B			Identification and characterization of two distinct ligand binding regions of cubilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC FACTOR-COBALAMIN; FACTOR VITAMIN-B-12 RECEPTOR; BRUSH-BORDER EXPRESSION; HEREDITARY MEGALOBLASTIC-ANEMIA-1; RAT; MEMBRANE; PROTEINS; ENDOCYTOSIS; KIDNEY; CELLS	Using polymerase chain reaction-amplified fragments of cubilin, an endocytic receptor of molecular mass 460 kDa, we have identified two distinct ligand binding regions. Region 1 of molecular mass 71 kDa, which included the 113-residue N terminus along with the eight epidermal growth factor (EGF)-like repeats and CUB domains 1 and 2, and region 2 of molecular mass 37 kDa consisting of CUB domains 6-8 bound both intrinsic factor-cobalamin (vitamin B-12; Cbl) (IF-Cbl) and albumin. Within these two regions, the binding of both ligands was confined to a 110-115-residue stretch that encompassed either the 113-residue N terminus or CUB domain 7 and 8. Ca2+ dependence of ligand binding or the ability of cubilin antiserum to inhibit ligand binding to the 113-residue N terminus was 60-65%. However, a combination of CUB domains 7 and 8 or 6-8 was needed to demonstrate significant Ca2+ dependence or inhibition of ligand binding by cubilin antiserum. Antiserum to EGF inhibited albumin but not IF-Cbl binding to the N-terminal cubilin fragment that included the eight EGF-like repeats. While the presence of excess albumin had no effect on binding to IF-Cbl, IF-Cbl in excess was able to inhibit albumin binding to both regions of cubilin. Reductive alkylation of the 113-residue N terminus or CUB 6-8, CUB 7, or CUB 8 domain resulted in the abolishment of ligand binding. These results indicate that (a) cubilin contains two distinct regions that bind both IF-Cbl and albumin and that (b) binding of both IF-Cbl and albumin to each of these regions can be distinguished and is regulated by the nonassisted formation of local disulfide bonds.	Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Seetharam, B (corresponding author), Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Rm 6061,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.							Aminoff M, 1999, NAT GENET, V21, P309, DOI 10.1038/6831; BATUMAN V, 1990, AM J PHYSIOL, V258, pF1259, DOI 10.1152/ajprenal.1990.258.5.F1259; Batuman V, 1998, AM J PHYSIOL-RENAL, V275, pF246, DOI 10.1152/ajprenal.1998.275.2.F246; Birn H, 2000, J CLIN INVEST, V105, P1353, DOI 10.1172/JCI8862; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; COLLAN Y, 1979, NEPHRON, V23, P297, DOI 10.1159/000181654; FYFE JC, 1991, J BIOL CHEM, V266, P4489; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; HILLE A, 1989, J BIOL CHEM, V264, P13460; KADERBHAI MA, 1985, EUR J BIOCHEM, V15, P167; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Kristiansen M, 2000, BLOOD, V96, P405; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Lindblom A, 1999, J BIOL CHEM, V274, P6374, DOI 10.1074/jbc.274.10.6374; MAHER PA, 1986, P NATL ACAD SCI USA, V83, P9001, DOI 10.1073/pnas.83.23.9001; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; MOHAMED SD, 1966, Q J MED, V139, P433; RAMANUJAM KS, 1991, J BIOL CHEM, V266, P13135; RAMANUJAM KS, 1994, ARCH BIOCHEM BIOPHYS, V315, P8, DOI 10.1006/abbi.1994.1464; RAMANUJAM KS, 1993, BIOCHIM BIOPHYS ACTA, V1146, P243, DOI 10.1016/0005-2736(93)90362-4; RAMANUJAM KS, 1993, COMP BIOCHEM PHYS A, V104, P771, DOI 10.1016/0300-9629(93)90153-U; SEETHARAM B, 1981, J BIOL CHEM, V256, P9813; SEETHARAM B, 1982, J BIOL CHEM, V257, P183; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1983, BIOCHEM BIOPH RES CO, V115, P238, DOI 10.1016/0006-291X(83)90995-6; Seetharam B, 1999, ANNU REV NUTR, V19, P173, DOI 10.1146/annurev.nutr.19.1.173; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM S, 1992, J BIOL CHEM, V267, P7421; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; TIRUPPATHI C, 1986, ANAL BIOCHEM, V153, P330, DOI 10.1016/0003-2697(86)90100-4; Yammani RR, 2001, AM J PHYSIOL-ENDOC M, V281, pE900, DOI 10.1152/ajpendo.2001.281.5.E900	32	41	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44777	44784		10.1074/jbc.M106419200	http://dx.doi.org/10.1074/jbc.M106419200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581259	hybrid			2022-12-25	WOS:000172406700060
J	Kroll, SL; Barth-Baus, D; Hensold, JO				Kroll, SL; Barth-Baus, D; Hensold, JO			The carboxyl-terminal domain of the granulocyte colony-stimulating factor receptor uncouples ribosomal biogenesis from cell cycle progression in differentiating 32D myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN MESSENGER-RNA; G-CSF RECEPTOR; TRANSLATIONAL CONTROL; C-MYC; PROTEIN-SYNTHESIS; TRANSCRIPTION FACTOR; V-MYC; INITIATION; EXPRESSION; GROWTH	Translational regulation plays an important role in development. In terminally differentiating cells a decrease in translation rate is common, although the regulatory mechanisms are unknown. We utilized 32Dcl3 myeloblast cells to investigate translational regulation during granulocyte colony-stimulating factor (G-CSF)-induced differentiation. G-CSF causes a significant decrease in translation rate compared with interleukin-3, which is a mitogen for these cells. Although these two cytokines exhibit modest differences in their effect on translation factor phosphorylation, they exhibit dramatic differences in their effect on ribosomal abundance and ribosomal DNA transcription. However, be. cause both cytokines stimulate cell cycling, G-CSF induces a dissociation of ribosomal biogenesis from cell cycle progression. This uncoupling of ribosomal biogenesis from cell cycle progression appears to be closely related to the transmission of a differentiation signal, because it is not observed in cells expressing a carboxyl-terminally truncated G-CSF receptor, which supports proliferation but not differentiation of these cells. Because a similar event occurs early in differentiation of murine erythroleukemic cells, this suggests that ribosomal content is a common target of differentiating agents.	Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Hensold, JO (corresponding author), Case Western Reserve Univ, Sch Med, Dept Med, 10900 Euclid Ave,BRB 333, Cleveland, OH 44106 USA.	joh2@po.cwru.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007147] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07147] Funding Source: Medline; NIDDK NIH HHS [DK43414] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alzuherri HM, 1999, J BIOL CHEM, V274, P4328, DOI 10.1074/jbc.274.7.4328; BILELLO JA, 1980, IN VIVO IN VITRO ERY, P229; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN AD, 1991, BLOOD, V78, P2426; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hensold JO, 1996, J BIOL CHEM, V271, P23246, DOI 10.1074/jbc.271.38.23246; Hensold JO, 1996, J BIOL CHEM, V271, P3385; Hermans MHA, 1999, J EXP MED, V189, P683, DOI 10.1084/jem.189.4.683; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; Hunter MG, 1998, J IMMUNOL, V160, P4979; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; Krichevsky AM, 1999, J BIOL CHEM, V274, P14295, DOI 10.1074/jbc.274.20.14295; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; MERRICK WC, 2000, CURRENT PROTOCOLS CE; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Morales J, 1997, J BIOL CHEM, V272, P6607, DOI 10.1074/jbc.272.10.6607; PALATNIK CM, 1984, CELL, V36, P1017, DOI 10.1016/0092-8674(84)90051-5; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Russell JE, 1996, BLOOD, V87, P5314, DOI 10.1182/blood.V87.12.5314.bloodjournal87125314; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SCHIMENTI KJ, 1992, CYTOMETRY, V13, P48, DOI 10.1002/cyto.990130109; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SHERTON CC, 1976, DEV BIOL, V48, P118, DOI 10.1016/0012-1606(76)90051-8; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SMITH M R, 1990, New Biologist, V2, P648; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TNHOMAS G, 2000, NAT CELL BIOL, V2, pE71; Um M, 2001, MOL CELL BIOL, V21, P2435, DOI 10.1128/MCB.21.7.2435-2448.2001; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Wickens M., 1996, TRANSLATIONAL CONTRO, P411; Wickens Marvin, 1992, Seminars in Developmental Biology, V3, P363; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2	77	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49410	49418		10.1074/jbc.M109577200	http://dx.doi.org/10.1074/jbc.M109577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598144	hybrid			2022-12-25	WOS:000173922100102
J	Wong, GW; Yasuda, S; Madhusudhan, MS; Li, LX; Yang, Y; Krilis, SA; Sali, A; Stevens, RL				Wong, GW; Yasuda, S; Madhusudhan, MS; Li, LX; Yang, Y; Krilis, SA; Sali, A; Stevens, RL			Human tryptase epsilon (PRSS22), a new member of the chromosome 16p13.3 family of human serine proteases expressed in airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MAST-CELLS; SYSTEMIC-ANAPHYLAXIS; COMPLEMENTARY-DNA; GENE-CLUSTER; MOUSE; PROTEIN; CLONING; SEQUENCE; MASTOCYTOSIS	Probing of the GenBank(TM) expressed sequence tag (EST) data base with varied human tryptase cDNAs identified two truncated ESTs that subsequently were found to encode overlapping portions of a novel human serine protease (designated tryptase E or protease, serine S1 family member 22 (PRSS22)). The tryptase epsilon gene resides on chromosome 16p13.3 within a 2.5-Mb complex of serine protease genes. Although at least 7 of the 114 genes in this complex encode enzymatically active proteases, only one tryptase epsilon-like gene was identified. The trachea and esophagus were found to contain the highest steady-state levels of the tryptase epsilon transcript in adult humans. Although the tryptase epsilon transcript was scarce in adult human lung, it was present in abundance in fetal lung. Thus, the tryptase epsilon gene is expressed in the airways in a developmentally regulated manner that is different from that of other human tryptase genes. At the cellular level, tryptase epsilon is a major product of normal pulmonary epithelial cells, as well as varied transformed epithelial cell lines. Enzymatically active tryptase epsilon is also constitutively secreted from these cells. The amino acid sequence of human tryptase epsilon is 38-44% identical to those of human tryptase alpha, tryptase betaI, tryptase betaII, tryptase 13111, transmembrane tryptase/tryptase gamma, marapsin, and Esp-1/testisin. Nevertheless, comparative protein structure modeling and functional studies using recombinant material revealed that tryptase epsilon has a substrate preference distinct from that of its other family members. These data indicate that the products of the chromosome 16p13.3 complex of tryptase genes evolved to carry out varied functions in humans.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ New S Wales, Dept Med, Kogarah, NSW 2217, Australia; St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW 2217, Australia; Rockefeller Univ, Pels Family Ctr Biochem & Struct Biol, Lab Mol Biophys, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of New South Wales Sydney; St George Hospital; Rockefeller University	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.		Yasuda, Shinsuke/A-4369-2012	Wong, G. William/0000-0002-5286-6506	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063284, P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054762, R01GM054762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-63284, HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline; NIGMS NIH HHS [GM-54762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENYON RC, 1991, INT ARCH ALLER A IMM, V94, P218, DOI 10.1159/000235364; CAUGHEY GH, 1993, GENOMICS, V15, P614, DOI 10.1006/geno.1993.1115; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; Davies BJ, 1998, J BIOL CHEM, V273, P23004, DOI 10.1074/jbc.273.36.23004; Friend DS, 1998, J IMMUNOL, V160, P5537; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; Hooper JD, 1999, CANCER RES, V59, P3199; Huang C, 2000, J BIOL CHEM, V275, P351, DOI 10.1074/jbc.275.1.351; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Inoue M, 1998, BIOCHEM BIOPH RES CO, V252, P307, DOI 10.1006/bbrc.1998.9645; Inoue M, 1999, BIOCHEM BIOPH RES CO, V266, P564, DOI 10.1006/bbrc.1999.1870; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li Y, 2001, BLOOD, V97, P3484, DOI 10.1182/blood.V97.11.3484; MAGNAGHI P, 1994, HUM MOL GENET, V3, P437, DOI 10.1093/hmg/3.3.437; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MORGAN JG, 1991, J IMMUNOL, V147, P3210; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Peisach E, 1999, BIOCHEMISTRY-US, V38, P11180, DOI 10.1021/bi991130r; PEREIRA HA, 1995, J LEUKOCYTE BIOL, V57, P805, DOI 10.1002/jlb.57.6.805; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PILAT D, 1994, GENOMICS, V24, P445, DOI 10.1006/geno.1994.1651; RAYMOND WW, 1995, J BIOL CHEM, V270, P13164, DOI 10.1074/jbc.270.22.13164; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1985, J IMMUNOL, V134, P526; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wong GW, 2001, J BIOL CHEM, V276, P20648, DOI 10.1074/jbc.M010422200; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	60	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49169	49182		10.1074/jbc.M108677200	http://dx.doi.org/10.1074/jbc.M108677200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11602603	hybrid			2022-12-25	WOS:000173922100073
J	Park, JG; Bose, A; Leszyk, J; Czech, MP				Park, JG; Bose, A; Leszyk, J; Czech, MP			PYK2 as a mediator of endothelin-1/G alpha(11) signaling to GLUT4 glucose transporters.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-STIMULATION; ACTIVATION; TRANSLOCATION; RECEPTOR; ARF6; TRAFFICKING; ALPHA; SRC	Endothelin-1 (ET-1) signaling through G alpha (q/11) stimulates translocation of intracellular GLUT4 glucose transporters to the plasma membrane of 3T3-L1 adipocytes by an unknown mechanism that requires protein tyrosine phosphorylation and ADP-ribosylation factor 6 (ARF6) but is independent of phosphatidylinositol 3 (PI3)-kinase. In contrast, insulin action on this process requires PI3-kinase but not ARF6. Here we report the identification of two proteins selectively tyrosine-phosphorylated in response to ET-1 but not insulin: the Ca2+-activated tyrosine kinase PYK2 and its physiological substrate, the adhesion scaffold protein paxillin. Endogenous paxillin as well as expressed Myc-tagged PYK2 or a Myc-tagged kinase-deficient PYK2 protein were acutely directed to F-actin-rich adhesion sites from the adipocyte cytoplasm in response to ET-1 but not insulin. CADTK-related non-kinase (CRNK) is a dominant negative form of PYK2 containing the C-terminal portion of the protein, which binds paxillin but lacks the PYK2 autophosphorylation site (Tyr(402)). CRNK expression in 3T3-L1 adipocytes inhibited ET-1-mediated F-actin polymerization and translocation of Myc-tagged GLUT4-enhanced green fluorescent protein (EGFP) to the plasma membrane without disrupting insulin action on these processes. These data reveal the tyrosine kinase PYK2 as a required signaling element in the regulation of GLUT4 recycling in 3T3-L1 adipocytes by ET-1, whereas insulin signaling is directed through a different pathway.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOU YC, 1994, BIOCHEM BIOPH RES CO, V202, P688, DOI 10.1006/bbrc.1994.1985; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Jeschke M, 1998, J BIOL CHEM, V273, P11354, DOI 10.1074/jbc.273.18.11354; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Lampson MA, 2000, J CELL SCI, V113, P4065; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; OKADA T, 1994, J BIOL CHEM, V269, P3568; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Schafer DA, 2000, TRAFFIC, V1, P892; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; TODD J, 2001, MOL CELL BIOL, V21, P5276; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wu-Wong JR, 2000, J CARDIOVASC PHARM, V36, pS179, DOI 10.1097/00005344-200036001-00055; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHEN Y, 2001, IN PRESS J BIOL CHEM; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	36	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47751	47754		10.1074/jbc.C100524200	http://dx.doi.org/10.1074/jbc.C100524200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602570	hybrid			2022-12-25	WOS:000172927000002
J	Riefler, GM; Firestein, BL				Riefler, GM; Firestein, BL			Binding of neuronal nitric-oxide synthase (nNOS) to carboxyl-terminal-binding protein (CtBP) changes the localization of CtBP from the nucleus to the cytosol - A novel function for targeting by the PDZ domain of nNOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; PSD-95; POTENTIATION; COREPRESSOR; EXPRESSION; MESSENGER; SEQUENCES; TISSUES; KINASE; MUTANT	Recent work suggests a role for PDZ domains in the targeting of binding partners to specific sites in the cell. To identify whether the PDZ domain of neuronal nitric-oxide synthase (nNOS) can play such a role, we performed affinity chromatography of brain extract with the nNOS PDZ domain. We identified the carboxyl-terminal-binding protein (CtBP), a phosphoprotein first identified as a binding partner to adenovirus EIA, as a nNOS binding partner. CtBP interacts with the PDZ domain of nNOS, and this interaction can be competed with peptide that binds to the PDZ peptide-binding site. In addition, binding of CtBP to nNOS is dependent on its carboxyl-terminal sequence -DXL, residues conserved between species that. fit the canonical sequence for nNOS PDZ binding. Immunoprecipitation studies show that CtBP and nNOS associate in the brain. When CtBP is expressed in Madin-Darby canine kidney cells, its distribution is primarily nuclear; however, when CtBP is co-expressed with nNOS, its localization becomes more cytosolic. This change in CtBP localization does not occur when its carboxyl-terminal nNOS PDZ binding motif is mutated or when CtBP is co-expressed with postsynaptic density 95, another PDZ domain-containing protein. Taken together, our data suggest a new function for nNOS as a regulator of CtBP nuclear localization.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Firestein, BL (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.			Firestein, Bonnie/0000-0002-1679-3565				Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Firestein BL, 1998, J NEUROCHEM, V71, P1846; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gonzalez-Mariscal L, 1999, EXP CELL RES, V248, P97, DOI 10.1006/excr.1999.4392; Hawkins RD, 1996, NEURON, V16, P465, DOI 10.1016/S0896-6273(00)80064-1; HECKER M, 1994, J NEUROCHEM, V62, P1524; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Park CS, 2000, NITRIC OXIDE-BIOL CH, V4, P459, DOI 10.1006/niox.2000.0300; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587	35	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48262	48268		10.1074/jbc.M106503200	http://dx.doi.org/10.1074/jbc.M106503200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11590170	hybrid			2022-12-25	WOS:000172927000071
J	Blanchard, F; Wang, YP; Kinzie, E; Duplomb, L; Godard, A; Baumann, H				Blanchard, F; Wang, YP; Kinzie, E; Duplomb, L; Godard, A; Baumann, H			Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; INTERNALIZATION MOTIF; INTERLEUKIN-6; ACTIVATION; LIGAND; CYTOKINES; PROTEINS; PHOSPHORYLATION; IDENTIFICATION; SUPPRESSOR	The cytokine receptor subunits gp130, leukemia inhibitory factor receptor alpha (LIFR alpha), and oncostatin M receptor beta (OSMR beta) transduce OSM signals that regulate gene expression and cell proliferation. After ligand binding and activation of the Janus protein-tyrosine kinase/STAT and mitogen-activated protein kinase signal transduction pathways, negative feedback processes are recruited. These processes attenuate receptor action by suppression of cytokine signaling and by downregulation of receptor protein expression. This study demonstrates that in human fibroblasts or epithelial cells, OSM first decreases the level of gp130, LIFR alpha, and OSMR beta by ligand-induced receptor degradation and then increases the level of the receptors by enhanced synthesis. The transcriptional induction of gp130 gene by OSM involves STAT3. Various cell lines expressing receptor subunits to the different interleukin-6 class cytokines revealed that only LIFRa degradation is promoted by activated ERK and that degradation of gp130, OSMR beta, and a fraction of LIFR alpha involves mechanisms that are separate from signal transduction. These mechanisms include ligand-mediated dimerization, internalization, and endosomal/lysosomal degradation. Proteosomal degradation appears to involve a fraction of receptor subunit proteins that are ubiquitinated independently of ligand binding.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Inst Biol, INSERM U463, F-44035 Nantes 01, France	Roswell Park Cancer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm)	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	heinz.baumann@roswellpark.org	Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Duplomb, Laurence/0000-0002-5715-3759	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA085580] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85580, CA 16056] Funding Source: Medline; NIDDK NIH HHS [DK 38866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cichy J, 1997, J BIOL CHEM, V272, P8250, DOI 10.1074/jbc.272.13.8250; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; dos Santos GMA, 2001, J BIOL CHEM, V276, P32635, DOI 10.1074/jbc.M103583200; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; FAN Z, 1994, J BIOL CHEM, V269, P27595; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Gibson RM, 2000, J BIOL CHEM, V275, P22574, DOI 10.1074/jbc.M907658199; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; Magrangeas F, 2001, EUR CYTOKINE NETW, V12, P309; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Richards CD, 1997, J IMMUNOL, V159, P2431; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; Thiel S, 1999, BIOCHEM J, V339, P15, DOI 10.1042/0264-6021:3390015; Thiel S, 1998, FEBS LETT, V441, P231, DOI 10.1016/S0014-5793(98)01559-2; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	33	87	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47038	47045		10.1074/jbc.M107971200	http://dx.doi.org/10.1074/jbc.M107971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11602599	hybrid			2022-12-25	WOS:000172768500050
J	Grundschober, C; Delaunay, F; Puhlhofer, A; Triqueneaux, G; Laudet, V; Bartfai, T; Nef, P				Grundschober, C; Delaunay, F; Puhlhofer, A; Triqueneaux, G; Laudet, V; Bartfai, T; Nef, P			Circadian regulation of diverse gene products revealed by mRNA expression profiling of synchronized fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-IMMUNOREACTIVITY; SUPRACHIASMATIC NUCLEUS; CELL-LINE; TRANSCRIPTION; RHYTHM; CYCLE; GLUTAMATE; HAMSTER; CLOCK; UNIT	Genes under a 24-h regulation period may represent drug targets relevant to diseases involving circadian dysfunctions. As a testing model of the circadian clock system, we have used synchronized rat fibroblasts that are known to express at least six genes in a circadian fashion. We have determined the expression patterns of 9957 transcripts every 4 h over a total period of 76 h using high density oligonucleotide microarrays. The spectral analysis of our mRNA profiling data indicated that similar to2% (85 genes) of all expressed genes followed a robust circadian pattern. We have confirmed the circadian expression of previously known clock or clock-driven genes, and we identified 81 novel circadian genes. The majority of the circadian-regulated gene products are known and are involved in diverse cellular functions. We have classified these circadian genes in seven clusters according to their phase of cycling. Our pathway analysis of the mRNA profiling data strongly suggests a direct link between circadian rhythm and cell cycle.	F Hoffmann La Roche & Co Ltd, Cent Nervous Syst Dept, CH-4070 Basel, Switzerland; Ecole Normale Super Lyon, CNRS, UMR 5665, F-69364 Lyon 07, France	Roche Holding; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Nef, P (corresponding author), F Hoffmann La Roche & Co Ltd, Cent Nervous Syst Dept, Bldg 69-410, CH-4070 Basel, Switzerland.			Delaunay, Franck/0000-0003-4927-1701				[Anonymous], TIME SERIES ANAL FOR; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bjarnason GA, 1999, AM J PATHOL, V154, P613, DOI 10.1016/S0002-9440(10)65306-0; Chambille I, 1999, BRAIN RES, V833, P27, DOI 10.1016/S0006-8993(99)01460-2; Denis GV, 2000, CELL GROWTH DIFFER, V11, P417; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HOLMES MC, 1995, MOL BRAIN RES, V28, P186, DOI 10.1016/0169-328X(94)00207-U; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Kornmann B, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e51; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; Leroy AnnickM., 2005, ROBUST REGRESSION OU, V589, DOI [10.1002/0471725382, DOI 10.1002/0471725382]; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Martin R. D., 1980, DIRECTIONS TIME SERI, P228; MARTIN RD, 1981, APPLIED TIME SERIES, V2, P683; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; MODJTAHEDI N, 1992, INT J CANCER, V52, P483, DOI 10.1002/ijc.2910520325; Pickard GE, 1997, BIOL CELL, V89, P513, DOI 10.1016/S0248-4900(98)80007-5; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Sankrithi N, 1999, J NEUROCHEM, V72, P605, DOI 10.1046/j.1471-4159.1999.0720605.x; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SMAALAND R, 1992, BLOOD, V79, P2281; Stamp JA, 1997, BRAIN RES, V756, P215, DOI 10.1016/S0006-8993(97)00199-6; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; 1997, USER B PERKINELMER L, V2	33	105	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46751	46758		10.1074/jbc.M107499200	http://dx.doi.org/10.1074/jbc.M107499200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598123	Green Published, hybrid			2022-12-25	WOS:000172768500012
J	Luk, EEC; Culotta, VC				Luk, EEC; Culotta, VC			Manganese superoxide dismutase in Saccharomyces cerevisiae acquires its metal co-factor through a pathway involving the Nramp metal transporter, Smf2p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; IRON UPTAKE; COPPER CHAPERONE; OXIDATIVE DAMAGE; BSD2 GENE; PROTEIN; GOLGI; PMR1; FAMILY; HOMEOSTASIS	Eukaryotes express both copper/zinc (SOD1)- and manganese (SOD2)-requiring superoxide dismutase enzymes that guard against oxidative damage. Although SOD1 acquires its copper through a specific copper trafficking pathway, nothing is known regarding the intracellular manganese trafficking pathway for SOD2. We demonstrate here that in Saccharomyces cerevisiae cells delivery of manganese to SOD2 in the mitochondria requires the Nramp metal transporter, Smf2p. SOD2 activity is greatly diminished in smf2 Delta mutants, even though the mature SOD2 polypeptide accumulates to norma levels in mitochondria. Treating smf2 Delta cells with manganese supplements corrected the SOD2 defect, as did elevating intracellular manganese through mutations in PMR1 Hence, manganese appears to be inaccessible to mitochondrial SOD2 in smf2 mutants. Cells lacking SMF2 also exhibited defects in manganese-dependent steps in protein glycosylation and showed an overall decrease in steady-state levels of accumulated manganese. By comparison, mutations in the cell surface Nramp transporter, Smf1p, had very little impact on manganese accumulation and trafficking. Smf2p resides in intracellular vesicles and shows no evidence of plasma membrane localization, even in an end4 mutant blocked for endocytosis. We propose a model in which Smf2p-containing vesicles play a central role in manganese trafficking to the mitochondria and other cellular sites as well.	Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Culotta, VC (corresponding author), Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.	vculotta@jhsph.edu		Luk, Ed/0000-0002-6619-2258	NIEHS NIH HHS [ES 08996] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008996] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrews NC, 2000, NAT REV GENET, V1, P208, DOI 10.1038/35042073; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DAUM G, 1982, J BIOL CHEM, V257, P3028; DIX DR, 1994, J BIOL CHEM, V269, P26092; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EDWARDS JA, 1975, BLOOD, V46, P381; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KUHN NJ, 1991, EUR J BIOCHEM, V195, P243, DOI 10.1111/j.1432-1033.1991.tb15700.x; LAPINSKAS P, 1995, THESIS J HOPKINS U B; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; LIANGTAO L, 2001, J BIOL CHEM, V276, P5036; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; Liu XF, 1999, J MOL BIOL, V289, P885, DOI 10.1006/jmbi.1999.2815; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Nasir MS, 1999, J BIOL INORG CHEM, V4, P775, DOI 10.1007/s007750050350; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Paidhungat M, 1998, GENETICS, V148, P1777; Paidhungat M, 1998, GENETICS, V148, P1787; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; RAM BP, 1985, CRC CR REV BIOCH MOL, V17, P257, DOI 10.3109/10409238509113606; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; Romero PA, 1997, BIOCHEM J, V321, P289, DOI 10.1042/bj3210289; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Sherman F., 1978, METHODS YEAST GENETI; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sorin A, 1997, J BIOL CHEM, V272, P9895; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	61	108	110	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47556	47562		10.1074/jbc.M108923200	http://dx.doi.org/10.1074/jbc.M108923200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11602606	hybrid			2022-12-25	WOS:000172768500115
J	Magill, CP; Jackson, SP; Bell, SD				Magill, CP; Jackson, SP; Bell, SD			Identification of a conserved archaeal RNA polymerase subunit contacted by the basal transcription factor TFB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START SITE SELECTION; FACTOR-TFIIB; FUNCTIONAL DOMAINS; PREINITIATION COMPLEX; FACTOR-IIB; SACCHAROMYCES-CEREVISIAE; PYROCOCCUS-FURIOSUS; FACTOR REQUIREMENTS; CRYSTAL-STRUCTURE; DNA-BINDING	Archaea possess two general transcription factors that are required to recruit RNA polymerase (RNA-P) to promoters in vitro. These are TBP, the TATA-box-binding protein and TFB, the archaeal homologue of TFIIB. Thus, the archaeal and eucaryal transcription machineries are fundamentally related. In both RNAP II and archaeal transcription systems, direct contacts between TFB/TFIIB and the RNAP have been demonstrated to mediate recruitment of the polymerase to the promoter. However the subunit(s) directly contacted by these factors has not been identified. Using systematic yeast two-hybrid and biochemical analyses we have identified an interaction between the N-terminal domain of TFB and an evolutionarily conserved subunit of the RNA polymerase, RpoK. Intriguingly, homologues of RpoK are found in all three nuclear RNA polymerases (Rpb6) and also in the bacterial RNA polymerase (oi-subunit).	MRC, Canc Cell Unit, Hutchison MRC Res Ctr, Cambridge CB2 2QH, England; Wellcome Trust & Canc Res Campaign, Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB3 3EJ, England	University of Cambridge	Bell, SD (corresponding author), MRC, Canc Cell Unit, Hutchison MRC Res Ctr, Hills Rd, Cambridge CB2 2QH, England.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Bell, Stephen/0000-0002-8474-6592				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bell SD, 1998, P NATL ACAD SCI USA, V95, P15218, DOI 10.1073/pnas.95.26.15218; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Darcy TJ, 1999, J BACTERIOL, V181, P4424, DOI 10.1128/JB.181.14.4424-4429.1999; Grossmann JG, 2001, BIOCHEMISTRY-US, V40, P6267, DOI 10.1021/bi0028946; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; Qureshi SA, 1997, EMBO J, V16, P2927, DOI 10.1093/emboj/16.10.2927; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Schleper Christa, 1995, P91; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	33	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46693	46696		10.1074/jbc.C100567200	http://dx.doi.org/10.1074/jbc.C100567200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11606563	hybrid			2022-12-25	WOS:000172768500003
J	Pflum, MKH; Tong, JK; Lane, WS; Schreiber, SL				Pflum, MKH; Tong, JK; Lane, WS; Schreiber, SL			Histone deacetylase I phosphorylation promotes enzymatic activity and complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTIONAL REPRESSION; PROTEIN-KINASE; CELL-DIFFERENTIATION; YEAST; INHIBITORS; NUCLEAR; TRICHOSTATIN; COMPONENTS; CLONING	Accessibility of the genome to DNA-binding transcription factors is regulated by proteins that control the acetylation of amino-terminal lysine residues on nucleosomal histones. Specifically, histone deacetylase (HDAC) proteins repress transcription by deacetylating histones. To date, the only known regulatory mechanism of HDAC1 function is via interaction with associated proteins. Although the control of HDAC1 function by protein interaction and recruitment is well precedented, we were interested in exploring HDAC1 regulation by post-translational modification. Human HDAC1 protein was analyzed by ion trap mass spectrometry, and two phosphorylated serine residues, Ser(421) and Ser(423), were unambiguously identified. Loss of phosphorylation at Ser(421) and Ser (423) due to mutation to alanine or disruption of the casein kinase 2 consensus sequence directing phosphorylation reduced the enzymatic activity and complex formation of HDAC1. Deletion of the highly charged carboxyl-terminal region of HDAC1 also decreased its deacetylase activity and protein associations, revealing its requirement in maintaining HDAC1 function. Our results reinforce the importance of protein associations in modulating HDAC1 function and provide the first step toward characterizing the role of post-translational modifications in regulating HDAC activity in vivo.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Harvard University; Harvard University	Schreiber, SL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	sls@slsiris.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38627, GM 19837] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; GRUNSTEIN M, 1992, SCI AM, V267, P68, DOI 10.1038/scientificamerican1092-68; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jung M, 1999, J MED CHEM, V42, P4669, DOI 10.1021/jm991091h; Kao HY, 2000, GENE DEV, V14, P55; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kolle D, 1999, BIOCHEMISTRY-US, V38, P6769, DOI 10.1021/bi982702v; KORNBERG RD, 1981, SCI AM, V244, P48, DOI 10.1038/scientificamerican0281-52; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Medina V, 1997, CANCER RES, V57, P3697; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Taunton J, 1996, J AM CHEM SOC, V118, P10412, DOI 10.1021/ja9615841; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5; VanLint C, 1996, GENE EXPRESSION, V5, P245; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	60	193	202	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47733	47741		10.1074/jbc.M105590200	http://dx.doi.org/10.1074/jbc.M105590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11602581	hybrid, Green Published			2022-12-25	WOS:000172768500138
J	Purdue, PE; Lazarow, PB				Purdue, PE; Lazarow, PB			Pex18p is constitutively degraded during peroxisome biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; UBIQUITIN-CONJUGATING ENZYME; MATRIX PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; PICHIA-PASTORIS; TARGETING SIGNAL; PTS2 RECEPTOR; 3-KETOACYL-COA THIOLASE; GENE ENCODES; FUNCTIONAL COMPLEMENTATION	Pex18p and Pex21p are structurally related yeast peroxins (proteins required for peroxisome biogenesis) that are partially redundant in function. One or the other is essential for the import into peroxisomes of proteins with type 2 peroxisomal targeting sequences (PTS2). These sequences bind to the soluble PTS2 receptor, Pex7p, which in turn binds to Pex18p (or Pex21p or possibly both). Here we show that Pex18p is constitutively degraded with a half-time of less than 10 min in wild-type Saccharomyces cerevisiae. This degradation probably occurs in proteasomes, because it requires the related ubiquitin-conjugating enzymes Ubc4p and Ubc5p and occurs normally in a mutant lacking the Pep4p vacuolar protease. The turnover of Pex18p stops, and Pex18p accumulates to a much higher than normal abundance in pex mutants in which the import of all peroxisomal matrix proteins is blocked. This includes mutants that lack peroxins involved in receptor docking at the membrane (Delta pex13 or Delta pex14), a mutant that lacks the peroxisomal member of the E2 family of ubiquitin-conjugating enzymes (Delta pex4), and others (Delta pex1). This stabilization in a variety of pex mutants indicates that Pex18p turnover is associated with its normal function. A Pex18p-Pex7p complex is detected by immunoprecipitation in wild type cells, and its abundance increases considerably in the Delta pex14 peroxisome biogenesis mutant. Cells that lack Pex7p fail to stabilize and accumulate Pex18p, indicating an important role for complex formation in the stabilization. Mono- and diubiquitinated forms of Pex18p are detected in wild-type cells, and there is no Pex18p turnover in a yeast doa4 mutant in which ubiquitin homeostasis is defective. These data represent, to the best of our knowledge, the first instance of an organelle biogenesis factor that is degraded constitutively and rapidly.	CUNY Mt Sinai Sch Med, Dept Cell Biol & Anat, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Purdue, PE (corresponding author), CUNY Mt Sinai Sch Med, Dept Cell Biol & Anat, 1190 5th Ave, New York, NY 10029 USA.				NIDDK NIH HHS [DK 19394] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019394, R37DK019394] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; CRANE DI, 1994, J BIOL CHEM, V269, P21835; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1999, PHILOS T ROY SOC B, V354, P1513, DOI 10.1098/rstb.1999.0495; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Purdue PE, 1998, J CELL BIOL, V143, P1859; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Terlecky SR, 2000, TRAFFIC, V1, P465, DOI 10.1034/j.1600-0854.2000.010604.x; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; THIERINGER R, 1991, MOL CELL BIOL, V11, P510, DOI 10.1128/MCB.11.1.510; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	52	66	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47684	47689		10.1074/jbc.M106823200	http://dx.doi.org/10.1074/jbc.M106823200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590152	hybrid			2022-12-25	WOS:000172768500131
J	Raczniak, G; Becker, HD; Min, B; Soll, D				Raczniak, G; Becker, HD; Min, B; Soll, D			A single amidotransferase forms asparaginyl-tRNA and glutaminyl-tRNA in Chlamydia trachomatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; THERMUS-THERMOPHILUS; PROTEIN-SYNTHESIS; GENOME SEQUENCE; AMINO-ACIDS; L-CELLS; PSITTACI; PURIFICATION; PHOSPHATE; PATHOGEN	Aminoacyl-tRNA is generally formed by aminoacyl-tRNA synthetases, a family of 20 enzymes essential for accurate protein synthesis. However, most bacteria generate one of the two amide aminoacyl-tRNAs, Asn-tRNA or Gln-tRNA, by transamidation of mischarged AsptRNA(Asn) or Glu-tRNA(Gln) catalyzed by a heterotrimeric amidotransferase (encoded by the gatA, gatB, and gatC genes). The Chlamydia trachomatis genome sequence reveals genes for 18 synthetases, whereas those for asparaginyl-tRNA synthetase and glutaminyl-tRNA synthetase are absent. Yet the genome harbors three gat genes in an operon-like arrangement (gatCAB). We reasoned that Chlamydia uses the gatCAB-encoded amidotransferase to generate both Asn-tRNA and Gln-tRNA. C. trachomatis aspartyl-tRNA synthetase and glutamyl-tRNA synthetase were shown to be non-discriminating synthetases that form the misacylated tRNA(Asn) and tRNA(Gln) species. A preparation of pure heterotrimeric recombinant C. trachomatis amidotransferase converted Asp-tRNA(Asn) and Glu-tRNA(Gln) into Asn-tRNA and Gln-tRNA, respectively. The enzyme used glutamine, asparagine, or ammonia as amide donors in the presence of either ATP or GTP. These results suggest that C. trachomatis employs the dual specificity gatCAB-encoded amidotransferase and 18 aminoacyl-tRNA synthetases to create the complete set of 20 aminoacyl-tRNAs.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.			Becker, Hubert/0000-0002-4102-7520				Becker HD, 2000, BIOCHEMISTRY-US, V39, P3216, DOI 10.1021/bi992573y; Becker HD, 2000, FEBS LETT, V476, P140, DOI 10.1016/S0014-5793(00)01697-5; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; Curi R, 1999, BRAZ J MED BIOL RES, V32, P15, DOI 10.1590/S0100-879X1999000100002; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; FRIIS RR, 1972, J BACTERIOL, V110, P706, DOI 10.1128/JB.110.2.706-721.1972; Gagnon Y, 1996, J BIOL CHEM, V271, P14856, DOI 10.1074/jbc.271.25.14856; HATCH TP, 1975, INFECT IMMUN, V12, P211, DOI 10.1128/IAI.12.1.211-220.1975; HATCH TP, 1975, J BACTERIOL, V122, P393, DOI 10.1128/JB.122.2.393-400.1975; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JAHN D, 1990, J BIOL CHEM, V265, P8059; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; PELASCHIER J, 2000, THESIS YALE U; Putz J, 1997, NUCLEIC ACIDS RES, V25, P1862, DOI 10.1093/nar/25.9.1862; Raczniak G, 2001, TOXICOLOGY, V160, P181, DOI 10.1016/S0300-483X(00)00454-6; Raushel FM, 1999, BIOCHEMISTRY-US, V38, P7891, DOI 10.1021/bi990871p; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; Salazar JC, 2001, FEBS LETT, V500, P129, DOI 10.1016/S0014-5793(01)02600-X; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; Scidmore MA, 1996, INFECT IMMUN, V64, P5366, DOI 10.1128/IAI.64.12.5366-5372.1996; SRIVASTAVA DK, 1986, SCIENCE, V234, P1081, DOI 10.1126/science.3775377; STANZEL M, 1994, EUR J BIOCHEM, V219, P435, DOI 10.1111/j.1432-1033.1994.tb19956.x; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	35	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45862	45867		10.1074/jbc.M109494200	http://dx.doi.org/10.1074/jbc.M109494200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585842	hybrid			2022-12-25	WOS:000172573100050
J	Shepard, LW; Yang, M; Xie, P; Browning, DD; Voyno-Yasenetskaya, T; Kozasa, T; Ye, RD				Shepard, LW; Yang, M; Xie, P; Browning, DD; Voyno-Yasenetskaya, T; Kozasa, T; Ye, RD			Constitutive activation of NF-kappa B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus involve G alpha(13) and RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; GENE-EXPRESSION; P115 RHOGEF; GRO-ALPHA; TRANSCRIPTION; CHEMOKINES; KINASE; GTPASES; HUMAN-HERPESVIRUS-8; IDENTIFICATION	The Kaposi's sarcoma herpesvirus (KSHV) open reading frame 74 encodes a G protein-coupled receptor (GPCR) for chemokines. Exogenous expression of this constitutively active GPCR leads to cell transformation and vascular overgrowth characteristic of Kaposi's sarcoma. We show here that expression of KSHV-GPCR in transfected cells results in constitutive transactivation of nuclear factor kappaB (NF-kappaB) and secretion of interleukin-8, and this response involves activation of Gals and RhoA. The induced expression of a NF-kappaB luciferase reporter was partially reduced by pertussis toxin and the G beta gamma scavenger transducin, and enhanced by co-expression of Gals and to a lesser extent, G alpha (q). These results indicate coupling of KSHV-GPCR to multiple G proteins for NF-kappaB activation. Expression of KSHV-GPCR led to stress fiber formation in NIH 3T3 cells. To examine the involvement of the G alpha (13)-RhoA pathway in KSHV-GPCR-mediated NF-kappaB activation, HeLa cells were transfected with KSHV-GPCR alone and in combination with the regulator of G protein signaling (RGS) from p115RhoGEF or a dominant negative RhoA(T19N). Both constructs, as well as the C3 exoenzyme from Clostritium botulinum, partially reduced NF-kappaB activation by KSHV-GPCR, and by a constitutively active G alpha (13)(Q226L). KSHV-GPCR-induced NF-kappaB activation is accompanied by increased secretion of IL-8, a function mimicked by the activated G alpha (13) but not by an activated G alpha (q)(Q209L). These results suggest coupling of KSHV-GPCR to the G alpha (13)-RhoA pathway in addition to other G proteins.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ye, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA.	yer@uic.edu	Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016; voyno-yasenetskaya, tatyana/A-3171-2008	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620	NIAID NIH HHS [AI40176] Funding Source: Medline; NIGMS NIH HHS [GM56159, GM61454] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040176, R56AI040176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM056159, R01GM061454] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Browning DD, 2000, AM J PHYSIOL-LUNG C, V279, pL1129, DOI 10.1152/ajplung.2000.279.6.L1129; Burger M, 1999, J IMMUNOL, V163, P2017; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Devalaraja MN, 1999, CANCER RES, V59, P1372; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hermouet S, 2000, LEUKEMIA LYMPHOMA, V38, P39, DOI 10.3109/10428190009060317; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; Maruyama I, 1997, ANN NY ACAD SCI, V811, P429, DOI 10.1111/j.1749-6632.1997.tb52024.x; Montaner S, 2001, CANCER RES, V61, P2641; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MORII N, 1995, METHOD ENZYMOL, V256, P196; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murdoch C, 2000, BLOOD, V95, P3032; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1137, DOI 10.1006/bbrc.1994.2784; Norgauer J, 1996, J IMMUNOL, V156, P1132; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; SCHINDLER R, 1990, BLOOD, V76, P1631; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Sodhi A, 2000, CANCER RES, V60, P4873; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; VAN AD, 1996, SCIENCE, V274, P787; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Ye RD, 1996, GENE EXPRESSION, V5, P205; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	63	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45979	45987		10.1074/jbc.M104783200	http://dx.doi.org/10.1074/jbc.M104783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590141	hybrid			2022-12-25	WOS:000172573100067
J	Wilstermann, AM; Osheroff, N				Wilstermann, AM; Osheroff, N			Base excision repair intermediates as topoisomerase II poisons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA CLEAVAGE; APURINIC APYRIMIDINIC SITES; ANTICANCER DRUGS; MAMMALIAN-CELLS; TARGETED DRUGS; ABASIC SITES; CHROMOSOMAL-ABERRATIONS; DEOXYRIBONUCLEIC-ACID; SPONTANEOUS MUTATION; ESCHERICHIA-COLI	Abasic sites are the most commonly formed DNA lesions in the cell and are produced by numerous endogenous and environmental insults. In addition, they are generated by the initial step of base excision repair (BER). When located within a topoisomerase II DNA cleavage site, "intact" abasic sites act as topoisomerase II poisons and dramatically stimulate enzyme-mediated DNA scission. However, most abasic sites in cells are not intact. They exist as processed BER intermediates that contain DNA strand breaks proximal to the damaged residue. When strand breaks are located within a topoisomerase II DNA cleavage site, they create suicide substrates that are not religated readily by the enzyme and can generate permanent double-stranded DNA breaks. Consequently, the effects of processed abasic sites on DNA cleavage by human topoisomerase II alpha were examined. Unlike substrates with intact abasic sites, model BER intermediates containing 5'- or 3'-nicked abasic sites or deoxyribosephosphate flaps were suicide substrates. Furthermore, abasic sites flanked by 5'- or 3'-nicks were potent topoisomerase II poisons, enhancing DNA scission similar to 10-fold compared with corresponding nicked oligonucleotides that lacked abasic sites. These findings suggest that topoisomerase II is able to convert processed BER intermediates to permanent double-stranded DNA breaks.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Robinson Res Bldg, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09385] Funding Source: Medline; NIGMS NIH HHS [GM53960] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen A H, 1994, Adv Pharmacol, V29A, P83; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; Bakshi RP, 2001, CRIT REV BIOCHEM MOL, V36, P1, DOI 10.1080/20014091074165; Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; CORBETT AH, 1992, J BIOL CHEM, V267, P683; DARPA P, 1990, CANCER RES, V50, P6919; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; FEIEDBERG EC, DNA REAPIR MUTAGENES, V135, P95; FELIX CA, 1995, CANCER RES, V55, P4287; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; Garvish JF, 1999, J BIOL CHEM, V274, P9786, DOI 10.1074/jbc.274.14.9786; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Holden Joseph A., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P1, DOI 10.2174/1568011013354859; HOLM C, 1989, CANCER RES, V49, P6365; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kohn KW, 1996, BIOESSAYS, V18, P505, DOI 10.1002/bies.950180613; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 1997, BIOCHEM J, V325, P1; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LIU LF, 1983, J BIOL CHEM, V258, P5365; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McCullough AK, 1998, J BIOL CHEM, V273, P13136, DOI 10.1074/jbc.273.21.13136; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nakamura J, 1999, CANCER RES, V59, P2522; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Osheroff N, 1998, BBA-GENE STRUCT EXPR, V1400, P1, DOI 10.1016/S0167-4781(98)00123-7; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Sabourin M, 2000, NUCLEIC ACIDS RES, V28, P1947, DOI 10.1093/nar/28.9.1947; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANDER M, 1983, J BIOL CHEM, V258, P8421; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Wilstermann AM, 2001, J BIOL CHEM, V276, P17727, DOI 10.1074/jbc.M100197200; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	70	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46290	46296		10.1074/jbc.M105733200	http://dx.doi.org/10.1074/jbc.M105733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591703	hybrid			2022-12-25	WOS:000172573100109
J	Calastretti, A; Bevilacqua, A; Ceriani, C; Vigano, S; Zancai, P; Capaccioli, S; Nicolin, A				Calastretti, A; Bevilacqua, A; Ceriani, C; Vigano, S; Zancai, P; Capaccioli, S; Nicolin, A			Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase	ONCOGENE			English	Article						apoptosis; BCL-2; mTOR; microtubules; p27; rapamycin	DOWN-REGULATES BCL-2; MAMMALIAN TARGET; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; MESSENGER-RNA; CELL-CYCLE; APOPTOSIS; RAPAMYCIN; PROTEIN	Rapamycin, a specific inhibitor of the serine/threonine mTOR kinase, markedly inhibited both cell growth and apoptosis in human B-cell lines. Besides arresting cells in G(1) by increasing p27(kip1), rapamycin tripled the cellular level of the BCL-2 protein. The activity was dose-dependent and specific for the p27(kip1) and BCL-2 proteins. Rapamycin did not affect bcl-2 mRNA although it increased cellular BCL-2 concentration by inhibiting phosphorylation, a mechanism initiating the decay process. To add new insight, we combined rapamycin treatment with treatment by taxol, which, by damaging microtubules, can phosphorylate BCL-2 and activate apoptosis. It was found that the mTOR kinase was activated in cells treated with taxol or with nocodazole although it was inhibited in cells pre-treated with rapamycin. BCL-2 phosphorylation, apoptosis and hyperdiploidy were also inhibited by rapamycin. In contrast, taxol-induced microtubule stabilization or metaphase synchronization were not inhibited by rapamycin. Taken together, these findings indicate that mTOR belongs to the enzymatic cascade that, starting from damaged microtubules, phosphorylates BCL-2. By regulating apoptosis, in addition to the control of a multitude of growth-related pathways, mTOR plays a nodal role in signaling G(1) and G(2)-M events.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; Ctr Riferimento Oncol, Div Expt Oncol, I-33081 Aviano, Italy; Univ Florence, Inst Gen Pathol, Florence, Italy	University of Milan; IRCCS Aviano (CRO); University of Florence	Nicolin, A (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	angelo.nicolin@unimi.it	Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424				Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AIELLO A, 1992, CYTOMETRY, V13, P502, DOI 10.1002/cyto.990130509; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Capaccioli S, 1996, ONCOGENE, V13, P105; Chadebech P, 1999, BIOCHEM BIOPH RES CO, V262, P823, DOI 10.1006/bbrc.1999.1291; Choi JH, 2000, CURR BIOL, V10, P861, DOI 10.1016/S0960-9822(00)00599-6; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; DYER MJS, 1990, BLOOD, V75, P709; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Itano Y, 1996, J NEUROCHEM, V67, P131; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Kitamura Y, 1997, JPN J PHARMACOL, V75, P195, DOI 10.1254/jjp.75.195; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; Koff A, 1995, Prog Cell Cycle Res, V1, P141; Konig A, 1997, BLOOD, V90, P4307; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; Metcalfe SM, 1997, ONCOGENE, V15, P1635, DOI 10.1038/sj.onc.1201341; Migita K, 1997, CLIN EXP IMMUNOL, V108, P199, DOI 10.1046/j.1365-2249.1997.d01-1002.x; Morelli S, 1997, P NATL ACAD SCI USA, V94, P8150, DOI 10.1073/pnas.94.15.8150; Morelli S, 1996, ANTI-CANCER DRUG DES, V11, P1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pratesi G, 2000, BIOCHEM PHARMACOL, V60, P77, DOI 10.1016/S0006-2952(00)00300-2; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Saille C, 1999, NEUROSCIENCE, V92, P1455, DOI 10.1016/S0306-4522(99)00089-5; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; Siegel DS, 1998, P NATL ACAD SCI USA, V95, P162, DOI 10.1073/pnas.95.1.162; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STEUBE KG, 1995, LEUKEMIA, V9, P1841; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TERADA N, 1995, J IMMUNOL, V155, P3418; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	62	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6172	6180		10.1038/sj.onc.1204751	http://dx.doi.org/10.1038/sj.onc.1204751			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593425	Green Published			2022-12-25	WOS:000171206300008
J	Gozuacik, D; Murakami, Y; Saigo, K; Chami, M; Mugnier, C; Lagorce, D; Okanoue, T; Urashima, T; Brechot, C; Paterlini-Brechot, P				Gozuacik, D; Murakami, Y; Saigo, K; Chami, M; Mugnier, C; Lagorce, D; Okanoue, T; Urashima, T; Brechot, C; Paterlini-Brechot, P			Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging	ONCOGENE			English	Article						hepatitis B virus; Alu-PCR; gene trap; cancer; insertional mutagenesis; hepatocellular carcinoma	HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; CELLS; INTEGRATION; GENOME; MUTAGENESIS; REPLICATION; IDENTIFY; PROTEINS; LEUKEMIA	Proviral tagging has been used in animals as a powerful tool for cancer genetics. We show that a similar approach is possible in patients with hepatocellular carcinoma (HCC) infected by Hepatitis B Virus (HBV), a human pararetrovirus which may act by insertional mutagenesis. In this work, the HBV genome is used as a probe to identify cancer-related genes. By using HBV-Alu-PCR, we obtained 21 HBV/cellular DNA junctions from 18 different patients. In six of 21, we found the HBV DNA integrated into a cellular gene: (1) Sarco/Endoplasmic Reticulum Calcium ATPase1 Gene; (2) Thyroid Hormone Receptor Associated Protein 150 alpha Gene; (3) Human Telomerase Reverse Transcriptase Gene; (4) Minichromosome Maintenance Protein (MCM)-Related Gene; (5) FR7, a new gene expressed in human liver and cancer tissues; and (6) Nuclear Matrix Protein p84 Gene. Seven junctions contained unique cellular sequences. In the remaining eight, the HBV DNA was next to repetitive sequences, five of them of LINE1 type. The cellular genes targeted by HBV are key regulators of cell proliferation and viability. Our results show that studies on HBV-related HCCs allow to identify cellular genes involved in cancer. We therefore propose this approach as a valuable tool for functional cancer genomic studies in humans.	Necker Inst, INSERM, U370, F-75015 Paris, France; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6020841, Japan; Chiba Univ, Dept Surg 2, Chiba 2638852, Japan; Necker Enfants Malad Hosp, Dept Biotech & Med Informat, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Kyoto Prefectural University of Medicine; Chiba University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Paterlini-Brechot, P (corresponding author), Necker Inst, INSERM, U370, F-75015 Paris, France.		Devrim, Gozuacik/C-3330-2008; Chami, Mounia/S-6471-2019	Devrim, Gozuacik/0000-0001-7739-2346; Chami, Mounia/0000-0003-1498-7187; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; Cecconi F, 2000, FEBS LETT, V480, P63, DOI 10.1016/S0014-5793(00)01779-8; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; CHISARI FV, 1995, HEPATOLOGY, V22, P1316, DOI 10.1016/0270-9139(95)90645-2; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Evans MJ, 1997, TRENDS GENET, V13, P370, DOI 10.1016/S0168-9525(97)01240-7; Fourel G, 1994, PRIMARY LIVER CANC E, P89; Freeman A, 1999, CLIN CANCER RES, V5, P2121; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JOHNSON PJ, 1994, PRIMARY LIVER CANC E, P31; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Largaespada DA, 2000, LEUKEMIA, V14, P1174, DOI 10.1038/sj.leu.2401852; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Musahl C, 1998, EXP CELL RES, V241, P260, DOI 10.1006/excr.1998.4041; ROBINSON WS, 1987, HEPATOLOGY, V7, pS64, DOI 10.1002/hep.1840070712; SCHLUTER V, 1994, ONCOGENE, V9, P1; Todovov IT, 1998, LAB INVEST, V78, P73; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0	32	88	95	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6233	6240		10.1038/sj.onc.1204835	http://dx.doi.org/10.1038/sj.onc.1204835			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593432				2022-12-25	WOS:000171206300015
J	Wadle, A; Thiel, G; Mischo, A; Jung, V; Pfreundschuh, M; Renner, C				Wadle, A; Thiel, G; Mischo, A; Jung, V; Pfreundschuh, M; Renner, C			Chromosomal localization and promoter analysis of the adenomatous polyposis coli binding protein RP1	ONCOGENE			English	Article						adenomatous polyposis coli tumour-suppressor; protein; tubulin binding proteins; RP1 protein; chromosomal localization; T-cell signalling	CAMP RESPONSE ELEMENT; APC GENE-PRODUCT; BETA-CATENIN; CYCLIN D1; YEAST; IDENTIFICATION; CANCER; CELLS; MICROTUBULES; EXPRESSION	characterized by the ability of its members to serve as interacting partners for the adenomatous polyposis coli (ADC) tumour suppressor protein and tubulin. Data obtained with highly conserved yeast homologues suggest that the EB1/RP1 protein family promotes cytoplasmic microtubule dynamics and contributes to the sensor mechanism controlling the cytokinesis checkpoint during mitosis. However, the precise function of this protein family in mammalian cells has not been elucidated so far and remains unclear. Here, we report on the genomic localization of the RP1 gene and the characterization of the corresponding promoter. The RP1 gene was found to be encoded on chromosome 18q21, a locus which is altered or deleted in up to 50% of all patients with colorectal cancer. Promoter analysis revealed that the RP1 gene is under the control of a strong promoter that was 10 times more active in mammalian cells when compared to SV40 promoter. Members of the cyclic AMP response element binding protein family (CREB1 and CREB2) could be identified as transcription factors binding specifically within the RP1 promoter sequence.	Univ Saarland, Sch Med, Dept Med 1, D-66421 Homburg, Germany; Univ Saarland, Sch Med, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Inst Human Genet, D-66421 Homburg, Germany	Saarland University; Saarland University; Saarland University	Renner, C (corresponding author), Univ Saarland, Sch Med, Dept Med 1, D-66421 Homburg, Germany.							Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Cibelli G, 1999, EUR J CELL BIOL, V78, P642, DOI 10.1016/S0171-9335(99)80049-1; Cibelli G, 1996, EUR J BIOCHEM, V236, P171, DOI 10.1111/j.1432-1033.1996.00171.x; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hsueh YP, 1997, J IMMUNOL, V158, P85; Jernvall P, 1999, BRIT J CANCER, V79, P903, DOI 10.1038/sj.bjc.6690144; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Ogunbiyi OA, 1998, J CLIN ONCOL, V16, P427, DOI 10.1200/JCO.1998.16.2.427; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Renner C, 1997, J IMMUNOL, V159, P1276; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sambrook J., 1989, MOL CLONING LAB MANU; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tarafa G, 2000, ONCOGENE, V19, P546, DOI 10.1038/sj.onc.1203353; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thiel G, 1996, GENE, V168, P173, DOI 10.1016/0378-1119(95)00739-3; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; VANDERVELDE G, 1994, WATER SCI TECHNOL, V29, P1; Zhang YM, 1998, HUM GENET, V103, P727	33	4	4	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5920	5929		10.1038/sj.onc.1204797	http://dx.doi.org/10.1038/sj.onc.1204797			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593399				2022-12-25	WOS:000171037200017
J	Chairoungdua, A; Kanai, Y; Matsuo, H; Inatomi, J; Kim, DK; Endou, H				Chairoungdua, A; Kanai, Y; Matsuo, H; Inatomi, J; Kim, DK; Endou, H			Identification and characterization of a novel member of the heterodimeric amino acid transporter family presumed to be associated with an unknown heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; MONOCLONAL-ANTIBODY 4F2; RED-BLOOD-CELLS; FUNCTIONAL-CHARACTERIZATION; SUBSTRATE SELECTIVITY; EXPRESSION CLONING; MOLECULAR-BIOLOGY; MEMBRANE-PROTEIN; SYSTEM ASC; GLYCOPROTEIN	We identified a novel amino acid transporter designated Asc-2 (for ase-type amino acid transporter 2). Asc-2 exhibited relatively low but significant sequence similarity to the members of the heterodimeric amino acid transporters. The cysteine residue responsible for the disulfide bond formation between transporters (light chains) and heavy chain subunits in the heterodimeric amino acid transporters is conserved for Asc-2. Asc-2 is, however, not colocalized with the already known heavy chains such as 4F2 heavy chain (4F2hc) or related to b(o,+) amino acid transporter (rBAT) in mouse kidney. Because Ase-2 solely expressed or coexpressed with 4F2hc or rBAT did not induce functional activity, we generated fusion proteins in which Asc-2 is connected with 4F2hc or rBAT. The fusion proteins were sorted to the plasma membrane and expressed the function corresponding to the Na'-independent small neutral amino acid transport system asc. Distinct from the already identified system asc transporter Ase-1 which is associated with 4F2hc, Ase-2-mediated transport is less stereoselective and did not accept some of the high affinity substrates of Asc-1 such as alpha-aminoisobutyric acid and beta-alanine. Ase-2 message was detected in kidney, placenta, spleen, lung, and skeletal muscle. In kidney, Asc-2 protein was present in the epithelial cells lining collecting ducts. In the Western blot analysis on mouse erythrocytes and kidney, Ase-2 was detected as multiple bands in the nonreducing condition, whereas the bands shifted to a single band at lower molecular weight, suggesting the association of Asc-2 with other protein(s) via a disulfide bond. The finding of Ase-2 would lead to the establishment of a new subgroup of heterodimeric amino acid transporter family which includes transporters associated not with 4F2hc or rBAT but with other unknown heavy chains.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Natl Def Med Coll, Dept Physiol 1, Tokorozawa, Saitama 3598513, Japan; Japan Sci & Technol Corp, PRESTO, Mitaka, Tokyo 1818611, Japan	Kyorin University; National Defense Medical College - Japan; Japan Science & Technology Agency (JST)	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.			Matsuo, Hirotaka/0000-0003-4302-8719				ALBI JL, 1994, J MEMBRANE BIOL, V140, P189; ALTMAN A, 1984, P NATL ACAD SCI-BIOL, V81, P2176, DOI 10.1073/pnas.81.7.2176; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; BURG MB, 1995, AM J PHYSIOL, V268, P983; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; FINCHAM DA, 1990, J EXP BIOL, V154, P355; FINCHAM DA, 1985, BIOCHEM J, V227, P13, DOI 10.1042/bj2270013; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; GALLARDO MA, 1993, J MEMBRANE BIOL, V134, P251; HARA H, 1976, AM J HEMATOL, V1, P453, DOI 10.1002/ajh.2830010410; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HEMLER ME, 1982, J IMMUNOL, V129, P623; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; JANS AWH, 1988, BIOCHIM BIOPHYS ACTA, V971, P157, DOI 10.1016/0167-4889(88)90187-5; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2000, J BIOL CHEM, V275, P20787, DOI 10.1074/jbc.M000634200; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1994, J BIOL CHEM, V269, P20599; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kim JY, 2001, BBA-BIOMEMBRANES, V1512, P335, DOI 10.1016/S0005-2736(01)00338-8; KUHLMANN MK, 1991, J BIOL CHEM, V266, P15042; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAW RO, 1991, COMP BIOCHEM PHYS A, V99, P263, DOI 10.1016/0300-9629(91)90001-S; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Matsuo H, 2000, NEUROREPORT, V11, P3507, DOI 10.1097/00001756-200011090-00021; Mizoguchi K, 2001, KIDNEY INT, V59, P1821, DOI 10.1046/j.1523-1755.2001.0590051821.x; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Nakauchi J, 2000, NEUROSCI LETT, V287, P231, DOI 10.1016/S0304-3940(00)01169-1; NORMAN PSR, 1987, J MEMBRANE BIOL, V96, P153, DOI 10.1007/BF01869241; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Segawa H, 1997, BIOCHEM J, V328, P657, DOI 10.1042/bj3280657; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VADGAMA JV, 1985, J BIOL CHEM, V260, P2912; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200	58	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49390	49399		10.1074/jbc.M107517200	http://dx.doi.org/10.1074/jbc.M107517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11591708	hybrid			2022-12-25	WOS:000173922100100
J	Key, TA; Bennett, TA; Foutz, TD; Gurevich, VV; Sklar, LA; Prossnitz, ER				Key, TA; Bennett, TA; Foutz, TD; Gurevich, VV; Sklar, LA; Prossnitz, ER			Regulation of formyl peptide receptor agonist affinity by reconstitution with arrestins and heterotrimeric G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REAL-TIME ANALYSIS; COUPLED RECEPTORS; 48-KDA PROTEIN; BETA-ARRESTIN; CRYSTAL-STRUCTURE; RHODOPSIN; ACTIVATION; BINDING; INTERNALIZATION; LIGAND	Although heptahelical chemoattractant and chemokine receptors are known to play a significant role in the host immune response and the pathophysiology of disease, the molecular mechanisms and transient macroassemblies underlying their activation and regulation remain largely uncharacterized. We report herein real time analyses of molecular assemblies involving the formyl peptide receptor (FPR), a well described member of the chemoattractant subfamily of G protein-coupled receptors (GPCRs), with both arrestins and heterotrimeric G proteins. In our system, the ability to define and discriminate distinct, in vitro receptor complexes relies on quantitative differences in the dissociation rate of a fluorescent agonist as well as the guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) sensitivity of the complex, as recently described for FPR-G protein interactions. In the current study, we demonstrate a concentration-and time-dependent reconstitution of liganded, phosphorylated FPR with exogenous arrestin-2 and -3 to form a high agonist affinity, nucleotide-insensitive complex with EC50 values of 0.5 and 0.9 muM, respectively. In contrast, neither arrestin-2 nor arrestin-3 altered the ligand dissociation kinetics of activated, nonphosphorylated FPR. Moreover, we demonstrated that the addition of G proteins was unable to alter the ligand dissociation kinetics or induce a GTPgammaS-sensitive state of the phosphorylated FPR. The properties of the phosphorylated FPR were entirely reversible upon treatment of the receptor preparation with phosphatase. These results represent to our knowledge the first report of the reconstitution of a detergent-solubilized, phosphorylated GPCR with arrestins and, furthermore, the first demonstration that phosphorylation of a nonvisual GPCR is capable of efficiently blocking G protein binding in the absence of arrestin. The significance of these results with respect to receptor desensitization and internalization are discussed.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85351 USA; Univ Calif Los Alamos Natl Labs, Natl Flow Cytometry Resource, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; Banner Research; Banner Health; Banner Sun Health Research Institute; United States Department of Energy (DOE); Los Alamos National Laboratory	Prossnitz, ER (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.		Prossnitz, Eric R./B-4543-2008; Gurevich, Vsevolod/A-3236-2008; Prossnitz, Eric/I-4599-2019	Gurevich, Vsevolod/0000-0002-3950-5351; Prossnitz, Eric/0000-0001-9190-8302	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI049392, R29AI036357, R01AI036357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM060799, R01GM063097] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01315] Funding Source: Medline; NEI NIH HHS [EY11500] Funding Source: Medline; NIAID NIH HHS [AI36357, AI49392] Funding Source: Medline; NIGMS NIH HHS [GM60799, GM63097] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bennett TA, 2001, J BIOL CHEM, V276, P22453, DOI 10.1074/jbc.M009679200; DE LA, 1980, J BIOL CHEM, V5255, P7108; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GUDERMANN T, 1995, J MOL MED, V73, P61; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nolan John P., 1998, P19; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Rane MJ, 1998, J BIOL CHEM, V273, P20916, DOI 10.1074/jbc.273.33.20916; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; Sklar LA, 2000, BIOTECHNIQUES, V28, P976, DOI 10.2144/00285rr03; SKLAR LA, 1989, J BIOL CHEM, V264, P8483; SKLAR LA, 1987, J BIOL CHEM, V262, P135; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	45	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49204	49212		10.1074/jbc.M109475200	http://dx.doi.org/10.1074/jbc.M109475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598142	hybrid			2022-12-25	WOS:000173922100077
J	Wang, W; Wu, JF; Zhang, ZY; Tong, TJ				Wang, W; Wu, JF; Zhang, ZY; Tong, TJ			Characterization of regulatory elements on the promoter region of p16(INK4a) that contribute to overexpression of p16 in senescent fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER DNA RECOGNITION; TRANSCRIPTION FACTORS; CELL-CYCLE; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; LIFE-SPAN; EXPRESSION; GENE; SP3	Cyclin-dependent kinase inhibitor p16(INK4a) is implicated in replicative senescence, cell immortalization, and tumor generation. However, the mechanism regulating its overexpression in senescent cells is unknown. We used the enhanced green fluorescent protein reporter system to scan regulatory elements in the upstream region of p16(INKa). The results of 5'-deletion studies indicated that the transcription regulatory elements contributing to overexpression of p16(INK4a) in senescent cells were located in the region of the p16(INK4a), promoter from -622 to -280 bp. According to the results of in vitro DNase I footprinting, EMSA, and Southwestern blotting, we found a novel negative regulatory element, the INK4a transcription silence element (ITSE), at -491 to -485 bp of the p16(INK4a), promoter. A 24-kDa protein that was highly expressed in young cells may inhibit the expression of p16(INK4a) by interacting with the ITSE. The activity of the p16(INK4a), promoter increased significantly in young cells when the ITSE was deleted. The GC-rich region of the p16(INK4a) promoter from -466 to -451 was a positive transcription regulatory element. Deletion of this region showed 91.4% loss of p16(INK4a) promoter activity in senescent cells, and the promoter activity decreased by 41.2% in young cells comparably.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University	Zhang, ZY (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100083, Peoples R China.							Adrian GS, 1996, J GERONTOL A-BIOL, V51, pB66, DOI 10.1093/gerona/51A.1.B66; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; CHEN PL, 2001, CHIN J GERIATR, V20, P44; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Fukami-Kobayashi J, 1998, EXP CELL RES, V241, P435, DOI 10.1006/excr.1998.4079; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Huschtscha LI, 1999, CARCINOGENESIS, V20, P921, DOI 10.1093/carcin/20.6.921; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; Jarrard DF, 1999, CANCER RES, V59, P2957; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LIU PH, 2001, CHIN J GERIATR, V20, P128; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Nielsen GP, 1999, LAB INVEST, V79, P1137; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Schnell T, 2000, HUM GENE THER, V11, P439, DOI 10.1089/10430340050015905; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yeager TR, 1999, CURR OPIN BIOTECH, V10, P465, DOI 10.1016/S0958-1669(99)00011-7; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	38	48	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48655	48661		10.1074/jbc.M108278200	http://dx.doi.org/10.1074/jbc.M108278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598130	hybrid			2022-12-25	WOS:000173922100008
J	Bruzzone, S; Franco, L; Guida, L; Zocchi, E; Contini, P; Bisso, A; Usai, C; De Flora, A				Bruzzone, S; Franco, L; Guida, L; Zocchi, E; Contini, P; Bisso, A; Usai, C; De Flora, A			A self-restricted CD38-connexin 43 cross-talk affects NAD(+) and cyclic ADP-ribose metabolism and regulates intracellular calcium in 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSMEMBRANE GLYCOPROTEIN CD38; GAP-JUNCTIONS; NAD(+); SURFACE; ACID; MITOCHONDRIAL; HYDROLYSIS; EXPRESSION; PHOSPHORYLATION	Connexin 43 (Cx43) hexameric hemichannels, recently demonstrated to mediate NAD(+) transport, functionally interact in the plasma membrane of several cells with the ectoenzyme CD38 that converts NAD(+) to the universal calcium mobilizer cyclic ADP-ribose (cADPR). Here we demonstrate that functional uncoupling between CD38 and Cx43 in CD38-transfected 3T3 murine fibroblasts is paralleled by decreased [Ca2+](i) levels as a result of reduced intracellular conversion of NAD(+) to cADPR. A sharp inverse correlation emerged between [Ca2+](i) levels and NAD(+) transport (measured as influx into cells and as efflux therefrom), both in the CD38(+) cells (high [Ca2+](i), low transport) and in the CD38(-) fibroblasts ow [Ca2+](i), high transport). These differences were correlated with distinctive extents of Cx43 phosphorylation in the two cell populations, a lower phosphorylation with high NAD(+) transport (CD38- cells) and vice versa (CD38(+) cells). Conversion of NAD(+)-permeable Cx43 to the phosphorylated, NAD(+)-impermeable form occurs via Ca2+-stimulated protein kinase C (PKC). Thus, a self-regulatory loop emerged in CD38(+) fibroblasts whereby high [Ca2+](i) restricts further Ca2+ mobilization by cADPR via PKC-mediated disruption of the Cx43-CD38 cross-talk. This mechanism may avoid: (i) leakage of NAD(+) from cells; (ii) depletion of intracellular NAD(+) by CD38; (iii) overproduction of intracellular cADPR resulting in potentially cytotoxic [Ca2+](i).	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; G Gaslini Inst Children, Genoa, Italy; Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy; CNR, Inst Cybernet & Biophys, Genoa, Italy	University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR)	De Flora, A (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV 1, I-16132 Genoa, Italy.	toninodf@unige.it	Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716; Usai, Cesare/0000-0001-8863-7759				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; ADEBANJO OA, 1996, AM J PHYSIOL, V207, pF469; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Bruzzone S, 2001, FASEB J, V15, P10; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora A, 2000, CHEM IMMUNOL, V75, P79; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Franco L, 2001, AM J PHYSIOL-LUNG C, V280, pL98; Franco L, 1998, FASEB J, V12, P1507; HERTZBERG EL, 1987, METHOD ENZYMOL, V139, P445; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KONTANI K, 1993, J BIOL CHEM, V268, P16895; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Mehta K, 2000, HUMAN CD38 RELATED M; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; NAKANISHI S, 1986, J ANTIBIOT, V39, P1066; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; PERACCHIA C, 1994, HDB MEMBRANE CHANNEL, P361; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; REYNHOUT JK, 1992, EXP CELL RES, V198, P337, DOI 10.1016/0014-4827(92)90388-O; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Ziegler M, 1997, BIOCHEM J, V326, P401, DOI 10.1042/bj3260401; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; Zocchi E, 2001, FASEB J, V15, P1610, DOI 10.1096/fj.00-0803fje	50	91	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48300	48308		10.1074/jbc.M107308200	http://dx.doi.org/10.1074/jbc.M107308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602597	hybrid			2022-12-25	WOS:000172927000076
J	Didichenko, SA; Thelen, M				Didichenko, SA; Thelen, M			Phosphatidylinositol 3-kinase C2 alpha contains a nuclear localization sequence and associates with nuclear speckles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II PHOSPHOINOSITIDE 3-KINASE; NUCLEOLAR LOCALIZATION; C2 DOMAIN; SPLICING FACTORS; ALPHA-ISOFORM; PROTEIN; KINASE; BINDING; LIVER; COLOCALIZATION	Phosphoinositide 3-kinase C2 alpha (PI3K-C2 alpha) belongs to the class II phosphatidylinositol 3-kinases, which are defined by their in vitro usage of phosphatidylinositol and phosphatidylinositol 4-phosphate as substrates. All type II phosphatidylinositol 3-kinases contain at their C terminus a C2-like domain. Here we demonstrate that Homo sapiens phosphoinositide 3-kinase C2 alpha (HsPI3K-C2 alpha) has dual cellular localization present in the cytoplasm and in the nucleus. A distinct nuclear localization signal sequence was identified by expressing HsPI3K-C2 alpha -green fluorescent protein fusion proteins in HeLa cells. The nuclear localization signal was mapped to a stretch of 11 amino acids (KRKTKISRKTR) located within C2-like domain of the kinase. In the cytoplasm and the nucleus HsPI3K-C2 alpha associates with macromolecular complexes that are resistant to detergent extraction. Indirect immunofluorescence reveals that in the nucleus HsPI3K-C2 alpha is enriched at distinct subnuclear domains known as nuclear speckles, which contain pre-mRNA processing factors and are functionally connected to RNA metabolism. Phosphorylation of HsPI3K-C2 alpha is induced by inhibition of RNA polymerase II-dependent transcription and coincides with enlargement and rounding up of the nuclear speckles. The results suggest that phosphorylation of HsPI3K-C2 alpha is inversely linked to mRNA transcription and supports the importance of phosphoinositides for nuclear activity.	Biomed Res Inst, CH-6500 Bellinzona, Switzerland	Universita della Svizzera Italiana	Didichenko, SA (corresponding author), Biomed Res Inst, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland.	marcus.thelen@irb.unisi.ch						Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; BISOTTO S, 1995, J CELL SCI, V108, P1873; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DANG CV, 1989, J BIOL CHEM, V264, P18019; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Gross SD, 1999, J CELL SCI, V112, P2647; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HEINZE H, 1988, J BIOL CHEM, V263, P4139; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Misawa H, 1998, BIOCHEM BIOPH RES CO, V244, P531, DOI 10.1006/bbrc.1998.8294; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Quaye IKE, 1996, EUR J CELL BIOL, V69, P151; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SINCLAIR GD, 1978, EXP CELL RES, V111, P1, DOI 10.1016/0014-4827(78)90230-6; Sindic A, 2001, J BIOL CHEM, V276, P17754, DOI 10.1074/jbc.M006533200; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Spector DL, 1993, CURR OPIN CELL BIOL, V5, P442, DOI 10.1016/0955-0674(93)90009-F; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yu HY, 1998, EUR J BIOCHEM, V251, P281, DOI 10.1046/j.1432-1327.1998.2510281.x; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zini N, 1996, HISTOCHEM CELL BIOL, V106, P457, DOI 10.1007/BF02473307	52	82	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48135	48142		10.1074/jbc.M104610200	http://dx.doi.org/10.1074/jbc.M104610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606566	hybrid			2022-12-25	WOS:000172927000054
J	O'Connor, KL; Mercurio, AM				O'Connor, KL; Mercurio, AM			Protein kinase A regulates Rac and is required for the growth factor-stimulated migration of carcinoma cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-6-BETA-4 INTEGRIN; CYCLIC-AMP; CHEMOTACTIC MIGRATION; ACTIN CYTOSKELETON; LAMELLAE FORMATION; RHO-GTPASES; ACTIVATION; ADHESION; INVASION; PHOSPHORYLATION	Members of the Rho family of small GTPases, such as Rho and Rac, are required for actin cytoskeletal reorganization during the migration of carcinoma cells. Phosphodiesterases are necessary for this migration because they alleviate cAMP-dependent protein kinase (PKA)mediated inhibition of RhoA (O'Connor, K. L., Shaw, L. M., and Mercurio, A. M. (1998) J. Cell Biol. 143, 1749-1760; O'Connor K. L., Nguyen, B.-K., and Mercurio, A. M. (2000), J. Cell Biol. 148, 253-258). In this study, we report that the migration of breast and squamous carcinoma cells toward either lysophosphatidic acid or epidermal growth factor involves not only phosphodiesterase activity but also cooperative signaling from PKA. Furthermore, we demonstrate that Rac1 activation in response to chemoattractant or beta (1) integrin clustering is regulated by PKA and that Rac1 is required for this migration. Also, we find that beta (1) integrin signaling stimulates the rapid and transient activation of PKA. A novel implication of these findings is that carcinoma cell migration is controlled by cAMP-dependent as well as cAMP inhibitory signaling mechanisms.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mercurio, AM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, 99 Broookline Ave, Boston, MA 02215 USA.	amercuzi@caregroup.harvard.edu	O'Connor, Kathleen L/H-2569-2013	O'Connor, Kathleen L/0000-0002-1088-9734	NCI NIH HHS [CA80789] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080789] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chung CY, 2000, P NATL ACAD SCI USA, V97, P5225, DOI 10.1073/pnas.97.10.5225; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kusama T, 2001, CANCER RES, V61, P4885; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Whittard JD, 2001, J CELL SCI, V114, P3265	39	121	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47895	47900		10.1074/jbc.M107235200	http://dx.doi.org/10.1074/jbc.M107235200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606581	hybrid			2022-12-25	WOS:000172927000024
J	Thuerauf, DJ; Hoover, H; Meller, J; Hernandez, J; Su, L; Andrews, C; Dillmann, WH; McDonough, PM; Glembotski, CC				Thuerauf, DJ; Hoover, H; Meller, J; Hernandez, J; Su, L; Andrews, C; Dillmann, WH; McDonough, PM; Glembotski, CC			Sarco/endoplasmic reticulum calcium ATPase-2 expression is regulated by ATF6 during the endoplasmic reticulum stress response - Intracellular signaling of calcium stress in a cardiac myocyte model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TRANSCRIPTIONAL INDUCTION; TRANSMEMBRANE PROTEIN; GENE-EXPRESSION; CELL-GROWTH; NF-Y; ELEMENT; GLUCOSE; CA2+; ER	The recently described transcription factor, ATF6, mediates the expression of proteins that compensate for potentially stressful changes in the endoplasmic reticulum (ER), such as reduced ER calcium. In cardiac myo. cytes the maintenance of optimal calcium levels in the sarcoplasmic reticulum (SR), a specialized form of the ER, is required for proper contractility. The present study investigated the hypothesis that ATF6 serves as a regulator of the expression of sarco/endoplasmic reticulum calcium ATPase-2 (SERCA2), a protein that transports calcium into the SR from the cytoplasm. Depletion of SR calcium in cultured cardiac myocytes fostered the translocation of ATF6 from the ER to the nucleus, activated the promoter for rat SERCA2, and led to increased levels of SERCA2 protein. SERCA2 promoter induction by calcium depletion was partially blocked by dominant-negative ATF6, whereas constitutively activated ATF6 led to SERCA2 promoter activation. Mutation analyses identified a promoter-proximal ER stress-response element in the rat SERCA2 gene that was required for maximal induction by ATF6 and calcium depletion. Although this element was shown to be responsible for all of the effects of ATF6 on SERCA2 promoter activation, it was responsible for only a portion of the effects of calcium depletion. Thus, SERCA2 induction in response to calcium depletion appears to be a potentially physiologically important compensatory response to this stress that involves intracellular signaling pathways that are both dependent and independent of ATF6.	San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, Inst Heart, San Diego, CA 92182 USA.	cglembotski@sciences.sdsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL056861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56861, HL-46345] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; CHEEK TR, 1993, J EXP BIOL, V184, P183; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730; Ho PD, 2001, CIRC RES, V88, P63, DOI 10.1161/01.RES.88.1.63; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kimura H, 1998, CELL SIGNAL, V10, P349, DOI 10.1016/S0898-6568(97)00134-4; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lamb GD, 2000, CLIN EXP PHARMACOL P, V27, P216, DOI 10.1046/j.1440-1681.2000.03224.x; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; Misquitta CM, 1999, CELL CALCIUM, V25, P277, DOI 10.1054/ceca.1999.0032; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Periasamy M, 2001, CIRC RES, V88, P373; Pieske B, 1999, CIRC RES, V85, P38; PROTSKO CR, 1995, J BIOL CHEM, V270, P6211; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Samuel CE, 1997, INT J HEMATOL, V65, P227; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tse FT, 1999, BIOESSAYS, V21, P861, DOI 10.1002/(SICI)1521-1878(199910)21:10<861::AID-BIES8>3.0.CO;2-9; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Heugten HAA, 1998, CARDIOVASC RES, V37, P503, DOI 10.1016/S0008-6363(97)00254-X; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	46	79	81	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48309	48317		10.1074/jbc.M107146200	http://dx.doi.org/10.1074/jbc.M107146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11595740	hybrid			2022-12-25	WOS:000172927000077
J	Brooks, DR; Denise, H; Westrop, GD; Coombs, GH; Mottram, JC				Brooks, DR; Denise, H; Westrop, GD; Coombs, GH; Mottram, JC			The stage-regulated expression of Leishmania mexicana CPB cysteine proteases is mediated by an intercistronic sequence element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRYPANOSOMA-BRUCEI; 3'-UNTRANSLATED REGION; CHAGASI PROMASTIGOTES; GENOMIC ORGANIZATION; GENE FAMILY; SURFACE GLYCOPROTEIN; INFECTIOUS FORM; PROTEINASE; GP63	The tandemly arranged CPB genes of Leishmania mexicana are polycistronically transcribed and encode cysteine proteases that are differentially stage-specific; CPB1 and CPB2 are expressed predominantly in meta-cyclics, whereas CPB3-CPB18 are expressed mainly in amastigotes. The mechanisms responsible for this differential expression have been studied via gene analysis and re-integration of individual CPB genes, and variants thereof, into a CPB-deficient parasite mutant. Comparison of the nucleotide sequences of the repeat units of CPB1 and CPB2 with CPB2.8 (typical of CPB3-CPB18) revealed two major regions of divergence as follows: one of 258 base pairs (bp) corresponding to the C-terminal extension of CPB2.8; another, designated InS, of 120 bp, with insertions totaling 57 bp, localized to the intercistronic region downstream of CPB1 and CPB2. Cell lines expressing CPB2.8 or CPB2 with the W-untranslated region and intercistronic sequence of CPB2.8 showed upregulation in amastigotes. Conversely, metacyclic-specific expression occurred with CPB2 or CPB2.8 with the W-untranslated region and intercistronic sequence of CPB2. Moreover, the InS down-regulated expression in amastigotes of a reporter gene integrated into the CPB locus. It is proposed that the InS mediates metacyclic-specific stage-regulated expression of CPB by affecting the maturation of polycistronic pre-mRNA, This is the first well defined cis-regulatory element implicated in post-transcriptional stage-specific gene expression in Leishmania.	Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	Mottram, JC (corresponding author), Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.			Denise, Hubert/0000-0001-9862-5890; Westrop, Gareth/0000-0002-8011-6219; Mottram, Jeremy/0000-0001-5574-3766				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Bai CY, 1998, NUCLEIC ACIDS RES, V26, P1597, DOI 10.1093/nar/26.7.1597; Bates EJ, 2000, NUCLEIC ACIDS RES, V28, P1211, DOI 10.1093/nar/28.5.1211; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Brittingham A, 2001, MOL BIOCHEM PARASIT, V112, P51, DOI 10.1016/S0166-6851(00)00346-7; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; D'Orso I, 2001, J BIOL CHEM, V276, P34801, DOI 10.1074/jbc.M102120200; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Drozdz M, 1999, RNA, V5, P1632, DOI 10.1017/S1355838299990623; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; FONG D, 1981, P NATL ACAD SCI-BIOL, V78, P7624, DOI 10.1073/pnas.78.12.7624; Frame MJ, 2000, PARASITOLOGY, V121, P367, DOI 10.1017/S0031182099006435; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Hotz HR, 1995, MOL BIOCHEM PARASIT, V75, P1, DOI 10.1016/0166-6851(95)02503-0; Huang T, 2001, MOL CELL BIOL, V21, P1111, DOI 10.1128/MCB.21.4.1111-1120.2001; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; Ivens AC, 1998, GENOME RES, V8, P135, DOI 10.1101/gr.8.2.135; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Kelly BL, 2001, MOL BIOCHEM PARASIT, V116, P101, DOI 10.1016/S0166-6851(01)00307-3; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Liu YM, 2001, RNA, V7, P176, DOI 10.1017/S1355838201002333; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; McCoy JJ, 1998, MOL BIOCHEM PARASIT, V95, P251, DOI 10.1016/S0166-6851(98)00112-1; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Misslitz A, 2000, MOL BIOCHEM PARASIT, V107, P251, DOI 10.1016/S0166-6851(00)00195-X; Molyneux D. H., 1997, Trypanosomiasis and leishmaniasis: biology and control., P39; Mottram JC, 1998, CURR OPIN MICROBIOL, V1, P455, DOI 10.1016/S1369-5274(98)80065-9; Mottram JC, 1997, J BIOL CHEM, V272, P14285, DOI 10.1074/jbc.272.22.14285; MOTTRAM JC, 1992, MOL MICROBIOL, V6, P1925, DOI 10.1111/j.1365-2958.1992.tb01365.x; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Myler PJ, 2000, BIOCHEM SOC T, V28, P527, DOI 10.1042/bst0280527; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1995, J BIOL CHEM, V270, P8884, DOI 10.1074/jbc.270.15.8884; ROBERTSON CD, 1992, FEMS MICROBIOL LETT, V94, P127, DOI 10.1111/j.1574-6968.1992.tb05301.x; ROBERTSON CD, 1994, MICROBIOL-SGM, V140, P417, DOI 10.1099/13500872-140-2-417; Sanderson SJ, 2000, BIOCHEM J, V347, P383, DOI 10.1042/0264-6021:3470383; SOUZA AE, 1992, FEBS LETT, V311, P124, DOI 10.1016/0014-5793(92)81382-V; SPITHILL TW, 1987, MOL BIOCHEM PARASIT, V24, P23, DOI 10.1016/0166-6851(87)90112-5; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wincker P, 1996, NUCLEIC ACIDS RES, V24, P1688, DOI 10.1093/nar/24.9.1688; Wu Y, 2000, MOL BIOCHEM PARASIT, V110, P345, DOI 10.1016/S0166-6851(00)00290-5	56	53	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47061	47069		10.1074/jbc.M108498200	http://dx.doi.org/10.1074/jbc.M108498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592967	hybrid			2022-12-25	WOS:000172768500053
J	Chiti, F; De Lorenzi, E; Grossi, S; Mangione, P; Giorgetti, S; Caccialanza, G; Dobson, CM; Merlini, G; Ramponi, G; Bellotti, V				Chiti, F; De Lorenzi, E; Grossi, S; Mangione, P; Giorgetti, S; Caccialanza, G; Dobson, CM; Merlini, G; Ramponi, G; Bellotti, V			A partially structured species of beta(2)-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY-ZONE-ELECTROPHORESIS; QUANTITATIVE-ANALYSIS; AMYLOID FIBRILS; IN-VITRO; BETA-2-MICROGLOBULIN; CONFORMATIONS; PROTEINS	The folding Of beta (2)-microglobulin (beta (2)-M), the protein forming amyloid deposits in dialysis-related amyloidosis, involves formation of a partially folded conformation named I-2, which slowly converts into the native fold, N. Here we show that the partially folded species I-2 can be separated from N by capillary electrophoresis. Data obtained with this technique and analysis of kinetic data obtained with intrinsic fluorescence indicate that the I-2 conformation is populated to similar to 14 +/- 8% at equilibrium under conditions of pH and temperature close to physiological. In the presence of fibrils extracted from patients, the I-2 conformer has a 5-fold higher propensity to aggregate than N, as indicated by the thioflavine T test and light scattering measurements. A mechanism of aggregation of beta (2)-M in vivo involving the association of the preformed fibrils with the fraction of I-2, existing at equilibrium is proposed from these results. The possibility of isolating and quantifying a partially folded conformer of beta (2)-M involved in the amyloidogenesis process provides new opportunities to monitor hemodialytic procedures aimed at the reduction of such species from the pool of circulating beta (2)-m but also to design new pharmaceutical approaches that consider such species as a putative molecular target.	Univ Pavia, Dipartimento Biochim, I-27100 Pavia, Italy; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Pavia, Dipartimento Chim Farmaceut, I-27100 Pavia, Italy; Policlin San Matteo, Biotechnol Labs, IRCCS, I-27100 Pavia, Italy; Univ Pavia, Ctr Interdipartimentale Biol Appl, I-27100 Pavia, Italy; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Pavia; University of Florence; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia; University of Pavia; University of Cambridge	Bellotti, V (corresponding author), Univ Pavia, Dipartimento Biochim, Via Taramelli 3B, I-27100 Pavia, Italy.		De Lorenzi, Ersilia/ABC-5635-2021; Bellotti, Vittorio/A-6201-2014; Merlini, Giampaolo/A-3817-2008; Giorgetti, Sofia/AAD-4341-2019	De Lorenzi, Ersilia/0000-0002-5450-7208; Bellotti, Vittorio/0000-0001-8678-662X; Merlini, Giampaolo/0000-0001-7680-3254; Giorgetti, Sofia/0000-0001-9438-6511; Mangione, Palma/0000-0003-0260-1400	Telethon [453/BI, GP0186Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ACKERMANS MT, 1991, J CHROMATOGR, V549, P345, DOI 10.1016/S0021-9673(00)91445-6; ARUGA E, 1993, LAB INVEST, V69, P223; Bellotti V, 1999, CELL MOL LIFE SCI, V55, P977, DOI 10.1007/s000180050348; Bellotti V, 1998, EUR J BIOCHEM, V258, P61, DOI 10.1046/j.1432-1327.1998.2580061.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; CONNORS LH, 1985, BIOCHEM BIOPH RES CO, V131, P1063, DOI 10.1016/0006-291X(85)90198-6; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Drueke TB, 2000, NEPHROL DIAL TRANSPL, V15, P17, DOI 10.1093/oxfordjournals.ndt.a027958; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; FLOEGE J, 1996, NEPHRON, V723, P9; Heegaard NHH, 2001, J BIOL CHEM, V276, P32657, DOI 10.1074/jbc.M104452200; Heegaard NHH, 2000, J CHROMATOGR A, V894, P319, DOI 10.1016/S0021-9673(00)00579-3; HILSER VJ, 1995, ANAL BIOCHEM, V224, P465, DOI 10.1006/abio.1995.1075; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Nangaku M, 1999, AM J MED SCI, V317, P410, DOI 10.1097/00000441-199906000-00010; SWENSON RP, 1982, J BIOL CHEM, V257, P8817; Verzola B, 2000, ANAL BIOCHEM, V282, P239, DOI 10.1006/abio.2000.4620; Weatherall DJ, 1995, OXFORD TXB MED, V2, P1512; ZAOUI PM, 1990, KIDNEY INT, V38, P962, DOI 10.1038/ki.1990.298	23	126	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46714	46721		10.1074/jbc.M107040200	http://dx.doi.org/10.1074/jbc.M107040200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590172	hybrid			2022-12-25	WOS:000172768500007
J	Nakama, T; Nureki, O; Yokoyama, S				Nakama, T; Nureki, O; Yokoyama, S			Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ANGSTROM CRYSTAL-STRUCTURE; PSEUDOMONIC ACID; ESCHERICHIA-COLI; ANTIBACTERIAL ACTIVITY; STAPHYLOCOCCUS-AUREUS; RESISTANCE; COMPLEX; ENZYME; SITE	An analogue of isoleucyl-adenylate (Ile-AMS) potently inhibits the isoleucyl-tRNA synthetases (IleRSs) from the three primary kingdoms, whereas the antibiotic mupirocin inhibits only the eubacterial and archaeal IleRSs, but not the eukaryotic enzymes, and therefore is clinically used against methicillin-resistant Staphylococcus aureus. We determined the crystal structures of the IleRS from the thermophilic eubacterium, Thermus thermophilus, in complexes with Ile-AMS and mupirocin at 3.0- and 2.5-Angstrom resolutions, respectively. A structural comparison of the IleRS-Ile-AMS complex with the adenylate complexes of other aminoacyl-tRNA synthetases revealed the common recognition mode of aminoacyladenylate by the class I aminoacyl-tRNA synthetases. The Ile-AMS and mupirocin, which have significantly different chemical structures, are recognized by many of the same amino acid residues of the IleRS, suggesting that the antibiotic inhibits the enzymatic activity by blocking the binding site of the high energy intermediate, Ile-AMP. In contrast, the two amino acid residues that concomitantly recognize Ile-AMS and mupirocin are different between the eubacterial/archaeal IleRSs and the eukaryotic IleRSs. Mutagenic analyses revealed that the replacement of the two residues significantly changed the sensitivity to mupirocin.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN Genome Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN Harima Inst, SPring 8, Mikazuki, Hyogo 6795148, Japan	University of Tokyo; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Nureki, O (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; Brown P, 1997, J MED CHEM, V40, P2563, DOI 10.1021/jm960738k; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAIN EB, 1977, J CHEM SOC PERK T, V3, P294; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; DYKE KGH, 1991, FEMS MICROBIOL LETT, V77, P195, DOI 10.1111/j.1574-6968.1991.tb04346.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; GILBART J, 1993, ANTIMICROB AGENTS CH, V37, P32, DOI 10.1128/AAC.37.1.32; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; Ilyin VA, 2000, PROTEIN SCI, V9, P218; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAHMAN M, 1987, LANCET, V2, P387; RAHMAN M, 1990, J MED MICROBIOL, V33, P97, DOI 10.1099/00222615-33-2-97; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; Sassanfar M, 1996, BIOCHEMISTRY-US, V35, P9995, DOI 10.1021/bi9603027; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; SUTHERLAND R, 1985, ANTIMICROB AGENTS CH, V27, P495, DOI 10.1128/AAC.27.4.495; YANAGISAWA T, 1994, J BIOL CHEM, V269, P24304	29	140	145	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47387	47393		10.1074/jbc.M109089200	http://dx.doi.org/10.1074/jbc.M109089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584022	hybrid			2022-12-25	WOS:000172768500094
J	Schaeffer, ML; Agnihotri, G; Volker, C; Kallender, H; Brennan, PJ; Lonsdale, JT				Schaeffer, ML; Agnihotri, G; Volker, C; Kallender, H; Brennan, PJ; Lonsdale, JT			Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID SYNTHESIS; FATTY-ACID; ESCHERICHIA-COLI; CELL-WALL; ANTIBIOTIC CERULENIN; BIOSYNTHESIS; INHIBITION; SYNTHETASE; TARGET; MUTANT	Mycolic acids are vital components of the Mycobacterium tuberculosis cell wall, and enzymes involved in their formation represent attractive targets for the discovery of novel anti-tuberculosis agents. Biosynthesis of the fatty acyl chains of mycolic acids involves two fatty acid synthetic systems, the multifunctional polypeptide fatty acid synthase I (FASI), which performs de novo fatty acid synthesis, and the dissociated FASII system, which consists of monofunctional enzymes, and acyl carrier protein (ACP) and elongates FASI products to long chain mycolic acid precursors. In this study, we present the initial characterization of purified KasA and KasB, two beta -ketoacyl-ACP synthase (KAS) enzymes of the M. tuberculosis FASII system. KasA and KasB were expressed in E. coli and purified by affinity chromatography. Both enzymes showed activity typical of bacterial KASs, condensing an acyl-ACP with malonyl-ACP. Consistent with the proposed role of FASII in mycolic acid synthesis, analysis of various acyl-ACP substrates indicated KasA and KasB had higher specificity for long chain acyl-ACPs containing at least 16 carbons. Activity of KasA and KasB increased with use of M. tuberculosis AcpM, suggesting that structural differences between AcpM and E. coli ACP may affect their recognition by the enzymes. Both enzymes were sensitive to KAS inhibitors cerulenin and thiolactomycin. These results represent important steps in characterizing KasA and KasB as targets for antimycobacterial drug discovery.	GlaxoSmithKline, Collegeville, PA 19426 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	GlaxoSmithKline; Colorado State University	Schaeffer, ML (corresponding author), GlaxoSmithKline, 1250 S Collegeville Rd, Collegeville, PA 19426 USA.	Merrill_L_Schaeffer@gsk.com			NIAID NIH HHS [AI 46393] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V2; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Barry CE, 2001, TRENDS MICROBIOL, V9, P237, DOI 10.1016/S0966-842X(01)02018-2; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BLOCH H, 1950, J EXP MED, V91, P197, DOI 10.1084/jem.91.2.197; Bloch K, 1975, Methods Enzymol, V35, P84, DOI 10.1016/0076-6879(75)35141-0; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Choi KH, 2000, J BIOL CHEM, V275, P28201; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; FELSENSTEIN J, 1993, PHYLIP VERSION 3 57; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Glickman MS, 2001, J BIOL CHEM, V276, P2228, DOI 10.1074/jbc.C000652200; HAYASHI T, 1984, J ANTIBIOT, V37, P1456, DOI 10.7164/antibiotics.37.1456; HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1111/j.1574-6968.1994.tb07194.x; KAWAGUCHI A, 1982, J BIOCHEM-TOKYO, V92, P7, DOI 10.1093/oxfordjournals.jbchem.a133933; Khandekar SS, 2001, J BIOL CHEM, V276, P30024, DOI 10.1074/jbc.M101769200; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kremer L, 2001, J BIOL CHEM, V276, P27967, DOI 10.1074/jbc.M103687200; Kremer L, 2001, J BIOL CHEM, V276, P26430, DOI 10.1074/jbc.M102022200; Liu J, 1999, P NATL ACAD SCI USA, V96, P4011, DOI 10.1073/pnas.96.7.4011; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; QUEMARD A, 1992, ANTIMICROB AGENTS CH, V36, P1316, DOI 10.1128/AAC.36.6.1316; QURESHI N, 1984, J BACTERIOL, V157, P46, DOI 10.1128/JB.157.1.46-52.1984; ROCK CO, 1981, METHOD ENZYMOL, V72, P379; Scarsdale JN, 2001, J BIOL CHEM, V276, P20516, DOI 10.1074/jbc.M010762200; Schaeffer ML, 2001, BBA-MOL CELL BIOL L, V1532, P67, DOI 10.1016/S1388-1981(01)00116-0; Schujman GE, 2001, J BACTERIOL, V183, P3032, DOI 10.1128/JB.183.10.3032-3040.2001; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; SWOFFORD DL, 1999, PAUPASTERIX PHYLOGEN; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Wang L, 2000, J BIOL CHEM, V275, P7224, DOI 10.1074/jbc.275.10.7224; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; Zimhony O, 2000, NAT MED, V6, P1043, DOI 10.1038/79558	48	115	118	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47029	47037		10.1074/jbc.M108903200	http://dx.doi.org/10.1074/jbc.M108903200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11600501	hybrid			2022-12-25	WOS:000172768500049
J	Zamora, R; Alarcon, L; Vodovotz, Y; Betten, B; Kim, PKM; Gibson, KF; Billiar, TR				Zamora, R; Alarcon, L; Vodovotz, Y; Betten, B; Kim, PKM; Gibson, KF; Billiar, TR			Nitric oxide suppresses the expression of Bcl-2 binding protein BNIP3 in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; BCL-2-BINDING PROTEIN; FUNCTIONAL-ANALYSIS; INHIBITS APOPTOSIS; ORGAN DYSFUNCTION; GUANYLATE-CYCLASE; GENE-EXPRESSION; HUMAN HOMOLOG; BH3 DOMAIN; SYNTHASE	Nitric oxide (NO) is not only an important signaling molecule, but it also regulates the expression of a number of genes in the liver. We have previously shown that apoptosis in hepatocytes exposed to tumor necrosis factor-a and actinomycin D is prevented by NO derived from the inducible nitric-oxide synthase (iNOS), by mechanisms that are both dependent on and independent of modulation of cyclic guanosine monophosphate (cGMP) subsequent to activation of soluble guanylyl cyclase (sGC). We hypothesize that one mechanism by which NO exerts these effects is by regulating the expression of genes involved in apoptosis. We used differential display-polymerase chain reaction to isolate NO-regulated genes in hepatocytes from iNOS knockout mice (to eliminate endogenous inducible NO production). Using this analysis, we identified a NO-suppressed gene fragment homologous with the pro-apoptotic Bcl-2 binding protein BNIP3. Northern analysis confirmed the NO-dependent suppression of BNIP3 in cultured cells. Similarly, the NO donor S-nitroso-N-acetyl-DL-penicillamine (1-1000 mum) down-regulated the expression of BNIP3 in both iNOS knockout and wild-type hepatocytes. This effect of NO was reversed by the sGC inhibitor 1H-(1,2,4)-oxadiazole[4,3-alpha ]quinoxalon-1-one (ODQ), suggesting the involvement of the sGC/cGMP pathway in the modulation of BNIP3 by NO. We propose that suppression of BNIP3 expression is one sGC/cGMP-dependent mechanism by which NO might affect the process of hepatocyte apoptosis.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zamora, R (corresponding author), Rangos Res Ctr, CHP, Dept Pediat Surg, 3705 5th Ave,Rm 8125, Pittsburgh, PA 15213 USA.	zamorar@pitt.edu	Zamora, Renato/ABE-6898-2020	Zamora, Renato/0000-0002-2223-3361	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R01GM044100, R37GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SG, 1999, BIOCHEM BIOPH RES CO, V260, P216, DOI 10.1006/bbrc.1999.0856; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Hakoda S, 1999, SURG TODAY, V29, P1059, DOI 10.1007/s005950050645; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Jarrar D, 1999, INT J MOL MED, V4, P575; Johnson ML, 1998, WORLD J SURG, V22, P187, DOI 10.1007/s002689900368; Juan TSC, 1996, ONCOGENE, V13, P749; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li JR, 2000, SEMIN PERINATOL, V24, P46, DOI 10.1016/S0146-0005(00)80055-5; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mahidhara R, 2000, CRIT CARE MED, V28, pN105, DOI 10.1097/00003246-200004001-00013; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Nakata M, 1999, CELL STRUCT FUNCT, V24, P451, DOI 10.1247/csf.24.451; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; Ou JH, 1997, NITRIC OXIDE-BIOL CH, V1, P404, DOI 10.1006/niox.1997.0136; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Remick DG, 1996, J LEUKOCYTE BIOL, V59, P471, DOI 10.1002/jlb.59.4.471; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; STAMLER JS, 1996, NITRIX OXIDE RES, P521; Szabo C, 1999, SHOCK, V12, P1, DOI 10.1097/00024382-199907000-00001; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Taylor BS, 1998, BIOCHEMISTRY-MOSCOW+, V63, P766; Tirmenstein MA, 2000, TOXICOL SCI, V53, P56, DOI 10.1093/toxsci/53.1.56; Tzeng E, 1996, MOL MED, V2, P211, DOI 10.1007/BF03401618; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Wang HR, 1998, J BIOCHEM-TOKYO, V124, P892, DOI 10.1093/oxfordjournals.jbchem.a022204; Wink David A., 1999, P245; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; YODOVOTZ Y, 2001, NITRIC OXIDE INFLAMM, P41; Zamora R, 2001, ARCH BIOCHEM BIOPHYS, V390, P287, DOI 10.1006/abbi.2001.2391; Zamora Ruben, 2000, Nitric Oxide, V4, P183	51	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46887	46895		10.1074/jbc.M101865200	http://dx.doi.org/10.1074/jbc.M101865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592958	hybrid			2022-12-25	WOS:000172768500030
J	Boeuf, H; Merienne, K; Jacquot, S; Duval, D; Zeniou, M; Hauss, C; Reinhardt, B; Huss-Garcia, Y; Dierich, A; Frank, DA; Hanauer, A; Kedinger, C				Boeuf, H; Merienne, K; Jacquot, S; Duval, D; Zeniou, M; Hauss, C; Reinhardt, B; Huss-Garcia, Y; Dierich, A; Frank, DA; Hanauer, A; Kedinger, C			The ribosomal S6 kinases, cAMP-responsive element-binding, and STAT3 proteins are regulated by different leukemia inhibitory factor signaling pathways in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; INDUCED TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION; CREB PHOSPHORYLATION; SELF-RENEWAL; MAPK PATHWAY; DNA-BINDING; RECEPTOR; GENE; LIF	Mouse embryonic stem (ES) cells remain "pluripotent" in vitro in the continuous presence of leukemia inhibitory factor (LIF). In the absence of LIF, ES cells are irreversibly committed to differentiate into various lineages. In this study we have set up an in vitro assay based on the anti-apoptotic activity of LIF to distinguish pluripotent from "differentiation-committed" ES cells. We have examined the phosphorylation profiles of known (STAT3 and ERKs) and identified new (ribosomal S6 kinases (RSKs) and cAMP-responsive element-binding protein (CREB)) LIF-regulated targets in ES and in ES-derived neuronal cells. We have demonstrated that although STAT3, a crucial player in the maintenance of ES cell pluripotency, is induced by LIF in all cell types tested, the LIF-dependent activation of RSKs is restricted to ES cells. We have shown that LIF-induced phosphorylation of RSKs in ES cells is dependent on ERKs, whereas STAT3 phosphorylation is not mediated by any known MAPK activities. Our results also demonstrate that the LIF-dependent phosphorylation of CREB is partially under the control of the RSK2 kinase.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France; Univ Zurich, Div Neuroanat & Behav, Inst Anat, Zurich, Switzerland; Ecole Super Biotechnol Strasbourg, FRE 2370, F-67400 Strasbourg, France; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Zurich; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Harvard University; Dana-Farber Cancer Institute	Kedinger, C (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163, F-67404 Illkirch Graffenstaden, France.	ln@igbmc.u-strasbg.fr	DUVAL, David/B-8586-2011	Merienne, Karine/0000-0003-2549-2315; Duval, David/0000-0001-6933-3354				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; ALOISI F, 1994, J IMMUNOL, V152, P5022; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bradley A, 1998, INT J DEV BIOL, V42, P943; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cheng JG, 1997, MOL CELL NEUROSCI, V9, P372, DOI 10.1006/mcne.1997.0635; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Foulkes NS, 1996, BBA-REV CANCER, V1288, pF101, DOI 10.1016/S0304-419X(96)00025-X; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gadient RA, 1998, BRAIN RES, V798, P140, DOI 10.1016/S0006-8993(98)00236-4; Gollob JA, 1999, J IMMUNOL, V162, P4472; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hoey T, 1999, Adv Immunol, V71, P145; HOGAN BL, 1994, LAB MANUAL, P255; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jacquot S, 1999, AM J MED GENET, V85, P214, DOI 10.1002/(SICI)1096-8628(19990730)85:3<214::AID-AJMG5>3.0.CO;2-1; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lake JA, 2000, J CELL SCI, V113, P555; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Pera MF, 2001, CURR OPIN GENET DEV, V11, P595, DOI 10.1016/S0959-437X(00)00238-0; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Scherer CA, 1996, CELL GROWTH DIFFER, V7, P1393; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shellard J, 1996, EUR CYTOKINE NETW, V7, P699; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Taupin J L, 1998, Int Rev Immunol, V16, P397, DOI 10.3109/08830189809043003; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Walton M, 1999, J NEUROCHEM, V73, P1836; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Westmoreland JJ, 2001, BIOCHEM BIOPH RES CO, V284, P674, DOI 10.1006/bbrc.2001.5031; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	85	47	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46204	46211		10.1074/jbc.M106718200	http://dx.doi.org/10.1074/jbc.M106718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581263	hybrid			2022-12-25	WOS:000172573100097
J	Yoo, SH; Oh, YS; Kang, MK; Huh, YH; So, SH; Park, HS; Park, HY				Yoo, SH; Oh, YS; Kang, MK; Huh, YH; So, SH; Park, HS; Park, HY			Localization of three types of the inositol 1,4,5-trisphosphate receptor/Ca2+ channel in the secretory granules and coupling with the Ca2+ storage proteins chromogranins A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSE-MEDIATED RELEASE; MEMBRANE-BINDING REGION; CYTOSOLIC CA2+; TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; CONFORMATIONAL CHANGE; ADRENAL-MEDULLA; CELLS; PH; EXPRESSION	Although the role of secretory granules as the inositol 1,4,5-trisphosphate (IP3)-sensitive intracellular Ca2+ store and the presence of the IP3 receptor (IP3R)/Ca2+ channel on the secretory granule membrane have been established, the identity of the IP3R types present in the secretory granules is not known. We have therefore investigated the presence of different types of IP3R in the secretory granules of bovine adrenal medullary chromaffin cells using immunogold electron microscopy and found the existence of all three types of IP3R in the secretory granules. To determine whether these IP(3)Rs interact with CGA and CGB, each IP3R isoform was cotransfected with CGA or CGB into NIH3T3 or COS-7 cells, and the expressed IP3R isoform. and CGA or CGB were co-immunoprecipitated. From these studies it was shown that all three types of IP3R form complexes with CGA and CGB in the cells. To further confirm whether the IP3R isoforms and CGA and CGB form a complex in the secretory granules the potential interaction between all three isoforms of IP3R and CGA and CGB was tested by co-immunoprecipitation experiements of the mixture of secretory granule lysates and the granule membrane proteins. The three isoforms of IP3R were shown to form complexes with CGA and CGB, indicating the complex formation between the three isoforms of IP3R and CGA and CGB in the secretory granules. Moreover, the pH-dependent Ca2+ binding property of CGB was also studied using purified recombinant CGB, and it was shown that CGB bound 93 mol of Ca2+/mol with a dissociation constant (K-d) of 1.5 mm at pH 5.5 but virtually no Ca2+ at pH 7.5. The high capacity, low affinity Ca2+-binding property of CGB at pH 5.5 is comparable with that of CGA and is in line with its role as a Ca2+ storage protein in the secretory granules.	Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Secretory Granule Res, Yu Sung Gu, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Yoo, SH (corresponding author), Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Secretory Granule Res, Yu Sung Gu, Taejon 305701, South Korea.							Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; Chen YA, 2001, J BIOL CHEM, V276, P26680, DOI 10.1074/jbc.M103522200; DeSmedt H, 1997, BIOCHEM J, V322, P575; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GILL BM, 1991, REGUL PEPTIDES, V33, P223, DOI 10.1016/0167-0115(91)90216-4; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; HAGN C, 1986, LAB INVEST, V55, P405; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Kang YK, 1997, FEBS LETT, V404, P87, DOI 10.1016/S0014-5793(97)00099-9; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; Kern Horst F., 1993, P9; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Mak DOD, 1999, J BIOL CHEM, V274, P22231, DOI 10.1074/jbc.274.32.22231; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MATTER N, 1993, J BIOL CHEM, V268, P732; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Mundorf ML, 1999, J NEUROCHEM, V73, P2397, DOI 10.1046/j.1471-4159.1999.0732397.x; Mundorf ML, 2000, J BIOL CHEM, V275, P9136, DOI 10.1074/jbc.275.13.9136; Murphy SM, 1998, J HISTOCHEM CYTOCHEM, V46, P1261, DOI 10.1177/002215549804601106; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; NORDMANN JJ, 1984, J NEUROCHEM, V42, P434, DOI 10.1111/j.1471-4159.1984.tb02696.x; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; Quesada I, 2001, BIOPHYS J, V80, P2133, DOI 10.1016/S0006-3495(01)76186-3; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMON JP, 1989, BIOCHEM J, V262, P1; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Thrower EC, 2001, BIOPHYS J, V80, p455A; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; Yoo SH, 2000, J BIOL CHEM, V275, P15067, DOI 10.1074/jbc.M909391199	57	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45806	45812		10.1074/jbc.M107532200	http://dx.doi.org/10.1074/jbc.M107532200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584008	hybrid			2022-12-25	WOS:000172573100042
J	Zhou, XM; Li, JX; Kucik, DF				Zhou, XM; Li, JX; Kucik, DF			The microtubule cytoskeleton participates in control of beta(2) integrin avidity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; BINDING PROTEIN-RHO; C-KINASE SUBSTRATE; CELL-ADHESION; ACTIN CYTOSKELETON; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; CONFORMATIONAL CHANGE; CYTOPLASMIC TAIL	Leukocyte avidity is regulated by cytoskeletal constraints, which keep beta (2) integrins in an inactive mode. Releasing these constraints results in increased lateral mobility and clustering of integrins, effectively activating adhesion. At least part of the constraint on beta (2) integrins is due to actin; whether other cytoskeletal components are involved has not previously been investigated. Microtubules are a candidate for control of integrin rearrangement, because they modulate focal adhesions, which are sites of interaction between integrins and the cytoskeleton. Here we report that both depolymerization of microtubules by colchicine or nocodazole and stabilization of microtubules by taxol increased the lateral mobility of beta (2) integrins, activating adhesion. Increased integrin mobility was accompanied by an increase in tyrosine phosphorylation of paxillin, a biochemical event associated with activation of beta (2) integrins. Further, C3 exoenzyme, an inhibitor of Rho, blocked induction of integrin mobility by nocodazole, but not by taxol, suggesting that there are multiple microtubule-dependent pathways to integrin rearrangement, only some of which require Rho activity. Taken together, our data suggest that a dynamic microtubule system is required to regulate integrin-cytoskeleton interactions. Furthermore, these data demonstrate that microtubules participate in control of integrin rearrangement, one of the earliest steps in activation of integrin-mediated adhesion.	Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60612 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Birmingham Med Ctr, Vet Affairs Med Res Serv, Birmingham, AL 35294 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Alabama System; University of Alabama Birmingham	Li, JX (corresponding author), Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina, Chicago, IL 60612 USA.	jxli@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG HC, 1993, RANDOM WALKS BIOL, P1; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHEUNG HT, 1980, CELL BIOL INT REP, V4, P1125, DOI 10.1016/0309-1651(80)90050-8; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEBRABANDER M, 1977, CELL BIOL INT REP, V1, P453, DOI 10.1016/0309-1651(77)90080-7; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IVANOVA OY, 1976, EXP CELL RES, V101, P207, DOI 10.1016/0014-4827(76)90431-6; Kadi A, 1998, BIOCHEM BIOPH RES CO, V246, P690, DOI 10.1006/bbrc.1998.8536; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Kucik DF, 1999, BIOPHYS J, V76, P314, DOI 10.1016/S0006-3495(99)77198-5; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SLICHENMYER WJ, 1990, J CLIN PHARMACOL, V30, P770, DOI 10.1002/j.1552-4604.1990.tb01873.x; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VASILIEV JM, 1970, J EMBRYOL EXP MORPH, V24, P625; VASILIEV JM, 1987, J CELL SCI, P1; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wright S D, 1986, Methods Enzymol, V132, P204; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Yue LL, 1999, J CELL PHYSIOL, V181, P355, DOI 10.1002/(SICI)1097-4652(199911)181:2<355::AID-JCP17>3.0.CO;2-B; Yue LL, 2000, CELL ADHES COMMUN, V7, P359, DOI 10.3109/15419060009109018; Yue LL, 2000, J BIOL CHEM, V275, P23948, DOI 10.1074/jbc.M001845200; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	59	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44762	44769		10.1074/jbc.M104029200	http://dx.doi.org/10.1074/jbc.M104029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579083	hybrid			2022-12-25	WOS:000172406700058
J	Shi, H; Norman, AW; Okamura, WH; Sen, A; Zemel, MB				Shi, H; Norman, AW; Okamura, WH; Sen, A; Zemel, MB			1 alpha,25-dihydroxyvitamin D-3 modulates human adipocyte metabolism via nongenomic action	FASEB JOURNAL			English	Article						human adipocytes; Ca2+ signaling; lipid metabolism	VITAMIN-D-RECEPTOR; CYTOSOLIC-FREE CALCIUM; D-ENDOCRINE SYSTEM; GENOMIC BIOLOGICAL RESPONSES; INSULIN-RESISTANCE; INTRACELLULAR CALCIUM; MEMBRANE-RECEPTOR; CELLS; AGOUTI; OBESITY	We reported recently that suppression of the renal 1 alpha ,25-dihyroxyvitamin D-3 (1 alpha ,25-(OH)(2)-D-3) production in aP2-agouti transgenic mice by increasing dietary calcium decreases adiposity. However, it was not clear whether this modulation of adipocyte metabolism by dietary calcium is a direct effect of inhibition of 1 alpha ,25-(OH)(2)-D-3-induced [Ca2+]i. Accordingly, we have now evaluated the direct role of 1 alpha ,25-(OH)(2)-D-3. Human adipocytes exhibited a 1 alpha ,25-(OH)(2)-D-3 dose-responsive (1-50 nM) increase in [Ca2+]i (P<0.01). This action was mimicked by 1<alpha>,25-dihydroxyluministerol(3) (1 alpha ,25-(OH)(2)-lumisterol(3)) (P<0.001), a specific agonist for a putative membrane vitamin D receptor (mVDR), and completely prevented by 1<beta>,25-dihydroxyvitamin D-3 (1 beta ,25-(OH)(2)-D-3), a specific antagonist for the mVDR. Similarly, 1 alpha ,25-(OH)(2)-D-3 (5 mM) caused 50%-100% increases in adipocyte fatty acid synthase (FAS) expression and activity (P<0.02), 61% increase in glycerol-3-phosphate dehydrogenase (GPDH) activity (P<0.01), and an 80% inhibition of isoproterenol-stimulated lipolysis (P<0.001), whereas 1<beta>,25-(OH)(2)-D-3 completely blocked all these effects. Notably, 1 alpha ,25-OH)(2)-lumisterol(3) exerted more potent effects in modulating adipocyte lipid metabolism, with 2.5- to 3.0-fold increases in FAS expression and activity (P<0.001) and a threefold increase in GPDH activity (P<0.001). Also 1 alpha ,25-(OH)(2)-lumisterol3 was approximately twice as potent in inhibiting basal lipolysis (P<0.025), whereas 1<beta>,25-(OH)(2)-D-3 completely blocked all these effects. These data suggest that 1 alpha ,25-(OH)(2)-D-3 modulates adipocyte Ca2+ signaling and, consequently, exerts a coordinated control over lipogenesis and lipolysis. Thus, a direct inhibition of 1 alpha ,25-(OH)(2)-D-3-induced [Ca2+](i) may contribute to an anti-obesity effect of dietary calcium, and the mVDR may represent an important target for obesity.	Univ Tennessee, Knoxville, TN 37996 USA; Univ Calif Riverside, Riverside, CA 92521 USA; Zen Bio, Res Triangle Pk, NC USA	University of Tennessee System; University of Tennessee Knoxville; University of California System; University of California Riverside	Zemel, MB (corresponding author), Univ Tennessee, 1215 W Cumberland Ave 229, Knoxville, TN 37996 USA.	mzemel@utk.edu		Zemel, Michael/0000-0003-4104-5750				Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; ANDERSEN T, 1988, METABOLISM, V37, P425, DOI 10.1016/0026-0495(88)90041-8; BARAN DT, 1991, J BONE MINER RES, V6, P1269; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; BELL NH, 1988, J BONE MINER RES, V3, P489; BELL NH, 1985, J CLIN INVEST, V76, P370, DOI 10.1172/JCI111971; BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; Davies KM, 2000, J CLIN ENDOCR METAB, V85, P4635, DOI 10.1210/jc.85.12.4635; DeLuca HF, 1998, NUTR REV, V56, pS4; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo-128-4-1687; EPSTEIN S, 1986, J BONE MINER RES, V1, P181; Fleet JC, 1999, NUTR REV, V57, P60, DOI 10.1111/j.1753-4887.1999.tb01779.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; Kajikawa M, 1999, ENDOCRINOLOGY, V140, P4706, DOI 10.1210/en.140.10.4706; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; LI YC, 1998, BONE, V23, pS263; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; Resnick L, 1999, PROG CARDIOVASC DIS, V42, P1, DOI 10.1016/S0033-0620(99)70006-X; Sanchez M, 1997, HYPERTENSION, V29, P531, DOI 10.1161/01.HYP.29.1.531; SHAN J, 1993, AM J HYPERTENS, V6, P983, DOI 10.1093/ajh/6.12.983; Shi H, 2000, PHYSIOL GENOMICS, V3, P75, DOI 10.1152/physiolgenomics.2000.3.2.75; Shi H, 1999, FASEB J, V13, P1833, DOI 10.1096/fasebj.13.13.1833; SHI H, 2000, FASEB J         1208; TORNQUIST K, 1989, ENDOCRINOLOGY, V124, P2765, DOI 10.1210/endo-124-6-2765; XUE B, 2001, FASEB J         0917; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; Xue BZ, 2000, J NUTR, V130, P2478, DOI 10.1093/jn/130.10.2478; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132	43	181	210	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2751	+		10.1096/fj.01-0584fje	http://dx.doi.org/10.1096/fj.01-0584fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606486				2022-12-25	WOS:000171920400007
J	Kuttler, F; Ame, P; Clark, H; Haughey, C; Mougin, C; Cahn, JY; Dang, CV; Raffeld, M; Fest, T				Kuttler, F; Ame, P; Clark, H; Haughey, C; Mougin, C; Cahn, JY; Dang, CV; Raffeld, M; Fest, T			c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli	ONCOGENE			English	Article						Burkitt's lymphoma; c-Myc; apoptosis; staurosporine; TNF alpha	TRANSCRIPTIONAL ACTIVATION DOMAIN; TRANSACTIVATION DOMAIN; CYCLE; FIBROBLASTS; PROTEIN; GENE; BINDING; ARREST; REGION; GROWTH	In addition to c-myc rearrangement, over 50% of Burkitt's lymphoma cases present clustered mutations in exon 2, where many of the functional activities of c-Myc protein are based. This report describes the functional consequences induced by tumour-derived c-myc mutations located in c-myc box II. Two mutated alleles were studied, focusing on the P138C mutation, and compared to wild-type c-myc. The c-Myc transformation, transactivation and apoptosis activities were explored based on cells over-expressing c-Myc. While the transcriptional activation activity was not affected, our experiments exploring the anchorage-independent growth capacity of c-Myc-transfected Rat1a cells showed that c-Myc box II mutants were less potent than wild-type c-Myc in promoting cell transformation. Considering the possibility that these mutations could be interfering with the ability of c-Myc to promote apoptosis, we tested c-Myc-transfected Rat1a fibroblasts under several conditions: serum deprivation-, staurosporine- and TNF alpha -induced cell death. Interestingly, the mutated alleles were characterized by an overall decrease in ability to mediate apoptosis. Our study indicates that point mutations located in c-Myc box II can decrease the ability of the protein to promote both transformation and apoptosis without modifying its transactivating activity.	Univ Hosp Jean Minjoz, Inst Etud & Transfert Genes, Dept Haematol & Cell Biol, F-25030 Besancon, France; NCI, Hematopathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA	Universite de Franche-Comte; CHU Besancon; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Fest, T (corresponding author), Univ Hosp Jean Minjoz, Inst Etud & Transfert Genes, Dept Haematol & Cell Biol, F-25030 Besancon, France.		Amé-Thomas, Patricia/C-3131-2017; Dang, Chi/Y-3375-2019	Amé-Thomas, Patricia/0000-0001-8042-9250; MOUGIN, CHRISTIANE/0000-0002-1573-8695; Dang, Chi/0000-0002-4031-2522; Kuttler, Fabien/0000-0003-2575-1989; fest, thierry/0000-0002-6437-4189				ASKEW DS, 1991, ONCOGENE, V6, P1915; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bernard B, 2001, CELL DEATH DIFFER, V8, P234, DOI 10.1038/sj.cdd.4400796; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; CLARK HM, 1994, CANCER RES, V54, P3383; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dhanaraj SN, 1996, EXP CELL RES, V224, P52, DOI 10.1006/excr.1996.0110; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; PULVERER BJ, 1994, ONCOGENE, V9, P59; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; Sakamuro D, 1995, ONCOGENE, V11, P2411; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stone B., 1987, ED RES Q, V11, P7; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YANO T, 1993, ONCOGENE, V8, P2741; YANO T, 1992, BLOOD, V80, P758	37	19	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6084	6094		10.1038/sj.onc.1204827	http://dx.doi.org/10.1038/sj.onc.1204827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593416				2022-12-25	WOS:000171056300016
J	Saadi-Kheddouci, S; Berrebi, D; Romagnolo, B; Cluzeaud, F; Peuchmaur, M; Kahn, A; Vandewalle, A; Perret, C				Saadi-Kheddouci, S; Berrebi, D; Romagnolo, B; Cluzeaud, F; Peuchmaur, M; Kahn, A; Vandewalle, A; Perret, C			Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene	ONCOGENE			English	Article						polycystic kidney disease; beta-catenin; transgenic mice	EPITHELIAL-CELLS; MOLECULAR-BASIS; ALDOLASE-B; E-CADHERIN; C-MYC; PKD1; PROTEIN; PRODUCT; TRANSCRIPTION; PROLIFERATION	Autosomal dominant polycystic kidney disease (ADPKD) is common and is a major cause of renal failure. Although the genetics of ADPKD are well known and have led to the discovery of polycystins, a new protein family, the pathogenesis of the disease remains largely unknown. Recent studies have indicated that the beta -catenin signaling pathway is one of the targets of the transduction pathway controlled by the polycystins. We have generated transgenic mice that overproduce an oncogenic form of beta -catenin in the epithelial cells of the kidney. These mice developed severe polycystic lesions soon after birth that affected the glomeruli, proximal, distal tubules and collecting ducts. The phenotype of these mice mimicked the human ADPKD phenotype. Cyst formation was associated with an increase in cell proliferation and apoptosis. The cell proliferation and apoptotic indexes was increased 4-5-fold and 3-4-fold, respectively, in cystic tubules of the transgenic mice compared to that of littermate controls. Our findings provide experimental genetic evidence that activation of the Wnt/beta -catenin signaling pathway causes polycystic kidney disease and support the view that dysregulation of the Wnt/beta -catenin signaling is involved in its pathogenesis.	ICGM, INSERM, U129, F-75014 Paris, France; Univ Paris 07, Hop Robert Debre, Serv Anatomopathol, EA3102, F-75019 Paris, France; Univ Paris 07, Inst Fed Rech 02, INSERM, U478, F-75870 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Perret, C (corresponding author), ICGM, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Perret-Mayeux, Christine/L-3297-2017; Romagnolo, Béatrice/D-5017-2017	Romagnolo, Béatrice/0000-0001-8772-3604; perret, christine/0000-0003-4710-7051				BARISONI L, 1995, AM J PATHOL, V147, P1728; Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bieche I, 1999, CANCER RES, V59, P2759; Cadoret A, 2001, CANCER RES, V61, P3245; Calvet JP, 1998, J NEPHROL, V11, P24; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; EKBLOM P, 1992, RENAL DEV, P475; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Grantham JJ, 1996, AM J KIDNEY DIS, V28, P788, DOI 10.1016/S0272-6386(96)90378-9; Gregori C, 1998, J BIOL CHEM, V273, P25237, DOI 10.1074/jbc.273.39.25237; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lanoix J, 1996, ONCOGENE, V13, P1153; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Romagnolo B, 1999, CANCER RES, V59, P3875; Romagnolo B, 1996, J BIOL CHEM, V271, P16820, DOI 10.1074/jbc.271.28.16820; Saez DE, 2000, J CELL BIOCHEM, V78, P62, DOI 10.1002/(SICI)1097-4644(20000701)78:1<62::AID-JCB6>3.3.CO;2-N; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Sorenson CM, 1999, AM J PHYSIOL-RENAL, V276, pF210, DOI 10.1152/ajprenal.1999.276.2.F210; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vainio SJ, 1999, INT J DEV BIOL, V43, P419; van Adelsberg J, 1999, DEV GENET, V24, P299, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<299::AID-DVG13>3.0.CO;2-J; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WILSON PD, 1991, AM J PHYSIOL, V260, P420; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724	46	196	217	0	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5972	5981		10.1038/sj.onc.1204825	http://dx.doi.org/10.1038/sj.onc.1204825			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593404				2022-12-25	WOS:000171056300004
J	Fulda, S; Kufer, MU; Meyer, E; van Valen, F; Dockhorn-Dworniczak, B; Debatin, KM				Fulda, S; Kufer, MU; Meyer, E; van Valen, F; Dockhorn-Dworniczak, B; Debatin, KM			Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer	ONCOGENE			English	Article						caspase-8; apoptosis; drugs; methylation; gene transfer	INHIBITORY PROTEIN EXPRESSION; CD95 APO-1/FAS SYSTEM; BRAIN-TUMOR CELLS; NEUROBLASTOMA-CELLS; DEFICIENT ACTIVATION; SIGNALING COMPLEX; TRAIL RECEPTOR-2; RESISTANCE; FLICE; INDUCTION	Resistance of tumors to treatment with cytotoxic drugs, irradiation or immunotherapy may be due to disrupted apoptosis programs. Here, we report in a variety of different tumor cells including Ewing tumor, neuroblastoma, malignant brain tumors and melanoma that caspase-8 expression acts as a key determinant of sensitivity for apoptosis induced by death-inducing ligands or cytotoxic drugs. In tumor cell lines resistant to TRAIL, anti-CD95 or TNF alpha, caspase-8 protein and mRNA expression was decreased or absent without caspase-8 gene loss. Methylation-specific PCR revealed hypermethylation of caspase-8 regulatory sequences in cells with impaired caspase-8 expression. Treatment with the demethylation agent 5-Aza-2 ' -deoxycylidine (5-dAzaC) reversed hypermethylation of caspase-8 resulting in restoration of caspase-8 expression and recruitment and activation of caspase-8 at the CD95 DISC upon receptor cross-linking thereby sensitizing for death receptor-, and importantly, also for drug-induced apoptosis. Inhibition of caspase-8 activity also inhibited apoptosis sensitization by 5-dAzaC. Similar to demethylation, introduction of caspase-8 by gene transfer sensitized for apoptosis induction. Hypermethylation of caspase-8 was linked to reduced caspase-8 expression in different tumor cell lines in vitro and, most importantly, also in primary tumor samples. Thus, these findings indicate that re-expression of caspase-8, e.g. by demethylation or caspase-8 gene transfer, might be an effective strategy to restore sensitivity for chemotherapy- or death receptor-induced apoptosis in various tumors in viva.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Univ Munster, Lab Expt Orthoped Res, D-48149 Munster, Germany; Univ Munster, Dept Pathol, D-48149 Munster, Germany	Ulm University; University of Munster; University of Munster	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.		Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DEVITA VT, 1990, MONOGR NCI, V10, P19; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2000, CANCER RES, V60, P3947; FULDA S, 2001, IN PRESS ONCOGENE; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; VANVALEN F, 1999, EWINGS SARCOMA FAMIL, P55; VANVALEN F, 2000, INT J CANCER, V88, P311; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	55	339	363	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5865	5877		10.1038/sj.onc.1204750	http://dx.doi.org/10.1038/sj.onc.1204750			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593392				2022-12-25	WOS:000171037200010
J	Coxon, FP; Helfrich, MH; Larijani, B; Muzylak, M; Dunford, JE; Marshall, D; McKinnon, AD; Nesbitt, SA; Horton, MA; Seabra, MC; Ebetino, FH; Rogers, MJ				Coxon, FP; Helfrich, MH; Larijani, B; Muzylak, M; Dunford, JE; Marshall, D; McKinnon, AD; Nesbitt, SA; Horton, MA; Seabra, MC; Ebetino, FH; Rogers, MJ			Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN-CONTAINING BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE; BONE-RESORPTION; PROTEIN PRENYLATION; IN-VITRO; MEVALONATE PATHWAY; SQUALENE SYNTHASE; MECHANISM; GTPASES; GROWTH	Nitrogen-containing bisphosphonate drugs inhibit bone resorption by inhibiting FPP synthase and thereby preventing the synthesis of isoprenoid lipids required for protein prenylation in bone-resorbing osteoclasts. NE10790 is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak antiresorptive agent. Although NE10790 was a poor inhibitor of FPP synthase, it did inhibit prenylation in J774 macrophages and osteoclasts, but only of proteins of molecular mass similar to 22-26 kDa, the prenylation of which was not affected by peptidomimetic inhibitors of either farnesyl transferase (FTI-277) or geranylgeranyl transferase I (GGTI-298). These 22-26-kDa proteins were shown to be geranylgeranylated by labelling J774 cells with [(3)H]geranylgeraniol. Furthermore, NE10790 inhibited incorporation of [(14)C]mevalonic acid into Rab6, but not into H-Ras or Rap1, proteins that are modified by FTase and GGTase I, respectively. These data demonstrate that NE10790 selectively prevents Rab prenylation in intact cells. In accord, NE10790 inhibited the activity of recombinant Rab GGTase in vitro, but did not affect the activity of recombinant FTase or GGTase I. NE10790 therefore appears to be the first specific inhibitor of Rab GGTase to be identified. In contrast to risedronate, NE10790 inhibited bone resorption in vitro without markedly affecting osteoclast number or the F-actin "ring" structure in polarized osteoclasts. However, NE10790 did alter osteoclast morphology, causing the formation of large intracellular vacuoles and protrusion of the basolateral membrane into large, "domed" structures that lacked microvilli. The anti-resorptive activity of NE10790 is thus likely due to disruption of Rab-dependent intracellular membrane trafficking in osteoclasts.	Univ Aberdeen, Sch Med, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Imperial Coll Sch Med, Div Biomed Sci, Cell & Mol Biol Sect, London SW7 2AZ, England; UCL, Bone & Mineral Ctr, London WC1E 6JJ, England; Procter & Gamble Pharmaceut, Cincinnati, OH 45040 USA	University of Aberdeen; Imperial College London; University of London; University College London; Procter & Gamble	Coxon, FP (corresponding author), Univ Aberdeen, Sch Med, Dept Med & Therapeut, Polwarth Bldg, Aberdeen AB25 2ZD, Scotland.	f.p.coxon@abdn.ac.uk	Seabra, Miguel/AAC-3099-2019; Larijani, Banafshe/H-3909-2015; Seabra, Miguel C/M-3280-2013	Larijani, Banafshe/0000-0003-4735-1169; Seabra, Miguel C/0000-0002-6404-4892; Dunford, James/0000-0002-9932-4042; Rogers, Michael/0000-0002-1818-9249				Abu-Amer Y, 1999, J BONE MINER RES, V14, P1855, DOI 10.1359/jbmr.1999.14.11.1855; AMIN D, 1992, J LIPID RES, V33, P1657; Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; Bialek-Wyrzykowska U, 2000, MOL MICROBIOL, V35, P1295, DOI 10.1046/j.1365-2958.2000.01782.x; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; Coxon FP, 1998, MOL PHARMACOL, V54, P631; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Hardcastle IR, 1999, BIOCHEM PHARMACOL, V57, P801, DOI 10.1016/S0006-2952(98)00349-9; Holstein SA, 1998, BIOORGAN MED CHEM, V6, P687, DOI 10.1016/S0968-0896(98)00034-0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Ory S, 2000, J CELL SCI, V113, P1177; Palokangas H, 1997, J CELL SCI, V110, P1767; Razzouk S, 1999, EUR J CELL BIOL, V78, P249, DOI 10.1016/S0171-9335(99)80058-2; Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006-2952(97)00151-2; Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193; Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.3.CO;2-C; Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756-3282(99)00116-7; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seabra MC, 1996, OPHTHALMIC GENET, V17, P43, DOI 10.3109/13816819609057869; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Seabra MC, 1998, METH MOL B, V84, P251; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756-3282(98)00120-3; VANTHOF RJ, 1995, INT J EXP PATHOL, V76, P205	37	140	142	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48213	48222		10.1074/jbc.M106473200	http://dx.doi.org/10.1074/jbc.M106473200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11581260	hybrid			2022-12-25	WOS:000172927000064
J	Taupin, JL; Legembre, P; Bitard, J; Daburon, S; Pitard, V; Blanchard, F; Duplomb, L; Godard, A; Jacques, Y; Moreau, JF				Taupin, JL; Legembre, P; Bitard, J; Daburon, S; Pitard, V; Blanchard, F; Duplomb, L; Godard, A; Jacques, Y; Moreau, JF			Identification of agonistic and antagonistic antibodies against gp190, the leukemia inhibitory factor receptor, reveals distinct roles for its two cytokine-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCER GP130; HIGH-AFFINITY BINDING; MONOCLONAL-ANTIBODIES; ERYTHROPOIETIN RECEPTOR; ONCOSTATIN-M; IL-6 FAMILY; ALPHA-CHAIN; LIF BINDING; ACTIVATION	The receptor for the cytokine leukemia inhibitory factor (LIF) associates the low affinity binding component gp190 and the high affinity converter gp130, both of which are members of the family of hematopoietic receptors characterized by the cytokine receptor homology (CRH) domain. The gp190 is among the very few members of this large family to contain two CRH domains. The membrane-distal one (herein called DI) is followed by an Ig-like domain, a membrane-proximal CRH domain called D2, and three type III fibronectin repeats. We raised a series of monoclonal antibodies specific for the human gp190. Among them was the blocking antibody 1C7, which was directed against the D1Ig region and which impaired the binding of LIF to gp190. Another blocking antibody, called 12D3, was directed against domain D2 and interfered with the reconstitution of the high affinity receptor complex, independently of the interaction between LIF and gp190. The blocking effect of these two antibodies concerned four cytokines known to use gp190, i.e. LIF, oncostatin M, ciliary neurotrophic factor, and cardiotrophin-1. Among 23 antibodies tested alone or in combination (two anti-D2 and 21 anti-D1Ig), only the mixture of the two anti-D2 antibodies displayed agonistic activity in the absence of the cytokine. Taken together, these results demonstrate that the two CRH domains of gp190 play different functions in ligand binding and receptor activation.	Univ Bordeaux 2, CNRS, UMR 5540, F-33076 Bordeaux, France; Inst Biol, INSERM U463, F-44035 Nantes, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm)	Taupin, JL (corresponding author), Univ Bordeaux 2, CNRS, UMR 5540, Batiment 1B,146 Rue Leo Saignat, F-33076 Bordeaux, France.		Blanchard, Frederic/AAS-1930-2021; Legembre, Patrick/U-1882-2019; Blanchard, Frederic/K-8018-2015; legembre, patrick/L-3475-2016	Blanchard, Frederic/0000-0003-1055-2573; Legembre, Patrick/0000-0001-6649-8049; Blanchard, Frederic/0000-0003-1055-2573; legembre, patrick/0000-0001-6649-8049; Duplomb, Laurence/0000-0002-5715-3759				Autissier P, 1997, EUR J IMMUNOL, V27, P794, DOI 10.1002/eji.1830270331; Autissier P, 1998, INT IMMUNOL, V10, P1881, DOI 10.1093/intimm/10.12.1881; Ballinger MD, 1998, NAT STRUCT BIOL, V5, P938, DOI 10.1038/2911; Blanchard F, 1997, INT IMMUNOL, V9, P1775, DOI 10.1093/intimm/9.12.1775; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DAndrea RJ, 1996, BLOOD, V87, P2641, DOI 10.1182/blood.V87.7.2641.bloodjournal8772641; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; Gu ZJ, 1996, J IMMUNOL METHODS, V190, P21, DOI 10.1016/0022-1759(95)00232-4; Hammacher A, 2000, BIOCHEM J, V345, P25, DOI 10.1042/0264-6021:3450025; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heymann D, 1996, CYTOKINE, V8, P197, DOI 10.1006/cyto.1996.0028; Kurth I, 2000, J IMMUNOL, V164, P273, DOI 10.4049/jimmunol.164.1.273; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Mellado M, 1997, J BIOL CHEM, V272, P9189; Muller-Newen G, 2000, J BIOL CHEM, V275, P4579, DOI 10.1074/jbc.275.7.4579; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; Pitard V, 1997, J IMMUNOL METHODS, V205, P177, DOI 10.1016/S0022-1759(97)00074-4; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; Sabath DF, 1999, BLOOD, V94, P365, DOI 10.1182/blood.V94.1.365.413a46_365_367; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Smith DK, 1998, PROTEIN SCI, V7, P886; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Taupin JL, 1999, J BIOL CHEM, V274, P14482, DOI 10.1074/jbc.274.20.14482; Taupin JL, 1997, CYTOKINE, V9, P112, DOI 10.1006/cyto.1996.0144; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999	33	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47975	47981		10.1074/jbc.M105476200	http://dx.doi.org/10.1074/jbc.M105476200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606572	hybrid			2022-12-25	WOS:000172927000035
J	Yang, JM; Fan, GH; Wadzinski, BE; Sakurai, H; Richmond, A				Yang, JM; Fan, GH; Wadzinski, BE; Sakurai, H; Richmond, A			Protein phosphatase 2A interacts with and directly dephosphorylates Re1A.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; CATALYTIC SUBUNIT; CELL-GROWTH; ACTIVATION; ALPHA; PHOSPHORYLATION; SIGNAL; UBIQUITINATION	Nuclear factor-kappaB (NF-kappaB)/Rel transcription factors are key regulators of a variety of genes involved in inflammatory responses, growth, differentiation, apoptosis, and development. There are increasing lines of evidence that NF-kappaB/Rel activity is controlled to a great extent by its phosphorylation state. In this study, we demonstrated that RelA physically associated with protein phosphatase 2A (PP2A) subunit A (PR65). Both the N- and C-terminal regions of RelA were responsible for the PP2A binding. RelA co-immunoprecipitated with PP2A in melanocytes in the absence of stimulation, indicating that RelA forms a signaling complex with PP2A in the cells. RelA was dephosphorylated by a purified PP2A core enzyme, a heterodimer formed by the catalytic subunit of PP2A (PP2Ac) and PR65, in a concentration-dependent manner. Okadaic acid, an inhibitor of PP2A at lower concentration, increased the basal phosphorylation of RelA in melanocytes and blocked the dephosphorylation of RelA after interleukin-1 stimulation. Interestingly, PP2A immunoprecipitated from melanocytes was able to dephosphorylate RelA, whereas PP2A immunoprecipitated from melanoma cell lines exhibited decreased capacity to dephosphorylate RelA in vitro. Moreover, in melanoma cells in which I kappaB kinase activity was inhibited by sulindac to a similar level as in melanocytes, the phosphorylation state of RelA and the relative NF-KB activity were still higher than those in normal melanocytes. These data suggest that the constitutive activation of RelA in melanoma cells (Yang, J., and Richmond, A. (2001) Cancer Res. 61, 4901-4909) could be due, at least in part, to the deficiency of PP2A, which exhibits decreased dephosphorylation of NF-kappaB/RelA.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Dept Vet Affairs, Nashville, TN 37212 USA; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan	Vanderbilt University; Vanderbilt University; Mitsubishi Tanabe Pharma Corporation	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, T2212 MCN,1161 21st Ave S, Nashville, TN 37232 USA.		Sakurai, Hiroaki/AAE-4294-2019; Richmond, Ann/A-3048-2014	Sakurai, Hiroaki/0000-0003-0657-9570; RICHMOND, ANN/0000-0002-9580-900X	NATIONAL CANCER INSTITUTE [R01CA056704, R01CA034590, P30CA068485, R23CA034590] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA068485, CA68485, R01 CA056704-09, R01 CA056704-08, CA56740, R01 CA056704-07, CA34590, R01 CA034590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIANNINI E, 1995, J IMMUNOL, V154, P4055; Gilmore TD, 1996, ONCOGENE, V13, P1367; HARPER JW, 1993, CELL, V75, P805; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Krueger KM, 1997, J BIOL CHEM, V272, P5; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; THEVENIN C, 1990, New Biologist, V2, P793; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Weil R, 1997, J BIOL CHEM, V272, P9942; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wuyts A, 2000, BIOCHEMISTRY-US, V39, P14549, DOI 10.1021/bi0011227; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yang JM, 2001, CANCER RES, V61, P4901; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	51	102	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47828	47833		10.1074/jbc.M106103200	http://dx.doi.org/10.1074/jbc.M106103200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11591705	Green Accepted, hybrid			2022-12-25	WOS:000172927000015
J	Ahn, JH; Park, SM; Cho, HS; Lee, MS; Yoon, JB; Vilcek, J; Lee, TH				Ahn, JH; Park, SM; Cho, HS; Lee, MS; Yoon, JB; Vilcek, J; Lee, TH			Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts - Mitogen-activated protein kinases and NF-kappa B-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL PROLIFERATION; DEATH DOMAIN; INHIBITORY PROTEIN; MEDIATED APOPTOSIS; UP-REGULATION; TNF RECEPTOR; INDUCTION; CD95; FADD	Many Fas-expressing cells do not undergo cell death upon Fas stimulation. In the normal human diploid cell line GM6112, the addition of soluble Fas ligand (sFasL) leads to morphological signs of cell death in less than 1% of cells. Treatment of serum-starved GM6112 fibroblasts with sFasL resulted in a rapid and transient phosphorylation of ERK1/2 without a significant increase in JNK and p38 activities. Unless co-treated with the protein synthesis inhibitor anisomycin, sFasL did not show gene-inducing activity in cells maintained in complete medium. However, when cells were serum-starved for 4 days, treatment with sFasL alone induced interleukin-6 gene expression and, less strongly, interleukin-8 gene expression. Sensitization of the gene-inducing activity by serum starvation correlated with NF-kappaB activation by sFasL. Furthermore, we found that the expression of FADD and caspase-8 was significantly reduced in serum-starved cells, whereas the level of cFLIP remained unchanged. Transfection of GM6112 cells with the antisense caspase-8 expression construct sensitized cells toward sFasL-induced NF-kappaB-dependent reporter activation. Our results support the notion that a change in the ratio of cFLIP and caspase-8 may be responsible for turning on the Fas-activated NF-kappaB pathway, which otherwise is supplanted by the death-inducing pathway.	Yonsei Univ, Coll Sci, Dept Biol, Sudaemoon Gu, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul 135710, South Korea; NYU, Med Ctr, Dept Microbiol, New York, NY 10016 USA	Yonsei University; Yonsei University; Sungkyunkwan University (SKKU); Samsung Medical Center; New York University	Lee, TH (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Sudaemoon Gu, 134 Shinchon Dong, Seoul 120749, South Korea.	thlee@yonsei.ac.kr	Lee, Myung Shik/C-9606-2011	Yoon, Jong-Bok/0000-0002-3563-0702	NATIONAL CANCER INSTITUTE [R01CA075071] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bretz JD, 1999, J BIOL CHEM, V274, P25433, DOI 10.1074/jbc.274.36.25433; Cheema ZF, 1999, J NEUROSCI, V19, P1754; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fulda S, 2000, CANCER RES, V60, P3947; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim CH, 1995, J INFLAMM, V45, P312; Kim S, 2000, J IMMUNOL, V164, P2931, DOI 10.4049/jimmunol.164.6.2931; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Lee ZH, 2001, J LEUKOCYTE BIOL, V69, P490; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leverkus M, 2000, BLOOD, V96, P2628; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; PORTON AM, 1996, J BIOL CHEM, V271, P8991; RENSINGEHL A, 1995, J INFLAMM, V45, P161; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Shinohara H, 2000, CANCER RES, V60, P1766; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Stassi G, 2000, NAT IMMUNOL, V1, P483, DOI 10.1038/82725; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wallach D, 1997, NATURE, V388, P123, DOI 10.1038/40516; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	42	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47100	47106		10.1074/jbc.M107385200	http://dx.doi.org/10.1074/jbc.M107385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11600497	hybrid			2022-12-25	WOS:000172768500058
J	Chen, CC; Mo, FE; Lau, LF				Chen, CC; Mo, FE; Lau, LF			The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR; FACTOR-BETA; INTEGRIN ALPHA(V)BETA(3); MATRICELLULAR PROTEINS; COLLAGEN LATTICES; ENDOTHELIAL-CELLS; MESENCHYMAL CELLS	Cyr61 is a heparin-binding, extracellular matrix-associated protein of the CCN family, which also includes connective tissue growth factor, Nov, WISP-1, WISP-2, and WISP-3. Cyr61 is capable of multiple functions, including induction of angiogenesis in vivo. Purified Cyr61 mediates cell adhesion and induces adhesive signaling, stimulates cell migration, enhances cell proliferation, and promotes cell survival in both fibroblasts and endothelial cells. In this study, we have used cDNA array hybridization to identify genes regulated by Cyr61 in primary human skin fibroblasts. The Cyr61-regulated genes fall into several groups known to participate in processes important for cutaneous wound healing, including: 1) angiogenesis and lymphogenesis (VEGF-A and VEGF-C); 2) inflammation (interleukin-1 beta); 3) extracellular matrix remodeling (MMP1, MMP3, TIMP1, uPA, and PAI-1); and 4) cell-matrix interactions (Col1 alpha1, Col1 alpha2, and integrins alpha (3) and alpha (5)). Cyr61-mediated gene expression requires heparin binding activity of Cyr61, cellular de novo transcription, and protein synthesis and is largely dependent on the activation of p42/p44 MAPKs. Cyr61 regulates gene expression not only in serum-free medium but also in fibroblasts cultured on various matrix proteins or in the presence of 10% serum. These effects of Cyr61 can be sustained for at least 5 days, consistent with the time course of wound healing in vivo. Interestingly, Cyr61 can interact with transforming growth factor-beta1 to regulate expression of specific genes in an antagonistic, additive, or synergistic manner. Furthermore, we show that the Cyr61 gene is highly induced in dermal fibroblasts of granulation tissue during cutaneous wound repair. Together, these results show that Cyr61 is inducibly expressed in granulation tissues after wounding and that Cyr61 activates a genetic program for wound repair in skin fibroblasts. We propose a model in which Cyr61 integrates its activities on endothelial cells, fibroblasts, and macrophages to regulate the processes of angiogenesis, inflammation, and matrix remodeling in the context of cutaneous wound healing.	Univ Illinois, Dept Mol Genet, Coll Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Dept Mol Genet, Coll Med, 900 S Ashland Ave, Chicago, IL 60607 USA.			Mo, Fan-E/0000-0002-0087-7043; Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA 46565, CA 80080] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chaudhary LR, 2000, J CELL BIOCHEM, V76, P354, DOI 10.1002/(SICI)1097-4644(20000301)76:3<354::AID-JCB2>3.0.CO;2-U; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMBRY RM, 1986, AM J PATHOL, V125, P81; HOGAN B, 1994, MANIPULATING MOUSE E, P373; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JONES PL, 1995, J CELL SCI, V108, P519; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; LANE TF, 1992, J BIOL CHEM, V267, P16736; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MO FE, 2001, THESIS U ILLINOIS CH; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Reunanen N, 2000, J BIOL CHEM, V275, P34634, DOI 10.1074/jbc.C000175200; Rezzonico R, 2000, BLOOD, V95, P3868; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756; SEGARINI PR, 2001, J BIOL CHEM     0822; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353	60	226	239	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47329	47337		10.1074/jbc.M107666200	http://dx.doi.org/10.1074/jbc.M107666200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584015	hybrid			2022-12-25	WOS:000172768500088
J	de Figueiredo, P; Doody, A; Polizotto, RS; Drecktrah, D; Wood, S; Banta, M; Strang, MS; Brown, WJ				de Figueiredo, P; Doody, A; Polizotto, RS; Drecktrah, D; Wood, S; Banta, M; Strang, MS; Brown, WJ			Inhibition of transferrin recycling and endosome tubulation by phospholipase A(2) antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MANNOSE 6-PHOSPHATE RECEPTORS; POLARIZED MDCK CELLS; CANINE KIDNEY-CELLS; TRANS-GOLGI NETWORK; BREFELDIN-A; MEMBRANE TUBULATION; PLASMA-MEMBRANE; HELA-CELLS; CARCINOMA A431-CELLS	We report here that a broad spectrum of phospholipase A(2) (PLA(2)) antagonists produce a concentration-dependent, differential block in the endocytic recycling pathway of transferrin (Tf) and Tf receptors (TfRs) but have no acute affect on Tf uptake from the cell surface. At low concentrations of antagonists (similar to1 muM), Tf and TfR accumulated in centrally located recycling endosomes, whereas at higher concentrations (similar to 10 muM), Tf-TfR accumulated in peripheral sorting endosomes. Several independent lines of evidence suggest that this inhibition of recycling may result from the inhibition of tubule formation. First, BFA-stimulated endosome tubule formation was similarly inhibited by PLA(2) antagonists. Second, endocytosed tracers were found in larger spherical endosomes in the presence of PLA(2) antagonists. And third, endosome tubule formation in a cell-free, cytosol-dependent reconstitution system was equally sensitive PLA(2) antagonists. These results are consistent with the conclusion that endosome membrane tubules are formed by the action of a cytoplasmic PLA(2) and that PLA(2)-dependent tubules are involved in intracellular recycling of Tf and TfR. When taken together with previous studies on the Golgi complex, these results also indicate that an intracellular PLA(2) activity provides a novel molecular mechanism for inducing tubule formation from multiple organelles.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Brown, WJ (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.		Brown, William/GXN-2777-2022		NIGMS NIH HHS [GM 60373] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060373] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; APODACA G, 1994, J BIOL CHEM, V269, P19005; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BANTA M, 1995, BIOCHEMISTRY-US, V34, P13359, DOI 10.1021/bi00041a012; BRETSCHER MS, 1985, EUR J CELL BIOL, V37, P78; CLUETT EB, 1993, J CELL BIOL, V120, P15, DOI 10.1083/jcb.120.1.15; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DAMKE H, 1991, J BIOL CHEM, V266, P24829; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; de Figueiredo P, 2000, TRAFFIC, V1, P504, DOI 10.1034/j.1600-0854.2000.010608.x; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; de Figueiredo P, 1999, MOL BIOL CELL, V10, P1763, DOI 10.1091/mbc.10.6.1763; DEFIGUEIREDO P, 1995, MOL BIOL CELL, V6, P871, DOI 10.1091/mbc.6.7.871; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Gaynor EC, 1998, MOL BIOL CELL, V9, P653, DOI 10.1091/mbc.9.3.653; GELB MH, 1994, FASEB J, V8, P916, DOI 10.1096/fasebj.8.12.8088457; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Handley D. A., 1989, COLLOIDAL GOLD PRINC, V1, P13; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KILLISCH I, 1992, J CELL SCI, V103, P211; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MCGRAW TE, 1999, CURRENT PROTOCOLS CE, V1; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Polizotto RS, 1999, J CELL BIOCHEM, V74, P670, DOI 10.1002/(SICI)1097-4644(19990915)74:4<670::AID-JCB16>3.3.CO;2-R; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; ROME LH, 1985, TRENDS BIOCHEM SCI, V10, P151, DOI 10.1016/0968-0004(85)90153-7; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWANSON JA, 1992, J CELL SCI, V103, P201; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; TOOZE J, 1992, J CELL BIOL, V118, P813, DOI 10.1083/jcb.118.4.813; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WAN JS, 1992, J BIOL CHEM, V267, P13446; WHITNEY JA, 1995, CELL, V83, P703; WILLINGHAM MC, 1984, P NATL ACAD SCI-BIOL, V81, P175, DOI 10.1073/pnas.81.1.175; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	79	59	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47361	47370		10.1074/jbc.M108508200	http://dx.doi.org/10.1074/jbc.M108508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585839	hybrid			2022-12-25	WOS:000172768500091
J	Eilers, T; Schwarz, G; Brinkmann, H; Witt, C; Richter, T; Nieder, J; Koch, B; Hille, R; Hansch, R; Mendel, RR				Eilers, T; Schwarz, G; Brinkmann, H; Witt, C; Richter, T; Nieder, J; Koch, B; Hille, R; Hansch, R; Mendel, RR			Identification and biochemical characterization of Arabidopsis thaliana sulfite oxidase - A new player in plant sulfur metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; CHICKEN LIVER; MOLECULAR-BIOLOGY; RESONANCE RAMAN; PURIFICATION; PROTEIN; MECHANISM; LEAVES; MITOCHONDRIA; CHLOROPLASTS	In mammals and birds, sulfite oxidase (SO) is a homodimeric molybdenum enzyme consisting of an N-terminal heme domain and a C-terminal molybdenum domain (EC 1.8.3.1). In plants, the existence of SO has not yet been demonstrated, while sulfite reductase as part of sulfur assimilation is well characterized. Here we report the cloning of a plant sulfite oxidase gene from Arabidopsis thaliana and the biochemical characterization of the encoded protein (At-SO). At-SO is a molybdenum enzyme with molybdopterin as an organic component of the molybdenum cofactor. In contrast to homologous animal enzymes, At-SO lacks the heme domain, which is evident both from the amino acid sequence and from its enzymological and spectral properties. Thus, among eukaryotes, At-SO is the only molybdenum enzyme yet described possessing no redox-active centers other than the molybdenum. UV-visible and EPR spectra as well as apparent K-m values are presented and compared with the hepatic enzyme. Subcellular analysis of crude cell extracts showed that SO was mostly found in the peroxisomal fraction. In molybdenum cofactor mutants, the activity of SO was strongly reduced. Using antibodies directed against At-SO, we show that a cross-reacting protein of similar size occurs in a wide range of plant species, including both herbacious and woody plants.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Bot, D-38023 Braunschweig, Germany; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Braunschweig University of Technology; University System of Ohio; Ohio State University	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Bot, D-38023 Braunschweig, Germany.		Schwarz, Guenter/ABE-9643-2021	Schwarz, Guenter/0000-0002-2118-9338; Hansch, Robert/0000-0003-1310-8419				BRAAKSMA FJ, 1982, THEOR APPL GENET, V64, P83, DOI 10.1007/BF00303657; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODY MS, 1995, BBA-PROTEIN STRUCT M, V1253, P133, DOI 10.1016/0167-4838(95)00194-4; COHEN HJ, 1972, J BIOL CHEM, V247, P7759; COHEN HJ, 1971, J BIOL CHEM, V246, P359; DITTRICH APM, 1992, PLANT PHYSIOL, V98, P738, DOI 10.1104/pp.98.2.738; GABARD J, 1988, MOL GEN GENET, V213, P275; Ganai BA, 1997, PHYTOCHEMISTRY, V45, P879, DOI 10.1016/S0031-9422(97)82709-4; Garrett RM, 1998, P NATL ACAD SCI USA, V95, P6394, DOI 10.1073/pnas.95.11.6394; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Garton SD, 1997, J AM CHEM SOC, V119, P2590, DOI 10.1021/ja963931c; Heber U, 1998, INT REV CYTOL, V177, P255; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; Johnson MK, 1997, J BIOL INORG CHEM, V2, P797, DOI 10.1007/s007750050198; JOLIVET P, 1995, PHYTOCHEMISTRY, V38, P9, DOI 10.1016/0031-9422(94)00651-9; JOLIVET P, 1995, PHYTOCHEMISTRY, V40, P667, DOI 10.1016/0031-9422(95)00406-W; Kappler U, 2000, J BIOL CHEM, V275, P13202, DOI 10.1074/jbc.275.18.13202; KESSLER DL, 1974, BIOCHIM BIOPHYS ACTA, V370, P389, DOI 10.1016/0005-2744(74)90100-4; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; LABRIE ST, 1992, MOL GEN GENET, V233, P169, DOI 10.1007/BF00587576; LAMY MT, 1980, BIOCHEM J, V185, P397, DOI 10.1042/bj1850397; Leustek T, 1999, PLANT PHYSIOL, V120, P637, DOI 10.1104/pp.120.3.637; Lopez-Huertas E, 1999, BIOCHEM J, V337, P531, DOI 10.1042/0264-6021:3370531; Mendel RR, 1999, CRIT REV PLANT SCI, V18, P33, DOI 10.1016/S0735-2689(99)00386-X; MENDEL RR, 1981, MOL GEN GENET, V181, P395, DOI 10.1007/BF00425618; Mendel RR, 1997, PLANTA, V203, P399, DOI 10.1007/s004250050206; Muller A. J., 1989, Molecular and genetic aspects of nitrate assimilation., P166; NEUBURGER M, 1982, ARCH BIOCHEM BIOPHYS, V217, P312, DOI 10.1016/0003-9861(82)90507-0; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; Raitsimring AM, 1998, J AM CHEM SOC, V120, P11263, DOI 10.1021/ja981903j; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Schwarz G, 2000, PLANT CELL, V12, P2455, DOI 10.1105/tpc.12.12.2455; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Veljovic-Jovanovic S, 1998, PLANT CELL PHYSIOL, V39, P1203, DOI 10.1093/oxfordjournals.pcp.a029321; YAMAYA T, 1992, PLANT PHYSIOL, V100, P1427, DOI 10.1104/pp.100.3.1427	39	151	162	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46989	46994		10.1074/jbc.M108078200	http://dx.doi.org/10.1074/jbc.M108078200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598126	hybrid			2022-12-25	WOS:000172768500044
J	Sarcina, M; Tobin, MJ; Mullineaux, CW				Sarcina, M; Tobin, MJ; Mullineaux, CW			Diffusion of phycobilisomes on the thylakoid membranes of the cyanobacterium Synechococcus 7942 - Effects of phycobilisome size, temperature, and membrane lipid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT LACKING PHOTOSYSTEM; EXCITATION-ENERGY TRANSFER; MOLECULAR CHARACTERIZATION; PORPHYRIDIUM-CRUENTUM; POLYPEPTIDE; LOCALIZATION; MOBILITY	A variant of fluorescence recovery after photobleaching allows us to observe the diffusion of photosynthetic complexes in cyanobacterial thylakoid membranes in vivo. The unicellular cyanobacterium Synechococcus sp. PCC7942 is a wonderful model organism for fluorescence recovery after photobleaching, because it has a favorable membrane geometry and is well characterized and transformable. In Synechococcus 7942 (as in other cyanobacteria) we find that photosystem II is immobile, but phycobilisomes diffuse rapidly on the membrane surface. The diffusion coefficient is 3 X 10(-10) cm(2) s(-1) at 30 degreesC. This shows that the association of phycobilisomes with reaction centers is dynamic; there are no stable phycobilisome-reaction center complexes in vivo. Ive report the effects of mutations that change the phycobilisome size and membrane lipid composition. 1) In a mutant with no phycobilisome rods, the phycobilisomes remain mobile with a slightly faster diffusion coefficient. This confirms that the diffusion we observe is of intact phycobilisomes rather than detached rod elements. The faster diffusion coefficient in the mutant indicates that the rate of diffusion is partly determined by the phycobilisome size. 2) The temperature dependence of the phycobilisome diffusion coefficient indicates that the phycobilisomes have no integral membrane domain. It is likely that association with the membrane is mediated by multiple weak interactions with lipid head groups. 3) Changing the lipid composition of the thylakoid membrane has a dramatic effect on phycobilisome mobility. The results cannot be explained in terms of changes in the fluidity of the membrane; they suggest that lipids play a role in controlling phycobilisome-reaction center interaction.	UCL, Dept Biol, London WC1E 6BT, England; SERC, Daresbury Lab, Cent Lab Res Councils, Warrington WA4 4AD, Cheshire, England	University of London; University College London; STFC Daresbury Laboratory	Mullineaux, CW (corresponding author), UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	c.mullineaux@ucl.ac.uk	Tobin, Mark J/B-8208-2015	Tobin, Mark J/0000-0003-1862-0649				Ajlani G, 1998, EUR J BIOCHEM, V257, P154, DOI 10.1046/j.1432-1327.1998.2570154.x; Ashby MK, 1999, PHOTOSYNTH RES, V61, P169, DOI 10.1023/A:1006217201666; Bald D, 1996, PHOTOSYNTH RES, V49, P103, DOI 10.1007/BF00117661; BHALERAO RP, 1995, PHOTOSYNTH RES, V45, P61, DOI 10.1007/BF00032236; BITTERSMANN E, 1991, BIOCHIM BIOPHYS ACTA, V1098, P105; CAPUANO V, 1991, J BIOL CHEM, V266, P7239; CASTENHOLZ RW, 1988, METHOD ENZYMOL, V167, P68; CLEMENTMETRAL JD, 1985, ARCH BIOCHEM BIOPHYS, V238, P10, DOI 10.1016/0003-9861(85)90135-3; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; GLAZER AN, 1984, BIOCHIM BIOPHYS ACTA, V768, P29, DOI 10.1016/0304-4173(84)90006-5; GLAZER AN, 1988, METHOD ENZYMOL, V167, P304; Gombos Z, 1997, PLANT PHYSIOL, V115, P551, DOI 10.1104/pp.115.2.551; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; HOUMARD J, 1990, P NATL ACAD SCI USA, V87, P2152, DOI 10.1073/pnas.87.6.2152; KATOH T, 1988, METHOD ENZYMOL, V167, P313; MacColl R, 1998, J STRUCT BIOL, V124, P311, DOI 10.1006/jsbi.1998.4062; Mann NH, 2000, FEBS LETT, V479, P72, DOI 10.1016/S0014-5793(00)01871-8; MULLINEAUX CW, 1992, BIOCHIM BIOPHYS ACTA, V1100, P285, DOI 10.1016/0167-4838(92)90483-T; MULLINEAUX CW, 1994, BBA-BIOENERGETICS, V1184, P71, DOI 10.1016/0005-2728(94)90155-4; Mullineaux CW, 1997, NATURE, V390, P421, DOI 10.1038/37157; Mullineaux CW, 1999, AUST J PLANT PHYSIOL, V26, P671, DOI 10.1071/PP99027; MURATA N, 1989, J BIOENERG BIOMEMBR, V21, P61, DOI 10.1007/BF00762212; MUSTARDY L, 1992, P NATL ACAD SCI USA, V89, P10021, DOI 10.1073/pnas.89.21.10021; O'Toole PJ, 1999, BBA-BIOMEMBRANES, V1419, P64, DOI 10.1016/S0005-2736(99)00048-6; REDLINGER T, 1982, P NATL ACAD SCI-BIOL, V79, P5542, DOI 10.1073/pnas.79.18.5542; Sarcina M, 2000, FEMS MICROBIOL LETT, V191, P25, DOI 10.1016/S0378-1097(00)00365-7; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SHEN GZ, 1995, PHOTOSYNTH RES, V44, P41, DOI 10.1007/BF00018295; SHERMAN DM, 1994, PLANT PHYSIOL, V106, P251, DOI 10.1104/pp.106.1.251; Sidler W. A., 1994, MOL BIOL CYANOBACTER, P139, DOI [10.1007/978-94-011-0227-8_7, DOI 10.1007/978-94-011-0227-8_7]; Sippola K, 1998, EUR J BIOCHEM, V251, P641, DOI 10.1046/j.1432-1327.1998.2510641.x; van Thor JJ, 1998, BOT ACTA, V111, P430, DOI 10.1111/j.1438-8677.1998.tb00731.x; VERMAAS WFJ, 1994, BBA-BIOENERGETICS, V1187, P181, DOI 10.1016/0005-2728(94)90107-4; Yu JJ, 1999, IUBMB LIFE, V48, P625, DOI 10.1080/152165499306513; Zhang CC, 1998, FEMS MICROBIOL LETT, V161, P285, DOI 10.1016/S0378-1097(98)00084-6; ZHANG F, 1993, BIOESSAYS, V15, P579, DOI 10.1002/bies.950150903	36	99	104	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46830	46834		10.1074/jbc.M107111200	http://dx.doi.org/10.1074/jbc.M107111200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590154	hybrid			2022-12-25	WOS:000172768500022
J	Shen, K; Keng, YF; Wu, L; Guo, XL; Lawrence, DS; Zhang, ZY				Shen, K; Keng, YF; Wu, L; Guo, XL; Lawrence, DS; Zhang, ZY			Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LOW-MOLECULAR-WEIGHT; SUBSTRATE-TRAPPING MUTANTS; SOLID-PHASE SYNTHESIS; INSULIN SENSITIVITY; O-PHOSPHOTYROSINE; KINASE INHIBITORS; STRUCTURAL BASIS; IN-VIVO; 1B	Protein-tyrosine phosphatases (PTPases) form a large family of enzymes that serve as key regulatory components in signal transduction pathways. Defective or inappropriate regulation of PTPase activity leads to aberrant tyrosine phosphorylation, which contributes to the development of many human diseases including cancers and diabetes. For example, recent gene knockout studies in mice identify PTP1B as a promising target for anti-diabetes/obesity drug discovery. Thus, there is intense interest in obtaining specific and potent PTPase inhibitors for biological studies and pharmacological development. However, given the highly conserved nature of the PTPase active site, it is unclear whether selectivity in PTPase inhibition can be achieved. We describe a combinatorial approach that is designed to target both the active site and a unique peripheral site in PTP1B. Compounds that can simultaneously associate with both sites are expected to exhibit enhanced affinity and specificity. We also describe a novel affinity-based high-throughput assay procedure that can be used for PTPase inhibitor screening. The combinatorial library/high-throughput screen protocols furnished a small molecule PTP1B inhibitor that is both potent (K-i = 2.4 nm) and selective (little or no activity against a panel of phosphatases including Yersinia PTPase, SHP1, SHP2, LAR, HePTP, PTP alpha, CD45, VHR, MKP3, Cdc25A, Stp1, and PP2C). These results demonstrate that it is possible to acquire potent, yet highly selective inhibitors for individual members of the large PTPase family of enzymes.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Bleasdale JE, 2001, BIOCHEMISTRY-US, V40, P5642, DOI 10.1021/bi002865v; BROWNSHIMER S, 1992, CANCER RES, V52, P478; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; BURKE TR, 1993, J ORG CHEM, V58, P1336, DOI 10.1021/jo00058a009; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Cohen P, 1999, CURR OPIN CHEM BIOL, V3, P459, DOI 10.1016/S1367-5931(99)80067-2; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GANEM B, 1974, TETRAHEDRON LETT, P917; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LAUNIKONIS A, 1986, AUST J CHEM, V39, P1053, DOI 10.1071/CH9861053; Lawrence DS, 1998, PHARMACOL THERAPEUT, V77, P81, DOI 10.1016/S0163-7258(97)00052-1; Lee TR, 1999, J MED CHEM, V42, P784, DOI 10.1021/jm980663f; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Montserat J, 1996, J BIOL CHEM, V271, P7868, DOI 10.1074/jbc.271.13.7868; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; SMYTH MS, 1994, TETRAHEDRON LETT, V35, P551, DOI 10.1016/S0040-4039(00)75835-7; Solas D, 1996, J ORG CHEM, V61, P1537, DOI 10.1021/jo9517508; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; WIENER JR, 1994, AM J OBSTET GYNECOL, V170, P1177, DOI 10.1016/S0002-9378(94)70118-0; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; WILLIAMS RM, 1991, J AM CHEM SOC, V113, P9276, DOI 10.1021/ja00024a038; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; Wrobel J, 1999, J MED CHEM, V42, P3199, DOI 10.1021/jm990260v; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Yokomatsu T, 1997, TETRAHEDRON, V53, P815, DOI 10.1016/S0040-4020(96)01063-0; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200	52	191	208	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47311	47319		10.1074/jbc.M106568200	http://dx.doi.org/10.1074/jbc.M106568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584002	hybrid			2022-12-25	WOS:000172768500086
J	Bussell, R; Eliezer, D				Bussell, R; Eliezer, D			Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; A-BETA COMPONENT; LEWY BODIES; IN-VITRO; NEURODEGENERATIVE DISORDERS; PROTEIN CONFORMATION; SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; BACKBONE DYNAMICS	alpha -Synuclein (alphaS) is a pre-synaptic protein that has been implicated as a possible causative agent in the pathogenesis of Parkinson's disease (PD). Two autosomal dominant missense mutations in the aS gene are associated with early onset PD. Because aS is found in an aggregated fibrillar form in the Lewy body deposits characteristic of Parkinson's patients, aggregation of the protein is believed to be related to its involvement in the disease process. The wild type (WT) and early onset mutants A30P and A53T display diverse in vitro aggregation kinetics even though the gross physicochemical and morphological properties of the mutants are highly similar. We used high resolution solution NMR spectroscopy to compare the structural and dynamic properties of the A53T and A30P mutants with those of WT aS in the free state. We found that the A30P mutation disrupts a region of residual helical structure that exists in the WT protein, whereas the A53T mutation results in a slight enhancement of a small region around the site of mutation with a preference for extended conformations. Based on these results and on the anticipated effects of these mutations on elements of secondary structure, we proposed a model of how these two PD-linked mutations influence aS fibril formation that is consistent with the documented differences in the fibrillization kinetics of the two mutants.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Program Struct Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol Biophys & Mol Med, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Eliezer, D (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	dae2005@med.cornell.edu	Eliezer, David/GRS-5702-2022		NATIONAL INSTITUTE ON AGING [R01AG019391, R37AG019391] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG019391, AG19391, R01 AG019391, R01 AG019391-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arima K, 2000, ACTA NEUROPATHOL, V100, P115, DOI 10.1007/s004010050002; Baba M, 1998, AM J PATHOL, V152, P879; Cavanagh John, 1996, P243; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2000, BIOCHEMISTRY-US, V39, P2894, DOI 10.1021/bi992545f; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, CLIN CHEM LAB MED, V39, P308, DOI 10.1515/CCLM.2001.047; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kruger R, 2000, J NEURAL TRANSM, V107, P31, DOI 10.1007/s007020050002; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	55	214	218	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45996	46003		10.1074/jbc.M106777200	http://dx.doi.org/10.1074/jbc.M106777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590151	hybrid			2022-12-25	WOS:000172573100069
J	Fu, MG; Zhang, JF; Zhu, XJ; Myles, DE; Willson, TM; Liu, XD; Chen, YQE				Fu, MG; Zhang, JF; Zhu, XJ; Myles, DE; Willson, TM; Liu, XD; Chen, YQE			Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; POTENTIAL MEDIATOR; ATHEROSCLEROSIS; MACROPHAGES; HYPERPLASIA; PATHWAY; LIGANDS; GENE	Activation of peroxisome proliferator-activated receptor gamma (PPAR gamma) after balloon injury significantly inhibits VSMC proliferation and neointima formation. However, the precise mechanisms of this inhibition have not been determined. We hypothesized that activation of PPAR gamma in vascular injury could attenuate VSMC growth and matrix production during vascular lesion formation. Since connective tissue growth factor (CTGF) is a key factor regulating extracellular matrix production, abrogation of transforming growth factor beta (TGF-beta) -induced CTGF production by PPAR gamma activation may be one of the mechanisms through which PPAR gamma agonists inhibit neointima formation after vascular injury. In this study, we demonstrate that the PPAR gamma natural ligand (15-deoxyprostaglandin J(2)) and a synthetic ligand (GW7845) significantly inhibit TGF-beta -induced CTGF production in a dose-dependent manner in HASMCs. In addition, suppression of CTGF mRNA expression is relieved by pretreatment with an antagonist of PPAR gamma (GW9662), suggesting that the inhibition of CTGF expression is mediated by PPAR gamma. To elucidate further the molecular mechanism by which PPAR gamma inhibits CTGF expression, an similar to2-kilobase pair CTGF promoter was cloned. We found that PPAR gamma activation inhibits TGF-beta -induced CTGF promoter activity in a dose-dependent manner, and suppression of CTGF promoter activity by PPAR gamma activation is completely rescued by overexpression of Smad3, but not by Smad4. Furthermore, PPAR gamma physically interacts with Smad3 but not Smad4 in vitro in glutathione S-transferase pull-down experiments. Taken together, the data suggest that PPAR gamma inhibits TGF-beta -induced CTGF expression in HASMCs by directly interfering with the Smad3 signaling pathway.	Morehouse Sch Med, Inst Cardiovasc Res, Atlanta, GA 30310 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Morehouse School of Medicine; GlaxoSmithKline; University of Colorado System; University of Colorado Boulder	Chen, YQE (corresponding author), Morehouse Sch Med, Inst Cardiovasc Res, 720 Westview Dr SW, Atlanta, GA 30310 USA.		feinstein, doug/M-9414-2019	LIU, XUEDONG/0000-0001-7209-4964; Myles, David/0000-0002-3839-0644	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008248] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 UH1 HL03676-02] Funding Source: Medline; NIGMS NIH HHS [S06GM08248] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KOLPAKOV V, 1995, CIRC RES, V76, P305, DOI 10.1161/01.RES.76.2.305; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Oemar BS, 1997, CIRCULATION, V95, P831; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200	30	151	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45888	45894		10.1074/jbc.M105490200	http://dx.doi.org/10.1074/jbc.M105490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590167	hybrid			2022-12-25	WOS:000172573100054
J	Goldshmit, Y; Erlich, S; Pinkas-Kramarski, R				Goldshmit, Y; Erlich, S; Pinkas-Kramarski, R			Neuregulin rescues PC12-ErbB4 cells from cell death induced by H2O2 - regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; HYDROGEN-PEROXIDE; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH; OXIDATIVE STRESS; H2O2-INDUCED APOPTOSIS	Neuregulins (NRGs), a large family of transmembrane polypeptide growth factors, mediate various cellular responses depending on the cell type and receptor expression. We previously showed that NRG mediates survival of PC12-ErbB4 cells from apoptosis induced by serum deprivation or tumor necrosis factor-a treatment. In the present study we show that NRG induces a significant protective effect from H2O2-induced death. This effect of NRG is mediated by the phosphatidylinositol 3-kinase (PI3K)-signaling pathway since NRG failed to rescue cells from H2O2 insult in the presence of the PI3K inhibitor, LY294002. Furthermore, the downstream effector of PI3K, protein kinase B/AKT, is activated by NRG in the presence of H2O2, and protein kinase B/AKT activation is inhibited by LY294002. In addition, our results demonstrate that reactive oxygen species (ROS) elevation induced by H2O2 is inhibited by NRG. LY294002, which blocks NRG-mediated rescue, increases ROS levels. Moreover, both H2O2-induced ROS elevation and cell death are reduced by expression of activated PI3K. These results suggest that PI3K-dependent pathways may regulate toxic levels of ROS generated by oxidative stress.	Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	lironit@post.tau.ac.il		Pinkas-Kramarski, Ronit/0000-0002-1000-369X				Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Calderon FH, 1999, J NEUROSCI RES, V56, P620; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN MGM, 1977, P NATL ACAD SCI USA, V74, P5559, DOI 10.1073/pnas.74.12.5559; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; de la Monte SM, 2000, CELL MOL LIFE SCI, V57, P1471, DOI 10.1007/PL00000630; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eilam R, 1998, P NATL ACAD SCI USA, V95, P1888, DOI 10.1073/pnas.95.4.1888; ENOKIDO Y, 1990, BRAIN RES, V536, P23, DOI 10.1016/0006-8993(90)90004-U; Erlich S, 2001, NEUROSCIENCE, V107, P353, DOI 10.1016/S0306-4522(01)00350-5; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Fernandez PA, 2000, NEURON, V28, P81, DOI 10.1016/S0896-6273(00)00087-8; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haviv R, 1999, J NEUROSCI RES, V55, P269; Hong F, 2001, LIFE SCI, V68, P1095, DOI 10.1016/S0024-3205(00)01012-2; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JACKSON GR, 1990, J NEUROSCI RES, V25, P360, DOI 10.1002/jnr.490250313; Kamata H, 1996, NEUROSCI LETT, V212, P179, DOI 10.1016/0304-3940(96)12806-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Knight JA, 1997, ANN CLIN LAB SCI, V27, P93; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Marchionni MA, 1999, ADV EXP MED BIOL, V468, P283; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PEREZPOLO JR, 1990, MOL NEUROBIOL, V4, P57, DOI 10.1007/BF02935585; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; RATAN RR, 1994, J NEUROCHEM, V62, P376; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yamakawa H, 2000, NEUROL RES, V22, P556; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YING Z, 1993, J CEREBR BLOOD F MET, V13, P378, DOI 10.1038/jcbfm.1993.51	62	114	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46379	46385		10.1074/jbc.M105637200	http://dx.doi.org/10.1074/jbc.M105637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590144	hybrid			2022-12-25	WOS:000172573100120
J	Mackem, S; Baumann, CT; Hager, GL				Mackem, S; Baumann, CT; Hager, GL			A glucocorticoid/retinoic acid receptor chimera that displays cytoplasmic/nuclear translocation in response to retinoic acid - A real time sensing assay for nuclear receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTORS; BINDING DOMAIN; LIVING CELLS; CRYSTAL-STRUCTURE; LOCALIZATION; HSP90; VISUALIZATION; FORM	Members of the nuclear receptor superfamily play key roles in a host of physiologic and pathologic processes from embryogenesis to cancer. Some members, including the retinoic acid receptor (RAR), are activated by ligand binding but are unaffected in their subcellular distribution, which is predominantly nuclear. In contrast, several members of the steroid receptor family, including the glucocorticoid receptor, are cytoplasmic and only translocate to the nucleus after ligand binding. We have constructed chimeras between RAR and glucocorticoid receptor that selectively respond to RAR agonists but display cytoplasmic localization in the absence of ligand. These chimeric receptors manifest both nuclear translocation and gene activation functions in response to physiological concentrations of PLAR ligands. The ability to achieve regulated subcellular trafficking with a heterologous ligand binding domain has implications both for current models of receptor translocation and for structural-functional conservation of ligand binding domains broadly across the receptor superfamily. When coupled to the green fluorescent protein, chimeric receptors offer a powerful new tool to 1) study mechanisms of steroid receptor translocation, 2) detect dynamic and graded distributions of ligands in complex microenvironments such as embryos, and 3) screen for novel ligands of "orphan" receptors in vivo.	NCI, Lab Receptor Biol & Gene Express, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hager, GL (corresponding author), NCI, Lab Receptor Biol & Gene Express, Canc Res Ctr, NIH, Bldg 41,Rm B602, Bethesda, MD 20892 USA.	hagerg@exchange.nci.nih.gov						Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hager GL, 1999, METHOD ENZYMOL, V302, P73, DOI 10.1016/S0076-6879(99)02011-X; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Maden M, 1998, DEVELOPMENT, V125, P4133; MCGRATH ME, 1994, J MOL BIOL, V237, P236, DOI 10.1006/jmbi.1994.1224; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1989, CANCER RES, V49, pS2222; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; WAGNER M, 1992, DEVELOPMENT, V116, P55; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	34	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45501	45504		10.1074/jbc.C100269200	http://dx.doi.org/10.1074/jbc.C100269200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585812	hybrid			2022-12-25	WOS:000172573100002
J	Mamedov, TG; Suzuki, K; Miura, K; Kucho, K; Fukuzawa, H				Mamedov, TG; Suzuki, K; Miura, K; Kucho, K; Fukuzawa, H			Characteristics and sequence of phosphoglycolate phosphatase from a eukaryotic green alga Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORESPIRATORY MUTANT; CHLOROPLAST; DEFICIENT; PROTEINS; PURIFICATION; ACTIVATION; ENZYMES; BINDING; SPINACH; CATION	Phosphoglycolate phosphatase (PGPase), a key enzyme of photorespiration in photosynthetic organisms, was purified from Chlamydomonas reinhardtii. The enzyme was an similar to 65-kDa homodimer with a pI value of 5.1 composed of similar to 32-kDa subunits not connected by any S-S bridges. It was also highly specific for phosphoglycolate with a K-m value of 140 mum and an optimal pH between 8 and 9. The activity was strongly inhibited by CaCl2, and it recovered competitively following the addition of MgCl2 or EGTA. A mobility shift was observed in SDS-polyacrylamide gel electrophoresis by the addition of CaCl2. indicating that the enzyme binds to Ca2+. The N-terminal region of amino acid sequence deduced from cDNA sequence that was not contained in the purified PGPase had similar characteristics to those of typical stroma-targeting transit peptides in C. reinhardtii. The following region of the deduced sequence containing 302 amino acid residues was similar to p-nitrophenylphosphatase-like proteins, although the purified PGPase did not hydrolyze p-nitrophenylphosphate. Genomic DNA fragments from wild type containing the sequence homologous to the cDNA for PGPase complemented the PGPase-deficient mutant pgp1. Possible regulatory mechanisms during adaptation to limiting CO2 were discussed based on the characteristics of the purified PGPase and the deduced amino acid sequence.	Tohoku Natl Agr Res Ctr, Plant Physiol Lab, Morioka, Iwate 0200198, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Plant Mol Biol Lab,Sakyo Ku, Kyoto 6068502, Japan	National Agriculture & Food Research Organization - Japan; Kyoto University	Suzuki, K (corresponding author), Tohoku Natl Agr Res Ctr, Plant Physiol Lab, Morioka, Iwate 0200198, Japan.		Fukuzawa, Hideya/I-5906-2018; Suzuki, Kensaku/A-5944-2012; Mammedov, Tarlan/J-3853-2013; Miura, Kenji/C-2803-2011; Miura, Kenji/AAB-4716-2020	Fukuzawa, Hideya/0000-0003-0963-5662; Suzuki, Kensaku/0000-0002-6006-9785; Miura, Kenji/0000-0003-1262-2176; Miura, Kenji/0000-0003-1262-2176				Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDERSON LE, 1971, BIOCHIM BIOPHYS ACTA, V235, P237, DOI 10.1016/0005-2744(71)90051-9; Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; BALDY P, 1989, PHOTOSYNTH RES, V22, P147, DOI 10.1007/BF00035445; BELANGER FC, 1987, PHOTOSYNTH RES, V14, P3, DOI 10.1007/BF00019588; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARLES SA, 1980, BIOCHEM J, V188, P775, DOI 10.1042/bj1880775; CHRISTELLER JT, 1978, J BIOL CHEM, V253, P1780; CHRISTELLER JT, 1978, J BIOL CHEM, V253, P1786; CHRISTELLER JT, 1978, J BIOL CHEM, V253, P1791; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; Fukuzawa H, 2001, P NATL ACAD SCI USA, V98, P5347, DOI 10.1073/pnas.081593498; HALL NP, 1987, PHOTOSYNTH RES, V11, P89, DOI 10.1007/BF00117676; HARDY P, 1986, PLANTA, V168, P245, DOI 10.1007/BF00402970; HERTIG C, 1980, BIOCHEM BIOPH RES CO, V97, P325, DOI 10.1016/S0006-291X(80)80171-9; HUSIC HD, 1984, ARCH BIOCHEM BIOPHYS, V229, P64, DOI 10.1016/0003-9861(84)90130-9; HUSIC HD, 1985, PLANT PHYSIOL, V79, P394, DOI 10.1104/pp.79.2.394; Ito M, 1997, COMPUT APPL BIOSCI, V13, P415; KERR M W, 1974, Biochemical Society Transactions, V2, P338; Krimm I, 1999, EUR J BIOCHEM, V265, P171, DOI 10.1046/j.1432-1327.1999.00701.x; Kucho K, 1999, PLANT PHYSIOL, V121, P1329, DOI 10.1104/pp.121.4.1329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAREK LF, 1991, PLANT PHYSIOL, V97, P420, DOI 10.1104/pp.97.1.420; MULLEY JC, 1990, CYTOGENET CELL GENET, V53, P175, DOI 10.1159/000132923; NORMAN EG, 1991, PLANT PHYSIOL, V95, P693, DOI 10.1104/pp.95.3.693; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RANDALL D D, 1976, Australian Journal of Plant Physiology, V3, P105; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROSE ZB, 1986, J BIOL CHEM, V261, P996; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; SEAL SN, 1987, J BIOL CHEM, V262, P13496; SOMERVILLE CR, 1979, NATURE, V280, P833, DOI 10.1038/280833a0; Suzuki K, 1999, PLANT CELL PHYSIOL, V40, P792, DOI 10.1093/oxfordjournals.pcp.a029607; SUZUKI K, 1990, PLANT PHYSIOL, V93, P231, DOI 10.1104/pp.93.1.231; SUZUKI K, 1995, PLANT CELL PHYSIOL, V36, P95; VERINVERGEAU C, 1979, PHYTOCHEMISTRY, V18, P1279, DOI 10.1016/0031-9422(79)83007-1; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; WOLFENDEN R, 1970, BIOCHEMISTRY-US, V9, P3404, DOI 10.1021/bi00819a018; WOLOSIUK RA, 1982, FEBS LETT, V140, P31, DOI 10.1016/0014-5793(82)80514-0; ZECHER R, 1982, INT J BIOCHEM, V14, P775, DOI 10.1016/0020-711X(82)90097-0	40	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45573	45579		10.1074/jbc.M103882200	http://dx.doi.org/10.1074/jbc.M103882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581250	Green Published, hybrid			2022-12-25	WOS:000172573100013
J	Fredenburgh, JC; Stafford, AR; Weitz, JI				Fredenburgh, JC; Stafford, AR; Weitz, JI			Conformational changes in thrombin when complexed by serpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-BINDING EXOSITE; HEPARIN-COFACTOR-II; HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; THROMBOMODULIN COMPLEX; MOLECULAR MECHANISMS; PROTEIN-C; INACTIVATION; PROTHROMBIN; INHIBITION	Thrombin possesses two positively charged surface domains, termed exosites, that orient substrates and inhibitors for reaction with the enzyme. Because the exosites also allosterically modulate thrombin's activity, we set out to determine whether the structure or function of the exosites changes when thrombin forms complexes with antithrombin, heparin cofactor II, or alpha (1)-antitrypsin (M358R), serpins that utilize both, one, or neither of the exosites, respectively. Using a hirudin-derived peptide to probe the integrity of exosite 1, no binding was detected when thrombin was complexed with heparin cofactor II or alpha (1)-antitrypsin (M358R), and the peptide exhibited a 55-fold lower affinity for the thrombin-antithrombin complex than for thrombin. Bound peptide or HD-1, an exosite 1-binding DNA aptamer, was displaced from thrombin by each of the three serpins. Thrombin binding to fibrin also was abrogated when the enzyme was complexed with serpins. These data reveal that, regardless of the initial mode of interaction, the function of exosite 1 is lost when thrombin is complexed by serpins. In contrast, the integrity of exosite 2 is largely retained when thrombin is complexed by serpins, because interaction with heparin or an exosite 2-directed DNA aptamer was only modestly altered. The disorganization of exosite 1 that occurs when thrombin is complexed by serpins is consistent with results of protease sensitivity studies and crystallographic analysis of a homologous enzyme-serpin complex.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Weitz, JI (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; ARITOMI M, 1993, THROMB HAEMOSTASIS, V70, P418; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; Baerga-Ortiz A, 2000, J MOL BIOL, V296, P651, DOI 10.1006/jmbi.1999.3447; BINNIE CG, 1993, BLOOD, V81, P3186; BISCHOFF R, 1991, BIOCHEMISTRY-US, V30, P3464, DOI 10.1021/bi00228a017; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK SC, 2000, HEMOSTASIS THROMBOSI, P321; BODE W, 1992, PROTEIN SCI, V1, P426; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; Colman RWCA, 2001, HEMOSTASIS THROMBOSI, P3; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; Duffy EJ, 1997, BIOCHEM J, V321, P361, DOI 10.1042/bj3210361; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; ESMON CT, 2000, HEMATOLOGY BASIC PRI, P1714; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Hogg PJ, 1997, THROMB HAEMOSTASIS, V77, P424; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; LIU LW, 1991, J BIOL CHEM, V266, P23632; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; Nesheim ME, 1999, FIBRINOLYSIS PROTEOL, V13, P72, DOI 10.1016/S0268-9499(99)90082-6; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Wells MJ, 1999, THROMB HAEMOSTASIS, V81, P325, DOI 10.1055/s-0037-1614472; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; WU QY, 1994, J BIOL CHEM, V269, P3725	45	23	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44828	44834		10.1074/jbc.M108710200	http://dx.doi.org/10.1074/jbc.M108710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584020	hybrid			2022-12-25	WOS:000172406700067
J	Levesque, L; Guzik, B; Guan, TL; Coyle, J; Black, BE; Rekosh, D; Hammarskjold, ML; Paschal, BM				Levesque, L; Guzik, B; Guan, TL; Coyle, J; Black, BE; Rekosh, D; Hammarskjold, ML; Paschal, BM			RNA export mediated by Tap involves NXT1-dependent interactions with the nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE TRANSPORT ELEMENT; MESSENGER-RNA; MONOCLONAL-ANTIBODIES; BINDING-PROTEIN; REV PROTEIN; P62 COMPLEX; IDENTIFICATION; MEX67P; CTE; GLYCOPROTEINS	Nuclear export of ribonucleoprotein complexes requires cis-acting signals and recognition by receptors that mediate translocation through the nuclear pore complex. Translocation is likely to involve a series of physical interactions between the ribonucleoprotein complex and nucleoporins within the nuclear pore complex. Here, we have characterized the function of NXT1 in the context of the Tap-dependent RNA export pathway. Tap has been implicated in the nuclear export of RNA transcripts derived from Mason-Pfizer monkey virus that contain the constitutive transport element. We demonstrate that NXT1 stimulates binding of a Tap-RNA complex to nucleoporins in vitro, and we provide mutational analysis that shows these interactions are necessary for nuclear export of an intron-containing viral mRNA in vivo. Tap contains separate domains for binding to nucleoporins and NXT1, both of which are critical for its export function. RNA export is mediated by a heterodimer of Tap and NXT1, and the function of NXT1 on this pathway is to regulate the affinity of the Tap-RNA complex for nucleoporins within the nuclear pore complex. We propose that NXT1-dependent binding of the Tap-RNA complex to the nucleoporin p62, which we have reconstituted in vitro using recombinant proteins, represents a single step of the translocation reaction.	Univ Virginia, Dept Biochem & Mol Genet, Ctr Cell Signaling, Hlth Sci Syst, Charlottesville, VA 22908 USA; Univ Virginia, Myles H Thaler Ctr AIDS & Human Retrovirus Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Virginia; University of Virginia; University of Virginia; Scripps Research Institute	Paschal, BM (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Ctr Cell Signaling, Hlth Sci Syst, Box 800577, Charlottesville, VA 22908 USA.		Guzik, Brian/ABB-7468-2021		NIAID NIH HHS [AI47008, AI34721] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034721, R01AI047008] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bear J, 1999, MOL CELL BIOL, V19, P6306; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Black BE, 1999, MOL CELL BIOL, V19, P8616; Black BE, 2001, J CELL BIOL, V152, P141, DOI 10.1083/jcb.152.1.141; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Clouse KN, 2001, NAT CELL BIOL, V3, P97, DOI 10.1038/35050625; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; Ernst RK, 1997, RNA, V3, P210; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; KADOWAKI T, 1994, MOL BIOL CELL, V5, P1253, DOI 10.1091/mbc.5.11.1253; Kang YB, 2000, J VIROL, V74, P5863, DOI 10.1128/JVI.74.13.5863-5871.2000; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Srinivasakumar N, 1997, J VIROL, V71, P5841, DOI 10.1128/JVI.71.8.5841-5848.1997; Steggerda SM, 2000, MOL BIOL CELL, V11, P703, DOI 10.1091/mbc.11.2.703; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Tan W, 2000, RNA, V6, P1762, DOI 10.1017/S1355838200000832; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374	43	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44953	44962		10.1074/jbc.M106558200	http://dx.doi.org/10.1074/jbc.M106558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579093	hybrid			2022-12-25	WOS:000172406700083
J	Schmidt, M; Fan, Z				Schmidt, M; Fan, Z			Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells	ONCOGENE			English	Article						chemotherapy; chemoprotection; Rb; cell cycle; CDK	HUMAN PAPILLOMAVIRUS TYPE-16; EPIDERMAL GROWTH-FACTOR; G(1) ARREST; RETINOBLASTOMA PROTEIN; E7 ONCOPROTEIN; CDK INHIBITORS; GENE; DIFFERENTIATION; P27(KIP1); BINDING	Inactivation of the retinoblastoma (Rb) protein caused by gene mutation, association with oncoproteins from small DNA viruses, mutational inactivation of p16(Ink4a), or overexpression of cyclin D is a common feature of many human cancer cells and is causally associated with the aberrant proliferation control of cancer cells; whereas normal cells maintain an integrated cell cycle machinery and are subject to cell cycle checkpoint control by cyclin-dependent kinase (CDK) inhibitors (CKIs). To determine whether this difference can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16(Ink4a), p21(Waf1), and p27(Kip1) in one CKI-responsive cell line (A431 human vulvar epidermoid carcinoma cells with functional Rb) and one CKI-unresponsive cell line (SiHa human cervical cancer cells with nonfunctional Rb). Expression of p16(Ink4a), p21(Waf1), or p27(Kip1) in both SiHa and A431 cells strongly inhibited CDK2 activity, indicating functional expression of the CDK inhibitors in both cell lines. However, only in A431 cells did expression of p16(Ink4a), p21(Waf1), or p27(Kip1) cause Rb dephosphorylation, arrest cell cycle traversal, and potently inhibit cell proliferation. Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) in SiHa cells failed to cause Rb dephosphorylation or to arrest cell cycle traversal, and such induction only minimally inhibited cell proliferation. We then compared the chemosensitivity of clones derived from these two cell lines when the CKIs were and were not induced. Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells. Our results support a novel chemotherapy strategy for treating patients with Rb pathway-impaired cancers by concurrent administration of chemotherapy with CKIs as chemoprotective agents for normal cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 36, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; Dellas A, 1998, ANTICANCER RES, V18, P3991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Fueyo J, 1998, INT J ONCOL, V12, P665; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; JONES RE, 1990, J BIOL CHEM, V265, P12782; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; KWOK TT, 1994, CANCER RES, V54, P2834; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; MUNGER K, 1992, CANCER SURV, V12, P197; Ruan S, 1998, CANCER RES, V58, P1538; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; SCHMIDT M, 2001, IN PRESS MOL PHARM; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; StCroix B, 1996, NAT MED, V2, P1204; Stone S, 1996, CANCER RES, V56, P3199; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; Wu XP, 1996, ONCOGENE, V12, P1397; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	41	28	42	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6164	6171		10.1038/sj.onc.1204814	http://dx.doi.org/10.1038/sj.onc.1204814			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593424				2022-12-25	WOS:000171206300007
J	Minic, Z; Pastra-Landis, S; Gaill, F; Herve, G				Minic, Z; Pastra-Landis, S; Gaill, F; Herve, G			Catabolism of pyrimidine Nucleotides in the deep-sea tube worm Riftia pachyptila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-NUCLEOTIDASE INHIBITOR; DIHYDROPYRIMIDINE DEHYDROGENASE; CHEMOAUTOTROPHIC SYMBIONTS; PARTIAL-PURIFICATION; KINETIC-PROPERTIES; ESCHERICHIA-COLI; INORGANIC CARBON; RAT-LIVER; NITROGEN; JONES	The present study describes the distribution and properties of enzymes of the catabolic pathway of pyrimidine nucleotides in Riftia pachyptila, a tubeworm living around deep-sea hydrothermal vents and known to be involved in a highly specialized symbiotic association with a bacterium. The catabolic enzymes, 5'-nucleotidase, uridine phosphorylase, and uracil reductase, are present in all tissues of the worm, whereas none of these enzymatic activities were found in the symbiotic bacteria. The 5'-nucleotidase activity was particularly high in the trophosome, the symbiont-harboring tissue. These results suggest that the production of nucleosides in the trophosome may represent an alternative source of carbon and nitrogen for R. pachyptila, because these nucleosides can be delivered to other parts of the worm. This process would complement the source of carbon and nitrogen from organic metabolites provided by the bacterial assimilatory pathways. The localization of the enzymes participating in catabolism, 5'-nucleotidase and uridine phosphorylase, and of the enzymes involved in the biosynthesis of pyrimidine nucleotides, aspartate transcarbamylase and dihydroorotase, shows a non-homogeneous distribution of these enzymes in the trophosome. The catabolic enzymes 5'-nucleotidase and uridine phosphorylase activities increase from the center of the trophosome to its periphery. In contrast, the anabolic enzymes aspartate transcarbamylase and dihydroorotase activities decrease from the center toward the periphery of the trophosome. We propose a general scheme of anatomical and physiological organization of the metabolic pathways of the pyrimidine nucleotides in R. pachyptila and its bacterial endosymbiont.	Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, F-75006 Paris, France; Wheaton Coll, Dept Chem, Norton, MA 02766 USA; Univ Paris 06, CNRS, UMR 7622, Biol Marine Lab, F-75252 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite	Herve, G (corresponding author), Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, 96 Blvd Raspail, F-75006 Paris, France.	gherve@ccr.jussieu.fr	Minic, Zoran/AAH-2091-2021					BERLIN RD, 1975, INT REV CYTOL, V42, P287, DOI 10.1016/S0074-7696(08)60983-3; BEUTLER E, 1982, BIOCHEM MED METAB B, V27, P334, DOI 10.1016/0006-2944(82)90038-2; BOREL JP, 1997, BIOCHIMIE DYNAMIQUE, P773; BOSCH C, 1984, CR ACAD SCI III-VIE, V299, P371; BOSMANN HB, 1971, BIOCHIM BIOPHYS ACTA, V227, P402, DOI 10.1016/0005-2744(71)90071-4; Bright M, 2000, MAR BIOL, V136, P621, DOI 10.1007/s002270050722; BURGER RM, 1975, BIOCHEMISTRY-US, V14, P2362, DOI 10.1021/bi00682a014; CAMICI M, 1985, BIOCHIM BIOPHYS ACTA, V840, P6, DOI 10.1016/0304-4165(85)90155-2; CAMPBELL TA, 1991, MOL BIOCHEM PARASIT, V47, P109, DOI 10.1016/0166-6851(91)90153-W; CAVANAUGH CM, 1981, SCIENCE, V213, P340, DOI 10.1126/science.213.4505.340; CHILDRESS JJ, 1993, NATURE, V362, P147, DOI 10.1038/362147a0; De Cian MC, 2000, J EXP BIOL, V203, P2907; DISTEL DL, 1987, MAR BIOL, V96, P97; ELKOUNI MH, 1982, P NATL ACAD SCI-BIOL, V79, P1037; ELLIMS PH, 1978, CLIN CHIM ACTA, V88, P99, DOI 10.1016/0009-8981(78)90155-9; FELBECK H, 1981, SCIENCE, V213, P336, DOI 10.1126/science.213.4505.336; FRITZSON P, 1969, BIOCHIM BIOPHYS ACTA, V178, P534, DOI 10.1016/0005-2744(69)90222-8; GAILL F, 1993, FASEB J, V7, P558, DOI 10.1096/fasebj.7.6.8472894; Gardiner S.L., 1993, MICROSCOPIC ANATOMY, V12, P371; Girguis PR, 2000, APPL ENVIRON MICROB, V66, P2783, DOI 10.1128/AEM.66.7.2783-2790.2000; GRONDAL EJM, 1987, BIOCHEM J, V245, P805, DOI 10.1042/bj2450805; HENTSCHEL U, 1993, NATURE, V366, P338, DOI 10.1038/366338a0; HERVE G, 1991, COLLOQ INSE, V203, P195; JENSEN MH, 1980, CLIN CHIM ACTA, V104, P221, DOI 10.1016/0009-8981(80)90199-0; Johnson S, 2000, FEMS MICROBIOL LETT, V192, P59, DOI 10.1016/S0378-1097(00)00409-2; Jones M.L., 1981, Proceedings of the Biological Society of Washington, V93, P1295; JONES ML, 1981, SCIENCE, V213, P333, DOI 10.1126/science.213.4505.333; Lee RW, 1999, J EXP BIOL, V202, P289; Lee RW, 1996, BIOL BULL, V190, P373, DOI 10.2307/1543030; LEGER D, 1988, BIOCHEMISTRY-US, V27, P4293, DOI 10.1021/bi00412a015; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADRIDMARINA V, 1986, J BIOL CHEM, V261, P444; MALLOL J, 1983, J NEUROCHEM, V40, P1205, DOI 10.1111/j.1471-4159.1983.tb13558.x; MASOOD R, 1987, ANN INST PASTEUR MIC, V138, P501, DOI 10.1016/0769-2609(87)90036-6; MILSTEIN OA, 1976, J BACTERIOL, V127, P1; Minic Z, 2001, J BIOL CHEM, V276, P23777, DOI 10.1074/jbc.M102249200; NAITO Y, 1976, BIOCHIM BIOPHYS ACTA, V438, P159, DOI 10.1016/0005-2744(76)90232-1; Nelson D.C., 1995, DEEP SEA HYDROTHERMA, P125; NEU HC, 1967, J BIOL CHEM, V242, P3905; NIEDZWICKI JG, 1983, BIOCHEM PHARMACOL, V32, P399, DOI 10.1016/0006-2952(83)90517-8; Niedzwiecka J, 1996, BIOCHEM BIOPH RES CO, V221, P471, DOI 10.1006/bbrc.1996.0619; NIEMANN MA, 1981, BIOCHIM BIOPHYS ACTA, V652, P347, DOI 10.1016/0005-2787(81)90124-6; PAGLIA DE, 1975, J BIOL CHEM, V250, P7973; PAPAS PW, 1983, MOL BIOCHEM PARASIT, V8, P1; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; POLYA GM, 1975, BIOCHIM BIOPHYS ACTA, V384, P443, DOI 10.1016/0005-2744(75)90045-5; POWELL MA, 1986, BIOL BULL, V171, P274, DOI 10.2307/1541923; RAJPUT A, 1992, INDIAN J BIOCHEM BIO, V29, P204; Schmitt U, 1996, ARCH BIOCHEM BIOPHYS, V332, P175, DOI 10.1006/abbi.1996.0330; Scocca J J, 1978, Methods Enzymol, V51, P432; SCOTT KM, 1994, PHYSIOL ZOOL, V67, P617, DOI 10.1086/physzool.67.3.30163761; Simon V, 2000, MAR BIOL, V136, P115, DOI 10.1007/s002270050014; SONADA T, 1978, BIOCHIM BIOPHYS ACTA, V521, P55; TORRANCE J, 1977, J LAB CLIN MED, V90, P563; TORRANCE JD, 1977, P NATL ACAD SCI USA, V74, P3701, DOI 10.1073/pnas.74.9.3701; UCHINO K, 1985, J ANTIBIOT, V38, P157, DOI 10.7164/antibiotics.38.157; West TP, 1997, ARCH MICROBIOL, V168, P237, DOI 10.1007/s002030050493; Zal F, 1996, J BIOL CHEM, V271, P8869, DOI 10.1074/jbc.271.15.8869; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	60	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					127	134		10.1074/jbc.M108035200	http://dx.doi.org/10.1074/jbc.M108035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11591717	hybrid			2022-12-25	WOS:000173087900018
J	Taghibiglou, C; Rashid-Kolvear, F; Van Iderstine, SC; Le-Tien, H; Fantus, IG; Lewis, GF; Adeli, K				Taghibiglou, C; Rashid-Kolvear, F; Van Iderstine, SC; Le-Tien, H; Fantus, IG; Lewis, GF; Adeli, K			Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B SECRETION; CULTURED RAT HEPATOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; LIVER ENDOPLASMIC-RETICULUM; ZUCKER FA/FA RATS; SKELETAL-MUSCLE; HEPG2 CELLS; RECEPTOR SUBSTRATE-1	A fructose-fed hamster model of insulin resistance was previously documented to exhibit marked hepatic very low density lipoprotein (VLDL) overproduction. Here, we investigated whether VLDL overproduction was associated with down-regulation of hepatic insulin signaling and insulin resistance. Hepatocytes isolated from fructose-fed hamsters exhibited significantly reduced tyrosine phosphorylation of the insulin receptor and insulin receptor substrates I and 2. Phosphatidylinositol 3-kinase activity as well as insulin-stimulated Akt-Ser(473) and Akt-Thr(308) phosphorylation were also significantly reduced with fructose feeding. Interestingly, the protein mass and activity of protein-tyrosine phosphatase-1B (PTP-1B) were significantly higher in fructose-fed hamster hepatocytes. Chronic ex vivo exposure of control hamster hepatocytes to high insulin also appeared to attenuate insulin signaling and increase PTP-1B. Elevation in PTP-1B coincided with marked suppression of ER-60, a cysteine protease postulated to play a role in intracellular apoB degradation, and an increase in the synthesis and secretion of apoB. Sodium orthovanadate, a general phosphatase inhibitor, partially restored insulin receptor phosphorylation and significantly reduced apoB secretion. In summary, we hypothesize that fructose feeding induces hepatic insulin resistance at least in part via an increase in expression of PTP-1B. Induction of hepatic insulin resistance may then contribute to reduced apoB degradation and enhanced VLDL particle assembly and secretion.	Hosp Sick Children, Div Clin Biochem, Dept Lab Med & Pathol, Toronto, ON M5G 1X8, Canada; Mt Sinai Hosp, Dept Med, Div Endocrinol & Metab, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Adeli, K (corresponding author), Hosp Sick Children, Div Clin Biochem, Dept Lab Med & Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Taghibiglou, Changiz/H-4590-2019	Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1992, BIOCHEM CELL BIOL, V70, P1301, DOI 10.1139/o92-177; Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; Bergman Richard N., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P205; Bezerra RMN, 2000, J NUTR, V130, P1531, DOI 10.1093/jn/130.6.1531; BJORNSSON OG, 1992, BIOCHEM J, V281, P381; BOURGEOIS CS, 1995, AM J PHYSIOL-ENDOC M, V269, pE208, DOI 10.1152/ajpendo.1995.269.2.E208; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; DASHTI N, 1989, J LIPID RES, V30, P1365; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Dirlewanger M, 2000, AM J PHYSIOL-ENDOC M, V279, pE907, DOI 10.1152/ajpendo.2000.279.4.E907; DURRINGTON PN, 1982, J CLIN INVEST, V70, P63, DOI 10.1172/JCI110604; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fujimoto WY., 2000, AM J MED S6A, V108, p9S, DOI DOI 10.1016/S0002-9343(00)00337-5; Garg A, 1996, DIABETES CARE, V19, P387, DOI 10.2337/diacare.19.4.387; Garg A, 1998, ENDOCRIN METAB CLIN, V27, P613, DOI 10.1016/S0889-8529(05)70029-3; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; Inui Y, 1997, INT J OBESITY, V21, P231, DOI 10.1038/sj.ijo.0800392; JACKSON TK, 1988, DIABETES, V37, P1234, DOI 10.2337/diabetes.37.9.1234; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; KasimKarakas SE, 1996, J LAB CLIN MED, V128, P208, DOI 10.1016/S0022-2143(96)90013-X; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MYKKANEN L, 1994, METABOLISM, V43, P523, DOI 10.1016/0026-0495(94)90088-4; PATSCH W, 1986, J BIOL CHEM, V261, P9603; PATSCH W, 1983, J CLIN INVEST, V71, P1161, DOI 10.1172/JCI110865; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REAVEN GM, 1993, J CLIN INVEST, V92, P141, DOI 10.1172/JCI116541; REAVEN GM, 1992, METABOLISM, V41, P16, DOI 10.1016/0026-0495(92)90088-R; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rondinone CM, 1999, DIABETOLOGIA, V42, P819, DOI 10.1007/s001250051232; SALHANICK AI, 1991, METABOLISM, V40, P275, DOI 10.1016/0026-0495(91)90109-A; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; SPARKS CE, 1986, METABOLISM, V35, P1128, DOI 10.1016/0026-0495(86)90026-0; SPARKS JD, 1994, METABOLISM, V43, P681, DOI 10.1016/0026-0495(94)90115-5; SPARKS JD, 1989, BIOCHEM J, V261, P83, DOI 10.1042/bj2610083; Sparks JD, 1996, BIOCHEM J, V313, P567, DOI 10.1042/bj3130567; SPARKS JD, 1994, BIOCHEM BIOPH RES CO, V205, P417, DOI 10.1006/bbrc.1994.2681; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; SREDY J, 1995, METABOLISM, V44, P1074, DOI 10.1016/0026-0495(95)90107-8; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Suga A, 2000, AM J PHYSIOL-ENDOC M, V278, pE677, DOI 10.1152/ajpendo.2000.278.4.E677; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Taghibiglou C, 2000, J LIPID RES, V41, P499; TASKINEN MR, 1995, CURR OPIN LIPIDOL, V6, P153, DOI 10.1097/00041433-199506000-00007; THERIAULT A, 1992, CLIN BIOCHEM, V25, P321, DOI 10.1016/0009-9120(92)80007-4; THORBURN AW, 1989, AM J CLIN NUTR, V49, P1155, DOI 10.1093/ajcn/49.6.1155; THORNGATE FE, 1994, P NATL ACAD SCI USA, V91, P5392, DOI 10.1073/pnas.91.12.5392; TOBEY TA, 1982, METABOLISM, V31, P608, DOI 10.1016/0026-0495(82)90100-7; TONKS NK, 1988, J BIOL CHEM, V263, P6731; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; URADE R, 1993, J BIOL CHEM, V268, P22004; von Wronski MA, 1998, METABOLISM, V47, P869, DOI 10.1016/S0026-0495(98)90128-7; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; Withers DJ, 2000, ENDOCRINOLOGY, V141, P1917, DOI 10.1210/en.141.6.1917; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SCJ, 1998, TRENDS CARDIOVAS MED, V8, P8, DOI 10.1016/S1050-1738(97)00120-5; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; YOSHINO G, 1992, METABOLISM, V41, P236, DOI 10.1016/0026-0495(92)90264-B; ZAVARONI I, 1980, METABOLISM, V29, P970, DOI 10.1016/0026-0495(80)90041-4; ZAVARONI I, 1982, METABOLISM, V31, P1077, DOI 10.1016/0026-0495(82)90155-X	81	192	201	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					793	803		10.1074/jbc.M106737200	http://dx.doi.org/10.1074/jbc.M106737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11598116	hybrid			2022-12-25	WOS:000173087900102
J	Dafforn, TR; Della, M; Miller, AD				Dafforn, TR; Della, M; Miller, AD			The molecular interactions of heat shock protein 47 (Hsp47) and their implications for collagen biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NEWLY SYNTHESIZED PROCOLLAGEN; ENDOPLASMIC-RETICULUM; DISULFIDE-ISOMERASE; ANGSTROM STRUCTURE; CHAPERONE HSP47; REACTIVE LOOP; BINDING; ALPHA(1)-ANTITRYPSIN; PH	Heat shock protein 47 (Hsp47) is a procollagen/collagen-specific molecular chaperone protein derived from the serpin family of proteins and essential for the early stages of collagen biosynthesis. In this paper, the results of an extensive biophysical analysis of mature recombinant mouse Hsp47 show the existence of both a structurally mesostable monomer with a 5-strand A-sheet and/or a hyperstable trimer; both states have biological activity. It is also demonstrated that Hsp47 is able to bind to a monomeric and partially folded conformation collagen mimic peptide (PPG)(10). Upon peptide binding Hsp47 has the capacity to induce the peptide backbone to fold into a polyproline type II conformation. Induction of this conformation results in (PPG)(10) peptides associating into higher order assemblies with increased stability compared with the monomeric peptide alone. These assemblies are similar to those observed by others (Go, N., and Suezaki, Y. (1973) Biopolyiners 12,1927-1930; Engel, J., Chen, H. T., Prockop, D. J., and Klump, H. (1977) Biopolymers 16, 601-622) when the peptide is dissolved at high concentration and are proposed to be long chains of peptides in a collagen-like configuration. Examination of the biophysical characteristics of both monomeric and trimeric Hsp47-(PPG)(10) complexes is also used to determine that the peptide-binding site does not reside in strand 4 position of sheet A, as observed for other serpins (Skinner, R., Chang, W. S. W., Jin, L., Pei, YL, Huntington, J. A., Abrahams, J. P., Carrell, R. W., and Lomas, D. A. (1998) J. Mol. BioL 283,9-14), leaving earlier proposals of a binding site near helix A viable.	Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, London SW7 2AZ, England; Univ Cambridge, Dept Haematol, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Imperial College London; University of Cambridge	Miller, AD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, Flowers Bldg,Armstrong Rd, London SW7 2AZ, England.		Miller, Andrew/G-8291-2019; Dafforn, Tim/A-9072-2015	Miller, Andrew/0000-0003-0661-249X; Dafforn, Tim/0000-0003-2257-6679				Becerril C, 1999, AM J RESP CELL MOL, V20, P1020, DOI 10.1165/ajrcmb.20.5.3288; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davids JW, 1995, BIOORG CHEM, V23, P427, DOI 10.1006/bioo.1995.1029; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ElThaher TSH, 1996, PROTEIN PEPTIDE LETT, V3, P1; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Engel J, 2000, MATRIX BIOL, V19, P235, DOI 10.1016/S0945-053X(00)00071-8; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; GO N, 1973, BIOPOLYMERS, V12, P1927, DOI 10.1002/bip.1973.360120818; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; Mayo KH, 1996, BIOPOLYMERS, V40, P359, DOI 10.1002/(SICI)1097-0282(1996)40:4<359::AID-BIP2>3.0.CO;2-V; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAGATA K, 1988, BIOCHEM BIOPH RES CO, V153, P428, DOI 10.1016/S0006-291X(88)81242-7; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Rocnik E, 2000, CIRCULATION, V101, P1229, DOI 10.1161/01.CIR.101.11.1229; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Sivasothy P, 1999, AM J RESP CRIT CARE, V159, pA481; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; SMITH T, 1995, J BIOL CHEM, V270, P18323, DOI 10.1074/jbc.270.31.18323; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; Sunamoto M, 1998, LAB INVEST, V78, P967; Takeda K, 2000, CORONARY ARTERY DIS, V11, P57, DOI 10.1097/00019501-200002000-00011; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thomson CA, 2000, BIOCHEM J, V349, P877, DOI 10.1042/bj3490877; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Williams RS, 2000, CIRCULATION, V101, P1227, DOI 10.1161/01.CIR.101.11.1227; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637	54	91	96	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49310	49319		10.1074/jbc.M108896200	http://dx.doi.org/10.1074/jbc.M108896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11592970	hybrid			2022-12-25	WOS:000173922100090
J	Lee, EY; Yoon, HY; Ahn, JY; Choi, SY; Cho, SW				Lee, EY; Yoon, HY; Ahn, JY; Choi, SY; Cho, SW			Identification of the GTP binding site of human glutamate dehydrogenase by cassette mutagenesis and photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HYPERAMMONEMIA SYNDROME; CLOSTRIDIUM-SYMBIOSUM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HUMAN-LIVER; ISOPROTEINS; HYPERINSULINISM; EXPRESSION; POLYMERASE	It has been reported that the hyperinsulinism-hyperammonemia syndrome is caused by mutations in glutamate dehydrogenase (GDH) gene that affects enzyme sensitivity to GTP-induced inhibition. To identify the GTP binding site(s) within human GDH, mutant GDHs at Tyr-266 or Lys-450 position were constructed by cassette mutagenesis. More than 90% of the initial activities were remained at the concentration of GTP up to 300 muM for the Lys-450 mutant GDHs regardless of their size, hydrophobicity, and ionization of the side chains, whereas the wild type GDH and the Tyr-266 mutant GDHs were completely inhibited by 30 muM GTP. The binding of GTP to the wild type GDH or the mutant GDHs was further examined by photoaffinity labeling with 8-[gamma-P-32]azidoguanosine 5'-triphosphate (S-N-3-GTP). Saturation of photoinsertion with 8-N-3-GTP occurred apparent Kd values near 20 muM for the wild type GDH or the Tyr-266 mutant GDH, and the photoinsertion of 8-N-3-[gamma-P-32]GTP was significantly decreased in the presence of 300 muM GTP. Unlike the wild type GDH or the Tyr-266 mutant GDH, less than 10% of photoinsertion was detected in the Lys-450 mutant GDH, and the photoinsertion was not affected by the presence of 300 muM GTP. The results with cassette mutagenesis and photoaffinity labeling demonstrate selectivity of the photoprobe for the GTP binding site and suggest that Lys-450, but not Tyr-266, is required for efficient binding of GTP to GDH. Interestingly, studies of the steady-state velocity showed that both the wild type GDH and the Tyr-266 mutant GDHs were inhibited by ATP at concentrations between 10 and 100 muM, whereas less than 10% of the initial activities of the Lys-450 mutant GDHs were diminished by ATP. These results indicate that Lys-450, but not Tyr-266, may be also responsible for the ATP inhibition; therefore, ATP bound to the GTP site.	Univ Ulsan, Coll Med, Dept Biochem, Songpa Ku, Seoul 138736, South Korea; Yonsei Univ, Coll Hlth Sci, Dept Med Technol, Wonju 222701, South Korea; Hallym Univ, Div Life Sci, Dept Genet Engn, Chunchon 200702, South Korea	University of Ulsan; Yonsei University; Hallym University	Cho, SW (corresponding author), Univ Ulsan, Coll Med, Dept Biochem, Songpa Ku, 388-1 Poongnap Dong, Seoul 138736, South Korea.	swcho@ame.seoul.kr						BAILEY J, 1982, J BIOL CHEM, V257, P5579; BRYLA J, 1994, METABOLISM, V43, P1187, DOI 10.1016/0026-0495(94)90064-7; CAMPBELL S, 1990, P NATL ACAD SCI USA, V87, P1243, DOI 10.1073/pnas.87.3.1243; Cho SW, 1999, J BIOL CHEM, V274, P13948, DOI 10.1074/jbc.274.20.13948; Cho SW, 1998, J BIOL CHEM, V273, P31125, DOI 10.1074/jbc.273.47.31125; Cho SW, 1996, BIOCHEMISTRY-US, V35, P13907, DOI 10.1021/bi9618575; CHO SW, 1995, EUR J BIOCHEM, V233, P340, DOI 10.1111/j.1432-1033.1995.340_1.x; Cho SW, 2001, EUR J BIOCHEM, V268, P3205, DOI 10.1046/j.1432-1327.2001.02209.x; Choi SY, 1999, J NEUROCHEM, V72, P2162, DOI 10.1046/j.1471-4159.1999.0722162.x; Colman RF, 1991, STUDY ENZYMES, P173; De Lonlay P, 2001, PEDIATR RES, V50, P353, DOI 10.1203/00006450-200109000-00010; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FRIEDEN C, 1959, J BIOL CHEM, V234, P809; GUNNERSEN D, 1992, P NATL ACAD SCI USA, V89, P11949, DOI 10.1073/pnas.89.24.11949; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JACOBSON MA, 1982, BIOCHEMISTRY-US, V21, P2177, DOI 10.1021/bi00538a029; JULLIARD JH, 1979, J BIOL CHEM, V254, P3427; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KOBERSTEIN R, 1973, EUR J BIOCHEM, V36, P545, DOI 10.1111/j.1432-1033.1973.tb02942.x; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; MCPHERSON MJ, 1983, NUCLEIC ACIDS RES, V11, P5257, DOI 10.1093/nar/11.15.5257; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; PAL PK, 1979, BIOCHEMISTRY-US, V18, P838, DOI 10.1021/bi00572a016; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Plaitakis A, 2000, J NEUROCHEM, V75, P1862, DOI 10.1046/j.1471-4159.2000.0751862.x; RICE DW, 1987, BIOCHEM J, V242, P789, DOI 10.1042/bj2420789; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; Santer R, 2001, HUM GENET, V108, P66, DOI 10.1007/s004390000432; Shashidharan P, 1997, J NEUROCHEM, V68, P1804; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; Smith TJ, 2001, J MOL BIOL, V307, P707, DOI 10.1006/jmbi.2001.4499; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; TELLER JK, 1995, BBA-PROTEIN STRUCT M, V1247, P231, DOI 10.1016/0167-4838(94)00240-H; TZIMAGIORGIS G, 1991, BIOCHIM BIOPHYS ACTA, V1089, P250, DOI 10.1016/0167-4781(91)90017-G; WOOTTON JC, 1974, P NATL ACAD SCI USA, V71, P4361, DOI 10.1073/pnas.71.11.4361; Yorifuji T, 1999, HUM GENET, V104, P476, DOI 10.1007/s004390050990	39	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47930	47936		10.1074/jbc.M108918200	http://dx.doi.org/10.1074/jbc.M108918200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11600502	hybrid			2022-12-25	WOS:000172927000029
J	McBee, JK; Van Hooser, JP; Jang, GF; Palczewski, K				McBee, JK; Van Hooser, JP; Jang, GF; Palczewski, K			Isomerization of 11-cis-retinoids to all-trans-retinoids in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL LIGHT DAMAGE; PIGMENT EPITHELIAL-CELLS; RECESSIVE RETINITIS-PIGMENTOSA; VISUAL CYCLE; BINDING PROTEIN; ASCORBIC-ACID; RAT RETINA; FUNDUS-ALBIPUNCTATUS; CONGENITAL AMAUROSIS; STARGARDT-DISEASE	The regeneration of 11-cis-retinal, the universal chromophore of the vertebrate retina, is a complex process involving photoreceptors and adjacent retinal pigment epithelial cells (RPE). 11-cis-Retinal is coupled to opsins in both rod and cone photoreceptor cells and is photoisomerized to all-trans-retinal by light. Here, we show that RPE microsomes can catalyze the reverse isomerization of 11-cis-retinol to all-trans-retinol (and 13-cis-retinol), and membrane exposure to UV light further enhances the rate of this reaction. This conversion is inhibited when 11-cis-retinol is in a complex with cellular retinaldehyde-binding protein (CRALBP), providing a clear demonstration of the protective effect of retinoid-binding proteins in retinoid processes in the eye, a function that has been long suspected but never proven. The reverse isomerization is nonenzymatic and specific to alcohol forms of retinoids, and it displays stereospecific preference for 11-cis-retinol and 13-eis-retinol but is much less efficient for 9-cis-retinol. The mechanism of reverse isomerization was investigated using stable isotope-labeled retinoids and radioactive tracers to show that this reaction occurs with the retention of configuration of the C-15 carbon of retinol through a mechanism that does not eliminate the hydroxyl group, in contrast to the enzymatic all-trans-retinol to 11-cis-retinol reaction. The activation energy for the conversion of 11-cis-retinol to all-trans-retinol is 19.5 kcal/mol, and 20.1 kcal/mol for isomerization of 13-cis-retinol to all-trans-retinol. We also demonstrate that the reverse isomerization occurs in vivo using exogenous 11-cis-retinol injected into the intravitreal space of wild type and Rpe65(-/-) mice, which have defective forward isomerization. This study demonstrates an uncharacterized activity of RPE microsomes that could be important in the normal flow of retinoids in the eye in vivo during dark adaptation.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu			NEI NIH HHS [T32 EY007031, F32 EY007031, R01 EY009339, EY07031, EY09339, EY66-3988] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; CROCKETT RS, 1984, CURR EYE RES, V3, P209, DOI 10.3109/02713688408997202; CROUCH RK, 1992, PHOTOCHEM PHOTOBIOL, V56, P251, DOI 10.1111/j.1751-1097.1992.tb02154.x; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Ferreri C, 2001, J AM CHEM SOC, V123, P4459, DOI 10.1021/ja0040969; FULTON BS, 1987, BIOCHEMISTRY-US, V26, P110, DOI 10.1021/bi00375a016; Gonzalez-Fernandez F, 1999, MOL VIS, V5, pU1; GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851; GROENENDIJK GWT, 1980, EUR J BIOCHEM, V106, P119; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0; Hao WS, 2000, METHOD ENZYMOL, V316, P413; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; Kuroiwa S, 2000, AM J OPHTHALMOL, V130, P672, DOI 10.1016/S0002-9394(00)00765-0; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LAW WC, 1988, BIOCHEMISTRY-US, V27, P4147, DOI 10.1021/bi00411a037; LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Mondal MS, 2000, BIOCHEMISTRY-US, V39, P5215, DOI 10.1021/bi9929554; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Organisciak D T, 1987, Prog Clin Biol Res, V247, P455; ORGANISCIAK DT, 1990, INVEST OPHTH VIS SCI, V31, P1195; ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599; ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580; ORGANISCIAK DT, 1984, CURR EYE RES, V3, P257, DOI 10.3109/02713688408997208; ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5; ORGANISCIAK DT, 1992, CURR EYE RES, V11, P231, DOI 10.3109/02713689209001774; Pakhomova S, 2001, NAT STRUCT BIOL, V8, P447, DOI 10.1038/87617; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; PAUTLER EL, 1990, PHOTOCHEM PHOTOBIOL, V51, P599, DOI 10.1111/j.1751-1097.1990.tb01972.x; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Ranchon I, 2001, INVEST OPHTH VIS SCI, V42, P1375; Rando RR, 1996, CHEM BIOL, V3, P255, DOI 10.1016/S1074-5521(96)90105-2; RAPP LM, 1992, INVEST OPHTH VIS SCI, V33, P3367; RAPP LM, 1990, INVEST OPHTH VIS SCI, V31, P1186; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; Roll B, 1995, BIOCHEM BIOPH RES CO, V217, P452, DOI 10.1006/bbrc.1995.2797; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SACK RA, 1978, VISION RES, V18, P423, DOI 10.1016/0042-6989(78)90052-4; Shimizu T, 1998, J BIOCHEM-TOKYO, V123, P953; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sorg O, 1999, DERMATOLOGY, V199, P302, DOI 10.1159/000018279; Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356; Stecher H, 1999, BIOCHEMISTRY-US, V38, P13542, DOI 10.1021/bi9913294; Stecher H, 2000, METHOD ENZYMOL, V316, P330; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; TANG G, 1994, PHOTODERMATOL PHOTO, V10, P1; Tao L, 1998, Mol Vis, V4, P25; Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828; Tran C, 2001, PHOTOCHEM PHOTOBIOL, V73, P425, DOI 10.1562/0031-8655(2001)073<0425:TDORCT>2.0.CO;2; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Van Hooser JP, 2000, METHOD ENZYMOL, V316, P565; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707	76	41	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48483	48493		10.1074/jbc.M105840200	http://dx.doi.org/10.1074/jbc.M105840200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604395	Green Accepted, hybrid			2022-12-25	WOS:000172927000101
J	D'Aurelio, M; Pallotti, F; Barrientos, A; Gajewski, CD; Kwong, JQ; Bruno, C; Beal, MF; Manfredi, G				D'Aurelio, M; Pallotti, F; Barrientos, A; Gajewski, CD; Kwong, JQ; Bruno, C; Beal, MF; Manfredi, G			In vivo regulation of oxidative phosphorylation in cells harboring a stop-codon mutation in mitochondrial DNA-encoded cytochrome c oxidase subunit I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN; MTDNA MUTATION; COX DEFICIENCY; GENE; ENCEPHALOMYOPATHY; PROTEIN; PATIENT; ELECTROPHORESIS; MICRODELETION; COMPLEXES	The mechanisms that regulate oxidative phosphorylation in mammalian cells are largely unknown. To address this issue, cybrids were generated by fusing osteosarcoma cells devoid of mitochondrial DNA (mtDNA) with platelets from a patient with a stop-codon mutation in cytochrome c oxidase subunit I (COX I). The molecular and biochemical characteristics of cybrids harboring varying levels of mutated mitochondrial DNA were studied. We found a direct correlation between the levels of mutated COX I DNA and mutated COX I mRNA, whereas the levels of COX I total mRNA were unchanged. COX I polypeptide synthesis and steady-state levels were inversely proportional to mutation levels. Cytochrome c oxidase subunit Il was reduced proportionally to COX I, indicating impairment in complex assembly. COX enzymatic activity was inversely proportional to the levels of mutated mtDNA. However, both cell respiration and ATP synthesis were preserved in cells with lower proportions of mutated genomes, with a threshold at similar to 40%, and decreased linearly with increasing mutated mtDNA. These results indicate that COX levels in mutated cells were not regulated at the transcriptional, translational, and post-translational levels. Because of a small excess of COX capacity, the levels of expression of COX subunits exerted a relatively tight control on oxidative phosphorylation.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Genoa, Ist Giannina Gaslini, Dept Pediat, I-16147 Genoa, Italy	Cornell University; Columbia University; Columbia University; University of Genoa; IRCCS Istituto Giannina Gaslini	Manfredi, G (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 525 E 68th St,A-505, New York, NY 10021 USA.		Kwong, Jennifer/L-4348-2019; Bruno, Claudio/A-3148-2015	Bruno, Claudio/0000-0002-3426-2901; Pallotti, Francesco/0000-0001-9946-8516				Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197; Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361; Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Glerum DM, 1997, FEBS LETT, V412, P410, DOI 10.1016/S0014-5793(97)00799-0; GROSS NJ, 1969, J BIOL CHEM, V244, P1552; Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; Hoffbuhr KC, 2000, J BIOL CHEM, V275, P13994, DOI 10.1074/jbc.275.18.13994; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900; Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; King M P, 1996, Methods Enzymol, V264, P339, DOI 10.1016/S0076-6879(96)64032-4; Kunz WS, 2000, J BIOL CHEM, V275, P27741; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lehtinen SK, 2000, GENETICS, V154, P363; Manfredi G, 2001, METHOD CELL BIOL, V65, P133, DOI 10.1016/S0091-679X(01)65008-8; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Papadopoulou LC, 1999, NAT GENET, V23, P333; POLOSA PL, 1991, J BIOL CHEM, V266, P10011; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Valnot I, 2000, AM J HUM GENET, V67, P1104; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	40	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46925	46932		10.1074/jbc.M106429200	http://dx.doi.org/10.1074/jbc.M106429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595737	hybrid			2022-12-25	WOS:000172768500035
J	Hui, YQ; Yang, GC; Galczenski, H; Figueroa, DJ; Austin, CP; Copeland, NG; Gilbert, DJ; Jenkins, NA; Funk, CD				Hui, YQ; Yang, GC; Galczenski, H; Figueroa, DJ; Austin, CP; Copeland, NG; Gilbert, DJ; Jenkins, NA; Funk, CD			The murine cysteinyl leukotriene 2 (CysLT(2)) receptor - cDNA and genomic cloning, alternative splicing, and in vitro characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HUMAN LUNG; RELEASE; AGONIST; TISSUE	Two classes of cysteinyl leukotriene receptor, CysLT(1) and CysLT(2), have been identified and pharmacologically characterized in human tissues. Although the CysLT(1) receptor mediates the proinflammatory effects of leukotrienes in human asthma, the physiological roles of CysLT(2) receptor are not defined, and a suitable mouse model would be useful in delineating function. We report here the molecular cloning and characterization of the mouse CysLT2 receptor (mCysLT(2)R) from heart tissue. mCysLT(2)R cDNA encodes a protein of 309 amino acids, truncated at both ends compared with the human ortholog (hCysLT(2)R). The gene resides on the central region of mouse chromosome 14 and is composed of 6 exons with the entire coding region located in the last exon. Two W-untranslated region splice variants were identified with the short form lacking exon 3 as the predominant transcript. Although the overall expression of mCysLT2R is very low, the highest expression was detected in spleen, thymus, and adrenal gland by ribonuclease protection assay, and discrete sites of expression in heart were observed by in situ hybridization. Intracellular calcium mobilization in response to cysteinyl leukotriene administration was detected in human embryonic kidney 293T cells transfected with recombinant mCysLT2R with a rank order of potency leukotriene C-4 (LTC4) = LTD4 > > LTE4. [H-3]LTD4 binding to membranes expressing mCysLT2R could be effectively competed by LTC, and LTD, and only partially inhibited by LTE4 and BAYu9773. The identification of mCysLT2R will be useful for establishing CysLT(2)R-deficient mice and determining novel leukotriene functions.	Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Philadelphia, PA 19104 USA; Merck & Co Inc, Dept Pharmacol, W Point, PA 19486 USA; NCI, Mouse Canc Genet Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	University of Pennsylvania; Merck & Company; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Rm 814 BRBII-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Back M, 2000, EUR J PHARMACOL, V401, P381, DOI 10.1016/S0014-2999(00)00452-0; Bisgaard H, 2001, PEDIATRICS, V107, P381, DOI 10.1542/peds.107.2.381; BUSSE WW, 1991, AM REV RESPIR DIS, V143, pS103, DOI 10.1164/ajrccm/143.5_Pt_2.S103; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Dahlen SE, 1999, CLIN REV ALLERG IMMU, V17, P179, DOI 10.1007/BF02737603; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; LETTS LG, 1983, ADV PROSTAG THROMB L, V11, P391; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2001, P NATL ACAD SCI USA, V98, P2256, DOI 10.1073/pnas.041624398; Martin V, 2001, BIOCHEM PHARMACOL, V62, P1193, DOI 10.1016/S0006-2952(01)00774-2; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; ORTIZ JL, 1995, BRIT J PHARMACOL, V115, P1382, DOI 10.1111/j.1476-5381.1995.tb16627.x; SAADI M, 1990, LIFE SCI, V46, P1857, DOI 10.1016/0024-3205(90)90238-M; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SAUSSY DL, 1989, J BIOL CHEM, V264, P19845; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; Walch L, 2000, AM J RESP CRIT CARE, V161, pS107, DOI 10.1164/ajrccm.161.supplement_1.ltta-21	26	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47489	47495		10.1074/jbc.M107556200	http://dx.doi.org/10.1074/jbc.M107556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591709	hybrid			2022-12-25	WOS:000172768500106
J	Iakhiaev, A; Pendurthi, UR; Rao, LVM				Iakhiaev, A; Pendurthi, UR; Rao, LVM			Active site blockade of factor VIIa alters its intracellular distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; ESCHERICHIA-COLI; GROWTH-FACTOR; BINDING; ACTIVATION; EXPRESSION; MECHANISM; CELLS; COAGULATION; FIBROBLASTS	Factor VIIa binding to tissue factor on cell surfaces not only triggers the coagulation cascade but also induces various intracellular responses that may contribute to many pathophysiological processes. Active site-inhibited factor VIIa, similar to factor VIIa, binds to tissue factor on cell surfaces and subsequently gets internalized and degraded. At present, it is unknown whether factor VIIa and active site-inhibited factor VIIa undergo a similar intracellular processing. The data presented herein show that although a fraction of both the internalized factor VIIa and active site-inhibited factor VIIa recycle back to the cell surface, the amount of active site-inhibited factor VIIa recycled back to the cell surface was substantially higher than that of factor VIIa. Furthermore, internalized factor VIIa and not active site-inhibited factor VIIa associates with nuclear fractions. Factor VIIa associated with the nuclear fraction was intact and functionally active. In contrast to factor VIIa, tissue factor is not found in the nuclear fraction. Additional studies show that the internalized factor VIIa specifically associates with cytoskeletal proteins, actin, and tubulin. In summary, the present data reveal that despite the common pathway of tissue factor-mediated processing, considerable differences exist in the trafficking of factor VIIa and active site-inhibited factor VIIa in fibroblasts.	Univ Texas Hlth Ctr, Biomed Res Div, Tyler, TX 75708 USA		Rao, LVM (corresponding author), Univ Texas Hlth Ctr, Biomed Res Div, 11937 US HWY 271, Tyler, TX 75708 USA.	Vijay.Rao@uthct.edu						BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Brossart P, 1997, BLOOD, V90, P1594, DOI 10.1182/blood.V90.4.1594.1594_1594_1599; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Citores L, 1999, MOL BIOL CELL, V10, P3835, DOI 10.1091/mbc.10.11.3835; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Hansen CB, 2001, BLOOD, V97, P1712, DOI 10.1182/blood.V97.6.1712; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; Hong SS, 1999, VIROLOGY, V262, P163, DOI 10.1006/viro.1999.9864; Iakhiaev A, 1999, J BIOL CHEM, V274, P36995, DOI 10.1074/jbc.274.52.36995; LE DT, 1992, J BIOL CHEM, V267, P15447; Mahdi F, 2000, THROMB RES, V99, P267, DOI 10.1016/S0049-3848(00)00245-0; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Pendurthi UR, 2002, VITAM HORM, V64, P323, DOI 10.1016/S0083-6729(02)64009-9; Prydz H, 1999, THROMB HAEMOSTASIS, V82, P183; RAO LVM, 1988, THROMB RES, V51, P373, DOI 10.1016/0049-3848(88)90373-8; Rao LVM, 2001, TRENDS CARDIOVAS MED, V11, P14, DOI 10.1016/S1050-1738(01)00077-9; Rao LVM, 2000, BLOOD COAGUL FIBRIN, V11, pS135, DOI 10.1097/00001721-200004001-00026; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; REFOLO LM, 1991, J NEUROSCI, V11, P3888; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Ruf W, 1999, THROMB HAEMOSTASIS, V82, P175; Ruf W, 1996, Curr Opin Hematol, V3, P379; Sai Y, 1998, J BIOCHEM-TOKYO, V123, P630; Semeraro N, 1997, THROMB HAEMOSTASIS, V78, P759; Siegbahn A, 2000, BLOOD, V96, P3452, DOI 10.1182/blood.V96.10.3452.h8003452_3452_3458; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Taylor FB, 1998, BLOOD, V91, P1609, DOI 10.1182/blood.V91.5.1609.1609_1609_1615; Taylor FB, 1996, HAEMOSTASIS, V26, P83; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199	38	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45895	45901		10.1074/jbc.M107603200	http://dx.doi.org/10.1074/jbc.M107603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590156	hybrid			2022-12-25	WOS:000172573100055
J	Nomura, M; Kaji, A; He, ZW; Ma, WY; Miyamoto, K; Yang, CS; Dong, ZG				Nomura, M; Kaji, A; He, ZW; Ma, WY; Miyamoto, K; Yang, CS; Dong, ZG			Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; P70 S6 KINASE; INDUCED AP-1 ACTIVATION; GREEN TEA; GROWTH-FACTOR; CANCER-CELLS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; MAMMALIAN TARGET; P53 MUTATIONS	In this study, we investigated the effect of tea polyphenols, (-)-epigallocatechin-3-gallate or theaflavins, on UVB-induced phosphatidylinositol 3-kinase (PIM activation in mouse epidermal JB6 Cl 41 cells. Pretreatment of cells with these polyphenols inhibited UVB-induced PI3K activation. Furthermore, UVB-induced activation of Akt and ribosomal p70 S6 kinase (p70 S6-K), PI3K downstream effectors, were also attenuated by the polyphenols. In addition to LY294002, a PI3K inhibitor, pretreatment with a specific mitogen-activated protein/ extracellular signal-regulated protein kinases (Erks) kinase I inhibitor, U0126, or a specific p38 kinase inhibitor, SB202190, blocked UVB-induced activation of both Akt and p70 S6-K. Pretreatment with LY294002 restrained UVB-induced phosphorylation of Erks, suggesting that in UVB signaling, the Erk pathway is mediated by PI3K. Moreover, pretreatment with rapamycin, an inhibitor of p70 S6-K, inhibited UVB-induced activation of p70 S6-K, but UVB-induced activation of Akt did not change. Interestingly, UVB-induced p70 S6-K activation was directly blocked by the addition of (-)-epigallocatechin-3-gallate or theaflavins, whereas these polyphenols showed only a weak inhibition on UVB-induced Akt activation. Because PI3K is an important factor in carcinogenesis, the inhibitory effect of these polyphenols on activation of PI3K and its downstream effects may further explain the anti-tumor promotion action of these tea constituents.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Kanazawa Univ, Dept Hosp Pharm, Sch Med, Kanazawa, Ishikawa 9200934, Japan; Rutgers State Univ, Canc Res Lab, Piscataway, NJ 08854 USA	University of Minnesota System; Kanazawa University; Rutgers State University New Brunswick	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu			NCI NIH HHS [CA81064, CA74916, CA27502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA081064, R29CA074916, P01CA027502, R01CA081064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Baxter NJ, 1997, BIOCHEMISTRY-US, V36, P5566, DOI 10.1021/bi9700328; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Bostrom J, 1998, CANCER RES, V58, P29; Brenneisen P, 2000, J BIOL CHEM, V275, P4336, DOI 10.1074/jbc.275.6.4336; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COFFER PJ, 1995, ONCOGENE, V11, P561; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Davies MA, 1999, CANCER RES, V59, P2551; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dong ZG, 1997, CANCER RES, V57, P4414; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fu YC, 2000, BIOMED ENVIRON SCI, V13, P170; Fukazawa H, 2000, CANCER RES, V60, P2104; Gensler HL, 1996, NUTR CANCER, V26, P325, DOI 10.1080/01635589609514488; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; HUANG MT, 1992, CARCINOGENESIS, V13, P947, DOI 10.1093/carcin/13.6.947; Kabuyama Y, 1998, FEBS LETT, V441, P297, DOI 10.1016/S0014-5793(98)01565-8; Katiyar S K, 1996, World Rev Nutr Diet, V79, P154; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Koh HK, 1995, ENVIRON HEALTH PERSP, V103, P255, DOI 10.2307/3432321; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moore SM, 1998, CANCER RES, V58, P5239; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Mukhtar H, 1999, P SOC EXP BIOL MED, V220, P234, DOI 10.1046/j.1525-1373.1999.d01-40.x; MURRAY NJ, 1994, EUR J BIOCHEM, V219, P923, DOI 10.1111/j.1432-1033.1994.tb18574.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; Nomura M, 2000, MOL CARCINOGEN, V28, P148, DOI 10.1002/1098-2744(200007)28:3<148::AID-MC3>3.0.CO;2-Q; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Record IR, 1998, NUTR CANCER, V32, P71, DOI 10.1080/01635589809514721; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; RONAI ZA, 1988, ONCOGENE, V2, P201; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Siebert KJ, 1999, J AGR FOOD CHEM, V47, P353, DOI 10.1021/jf980703o; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; Trevisanato SI, 2000, NUTR REV, V58, P1, DOI 10.1111/j.1753-4887.2000.tb01818.x; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; WANG ZY, 1992, CANCER RES, V52, P1162; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wiseman SA, 1997, CRIT REV FOOD SCI, V37, P705, DOI 10.1080/10408399709527798; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	99	81	86	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46624	46631		10.1074/jbc.M107897200	http://dx.doi.org/10.1074/jbc.M107897200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591714	hybrid			2022-12-25	WOS:000172573100149
J	Siri, P; Candela, N; Zhang, YL; Ko, C; Eusufzai, S; Ginsberg, HN; Huang, LS				Siri, P; Candela, N; Zhang, YL; Ko, C; Eusufzai, S; Ginsberg, HN; Huang, LS			Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRANSGENIC MICE; TRANSFER PROTEIN; FATTY-ACIDS; LDL RECEPTOR; ABETALIPOPROTEINEMIA GENE; METABOLIC BASIS; MESSENGER-RNA; CHOLESTEROL; RAT	A mouse model of insulin resistance and its associated dyslipidemia was generated by crossing mice expressing human apolipoprotein B (apoB) with mice lacking only brown adipose tissue (BATless). On a high fat diet, male apoB/BATless mice became obese, hypercholesterolemic, hypertriglyceridemic, and hyperinsulinemic compared with control apoB mice. Fast performance liquid chromatography revealed increased triglyceride concentrations in intermediate density lipoprotein/low density lipoprotein (LDL) and reduced high density lipoprotein cholesterol concentrations. Inhibition of lipolysis by the drug, tetrahydrolipostatin, demonstrated that very low density lipoprotein-sized particles were initially secreted. Metabolic studies employing Triton WR-1339 and either [H-3]glycerol or [H-3]palmitate showed that the hypertriglyceridemia in apoB/BATless mice was due to the increased synthesis and secretion of triglyceride. Furthermore, lipoprotein lipase and hepatic lipase activities were not defective. ApoB was also secreted at increased rates in the apoB/BATless mice. Similar levels of apoB mRNA in apoB and apoB/BATless mice indicated that apoB secretion was regulated posttranscriptionally. LDL receptor mRNA was increased in the apoB/BATless mice, indicating that the observed increase in apoB-lipoprotein secretion was not due to their decreased reuptake. Finally, mRNA levels of the large subunit of microsomal triglyceride transfer protein, a required component for very low density protein assembly, were not different between apoB and apoB/ BATless mice. This rodent model should prove useful in exploring mechanisms underlying the regulation of apoB secretion in the context of insulin resistance.	Columbia Univ Coll Phys & Surg, Dept Med, Div Prevent Med & Nutr, New York, NY 10032 USA	Columbia University	Huang, LS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Prevent Med & Nutr, 630 W 168th St, New York, NY 10032 USA.	lh99@columbia.edu			NHLBI NIH HHS [HL57217, HL07343, HL55638] Funding Source: Medline; NIDDK NIH HHS [2T32 DK07328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055638, P01HL057217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORNSSON OG, 1992, BIOCHEM J, V281, P381; Brown MS, 1998, NUTR REV, V56, pS1; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; CHAIT A, 1980, EUR J CLIN INVEST, V10, P17, DOI 10.1111/j.1365-2362.1980.tb00004.x; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; CORSINI A, 1992, ATHEROSCLEROSIS, V93, P95, DOI 10.1016/0021-9150(92)90203-S; CORTNER JA, 1987, J LIPID RES, V28, P195; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DIXON JL, 1993, J LIPID RES, V34, P167; FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; Ginsberg HN, 1996, DIABETES, V45, pS27, DOI 10.2337/diab.45.3.S27; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hamann A, 1998, Z ERNAHRUNGSWISS, V37, P1; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HEINEMANN T, 1994, J LIPID RES, V35, P2200; Hocquette JF, 1998, COMP BIOCHEM PHYS B, V121, P201, DOI 10.1016/S0305-0491(98)10090-1; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; JIANG XC, 1993, J BIOL CHEM, V268, P27406; KISSEBAH AH, 1987, DIABETES METAB REV, V3, P619, DOI 10.1002/dmr.5610030302; LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633; LEWIS GF, 1993, DIABETES, V42, P833, DOI 10.2337/diabetes.42.6.833; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MACIEJKO JJ, 1987, CLIN CHEM, V33, P2065; Malmstrom R, 1997, ARTERIOSCL THROM VAS, V17, P1454, DOI 10.1161/01.ATV.17.7.1454; Malmstrom R, 1998, DIABETES, V47, P779, DOI 10.2337/diabetes.47.5.779; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Nadler ST, 2001, J NUTR, V131, P2078, DOI 10.1093/jn/131.8.2078; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; OTWAY S, 1967, J PHYSIOL-LONDON, V190, P321, DOI 10.1113/jphysiol.1967.sp008211; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SALMON DMW, 1973, BIOCHEM J, V136, P551, DOI 10.1042/bj1360551; SCANU ANGELO M., 1965, ADVANCE LIPID RES, V3, P63; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SPARKS JD, 1994, BIOCHEM BIOPH RES CO, V205, P417, DOI 10.1006/bbrc.1994.2681; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; Tietge UJF, 1999, J LIPID RES, V40, P2134; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Voyiaziakis E, 1998, J LIPID RES, V39, P313; Voyiaziakis E, 1999, J LIPID RES, V40, P2004; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; WU XJ, 1994, J LIPID RES, V35, P1200; Yao ZM, 1997, J LIPID RES, V38, P1937; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	70	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46064	46072		10.1074/jbc.M108909200	http://dx.doi.org/10.1074/jbc.M108909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11598138	hybrid			2022-12-25	WOS:000172573100078
J	Baig, AH; Swords, FM; Noon, LA; King, PJ; Hunyady, L; Clark, AJL				Baig, AH; Swords, FM; Noon, LA; King, PJ; Hunyady, L; Clark, AJL			Desensitization of the Y1 cell adrenocorticotropin receptor - Evidence for a restricted heterologous mechanism implying a role for receptor-effector complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BETA(2)-ADRENERGIC RECEPTOR; MESSENGER-RNA; ACTH RECEPTORS; MOUSE; CORTICOTROPIN; PHOSPHORYLATION; SEQUESTRATION; EXPRESSION; CLONING	Receptor desensitization provides a potential mechanism for the regulation of adrenocortical adrenocorticotropin (ACTH) responsiveness. Using the mouse adrenocortical Y1 cell line we demonstrate that ACTH effectively desensitizes the cAMP response of its own receptor, the melanocortin 2 receptor (MC2R), in these cells with a maximal effect between 30 and 60 min. Neither forskolin nor isoproterenol (in Y1 cells stably transfected with the beta (2)-adrenergic receptor) desensitize this ACTH response. ACTH desensitizes its receptor at concentrations at which only a fraction of receptors are occupied, implying that this mechanism acts on agonist-unoccupied receptors. Y1 cells express G protein-coupled receptor kinase (GRK) 2 and 5, but stable expression of a dominant negative GRK2 (K220W) only marginally reduces the desensitization by ACTH. The protein kinase A (PKA) inhibitor, H89, extinguishes almost the entire desensitization response over the initial 30-min period at all concentrations of ACTH. A mutant MC2R in which the single consensus PKA phosphorylation site has been mutated (S208A) when expressed in MC2R-negative Y6 cells is also unable to desensitize. These data imply a heterologous, PKA-dependent, mode of desensitization, which is restricted to agonist-occupied and -unoccupied MC2R, possibly as a consequence of receptor/effector complexes that functionally compartmentalize this receptor.	Univ London, Queen Marys Sch Med, Dept Endocrinol, London EC1A 7BE, England; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary	University of London; Queen Mary University London; Semmelweis University	Clark, AJL (corresponding author), Univ London, Queen Marys Sch Med, Dept Endocrinol, W Smithfield, London EC1A 7BE, England.	aj.clark@mds.qmw.ac.uk	Noon, Luke A/H-4141-2014	Noon, Luke A/0000-0002-0502-4322; Baig, Asma/0000-0002-3764-1456				ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BUCKLEY DI, 1981, P NATL ACAD SCI-BIOL, V78, P7431, DOI 10.1073/pnas.78.12.7431; Cammas FM, 1997, MOL ENDOCRINOL, V11, P867, DOI 10.1210/me.11.7.867; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Clark AJL, 1996, BAILLIERE CLIN ENDOC, V10, P29, DOI 10.1016/S0950-351X(96)80282-5; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Elias LLK, 1999, J CLIN ENDOCR METAB, V84, P2766, DOI 10.1210/jc.84.8.2766; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYNES RC, 1958, J BIOL CHEM, V233, P1220; LEBRETHON MC, 1994, J CLIN INVEST, V93, P1828, DOI 10.1172/JCI117168; LEFKOWITZ RJ, 1970, P NATL ACAD SCI USA, V65, P745, DOI 10.1073/pnas.65.3.745; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Liakos P, 1998, ENDOCR RES, V24, P427, DOI 10.3109/07435809809032628; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MORERA AM, 1978, BIOCHEM BIOPH RES CO, V83, P1553, DOI 10.1016/0006-291X(78)91398-0; Mountjoy KG, 2000, RECEPTORS, P209; MOUNTJOY KG, 1994, MOL CELL ENDOCRINOL, V99, pR17, DOI 10.1016/0303-7207(94)90160-0; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PENHOAT A, 1989, P NATL ACAD SCI USA, V86, P4978, DOI 10.1073/pnas.86.13.4978; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Tepe NM, 2000, J RECEPT SIGNAL TR R, V20, P75, DOI 10.3109/10799890009150038; TSUGA H, 1994, J BIOL CHEM, V269, P32522; WATT VM, 1982, J BIOL CHEM, V257, P1684; Xia Y, 1996, CELL TISSUE RES, V286, P63, DOI 10.1007/s004410050675; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274	36	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44792	44797		10.1074/jbc.M108572200	http://dx.doi.org/10.1074/jbc.M108572200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579104	hybrid			2022-12-25	WOS:000172406700062
J	Gomez-Angelats, M; Cidlowski, JA				Gomez-Angelats, M; Cidlowski, JA			Protein kinase C regulates FADD recruitment and death-inducing signaling complex formation in Fas/CD95-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; CD95-MEDIATED APOPTOSIS; CELL SHRINKAGE; CD95 FAS/APO-1; PHORBOL ESTER; ACTIVATION; RESISTANCE; EXPRESSION; RECEPTOR; INHIBITION	Activation of protein kinase C (PKC) triggers cellular signals that inhibit Fas/CD95-induced cell death in Jurkat T-cells by poorly defined mechanisms. Previously, we have shown that one effect of PKC on Fas/CD95-dependent cell death occurs through inhibition of cell shrinkage and K+ efflux (Gomez-Angelats, M., Bortner, C. D., and Cidlowski, J. A. (2000) J. Biol. Chem. 275, 19609-19619). Here we report that PKC alters Fas/CD95 signaling from the plasma membrane to the activation of caspases by exerting a profound action on survival/cell death decisions. Specific activation of PKC with 12-O-tetradecanoylphorbol-13-acetate or bryostatin-1 induced translocation of PKC from the cytosol to the membrane and effectively inhibited cell shrinkage and cell death triggered by anti-Fas antibody in Jurkat cells. In contrast, inhibition of classical PKC isotypes with Go6976 exacerbated the effect of Fas activation on both apoptotic volume decrease and cell death. PKC activation/inhibition did not affect anti-Fas antibody binding to the cell surface, intracellular levels of FADD ((F) under bar as-(a) under bar ssociated protein with (d) under bar eath (d) under bar omain), or c-FLIP (cellular (FL) under bar ICE-like (i) under bar nhibitory (p) under bar rotein) expression. However, processing/activation of both caspase-8 and caspase-3 and BID cleavage were markedly blocked upon PKC activation and, conversely, were augmented during PKC inhibition, suggesting a role for PKC upstream of caspase-8 processing and activation. Analysis of death-inducing signaling complex (DISC) formation was carried out to examine the influence of PKC on recruitment of both FADD and procaspase-8 to the Fas receptor. PKC activation blocked FADD recruitment and caspase-8 activation and thus DISC formation in both type I and II cells. In contrast, inhibition of classical PKCs promoted the opposite effect on the Fas pathway by rapidly increasing FADD recruitment, caspase-8 activation, and DISC formation. Together, these data show that PKC finely modulates Fas/CD95 signaling by altering the efficiency of DISC formation.	NIEHS, Lab Signal Transduct, Mol Endocrinol Grp, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, Mol Endocrinol Grp, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	cidlowski@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Fenton RG, 1998, CANCER RES, V58, P3391; Foote LC, 1996, J IMMUNOL, V157, P2749; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irisarri M, 2000, LEUKEMIA, V14, P2149, DOI 10.1038/sj.leu.2401954; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JARVIS WD, 1994, BIOCHEM PHARMACOL, V47, P839; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Karas M, 2001, HUM IMMUNOL, V62, P32, DOI 10.1016/S0198-8859(00)00223-8; KEENAN C, 1995, EUR J IMMUNOL, V25, P13, DOI 10.1002/eji.1830250104; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; KVANTA A, 1991, FEBS LETT, V283, P321, DOI 10.1016/0014-5793(91)80618-D; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MODIANO JF, 1991, J BIOL CHEM, V266, P10552; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Mueller CM, 2000, J IMMUNOL, V165, P1854, DOI 10.4049/jimmunol.165.4.1854; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; Scaffidi C, 2000, METHOD ENZYMOL, V322, P363; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Suzuki A, 2001, NAT MED, V7, P88, DOI 10.1038/83401; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wei MC, 2000, GENE DEV, V14, P2060; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	58	85	87	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44944	44952		10.1074/jbc.M104919200	http://dx.doi.org/10.1074/jbc.M104919200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581255	hybrid			2022-12-25	WOS:000172406700082
J	Kowcun, A; Honson, N; Plettner, E				Kowcun, A; Honson, N; Plettner, E			Olfaction in the gypsy moth, Lymantria dispar - Effect of pH, ionic strength, and reductants on pheromone transport by pheromone-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBYX-MORI; ANTHERAEA-POLYPHEMUS; SENSORY DENDRITES; SILKWORM MOTH; PORE TUBULES; NUN MOTH; SILKMOTH; MEMBRANE; DISCRIMINATION; ENANTIOMERS	The pheromone-binding proteins (PBPs) are 16-kDa abundant proteins in specialized olfactory hairs in insects. The mechanism by which the PBPs remove the pheromone from the inner surface of sensory hairs and deliver it to the sensory cell remains unclear. Existing qualitative models postulate that pheromone is released near the dendrite by a decrease in pH or by a reduced form of the PBP. This study focuses on the two PBPs from the gypsy moth and the enantiomers of the pheromone cis-2-methyl-7,8-epoxyoctadecane. The pH dependence of pheromone binding has revealed three ionizations that are important. The type of ligand influences two of these ionizations. We propose that the (-)-enantiomer of the pheromone interacts with one of the ionizable residues on the protein while the (+)-enantiomer does not. Simultaneous variation of pH and KCl concentration in the physiological range or reduction of disulfide bridges does not change the affinity of PBP for pheromone. We propose a revised model of pheromone transport from the inner surface of the sensory hair to the sensory neuron.	Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Plettner, E (corresponding author), Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada.							BARBER J, 1980, BIOCHIM BIOPHYS ACTA, V594, P253, DOI 10.1016/0304-4173(80)90003-8; Campanacci V, 1999, EUR J BIOCHEM, V264, P707, DOI 10.1046/j.1432-1327.1999.00666.x; CARDE RT, 1977, ENVIRON ENTOMOL, V6, P768, DOI 10.1093/ee/6.6.768; CUNNINGHAM LW, 1959, J BIOL CHEM, V234, P1447; Damberger F, 2000, PROTEIN SCI, V9, P1038, DOI 10.1110/ps.9.5.1038; Danty E, 1999, J NEUROSCI, V19, P7468, DOI 10.1523/JNEUROSCI.19-17-07468.1999; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; Grant GG, 1996, NATURWISSENSCHAFTEN, V83, P328, DOI 10.1007/BF01152217; Gries G, 1996, NATURWISSENSCHAFTEN, V83, P382, DOI 10.1007/BF01142006; HANSEN K, 1984, PHYSIOL ENTOMOL, V9, P9, DOI 10.1111/j.1365-3032.1984.tb00676.x; Hildebrand J.G., 1980, RECEPTORS NEUROTRANS, P261; KAISSLIN.KE, 1970, NATURWISSENSCHAFTEN, V57, P23, DOI 10.1007/BF00593550; Kaissling K.-E., 1971, Handbook of sensory physiology, Vol. IV, P351; Kaissling K-E, 1987, RH WRIGHT LECT INSEC; Kaissling KE, 2001, CHEM SENSES, V26, P125, DOI 10.1093/chemse/26.2.125; KAISSLING KE, 1977, CHEM CONTROL INSECT, P45; KANAUJIA S, 1985, J INSECT PHYSIOL, V31, P71, DOI 10.1016/0022-1910(85)90044-7; KEIL TA, 1982, TISSUE CELL, V14, P451, DOI 10.1016/0040-8166(82)90039-8; KEIL TA, 1984, TISSUE CELL, V16, P131, DOI 10.1016/0040-8166(84)90025-9; KEIL TA, 1984, TISSUE CELL, V16, P705, DOI 10.1016/0040-8166(84)90004-1; KRAMER JJD, 1987, PHEROMONE BIOCH, P433; Krieger J, 1999, SCIENCE, V286, P720, DOI 10.1126/science.286.5440.720; KRIEGER J, 1993, INSECT BIOCHEM MOLEC, V23, P449, DOI 10.1016/0965-1748(93)90052-T; Leal WS, 2000, BIOCHEM BIOPH RES CO, V268, P521, DOI 10.1006/bbrc.2000.2158; Leal WS, 1999, FEBS LETT, V464, P85, DOI 10.1016/S0014-5793(99)01683-X; MAIDA R, 1993, INSECT BIOCHEM MOLEC, V23, P243, DOI 10.1016/0965-1748(93)90005-D; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; Merritt TJS, 1998, J MOL EVOL, V46, P272, DOI 10.1007/PL00006303; MILLER JR, 1977, J INSECT PHYSIOL, V23, P1447, DOI 10.1016/0022-1910(77)90171-8; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; Plettner E, 2000, BIOCHEMISTRY-US, V39, P8953, DOI 10.1021/bi000461x; Prestwich G.D., 1987, P473; Rogers ME, 1997, J BIOL CHEM, V272, P14792, DOI 10.1074/jbc.272.23.14792; Sandler BH, 2000, CHEM BIOL, V7, P143, DOI 10.1016/S1074-5521(00)00078-8; Scaloni A, 1999, BIOCHEM BIOPH RES CO, V266, P386, DOI 10.1006/bbrc.1999.1791; SCHNEIDER D, 1968, NATURWISSENSCHAFTEN, V55, P395, DOI 10.1007/BF00593307; SCHNEIDER D, 1977, J COMP PHYSIOL, V113, P1, DOI 10.1007/BF00610450; Skoog D.A., 1988, FUNDAMENTALS ANAL CH, V5th, P124; VANDENBERG MJ, 1991, J INSECT PHYSIOL, V37, P79, DOI 10.1016/0022-1910(91)90022-R; Vogt R.G., 1987, P385; VOGT RG, 1989, J NEUROSCI, V9, P3332; Vogt RG, 1999, CHEM SENSES, V24, P481, DOI 10.1093/chemse/24.5.481; VOGT RG, 1990, NATO ASI SERIES H, V39, P33; Wojtasek H, 1999, J BIOL CHEM, V274, P30950, DOI 10.1074/jbc.274.43.30950; ZIEGELBERGER G, 1995, EUR J BIOCHEM, V232, P706, DOI 10.1111/j.1432-1033.1995.tb20864.x	46	39	42	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44770	44776		10.1074/jbc.M104688200	http://dx.doi.org/10.1074/jbc.M104688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581252	hybrid			2022-12-25	WOS:000172406700059
J	Kondo, M; Ji, L; Kamibayashi, C; Tomizawa, Y; Randle, D; Sekido, Y; Yokota, J; Kashuba, V; Zabarovsky, E; Kuzmin, I; Lerman, M; Roth, J; Minna, JD				Kondo, M; Ji, L; Kamibayashi, C; Tomizawa, Y; Randle, D; Sekido, Y; Yokota, J; Kashuba, V; Zabarovsky, E; Kuzmin, I; Lerman, M; Roth, J; Minna, JD			Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells	ONCOGENE			English	Article						tumor suppressor gene; growth inhibition; lung cancer	HUMAN-CHROMOSOME 3P21.3; LOCUS; IDENTIFICATION; SEARCH	Recently we identified FUS1 as a candidate tumor suppressor gene (TSG) in the 120 kb 3p21.3 critical region contained in nested lung and breast cancer homozygous deletions. Mutation of FUS1 is infrequent in lung cancers which we have confirmed in 40 other primary lung cancers. In addition, we found no evidence for FUS1 promoter region methylation. Because haplo-insufficiency or low expression of Fus1 may play a role in lung tumorigenesis, we tested the effect of exogenously induced overexpression of Fus1 protein and found 60-80% inhibition of colony formation for non-small cell lung cancer lines NCI-H1299 (showing allele loss for FUS1) and NCI-H322 (containing only a mutated FUS1 allele) in vitro. By contrast, a similar level of expression of a tumor-acquired mutant form of FUS1 protein did not significantly suppress colony formation. Also, induced expression of Fus1 under the control of an Ecdysone regulated promoter decreased colony formation 75%, increased the doubling time twofold, and arrested H1299 cells in G1. In conclusion, our data are consistent with the hypothesis that FUS1 may function as a 3p21.3 TSG, warranting further studies of its function in the pathogenesis of human cancers.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 466, Japan; Natl Canc Ctr, Res Inst, Div Biol, Tokyo 104, Japan; Karolinska Inst, MTC, Stockholm, Sweden; Karolinska Inst, CGR, Stockholm, Sweden; Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; Nagoya University; National Cancer Center - Japan; Karolinska Institutet; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd,NB8-206, Dallas, TX 75390 USA.		Kashuba, Vladimir/AAO-7742-2020; Kondo, Masashi/I-7378-2014; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017; Sekido, Yoshitaka/P-9756-2015	Kashuba, Vladimir I/0000-0001-9416-8282; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, CA 71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; DALY MC, 1993, ONCOGENE, V8, P1721; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; HIBI K, 1992, ONCOGENE, V7, P445; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lerman MI, 2000, CANCER RES, V60, P6116; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Roche J, 1996, ONCOGENE, V12, P1289; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; Wistuba II, 2000, CANCER RES, V60, P1949; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	21	68	80	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6258	6262		10.1038/sj.onc.1204832	http://dx.doi.org/10.1038/sj.onc.1204832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593436				2022-12-25	WOS:000171206300019
J	Klein, C; Planker, E; Diercks, T; Kessler, H; Kunkele, KP; Lang, K; Hansen, S; Schwaiger, M				Klein, C; Planker, E; Diercks, T; Kessler, H; Kunkele, KP; Lang, K; Hansen, S; Schwaiger, M			NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; C-TERMINAL PEPTIDE; BINDING DOMAIN; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; OLIGOMERIZATION DOMAIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; LAC REPRESSOR; WILD-TYPE	The p53 protein is a transcription factor that acts as the major tumor suppressor in mammals. The core DNA-binding domain is mutated in about 50%, of all human tumors. The crystal structure of the core domain in complex with DNA illustrated how a single core domain specifically interacts with its DNA consensus site and how it is inactivated by mutation. However, no structural information for the tetrameric full-length p53-DNA complex is available. Here, we present novel experimental insight into the dimerization of two p53 core domains upon cooperative binding to consensus DNA in solution obtained by NMR. The NMR data show that the p53 core domain itself does not appear to undergo major conformational changes upon addition of DNA and elucidate the dimerization interface between two DNA-bound core domains, which includes the short HI helix. A NMR-based model for the dimeric p53 core-DNA complex incorporates these data and allows the conclusion that the dimerization interface also forms the actual interface in the tetrameric p53-DNA complex. The significance of this interface is further corroborated by the finding that hot spot mutations map to the HI helix, and by the binding of the putative p53 inhibitor 53BP2 to this region via one of its ankyrin repeats. Based on symmetry considerations it is proposed that tetrameric p53 might link non-contigous DNA consensus sites in a sandwich-like manner generating DNA loops as observed for transcriptionally active p53 complexes.	Roche Diagnost GmbH, Pharma Res, D-82372 Penzberg, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Novaspin Biotech GmbH, D-85748 Garching, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Roche Holding; Max Planck Society; Technical University of Munich	Hansen, S (corresponding author), Roche Diagnost GmbH, Pharma Res, D-82372 Penzberg, Germany.		Kessler, Horst/C-1178-2010; Diercks, Tammo/AAT-3731-2021; Diercks, Tammo/G-1167-2011; Klein, Christian/G-1336-2010	Diercks, Tammo/0000-0002-5200-0905; Diercks, Tammo/0000-0002-5200-0905; Klein, Christian/0000-0001-7594-7280				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Appella E, 1998, J PROTEIN CHEM, V17, P527; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Davison TS, 2001, J MOL BIOL, V307, P605, DOI 10.1006/jmbi.2001.4450; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Hoffmann R, 1998, BIOCHEMISTRY-US, V37, P13755, DOI 10.1021/bi980760a; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; JACKSON P, 1995, GENE EXPRESSION, V5, P19; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jerschow A, 1998, J MAGN RESON, V134, P17, DOI 10.1006/jmre.1998.1491; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Kong XT, 2001, J BIOL CHEM, V276, P32990, DOI 10.1074/jbc.M103681200; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; Lebrun A, 2001, PROTEIN ENG, V14, P233, DOI 10.1093/protein/14.4.233; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; Matsumura I, 1999, PROTEIN SCI, V8, P731; Mattiello DL, 1996, J AM CHEM SOC, V118, P3253, DOI 10.1021/ja953186o; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Mulder FAA, 2000, J BIOMOL NMR, V18, P173, DOI 10.1023/A:1008317825976; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nichols NM, 2001, BIOCHEMISTRY-US, V40, P3847, DOI 10.1021/bi002088z; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Orekhov VY, 1995, APPL MAGN RESON, V9, P581, DOI 10.1007/BF03162365; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pennisi E, 1996, SCIENCE, V274, P921, DOI 10.1126/science.274.5289.921; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PETROS AM, 1990, BIOCHEMISTRY-US, V29, P10041, DOI 10.1021/bi00495a005; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Xirodimas DP, 1999, J BIOL CHEM, V274, P28042, DOI 10.1074/jbc.274.39.28042; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200	97	70	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49020	49027		10.1074/jbc.M107516200	http://dx.doi.org/10.1074/jbc.M107516200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11606582	hybrid			2022-12-25	WOS:000173922100054
J	Lukashev, D; Caldwell, C; Ohta, A; Chen, P; Sitkovsky, M				Lukashev, D; Caldwell, C; Ohta, A; Chen, P; Sitkovsky, M			Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; FACTOR 1-ALPHA; FACTOR GENE; TRANSCRIPTIONAL REGULATION; DEGRADATION DOMAIN; O-2 HOMEOSTASIS; FACTOR-I; CELLS; RECEPTOR	Cell adaptation to hypoxia is partially accomplished by hypoxia-inducible transcription factor-1 (HIF-1). Here we report the hypoxia-independent up-regulation of HIF-1alpha subunit in antigen receptor-activated T cells. This is explained by a selective up-regulation of alternatively spliced mRNA isoform I.1 that encodes the HIF-1alpha protein without the first 12 N-terminal amino acids. We show that both short (I.1) and long (I.2) HIF-1alpha isoforms display similar DNA binding and transcriptional activities. Major differences were observed between these two HIF-1alpha isoforms in their expression patterns with respect to the resting and activated T lymphocytes in hypoxic and normoxic conditions. The T cell antigen receptor (TCR)-triggered activation of normal ex vivo T cells and differentiated T cells results in up-regulation of expression of I.1 isoform of HIF-1alpha mRNA without an effect on constitutive I.2 HIF-1alpha mRNA expression. The accumulation of I.1 HIF-1alpha mRNA isoform in T lymphocytes is also demonstrated during cytokine-mediated inflammation in vivo, suggesting a physiological role of short HIF-1alpha isoform in activated lymphocytes. The TCR-triggered, protein kinase C and Ca2+/calcineurin-mediated HIF-1alpha I.1 mRNA induction is protein synthesis-independent, suggesting that the HIF-1alpha I.1 gene is expressed as an immediate early response gene. Therefore, these data predict a different physiological role of short and long isoforms of HIF-1alpha in resting and activated cells.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sitkovsky, M (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10,Rm 11N311, Bethesda, MD 20892 USA.		Lukashev, Dmitriy/F-8133-2010	Caldwell, Charles/0000-0003-1692-4550	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000626] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Apasov SG, 1999, INT IMMUNOL, V11, P179, DOI 10.1093/intimm/11.2.179; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Dewhirst MW, 1998, SEMIN RADIAT ONCOL, V8, P143, DOI 10.1016/S1053-4296(98)80040-4; Ema M, 1996, MOL CELL BIOL, V16, P5865; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FREEMAN MR, 1995, CANCER RES, V55, P4140; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; HOSKIN DW, 1994, INT J CANCER, V59, P854, DOI 10.1002/ijc.2910590625; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; HuLi J, 1997, P NATL ACAD SCI USA, V94, P3189, DOI 10.1073/pnas.94.7.3189; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jelkmann W, 1998, J INTERF CYTOK RES, V18, P555, DOI 10.1089/jir.1998.18.555; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KELLY K, 1995, CURR OPIN IMMUNOL, V7, P327, DOI 10.1016/0952-7915(95)80106-5; Koshiba M, 1997, P NATL ACAD SCI USA, V94, P831, DOI 10.1073/pnas.94.3.831; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; LOEFFLER DA, 1990, INT J CANCER, V45, P462, DOI 10.1002/ijc.2910450315; Luo G, 1997, GENE EXPRESSION, V6, P287; MATHERNE GP, 1990, PEDIATR RES, V28, P348, DOI 10.1203/00006450-199010000-00010; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Picker L.J., 1999, FUNDAMENTAL IMMUNOLO, P479; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Richard DE, 2000, J BIOL CHEM, V275, P26765; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Sogawa K, 1997, J BIOCHEM, V122, P1075; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Tiegs G, 1997, ACTA GASTRO-ENT BELG, V60, P176; VANBELLE H, 1987, AM J PHYSIOL, V252, pH886, DOI 10.1152/ajpheart.1987.252.5.H886; VAUPEL P, 1989, CANCER RES, V49, P6449; VAUPEL PW, 1981, CANCER RES, V41, P2008; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 1997, EUR J BIOCHEM, V246, P155, DOI 10.1111/j.1432-1033.1997.t01-1-00155.x; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 1997, BIOL CHEM, V378, P609; Westermann J, 1999, IMMUNOL TODAY, V20, P302, DOI 10.1016/S0167-5699(99)01474-7; Whitmore D, 1998, CURR OPIN NEUROBIOL, V8, P635, DOI 10.1016/S0959-4388(98)80092-5; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	61	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48754	48763		10.1074/jbc.M104782200	http://dx.doi.org/10.1074/jbc.M104782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11602577	hybrid			2022-12-25	WOS:000173922100020
J	Song, HK; Mulrooney, SB; Huber, R; Hausinger, RP				Song, HK; Mulrooney, SB; Huber, R; Hausinger, RP			Crystal structure of Klebsiella aerogenes UreE, a nickel-binding metallochaperone for urease activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; IN-VIVO; APOPROTEIN COMPLEXES; ACCESSORY PROTEIN; METAL-BINDING; PURIFICATION; IDENTIFICATION; CRYSTALLOGRAPHY; MOLSCRIPT; PROGRAM	UreE is proposed to be a metallochaperone that delivers nickel ions to urease during activation of this bacterial virulence factor. Wild-type Klebsiella aerogenes UreE binds approximately six nickel ions per homodimer, whereas H144*UreE (a functional C-terminal truncated variant) was previously reported to bind two. We determined the structure of H144*UreE by multi-wavelength anomalous diffraction and refined it to 1.5 Angstrom resolution. The present structure reveals an Hsp40-like peptide-binding domain, an wAtx1-like metal-binding domain, and a flexible C terminus. Three metal-binding sites per dimer, defined by structural analysis of Cu-H144*UreE, are on the opposite face of the Atx1-like domain than observed in the copper metallochaperone. One metal bridges the two subunits via the pair of His-96 residues, whereas the other two sites involve metal coordination by His-110 and His-112 within each subunit. In contrast to the copper metallochaperone mechanism involving thiol ligand exchanges between structurally similar chaperones and target proteins, we propose that the Hsp40-like module interacts with urease apoprotein and/or other urease accessory proteins, while the Atx1-like domain delivers histidyl-bound nickel to the urease active site.	Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Max Planck Inst Biochem, Abt Strukt Forsch, D-82152 Planegg Martinsried, Germany; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Max Planck Society; Michigan State University	Song, HK (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	hksong@red.dfci.harvard.edu; hausinge@msu.edu	Song, Hyun Kyu/D-6763-2016	Song, Hyun Kyu/0000-0001-5684-4059; Hausinger, Robert/0000-0002-3643-2054	NIDDK NIH HHS [R01 DK045686, DK45686] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Brayman TG, 1996, J BACTERIOL, V178, P5410, DOI 10.1128/jb.178.18.5410-5416.1996; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Colpas GJ, 1998, J BIOL INORG CHEM, V3, P150, DOI 10.1007/s007750050216; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; Colpas GJ, 2000, J BIOL CHEM, V275, P10731, DOI 10.1074/jbc.275.15.10731; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ha NC, 2001, NAT STRUCT BIOL, V8, P505, DOI 10.1038/88563; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hausinger R.P., 2001, HDB METALLOPROTEINS, P867; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Jabri E, 1996, BIOCHEMISTRY-US, V35, P10616, DOI 10.1021/bi960424z; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minor W, 2000, STRUCTURE, V8, pR105, DOI 10.1016/S0969-2126(00)00139-8; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Moncrief MBC, 1996, J BACTERIOL, V178, P5417, DOI 10.1128/jb.178.18.5417-5421.1996; Moncrief MBC, 1997, J BACTERIOL, V179, P4081, DOI 10.1128/jb.179.13.4081-4086.1997; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Olson JW, 2000, J BACTERIOL, V182, P1702, DOI 10.1128/JB.182.6.1702-1705.2000; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; PARK IS, 1995, J BACTERIOL, V177, P1947, DOI 10.1128/jb.177.8.1947-1951.1995; Pearson MA, 1997, BIOCHEMISTRY-US, V36, P8164, DOI 10.1021/bi970514j; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Watt RK, 1998, J BIOL CHEM, V273, P10019, DOI 10.1074/jbc.273.16.10019; Watt RK, 1999, CELL MOL LIFE SCI, V56, P604, DOI 10.1007/s000180050456; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; 1994, ACTA CRYSTALLOG D, V50, P760	47	76	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49359	49364		10.1074/jbc.M108619200	http://dx.doi.org/10.1074/jbc.M108619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11591723	hybrid			2022-12-25	WOS:000173922100096
J	Yue, JC; Liu, J; Shen, X				Yue, JC; Liu, J; Shen, X			Inhibition of phosphatidylinositol 4-kinase results in a significant reduced respiratory burst in formyl-methionyl-leucyl-phenylalanine-stimulated human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PURIFICATION; SENSITIVITY; ENDOCYTOSIS; ACTIVATION; CHEMOKINES; LOCATION; CLONING; PI3K	The effects of phenylarsine oxide and a monoclonal antibody directed against type II phosphatidylinositol 4-kinase (PI4K) on the N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated respiratory burst and the PI4K activity in neutrophils were investigated. Fluorescence microscopic imaging showed that the antibody labeled with LANBD amide (N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethyl-enediamine) could enter into the cytosol possibly by endocytosis. It was found that the antibody inhibited the fMLP-stimulated respiratory burst but had little effect on the phorbol myristate acetate-activated respiratory burst in neutrophils, whereas phenylarsine oxide inhibited both. It was found that even at higher concentration, the antibody could not completely inhibit the cell response. Using cells preincubated with human immunoglobulin G of the same concentration as the control, the maximal inhibition of the fMLP-stimulated respiratory burst by the antibody against type II PI4K was found to be about 70%, whereas the PI4K activity was inhibited by only about 40%. The discrepancy in depressing the cell response and the enzyme activity may be the result of depletion of the phosphatidylinositol 4,5-bisphosphate or phosphatidylinositol 3,4,5-trisphosphate pools during the incubation of cells with the antibody. Both the 40% inhibition of PI4K activity and 70% depression of the respiratory burst by the type II P4K antibody may imply that at least 40% of the phosphatidylinositol 4,5-biphosphate was synthesized promptly by all forms of PI4K and phosphatidylinositol-4-phosphate 5-kinase in the fMLP-activated cells. The results suggest that PI4K plays a central role in either phospholipase C or PI3K signaling and that PI3K, PI4K, and phosphatidylinositol 4-phosphate 5-kinase must be considered as an integrated family for the phosphatidylinositol 3,4,5-trisphosphate initiated signaling.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomol, Beijing 100101, Peoples R China; Chinese Acad Sci, Dept Cell Biophys, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences	Shen, X (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomol, 15 Datun Rd, Beijing 100101, Peoples R China.	shenxun@sun5.ibp.ac.cn						Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berg K, 1999, CANCER RES, V59, P1180; Condliffe AM, 1998, FEBS LETT, V439, P147, DOI 10.1016/S0014-5793(98)01358-1; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Kiliaan AJ, 1996, CELL TISSUE RES, V285, P51, DOI 10.1007/s004410050619; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MATTANA J, 1995, AM J PATHOL, V147, P529; Megias L, 2000, INT J DEV BIOL, V44, P209; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nishioka H, 1998, FEBS LETT, V441, P63, DOI 10.1016/S0014-5793(98)01526-9; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; Reynolds AJ, 1999, J NEUROCHEM, V73, P87, DOI 10.1046/j.1471-4159.1999.0730087.x; SCHOLZ G, 1991, EUR J BIOCHEM, V201, P249, DOI 10.1111/j.1432-1033.1991.tb16281.x; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Sorensen SD, 1998, MOL PHARMACOL, V53, P827; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Yue JC, 1999, PROG BIOCHEM BIOPHYS, V26, P473; Yue JC, 2000, CHIN J BIOCH MOL BIO, V16, P234	30	11	11	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49093	49099		10.1074/jbc.M101328200	http://dx.doi.org/10.1074/jbc.M101328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11592957	hybrid			2022-12-25	WOS:000173922100063
J	Boix, E; Swaminathan, GJ; Zhang, YN; Natesh, R; Brew, K; Acharya, KR				Boix, E; Swaminathan, GJ; Zhang, YN; Natesh, R; Brew, K; Acharya, KR			Structure of UDP complex of UDP-galactose :beta-galactoside-alpha-1,3-galactosyltransferase at 1.53-angstrom resolution reveals a conformational change in the catalytically important C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE REFINEMENT; EXPRESSION CLONING; CRYSTAL-STRUCTURES; GALACTOSYLTRANSFERASE; GLYCOSYLTRANSFERASES; MECHANISM; BIOSYNTHESIS; PARAMETERS; MOLSCRIPT; EVOLUTION	UDP-galactose:beta -galactosyl alpha -1,3-galactosyltransferase (alpha 3GT) catalyzes the transfer of galactose from UDP-alpha -D-galactose into an alpha -1,3 linkage with beta -galactosyl groups in glycoconjugates. The enzyme is expressed in many mammalian species but is absent from humans, apes, and old world monkeys as a result of the mutational inactivation of the gene; in humans, a large fraction of natural antibodies are directed against its product, the alpha -galactose epitope. a3GT is a member of a family of metal-dependent retaining glycosyltransferases including the histo-blood group A and B synthases. A crystal structure of the catalytic domain of a3GT was recently reported (Gastinel, L. N., Bignon, C., Misra, A. K., Hindsgaul, O., Shaper, J. H., and Joziasse, D. H. (2001) EMBO J. 20,638-649). However, because of the limited resolution (2.3 Angstrom) and high mobility of the atoms (as indicated by high B-factors) this structure,(form I) does not provide a clear depiction of the catalytic site of the enzyme. Here we report a new, highly ordered structure for the catalytic domain of a3GT at 1.53-Angstrom resolution (form II). This provides a more accurate picture of the details of the catalytic site that includes a bound UDP molecule and a Mn2+ cofactor. Significantly, in the new structure, the C-terminal segment (residues 358-368) adopts a very different, highly structured conformation and appears to form part of the active site. The properties of an Arg-365 to Lys mutant indicate that this region is important for catalysis, possibly reflecting its role in a donor substrate-induced conformational change.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33341 USA	University of Bath; State University System of Florida; Florida Atlantic University	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.		NATESH, Ramanathan/C-4488-2008; Brew, Keith/A-6746-2009; Boix, Ester/B-9038-2012; Brew, Keith/W-1643-2019	NATESH, Ramanathan/0000-0002-1145-5962; Brew, Keith/0000-0003-1306-1032; Boix, Ester/0000-0003-1790-2142; Acharya, K. Ravi/0000-0002-3009-4058; Swaminathan, Jawahar/0000-0002-0215-4084	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058773] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58773] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Breton C, 1998, J BIOCHEM, V123, P1000; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gijsen HJM, 1996, CHEM REV, V96, P443, DOI 10.1021/cr950031q; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nixon B, 2001, CELLS TISSUES ORGANS, V168, P46, DOI 10.1159/000016805; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; POWELL JT, 1976, J BIOL CHEM, V251, P3645; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shetterly S, 2001, GLYCOBIOLOGY, V11, P645, DOI 10.1093/glycob/11.8.645; Shi XD, 2001, DEVELOPMENT, V128, P645; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Watt GM, 1997, CURR OPIN STRUC BIOL, V7, P652, DOI 10.1016/S0959-440X(97)80074-7; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; Zhang YN, 2001, J BIOL CHEM, V276, P11567, DOI 10.1074/jbc.M006530200; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	42	79	80	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48608	48614		10.1074/jbc.M108828200	http://dx.doi.org/10.1074/jbc.M108828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11592969	hybrid			2022-12-25	WOS:000172927000116
J	Kawabe, H; Nakanishi, H; Asada, M; Fukuhara, A; Morimoto, K; Takeuchi, M; Takai, Y				Kawabe, H; Nakanishi, H; Asada, M; Fukuhara, A; Morimoto, K; Takeuchi, M; Takai, Y			Pilt, a novel peripheral membrane protein at tight junctions in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PDZ DOMAIN; GUANYLATE-KINASE; ADHERENS JUNCTIONS; ADHESION MOLECULE; SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; BINDING PROTEIN; SEC6/8 COMPLEX; ZO-1	Tight junctions (TJs) serve as a barrier that prevents solutes and water from passing through the paracellular pathway, and as a fence between the apical and basolateral plasma membranes in epithelial cells. TJs consist of transmembrane proteins (claudin, occludin, and JAM) and many peripheral membrane proteins, including actin filament (F-actin)-binding scaffold proteins (ZO-1, -2, and -3), non-F-actin-binding scaffold proteins (MAGI-1), and cell polarity molecules (ASIP/PAR-3 and PAR-6). We identified here a novel peripheral membrane protein at TJs from a human cDNA library and named it Pilt (for protein incorporated later into TJs), because it was incorporated into TJs later after the claudin-based junctional strands were formed. Pilt consists of 547 amino acids with a calculated M-r of 60,704. Pilt has a proline-rich domain. In cadherin-deficient L cells stably expressing claudin or JAM, Pilt was not recruited to claudin-based or JAM-based cell-cell contact sites, suggesting that Pilt does not directly interact with claudin or JAM. The present results indicate that Pilt is a novel component of TJs.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Fukuhara, Atsunori/A-9601-2018; Kawabe, Hiroshi/U-7325-2018	Fukuhara, Atsunori/0000-0002-6289-3778; Nakanishi, Hiroyuki/0000-0002-9765-0266; Kawabe, Hiroshi/0000-0001-5650-8696				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Ozaki H, 1999, J IMMUNOL, V163, P553; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889; YONEMURA S, 1995, J CELL SCI, V108, P127; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	67	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48350	48355		10.1074/jbc.M107335200	http://dx.doi.org/10.1074/jbc.M107335200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602598	hybrid			2022-12-25	WOS:000172927000083
J	Storey, MK; Clay, KL; Kutateladze, T; Murphy, RC; Overduin, M; Voelker, DR				Storey, MK; Clay, KL; Kutateladze, T; Murphy, RC; Overduin, M; Voelker, DR			Phosphatidylethanolamine has an essential role in Saccharomyces cerevisiae that is independent of its ability to form hexagonal phase structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; PHOSPHATIDYLSERINE DECARBOXYLASE; LIPID POLYMORPHISM; NULL ALLELE; CELL-WALL; YEAST; PROTEIN; GENE; ETHANOLAMINE	Two yeast enzymes, Psd1p and Psd2p, catalyze the decarboxylation of phosphatidylserine to produce phosphatidylethanolamine (PtdEtn). Mitochondrial Psd1p provides similar to 90% of total cellular phosphatidylserine decarboxylase activity. When the PSD1 gene is deleted, the resultant strain (psd1 Delta) grows normally at 30 degreesC in glucose and in the absence of exogenous choline or ethanolamine. However, at elevated temperature (37 degreesC) or on the nonfermentable carbon source lactate, the growth of psd1 Delta strains is minimal without ethanolamine supplementation. The reduced growth and viability correlate with a PtdEtn content below 4% of total phospholipid. These results suggest that there is a critical level of PtdEtn required to support growth. This theory is supported by growth data revealing that a psd1 Delta psd2 Delta dpl1 Delta strain can only grow in the presence of ethanolamine. In contrast, a psd1 Delta psd2 Delta strain, which makes low levels of PtdEtn from sphingolipid breakdown, can be rescued by ethanolamine, choline, or the ethanolamine analogue propanolamine. psd1 Delta psd2 Delta cells grown in 2 mM propanolamine accumulate a novel lipid, which was determined by mass spectrometry to be phosphatidylpropanolamine (PtdPrn). PtdPrn can comprise up to 40% of the total phospholipid content in supplemented cells at the expense of phosphatidylcholine and PtdEtn. The absolute level of PtdEtn required for growth when PtdPrn is present appears to be 1% of the total phospholipid content. The essential function of the PtdEtn in the presence of propanolamine does not appear to be the formation of hexagonal phase lipid, insofar as PtdPrn readily forms hexagonal phase structures detectable by P-31 NMR.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA.	voelkerd@njc.org	Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Kutateladze, Tatiana/0000-0001-7375-6990	NCI NIH HHS [CA85716] Funding Source: Medline; NHLBI NIH HHS [HL34303] Funding Source: Medline; NIGMS NIH HHS [GM32453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085716] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032453, R37GM032453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; Cullis P.R., 1996, NEW COMPREHENSIVE BI, V31, P1; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; CULLIS PR, 1986, BIOCHEM SOC T, V14, P242, DOI 10.1042/bst0140242; DAVIDSON FM, 1958, BIOCHEM J, V69, P458, DOI 10.1042/bj0690458; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; GRUNER SM, 1985, ANNU REV BIOPHYS BIO, V14, P211, DOI 10.1146/annurev.biophys.14.1.211; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Huang CH, 1999, BBA-REV BIOMEMBRANES, V1422, P273, DOI 10.1016/S0005-2736(99)00099-1; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Logue JA, 2000, J EXP BIOL, V203, P2105; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; Mikhaleva NI, 2001, FEBS LETT, V493, P85, DOI 10.1016/S0014-5793(01)02288-8; Mondesert G, 1997, GENETICS, V147, P421; Mouyna I, 2000, J BIOL CHEM, V275, P14882, DOI 10.1074/jbc.275.20.14882; Murphy R. C., 1993, MASS SPECTROMETRY LI; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SENAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1023, P283, DOI 10.1016/0005-2736(90)90424-M; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Storey MK, 2001, BBA-MOL CELL BIOL L, V1532, P234, DOI 10.1016/S1388-1981(01)00129-9; TRIVEDI A, 1982, BIOCHIM BIOPHYS ACTA, V692, P202, DOI 10.1016/0005-2736(82)90522-3; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Umeda M, 1999, CHEM PHYS LIPIDS, V101, P81, DOI 10.1016/S0009-3084(99)00057-2; VERKLEIJ AJ, 1984, CIBA F SYMP, V103, P45; VERKLEIJ AJ, 1980, BIOCHIM BIOPHYS ACTA, V600, P620, DOI 10.1016/0005-2736(80)90465-4; Xie ZH, 2001, MOL BIOL CELL, V12, P1117, DOI 10.1091/mbc.12.4.1117; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614	46	103	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48539	48548		10.1074/jbc.M109043200	http://dx.doi.org/10.1074/jbc.M109043200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602607	hybrid			2022-12-25	WOS:000172927000108
J	Zhou, H; Li, SH; Li, XJ				Zhou, H; Li, SH; Li, XJ			Chaperone suppression of cellular toxicity of Huntingtin is independent of polyglutamine aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; AMYLOID-LIKE FIBRILS; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; DEPENDENT INTERACTION; NEGATIVE REGULATION; TERMINAL FRAGMENTS; APAF-1 APOPTOSOME; GLUTAMINE REPEATS	Polyglutamine protein aggregation is associated with eight inherited neurodegenerative disorders. In Huntington's disease, N-terminal fragments of mutant hunting tin form intracellular aggregates and mediate cellular toxicity. Recent studies have shown that chaperones inhibit polyglutamine-mediated aggregation and cellular toxicity. Because chaperones also inhibit caspase activation to protect cells from death, it remains unclear whether the protective effect of chaperones on polyglutamine-mediated cellular toxicity is dependent on their inhibition of protein aggregation. In this study, we show that several chaperones including HSP 40, HSP 70, and N-ethylmaleimide-sensitive factor can inhibit cellular toxicity caused by N-terminal mutant huntingtin fragments. However, only HSP 40 is able to inhibit huntingtin aggregation. Furthermore, time-course study suggests that the protection of chaperones against huntingtin toxicity is not the result of their suppression of huntingtin aggregation. Chaperones inhibit caspase-3 and caspase-9 activation mediated by mutant huntingtin, and this inhibition is independent of huntingtin aggregation. We propose that the inhibition of caspase activity by chaperones is involved in their suppression of polyglutamine toxicity.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA	Emory University	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Genet, 1462 Clifton Rd, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036232, R01NS041669] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41669, NS36232] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Chai YH, 1999, J NEUROSCI, V19, P10338; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Haas A, 1998, TRENDS CELL BIOL, V8, P471, DOI 10.1016/S0962-8924(98)01388-9; Han SY, 2000, BIOCHEM J, V352, P165, DOI 10.1042/0264-6021:3520165; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; Li SH, 2000, HUM MOL GENET, V9, P2859, DOI 10.1093/hmg/9.19.2859; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Moulder KL, 1999, J NEUROSCI, V19, P705; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1054/csac.1998.0129; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	52	94	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48417	48424		10.1074/jbc.M104140200	http://dx.doi.org/10.1074/jbc.M104140200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606565	hybrid			2022-12-25	WOS:000172927000093
J	Dodd, JR; Christie, DL				Dodd, JR; Christie, DL			Cysteine 144 in the third transmembrane domain of the creatine transporter is located close to a substrate-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-NOREPINEPHRINE TRANSPORTERS; SEROTONIN TRANSPORTER; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; NORADRENALINE TRANSPORTER; FUNCTIONAL EXPRESSION; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CULTURED-CELLS; AMINO-ACID	All creatine transporters contain a cysteine residue (Cys(144)) in the third transmembrane domain that is not present in other members of the Na+,Cl--dependent family of neurotransmitter transporters. Site-directed mutagenesis and reaction with methane thiosulfonates were used to investigate the importance of Cys 144 for transporter function. Replacement of Cys 144 with Ser did not significantly affect the kinetics or activity of the transporter, whereas a C144A mutant had a higher K-m(0.33 compared with 0.18 mm). Substitution of Cys(144) with Leu gave a mutant with a 5-fold higher K-m and a reduced specificity for substrate. Low concentrations of 2-aminoethyl methanethiosulfonate (MTSEA) resulted in rapid inactivation of the creatine transporter. The C144S mutant was resistant to inactivation, indicating that modification of Cys 144 was responsible for the loss of transport activity. Creatine and analogues that function as substrates of the creatine transporter were able to protect from Aff SEA inactivation. Na+ and Cl- ions were not necessary for MTSEA inactivation, but Na+ was found to be important for creatine protection from inactivation. Our results indicate that cysteine 144 is close to the binding site or part of a permeation channel for creatine.	Univ Auckland, Sch Biol Sci, Prot Struct & Funct Res Grp, Auckland 1, New Zealand	University of Auckland	Christie, DL (corresponding author), Univ Auckland, Sch Biol Sci, Prot Struct & Funct Res Grp, Private Bag 92019, Auckland 1, New Zealand.		Christie, David L/C-8065-2009					AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; DALY MM, 1980, ARCH BIOCHEM BIOPHYS, V203, P317, DOI 10.1016/0003-9861(80)90182-4; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Dodd JR, 1999, BBA-GEN SUBJECTS, V1472, P128, DOI 10.1016/S0304-4165(99)00113-0; FITSCH CD, 1968, J BIOL CHEM, V243, P2024; GIROS B, 1994, J BIOL CHEM, V269, P15985; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; GUIMBAL C, 1994, J MOL BIOL, V241, P317, DOI 10.1006/jmbi.1994.1507; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; Ishii TM, 1998, METHOD ENZYMOL, V293, P53; Javitch JA, 1998, METHOD ENZYMOL, V296, P331; JUNG H, 1994, BIOCHEMISTRY-US, V33, P12160, DOI 10.1021/bi00206a019; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Kippenberger AG, 1999, J NEUROCHEM, V73, P1024, DOI 10.1046/j.1471-4159.1999.0731024.x; LOIKE JD, 1986, AM J PHYSIOL, V251, pC128, DOI 10.1152/ajpcell.1986.251.1.C128; MAYSER W, 1992, FEBS LETT, V305, P31, DOI 10.1016/0014-5793(92)80649-2; MOLLER A, 1989, J NEUROCHEM, V52, P544, DOI 10.1111/j.1471-4159.1989.tb09154.x; Nelson N, 1998, J NEUROCHEM, V71, P1785; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Saltarelli MD, 1996, DEV NEUROSCI-BASEL, V18, P524, DOI 10.1159/000111450; SCHLOSS P, 1994, BIOCHEM BIOPH RES CO, V198, P637, DOI 10.1006/bbrc.1994.1093; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; SMITH KE, 1992, MOL PHARMACOL, V42, P563; SORA I, 1994, BIOCHEM BIOPH RES CO, V204, P419, DOI 10.1006/bbrc.1994.2475; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; WALKER J, 1976, ADV ENZYMOLOGY RELAT, V50, P177; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021	35	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46983	46988		10.1074/jbc.M107137200	http://dx.doi.org/10.1074/jbc.M107137200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598117	hybrid			2022-12-25	WOS:000172768500043
J	Driggers, PH; Segars, JH; Rubino, DM				Driggers, PH; Segars, JH; Rubino, DM			The proto-oneoprotein Brx activates estrogen receptor beta by a p38 mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; BREAST-CANCER; GROWTH-FACTOR; DBL FAMILY; C-JUN; STRESS; CELLS; PHOSPHORYLATION; DIFFERENTIATION; TRANSFORMATION	The estrogen receptors (ERs) are ligand-inducible transcription factors that play key roles in the control of growth and differentiation in reproductive tissues. We showed that the novel Dbl family proto-oncoprotein Brx enhances ligand-dependent activity of ER alpha via a Cdc42-dependent pathway. Brx also significantly enhances ligand-dependent activity of ER beta. This enhancement is not affected by inhibition of p44/42 mitogen-activated protein kinase (MAPK) activation by PD98059. However, addition of the p38 MAPK inhibitor SB202190 abrogates the enhancement of ER beta activity by Brx, showing that p38 MAPK activity is required for the enhancement of ER beta function by Brx. In COS-7 cells, transfection of Brx leads to activation of endogenous p38 MAPK activity. Co-expression of the beta2 isoform of human p38 MAPK and a constitutively active form of the p38 MAPK kinase MKK6 (MKK6-EE) synergistically augments ligand-dependent activity of ER beta. Our findings suggest that p38 MAPKs may be important regulators of ER beta activity.	Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA; US Mil Canc Inst, Bethesda, MD 20814 USA; NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Driggers, PH (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.				Intramural NIH HHS [Z99 HD999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Miller BT, 2000, AM J OBSTET GYNECOL, V182, P286, DOI 10.1016/S0002-9378(00)70213-4; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Puri PL, 2000, GENE DEV, V14, P574; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VAN AL, 1997, GENE DEV, V11, P2295	38	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46792	46797		10.1074/jbc.M106927200	http://dx.doi.org/10.1074/jbc.M106927200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579095	hybrid, Green Accepted			2022-12-25	WOS:000172768500017
J	Ko, TP; Chen, YK; Robinson, H; Tsai, PC; Gao, YG; Chen, APC; Wang, AHJ; Liang, PH				Ko, TP; Chen, YK; Robinson, H; Tsai, PC; Gao, YG; Chen, APC; Wang, AHJ; Liang, PH			Mechanism of product chain length determination and the role of a flexible loop in Escherichia coli undecaprenyl-pyrophosphate synthase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-DIPHOSPHATE SYNTHASE; SITE-DIRECTED MUTAGENESIS; BACILLUS-STEAROTHERMOPHILUS; CONSERVED ASPARTATE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; IDENTIFICATION; RESIDUES; PRENYLTRANSFERASE; PURIFICATION	The Escherichia coli undecaprayl-pyrophosphate synthase (UPPs) structure has been solved using the single wavelength anomalous diffraction method. The putative substrate-binding site is located near the end of the betaA-strand with Asp-26 playing a critical catalytic role. In both subunits, an elongated hydrophobic tunnel is found, surrounded by four beta -strands (betaA-betaB-betaD-betaC) and two helices (alpha2 and alpha3) and lined at the bottom with large residues Ile-62, Leu-137, Val-105, and His-103. The product distributions formed by the use of the I62A, V105A, and H103A mutants are similar to those observed for wild-type UPPs. Catalysis by the L137A UPPs, on the other hand, results in predominantly the formation of the C-70 polymer rather than the C-55 polymer. Ala-69 and Ala-143 are located near the top of the tunnel. In contrast to the A143V reaction, the C-30 intermediate is formed to a greater extent and is longer lived in the process catalyzed by the A69L mutant. These findings suggest that the small side chain of Ala-69 is required for rapid elongation to the C-55 product, whereas the large hydrophobic side chain of Leu-137 is required to limit the elongation to the C-55 product. The roles of residues located on a flexible loop were investigated. The S71A, N74A, or R77A mutants displayed 25-200-fold decrease in k(cat) values. W75A showed an 8-fold increase of the FPP K-m value, and 22-33-fold increases in the IPP K-m values were observed for E81A and S71A. The loop may function to bridge the interaction of IPP with FPP, needed to initiate the condensation reaction and serve as a hinge to control the substrate binding and product release.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Wang, AHJ (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	ahjwang@gate.sinica.edu.tw	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041612] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41612] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1985, METHOD ENZYMOL, V110, P281; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUKHTIYAROV YE, 1993, J BIOCHEM-TOKYO, V113, P721, DOI 10.1093/oxfordjournals.jbchem.a124110; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; Fujikura K, 2000, J BIOCHEM, V128, P917, DOI 10.1093/oxfordjournals.jbchem.a022842; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JOLY A, 1993, J BIOL CHEM, V268, P26983; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kharel Y, 2001, J BIOL CHEM, V276, P28459, DOI 10.1074/jbc.M102057200; KOYAMA T, 1995, BIOCHEM BIOPH RES CO, V212, P681, DOI 10.1006/bbrc.1995.2022; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464; Ogura K, 1997, Subcell Biochem, V28, P57; OGURA K, 1997, DYNAMIC ASPECTS NATU, P1; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Ohnuma S, 1998, J BIOL CHEM, V273, P26705, DOI 10.1074/jbc.273.41.26705; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P10936, DOI 10.1021/bi000992l; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P13856, DOI 10.1021/bi001226h; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Quellhorst GJ, 1998, BIOCHEM BIOPH RES CO, V244, P546, DOI 10.1006/bbrc.1998.8098; RIP JW, 1985, PROG LIPID RES, V24, P269, DOI 10.1016/0163-7827(85)90008-6; ROBYT J, 1998, ESSENTIALS CARBOHYDR, P305; Schulbach MC, 2000, J BIOL CHEM, V275, P22876, DOI 10.1074/jbc.M003194200; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072	40	78	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47474	47482		10.1074/jbc.M106747200	http://dx.doi.org/10.1074/jbc.M106747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581264	hybrid			2022-12-25	WOS:000172768500104
J	Marsin, S; McGovern, S; Ehrlich, SD; Bruand, C; Polard, P				Marsin, S; McGovern, S; Ehrlich, SD; Bruand, C; Polard, P			Early steps of Bacillus subtilis primosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN PRIA; ESCHERICHIA-COLI; DNA-REPLICATION; NUCLEOTIDE-SEQUENCE; RECOMBINATION; INITIATION; BINDING; GENE; SITE	Primosomes are nucleoprotein assemblies designed for the activation of DNA replication forks. Their primary role is to recruit the replicative helicase onto single-stranded DNA. The "replication restart" primosome, defined in Escherichia coli, is involved in the reactivation of arrested replication forks. Binding of the PriA protein to forked DNA triggers its assembly. PriA is conserved in bacteria, but its primosomal partners are not. In Bacillus subtilis, genetic analysis has revealed three primosomal proteins, DnaB, DnaD, and DnaI, that have no obvious homologues in E. coli. Interestingly, they are involved in primosome function both at arrested replication forks and at the chromosomal origin. Our biochemical analysis of the DnaB, and DnaD proteins unravels their role in primosome assembly. They are both multimeric and bind individually to DNA. Furthermore, DnaD stimulates DnaB binding activities. DnaD alone and the DnaD/DnaB pair interact specifically with PriA of B. subtilis on several DNA substrates. This suggests that the nucleoprotein assembly is sequential in the PriA, DnaD, DnaB order. The preferred DNA substrate mimics an arrested DNA replication fork with unreplicated lagging strand, structurally identical to a product of recombinational repair of a stalled replication fork.	INRA, Lab Genet Microbienne, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Polard, P (corresponding author), INRA, Lab Genet Microbienne, Domaine de Vilvert, F-78352 Jouy En Josas, France.	polard@biotec.jouy.inra.fr	Bruand, Claude/AAF-7695-2020; Ehrlich, S./Y-2423-2019	Ehrlich, S./0000-0002-7563-4046; Bruand, Claude/0000-0002-2367-0782; MARSIN, Stephanie/0000-0002-7074-7818				BRUAND C, 1995, MICROBIOL-UK, V141, P1199, DOI 10.1099/13500872-141-5-1199; BRUAND C, 1995, EMBO J, V14, P2642, DOI 10.1002/j.1460-2075.1995.tb07262.x; Bruand C, 2001, MOL MICROBIOL, V42, P245, DOI 10.1046/j.1365-2958.2001.02631.x; BRUAND C, 1995, MICROBIOL-UK, V141, P321, DOI 10.1099/13500872-141-2-321; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; Imai Y, 2000, MOL MICROBIOL, V36, P1037, DOI 10.1046/j.1365-2958.2000.01928.x; Ishigo-oka D, 2001, J BACTERIOL, V183, P2148, DOI 10.1128/JB.183.6.2148-2150.2001; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kolb SJ, 1998, J BIOL CHEM, V273, P31555, DOI 10.1074/jbc.273.47.31555; KOONIN EV, 1992, NUCLEIC ACIDS RES, V20, P1997, DOI 10.1093/nar/20.8.1997; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; MARIANS KJ, 1996, ESCHERICHIA COLI SAL, P749; MASAI H, 1996, FRONT BIOSCI, V1, P48; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Moriya S, 1999, PLASMID, V41, P17, DOI 10.1006/plas.1998.1381; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; OGASAWARA N, 1986, NUCLEIC ACIDS RES, V14, P9989, DOI 10.1093/nar/14.24.9989; Polard P, 1996, J MOL BIOL, V264, P68, DOI 10.1006/jmbi.1996.0624; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 2000, GENETICS, V155, P487; Sandler SJ, 1996, GENETICS, V143, P5; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUEOKA N, 1993, PROG NUCL ACIDS RES, V59, P35; WAHLE E, 1989, J BIOL CHEM, V264, P2469; Yoshiakwa H., 1993, P507; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337	41	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45818	45825		10.1074/jbc.M101996200	http://dx.doi.org/10.1074/jbc.M101996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585815	Green Published, hybrid			2022-12-25	WOS:000172573100044
J	Weiss, S; Rossi, R; Pellegrino, MA; Bottinelli, R; Geeves, MA				Weiss, S; Rossi, R; Pellegrino, MA; Bottinelli, R; Geeves, MA			Differing ADP release rates from myosin heavy chain isoforms define the shortening velocity of skeletal muscle fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALI LIGHT-CHAIN; ACTOMYOSIN ATPASE; CONTRACTION; ACTIN; MECHANISM; PROTEINS; SLOW; QUANTITIES; PHOTOLYSIS; DIVERSITY	To understand mammalian skeletal myosin isoform diversity, pure myosin isoforms of the four major skeletal muscle myosin types (myosin heavy chains I, IIA, IIX, and IIB) were extracted from single rat muscle fibers. The extracted myosin (1-2 mug/15-mm length) was sufficient to define the actomyosin dissociation reaction in flash photolysis using caged-ATP (Weiss, S., Chizhov, I., and Geeves, M. A. (2000) J. Muscle Res. Cell Motil. 21, 423-432). The ADP inhibition of the dissociation reaction was also studied to give the ADP affinity for actomyosin (K-AD). The apparent second order rate constant of actomyosin dissociation gets faster (K(1)k(+2) = 0.17 -0.26 mum(-1).s(-1)), whereas the affinity for ADP is weakened (250-930 mum) in the isoform order I, IIA, IIX, IIB. Both sets of values correlate well with the measured maximum shortening velocity (V-0) of the parent fibers. If the value of KAD is controlled largely by the rate constant of ADP release (k(-AD)), then the estimated value of k(-AD) is sufficiently low to limit V.. In contrasts [ATP]K(1)k(+2) at a physiological concentration of 5 mm ATP would be 2.5-6 times faster than k(-AD).	Univ Kent, Res Sch Biosci, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ Pavia, Inst Human Physiol, I-27100 Pavia, Italy	University of Kent; University of Pavia	Geeves, MA (corresponding author), Univ Kent, Res Sch Biosci, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	mag@ukc.ac.uk	Bottinelli, Roberto/AAC-1904-2020; Geeves, Michael/F-7583-2011; Pellegrino, Maria Antonietta/AAC-4680-2022	Bottinelli, Roberto/0000-0002-4960-7490; Geeves, Michael/0000-0002-9364-8898; Pellegrino, Maria Antonietta/0000-0002-1653-1266				BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V481, P663, DOI 10.1113/jphysiol.1994.sp020472; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; Canepari M, 2000, J MUSCLE RES CELL M, V21, P375, DOI 10.1023/A:1005640004495; Canepari M, 1999, EXP PHYSIOL, V84, P803, DOI 10.1111/j.1469-445X.1999.00350.x; Chizhov I, 1996, BIOPHYS J, V71, P2329, DOI 10.1016/S0006-3495(96)79475-4; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABUCHI K, 1980, MUSCLE NERVE, V3, P233, DOI 10.1002/mus.880030308; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; PATE E, 1992, AM J PHYSIOL, V262, pC1039; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; RANATUNGA KW, 1984, J PHYSIOL-LONDON, V351, P517, DOI 10.1113/jphysiol.1984.sp015260; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STARON RS, 1987, PFLUG ARCH EUR J PHY, V409, P67, DOI 10.1007/BF00584751; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; Weiss S, 2000, J MUSCLE RES CELL M, V21, P423, DOI 10.1023/A:1005690106951; WEST JJ, 1967, J BIOL CHEM, V242, P1140; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020	33	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45902	45908		10.1074/jbc.M107434200	http://dx.doi.org/10.1074/jbc.M107434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590173	hybrid			2022-12-25	WOS:000172573100056
J	Turkson, J; Ryan, D; Kim, JS; Zhang, Y; Chen, Z; Haura, E; Laudano, A; Sebti, S; Hamilton, AD; Jove, R				Turkson, J; Ryan, D; Kim, JS; Zhang, Y; Chen, Z; Haura, E; Laudano, A; Sebti, S; Hamilton, AD; Jove, R			Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; JAK-STAT PATHWAY; CONSTITUTIVE ACTIVATION; TRANSCRIPTIONAL ACTIVATION; MYELOID DIFFERENTIATION; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; MYCOSIS-FUNGOIDES	Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic signaling proteins that participates in normal cellular responses to cytokines and growth factors. Frequently, however, constitutive activation of certain STAT family members, particularly Stat3, has accompanied a wide variety of human malignancies. To identify small molecule inhibitors of Stat3, we investigated the ability of the Stat3 SH2 domain-binding peptide, PY*LKTK (where Y* represents phosphotyrosine), to disrupt Stat3 activity in vitro. The presence of PY*LKTK, but not PYLKTK or PFLKTK, in nuclear extracts results in significant reduction in the levels of DNA binding activities of Stat3, to a lesser extent of Stat1, and with no effect on that of Stat5. Analyses of alanine scanning mutagenesis and deletion derivatives of PY*LKTK reveal that the Leu residue at the Y+1 position and a substituent at the Y-1 position (but not necessarily Pro) are essential for the disruption of active Stat3, thereby mapping the minimum active sequence to the tripeptide, XY*L. Studies involving bead-coupled PY*LKTK peptide demonstrate that this phosphopeptide directly complexes with Stat3 monomers in vitro, suggesting that PY*LKTK disrupts Stat3:Stat3 dieters. As evidence for the functional importance of peptide-directed inhibition of Stat3, PY*LKTK-mts (rots, membrane translocating sequence) selectively inhibits constitutive and ligand-induced Stat3 activation in vivo. Furthermore, PY*LKTK-mts suppresses transformation by the Src oncoprotein, which has been shown previously to require constitutive Stat3 activation. Altogether, we have identified a minimal peptide that inhibits Stat3 signaling and provides the conceptual basis for use of this peptide as a lead for novel peptidomimetic drug design.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA; Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University; University System Of New Hampshire; University of New Hampshire	Turkson, J (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC 4019,12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA055652, P01CA078038] Funding Source: NIH RePORTER; NCI NIH HHS [CA78038, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Ben-Bassat H, 2000, CURR PHARM DESIGN, V6, P933, DOI 10.2174/1381612003400182; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chakraborty A, 2000, BLOOD CELL MOL DIS, V26, P320, DOI 10.1006/bcmd.2000.0309; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Inoue M, 1997, J BIOL CHEM, V272, P9550; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Mikita T, 1998, J BIOL CHEM, V273, P17634, DOI 10.1074/jbc.273.28.17634; Miknyoczki SJ, 1999, CLIN CANCER RES, V5, P2205; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 1999, CANCER RES, V59, P5059; Planas AM, 1997, J NEUROCHEM, V68, P1345; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephens JM, 1996, J BIOL CHEM, V271, P10441, DOI 10.1074/jbc.271.18.10441; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZVELEBIL MJJM, 1995, PROTEIN ENG, V8, P527, DOI 10.1093/protein/8.6.527	65	364	408	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45443	45455		10.1074/jbc.M107527200	http://dx.doi.org/10.1074/jbc.M107527200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579100	hybrid			2022-12-25	WOS:000172406700142
J	Khan, MM; Nomura, T; Kim, H; Kaul, SC; Wadhwa, R; Zhong, S; Pandolfi, PP; Ishi, S				Khan, MM; Nomura, T; Kim, H; Kaul, SC; Wadhwa, R; Zhong, S; Pandolfi, PP; Ishi, S			PML-RAR alpha alleviates the transcriptional repression mediated by tumor suppressor Rb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE COMPLEX; RETINOBLASTOMA PROTEIN; GENE-PRODUCT; N-COR; RECEPTOR; TRANSLOCATION; COMPONENT; SMRT; LOCALIZATION	A fusion between the promyelocytic leukemia (PML) protein and the retinoic acid receptor-alpha (RAR alpha) results in the transforming protein of acute promyelocytic leukemia, PMM-RAR alpha. PML has growth-suppressive properties and is localized within distinct nuclear structures referred to as nuclear bodies. PML participates in numerous cellular functions, including transcriptional activation, apoptosis, and transcriptional repression, whereas PMM-RAR alpha blocks these functions. However, the role played by PMM-RAR alpha in leukemogenesis remains unclear. Here we report that PML is required for transcriptional repression mediated by the tumor suppressor Rb. Rb interacts with the histone decaetylase (HDAC) complex containing co-repressors and represses the transcription of the E2F target genes. Overexpression of PAM enhanced Rb-mediated repression. The degree of Rb-mediated repression was weakened by injecting antiPML antibodies and was lower in PML-deficient mouse embryonic fibroblasts. PAM-RAR alpha inhibited Rb-mediated repression, and two co-repressor-interacting sites on the PML-RAR alpha molecule were required for this activity. Furthermore, PMM-RAR alpha blocked the interaction between Rb and HDAC. Thus, aberrant binding of PML-RAR alpha to co-repressor-HDAC complexes may inhibit their association with Rb, resulting in the abrogation of Rb activity. Thus, the disruption of Rb-mediated repression may be a contributory factor in leukemogenesis.	RIKEN, Mol Genet Lab, Tsukuba Inst, Tsukuba, Ibaraki 3050074, Japan; CREST, Project JST, Tsukuba, Ibaraki 3050074, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mol & Cell Biol, Tsukuba, Ibaraki 3058566, Japan; Chugai Res Inst Mol Med, Ibaraki, Osaka 3004101, Japan; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Human Genet,Sloan Kettering Div, Program Mol Biol,Grad Sch Med Sci, New York, NY 10021 USA	RIKEN; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Cornell University; Memorial Sloan Kettering Cancer Center	Ishi, S (corresponding author), RIKEN, Mol Genet Lab, Tsukuba Inst, Tsukuba, Ibaraki 3050074, Japan.		Kaul, Sunil C/L-8671-2018	Kaul, Sunil C/0000-0002-0046-3916				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cao TY, 1998, J CELL SCI, V111, P1319; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang EY, 2000, GENE DEV, V14, P45; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kao HY, 2000, GENE DEV, V14, P55; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEVINS JR, 1992, SCIENCE, V258, P424; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PAGGI MG, 1995, CANCER RES, V55, P4552; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wang ZG, 1998, SCIENCE, V279, P1547; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	32	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43491	43494		10.1074/jbc.C100532200	http://dx.doi.org/10.1074/jbc.C100532200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11583987	hybrid			2022-12-25	WOS:000172297700002
J	Pierantoni, GM; Fedele, M; Pentimalli, F; Benvenuto, G; Pero, R; Viglietto, G; Santoro, M; Chiariotti, L; Fusco, A				Pierantoni, GM; Fedele, M; Pentimalli, F; Benvenuto, G; Pero, R; Viglietto, G; Santoro, M; Chiariotti, L; Fusco, A			High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth	ONCOGENE			English	Article						HMGI(Y); HIPK2; serine-threonine kinase; growth inhibition; yeast two-hybrid screening	IFN-BETA GENE; EXPRESS HIGH-LEVELS; FACTOR HMGI-C; SERINE/THREONINE KINASE; TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; VIRUS INDUCTION; THYROID-CELLS; DNA-BINDING; SEQUENCE	The HMGI proteins (HMGI, HMGY and HMGI-C) have an important role in the chromatin organization and interact with different transcriptional factors. The HMGI genes are expressed at very low levels in normal adult tissues, whereas they are very abundant during embryonic development and in several experimental and human tumours. In order to isolate proteins interacting with the HMGI(Y) proteins, a yeast two-hybrid screening was performed using the HMGI(Y) protein as bait. This analysis led to the isolation of homeodomain-interacting protein kinase-2 (HIPK2), a serine/threonine nuclear kinase. HIPK2 co-immunoprecipitates with the HMGI(Y) protein in 293T cells. The interaction between HIPK2 and HMGI(Y) occurs through the PEST domain of HIPK2 and it is direct because in vitro translated HIPK2 binds HMGI(Y). We also show that HIPK2 is able to phosphorylate the HMGI(Y) protein by an in vitro kinase assay. In order to understand a possible role of HIPK2 gene in cell growth we performed a colony assay which showed an impressive HIPK2 inhibitory effect on normal thyroid cells. Flow cytometric analysis would indicate the block of cell growth at the G2/M phase of the cell cycle. Since normal thyroid cells do not express detectable HMGI(Y) protein levels, we assume that the HIPK2 inhibitory effect is independent from the interaction with the HMGI(Y) protein.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fondaz Senatore Pascale, Ist Nazl Tumori, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.		Fedele, Monica/C-1417-2015; Pentimalli, Francesca/K-4936-2014; Pero, Raffaela/L-1461-2015; Viglietto, Giuseppe/AAC-2852-2019; Pierantoni, Giovanna Maria/O-7527-2015; Chiariotti, Lorenzo/AAC-5262-2022	Fedele, Monica/0000-0002-9171-1312; Pentimalli, Francesca/0000-0003-4740-6801; Pero, Raffaela/0000-0003-2182-5530; Viglietto, Giuseppe/0000-0003-2327-7515; Pierantoni, Giovanna Maria/0000-0003-4078-8528; BENVENUTO, Giovanna/0000-0001-7155-2935; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; Fusco, Alfredo/0000-0003-3332-5197				Abe N, 2000, CANCER RES, V60, P3117; ABE N, 1999, CANCER RES, V56, P1896; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Fedele M, 1996, CANCER RES, V56, P1896; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Li X, 2000, BIOCHEM BIOPH RES CO, V277, P513, DOI 10.1006/bbrc.2000.3700; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; ROGERS S, 1986, SCIENCE, V234, P3674; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAMIMI Y, 1993, CANCER RES, V53, P5512; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tkachenko A, 1997, CANCER RES, V57, P2276; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Xiao S, 1997, AM J PATHOL, V150, P901; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	50	76	84	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6132	6141		10.1038/sj.onc.1204635	http://dx.doi.org/10.1038/sj.onc.1204635			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593421	Bronze			2022-12-25	WOS:000171206300004
J	McIlhatton, MA; Burrows, JF; Donaghy, PG; Chanduloy, S; Johnston, PG; Russell, SEH				McIlhatton, MA; Burrows, JF; Donaghy, PG; Chanduloy, S; Johnston, PG; Russell, SEH			Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3	ONCOGENE			English	Article						septin gene; genomic organisation; complex splicing	ACUTE MYELOID-LEUKEMIA; CELL-DIVISION CYCLE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN SEPTIN; OVARIAN-TUMORS; PROTEIN-KINASE; YEAST; CYTOKINESIS; FAMILY; REGION	The Ov/Br septin gene, which is also a fusion partner of MLL in acute myeloid leukaemia, is a member of a family of novel GTP binding proteins that have been implicated in cytokinesis and exocytosis. In this study, we describe the genomic and transcriptional organization of this gene, detailing seventeen exons distributed over 240 kb of sequence. Extensive database analyses identified orthologous rodent cDNAs that corresponded to new, unidentified 5 ' splice variants of the Ov/Br septin gene, increasing the total number of such variants to six. We report that splicing events, occurring at noncanonical sites within the body of the 3 ' terminal exon, remove either 1801 by or 1849 by of non-coding sequence and facilitate access to a secondary open reading frame of 44 amino acids maintained near the end of the 3 ' UTR. These events constitute a novel coding arrangement and represent the first report of such a design being implemented by a eukaryotic gene. The various Ov/Br proteins either differ minimally at their amino and carboxy termini or are equivalent to truncated versions of larger isoforms. Northern analysis with an Ov/Br septin 3 ' UTR probe reveals three transcripts of 4.4, 4 and 3 kb, the latter being restricted to a sub-set of the tissues tested. Investigation of the identified Ov/Br septin isoforms by RT-PCR confirms a complex transcriptional pattern, with several isoforms showing tissue-specific distribution. To date, none of the other human septins have demonstrated such transcriptional complexity.	Queens Univ Belfast, Dept Oncol, Ctr Canc, Belfast City Hosp, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Russell, SEH (corresponding author), Queens Univ Belfast, Dept Oncol, Ctr Canc, Belfast City Hosp, U Floor, Belfast BT9 7AB, Antrim, North Ireland.	seh.russell@qub.ac.uk						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; DeVirgilio C, 1996, MICROBIOL-SGM, V142, P2897, DOI 10.1099/13500872-142-10-2897; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Fares H, 1996, J CELL BIOL, V132, P399, DOI 10.1083/jcb.132.3.399; FARES H, 1995, MOL BIOL CELL, V6, P1843, DOI 10.1091/mbc.6.12.1843; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Fung ET, 1999, FEBS LETT, V451, P203, DOI 10.1016/S0014-5793(99)00559-1; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kilpartick GJ, 1999, TRENDS PHARMACOL SCI, V20, P294, DOI 10.1016/S0165-6147(99)01355-3; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Mori T, 1996, CYTOGENET CELL GENET, V73, P224, DOI 10.1159/000134343; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Russell SEH, 2000, CANCER RES, V60, P4729; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sorensen AB, 2000, J VIROL, V74, P2161, DOI 10.1128/JVI.74.5.2161-2168.2000; Taki T, 1999, CANCER RES, V59, P4261; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; Yagi M, 1998, GENE, V212, P229, DOI 10.1016/S0378-1119(98)00146-2; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422	45	68	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5930	5939		10.1038/sj.onc.1204752	http://dx.doi.org/10.1038/sj.onc.1204752			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593400				2022-12-25	WOS:000171037200018
J	Michalowski, J; Seavey, SE; Mendrysa, SM; Perry, ME				Michalowski, J; Seavey, SE; Mendrysa, SM; Perry, ME			Defects in transcription coupled repair interfere with expression of p90(MDM2) in response to ultraviolet light	ONCOGENE			English	Article						p53; MDM2; ultraviolet; transcription	RNA-POLYMERASE-II; WILD-TYPE P53; NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; DNA-DAMAGE; UV IRRADIATION; MDM2 GENE; COCKAYNES-SYNDROME; PYRIMIDINE DIMERS; FEEDBACK LOOP	Ultraviolet (UV) irradiation transiently stabilizes p53 through a mechanism that may require a decrease in the activity of the ubiquitin ligase, p90(MDM2). Conversely, the recovery of low levels of p53 following UV exposure may depend on an increase in p90(MDM2). The level of p90(MDM2) is increased by UV light following the p53-dependent induction of an internal mdm2 promoter, P2. If this induction of mdm2 were critical for the recovery of low levels of p53 following UV exposure, defects in mdm2's transcription would result in a prolonged increase in p53. Cells defective in transcription coupled repair (TCR) maintain high levels of p53 for a prolonged period following UV exposure. Such cells also have defects in general transcription after UV irradiation. We investigated whether TCR-deficient cells express diminished levels of mdm2 mRNA and p90(MDM2) following UV exposure. We found that transcription of mdm2 was reduced in TCR-deficient cells. The uninducible mdm2 promoter, P1, was more sensitive to the inhibitory effects of UV irradiation than the P2 promoter. The decrease in transcription from the P1 promoter was sufficient to reduce the level of p90(MDM2) and correlated with a prolonged increase in p53. Thus, p53-independent transcription of mdm2 appears critical to p53's regulation.	Univ Wisconsin, Sch Med, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Perry, ME (corresponding author), Univ Wisconsin, Sch Med, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [CA-07175, CA-09135, CA-70781] Funding Source: Medline; NIGMS NIH HHS [GM-07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA070781, R29CA070781, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; Geyer RK, 2000, CELL GROWTH DIFFER, V11, P149; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Huang JH, 1998, ONCOGENE, V17, P401, DOI 10.1038/sj.onc.1201951; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; JUVEN T, 1993, ONCOGENE, V8, P3411; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Landers JE, 1997, CANCER RES, V57, P3562; LI G, 1995, CANCER RES, V55, P2070; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; van Hoffen A, 1999, NUCLEIC ACIDS RES, V27, P2898, DOI 10.1093/nar/27.14.2898; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	46	5	5	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5856	5864		10.1038/sj.onc.1204721	http://dx.doi.org/10.1038/sj.onc.1204721			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593391				2022-12-25	WOS:000171037200009
J	Subauste, MC; List, B; Guan, XJ; Hahn, KM; Lerner, R; Gilula, NB				Subauste, MC; List, B; Guan, XJ; Hahn, KM; Lerner, R; Gilula, NB			A catalytic antibody produces fluorescent tracers of gap junction communication in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE-SYSTEM; CONNEXIN43; HYDROLYSIS; MECHANISM; MELANOMA	The antibody 38C2 efficiently catalyzed a retro-Michael reaction to convert a novel, cell-permeable flu. orogenic substrate into fluorescein within living cells. In vitro, the antibody converted the substrate to fluorescein with a k(cat) of 1.7 x 10(-5) s(-1) and a catalytic proficiency (k(cat)/k(uncat)K(m)) of 1.4 x 10(10) M-1 (K-m = 7 mum). For hybridoma cells expressing antibody or Chinese Hamster Ovarian (CHO) cells injected with antibody, incubation of the substrate in the extracellular medium resulted in bright intracellular fluorescence distinguishable from autofluorescence or noncatalyzed conversion of substrate. CHO cells loaded with antibody were 12 times brighter than control cells, and more than 85% of injected cells became fluorescent. The fluorescein produced by the antibody traveled into neighboring cells through gap junctions, as demonstrated by blocking dye transfer using the gap junction inhibitor oleamide. The presence of functional gap junctions in CHO cells was confirmed through oleamide inhibition of lucifer yellow transfer. These studies demonstrate the utility of the intracellular antibody reaction, which could generate tracer dyes in specific cells within complex multicellular environments simply by bathing the system in substrate.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Subauste, MC (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Hahn, Klaus/0000-0002-1970-7562	NIAID NIH HHS [AI 01684] Funding Source: Medline; NIGMS NIH HHS [R01 GM 57464, R01 GM057464] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057464] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alves LA, 1998, IMMUNOL TODAY, V19, P269, DOI 10.1016/S0167-5699(98)01256-0; Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; Castleman K. R., 1996, DIGITAL IMAGE PROCES; Ersoy O, 1999, BIOORGAN MED CHEM, V7, P279, DOI 10.1016/S0968-0896(98)00203-X; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; Hsu MY, 2000, J CELL SCI, V113, P1535; Ito A, 2000, J CLIN INVEST, V105, P1189, DOI 10.1172/JCI8257; Krenacs T, 1997, EUR J IMMUNOL, V27, P1489, DOI 10.1002/eji.1830270627; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Lin CH, 1997, P NATL ACAD SCI USA, V94, P11773, DOI 10.1073/pnas.94.22.11773; List B, 1998, P NATL ACAD SCI USA, V95, P15351, DOI 10.1073/pnas.95.26.15351; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; Oviedo-Orta E, 2000, IMMUNOLOGY, V99, P578, DOI 10.1046/j.1365-2567.2000.00991.x; Saunders MM, 2001, CANCER RES, V61, P1765; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Smithrud DB, 2000, P NATL ACAD SCI USA, V97, P1953, DOI 10.1073/pnas.040534397; Suzuki H, 2000, J PROTEIN CHEM, V19, P419, DOI 10.1023/A:1026446219097; Turner JM, 2000, CHEM-EUR J, V6, P2772, DOI 10.1002/1521-3765(20000804)6:15<2772::AID-CHEM2772>3.0.CO;2-J; Wentworth P, 1998, P NATL ACAD SCI USA, V95, P5971, DOI 10.1073/pnas.95.11.5971	20	6	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49164	49168		10.1074/jbc.M105700200	http://dx.doi.org/10.1074/jbc.M105700200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11606573	hybrid			2022-12-25	WOS:000173922100072
J	Brooun, A; Richman, DD; Kornbluth, RS				Brooun, A; Richman, DD; Kornbluth, RS			HIV-1 preintegration complexes preferentially integrate into longer target DNA molecules in solution as detected by a sensitive, polymerase chain reaction-based integration assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL NUCLEIC-ACIDS; RETROVIRAL DNA; CDNA INTEGRATION; STRAND-TRANSFER; PROTEIN; AUTOINTEGRATION; ORGANIZATION; EXPRESSION; INHIBITORS	After entering a cell and undergoing reverse transcription, the retroviral genome is contained in a preintegration complex (PIC) that mediates its integration into host cell DNA. PICs have been shown to prefer torsionally strained DNA, but the effect of target DNA length has not been previously examined. In this report, concatemerization of a repeating 105-base pair unit was used to vary target DNA length independently from basic DNA sequence, while maintaining both PICs and target DNAs in solution. Integration junctions were quantified by real-time fluorescence-monitored polymerase chain reaction amplification using primers in the viral long terminal repeat and the target DNA. Unreacted target DNA severely inhibited the post-reaction polymerase chain reaction detection step, requiring its removal using lambda exonuclease digestion. Integration into a 32-unit concatemer of target DNA was markedly more efficient than integration into a monomeric unit, indicating that longer target DNA was preferred. This substrate was used to construct a simple, robust, and adaptable assay that can serve as a method for studying the host cell factors that enhance PIC integration, and as a drug discovery platform for integration inhibitors active against PICs.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Kornbluth, RS (corresponding author), Univ Calif San Diego, Dept Med, 0679,9500 Gilman Dr, La Jolla, CA 92093 USA.	rkornbluth@ucsd.edu		Kornbluth, Richard/0000-0002-0218-2026	NHLBI NIH HHS [HL 57911] Funding Source: Medline; NIAID NIH HHS [AI 25316, AI 36214, AI 07384] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025316, P30AI036214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; Bor YC, 1996, VIROLOGY, V222, P283, DOI 10.1006/viro.1996.0422; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; Farnet CM, 1996, P NATL ACAD SCI USA, V93, P9742, DOI 10.1073/pnas.93.18.9742; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; FARNET CM, 1991, J VIROL, V65, P6942, DOI 10.1128/JVI.65.12.6942-6952.1991; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Hansen MST, 1999, NAT BIOTECHNOL, V17, P578, DOI 10.1038/9886; Hansen MST, 1998, GENET ENG P, V20, P41; HAZUDA DJ, 1994, NUCLEIC ACIDS RES, V22, P1121, DOI 10.1093/nar/22.6.1121; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Kainz P, 2000, BBA-GENE STRUCT EXPR, V1494, P23, DOI 10.1016/S0167-4781(00)00200-1; Kainz P, 2000, BIOTECHNIQUES, V28, P278, DOI 10.2144/00282st04; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MILLER MD, 1995, CURR BIOL, V5, P1047, DOI 10.1016/S0960-9822(95)00209-0; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; PRINCE JT, 1995, BIOCHEMISTRY-US, V34, P10879, DOI 10.1021/bi00034a022; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Shibagaki Y, 1997, J BIOL CHEM, V272, P8361, DOI 10.1074/jbc.272.13.8361; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; Wei SQ, 1997, EMBO J, V16, P7511, DOI 10.1093/emboj/16.24.7511; Winkler S, 2000, BIOCHEMISTRY-US, V39, P12739, DOI 10.1021/bi001335w; Winkler S, 1999, INT J BIOL MACROMOL, V24, P265, DOI 10.1016/S0141-8130(98)00088-9; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995	37	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46946	46952		10.1074/jbc.M108000200	http://dx.doi.org/10.1074/jbc.M108000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595745	hybrid			2022-12-25	WOS:000172768500038
J	Fuku, A; Inoue, N; Matsumoto, M; Nomura, M; Yamada, K; Matsuda, Y; Toyoshima, K; Seya, T				Fuku, A; Inoue, N; Matsumoto, M; Nomura, M; Yamada, K; Matsuda, Y; Toyoshima, K; Seya, T			Molecular cloning and functional characterization of chicken toll-like receptors - A single chicken toll covers multiple molecular patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-SYSTEM; B-CELLS; DROSOPHILA TOLL; CUTTING EDGE; GENE; LIPOPOLYSACCHARIDE; PROTEIN; RECOGNITION; ACTIVATION; LIPOPEPTIDE	Toll-like receptors (TLR) in the innate immune system have not been identified in non-mammalian vertebrates. Two types of TLR were cloned from a chicken bursa cDNA library using degenerate primers based on the consensus sequences of mouse and Drosophila Toll and designated as chicken TLR (chTLR) type 1 and type 2. Of the nine human TLRs reported to date, these chTLRs showed the highest homology to human TLR2. The extracellular regions of type 1 and type 2 contained a distinct similar to 200-amino acid stretch and were 45.3 and 46.3% homologous to that of human TLR2. The intracellular Toll/interleukin-1R homology domain of type I and type 2 was perfectly identical to each other and highly homologous (80.7%) to that of human TLR2. Both types were widely detected by reverse transcriptase-polymerase chain reaction and immunoblotting in various chicken organs, especially those rich in connective tissue. Both genes were mapped to chromosome 4q1.1, suggesting that they arose by gene duplication. By reporter gene assay, type 2 and to a lesser extent type 1, selectively signaled the presence of mycoplasma macrophage-activating lipopeptide-2/M161Ag in the human embryonic kidney 293 cell system. Cotransfection of type 2 and human CD14 or MD-2 into human embryonic kidney 293 cells allowed the response to Escherichia coli lipopolysaccharide (LPS), whereas type I did not signal LPS or any other microbial components tested. These results indicated that chTLR type 2 covers two major microbe patterns, lipoproteins and LPS, which are regulated by TLR2 and TLR4 in mammals. In oviparous animals, the duplicated TLRs in the pattern-recognition system may function for host-pathogen discrimination in a manner that is distinct from that in mammals.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan; Nara Inst Sci & Technol, Dept Mol Immunol, Nara 6310101, Japan; Osaka Univ, Dept Pharmaceut Sci, Div Environm Pharmacol, Suita, Osaka 5650022, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Lab Cytogenet,Kita Ku, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Fac Sci, Chromosome Res Unit, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Nara Institute of Science & Technology; Osaka University; Hokkaido University; Hokkaido University	Seya, T (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan.		Seya, Tsukasa/A-4336-2012; Inoue, Naokazu/A-9911-2009	Inoue, Naokazu/0000-0002-6187-8293				Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Boyd Y, 2001, IMMUNOGENETICS, V52, P294, DOI 10.1007/s002510000268; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COOPER EL, 1992, SCAND J IMMUNOL, V35, P247, DOI 10.1111/j.1365-3083.1992.tb02857.x; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Goitsuka R, 1997, J IMMUNOL, V159, P3126; GOUBIN G, 1983, NATURE, V302, P114, DOI 10.1038/302114a0; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu JX, 1997, GENOME RES, V7, P693, DOI 10.1101/gr.7.7.693; Inoue N, 2001, J IMMUNOL, V166, P424, DOI 10.4049/jimmunol.166.1.424; INOUE N, 2001, SCAND J IMMUNOL, V54, P80; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Kaiser P, 2000, MICROBIOL-UK, V146, P3217, DOI 10.1099/00221287-146-12-3217; Kaufman J, 1999, NATURE, V401, P923, DOI 10.1038/44856; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MCMICHAEL A, 1999, IMMUNOBIOLOGY IMMUNE, P363; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Miura Y, 1998, BLOOD, V92, P2815, DOI 10.1182/blood.V92.8.2815.420k09_2815_2822; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Nishiguchi M, 2001, J IMMUNOL, V166, P2610, DOI 10.4049/jimmunol.166.4.2610; Nishimura H, 2001, IMMUNOLOGY, V103, P519, DOI 10.1046/j.1365-2567.2001.01263.x; Ogata H, 2000, J EXP MED, V192, P23, DOI 10.1084/jem.192.1.23; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rescigno M, 1999, IMMUNOL TODAY, V20, P200, DOI 10.1016/S0167-5699(98)01427-3; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Suzuki T, 1999, CYTOGENET CELL GENET, V87, P32, DOI 10.1159/000015388; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1	44	146	157	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47143	47149		10.1074/jbc.M103902200	http://dx.doi.org/10.1074/jbc.M103902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590137	hybrid			2022-12-25	WOS:000172768500064
J	Gao, Y; Xing, J; Streuli, M; Leto, TL; Zheng, Y				Gao, Y; Xing, J; Streuli, M; Leto, TL; Zheng, Y			Trp(56) of Rac1 specifies interaction with a subset of guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL HOMOLOGY DOMAIN; CRYSTAL-STRUCTURE; RHO-GTPASES; ONCOGENIC DBL; GTP ANALOG; FAMILY; TRIO; PROTEIN; ACTIVATION; KINASE	Signaling specificity of Rho GTPase pathways is achieved in part by selective interaction between members of the Dbl family guanine nucleotide exchange factors (GEFs) and their Rho GTPase substrates. For example, Trio, GEF-H1, and Tiam1 are a subset of GEFs that specifically activate Rac1 but not the closely related Cdc42. The Rac1 specificity of these GEFs appears to be governed by Rac1-GEF binding interaction. To understand the detailed mechanism underlying the GEF specificity issue, we have analyzed a panel of chimeras made between Rac1 and Cdc42 and examined a series of point mutants of Racl made at the switch I, switch II, and beta (2)/beta (3) regions for their ability to interact with and to be activated by the GEFs. The results reveal that Rac1 residues of both the switch I and switch II regions are involved in GEF docking and GEF-mediated nucleotide disruption, because mutation of Asp(38), Asn(39), Gln(61), Tyr(64), or Arg(66)/Leu(67) into Ala results in the loss of GEF binding, whereas mutation at Tyr(32), Asp(65), or Leu(70)/ Ser(71) leads to the loss of GEF catalysis while retaining the binding capability. The region between amino acids 53-72 of Rac1 is required for specific recognition and activation by the GEFs, and Trp(56) in beta (3), appears to be the critical determinant. Introduction of Trp(56) to Cdc42 renders it fully responsive to the Rac-specific GEF in vitro and in cells. Further, a polypeptide derived from the beta (3) region of Rac1 including the Trp,56 residue serves as a specific inhibitor for Rac1 interaction with the GEFs. Taken together, these results indicate that Trp-56 is the necessary and sufficient determinant of Rac1 for discrimination by the subset of Rac1-specific GEFs and suggest that a compound mimicking Trp 56 action could be explored as an interfering reagent specifically targeting Rac1 activation.	Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Zheng, Y (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA.	yzheng@utmem.edu	Zheng, Yi/J-7235-2015; Xing, Jinchuan/A-2489-2012	Zheng, Yi/0000-0001-7089-6074; 	NIGMS NIH HHS [GM 53943, GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943, R01GM060523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; De molina AR, 2001, INT J ONCOL, V19, P5; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; HART MJ, 1994, J BIOL CHEM, V269, P16992; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOVILLA N, 2001, IN PRESS ONCOGENE; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; VAN AL, 1997, GENE DEV, V11, P2295; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	41	83	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47530	47541		10.1074/jbc.M108865200	http://dx.doi.org/10.1074/jbc.M108865200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595749	hybrid			2022-12-25	WOS:000172768500112
J	Secher, T; Lenz, C; Cazzamali, G; Sorensen, G; Williamson, M; Hansen, GN; Svane, P; Grimmelikhuijzen, CJP				Secher, T; Lenz, C; Cazzamali, G; Sorensen, G; Williamson, M; Hansen, GN; Svane, P; Grimmelikhuijzen, CJP			Molecular cloning of a functional allatostatin gut/brain receptor and an allatostatin preprohormone from the silkworm Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPTERAN LEU-CALLATOSTATIN; PROTEIN-COUPLED RECEPTOR; DROSOPHILA-MELANOGASTER; GENOMIC ORGANIZATION; DEVELOPMENTAL REGULATION; DIPLOPTERA-PUNCTATA; FRONTAL GANGLION; GALANIN RECEPTOR; IDENTIFICATION; COCKROACH	The cockroach-type or A-type allatostatins are inhibitory insect neuropeptides with the C-terminal sequence Tyr/Phe-X-Phe-Gly-Leu-NH2. Here, we have cloned an A-type allatostatin receptor from the silkworm Bombyx mori (BAR). BAR is 361 amino acid residues long, has seven transmembrane domains, shows 60% amino acid residue identity with the first Drosophila allatostatin receptor (DAR-1), and 48%, identity with the second Drosophila allatostatin receptor (DAR-2). The BAR gene has two introns and three exons. These two introns coincide with and have the same intron phasing as two introns in the DAR-1 and DAR-2 genes, showing that the three receptors are not only structurally but also evolutionarily related. Furthermore, we have cloned a Boinbyx allatostatin preprohormone that contains eight different A. type allatostatins. Chinese hamster ovary cells permanently transfeeted with BAR DNA react on the addition of 4 x 10(-9)M Bombyx A-type allatostatins with a second messenger cascade (measured as bioluminescence), showing that BAR is a functional A-type allatostatin receptor. Southern blots suggest that Bombyx has at least one other BAR-related gene in addition to the BAR gene described in this paper. Northern blots and quantitative reverse transcriptase-polymerase chain reaction of different larval tissues show that BAR mRNA is mainly expressed in the gut and to a much lesser extent in the brain. To our knowledge, this is the first report on the molecular cloning and functional expression of an insect gut/brain peptide hormone receptor.	Univ Copenhagen, Inst Zool, Dept Cell Biol, DK-2100 Copenhagen, Denmark	University of Copenhagen	Grimmelikhuijzen, CJP (corresponding author), Univ Copenhagen, Inst Zool, Dept Cell Biol, Univ Pk 15, DK-2100 Copenhagen, Denmark.			Grimmelikhuijzen, Cornelis Johannes Pieter/0000-0001-6486-2046				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Audsley N, 2000, J COMP NEUROL, V424, P37, DOI 10.1002/1096-9861(20000814)424:1&lt;37::AID-CNE3&gt;3.0.CO;2-9; Auerswald L, 2001, BIOCHEM BIOPH RES CO, V282, P904, DOI 10.1006/bbrc.2001.4659; Bendena WG, 1999, ANN NY ACAD SCI, V897, P311, DOI 10.1111/j.1749-6632.1999.tb07902.x; Bendena WG, 1997, ANN NY ACAD SCI, V814, P53, DOI 10.1111/j.1749-6632.1997.tb46144.x; Birgul N, 1999, EMBO J, V18, P5892, DOI 10.1093/emboj/18.21.5892; Bowser PRF, 2000, GEN COMP ENDOCR, V119, P1, DOI 10.1006/gcen.2000.7483; Davey M, 1999, INSECT BIOCHEM MOLEC, V29, P1119, DOI 10.1016/S0965-1748(99)00092-2; Davis NT, 1997, J COMP NEUROL, V385, P265, DOI 10.1002/(SICI)1096-9861(19970825)385:2<265::AID-CNE6>3.0.CO;2-#; Duve H, 1997, PEPTIDES, V18, P1301, DOI 10.1016/S0196-9781(97)00188-5; Duve H, 1997, CELL TISSUE RES, V289, P73, DOI 10.1007/s004410050853; Duve H, 1999, J COMP NEUROL, V413, P405, DOI 10.1002/(SICI)1096-9861(19991025)413:3&lt;405::AID-CNE4&gt;3.0.CO;2-R; Duve H, 2000, CELL TISSUE RES, V300, P153, DOI 10.1007/s004410050056; East P, 1996, REGUL PEPTIDES, V67, P1, DOI 10.1016/S0167-0115(96)00109-7; Eriksen KK, 2000, GENOME RES, V10, P924, DOI 10.1101/gr.10.7.924; Hauser F, 1998, BIOCHEM BIOPH RES CO, V249, P822, DOI 10.1006/bbrc.1998.9230; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; Lenz C, 2000, BIOCHEM BIOPH RES CO, V273, P1126, DOI 10.1006/bbrc.2000.3062; Lenz C, 2000, BIOCHEM BIOPH RES CO, V273, P571, DOI 10.1006/bbrc.2000.2964; Lenz C, 2000, BIOCHEM BIOPH RES CO, V269, P91, DOI 10.1006/bbrc.2000.2251; Lorenz MW, 2000, INSECT BIOCHEM MOLEC, V30, P711, DOI 10.1016/S0965-1748(00)00042-4; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Parker EM, 1995, MOL BRAIN RES, V34, P179, DOI 10.1016/0169-328X(95)00159-P; Pratt GE, 1997, J INSECT PHYSIOL, V43, P627, DOI 10.1016/S0022-1910(97)00022-X; PRATT GE, 1991, P NATL ACAD SCI USA, V88, P2412, DOI 10.1073/pnas.88.6.2412; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Tazima Y, 1978, SILKWORM IMPORTANT L; Veelaert D, 1996, MOL CELL ENDOCRINOL, V122, P183, DOI 10.1016/0303-7207(96)03889-0; Wang S, 1997, MOL PHARMACOL, V52, P337, DOI 10.1124/mol.52.3.337; WEAVER RJ, 2000, RECENT ADV ARTHROPOD, P3; Williamson M, 2001, BIOCHEM BIOPH RES CO, V282, P124, DOI 10.1006/bbrc.2001.4565; Williamson M, 2001, BIOCHEM BIOPH RES CO, V281, P544, DOI 10.1006/bbrc.2001.4402	34	64	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47052	47060		10.1074/jbc.M106675200	http://dx.doi.org/10.1074/jbc.M106675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590150	hybrid			2022-12-25	WOS:000172768500052
J	Shinkai, A; Loeb, LA				Shinkai, A; Loeb, LA			In vivo mutagenesis by Escherichia coli DNA polymerase I - Ile(709) in motif a functions in base selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; KLENOW FRAGMENT; III HOLOENZYME; 3'-5'-EXONUCLEASE SITES; REPLICATION FIDELITY; FRAMESHIFT FIDELITY; ACTIVE-SITE; O-HELIX; MUTATOR; MUTANTS	The fidelity of DNA replication by Escherichia coli DNA polymerase I (pol I) was assessed in vivo using a reporter plasmid bearing a ColE1-type origin and an ochre codon in the beta -lactamase gene. We screened 53 single mutants within the region Val(700)-Arg(712) in the polymerase active-site motif A. Only replacement of Ile (709) yielded mutator polymerases, with substitution of Met, Asn, Phe, or Ala increasing the beta -lactamase reversion frequency 5-23-fold. Steady-state kinetic analysis of the I709F polymerase revealed reductions in apparent K-m values for both insertion of non-complementary nucleotides and extension of mispaired primer termini. Abolishment of the 3'-5' exonuclease activity of wildtype pol I increased mutation frequency 4-fold, whereas the combination of I709F and lack of the 3'-5' exonuclease yielded a 400-fold increase. We conclude that accurate discrimination of the incoming nucleotide at the polymerase domain is more critical than exonucleolytic proofreading for the fidelity of pol I in vivo. Surprisingly, the I709F polymerase enhanced mutagenesis in chromosomal DNA, although the increase was 10-fold less than in plasmid DNA. Our findings indicate the feasibility of obtaining desired mutations by replicating a target gene at a specific locus in a plasmid under continuous selection pressure.	Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, POB 357705, Seattle, WA 98195 USA.		Shinkai, Akeo/E-8354-2013	Shinkai, Akeo/0000-0002-9867-0832	NCI NIH HHS [CA 78885] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078885] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Bebenek A, 2001, J BIOL CHEM, V276, P10387, DOI 10.1074/jbc.M007707200; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOYLE JM, 1970, NATURE, V226, P708, DOI 10.1038/226708a0; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; COOPER PK, 1972, P NATL ACAD SCI USA, V69, P1156, DOI 10.1073/pnas.69.5.1156; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; Fabret C, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e95; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; Kornberg A., 1992, DNA REPLICATION; KUEMPEL PL, 1970, BIOCHEM BIOPH RES CO, V41, P973, DOI 10.1016/0006-291X(70)90180-4; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; Loeb LA, 2001, CANCER RES, V61, P3230; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; OKAZAKI R, 1971, P NATL ACAD SCI USA, V68, P2954, DOI 10.1073/pnas.68.12.2954; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Suzuki M, 1997, J BIOL CHEM, V272, P11228; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Tuske S, 2000, J BIOL CHEM, V275, P23759, DOI 10.1074/jbc.M001804200; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; WITKIN EM, 1992, J BACTERIOL, V174, P4166, DOI 10.1128/jb.174.12.4166-4168.1992	45	31	34	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46759	46764		10.1074/jbc.M104780200	http://dx.doi.org/10.1074/jbc.M104780200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11602576	hybrid			2022-12-25	WOS:000172768500013
J	Massiera, F; Bloch-Faure, M; Ceiler, D; Murakami, K; Fukamizu, A; Gasc, JM; Quignard-Boulange, A; Negrel, R; Ailhaud, G; Seydoux, J; Meneton, P; Teboul, M				Massiera, F; Bloch-Faure, M; Ceiler, D; Murakami, K; Fukamizu, A; Gasc, JM; Quignard-Boulange, A; Negrel, R; Ailhaud, G; Seydoux, J; Meneton, P; Teboul, M			Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation	FASEB JOURNAL			English	Article						adipose tissue development; transgenic mice; renin	GENE-EXPRESSION; RENIN-ACTIVITY; HYPERTENSION; SECRETION; SUBSTRATE; OBESITY; PLASMA; SYSTEM; NUMBER; WHITE	White adipose tissue and liver are important angiotensinogen (AGT) production sites. Until now, plasma AGT was considered to be a reflection of hepatic production. Because plasma AGT concentration has been reported to correlate with blood pressure, and to be associated with body mass index, we investigated whether adipose AGT is released locally and into the blood stream. For this purpose, we have generated transgenic mice either in which adipose AGT is overexpressed or in which AGT expression is restricted to adipose tissue. This was achieved by the use of the aP2 adipocyte-specific promoter driving the expression of rat agt cDNA in both wild-type and hypotensive AGT-deficient mice. Our results show that in both genotypes, targeted expression of AGT in adipose tissue increases fat mass. Mice whose AGT expression is restricted to adipose tissue have AGT circulating in the blood stream, are normotensive, and exhibit restored renal function compared with AGT-deficient mice. Moreover, mice that overexpress adipose AGT have increased levels of circulating AGT, compared with wild-type mice, and are hypertensive. These animal models demonstrate that AGT produced by adipose tissue plays a role in both local adipose tissue development and in the endocrine system, which supports a role of adipose AGT in hypertensive obese patients.	Fac Sci, Inst Signaling Dev & Canc, CNRS, UMR 6543, F-06108 Nice 2, France; INSERM, U367, Paris, France; Univ Tsukuba, Tsukuba, Ibaraki 305, Japan; Coll France, INSERM, U36, Paris, France; INSERM, U465, Paris, France; Fac Med, Dept Physiol, Geneva, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Tsukuba; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Geneva	Teboul, M (corresponding author), Fac Sci, Inst Signaling Dev & Canc, CNRS, UMR 6543, Parc Valrose, F-06108 Nice 2, France.	teboulm@unice.fr	Meneton, Pierre/T-1216-2019; fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Teboul, Michele/0000-0002-3418-4384; Ailhaud, Gerard/0000-0003-0596-2906				Aubert J, 1997, BIOCHEM J, V328, P701, DOI 10.1042/bj3280701; Aubert J, 1998, BIOCHEM BIOPH RES CO, V250, P77, DOI 10.1006/bbrc.1998.9185; BAZIN R, 2000, ASSAYS LIPOGENIC ENZ; BLOEM LJ, 1995, J CLIN INVEST, V95, P948, DOI 10.1172/JCI117803; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Caulfield M, 1996, HYPERTENSION, V28, P1123, DOI 10.1161/01.HYP.28.6.1123; CRANDALL DL, 1994, J LIPID RES, V35, P1378; Engeli S, 1999, J HYPERTENS, V17, P555, DOI 10.1097/00004872-199917040-00014; Forrester T, 1996, J HYPERTENS, V14, P315, DOI 10.1097/00004872-199603000-00007; GIRARDIER L, 1995, J PHYSIOL-LONDON, V488, P779, DOI 10.1113/jphysiol.1995.sp021009; HEGELE RA, 1995, CIRCULATION, V92, P1089, DOI 10.1161/01.CIR.92.5.1089; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Jones BH, 1997, ENDOCRINOLOGY, V138, P1512, DOI 10.1210/en.138.4.1512; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; Karlsson C, 1998, J CLIN ENDOCR METAB, V83, P3925, DOI 10.1210/jc.83.11.3925; Kihara M, 1998, KIDNEY INT, V53, P548, DOI 10.1046/j.1523-1755.1998.00801.x; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; Kim HS, 1999, J BIOL CHEM, V274, P14210, DOI 10.1074/jbc.274.20.14210; LAVAU M, 1977, P SOC EXP BIOL MED, V156, P251, DOI 10.3181/00379727-156-39916; Mark AL, 1999, HYPERTENSION, V33, P537, DOI 10.1161/01.HYP.33.1.537; Mazzolai L, 1998, HYPERTENSION, V31, P1324, DOI 10.1161/01.HYP.31.6.1324; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; Mynatt RL, 1997, P NATL ACAD SCI USA, V94, P919, DOI 10.1073/pnas.94.3.919; OLIVER WJ, 1966, P SOC EXP BIOL MED, V122, P923; ROCCHINI AP, 1995, J NUTR, V125, pS1718; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Saint-Marc P, 2001, ENDOCRINOLOGY, V142, P487, DOI 10.1210/en.142.1.487; Schling P, 1999, INT J OBESITY, V23, P336, DOI 10.1038/sj.ijo.0800821; Schorr U, 1998, J HYPERTENS, V16, P1475, DOI 10.1097/00004872-199816100-00011; Shenoy U, 1997, AM J PHYSIOL-CELL PH, V272, pC989, DOI 10.1152/ajpcell.1997.272.3.C989; SIBONY M, 1995, LAB INVEST, V73, P586; Stec DE, 1999, J BIOL CHEM, V274, P21285, DOI 10.1074/jbc.274.30.21285; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Umemura S, 1997, AM J HYPERTENS, V10, P629, DOI 10.1016/S0895-7061(97)00053-8; van Harmelen V, 2000, OBES RES, V8, P337, DOI 10.1038/oby.2000.40; WALKER WG, 1979, HYPERTENSION, V1, P287, DOI 10.1161/01.HYP.1.3.287	36	379	394	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2727	+		10.1096/fj.01-0457fje	http://dx.doi.org/10.1096/fj.01-0457fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606482				2022-12-25	WOS:000171920400011
J	Kim, S; Kim, Y				Kim, S; Kim, Y			Active site residues of cephalosporin acylase are critical not only for enzymatic catalysis but also for post-translational modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; C ACYLASE; PSEUDOMONAS; SUBUNIT; PROGRAM; CLONING	Cephalosporin acylase (CA) is a recently identified N-terminal hydrolase. It is also a commercially important enzyme in producing 7-aminocephalosporanic acid (7-ACA), a backbone chemical in synthesizing semi-synthetic cephalosporin antibiotics. CA is translated as an inactive single chain precursor, being post-translationally modified into an active enzyme. The post-translational modification takes place in two steps. The first intramolecular autocatalytic proteolysis takes place at one end of the spacer peptide by a nucleophilic Ser or Thr, which in turn becomes a new N-terminal Ser or Thr. The second intermolecular modification cleaves off the other end of the spacer peptide by another CA. Two binary structures in complex with glutaryl-7-ACA (the most favored substrate of CAs) and glutarate (side chain of glutaryl-7-ACA) were determined, and they revealed the detailed interactions of glutaryl-7-ACA with the active site residues (Y. Kim and W. G. J. Hol (2001) Chem Biol., in press). In this report: 1) we have mutated key active site residues into nonfunctional amino acids, and their roles in catalysis were further analyzed; 2) we performed mutagenesis studies indicating that secondary intermolecular modification is carried out in the same active site where deacylation reaction of CA occurs; and 3) the cleavage site of secondary intermolecular modification by another CA was identified in the spacer peptide using mutational analysis. Finally, a schematic model for intermolecular cleavage of CA is proposed.	Yeungnam Univ, Sch Chem Engn & Technol, Kyongsan 712749, South Korea	Yeungnam University	Kim, Y (corresponding author), Yeungnam Univ, Sch Chem Engn & Technol, Kyongsan 712749, South Korea.	ykim1@yu.ac.kr	Kim, Youngsoo/D-6046-2012					ARAMORI I, 1992, J FERMENT BIOENG, V73, P185, DOI 10.1016/0922-338X(92)90158-Q; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; ISHII Y, 1995, EUR J BIOCHEM, V230, P773; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim DW, 1999, J MICROBIOL, V37, P200; Kim Y, 2000, STRUCTURE, V8, P1059, DOI 10.1016/S0969-2126(00)00505-0; KIM Y, 2001, IN PRESS CHEM BIOL; Kwon TH, 2000, J STRUCT BIOL, V131, P79, DOI 10.1006/jsbi.2000.4256; Lee YS, 1996, J MICROBIOL BIOTECHN, V6, P375; Lee YS, 1998, J BACTERIOL, V180, P4576, DOI 10.1128/JB.180.17.4576-4582.1998; Lee YS, 2000, J BIOL CHEM, V275, P39200, DOI 10.1074/jbc.M002504200; Li Y, 1999, EUR J BIOCHEM, V262, P713, DOI 10.1046/j.1432-1327.1999.00417.x; MATSUDA A, 1987, J BACTERIOL, V169, P5815, DOI 10.1128/jb.169.12.5815-5820.1987; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Saito Y, 1996, APPL ENVIRON MICROB, V62, P2919, DOI 10.1128/AEM.62.8.2919-2925.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TISCHER W, 1992, ANN NY ACAD SCI, V672, P502; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; YOON KH, GENBANK	23	28	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48376	48381		10.1074/jbc.M109603200	http://dx.doi.org/10.1074/jbc.M109603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604409	hybrid			2022-12-25	WOS:000172927000087
J	Okamoto, PM; Gamby, C; Wells, D; Fallon, J; Vallee, RB				Okamoto, PM; Gamby, C; Wells, D; Fallon, J; Vallee, RB			Dynamin isoform-specific interaction with the Shank/ProSAP scaffolding proteins of the postsynaptic density and actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; GTP-BINDING PROTEINS; SYNAPTIC TRANSMISSION; MAMMALIAN-CELLS; SH3 DOMAIN; DIFFERENTIAL EXPRESSION; MEDIATED ENDOCYTOSIS; GLUTAMATE RECEPTORS; DENDRITIC SPINES; NERVE-TERMINALS	Dynamin is a GTPase involved in endocytosis and other aspects of membrane trafficking. A critical function in the presynaptic compartment attributed to the brain-specific dynamin isoform, dynamin-1, is in synaptic vesicle recycling. We report that dynamin-2 specifically interacts with members of the Shank/ProSAP family of postsynaptic density scaffolding proteins and present evidence that dynamin-2 is specifically associated with the postsynaptic density. These data are consistent with a role for this otherwise broadly distributed form of dynamin in glutamate receptor down-regulation and other aspects of postsynaptic membrane turnover.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	University of Massachusetts System; University of Massachusetts Worcester; Brown University	Vallee, RB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.	Richard.Vallee@umassmed.edu			NCRR NIH HHS [P20 RR015578-020002, P20 RR015578] Funding Source: Medline; NIGMS NIH HHS [GM26701] Funding Source: Medline; NINDS NIH HHS [P01 NS039321-020002, P01 NS039321] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039321] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Estes PS, 1996, J NEUROSCI, V16, P5443; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Gold ES, 1999, J EXP MED, V190, P1849, DOI 10.1084/jem.190.12.1849; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GOSLIN GBA, 1991, RAT HIPPOCAMPAL NEUR, P339; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hunt CA, 1996, J NEUROSCI, V16, P1380; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; NAKATA T, 1991, NEURON, V7, P461, DOI 10.1016/0896-6273(91)90298-E; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; TUMA PL, 1993, J BIOL CHEM, V268, P17240; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463	70	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48458	48465		10.1074/jbc.M104927200	http://dx.doi.org/10.1074/jbc.M104927200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11583995	Green Accepted, hybrid			2022-12-25	WOS:000172927000098
J	Rong, LW; Liang, C; Hsu, ML; Guo, XF; Roques, BP; Wainberg, MA				Rong, LW; Liang, C; Hsu, ML; Guo, XF; Roques, BP; Wainberg, MA			HIV-1 nucleocapsid protein and the secondary structure of the binary complex formed between tRNA(Lys.3) and viral RNA template play different roles during initiation of (-) strand DNA reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMER-BINDING-SITE; ACID-CHAPERONE ACTIVITY; ANNEALING ACTIVITIES; GENETIC-ANALYSIS; TYPE-1 HIV-1; RICH LOOP; IN-VITRO; TRNA(3)(LYS); ELONGATION	In human immunodeficiency virus type 1 (HIV-1), the tRNA(Lys.3) primer and viral RNA template can form a specific complex that is characterized by extensive inter- and intramolecular interactions. Initiation of reverse transcription from this complex has been shown to be distinguished from subsequent elongation by early pausing events, such as at the +1 and +3 nucleotide positions. One major concern regarding the biological relevance of these results is that most kinetic studies of HIV-1 reverse transcription have been performed using tRNA(Lys.3)-viral (v) RNA complexes that were formed by heat annealing. In contrast, tRNA(Lys.3) in viruses is placed onto the primer binding site by nucleocapsid (NC) sequences of the Gag protein. In this study, we have further characterized the initiation features of reverse transcription in the presence of HIV-1 NC protein. In contrast to results obtained with a heat-annealed tRNA(Lys.3.)vRNA complex, we found that polymerization reactions catalyzed by HIV-1 reverse transcriptase did not commonly pause at the +1 nucleotide position when a NC-annealed RNA complex was used, and that this was true regardless whether NC was actually still present during reverse transcription. This activity of NC required both zinc finger motifs, as demonstrated by experiments that employed zinc finger-mutated forms of NC protein (H23C NC and ddNC), supporting the involvement of the zinc fingers in the RNA chaperone activity of NC. However, NC was not able to help reverse transcriptase to escape the +3 pausing event. Mutagenesis of a stem structure within the tRNA(Lys.3). vRNA complex led to disappearance of the +3 pausing event as well as to significantly reduced rates of reverse transcription. Thus, this stem structure is essential for optimal reverse transcription, despite its role in promotion of the +3 pausing event.	Lady Davis Jewish Gen Hosp, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; URA D1500 CNRS, U266 INSERM, Dept Pharmacochim Mol & Struct, Unite Enseignement Rech Sci Pharmaceut & Biol, F-75270 Paris 06, France	McGill University; McGill University; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Wainberg, MA (corresponding author), Lady Davis Jewish Gen Hosp, McGill AIDS Ctr, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mark.wainberg@mcgill.ca						Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624, DOI 10.1128/AAC.39.7.1624; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DAS AT, 1995, NUCLEIC ACIDS RES, V23, P1319, DOI 10.1093/nar/23.8.1319; Das AT, 1997, J GEN VIROL, V78, P837, DOI 10.1099/0022-1317-78-4-837; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; Huang Y, 1998, J VIROL, V72, P3907, DOI 10.1128/JVI.72.5.3907-3915.1998; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; Kang SM, 1999, J VIROL, V73, P1818, DOI 10.1128/JVI.73.3.1818-1827.1999; Kang SM, 1996, VIROLOGY, V222, P401, DOI 10.1006/viro.1996.0437; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Lanchy JM, 1996, BIOCHIMIE, V78, P1087, DOI 10.1016/S0300-9084(97)86734-X; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; Liang C, 1998, J BIOL CHEM, V273, P21309, DOI 10.1074/jbc.273.33.21309; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; MULLER G, 1994, J MOL BIOL, V242, P422, DOI 10.1006/jmbi.1994.1592; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Rong LW, 1998, J VIROL, V72, P9353, DOI 10.1128/JVI.72.11.9353-9358.1998; Skripkin E, 1996, NUCLEIC ACIDS RES, V24, P509, DOI 10.1093/nar/24.3.509; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; Wakefield JK, 1996, VIROLOGY, V220, P290, DOI 10.1006/viro.1996.0317; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1994, J BIOL CHEM, V269, P31491; Yu Q, 1999, VIROLOGY, V254, P160, DOI 10.1006/viro.1998.9542; Zhang JL, 2000, VIROLOGY, V268, P251, DOI 10.1006/viro.2000.0194; Zhang ZJ, 1998, RNA, V4, P394	51	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47725	47732		10.1074/jbc.M105124200	http://dx.doi.org/10.1074/jbc.M105124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11602578	hybrid			2022-12-25	WOS:000172768500137
J	Hegde, SS; Javid-Majd, F; Blanchard, JS				Hegde, SS; Javid-Majd, F; Blanchard, JS			Overexpression and mechanistic analysis of chromosomally encoded aminoglycoside 2 '-N-acetyltransferase (AAC(2 ')-Ic) from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODIFYING ENZYMES; PROVIDENCIA-STUARTII; RESISTANCE; ANTIBIOTICS; GENES; GENTAMICIN	The chromosomally encoded aminoglycoside N-acetyltransferase, AAC(2')-Ic, of Mycobacterium tuberculosis has a yet unidentified physiological function. The aac(2')-Ic gene was cloned and expressed in Escherichia coli, and AAC(2')-Ic was purified. Recombinant AAC(2')-Ic was a soluble protein of 20,000 Da and acetylated all aminoglycosides substrates tested in vitro, including therapeutically important antibiotics. Acetyl-CoA was the preferred acyl donor. The enzyme, in addition to acetylating aminoglycosides containing 2'-amino substituents, also acetylated kanamycin A and amikacin that contain a 2'-hydroxyl substituent, although with lower activity, indicating the capacity of the enzyme to perform both N-acetyl and O-acetyl transfer. The enzyme exhibited "substrate activation" with many aminoglycoside substrates while exhibiting Michaelis-Menten kinetics with others. Kinetic studies supported a random kinetic mechanism for AAC(2')-Ic. Comparison of the kinetic parameters of different aminoglycosides suggested that their hexopyranosyl residues and, to a lesser extent, the central aminocyclitol residue carry the major determinants of substrate affinity.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Blanchard, JS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				PHS HHS [A133696] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ainsa JA, 1997, MOL MICROBIOL, V24, P431, DOI 10.1046/j.1365-2958.1997.3471717.x; Azucena E, 2001, DRUG RESIST UPDATE, V4, P106, DOI 10.1054/drup.2001.0197; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; Cleland W W, 1979, Methods Enzymol, V63, P103; COURVALIN P, 1980, J BACTERIOL, V143, P541, DOI 10.1128/JB.143.2.541-551.1980; Davies J, 1997, TRENDS MICROBIOL, V5, P234, DOI 10.1016/S0966-842X(97)01033-0; DAVIS BD, 1987, MICROBIOL REV, V51, P341, DOI 10.1128/MMBR.51.3.341-350.1987; Franklin K, 2001, ANTIMICROB AGENTS CH, V45, P2238, DOI 10.1128/AAC.45.8.2238-2244.2001; HANCOCK REW, 1981, J ANTIMICROB CHEMOTH, V8, P249, DOI 10.1093/jac/8.4.249; Magnet S, 2001, BIOCHEMISTRY-US, V40, P3700, DOI 10.1021/bi002736e; MILLER GH, 1995, J CHEMOTHERAPY, V7, P31; Mingeot-Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P727, DOI 10.1128/AAC.43.4.727; Moore RA, 1999, ANTIMICROB AGENTS CH, V43, P465, DOI 10.1128/AAC.43.3.465; MURRAY BE, 1991, J INFECT DIS, V163, P1185, DOI 10.1093/infdis/163.6.1185; Payie KG, 1997, J BACTERIOL, V179, P4106, DOI 10.1128/jb.179.13.4106-4114.1997; RADHIKA K, 1984, J BIOL CHEM, V258, P12543; RADHIKA K, 1984, BIOCHEMISTRY-US, V23, P5118; RATHER PN, 1993, J BACTERIOL, V175, P6492, DOI 10.1128/jb.175.20.6492-6498.1993; Rather PN, 1998, DRUG RESIST UPDATE, V1, P285, DOI 10.1016/S1368-7646(98)80044-7; Rudant E, 1999, SYST APPL MICROBIOL, V22, P59, DOI 10.1016/S0723-2020(99)80028-9; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; TABER HW, 1987, MICROBIOL REV, V51, P439, DOI 10.1128/MMBR.51.4.439-457.1987; WILLIAMS JW, 1978, J BIOL CHEM, V253, P5908; WILLIAMS JW, 1978, J BIOL CHEM, V253, P5902; Wright GD, 1997, ANTIMICROB AGENTS CH, V41, P956, DOI 10.1128/AAC.41.5.956; Wright GD, 1999, CURR OPIN MICROBIOL, V2, P499, DOI 10.1016/S1369-5274(99)00007-7	26	71	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45876	45881		10.1074/jbc.M108810200	http://dx.doi.org/10.1074/jbc.M108810200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590162	hybrid			2022-12-25	WOS:000172573100052
J	Levavasseur, F; Miyadera, H; Sirois, J; Tremblay, ML; Kita, K; Shoubridge, E; Hekimi, S				Levavasseur, F; Miyadera, H; Sirois, J; Tremblay, ML; Kita, K; Shoubridge, E; Hekimi, S			Ubiquinone is necessary for mouse embryonic development but is not essential for mitochondrial respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; COENZYME-Q; CLK-1; PROTEIN; GENE	Ubiquinone (UQ) is a lipid found in most biological membranes and is a co-factor in many redox processes including the mitochondrial respiratory chain. UQ has been implicated in protection from oxidative stress and in the aging process. Consequently, it is used as a dietary supplement and to treat mitochondrial diseases. Mutants of the clk-1 gene of the nematode Caenorhabditis elegans are fertile and have an increased life span, although they do not produce UQ but instead accumulate a biosynthetic intermediate, demethoxyubiquinone (DMQ). DMQ appears capable to partially replace UQ for respiration in vivo and in vitro. We have produced a vertebrate model of cells and tissues devoid of UQ by generating a knockout mutation of the murine orthologue of clk-1 (mclk1). We find that mclk1-/- embryonic stem cells and embryos accumulate DMQ instead of UQ. As in the nematode mutant, the activity of the mitochondrial respiratory chain of -/- embryonic stem cells is only mildly affected (65% of wild-type oxygen consumption). However, mclk1-/- embryos arrest development at midgestation, although earlier developmental stages appear normal. These findings indicate that UQ is necessary for vertebrate embryonic development but suggest that mitochondrial respiration is not the function for which UQ is essential when DMQ is present.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Univ Tokyo, Dept Biomed Chem, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada	McGill University; University of Tokyo; McGill University; McGill University; McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.			Kita, Kiyoshi/0000-0002-0426-4308				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Auerbach W, 2000, BIOTECHNIQUES, V29, P1024, DOI 10.2144/00295st04; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891-5849(00)00307-5; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Gille L, 2000, ARCH BIOCHEM BIOPHYS, V375, P347, DOI 10.1006/abbi.1999.1649; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hekimi S, 2000, RES PRO CEL, V29, P81; Jiang N, 2001, J BIOL CHEM, V276, P29218, DOI 10.1074/jbc.M103686200; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Scott AE, 2001, TOXICOL APPL PHARM, V171, P149, DOI 10.1006/taap.2000.9115; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WONG A, 1995, GENETICS, V139, P1247	25	104	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46160	46164		10.1074/jbc.M108980200	http://dx.doi.org/10.1074/jbc.M108980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585841	hybrid			2022-12-25	WOS:000172573100091
J	Moore, LJ; Kiley, PJ				Moore, LJ; Kiley, PJ			Characterization of the dimerization domain in the FNR transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; ESCHERICHIA-COLI; GENE-EXPRESSION; 4FE-4S CLUSTER; COILED-COILS; PROTEIN; SULFUR; CONVERSION; REGULATOR; STABILITY	The global anaerobic regulator FNR from Escherichia coli is a dimeric Fe-S protein that is inactivated by O-2 through disruption of its [4Fe-4S] cluster and conversion to a monomeric form. As a first step in elucidating the molecular interactions that control FNR dimerization, we have performed alanine-scanning mutagenesis of a potential dimerization domain. Replacement of many hydrophobic residues (Met-143, Met-144, Leu-146, Met-147, Ile-151, Met-157, and Ile-158) and two charged residues (Arg-140 and Arg-145) with Ala decreased FNR activity in vivo. Size exclusion chromatography and Fe-S cluster analysis of three representative mutant proteins, FNR-M147A, FNR-I151A, and FNR-I158A, showed that the Ala substitutions produced specific defects in dimerization. Because hydrophobic side chains are known to stabilize subunit-subunit interactions between a-helices, we propose that Met-147, Ile-151, and Ile-158 lie on the same face of an a-helix that constitutes a dimerization interface. This alignment would also position Arg-140, Met-144, and Asp-154 on the same helical face. In support of the unusual positioning of a negatively charged residue at the dimer interface, we found that replacing Asp-154 with Ala repaired the defects caused by Ala substitutions of other residues located on the same helical face. These data also suggest that Asp-154 has an inhibitory effect on dimerization, which may be a key element in the control of FNR dimerization by O-2 availability.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Kiley, PJ (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave,574 Med Sci, Madison, WI 53706 USA.	pjkiley@facstaff.wisc.edu		Kiley, Patricia/0000-0002-8771-1782				Bates DM, 2000, J BIOL CHEM, V275, P6234, DOI 10.1074/jbc.275.9.6234; BATES DM, 1995, J BACTERIOL, V177, P3972, DOI 10.1128/jb.177.14.3972-3978.1995; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Guest John R., 1996, P317; HODGES RS, 1973, COLD SPRING HARB SYM, V37, P299, DOI 10.1101/SQB.1973.037.01.040; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOUNG JK, 1995, GENE DEV, V9, P2986, DOI 10.1101/gad.9.23.2986; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lamberg KE, 2000, MOL MICROBIOL, V38, P817, DOI 10.1046/j.1365-2958.2000.02172.x; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; Lee AI, 1999, J BACTERIOL, V181, P5309, DOI 10.1128/JB.181.17.5309-5316.1999; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MELVILLE SB, 1990, J BIOL CHEM, V265, P18733; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PASCAL MC, 1986, FEMS MICROBIOL LETT, V36, P35; Patschkowski T, 2000, BACTERIAL STRESS RESPONSES, P61; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; SPIRO S, 1989, MOL MICROBIOL, V3, P601, DOI 10.1111/j.1365-2958.1989.tb00207.x; SPIRO S, 1987, J GEN MICROBIOL, V133, P3279; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; TROPSHA A, 1991, P NATL ACAD SCI USA, V88, P9488, DOI 10.1073/pnas.88.21.9488; VanSpanning RJM, 1997, MOL MICROBIOL, V23, P893, DOI 10.1046/j.1365-2958.1997.2801638.x; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZIEGLELHOFFER E, THESIS U WISCONSIN M	39	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45744	45750		10.1074/jbc.M106569200	http://dx.doi.org/10.1074/jbc.M106569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581261	hybrid			2022-12-25	WOS:000172573100034
J	Sass, E; Blachinsky, E; Karniely, S; Pines, O				Sass, E; Blachinsky, E; Karniely, S; Pines, O			Mitochondrial and cytosolic isoforms of yeast fumarase are derivatives of a single translation product and have identical amino termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-MALIC ACID; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; FUM1 GENE; PROTEIN; INITIATION; CLEAVAGE; PATHWAY; IMPORT; MOD5	We have previously proposed that a single translation product of the FUM1 gene encoding fumarase is distributed between the cytosol and mitochondria of Saccharomyces cerevisiae and that all fumarase translation products are targeted and processed in mitochondria before distribution. Alternative models for fumarase distribution have been proposed that require more than one translation product. In the current work (i) we show by using sequential Edman degradation and mass spectrometry that fumarase cytosolic and mitochondrial isoenzymes have an identical amino terminus that is formed by cleavage by the mitochondrial processing peptidase, (ii) we have generated fumarase mutants in which the second potential translation initiation codon (Met-24) has been substituted, yet the protein is processed efficiently and retains its ability to be distributed between the cytosol and mitochondria, and (iii) we show that although a signal peptide is required for fumarase targeting to mitochondria the specific fumarase signal peptide and the sequence immediately downstream to the cleavage site are not required for the dual distribution phenomenon. Our results are discussed in light of our model of fumarase targeting and distribution that suggests rapid folding into an import-incompetent state and retrograde movement of the processed protein back to the cytosol through the translocation pore.	Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Pines, O (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel.		Karniely, Sharon/AAN-7886-2021; pines, ophry/C-4086-2011	pines, ophry/0000-0001-7126-2575				Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; BLACHINSKY E, 2001, THESIS HEBREW U JERU; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; Haucke V, 1997, MOL CELL BIOL, V17, P4024, DOI 10.1128/MCB.17.7.4024; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; KANAREK L, 1964, J BIOL CHEM, V5, P465; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; PELEG Y, 1990, APPL ENVIRON MICROB, V56, P2777, DOI 10.1128/AEM.56.9.2777-2783.1990; Pines O, 1996, APPL MICROBIOL BIOT, V46, P393, DOI 10.1007/s002530050835; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Rahali V, 1999, J PROTEIN CHEM, V18, P1, DOI 10.1023/A:1020635130077; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; SUZUKI T, 1992, EUR J BIOCHEM, V207, P767, DOI 10.1111/j.1432-1033.1992.tb17107.x; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; VESTLING MM, 1994, RAPID COMMUN MASS SP, V8, P786, DOI 10.1002/rcm.1290080925; Weitzman PDJ, 1969, METHOD ENZYMOL, V8, P22, DOI 10.1016/0076-6879(69)13009-8; Worthington CC, 1988, WORTHINGTON MANUAL; WU M, 1995, BIOCHEM BIOPH RES CO, V215, P578, DOI 10.1006/bbrc.1995.2504; WU M, 1987, J BIOL CHEM, V262, P12275	30	70	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46111	46117		10.1074/jbc.M106061200	http://dx.doi.org/10.1074/jbc.M106061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585823	hybrid			2022-12-25	WOS:000172573100085
J	Tandori, J; Baciou, L; Alexov, E; Maroti, P; Schiffer, M; Hanson, DK; Sebban, P				Tandori, J; Baciou, L; Alexov, E; Maroti, P; Schiffer, M; Hanson, DK; Sebban, P			Revealing the involvement of extended hydrogen bond networks in the cooperative function between distant sites in bacterial reaction centers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; MUTANT REACTION CENTERS; RHODOBACTER-SPHAEROIDES; ELECTRON-TRANSFER; PROTON-TRANSFER; FREE-ENERGY; Q(B); MUTATIONS; DELIVERY; QUINONES	In reaction center proteins of photosynthetic bacteria, the amplitude of proton uptake induced by the one-electron reduction of either of the two quinone electron acceptors (Q(A) and Q(B)) is an intrinsic observable of the electrostatic interactions associated with the redox function of the complex. We report here that, in Rhodobacter capsulatus, complete restoration of proton uptake (upon formation of Q(A)(-) and Q(B)(-)) to the level found in the wild type is observed in a mutant reaction center in which a tyrosine substitution in the QA environment (Ala(M274) --> Tyr) is coupled with mutations of acidic residues near QR (Glu(L212) --> Ala/Asp(L213) --> Ala) that initially cancel the proton uptake above pH 8. This result demonstrates that proton uptake occurs by strong cooperation between structural motifs, such as hydrogen-bonded networks, that span the 18 Angstrom distance between the two quinone acceptors.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Univ Szeged, Dept Biophys, H-6722 Szeged, Hungary; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, Dept Biochem, New York, NY 10032 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Szeged University; Columbia University; Howard Hughes Medical Institute; Columbia University; United States Department of Energy (DOE); Argonne National Laboratory	Sebban, P (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.							Alexov E, 2000, BIOCHEMISTRY-US, V39, P5940, DOI 10.1021/bi9929498; Alexov EG, 1999, BIOCHEMISTRY-US, V38, P8253, DOI 10.1021/bi982700a; Alexov EG, 1997, BIOPHYS J, V72, P2075, DOI 10.1016/S0006-3495(97)78851-9; BEROZA P, 1995, BIOPHYS J, V68, P2233, DOI 10.1016/S0006-3495(95)80406-6; Brzezinski P, 1997, BBA-BIOENERGETICS, V1321, P149, DOI 10.1016/S0005-2728(97)00052-2; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; Fritzsch G, 1998, PHOTOSYNTH RES, V55, P127, DOI 10.1023/A:1006088232755; HANSON DK, 1993, P NATL ACAD SCI USA, V90, P8929, DOI 10.1073/pnas.90.19.8929; Hanson DK, 1998, PHOTOSYNTH RES, V55, P275, DOI 10.1023/A:1005901510444; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; MAROTI P, 1995, NAT STRUCT BIOL, V2, P1057, DOI 10.1038/nsb1295-1057; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P329, DOI 10.1016/0005-2728(88)90092-8; MCPHERSON PH, 1994, BIOCHEMISTRY-US, V33, P1181, DOI 10.1021/bi00171a018; MCPHERSON PH, 1988, BIOCHIM BIOPHYS ACTA, V934, P348, DOI 10.1016/0005-2728(88)90093-X; Miksovska J, 1996, BIOCHEMISTRY-US, V35, P15411, DOI 10.1021/bi961299u; Miksovska J, 1997, BIOCHEMISTRY-US, V36, P12216, DOI 10.1021/bi970442w; Rabenstein B, 2000, BIOCHEMISTRY-US, V39, P10487, DOI 10.1021/bi000413c; SEBBAN P, 1995, BIOCHIMIE, V77, P677, DOI 10.1016/0300-9084(96)88183-1; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Valerio-Lepiniec M, 1999, BIOCHEMISTRY-US, V38, P390, DOI 10.1021/bi980500t	20	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45513	45515		10.1074/jbc.C100537200	http://dx.doi.org/10.1074/jbc.C100537200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11604387	hybrid			2022-12-25	WOS:000172573100005
J	Sonnenburg, ED; Gao, T; Newton, AC				Sonnenburg, ED; Gao, T; Newton, AC			The phosphoinositide-dependent kinase, PDK-1, phosphorylates conventional protein kinase C isozymes by a mechanism that is independent of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; DOWN-REGULATION; ACTIVATION; TRANSLOCATION; ALPHA; SITE; ZETA; PKC; AUTOPHOSPHORYLATION	Phosphorylation by the phosphoinositide-dependent kinase, PDK-1, is required for the activation of diverse members of the AGC family of protein kinases, including the protein kinase C (PKC) isozymes. Here we explore the subcellular location of the PDK-1-mediated phosphorylation of conventional PKCs, and we address whether this phosphorylation is regulated by phosphoinositide 3-kinase. Pulse-chase experiments reveal that newly synthesized endogenous PKC a is primarily phosphorylated in the membrane fraction of COS-7 cells, where it is processed to a species that is phosphorylated at the activation loop and at two carboxyl-terminal positions. This "mature" species is then released into the cytosol. Deletion of the plekstrin homology domain of PDK-1 results in a 4-fold increase in the rate of processing of PKC indicating an autoinhibitory role for this domain. Autoinhibition by the plekstrin homology domain is not relieved by binding 3'-phosphoinositides; PKC is phosphorylated at a similar rate in serum-treated cells and serum-starved cells treated with the phosphoinositide 3-kinase inhibitors, LY294002 and wortmannin. Under the same conditions, the PDK-1-catalyzed phosphorylation of another substrate, Akt/protein kinase B, is abolished by these inhibitors. Our data are consistent with a model in which PDK-1 phosphorylates newly synthesized PKC by a mechanism that is independent of 3'-phosphoinositides.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NIDDK NIH HHS [P01 DK54441] Funding Source: Medline; NIGMS NIH HHS [2T32 GM07752, GM 43154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R01GM043154, R37GM043154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; England K, 2001, J BIOL CHEM, V276, P10437, DOI 10.1074/jbc.M009421200; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Gysin S, 1996, EUR J BIOCHEM, V240, P747, DOI 10.1111/j.1432-1033.1996.0747h.x; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li Y, 2001, J BIOL CHEM, V276, P20323, DOI 10.1074/jbc.M101309200; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR JW, 1994, J BIOL CHEM, V269, P27715; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Standaert ML, 2001, BIOCHEMISTRY-US, V40, P249, DOI 10.1021/bi0018234; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	40	99	102	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45289	45297		10.1074/jbc.M107416200	http://dx.doi.org/10.1074/jbc.M107416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579098	hybrid			2022-12-25	WOS:000172406700124
J	Engelhardt, S; Boknik, P; Keller, U; Neumann, J; Lohse, MJ; Hein, L				Engelhardt, S; Boknik, P; Keller, U; Neumann, J; Lohse, MJ; Hein, L			Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the beta(1)-adrenergic receptor	FASEB JOURNAL			English	Article						transgenic mouse; heart failure; triadin; sarcoplasmic reticulum	CALSEQUESTRIN-BINDING-PROTEIN; SARCOPLASMIC-RETICULUM; BETA(2)-ADRENERGIC RECEPTOR; MYOCARDIAL-FUNCTION; CA2+ TRANSPORT; MOUSE HEARTS; IN-VIVO; PHOSPHOLAMBAN; GENE; FAILURE	Chronic stimulation of cardiac beta (1)-adrenergic receptors contributes to disease progression and mortality in patients and animal models of heart failure. To search for the mechanism of adrenergic impairment of cardiac function in vivo, we studied transgenic mice with cardiac-specific overexpression of beta (1)-adrenergic receptors. Transgenic mice with cardiac overexpression of beta (1)-adrenergic receptors showed progressive left ventricular fibrosis starting at 4 months of age. Left ventricular catheterization revealed a modest enhancement of contractility and relaxation at 2 months of age, followed by progressive dysfunction in both parameters and ultimately cardiac failure. When the effects of endogenous catecholamines were blocked by the beta -receptor antagonist propranolol, maximal rate of contractility (dp/dt(max)) and maximal rate of relaxation (dp/dt(min)) were significantly blunted in 2-month-old beta (1)-receptor transgenic mice. Isolated cardiomyocytes from these animals displayed markedly altered calcium transients with significant prolongation of the intracellular calcium transient compared with nontransgenic littermates. We determined the expression of sarcoplasmic reticulum proteins involved in calcium handling by RNase protection assay and by immunoblotting. Although the expression of calsequestrin, triadin, and phospholamban was not altered, we observed a progressive decrease in junctin abundance in beta (1)-receptor transgenic mice (P<0.001 TG vs. WT). Altered expression of the sarcoplasmic reticulum protein junctin may be involved in the pathogenesis of cardiac failure after chronic stimulation of <beta>(1)-adrenergic receptors.	Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany; Univ Munster, Inst Pharmakol & Toxikol, D-4400 Munster, Germany	University of Wurzburg; University of Munster	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de	Engelhardt, Stefan/AAA-9329-2019; Lohse, Martin J/A-7160-2012	Engelhardt, Stefan/0000-0001-5378-8661; Lohse, Martin J/0000-0002-0599-3510				Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; BRILLANTES AM, 1992, CIRC RES, V71, P18, DOI 10.1161/01.RES.71.1.18; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; Brodde OE, 1999, PHARMACOL REV, V51, P651; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Hajjar RJ, 1997, CIRCULATION, V95, P423; Harding VB, 2001, P NATL ACAD SCI USA, V98, P5809, DOI 10.1073/pnas.091102398; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Hjalmarson A, 1999, LANCET, V353, P2001; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; Kirchhefer U, 2001, J BIOL CHEM, V276, P4142, DOI 10.1074/jbc.M006443200; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Lechat P, 1999, LANCET, V353, P9; Liggett SB, 2000, CIRCULATION, V101, P1707; Linck B, 2000, J PHARMACOL EXP THER, V294, P648; Loukianov E, 1998, CIRC RES, V83, P889; Lowes BD, 2000, CLIN CARDIOL, V23, P11; MacMahon S, 1997, LANCET, V349, P375; Maurice JP, 1999, J CLIN INVEST, V104, P21, DOI 10.1172/JCI6026; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MOVSESIAN MA, 1994, CIRCULATION, V90, P653, DOI 10.1161/01.CIR.90.2.653; Neumann J, 1998, J MOL CELL CARDIOL, V30, P1991, DOI 10.1006/jmcc.1998.0760; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Rockman HA, 1996, J CLIN INVEST, V97, P1618, DOI 10.1172/JCI118587; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; Shah AS, 2000, CIRCULATION, V101, P408, DOI 10.1161/01.CIR.101.4.408; Shorofsky SR, 1999, CIRC RES, V84, P424, DOI 10.1161/01.RES.84.4.424; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Steinberg SF, 1999, CIRC RES, V85, P1101; VATNER DE, 1994, CIRCULATION, V90, P1423, DOI 10.1161/01.CIR.90.3.1423; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; Wiesmann F, 2001, CIRC RES, V88, P563, DOI 10.1161/01.RES.88.6.563; Xiao RP, 1999, CIRC RES, V85, P1092; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Yamaguchi N, 1998, BIOCHEM J, V335, P541, DOI 10.1042/bj3350541; Zaugg M, 2000, CIRCULATION, V102, P344; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zhang L, 2001, J MOL CELL CARDIOL, V33, P233, DOI 10.1006/jmcc.2000.1295	49	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2718	+		10.1096/fj.01-0107fje	http://dx.doi.org/10.1096/fj.01-0107fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606476				2022-12-25	WOS:000171920400017
J	Okada, M; Fujita, T; Sakaguchi, T; Olson, KE; Collins, T; Stern, DM; Yan, SF; Pinsky, DJ				Okada, M; Fujita, T; Sakaguchi, T; Olson, KE; Collins, T; Stern, DM; Yan, SF; Pinsky, DJ			Extinguishing Egr-1-dependent inflammatory and thrombotic cascades following lung transplantation	FASEB JOURNAL			English	Article						early growth response-1; antisense oligodeoxyribonucleotide; transcription factor; ischemia	INTERCELLULAR-ADHESION MOLECULE-1; PRIMARY GRAFT FAILURE; GENE-EXPRESSION; FIBRIN DEPOSITION; COMPARATIVE INHIBITION; OXYGEN DEPRIVATION; HYPOXIA; PRESERVATION; INJURY; TRANSCRIPTION	Hypoxic induction of the early growth response-1 (Egr-1) transcription factor initiates proinflammatory and procoagulant gene expression. Orthotopic/isogeneic rat lung transplantation triggers Egr-1 expression and nuclear DNA binding activity corresponding to Egr-1, which leads to increased expression of downstream target genes such as interleukin-1, tissue factor, and plasminogen activator inhibitor-1. The devastating functional consequences of Egr-1 up-regulation in this setting are prevented by treating donor lungs with a phosphorothioate antisense oligodeoxyribonucleotide directed against the Egr-1 translation initiation site, which blocks expression of Egr-1 and its gene targets. Post-transplant graft leukostasis, inflammation, and thrombosis are consequently diminished, with marked improvement in graft function and recipient survival. Blocking expression of a proximal transcription factor, which activates deleterious inflammatory and coagulant effector mechanisms, is an effective molecular strategy to improve organ preservation.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Harvard Univ, Sch Med, Boston, MA USA	Columbia University; Harvard University; Harvard Medical School	Pinsky, DJ (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	djp5@columbia.edu	Tomoyuki, Fujita/AAC-7464-2020					Belperio JA, 2000, J IMMUNOL, V165, P461, DOI 10.4049/jimmunol.165.1.461; Boasquevisque CHR, 1999, J THORAC CARDIOV SUR, V117, P8; CANONICO AE, 1994, J APPL PHYSIOL, V77, P415, DOI 10.1152/jappl.1994.77.1.415; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Christie JD, 1998, CHEST, V114, P51, DOI 10.1378/chest.114.1.51; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dragun D, 1998, KIDNEY INT, V54, P2113, DOI 10.1046/j.1523-1755.1998.00189.x; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANCIS CW, 1980, BLOOD, V56, P456; GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978, DOI 10.1152/jappl.1985.59.6.1978; Harringer W, 1999, EUR J CARDIO-THORAC, V16, P546, DOI 10.1016/S1010-7940(99)00313-9; Hopkinson DN, 1998, J HEART LUNG TRANSPL, V17, P525; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Mal H, 1998, CHEST, V113, P645, DOI 10.1378/chest.113.3.645; MARCUSSEKURA CJ, 1987, NUCLEIC ACIDS RES, V15, P5749, DOI 10.1093/nar/15.14.5749; Meyers BF, 1999, ANN SURG, V230, P362, DOI 10.1097/00000658-199909000-00009; Naka Y, 1997, P NATL ACAD SCI USA, V94, P757, DOI 10.1073/pnas.94.2.757; Naka Y, 1997, TRANSPLANTATION, V64, P1248, DOI 10.1097/00007890-199711150-00004; NAKA Y, 1995, J THORAC CARDIOV SUR, V109, P206, DOI 10.1016/S0022-5223(95)70380-2; Okada K, 2000, J BIOL CHEM, V275, P21468, DOI 10.1074/jbc.M002682200; PINSKY DJ, 1995, THROMB HAEMOSTASIS, V74, P58; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; Pinsky DJ, 1996, J CLIN INVEST, V97, P493, DOI 10.1172/JCI118440; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; SACHAR DB, 1996, GASTR HEPAT, V1, P309; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Toda K, 2000, CIRC RES, V86, P166, DOI 10.1161/01.RES.86.2.166; Wang CY, 2000, CIRC RES, V86, P982, DOI 10.1161/01.RES.86.9.982; WHITEHEAD BF, 1993, TRANSPLANTATION, V56, P956, DOI 10.1097/00007890-199310000-00034; Yan SF, 2000, J BIOL CHEM, V275, P11921, DOI 10.1074/jbc.275.16.11921; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	41	54	67	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2757	+		10.1096/fj.01-0490fje	http://dx.doi.org/10.1096/fj.01-0490fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606484				2022-12-25	WOS:000171920400009
J	Alevizos, I; Mahadevappa, M; Zhang, X; Ohyama, H; Kohno, Y; Posner, M; Gallagher, GT; Varvares, M; Cohen, D; Kim, D; Kent, R; Donoff, RB; Todd, R; Yung, CM; Warrington, JA; Wong, DTW				Alevizos, I; Mahadevappa, M; Zhang, X; Ohyama, H; Kohno, Y; Posner, M; Gallagher, GT; Varvares, M; Cohen, D; Kim, D; Kent, R; Donoff, RB; Todd, R; Yung, CM; Warrington, JA; Wong, DTW			Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis	ONCOGENE			English	Article						oral cancer; gene expression; laser capture microdissection; microarrays	SQUAMOUS-CELL CARCINOMA; NEUROMEDIN U; PROGNOSTIC-SIGNIFICANCE; METABOLIZING-ENZYMES; HUMAN HEAD; IDENTIFICATION; TISSUE; TUMOR; OVEREXPRESSION; POLYMORPHISMS	Large scale gene expression profiling was carried out on laser capture microdissected (LCM) tumor and normal oral epithelial cells and analysed on high-density oligonucleotide microarrays. About 600 genes were found to be oral cancer associated. These oral cancer associated genes include oncogenes, tumor suppressors, transcription factors, xenobiotic enzymes, metastatic proteins, differentiation markers, and genes that have not been implicated in oral cancer. The database created provides a verifiable global profile of gene expression during oral carcinogenesis, revealing the potential role of known genes as well as genes that have not been previously implicated in oral cancer.	Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Biol, Boston, MA 02115 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; China Med Univ, Dept Biol, Shenyang 110001, Peoples R China; Dana Farber Canc Inst, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA; Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02115 USA; Univ Nebraska, Coll Dent, Ctr Med, Lincoln, NE 68583 USA; Forsyth Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA; Chung Shan Med & Dent Coll, Taichung, Taiwan	Harvard University; Harvard School of Dental Medicine; Affymetrix; China Medical University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Eye & Ear Infirmary; University of Nebraska System; University of Nebraska Lincoln; Harvard University; Forsyth Institute; Harvard University; Massachusetts General Hospital; Chung Shan Medical University	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Biol, 188 Longwood Ave, Boston, MA 02115 USA.	dwong@warren.med.harvard.edu	Todd, Robert/GWM-4486-2022		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P30DE011814, P01DE012467, R29DE011983] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01 DE12467, P30 DE11814, R29 DE11983] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; JANOT F, 1993, CARCINOGENESIS, V14, P1279, DOI 10.1093/carcin/14.7.1279; Jourenkova-Mironova N, 1999, INT J CANCER, V81, P44, DOI 10.1002/(SICI)1097-0215(19990331)81:1<44::AID-IJC9>3.0.CO;2-A; JUNIEN C, 1983, AM J HUM GENET, V35, P584; Katoh T, 1999, INT J CANCER, V83, P606, DOI 10.1002/(SICI)1097-0215(19991126)83:5<606::AID-IJC6>3.3.CO;2-G; Kawamata H, 1997, INT J CANCER, V70, P120, DOI 10.1002/(SICI)1097-0215(19970106)70:1<120::AID-IJC18>3.0.CO;2-P; Kimura Y, 2000, CANCER LETT, V155, P163, DOI 10.1016/S0304-3835(00)00423-7; Kurokawa Hideo, 1998, Fukuoka Acta Medica, V89, P321; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Leethanakul C, 2000, ORAL ONCOL, V36, P474, DOI 10.1016/S1368-8375(00)00039-7; LIN LM, 1991, J ORAL PATHOL MED, V20, P479, DOI 10.1111/j.1600-0714.1991.tb00408.x; Liu CM, 1999, BRIT J CANCER, V79, P360, DOI 10.1038/sj.bjc.6690057; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lotan R, 1997, ENVIRON HEALTH PERSP, V105, P985, DOI 10.2307/3433315; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Magary SP, 2000, OTOLARYNG HEAD NECK, V122, P712, DOI 10.1016/S0194-5998(00)70202-6; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Mighell AJ, 1997, ORAL ONCOL, V33, P155, DOI 10.1016/S0964-1955(96)00074-7; MURAMATSU H, 1995, CANCER RES, V55, P6210; MURRAY GI, 1994, GUT, V35, P599, DOI 10.1136/gut.35.5.599; Ohyama H, 2000, BIOTECHNIQUES, V29, P530, DOI 10.2144/00293st05; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Park JY, 1997, CANCER EPIDEM BIOMAR, V6, P791; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Porte H, 1998, CLIN CANCER RES, V4, P1375; Raddatz R, 2000, J BIOL CHEM, V275, P32452, DOI 10.1074/jbc.M004613200; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Sato M, 1999, CARCINOGENESIS, V20, P1927, DOI 10.1093/carcin/20.10.1927; Sgroi DC, 1999, CANCER RES, V59, P5656; Shillitoe EJ, 2000, ORAL ONCOL, V36, P8, DOI 10.1016/S1368-8375(99)00071-8; SHIN DM, 1994, CANCER EPIDEM BIOMAR, V3, P697; SHINTANI S, 1995, CANCER LETT, V95, P79, DOI 10.1016/0304-3835(95)03866-U; Strojan P, 2000, CLIN CANCER RES, V6, P1052; SUO Z, 1993, HISTOPATHOLOGY, V23, P45, DOI 10.1111/j.1365-2559.1993.tb01182.x; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; VIAENE AI, 1995, HISTOCHEM J, V27, P69, DOI 10.1007/BF00164174; vonBiberstein SE, 1996, ARCH OTOLARYNGOL, V122, P751; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Warrington JA, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P119; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yeudall WA, 1997, MOL CARCINOGEN, V18, P89, DOI 10.1002/(SICI)1098-2744(199702)18:2<89::AID-MC4>3.0.CO;2-L	47	185	210	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6196	6204		10.1038/sj.onc.1204685	http://dx.doi.org/10.1038/sj.onc.1204685			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593428				2022-12-25	WOS:000171206300011
J	Wang, RH; Liu, CWY; Avramis, VI; Berndt, N				Wang, RH; Liu, CWY; Avramis, VI; Berndt, N			Protein phosphatase 1 alpha-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein	ONCOGENE			English	Article						protein phosphatase 1; retinoblastoma protein; caspase; protein phosphorylation; cell cycle; apoptosis	CELL-CYCLE PROGRESSION; INHIBITOR OKADAIC ACID; CATALYTIC SUBUNIT; GENE-PRODUCT; MAMMALIAN-CELLS; PHOSPHORYLATION; DEATH; ACTIVATION; CLEAVAGE; ARREST	Protein phosphatase I (PPI) plays important roles in many different aspects of cellular activities including cell cycle control. One important function of PP1 is to activate the retinoblastoma protein pRB. Here we show that pRB is one of PPI's downstream targets during apoptosis. When HL-60 cells synchronized at the G1/S boundary were treated with pro-apoptotic cytosine arabinoside (araC), PP1 alpha protein increased twofold and PP1 activity about 30% within I h. This was followed by pRB dephosphorylation, pRB cleavage by caspases, DNA fragmentation, the appearance of cells with < 2n DNA content and finally, dying and dead cells. In vitro, pRB was protected from caspase-3 digestion by prior Cdk-mediated phosphorylation, whereas PP1 alpha converted phospho-pRB into an efficient substrate for caspase-3. Introduction of active PP1 alpha into HL-60 cells by electroporation was sufficient to induce characteristics of apoptosis. Similarly, araC-resistant cells, normally unable to die in response to araC, initiated apoptosis when electroporated with active PP1 alpha. This was also accompanied by pRB cleavage. In contrast, introduction of inhibitor-2 delayed the onset of araC-induced apoptosis, whereas concomitant introduction of PP1 alpha and inhibitor-2 completely prevented PP1 alpha -induced apoptosis. These results suggest that dephosphorylation of key proteins by PP1 alpha may be crucial for the initiation of apoptosis and further support the concept of PPI serving as a potential target for anti-cancer therapy.	Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Berndt, N (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NCI NIH HHS [CA 54167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054167] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; BAXTER GD, 1992, J IMMUNOL, V148, P1949; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berndt N., 2000, EMERGING THER TARGET, V4, P581; BERNDT N, 1995, ADV PROTEIN PHOSPHAT, V9, P63; Berndt N., 1999, FRONT BIOSCI, V4, pD22, DOI DOI 10.2741/BERNDT;PMID:9872729; Berry DE, 1996, ONCOGENE, V12, P1809; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cheng AY, 2000, J BIOL CHEM, V275, P1846, DOI 10.1074/jbc.275.3.1846; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; Dohadwala M, 1998, METH MOL B, V93, P191; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUNIGAN DD, 1995, VIROLOGY, V207, P460, DOI 10.1006/viro.1995.1105; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fan GS, 1996, ONCOGENE, V12, P1909; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HOTZ MA, 1994, CYTOMETRY, V15, P237, DOI 10.1002/cyto.990150309; INOMATA M, 1995, J CANCER RES CLIN, V121, P729, DOI 10.1007/BF01213319; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin-Aragon S, 2000, ANTICANCER RES, V20, P139; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Morimoto Y, 1997, EXP CELL RES, V230, P181, DOI 10.1006/excr.1996.3404; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Puntoni F, 1999, BIOCHEM BIOPH RES CO, V266, P279, DOI 10.1006/bbrc.1999.1800; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Spector D. L., 1998, CELLS LAB MANUAL; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Taylor BK, 2000, AM J PHYSIOL-LUNG C, V278, pL1062, DOI 10.1152/ajplung.2000.278.5.L1062; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZHENG B, 1991, J BIOL CHEM, V266, P10031	55	65	66	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6111	6122		10.1038/sj.onc.1204829	http://dx.doi.org/10.1038/sj.onc.1204829			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593419				2022-12-25	WOS:000171206300002
J	Cordeiro, Y; Machado, F; Juliano, L; Juliano, MA; Brentani, RR; Foguel, D; Silva, JL				Cordeiro, Y; Machado, F; Juliano, L; Juliano, MA; Brentani, RR; Foguel, D; Silva, JL			DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HELICES; BINDING; YEAST; DISEASE; PRP; POLYMERIZATION; REPLICATION; RECOGNITION; MODEL; STATE	The main hypothesis for prion diseases proposes that the cellular protein (PrPc) can be altered into a misfolded, beta-sheet-rich isoform (PrPSc), which in most cases undergoes aggregation. In an organism infected with PrPSc, PrPC is converted into the beta-sheet form, generating more PrPSc. We find that sequence-specific DNA binding to recombinant murine prion protein (mPrP(23-231)) converts it from an alpha-helical conformation (cellular isoform) into a soluble, beta-sheet isoform similar to that found in the fibrillar state. The recombinant murine prion protein and prion domains bind with high affinity to DNA sequences. Several double-stranded DNA sequences in molar excess above 2:1 (pH 4.0) or 0.5:1 (pH 5.0) completely inhibit aggregation of prion peptides, as measured by light scattering, fluorescence, and circular dichroism spectroscopy. However, at a high concentration, fibers (or peptide aggregates) can rescue the peptide bound to the DNA, converting it to the aggregating form. Our results indicate that a macromolecular complex of prion-DNA may act as an intermediate for the formation of the growing fiber. We propose that host nucleic acid may modulate the delicate balance between the cellular and the misfolded conformations by reducing the protein mobility and by making the protein-protein interactions more likely. In our model, the infectious material would act as a seed to rescue the protein bound to nucleic acid. Accordingly, DNA would act on the one hand as a guardian of the Se conformation, preventing its propagation, but on the other hand may catalyze Sc conversion and aggregation if a threshold level is exceeded.	Univ Fed Rio de Janeiro, Programa Biol Estruct, Dept Bioquim Med, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Estado Sao Paulo, Dept Biofis, BR-04023900 Sao Paulo, Brazil; Inst Ludwig Pesquisa Sobre Canc, BR-01509010 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Estadual Paulista; Universidade Federal de Sao Paulo (UNIFESP)	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Programa Biol Estruct, Dept Bioquim Med, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil.	foguel@bioqmed.ufrj.br; jerson@bioqmed.ufrj.br	Silva, Jerson/J-8984-2014; Cordeiro, Yraima/J-7619-2012; Juliano, Luiz/D-7204-2012; SILVA, JERSON Lima/GRF-1442-2022	Silva, Jerson/0000-0001-9523-9441; Cordeiro, Yraima/0000-0003-4278-212X; Juliano, Luiz/0000-0002-5589-2822; SILVA, JERSON Lima/0000-0001-9523-9441; Foguel, Debora/0000-0001-7312-7115				ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; [Anonymous], 1996, CIRCULAR DICHROISM C; Antson AA, 2000, CURR OPIN STRUC BIOL, V10, P87, DOI 10.1016/S0959-440X(99)00054-8; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Bons N, 1999, P NATL ACAD SCI USA, V96, P4046, DOI 10.1073/pnas.96.7.4046; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; CANETE M, 1987, CELL MOL BIOL, V33, P191; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Cohen FE, 1999, J MOL BIOL, V293, P313, DOI 10.1006/jmbi.1999.2990; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; FOGUEL D, 1994, P NATL ACAD SCI USA, V91, P8244, DOI 10.1073/pnas.91.17.8244; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Gaspar LP, 2001, J BIOL CHEM, V276, P7415, DOI 10.1074/jbc.M010037200; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kaneko K, 2000, J MOL BIOL, V295, P997, DOI 10.1006/jmbi.1999.3386; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; Kelly JW, 1998, P NATL ACAD SCI USA, V95, P930, DOI 10.1073/pnas.95.3.930; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Lima LMTR, 2000, P NATL ACAD SCI USA, V97, P14289, DOI 10.1073/pnas.250352197; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Mohana-Borges R, 2000, J BIOL CHEM, V275, P4708, DOI 10.1074/jbc.275.7.4708; Nandi PK, 1998, ARCH VIROL, V143, P1251, DOI 10.1007/s007050050373; Nandi PK, 1999, ARCH VIROL, V144, P1751, DOI 10.1007/s007050050702; Nandi PK, 1997, ARCH VIROL, V142, P2537, DOI 10.1007/s007050050261; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PHILLIPS SEV, 1994, ANNU REV BIOPH BIOM, V23, P671, DOI 10.1146/annurev.bb.23.060194.003323; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; VENYAMINOV SY, 1994, ANAL BIOCHEM, V222, P176, DOI 10.1006/abio.1994.1470; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; WANG JM, 1992, J PROTEIN CHEM, V11, P157, DOI 10.1007/BF01025220; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Wickner RB, 1999, J BIOL CHEM, V274, P555, DOI 10.1074/jbc.274.2.555; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	60	187	204	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49400	49409		10.1074/jbc.M106707200	http://dx.doi.org/10.1074/jbc.M106707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11604397	hybrid			2022-12-25	WOS:000173922100101
J	Bender, MH; Yother, J				Bender, MH; Yother, J			CpsB is a modulator of capsule-associated tyrosine kinase activity in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-PROTEIN PHOSPHATASE; POLYSACCHARIDE BIOSYNTHESIS; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; ACINETOBACTER-JOHNSONII; RHIZOBIUM-MELILOTI; GENE-CLUSTER; EXOPOLYSACCHARIDE; TYPE-3; LOCUS	Tyrosine phosphorylation is associated with polysaccharide synthesis in a number of Gram-positive and Gram-negative bacteria. In Streptococcus pneumoniae, CpsB, CpsC, and CpsD affect tyrosine phosphorylation and are critical for the production of a mature capsule in vitro. To characterize the interactions between these proteins and the phosphorylation event they modulate, cps2B, cps2C, and cps2D from the capsule type 2 S. pneumoniae D39 were cloned and expressed both individually and in combination in Escherichia coli. Cps2D purified from E. coli was not phosphorylated unless it was co-expressed with its cognate transmembrane domain, Cps2C. Purified phosphorylated Cps2D had tyrosine kinase activity and could phosphorylate both dephosphorylated Cps2D and an exogenous substrate (poly-Glu-Tyr) in the absence of ATP. Cps2B exhibited phosphatase activity against both purified phosphorylated Cps2D and p-nitrophenyl phosphate. An additional role for Cps2B as an inhibitor of Cps2D phosphorylation was demonstrated in both co-expression experiments in E. coli and in vitro experiments where it blocked the transphosphorylation of Cps2D even in the presence of the phosphatase inhibitor sodium orthovanadate. eps2C and cps2D deletion mutants in S. pneumoniae produced no detectable mature capsule during laboratory culture. Both were avirulent in systemic mouse infections and were unable to colonize the nasopharynx, suggesting that the failure to produce capsule was not dependent on the environment. Based on these results, we propose a model for capsule regulation where CpsB, CpsC, CpsD, and ATP form a stable complex that enhances capsule synthesis.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Yother, J (corresponding author), Univ Alabama, Dept Microbiol, BBRB 661-12,845 19th St S, Birmingham, AL 35294 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053017, T32GM008111] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07553] Funding Source: Medline; NIAID NIH HHS [AI28457] Funding Source: Medline; NIGMS NIH HHS [T32 GM08111, GM53017] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrecubieta C, 1995, GENE, V167, P1, DOI 10.1016/0378-1119(95)00657-5; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; AVERY OSWALD T., 1931, JOUR EXP MED, V54, P73, DOI 10.1084/jem.54.1.73; Becker A, 1998, J BACTERIOL, V180, P395, DOI 10.1128/JB.180.2.395-399.1998; Becker Y, 1995, VIRUS GENES, V11, P191, DOI 10.1007/BF01728658; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; BROWN EJ, 1985, CURR TOP MICROBIOL, V121, P159; Caimano MJ, 1998, MICROB DRUG RESIST, V4, P11, DOI 10.1089/mdr.1998.4.11; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; Cieslewicz MJ, 2001, J BIOL CHEM, V276, P139, DOI 10.1074/jbc.M005702200; DILLARD JP, 1994, MOL MICROBIOL, V12, P959, DOI 10.1111/j.1365-2958.1994.tb01084.x; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; Gonzalez JE, 1998, P NATL ACAD SCI USA, V95, P13477, DOI 10.1073/pnas.95.23.13477; Grangeasse C, 1999, IUBMB LIFE, V48, P339; Grangeasse C, 1997, GENE, V204, P259, DOI 10.1016/S0378-1119(97)00554-4; Grangeasse C, 1998, J MOL BIOL, V278, P339, DOI 10.1006/jmbi.1998.1650; Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; Hardy GG, 2001, INFECT IMMUN, V69, P2309, DOI 10.1128/IAI.69.4.2309-2317.2001; HENRICHSEN J, 1995, J CLIN MICROBIOL, V33, P2759, DOI 10.1128/JCM.33.10.2759-2762.1995; Iannelli F, 1999, J BACTERIOL, V181, P2652, DOI 10.1128/JB.181.8.2652-2654.1999; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; JANSSON PE, 1988, CARBOHYD RES, V182, P111, DOI 10.1016/0008-6215(88)84095-3; Jespersgaard C, 1999, INFECT IMMUN, V67, P6543; Kolkman MAB, 1997, MOL MICROBIOL, V26, P197, DOI 10.1046/j.1365-2958.1997.5791940.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magee AD, 2001, INFECT IMMUN, V69, P3755, DOI 10.1128/IAI.69.6.3755-3761.2001; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; Morona JK, 1997, MOL MICROBIOL, V23, P751, DOI 10.1046/j.1365-2958.1997.2551624.x; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; Sau S, 1997, MICROBIOL-UK, V143, P2395, DOI 10.1099/00221287-143-7-2395; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; Thaller MC, 1997, FEMS MICROBIOL LETT, V146, P191, DOI 10.1016/S0378-1097(96)00474-0; vanKranenburg R, 1997, MOL MICROBIOL, V24, P387, DOI 10.1046/j.1365-2958.1997.3521720.x; Vincent C, 1999, J BACTERIOL, V181, P3472, DOI 10.1128/JB.181.11.3472-3477.1999; Vincent C, 2000, J MOL BIOL, V304, P311, DOI 10.1006/jmbi.2000.4217; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WINKELSTEIN JA, 1981, REV INFECT DIS, V3, P289; WOOD WB, 1949, J EXP MED, V90, P85, DOI 10.1084/jem.90.1.85; WUGEDITSCH T, 2001, J BIOL CHEM, V26, P2631; YOTHER J, 1992, J BACTERIOL, V174, P610, DOI 10.1128/jb.174.2.610-618.1992; Yother J, 1999, GENETICS OF BACTERIALS POLYSACCHARIDES, P161	43	68	77	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47966	47974		10.1074/jbc.M105448200	http://dx.doi.org/10.1074/jbc.M105448200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606571	hybrid			2022-12-25	WOS:000172927000034
J	Masters, J; Hinek, AA; Uddin, S; Platanias, LC; Zeng, W; McFadden, G; Fish, EN				Masters, J; Hinek, AA; Uddin, S; Platanias, LC; Zeng, W; McFadden, G; Fish, EN			Poxvirus infection rapidly activates tyrosine kinase signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR 5; VACCINIA VIRUS; DOWN-REGULATION; HIV-1 GP120; ENTRY; CD4; PHOSPHORYLATION; ASSOCIATION; PROTEINS; INSULIN	Viruses have evolved a number of strategies to gain entry and replicate in host target cells that, for human immunodeficiency virus (HIV) and the poxvirus, myxoma virus, involve appropriating chemokine receptors. In this report we demonstrate that activation of multiple intracellular tyrosine phosphorylation events rapidly ensues following virus adsorption to NIH 3T3.CD4.CCR5 cells and affects the ultimate level of myxoma virus replication. UV-inactivated myxoma virus induces the rapid phosphorylation of CCR5 on tyrosine residues, the association of CCR5 with Jaks and p56(lck), and their phosphorylation-activation within minutes of virus adsorption. Additionally, we provide evidence for myxoma virus-inducible signal transducers and activators of transcription (Stat) and insulin receptor substrate (IRS) activation. In contrast to CCR5 activation effected by HIV Env protein, these myxoma virus-inducible phosphorylation events are not sensitive to pertussis toxin treatment. Moreover, in cells that are non-permissive for myxoma virus infection, we provide evidence that myxoma virus fails to invoke this tyrosine phosphorylation cascade. Consistent with the observation that infection of CCR5-expressing cells is blocked by herbimycin A and the Jak 2 inhibitor, tyrophostin AG490, we infer that viral infectivity may be dependent on non-G-protein-coupled signal transduction pathways triggered by the infecting myxoma virus particle. This provides a novel post-binding mechanism by which viruses can co-opt a cellular receptor to permit productive virus infection.	Univ Toronto, Toronto Gen Res Inst, Hlth Network, Dept Cell & Mol Biol,Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; Univ Illinois, Hematol Oncol Sect, Chicago, IL 60607 USA; Vet Affairs Hosp, Chicago, IL 60607 USA; Univ Western Ontario, John P Robarts Res Inst, London, ON 46G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON 46G 2V4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Western University (University of Western Ontario); Western University (University of Western Ontario)	Fish, EN (corresponding author), Univ Toronto, Toronto Gen Res Inst, Hlth Network, Dept Cell & Mol Biol,Div Cell & Mol Biol, Canadian Blood Serv Bldg,67 Coll St,Rm 424, Toronto, ON M5G 2M1, Canada.	en.fish@utoronto.ca		Uddin, Shahab/0000-0003-1886-6710	NCI NIH HHS [CA73381, CA77816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816, R29CA073381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alfano M, 1999, J EXP MED, V190, P597, DOI 10.1084/jem.190.5.597; BARRY M, 1995, J VIROL, V69, P5243, DOI 10.1128/JVI.69.9.5243-5251.1995; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Cicala C, 1999, J IMMUNOL, V163, P420; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Fenner F, 2000, FEMS MICROBIOL REV, V24, P123, DOI 10.1111/j.1574-6976.2000.tb00536.x; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; GHISLAIN J, 1994, J IMMUNOL, V153, P3655; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Lalani AS, 2000, IMMUNOL TODAY, V21, P100, DOI 10.1016/S0167-5699(99)01556-X; Lalani AS, 1999, SCIENCE, V286, P1968, DOI 10.1126/science.286.5446.1968; Liu QH, 2000, P NATL ACAD SCI USA, V97, P4832, DOI 10.1073/pnas.090521697; Locker JK, 2000, MOL BIOL CELL, V11, P2497, DOI 10.1091/mbc.11.7.2497; Mashikian MV, 1999, J IMMUNOL, V163, P3123; MCFADDEN G, 1994, ENCY VIROLOGY, P1153; Nash P, 1999, IMMUNOL REV, V168, P103, DOI 10.1111/j.1600-065X.1999.tb01286.x; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Pease JE, 1998, SEMIN IMMUNOL, V10, P169, DOI 10.1006/smim.1998.0129; Ramsey-Ewing A, 1998, VIROLOGY, V242, P138, DOI 10.1006/viro.1997.8985; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Su SB, 1999, J IMMUNOL, V162, P7128; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Uddin S, 1998, BRIT J HAEMATOL, V101, P446, DOI 10.1046/j.1365-2141.1998.00731.x; Wang JM, 1999, J EXP MED, V190, P591, DOI 10.1084/jem.190.5.591; White MF, 1998, RECENT PROG HORM RES, V53, P119; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496	33	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48371	48375		10.1074/jbc.M108019200	http://dx.doi.org/10.1074/jbc.M108019200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11591716	hybrid			2022-12-25	WOS:000172927000086
J	Shin, JM; Goldshleger, R; Munson, KB; Sachs, G; Karlish, SJD				Shin, JM; Goldshleger, R; Munson, KB; Sachs, G; Karlish, SJD			Selective Fe2+-catalyzed oxidative cleavage of gastric H+,K+-ATPase - Implications for the energy transduction mechanism of P-type cation pumps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; CONFORMATIONAL TRANSITIONS; STRUCTURAL ASPECTS; CRYSTAL-STRUCTURE; + K+)-ATPASE; H,K ATPASE; H,K-ATPASE; NA,K-ATPASE	In the presence of ascorbate/H2O2, Fe2+ ions or the ATP-Fe2+ complex catalyze selective cleavage of the alpha subunit of gastric H+, K+-ATPase. The electrophoretic mobilities of the fragments and dependence of the cleavage patterns on E-1 and E-2 conformational states are essentially identical to those described previously for renal Na+, K+-ATPase. The cleavage pattern of H+, K+-ATPase by Fe2+ ions is consistent with the existence of two Fe2+ sites: site I within highly conserved sequences in the P and A domains, and site 2 at the cytoplasmic entrance to trans-membrane segments M3 and MI. The change in the pattern of cleavage catalyzed by Fe2+ or the ATP-Fe2+ complex induced by different ligands provides evidence for large conformational movements of the N, P, and A cytoplasmic domains of the enzyme. The results are consistent with the Ca2+-ATPase crystal structure (Protein Data Bank identification code 1EUL; Toyoshima, C., Nakasako, M., Nomura, H., and Ogawa, H. (2000) Nature 405, 647-655), an E1Ca2+ conformation, and a theoretical model of Ca2+-ATPase in an E2 conformation (Protein Data Bank identification code 1FQU). Thus, it can be presumed that the movements of N, P, and A cytoplasmic domains, associated with the E-1 <----> E-2 transitions, are similar in all P-type ATPases. Fe-2-catalyzed cleavage patterns also reveal sequences involved in phosphate, Mg2+, and ATP binding, which have not yet been shown in crystal structures, as well as changes which occur in E-1 <----> E2 transitions, and subconformations induced by H+, K+-ATPase-specific ligands such as SCH28080.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Calif Los Angeles, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90024 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	Weizmann Institute of Science; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	steven.karlish@weizmann.ac.il			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK053462, R01DK046917, R01DK017294, P30DK041301, R37DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK17294, DK46917, DK53462, DK41301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRZEZINSKI P, 1988, BIOCHIM BIOPHYS ACTA, V942, P215, DOI 10.1016/0005-2736(88)90022-3; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; FUKUSHIMA Y, 1978, J BIOL CHEM, V253, P6853; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; Goldshleger R, 2001, J BIOENERG BIOMEMBR, V33, P387, DOI 10.1023/A:1010615422932; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HELMICHDEJONG ML, 1987, BIOCHIM BIOPHYS ACTA, V905, P358, DOI 10.1016/0005-2736(87)90464-0; HELMICHDEJONG ML, 1986, BIOCHIM BIOPHYS ACTA, V858, P254, DOI 10.1016/0005-2736(86)90330-5; HELMICHDEJONG ML, 1985, BIOCHIM BIOPHYS ACTA, V821, P377, DOI 10.1016/0005-2736(85)90041-0; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V525, P252, DOI 10.1016/0005-2744(78)90219-X; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; LORENTZON P, 1988, J BIOL CHEM, V263, P10705; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melle-Milovanovic D, 1998, ACTA PHYSIOL SCAND, V163, P147; MENDLEIN J, 1990, J BIOL CHEM, V265, P5030; MERCIER F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P151, DOI 10.1016/0005-2736(93)90036-Y; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Ogawa H, 1998, BIOPHYS J, V75, P41, DOI 10.1016/S0006-3495(98)77493-4; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pedersen PA, 2000, J BIOL CHEM, V275, P37588, DOI 10.1074/jbc.M005610200; PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027; POST RL, 1972, J BIOL CHEM, V247, P6530; RABON E, 1985, J BIOL CHEM, V260, P200; RABON E, 1991, J BIOL CHEM, V266, P12395; RABON EC, 1993, J BIOL CHEM, V268, P8012; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RABON EC, 1990, J BIOL CHEM, V265, P19594; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; RENDI R, 1964, BIOCHIM BIOPHYS ACTA, V89, P520, DOI 10.1016/0926-6569(64)90078-1; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; SACHS G, 1992, ANN NY ACAD SCI, V671, P204; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHIN JM, 1994, J BIOL CHEM, V269, P22533; Shin JM, 1997, ANN NY ACAD SCI, V834, P65, DOI 10.1111/j.1749-6632.1997.tb52226.x; SOUMARMON A, 1984, J BIOL CHEM, V259, P1861; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STEWART B, 1981, J BIOL CHEM, V256, P2682; Tal DM, 2001, BIOCHEMISTRY-US, V40, P12505, DOI 10.1021/bi011167n; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VANDERHIJDEN HTWM, 1991, BIOCHIM BIOPHYS ACTA, V1061, P141, DOI 10.1016/0005-2736(91)90278-G; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	54	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48440	48450		10.1074/jbc.M106864200	http://dx.doi.org/10.1074/jbc.M106864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11585827	hybrid			2022-12-25	WOS:000172927000096
J	Barbieri, MA; Heath, CM; Peters, EM; Wells, A; Davis, JN; Stahl, PD				Barbieri, MA; Heath, CM; Peters, EM; Wells, A; Davis, JN; Stahl, PD			Phosphatidylinositol-4-phosphate 5-kinase-1 beta is essential for epidermal growth factor receptor-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-PHOSPHATE 5-KINASE; PHOSPHOINOSITIDE KINASES; MEMBRANE TRAFFICKING; PHOSPHOLIPASE-C; ALPHA; 4,5-BISPHOSPHATE; MOVEMENT; CLATHRIN; DOMAINS	Phosphatidylinositol-4,5-bisphosphate (PIP2) is known to play an important role in signal transduction and membrane trafficking. We show that one enzyme responsible for PIP2 production, phosphatidylinositol-4-phosphate 5-kinase type 1 beta (PIPK beta), is essential for epidermal growth factor receptor (EGFR)-mediated endocytosis. Expression of murine PIPK beta in NR6 cells expressing EGFR strikingly increased receptor internalization. Moreover, the kinase was shown to form an immunoprecipitable complex with EGFR. Expression of either a truncated kinase or a kinase dead mutant inhibited EGFR endocytosis and also blocked the membrane recruitment of PIPK beta and both clathrin light chain and dynamin. Our results delineate a novel mechanism by which PIPK beta regulates receptor-mediated endocytosis and receptor tyrosine kinase membrane traffic.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Washington University (WUSTL); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Campus Box 8228, St Louis, MO 63110 USA.		Stahl, Philip/D-6315-2012	Wells, Alan/0000-0002-1637-8150	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015, R01AI035884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35884, AI 20015] Funding Source: Medline; NIGMS NIH HHS [GM 42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; COCHET C, 1991, J BIOL CHEM, V266, P637; Cremona O, 2001, J CELL SCI, V114, P1041; Davis JN, 1997, MOL CELL BIOL, V17, P7398, DOI 10.1128/MCB.17.12.7398; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; LI GP, 1993, J BIOL CHEM, V268, P24475; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867	30	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47212	47216		10.1074/jbc.C100490200	http://dx.doi.org/10.1074/jbc.C100490200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581249	hybrid			2022-12-25	WOS:000172768500073
J	Hisamoto, K; Ohmichi, M; Kanda, Y; Adachi, K; Nishio, Y; Hayakawa, J; Mabuchi, S; Takahashi, K; Tasaka, K; Miyamoto, Y; Taniguchi, N; Murata, Y				Hisamoto, K; Ohmichi, M; Kanda, Y; Adachi, K; Nishio, Y; Hayakawa, J; Mabuchi, S; Takahashi, K; Tasaka, K; Miyamoto, Y; Taniguchi, N; Murata, Y			Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; BREAST-CANCER; GROWTH-FACTOR; ER-ALPHA; ACTIVATION; BETA; INHIBITOR; PROMOTER	Raloxifene is a tissue-selective estrogen receptor modulator. The effect of estrogen on cardiovascular disease is mainly dependent on direct actions on the vascular wall involving activation of endothelial nitric oxide synthase (eNOS) via Akt and extracellular signal-regulated protein kinase (ERK) cascades. Although raloxifene is also known to activate eNOS in the vascular endothelium, the molecular mechanism responsible for this effect remains to be elucidated. In studies of both human umbilical vein endothelial cells and simian virus 40-transformed rat lung vascular endothelial cells (TRLECs), the raloxifene analog LY117018 caused acute phosphorylation of eNOS that was unaffected by actinomycin D and was blocked by the pure estrogen receptor antagonist IC1182,780. Activation of Akt by raloxifene reached a plateau at 15-30 min and declined thereafter, a similar time frame to that of Akt activation by 17 beta -estradiol. On the other hand, both activation and phosphorylation of ERK by raloxifene showed a biphasic pattern (peaks at 5 min and 1 h), whereas ERK activation and phosphorylation by 17 beta -estradiol reached a plateau at 5 min and declined thereafter. A MEK inhibitor, PD98059, had no effect on the raloxifene-induced Akt activity, suggesting an absence of cross-talk between the ERK and Akt cascades. Either exogenous expression of a dominant-negative Akt or pretreatment of TRLECs with PD98059 decreased the raloxifene-induced eNOS phosphorylation. Moreover, raloxifene stimulated the activation of Akt, ERK, and eNOS in Chinese hamster ovary cells expressing estrogen receptor a but not Chinese hamster ovary cells expressing estrogen receptor beta. Our findings suggest that raloxifene-induced eNOS phosphorylation is mediated by estrogen receptor a via a nongenomic mechanism and is differentially mediated by Akt- and ERK-dependent cascades.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	masa@gyne.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Mabuchi, Seiji/AAX-1986-2020; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; Coffer PJ, 1998, BIOCHEM J, V335, P1; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Cox DA, 1996, PHARMACOL REV, V48, P3; CUMMINGS S, 1998, P ASCO, V17, P3; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duh JL, 1997, PHARMACEUT RES, V14, P186, DOI 10.1023/A:1012048626963; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; Figtree GA, 1999, CIRCULATION, V100, P1095, DOI 10.1161/01.CIR.100.10.1095; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hayakawa J, 2000, CANCER RES, V60, P5988; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jiang BB, 1998, J CARDIOVASC PHARM, V31, pS142, DOI 10.1097/00005344-199800001-00042; JORDAN VC, 1998, P AN M AM SOC CLIN, V17, P466; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kimura A, 2000, J BIOL CHEM, V275, P3667, DOI 10.1074/jbc.275.5.3667; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P982, DOI 10.1016/0002-9378(95)90247-3; Mandlekar S, 2000, CANCER RES, V60, P5995; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Miller VM, 1999, CIRC RES, V85, P979; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; SCHWARTZ J, 1995, J CLIN PHARMACOL, V35, P314, DOI 10.1002/j.1552-4604.1995.tb04066.x; SEO HG, 1995, BIOCHEM BIOPH RES CO, V208, P10, DOI 10.1006/bbrc.1995.1298; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Simoncini T, 2000, J CLIN ENDOCR METAB, V85, P2966, DOI 10.1210/jc.85.8.2966; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Steinberg D, 1997, CIRCULATION, V95, P1062; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Yokoi T, 2000, J BIOL CHEM, V275, P21639, DOI 10.1074/jbc.M910252199; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zuckerman SH, 1996, ATHEROSCLEROSIS, V126, P65	72	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47642	47649		10.1074/jbc.M103853200	http://dx.doi.org/10.1074/jbc.M103853200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595733	hybrid			2022-12-25	WOS:000172768500125
J	Kwon, KB; Yang, JY; Ryu, DG; Rho, HW; Kim, JS; Park, JW; Kim, HR; Park, BH				Kwon, KB; Yang, JY; Ryu, DG; Rho, HW; Kim, JS; Park, JW; Kim, HR; Park, BH			Vibrio vulnificus cytolysin induces superoxide anion-initiated apoptotic signaling pathway in human ECV304 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRONE SPIN TRAPS; EXTRACELLULAR CYTOLYSIN; ENDOTHELIAL-CELLS; DNA FRAGMENTATION; OXIDATIVE STRESS; PORE FORMATION; CYTOCHROME-C; ALPHA-TOXIN; MAST-CELLS; THYMOCYTES	Previous studies showed that exposure to Vibrio vulnificus cytolysin (VVC) caused characteristic morphologic changes and dysfunction of vascular structures in lung. VVC showed cytotoxicity for mammalian cells in culture and acted as a vascular permeability factor. In this study, the underlying mechanisms of VVC-induced cytotoxicity was investigated on ECV304 cell, a human vascular endothelial cell line. When cells were exposed to 0.4 hemolytic units (HU) of VVC, consecutive apoptotic events were observed; the elevation of superoxide anion (O(2)(-)over dot) the release of cytochrome c, the activation of caspase-3, the cleavage of poly(ADP-ribose) polymerase, and the DNA fragmentation. The pretreatment with 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO), O(2)(-)over dot scavenger, completely abolished O(2)(-)over dot 2 2 levels and downstream apoptotic events. Moreover, pretreatment with cyclosporin A (CsA), a mitochondrial permeability transition inhibitor, was capable of attenuating O(2)(-)over dot-mediated cytochrome c release and caspase-3 activation, and consequent apoptosis. Apoptosis, as demonstrated by oligonucleosomal DNA fragmentation and fluorescence microscopy, was induced 24 h after VVC treatment, which was also prevented by caspase-3 inhibitor, Ac-DEVD-CHO. Caspase-1 inhibitor, Ac-YVAD-CHO, did not protect ECV 304 cells from apoptosis. These results suggest a scenario where VVC-induced apoptosis is triggered by the generation of O(2)(-)over dot release of 2 cytochrome c from mitochondria, activation of caspase-3, degradation of poly(ADP-ribose) polymerase, and DNA fragmentation. The induction of apoptosis in endothelial cells by VVC may provide a pivotal mechanism for understanding the pathophysiology of septicemia.	Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561756, South Korea; Chonbuk Natl Univ, Sch Med, Inst Med Sci, Chonju 561756, South Korea; Won Kwang Univ, Sch Oriental Med, Dept Physiol, Iksan 570749, South Korea	Jeonbuk National University; Jeonbuk National University; Wonkwang University	Park, BH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561756, South Korea.	bhpark@moak.chonbuk.ac.kr						ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; BERNHEIMER AW, 1963, J GEN MICROBIOL, V30, P455, DOI 10.1099/00221287-30-3-455; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BLAKE PA, 1979, NEW ENGL J MED, V300, P1, DOI 10.1056/NEJM197901043000101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHEN YJ, 1994, MICROB PATHOGENESIS, V17, P203, DOI 10.1006/mpat.1994.1066; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Eguchi Y, 1997, CANCER RES, V57, P1835; ELSTEIN KH, 1994, EXP CELL RES, V211, P322, DOI 10.1006/excr.1994.1094; Galitovsky VE, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1374; GRAY LD, 1985, INFECT IMMUN, V48, P62, DOI 10.1128/IAI.48.1.62-72.1985; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAMEED A, 1989, J EXP MED, V169, P765, DOI 10.1084/jem.169.3.765; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JONAS D, 1994, INFECT IMMUN, V62, P1304, DOI 10.1128/IAI.62.4.1304-1312.1994; KIM HR, 1993, LIFE SCI, V53, P571, DOI 10.1016/0024-3205(93)90714-E; Kim Hyung-Rho, 1992, Korean Journal of Biochemistry, V24, P7; Kim JS, 1998, MICROBIOL IMMUNOL, V42, P837, DOI 10.1111/j.1348-0421.1998.tb02359.x; Kim JS, 1997, EXP MOL MED, V29, P117, DOI 10.1038/emm.1997.17; KIZAKI H, 1989, J IMMUNOL, V143, P1790; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KREGER A, 1981, INFECT IMMUN, V33, P583, DOI 10.1128/IAI.33.2.583-590.1981; KREGER AS, 1988, METHOD ENZYMOL, V165, P176; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MIYOSHI S, 1988, MICROBIOL IMMUNOL, V32, P1025, DOI 10.1111/j.1348-0421.1988.tb01467.x; MIYOSHI S, 1993, J TOXICOL-TOXIN REV, V12, P253, DOI 10.3109/15569549309014409; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OEZ S, 1990, BLUT, V60, P97, DOI 10.1007/BF01720515; OLIVER JD, 1986, DIAGN MICR INFEC DIS, V5, P99, DOI 10.1016/0732-8893(86)90112-4; ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603; Park JW, 1996, INFECT IMMUN, V64, P2873, DOI 10.1128/IAI.64.7.2873-2876.1996; PARK JW, 1994, BBA-BIOMEMBRANES, V1194, P166, DOI 10.1016/0005-2736(94)90216-X; PARK SD, 1991, J AM ACAD DERMATOL, V24, P397, DOI 10.1016/0190-9622(91)70059-B; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; Shen HM, 2001, FREE RADICAL BIO MED, V30, P9, DOI 10.1016/S0891-5849(00)00421-4; SHULACHEV VP, 1998, BIOCHIM BIOPHYS ACTA, V1363, P100; SIMPSON LM, 1987, INFECT IMMUN, V55, P269, DOI 10.1128/IAI.55.1.269-272.1987; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SMITH GC, 1982, INFECT IMMUN, V35, P1155, DOI 10.1128/IAI.35.3.1155-1156.1982; SUN XM, 1992, ANAL BIOCHEM, V204, P351, DOI 10.1016/0003-2697(92)90251-2; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Torres-Roca JF, 2000, J IMMUNOL, V165, P4822, DOI 10.4049/jimmunol.165.9.4822; WALEV I, 1995, INFECT IMMUN, V63, P1188, DOI 10.1128/IAI.63.4.1188-1194.1995; Wilson MR, 1998, BIOCHEM CELL BIOL, V76, P573, DOI 10.1139/bcb-76-4-573; WRIGHT AC, 1991, INFECT IMMUN, V59, P192, DOI 10.1128/IAI.59.1.192-197.1991; WRIGHT AC, 1981, INFECT IMMUN, V34, P503, DOI 10.1128/IAI.34.2.503-507.1981; YAMANAKA H, 1990, J MED MICROBIOL, V32, P39, DOI 10.1099/00222615-32-1-39; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZITZER A, 1995, MED MICROBIOL IMMUN, V184, P37, DOI 10.1007/BF00216788	58	62	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47518	47523		10.1074/jbc.M108645200	http://dx.doi.org/10.1074/jbc.M108645200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591724	hybrid			2022-12-25	WOS:000172768500110
J	Riedinger, HJ; van Betteraey-Nikoleit, M; Hilfrich, U; Eisele, KH; Probst, H				Riedinger, HJ; van Betteraey-Nikoleit, M; Hilfrich, U; Eisele, KH; Probst, H			Oxygen-dependent regulation of in vivo replication of simian virus 40 DNA is modulated by glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; EHRLICH ASCITES-CELLS; RIBONUCLEOTIDE REDUCTASE; LACTATE-DEHYDROGENASE; REPLICON INITIATION; TUMOR-CELLS; HYPOXIA; BINDING; PROTEIN; METABOLISM	Simian virus 40 (SV40)-infected CV1 cells exposed to hypoxia show an inhibition of viral replication. Reoxygenation after several hours of hypoxia results in new initiations followed by a nearly synchronous round of SV40 replication. In this communication, we examined the effect of glucose on inhibition of viral DNA replication under hypoxia. We found that glucose stimulated SV40 DNA replication under hypoxia in two different ways. First, the rate of DNA synthesis, i.e. the fork propagation rate, increased. This effect seemed to be mediated by inhibition of mitochondrial respiration by glucose (Crabtree effect). Inhibition of mitochondrial respiration probably resulted in a higher intracellular oxygen concentration and an activation of oxygen-dependent ribonucleotide reductase, which provides the precursors for DNA synthesis. This glucose effect was consequently strongly dependent on the strength of hypoxia and the extent of intracellular respiration; hypoxic gassing with 10 ppm instead of 200-400 ppm O-2 or treatment of hypoxic cells with a mitochondrial uncoupler (carbonyl cyanide m-chlorophenylhydrazone) reduced the glucose effect on replication, whereas antimycin A, an inhibitor of respiration, increased it. The second effect of glucose concerned initiation, i.e. stimulation of unwinding of the viral origin. This effect was not influenced by the strength of hypoxia or the extent of cellular respiration and seemed, therefore, not to be mediated through a Crabtree effect. No evidence for a direct correlation between the cellular ATP concentration and the extent of SV40 replication under hypoxia was found. The effect of glucose on replication under hypoxia was not restricted to SV40-infected CV1 cells but was also detectable in HeLa cells. This suggests it to be a mechanism of more general validity.	Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Riedinger, HJ (corresponding author), Univ Tubingen, Inst Physiol Chem, Hoppe Seyler Str 4, D-72076 Tubingen, Germany.	hans-joerg.riedinger@uni-tuebingen.de						AW TY, 1987, AM J PHYSIOL, V253, pF440, DOI 10.1152/ajprenal.1987.253.3.F440; Brischwein K, 1997, EUR J BIOCHEM, V244, P286, DOI 10.1111/j.1432-1033.1997.00286.x; Bruckner BA, 1999, METABOLISM, V48, P422, DOI 10.1016/S0026-0495(99)90098-7; CALISSANO P, 1985, EXP CELL RES, V161, P117, DOI 10.1016/0014-4827(85)90496-3; CATTANEO A, 1985, EXP CELL RES, V161, P130, DOI 10.1016/0014-4827(85)90497-5; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DIDDENS H, 1987, INT J CANCER, V40, P635, DOI 10.1002/ijc.2910400511; DREIER T, 1993, FEBS LETT, V336, P445, DOI 10.1016/0014-5793(93)80853-M; Graven KK, 1998, J LAB CLIN MED, V132, P456, DOI 10.1016/S0022-2143(98)90122-6; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; JINDAL HK, 1990, J BIOL CHEM, V265, P6540; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Ogiso Y, 1999, BIOCHEM BIOPH RES CO, V258, P448, DOI 10.1006/bbrc.1999.0635; OTTE P, 1991, Z RHEUMATOL, V50, P304; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Probst G, 1999, BIOL CHEM, V380, P1371, DOI 10.1515/BC.1999.177; PROBST H, 1989, EXP CELL RES, V180, P563, DOI 10.1016/0014-4827(89)90084-0; PROBST H, 1983, BIOCHIM BIOPHYS ACTA, V740, P200, DOI 10.1016/0167-4781(83)90078-7; PROBST H, 1989, BIOCHEM BIOPH RES CO, V163, P334, DOI 10.1016/0006-291X(89)92140-2; PROBST H, 1980, BIOCHEM BIOPH RES CO, V94, P55, DOI 10.1016/S0006-291X(80)80186-0; PROBST H, 1983, BIOCHEM BIOPH RES CO, V110, P688, DOI 10.1016/0006-291X(83)91204-4; PROBST H, 1984, EXP CELL RES, V154, P327, DOI 10.1016/0014-4827(84)90157-5; PROBST H, 1988, CANCER RES, V48, P2053; PROBST H, 1988, OXYGEN SENSING TISSU, P77; Riedinger HJ, 1999, J VIROL, V73, P2243, DOI 10.1128/JVI.73.3.2243-2252.1999; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; Sambook J., 1989, MOL CLONING LAB MANU, P743; Satake S, 1998, BIOL CELL, V90, P161, DOI 10.1016/S0248-4900(98)80337-7; SCHLAPPACK OK, 1991, BRIT J CANCER, V64, P663, DOI 10.1038/bjc.1991.378; SHMAKOV N L, 1984, Meditsinskaya Radiologiya, V29, P17; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; STAHL H, 1983, J VIROL, V47, P65, DOI 10.1128/JVI.47.1.65-76.1983; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Vaupel P, 1996, EXPERIENTIA, V52, P464, DOI 10.1007/BF01919317; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; Wojtczak L, 1996, ACTA BIOCHIM POL, V43, P361	40	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47122	47130		10.1074/jbc.M106938200	http://dx.doi.org/10.1074/jbc.M106938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11606577	hybrid			2022-12-25	WOS:000172768500061
J	Terada, M; Kuroda, T; Matsuyama, S; Tokuda, H				Terada, M; Kuroda, T; Matsuyama, S; Tokuda, H			Lipoprotein sorting signals evaluated as the Lo1A-dependent release of lipoproteins from the cytoplasmic membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; LOCALIZATION; PROTEIN; TRANSPORT; SEQUENCE; BACTERIA; SYSTEM	Escherichia coli lipoproteins are anchored to either the inner or outer membrane through fatty acyl chains covalently attached to an N-terminal cysteine. Aspartate at position 2 functions to retain lipoproteins in the inner membrane, although the retention is perturbed depending on the residue at position 3. We previously revealed that LolCDE and LolA play critical roles in this lipoprotein sorting. To clarify the sorting signals, the LolA-dependent release of lipoprotein derivatives having various residues at positions 2 and 3 was examined in spheroplasts. When the residue at position 3 was serine, only aspartate at position 2 caused the retention of lipoproteins in spheroplasts. We then examined the release of derivatives having aspartate at position 2 and various residues at position 3. Strong inner membrane retention occurred with a limited number of species of residues at position 3. These residues were present at position 3 of native lipoproteins having aspartate at position 2, whereas residues that inhibited the retention were not. It was also found that a strong inner membrane retention signal having residues other than Aspartate at position 2 could be formed through the combination of the residues at positions 2 and 3. These results indicate that the inner membrane localization of native lipoproteins is ensured by the use of a limited number of strong inner membrane retention signals.	Univ Tokyo, Inst Biol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Biol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; DENFERT C, 1987, EMBO J, V6, P3531, DOI 10.1002/j.1460-2075.1987.tb02679.x; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; KLEIN JR, 1991, MOL GEN GENET, V230, P230, DOI 10.1007/BF00290673; Kobayashi K, 2001, J BACTERIOL, V183, P2646, DOI 10.1128/JB.183.8.2646-2653.2001; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SEIFFER D, 1993, FEMS MICROBIOL LETT, V107, P175; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995	18	93	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47690	47694		10.1074/jbc.M109307200	http://dx.doi.org/10.1074/jbc.M109307200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592971	hybrid			2022-12-25	WOS:000172768500132
J	Vissers, MCM; Lee, WG; Hampton, MB				Vissers, MCM; Lee, WG; Hampton, MB			Regulation of apoptosis by vitamin C - Specific protection of the apoptotic machinery against exposure to chlorinated oxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOCHLOROUS ACID; ASCORBIC-ACID; HYDROGEN-PEROXIDE; CASPASE ACTIVATION; GROWTH ARREST; ANTIOXIDANT; CELLS; OXIDATION; MYELOPEROXIDASE; CHLORAMINES	We have investigated the ability of intracellular vitamin C to protect human umbilical vein endothelial cells from exposure to hypochlorous acid (HOCl) and a range of derived chloramines. Ascorbate provided minimal protection against the cytotoxicity induced by these oxidants, as measured by propidium iodide uptake. In contrast, there was a marked effect on apoptosis, monitored by caspase-3 activation and phosphatidylserine exposure. Extended incubation of the cells with glycine chloramine or histamine chloramine completely blocked apoptosis initiated in the cells by serum withdrawal. This effect was significantly abrogated by ascorbate. Inhibition of apoptosis required the oxidant to be present for an extended period after serum withdrawal and occurred prior to caspase-3 activation. General protection of thiols by ascorbate was not responsible for the protection of apoptosis, because intracellular oxidation by HOCl or chloramines was not prevented in supplemented cells. The results suggest a new role for vitamin C in the regulation of apoptosis. We propose that, by protection of an oxidant-sensitive step in the initiation phase, ascorbate allows apoptosis to proceed in endothelial cells under sustained oxidative stress.	Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, Christchurch 8001, New Zealand	University of Otago	Vissers, MCM (corresponding author), Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, POB 4345, Christchurch 8001, New Zealand.	margret.vissers@chmeds.ac.nz	Vissers, Margreet C M/T-4159-2017; Hampton, Mark B/A-8490-2008; Lee, Don/AAE-7069-2021	Hampton, Mark B/0000-0002-7349-3729; Lee, Don/0000-0002-2199-5364				BARNES MJ, 1975, ANN NY ACAD SCI, V258, P264, DOI 10.1111/j.1749-6632.1975.tb29287.x; Berger TM, 1997, J BIOL CHEM, V272, P15656, DOI 10.1074/jbc.272.25.15656; BIRDWELL CR, 1978, P NATL ACAD SCI USA, V75, P3273, DOI 10.1073/pnas.75.7.3273; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; FOLKES LK, 1995, ARCH BIOCHEM BIOPHYS, V323, P120, DOI 10.1006/abbi.1995.0017; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GAZDA M, 1994, INORG CHEM, V33, P118, DOI 10.1021/ic00079a022; GOLDSCHMIDT MC, 1991, AM J CLIN NUTR, V54, pS1214, DOI 10.1093/ajcn/54.6.1214s; Halliwell B., 1997, Vitamin C in health and disease., P59; HALLIWELL B, 1999, FREE RADICAL BIO MED, P200; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HU ML, 1993, J LAB CLIN MED, V121, P257; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Kanno S, 2000, BIOL PHARM BULL, V23, P37; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; LEE W, 1982, CLIN CHEM, V28, P2165; LEIST M, 2001, FREE RADIC BIOL MED, V21, P297; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; McKenzie SJ, 1996, J CLIN INVEST, V98, P136, DOI 10.1172/JCI118757; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Prutz WA, 1996, ARCH BIOCHEM BIOPHYS, V332, P110, DOI 10.1006/abbi.1996.0322; Prutz WA, 1998, ARCH BIOCHEM BIOPHYS, V349, P183, DOI 10.1006/abbi.1997.0440; Prutz WA, 1999, ARCH BIOCHEM BIOPHYS, V371, P107, DOI 10.1006/abbi.1999.1377; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Pullar JM, 2000, IUBMB LIFE, V50, P259, DOI 10.1080/15216540051080958; Pullar JM, 2001, J BIOL CHEM, V276, P22120, DOI 10.1074/jbc.M102088200; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; SAMUELS MP, 1987, ARCH DIS CHILD, V62, P1099, DOI 10.1136/adc.62.11.1099; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Smirnoff N, 2000, CURR OPIN PLANT BIOL, V3, P229, DOI 10.1016/S1369-5266(00)00069-8; Stefan C, 1997, CHEM RES TOXICOL, V10, P636, DOI 10.1021/tx970006a; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; TATSUMI T, 1994, AM J PHYSIOL-HEART C, V267, pH1597, DOI 10.1152/ajpheart.1994.267.4.H1597; Thomas EL, 2000, REDOX REP, V5, P191, DOI 10.1179/135100000101535744; Tsao C. S., 1997, Vitamin C in health and disease., P25; TU B, 1995, TOXICOLOGY, V98, P125, DOI 10.1016/0300-483X(94)02977-3; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vile GF, 1998, ARCH BIOCHEM BIOPHYS, V359, P51, DOI 10.1006/abbi.1998.0881; Vile GF, 2000, ARCH BIOCHEM BIOPHYS, V377, P122, DOI 10.1006/abbi.2000.1706; VISSERS MCM, 1990, FREE RADICAL BIO MED, V8, P331, DOI 10.1016/0891-5849(90)90098-4; Vissers MCM, 1999, BIOCHEM J, V344, P443, DOI 10.1042/0264-6021:3440443; VISSERS MCM, 1995, BIOCHEM J, V307, P57, DOI 10.1042/bj3070057; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010; WINTERBOURN CC, 1983, BIOCHIM BIOPHYS ACTA, V763, P175, DOI 10.1016/0167-4889(83)90041-1; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Witenberg B, 1999, RADIAT RES, V152, P468, DOI 10.2307/3580142	55	60	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46835	46840		10.1074/jbc.M107664200	http://dx.doi.org/10.1074/jbc.M107664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590157	hybrid			2022-12-25	WOS:000172768500023
J	Wilhelm, M; Uzun, O; Mules, EH; Gabriel, A; Wilhelm, FX				Wilhelm, M; Uzun, O; Mules, EH; Gabriel, A; Wilhelm, FX			Polypurine tract formation by Ty1 RNase H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND DNA-SYNTHESIS; REVERSE-TRANSCRIPTASE; HUMAN-IMMUNODEFICIENCY; HYBRID DUPLEX; IMMEDIATELY UPSTREAM; CRYSTAL-STRUCTURE; 2ND ORIGIN; PRIMER; SEQUENCE; MECHANISM	To better understand the mechanism by which Ty1 RNase H creates the polypurine tract (PPT) primer, we have demonstrated the polymerase-dependent hydrolytic activity of Ty1 reverse transcriptase (RT) during minus-strand synthesis. Using RNase H and polymerase mutants of the recombinant Ty1 RT protein, we show that the two domains of Ty1 RT can act independently of one another. Our results indicate that RNA/DNA substrates containing a short RNA PPT, which serve as primers for plus-strand DNA synthesis, are relatively resistant to RNase H cleavage. RNA substrates with a correct 5 ' end but with 3 ' end extending beyond the plus-strand initiation site were cleaved specifically to generate the correct 3 ' end of the PPT. Using long RNA/DNA duplexes containing the PPT, we show that Ty1 RT is able to make specific internal cleavages that could generate the plus-strand primer with correct 5 ' and 3 ' ends. Long RNA/DNA duplexes with mutations in the PPT or in a U-rich region upstream of the PPT, which abolish plus-strand initiation in vivo, were not cleaved specifically at the 5 ' end of the PPT. Our work demonstrates that the in vitro enzyme can recapitulate key processes that control proper replication in vivo.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Rutgers State University New Brunswick	Wilhelm, FX (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, CABM 306,679 Hoes Ln, Piscataway, NJ 08854 USA.	wilhelm@ibmc.u-strasbg.fr			NIGMS NIH HHS [GM 60534] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060534] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Han GW, 1997, J MOL BIOL, V269, P811, DOI 10.1006/jmbi.1997.1085; HEYMAN T, 1995, J MOL BIOL, V253, P291, DOI 10.1006/jmbi.1995.0553; Ilyinskii PO, 1998, EMBO J, V17, P3766, DOI 10.1093/emboj/17.13.3766; KATI WM, 1992, J BIOL CHEM, V267, P25988; Noad RJ, 1998, J BIOL CHEM, V273, P32568, DOI 10.1074/jbc.273.49.32568; POCHART P, 1993, NUCLEIC ACIDS RES, V21, P3513, DOI 10.1093/nar/21.15.3513; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Robson ND, 2000, J VIROL, V74, P10293, DOI 10.1128/JVI.74.22.10293-10303.2000; Robson ND, 1999, J VIROL, V73, P948, DOI 10.1128/JVI.73.2.948-957.1999; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Schultz SJ, 2000, J BIOL CHEM, V275, P32299, DOI 10.1074/jbc.M000021200; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Stetor SR, 1999, BIOCHEMISTRY-US, V38, P3656, DOI 10.1021/bi982764l; Telesnitsky A., 1997, P121; Uzun O, 2001, J VIROL, V75, P6337, DOI 10.1128/JVI.75.14.6337-6347.2001; Wilhelm M, 1999, NUCLEIC ACIDS RES, V27, P4547, DOI 10.1093/nar/27.23.4547; Wilhelm M, 2000, BIOCHEM J, V348, P337, DOI 10.1042/0264-6021:3480337; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Xiong Y, 1998, STRUCTURE, V6, P1493, DOI 10.1016/S0969-2126(98)00148-8; Xiong Y, 2000, NUCLEIC ACIDS RES, V28, P2171, DOI 10.1093/nar/28.10.2171; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	29	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47695	47701		10.1074/jbc.M106067200	http://dx.doi.org/10.1074/jbc.M106067200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595735	hybrid			2022-12-25	WOS:000172768500133
J	Kawai, H; Nie, LH; Wiederschain, D; Yuan, ZM				Kawai, H; Nie, LH; Wiederschain, D; Yuan, ZM			Dual role of p300 in the regulation of p53 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; DEGRADATION; MDM2; PHOSPHORYLATION; ACETYLATION; BINDING	While the function of p300 as a transcriptional coactivator of p53 is well documented, its role in the regulation of p53 stability remains ill-defined since opposite effects of p300 on p53 levels have been reported. We show here that p300 stabilizes both p53 and its negative regulator MDM2, thereby enhancing the p53/MDM2 negative regulatory loop. Binding of p300 is associated with the retention of p53 in the nucleus, which results in the accumulation of p53 in an acetylase-independent manner. Stabilization of MDM2, on the other hand, requires the acetylase activity of p300. Importantly, MDM2, once expressed, is able to reverse the stabilizing effect of p300 on p53. A temperature-permissive p53-expressing cell line enabled us to demonstrate the completely opposite roles of p300 in the regulation of p53 stability, depending on the expression of MDM2. Prior to p53 activation, when MDM2 levels are low, p300 acts as a positive regulator to increase p53 levels. Upon shifting to permissive temperature, however, when MDM2 expression is induced, p300 becomes a negative regulator of p53 by stabilizing MDM2 and thereby augmenting MDM2's ability to target p53 for degradation.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Program Biol Sci Publ Hlth, Grad Sch Arts & Sci, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Bldg 1,Rm 209,665 Huntington Ave, Boston, MA 02115 USA.			Kawai, Hidehiko/0000-0003-2213-7166				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	15	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45928	45932		10.1074/jbc.M107770200	http://dx.doi.org/10.1074/jbc.M107770200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591713	hybrid			2022-12-25	WOS:000172573100060
J	Dick, GM; Sanders, KM				Dick, GM; Sanders, KM			(Xeno)estrogen sensitivity of smooth muscle BK channels conferred by the regulatory beta 1 subunit - A study of beta 1 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; CA2+-ACTIVATED K+ CHANNEL; DEPENDENT PROTEIN-KINASE; RAT CEREBRAL-ARTERIES; HIGH-CONDUCTANCE; CA CHANNELS; CALCIUM; TAMOXIFEN; CELLS; INHIBITION	Estrogen and xenoestrogens (i.e. agents that are not steroids but possess estrogenic activity) increase the open probability (P-o) of large conductance Ca2+-activated K+ (BK) channels in smooth muscle. The mechanism of action may involve the regulatory beta1 subunit. We used beta1 subunit knockout (beta1(-/-)) mice to test the hypothesis that the regulatory beta1 subunit is essential for the activation of BK channels by tamoxifen, 4-OH tamoxifen (a major biologically active metabolite), and 17 beta -estradiol in native myocytes. Patch clamp recordings demonstrate BK channels from beta1(-/-) mice were similar to wild type with the exception of markedly reduced Ca2+/voltage sensitivity and faster activation kinetics. In wild type myocytes, (xeno)estrogens increased NPo (P-o x the number of channels, N), shifted the voltage of half-activation (V-1/2) to more negative potentials, and decreased unitary conductance. These effects were non-genomic and direct, because they were rapid, reversible, and observed in cell-free patches. None of the (xeno)estrogens increased the NP. of BK channels from beta1(-/-) mice, but all three agents decreased single channel conductance. Thus, (xeno)estrogens increase BK NP. through a mechanism involving the beta1 subunit. The decrease in conductance did not require the beta1 subunit and probably reflects an interaction with the pore-forming a subunit. We demonstrate regulation of smooth muscle BK channels by physiological (steroid hormones) and pharmacological (chemotherapeutic) agents and reveal the critical role of the beta1 subunit in these responses in native myocytes.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Dick, GM (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Anderson Med Bldg 352, Reno, NV 89557 USA.	greg@physio.unr.edu	Dick, Gregory/G-3032-2010	Dick, Gregory/0000-0003-1444-6436	NIDDK NIH HHS [F32 DK09947, DK41315] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009947, P01DK041315] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen MC, 1998, EUR J PHARMACOL, V354, P261, DOI 10.1016/S0014-2999(98)00454-3; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BORGNA JL, 1981, J BIOL CHEM, V256, P859; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Dick GM, 1999, BRIT J PHARMACOL, V127, P1819, DOI 10.1038/sj.bjp.0702730; Dick GM, 2001, J BIOL CHEM, V276, P34594, DOI 10.1074/jbc.M104689200; Doughty JM, 1998, J PHYSIOL-LONDON, V507, P433, DOI 10.1111/j.1469-7793.1998.433bt.x; Fettiplace R, 1999, ANNU REV PHYSIOL, V61, P809, DOI 10.1146/annurev.physiol.61.1.809; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; Hardy SP, 1998, FEBS LETT, V434, P236, DOI 10.1016/S0014-5793(98)00974-0; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; Koh SD, 1997, AM J PHYSIOL-CELL PH, V273, pC2010, DOI 10.1152/ajpcell.1997.273.6.C2010; Kostrzewska A, 1997, AM J OBSTET GYNECOL, V176, P381, DOI 10.1016/S0002-9378(97)70503-9; LATORRE R, 1982, P NATL ACAD SCI-BIOL, V79, P805, DOI 10.1073/pnas.79.3.805; LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842; MARSHALL K, 1987, BRIT J PHARMACOL, V92, P429, DOI 10.1111/j.1476-5381.1987.tb11339.x; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Nelson MT, 1997, J PHYSIOL-LONDON, V502, P259, DOI 10.1111/j.1469-7793.1997.259bk.x; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Silberberg SD, 1996, BIOPHYS J, V70, P2640, DOI 10.1016/S0006-3495(96)79833-8; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Welsh DG, 2000, J PHYSIOL-LONDON, V527, P139, DOI 10.1111/j.1469-7793.2000.t01-1-00139.x; White RE, 2000, CIRC RES, V86, P897, DOI 10.1161/01.RES.86.8.897	41	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44835	44840		10.1074/jbc.M106851200	http://dx.doi.org/10.1074/jbc.M106851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11590153	hybrid			2022-12-25	WOS:000172406700068
J	Lu, RQ; Pitha, PM				Lu, RQ; Pitha, PM			Monocyte differentiation to macrophage requires interferon regulatory factor 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; POSITIVE FEEDBACK; VIRUS-INFECTION; ALPHA GENES; CELLS; IRF-7; PROLIFERATION; ACTIVATION; EXPRESSION; INDUCTION	Interferon regulatory factors are a growing family of transcription factor that have been implicated in cellular events such as cell-growth regulation, antiviral defense, and development of the immune system. Interferon regulatory factor 7 (IRF-7) is expressed predominantly in lymphoid tissues and has been studied extensively in the context of viral infection and the induction of interferon and cytokine gene expression. In this paper, the involvement of IRF-7 in monocyte differentiation was examined in U937, HL60, and human primary macrophages. We report the induction of IRF-7 expression by 12-O-tetradecanoylphorbol-13-acetate in U937 and HL60 cells and demonstrate that this induction is essential for the monocyte differentiation to macrophages. We show that the monocyte differentiation is inhibited in cells expressing a dominant negative IRF-7 mutant, as evidenced by decreased expression of two macrophage-differentiation markers, CD11b and CD11c, and impaired phagocytic activity. In addition, we demonstrate that overexpression of IRF-7 is sufficient to trigger monocyte differentiation and to induce cell cycle arrest. The identification of IRF-7 as a key regulator in monocyte differentiation suggests a novel function of IRF-7 in innate immunity.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737, R21AI048081, R21AI019737] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19737-18, AI 48081] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Fantuzzi L, 2000, J LEUKOCYTE BIOL, V68, P391; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lohoff M, 2000, J EXP MED, V192, P325, DOI 10.1084/jem.192.3.325; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Manzella L, 1999, EUR J IMMUNOL, V29, P3009, DOI 10.1002/(SICI)1521-4141(199909)29:09<3009::AID-IMMU3009>3.0.CO;2-H; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2001, J VIROL, V75, P341, DOI 10.1128/JVI.75.1.341-350.2001; Zhang LW, 2000, J VIROL, V74, P1061, DOI 10.1128/JVI.74.3.1061-1068.2000	31	69	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45491	45496		10.1074/jbc.C100421200	http://dx.doi.org/10.1074/jbc.C100421200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11585813	hybrid			2022-12-25	WOS:000172406700148
J	Wilson, GM; Sutphen, K; Bolikal, S; Chuang, KY; Brewer, G				Wilson, GM; Sutphen, K; Bolikal, S; Chuang, KY; Brewer, G			Thermodynamics and kinetics of Hsp70 association with A+U-rich mRNA-destabilizing sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; MOLECULAR CHAPERONE DNAK; HEAT-SHOCK RESPONSE; PROTEIN INTERACTIONS; BINDING ACTIVITY; MAMMALIAN-CELLS; ELEMENT; AUF1; DEGRADATION; RECOGNITION	Rapid mRNA degradation directed by A + U-rich elements (AREs) is mediated by the interaction of specific RNA-binding proteins to these sequences. The protein chaperone Hsp70 has been identified in a cellular complex containing the ARE-binding protein AUF1 and has also been detected in direct contact with A + U-rich RNA substrates, indicating that Hsp70 may be involved in the regulation of ARE-directed mRNA turnover. By using gel mobility shift and fluorescence anisotropy assays, we have determined that Hsp70 directly and specifically associates with U-rich RNA substrates in solution. With the ARE from tumor necrosis factor alpha (TNF alpha) mRNA, Hsp70 forms a dynamic complex consistent with a 1:1 association of protein:RNA but demonstrates cooperative binding behavior on polyuridylate substrates. Unlike AUF1, the RNA binding activity of Hsp70 is not regulated by ion-dependent folding of the TNF alpha ARE, suggesting that AUF1 and Hsp70 recognize distinct binding determinants on this RNA substrate. Binding of Hsp70 to the TNF alpha ARE is driven entirely by enthalpy at physiological temperatures, indicating that burial of hydrophobic surfaces is likely the principal mechanism stabilizing the Hsp70-RNA complex. Potential roles for the interaction of Hsp70 with ARE-containing mRNAs in the regulation of mRNA turnover and/or translational efficiency are discussed.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wilson, GM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA.	wilsongm@umdnj.edu; brewerga@umdnj.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; BEAUDETTE NV, 1980, CRC CR REV BIOCH MOL, V9, P145, DOI 10.3109/10409238009105433; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Brewer G, 1999, J BIOL CHEM, V274, P16174, DOI 10.1074/jbc.274.23.16174; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Carter DA, 1997, FEBS LETT, V416, P81, DOI 10.1016/S0014-5793(97)01174-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Hall KB, 1995, METHOD ENZYMOL, V259, P261; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kasper P, 2000, PROTEINS, V40, P185, DOI 10.1002/(SICI)1097-0134(20000801)40:2<185::AID-PROT20>3.0.CO;2-X; Katsamba PS, 2001, J BIOL CHEM, V276, P21476, DOI 10.1074/jbc.M101624200; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mamelak D, 2001, J BIOL CHEM, V276, P449, DOI 10.1074/jbc.M006732200; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; RAYMOND V, 1989, ONCOGENE RES, V5, P1; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Smykal P, 2000, EUR J BIOCHEM, V267, P2195, DOI 10.1046/j.1432-1327.2000.01223.x; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	66	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44450	44456		10.1074/jbc.M108521200	http://dx.doi.org/10.1074/jbc.M108521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581272	hybrid			2022-12-25	WOS:000172406700015
J	Hu, B; Mei, QB; Yao, XJ; Smith, E; Barry, WH; Liang, BT				Hu, B; Mei, QB; Yao, XJ; Smith, E; Barry, WH; Liang, BT			A novel contractile phenotype with cardiac transgenic expression of the human P2X(4) receptor	FASEB JOURNAL			English	Article						contractility; heart; P2X channel; purines; heart failure	ADENOSINE-TRIPHOSPHATE; MOLECULAR-CLONING; EXTRACELLULAR ATP; ISOLATED RAT; RELEASE; MECHANISM; HEART; DIFFERENTIATION; NOMENCLATURE; TRANSIENTS	The P2X(4) receptor is a newly identified receptor expressed in the heart cell. Its function was elucidated with cardiac transgenic (TG) expression of the receptor by using the myocardium-specific alpha -myosin heavy chain promoter. The presence of the transgene was determined by polymerase chain reaction by using primers specific to the receptor and the vector linker region, by Southern blotting of the genomic DNA, and by immunoblotting and immunohistochemistry of both isolated cardiac myocytes and intact hearts. In intact heart study, the P2X(4) receptor TG mouse exhibited significantly elevated basal cardiac contractility with greater rates of contraction and relaxation, left ventricular developed pressure, and cardiac output compared with nontransgenic (NTG) animals but showed no evidence of hypertrophy or heart failure. The TG heart also showed a greater increase of cardiac contractility in response to the P2X receptor agonist 2-methylthioATP, consistent with overexpression of a functional P2X(4) receptor with consequent increase in the receptor-mediated response. In isolated cardiac cell study, the TG heart cell showed a similar level of basal contraction amplitude as the NTG heart cell while exhibiting a threefold greater increase in contractility during stimulation by 2-methylthioATP. Thus, an increased responsiveness of the overexpressed P2X(4) receptor to endogenous ATP is responsible for the enhanced basal cardiac performance in the intact TG heart. The sustained enhanced contractile function with no associated heart pathology in the P2X(4) receptor TG mouse suggests a novel physiologic role of the P2X(4) receptor, that of stimulating the cardiac contractility.	Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Utah, Med Ctr, Dept Med, Salt Lake City, UT 84132 USA	University of Pennsylvania; University of Pennsylvania; Utah System of Higher Education; University of Utah	Liang, BT (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, 956 BRBII III,421 Curie Blvd, Philadelphia, PA 19104 USA.	liangb@mail.med.upenn.edu						CHRISTIE A, 1992, J PHYSIOL-LONDON, V445, P369, DOI 10.1113/jphysiol.1992.sp018929; CLEMENS MG, 1981, J PHYSIOL-LONDON, V312, P143, DOI 10.1113/jphysiol.1981.sp013621; Collo G, 1996, J NEUROSCI, V16, P2495; DANZIGER RS, 1988, CELL CALCIUM, V9, P193, DOI 10.1016/0143-4160(88)90023-1; DEYOUNG MB, 1989, AM J PHYSIOL, V257, pC750, DOI 10.1152/ajpcell.1989.257.4.C750; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; FORRESTER T, 1977, J PHYSIOL-LONDON, V268, P371, DOI 10.1113/jphysiol.1977.sp011862; FREDHOLM BB, 1982, ACTA PHYSIOL SCAND, V116, P285, DOI 10.1111/j.1748-1716.1982.tb07142.x; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; Khakh BS, 2001, PHARMACOL REV, V53, P107; Le KT, 1998, NEUROSCIENCE, V83, P177, DOI 10.1016/S0306-4522(97)00365-5; Le KT, 1998, J NEUROSCI, V18, P7152; Mei QB, 2001, AM J PHYSIOL-HEART C, V281, pH334, DOI 10.1152/ajpheart.2001.281.1.H334; Murry CE, 1996, J CLIN INVEST, V98, P2209, DOI 10.1172/JCI119030; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; PODRASKY E, 1997, AM J PHYSIOL-HEART C, V273, pH2380; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; SCAMPS F, 1990, CIRC RES, V67, P1007, DOI 10.1161/01.RES.67.4.1007; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Soto M, 1996, BIOCHEM BIOPH RES CO, V223, P456, DOI 10.1006/bbrc.1996.0915; Townsend-Nicholson A, 1999, MOL BRAIN RES, V64, P246, DOI 10.1016/S0169-328X(98)00328-3; Vassort G, 2001, PHYSIOL REV, V81, P767, DOI 10.1152/physrev.2001.81.2.767; VIAL C, 1987, J MOL CELL CARDIOL, V19, P187, DOI 10.1016/S0022-2828(87)80561-8; Yao AS, 1998, CIRC RES, V82, P657, DOI 10.1161/01.RES.82.6.657; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001	28	43	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2001	15	12					2739	+		10.1096/fj.01-0445fje	http://dx.doi.org/10.1096/fj.01-0445fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11606481				2022-12-25	WOS:000171920400012
J	De Rienzo, A; Balsara, BR; Apostolou, S; Jhanwar, SC; Testa, JR				De Rienzo, A; Balsara, BR; Apostolou, S; Jhanwar, SC; Testa, JR			Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma	ONCOGENE			English	Article						malignant mesothelioma; LOH; chromosome arm 15q; tumor suppressor gene	TUMOR-SUPPRESSOR GENE; COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC LOSS; DELETIONS; CANCER; CARCINOMAS; MUTATIONS; NF2; 14Q; 6Q	Previous comparative genomic hybridization and allelic loss analyses demonstrated frequent deletions from 15q11.1-15 in malignant mesothelioma. Recurrent losses of 15q11-22 have also been reported in several other tumor types such as breast and colorectal cancers. To more precisely map the commonly deleted region, we have performed a high density loss of heterozygosity analysis of 46 malignant mesotheliomas, using 26 polymorphic microsatellite markers spanning the entire long arm of chromsome 15. Allelic loss from 15q was observed in 22 of 46 (48%) cases. These analyses have defined a minimally deleted region of similar to3-cM, which was confirmed to reside at 15q15 by fluorescence in situ hybridization analysis with yeast artificial chromosome probes. No tumor suppressor genes have been reported to map to this site. The minimally deleted region identified in this investigation overlaps those observed in other kinds of cancer, and is the smallest site of recurrent 15q loss identified to date in human tumors. The identification of this commonly deleted site implicates a putative tumor suppressor gene(s) at 15q15 involved in diverse forms of human neoplasia.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA-45745, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 1996, CYTOGENET CELL GENET, V74, P248, DOI 10.1159/000134426; ANTMAN KH, 1981, SEMIN ONCOL, V8, P313; ANTMAN KH, 1989, MESOTHELIOMA; Attanoos RL, 1997, HISTOPATHOLOGY, V30, P403, DOI 10.1046/j.1365-2559.1997.5460776.x; Balsara BR, 1999, CANCER RES, V59, P450; Bell DW, 1997, CANCER RES, V57, P4057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bisconti M, 2000, RESPIRATION, V67, P223, DOI 10.1159/000029493; Bjorkqvist AM, 1997, BRIT J CANCER, V75, P523, DOI 10.1038/bjc.1997.91; Bjorkqvist AM, 1999, BRIT J CANCER, V81, P1111, DOI 10.1038/sj.bjc.6690816; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; CHENG JQ, 1994, CANCER RES, V54, P5547; Collins A, 1996, GENOMICS, V36, P157, DOI 10.1006/geno.1996.0436; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; De Rienzo A, 2000, GENE CHROMOSOME CANC, V28, P337, DOI 10.1002/1098-2264(200007)28:3<337::AID-GCC12>3.0.CO;2-B; DODSON MK, 1993, CANCER RES, V53, P4456; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.0.CO;2-7; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; LYNCH HT, 1985, CANCER GENET CYTOGEN, V15, P25, DOI 10.1016/0165-4608(85)90128-1; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pache JC, 1998, AM J PATHOL, V152, P333; Park WS, 2000, CANCER RES, V60, P70; POPESCU NC, 1988, CANCER RES, V48, P142; Schmutte C, 1999, CANCER RES, V59, P4564; SEEMAYER TA, 1989, LAB INVEST, V60, P585; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tahara H, 1996, CANCER RES, V56, P599; Testa JR, 1998, CANCER RES, V58, P4505; Tomlinson I, 1999, GASTROENTEROLOGY, V116, P789, DOI 10.1016/S0016-5085(99)70061-2; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wick W, 1996, ONCOGENE, V12, P973	37	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6245	6249		10.1038/sj.onc.1204828	http://dx.doi.org/10.1038/sj.onc.1204828			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593434				2022-12-25	WOS:000171206300017
J	Kihara-Negishi, F; Yamamoto, H; Suzuki, M; Yamada, T; Sakurai, T; Tamura, T; Oikawa, T				Kihara-Negishi, F; Yamamoto, H; Suzuki, M; Yamada, T; Sakurai, T; Tamura, T; Oikawa, T			In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression	ONCOGENE			English	Article						PU.1; HDAC1; transcriptional repression	HISTONE DEACETYLASES; ACTIVATION DOMAIN; ETS FAMILY; BINDING PROTEIN; THYROID-HORMONE; EXPRESSION; RECEPTOR; P300; P53; DIFFERENTIATION	We previously reported that overexpression of PU.1, a member of the Ets family of transcription factors, induces differentiation inhibition and apoptosis associated with c-Myc down-regulation in murine erythroleukemia (MEL) cells. To understand the molecular mechanism by which c-Myc is down-regulated due to overexpression of PU.1, we performed luciferase reporter assays using the mouse c-myc promoter. PU.1 repressed the activities of not only the c-myc promoter but also several other promoters. Experiments with deletion mutants of PU.1 revealed that the C-terminal region spanning amino acids (aa) 123-272 including the PEST and ETS domains but not the activation domain was sufficient for this transcriptional repression. It was unlikely that the repression was due to sequestration of a limited amount of CBP/p300 nor pCAF, because overexpression of these co-activators did not relieve PU.1-mediated transcriptional repression. Instead, it was found that the C-terminal aa 101-272 of PU.1 formed a complex with mSin3A and HDAC1 in vivo, which was speculated to be associated with the repression. The C-terminal region of PU.1 also formed a complex with the basic transcription factor TBP in vitro and in vivo. Our results suggest that overexpression of PU.1 induces transcriptional repression in several gene promoters including the c-myc promoter which may be mediated by its complex formation with HDACs.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan	Chiba University	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawa@sasaki.or.jp						Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSS IL, 1994, ONCOGENE, V9, P121; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	48	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6039	6047		10.1038/sj.onc.1204756	http://dx.doi.org/10.1038/sj.onc.1204756			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593411				2022-12-25	WOS:000171056300011
J	Bourguignon, LYW; Zhu, HB; Zhou, B; Diedrich, F; Singleton, PA; Hung, MC				Bourguignon, LYW; Zhu, HB; Zhou, B; Diedrich, F; Singleton, PA; Hung, MC			Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN; VAV PROTOONCOGENE PRODUCT; ANKYRIN-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; MEMBRANE-CYTOSKELETON; DEPENDENT ACTIVATION; CD44 INTERACTION; ADAPTER PROTEIN; HUMAN-BREAST	In this study we initially examined the interaction between CD44v3 (a hyaluronan (HA) receptor) and Vav2 (a guanine nucleotide exchange factor) in human ovarian tumor cells (SK-OV-3.ipl cell line). Immunological data indicate that both CD44v3 and Vav2 are expressed in SK-OV-3.ipl cells and that these two proteins are physically linked as a complex in vivo. By using recombinant fragments of Vav2 and in vitro binding assays, we have detected a specific binding interaction between the SH3-SH2-SH3 domain of Vav2 and the cytoplasmic domain of CD44. In addition, we have observed that the binding of HA to CD44v3 activates Vav2-mediated Rac1 signaling leading to ovarian tumor cell migration. Further analyses indicate that the adaptor molecule, growth factor receptor-bound protein 2 (Grb2) that is bound to p185(HER2) (an oncogene product), is also associated with the CD44v3-Vav2 complex. HA binding to SK-OV-3.ipl cells promotes recruitment of both Grb2 and p185(HER2) to the CD44v3-Vav2 complex leading to Ras activation and ovarian tumor cell growth. In order to determine the role of Grb2 in CD44v3 signaling, we have transfected SK-OV-3.ipl cells with Grb2 mutant cDNAs (e.g. DeltaN-Grb2 that has a deletion in the amino-terminal SH3 domain or DeltaC-Grb2 that has a deletion in the carboxyl-terminal SH3 domain). Our results clearly indicate that the SH3 domain deletion mutants of Grb2 (i.e. the DeltaN-Grb2 (and to a lesser extent the DeltaC-Grb2 mutant) not only block their association with p185(HER2) but also significantly impair their binding to the CD44v3-Vav2 complex and inhibit HA/CD44v3-induced ovarian tumor cell behaviors. Taken together, these findings strongly suggest that the interaction of CD44v3-Vav2 with Grb2-p185(HER2) plays an important role in the co-activation of both Rac1 and Ras signaling that is required for HA-mediated human ovarian tumor progression.	Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; University of Texas System; UTMD Anderson Cancer Center	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA66163, CA 78633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078633, R01CA066163] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; ADAMS JM, 1992, ONCOGENE, V7, P611; Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BERCHUCK A, 1990, CANCER RES, V50, P4087; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANNISTRA SA, 1995, CLIN CANCER RES, V1, P333; CANNISTRA SA, 1993, CANCER RES, V53, P3830; Cantrell D, 1998, TRENDS CELL BIOL, V8, P180, DOI 10.1016/S0962-8924(98)01264-1; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; GREEN SJ, 1988, EXP CELL RES, V178, P224, DOI 10.1016/0014-4827(88)90393-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIAO HX, 1995, J IMMUNOL, V155, P3938; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MERZAK A, 1994, CANCER RES, V54, P3988; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Romero F, 1996, MOL CELL BIOL, V16, P37; Romero F, 1998, J BIOL CHEM, V273, P5923, DOI 10.1074/jbc.273.10.5923; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Sastry L, 1997, INT J CANCER, V70, P208, DOI 10.1002/(SICI)1097-0215(19970117)70:2<208::AID-IJC12>3.0.CO;2-E; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; UNDERHILL C, 1992, J CELL SCI, V103, P293; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YANG SS, 1995, J BIOL CHEM, V270, P18212, DOI 10.1074/jbc.270.31.18212; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1996, ONCOGENE, V12, P2309; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	98	159	165	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48679	48692		10.1074/jbc.M106759200	http://dx.doi.org/10.1074/jbc.M106759200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11606575	hybrid			2022-12-25	WOS:000173922100011
J	Faouzi, S; Burckhardt, BE; Hanson, JC; Campe, CB; Schrum, LW; Rippe, RA; Maher, JJ				Faouzi, S; Burckhardt, BE; Hanson, JC; Campe, CB; Schrum, LW; Rippe, RA; Maher, JJ			Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID-ARTHRITIS SYNOVIOCYTES; APOPTOTIC CELLS; CASPASE INHIBITOR; IL-8 SECRETION; CXC CHEMOKINE; LIVER-INJURY; IN-VIVO; TRANSCRIPTION; ACTIVATION; EXPRESSION	Agonistic antibodies against the Fas receptor, when administered to mice in vivo, cause significant apoptosis in the liver. In this study we show that anti-Fas antibody not only causes apoptosis of liver cells but also provokes hepatic inflammation. Two hours after injection of anti-Fas, when mice displayed evidence of caspase-3 activation and apoptosis, we found significant hepatic induction of the CXC chemokines macrophage inflammatory protein-2 and KC. Coincident with the chemokine induction was infiltration of the hepatic parenchyma by neutrophils. Neutralization experiments identified that chemokines were the cause of Fas-induced hepatic inflammation, with KC having the predominant effect. Chemokine induction in the livers of anti-Fas-treated mice was not associated with activation of NF-kappaB. Instead, it coincided with nuclear translocation of activator protein-1 (AP-1). AP-1 activation in liver was detected 1-2 h after anti-Fas treatment, suggesting a connection to the onset of apoptosis. When apoptosis was prevented by pretreating mice with a caspase-3 inhibitor, AP-1 activation and hepatic chemokine production were both significantly reduced. Hepatic inflammation was also reduced by 70%. Taken together, these findings indicate that Fas ligation can induce inflammation in the liver in vivo. Inflammation does not arise from Fas-mediated signaling through NF-kappaB; rather, it represents an indirect effect, requiring activation of caspase-3 and nuclear translocation of AP-1.	Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Univ N Carolina, Dept Med, Div Digest Dis & Nutr, Chapel Hill, NC 27599 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill	Maher, JJ (corresponding author), San Francisco Gen Hosp, Liver Ctr Lab, Bldg 40,Rm 4102,1001 Potrero Ave, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007810, R01AA010459, R29AA010459] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10459, AA07810, AA00215] Funding Source: Medline; NIDDK NIH HHS [DK34987, DK26743, P30 DK026743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Dallegri F, 1997, INFLAMM RES, V46, P382, DOI 10.1007/s000110050208; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Faouzi S, 1999, LAB INVEST, V79, P485; Giles KM, 2000, BRIT J HAEMATOL, V109, P1, DOI 10.1046/j.1365-2141.2000.01805.x; Hagimoto N, 1999, AM J RESP CELL MOL, V21, P436, DOI 10.1165/ajrcmb.21.3.3397; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; HUANG SL, 1992, BIOCHEM BIOPH RES CO, V184, P922, DOI 10.1016/0006-291X(92)90679-F; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Keane MP, 1999, J IMMUNOL, V162, P5511; Kuwano K, 2001, AM J PHYSIOL-LUNG C, V280, pL316, DOI 10.1152/ajplung.2001.280.2.L316; Lawson JA, 1998, HEPATOLOGY, V28, P761, DOI 10.1002/hep.510280324; LEE J, 1995, J IMMUNOL, V155, P2158; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Lentsch AB, 1998, HEPATOLOGY, V27, P1172; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; Moore TA, 2000, J IMMUNOL, V164, P908, DOI 10.4049/jimmunol.164.2.908; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OHMORI Y, 1995, J IMMUNOL, V155, P3593; Okamoto K, 1997, ARTHRITIS RHEUM, V40, P919, DOI 10.1002/art.1780400521; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; Saas P, 1999, J IMMUNOL, V162, P2326; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Sekine C, 1996, BIOCHEM BIOPH RES CO, V228, P14, DOI 10.1006/bbrc.1996.1610; Uchimura E, 2000, J LEUKOCYTE BIOL, V67, P780, DOI 10.1002/jlb.67.6.780; Uchimura E, 1997, BIOCHEM BIOPH RES CO, V239, P799, DOI 10.1006/bbrc.1997.7556; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WIDMER U, 1993, J IMMUNOL, V150, P4996; Wollert KC, 2000, CIRCULATION, V101, P1172, DOI 10.1161/01.CIR.101.10.1172; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yoshidome H, 1999, J SURG RES, V81, P33, DOI 10.1006/jsre.1998.5490	48	170	179	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49077	49082		10.1074/jbc.M109791200	http://dx.doi.org/10.1074/jbc.M109791200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11602613	hybrid, Green Published			2022-12-25	WOS:000173922100061
J	Barany, M; Barron, JT; Gu, LP; Barany, K				Barany, M; Barron, JT; Gu, LP; Barany, K			Exchange of the actin-bound nucleotide in intact arterial smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN PHOSPHORYLATION; FORCE DEVELOPMENT; F-ACTIN; POLYMERIZATION; DYNAMICS; MYOSIN; THYMOSIN-BETA-4; CONTRACTION; CELLS; PI	The actin-bound ADP was separated from cytoplasmic nucleotides by treatment of intact arterial smooth muscle with 50% ethanol. In P-32-labeled smooth muscle the actin-bound ADP and phosphate readily exchanged with the cytoplasmic [gamma,beta-P-32]ATP; the specific radioactivity of actin-bound ADP was equal to that of the beta -phosphate of cytoplasmic ATP and the specific radioactivity of actin-bound phosphate was equal to that of the gamma -phosphate of cytoplasmic ATP. In contrast, the exchange of the actin-bound ADP in skeletal muscle was very slow. The presence of cytoplasmic ATP was required for the exchange of the actin-bound ADP and phosphate; if ATP synthesis was inhibited the exchange was also inhibited. The extent of exchange was reduced in muscles contracted by histamine or K+, as compared with resting muscles. The exchange was also shown in other mammalian smooth muscles, uterus, urinary bladder, and stomach. The data indicate a dynamic state of actin in smooth muscle. The data also suggest that polymerization-depolymerization of actin is part of the contraction-relaxation cycle of smooth muscle.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Rush Med Coll, Cardiol Sect, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University	Barany, M (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA.							Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BARANY K, 1985, J BIOL CHEM, V260, P7126; BARANY M, 1959, BIOCHIM BIOPHYS ACTA, V35, P293, DOI 10.1016/0006-3002(59)90378-6; BARANY M, 1993, BIOCHIM BIOPHYS ACTA, V1179, P229, DOI 10.1016/0167-4889(93)90146-G; BARRON JT, 1989, BIOCHIM BIOPHYS ACTA, V1010, P278, DOI 10.1016/0167-4889(89)90174-2; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; COHN WE, 1957, METHOD ENZYMOL, V3, P724, DOI 10.1016/S0076-6879(57)03450-3; Conley CA, 2001, AM J PHYSIOL-CELL PH, V280, pC1645, DOI 10.1152/ajpcell.2001.280.6.C1645; DILLON PF, 1996, BIOCH SMOOTH MUSCLE, P393; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HAYASHI T, 1960, FED PROC, V19, P256; Jones KA, 1999, J PHYSIOL-LONDON, V519, P527, DOI 10.1111/j.1469-7793.1999.0527m.x; KOPP SJ, 1990, BIOCHIM BIOPHYS ACTA, V1055, P27, DOI 10.1016/0167-4889(90)90087-T; KOPP SJ, 1979, J BIOL CHEM, V254, P2007; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; LILIENTHAL JL, 1950, J BIOL CHEM, V182, P501; MARTONOSI A, 1960, J BIOL CHEM, V235, P1700; MARTONOSI A, 1960, J BIOL CHEM, V235, P1707; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; MOMMAERTS WFHM, 1951, J BIOL CHEM, V188, P559; Morgan KG, 2001, AM J PHYSIOL-CELL PH, V280, pC1634, DOI 10.1152/ajpcell.2001.280.6.C1634; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; PULLMAN ME, 1967, METHOD ENZYMOL, V10, P57; ROCKSTEIN M, 1951, ANAL CHEM, V23, P1500, DOI 10.1021/ac60058a044; STRAUB FB, 1950, BIOCHIM BIOPHYS ACTA, V4, P455, DOI 10.1016/0006-3002(50)90052-7; Straub FB., 1943, STUDIES I MED CHEM U, VIII, P23; Straub FB, 1942, STUD I MED CHEM U SZ, V2, P3; STROHMAN RC, 1962, J BIOL CHEM, V237, P363; SZENTGYORGYI AG, 1951, J BIOL CHEM, V192, P361; VERHOEVEN AJM, 1988, ANAL BIOCHEM, V174, P672, DOI 10.1016/0003-2697(88)90072-3; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375	35	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48398	48403		10.1074/jbc.M106227200	http://dx.doi.org/10.1074/jbc.M106227200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602582	hybrid			2022-12-25	WOS:000172927000090
J	Keates, S; Sougioultzis, S; Keates, AC; Zhao, DZ; Peek, RM; Shaw, LM; Kelly, CP				Keates, S; Sougioultzis, S; Keates, AC; Zhao, DZ; Peek, RM; Shaw, LM; Kelly, CP			cag plus Helicobacter pylori induce transactivation of the epidermal growth factor receptor in AGS gastric epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PATHOGENICITY ISLAND; EGF RECEPTOR; COUPLED RECEPTORS; VIRULENCE FACTORS; COS-7 CELLS; EXPRESSION; PHOSPHORYLATION; TRANSLOCATION	The gastric pathogen Helicobacter pylori is known to activate epithelial cell signaling pathways that regulate numerous inflammatory response genes. The aim of this study was to elucidate the pathway leading to extracellular signal-regulated kinase (ERK) 1/2 phosphorylation in H. pylori-infected AGS gastric epithelial cells. We find that H. pylori, via activation of the epidermal growth factor (EGF) receptor activates the small GTP-binding protein Ras, which in turn, mediates ERK1/2 phosphorylation. cag+ strains of H. pylori are able to induce greater EGF receptor activation than cag- strains, and studies with isogenic mutants indicate that an intact type IV bacterial secretion system is required for this effect. Blockade of EGF receptor activation using tyrphostin AG1478 prevents H. pylori-mediated Ras activation, inhibits ERK1/2 phosphorylation, and substantially decreases interleukin-8 gene expression and protein production. Investigations into the mechanism of EGF receptor activation, using heparin, a metalloproteinase inhibitor and neutralizing antibodies reveal that H. pylori transactivates the EGF receptor via activation of the endogenous ligand heparin-binding EGF-like growth factor. Transactivation of gastric epithelial cell EGF receptors may be instrumental in regulating both proliferative and inflammatory responses induced by cag+ H. pylori infection.	Harvard Univ, Div Gastroenterol, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Dept Pathol, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Vanderbilt Univ, Med Ctr, Div Gastroenterol, Nashville, TN 37232 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Vanderbilt University	Keates, S (corresponding author), Harvard Univ, Div Gastroenterol, Sch Med, Beth Israel Deaconess Med Ctr, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R29CA077955, R21CA081325, R01CA077955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, R01DK054920, R01DK058858] Funding Source: NIH RePORTER; NCI NIH HHS [CA77955, CA81325] Funding Source: Medline; NIDDK NIH HHS [DK54920, DK58858, DK58587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adomeit A, 1999, MOL CELL BIOL, V19, P5289; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Bliss CM, 1998, INFECT IMMUN, V66, P5357, DOI 10.1128/IAI.66.11.5357-5363.1998; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COFFER PJ, 1995, ONCOGENE, V11, P561; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; Huang JQ, 1998, GASTROENTEROLOGY, V114, P1169, DOI 10.1016/S0016-5085(98)70422-6; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Keates S, 1999, J IMMUNOL, V163, P5552; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59; Linevsky JK, 1997, AM J PHYSIOL-GASTR L, V273, pG1333, DOI 10.1152/ajpgi.1997.273.6.G1333; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Pai R, 1998, AM J PATHOL, V152, P1617; Peek RM, 1995, LAB INVEST, V73, P760; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Romano M, 1998, J CLIN INVEST, V101, P1604, DOI 10.1172/JCI1174; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Sharma SA, 1998, J IMMUNOL, V160, P2401; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z	33	177	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48127	48134		10.1074/jbc.M107630200	http://dx.doi.org/10.1074/jbc.M107630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604402	hybrid			2022-12-25	WOS:000172927000053
J	Sakamoto, JJ; Sasaki, M; Tsuchido, T				Sakamoto, JJ; Sasaki, M; Tsuchido, T			Purification and characterization of a Bacillus subtilis 168 nuclease, YokF, involved in chromosomal DNA degradation and cell death caused by thermal shock treatments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOCOCCUS-LACTIS; SIGNAL PEPTIDASE; SECRETION; ENDONUCLEASE; EXPRESSION; SEQUENCE; GENES; LIPOPROTEIN; APOPTOSIS	We purified and characterized a 39-kDa Bacillus subtilis 168 nuclease that has been suggested in this laboratory to be involved in chromosomal DNA degradation induced by lethal heat and cold shock treatments in vivo. The nuclease activity was inhibited in vitro by aurintricalboxylic acid but not by Zn2+. By the mutant analysis, we identified the 39-kDa nuclease as a product of yokF gene. The yokF gene contained a putative lipoprotein signal peptide motif. After in vivo exposure to lethal heat and cold stresses, the chromosomal DNA fragmentation was reduced in the yokF mutant, which demonstrated about a 2-10-fold higher survival rate than the wild type. The yokF mutant was found to be more sensitive to mitomycin C than the wild type. The transformation efficiency of the yokF mutant was about 10 times higher than that of the wild type. It is suggested that when B. subtilis cells are exposed to a stressful thermal shock resulting in membrane perturbation, YokF nuclease consequently dislocates into the cytoplasm and then attacks DNA.	Kansai Univ, Dept Biotechnol, Fac Engn, Suita, Osaka 5648680, Japan; Kansai Univ, High Technol Res Ctr, Suita, Osaka 5648680, Japan	Kansai University; Kansai University	Tsuchido, T (corresponding author), Kansai Univ, Dept Biotechnol, Fac Engn, Yamate Cho, Suita, Osaka 5648680, Japan.			Mori, Miho/0000-0002-9651-9856				AHRENHOLTZ I, 1994, APPL ENVIRON MICROB, V60, P3746, DOI 10.1128/AEM.60.10.3746-3751.1994; Bendjennat M, 1997, J BACTERIOL, V179, P2210, DOI 10.1128/jb.179.7.2210-2220.1997; BRIDGES BA, 1969, J GEN MICROBIOL, V58, P115, DOI 10.1099/00221287-58-1-115; COUGHLIN SA, 1983, ANAL BIOCHEM, V133, P322, DOI 10.1016/0003-2697(83)90091-X; CRINE P, 1976, ANAL BIOCHEM, V75, P583, DOI 10.1016/0003-2697(76)90113-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ghim S Y, 1998, DNA Res, V5, P195, DOI 10.1093/dnares/5.3.195; GROEZ N, 1977, BIOCHEM BIOPH RES CO, V77, P1183; Handa N, 2000, J BACTERIOL, V182, P2218, DOI 10.1128/JB.182.8.2218-2229.2000; Hegarty CP, 1940, J BACTERIOL, V39, P475, DOI 10.1128/JB.39.5.475-484.1940; ISHIZAWA M, 1991, NUCLEIC ACIDS RES, V19, P5792, DOI 10.1093/nar/19.20.5792; Jarvill-Taylor KJ, 1999, J BACTERIOL, V181, P1853, DOI 10.1128/JB.181.6.1853-1860.1999; JEKEL M, 1995, GENE, V154, P55, DOI 10.1016/0378-1119(94)00835-G; KADOTA H, 1978, SPORES, V7, P27; KERR IM, 1965, BIOCHEM BIOPH RES CO, V20, P154, DOI 10.1016/0006-291X(65)90339-6; Kleanthous C, 1998, MOL MICROBIOL, V28, P227, DOI 10.1046/j.1365-2958.1998.00811.x; KOOISTRA J, 1991, J BACTERIOL, V173, P3644, DOI 10.1128/JB.173.12.3644-3655.1991; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lazarevic V, 1999, MICROBIOL-UK, V145, P1055, DOI 10.1099/13500872-145-5-1055; Le Loir Y, 1998, J BACTERIOL, V180, P1895, DOI 10.1128/JB.180.7.1895-1903.1998; Leskela S, 1999, MOL MICROBIOL, V31, P1075, DOI 10.1046/j.1365-2958.1999.01247.x; LIN J-J, 1992, Proceedings of the National Science Council Republic of China Part B Life Sciences, V16, P1; MCGRATH RA, 1966, NATURE, V212, P534, DOI 10.1038/212534a0; MERCHANTE R, 1995, J BACTERIOL, V177, P6176, DOI 10.1128/jb.177.21.6176-6183.1995; MILLER JR, 1987, J BACTERIOL, V169, P3508, DOI 10.1128/jb.169.8.3508-3514.1987; Poquet I, 1998, J BACTERIOL, V180, P1904, DOI 10.1128/JB.180.7.1904-1912.1998; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SAMBROOKS J, 1992, MOL CLONING LAB MANU; SATO M, 1968, J GEN APPL MICROBIOL, V14, P417, DOI 10.2323/jgam.14.417; SATO M, 1970, J GEN APPL MICROBIOL, V16, P279, DOI 10.2323/jgam.16.4_279; SCHER B, 1976, J BACTERIOL, V126, P429, DOI 10.1128/JB.126.1.429-438.1976; SCHER B, 1973, BIOCHEM BIOPH RES CO, V553, P595; SHEMYAKIN MF, 1979, EUR J BIOCHEM, V98, P417, DOI 10.1111/j.1432-1033.1979.tb13201.x; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; SUTER W, 1982, MUTAT RES, V97, P1, DOI 10.1016/0165-1161(82)90015-2; SVARACHORN A, 1991, J FERMENT BIOENG, V71, P281, DOI 10.1016/0922-338X(91)90283-M; TAKANO M, 1982, J FERMENT TECHNOL, V82, P189; TAYLOR RG, 1993, NUCLEIC ACIDS RES, V21, P1677, DOI 10.1093/nar/21.7.1677; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1999, J BIOL CHEM, V274, P28191, DOI 10.1074/jbc.274.40.28191; Tsuchido T., 1996, BIOCONTROL SCI, V1, P19, DOI [10.4265/bio.1.19, DOI 10.4265/BIO.1.19]; VANSINDEREN D, 1995, MOL MICROBIOL, V15, P213; VOSMAN B, 1988, J BACTERIOL, V170, P3703, DOI 10.1128/jb.170.8.3703-3710.1988; WOODCOCK E, 1972, NATURE-NEW BIOL, V237, P76, DOI 10.1038/newbio237076a0; Yamanaka K, 1997, FEMS MICROBIOL LETT, V150, P269, DOI 10.1111/j.1574-6968.1997.tb10380.x	46	16	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47046	47051		10.1074/jbc.M106205200	http://dx.doi.org/10.1074/jbc.M106205200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584000	hybrid			2022-12-25	WOS:000172768500051
J	Seekoe, T; Peall, S; McIntosh, DB				Seekoe, T; Peall, S; McIntosh, DB			Thapsigargin and dimethyl sulfoxide activate medium P-i <-> HOH oxygen exchange catalyzed by sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ TRANSPORT ATPASE; CALCIUM ADENOSINE-TRIPHOSPHATASE; S3 STALK SEGMENT; INORGANIC-PHOSPHATE; OCCLUDED STATE; TIGHT-BINDING; RAPID RELEASE; PHOSPHORYLATION; INHIBITION; CA-2+-ATPASE	Thapsigargin is a potent inhibitor of sarcoplasmic reticulum. Ca2+-ATPase. It binds the Ca2+-free E2 conformation in the picomolar range, supposedly resulting in a largely catalytically inactive species. We now find that thapsigargin has little effect on medium P-i <----> HOH oxygen exchange and that this activity is greatly stimulated (up to 30-fold) in the presence of 30% (v/v) Me2SO. Assuming a simple two-step mechanism, we have evaluated the effect of thapsigargin and Me,SO on the four rate constants governing the reaction of Pi with Ca2+-ATPase. The principal effect of thapsigargin alone is to stimulate EP hydrolysis (k(-2)), whereas that of Me2SO is to greatly retard P-i. dissociation (k(-1)), accounting for its well known effect on increasing the apparent affinity for Pi. These effects persist when the agents are used in combination and substantially account for the activated oxygen exchange (upsilon (exchange) = k(-2)[EP]). Kinetic simulations show that the over;YI rate constant for the formation of EP is very fast (similar to 300 s(-1)) when the exchange is maximal. Thapsigargin greatly stabilizes Ca (2+)-ATPase against denaturation in detergent in the absence of Ca2+, as revealed by glutaraldehyde cross-linking, suggesting that the membrane helices lock together. It seems that the reactions at the phosphorylation site, associated with the activated exchange reaction, are occurring without much movement of the transport site helices, and we suggest that they may be associated solely with an occluded H+ state.	Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa; Dept Hlth, Forens Chem Labs, ZA-7915 Cape Town, South Africa	University of Cape Town	McIntosh, DB (corresponding author), Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa.	davidmci@chempath.uct.ac.za						ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ARIKI M, 1980, BIOCHEMISTRY-US, V19, P2001, DOI 10.1021/bi00550a042; CARVALHOALVES PC, 1987, J BIOL CHEM, V262, P6610; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Cornelius F, 1998, BIOCHEMISTRY-US, V37, P16686, DOI 10.1021/bi981571v; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DANKO S, 2001, FEBS LETT, V2456, P1; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; DAVIDSON GA, 1996, BIOCHIM BIOPHYS ACTA, V1286, P187; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; DEMEIS L, 1988, J BIOL CHEM, V263, P157; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; FORBUSH B, 1988, J BIOL CHEM, V263, P7961; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FORGE V, 1993, J BIOL CHEM, V268, P10961; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; GUILLAIN F, 1984, BIOCHEMISTRY-US, V23, P4754, DOI 10.1021/bi00315a034; Hackney D D, 1980, Methods Enzymol, V64, P60; HACKNEY DD, 1978, P NATL ACAD SCI USA, V75, P3133, DOI 10.1073/pnas.75.7.3133; HAO LN, 1994, J BIOL CHEM, V269, P14268; Hua SM, 1997, BIOCHEMISTRY-US, V36, P11865, DOI 10.1021/bi970105n; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, J BIOL CHEM, V265, P19524; LOOMIS CR, 1982, BIOCHEMISTRY-US, V21, P151, DOI 10.1021/bi00530a026; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; MARTIN DW, 1981, BIOCHEMISTRY-US, V20, P4597, DOI 10.1021/bi00519a013; MCINTOSH DB, 1988, J BIOL CHEM, V263, P12220; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MCINTOSH DB, 1985, BIOCHEMISTRY-US, V24, P1244, DOI 10.1021/bi00326a029; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MINTZ E, 1993, BIOCHIM BIOPHYS ACTA, V1162, P227, DOI 10.1016/0167-4838(93)90152-H; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; Moutin MJ, 1998, EUR J BIOCHEM, V251, P682, DOI 10.1046/j.1432-1327.1998.2510682.x; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; STEMPEL KE, 1986, METHOD ENZYMOL, V126, P618; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	64	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46737	46744		10.1074/jbc.M106320200	http://dx.doi.org/10.1074/jbc.M106320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595736	Green Published, hybrid			2022-12-25	WOS:000172768500010
J	Wickstrom, C; Carlstedt, I				Wickstrom, C; Carlstedt, I			N-terminal cleavage of the salivary MUC5B mucin - Analogy with the von Willebrand propolypeptide?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; CERVICAL-MUCUS GLYCOPROTEINS; DISULFIDE-BONDED DIMERS; GENOMIC ORGANIZATION; VONWILLEBRAND-FACTOR; HETEROLOGOUS CELLS; MOLECULAR-CLONING; IDENTIFICATION; SEQUENCE; PROTEINS	Sequence similarities between the oligomeric mucins (MUC2, MUC5AC, MUC5B) and the von Willebrand factor suggest that they may be assembled in a similar way. After oligomerization, a fragment corresponding to the D1 and D2 domains is released from the von Willebrand factor. This cleavage does not appear to occur in pig submaxillary mucin, the only mammalian mucin in which this cleavage has been examined thus far, but whether other oligomeric mucins undergo N terminus proteolysis is not known. Antibodies recognizing the D1, D2, D3, and the first Cys domains in MUC5B were established and used to investigate to what extent proteolytic cleavage occurs within the N-terminal part of salivary MUM. The antibodies against the D1 and D2 domains identified a polypeptide corresponding in size to a MUC5B fragment generated by cleavage within the D' domain analogously with the von Willebrand factor propolypeptide. The antibodies did not recognize the main mucin population, suggesting that the major part of salivary MUC5B is subjected to this cleavage. An antibody recognizing the D3 domain was used to reveal a second cleavage site in the "soluble" but not in the "insoluble" MUM fraction: the first structural difference observed between soluble and insoluble salivary MUM. The identification of these cleavage events shows that the N-terminal sites for MUM oligomerization are present in the D3 domain and/or in domains located C-terminal to this part of the molecule.	Lund Univ, BMC, Dept Cell & Mol Biol, Mucosal Biol Grp, S-22184 Lund, Sweden; Malmo Univ, Fac Odontol, S-21421 Malmo, Sweden	Lund University; Malmo University	Carlstedt, I (corresponding author), Lund Univ, BMC, Dept Cell & Mol Biol, Mucosal Biol Grp, C13, S-22184 Lund, Sweden.		Wickstrom, Claes/B-6338-2008	Wickstrom, Claes/0000-0002-8183-8846				BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; CARLSTEDT I, 1983, BIOCHEM J, V213, P427, DOI 10.1042/bj2130427; Carlstedt I, 1995, BIOCHEM SOC T, V23, P845, DOI 10.1042/bst0230845; Desseyn JL, 1998, J BIOL CHEM, V273, P30157, DOI 10.1074/jbc.273.46.30157; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; DEVINE PL, 1992, BIOTECHNIQUES, V12, P160; GUM JR, 1994, J BIOL CHEM, V269, P2440; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; HOVENBERG HW, 1996, GLYCOCONJUGATE J, V13, P1; Keates AC, 1997, BIOCHEM J, V324, P295, DOI 10.1042/bj3240295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NORDMAN H, 2000, THESIS LUND U; Perez-Vilar J, 1998, J BIOL CHEM, V273, P34527, DOI 10.1074/jbc.273.51.34527; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; SHEEHAN JK, 1987, BIOCHEM J, V245, P757, DOI 10.1042/bj2450757; Thornton DJ, 1997, J BIOL CHEM, V272, P9561; THORNTON DJ, 1989, ANAL BIOCHEM, V182, P160, DOI 10.1016/0003-2697(89)90735-5; van Klinken BJW, 1998, AM J PHYSIOL-GASTR L, V274, pG871, DOI 10.1152/ajpgi.1998.274.5.G871; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; WAGNER DD, 1987, P NATL ACAD SCI USA, V84, P1955, DOI 10.1073/pnas.84.7.1955; Wickstrom C, 2000, BIOCHEM J, V351, P421, DOI 10.1042/0264-6021:3510421; Wickstrom C, 1998, BIOCHEM J, V334, P685, DOI 10.1042/bj3340685; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; Xu GQ, 2000, EUR J BIOCHEM, V267, P2998, DOI 10.1046/j.1432-1327.2000.01319.x	28	28	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47116	47121		10.1074/jbc.M106593200	http://dx.doi.org/10.1074/jbc.M106593200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11602588	hybrid			2022-12-25	WOS:000172768500060
J	Arrate, MP; Rodriguez, JM; Tran, TM; Brock, TA; Cunningham, SA				Arrate, MP; Rodriguez, JM; Tran, TM; Brock, TA; Cunningham, SA			Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; IMMUNOGLOBULIN SUPERFAMILY; SEGMENTAL DIFFERENTIATIONS; LEUKOCYTE RECRUITMENT; VASCULAR ENDOTHELIUM; MONOCLONAL-ANTIBODY; PLATELET ACTIVATION; F11 RECEPTOR; MEMBER; TRANSMIGRATION	We have identified a third member of the junctional adhesion molecule (JAM) family. At the protein level JAM3 displays 36 and 32% identity to JAM2 and JAM1, respectively. The coding region is distributed over 9 exons and maps to chromosome 11q25. The gene shows widespread tissue expression with higher levels apparent in the kidney, brain, and placenta. At the cellular level we show expression of JAM3 transcript within endothelial cells. Our major finding is that JAM3 and JAM2 are binding partners. Thus, JAM3 ectodomain binds firmly to JAM2-Fc. This heterotypic interaction is maintained when JAM3-Fc is used to capture Chinese hamster ovary cells expressing full-length JAM2. In static adhesion assays we show that JAM3 is unable to bind to leukocyte cell lines. This is consistent with the lack of JAM2 expression. However, using JAM2-Fc pulldown experiments in combination with polyclonal anti-JAM3 serum, we demonstrate that JAM3 is the previously uncharacterized 43-kDa counter-receptor that mediates JAM2 adhesion to T cells. Most significantly we demonstrate up-regulation of JAM3 protein on peripheral blood lymphocytes following activation. Finally we show the utility of JAM3 ectodomain as an inhibitor of JAM2 adhesion.	Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA		Cunningham, SA (corresponding author), Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA.							Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Ebnet K, 2000, J BIOL CHEM, V275, P27979; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Gupta SK, 2000, IUBMB LIFE, V50, P51; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; KORNECKI E, 1990, J BIOL CHEM, V265, P10042; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; Lechner F, 2000, J INFECT DIS, V182, P978, DOI 10.1086/315765; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Liu Y, 2000, J CELL SCI, V113, P2363; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Mayhan WG, 2001, MICROCIRCULATION, V8, P89, DOI 10.1038/sj.mn.7300154; Michel C. C., 1995, Microcirculation (New York), V2, P125, DOI 10.3109/10739689509146761; Muller WA, 1999, J LEUKOCYTE BIOL, V66, P698, DOI 10.1002/jlb.66.5.698; NAIK UP, 1995, BIOCHEM J, V310, P155, DOI 10.1042/bj3100155; Ozaki H, 2000, BIOCHEM BIOPH RES CO, V276, P873, DOI 10.1006/bbrc.2000.3574; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SIMIONESCU M, 1975, J CELL BIOL, V67, P863, DOI 10.1083/jcb.67.3.863; SIMIONESCU M, 1976, J CELL BIOL, V68, P705, DOI 10.1083/jcb.68.3.705; Smith DK, 1997, J MOL BIOL, V274, P530, DOI 10.1006/jmbi.1997.1432; Sobocka MB, 2000, BLOOD, V95, P2600; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Wiedle G, 2001, CRIT REV CL LAB SCI, V38, P1, DOI 10.1080/20014091084164; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4; Woodside DG, 1996, J IMMUNOL, V157, P700	39	171	199	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45826	45832		10.1074/jbc.M105972200	http://dx.doi.org/10.1074/jbc.M105972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590146	hybrid			2022-12-25	WOS:000172573100045
J	Zhang, XG; Steiner, MS; Rinaldy, A; Lu, Y				Zhang, XG; Steiner, MS; Rinaldy, A; Lu, Y			Apoptosis induction in prostate cancer cells by a novel gene product, pHyde, involves caspase-3	ONCOGENE			English	Article						pHyde; apoptosis; caspase-3; prostate cancer	DNA FRAGMENTATION; MAMMALIAN HOMOLOG; DEATH; CLEAVAGE; PROTEASE; ACTIVATION; INHIBITOR; PATHWAYS; CED-3; LINES	A novel gene, pHyde, was recently cloned from Dunning rat prostate cancer cells. A recombinant adenovirus containing pHyde cDNA gene (AdpHyde) was generated to investigate the biological function of pHyde protein. AdpHyde inhibited the growth of human prostate cancer cells. Apoptosis was induced in AdpHyde transduced cells as demonstrated by DAPI (4', 6-diamino-2-phenylindole), TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick and labeling) staining, and flow cytometry assays. Apoptosis was also induced in human xenograft prostate cancer tumors growing in nude mice following treatment with AdpHyde. AdpHyde transduction resulted in a dose-dependent stimulation of caspase-3 activity in DU145 cells which was blocked by DEVD (succinyl-Asp-Glu-Val-Asp-aldehyde) and VAD (benzyloxycarbonyl - Val - Ala - Asp -fluoromethylketone), inhibitors specifically against caspase-3. Moreover, cancer cells that lacked expression of endogenous caspase-3 were not or barely inhibited by pHyde. These results taken together suggest that pHyde inhibits cancer growth by inducing apoptosis through a caspase-3 dependent pathway.	Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Urol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Lu, Y (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Urol, 956 Court Ave, Memphis, TN 38163 USA.							Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; CARTER HB, 1990, J UROLOGY, V143, P742, DOI 10.1016/S0022-5347(17)40078-4; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; El Etreby MF, 1998, BREAST CANCER RES TR, V51, P149, DOI 10.1023/A:1006078032287; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; HYER ML, 2000, MOL THER, V1, pS322; JACKMAN J, 1998, CURRENT PROTOCOLS CE; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu Y, 1999, CANCER GENE THER, V6, P64, DOI 10.1038/sj.cgt.7700011; Lu Yi, 1995, Molecular and Cellular Differentiation, V3, P175; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Okuma E, 2000, LEUKEMIA, V14, P612, DOI 10.1038/sj.leu.2401716; Oridate N, 1996, CLIN CANCER RES, V2, P855; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rinaldy AR, 1999, DNA CELL BIOL, V18, P829, DOI 10.1089/104454999314827; Rokhlin OW, 1997, CANCER RES, V57, P1758; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SANDBERG AA, 1992, HUM PATHOL, V23, P368, DOI 10.1016/0046-8177(92)90083-F; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Steiner MS, 2000, CANCER RES, V60, P4419; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WOLK A, 1998, J NATL CANCER I, V90, P876; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zhang XW, 1999, ANTI-CANCER DRUG, V10, P569, DOI 10.1097/00001813-199907000-00009	40	25	45	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5982	5990		10.1038/sj.onc.1204831	http://dx.doi.org/10.1038/sj.onc.1204831			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593405				2022-12-25	WOS:000171056300005
J	Wang, DA; Lorincz, Z; Bautista, DL; Liliom, K; Tigyi, G; Parrill, AL				Wang, DA; Lorincz, Z; Bautista, DL; Liliom, K; Tigyi, G; Parrill, AL			A single amino acid determines lysophospholipid specificity of the S1P(1) (EDG1) and LPA(1) (EDG2) phospholipid growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; CANNABINOID RECEPTOR; LYSINE RESIDUE; SPHINGOSINE-1-PHOSPHATE; LIGAND; CELLS	The phospholipid growth factors sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) are ligands for the related G protein-coupled receptors S1P(1)/EDG1 and LPA(1)/EDG2, respectively. We have developed a model of LPA(1) that predicts interactions between three polar residues and LPA. One of these, glutamine 125, which is conserved in the LPA receptor subfamily (LPA(1)/EDG2, LPA(2)/EDG4, and LPA(3)/EDG7), hydrogen bonds with the LPA hydroxyl group. Our previous S1P, study identified that the corresponding glutamate residue, conserved in all S1P receptors, ion pairs with the S1P ammonium. These two results predict that this residue might influence ligand recognition and specificity. Characterization of glutamate/glutamine interchange point mutants of S1P(1) and LPA(1) validated this prediction as the presence of glutamate was required for S1P recognition, whereas LPA recognition was possible with either glutamine or glutamate. The most likely explanation for this dual specificity behavior is a shift in the equilibrium between the acid and conjugate base forms of glutamic acid due to other amino acids surrounding that position in LPA(1), producing a mixture of receptors including those having an anionic glutamate that recognize S1P and others with a neutral glutamic acid that recognize LPA. Thus, computational modeling of these receptors provided valid information necessary for understanding the molecular pharmacology of these receptors.	Univ Memphis, Dept Chem, Memphis, TN 38152 USA; Univ Memphis, Computat Res Mat Inst, Memphis, TN 38152 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Memphis; University of Memphis; University of Tennessee System; University of Tennessee Health Science Center	Parrill, AL (corresponding author), Univ Memphis, Dept Chem, Memphis, TN 38152 USA.		Liliom, Karoly/A-6563-2011	Liliom, Karoly/0000-0002-7177-6872; Parrill, Abby/0000-0003-1658-8497	NCI NIH HHS [CA92160] Funding Source: Medline; NHLBI NIH HHS [HL61469] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Chin CN, 1998, J NEUROCHEM, V70, P366; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Elphick MR, 2001, PHILOS T R SOC B, V356, P381, DOI 10.1098/rstb.2000.0787; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; GOETZL AJ, 2000, CYTOKINE REFERENCE, P1407; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lynch KR, 1997, MOL PHARMACOL, V52, P75, DOI 10.1124/mol.52.1.75; McAllister G, 2000, MOL PHARMACOL, V58, P407, DOI 10.1124/mol.58.2.407; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Salzet M, 2000, EUR J BIOCHEM, V267, P4917, DOI 10.1046/j.1432-1327.2000.01550.x; Song ZH, 1996, MOL PHARMACOL, V49, P891; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; STANKIEWICZ PJ, 1995, MET IONS BIOL SYST, V31, P660; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; Tao Q, 1999, MOL PHARMACOL, V55, P605; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Van Brocklyn JR, 2000, BLOOD, V95, P2624; ZHANG DQ, 1994, FEBS LETT, V337, P207, DOI 10.1016/0014-5793(94)80274-2	28	89	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49213	49220		10.1074/jbc.M107301200	http://dx.doi.org/10.1074/jbc.M107301200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11604399	hybrid			2022-12-25	WOS:000173922100078
J	Atamna, H; Liu, JK; Ames, BN				Atamna, H; Liu, JK; Ames, BN			Heme deficiency selectively interrupts assembly of mitochondrial complex IV in human fibroblasts - Relevance to aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CHROMATOGRAPHY MASS-SPECTROMETRY; OXYGEN-FREE-RADICALS; MAMMALIAN FERROCHELATASE; ALZHEIMERS-DISEASE; ESCHERICHIA-COLI; NITRIC-OXIDE; HUMAN-CELLS; IN-VIVO; IRON	Heme deficiency was studied in young and old normal human fibroblasts (IMR90). Regardless of age, heme deficiency increased the steady-state level of oxidants and lipid peroxidation and sensitized the cells to fluctuations in intracellular Ca2+. Heme deficiency selectively decreased the activity and protein content of mitochondrial complex IV (cytochrome c oxidase) by 95%, indicating a decrease in successful assembly. Complexes I-III and catalase remained intact under conditions of heme deficiency, whereas ferrochelatase was up-regulated. Complex]IV is the only hemeprotein in the cell that contains heme a, which may account for its susceptibility. The rate of removal and assembly of complex IV declines with age. These findings are relevant to worldwide iron deficiency in women and children and to an age-related decline in complex IV in Alzheimer's disease patients.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California Berkeley	Ames, BN (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.		Liu, Jiankang/A-1610-2011		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017140] Funding Source: NIH RePORTER; NIA NIH HHS [AG17140] Funding Source: Medline; NIEHS NIH HHS [ES01896] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACKRELL BAC, 1984, J BIOL CHEM, V259, P53; Albers DS, 2000, J NEURAL TRANSM-SUPP, P133; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AMURO N, 1984, BIOCHIM BIOPHYS ACTA, V781, P14, DOI 10.1016/0167-4781(84)90118-0; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; ATAMNA H, 1995, J BIOL CHEM, V270, P24876, DOI 10.1074/jbc.270.42.24876; BADAWY AAB, 1978, BIOCHEM J, V172, P487, DOI 10.1042/bj1720487; Barja G, 1998, ANN NY ACAD SCI, V854, P224, DOI 10.1111/j.1749-6632.1998.tb09905.x; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x; BIRTHMACHIN M, 1993, METHODS TOXICOLOGY M, V2, P51; BITAR MS, 1987, MECH AGEING DEV, V38, P189, DOI 10.1016/0047-6374(87)90078-9; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; DAILEY HA, 1982, J BIOL CHEM, V257, P4714; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; FERREIRA GC, 1994, J BIOL CHEM, V269, P4396; Feuers RJ, 1998, ANN NY ACAD SCI, V854, P192, DOI 10.1111/j.1749-6632.1998.tb09902.x; FREEDMAN ML, 1987, BLOOD CELLS, V13, P227; FURUKAWA T, 1995, BIOCHEM J, V310, P533, DOI 10.1042/bj3100533; Gabbita SP, 1997, FREE RADICAL BIO MED, V23, P191, DOI 10.1016/S0891-5849(97)00043-9; Gamble JT, 2000, DRUG METAB DISPOS, V28, P373; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; HOLT PS, 1987, TOXICOL LETT, V39, P301, DOI 10.1016/0378-4274(87)90246-3; HUNDT E, 1980, FEBS LETT, V115, P95, DOI 10.1016/0014-5793(80)80734-4; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lecerof D, 2000, J MOL BIOL, V297, P221, DOI 10.1006/jmbi.2000.3569; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Liu JK, 1997, ANAL BIOCHEM, V245, P161, DOI 10.1006/abio.1996.9990; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; NAKAI T, 1994, J BIOCHEM-TOKYO, V116, P752, DOI 10.1093/oxfordjournals.jbchem.a124592; Nihei C, 2001, MOL GENET GENOMICS, V265, P394, DOI 10.1007/s004380100444; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Ojaimi J, 1999, MECH AGEING DEV, V111, P39, DOI 10.1016/S0047-6374(99)00071-8; Ojaimi J, 1999, ANN NEUROL, V46, P656, DOI 10.1002/1531-8249(199910)46:4<656::AID-ANA16>3.3.CO;2-H; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PONKA P, 1993, STEM CELLS, V11, P24, DOI 10.1002/stem.5530110607; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Robinson BH, 2000, PEDIATR RES, V48, P581, DOI 10.1203/00006450-200011000-00004; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; SCOTTO AW, 1983, ARCH BIOCHEM BIOPHYS, V222, P150, DOI 10.1016/0003-9861(83)90512-X; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; Szibor M, 2001, ANTIOXID REDOX SIGN, V3, P515, DOI 10.1089/15230860152409149; Taketani S, 2000, EUR J BIOCHEM, V267, P4685, DOI 10.1046/j.1432-1327.2000.01519.x; TANGERAS A, 1986, BIOCHIM BIOPHYS ACTA, V882, P77, DOI 10.1016/0304-4165(86)90058-9; TORII K, 1992, AM J RESP CELL MOL, V6, P88, DOI 10.1165/ajrcmb/6.1.88; TYLER D, 1992, MITOCHONDRION HLTH D; Villani G, 2000, FREE RADICAL BIO MED, V29, P202, DOI 10.1016/S0891-5849(00)00303-8; WALTER PB, 2001, IN PRESS P NATL ACAD; WEINSTEIN JD, 1986, ARCH BIOCHEM BIOPHYS, V245, P44, DOI 10.1016/0003-9861(86)90188-8; WIELBURSKI A, 1983, BIOCHEM J, V212, P829, DOI 10.1042/bj2120829; Wright G, 2001, EXP CELL RES, V263, P107, DOI 10.1006/excr.2000.5096; Yeo HC, 1999, METHOD ENZYMOL, V300, P70; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957	72	125	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48410	48416		10.1074/jbc.M108362200	http://dx.doi.org/10.1074/jbc.M108362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11598132	hybrid			2022-12-25	WOS:000172927000092
J	Baumgrass, R; Weiwad, M; Erdmann, F; Liu, JO; Wunderlich, D; Grabley, S; Fischer, G				Baumgrass, R; Weiwad, M; Erdmann, F; Liu, JO; Wunderlich, D; Grabley, S; Fischer, G			Reversible inhibition of calcineurin by the polyphenolic aldehyde gossypol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOPHILIN LIGAND COMPLEXES; PROLYL CIS/TRANS ISOMERASES; CYCLOPHILIN-CYCLOSPORINE-A; TRANSCRIPTION FACTOR NFAT1; DEPENDENT PROTEIN-KINASE; BINUCLEAR METAL CENTER; PHOSPHATASE-ACTIVITY; AUTOINHIBITORY DOMAIN; ESCHERICHIA-COLI; CANCER CELLS	The reversible inhibition of calcineurin (CaN), which is the only Ca2+/calmodulin-dependent protein Ser/Thr phosphatase, is thought to be a key functional event for most cyclosporin A (CsA)- and tacrolimus (FK506)-mediated biological effects. In addition to CaN inhibition, however, CsA and FK506 have multiple biochemical effects because of their action in a gain-of-function model that requires prior binding to immunophilic proteins. We screened a small molecule library for direct inhibitors of CaN using CaN-mediated dephosphorylation of P-33-labeled 19-residue phosphopeptide substrate (RII phosphopeptide) as an assay and found the polyphenolic aldehyde gossypol to be a novel CaN inhibitor. Unlike CsA and FK506, gossypol does not require a matchmaker protein for reversible CaN inhibition with an IC50 value of 15 muM. Gossypolone, a gossypol analog, showed improved inhibition of both RII phosphopeptide and p-nitrophenyl phosphate dephosphorylation with an IC50 of 9 and 6 muM, respectively. In contrast, apogossypol hexaacetate was inactive. Gossypol acts noncompetitively, interfering with the binding site for the cyclophilin 18(.)CsA complex in CaN. In contrast to CsA and FK506, gossypol does not inactivate the peptidyl-prolyl-cis/trans-isomerase activity of immunophilins. Similar to CsA and FK506, T cell receptor signaling induced by phorbol 12-myristate 13-acetate/ionomycin is inhibited by gossypol in a dose-dependent manner, demonstrated by the inhibition of nuclear factor of activated T cell (NFAT) cl translocation from the cytosol into the nucleus and suppression of NFAT-luciferase reporter gene activity.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle Saale, Germany; Hans Knoll Inst Nat Prod Res, D-07745 Jena, Germany; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Max Planck Society; Hans Knoll Institute (HKI); Johns Hopkins University; Johns Hopkins University	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle Saale, Germany.			Baumgrass, Ria/0000-0002-3289-1608				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; BARTZ SR, 1995, P NATL ACAD SCI USA, V92, P5381, DOI 10.1073/pnas.92.12.5381; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; Bogumil R, 2000, EUR J BIOCHEM, V267, P1407, DOI 10.1046/j.1432-1327.2000.01133.x; BORN TL, 1995, J BIOL CHEM, V270, P25651, DOI 10.1074/jbc.270.43.25651; Brill GM, 1996, J ANTIBIOT, V49, P124, DOI 10.7164/antibiotics.49.124; CHAN CP, 1986, J BIOL CHEM, V261, P9890; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COYLE T, 1994, J NEURO-ONCOL, V19, P25, DOI 10.1007/BF01051046; DONELLADEANA A, 1991, BIOCHIM BIOPHYS ACTA, V1094, P130, DOI 10.1016/0167-4889(91)90034-U; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; Enz A, 1997, BIOORG MED CHEM LETT, V7, P2513, DOI 10.1016/S0960-894X(97)10005-1; Enz A, 1997, BIOCHEM PHARMACOL, V54, P321, DOI 10.1016/S0006-2952(97)00175-5; ENZ A, 1994, ANAL BIOCHEM, V216, P147, DOI 10.1006/abio.1994.1018; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; Fakata KL, 1998, BIOCHEM PHARMACOL, V55, P2017, DOI 10.1016/S0006-2952(98)00076-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FLACK MR, 1993, J CLIN ENDOCR METAB, V76, P1019, DOI 10.1210/jc.76.4.1019; FRICK J, 1988, CONTRACEPTION, V37, P153, DOI 10.1016/0010-7824(88)90125-4; GILBERT NE, 1995, LIFE SCI, V57, P61, DOI 10.1016/0024-3205(95)00243-Y; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Gomez MS, 1997, MOL BIOCHEM PARASIT, V90, P235, DOI 10.1016/S0166-6851(97)00140-0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Gualberto A, 1998, J BIOL CHEM, V273, P7088, DOI 10.1074/jbc.273.12.7088; Janowski B, 1997, BIOORGAN MED CHEM, V5, P179, DOI 10.1016/S0968-0896(96)00198-8; JINSART W, 1991, BIOL CHEM H-S, V372, P819, DOI 10.1515/bchm3.1991.372.2.819; KHANDELWAL RL, 1976, J BIOL CHEM, V251, P4850; KIM IC, 1984, CONTRACEPTION, V30, P253, DOI 10.1016/0010-7824(84)90088-X; KOCH C, 1999, DRUG DISCOVERY NATUR, P263; KREBS EG, 1958, J BIOL CHEM, V231, P73; Ligueros M, 1997, BRIT J CANCER, V76, P21, DOI 10.1038/bjc.1997.330; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P9430, DOI 10.1074/jbc.273.16.9430; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; Nakayama GR, 1998, J BIOMOL SCREEN, V3, P43, DOI 10.1177/108705719800300106; NELSON PA, 1993, J IMMUNOL, V150, P2139; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; Perrino BA, 1999, ARCH BIOCHEM BIOPHYS, V372, P159, DOI 10.1006/abbi.1999.1485; POSO H, 1980, LANCET, V1, P885; RICHTER A, 1995, BIOCHEM PHARMACOL, V49, P367, DOI 10.1016/0006-2952(94)00423-J; RUSSELL DH, 1987, J IMMUNOL, V138, P276; Sagoo JK, 1996, BIOCHEM J, V320, P879, DOI 10.1042/bj3200879; SCHREIBER SL, 1993, ACCOUNTS CHEM RES, V26, P412, DOI 10.1021/ar00032a004; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shidaifat F, 1997, ANTICANCER RES, V17, P1003; Sullivan E, 1997, J BIOMOL SCREEN, V2, P19, DOI 10.1177/108705719700200105; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; Tatlock JH, 1997, BIOORG MED CHEM LETT, V7, P1007, DOI 10.1016/S0960-894X(97)00141-8; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; Vander Jagt DL, 2000, CURR MED CHEM, V7, P479, DOI 10.2174/0929867003375119; WAELKENS E, 1984, BIOCHEM BIOPH RES CO, V120, P397, DOI 10.1016/0006-291X(84)91267-1; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P12400, DOI 10.1021/bi962972i; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040; ZARNT T, 1995, BIOCHEM J, V305, P159, DOI 10.1042/bj3050159; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	63	72	80	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47914	47921		10.1074/jbc.M103273200	http://dx.doi.org/10.1074/jbc.M103273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11598106	hybrid			2022-12-25	WOS:000172927000027
J	Cha, H; Lee, EK; Shapiro, P				Cha, H; Lee, EK; Shapiro, P			Identification of a C-terminal region that regulates mitogen-activated protein kinase kinase-1 cytoplasmic localization and ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATION; CELL-CYCLE; MEK1; PROGRESSION; SEQUENCE; COMPLEX; BINDING; DOMAIN; ALPHA; MKK1	The C-terminal region of mitogen-activated protein kinase kinase-1 and 2 (MKK1 and MKK2) may function in regulating interactions with upstream kinases or the magnitude and duration of ERK mitogen-activated protein kinase activity. The MKK C-terminal region contains a proline-rich region that reportedly functions in regulating interactions with the Raf-1 kinase and ERK activity. In addition, phosphorylation sites in the C terminus of MKK1 have been suggested to either sustain or attenuate MKKI activity. To further understand how phosphorylation at the C terminus of MKK1 and protein interactions regulate MKK1 function, we have generated several MKK1 C-terminal deletion mutants and examined their function in regulating MKK1 localization, ERR protein activation, and cell growth. A deletion of C-terminal amino acids encompassing two putative ce-helices between residues 330 and 379 caused a redistribution of mutant MKK1 proteins to membrane compartments. Immunofluorescence analysis of MKK1 mutants revealed a loss of homogenous cytosolic distribution that is typically observed with MKKI wild type, suggesting this region regulates MKK1 cellular localization. In contrast, MKK1 C-terminal deletion mutants localized to various sized punctate regions that overlapped with lysosome compartments. ERK activation in response to constitutively active Raf-1 or growth factor stimulus was attenuated in cells expressing MKK1. C-terminal deletion mutants. This could be partly explained by the inability of Raf-1 to phosphorylate MKK1 C-terminal deletion mutants even though the phosphorylation sites were intact in these mutants. Finally, we show that cells expressing MKK1 C-terminal deletion mutants displayed characteristic patterns of apoptotic cell death and reduced cell proliferation. These findings identify a novel C-terminal region between amino acid residues 330 and 379 on MKK1 that is necessary for regulating the cytoplasmic distribution and subsequent ERK protein activation necessary for cell survival and viability.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Shapiro, P (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.	pshapiro@rx.umaryland.edu	Cha, Hyuk-Jin/AAB-8508-2020	Cha, Hyuk-Jin/0000-0001-9277-2662				Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Johnson VL, 2000, J CELL SCI, V113, P2941; Krajci D, 2000, EUR J CELL BIOL, V79, P365, DOI 10.1078/S0171-9335(04)70041-2; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; McGuire TF, 2001, J BIOL CHEM, V276, P26365, DOI 10.1074/jbc.M010101200; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Resing KA, 1998, BIOCHEMISTRY-US, V37, P463, DOI 10.1021/bi971750x; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765	29	20	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48494	48501		10.1074/jbc.M107601200	http://dx.doi.org/10.1074/jbc.M107601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604401				2022-12-25	WOS:000172927000102
J	Chen, J; Baskerville, C; Han, QW; Pan, ZXK; Huang, S				Chen, J; Baskerville, C; Han, QW; Pan, ZXK; Huang, S			alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; ALPHA-V-BETA-3 INTEGRIN; VITRONECTIN RECEPTOR; DEPENDENT ACTIVATION; CYTOPLASMIC TAIL; EPITHELIAL-CELLS; TUMOR INVASION; MAP KINASE; IN-VITRO; METASTASIS	We reported previously that endogenous p38 ALAPK activity is elevated in invasive breast cancer cells and that constitutive p38 MAPK activity is important for overproduction of uPA in these cells (Huang, S., New, L., Pan, Z., Han, J., and Nemerow, G. R. (2000) J. Biol. Chem. 275, 12266-12272). However, it is unclear how elevated endogenous p38 MAPK activity is maintained in invasive breast cancer cells. In the present study, we found that blocking a, integrin functionality with a function-blocking monoclonal antibody or down-regulating alpha (v) integrin expression with alpha (v)-specific antisense oligonucleotides significantly decreased the levels of active p38 MAPK and inhibited cell-associated uPA expression in invasive breast cancer MDA-ME-231 cells. These results suggest a function link between alpha (v) integrin, p38 MAPK activity, and uPA expression in invasive tumor cells. We also found that vitronectin/alpha (v) integrin ligation specifically induced p38 MAPK activation and uPA up-regulation in invasive MDA-MB-231 cells but not in non-invasive MCF7 cells. Finally, using a panel of melanoma cells, we demonstrated that the cytoplasmic tail of a, integrin subunit is required for alpha (v) integrin ligation-induced p38 MAPK activation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Huang, S (corresponding author), Scripps Res Inst, Dept Immunol, IMM-19,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@scripps.edu						Alonso DF, 1996, BREAST CANCER RES TR, V40, P209, DOI 10.1007/BF01806809; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BERINSTEIN A, 1995, J VIROL, V69, P2664, DOI 10.1128/JVI.69.4.2664-2666.1995; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Bouchet C, 1998, BRIT J CANCER, V77, P1495, DOI 10.1038/bjc.1998.246; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Carriero MV, 1999, CANCER RES, V59, P5307; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; CHERESH DA, 1991, CANCER METAST REV, V10, P3, DOI 10.1007/BF00046839; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; DUGGAN C, 1995, INT J CANCER, V61, P597, DOI 10.1002/ijc.2910610502; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Farina AR, 1998, INT J CANCER, V75, P721; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Filardo EJ, 1996, J CELL SCI, V109, P1615; Foekens JA, 2000, CANCER RES, V60, P636; Frandsen TL, 2001, CANCER RES, V61, P532; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Haeckel C, 1998, INT J CANCER, V77, P153, DOI 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.3.CO;2-2; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Huang S, 2000, ONCOGENE, V19, P1915, DOI 10.1038/sj.onc.1203509; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Khatib AM, 2001, INT J CANCER, V91, P300, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1055>3.3.CO;2-E; KIM JP, 1994, J BIOL CHEM, V269, P26926; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; Klekotka PA, 2001, J BIOL CHEM, V276, P32353, DOI 10.1074/jbc.M101921200; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; Koistinen P, 1999, MATRIX BIOL, V18, P239, DOI 10.1016/S0945-053X(99)00022-0; Kruger A, 2000, CANCER GENE THER, V7, P292, DOI 10.1038/sj.cgt.7700144; Ma D, 1997, BLOOD, V90, P2738, DOI 10.1182/blood.V90.7.2738.2738_2738_2746; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; MICHAEL SI, 1995, GENE THER, V2, P660; Miyake H, 1999, INT J ONCOL, V14, P535; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; PEREYRAALFONSO S, 1988, INT J CANCER, V42, P59, DOI 10.1002/ijc.2910420112; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Solomayer EF, 1997, BRIT J CANCER, V76, P812, DOI 10.1038/bjc.1997.467; Sonohara S, 1998, INT J CANCER, V76, P77, DOI 10.1002/(SICI)1097-0215(19980330)76:1<77::AID-IJC13>3.0.CO;2-D; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Wang GJ, 1998, P NATL ACAD SCI USA, V95, P6296, DOI 10.1073/pnas.95.11.6296; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilcox-Adelman SA, 2000, CELL ADHES COMMUN, V7, P477, DOI 10.3109/15419060009040305; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437; Xue W, 1997, CANCER RES, V57, P1682; Yang JL, 2000, INT J CANCER, V89, P431, DOI 10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	62	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47901	47905		10.1074/jbc.M107574200	http://dx.doi.org/10.1074/jbc.M107574200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606583	hybrid			2022-12-25	WOS:000172927000025
J	Rodriguez, R; Matsuda, M; Perisic, O; Bravo, J; Paul, A; Jones, NP; Light, Y; Swann, K; Williams, RL; Katan, M				Rodriguez, R; Matsuda, M; Perisic, O; Bravo, J; Paul, A; Jones, NP; Light, Y; Swann, K; Williams, RL; Katan, M			Tyrosine residues in phospholipase C gamma 2 essential for the enzyme function in B-cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; C-GAMMA; SRC-FAMILY; KINASE; ACTIVATION; PROTEIN; BLNK; PHOSPHORYLATION; SYK; IDENTIFICATION	Phospholipase C gamma (PLC gamma) isoforms are regulated through activation of tyrosine kinase-linked receptors. The importance of growth factor-stimulated phosphorylation of specific tyrosine residues has been documented for PLC gamma1; however, despite the critical importance of PLC gamma2 in B-cell signal transduction, neither the tyrosine kinase(s) that directly phosphorylate PLC gamma2 nor the sites in PLC gamma2 that become phosphorylated after stimulation are known. By measuring the ability of human PLC gamma2 to restore calcium responses to the B-cell receptor stimulation or oxidative stress in a B-cell line (DT40) deficient in PLC gamma2, we have demonstrated that two tyrosine residues, Tyr(753) and Tyr(759), were important for the PLC gamma2 signaling function. Furthermore, the double mutation Y753F/Y759F in PLC gamma2 resulted in a loss of tyrosine phosphorylation in stimulated DT40 cells. Of the two kinases that previously have been proposed to phosphorylate PLC gamma2, Btk, and Syk, purified Btk had much greater ability to phosphorylate recombinant PLC gamma2 in vitro, whereas Syk efficiently phosphorylated adapter protein BLNK. Using purified proteins to analyze the formation of complexes, we suggest that function of Syk is to phosphorylate BLNK, providing binding sites for PLC gamma2. Further analysis of PLC gamma2 tyrosine residues phosphorylated by Btk and several kinases from the Src family has suggested multiple sites of phosphorylation and, in the context of a peptide incorporating residues Tyr(753) and Tyr(759), shown preferential phosphorylation of Tyr(753).	Inst Canc Res, Chester Beatty Labs, Canc Res Campaign, Ctr Cell & Mol Biol, London SW3 6JB, England; MRC, Mol Biol Lab, Med Res Council Ctr, Cambridge CB2 2QH, England; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; University College London	Katan, M (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res Campaign, Ctr Cell & Mol Biol, Fulham Rd, London SW3 6JB, England.	matilda@icr.ac.uk	Bravo, Jeronimo/K-9103-2014	Bravo, Jeronimo/0000-0001-6695-2846; Perisic, Olga/0000-0002-3842-2896; Swann, Karl/0000-0002-4355-1449	MRC [MC_U105184308] Funding Source: UKRI; Medical Research Council [MC_U105184308] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Satterthwaite A, 1996, ANNU REV IMMUNOL, V14, P131, DOI 10.1146/annurev.immunol.14.1.131; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tomlinson M G, 2001, BMC Immunol, V2, P4, DOI 10.1186/1471-2172-2-4; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1992, J BIOL CHEM, V267, P10447; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Williams RL, 1996, STRUCTURE, V4, P1387, DOI 10.1016/S0969-2126(96)00146-3; Yamamoto T, 2001, FEBS LETT, V491, P272, DOI 10.1016/S0014-5793(01)02208-6; Yu H, 1998, EXP CELL RES, V243, P113, DOI 10.1006/excr.1998.4132	36	61	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47982	47992		10.1074/jbc.M107577200	http://dx.doi.org/10.1074/jbc.M107577200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606584	hybrid			2022-12-25	WOS:000172927000036
J	Schwenger, GTF; Fournier, G; Kok, CC; Mordvinov, VA; Yeoman, D; Sanderson, CJ				Schwenger, GTF; Fournier, G; Kok, CC; Mordvinov, VA; Yeoman, D; Sanderson, CJ			GATA-3 has dual regulatory functions in human interleukin-5 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; NUCLEAR FACTOR; IL-5 GENE; BINDING PROTEINS; CUTTING EDGE; TH1 CELLS; EXPRESSION; PROMOTER; ELEMENT; ENHANCER	Interleukin-5 (IL-5) is a T-cell cytokine involved in Type 2 diseases and is commonly described as being coordinately regulated with other Type 2 cytokines, such as IL-4 and IL-13. Considering the unique control of eosinophilia by IL-5, such coordinate regulation would be surprising. In fact, the biological specificity of eosinophilia and its control by IL-5 suggests a unique and independent control of IL-5 regulation. In this report we show the binding of GATA-3 to three sites in the human IL-5 promoter in the human T-cell line PER117. The previously identified -70 site and another site at position -152 are shown to positively regulate IL-5 transcription. More importantly, the site located at -400 acts as a powerful repressor of IL-5 transcription with mutagenesis of this site allowing a high level expression of IL-5 without the activation of other factors normally required for IL-5 expression. Whereas GATA-3 has been proposed to be involved in the regulation of the IL-4/IL5/IL-13 locus, we show here that it has another function in controlling IL-5 transcription that supports the observed unique biological function of this cytokine.	Curtin Univ Technol, Dept Mol Immunol, Perth, WA 6000, Australia; Western Australian Inst Med Res Level 5, Perth, WA 6000, Australia; Inst Francais Boissons Brasserie & Malterie, Biol Mol Lab, F-54500 Vandoeuvre Les Nancy, France; Free Univ Brussels, Fac Med, Expt Immunol Lab, B-1070 Brussels, Belgium	Curtin University; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schwenger, GTF (corresponding author), Curtin Univ Technol, Dept Mol Immunol, Med Res Fdn Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.		Mordvinov, Viatcheslav A/S-8277-2017	Mordvinov, Viatcheslav A/0000-0002-6173-0774				Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; De Boer ML, 1999, INT J BIOCHEM CELL B, V31, P1221, DOI 10.1016/S1357-2725(99)00069-2; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; JUNG T, 1995, EUR J IMMUNOL, V25, P2413, DOI 10.1002/eji.1830250843; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; KEES UR, 1994, J IMMUNOL METHODS, V168, P1, DOI 10.1016/0022-1759(94)90202-X; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; Krug N, 1998, AM J RESP CRIT CARE, V158, P754, DOI 10.1164/ajrccm.158.3.9507038; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lee HJ, 1998, J IMMUNOL, V160, P2343; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; Miyatake S, 2000, IUBMB LIFE, V49, P473; Mordvinov VA, 1999, J ALLERGY CLIN IMMUN, V103, P1125, DOI 10.1016/S0091-6749(99)70188-0; Mordvinov VA, 1999, J IMMUNOL METHODS, V228, P163, DOI 10.1016/S0022-1759(99)00088-5; Mori A, 1997, INT ARCH ALLERGY IMM, V113, P272, DOI 10.1159/000237570; Nawijn MC, 2001, J IMMUNOL, V167, P724, DOI 10.4049/jimmunol.167.2.724; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Pomerantz O, 1998, NUCLEIC ACIDS RES, V26, P5684, DOI 10.1093/nar/26.24.5684; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Ranganath S, 1998, J IMMUNOL, V161, P3822; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Schwenger GTF, 1999, J ALLERGY CLIN IMMUN, V104, P820, DOI 10.1016/S0091-6749(99)70293-9; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Yamanaka R, 1998, INT J MOL MED, V1, P213; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	34	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48502	48509		10.1074/jbc.M107836200	http://dx.doi.org/10.1074/jbc.M107836200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11579103	hybrid			2022-12-25	WOS:000172927000103
J	Hausrath, AC; Capaldi, RA; Matthews, BW				Hausrath, AC; Capaldi, RA; Matthews, BW			The conformation of the epsilon- and gamma-subunits within the Escherichia coli F-1 ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE; F1F0-TYPE ATPASE; SYNTHASE; RESOLUTION; F-1-ATPASE; F1-ATPASE; PACKAGE; COMPLEX	F-1 is the water-soluble portion of the ubiquitous F1F0 ATP synthase. Its structure includes three alpha- and three beta -subunits, arranged as a hexameric disc, plus a gamma -subunit that penetrates the center of the disc akin to an axle. Recently Hausrath et al. (Hausrath, A. C., Gruber, G., Matthews, B. W., and Capaldi, R. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13697-13702) obtained an electron density map of E. coli F-1 at 4.4-Angstrom resolution in which the coiled-coil a-helices of the gamma -subunit could be seen to extend 45 Angstrom from the base of the alpha (3)beta (3) hexamer. Subsequently the structure of a truncated form of the E. coli gamma -subunit in complex with epsilon has been described (Rodgers, A. J. W., and Wilce, M. C. J. (2000) Nat. Struct. Biol. 7, 1051-1054). In the present study the 4.4-Angstrom resolution electron density map of E. coli F-1 is re-evaluated in light of the newly available data on the gamma- and epsilon -subunits. It is shown that the map of the F-1 complex is consistent with the structure of the isolated subunits. When E. coli F-1 is compared with that from beef heart, the structures of the E. coli gamma- and epsilon -subunits are seen to be generally similar to their counterparts in the bovine enzyme but to undergo major shifts in position. In particular, the two long, coiled-coil alpha -helices that lie along the axis of F-1 both unwind and rotate. Also the c-subunit rotates around the axis by 81 degrees and undergoes a net translation of about 23 Angstrom. It is argued that these large-scale changes in conformation reflect distinct functional states that occur during the rotation of the gamma -subunit within the alpha (3)beta (3) hexamer.	Univ Oregon, Howard Hughes Med Inst, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Howard Hughes Med Inst, Dept Phys, Eugene, OR 97403 USA; Univ Oregon, Howard Hughes Med Inst, Dept Biol, Eugene, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon; Howard Hughes Medical Institute; University of Oregon; Howard Hughes Medical Institute; University of Oregon	Matthews, BW (corresponding author), Univ Oregon, Howard Hughes Med Inst, Inst Mol Biol, Eugene, OR 97403 USA.				NHLBI NIH HHS [HL 24526] Funding Source: Medline; NIGMS NIH HHS [GM 20066] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020066, R01GM020066] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; EVANS PR, 1991, CRYSTALLOGRAPHIC COM, V5, P136; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; READ RJ, 1991, CRYSTALLOGRAPHIC COM, V5, P158; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; ZHANG XJ, 1995, J APPL CRYSTALLOGR, V28, P624, DOI 10.1107/S0021889895001063	29	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47227	47232		10.1074/jbc.M107536200	http://dx.doi.org/10.1074/jbc.M107536200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585832	hybrid			2022-12-25	WOS:000172768500075
J	Lin, YC; Shih, JW; Hsu, CL; Lin, JJ				Lin, YC; Shih, JW; Hsu, CL; Lin, JJ			Binding and partial denaturing of g-quartet DNA by Cdc13p of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUADRUPLEX TELOMERIC DNA; YEAST GENE-PRODUCT; CRYSTAL-STRUCTURE; RAT HEPATOCYTES; NUCLEIC-ACIDS; BETA-SUBUNIT; IN-VITRO; S-PHASE; PROTEIN; PARALLEL	The protein Cdc13p binds telomeres in vivo and is essential for the maintenance of the telomeres of Saccharomyces cerevisiae. In addition, Cdc13p is known to bind single-stranded TG(1-3) DNA in vitro. Here we have shown that Cdc13p also binds DNA quadruplex, G-quartet, formed by TG(1-3) DNA. Moreover, the binding of Cdc13p causes a partial denaturing of the G-quartet DNA. Formation of DNA quadruplexes may involve the intermolecular association of TG(1-3) DNA and inhibit the extension of telomeres by telomerase. Thus, our finding suggests that Cdc13p may disrupt telomere association and facilitate telomere replication.	Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lin, JJ (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	jjlin@ym.edu.tw	Lin, Jing-Jer/G-8068-2015; Shih, Jing-Wen/J-4555-2017	Shih, Jing-Wen/0000-0002-0417-9015; LIN, JING-JER/0000-0001-8250-7398				ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; BLACKBURN EH, 1990, J BIOL CHEM, V265, P5919; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Lin YC, 2001, J BIOL CHEM, V276, P24588, DOI 10.1074/jbc.M101642200; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Qi HY, 2000, GENE DEV, V14, P1777; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; VENCZEL EA, 1993, BIOCHEMISTRY-US, V32, P6220, DOI 10.1021/bi00075a015; WALSH K, 1992, J BIOL CHEM, V267, P13714; Wang MJ, 2000, NUCLEIC ACIDS RES, V28, P4733, DOI 10.1093/nar/28.23.4733; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	39	35	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47671	47674		10.1074/jbc.M104989200	http://dx.doi.org/10.1074/jbc.M104989200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585819	hybrid			2022-12-25	WOS:000172768500129
J	Minami, T; Aird, WC				Minami, T; Aird, WC			Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-kappa B and GATA motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; E-SELECTIN EXPRESSION; GENE-EXPRESSION; TRANSCRIPTION FACTORS; NEUTROPHIL ADHESION; IN-VITRO; ACTIVATION; RECEPTOR; VCAM-1; BINDING	The goal of this study was to delineate the transcriptional mechanisms underlying thrombin-mediated induction of vascular adhesion molecule-1 (VCAM-1). Treatment of human umbilical vein endothelial cells with thrombin resulted in a 3.3-fold increase in VCAM-1 promoter activity. The upstream promoter region of VCAM-1 contains a thrombin response element, two nuclear factor kappaB (NF-kappaB) motifs, and a tandem GATA motif. In transient transfection assays, mutation of the thrombin response element had no effect on thrombin induction. In contrast, mutation of either NF-kappaB site resulted in a complete loss of induction, whereas a mutation of the two GATA motifs resulted in a significant reduction in thrombin stimulation. In electrophoretic mobility shift assays, nuclear extracts from thrombin-treated endothelial cells displayed markedly increased binding to the tandem NF-kappaB and GATA motifs. The NF-kappaB complex was supershifted with anti-p65 antibodies, but not with antibodies to RelB, c-Rel, p50, or p52. The GATA complex was supershifted with antibodies to GATA-2, but not GATA-3 or GATA-6. A construct containing tandem copies of the VCAM-1 GATA motifs linked to a minimal thymidine kinase promoter was induced 2.4-fold by thrombin. Taken together, these results suggest that thrombin stimulation of VCAM-1 in endothelial cells is mediated by the coordinate action of NF-kappaB and GATA transcription factors.	Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Dept Mol Med, RW-663, Boston, MA 02215 USA.				NHLBI NIH HHS [HL 63609-02, HL 59316-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL059316, P50HL063609, P01HL059316] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; AIRD WC, 1994, J BIOL CHEM, V269, P883; Aird WC, 2001, CRIT CARE MED, V29, pS28, DOI 10.1097/00003246-200107001-00013; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; COLOTTA F, 1994, AM J PATHOL, V144, P975; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P52; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Gross PL, 2000, SEMIN THROMB HEMOST, V26, P463, DOI 10.1055/s-2000-13202; Hayashi T, 1999, MOL CELL BIOL, V19, P8646; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Kaplanski G, 1998, BLOOD, V92, P1259, DOI 10.1182/blood.V92.4.1259.416k11_1259_1267; Kaplanski G, 1997, J IMMUNOL, V158, P5435; Lee YW, 2001, J LIPID RES, V42, P783; Li QJ, 2000, BLOOD, V96, P3696, DOI 10.1182/blood.V96.12.3696.h8003696_3696_3706; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MALIK AB, 1992, SEMIN THROMB HEMOST, V18, P193, DOI 10.1055/s-2007-1002425; MARRA F, 1995, HEPATOLOGY, V22, P780, DOI 10.1002/hep.1840220314; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; Rahman A, 1999, J IMMUNOL, V162, P5466; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Simoncini T, 2000, CIRC RES, V87, P19, DOI 10.1161/01.RES.87.1.19; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; Tarumoto T, 2000, BLOOD, V96, P1716, DOI 10.1182/blood.V96.5.1716.h8001716_1716_1722; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZIMMERMAN GA, 1985, CIRCULATION, V72, P718, DOI 10.1161/01.CIR.72.4.718; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	47	83	88	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47632	47641		10.1074/jbc.M108363200	http://dx.doi.org/10.1074/jbc.M108363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590177	hybrid			2022-12-25	WOS:000172768500124
J	Liu, QJ; Ling, TY; Shieh, HS; Johnson, FE; Huang, JS; Huang, SS				Liu, QJ; Ling, TY; Shieh, HS; Johnson, FE; Huang, JS; Huang, SS			Identification of the high affinity binding site in transforming growth factor-beta involved in complex formation with alpha(2)-macroglobulin - Implications regarding the molecular mechanisms of complex formation between alpha(2)-macroglobulin and growth factors, cytokines, and hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; MULTIFUNCTIONAL BINDING; ALPHA-MACROGLOBULIN; CRYSTAL-STRUCTURE; FACTOR-BB; FACTOR-BETA-1; PEPTIDE; GROWTH-FACTOR-BETA-2; INHIBITION	The biological activities of transforming growth factor-beta isoforms (TGF-beta (1,2)) are known to be modulated by alpha (2)-macroglobulin (alpha M-2). alpha M-2 forms complexes with numerous growth factors, cytokines, and hormones, including TGF-beta. Identification of the binding sites in TGF-beta isoforms responsible for high affinity interaction with a2M many unravel the molecular basis of the complex formation. Here we demonstrate that among nine synthetic pentacosapeptides with overlapping amino acid sequences spanning the entire TGF-beta (1), molecule, the peptide (residues 41-65) containing Trp-52 exhibited the most potent activity in inhibiting the formation of complexes between I-125-TGF-beta (1) and activated alpha M-2 (alpha M-2*) as determined by nondenaturing polyacrylamide gel electrophoresis and by plasma clearance in mice. TGF-beta (2) peptide containing the homologous sequence and Trp-52 was as active as the TGF-beta (1) peptide, whereas the corresponding TGF-beta (3) peptide lacking Trp-52, was inactive. The replacement of the Trp-52 with alanine abolished the inhibitory activities of these peptides. I-125-TGF-beta (3), which lacks Trp-52, bound to a2M* with an affinity lower than that of I-125-TGF-beta (1). Furthermore, unlabeled TGF-beta (3) and the mutant TGF-beta (1)W52A, in which Trp-52 was replaced with alanine, were less potent than unlabeled TGF-P, in blocking I-125-TGF-beta (1) binding to alpha M-2*.TGF-beta (1) and TGF-beta (2) peptides containing Trp-52 were also effective in inhibiting I-125-nerve growth factor binding to a2M*. These results suggest that Trp-52 is involved in high affinity binding of TGF-beta to alpha M-2*. They also imply that TGF-beta and other growth factors/cytokines/hormones may form complexes with a2M* via a common mechanism involving the interactions between topologically exposed Trp and/or other hydrophobic residues and a hydrophobic region in alpha M-2*.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Surg, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Pharmacia Monsanto, Searle Discovery Res, St Louis, MO 63198 USA	Saint Louis University; Saint Louis University; Academia Sinica - Taiwan	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.			Ling, Thai-Yen/0000-0002-3992-883X	NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1152, DOI 10.1021/bi00055a021; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BIRKENMEIER G, 1994, METHOD ENZYMOL, V228, P264; BORTH W, 1994, ANN NY ACAD SCI, V737, P267, DOI 10.1111/j.1749-6632.1994.tb44317.x; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; Cote N, 1998, CAN J VET RES, V62, P279; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; Gonias SL, 2000, J BIOL CHEM, V275, P5826, DOI 10.1074/jbc.275.8.5826; Harthun NL, 1998, J IMMUNOTHER, V21, P85, DOI 10.1097/00002371-199803000-00001; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; Huang SS, 1999, J BIOL CHEM, V274, P27754, DOI 10.1074/jbc.274.39.27754; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; HUANG SS, 1988, J BIOL CHEM, V263, P1535; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; LAMARRE J, 1990, LAB INVEST, V62, P545; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LIEBL DJ, 1993, BIOCHEM BIOPH RES CO, V193, P1255, DOI 10.1006/bbrc.1993.1760; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERWIN JR, 1991, AM J PATHOL, V138, P37; Narita M, 1997, J NEUROCHEM, V69, P1904; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHAH M, 1995, J CELL SCI, V108, P985; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1984, MOL CELL BIOCHEM, V58, P121, DOI 10.1007/BF00240611; Webb DJ, 1996, BIOCHEM J, V320, P551, DOI 10.1042/bj3200551; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473	46	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46212	46218		10.1074/jbc.M105177200	http://dx.doi.org/10.1074/jbc.M105177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583997	hybrid			2022-12-25	WOS:000172573100098
J	Tsirigotis, M; Zhang, M; Chiu, RK; Wouters, BG; Gray, DA				Tsirigotis, M; Zhang, M; Chiu, RK; Wouters, BG; Gray, DA			Sensitivity of mammalian cells expressing mutant ubiquitin to protein-damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAGGED UBIQUITIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS INCLUSIONS; NEURONAL INCLUSIONS; DEGRADATION; CADMIUM; YEAST; DISEASE; PROTEOLYSIS	There is convincing evidence from studies in yeast that a functional ubiquitin/proteasome pathway is required to degrade misfolded or oxidatively damaged proteins but for technical reasons, it has been difficult to perform comparable studies in mammalian cells. To investigate the possibility that the ubiquitin/proteasome pathway is cytoprotective for mammalian cells, we have introduced epitope-tagged wild-type ubiquitin or dominant-negative mutant versions of ubiquitin into mouse HT4 neuroblastoma cells. Cells expressing mutant versions of ubiquitin were found to be sensitive to cadmium, an agent that causes oxidative damage to cellular components, and to canavanine, an amino acid analog that generates misfolded proteins. The greatest sensitivity to canavanine was observed in cells expressing a mutant version of ubiquitin unable to support the formation of Lys(48) linkages. Substrates of the proteasome were found to accumulate in these cells, suggesting a general deficit in proteolysis. Our data suggest that defects in the ubiquitin-mediated proteolytic system predispose mammalian cells to the toxic effects of abnormal protein.	Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Microbiol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Immunol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Gray, DA (corresponding author), Ottawa Reg Canc Ctr, Ctr Canc Therapeut, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada.	Doug.Gray@orcc.on.ca	Wouters, Bradly/T-1525-2017; Wakeley, Philip R/D-7473-2011; /U-3554-2018	Wouters, Bradly/0000-0002-8187-592X; /0000-0002-8634-4984				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Arima K, 1998, ACTA NEUROPATHOL, V96, P75, DOI 10.1007/s004010050862; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BEERS EP, 1993, J BIOL CHEM, V268, P21645; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; CHEN YP, 1995, BBA-MOL CELL RES, V1268, P59, DOI 10.1016/0167-4889(95)00044-S; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Duyckaerts C, 1999, ACTA NEUROPATHOL, V97, P201, DOI 10.1007/s004010050975; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; Figueiredo-Pereira ME, 1999, MOL BIOL REP, V26, P65, DOI 10.1023/A:1006909918866; FigueiredoPereira ME, 1997, MOL BIOL REP, V24, P35, DOI 10.1023/A:1006848405975; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; FUKUDA T, 1993, ACTA PATHOL JAPON, V43, P545; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hayashi Y, 1998, ACTA NEUROPATHOL, V95, P479, DOI 10.1007/s004010050828; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Jackson M, 1996, ACTA NEUROPATHOL, V91, P127, DOI 10.1007/s004010050403; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kimber TE, 1998, J NEUROL SCI, V160, P33, DOI 10.1016/S0022-510X(98)00169-5; Lambertson D, 1999, GENETICS, V153, P69; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LENNOX G, 1988, NEUROSCI LETT, V94, P211, DOI 10.1016/0304-3940(88)90297-2; Ling R, 2000, ANAL BIOCHEM, V282, P54, DOI 10.1006/abio.2000.4586; LOWE J, 1993, BRAIN PATHOL, V3, P55, DOI 10.1111/j.1750-3639.1993.tb00726.x; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Sieradzan KA, 1999, EXP NEUROL, V156, P92, DOI 10.1006/exnr.1998.7005; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stohs Sidney J., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P201; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsirigotis M, 2001, BIOTECHNIQUES, V31, P120, DOI 10.2144/01311rr03; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; Yamanouchi H, 1997, ACTA NEUROPATHOL, V93, P528, DOI 10.1007/s004010050648	44	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46073	46078		10.1074/jbc.M109023200	http://dx.doi.org/10.1074/jbc.M109023200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11598140	hybrid			2022-12-25	WOS:000172573100079
J	Xu, GM; Sikaneta, T; Sullivan, BM; Zhang, QH; Andreucci, M; Stehle, T; Drummond, L; Arnaout, MA				Xu, GM; Sikaneta, T; Sullivan, BM; Zhang, QH; Andreucci, M; Stehle, T; Drummond, L; Arnaout, MA			Polycystin-1 interacts with intermediate filaments.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKD1 GENE-PRODUCT; KIDNEY-DISEASE; IN-VITRO; PROTEIN PHOSPHATASE; MEMBRANE-FUSION; MDCK CELLS; DESMOSOMES; DOMAIN; IDENTIFICATION; MICE	Polycystin-1, the protein defective in a majority of patients with autosomal dominant polycystic kidney disease, is a ubiquitously expressed multi-span transmembrane protein of unknown function. Subcellular localization studies found this protein to be a component of various cell junctional complexes and to be associated with the cytoskeleton, but the specificity and nature of such associations are not known. To identify proteins that interact with the polycystin-1 C-tail (P1CT), this segment was used as bait in a yeast two-hybrid screening of a kidney epithelial cell library. The intermediate filament (IF) protein vimentin was identified as a strong polycystin-1-interacting partner. Cytokeratins K8 and K18 and desmin were also found to interact with P1CT. These interactions were mediated by coiled-coil motifs in polycystin-1 and IF proteins. Vimentin, cytokeratins K8 and K18, and desmin also bound directly to P1CT in GST pull-down and in in vitro filament assembly assays. Two observations confirmed these interactions in vivo: (i) a cell membrane-anchored form of recombinant P1CT decorated the IF network and was found to associate with the cytoskeleton in detergent-solubilized cells and (ii) endogenous polycystin-1 distributed with IF at desmosomal junctions. Polycystin-1 may utilize this association for structural, storage, or signaling functions.	Massachusetts Gen Hosp, Renal Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Bldg 149,13th St, Boston, MA 02129 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054711] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK54711] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen E, 1996, J CELL BIOL, V133, P1367, DOI 10.1083/jcb.133.6.1367; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; BROWN D, 1998, J AM SOC NEPHROL, V9, P371; Carr CM, 2000, NATURE, V404, P347, DOI 10.1038/35006200; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; Eckes B, 1998, J CELL SCI, V111, P1897; Faigle W, 2000, MOL BIOL CELL, V11, P3485, DOI 10.1091/mbc.11.10.3485; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; Foggensteiner L, 2000, J AM SOC NEPHROL, V11, P814, DOI 10.1681/ASN.V115814; Fuchs E, 1997, MOL BIOL CELL, V8, P189, DOI 10.1091/mbc.8.2.189; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Herrmann H, 2000, J MOL BIOL, V298, P817, DOI 10.1006/jmbi.2000.3719; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Ho CL, 1998, J CELL SCI, V111, P1767; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; Inada H, 1998, BIOCHEM BIOPH RES CO, V253, P21, DOI 10.1006/bbrc.1998.9732; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; KELLY DE, 1981, ANAT REC, V199, P1, DOI 10.1002/ar.1091990102; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; KIM K, 1997, J AM SOC NEPHROL, V8, P375; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; Leung CL, 1996, J BIOL CHEM, V271, P14041, DOI 10.1074/jbc.271.24.14041; Li HP, 1999, BIOCHEM BIOPH RES CO, V259, P356, DOI 10.1006/bbrc.1999.0780; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; McNutt N S, 1973, Prog Biophys Mol Biol, V26, P45; MENG JJ, 1994, J BIOL CHEM, V269, P18679; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Neophytou P, 1996, HUM GENET, V98, P437, DOI 10.1007/s004390050235; North AJ, 1999, J CELL SCI, V112, P4325; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 1999, BIOCHEM BIOPH RES CO, V259, P539, DOI 10.1006/bbrc.1999.0810; Perrichot R, 2000, Hum Mutat, V15, P582, DOI 10.1002/1098-1004(200006)15:6<582::AID-HUMU20>3.3.CO;2-2; Peters DJM, 1999, J PATHOL, V188, P439, DOI 10.1002/(SICI)1096-9896(199908)188:4<439::AID-PATH367>3.0.CO;2-P; Piepenhagen PA, 1995, AM J PHYSIOL-CELL PH, V269, pC1433, DOI 10.1152/ajpcell.1995.269.6.C1433; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; QIAN E, 1997, J AM SOC NEPHROL, V8, P1753; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Scheffers MS, 2000, HUM MOL GENET, V9, P2743, DOI 10.1093/hmg/9.18.2743; SHEU HM, 1989, EXP CELL RES, V185, P176, DOI 10.1016/0014-4827(89)90047-5; Thormahlen M, 1998, J STRUCT BIOL, V122, P30, DOI 10.1006/jsbi.1998.3986; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WARD CJ, 1994, CELL, V77, P881; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PD, 1999, LAB INVEST, V79, P1311; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	74	66	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46544	46552		10.1074/jbc.M107828200	http://dx.doi.org/10.1074/jbc.M107828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581269	hybrid			2022-12-25	WOS:000172573100140
J	Tanaka, M; Morishima, I; Akagi, T; Hashikawa, T; Nukina, N				Tanaka, M; Morishima, I; Akagi, T; Hashikawa, T; Nukina, N			Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; NEURODEGENERATIVE DISEASES; HUNTINGTONS-DISEASE; CRYSTAL-STRUCTURE; PROTEIN; APOMYOGLOBIN; FLUORESCENCE; INCLUSIONS; MUTANT; INTACT	An aberrant structure of the expanded polyglutamine might be involved in the formation of aggregates in CAG repeat diseases. To elucidate structural properties of the expanded polyglutamine, we prepared sperm whale myoglobin (Mb) mutants, in which 12, 28, 35, and 50 repeats of glutamine were inserted at the corner between the C and D helices (Gln(12), Gln(28), Gln(35), and Gln(50), respectively). Circular dichroism and IR spectroscopies showed that the expanded polyglutamine, which was recognized by the monoclonal antibody 1C2 in Gln(28), Gln(35), and Gln(50) Mb forms an antiparallel beta -pleated sheet structure. Gln(50) Mb aggregates were found to comprise an intermolecular antiparallel beta -pleated sheet. Fluorescence together with H-1 NMR spectra revealed partial unfolding of the protein surface in Gln(35) and Gln(50) Mb, although the structural changes in the protein core were rather small. The present results indicate that the fluctuating beta -pleated sheet of the expanded polyglutamine exposed on the protein surface facilitates the formation of aggregates through intermolecular interactions. The present study has first established and characterized structural properties of a molecular model for polyglutamine diseases in which various lengths of polyglutamine including a pathologically expanded glutamine repeat were inserted into a structurally known protein.	RIKEN, Brain Sci Inst, Lab CAG Repeat Dis, Wako, Saitama 3510198, Japan; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; RIKEN, Brain Sci Inst, Lab Neural Architecture, Wako, Saitama 3510198, Japan	RIKEN; Kyoto University; RIKEN	Nukina, N (corresponding author), RIKEN, Brain Sci Inst, Lab CAG Repeat Dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Tanaka, Motomasa/N-5064-2015; Nukina, Nobuyuki/GPP-6265-2022	Tanaka, Motomasa/0000-0002-2994-7703; 				Altschuler EL, 1997, J PEPT RES, V50, P73; Chen YW, 1999, P NATL ACAD SCI USA, V96, P1257, DOI 10.1073/pnas.96.4.1257; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Dong A, 1998, ARCH BIOCHEM BIOPHYS, V355, P275, DOI 10.1006/abbi.1998.0718; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Fink AL, 1998, FOLD DES, V3, P19, DOI 10.1016/S1359-0278(98)00005-4; HIRSCH RE, 1980, BIOCHEM BIOPH RES CO, V93, P432, DOI 10.1016/0006-291X(80)91096-7; JENNINGS PA, 1993, SCIENCE, V262, P92; LAMAR GN, 1986, J AM CHEM SOC, V108, P5568, DOI 10.1021/ja00278a033; LAMAR GN, 1980, J AM CHEM SOC, V102, P1822, DOI 10.1021/ja00526a011; Luo YZ, 1998, J MOL BIOL, V279, P49, DOI 10.1006/jmbi.1998.1774; McGowan DP, 2000, NEUROSCIENCE, V100, P677, DOI 10.1016/S0306-4522(00)00391-2; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; PARCZEL A, 1993, INT J PEPT PROT RES, V41, P223; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; POSTNIKOVA GB, 1991, EUR J BIOCHEM, V198, P223, DOI 10.1111/j.1432-1033.1991.tb16005.x; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RAJARATHNAM K, 1993, BIOCHEMISTRY-US, V32, P5670, DOI 10.1021/bi00072a024; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TOWNEND R, 1966, BIOCHEM BIOPH RES CO, V23, P163, DOI 10.1016/0006-291X(66)90522-5; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0	26	90	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45470	45475		10.1074/jbc.M107502200	http://dx.doi.org/10.1074/jbc.M107502200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584007	hybrid			2022-12-25	WOS:000172406700145
J	Wei, JPJ; Srinivasan, C; Han, H; Valentine, JS; Gralla, EB				Wei, JPJ; Srinivasan, C; Han, H; Valentine, JS; Gralla, EB			Evidence for a novel role of copper-zinc superoxide dismutase in zinc metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE LYS7 GENE; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; MOLECULAR-BIOLOGY; FREE-IRON; YEAST; MUTANTS; PROTEINS; DETOXIFICATION; HOMEOSTASIS	The LYS7 gene in Saccharomyces cerevisiae encodes a protein (yCCS) that delivers copper to the active site of copper-zinc superoxide dismutase (CuZn-SOD, a product of the SOD) gene). In yeast lacking Lys7 (lys7 Delta), the SOD1 polypeptide is present but inactive. Mutants lacking the SOD1 polypeptide (sod1 Delta) and lys7 Delta yeast show very similar phenotypes, namely poor growth in air and aerobic auxotrophies for lysine and methionine. Here, we demonstrate certain phenotypic differences between these strains: 1) lys7 Delta cells are slightly less sensitive to paraquat than sod1 Delta cells, 2) EPR-detectable or "free" iron is dramatically elevated in sod1 Delta mutants but not in lys7 Delta yeast, and 3) although sod1 Delta mutants show increased sensitivity to extracellular zinc, the lys7 Delta strain is as resistant as wild type. To restore the SOD catalytic activity but not the zinc-binding capability of the SOD1 polypeptide, we overexpressed Mn-SOD from Bacillus stearothermophilus in the cytoplasm of sod1 Delta yeast. Paraquat resistance was restored to wild-type levels, but zinc was not. Conversely, expression of a mutant CuZn-SOD that binds zinc but has no SOD activity (H46C) restored zinc resistance but not paraquat resistance. Taken together, these results strongly suggest that CuZn-SOD, in addition to its antioxidant properties, plays a role in zinc homeostasis.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Gralla, EB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.		Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM08042, GM08496] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042, T32GM008496] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; Corson LB, 1999, J BIOL CHEM, V274, P27590, DOI 10.1074/jbc.274.39.27590; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRALLA EB, 1997, OXIDATIVE STRESS MOL, P495; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Kaiser C., 1994, METHODS YEAST GENETI; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; Lu Y, 1996, INORG CHEM, V35, P1692, DOI 10.1021/ic9513189; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; NISHIDA CR, 1994, P NATL ACAD SCI USA, V91, P9906, DOI 10.1073/pnas.91.21.9906; Nishimura K, 1998, J BACTERIOL, V180, P1962, DOI 10.1128/JB.180.7.1962-1964.1998; Pearce DA, 1999, J BACTERIOL, V181, P4774, DOI 10.1128/JB.181.16.4774-4779.1999; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; [No title captured]	32	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44798	44803		10.1074/jbc.M104708200	http://dx.doi.org/10.1074/jbc.M104708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581253	hybrid			2022-12-25	WOS:000172406700063
J	Hideshima, T; Nakamura, N; Chauhan, D; Anderson, KC				Hideshima, T; Nakamura, N; Chauhan, D; Anderson, KC			Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; IL-6; SHP2; P13-K; Akt; apoptosis; caspase-9	PROTEIN-KINASE-B; DEXAMETHASONE-INDUCED APOPTOSIS; PLECKSTRIN-HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; CELL-GROWTH; TRANSDUCTION PATHWAY; INHIBITS APOPTOSIS; PLASMA-CELLS; PHOSPHORYLATION; ACTIVATION	Previous studies demonstrate that interleukin-6 (IL-6) mediates growth and survival in human multiple myeloma (MM) cells via the MEK/MAPK and JAK/STAT signaling pathways, respectively. IL-6 also confers protection against Dexamethasone (Dex)-induced apoptosis via activation of protein tyrosine phosphatase (SHP2). In the current study, we characterized IL-6 triggered phophatidylinositol-3 kinase/Akt kinase (PI3K/Akt) signaling in MM cells. IL-6 induces Akt/PKB phosphorylation in a time and dose dependent manner in MMAS MM cells. IL-6 also induced phosphorylation of downstream targets of Akt, including Bad, GSK-3 beta, and FKHR, confirming Akt activation. Inhibition of Akt activation by the PI3-K inhibitor LY294002 partially blocked IL-6 triggered MEK/MAPK activation and proliferation in MMAS cells, suggesting cross-talk between PI3-K and MEK signaling. We demonstrate that Dex-induced apoptosis in MM.1S cells is mediated by downstream activation of caspase-9, with resultant caspase-3 cleavage; and conversely, that IL-6 triggers activation of PI3-K and its association with SHP2, inactivates caspase-9, and protects against Dex-induced apoptosis. LY294002 completely abrogates this signaling cascade, further confirming the importance of PI3-K/Akt signaling in conferring the protective effect of IL-6 against Dex-induced apoptosis. Finally, we show that IL-6 triggered PI3-K/Akt signaling in MMAS cells inactivates forkhead transcriptional factor (FKHR), with related G1/S phase transition, whereas LY294002 blocks this signaling, resulting in upregulation of p27(KIPI) and G1 growth arrest. Our data therefore suggest that PI3-K/ Akt signaling mediates growth, survival, and cell cycle regulatory effects of IL-6 in MM.	Dana Farber Canc Inst, Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, M557,44 Binney St, Boston, MA 02115 USA.				NIMH NIH HHS [R01 MH 50947, P01 MH 78378] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050947] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chung TDK, 2000, PROSTATE, V42, P1; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Ge NL, 2000, BLOOD, V96, P2856; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2000, CLIN CANCER RES, V6, P1180; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KLEIN B, 1989, BLOOD, V73, P517; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343; Ogata A, 1997, J IMMUNOL, V159, P2212; Ogawa M, 2000, CANCER RES, V60, P4262; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tu YP, 2000, CANCER RES, V60, P6763; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	50	390	402	0	23	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5991	6000		10.1038/sj.onc.1204833	http://dx.doi.org/10.1038/sj.onc.1204833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593406				2022-12-25	WOS:000171056300006
J	Knight, MJ; Riffkin, CD; Muscat, AM; Ashley, DM; Hawkins, CJ				Knight, MJ; Riffkin, CD; Muscat, AM; Ashley, DM; Hawkins, CJ			Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells	ONCOGENE			English	Article						apoptosis; glioma; resistance; TRAIL; Fas; Bcl-2	INHIBITORY PROTEIN EXPRESSION; HUMAN-MELANOMA CELLS; MEDIATED APOPTOSIS; MALIGNANT GLIOMA; DECOY RECEPTOR; DEATH PATHWAY; LIGAND TRAIL; CASPASE-8; GENE; AMPLIFICATION	FasL and TNF-related apoptosis-inducing ligand (TRAIL) belong to a subgroup of the TNF superfamily which induce apoptosis by binding to their death domain containing receptors. In the present study we have utilized a panel of seven cell lines derived from human malignant gliomas to characterize molecular pathways through which FasL and TRAIL induce apoptosis in sensitive glioma cells and the mechanisms of resistance in cell lines which survive the death stimuli. Our findings indicate that FADD and Caspase-8 are essential for FasL and TRAIL mediated apoptosis in glioma cells. One sensitive cell line (D270) can be protected from FasL and TRAIL induced death by anti-apoptotic Bcl-2 family members while another (D645) cannot, implying that these lines may represent glioma examples of type II and type I cells respectively. For the first time we demonstrate resistance to FasL but not to TRAIL within the one glioma cell line. Furthermore, we report distinct mechanisms of resistance within different glioma lines, including downregulation of Caspase-8 in U373MG. Cycloheximide sensitized four of the resistant cell lines suggesting the presence of labile inhibitors. None of the known apoptosis inhibitors examined accounted for the observed resistance, suggesting novel inhibitors may exist in glioma cells.	Royal Childrens Hosp, Dept Haematol & Oncol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic, Australia	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Royal Melbourne Hospital; University of Melbourne	Hawkins, CJ (corresponding author), Royal Childrens Hosp, Dept Haematol & Oncol, Flemington Rd, Parkville, Vic 3052, Australia.		Hawkins, Christine/B-8769-2011	Hawkins, Christine/0000-0001-8120-1071				Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hao CH, 2001, CANCER RES, V61, P1162; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hosli P, 1998, ANN ONCOL, V9, P589; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jenkins M, 2000, J BIOL CHEM, V275, P7988, DOI 10.1074/jbc.275.11.7988; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Keane MM, 1999, CANCER RES, V59, P734; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Myc A, 1999, ENDOCRINOLOGY, V140, P5431, DOI 10.1210/en.140.11.5431; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1999, CELL MOL LIFE SCI, V56, P481, DOI 10.1007/s000180050447; Roth W, 2001, CANCER RES, V61, P2759; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Somia NV, 1999, P NATL ACAD SCI USA, V96, P12667, DOI 10.1073/pnas.96.22.12667; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wrone-Smith T, 2001, EXP HEMATOL, V29, P572, DOI 10.1016/S0301-472X(01)00627-0; Wu M, 2000, J NEUROSCI RES, V61, P464, DOI 10.1002/1097-4547(20000815)61:4<464::AID-JNR14>3.0.CO;2-G; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XJ, 2000, BIOCHEM BIOPH RES CO, V277, P487, DOI 10.1006/bbrc.2000.3699; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	64	84	88	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5789	5798		10.1038/sj.onc.1204810	http://dx.doi.org/10.1038/sj.onc.1204810			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593384				2022-12-25	WOS:000171037200002
J	Zhang, F; Taipale, M; Heiskanen, A; Laiho, M				Zhang, F; Taipale, M; Heiskanen, A; Laiho, M			Ectopic expression of Cdk6 circumvents transforming growth factor-beta mediated growth inhibition	ONCOGENE			English	Article						TGF-beta; cyclin-dependent kinase; cyclin-dependent kinase inhibitors; cell cycle regulation	CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITOR; TGF-BETA; EPITHELIAL-CELLS; MAMMALIAN-CELLS; P15(INK4B); PROTEIN; INK4; COMPLEXES; P27(KIP1)	Transforming growth factor-beta (TGF-beta) induced growth arrest of cells involves regulation of the activities of both D- and E-type cyclin kinase complexes thought to be mediated primarily by the regulation of p15(Ink4b) and p27(Kip1) cyclin kinase inhibitors. We show here that TGF-beta downregulates Cdk6 and that transient and stable expression of Cdk6 in Mv1Lu mink epithelial cells overrides TGF-beta mediated arrest. The main effect of the ectopic Cdk6 expression was to sequester TGF-P induced p15(Ink4b) and to maintain more p27(Kip1) in cyclin D-complexes preventing the complete shift of p27(Kip1) to Cdk2 invoked by TGF-beta. This led to the presence of an active cyclinD-Cdk6-p27(Kip1) complex and partially active cyclin E-Cdk2 complex and resulted in the failure of TGF-beta to fully arrest Mv1Lu cell growth. Though dominant negative Cdk6, expressed similarly in the cells, sequestered both p15(Ink4b) and p27(Kip1), it lacks kinase activity and was unable to override the TGF-beta arrest. The results demonstrate that downregulation of Cdk6 kinase is required for the enforcement of the G(1)-phase arrest by TGF-beta and results in changes in association of the p15(Ink4b) and p27(Kip1) inhibitors with D- and E-type cyclin kinase complexes.	Univ Helsinki, Mol Canc Biol Res Program, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland	University of Helsinki	Laiho, M (corresponding author), Univ Helsinki, Mol Canc Biol Res Program, Dept Virol, Haartman Inst, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.			Taipale, Minna/0000-0002-1905-2551				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Costello JF, 1997, CANCER RES, V57, P1250; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Easton J, 1998, CANCER RES, V58, P2624; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Parry D, 1999, MOL CELL BIOL, V19, P1775; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tsubari M, 1997, CANCER RES, V57, P2966; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Warner BJ, 1999, MOL CELL BIOL, V19, P5913	36	8	9	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5888	5896		10.1038/sj.onc.1204745	http://dx.doi.org/10.1038/sj.onc.1204745			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593394				2022-12-25	WOS:000171037200012
J	Venkatesan, S; Petrovic, A; Van Ryk, DI; Locati, M; Weissman, D; Murphy, PM				Venkatesan, S; Petrovic, A; Van Ryk, DI; Locati, M; Weissman, D; Murphy, PM			Reduced cell surface expression of CCR5 in CCR5 Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HIV-1 CORECEPTOR; ENDOPLASMIC-RETICULUM; MOLECULAR-MECHANISMS; CHEMOKINE RECEPTORS; CD4(+) LYMPHOCYTES; MIP-1 ALPHA; BETA; IDENTIFICATION; INFECTION	Macrophage tropic (M-tropic) human immunodeficiency virus (HIV) infection of primary human T cells and macrophages requires optimal cell surface expression of the chemokine receptor CCR5 in addition to CD4. Natural mutations of CCR5 that impair surface expression bestow in the homozygous state complete resistance to M-tropic HIV infection. ccr5Delta32 is the major prototype of such mutants. ccr5Delta32 heterozygosity is associated with delayed onset of AIDS and reduced risk of initial transmission, and this correlates with reduced levels of CCR5 and reduced infectability of CD4+ cells. In addition to gene dosage, sequestration of wild type (WT) CCR5 by mutant protein has been proposed as a mechanism to explain reduced surface expression of CCR5 in cells from ccr5Delta32 and CCR5-893(-) heterozygotes. However, here we demonstrate that a molar excess of ccr5Delta32 or related deletion mutants does not significantly impair the cell surface density of co-expressed WT receptor either in human epithelial cells or Jurkat T cells. Further, ligand-dependent signaling and M-tropic HIV usage of WT receptor are also unaffected. Nascent WT receptor does associate with ccr5Delta32 and related mutant proteins and with other unrelated CC and CXC chemokine receptors under transient labeling conditions. However, using confocal microscopy, we demonstrate that in the steady state, WT and truncated CCR5 proteins segregate into nonoverlapping subcellular compartments. These findings together with the observed and known variability in the cell surface density of CCR5 on quiescent PBLs lead us to conclude that reduced CCR5 gene dosage rather than receptor sequestration is the major determinant of reduced CCR5 expression in cells from ccr5Delta32 heterozygotes.	NIAID, LMM, NIH, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Ist Patol Gen, I-20133 Milan, Italy; Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Pennsylvania	Venkatesan, S (corresponding author), NIAID, LMM, NIH, Bldg 10,Rm 6A05, Bethesda, MD 20892 USA.	aradhana@helix.nih.gov	Locati, Massimo/H-8404-2015; Locati, Massimo/ABF-6807-2021	Locati, Massimo/0000-0003-3077-590X; 				Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J BIOL CHEM, V271, P11034; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Howard OMZ, 1999, J BIOL CHEM, V274, P16228, DOI 10.1074/jbc.274.23.16228; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Latronico AC, 1999, AM J HUM GENET, V65, P949, DOI 10.1086/302602; Lee SP, 2000, NEUROPSYCHOPHARMACOL, V23, pS32, DOI 10.1016/S0893-133X(00)00155-X; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Marmor M, 2001, J ACQ IMMUN DEF SYND, V27, P472, DOI 10.1097/00126334-200108150-00009; Mellado M, 1999, NATURE, V400, P723, DOI 10.1038/23382; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Paxton WA, 1999, IMMUNOL LETT, V66, P71, DOI 10.1016/S0165-2478(98)00154-0; Paxton WA, 1998, VIROLOGY, V244, P66, DOI 10.1006/viro.1998.9082; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; SUNG CH, 1994, J NEUROSCI, V14, P5818; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; VENKATESAN S, 1992, J VIROL, V66, P7469, DOI 10.1128/JVI.66.12.7469-7480.1992; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	69	66	68	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 18	2002	277	3					2287	2301		10.1074/jbc.M108321200	http://dx.doi.org/10.1074/jbc.M108321200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CW	11604406	hybrid			2022-12-25	WOS:000173421300089
J	Askew, YS; Pak, SC; Luke, CJ; Askew, DJ; Cataltepe, S; Mills, DR; Kato, H; Lehoczky, J; Dewar, K; Birren, B; Silverman, GA				Askew, YS; Pak, SC; Luke, CJ; Askew, DJ; Cataltepe, S; Mills, DR; Kato, H; Lehoczky, J; Dewar, K; Birren, B; Silverman, GA			SERPINB12 is a novel member of the human ov-serpin family that is widely expressed and inhibits trypsin-like serine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHYMOTRYPSIN; MECHANISM; GENE; SCCA2; SUPERFAMILY; EVOLUTION; CONTAINS; THROMBIN; CLEAVAGE; CLONING	Members of the human serpin family regulate a diverse array of serine and cysteine proteinases associated with essential biological processes such as fibrinolysis, coagulation, inflammation, cell mobility, cellular differentiation, and apoptosis. Most serpins are secreted and attain physiologic concentrations in the blood and extracellular fluids. However, a subset of the serpin superfamily, the ov-serpins, also resides intracellularly. Using high throughput genomic sequence, we identified a novel member of the human ov-serpin gene family, SERPINB12. The gene mapped to the ov-serpin cluster at 18q21 and resided between SERPINB5 (maspin) and SERPINB13 (headpin). The presence of SERPINB12 in silico was confirmed by cDNA cloning. Expression studies showed that SERPINB12 was expressed in many tissues, including brain, bone marrow, lymph node, heart, lung, liver, pancreas, testis, ovary, and intestines. Based on the presence of Arg and Ser at the reactive center of the RSL, SERPINB12 appeared to be an inhibitor of trypsin-like serine proteinases. This hypothesis was confirmed because recombinant SERPINB12 inhibited human trypsin and plasmin but not thrombin, coagulation factor Xa, or urokinase-type plasminogen activator. The second-order rate constants for the inhibitory reactions were 2.5 +/- 1.6 x 10(5) and 1.6 +/- 0.2 x 10(4) m(-1) s(-1), respectively. These data show that SERPINB12 encodes for a new functional member of the human ov-serpin family.	Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA; Yamaguchi Univ, Sch Med, Dept Obstet & Gynecol, Ube, Yamaguchi 7558505, Japan; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02141 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Yamaguchi University; Massachusetts Institute of Technology (MIT); Whitehead Institute	Silverman, GA (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, 300 Longwood Ave,Enders 970, Boston, MA 02115 USA.	gary.silverman@tch.harvard.edu	Silverman, Gary/AAJ-1269-2020	Pak, Stephen/0000-0002-8089-3237	NCI NIH HHS [CA87006, CA86002] Funding Source: Medline; NICHD NIH HHS [HD07466, HD28475] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD028475, R01HD028475] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA086002, R01CA087006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartuski AJ, 1997, GENOMICS, V43, P321, DOI 10.1006/geno.1997.4827; Bird CH, 2001, MOL CELL BIOL, V21, P5396, DOI 10.1128/MCB.21.16.5396-5407.2001; Bird PI, 1999, IMMUNOL CELL BIOL, V77, P47, DOI 10.1046/j.1440-1711.1999.00787.x; CARRELL RW, 1989, MOL BIOL MED, V6, P35; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; De Falco S, 2001, J BIOL CHEM, V276, P36613, DOI 10.1074/jbc.M102377200; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; EVANS E, 1995, GENOMICS, V28, P235, DOI 10.1006/geno.1995.1136; Eyre HJ, 1996, GENOMICS, V37, P406, DOI 10.1006/geno.1996.0580; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Katz SG, 1999, HUM MOL GENET, V8, P87, DOI 10.1093/hmg/8.1.87; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; Luke C, 2000, BIOCHEMISTRY-US, V39, P7081, DOI 10.1021/bi000050g; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Scott FL, 1999, GENOMICS, V62, P490, DOI 10.1006/geno.1999.6021; SILVERMAN GA, 1991, GENOMICS, V9, P219, DOI 10.1016/0888-7543(91)90245-A; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SILVERMAN GA, 1993, MOL CELL BIOL, V13, P5469, DOI 10.1128/MCB.13.9.5469; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Uemura Y, 2000, INT J CANCER, V89, P368, DOI 10.1002/1097-0215(20000720)89:4<368::AID-IJC9>3.0.CO;2-6; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	39	38	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49320	49330		10.1074/jbc.M108879200	http://dx.doi.org/10.1074/jbc.M108879200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11604408	hybrid			2022-12-25	WOS:000173922100091
J	Elias, MD; Tanaka, M; Sakai, M; Toyama, H; Matsushita, K; Adachi, O; Yamada, M				Elias, MD; Tanaka, M; Sakai, M; Toyama, H; Matsushita, K; Adachi, O; Yamada, M			C-terminal periplasmic domain of Escherichia coli quinoprotein glucose dehydrogenase transfers electrons to ubiquinone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE RESPIRATORY-CHAIN; GLUCONOBACTER-SUBOXYDANS; ALCOHOL-DEHYDROGENASE; BINDING-SITE; PQQ; TRANSPORT; REDUCTION; GENE; RECONSTITUTION; MITOCHONDRIAL	Membrane-bound quinoprotein glucose dehydrogenase (GDH) in Escherichia coli donates electrons directly to ubiquinone during the oxidation Of D-glucose as a substrate, and these electrons are subsequently transferred to ubiquinol oxidase in the respiratory chain. To determine whether the specific ubiquinone-reacting site of GDH resides in the N-terminal transmembrane domain or in the large C-terminal periplasmic catalytic domain (cGDH), we constructed a fusion protein between the signal sequence of beta -lactamase and cGDH. This truncated GDH was found to complement a GDH gene-disrupted strain in vivo. The signal sequence of the fused protein was shown to be cleaved off, and the remaining cGDH was shown to be recovered in the membrane fraction, suggesting that cGDH has a membrane-interacting site that is responsible for binding to membrane, like peripheral proteins. Kinetic analysis and reconstitution experiments revealed that cGDH has ubiquinone reductase activity nearly equivalent to that of the wild-type GDH. Thus, it is likely that the C-terminal periplasmic domain of GDH possesses a ubiquinone-reacting site and transfers electrons directly to ubiquinone.	Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan	Yamaguchi University	Yamada, M (corresponding author), Yamaguchi Univ, Fac Agr, Dept Biol Chem, 1677-1 Yoshida, Yamaguchi 7538515, Japan.	yamada@agr.yamaguchi-u.ac.jp		Yamada, Mamoru/0000-0003-4354-7324				AMEYAMA M, 1986, AGR BIOL CHEM TOKYO, V50, P49, DOI 10.1080/00021369.1986.10867348; AMEYAMA M, 1981, FEBS LETT, V130, P179, DOI 10.1016/0014-5793(81)81114-3; ANTHONY C, 1992, BIOCHIM BIOPHYS ACTA, V1099, P1, DOI 10.1016/0005-2728(92)90181-Z; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; Cozier GE, 1999, BIOCHEM J, V340, P639, DOI 10.1042/0264-6021:3400639; Cozier GE, 1995, BIOCHEM J, V312, P679, DOI 10.1042/bj3120679; DUINE JA, 1979, FEBS LETT, V108, P443, DOI 10.1016/0014-5793(79)80584-0; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; Elias MD, 2000, J BIOL CHEM, V275, P7321, DOI 10.1074/jbc.275.10.7321; Frebortova J, 1998, BBA-BIOENERGETICS, V1363, P24, DOI 10.1016/S0005-2728(97)00090-X; FRIEDRICH T, 1990, FEBS LETT, V265, P37, DOI 10.1016/0014-5793(90)80878-M; Goodwin PM, 1998, ADV MICROB PHYSIOL, V40, P1, DOI 10.1016/S0065-2911(08)60129-0; HOMMES RWJ, 1984, FEMS MICROBIOL LETT, V24, P329, DOI 10.1016/0378-1097(84)90274-X; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MANIATES T, 2001, MOL CLONING LAB MANU; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsushita K, 1996, J BIOL CHEM, V271, P4850; MATSUSHITA K, 1989, J BIOCHEM, V105, P633, DOI 10.1093/oxfordjournals.jbchem.a122716; MATSUSHITA K, 1987, J BACTERIOL, V169, P205, DOI 10.1128/jb.169.1.205-209.1987; Matsushita K, 1997, MICROBIOL-UK, V143, P3149, DOI 10.1099/00221287-143-10-3149; MATSUSHITA K, 1991, J BACTERIOL, V173, P3440, DOI 10.1128/jb.173.11.3440-3445.1991; Miyoshi H, 1999, BBA-BIOENERGETICS, V1412, P29, DOI 10.1016/S0005-2728(99)00009-2; NAKAZAWA T, 1980, J BACTERIOL, V144, P222, DOI 10.1128/JB.144.1.222-231.1980; OKUDA J, 2000, J BIOCH MOL BIOL BIO, V4, P415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato-Watanabe M, 1998, BIOCHEMISTRY-US, V37, P12744, DOI 10.1021/bi981184l; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; Sode K, 1997, BIOTECHNOL LETT, V19, P1073, DOI 10.1023/A:1018428224215; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; Tsatsos PH, 1998, BIOCHEMISTRY-US, V37, P9884, DOI 10.1021/bi9809270; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; Yamada M, 1998, J BIOL CHEM, V273, P22021, DOI 10.1074/jbc.273.34.22021; YAMADA M, 1993, J BIOL CHEM, V268, P12812; YAMADA M, 1993, J BACTERIOL, V175, P568, DOI 10.1128/JB.175.2.568-571.1993; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	36	21	21	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48356	48361		10.1074/jbc.M107355200	http://dx.doi.org/10.1074/jbc.M107355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604400	hybrid			2022-12-25	WOS:000172927000084
J	Hillier, W; Hendry, G; Burnap, RL; Wydrzynski, T				Hillier, W; Hendry, G; Burnap, RL; Wydrzynski, T			Substrate water exchange in photosystem II depends on the peripheral proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-STABILIZING PROTEIN; PHOTOSYNTHETIC OXYGEN-EVOLUTION; EXTRINSIC PROTEINS; 33-KDA PROTEIN; EXOGENOUS REDUCTANTS; CYTOCHROME C-550; EVOLVING COMPLEX; PROTON-TRANSFER; OXIDIZING SIDE; CORE COMPLEX	The O-18 exchange rates for the substrate water bound in the S-3 state were determined in different photosystem. II sample types using time-resolved mass spectrometry. The samples included thylakoid membranes, salt-washed Triton X-100-prepared membrane fragments, and purified core complexes from spinach and cyanobacteria. For each sample type, two kinetically distinct isotopic exchange rates could be resolved, indicating that the biphasic exchange behavior for the substrate water is inherent to the O-2-evolving catalytic site in the S3 state. However, the fast phase of exchange became somewhat slower (by a factor of similar to2) in NaCl-washed membrane fragments and core complexes from spinach in which the 16- and 23-kDa extrinsic proteins have been removed, compared with the corresponding rate for the intact samples. For CaCl2-washed membrane fragments in which the 33-kDa manganese stabilizing protein (MSP) has also been removed, the fast phase of exchange slowed down even further (by a factor of similar to3). Interestingly, the slow phase of exchange was little affected in the samples from spinach. For core complexes prepared from Synechocystis PCC 6803 and Synechococcus elongatus, the fast and slow exchange rates were variously affected. Nevertheless, within the experimental error, nearly the same exchange rates were measured for thylakoid samples made from wild type and an MSP-lacking mutant of Synechocystis PCC 6803. This result could indicate that the MSP has a slightly different function in eukaryotic organisms compared with prokaryotic organisms. In all samples, however, the differences in the exchange rates are relatively small. Such small differences are unlikely to arise from major changes in the metal-ligand structure at the catalytic site. Rather, the observed differences may reflect subtle long range effects in which the exchange reaction coordinates become slightly altered. We discuss the results in terms of solvent penetration into photosystem II and the regional dielectric around the catalytic site.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Oklahoma State Univ, Dept Microbiol & Mol Genet, Stillwater, OK 74078 USA; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 0200, Australia	Michigan State University; Oklahoma State University System; Oklahoma State University - Stillwater; Australian National University	Hillier, W (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.	Hillier@photon.cem.msu.edu	Wydrzynski, Thomas/C-9630-2009; Hillier, Warwick/D-1034-2009					AKERLUND HE, 1982, BIOCHIM BIOPHYS ACTA, V681, P1, DOI 10.1016/0005-2728(82)90271-7; Al-Khaldi SF, 2000, PLANT MOL BIOL, V43, P33, DOI 10.1023/A:1006419928712; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Bricker TM, 1998, BBA-BIOENERGETICS, V1409, P50, DOI 10.1016/S0005-2728(98)00148-0; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BRICKER TM, 1996, ADV PHOTOSYNTH, V4, P113; BRITT DR, 1996, OXYGENIC PHOTOSYNTHE, V4, P137; Britt RD, 2000, ANNU REV BIOPH BIOM, V29, P463, DOI 10.1146/annurev.biophys.29.1.463; Burda K, 2001, BBA-BIOENERGETICS, V1506, P47, DOI 10.1016/S0005-2728(01)00182-7; Burda K, 2001, FEBS LETT, V491, P81, DOI 10.1016/S0014-5793(01)02175-5; Burnap RL, 1996, BIOCHEMISTRY-US, V35, P874, DOI 10.1021/bi951964j; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; Campbell KA, 1998, BIOCHEMISTRY-US, V37, P5039, DOI 10.1021/bi9800552; Debus RJ, 2000, MET IONS BIOL SYST, V37, P657; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; Denisov VP, 1996, NAT STRUCT BIOL, V3, P505, DOI 10.1038/nsb0696-505; Dwyer JJ, 2000, BIOPHYS J, V79, P1610, DOI 10.1016/S0006-3495(00)76411-3; ENAMI I, 1994, BBA-BIOENERGETICS, V1185, P75, DOI 10.1016/0005-2728(94)90195-3; Enami I, 1995, BBA-BIOENERGETICS, V1232, P208, DOI 10.1016/0005-2728(95)00122-0; GHANOTAKIS DF, 1984, BIOCHIM BIOPHYS ACTA, V767, P524, DOI 10.1016/0005-2728(84)90051-3; Halle B, 1999, NATO ADV SCI I A-LIF, V305, P233; Halle B., 1999, BIOL MAGN RESON, V17, P419; Haumann M, 1997, PHOTOSYNTH RES, V51, P193, DOI 10.1023/A:1005861917596; Hillier W, 2000, BIOCHEMISTRY-US, V39, P4399, DOI 10.1021/bi992318d; Hillier W, 2001, BBA-BIOENERGETICS, V1503, P197, DOI 10.1016/S0005-2728(00)00225-5; Hillier W, 1998, BIOCHEMISTRY-US, V37, P16908, DOI 10.1021/bi980756z; Hoganson CW, 2000, MET IONS BIOL SYST, V37, P613; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; KUWABARA T, 1983, PLANT CELL PHYSIOL, V24, P741, DOI 10.1093/oxfordjournals.pcp.a076571; Kuzek D, 2001, BBA-BIOENERGETICS, V1503, P123, DOI 10.1016/S0005-2728(00)00218-8; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; MIYAO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P151, DOI 10.1016/0005-2728(87)90016-8; Mulkidjanian AY, 1999, BBA-BIOENERGETICS, V1410, P1, DOI 10.1016/S0005-2728(98)00174-1; Nugent JHA, 2001, BBA-BIOENERGETICS, V1503, P138, DOI 10.1016/S0005-2728(00)00223-1; ONO T, 1984, FEBS LETT, V168, P281, DOI 10.1016/0014-5793(84)80263-X; ONO TA, 1983, FEBS LETT, V164, P255, DOI 10.1016/0014-5793(83)80297-X; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; Razeghifard MR, 1997, BIOCHEMISTRY-US, V36, P14474, DOI 10.1021/bi970116g; Richens DT., 1997, CHEM AQUA IONS; Schlodder E, 1999, J BIOL CHEM, V274, P30387, DOI 10.1074/jbc.274.43.30387; SEIDLER A, 1997, BIOCHIM BIOPHYS ACTA, V1277, P35; SHARP RR, 1980, BIOCHIM BIOPHYS ACTA, V592, P169, DOI 10.1016/0005-2728(80)90123-1; Shen JR, 1998, BIOCHEMISTRY-US, V37, P1551, DOI 10.1021/bi971676i; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; TAMURA N, 1990, PLANT CELL PHYSIOL, V31, P469; TAMURA N, 1985, BIOCHIM BIOPHYS ACTA, V809, P245, DOI 10.1016/0005-2728(85)90068-4; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; Tommos C, 1998, ACCOUNTS CHEM RES, V31, P18, DOI 10.1021/ar9600188; VANLEEUWEN PJ, 1993, PHOTOSYNTH RES, V38, P169, DOI 10.1007/BF00146416; VANLEEUWEN PJ, 1991, PHOTOSYNTH RES, V28, P149, DOI 10.1007/BF00054128; Vrettos JS, 2001, BIOCHEMISTRY-US, V40, P7937, DOI 10.1021/bi010679z; Vrettos JS, 2001, BBA-BIOENERGETICS, V1503, P229, DOI 10.1016/S0005-2728(00)00214-0; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Wydrzynski T, 1996, PHYSIOL PLANTARUM, V96, P342, DOI 10.1111/j.1399-3054.1996.tb00224.x; Zouni A, 2000, BBA-BIOENERGETICS, V1457, P103, DOI 10.1016/S0005-2728(00)00100-6; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589; Zouni A, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P925	64	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46917	46924		10.1074/jbc.M102954200	http://dx.doi.org/10.1074/jbc.M102954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595731	hybrid			2022-12-25	WOS:000172768500034
J	Scholich, K; Pierre, S; Patel, TB				Scholich, K; Pierre, S; Patel, TB			Protein associated with Myc (PAM) is a potent inhibitor of adenylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CRYSTAL-STRUCTURE; C-ELEGANS; KINASE-II; IN-VIVO; STIMULATION; EXPRESSION; CLONING; IDENTIFICATION; CALMODULIN	Using the yeast two-hybrid assay and the second of the two large cytosolic domains of type V adenylyl cyclase (ACV) as bait, we identified a small region (amino acids 1028-1231) in the protein associated with Myc (PAM) as an interaction site for ACV. This small region of PAM as well as purified full-length PAM inhibited the activity of ACV. Additionally, full-length PAM was a very potent inhibitor of ACI and AC activities in S49 cyc(-) cells and HeLa cells with IC50 values in the pm and low nm range. Moreover, the regulator of chromatin condensation I-like domain of PAM (amino acids 446-1062) was sufficient and as potent as full-length PAM at inhibiting the activity of ACV. Interestingly, full-length PAM did not inhibit ACII activity that was stimulated by either forskolin of G alpha (s). When endogenous levels of PAM in HeLa cells were decreased using antisense oligode-oxynucleotides, the basal cAMP content was elevated and the dose-response curve for vasoactive intestinal peptide-elicited cAMP accumulation in HeLa cells was shifted to the left. Therefore, we conclude that PAM is a very potent, novel inhibitor of specific isoforms of AC. Furthermore, the regulator of chromatin condensation I-like domain of PAM is sufficient to exert the effects of the full-length protein on AC and decreases in endogenous PAM levels in HeLa cells can modulate both basal and agonist stimulated cAMP accumulation.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Vasc Biol Ctr, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Patel, TB (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; CHEN ZT, 1995, J BIOL CHEM, V270, P27525, DOI 10.1074/jbc.270.46.27525; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KASSIS S, 1982, J BIOL CHEM, V257, P5312; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; NAIR BG, 1990, J BIOL CHEM, V265, P21317; Patel TB, 2001, GENE, V269, P13, DOI 10.1016/S0378-1119(01)00448-6; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Schaefer AM, 2000, NEURON, V26, P345, DOI 10.1016/S0896-6273(00)81168-X; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Smit Martine J., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P1; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Sun H, 1997, J BIOL CHEM, V272, P5413, DOI 10.1074/jbc.272.9.5413; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 2001, J BIOL CHEM, V276, P8500, DOI 10.1074/jbc.M010361200; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zhen M, 2000, NEURON, V26, P331, DOI 10.1016/S0896-6273(00)81167-8	48	43	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47583	47589		10.1074/jbc.M107816200	http://dx.doi.org/10.1074/jbc.M107816200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590159	hybrid			2022-12-25	WOS:000172768500118
J	Aydemir-Koksoy, A; Abramowitz, J; Allen, JC				Aydemir-Koksoy, A; Abramowitz, J; Allen, JC			Ouabain-induced signaling and vascular smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DIGITALIS-LIKE-FACTOR; ANGIOTENSIN-II; NA+/K+-ATPASE; INTRACELLULAR NA+; TRANSDUCTION; TRANSACTIVATION; MECHANISMS; SECRETION; ADDUCIN	The hypothesis of this study is that the sodium pump complex acts as an intracellular signal-transducing molecule in canine vascular smooth muscle cells through its interaction with other membrane and cytoskeletal proteins. We have demonstrated that 1 nM ouabain induced transactivation of the epidermal growth factor receptor (EGFR), resulting in increased proliferation and bromodeoxyuridine (BrdUrd) uptake. Immunoprecipitation and Western blotting showed that the EGFR and Src were phosphorylated within 5 min of 10(-9) M ouabain stimulation. Both ouabain-induced DNA synthesis (BrdUrd uptake) and MAPK42/44 phosphorylation were inhibited by the Src inhibitor PP2, the EGFR kinase inhibitor AG1478, the tyrosine kinase inhibitor genistein, and the MEK1 inhibitor PD98059. Ouabain concentrations higher than 1 nM had little or no stimulating effect on proliferation or BrdUrd uptake but did minimally activate ERK1/2. Thus, low concentrations of ouabain, which do not inhibit the sodium pump sufficiently to perturb the resting cellular ionic milieu, initiate a transactivational signaling cascade leading to vascular smooth muscle cell proliferation.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Cardiovasc Sci Sect, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Allen, JC (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.	juliusa@bcm.tmc.edu	Abramowitz, Joel/A-2620-2015	Allen, Jeffrey/0000-0001-9957-6664	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024585] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24585] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN JC, 1989, AM J PHYSIOL, V256, pC786, DOI 10.1152/ajpcell.1989.256.4.C786; Aydemir-Koksoy A, 2001, AM J PHYSIOL-HEART C, V280, pH1869, DOI 10.1152/ajpheart.2001.280.4.H1869; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; Danto SI, 1998, AM J PHYSIOL-CELL PH, V275, pC82, DOI 10.1152/ajpcell.1998.275.1.C82; Demoliou-Mason CD, 1998, BIOL SIGNAL RECEPT, V7, P90; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; Ferrandi M, 1999, AM J PHYSIOL-HEART C, V277, pH1338, DOI 10.1152/ajpheart.1999.277.4.H1338; GESCHWIND A, 2001, ONCOGENE, V20, P1594; GOLOMB E, 1994, AM J HYPERTENS, V7, P69, DOI 10.1093/ajh/7.1.69; GOTO A, 1992, PHARMACOL REV, V44, P377; GOTO A, 1990, BIOCHEM BIOPH RES CO, V173, P1093, DOI 10.1016/S0006-291X(05)80898-8; Haas M, 2000, J BIOL CHEM, V275, P27832; Haendeler J, 2000, REGUL PEPTIDES, V95, P1, DOI 10.1016/S0167-0115(00)00133-6; Hamlyn JM, 1998, CLIN EXP HYPERTENS, V20, P523, DOI 10.3109/10641969809053230; Ishida Mari, 1997, Keio Journal of Medicine, V46, P61; Iwasaki H, 1998, J CARDIOVASC PHARM, V31, pS182, DOI 10.1097/00005344-199800001-00052; KAHN A M, 1992, Journal of the American Society of Nephrology, V3, P522; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; KRAMER HJ, 1991, AM J HYPERTENS, P481; LAREDO J, 1995, BIOCHEM BIOPH RES CO, V212, P487, DOI 10.1006/bbrc.1995.1996; Leserer M, 2000, IUBMB LIFE, V49, P405; Liu J, 2000, J BIOL CHEM, V275, P27838; LOMPRE AM, 1999, CLIN EXP PHARM PHYSL, V26, P1; NAKAGAWA Y, 1992, J BIOL CHEM, V267, P8785; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; SCHMITZ G, 1991, ATHEROSCLEROSIS, V88, P109, DOI 10.1016/0021-9150(91)90074-D; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611, DOI 10.1111/j.1365-201X.1998.tb10705.x; Takahashi H, 2000, HYPERTENS RES, V23, pS1, DOI 10.1291/hypres.23.Supplement_S1; Tripodi G, 1996, J CLIN INVEST, V97, P2815, DOI 10.1172/JCI118737; Turner NA, 2001, CELL SIGNAL, V13, P269, DOI 10.1016/S0898-6568(01)00135-8; Velarde V, 1999, AM J PHYSIOL-CELL PH, V277, pC253, DOI 10.1152/ajpcell.1999.277.2.C253	32	131	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46605	46611		10.1074/jbc.M106178200	http://dx.doi.org/10.1074/jbc.M106178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579090	hybrid			2022-12-25	WOS:000172573100147
J	Chang, HSW; Julin, DA				Chang, HSW; Julin, DA			Structure and function of the Escherichia coli RecE protein, a member of the RecB nuclease domain family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROCELLULOSE-FILTER-BINDING; EXONUCLEASE-VIII; EVOLUTIONARY RELATIONSHIPS; ENDONUCLEASE ACTIVITY; CONSENSUS SEQUENCE; STRANDED-DNA; RAC PROPHAGE; ACTIVE-SITE; ENZYME; IDENTIFICATION	The RecB subunit of the Escherichia coli RecBCD enzyme has both helicase and nuclease activities. The helicase function was localized to an N-terminal domain, whereas the nuclease activity was found in a C-terminal domain. Recent analysis has uncovered a group of proteins that have weak amino acid sequence similarity to the RecB nuclease domain and that are proposed to constitute a family of related proteins (Axavind, L., Walker, D. R., and Koonin, E. V. (1999) Nucleic Acids Res. 27,1223-1242). One is the E. coli RecE protein (exonuclease VIII), an ATP-independent exonuclease that degrades the 5 ' -terminated strand of double-stranded DNA. We have made mutations in several residues of RecE that align with the critical residues of RecB, and we find that the mutations reduce or abolish the nuclease activity of RecE but do not affect the enzyme binding to linear double-stranded DNA. Proteolysis experiments with subtilisin show that a stable 34-kilodalton C-terminal domain that contains these critical residues has nuclease activity, whereas no stable proteolytic fragments accumulate from the N-terminal portion of RecE. These results show that RecE has a nuclease domain and active site that are similar to RecB, despite the very weak sequence similarity between the two proteins. These similarities support the hypothesis that the nuclease domains of the two proteins are evolutionarily related.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Julin, DA (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	dj13@umail.umd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039777, R29GM039777] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39777] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; CAMPBELL AM, 1996, ESCHERICHIA COLI SAL, V2, P2041; CHU CC, 1989, J BACTERIOL, V171, P2101, DOI 10.1128/jb.171.4.2101-2109.1989; CLARK AJ, 1993, J BACTERIOL, V175, P7673, DOI 10.1128/JB.175.23.7673-7682.1993; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; JOSEPH JW, 1983, J BIOL CHEM, V258, P411; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KOOISTRA J, 1993, MOL MICROBIOL, V7, P915, DOI 10.1111/j.1365-2958.1993.tb01182.x; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; KORANGY F, 1992, J BIOL CHEM, V267, P1733; KORANGY F, 1992, J BIOL CHEM, V267, P1727; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KUSHNER SR, 1974, P NATL ACAD SCI USA, V71, P3593, DOI 10.1073/pnas.71.9.3593; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LUISIDELUCA C, 1988, J BACTERIOL, V170, P5797, DOI 10.1128/jb.170.12.5797-5805.1988; Luneberg E, 2001, MOL MICROBIOL, V39, P1259, DOI 10.1111/j.1365-2958.2001.02314.x; Matsuo Y, 1999, PROTEINS, V35, P70, DOI 10.1002/(SICI)1097-0134(19990401)35:1<70::AID-PROT7>3.0.CO;2-9; Moreira D, 2000, MOL MICROBIOL, V35, P1, DOI 10.1046/j.1365-2958.2000.01692.x; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Murzin AG, 1998, CURR OPIN STRUC BIOL, V8, P380, DOI 10.1016/S0959-440X(98)80073-0; Muyrers JPP, 2000, GENE DEV, V14, P1971; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221; PATTERSON C, 1988, MOL BIOL EVOL, V5, P603; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Ponting CP, 2000, ADV PROTEIN CHEM, V54, P185, DOI 10.1016/S0065-3233(00)54007-8; Rost B, 1997, FOLD DES, V2, pS19, DOI 10.1016/S1359-0278(97)00059-X; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Wang JD, 2000, J BIOL CHEM, V275, P507, DOI 10.1074/jbc.275.1.507; WILLIS DK, 1985, J BACTERIOL, V162, P1166, DOI 10.1128/JB.162.3.1166-1172.1985; Wolf YI, 2000, J MOL BIOL, V299, P897, DOI 10.1006/jmbi.2000.3786; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018; Yu M, 1998, J MOL BIOL, V283, P797, DOI 10.1006/jmbi.1998.2127; Yu M, 1998, P NATL ACAD SCI USA, V95, P981, DOI 10.1073/pnas.95.3.981; Zhang XJJ, 1999, NUCLEIC ACIDS RES, V27, P4200, DOI 10.1093/nar/27.21.4200	50	15	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46004	46010		10.1074/jbc.M108627200	http://dx.doi.org/10.1074/jbc.M108627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590160	hybrid			2022-12-25	WOS:000172573100070
J	Kovacic, HN; Irani, K; Goldschmidt-Clermont, PJ				Kovacic, HN; Irani, K; Goldschmidt-Clermont, PJ			Redox regulation of human Rac1 stability by the proteasome in human aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE; SIGNAL-TRANSDUCTION; SUPEROXIDE; FIBROBLASTS; PATHWAY; PROLIFERATION; EXPRESSION; HOMOLOG; RAS	Rac1 has been shown to activate a NADPH oxidase complex producing superoxide anions in a variety of mammalian cell types. We evaluated the impact of Rac1-induced reactive oxygen species production on the turnover of Rae1 itself in human aortic endothelial cells. The concentration of a constitutively active mutant of Rae1 (Rac1(V12)) was increased by treatment of the cells with diphenylene iodinium (DPI), an inhibitor of the NADPH oxidase. Such an effect was not observed for the dominant negative form of Rae1 (Rac1(N17)). We showed a decrease in proteolytic degradation of Rac1(V12) in the presence of DPI, and showed that short term treatment with H2O2 reverses the effect of DPI. We found that proteasome inhibitors (lactacystin and MG132) increased Rac1(V12) protein level. In support of this finding, we have identified in the primary sequence of Rac1 a potential destruction box domain, which is known to be a signal for protein degradation mediated by the ubiquitin/proteasome system. We show that Rac1(V12) is ubiquitinated before degradation. By contrast Rae1(N17) induces an accumulation of the ubiquitinated form of Rac1. These results suggest that Rae1 activation of NADPH oxidase is necessary for the proteolytic degradation of Rac1 itself.	Univ Mediterranee, UMR CNRS 6032, Fac Pharm, F-13385 Marseille, France; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21287 USA; Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Johns Hopkins University; Duke University	Kovacic, HN (corresponding author), Univ Mediterranee, UMR CNRS 6032, Fac Pharm, 27 Bd J Moulin, F-13385 Marseille, France.			Irani, Kaikobad/0000-0001-9194-7387; Kovacic, Herve/0000-0001-6509-4210				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chiou SK, 1998, VIROLOGY, V244, P108, DOI 10.1006/viro.1998.9077; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Oikawa T, 1998, BIOCHEM BIOPH RES CO, V246, P243, DOI 10.1006/bbrc.1998.8604; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Senadheera D, 2001, INT J MOL MED, V8, P127; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4	29	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45856	45861		10.1074/jbc.M107925200	http://dx.doi.org/10.1074/jbc.M107925200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585836	hybrid			2022-12-25	WOS:000172573100049
J	Bogatkevich, GS; Tourkina, E; Silver, RM; Ludwicka-Bradley, A				Bogatkevich, GS; Tourkina, E; Silver, RM; Ludwicka-Bradley, A			Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH MUSCLE ACTIN; IDIOPATHIC PULMONARY-FIBROSIS; BRONCHOALVEOLAR LAVAGE FLUID; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; ALVEOLAR MYOFIBROBLASTS; BINDING-PROTEIN; MESSENGER-RNA; CYCLIN D1; PROLIFERATION	Myofibroblasts are ultrastructurally and metabolically distinctive fibroblasts that express smooth muscle (SM)-alpha actin and are associated with various fibrotic lesions. The present study was undertaken to investigate the myofibroblast phenotype that appears after activation of normal lung fibroblasts by thrombin. We demonstrate that thrombin induces smooth muscle-a actin expression and rapid collagen gel contraction by normal lung fibroblasts via the proteolytically activated receptor-1 and independent of transforming growth factor-beta pathway. Using antisense oligonucleotides we demonstrate that a decreased level of PKC epsilon abolishes SM-alpha actin expression and collagen gel contraction induced by thrombin in normal lung fibroblasts. Inhibition of PKC epsilon translocation also abolishes thrombin-induced collagen gel contraction, SM-alpha actin increase, and its organization by normal lung fibroblasts, suggesting that activation of PKC epsilon is required for these effects. In normal lung fibroblasts PKC epsilon binds to SM-alpha actin after thrombin treatment, but in activated fibroblasts derived from scleroderma lung they associate even in untreated cells. This suggests that SM-alpha actin may serve as a substrate for PKC epsilon in lung fibroblasts when activated by thrombin. We propose that thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via a PKC-dependent pathway. Thrombin-induced differentiation of normal lung fibroblasts to a myofibroblast phenotype resembles the phenotype observed in scleroderma lung fibroblasts. Therefore, we conclude that chronic exposure to thrombin after microvascular injury leads to activation of normal lung fibroblasts and to the appearance of a myofibroblast phenotype in vivo. Our study provides novel, compelling evidence that thrombin is an important mediator of the interstitial lung fibrosis associated with scleroderma.	Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA	Medical University of South Carolina	Ludwicka-Bradley, A (corresponding author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Suite 912,POB 250623, Charleston, SC 29425 USA.	bradleyh@musc.edu		Ludwicka-Bradley, Anna/0000-0002-3122-4678	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001070] Funding Source: NIH RePORTER; NCRR NIH HHS [RR1070-1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Bachhuber BG, 1997, J VASC RES, V34, P41, DOI 10.1159/000159200; BIWAS P, 1995, FEBS LETT, V373, P146; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRETSCHNEIDER E, 1995, BIOCHEM PHARMACOL, V49, P33, DOI 10.1016/0006-2952(94)00404-A; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Byeon MK, 2000, MOL BIOL CELL, V11, p332A; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dabbagh K, 1998, THROMB HAEMOSTASIS, V79, P405; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; DESMOULIERE A, 1995, VASCULAR SMOOTH MUSC, P329; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; GODIN D, 1995, BRIT J PHARMACOL, V115, P903, DOI 10.1111/j.1476-5381.1995.tb15895.x; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRAY AJ, 1995, AM J RESP CELL MOL, V12, P684, DOI 10.1165/ajrcmb.12.6.7766431; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Hellbert K, 2000, ADV ENZYME REGUL, V40, P49, DOI 10.1016/S0065-2571(99)00038-2; HERNANDEZRODRIGUEZ NA, 1995, LANCET, V346, P1071, DOI 10.1016/S0140-6736(95)91744-6; HEWITSON TD, 1995, AM J NEPHROL, V15, P111, DOI 10.1159/000168813; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KANG YH, 1991, J HISTOCHEM CYTOCHEM, V39, P413, DOI 10.1177/39.4.2005371; KAPANCI Y, 1995, AM J RESP CRIT CARE, V152, P2163, DOI 10.1164/ajrccm.152.6.8520791; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KOTANI I, 1995, THROMB RES, V77, P493, DOI 10.1016/0049-3848(95)00025-9; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KUHN C, 1991, AM J PATHOL, V138, P1257; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; Low RB, 1999, CURR TOPICS PATHOL, V93, P19; LUDWICKA A, 1995, J RHEUMATOL, V22, P1876; LUDWICKA A, 1992, J RHEUMATOL, V19, P1716; Ludwicka-Bradley A, 2000, AM J RESP CELL MOL, V22, P235, DOI 10.1165/ajrcmb.22.2.3642; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062; MALARKEY K, 1995, BRIT J PHARMACOL, V116, P2267, DOI 10.1111/j.1476-5381.1995.tb15063.x; Maruyama N, 2000, J RHEUMATOL, V27, P2777; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MITCHELL J, 1989, LAB INVEST, V60, P643; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; OHBA T, 1994, AM J RESP CELL MOL, V10, P405, DOI 10.1165/ajrcmb.10.4.7510986; Pache JC, 1998, MODERN PATHOL, V11, P1064; Papadimitriou E, 1997, AM J PHYSIOL-CELL PH, V272, pC1112, DOI 10.1152/ajpcell.1997.272.4.C1112; Phan SH, 1996, KIDNEY INT, V49, pS46; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Slater SJ, 2000, BIOCHEMISTRY-US, V39, P271, DOI 10.1021/bi9916527; Steen VD, 2000, ARTHRITIS RHEUM-US, V43, P2437, DOI 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U; STEEN VD, 1994, ARTHRITIS RHEUM, V37, P1283, DOI 10.1002/art.1780370903; TANI K, 1991, AM J RESP CELL MOL, V5, P34, DOI 10.1165/ajrcmb/5.1.34; Tourkina E, 2001, ARTHRITIS RHEUM-US, V44, P1370, DOI 10.1002/1529-0131(200106)44:6<1370::AID-ART230>3.0.CO;2-2; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; VYALOV SL, 1993, AM J PATHOL, V143, P1754; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; YANPING X, 1995, J BIOL CHEM, V270, P23887; Zhang HY, 1996, AM J PATHOL, V148, P527; Zhang HY, 1999, AM J RESP CELL MOL, V21, P658, DOI 10.1165/ajrcmb.21.6.3720; ZHANG K, 1994, AM J PATHOL, V145, P114	64	158	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45184	45192		10.1074/jbc.M106441200	http://dx.doi.org/10.1074/jbc.M106441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579091	hybrid			2022-12-25	WOS:000172406700111
J	Crowder, CM; Westover, EJ; Kumar, AS; Ostlund, RE; Covey, DF				Crowder, CM; Westover, EJ; Kumar, AS; Ostlund, RE; Covey, DF			Enantiospecificity of cholesterol function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL FATES; CAENORHABDITIS-ELEGANS; PHOSPHOLIPID STRUCTURE; STEROL-METABOLISM; LET-60; VULVAR; GENE; RAS; REQUIREMENT; STABILITY	The importance of the absolute configuration of cholesterol for its function in vivo is unknown. To directly test this question in viva, we synthesized the enantiomer of cholesterol (ent-cholesterol) and tested its ability to substitute for natural cholesterol (not-cholesterol) in the growth, viability, and behavior of Caenorhabditis elegans, a cholesterol auxotroph. First-generation animals grown on ent-cholesterol were viable with only mild behavioral defects. However, ent-cholesterol produced 100% lethality/arrest of their second generation progeny. Isotopically labeled ent-cholesterol incorporated into animals, indicating that its lethality was not secondary to cholesterol starvation. When mixed with not-cholesterol, ent-cholesterol was not inert; rather, it antagonized the activity of not-cholesterol. These results demonstrate for the first tine that the absolute configuration of cholesterol, not just its physical properties, is essential for its functions in viva.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Covey, DF (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Eulcid Ave, St Louis, MO 63110 USA.	dcovey@molecool.wustl.edu			NIGMS NIH HHS [GM47969] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047969] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1986, BIOCHIM BIOPHYS ACTA, V856, P36, DOI 10.1016/0005-2736(86)90006-4; AGARWAL K, 1986, BIOCHIM BIOPHYS ACTA, V883, P468, DOI 10.1016/0304-4165(86)90286-2; ARNETT EM, 1982, J AM CHEM SOC, V104, P636, DOI 10.1021/ja00366a054; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CHITWOOD DJ, 1984, LIPIDS, V19, P500, DOI 10.1007/BF02534482; DUTKY SR, 1967, NEMATOLOGICA, V13, P140; GHOSH D, 1971, CHEM PHYS LIPIDS, V7, P173, DOI 10.1016/0009-3084(71)90030-2; GUYER W, 1983, CHEM PHYS LIPIDS, V33, P313, DOI 10.1016/0009-3084(83)90025-7; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMETTER A, 1982, CHEM PHYS LIPIDS, V31, P283, DOI 10.1016/0009-3084(82)90063-9; HIEB WF, 1968, SCIENCE, V160, P778, DOI 10.1126/science.160.3829.778; Hoekstra D, 2000, CURR OPIN CELL BIOL, V12, P496, DOI 10.1016/S0955-0674(00)00122-8; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; Ingham PW, 2000, CURR BIOL, V10, pR180, DOI 10.1016/S0960-9822(00)00346-8; Kumar AS, 1999, TETRAHEDRON LETT, V40, P823, DOI 10.1016/S0040-4039(98)02588-X; Kuwabara PE, 2000, GENE DEV, V14, P1933; Lalitha S, 2001, CHEM COMMUN, P1192, DOI 10.1039/b104081m; Lalitha S, 2001, J SUPRAMOL CHEM, V1, P53; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; LOZANO R, 1984, COMP BIOCHEM PHYS C, V79, P21, DOI 10.1016/0742-8413(84)90156-7; LU NC, 1977, NEMATOLOGICA, V23, P57, DOI 10.1163/187529277X00228; Matyash V, 2001, MOL BIOL CELL, V12, P1725, DOI 10.1091/mbc.12.6.1725; MICKUS DE, 1992, J AM CHEM SOC, V114, P359, DOI 10.1021/ja00027a055; Ostlund RE, 1996, J MASS SPECTROM, V31, P1291, DOI 10.1002/(SICI)1096-9888(199611)31:11<1291::AID-JMS424>3.0.CO;2-5; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; SULSTON J, 1988, MONOGRAPH, V17, P587; Yochem J, 1999, DEVELOPMENT, V126, P597; Yochem J, 1997, MOL CELL BIOL, V17, P2716, DOI 10.1128/MCB.17.5.2716	31	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44369	44372		10.1074/jbc.C100535200	http://dx.doi.org/10.1074/jbc.C100535200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11598105	hybrid			2022-12-25	WOS:000172406700003
J	Uversky, VN; Lee, HJ; Li, J; Fink, AL; Lee, SJ				Uversky, VN; Lee, HJ; Li, J; Fink, AL; Lee, SJ			Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; MOLTEN GLOBULE; ALZHEIMERS-DISEASE; LEWY BODIES; IN-VITRO; AGGREGATION; DEMENTIA; FIBRILLIZATION; MUTATION; PROTEINS	Aggregation of alpha -synuclein is tightly associated with many neurodegenerative diseases, such as Parkinson's disease, dementia with Lewy body, Lewy body variant of Alzheimer's disease, multiple system atrophy, and Hallervorden-Spatz disease, implicating a crucial role of aggregated forms of alpha -synuclein in the pathogenesis. Here, we examined the effect of elevated temperature on the oligomerization and structural changes of alpha -synuclein in the early stage of aggregation and show that self-assembly is crucial for the stabilization of a partially folded conformation. The efficiency of alpha -synuclein oligomerization increased proportional to the temperature increase, both in purified form and in crude cytosolic preparation. This oligomerization coincided with a small but reproducible change in the circular dichroism spectrum and an increase in the 1-anilinonaphthalene-8-sulfonic acid binding. The hydrodynamic dimensions of the dimer measured by size exclusion chromatography suggest a pre-molten globule-like structure. These data suggest that partially folded alpha -synuclein, which is unstable in the monomeric form, is stabilized by self-assembly and that these oligomers may evolve into the fibril nucleus.	Parkinsons Inst, Sunnyvale, CA 94089 USA; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142292, Moscow Region, Russia	University of California System; University of California Santa Cruz; Russian Academy of Sciences	Lee, SJ (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.		Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Lee, Seung-Jae/0000-0002-5155-5335	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010806] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10806] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baba M, 1998, AM J PATHOL, V152, P879; Campbell BCV, 2000, NEUROBIOL DIS, V7, P192, DOI 10.1006/nbdi.2000.0286; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Langston JW, 1998, EXP NEUROL, V154, P684, DOI 10.1006/exnr.1998.6975; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tcherkasskaya O, 2001, PROTEINS, V44, P244, DOI 10.1002/prot.1089; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, BIOCHEMISTRY-US, V33, P2782, DOI 10.1021/bi00176a006; Uversky VN, 1994, INT J BIOCHROMATOGR, P103; UVERSKY VN, 2001, IN PRESS EUR J BIOCH; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	30	149	153	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43495	43498		10.1074/jbc.C100551200	http://dx.doi.org/10.1074/jbc.C100551200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11590163	hybrid			2022-12-25	WOS:000172297700003
J	Garcia-Bermejo, ML; Leskow, FC; Fujii, T; Wang, QM; Blumberg, PM; Ohba, M; Kuroki, T; Han, KC; Lee, J; Marquez, VE; Kazanietz, MG				Garcia-Bermejo, ML; Leskow, FC; Fujii, T; Wang, QM; Blumberg, PM; Ohba, M; Kuroki, T; Han, KC; Lee, J; Marquez, VE; Kazanietz, MG			Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKC alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY CONSTRAINED ANALOGS; ESTER TUMOR PROMOTERS; PHORBOL ESTER; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; PROTEOLYTIC ACTIVATION; SUPPRESSES APOPTOSIS; HUMAN KERATINOCYTES; DAG-LACTONES; PHASE-II; IN-VIVO	Phorbol esters, the archetypical (PKC) activators, induce apoptosis in androgen-sensitive LNCaP prostate cancer cells. In this study we evaluate the effect of a novel class of PKC ligands, the diacylglycerol (DAG)-lactones, as inducers of apoptosis in LNCaP cells. These unique ligands were designed using novel pharmacophore- and receptor-guided approaches to achieve highly potent DAG surrogates. Two of these compounds, HK434 and HK654, induced apoptosis in LNCaP cells with much higher potency than oleoyl-acetyl-glycerol or phorbol 12,13-dibutyrate. Moreover, different PKC isozymes were found to mediate the apoptotic effect of phorbol 12-myristate 13-acetate (PMA) and HK654 in LNCaP cells. Using PKC inhibitors and dominant negative PKC isoforms, we found that both PKCalpha and PKCdelta mediated the apoptotic effect of PMA, whereas only PKCalpha was involved in the effect of the DAG-lactone. The PKCalpha selectivity of HK654 in LNCaP cells contrasts with similar potencies in vitro for binding and activation of PKCalpha and PKCdelta. Consistent with the differences in isoform dependence in intact cells, PMA and HK654 show marked differences in their abilities to translocate PKC isozymes. Both PMA and HK654 induce a marked redistribution of PKCalpha to the plasma membrane. On the other hand, unlike PMA, HK654 translocates PKCdelta predominantly to the nuclear membrane. Thus, DAG-lactones have a unique profile of activation of PKC isozymes for inducing apoptosis in LNCaP cells and represent the first example of a selective activator of a classical PKC in cellular models. An attractive hypothesis is that selective activation of PKC isozymes by pharmacological agents in cells can be achieved by differential intracellular targeting of each PKC.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; NCI, Ctr Canc Res, Lab Cellular Carcinogenesis & Tumor Promot, NIH, Bethesda, MD 20892 USA; Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428555, Japan; Seoul Natl Univ, Coll Pharm, Lab Med Chem, Kwanak Ku, Seoul 151742, South Korea; NCI, Ctr Canc Res, Lab Med Chem, NIH, Frederick, MD 21701 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Showa University; Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, 816 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelo@spirit.gcrc.upenn.edu	Wang, Qiming Jane/B-6064-2012; Marquez, Victor/AAP-3549-2021; García-Bermejo, María Laura/E-1542-2015; Kuroki, Toshio/A-9500-2011	Wang, Qiming Jane/0000-0002-9502-4851; García-Bermejo, María Laura/0000-0002-8167-2276; Kuroki, Toshio/0000-0001-6369-4351; Lee, Jeewoo/0000-0002-7832-6719	NCI NIH HHS [R01 CA89202-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benzaria S, 1998, BIOORG MED CHEM LETT, V8, P3403, DOI 10.1016/S0960-894X(98)00614-3; BERKNER KL, 1992, CURR TOP MICROBIOL, V158, P39; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; Bruckheimer EM, 2000, ONCOGENE, V19, P5251, DOI 10.1038/sj.onc.1203881; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garzotto M, 1998, CANCER RES, V58, P2260; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gonzalez R, 1999, MELANOMA RES, V9, P599, DOI 10.1097/00008390-199912000-00010; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kazanietz MG, 2000, BIOCHEM PHARMACOL, V60, P1417, DOI 10.1016/S0006-2952(00)00470-6; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Keenan C, 1999, CELL IMMUNOL, V196, P104, DOI 10.1006/cimm.1999.1549; Kiley SC, 1999, CANCER RES, V59, P3230; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; Leirdal M, 1999, BRIT J CANCER, V80, P1558, DOI 10.1038/sj.bjc.6690560; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Marquez VE, 1999, PHARMACOL THERAPEUT, V82, P251, DOI 10.1016/S0163-7258(98)00048-5; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Nacro K, 2000, J MED CHEM, V43, P921, DOI 10.1021/jm9904607; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OJEDA F, 1992, INT J RADIAT BIOL, V61, P663, DOI 10.1080/09553009214551471; Okuda H, 1999, ONCOGENE, V18, P5604, DOI 10.1038/sj.onc.1202946; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; Tamamura H, 2000, J MED CHEM, V43, P3209, DOI 10.1021/jm990613q; TENG K, 1992, J AM CHEM SOC, V114, P1059, DOI 10.1021/ja00029a039; Varterasian ML, 2000, CLIN CANCER RES, V6, P825; Wan QJ, 2000, J BIOL CHEM, V275, P12136, DOI 10.1074/jbc.275.16.12136; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725	58	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					645	655		10.1074/jbc.M107639200	http://dx.doi.org/10.1074/jbc.M107639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11584014	hybrid			2022-12-25	WOS:000173087900085
J	Masamune, A; Kikuta, K; Satoh, M; Sakai, Y; Satoh, A; Shimosegawa, T				Masamune, A; Kikuta, K; Satoh, M; Sakai, Y; Satoh, A; Shimosegawa, T			Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B; COLLAGEN GENE-EXPRESSION; PPAR-GAMMA; ENDOTHELIAL-CELLS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); TRANSCRIPTIONAL REGULATION; NEGATIVE REGULATOR; KINASE; IDENTIFICATION	Activated pancreatic stellate cells (PSCs) have recently been implicated in the pathogenesis of pancreatic fibrosis and inflammation. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a ligand-activated transcription factor which controls growth, differentiation, and inflammation in different tissues. Roles of PPAR-gamma activation in PSCs are poorly characterized. Here we examined the effects of PPAR-gamma ligands on the key parameters of PSC activation. PSCs were isolated from rat pancreas tissue, and used in their culture-activated, myofibroblast-like phenotype. Activation of PPAR-gamma was induced with 15-deoxy-Delta (12,14) -prostaglandin J(2) (15d-PGJ(2)) or with troglitazone. Expression of PPAR-gamma was predominantly localized in the nuclei, and PPAR-gamma was transcriptionally active after ligand stimulation. PPAR-gamma ligands inhibited platelet-derived growth factor-induced proliferation. This effect was associated with inhibition of cell cycle progression beyond the G(1) phase. PPAR-gamma ligands decreased a-smooth muscle actin protein expression and alpha1(1) procollagen and prolyl 4-hydroxylase(alpha) mRNA levels. Activation of PPAR-gamma also resulted in the inhibition of inducible monocyte chemoattractant protein-1 expression. 15d-PGJ(2), but not troglitazone, inhibited the degradation of IKB-alpha and consequent NF-B-K activation. In conclusion, activation of PPAR-y inhibited profibrogenic and proinflammatory actions in activated PSCs, suggesting a potential application of PPAR-y ligands in the treatment of pancreatic fibrosis and inflammation.	Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 9808574, Japan	Tohoku University	Masamune, A (corresponding author), Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.							Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Apte MV, 1999, GUT, V44, P534, DOI 10.1136/gut.44.4.534; Apte MV, 1998, GUT, V43, P128, DOI 10.1136/gut.43.1.128; Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BOCKMAN JA, 1998, GASTROENTEROLOGY, V115, P1049; Camp HS, 1997, J BIOL CHEM, V272, P10811; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Chen AP, 1999, J BIOL CHEM, V274, P158, DOI 10.1074/jbc.274.1.158; Chen AP, 1996, J BIOL CHEM, V271, P25994, DOI 10.1074/jbc.271.42.25994; Chen AP, 2000, MOL CELL BIOL, V20, P2818, DOI 10.1128/MCB.20.8.2818-2826.2000; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; GharaeeKermani M, 1996, J BIOL CHEM, V271, P17779, DOI 10.1074/jbc.271.30.17779; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GRILLI M, 1993, INT REV CYTOL, V143, P1; Haber PS, 1999, AM J PATHOL, V155, P1087, DOI 10.1016/S0002-9440(10)65211-X; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; Osada S, 1997, GENES CELLS, V2, P315, DOI 10.1046/j.1365-2443.1997.1220319.x; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Saurer L, 2000, GASTROENTEROLOGY, V118, P356, DOI 10.1016/S0016-5085(00)70218-6; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wells RG, 1998, GASTROENTEROLOGY, V115, P491, DOI 10.1016/S0016-5085(98)70216-1; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	43	112	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					141	147		10.1074/jbc.M107582200	http://dx.doi.org/10.1074/jbc.M107582200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11606585	hybrid			2022-12-25	WOS:000173087900020
J	Bennett, TA; Foutz, TD; Gurevich, VV; Sklar, LA; Prossnitz, ER				Bennett, TA; Foutz, TD; Gurevich, VV; Sklar, LA; Prossnitz, ER			Partial phosphorylation of the N-formyl peptide receptor inhibits G protein association independent of arrestin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; COUPLED RECEPTORS; BETA-ARRESTIN; TERNARY COMPLEX; 48-KDA PROTEIN; DESENSITIZATION; INTERNALIZATION; RHODOPSIN; ENDOCYTOSIS; KINASES	It is now well accepted that G protein-coupled receptors activated by agonist binding become targets for phosphorylation, leading to desensitization of the receptor. Using a series of phosphorylation deficient mutants of the N-formyl peptide receptor (FPR), we have explored the role of phosphorylation on the ability of the receptor to interact with G proteins and arrestins. Using a fluorometric assay in conjunction with solubilized receptors, we demonstrate that phosphorylation of the wild type FPR lowers its affinity for G protein, whereas mutant receptors lacking four potential phosphorylation sites retain their ability to couple to G protein. Phosphorylated mutant receptors lacking only two potential phosphorylation sites are again unable to couple to G protein. Furthermore, whereas stimulated wild type FPR in whole cells colocalizes with arrestin-2, and the solubilized, phosphorylated FPR binds arrestin-2, the stimulated receptors lacking four potential phosphorylation sites display no interaction with arrestin-2. However, the mutant receptors lacking only two potential phosphorylation sites are restored in their ability to bind and colocalize with arrestin-2. Thus, there is a submaximal threshold of FPR phosphorylation that simultaneously results in an inhibition of G protein binding and an induction of arrestin binding. These results are the first to demonstrate that less than maximal levels of receptor phosphorylation can block G protein binding, independent of arrestin binding. We therefore propose that phosphorylation alone may be sufficient to desensitize the FPR in vivo, raising the possibility that for certain G protein-coupled receptors, desensitization may not be the primary function of arrestin.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85351 USA; Natl Flow Cytometry Resource, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; Banner Research; Banner Health; Banner Sun Health Research Institute	Prossnitz, ER (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.		Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008; Gurevich, Vsevolod/A-3236-2008	Prossnitz, Eric/0000-0001-9190-8302; Gurevich, Vsevolod/0000-0002-3950-5351	NCRR NIH HHS [RR01315] Funding Source: Medline; NEI NIH HHS [EY11500] Funding Source: Medline; NIAID NIH HHS [AI36357, AI43932] Funding Source: Medline; NIGMS NIH HHS [GM60799] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036357, R01AI043932, R01AI036357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM060799] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bennett TA, 2001, J BIOL CHEM, V276, P22453, DOI 10.1074/jbc.M009679200; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Davies EV, 1998, INT J MOL MED, V1, P485; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; Gibson SK, 1998, BIOCHEMISTRY-US, V37, P11393, DOI 10.1021/bi980933w; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; POSNER RG, 1994, MOL PHARMACOL, V45, P65; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Ricevuti G, 1997, ANN NY ACAD SCI, V832, P426, DOI 10.1111/j.1749-6632.1997.tb46269.x; Roseberry AG, 2001, J CELL SCI, V114, P739; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; Sklar LA, 2000, BIOTECHNIQUES, V28, P976, DOI 10.2144/00285rr03; SKLAR LA, 1989, J BIOL CHEM, V264, P8483; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; ZIGMOND SH, 1982, J CELL BIOL, V92, P34, DOI 10.1083/jcb.92.1.34	42	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49195	49203		10.1074/jbc.M106414200	http://dx.doi.org/10.1074/jbc.M106414200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11602585	hybrid			2022-12-25	WOS:000173922100076
J	Prescott, JE; Osthus, RC; Lee, LA; Lewis, BC; Shim, H; Barrett, JF; Guo, QB; Hawkins, AL; Griffin, CA; Dang, CV				Prescott, JE; Osthus, RC; Lee, LA; Lewis, BC; Shim, H; Barrett, JF; Guo, QB; Hawkins, AL; Griffin, CA; Dang, CV			A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE GENE; REVERSE-TRANSCRIPTASE GENE; DNA-BINDING; CELL-CYCLE; TRANSACTIVATION DOMAIN; ESSENTIAL COFACTOR; BURKITT-LYMPHOMA; TUMOR-SUPPRESSOR; TARGET GENES; BETA-CATENIN	We have identified a novel c-Myc-responsive gene, named JPO1, by representational difference analysis. JPO1 responds to two inducible c-Myc systems and behaves as a direct c-Myc target gene. JPO1 mRNA expression is readily detectable in the thymus, small intestine, and colon, whereas expression is relatively low in spleen, bone marrow, and peripheral leukocytes. We cloned a full-length JPO1 cDNA that encodes a 47-kDa nuclear protein. To determine the role of JPO1 in Myc-mediated cellular phenotypes, stable Rat1a fibroblasts overexpressing JPO1 were tested and compared with transformed Rat1a-Myc cells. Although JPO1 has a diminished transforming activity as compared with c-Myc, JPO1 complements a transformation-defective My-c Box II mutant in the Rat1a transformation assay. This complementation provides evidence for a genetic link between c-Myc and JPO1. Similar to c-Myc, JPO1 overexpression enhances the clonogenicity of CB33 human lymphoblastoid cells in methylcellulose assays. These observations suggest that JPO1 participates in c-Myc-mediated transformation, supporting an emerging concept that c-Myc target genes constitute nodal points in a network of pathways that lead from c-Myc to various Myc-related phenotypes and ultimately to tumorigenesis.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Program Human Genet & Mol Biol, Baltimore, MD 21205 USA; Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA; Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Dang, CV (corresponding author), Johns Hopkins Univ, Sch Med, Ross Res Bldg,Rm 1025,720 Rutland Ave, Baltimore, MD 21205 USA.		Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NATIONAL CANCER INSTITUTE [K11CA064258, R01CA057341] Funding Source: NIH RePORTER; NCI NIH HHS [CA57341, CA64258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAJALICA S, 1995, GENE CHROMOSOME CANC, V13, P34, DOI 10.1002/gcc.2870130106; BajalicaLagercrantz S, 1996, CANCER GENET CYTOGEN, V90, P102, DOI 10.1016/S0165-4608(96)00092-1; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISHOP JM, 1982, ADV CANCER RES, V37, P1, DOI 10.1016/S0065-230X(08)60880-5; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Christiansen H, 1996, PLANT MOL BIOL, V32, P809, DOI 10.1007/BF00020479; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dang CV, 1999, MOL CELL BIOL, V19, P1; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Guo QM, 2000, CANCER RES, V60, P5922; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Horikawa I, 1999, CANCER RES, V59, P826; Horn J, 1999, EUR J BIOCHEM, V265, P441, DOI 10.1046/j.1432-1327.1999.00768.x; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kolligs FT, 2000, GENE DEV, V14, P1319; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MUNZEL P, 1991, J CANCER RES CLIN, V117, P603, DOI 10.1007/BF01613296; NAOE T, 1988, CANCER GENET CYTOGEN, V34, P77, DOI 10.1016/0165-4608(88)90171-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; Takakura M, 1999, CANCER RES, V59, P551; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu SJ, 1996, ONCOGENE, V12, P621; ZACCARIA A, 1989, CANCER GENET CYTOGEN, V42, P191, DOI 10.1016/0165-4608(89)90087-3; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	61	45	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48276	48284		10.1074/jbc.M107357200	http://dx.doi.org/10.1074/jbc.M107357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11598121	hybrid			2022-12-25	WOS:000172927000073
J	Sokol, SY; Li, ZG; Sacks, DB				Sokol, SY; Li, ZG; Sacks, DB			The effect of IQGAP1 on Xenopus embryonic ectoderm requires Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RASGAP-RELATED PROTEIN; SMALL GTPASES; ACTIVATING PROTEINS; CELL-ADHESION; ACTIN; RHO; CYTOKINESIS; BINDING; IDENTIFICATION; RAC1	IQGAP1 contains a number of protein recognition motifs through which it binds to targets. Several in vitro studies have documented that IQGAP1 interacts directly with calmodulin, actin, E-cadherin, beta -catenin, and the small GTPases Cdc42 and Rac. Nevertheless, direct demonstration of in vivo function of mammalian IQGAP1 is limited. Using a novel assay to evaluate in vivo function of IQGAP1, we document here that microinjection of IQGAP1 into early Xenopus embryos generates superficial ectoderm. lesions at late blastula stages. This activity was retained by the mutated variants of IQGAP1 in which the calponin homology domain or the WW domain was deleted. By contrast, deletion of the IQ (IQGAP1-Delta IQ), Ras-GAP-related (IQGAP1-Delta GRD), or C-terminal (IQGAP1-DeltaC) domains abrogated the effect of IQGAP1 on the embryos. None of the latter mutants bound Cdc42, suggesting that the binding of Cdc42 by IQGAP1 is critical for its function. Moreover, overexpression of IQGAP1, but not IQGAP1-Delta GRD, significantly increased the amount of active Cdc42 in embryonic cells. Co-injection of wild type IQGAP1 with dominant negative Cdc42, but not the dominant negative forms of Rac or Rho, blocked the effect of IQGAP1 on embryonic ectoderm. Together these data indicate that the activity of IQGAP1 in embryonic ectoderm. requires Cdc42 function.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Thorn 530, Boston, MA 02115 USA.			Sokol, Sergei/0000-0002-3963-9202; Sacks, David/0000-0003-3100-0735				Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Eng K, 1998, CURR BIOL, V8, P611, DOI 10.1016/S0960-9822(98)70248-9; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Faix J, 1996, FEBS LETT, V394, P251, DOI 10.1016/0014-5793(96)00963-5; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MERRIAM RW, 1983, J EMBRYOL EXP MORPH, V76, P51; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Sambrook J., 2002, MOL CLONING LAB MANU; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999	35	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48425	48430		10.1074/jbc.M107975200	http://dx.doi.org/10.1074/jbc.M107975200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11584017	hybrid			2022-12-25	WOS:000172927000094
J	Destoumieux-Garzon, D; Saulnier, D; Garnier, J; Jouffrey, C; Bulet, P; Bachere, E				Destoumieux-Garzon, D; Saulnier, D; Garnier, J; Jouffrey, C; Bulet, P; Bachere, E			Crustacean immunity - Antifungal peptides are generated from the C terminus of shrimp hemocyanin in response to microbial challenge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; SEQUENCE HOMOLOGY; INSECT IMMUNITY; CDNA CLONING; PENAEIDINS; HEMOLYMPH; PROTEINS; PROPHENOLOXIDASE; PURIFICATION; EXPRESSION	We report here the isolation from plasma of two penaeid shrimp species of novel peptides/polypeptides with exclusive antifungal activities. A set of three molecules was purified with molecular masses at 2.7 kDa (Penaeus vannamei), 7.9 kDa, and 8.3 kDa (Penaeus stylirostris). Primary structure determination was performed by a combination of Edman degradation and mass spectrometry. The peptides display 95-100% sequence identity with a C-terminal sequence of hemocyanin, indicating that they are cleaved fragments of the shrimp respiratory protein. Specific immunodetection of the hemocyanin-derived (poly)peptides revealed that experimental microbial infections increase their relative concentration in plasma as compared with nonstimulated animals. Thus, the production of antifungal (poly)peptides by limited proteolysis of hemocyanin could be relevant to a shrimp immune reaction that would confer a new function to the multifunctional respiratory pigment of crustaceans.	Univ Montpellier 2, UMR 5098, CNRS, IFREMER, CC 80,Pl Eugene Bataillon, F-34095 Montpellier, France; IFREMER, Ctr Oceanol Pacifique, Taravao, Tahiti, France; Inst Biol Mol & Cellulaire, UPR 9022 CNRS, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier; Ifremer; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Bachere, E (corresponding author), Univ Montpellier 2, UMR 5098, CNRS, IFREMER, CC 80,Pl Eugene Bataillon, F-34095 Montpellier, France.	evelyne.bachere@ifremer.fr	BULET, Philippe/C-8557-2014; Destoumieux-Garzon, Delphine/O-3328-2014	BULET, Philippe/0000-0001-9016-265X; saulnier, denis/0000-0003-1422-0242; Destoumieux-Garzon, Delphine/0000-0002-8793-9138				Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; Brogden KA, 1996, P NATL ACAD SCI USA, V93, P412, DOI 10.1073/pnas.93.1.412; Brogden KA, 1997, ANTIMICROB AGENTS CH, V41, P1615, DOI 10.1128/AAC.41.7.1615; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CRISP LM, 1989, MYCOLOGIA, V81, P709, DOI 10.2307/3759875; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; DEPLEDGE MH, 1989, HELGOLANDER MEERESUN, V43, P207, DOI 10.1007/BF02367900; Destoumieux D, 2000, J CELL SCI, V113, P461; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Destoumieux D, 1999, EUR J BIOCHEM, V266, P335, DOI 10.1046/j.1432-1327.1999.00855.x; Dionysius DA, 1997, J DAIRY SCI, V80, P667, DOI 10.3168/jds.S0022-0302(97)75985-X; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Fogaca AC, 1999, J BIOL CHEM, V274, P25330, DOI 10.1074/jbc.274.36.25330; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; ISHIMARU K, 1995, INT J SYST BACTERIOL, V45, P134, DOI 10.1099/00207713-45-1-134; Iwanaga S, 1998, J BIOCHEM, V123, P1; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; Kim HS, 2000, J IMMUNOL, V165, P3268, DOI 10.4049/jimmunol.165.6.3268; Kuwata H, 1998, BBA-PROTEIN STRUCT M, V1429, P129, DOI 10.1016/S0167-4838(98)00224-6; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; LEE SY, 1995, BIOL PHARM BULL, V18, P1049, DOI 10.1248/bpb.18.1049; Lee YJ, 1996, BIOCHEM BIOPH RES CO, V218, P6, DOI 10.1006/bbrc.1996.0002; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Lightner D.V., 1983, CRC HDB MARICULTURE, P289; Michaut L, 1996, FEBS LETT, V395, P6, DOI 10.1016/0014-5793(96)00992-1; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Paul RJ, 1997, ZOOL-ANAL COMPLEX SY, V100, P298; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sellos D, 1997, FEBS LETT, V407, P153, DOI 10.1016/S0014-5793(97)00350-5; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SONG YL, 1993, B I ZOOL ACAD SINICA, V32, P217; Tasiemski A, 2000, MOL BRAIN RES, V76, P237, DOI 10.1016/S0169-328X(00)00005-X; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8	39	276	311	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47070	47077		10.1074/jbc.M103817200	http://dx.doi.org/10.1074/jbc.M103817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598107	hybrid			2022-12-25	WOS:000172768500054
J	Le Clainche, C; Didry, D; Carlier, MF; Pantaloni, D				Le Clainche, C; Didry, D; Carlier, MF; Pantaloni, D			Activation of Arp2/3 complex by Wiskott-Aldrich Syndrome protein is linked to enhanced binding of ATP to Arp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN POLYMERIZATION; F-ACTIN; N-WASP; ORGANIZATION; MOTILITY	In response to signaling, the Arp2/3 complex (actin-related proteins 2 and 3 complex) is activated by binding the C-terminal MA) domain of proteins of the Wiskott-Aldrich Syndrome family to promote the formation of a branched actin filament array, responsible for cell protrusion. The Arp2/3 complex exists in different structural/functional states: the inactive Arp2/3, the activated WA-Arp,2/3 complex, the ternary G-actin-WA-Arp2/3 complex, which branches the filaments. This work addresses the role of ATP binding in Arp2/3 function. Using photocross-linking, hydrodynamic, and fluorescence techniques, we show that in the inactive Arp2/3 complex only one rapidly exchangeable ATP is tightly bound to Arp3 with an affinity of 10(8) m(-1). Upon activation of the Arp2/3 complex by WA, ATP binds to Arp2 with high affinity (10(7) m(-1)), implying that a large structural change of Arp2 is linked to Arp2/3 activation. ATP is rapidly exchangeable on Arp2 and Arp3 in WA-Arp2/3 and G-actin-WA-Arp2/3 complexes. ATP is not hydrolyzed in inactive Arp,2/3, in WA-Arp2/3, nor in G-actin-WA-Arp2/3. Arp2 has a greater specificity than Arp3 for ATP versus ATP analogs. Using functional assays of actin polymerization in branched filaments, we show that binding of ATP to Arp2 is required for filament branching.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.		Le Clainche, Christophe/A-4782-2015	Le Clainche, Christophe/0000-0001-5659-677X				Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOCKRIN S, 1980, BIOCHEMISTRY-US, V19, P5358; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Wear MA, 2000, CURR BIOL, V10, pR891, DOI 10.1016/S0960-9822(00)00845-9; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200	20	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46689	46692		10.1074/jbc.C100476200	http://dx.doi.org/10.1074/jbc.C100476200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598103	hybrid			2022-12-25	WOS:000172768500002
J	Legrand, G; Humez, S; Slomianny, C; Dewailly, E; Vanden Abeele, F; Mariot, P; Wuytack, F; Prevarskaya, N				Legrand, G; Humez, S; Slomianny, C; Dewailly, E; Vanden Abeele, F; Mariot, P; Wuytack, F; Prevarskaya, N			Ca2+ pools and cell growth - Evidence for sarcoendoplasmic Ca2+-ATPases 2B involvement in human prostate cancer cell growth control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM CALCIUM-PUMP; INTRACELLULAR CALCIUM; MONOCLONAL-ANTIBODY; TUMOR PROMOTER; APOPTOSIS; THAPSIGARGIN; EXPRESSION; LINE; INHIBITOR; ANDROGENS	The present study demonstrates for the first time that intracellular calcium-ATPases and calcium pool content are closely associated with prostate cancer LNCaP cell growth. Cell growth was modulated by changing the amount of epidermal growth factor, serum, and andro-gene in culture media. Using the microspectrofluorimetric method with Fura-2 and Mag Fura-2 as probes, we show that in these cells, the growth rate is correlated with intracellular calcium pool content. Indeed, an increased growth rate is correlated with an increase in the calcium pool filling state, whereas growth-inhibited cells show a reduced calcium pool load. Using Western blotting and immunocytochemistry, we show that endoplasmic reticulum calcium pump expression is closely linked to LNCaP cell growth, and are a common target of physiological stimuli that control cell growth. Moreover, we clearly demonstrate that inhibition of these pumps, using thapsigargin, inhibits LNCaP cell growth and prevents growth factor from stimulating cell proliferation. Our results thus provide evidence for the essential role of functional endoplasmic reticulum calcium pumps and calcium pool in control of prostate cancer LNCaP cell growth, raising the prospect of new targets for the treatment of prostate cancer.	Univ Sci & Tech Lille Flandres Artois, Lab Physiol Cellulaire, INSERM, EPI 9938, F-59655 Villeneuve Dascq, France; Univ Artois, Fac Sci Jean Perrin, F-62300 Lens, France; Catholic Univ Louvain, Dept Mol Cell Biol, Fysiol Lab, B-3000 Louvain, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite d'Artois; Universite Catholique Louvain	Legrand, G (corresponding author), Univ Sci & Tech Lille Flandres Artois, Lab Physiol Cellulaire, INSERM, EPI 9938, Bat SN3, F-59655 Villeneuve Dascq, France.	legrandg@pop.univ-lille1.fr	Vanden Abeele, Fabien/O-6012-2017; Slomianny, Christian/L-8285-2018	Vanden Abeele, Fabien/0000-0001-7111-7220; Mariot, Pascal/0000-0001-7226-9162; Prevarskaya, natacha/0000-0003-0316-197X				BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERCHEM GJ, 1995, CANCER RES, V55, P735; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Bridges AJ, 1996, J MED CHEM, V39, P267, DOI 10.1021/jm9503613; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; Cheng GM, 1996, ARCH BIOCHEM BIOPHYS, V329, P65, DOI 10.1006/abbi.1996.0192; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; FONG CJ, 1992, CANCER RES, V52, P5887; FURUYA Y, 1994, CANCER RES, V54, P6167; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kuo TH, 1997, CELL CALCIUM, V21, P399, DOI 10.1016/S0143-4160(97)90051-8; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; MACDONALD A, 1992, BRIT J CANCER, V65, P177, DOI 10.1038/bjc.1992.37; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; Merle PL, 1997, J MOL CELL CARDIOL, V29, P2687, DOI 10.1006/jmcc.1997.0500; Michalak M, 1998, BIOCHEM CELL BIOL, V76, P779, DOI 10.1139/bcb-76-5-779; Nava VE, 2000, CANCER RES, V60, P4468; OLEA N, 1990, ENDOCRINOLOGY, V126, P1457, DOI 10.1210/endo-126-3-1457; PANDIELLA A, 1987, EXP CELL RES, V170, P175, DOI 10.1016/0014-4827(87)90127-3; PETROW V, 1986, PROSTATE, V9, P343, DOI 10.1002/pros.2990090405; Preston GA, 1997, CANCER RES, V57, P537; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; Prinsloo SE, 2001, ADV CLIN CHEM, V35, P101, DOI 10.1016/S0065-2423(01)35016-3; SACED B, 1997, PROSTATE, V31, P145; SCHUURMANS ALG, 1989, UROL INT, V44, P71, DOI 10.1159/000281473; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Singh SM, 2000, CURR MED CHEM, V7, P211, DOI 10.2174/0929867003375371; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Stokes DL, 2000, EUR J BIOCHEM, V267, P5274, DOI 10.1046/j.1432-1327.2000.01569.x; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Webber MM, 1997, PROSTATE, V30, P58; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765	42	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47608	47614		10.1074/jbc.M107011200	http://dx.doi.org/10.1074/jbc.M107011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11606580	hybrid			2022-12-25	WOS:000172768500121
J	Ogris, M; Carlisle, RC; Bettinger, T; Seymour, LW				Ogris, M; Carlisle, RC; Bettinger, T; Seymour, LW			Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-IMMUNOGENICITY RELATIONSHIP; DNA/TRANSFERRIN-PEI COMPLEXES; MAMMALIAN-CELLS; LOCALIZATION SEQUENCE; CULTURED-CELLS; PLASMID DNA; PEPTIDE; EXPRESSION; POLYETHYLENIMINE; TRANSFECTION	Entry of exogenously applied DNA into the cytoplasm and subsequent transport into the nucleus are major cellular barriers for nonviral gene delivery vectors. To overcome these barriers, we have covalently attached the cationic peptide melittin to poly(ethylenimine) (PEI). This conjugate condensed DNA into small, discrete particles (< 100 nm in diameter), and the membrane lytic activity of melittin enabled efficient release of the DNA into the cytoplasm, as monitored by fluorescence microscopy and flow cytometry. Compared with PEI, the transfection activity was strongly increased within a broad range of cell lines and types tested, including different tumor cell lines but also primary hepatocytes and human umbilical vein endothelial cells. The early onset of gene expression (within 4 h, reaching maximal values after 12 h) and the high reporter gene expression achieved in slowly dividing or confluent cells suggested a further role of melittin after releasing the DNA into the cytoplasm. Intracytoplasmic microinjection of melittin-containing PEI-DNA complexes into fibroblasts produced 40% cellular frequency of reporter gene expression that was inhibitable by co-injection of wheat germ agglutinin, whereas simple PEI-DNA complexes showed only 10%. These data suggest that melittin enables release of nonviral gene transfer particles into the cytoplasm and also enhances their transport into the nucleus, possibly via the cationic cluster KRKR near the C terminus of the peptide.	Univ Birmingham, Canc Res Campaign, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Ogris, M (corresponding author), Univ Munich, Dept Pharm, Butenandtstr 5-13, D-81377 Munich, Germany.	manfred.ogris@cup.uni-muenchen.de	Carlisle, Robert/C-3049-2009	Ogris, Manfred/0000-0002-4576-6961				Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726; Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102; CARLISLE RC, 2001, IN PRESS MOL THER; Collas P, 1996, TRANSGENIC RES, V5, P451, DOI 10.1007/BF01980210; Dash PR, 1999, GENE THER, V6, P643, DOI 10.1038/sj.gt.3300843; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; Eilbracht J, 2001, P NATL ACAD SCI USA, V98, P3849, DOI 10.1073/pnas.071042298; Erbacher P, 1996, EXP CELL RES, V225, P186, DOI 10.1006/excr.1996.0169; Finsinger D, 2000, GENE THER, V7, P1183, DOI 10.1038/sj.gt.3301227; GEISOW MJ, 1984, EXP CELL RES, V150, P29, DOI 10.1016/0014-4827(84)90698-0; Heiss NS, 1999, HUM MOL GENET, V8, P2515, DOI 10.1093/hmg/8.13.2515; KICHLER A, 1999, NONVIRAL VECTORS GEN, P191; KING TP, 1993, BIOCHEMISTRY-US, V32, P3506, DOI 10.1021/bi00064a039; KING TP, 1994, J IMMUNOL, V153, P1124; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; LEGENDRE JY, 1993, P NATL ACAD SCI USA, V90, P893, DOI 10.1073/pnas.90.3.893; Legendre JY, 1997, BIOCONJUGATE CHEM, V8, P57, DOI 10.1021/bc960076d; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MURPHY RF, 1982, CYTOMETRY, V2, P402; Ogris M, 2000, BBA-GEN SUBJECTS, V1474, P237, DOI 10.1016/S0304-4165(00)00018-0; Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745; Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900; Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101; PLANK C, 1994, J BIOL CHEM, V269, P12918; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Poulain L, 2000, CANCER GENE THER, V7, P644, DOI 10.1038/sj.cgt.7700170; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; Subramaniam PS, 1999, J BIOL CHEM, V274, P403, DOI 10.1074/jbc.274.1.403; Subramanian A, 1999, NAT BIOTECHNOL, V17, P873, DOI 10.1038/12860; Tseng WC, 1999, BBA-GENE STRUCT EXPR, V1445, P53, DOI 10.1016/S0167-4781(99)00039-1; Vacik J, 1999, GENE THER, V6, P1006, DOI 10.1038/sj.gt.3300924; WAGNER E, 1991, BIOCONJUGATE CHEM, V2, P226, DOI 10.1021/bc00010a006; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91	36	181	195	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47550	47555		10.1074/jbc.M108331200	http://dx.doi.org/10.1074/jbc.M108331200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11600500	hybrid, Green Published			2022-12-25	WOS:000172768500114
J	Tong, XJ; Xie, D; O'Kelly, J; Miller, CW; Muller-Tidow, C; Koeffler, HP				Tong, XJ; Xie, D; O'Kelly, J; Miller, CW; Muller-Tidow, C; Koeffler, HP			Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; PRB-RELATED P130; G(1) ARREST; IN-VIVO; DIFFERENTIAL EXPRESSION; INTEGRIN; PROTEIN; PRB2/P130; PRODUCT	Cysteine-rich protein 61 (Cyr61) is a member of a family of growth factor-inducible immediate-early genes. It regulates cell adhesion, migration, proliferation, and differentiation and is involved in tumor growth. In our experiments, the role of Cyr61 in non-small cell lung cancer (NSCLC) was examined. Expression of Cyr61 mRNA was decreased markedly in four of five human lung tumor samples compared with their normal matched lung samples. NSCLC cell lines NGI-H520 and H460, which have no endogenous Cyr61, formed 60-90% fewer colonies after being transfected with a Cyr61 cDNA expression vector than cells transfected with the same amount of empty vector. After stable transfection of a Cyr61 cDNA expression vector, proliferation of both H520-Cyr61 and H460-Cyr61 sublines decreased remarkably compared with the cells stably transfected with empty vector. The addition of antibody against Cyr61 partially rescued the growth suppression of both H520Cyr61 and H460-Cyr61 cells. Cell cycle analysis revealed that both H520-Cyr61 and H460-Cyr61 cells developed G(1) arrest, prominently up-regulated expression of p53 and p21(WaF1), and had decreased activity of cyclin-dependent kinase 2. The increase of pocket protein pRB2/p130 was also detected in these cells. Notably, both of the Cyr61-stably transfected lung cancer cell lines developed smaller tumors than those formed by the wild-type cells in nude mice. Taken together, we conclude that Cyr61 may play a role as a tumor suppressor in NSCLC.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Munich, Dept Med Hematol & Oncol, D-48129 Munster, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Munich	Tong, XJ (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Davis Bldg,Rm 5022,8700 Beverly Blvd, Los Angeles, CA 90048 USA.		Müller-Tidow, Carsten/O-7207-2018; Müller-Tidow, Carsten CMT/B-5257-2014	Müller-Tidow, Carsten/0000-0002-7166-5232; Xie, Dong/0000-0002-1150-8657				Albrecht C, 2000, J BIOL CHEM, V275, P28929, DOI 10.1074/jbc.M003053200; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CLIN CANCER RES, V6, P754; Gottschalk AR, 2001, CANCER RES, V61, P2105; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Hirasaki S, 2001, HEPATOL RES, V19, P294, DOI 10.1016/S1386-6346(00)00101-7; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lechner A, 2000, BONE, V27, P53, DOI 10.1016/S8756-3282(00)00294-5; Leoncini L, 1999, CLIN CANCER RES, V5, P4065; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Narayanan BA, 1999, CANCER LETT, V136, P215, DOI 10.1016/S0304-3835(98)00323-1; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Pilarsky CP, 1998, PROSTATE, V36, P85; Ponzio G, 1998, ONCOGENE, V17, P1159, DOI 10.1038/sj.onc.1202040; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; Stiegler P, 1999, ANAL QUANT CYTOL, V21, P363; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Tsai MS, 2000, CANCER RES, V60, P5603; WALDMAN T, 1995, CANCER RES, V55, P5187; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Xu LF, 2000, GENE DEV, V14, P585; Zi XL, 1998, CLIN CANCER RES, V4, P1055	49	116	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47709	47714		10.1074/jbc.M107878200	http://dx.doi.org/10.1074/jbc.M107878200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598125	hybrid			2022-12-25	WOS:000172768500135
J	Hassa, PO; Covic, M; Hasan, S; Imhof, R; Hottiger, MO				Hassa, PO; Covic, M; Hasan, S; Imhof, R; Hottiger, MO			The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-DEFICIENT MICE; NITRIC-OXIDE SYNTHASE; ADP-RIBOSE POLYMERASE; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; DEPENDENT TRANSCRIPTION; GENE-EXPRESSION; CELL-DEATH; PROTEINS; DOMAIN	Poly(ADP-ribose) polymerase 1 (PARP-1)-deficient mice are protected against septic shock, diabetes type 1, stroke, and inflammation. We report that primary cells from PARP-1(-1-) animals are impaired in kappaB-dependent transcriptional activation induced by different stimuli involved in inflammatory and genotoxic stress signaling. PARP-1 was also required for p65-mediated transcriptional activation. PARP-1 enzymatic inhibitors did not inhibit the transcriptional activation of a kappaB-dependent reporter gene in wild type cells. Remarkably, neither the enzymatic activity nor the DNA binding activity of PARP-1 was required for kappaB-dependent transcriptional activation in PARP-1(-/-) cells complemented with different PARP-1 mutants. However, PARP-1 interacted in vitro directly with both subunits of NF-kappaB (p50 and p65), and mapping of the interaction domains revealed that both subunits bind to different PARP-1 domains. Furthermore, a PARP-1 mutant lacking the enzymatic and DNA binding activity interacted comparably to the wild type PARP-1 with p65 or p50. Finally, we showed that PARP-1 is activating the natural inducible nitric-oxide synthase and P-selectin promoter in a kappaB-dependent manner upon stimulation of the cells with inflammatory stimuli or cotransfection of p65. Our results provide evidence that neither the DNA binding nor the enzymatic activity of PARP-1 but its direct protein-protein interaction with both subunits of NF-kappaB is required for its coactivator function, thus expanding the role of PARP-1 as an essential and novel classical transcriptional coactivator for kappaB-dependent gene expression in vivo.	Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hottiger, MO (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270				Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALTHAUS FR, 1992, J CELL SCI, V102, P663; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; Desnoyers S, 1996, MOL CELL BIOCHEM, V159, P155, DOI 10.1007/BF00420918; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HEINE H, 1995, J IMMUNOL, V155, P4899; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; Kuhnle S, 1999, BIOCHEM BIOPH RES CO, V263, P433, DOI 10.1006/bbrc.1999.1393; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Rolli V, 1997, BIOCHEMISTRY-US, V36, P12147, DOI 10.1021/bi971055p; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Soriano FG, 2001, J MOL MED, V79, P437, DOI 10.1007/s001090100236; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1996, J IMMUNOL, V156, P350	55	255	267	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45588	45597		10.1074/jbc.M106528200	http://dx.doi.org/10.1074/jbc.M106528200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590148	hybrid			2022-12-25	WOS:000172573100015
J	Huber, CG; Timperio, AM; Zolla, L				Huber, CG; Timperio, AM; Zolla, L			Isoforms of photosystem II antenna proteins in different plant species revealed by liquid chromatography-electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; LIGHT-HARVESTING COMPLEX; REACTION-CENTER SUBUNITS; IDENTIFICATION; CHLOROPLAST; POLYPEPTIDES; MEMBRANES; GENES; RESOLUTION; SYSTEM	The high selectivity offered by reversed-phase highperformance liquid chromatography on-line coupled to electrospray ionization mass spectrometry has been utilized to characterize the major and minor light-harvesting proteins of photosystem II (Lhcb). Isomeric forms of the proteins, revealed either on the basis of different hydrophobicity enabling their chromatographic separation or on the basis of different molecular masses identified within one single chromatographic peak, were readily identified in a number of monocot and dicot species. The presence of several Lhcb1 isoforms (preferably in dicots) can explain the tendency of dicot Lhcb1 to form trimeric aggregates. The Lhcb1 molecular masses ranged from 24,680 to 25,014 among different species, whereas within the same species, the isoforms differed by 14-280 mass units. All Lhcb1 proteins appear to be highly conserved among different species such that they belong to a single gene group that has several different gene family members. In all species examined, the number of isoforms corresponded more or less to the genes cloned previously. Two isoforms of Lhcb3 were found in petunia and tomato. For Lhcb6, the most divergent of all light-harvesting proteins, the greatest number of isoforms was found in petunia, tobacco, tomato, and rice. Lhcb2, Lhcb4, and Lhcb5 were present in only one form. The isoforms are assumed to play an important role in the adaptation of plants to environmental changes.	Loepold Franzens Univ, Inst Analyt Chem & Radiochem, A-6020 Innsbruck, Austria; Univ Tuscia, Dept Environm Sci, I-01100 Viterbo, Italy	University of Innsbruck; Tuscia University	Huber, CG (corresponding author), Loepold Franzens Univ, Inst Analyt Chem & Radiochem, Innrain 52A, A-6020 Innsbruck, Austria.		Timperio, Anna Maria/AAN-4248-2020; Huber, Christian G./E-5445-2011	Timperio, Anna Maria/0000-0001-8457-042X; Huber, Christian G./0000-0001-8358-1880				BASSI R, 1987, J BIOL CHEM, V262, P13333; BASSI R, 1991, PLANTA, V183, P423, DOI 10.1007/BF00197742; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; BENNETT J, 1980, P NATL ACAD SCI-BIOL, V77, P5253, DOI 10.1073/pnas.77.9.5253; BERGANTINO E, 1995, J BIOL CHEM, V270, P8474, DOI 10.1074/jbc.270.15.8474; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; BROWNE CA, 1982, ANAL BIOCHEM, V124, P201, DOI 10.1016/0003-2697(82)90238-X; Corradini D, 2000, J CHROMATOGR A, V886, P111, DOI 10.1016/S0021-9673(00)00449-0; CORTES HJ, 1992, J CHROMATOGR, V626, P3, DOI 10.1016/0021-9673(92)85324-M; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; De Luca C, 1999, J PHOTOCH PHOTOBIO B, V49, P50, DOI 10.1016/S1011-1344(99)00016-0; Dekker JP, 1999, FEBS LETT, V449, P211, DOI 10.1016/S0014-5793(99)00442-1; DEMMIN DS, 1989, J MOL EVOL, V29, P266, DOI 10.1007/BF02100210; DUNSMUIR P, 1985, NUCLEIC ACIDS RES, V13, P2503, DOI 10.1093/nar/13.7.2503; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GREEN BR, 1992, FEBS LETT, V305, P18, DOI 10.1016/0014-5793(92)80646-X; GRIFFITHS WJ, 2000, EXS, P8869; HANCOCK W, 1999, ANAL CHEM, V1, P742; Huber CG, 1999, J CHROMATOGR A, V849, P161, DOI 10.1016/S0021-9673(99)00532-4; HUNER NPA, 1992, PLANT PHYSIOL, V99, P830, DOI 10.1104/pp.99.3.830; IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; JANSSON S, 1990, BIOCHIM BIOPHYS ACTA, V1019, P110, DOI 10.1016/0005-2728(90)90130-V; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMPPA GK, 1987, J CELL BIOL, V105, P2641, DOI 10.1083/jcb.105.6.2641; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P69, DOI 10.1016/0005-2728(87)90213-1; Li JX, 2000, PLANT PHYSIOL, V123, P807, DOI 10.1104/pp.123.3.807; MATOO AK, 1987, P NATL ACAD SCI USA, V84, P1497; Opiteck GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/ac961155l; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; PETER GF, 1991, J BIOL CHEM, V266, P16745; PICHERSKY E, 1985, GENE, V40, P247, DOI 10.1016/0378-1119(85)90047-2; Premstaller A, 2001, ANAL CHEM, V73, P2390, DOI 10.1021/ac010046q; SCHWARTZ E, 1990, PLANT MOL BIOL, V15, P157, DOI 10.1007/BF00017734; Sharma J, 1997, J BIOL CHEM, V272, P33158, DOI 10.1074/jbc.272.52.33158; Sharma J, 1997, J BIOL CHEM, V272, P3935, DOI 10.1074/jbc.272.7.3935; Sharma J, 1997, J BIOL CHEM, V272, P33153, DOI 10.1074/jbc.272.52.33153; SIGRIST M, 1992, BIOCHIM BIOPHYS ACTA, V1098, P191, DOI 10.1016/S0005-2728(05)80336-6; STOCKINGER EJ, 1994, PLANT PHYSIOL, V104, P1475, DOI 10.1104/pp.104.4.1475; Szabo I, 2001, J BIOL CHEM, V276, P13784, DOI 10.1074/jbc.M008081200; Zolla L, 1999, PHOTOSYNTH RES, V61, P281, DOI 10.1023/A:1006397419473; Zolla L, 2000, PROTEINS, V41, P398, DOI 10.1002/1097-0134(20001115)41:3<398::AID-PROT110>3.0.CO;2-K; ZOLLA L, RECENT RES DEV BIOEN	47	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45755	45761		10.1074/jbc.M106700200	http://dx.doi.org/10.1074/jbc.M106700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581262	hybrid			2022-12-25	WOS:000172573100036
J	Lin, YH; Yang-Yen, HF				Lin, YH; Yang-Yen, HF			The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; HEMATOPOIETIC-CELLS; NEOPLASTIC TRANSFORMATION; INTERLEUKIN-3; RECEPTOR; RNA; TRANSDUCTION; EXPRESSION; APOPTOSIS	We have recently demonstrated that the gene encoding the osteopontin (OPN) protein is activated both by interleukin-3 and granulocyte-macrophage colony-stimulating factor signaling pathways and that, through binding to the cell surface receptor CD44, OPN contributes to the survival activities of interleukin (IL)-3 and GM-CSF (Lin, Y.-H., Huang, C.-J., Chao, J.-R., Chen, S.-T., Lee, S.-F., Yen, J. J.-Y., and Yang-Yen, H.-F. (2000) Mot. Cell. Biol. 20, 2734 -2742). In this report, we demonstrate that the CD44-binding domain of OPN involves a region containing amino acid residues from 121 to 140 and that both threonine and serine at positions 137 and 147, respectively, are essential for the survival stimulatory effect of OPN. Substitution of either residue with alanine results into a dominant negative mutant that overrides the survival effect of IL-3. Upon binding to the CD44 receptor, the wild-type OPN but not the inactive mutant induces activation of phosphatidylinositol 3-kinase and Akt. Last, we demonstrate that two waves of Akt activation are detected in IL-3-treated cells and that the survival promoting effect of OPN is mediated predominantly through the phosphatidylinositol 3-kinase/Akt signaling pathway. Together, our results suggest that a positive autoregulatory loop is involved in the survival pathway of IL-3.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Acad Sinica, Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Defense Medical Center	Yang-Yen, HF (corresponding author), Acad Sinica, Inst Mol Biol, 128 Yen Jiou Yuan Rd,Sect 2, Taipei 11529, Taiwan.	imbyy@ccvax.sinica.edu.tw	Yang-Yen, Hsin-Fang/ABA-5808-2021	Yang-Yen, Hsin-Fang/0000-0001-9048-4800				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BEHREND EI, 1994, CANCER RES, V54, P832; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DURONIO V, 1992, J BIOL CHEM, V267, P21856; GARDNER HAR, 1994, ONCOGENE, V9, P2321; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liaw L, 1998, J CLIN INVEST, V101, P1468; Lin YH, 2000, MOL CELL BIOL, V20, P2734, DOI 10.1128/MCB.20.8.2734-2742.2000; Minshall C, 1996, J IMMUNOL, V156, P939; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Oates AJ, 1996, ONCOGENE, V13, P97; RODAN GA, 1995, ANN NY ACAD SCI, V760, P1, DOI 10.1111/j.1749-6632.1995.tb44614.x; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SENGER DR, 1988, CANCER RES, V48, P5770; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SINGH K, 1992, J BIOL CHEM, V267, P23847; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SU LC, 1995, ONCOGENE, V10, P2163; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	45	198	215	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46024	46030		10.1074/jbc.M105132200	http://dx.doi.org/10.1074/jbc.M105132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590166	hybrid			2022-12-25	WOS:000172573100073
J	Nemeria, N; Yan, Y; Zhang, Z; Brown, AM; Arjunan, P; Furey, W; Guest, JR; Jordan, F				Nemeria, N; Yan, Y; Zhang, Z; Brown, AM; Arjunan, P; Furey, W; Guest, JR; Jordan, F			Inhibition of the Escherichia coli pyruvate dehydrogenase complex E1 subunit and its tyrosine 177 variants by thiamin 2-thiazolone and thiamin 2-thiothiazolone diphosphates - Evidence for reversible tight-binding inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DECARBOXYLASE; ENZYMES; FLUORESCENCE; ACTIVATION; SUBSTRATE; MECHANISM; KINETICS; RESIDUES; OXIDASE	Variants of the pyruvate dehydrogenase subunit (El; EC 1.2.4.1) of the Escherichia coli pyruvate dehydrogenase multienzyme complex with Y177A and Y177F substitutions were created. Both variants displayed pyruvate dehydrogenase multienzyme complex activity at levels of 11% (Y177A El) and 7% (Y177F El) of the parental enzyme. The K-m values for thiamin diphosphate (ThDP) were 1.58 mum (parental El) and 6.65 mum (Y177A EI), whereas the Y177F El variant was not saturated at 200 mum. According to fluorescence studies, binding of ThDP was unaffected by the Tyr(117) substitutions. The ThDP analogs thiamin 2-thiazolone diphosphate (ThTDP) and thiamin 2-thiothiazolone diphosphate (ThTTDP) behaved as tight-binding inhibitors of parental El (K-i = 0.003 mum for ThTDP and K-i = 0.064 mum for ThTTDP) and the Y177A and Y177F variants. This analysis revealed that ThTDP and ThTTDP bound to parental El via a two-step mechanism, but that ThTDP bound to the Y177A variant via a one-step mechanism. Binding of ThTDP was affected and that of ThTTDP was unaffected by substitutions at Tyr(177). Addition of ThDP or ThTDP to parental El resulted in similar CD spectral changes in the near-UV region. In contrast, binding of ThTTDP to either parental El or the Y177A and Y177F variants was accompanied by the appearance of a positive band at 330 nm, indicating that ThTTDP was bound in a chiral environment. In combination with x-ray structural evidence on the location of Tyr(177), the kinetic and spectroscopic data suggest that Tyr(177) has a role in stabilization of some transition state(s) in the reaction pathway, starting with the free enzyme and culminating with the first irreversible step (decarboxylation), as well as in reductive acetylation of the dihydrolipoamide acetyltransferase component.	Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA; Rutgers State Univ, Program Cellular & Mol Biodynam, Newark, NJ 07102 USA; Vet Affairs Med Ctr, Biocrystallog Lab, Pittsburgh, PA 15240 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Newark; Rutgers State University New Brunswick; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Sheffield	Jordan, F (corresponding author), Rutgers State Univ, Dept Chem, 73 Warren St, Newark, NJ 07102 USA.	frjordan@newark.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-62330, GM-13198, GM-48195, GM-50380] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BISSWANG.H, 1974, EUR J BIOCHEM, V48, P377, DOI 10.1111/j.1432-1033.1974.tb03779.x; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; FERSHT A, 1999, STRUCTURE MECH PROTE, P106; Gutowski J A, 1979, Methods Enzymol, V62, P120; GUTOWSKI JA, 1976, J BIOL CHEM, V251, P2863; Hajipour G, 1999, BIOORGAN MED CHEM, V7, P887, DOI 10.1016/S0968-0896(98)00269-7; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HENNING J, 1996, BIOCH PHYSL THIAMIN, P235; JORDAN F, 1998, BIOCHIM BIOPHYS ACTA, V1385, P187; JORDAN F, 1986, THIAMIN PYROPHOSPHAT, P79; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KLUGER R, 1984, J BIOL CHEM, V259, P8960; KOCHETOV GA, 1970, BIOCHEM BIOPH RES CO, V41, P1134, DOI 10.1016/0006-291X(70)90203-2; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; Lakowicz JR, 1983, PRINCIPLES FLUORESCE, P489; Li HJ, 1999, BIOCHEMISTRY-US, V38, P9992, DOI 10.1021/bi9902438; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; MCNALLY AJ, 1995, J BIOL CHEM, V270, P19736, DOI 10.1074/jbc.270.34.19736; MESHALKINA LE, 1979, BIOCHIM BIOPHYS ACTA, V571, P218, DOI 10.1016/0005-2744(79)90092-5; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; Nemeria N, 1998, BIOCHEMISTRY-US, V37, P911, DOI 10.1021/bi9722251; OBRIEN TA, 1980, J BIOL CHEM, V255, P3302; SEGEL IH, 1993, ENZYME KINETICS BEHA, P72; SHIN W, 1977, J AM CHEM SOC, V99, P3491, DOI 10.1021/ja00452a050; SHREVE DS, 1983, J BIOL CHEM, V258, P2405; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; Tittmann K, 2000, BIOCHEMISTRY-US, V39, P10747, DOI 10.1021/bi0004089; Tripatara A, 1999, ARCH BIOCHEM BIOPHYS, V367, P39, DOI 10.1006/abbi.1999.1231; Williams J W, 1979, Methods Enzymol, V63, P437; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200; Yi JZ, 1996, J BIOL CHEM, V271, P33192, DOI 10.1074/jbc.271.52.33192	36	90	96	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45969	45978		10.1074/jbc.M104116200	http://dx.doi.org/10.1074/jbc.M104116200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583990	hybrid			2022-12-25	WOS:000172573100066
J	Schofield, MJ; Brownewell, FE; Nayak, S; Du, CW; Kool, ET; Hsieh, P				Schofield, MJ; Brownewell, FE; Nayak, S; Du, CW; Kool, ET; Hsieh, P			The Phe-X-Glu DNA binding motif of MutS - The role of hydrogen bonding in mismatch recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE MSH2-MSH6 COMPLEX; REPAIR PROTEIN MUTS; HETERODUPLEX DNA; HMUTS-ALPHA; MSH6; REPLICATION; MUTATION; SUBUNIT; ANALOGS; CANCER	The crystal structures of MutS protein from Thermus aquaticus and Escherichia coli in a complex with a mismatch-containing DNA duplex reveal that the Glu residue in a conserved Phe-X-Glu motif participates in a hydrogen-bonded contact with either an unpaired thymidine or the thymidine of a G-T base-base mismatch. Here, the role of hydrogen bonding in mismatch recognition by MutS is assessed. The relative affinities of MutS for DNA duplexes containing nonpolar shape mimics of A and T, 4-methylbenzimidazole (Z), and difluoro-toluene (F), respectively, that lack hydrogen bonding donors and acceptors, are determined in gel mobility shift assays. The results provide support for an induced fit mode of mismatch binding in which duplexes destabilized by mismatches are preferred substrates for kinking by MutS. Hydrogen bonding between the O is an element of2 group of Glu and the mismatched base contributes only marginally to mismatch recognition and is significantly less important than the aromatic ring stack with the conserved Phe residue. A MutS protein in which Ala is substituted for Glu(38) is shown to be defective for mismatch repair in vivo. DNA binding studies reveal a novel role for the conserved Glu residue in the establishment of mismatch discrimination by MutS.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University	Hsieh, P (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 10,Rm 9D06, Bethesda, MD 20892 USA.			Brownewell, Floyd/0000-0002-9304-1690; Kool, Eric/0000-0002-7310-2935	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052956] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52956] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alani E, 1996, MOL CELL BIOL, V16, P5604; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Das Gupta R, 2000, NAT GENET, V24, P53, DOI 10.1038/71684; Dufner P, 2000, J BIOL CHEM, V275, P36550, DOI 10.1074/jbc.M005987200; FENG G, 1995, BIOTECHNIQUES, V19, P956; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Guckian KM, 1998, J ORG CHEM, V63, P9652, DOI 10.1021/jo9805100; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Ingleston SM, 2000, EMBO J, V19, P6266, DOI 10.1093/emboj/19.22.6266; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Ren RXF, 1996, J AM CHEM SOC, V118, P7671, DOI 10.1021/ja9612763; SCHMITT E, 1993, J MOL BIOL, V233, P615, DOI 10.1006/jmbi.1993.1540; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; SU SS, 1988, J BIOL CHEM, V263, P6829; Yamamoto A, 2000, NUCLEIC ACIDS RES, V28, P3564, DOI 10.1093/nar/28.18.3564	27	79	80	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45505	45508		10.1074/jbc.C100449200	http://dx.doi.org/10.1074/jbc.C100449200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11602569	hybrid			2022-12-25	WOS:000172573100003
J	Zelcer, N; Saeki, T; Reid, G; Beijnen, JH; Borst, P				Zelcer, N; Saeki, T; Reid, G; Beijnen, JH; Borst, P			Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER; GENE-TRANSFER; GLUTATHIONE; RAT; EXPRESSION; EXPORT; MRP3; LOCALIZATION; CELLS; GLYCOPROTEIN	We have characterized the substrate specificity and mechanism of transport of the human multidrug resistance-associated protein 3 (MRP3). A murine fibroblastlike cell line generated from the kidneys of mice that lack Mdr1a/b and Mrp1 was retrovirally transduced with MRP3 cDNA. Stable clones overproducing MRP3 were resistant to the epipodophyllotoxins etoposide and teniposide but not to vincristine, doxorubicin, and cisplatin, drugs suggested to be MRP3 substrates by others. The resistance to etoposide was associated with reduced cellular accumulation and enhanced efflux of this drug and was not affected by depleting cells of glutathione but was inhibited by several common organic anion transport inhibitors. Membrane vesicles from infected insect cells expressing MRP3 mediated ATP-dependent transport of estradiol 17-beta -D-glucuronide, leukotriene C-4, dinitrophenyl S-glutathione but not glutathione itself, and etoposide glucuronide, a major metabolite of etoposide in vivo. The transport of estradiol 17-beta -D-glucuronide by MRP3 was inhibited in a concentration-dependent manner by both etoposide and methotrexate. Even though etoposide glucuronide is an excellent substrate for MRP3, this compound is not involved in the etoposide resistance of our MRP3 cells, as these cells extrude unmodified etoposide rather than etoposide glucuronide.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Slotervaart Hospital	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	pborst@nki.nl	Zelcer, Noam/C-6393-2009	Reid, Glen/0000-0001-6465-5223; Zelcer, Noam/0000-0001-6935-7532				Allen JD, 2000, CANCER RES, V60, P5761; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; Grignani F, 1998, CANCER RES, V58, P14; HANDE K, 1988, CANCER RES, V48, P1829; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; Jedlitschky G, 1996, CANCER RES, V56, P988; Johnson DR, 2001, CANCER RES, V61, P1469; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Klein M, 1996, J BIOL CHEM, V271, P29666, DOI 10.1074/jbc.271.47.29666; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1997, CANCER RES, V57, P3537; Loe DW, 1998, CANCER RES, V58, P5130; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ogawa K, 2000, AM J PHYSIOL-GASTR L, V278, pG438, DOI 10.1152/ajpgi.2000.278.3.G438; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Rappa G, 1997, CANCER RES, V57, P5232; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; Sakamoto H, 1999, CANCER LETT, V135, P113; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Soroka CJ, 2001, HEPATOLOGY, V33, P783, DOI 10.1053/jhep.2001.23501; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797; Young LC, 2001, CLIN CANCER RES, V7, P1798; Young LC, 1999, CLIN CANCER RES, V5, P673; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zeng H, 1999, CANCER RES, V59, P5964; Zeng H, 2000, CANCER RES, V60, P4779	42	220	226	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46400	46407		10.1074/jbc.M107041200	http://dx.doi.org/10.1074/jbc.M107041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581266	hybrid			2022-12-25	WOS:000172573100123
J	Leventhal, AR; Chen, WG; Tall, AR; Tabas, I				Leventhal, AR; Chen, WG; Tall, AR; Tabas, I			Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NIEMANN-PICK-DISEASE; UNESTERIFIED CHOLESTEROL; CHEMICAL-COMPOSITION; ACYL TRANSFERASE; J774 MACROPHAGES; CELLS; METABOLISM; RECEPTOR; STORAGE	Cholesterol efflux from macrophage foam cells, a key step in reverse cholesterol transport, requires trafficking of cholesterol from intracellular sites to the plasma membrane. Sphingomyelin is a cholesterol-binding molecule that transiently exists with cholesterol in endosomes and lysosomes but is rapidly hydrolyzed by lysosomal sphingomyelinase (L-SMase), a product of the acid sphingomyelinase (ASM) gene. We therefore hypothesized that sphingomyelin hydrolysis by L-SMase enables cholesterol efflux by preventing cholesterol sequestration by sphingomyelin. Macrophages from wildtype and ASM knockout mice were incubated with [H-3]cholesteryl ester-labeled acetyl-LDL and then exposed to apolipoprotein A-I or high density lipoprotein. In both cases, [H-3]cholesterol efflux was decreased substantially in the ASM knockout macrophages. Similar results were shown for ASM knockout macrophages labeled long-term with [H-3]cholesterol added directly to medium, but not for those labeled for a short period, suggesting defective efflux from intracellular stores but not from the plasma membrane. Cholesterol trafficking to acyl-coenzyme A.-cholesterol acyltransferase (ACAT) was also defective in ASM knockout macrophages. Using filipin to probe cholesterol in macrophages incubated with acetyl-LDL, we found there was modest staining in the plasma membrane of wild-type macrophages but bright, perinuclear fluorescence in ASM knockout macrophages. Last, when wild-type macrophages were incubated with excess sphingomyelin to "saturate" L-SMase, [H-3]cholesterol efflux was decreased. Thus, sphingomyelin accumulation due to L-SMase deficiency leads to defective cholesterol trafficking and efflux, which we propose is due to sequestration of cholesterol by sphingomyelin and possibly other mechanisms. This model may explain the low plasma high density lipoprotein found in ASM-deficient humans and may implicate L-SMase deficiency and/or sphingomyelin enrichment of lipoproteins as novel atherosclerosis risk factors.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Eckhardt, Erik/G-1567-2010; Tall, Alan/AAT-8528-2021		NCI NIH HHS [P30 CA13696] Funding Source: Medline; NCRR NIH HHS [S10 RR13701, S10 RR10506] Funding Source: Medline; NHLBI NIH HHS [HL-56984] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013701, S10RR010506] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Botelho RJ, 2000, J BIOL CHEM, V275, P15717, DOI 10.1074/jbc.M910068199; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jiang XC, 2000, ARTERIOSCL THROM VAS, V20, P2614, DOI 10.1161/01.ATV.20.12.2614; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LEVADE T, 1988, J INHERIT METAB DIS, V11, P151, DOI 10.1007/BF01799864; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MAOR I, 1995, ARTERIOSCL THROM VAS, V15, P1378, DOI 10.1161/01.ATV.15.9.1378; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; RAPP JH, 1983, J LIPID RES, V24, P1329; Reagan JM, 2000, J BIOL CHEM, V275, P38104, DOI 10.1074/jbc.M005296200; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; RINNINGER F, 1995, BBA-LIPID LIPID MET, V1255, P141, DOI 10.1016/0005-2760(94)00228-Q; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Rothblat GH, 1999, J LIPID RES, V40, P781; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SHIO H, 1979, LAB INVEST, V41, P160; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Tall AR, 1998, EUR HEART J, V19, pA31; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; TANGIRALA RK, 1993, J BIOL CHEM, V268, P9653; VIANA MB, 1990, J MED GENET, V27, P499, DOI 10.1136/jmg.27.8.499; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Worgall TS, 2000, CIRCULATION, V102, P30; XU XX, 1991, J BIOL CHEM, V266, P17040; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	57	91	99	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44976	44983		10.1074/jbc.M106455200	http://dx.doi.org/10.1074/jbc.M106455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579092	hybrid			2022-12-25	WOS:000172406700086
J	Pinheiro, TJT; Venning, JD; Jackson, JB				Pinheiro, TJT; Venning, JD; Jackson, JB			Fast hydride transfer in proton-translocating transhydrogenase revealed in a rapid mixing continuous flow device	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; NADP(H)-BINDING COMPONENT DIII; RHODOSPIRILLUM-RUBRUM; ESCHERICHIA-COLI; ENERGY TRANSDUCTION; CRYSTAL-STRUCTURE; DOMAIN III; BINDING; RECOMBINANT; RESOLUTION	Transhydrogenase couples the redox reaction between NAD(II) and NADP(H) to proton translocation across a membrane. Coupling is achieved through changes in protein conformation. Upon mixing, the isolated nucleotide-binding components of transhydrogenase (dI, which binds NAD(H), and dIII, which binds NADP(H)) form a catalytic dI(2)-dIII(1) complex, the structure of which was recently solved by x-ray crystallography. The fluorescence from an engineered Trp in dIII changes when bound NADP(+) is reduced. Using a continuous flow device, we have measured the Trp fluorescence change when dI(2).dIII(1) complexes catalyze reduction of NADP(+) by NADH on a sub-millisecond scale. At elevated NADH concentrations, the first-order rate constant of the reaction approaches 21,200 s(-1), which is larger than that measured for redox reactions of nicotinamide nucleotides in other, soluble enzymes. Rather high concentrations of NADH are required to saturate the reaction. The deuterium isotope effect is small. Comparison with the rate of the reverse reaction (oxidation of NADPH by NAD(+)) reveals that the equilibrium constant for the redox reaction on the complex is >36. This high value might be important in ensuring high turnover rates in the intact enzyme.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Birmingham; University of Warwick	Jackson, JB (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	j.b.jackson@bham.ac.uk						Bell R, 1980, TUNNEL EFFECT CHEM; Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; BIZOUARN T, 1995, BBA-BIOENERGETICS, V1229, P49, DOI 10.1016/0005-2728(94)00186-9; Bizouarn T, 2000, BBA-BIOENERGETICS, V1457, P211, DOI 10.1016/S0005-2728(00)00103-1; Bragg PD, 2001, ARCH BIOCHEM BIOPHYS, V388, P299, DOI 10.1006/abbi.2001.2298; Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; FERSHT A, 1985, ENZYME STRUCTURE MEC, P130; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; GLICKMAN MH, 1994, J AM CHEM SOC, V116, P793, DOI 10.1021/ja00081a060; GRANT KL, 1989, BIOCHEMISTRY-US, V28, P6597, DOI 10.1021/bi00442a010; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; HOEK JB, 1988, BIOCHEM J, V254, P1; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 1999, FEBS LETT, V464, P1, DOI 10.1016/S0014-5793(99)01644-0; Jeeves M, 2000, BBA-BIOENERGETICS, V1459, P248, DOI 10.1016/S0005-2728(00)00159-6; JENCKS WP, 1983, CURR TOP MEMBR TRANS, V19, P1; LEE CHUAN-PU, 1965, BIOCHIM BIOPHYS BIOPHYS ACTA, V105, P397; LITTLE JW, 1972, ANAL BIOCHEM, V48, P217, DOI 10.1016/0003-2697(72)90184-4; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; Peake SJ, 1999, BBA-BIOENERGETICS, V1413, P81, DOI 10.1016/S0005-2728(99)00084-5; PERSSON B, 1987, ARCH BIOCHEM BIOPHYS, V259, P341, DOI 10.1016/0003-9861(87)90500-5; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; Shastry MCR, 1998, BIOPHYS J, V74, P2714, DOI 10.1016/S0006-3495(98)77977-9; Venning JD, 2000, J BIOL CHEM, V275, P19490, DOI 10.1074/jbc.M000577200; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; Venning JD, 1999, BIOCHEM J, V341, P329, DOI 10.1042/0264-6021:3410329; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; VIOLA RE, 1979, ANAL BIOCHEM, V96, P334, DOI 10.1016/0003-2697(79)90590-6; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	36	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44757	44761		10.1074/jbc.M109227200	http://dx.doi.org/10.1074/jbc.M109227200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577115	hybrid			2022-12-25	WOS:000172406700057
J	Steele, IA; Edmondson, RJ; Bulmer, JN; Bolger, BS; Leung, HY; Davies, BR				Steele, IA; Edmondson, RJ; Bulmer, JN; Bolger, BS; Leung, HY; Davies, BR			Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer	ONCOGENE			English	Article						FGF receptor 2; ovarian cancer; ovarian surface epithelium	FIBROBLAST-GROWTH-FACTOR; E-CADHERIN EXPRESSION; SURFACE EPITHELIUM; PROSTATE-CANCER; CELLS; KERATINOCYTE; FAMILY; SPECIFICITY; CARCINOMAS; TISSUES	Epithelial ovarian cancers (EOCs) arise in the Ovarian Surface Epithelium (OSE). This tissue is a simple, poorly committed mesothelium which exhibits characteristics of epithelial and mesenchymal cells when grown in culture. In contrast, EOCs frequently exhibit properties of complex epithelial tissues of the female reproductive tract, such as oviductal, endometrial and cervical epithelia, and show induction of expression of epithelial markers such as E-cadherin. Fibroblast Growth Factor Receptor 2 isoform IIIb (FGF receptor 2-IIIb) is a spliced variant of FGF receptor 2 that binds the ligands FGF-1 and FGF-7 with high affinity, and is expressed exclusively by epithelial cells. We have studied the expression of FGF receptor 2-IIIb and its ligands in primary cultures of normal human OSE, EOC cell lines and snap frozen tissue from EOCs. Expression of FGF receptor 2-IIIb mRNA is undetectable in normal OSE, but is expressed in 16/20 (80%) of EOCs. FGFs 1 and 7 mRNAs are expressed in normal OSE, whilst only 4/20 (20%) and 12/20 (60%) of EOCs demonstrated expression for these ligands respectively. However, FGF-7 protein was detected in 70% (mean level = 0.7 ng/ml) of ascitic fluids obtained from patients with EOC. FGFs 1 and 7 stimulate DNA synthesis in EOC cell lines that express FGF receptor 2-IIlb. Moreover, DNA synthesis in these cell lines can be partially blocked by blocking antisera to FGFs 1 and 7. It is suggested that induction of expression of FGF receptor 2-IIIb may play a role in the development of EOCs by rendering the OSE susceptible to paracrine and/or autocrine stimulation by its requisite FGF ligands.	Newcastle Univ, Sch Med, Dept Surg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Queen Elizabeth Hosp, No Gynaecol Oncol Ctr, Gateshead, Tyne & Wear, England; Royal Victoria Infirm, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Davies, BR (corresponding author), Newcastle Univ, Sch Med, Dept Surg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	B.R.Davies@ncl.ac.uk		Edmondson, Richard/0000-0003-2553-4423; Leung, Hing Y./0000-0002-3933-3975				Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bast RC, 1995, J CELL BIOCHEM, P219; BERCHUCK A, 1993, CANCER, V71, P545; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; De Medina SGD, 1999, ONCOGENE, V18, P5722, DOI 10.1038/sj.onc.1202958; DIBLASIO AM, 1993, AM J OBSTET GYNECOL, V169, P1517, DOI 10.1016/0002-9378(93)90428-L; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HERNANDEZ E, 1989, MANUAL GYNECOLOGIC C, P57; INOUE M, 1992, AM J CLIN PATHOL, V98, P76, DOI 10.1093/ajcp/98.1.76; KLUG TL, 1984, CANCER RES, V44, P1048; KRUK PA, 1990, LAB INVEST, V63, P132; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; MainesBandiera SL, 1997, INT J GYNECOL PATHOL, V16, P250, DOI 10.1097/00004347-199707000-00010; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mehta PB, 2000, J UROLOGY, V164, P2151, DOI 10.1016/S0022-5347(05)66988-1; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PARROTT JA, 1994, ENDOCRINOLOGY, V135, P569, DOI 10.1210/en.135.2.569; PETERS KG, 1992, DEVELOPMENT, V114, P233; RESTA L, 1993, OBSTET GYNECOL, V82, P181; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Scully RE, 1995, J CELL BIOCHEM, P208; SCULLY RE, 1977, AM J PATHOL, V87, P686; SCULLY RE, 1992, OVARIAN CANCER, V2, P199; Sundfeldt K, 1997, INT J CANCER, V74, P275, DOI 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.3.CO;2-V; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Westermann AM, 1997, CANCER TREAT REV, V23, P113, DOI 10.1016/S0305-7372(97)90024-4; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YOUNG RH, 1989, DIAGNOSTIC SURGICAL, P1655	38	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5878	5887		10.1038/sj.onc.1204755	http://dx.doi.org/10.1038/sj.onc.1204755			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593393				2022-12-25	WOS:000171037200011
J	Cowling, RT; Gurantz, D; Peng, JF; Dillmann, WH; Greenberg, BH				Cowling, RT; Gurantz, D; Peng, JF; Dillmann, WH; Greenberg, BH			Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-INFARCTION; ALTERED REGULATION; TRANSGENIC MICE; GENE-EXPRESSION; HEART-FAILURE; ACTIVATION; CELLS; BETA; CAPTOPRIL; SURVIVAL	Tumor necrosis factor-a (TNF-alpha) and interleukin-1beta up-regulate type 1 angiotensin IIreceptor (AT(1)) mRNA and protein in cultured neonatal rat cardiac fibroblasts. The use of pharmacologic inhibitors and a degradation-resistant mutant IkappaB-alpha demonstrated that the transcription factor nuclear factor-kappaB (NF-kappaB) is necessary for cytokine-induced AT, up-regulation. The increase in AT(1) mRNA with TNF-alpha treatment is slow, reaching Significance by 6-12 h and peaking by 24-48 h. Electrophoretic mobility shift assays revealed that NF-kappaB nuclear translocation was maintained for greater than or equal to24 h with a single dose of TNF-alpha. Since prolonged NF-KB activation appeared necessary to maximize AT(1) up-regulation, the mechanism of persistent NF-kappaB activation was studied further. Stimulation with TNF-alpha induced a >10x increase in IkappaB kinase (IKK) activity that quickly diminished by 20 min. IkappaB-alpha and IkappaB-beta proteins were degraded during this time, and IkappaB-alpha was resynthesized subsequently by NF-kappaB-dependent transcription. However, IkappaB isoforms and IKK activity did not return completely to unstimulated values during a 12-h time course. These results suggest that low but persistent IKK activity and IkappaB degradation lead to prolonged NF-kappaB nuclear translocation and maximal AT(1) up-regulation in the continued presence of TNF-alpha.	Univ Calif San Diego, Med Ctr, Dept Med Cardiol, San Diego, CA 92103 USA; Univ Calif San Diego, Med Ctr, Div Cardiol, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Div Endocrinol & Metab, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Greenberg, BH (corresponding author), Univ Calif San Diego, Med Ctr, Dept Med Cardiol, 200 W Arbor Dr, San Diego, CA 92103 USA.	bgreenberg@ucsd.edu						AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; Aupperle KR, 1999, J IMMUNOL, V163, P427; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; BELTRAMI CA, 1994, CIRCULATION, V89, P151, DOI 10.1161/01.CIR.89.1.151; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; Eder J, 1997, TRENDS PHARMACOL SCI, V18, P319, DOI 10.1016/S0165-6147(97)01097-3; Funakoshi M, 2001, BIOCHEM BIOPH RES CO, V283, P248, DOI 10.1006/bbrc.2001.4759; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GUO DF, 1995, CIRC RES, V77, P249, DOI 10.1161/01.RES.77.2.249; Gurantz D, 1999, CIRC RES, V85, P272, DOI 10.1161/01.RES.85.3.272; Han YQ, 1997, J BIOL CHEM, V272, P9825; HANATANI A, 1995, J MOL CELL CARDIOL, V27, P1905, DOI 10.1016/0022-2828(95)90013-6; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Jacobs M, 1999, J MOL CELL CARDIOL, V31, P1949, DOI 10.1006/jmcc.1999.1007; Jobin C, 1997, J IMMUNOL, V158, P226; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; JOHNSTON CI, 1993, AM HEART J, V126, P756, DOI 10.1016/0002-8703(93)90925-Y; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KIM NN, 1995, AM J PHYSIOL-ENDOC M, V269, pE426, DOI 10.1152/ajpendo.1995.269.3.E426; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AA, 1995, J MOL CELL CARDIOL, V27, P2347, DOI 10.1016/S0022-2828(95)91983-X; Lefroy DC, 1996, J MOL CELL CARDIOL, V28, P429, DOI 10.1006/jmcc.1996.0039; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li YY, 2000, P NATL ACAD SCI USA, V97, P12746, DOI 10.1073/pnas.97.23.12746; MATSUBARA H, 1994, J CLIN INVEST, V93, P1592, DOI 10.1172/JCI117139; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Milavetz JJ, 1996, J AM COLL CARDIOL, V27, P714, DOI 10.1016/0735-1097(95)00506-4; Ohtani S, 1997, J Card Fail, V3, P303, DOI 10.1016/S1071-9164(97)90030-0; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFEFFER JM, 1985, CIRC RES, V57, P84, DOI 10.1161/01.RES.57.1.84; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; Sasamura H, 1997, HYPERTENSION, V30, P35, DOI 10.1161/01.HYP.30.1.35; Schnee JM, 2000, CARDIOVASC RES, V46, P264, DOI 10.1016/S0008-6363(00)00044-4; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun Y, 1996, CARDIOVASC RES, V31, P518; Sun Y, 1997, J LAB CLIN MED, V129, P439; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VAN AD, 1996, SCIENCE, V274, P787; VANKRIMPEN C, 1991, J MOL CELL CARDIOL, V23, P1245, DOI 10.1016/0022-2828(91)90082-W; VILLARREAL FJ, 1993, CIRCULATION, V88, P2849, DOI 10.1161/01.CIR.88.6.2849; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weber KT, 1997, CIRCULATION, V96, P4065; WOLLERT KC, 1994, CIRCULATION, V90, P2457, DOI 10.1161/01.CIR.90.5.2457; Wyse B, 1997, ENDOCRINOLOGY, V138, P4176, DOI 10.1210/en.138.10.4176; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808	63	72	78	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5719	5724		10.1074/jbc.M107515200	http://dx.doi.org/10.1074/jbc.M107515200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11600498	hybrid			2022-12-25	WOS:000173989200006
J	Diez-Sampedro, A; Wright, EM; Hirayama, BA				Diez-Sampedro, A; Wright, EM; Hirayama, BA			Residue 457 controls sugar binding and transport in the Na+/glucose cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SGLT1; NA+; EXPRESSION; KINETICS	The Na+/glucose cotransporter (SGLT1) is highly selective for its natural substrates, D-galactose and D-galactose. We have investigated the structural basis of this sugar selectivity on the human isoform of SGLT1, single site mutants of hSGLT1, and the pig SGLT3 isoform, expressed in Xenopus oocytes using electrophysiological methods and the effects of cysteine-specific reagents. Kinetics of transport of glucose analogues, each modified at one position of the pyranose ring, were determined for each transporter. Correlation of kinetics with amino acid sequences indicates that residue Gln-457 sequentially interacts with O1 of the pyranose in the binding site, and with O5 in the translocation pathway. Furthermore, correlation of the selectivity characteristics of the SGLT isoforms (SGLT1 transports both glucose and galactose, but SGLT2 and SGLT3 transport only glucose) with amino acid sequence differences, suggests that residue 460 (threonine in SGLT1, and serine in SGLT2 and SGLT3) are involved in hydrogen bonding to O4 of the pyranose. In addition, the results show that substrate specificity of binding is not correlated to substrate specificity of transport, suggesting there are at least two steps in the sugar translocation process.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Ctr Hlth Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hirayama, BA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Ctr Hlth Sci, 53-231CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	bhirayama@mednet.ucla.edu			NIDDK NIH HHS [DK19567, DK44602] Funding Source: Medline; NIGMS NIH HHS [GM99004, GM52094] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044602, R01DK019567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM052094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURANT CF, 1992, J BIOL CHEM, V267, P14523; Diez-Sampedro A, 2000, J MEMBRANE BIOL, V176, P111, DOI 10.1007/s002320001081; Diez-Sampedro A, 2001, AM J PHYSIOL-RENAL, V280, pF278, DOI 10.1152/ajprenal.2001.280.2.F278; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; Hirayama BA, 2001, BRIT J PHARMACOL, V134, P484, DOI 10.1038/sj.bjp.0704274; Jeffrey G.A., 1997, INTRO HYDROGEN BONDI, P15; KONG CT, 1993, J BIOL CHEM, V268, P1509; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Panayotova-Heiermann M, 1999, FEBS LETT, V459, P386, DOI 10.1016/S0014-5793(99)01292-2; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; RAO VSR, 1998, CONFORMATIONS CARBOH, P303; WILSON TH, 1962, INTESTINAL ABSORPTIO, P69	21	78	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49188	49194		10.1074/jbc.M108286200	http://dx.doi.org/10.1074/jbc.M108286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11602601	hybrid			2022-12-25	WOS:000173922100075
J	Kayyali, R; Porter, JB; Liu, ZD; Davies, NA; Nugent, JH; Cooper, CE; Hider, RC				Kayyali, R; Porter, JB; Liu, ZD; Davies, NA; Nugent, JH; Cooper, CE; Hider, RC			Structure-function investigation of the interaction of 1-and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; IRON-CHELATING-AGENTS; ACTIVE-SITE IRON; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; PHYSICOCHEMICAL PROPERTIES; BIOLOGICAL EVALUATION; SMALL-SUBUNIT; CELL-GROWTH; PROTEIN R2	The structural and physiochemical properties of 3-hydroxypyridin-4-one chelators (HPOs) which influence inhibition of the iron-containing metalloenzymes ribonucleotide reductase (RR) and 5-lipoxygenase (5-LO) have been investigated. HPOs with substituents at the land 2-positions of the pyridinone ring have been synthesized, and their inhibitory properties compared with those of desferrioxamine (DFO). Varying the alkyl substituents does not affect the affinity constant of these ligands for iron(III), but permits a systematic investigation of the effect of hydrophobicity and molecular shape on inhibitory properties. The inhibition of RR was monitored, indirectly by measuring tritiated thymidine incorporation into DNA and directly by the quantification of the EPR signal of the enzyme tyrosyl radical. 5-LO inhibition was examined spectrophotometrically, measuring the rate of linoleic hydroperoxide formation by soybean lipoxygenase. The results indicate that the substituent size introduced at the 2-position of the HPO ring is critical for determining inhibition of both enzymes. Large substituents on the 2-position, introduce a steric factor which interferes with accessibility to the iron centers. These studies have identified chelators such as 1,6-dimethyl-2-(N-4',N-propylsuccinamido) methyl-3-hydroxypyridin-4-one (CP358), which causes only a 10% inhibition of 5-LO after 24 h of incubation at 110 muM IBE (iron-binding equivalents) in comparison to simple dialkyl HPOs such as Deferiprone (CP20) which cause up to 70% inhibition. Using EPR spectroscopy, CP358 inhibits RR at a slower rate than CP20, while chelating intracellular iron(III) at a similar rate, a finding consistent with an indirect inhibition of the tyrosyl radical. However, hepatocellular iron is mobilized at a faster rate by CP358 (P < 0.001). These findings demonstrate that it is possible to design bidentate HPOs which access intracellular iron pools rapidly while inhibiting non-heme iron-containing enzymes relatively slowly, at rates comparable to DFO. It is anticipated that such compounds will possess a superior therapeutic safety margin to currently available bidentate HPOs.	UCL, Sch Med, Dept Clin Hematol, London WC1E 6HX, England; Kings Coll London, Dept Pharm, London SE1 8WA, England; UCL, Dept Biol Chem, London WC1E 6HX, England; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	University of London; University College London; UCL Medical School; University of London; King's College London; University of London; University College London; University of Essex	Kayyali, R (corresponding author), UCL, Sch Med, Dept Clin Hematol, 98 Chenies Mews, London WC1E 6HX, England.	r.kayyali@ucl.ac.uk	Cooper, Chris/AAK-9729-2020	Cooper, Chris/0000-0003-0381-3990; Porter, John/0000-0003-3000-9359				Abeysinghe RD, 1996, J BIOL CHEM, V271, P7965, DOI 10.1074/jbc.271.14.7965; BATT DG, 1990, J MED CHEM, V33, P360, DOI 10.1021/jm00163a058; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRITTENHAM GM, 1992, BLOOD, V80, P569; CAMMACK R, 1993, METHOD ENZYMOL, V227, P353, DOI 10.1016/0076-6879(93)27014-8; CHASTEEN ND, 1993, BIOCHEMISTRY-US, V32, P9763, DOI 10.1021/bi00088a031; CHITAMBAR CR, 1988, BLOOD, V72, P1930; Cooper CE, 1996, J BIOL CHEM, V271, P20291, DOI 10.1074/jbc.271.34.20291; DOBBIN PS, 1993, J MED CHEM, V36, P2448, DOI 10.1021/jm00069a002; Ellis BL, 1996, J MED CHEM, V39, P3659, DOI 10.1021/jm960220g; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; HIDER RC, 1992, P ROY SOC EDINB B, V99, P137, DOI 10.1017/S0269727000013117; HILETI D, 1995, BRIT J HAEMATOL, V89, P181, DOI 10.1111/j.1365-2141.1995.tb08927.x; HOYES KP, 1993, EXP HEMATOL, V21, P86; HOYES KP, 1992, CANCER RES, V52, P4591; HUEBERS H, 1981, P NATL ACAD SCI-BIOL, V78, P621, DOI 10.1073/pnas.78.1.621; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; KJOLLERLARSEN I, 1982, EUR J BIOCHEM, V125, P75; Kuban RJ, 1998, BIOCHEM J, V332, P237, DOI 10.1042/bj3320237; LASSMANN G, 1993, ARCH BIOCHEM BIOPHYS, V300, P132, DOI 10.1006/abbi.1993.1018; MILLS K, 1983, IMMUNOL LETT, V6, P241, DOI 10.1016/0165-2478(83)90012-3; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MUSSER JH, 1992, J MED CHEM, V35, P2503; NAITO Y, 1991, CHEM PHARM BULL, V39, P1736; NELSON MJ, 1991, J BIOL CHEM, V266, P8225; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; PORTER JB, 1988, BLOOD, V72, P1497; PORTER JB, 1991, BLOOD, V78, P2727; PORTER JB, 1995, COLLOQ INSE, V234, P371; POTSCH S, 1995, FEBS LETT, V374, P95, DOI 10.1016/0014-5793(95)01082-P; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SIMPSON RJ, 1992, BIOCHIM BIOPHYS ACTA, V1156, P19, DOI 10.1016/0304-4165(92)90090-H; SUMMERS JB, 1990, J MED CHEM, V33, P992, DOI 10.1021/jm00165a017; SWARTS JC, 1995, BBA-PROTEIN STRUCT M, V1247, P215, DOI 10.1016/0167-4838(94)00233-7; THELANDER L, 1983, J BIOL CHEM, V258, P4063; THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9; YOUNG SP, 1980, BIOCHIM BIOPHYS ACTA, V633, P145, DOI 10.1016/0304-4165(80)90400-6; ZHANG YY, 1993, J BIOL CHEM, V268, P2535	43	17	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48814	48822		10.1074/jbc.M109551200	http://dx.doi.org/10.1074/jbc.M109551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11602611	hybrid			2022-12-25	WOS:000173922100027
J	Luker, GD; Flagg, TP; Sha, Q; Luker, KE; Pica, CM; Nichols, CG; Piwnica-Worms, D				Luker, GD; Flagg, TP; Sha, Q; Luker, KE; Pica, CM; Nichols, CG; Piwnica-Worms, D			MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MULTIDRUG-RESISTANCE; DRUG TRANSPORT; ION-TRANSPORT; CELLS; PROTEIN; MITOCHONDRIAL; RETENTION; CHANNELS; LOCALIZATION	MDR1 (multidrug resistance) P-glycoprotein (Pgp; ABCB1) decreases intracellular concentrations of structurally diverse drugs. Although Pgp is generally thought to be an efflux transporter, the mechanism of action remains elusive. To determine whether Pgp confers drug resistance through changes in transmembrane potential (E-m) or ion conductance, we studied electrical currents and drug transport in Pgp-negative MCF-7 cells and MCF-7/MDR1 stable transfectants that were established and maintained without chemotherapeutic drugs. Although E-m and total membrane conductance did not differ between MCF-7 and MCF-7/MDR1 cells, Pgp reduced unidirectional influx and steady-state cellular content of Tc-Sestamibi, a substrate for MDR1 Pgp, without affecting unidirectional efflux of substrate from cells. Depolarization of membrane potentials with various concentrations of extracellular K+ in the presence of valinomycin did not inhibit the ability of Pgp to reduce intracellular concentration of Tc-Sestamibi, strongly suggesting that the drug transport activity of MDR1 Pgp is independent of changes in E-m or total ion conductance. Tetraphenyl borate, a lipophilic anion, enhanced unidirectional influx of Tc-Sestamibi to a greater extent in MCF-7/MDR1 cells than in control cells, suggesting that Pgp may, directly or indirectly, increase the positive dipole potential within the plasma membrane bilayer. Overall, these data demonstrate that changes in E-m or macroscopic conductance are not coupled with function of Pgp in multidrug resistance. The dominant effect of MDR1 Pgp in this system is reduction of drug influx, possibly through an increase in intramembranous dipole potential.	Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, D (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, POB 8225,510 S Kingshighway Blvd, St Louis, MO 63110 USA.	piwnica-wormsd@mir.wustl.edu	Nichols, Colin/D-6336-2012	luker, gary/0000-0001-6832-2581	NHLBI NIH HHS [HL03683] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003683] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Asawakarn T, 2001, J BIOL CHEM, V276, P38457, DOI 10.1074/jbc.M103269200; BACKUS M, 1993, AM J PHYSIOL, V265, pC178, DOI 10.1152/ajpcell.1993.265.1.C178; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BORNMANN WG, 1994, BIOCHEMISTRY-US, V33, P12665, DOI 10.1021/bi00208a018; BROCKMAN H, 1994, CHEM PHYS LIPIDS, V73, P57, DOI 10.1016/0009-3084(94)90174-0; Callaghan R, 1997, BBA-BIOMEMBRANES, V1328, P109, DOI 10.1016/S0005-2736(97)00079-5; CHERNOFF DM, 1993, BIOCHIM BIOPHYS ACTA, V1147, P262, DOI 10.1016/0005-2736(93)90011-N; CORNELIUS F, 1995, BBA-BIOMEMBRANES, V1235, P183, DOI 10.1016/0005-2736(95)80004-Y; Dantzig AH, 1996, CANCER RES, V56, P4171; DAVIS S, 1985, J BIOL CHEM, V260, P3844; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; FRANKLIN JC, 1993, BIOPHYS J, V65, P289, DOI 10.1016/S0006-3495(93)81051-8; FREZARD F, 1991, EUR J BIOCHEM, V196, P483, DOI 10.1111/j.1432-1033.1991.tb15840.x; Fritz F, 1999, BIOCHEMISTRY-US, V38, P4214, DOI 10.1021/bi981929n; Gallois L, 1996, EUR J BIOCHEM, V241, P879, DOI 10.1111/j.1432-1033.1996.00879.x; Gerard V, 1998, J EXP BIOL, V201, P21; Hoffman MM, 1997, BIOCHEMISTRY-US, V36, P11153, DOI 10.1021/bi970530g; Hoffman MM, 1996, J GEN PHYSIOL, V108, P295, DOI 10.1085/jgp.108.4.295; HYAFIL F, 1993, CANCER RES, V53, P4595; Idriss HT, 2000, J PHYSIOL-LONDON, V524, P629, DOI 10.1111/j.1469-7793.2000.00629.x; Jongsma APM, 2000, EUR J BIOCHEM, V267, P5369, DOI 10.1046/j.1432-1327.2000.01560.x; Kim H, 1997, AM J PHYSIOL-CELL PH, V273, pC687, DOI 10.1152/ajpcell.1997.273.2.C687; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; Luker GD, 2000, BIOCHEMISTRY-US, V39, P7651, DOI 10.1021/bi9928593; Luker GD, 1997, BIOCHEMISTRY-US, V36, P14218, DOI 10.1021/bi971931z; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; PIWNICAWORMS D, 1993, CANCER RES, V53, P977; PIWNICAWORMS D, 1983, J GEN PHYSIOL, V81, P731, DOI 10.1085/jgp.81.5.731; PIWNICAWORMS D, 1995, BIOCHEMISTRY-US, V34, P12210, DOI 10.1021/bi00038a015; PIWNICAWORMS D, 1990, CIRCULATION, V82, P1826, DOI 10.1161/01.CIR.82.5.1826; PIWNICAWORMS D, 1994, MAGN RESON IMAGING, V12, P641, DOI 10.1016/0730-725X(94)92459-7; Pohl EE, 1998, BBA-BIOMEMBRANES, V1373, P170, DOI 10.1016/S0005-2736(98)00098-4; Robinson LJ, 1996, BIOCHEM PHARMACOL, V52, P1081, DOI 10.1016/0006-2952(96)81736-9; Roepe PD, 2000, CURR PHARM DESIGN, V6, P241, DOI 10.2174/1381612003401163; Romsicki Y, 1999, BIOCHEMISTRY-US, V38, P6887, DOI 10.1021/bi990064q; RUETZ S, 1994, J BIOL CHEM, V269, P12277; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Sharma V, 1996, J MED CHEM, V39, P3483, DOI 10.1021/jm950823c; Sharma V, 1999, CHEM REV, V99, P2545, DOI 10.1021/cr980429x; Sikic BI, 1997, CANCER CHEMOTH PHARM, V40, pS13, DOI 10.1007/s002800051055; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Wadkins RM, 1997, INT REV CYTOL, V171, P121; WEI LY, 1995, BIOPHYS J, V69, P883, DOI 10.1016/S0006-3495(95)79962-3; WOODFORK KA, 1995, J CELL PHYSIOL, V162, P163, DOI 10.1002/jcp.1041620202; YAMASHITA N, 1987, CANCER RES, V47, P3736	54	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49053	49060		10.1074/jbc.M105192200	http://dx.doi.org/10.1074/jbc.M105192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598111	hybrid			2022-12-25	WOS:000173922100058
J	Peden, AA; Park, GY; Scheller, RH				Peden, AA; Park, GY; Scheller, RH			The di-leucine motif of vesicle-associated membrane protein 4 is required for its localization and AP-1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SORTING SIGNALS; TRAFFICKING; CELLS; TRANSPORT; DISTINCT; SNARE; SPECIFICITY; ENDOSOMES; COMPLEXES	Heterotetrameric adaptor complexes and SNAREs play key roles in the specificity of membrane budding and fusion. Here we test the hypothesis that vesicle budding and membrane fusion are coupled by the interaction of these molecules. We investigate the role of the di-leucine motif of vesicle-associated membrane protein 4 (VAMP4) in adaptor binding and localization of VAMP4. Mutation of the di-leucine motif inhibits AP-1 binding in vitro and affects the steady state distribution of VAMP4 in vivo.	Genentech Inc, San Francisco, CA 94080 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Roche Holding; Genentech; Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.			Peden, Andrew/0000-0003-0144-7712				Advani RJ, 1999, J CELL BIOL, V146, P765, DOI 10.1083/jcb.146.4.765; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Salem N, 1998, NAT NEUROSCI, V1, P551, DOI 10.1038/2787; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Steegmaier M, 2000, MOL BIOL CELL, V11, P2719, DOI 10.1091/mbc.11.8.2719; Steegmaier M, 2000, TRAFFIC, V1, P553, DOI 10.1034/j.1600-0854.2000.010705.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	24	71	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49183	49187		10.1074/jbc.M106646200	http://dx.doi.org/10.1074/jbc.M106646200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598115	hybrid			2022-12-25	WOS:000173922100074
J	Ahmed, S; Saini, S; Arora, S; Singh, J				Ahmed, S; Saini, S; Arora, S; Singh, J			Chromodomain protein Swi6-mediated role of DNA polymerase a in establishment of silencing in fission yeast.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWITCHING GENE SWI6; MATING-TYPE REGION; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; EPIGENETIC INHERITANCE; CHROMOSOME SEGREGATION; CHROMATIN-STRUCTURE; HISTONE H3; REPLICATION; DOMAINS	Although DNA replication has been thought to play an important role in the silencing of mating type loci in Saccharomyces cerevisiae, recent studies indicate that silencing can be decoupled from replication. In Schizo-saccharomyces pombe, mating type silencing is brought about by the trans-acting proteins, namely Swi6, Clr1-Clr4, and Rhp6, in cooperation with the cis-acting silencers. The latter contain an autonomous replication sequence, suggesting that DNA replication may be critical for silencing in S. pombe. To investigate the connection between DNA replication and silencing in S. pombe, we analyzed several temperature-sensitive mutants of DNA polymerase a. We find that one such mutant, swi7H4, exhibits silencing defects at mat, centromere, and telomere loci. This effect is independent of the checkpoint and replication defects of the mutant. Interestingly, the extent of the silencing defect in the swi7H4 mutant at the silent mat2 locus is further enhanced in absence of the cis-acting, centromere-proximal silencer. The chromodomain protein Swi6, which is required for silencing and is localized to mat and other heterochromatin loci, interacts with DNA polymerase alpha in vivo and in vitro in wild type cells. However, it does not interact with the mutant pola and is delocalized away from the silent mat loci in the mutant. Our results demonstrate a role of DNA polymerase a in the establishment of silencing. We propose a recruitment model for the coupling of DNA replication with the establishment of silencing by the chromodomain protein Swi6, which may be applicable to higher eukaryotes.	Inst Microbial Technol, Chandigarh 160036, India; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Rutgers State University New Brunswick; Rutgers State University Medical Center	Singh, J (corresponding author), Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.	jag@imtech.res.in						Ahmed S, 2001, CURR SCI INDIA, V80, P1337; AHMED S, 2000, THESIS PANJAB U CHAN; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bhaumik D, 1998, MOL BIOL CELL, V9, P2107, DOI 10.1091/mbc.9.8.2107; Ehrenhofer-Murray AE, 1999, GENETICS, V153, P1171; EKWALL K, 1991, YEAST, V7, P745, DOI 10.1002/yea.320070709; EKWALL K, 1994, GENETICS, V136, P53; Ekwall K, 1996, J CELL SCI, V109, P2637; EKWALL K, 1999, CHROMOSOME STRUCTURA, P47; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Grewal SIS, 1998, GENETICS, V150, P563; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; KLAR AJS, 1992, MOL CELLULAR BIOL YE, V2, P583; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; OLSSON T, 1993, NUCLEIC ACIDS RES, V21, P855; Pidoux AL, 2000, J CELL SCI, V113, P4177; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; SINGH PB, 1994, J CELL SCI, V107, P2653; Smith JS, 1999, MOL CELL BIOL, V19, P3184; THON G, 1992, GENETICS, V131, P287; THON G, 1994, GENETICS, V138, P29; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang GZ, 2000, MOL CELL BIOL, V20, P6970, DOI 10.1128/MCB.20.18.6970-6983.2000; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WOLFFE AP, 1991, J CELL SCI, V99, P201; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	38	32	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47814	47821		10.1074/jbc.M109186200	http://dx.doi.org/10.1074/jbc.M109186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11581276	hybrid			2022-12-25	WOS:000172927000013
J	Gruber, A; Wheat, JC; Kuhen, KL; Looney, DJ; Wong-Staal, F				Gruber, A; Wheat, JC; Kuhen, KL; Looney, DJ; Wong-Staal, F			Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CD4(+) T-CELLS; IN-VITRO; ANTIGEN PRESENTATION; VIRAL PROTEASE; INFECTION; ACTIVATION; RECEPTOR; PATHWAY; SUSCEPTIBILITY	Recent findings show that human immunodeficiency virus (HIV)-1 protease inhibitors designed to specifically inhibit the aspartic protease of HIV-1 nonetheless exert various effects on immune cell function in vitro and in vivo. Dendritic cells (DC), central players of the immune system, express several aspartic proteases that are important for DC function. In the present study, we demonstrate that all of the HIV-1 protease inhibitors tested affect DC maturation. In addition, saquinavir had a strong inhibitory effect on the T-cell stimulatory capacity of mature DC. In contrast, indinavir had only a slight effect on DC induced T-cell proliferation and allowed efficient transduction of DC with a replication-incompetent HIV-1 vector designed for DC-based immunotherapy. HIV-1 protease inhibitors that have little or no effect on DC function may be preferable for combination with immunotherapy for HIV/AIDS.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Adm Med Ctr, Infect Dis Div, La Jolla, CA 92093 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gruber, A (corresponding author), Dana Farber Canc Inst, 44 Binney St,JFB-809,Rm 426, Boston, MA 02115 USA.				NIAID NIH HHS [P30 AI36214-06, AI45992, AI44372] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI045992, P30AI036214, R21AI044372] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Annunziata CM, 2000, BLOOD, V96, P2841; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Atzori C, 2000, J INFECT DIS, V181, P1629, DOI 10.1086/315437; Bode H, 1999, AIDS, V13, P2595, DOI 10.1097/00002030-199912240-00016; BUGELSKI PJ, 1992, AIDS RES HUM RETROV, V8, P1951, DOI 10.1089/aid.1992.8.1951; CAMERON PU, 1994, AIDS RES HUM RETROV, V10, P61, DOI 10.1089/aid.1994.10.61; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Chinnasamy N, 2000, HUM GENE THER, V11, P1901, DOI 10.1089/10430340050129512; DIMENT S, 1990, J IMMUNOL, V145, P417; DIMENT S, 1985, J BIOL CHEM, V260, P5311; Essajee SM, 1999, AIDS, V13, P2523, DOI 10.1097/00002030-199912240-00005; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Gandhi RT, 1998, J EXP MED, V187, P1113, DOI 10.1084/jem.187.7.1113; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; Granelli-Piperno A, 2000, J IMMUNOL, V165, P6620, DOI 10.4049/jimmunol.165.11.6620; Gruber A, 2000, BLOOD, V96, P1327, DOI 10.1182/blood.V96.4.1327.h8001327_1327_1333; Gruber A, 2001, IMMUNOL LETT, V78, P209, DOI 10.1016/S0165-2478(01)00246-2; Gruber A, 1999, IMMUNOPHARMACOLOGY, V41, P227, DOI 10.1016/S0162-3109(99)00035-1; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; Hewitt EW, 1997, J IMMUNOL, V159, P4693; JACOBSEN H, 1992, J VIROL, V66, P5087, DOI 10.1128/JVI.66.8.5087-5091.1992; Kaplan AH, 1996, J VIROL, V70, P5840, DOI 10.1128/JVI.70.9.5840-5844.1996; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Levitz SM, 1998, NEW ENGL J MED, V338, P1074, DOI 10.1056/NEJM199804093381517; McLellan AD, 1996, EUR J IMMUNOL, V26, P1204, DOI 10.1002/eji.1830260603; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Perrin L, 1998, SCIENCE, V280, P1871, DOI 10.1126/science.280.5371.1871; Pickl WF, 1996, J IMMUNOL, V157, P3850; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rouzaut A, 2000, ARCH BIOCHEM BIOPHYS, V374, P153, DOI 10.1006/abbi.1999.1587; Schmidtke G, 1999, J BIOL CHEM, V274, P35734, DOI 10.1074/jbc.274.50.35734; Schroers R, 2000, MOL THER, V1, P171, DOI 10.1006/mthe.2000.0027; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Uchida H, 1997, ANTIVIR RES, V36, P107, DOI 10.1016/S0166-3542(97)00047-8; Washington CB, 1998, J ACQ IMMUN DEF SYND, V19, P203, DOI 10.1097/00042560-199811010-00001; Weichold FF, 1999, J HUMAN VIROL, V2, P261	40	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47840	47843		10.1074/jbc.M105582200	http://dx.doi.org/10.1074/jbc.M105582200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602580	hybrid			2022-12-25	WOS:000172927000017
J	Jacobs, AT; Ignarro, LJ				Jacobs, AT; Ignarro, LJ			Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR IRF-1; ACTIVATED PROTEIN-KINASE; DNA-BINDING-PROTEINS; REGULATORY FACTOR-I; MURINE MACROPHAGES; SIGNALING PATHWAYS; MOUSE MACROPHAGES; IFN-GAMMA; GENE	The production of nitric oxide by macrophages has been implicated as a host defense mechanism against microbial pathogens and tumor cells. Recent reports have implicated interferon-alpha/beta (IFN-alpha/beta) as an autocrine/paracrine signal critical for the induction of murine iNOS. In this report we have systematically investigated the role of IFN-beta in the induction of iNOS in the murine macrophage cell line, RAW 264.7. First, we demonstrate that IFN-beta expression is highly up-regulated, and is secreted in response to lipopolysaccharide (LPS). Treatment of RAW macrophages with LPS results in a time-dependent phosphorylation of STAT-1 on both tyrosine residue 701 (Tyr-701) and serine residue 727 (Ser-727) that is consistent with the timing of endogenous IFN-beta expression. LPS also induces interferon regulatory factor-1 expression with similar kinetics. We further demonstrate that exogenous IFN-beta accelerates the induction of iNOS by LPS. The acceleration of iNOS induction is observed at the levels of transcription, protein expression, and NO formation. Accordingly, we propose that the cytokine environment of macrophages may determine the rate and magnitude of nitric oxide production, thereby regulating the cytotoxic response to pathogen challenge.	Univ Calif Los Angeles, Dept Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Ignarro, LJ (corresponding author), Univ Calif Los Angeles, Dept Pharmacol, Los Angeles, CA 90095 USA.	lignarro@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040922, R01HL035014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40922, HL 35014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bauer PM, 1999, BIOCHEM BIOPH RES CO, V262, P355, DOI 10.1006/bbrc.1999.1210; Buga GM, 1998, AM J PHYSIOL-REG I, V275, pR1256, DOI 10.1152/ajpregu.1998.275.4.R1256; CUI SJ, 1994, CANCER RES, V54, P2462; DIRKS W, 1989, J INTERFERON RES, V9, P125, DOI 10.1089/jir.1989.9.125; Familletti P C, 1981, Methods Enzymol, V78, P387; FUJIHARA M, 1994, J BIOL CHEM, V269, P12773; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; Ganster RW, 2000, NITRIC OXIDE BIOL PA, P129; Gao JJ, 2000, EUR J IMMUNOL, V30, P1551, DOI 10.1002/1521-4141(200006)30:6<1551::AID-IMMU1551>3.0.CO;2-Y; Gao JJ, 1998, J IMMUNOL, V161, P4803; GESSANI S, 1989, J VIROL, V63, P2785, DOI 10.1128/JVI.63.6.2785-2789.1989; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hattori Y, 1996, BIOCHEM MOL BIOL INT, V40, P889; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; Ignarro LJ, 2001, P NATL ACAD SCI USA, V98, P4202, DOI 10.1073/pnas.071054698; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Lopez-Collazo E, 1998, J IMMUNOL, V160, P2889; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Vadiveloo PK, 2000, CYTOKINE, V12, P1639, DOI 10.1006/cyto.2000.0766; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHANG XO, 1994, INFECT IMMUN, V62, P33, DOI 10.1128/IAI.62.1.33-40.1994; ZHOU AQ, 1995, J INTERF CYTOK RES, V15, P897, DOI 10.1089/jir.1995.15.897; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	47	163	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47950	47957		10.1074/jbc.M106639200	http://dx.doi.org/10.1074/jbc.M106639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602590	hybrid			2022-12-25	WOS:000172927000032
J	Dondi, E; Pattyn, E; Lutfalla, G; Van Ostade, X; Uze, G; Pellegrini, S; Tavernier, J				Dondi, E; Pattyn, E; Lutfalla, G; Van Ostade, X; Uze, G; Pellegrini, S; Tavernier, J			Down-modulation of type 1 interferon responses by receptor cross-competition for a shared Jak kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; I INTERFERON; ALPHA-INTERFERON; TYROSINE KINASE; TYK2; ACTIVATION; PROTEIN; SUBUNIT; PHOSPHORYLATION; EXPRESSION	In contrast to the large number of class I and II cytokine receptors, only four Janus kinase (Jak) proteins are expressed in mammalian cells, implying the shared use of these kinases by many different receptor complexes. Consequently, if receptor numbers exceed the amount of available Jak, cross-interference patterns can be expected. We have engineered two model cellular systems expressing two different exogenous Tyk2-interacting receptors. A receptor chimera was generated wherein the extracellular part of the interferon type 1 receptor (Ifnar1) component of the interferon-alpha/beta receptor is replaced by the equivalent domain of the erythropoietin receptor. Despite Tyk2 activation, erythropoietin treatment of cells expressing this erythropoietin receptor/Ifnar1 chimera did not evoke any detectable IFN-type response. However, a dose-dependent interference with signal transduction via the endogenous Ifnar complex was found for STAT1, STAT2, STAT3, Tyk2, and Jak1 activation, for gene induction, and for antiviral activity. In a similar approach, cells expressing the beta1 chain of the interleukin-12 receptor showed a reduced transcriptional response to IFN-alpha as well as reduced STAT and kinase activation. In both model systems, titration of the Tyk2 kinase away from the Ifnar1 receptor chain accounts for the observed cross-interference.	Inst Pasteur, Lab Signalisat Cytokines, F-75724 Paris 15, France; State Univ Ghent VIB, Dept Med Prot Res, B-9000 Ghent, Belgium; Inst Genet Mol, CNRS, EP2030, F-34293 Montpellier, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Flanders Institute for Biotechnology (VIB); Ghent University; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Pellegrini, S (corresponding author), Inst Pasteur, Lab Signalisat Cytokines, 25 Rue Dr Roux, F-75724 Paris 15, France.	pellegri@pasteur.fr	Pellegrini, Sandra/Y-6351-2019; Van Ostade, Xaveer/AAG-9587-2020; Pellegrini, Sandra -/G-5546-2015; Van Ostade, Xaveer WMP/D-1702-2015; Uzé, Gilles/O-6383-2019; Lutfalla, Georges/AAW-9386-2021	Pellegrini, Sandra/0000-0001-5837-7589; Pellegrini, Sandra -/0000-0001-5837-7589; Van Ostade, Xaveer WMP/0000-0003-4078-3014; Dondi, Elisabetta/0000-0003-0975-459X; Uze, Gilles/0000-0002-4150-5772; LUTFALLA, Georges/0000-0002-6591-7894				Bailey N.T.J., 1959, STAT METHODS BIOL, P33; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Fantuzzi L, 1997, EUR J IMMUNOL, V27, P1075, DOI 10.1002/eji.1830270506; Farrar JD, 2000, NAT IMMUNOL, V1, P65, DOI 10.1038/76932; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; Goldman LA, 1999, J INTERF CYTOK RES, V19, P15, DOI 10.1089/107999099314379; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hardy MP, 2001, BLOOD, V97, P473, DOI 10.1182/blood.V97.2.473; HUGHES AL, 1995, J MOL EVOL, V41, P539, DOI 10.1007/BF00175811; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Leu JH, 2000, DNA CELL BIOL, V19, P431, DOI 10.1089/10445490050085924; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Pattyn E, 1999, J BIOL CHEM, V274, P34838, DOI 10.1074/jbc.274.49.34838; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Rogge L, 1999, J IMMUNOL, V162, P3926; Rogge L, 1998, J IMMUNOL, V161, P6567; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; TAVERNIER J, 1996, BLOOD CEL B, V7, P321; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; UZE G, 1994, J MOL BIOL, V243, P245, DOI 10.1006/jmbi.1994.1651; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; Van Ostade X, 1999, EUR J BIOCHEM, V259, P954, DOI 10.1046/j.1432-1327.1999.00148.x; Wu CY, 1996, EUR J IMMUNOL, V26, P345, DOI 10.1002/eji.1830260212; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392; Zou J, 1997, J BIOL CHEM, V272, P6073, DOI 10.1074/jbc.272.9.6073	46	34	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47004	47012		10.1074/jbc.M104316200	http://dx.doi.org/10.1074/jbc.M104316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11602573	hybrid			2022-12-25	WOS:000172768500046
J	Greasley, PJ; Fanelli, F; Scheer, A; Abuin, L; Nenniger-Tosato, M; DeBenedetti, PG; Cotecchia, S				Greasley, PJ; Fanelli, F; Scheer, A; Abuin, L; Nenniger-Tosato, M; DeBenedetti, PG; Cotecchia, S			Mutational and computational analysis of the alpha(1b)-adrenergic receptor. Involvement of basic and hydrophobic residues in receptor activation and G protein coupling.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND INTRACELLULAR LOOP; AMINO-ACID; HORMONE RECEPTOR; ALPHA-SUBUNITS; BINDING-SITES; RHODOPSIN; MECHANISMS; SELECTIVITY; RECOGNITION; SEQUENCE	To investigate their role in receptor coupling to G(q), we mutated all basic amino acids and some conserved hydrophobic residues of the cytosolic surface of the alpha (1b)-adrenergic receptor (AR). The wild type and mutated receptors were expressed in COS-7 cells and characterized for their ligand binding properties and ability to increase inositol phosphate accumulation. The experimental results have been interpreted in the context of both an ab initio model of the alpha (1b)-AR and of a new homology model built on the recently solved crystal structure of rhodopsin. Among the twenty-three basic amino acids mutated only mutations of three, Arg(254) and Lys(258) in the third intracellular loop and Lys(291) at the cytosolic extension of helix 6, markedly impaired the receptor-mediated inositol phosphate production. Additionally, mutations of two conserved hydrophobic residues, Val(147) and Leu(151) in the second intracellular loop had significant effects on receptor function. The functional analysis of the receptor mutants in conjunction with the predictions of molecular modeling supports the hypothesis that Arg(254), Lys(258), as well as Leu(151) are directly involved in receptor-G protein interaction and/or receptor-mediated activation of the G protein. In contrast, the residues belonging to the cytosolic extensions of helices 3 and 6 play a predominant role in the activation process of the alpha (1b)-AR. These findings contribute to the delineation of the molecular determinants of the alpha (1b)-Ar/G(q) interface.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Modena, Dipartimento Chim, I-41100 Modena, Italy	University of Lausanne; Universita di Modena e Reggio Emilia	Cotecchia, S (corresponding author), Fac Med, Inst Pharmacol & Toxicol, 27 Rue du Bugnon, CH-1005 Lausanne, Switzerland.		Fanelli, Francesca/O-8807-2014	Fanelli, Francesca/0000-0002-7620-6895				ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Damaj BB, 1996, FASEB J, V10, P1426, DOI 10.1096/fasebj.10.12.8903513; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Fanelli F, 1998, METHODS, V14, P302, DOI 10.1006/meth.1998.0586; Fanelli F, 1999, PROTEINS, V37, P145, DOI 10.1002/(SICI)1097-0134(19991101)37:2<145::AID-PROT1>3.0.CO;2-R; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; HOGGER P, 1995, J BIOL CHEM, V270, P7405; Horn F, 2000, PROTEINS, V41, P448, DOI 10.1002/1097-0134(20001201)41:4<448::AID-PROT30>3.0.CO;2-C; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Jin H, 1998, BBA-MOL CELL RES, V1402, P165, DOI 10.1016/S0167-4889(97)00159-6; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Lee NH, 1996, MOL PHARMACOL, V50, P140; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Loewen MC, 2001, P NATL ACAD SCI USA, V98, P4888, DOI 10.1073/pnas.051633098; Mathi SK, 1997, MOL ENDOCRINOL, V11, P424, DOI 10.1210/me.11.4.424; MORO O, 1993, J BIOL CHEM, V268, P22273; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; Oliveira L, 1999, PROTEIN ENG, V12, P1087, DOI 10.1093/protein/12.12.1087; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Scheer A, 2000, MOL PHARMACOL, V57, P219; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; Wade SM, 1996, MOL PHARMACOL, V50, P351; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P25798	42	78	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46485	46494		10.1074/jbc.M105791200	http://dx.doi.org/10.1074/jbc.M105791200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585821	hybrid			2022-12-25	WOS:000172573100134
J	Velarde, G; Ford, RC; Rosenberg, MF; Powis, SJ				Velarde, G; Ford, RC; Rosenberg, MF; Powis, SJ			Three-dimensional structure of transporter associated with antigen processing (TAP) obtained by single particle image analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; MAJOR HISTOCOMPATIBILITY COMPLEX; PUTATIVE PEPTIDE TRANSPORTER; MHC-LINKED TRANSPORTER; ABC TRANSPORTER; ELECTRON-MICROSCOPY; NUCLEOTIDE-BINDING; MEMBRANE TOPOLOGY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	dThe transporter associated with antigen processing (TAP) is an ATP binding cassette transporter responsible for peptide translocation into the lumen of the endoplasmic reticulum for assembly with major histocompatibility complex class I molecules. Immunoaffinity-purified TAP particles comprising TAP1 and TAP2 polypeptides, and TAP2 particles alone were characterized after detergent solubilization and studied by electron microscopy. Projection structures of TAP1+2 particles reveal a molecule similar to 10 nm across with a deeply staining central region, whereas TAP2 molecules are smaller in projection. A three-dimensional structure of TAP reveals it is isolated as a single heterodimeric complex, with the TAP1 and TAP2 subunits combining to create a central 3-nm-diameter pocket on the predicted endoplasmic reticulum-lumenal side, Its structural similarity to other ABC transporters demonstrates a common tertiary structure for this diverse family of membrane proteins.	Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee, Scotland; UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Dundee; University of Manchester	Powis, SJ (corresponding author), Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee, Scotland.			Ford, Robert/0000-0002-0958-1505; Powis, Simon/0000-0003-4218-2984				Alberts P, 2001, CURR BIOL, V11, P242, DOI 10.1016/S0960-9822(01)00073-2; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; Armandola EA, 1996, EUR J IMMUNOL, V26, P1748, DOI 10.1002/eji.1830260813; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Burgess SA, 1997, J CELL BIOL, V139, P675, DOI 10.1083/jcb.139.3.675; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Deverson EV, 1998, J IMMUNOL, V160, P2767; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; Deverson EV, 2001, GENES IMMUN, V2, P48, DOI 10.1038/sj.gene.6363727; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gileadi U, 1997, J BIOL CHEM, V272, P11103; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Katayama E, 1998, ADV EXP MED BIOL, V453, P37; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kitmitto A, 1998, J BIOL CHEM, V273, P29592, DOI 10.1074/jbc.273.45.29592; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Knittler MR, 1998, J IMMUNOL, V161, P5967; Lacaille VG, 1998, J BIOL CHEM, V273, P17386, DOI 10.1074/jbc.273.28.17386; Lapinski PE, 2000, J BIOL CHEM, V275, P6831, DOI 10.1074/jbc.275.10.6831; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; Momburg F, 1996, J IMMUNOL, V156, P1756; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Newitt S, 1999, TRANSPL P, V31, P1519, DOI 10.1016/S0041-1345(99)00024-X; NIGGINS CF, 1992, ANN REV CELL BIOL, V8, P67; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; Tsiotis G, 1997, BBA-BIOENERGETICS, V1322, P163, DOI 10.1016/S0005-2728(97)00073-X; Uebel S, 1997, FEBS LETT, V416, P359, DOI 10.1016/S0014-5793(97)01222-2; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	66	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46054	46063		10.1074/jbc.M108435200	http://dx.doi.org/10.1074/jbc.M108435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11595746	hybrid			2022-12-25	WOS:000172573100077
J	Jiang, W; Zhou, L; Breyer, B; Feng, T; Cheng, HW; Haydon, R; Ishikawa, A; He, TC				Jiang, W; Zhou, L; Breyer, B; Feng, T; Cheng, HW; Haydon, R; Ishikawa, A; He, TC			Tetracycline-regulated gene expression mediated by a novel chimeric repressor that recruits histone deacetylases in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TN10 TET REPRESSOR; MAMMARY-TUMOR VIRUS; INDUCIBLE GENE; TRANSGENIC MICE; TRANSCRIPTIONAL REGULATION; IN-VIVO; TRANSACTIVATOR SYSTEM; HUMAN CYTOMEGALOVIRUS; CULTURED-CELLS; PROMOTER	Regulated gene expression will provide important platforms from which gene functions can be investigated and safer means of gene therapy may be developed. Histone deacetylases have recently been shown to play an important role in regulating gene expression. Here we investigated whether a more tightly controlled expression could be achieved by using a novel chimeric repressor that recruits histone deacetylases to a tetracycline-responsive promoter. This chimeric repressor was engineered by fusing the tetracycline repressor (TetR) with an mSin3-interacting domain of human Mad1 and was shown to bind the tetO(2) element with high affinity, and its binding was efficiently abrogated by doxycycline. The chimeric repressor was shown to directly interact with mSin3 of the historic deacetylase complex. This inducible system was further simplified by using a single vector that contained both a chimeric repressor expression cassette and a tetracycline-responsive promoter. When transiently introduced into mammalian cells, the chimeric repressor system exhibited a significantly lower basal level of luciferase activity (up to 25-fold) than that of the TetR control. When stably transfected into HEK 293 cells, the chimeric repressor system was shown to exert a tight control of green fluorescent protein expression in a doxycycline dose- and time-dependent fashion. Therefore, this novel chimeric repressor provides an effective means for more tightly regulated gene expression, and the simplified inducible system may be used for a broad range of basic and clinical studies.	Univ Chicago, Med Ctr, Oncol Mol Lab, Dept Surg, Chicago, IL 60637 USA; Chongqing Univ Med Sci, Dept Biochem & Mol Biol, Chongqing 400046, Peoples R China; Yamagata Univ, Sch Med, Dept Orthopaed Surg, Yamagata 9909585, Japan	University of Chicago; University of Chicago Medical Center; Chongqing Medical University; Yamagata University	He, TC (corresponding author), Univ Chicago, Med Ctr, Oncol Mol Lab, Dept Surg, 5841 S Maryland Ave,MC 3079,Rm J-611, Chicago, IL 60637 USA.							Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Akagi K, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e23; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Bello B, 1998, DEVELOPMENT, V125, P2193; Berens C, 1997, J BIOL CHEM, V272, P6936, DOI 10.1074/jbc.272.11.6936; BERENS C, 1995, MOL MICROBIOL, V18, P437, DOI 10.1111/j.1365-2958.1995.mmi_18030437.x; Blau HM, 1999, P NATL ACAD SCI USA, V96, P797, DOI 10.1073/pnas.96.3.797; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; EVGENEV M, 1979, MOL GEN GENET, V176, P275, DOI 10.1007/BF00273222; FINCATO G, 1991, BLOOD, V77, P579; GATZ C, 1988, P NATL ACAD SCI USA, V85, P1394, DOI 10.1073/pnas.85.5.1394; GAZIT G, 1995, CANCER RES, V55, P1660; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gschwend JE, 1997, PROSTATE, V33, P166; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; Hoppe UC, 2000, MOL THER, V1, P159, DOI 10.1006/mthe.1999.0023; HU MCT, 1990, MOL CELL BIOL, V10, P6141, DOI 10.1128/MCB.10.12.6141; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kaszycki P, 1996, J PROTEIN CHEM, V15, P607, DOI 10.1007/BF01886743; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim HJ, 1998, ARCH PHARM RES, V21, P320, DOI 10.1007/BF02975295; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KO MSH, 1989, DNA-J MOLEC CELL BIO, V8, P127, DOI 10.1089/dna.1.1989.8.127; KOTHARY R, 1989, DEVELOPMENT, V105, P707; Kringstein AM, 1998, P NATL ACAD SCI USA, V95, P13670, DOI 10.1073/pnas.95.23.13670; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee AV, 1997, BIOTECHNIQUES, V23, P1062, DOI 10.2144/97236st02; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MIKULITS W, 1995, NUCLEIC ACIDS RES, V23, P2342, DOI 10.1093/nar/23.12.2342; NATZLE JE, 1992, DEV GENET, V13, P331, DOI 10.1002/dvg.1020130504; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Orth P, 1998, J MOL BIOL, V279, P439, DOI 10.1006/jmbi.1998.1775; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rossi FMV, 2000, MOL CELL, V6, P723, DOI 10.1016/S1097-2765(00)00070-8; Rossi FMV, 1998, CURR OPIN BIOTECH, V9, P451, DOI 10.1016/S0958-1669(98)80028-1; Rossi FMV, 1998, NAT GENET, V20, P389, DOI 10.1038/3871; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHWEINFEST CW, 1988, GENE, V71, P207, DOI 10.1016/0378-1119(88)90093-5; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SIZEMORE C, 1990, NUCLEIC ACIDS RES, V18, P2875, DOI 10.1093/nar/18.10.2875; SMITH LD, 1988, J MOL BIOL, V203, P949, DOI 10.1016/0022-2836(88)90120-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAKAHASHI M, 1991, ANAL BIOCHEM, V199, P197, DOI 10.1016/0003-2697(91)90089-C; TAKEKOSHI M, 1993, J GEN VIROL, V74, P1649, DOI 10.1099/0022-1317-74-8-1649; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wheeler GN, 2000, CURR BIOL, V10, P849, DOI 10.1016/S0960-9822(00)00596-0; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13-1939; ZERNIK J, 1991, BIOCHEM BIOPH RES CO, V176, P1149, DOI 10.1016/0006-291X(91)90405-V	66	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45168	45174		10.1074/jbc.M106924200	http://dx.doi.org/10.1074/jbc.M106924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581265	hybrid			2022-12-25	WOS:000172406700109
J	Ng, CJ; Wadleigh, DJ; Gangopadhyay, A; Hama, S; Grijalva, VR; Navab, M; Fogelman, AM; Reddy, ST				Ng, CJ; Wadleigh, DJ; Gangopadhyay, A; Hama, S; Grijalva, VR; Navab, M; Fogelman, AM; Reddy, ST			Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; INHIBITS 3 STEPS; PLASMA-LIPOPROTEINS; DIABETES-MELLITUS; GENETIC-VARIATION; POLYMORPHISMS; ASSOCIATION; PON2; ASSAY	The oxidation of apolipoprotein B-containing lipoproteins and cell membrane lipids is believed to play an integral role in the development of fatty streak lesions, an initial step in atherogenesis. We have previously shown that two antioxidant-like enzymes, paraoxonase (PON)-1 and PON3, are high density lipoprotein-associated proteins capable of preventing the oxidative modification of low density lipoprotein (LDL) (Reddy, S. T., Wadleigh, D. J., Grijalva, V., Ng, C., Hama, S., Gango-padhyay, A., Shih, D. M., Lusis, A. J., Navab, M., and Fogelman, A. M. (2001) Arterioscler. Thromb. Vase. Biol. 21, 542-547). In the present study, we demonstrate that PON2 (i) is not associated with high density lipoprotein; (ii) has antioxidant properties; and (iii) prevents LDL lipid peroxidation, reverses the oxidation of mildly oxidized LDL (MM-LDL), and inhibits the ability of MM-LDL to induce monocyte chemotaxis. The PON2 protein was overexpressed in HeLa cells using the tetracycline-inducible ("Tet-On") system, and its antioxidant capacity was measured in a fluorometric assay. Cells that overexpressed PON2 showed significantly less intracellular oxidative stress following treatment with hydrogen peroxide or oxidized phospholipid. Moreover, cells that overexpressed PON2 were also less effective in oxidizing and modifying LDL and, in fact, were able to reverse the effects of preformed MM-LDL. Our results suggest that PON2 possesses antioxidant properties similar to those of PON1 and PON3. However, in contrast to PON1 and PON3, PON2 may exert its antioxidant functions at the cellular level, joining the host of intracellular antioxidant enzymes that protect cells from oxidative stress.	Univ Calif Los Angeles, Dept Med, Atherosclerosis Res Unit, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Reddy, ST (corresponding author), Univ Calif Los Angeles, Dept Med, Atherosclerosis Res Unit, A8-131 CHS,650 Charles E Young Dr S, Los Angeles, CA 90095 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R01HL071776] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568, R01 HL071776] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Boright AP, 1998, ATHEROSCLEROSIS, V139, P131, DOI 10.1016/S0021-9150(98)00071-9; Busch CP, 1999, PHARMACOGENETICS, V9, P351, DOI 10.1097/00008571-199906000-00010; Draganov DI, 2000, J BIOL CHEM, V275, P33435, DOI 10.1074/jbc.M004543200; DURRINGTON RN, 2001, ARTERIOSCLEROSIS, V21, P473; Fanella S, 2000, CLIN CHEM LAB MED, V38, P413, DOI 10.1515/CCLM.2000.060; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hegele RA, 1998, CLIN GENET, V54, P394; Imai Y, 2000, ATHEROSCLEROSIS, V149, P435, DOI 10.1016/S0021-9150(99)00340-8; Kobayashi M, 1998, P NATL ACAD SCI USA, V95, P12787, DOI 10.1073/pnas.95.22.12787; La Du BN, 2001, ARTERIOSCL THROM VAS, V21, P467, DOI 10.1161/01.ATV.21.4.467; La Du BN, 1992, PHARMACOGENETICS DRU, P51; Mackness B, 2000, CLIN SCI, V98, P355, DOI 10.1042/CS19990239; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness MI, 1997, LANCET, V349, P851, DOI 10.1016/S0140-6736(05)61755-2; MAIER JAM, 1994, EUR J BIOCHEM, V221, P35, DOI 10.1111/j.1432-1033.1994.tb18712.x; Mochizuki H, 1998, GENE, V213, P149, DOI 10.1016/S0378-1119(98)00193-0; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2000, J LIPID RES, V41, P1495; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Navab M, 2001, ARTERIOSCL THROM VAS, V21, P481, DOI 10.1161/01.ATV.21.4.481; Odawara M, 1997, J CLIN ENDOCR METAB, V82, P2257, DOI 10.1210/jc.82.7.2257; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225; Reddy ST, 2001, ARTERIOSCL THROM VAS, V21, P542, DOI 10.1161/01.ATV.21.4.542; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sanghera DK, 1998, AM J HUM GENET, V62, P36, DOI 10.1086/301669; SHIH D, IN PRESS PARAOXONASE; Suehiro T, 1996, INT J CARDIOL, V57, P69, DOI 10.1016/S0167-5273(96)02779-9; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597	34	373	404	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44444	44449		10.1074/jbc.M105660200	http://dx.doi.org/10.1074/jbc.M105660200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579088	hybrid			2022-12-25	WOS:000172406700014
J	Bosc, DG; Goueli, BS; Janknecht, R				Bosc, DG; Goueli, BS; Janknecht, R			HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1	ONCOGENE			English	Article						ER81; gene transcription; HER2/Neu; MAP kinase; matrix metalloproteinase-1; protein phosphorylation	PROTEIN-KINASE; MAP-KINASE; MATRIX-METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; BREAST-CANCER; PEA3 GROUP; EXPRESSION; CELL; PHOSPHORYLATION; BINDING	In this study, we show that the ETS transcription factor ER81 directly binds to and activates the promoter of the matrix metalloproteinase gene, MMP-1. Further, the oncoprotein HER2/Neu synergizes with ER81 to stimulate MMP-1 transcription, The activation of ER81 by HER2/Neu is mediated by MAP kinases, which phosphorylate ER81 in its N-terminal activation domain. Four respective phosphorylation sites have been identified. Blocking phosphorylation at these sites decreases ER81 transcriptional activity, which can be further diminished by abolishment of phosphorylation at two non-MAP kinase sites, Altogether, our results reveal mechanisms of how phosphorylation of ER81 regulates the expression of target genes such as MMP-1, which may be important for many physiological processes from embryogenesis to adulthood as well as for tumor metastasis.	Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Guggenheim Bldg 1501A,200 1st St SW, Rochester, MN 55905 USA.	janknecht.ralf@mayo.edu		Janknecht, Ralf/0000-0003-1741-1562	NCI NIH HHS [CA 85257, R01 CA085257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Benbow U, 1999, CLIN CANCER RES, V5, P203; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Brummer O, 1999, VIRCHOWS ARCH, V435, P566, DOI 10.1007/s004280050442; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buttice G, 1996, ONCOGENE, V13, P2297; Buzard GS, 1999, J CANCER RES CLIN, V125, P653, DOI 10.1007/s004320050330; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; Durko M, 1997, BBA-MOL CELL RES, V1356, P271, DOI 10.1016/S0167-4889(97)00004-9; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fini ME, 1998, BIOL EXTRAC, P299; Garbett EA, 2000, J CLIN PATHOL-MOL PA, V53, P99, DOI 10.1136/mp.53.2.99; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hung MC, 1999, SEMIN ONCOL, V26, P51; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Johansson N, 2000, J CELL SCI, V113, P227; Kindler-Rohrborn A, 2000, CANCER RES, V60, P4756; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MOLL UM, 1990, HISTOCHEMISTRY, V94, P555, DOI 10.1007/BF00272621; MONTE D, 1995, ONCOGENE, V11, P771; MUIR D, 1995, CLIN EXP METASTAS, V13, P303, DOI 10.1007/BF00133486; Nakopoulou L, 1999, HUM PATHOL, V30, P436, DOI 10.1016/S0046-8177(99)90120-X; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; White LA, 1997, CONNECT TISSUE RES, V36, P321, DOI 10.3109/03008209709160231; Yang BS, 1996, MOL CELL BIOL, V16, P538	56	94	94	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6215	6224		10.1038/sj.onc.1204820	http://dx.doi.org/10.1038/sj.onc.1204820			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593430				2022-12-25	WOS:000171206300013
J	Chen, XF; Thakkar, H; Tyan, F; Gim, S; Robinson, H; Lee, C; Pandey, SK; Nwokorie, C; Onwudiwe, N; Srivastava, RK				Chen, XF; Thakkar, H; Tyan, F; Gim, S; Robinson, H; Lee, C; Pandey, SK; Nwokorie, C; Onwudiwe, N; Srivastava, RK			Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer	ONCOGENE			English	Article						TRAIL; apoptosis; prostate cancer; mitochondria; Akt; PTEN	PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; CYTOCHROME-C; CELL-DEATH; FREQUENT INACTIVATION; TUMORICIDAL ACTIVITY; NEGATIVE REGULATION; SURVIVAL SIGNALS	TRAIL/Apo-2L is a member of the tumor necrosis factor superfamily and has recently been shown to induce apoptosis in cancer cells, but not in normal cells. In nude mice injected with human tumors, TRAIL reduces the size of these tumors without side effects. Akt promotes cell survival and block apoptosis. Some prostate cancer cells express high levels of Akt due to lack of active lipid phosphatase PTEN, a negative regulator of PI-3 kinase pathway, which may be responsible for drug resistance. The objective of this paper is to investigate the intracellular molecules that regulate TRAIL resistance. We have examined caspase-8 activity, BID cleavage, Akt activity, mitochondrial membrane potential (AT.) and apoptosis in prostate cancer (LNCap, PC-3, PC-3M and DU145) cells treated with or without TRAIL. PC-3, PC-3M and DU145 cells are sensitive to TRAIL, whereas LNCap cells are resistant. LNCap cells express the highest level of constitutively active Akt, which is directly correlated with TRAIL resistance. TRAIL activates caspase-8 in all the cell lines. Downregulation of constitutively active Akt by PI-3 kinase inhibitors (wortmannin and LY-294002), dominant negative Akt or PTEN, renders LNCap cells sensitive to TRAIL. Inhibition of TRAIL sensitivity occurs at the level of BID cleavage. Inhibition of protein synthesis by cycloheximide also causes LNCap cells sensitive to TRAIL. Overexpression of Bcl-2 or Bcl-X-L inhibits TRAIL-induced Delta Psi (m) and apoptosis. Overexpression of constitutively active Akt in PC-3M cells (express very low levels of constitutively active Akt) restores TRAIL resistance. These data suggest that elevated Akt activity protects LNCap cells from TRAIL-induced apoptosis, and the PI-3 kinase/Akt pathway may inhibit apoptotic signals by inhibiting processing of BID. Thus, constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Greenebaum Canc Ctr, 20 N Pine St, Baltimore, MD 21201 USA.							Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheney IW, 1998, CANCER RES, V58, P2331; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Green D R, 1998, Results Probl Cell Differ, V24, P45; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Guldberg P, 1997, CANCER RES, V57, P3660; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Ittmann MM, 1998, ONCOL REP, V5, P1329; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Keane MM, 1999, CANCER RES, V59, P734; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim JH, 2000, INTELL AUTOM SOFT CO, V6, P3, DOI 10.1080/10798587.2000.10768155; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; Long RJ, 1997, J ANDROL, V18, P15; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mori S, 1999, J IMMUNOL, V162, P5616; Muzio M, 1998, INT J CLIN LAB RES, V28, P141, DOI 10.1007/s005990050035; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Okami K, 1998, CANCER RES, V58, P509; Orlinick J R, 1999, Int Rev Immunol, V18, P293, DOI 10.3109/08830189909088485; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Petrylak DP, 1999, UROLOGY, V54, P30, DOI 10.1016/S0090-4295(99)00452-5; Pisters LL, 1999, SEMIN ONCOL, V26, P202; Rasheed BKA, 1997, CANCER RES, V57, P4187; Richie JP, 1999, UROLOGY, V54, P15, DOI 10.1016/S0090-4295(99)00449-5; Rieger J, 1999, ACTA NEUROPATHOL, V97, P1, DOI 10.1007/s004010050948; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sekulic A, 2000, CANCER RES, V60, P3504; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivastava Rakesh K., 2000, Molecular Cell Biology Research Communications, V4, P67, DOI 10.1006/mcbr.2001.0265; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Tonks NK, 1999, SCIENCE, V286, P2096, DOI 10.1126/science.286.5447.2096; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	87	252	262	1	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6073	6083		10.1038/sj.onc.1204736	http://dx.doi.org/10.1038/sj.onc.1204736			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593415				2022-12-25	WOS:000171056300015
J	Ugolini, F; Charafe-Jauffret, E; Bardou, VJ; Geneix, J; Adelaide, J; Labat-Moleur, F; Penault-Llorca, F; Longy, M; Jacquemier, J; Birnbaum, D; Pebusque, MJ				Ugolini, F; Charafe-Jauffret, E; Bardou, VJ; Geneix, J; Adelaide, J; Labat-Moleur, F; Penault-Llorca, F; Longy, M; Jacquemier, J; Birnbaum, D; Pebusque, MJ			WNT pathway and mammary carcinogenesis: Loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; in situ hybridization; chromosome 8	BREAST-CANCER; CYCLIN D1; ESTROGEN-RECEPTOR; DIFFERENTIAL EXPRESSION; SPEMANN ORGANIZER; TISSUE-SECTIONS; BETA-CATENIN; FOLLOW-UP; IN-SITU; GROWTH	Secreted Frizzled-related protein 1 (SFRP1) encodes a member of a protein family that contains a cysteine-rich domain similar to the WNT-binding site of Frizzled receptors and regulates the WNT pathway. The WNT pathway is frequently altered in human cancers. We have defined the pattern of SFRP1 mRNA expression in the progression of breast cancer. We show that SFRP1 is expressed in the epithelial component of normal breast, in the in situ component of ductal carcinomas and is lost in more than 80% of invasive breast carcinomas except the medullary type. Loss of SFRP1 expression is correlated with the presence of hormonal receptors. Conversely, the maintenance of SFRP1 in carcinomas is correlated with the presence of lymphoplasmocytic stroma. No significant association was observed between SFRP1 status and the level of apoptosis in tumoral cells.	INSERM, U119, IFR 57, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Anat Pathol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; CHRU, Pathol Cellulaire Lab, Grenoble, France; Ctr Jean Perrin, Anat Pathol Lab, Clermont Ferrand, France; Inst Bergonie, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); CHU Grenoble Alpes; UNICANCER; Centre Jean Perrin; UNICANCER; Institut Bergonie	Pebusque, MJ (corresponding author), INSERM, U119, IFR 57, Oncol Mol Lab, 27 Bd Lei Roure, F-13009 Marseille, France.	pebusque@marseille.inserm.fr	ADELAIDE, José JA/O-4390-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	ADELAIDE, José JA/0000-0003-4364-9857; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Birnbaum, Daniel/0000-0001-7920-9883				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; CHURCH GM, 1984, P NATL ACAD SCI USA, V81, P945; Dale TC, 1996, CANCER RES, V56, P4320; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUGUET EL, 1994, CANCER RES, V54, P2615; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Jacquemier JD, 1998, J PATHOL, V184, P130; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Labat-Moleur F, 1998, J HISTOCHEM CYTOCHEM, V46, P327, DOI 10.1177/002215549804600306; Lakhani SR, 1999, J PATHOL, V187, P272, DOI 10.1002/(SICI)1096-9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Pedersen L, 1997, APMIS, V105, P4; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; PHILIPPE JM, 1998, TECHNICAL TIPS LINE; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; Ross JS, 1999, AM J CLIN PATHOL, V112, pS53; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shoker BS, 1999, HISTOPATHOLOGY, V35, P393; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simpson JF, 2000, AM J PATHOL, V156, P5, DOI 10.1016/S0002-9440(10)64698-6; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEILLET C, 1990, ONCOGENE, V5, P147; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; vanDiest PJ, 1997, AM J PATHOL, V150, P705; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vos CBJ, 1999, J PATHOL, V187, P279; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zorn AM, 1997, CURR BIOL, V7, pR501, DOI 10.1016/S0960-9822(06)00248-X; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	155	165	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5810	5817		10.1038/sj.onc.1204706	http://dx.doi.org/10.1038/sj.onc.1204706			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593386				2022-12-25	WOS:000171037200004
J	Boysen, RI; Jong, AJO; Wilce, JA; King, GF; Hearn, MTW				Boysen, RI; Jong, AJO; Wilce, JA; King, GF; Hearn, MTW			Role of interfacial hydrophobic residues in the stabilization of the leucine zipper structures of the transcription factors c-Fos and c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTHALPY-ENTROPY COMPENSATION; HELICAL COILED-COILS; INTERACTION CHROMATOGRAPHY; BINDING THERMODYNAMICS; PROTEIN STABILITY; BEHAVIOR; DNA; ENERGETICS; RETENTION; WATER	This study documents a new and versatile experimental approach to study the relative stabilization energetics of recombinant polypeptide and protein mutants. In particular, the effect of temperature change over the range of T = 278-338 K on the thermodynamics of interaction of several leucine zipper coiled-coil polypeptides related to the transcription factors, c-Fos and c-Jun, following binding to immobilized n-octyl ligands has been determined. Plots of the change in heat capacity, DeltaC(P)(0), versus T, in combination with the corresponding van't Hoff plots, allow the energetics of the interaction of polypeptides with n-octyl ligands to be rationalized and the respective mid-point transition temperatures, T-m values, determined for the melting of their supramolecular structures. The derived experimental data correlated well with information available from other procedures, confirming that this new approach provides complementary insight into the interaction thermodynamics and the molecular nature of the thermal stability of recombinant polypeptides in non-polar or other types of chemical environments.	Monash Univ, Dept Biochem & Mol Biol, Ctr Bioproc Technol, Clayton, Vic 3800, Australia; Univ Western Australia, Dept Chem & Biochem, Nedlands, WA 6907, Australia; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA	Monash University; University of Western Australia; University of Connecticut	Hearn, MTW (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Ctr Bioproc Technol, POB 13D, Clayton, Vic 3800, Australia.		Boysen, Reinhard/H-9646-2014; King, Glenn F/J-5059-2012; Wilce, Jacqueline/N-5018-2017	Boysen, Reinhard/0000-0002-7063-6958; King, Glenn F/0000-0002-2308-2200; Wilce, Jacqueline/0000-0002-8344-2626				Bains NPS, 1999, LETT PEPT SCI, V6, P381; Bains NPS, 1997, LETT PEPT SCI, V4, P67; Berman HM, 1999, CURR OPIN BIOTECH, V10, P76, DOI 10.1016/S0958-1669(99)80014-7; Beyermann M, 1996, J MED CHEM, V39, P3324, DOI 10.1021/jm960116z; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Borea Pier Andrea, 1992, Molecular Neuropharmacology, V2, P273; Boysen R. I., 2001, CURRENT PROTOCOLS PR, P1; Boysen RI, 1999, BIOPHYS CHEM, V77, P79, DOI 10.1016/S0301-4622(99)00002-2; CHEN BL, 1992, BIOCHEMISTRY-US, V31, P1464, DOI 10.1021/bi00120a025; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Durr E, 2000, BIOCHEMISTRY-US, V39, P4472, DOI 10.1021/bi992948f; EISENHABER F, 1995, J COMPUT CHEM, V16, P273, DOI 10.1002/jcc.540160303; EISENHABER F, 1993, J COMPUT CHEM, V14, P1272, DOI 10.1002/jcc.540141103; Gallicchio E, 1998, J AM CHEM SOC, V120, P4526, DOI 10.1021/ja974061h; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Haidacher D, 1996, P NATL ACAD SCI USA, V93, P2290, DOI 10.1073/pnas.93.6.2290; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; Hearn MTW, 1999, PEPTIDE SCIENCE - PRESENT AND FUTURE, P240; Hearn MTW, 1999, ANAL CHEM, V71, P4874, DOI 10.1021/ac990028x; HEARN MTW, 2001, THEORY PRACTICE BIOC, P72; HEARN MTW, 2001, SYNTHESIS PEPTIDES P; HEARN MTW, 2000, HDB BIOSEPARATION, P72; JUNIUS FK, 1993, EUR J BIOCHEM, V214, P415, DOI 10.1111/j.1432-1033.1993.tb17937.x; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Klotz IM, 1999, J PHYS CHEM B, V103, P5910, DOI 10.1021/jp9913057; Kohn WD, 1997, J MOL BIOL, V267, P1039, DOI 10.1006/jmbi.1997.0930; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; Kovrigin EL, 2000, BIOPHYS CHEM, V83, P45, DOI 10.1016/S0301-4622(99)00122-2; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lin FY, 2001, ANAL CHEM, V73, P3875, DOI 10.1021/ac0102056; Liu L, 2000, BIOPHYS CHEM, V84, P239, DOI 10.1016/S0301-4622(00)00130-7; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; Mallardi A, 1998, J PHYS CHEM B, V102, P9168, DOI 10.1021/jp982464d; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MELANDER WR, 1984, J CHROMATOGR, V317, P67, DOI 10.1016/S0021-9673(01)91648-6; MONERA OD, 1993, J BIOL CHEM, V268, P19218; Murphy KP, 1999, MED RES REV, V19, P333, DOI 10.1002/(SICI)1098-1128(199907)19:4<333::AID-MED6>3.0.CO;2-5; MURPHY KP, 1991, J MOL BIOL, V222, P699, DOI 10.1016/0022-2836(91)90506-2; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; Purcell AW, 1999, J CHROMATOGR A, V852, P43, DOI 10.1016/S0021-9673(99)00440-9; Purcell AW, 1999, ANAL CHEM, V71, P2440, DOI 10.1021/ac9808369; Ramirez-Carrozzi VR, 2001, J BIOL CHEM, V276, P21797, DOI 10.1074/jbc.M101494200; Ramirez-Carrozzi VR, 2001, J MOL BIOL, V305, P411, DOI 10.1006/jmbi.2000.4286; Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c; Ross PD, 1996, BIOPHYS J, V71, P2144, DOI 10.1016/S0006-3495(96)79415-8; Silverstein KAT, 1998, J AM CHEM SOC, V120, P3166, DOI 10.1021/ja973029k; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Sussman JL, 1998, ACTA CRYSTALLOGR D, V54, P1078, DOI 10.1107/S0907444998009378; TEHAN MC, 2000, J BIOL CHEM, V275, P37454; Vailaya A, 1996, IND ENG CHEM RES, V35, P2964, DOI 10.1021/ie9507437; WEILAND GA, 1979, NATURE, V281, P114, DOI 10.1038/281114a0; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; Yu YH, 1996, BIOPHYS CHEM, V59, P299, DOI 10.1016/0301-4622(95)00131-X	59	23	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					23	31		10.1074/jbc.M104556200	http://dx.doi.org/10.1074/jbc.M104556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11602575	hybrid			2022-12-25	WOS:000173087900005
J	Mahadev, K; Wu, XD; Zilbering, A; Zhu, L; Lawrence, JTR; Goldstein, BJ				Mahadev, K; Wu, XD; Zilbering, A; Zhu, L; Lawrence, JTR; Goldstein, BJ			Hydrogen peroxide generated during cellular insulin stimulation is integral to activation of the distal insulin signaling cascade in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; OXIDATIVE STRESS; RECEPTOR KINASE; REDOX REGULATION; ANGIOTENSIN-II; RAT ADIPOCYTES; MUSCLE-CELLS; S6 KINASE	In a variety of cell types, insulin stimulation elicits the rapid production of H2O2, which causes the oxidative inhibition of protein-tyrosine phosphatases and enhances the tyrosine phosphorylation of proteins in the early insulin action cascade (Mahadev, K., Zilbering, A., Zhu, L., and Goldstein, B. J. (2001) J. Biol. Chem. 276, 21938-21942). In the present work, we explored the potential role of insulin-induced 11,02 generation on downstream insulin signaling using diphenyleneiodonium (I)PI), an inhibitor of cellular NADPH oxidase that blocks insulin-stimulated cellular H2O2 production. DPI completely inhibited the activation of phosphatidylinositol (PI) T-kinase activity by insulin and reduced the insulin-induced activation of the serine kinase Alit by up to 49%; these activities were restored when H2O2 was added back to cells that had been pretreated with DPI. Interestingly, the H2O2-induced activation of Akt was entirely mediated by upstream stimulation of PI T-kinase activity, since treatment of 3T3-L1 adipocytes with the PI 3'-kinase inhibitors wortmannin or LY294002 completely blocked the subsequent activation of Alit by exogenous H2O2. Preventing oxidant generation with DPI also blocked insulin-stimulated glucose uptake and GLUT4 translocation to the plasma membrane, providing further evidence for an oxidant signal in the regulation of the distal insulin-signaling cascade. Finally, in contrast to the cellular mechanism of H2O2 generation by other growth factors, such as platelet-derived growth factor, we also found that insulin-stimulated cellular production of H2O2 may occur through a unique pathway, independent of cellular PI 3'-kinase activity. Overall, these data provide insight into the physiological role of insulin-dependent H2O2 generation, which is not only involved in the regulation of tyrosine phosphorylation events in the early insulin signaling cascade but also has important effects on the regulation of downstream insulin signaling, involving the activation of PI 3'-kinase, Akt, and ultimately cellular glucose transport in response to insulin.	Thomas Jefferson Univ, Jefferson Med Coll,Dept Med, Dorrance H Hamilton Res Labs, Div Endocrinol & Metab Dis, Philadelphia, PA 19107 USA; Univ Penn, Sch Med, Cox Inst,Dept Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Jefferson University; Howard Hughes Medical Institute; University of Pennsylvania	Goldstein, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll,Dept Med, Dorrance H Hamilton Res Labs, Div Endocrinol & Metab Dis, Jefferson Alumni Hall,Suite 349,1020 Locust St, Philadelphia, PA 19107 USA.	Barry.Goldstein@mail.tju.edu						AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady MJ, 1999, J CLIN INVEST, V104, P675, DOI 10.1172/JCI8216; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CZECH MP, 1972, J BIOL CHEM, V247, P6218; CZECH MP, 1974, J BIOL CHEM, V249, P1001; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Gagnon AM, 1998, OBES RES, V6, P157, DOI 10.1002/j.1550-8528.1998.tb00330.x; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; GOLDSTEIN BJ, 2000, DIABETES MELLITUS FU, P206; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; GUY GR, 1993, J BIOL CHEM, V268, P2141; Hansen LL, 1999, J BIOL CHEM, V274, P25078, DOI 10.1074/jbc.274.35.25078; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Kennedy BP, 2000, BIOCHEM PHARMACOL, V60, P877, DOI 10.1016/S0006-2952(00)00305-1; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIS VR, 1970, J BIOL CHEM, V245, P23; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MAY JM, 1979, J BIOL CHEM, V254, P9017; MAY JM, 1979, J BIOL CHEM, V254, P2214; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; OKADA T, 1994, J BIOL CHEM, V269, P3568; Patti Mary-Elizabeth, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P89; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; PIKE LJ, 1984, J BIOL CHEM, V259, P9913; Rudich A, 1999, DIABETOLOGIA, V42, P949, DOI 10.1007/s001250051253; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Schmid E, 1999, FASEB J, V13, P1491, DOI 10.1096/fasebj.13.12.1491; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SHAW M, 1998, BIOCHEM J, V336, P1; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; Tirosh A, 1999, J BIOL CHEM, V274, P10595, DOI 10.1074/jbc.274.15.10595; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White MF, 1998, RECENT PROG HORM RES, V53, P119; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; Zhu L, 2001, FASEB J, V15, P1637, DOI 10.1096/fj.00-0795fje	53	249	261	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48662	48669		10.1074/jbc.M105061200	http://dx.doi.org/10.1074/jbc.M105061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11598110	hybrid			2022-12-25	WOS:000173922100009
J	Saburi, S; Nadano, D; Akama, TO; Hirama, K; Yamanouchi, K; Naito, K; Tojo, H; Tachi, C; Fukuda, MN				Saburi, S; Nadano, D; Akama, TO; Hirama, K; Yamanouchi, K; Naito, K; Tojo, H; Tachi, C; Fukuda, MN			The trophinin gene encodes a novel group of MAGE proteins, magphinins, and regulates cell proliferation during gametogenesis in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; EMBRYO IMPLANTATION; NECDIN GENE; GERM-CELLS; EXPRESSION; IDENTIFICATION; TROPHOBLAST; INTERACTS; ADHESION; ANTIGEN	Trophinin is a membrane protein that mediates apical cell adhesion between trophoblastic cells and luminal epithelial cells of the endometrium and is implicated in the initial attachment during the process of human embryo implantation. The present study identified novel trophinin gene transcripts, which encode proteins structurally distinct from trophinin protein in the mouse. We designated these proteins "magphinins," because they share consensus amino acid sequences with MAGE (melanoma-associated antigen) superfamily proteins. Among many MAGE proteins, magphinins are closely related to NRAGE, which mediates p75 neurotrophin receptor-dependent apoptosis, and necdin, which is a strong suppressor of cell proliferation in post-mitotic neurons. There are three major forms of magphinins, i.e. magphinin-alpha, -beta, and -gamma, in the mouse, which are formed due to alternative usage of different exons. Northern blot analysis revealed that magphinins are expressed in brain, ovary, testis, and epididymis. In addition, Western blot analysis and in vitro translation experiments showed that magphinins expressed in the mouse ovary and testis are translation products utilizing the second initiation AUG codon and contain an active nuclear localization signal. Ectopic expression of magphinins in mammalian cells resulted in nuclear localization of magphinin and suppressed cell proliferation. Immunohistochemistry of the mouse ovary and testis showed that magphinin proteins are distributed in the cytoplasm of the male and female germ cells, whereas these proteins are translocated to the nucleus at a specific stage of gametogenesis. These results strongly suggest that magphinins regulate cell proliferation during gametogenesis in the mouse.	Burnham Inst, Dept Glycobiol, La Jolla, CA 92037 USA; Univ Tokyo, Inst Med Sci, Microbiol Lab, Tokyo 1088639, Japan; Univ Tokyo, Lab Appl Genet, Dept Anim Resource Sci, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Azabu Univ, Lab Dev & Reprod Biotechnol, Sch Vet Med & Life Sci, Kanagawa 2298501, Japan	Sanford Burnham Prebys Medical Discovery Institute; University of Tokyo; University of Tokyo; Azabu University	Fukuda, MN (corresponding author), Burnham Inst, Dept Glycobiol, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034108] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34108] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; CAO G, 1991, EXP CELL RES, V193, P405, DOI 10.1016/0014-4827(91)90113-9; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Chomez P, 2001, CANCER RES, V61, P5544; CHOMEZ P, 1995, IMMUNOGENETICS, V43, P97; De Plaen E, 1999, GENOMICS, V55, P176, DOI 10.1006/geno.1998.5638; DEBACKER O, 1995, GENOMICS, V28, P74, DOI 10.1006/geno.1995.1108; FUKUDA MN, 1995, GENE DEV, V9, P1199, DOI 10.1101/gad.9.10.1199; Fukuda MN, 1999, EMBRYO IMPLANTATION, P132; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOFMANN MC, 1992, EXP CELL RES, V201, P417, DOI 10.1016/0014-4827(92)90291-F; Jurk M, 1998, INT J CANCER, V75, P762, DOI 10.1002/(SICI)1097-0215(19980302)75:5<762::AID-IJC16>3.0.CO;2-8; Kleene KC, 1996, MOL REPROD DEV, V43, P268, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;268::AID-MRD17&gt;3.0.CO;2-#; KOCHER T, 1995, CANCER RES, V55, P2236; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lucas S, 1999, CANCER RES, V59, P4100; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mertineit C, 1998, DEVELOPMENT, V125, P889; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; Osterlund C, 2000, CANCER RES, V60, P1054; Pack SD, 1997, CYTOGENET CELL GENET, V79, P123, DOI 10.1159/000134698; Pold M, 1999, GENOMICS, V59, P161, DOI 10.1006/geno.1999.5870; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; SHULTZTHATER E, 1994, INT J CANCER, V59, P435; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P5027, DOI 10.1073/pnas.95.9.5027; Suzuki N, 1999, BIOL REPROD, V60, P621, DOI 10.1095/biolreprod60.3.621; Suzuki N, 2000, ENDOCRINOLOGY, V141, P4247, DOI 10.1210/en.141.11.4247; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tsai TF, 1999, HUM MOL GENET, V8, P1357, DOI 10.1093/hmg/8.8.1357; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032	39	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49378	49389		10.1074/jbc.M108584200	http://dx.doi.org/10.1074/jbc.M108584200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11590179	hybrid			2022-12-25	WOS:000173922100099
J	Hu, JG; Igarashi, A; Kamata, M; Nakagawa, H				Hu, JG; Igarashi, A; Kamata, M; Nakagawa, H			Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); Retards A beta aggregation, deposition, fibril formation, and inhibits cytotoxicity.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-BARRIER FUNCTION; GENE POLYMORPHISM; PRECURSOR PROTEIN; TETRAZOLIUM SALT; DISEASE; ACE; NEUROTOXICITY; ASSOCIATION; SERUM; APP	We have demonstrated that the angiotensin-converting enzyme (ACE) genotype is associated with Alzheimer's disease (AD) in the Japanese population (1). To determine why ACE affects susceptibility to AD, we examined the effect of purified ACE on aggregation of the amyloid P-peptide (AP) in vitro. Surprisingly, ACE was found to significantly inhibit A beta aggregation in a dose response manner. The inhibition of aggregation was specifically blocked by preincubation of ACE with an ACE inhibitor, lisinopril. ACE was confirmed to retard A beta fibril formation with electron microscopy. ACE inhibited A beta deposits on a synthaloid plate, which was used to monitor AP deposition on autopsied brain tissue. ACE also significantly inhibited A beta cytotoxicity on PC12 h. The most striking fact was that ACE degraded A beta by cleaving A beta-(1-40) at the site Asp(7)-Ser(8). This was proven with reverse-phase HPLC, amino acid sequence analysis, and MALDI-TOF/MS. Compared with A beta-(1-40), aggregation and cytotoxic effects of the degradation products A beta-(1-7) and A beta-(8-40) peptides were reduced or virtually absent. These findings led to the hypothesis that ACE may affect susceptibility to AD by degrading A beta and preventing the accumulation of amyloid plaques in vivo.	R&D Ctr, Bio Med Lab, Kawagoe, Saitama 3501101, Japan		Igarashi, A (corresponding author), R&D Ctr, Bio Med Lab, 1361-1 Matoba, Kawagoe, Saitama 3501101, Japan.							Abbud ZA, 1998, AM J CARDIOL, V81, P244, DOI 10.1016/S0002-9149(97)00876-X; Albrecht D, 1997, REGUL PEPTIDES, V70, P105, DOI 10.1016/S0167-0115(97)00015-3; Alvarez R, 1999, J NEUROL NEUROSUR PS, V67, P733, DOI 10.1136/jnnp.67.6.733; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; Crawford F, 2000, NEUROSCI LETT, V280, P215, DOI 10.1016/S0304-3940(00)00791-6; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; Farrer LA, 2000, ARCH NEUROL-CHICAGO, V57, P210, DOI 10.1001/archneur.57.2.210; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Hu J, 1999, NEUROSCI LETT, V277, P65, DOI 10.1016/S0304-3940(99)00827-7; Ishiyama M, 1997, TALANTA, V44, P1299, DOI 10.1016/S0039-9140(97)00017-9; Ishiyama M., 1995, In Vitro Toxicology, V8, P187; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Kakinuma Y, 1998, NAT MED, V4, P1078, DOI 10.1038/2070; Kakinuma Y, 1997, NEUROSCI LETT, V232, P167, DOI 10.1016/S0304-3940(97)00605-8; Kamata M, 2001, INT J ANDROL, V24, P225, DOI 10.1046/j.1365-2605.2001.00288.x; KASAHARA Y, 1981, CLIN CHEM, V27, P1922; Kehoe PG, 1999, NAT GENET, V21, P71, DOI 10.1038/5009; Kramar EA, 1997, REGUL PEPTIDES, V68, P131, DOI 10.1016/S0167-0115(96)02116-7; Ledru F, 1998, AM J CARDIOL, V82, P160, DOI 10.1016/S0002-9149(98)00304-X; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LIEBERMAN J, 1975, AM J MED, V59, P365, DOI 10.1016/0002-9343(75)90395-2; Lorenzo A, 1996, ANN NY ACAD SCI, V777, P89, DOI 10.1111/j.1749-6632.1996.tb34406.x; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Mok SS, 2000, J NEUROSCI RES, V61, P449, DOI 10.1002/1097-4547(20000815)61:4<449::AID-JNR12>3.0.CO;2-N; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pederson ES, 1998, REGUL PEPTIDES, V74, P97, DOI 10.1016/S0167-0115(98)00028-7; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Reardon KA, 2000, AUST NZ J MED, V30, P48, DOI 10.1111/j.1445-5994.2000.tb01054.x; REID IA, 1992, AM J PHYSIOL, V262, pE763, DOI 10.1152/ajpendo.1992.262.6.E763; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Skoog I, 1998, NEUROLOGY, V50, P966, DOI 10.1212/WNL.50.4.966; Small DH, 1998, NEUROCHEM RES, V23, P795, DOI 10.1023/A:1022471729291; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Vleming LJ, 1999, CLIN NEPHROL, V51, P133; Wright JW, 1999, J NEUROSCI, V19, P3952; YANKNER BA, 1992, NEUROBIOL AGING, V13, P615, DOI 10.1016/0197-4580(92)90067-8; Yu GSP, 1998, NEUROSCI LETT, V254, P125, DOI 10.1016/S0304-3940(98)00685-5; Zhuo JL, 1998, J HYPERTENS, V16, P2027, DOI 10.1097/00004872-199816121-00026	45	297	306	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47863	47868		10.1074/jbc.M104068200	http://dx.doi.org/10.1074/jbc.M104068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604391	hybrid			2022-12-25	WOS:000172927000020
J	Selmi, B; Boretto, J; Sarfati, SR; Guerreiro, C; Canard, B				Selmi, B; Boretto, J; Sarfati, SR; Guerreiro, C; Canard, B			Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; COMBINATION THERAPY; REDUCED SENSITIVITY; DNA-POLYMERASES; HIV-1; TYPE-1; INHIBITORS; MUTATION; SUSCEPTIBILITY; 2',3'-DIDEOXYCYTIDINE	The amino acid change K65R in human immunodeficiency virus type I-reverse transcriptase (RT) confers viral resistance to various 2',3'-dideoxynucleoside drugs in vivo. Using pre-steady state kinetic methods, we found that K65R-reverse transcriptase is 3.2-14-fold resistant to 2',3'-dideoxynucleotides in vitro relative to wild-type reverse transcriptase, in agreement with resistance levels observed in vivo. A decreased catalytic rate constant k(pol) mostly accounts for the lower incorporation efficiency observed for 2',3'-dideoxynucleotides. Examination of the crystal structure of the RT.DNA.dNTP complex suggested that both the charge at position 65 and the 3'-OH of the incoming nucleotide act in synergy during the creation of the phosphodiester bond, resulting in a more pronounced decreased catalytic rate constant for 2,3'-dideoxynucleotides than for dNTPs. This type of intramolecular activation of the leaving phosphate by the W-OH group appears to be conserved in several nucleotide phosphotransferases. These data were used to design dideoxynucleotide analogues targeting K65R RT specifically. alpha -Boranophosphate ddATP was found to be a 2-fold better substrate than dATP and inhibited DNA synthesis by K65R RT 153-fold better than ddATP. This complete suppression of drug resistance at the nucleotide level could serve for other reverse transcriptases for which drug resistance is achieved at the catalytic step.	CNRS, UMR 6098, F-13288 Marseille 9, France; Univ Aix Marseille 1, UMR 6098, F-13288 Marseille, France; Univ Aix Marseille 2, UMR 6098, F-13288 Marseille 9, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Canard, B (corresponding author), CNRS, UMR 6098, ESIL-Case 925,163 Ave Luminy, F-13288 Marseille 9, France.			Canard, Bruno/0000-0003-4924-1991				Arion D, 1996, J BIOL CHEM, V271, P19860, DOI 10.1074/jbc.271.33.19860; Balzarini J, 1999, BIOCHEM PHARMACOL, V58, P1; Bazmi HZ, 2000, ANTIMICROB AGENTS CH, V44, P1783, DOI 10.1128/AAC.44.7.1783-1788.2000; Boretto J, 2001, ANAL BIOCHEM, V292, P139, DOI 10.1006/abio.2001.5045; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eckstein F, 1995, METHOD ENZYMOL, V262, P189; Foli A, 1996, ANTIVIR RES, V32, P91, DOI 10.1016/0166-3542(95)00985-X; GU ZX, 1995, P NATL ACAD SCI USA, V92, P2760, DOI 10.1073/pnas.92.7.2760; GU ZX, 1995, ANTIMICROB AGENTS CH, V39, P1888, DOI 10.1128/AAC.39.8.1888; GU ZX, 1994, J BIOL CHEM, V269, P28118; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Harrigan PR, 2000, J INFECT DIS, V181, P912, DOI 10.1086/315317; He KH, 1998, J ORG CHEM, V63, P5769, DOI 10.1021/jo972002g; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KATI WM, 1992, J BIOL CHEM, V267, P25988; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Miller V, 2000, AIDS, V14, P163, DOI 10.1097/00002030-200001280-00012; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROUSSEL A, 1991, SILICON GRAPHICS DIR, P97; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; Selmi B, 2001, J BIOL CHEM, V276, P13965, DOI 10.1074/jbc.M009837200; Shahs FS, 2000, J BIOL CHEM, V275, P27037; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Wainberg MA, 1999, ANTIVIR THER, V4, P87; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	36	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48466	48472		10.1074/jbc.M107003200	http://dx.doi.org/10.1074/jbc.M107003200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606579	hybrid			2022-12-25	WOS:000172927000099
J	von Bergen, M; Barghorn, S; Li, L; Marx, A; Biernat, J; Mandelkow, EM; Mandelkow, E				von Bergen, M; Barghorn, S; Li, L; Marx, A; Biernat, J; Mandelkow, EM; Mandelkow, E			Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; ALZHEIMERS-DISEASE; FTDP-17 MUTATIONS; MICROTUBULE-BINDING; AMYLOID FIBRILS; ISOFORMS; PHOSPHORYLATION; POLYMERIZATION; MISSENSE; CONFORMATION	The microtubule-associated protein tau is a natively unfolded protein in solution, yet it is able to polymerize into the ordered paired helical filaments (PHF) of Alzheimer's disease. In the splice isoforms lacking exon 10, this process is facilitated by the formation of P-structure around the hexapeptide motif PHF6 ((306)VQIVYK(311)) encoded by exon 11. We have investigated the structural requirements for PHF polymerization in the context of adult tau isoforms containing four repeats (including exon 10). In addition to the PHF6 motif there exists a related PHF6* Motif ((275)VQIINK(280)) in the repeat encoded by the alternatively spliced exon 10. We show that this PHF6* motif also promotes aggregation by the formation of P-structure and that there is a cross-talk between the two hexapeptide motifs during PHF aggregation. We also show that two of the tau mutations found in hereditary frontotemporal dementias, Delta K280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta -structure around the hexapeptide motifs.	Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Max Planck Society	Mandelkow, E (corresponding author), Max Planck Unit Struct Mol Biol, Notkestr 85, D-22607 Hamburg, Germany.		von Bergen, Martin/D-7960-2011	von Bergen, Martin/0000-0003-2732-2977				Arrasate M, 1999, FEBS LETT, V446, P199, DOI 10.1016/S0014-5793(99)00210-0; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Eidenmuller J, 2000, BIOCHEMISTRY-US, V39, P13166, DOI 10.1021/bi001290z; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Giannetti AM, 2000, PROTEIN SCI, V9, P2427, DOI 10.1110/ps.9.12.2427; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 1998, PROG BRAIN RES, V117, P287; Goedert M, 2000, BBA-MOL BASIS DIS, V1502, P110, DOI 10.1016/S0925-4439(00)00037-5; Goedert M, 1999, NAT MED, V5, P454, DOI 10.1038/7454; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HARADA M, 1971, J HISTOCHEM CYTOCHEM, V19, P1; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; HECHT MH, 1994, P NATL ACAD SCI USA, V91, P8729, DOI 10.1073/pnas.91.19.8729; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 2000, ANN NY ACAD SCI, V920, P63; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; Jicha GA, 1999, NEUROSCI LETT, V260, P153, DOI 10.1016/S0304-3940(98)00980-X; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; King ME, 2000, J NEUROCHEM, V74, P1749, DOI 10.1046/j.1471-4159.2000.0741749.x; Kirschner DA, 2000, J STRUCT BIOL, V130, P87, DOI 10.1006/jsbi.2000.4293; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Lansbury PT, 2000, CHEM BIOL, V7, pR9, DOI 10.1016/S1074-5521(00)00068-5; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Lee VMY, 1999, NEURON, V24, P507, DOI 10.1016/S0896-6273(00)81106-X; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; Nacharaju P, 1999, FEBS LETT, V447, P195, DOI 10.1016/S0014-5793(99)00294-X; Perez M, 1996, J NEUROCHEM, V67, P1183; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Rizzu P, 2000, HUM MOL GENET, V9, P3075, DOI 10.1093/hmg/9.20.3075; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Serpell LC, 1999, METHOD ENZYMOL, V309, P526; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; SUSI H, 1983, BIOCHEM BIOPH RES CO, V115, P391, DOI 10.1016/0006-291X(83)91016-1; Tremblay P, 1998, P NATL ACAD SCI USA, V95, P12580, DOI 10.1073/pnas.95.21.12580; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Wille H, 1996, J MOL BIOL, V259, P608, DOI 10.1006/jmbi.1996.0343; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; Wilson DM, 1997, AM J PATHOL, V150, P2181; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506	67	401	411	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48165	48174		10.1074/jbc.M105196200	http://dx.doi.org/10.1074/jbc.M105196200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11606569	hybrid			2022-12-25	WOS:000172927000058
J	Flaishon, L; Lantner, F; Hershkoviz, R; Levo, Y; Shachar, I				Flaishon, L; Lantner, F; Hershkoviz, R; Levo, Y; Shachar, I			Low levels of IFN-gamma down-regulate the integrin-dependent adhesion of B cells by activating a pathway that interferes with cytoskeleton rearrangement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; HEAT-STABLE ANTIGEN(HI); PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; LYMPHOCYTE RECIRCULATION; LEUKOCYTE TRAFFICKING; MIGRATION; MATURATION; PHOSPHORYLATION; ROLES	In order to fully mature and participate in the humoral immune response, immature B cells must first migrate into specific areas in the spleen where they differentiate into mature cells. However, before their maturation in the spleen, immature B cells must be excluded from non-splenic secondary lymphoid organs where any antigen encounter would lead to the death of the cells because of the negative selection process. We have recently shown that immature B cells can actively exclude themselves from antigen-enriched sites by down-regulating their integrin-mediated adhesion in a process mediated by interferon-gamma (IFN-gamma). In this study, we followed the pathway by which IFN-gamma regulates the homing of B cells. We show here that the inhibitory signal of IFN-gamma is transmitted through the IFN-gamma receptor whose engagement leads to the activation of PI3K. This PI3K activation subsequently leads to the inhibition of PKC alpha phosphorylation and cytoskeleton rearrangement required for promoting integrin-mediated adhesion and migration of B cells.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Sourasky Med Ctr, IL-64239 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, Herzel St, IL-76100 Rehovot, Israel.							ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Bowman EP, 2000, J EXP MED, V191, P1303, DOI 10.1084/jem.191.8.1303; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Coffer PJ, 1998, BIOCHEM J, V335, P1; Flaishon L, 2000, J EXP MED, V192, P1381, DOI 10.1084/jem.192.9.1381; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Harakawa N, 1997, J LEUKOCYTE BIOL, V61, P500, DOI 10.1002/jlb.61.4.500; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; HOGG N, 1995, IMMUNOL TODAY, V16, P327, DOI 10.1016/0167-5699(95)80147-2; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LORTAN JE, 1987, EUR J IMMUNOL, V17, P1311, DOI 10.1002/eji.1830170914; MACKAY CR, 1993, IMMUNOL TODAY, V14, P99, DOI 10.1016/0167-5699(93)90205-Y; MYERS MG, 1994, J BIOL CHEM, V269, P28783; PAIGE CJ, 1978, J IMMUNOL, V121, P641; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Shachar I, 1996, SCIENCE, V274, P106, DOI 10.1126/science.274.5284.106; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Wu DQ, 2000, J CELL SCI, V113, P2935	40	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46701	46706		10.1074/jbc.M103484200	http://dx.doi.org/10.1074/jbc.M103484200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585817	hybrid			2022-12-25	WOS:000172768500005
J	Kao, HY; Verdel, A; Tsai, CC; Simon, C; Juguilon, H; Khochbin, S				Kao, HY; Verdel, A; Tsai, CC; Simon, C; Juguilon, H; Khochbin, S			Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCYTE ENHANCER FACTOR-2; MEF2 TRANSCRIPTION FACTOR; MADS BOX; NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; N-COR; REPRESSION; ACTIVATION; BINDING; COMPLEX	Here we show that HDAC7, a member of the class II histone deacetylases, specifically targets several members of myocyte enhancer factors, MEF2A, -2C, and -2D, and inhibits their transcriptional activity. Furthermore, we demonstrate that DNA-bound MEF2C is capable of recruiting HDAC7, demonstrating that the HDAC7-dependent repression of transcription is not due to the inhibition of the MEF2 DNA binding activity. The data also suggest that the promoter bound MEF2 is potentially capable of remodeling adjacent nucleosomes via the recruitment of HDAC7. We have also observed a nucleocytoplasmic shuttling of HDAC7 and dissected the mechanism involved. In NIH3T3 cells, HDAC7 was primarily localized in the cytoplasm, essentially due to an active CRM1-dependent export of the protein from the nucleus. Interestingly, in HeLa cells, HDAC7 was predominantly nuclear. In these cells we could restore the cytoplasmic localization of HDAC7 by expressing CaMK I. This CaMK I-induced nuclear export of HDAC7 was abolished when three critical serines, Ser-178, Ser-344, and Ser-479, of HDAC7 were mutated. We show that these serines are involved in the direct interaction of HDAC7 with 14-3-3. Mutations of these serine residues weakened the association with 14-3-3 and dramatically enhanced the repression activity of HDAC7 in NIH3T3 cells, but not in HeLa cells. Data presented in this work clearly show that the signal dependent subcellular localization of HDAC7 is essential in controlling its activities. The data also show that the cellular concentration of factors such as 14-3-3, CaMK I, and other yet unknown molecules may determine the subcellular localization of an individual HDAC member in a cell type and HDAC-specific manner.	Case Western Reserve Univ, Dept Biochem, Sch Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Fac Med, Equipe Chromatine & Express Genes, INSERM U309, Inst Albert Bonniot, F-38706 La Tronche, France; Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Howard Hughes Medical Institute; Salk Institute	Kao, HY (corresponding author), Case Western Reserve Univ, Dept Biochem, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Verdel, André/M-5201-2013; Khochbin, Saadi/M-8090-2013	Khochbin, Saadi/0000-0002-0455-0857; VERDEL, Andre/0000-0001-6048-3794	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026444, R01GM026444] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54418] Funding Source: Medline; NICHD NIH HHS [HD 27183] Funding Source: Medline; NIGMS NIH HHS [GM 26444] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang EY, 2000, GENE DEV, V14, P45; Kao HY, 2000, GENE DEV, V14, P55; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taylor JM, 1997, MOL CELL BIOL, V17, P5550, DOI 10.1128/MCB.17.9.5550; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	64	196	202	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47496	47507		10.1074/jbc.M107631200	http://dx.doi.org/10.1074/jbc.M107631200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585834	hybrid			2022-12-25	WOS:000172768500107
J	Yamada, Y; Nagashima, M; Tsutsuura, M; Kobayashi, T; Seki, S; Makita, N; Horio, Y; Tohse, N				Yamada, Y; Nagashima, M; Tsutsuura, M; Kobayashi, T; Seki, S; Makita, N; Horio, Y; Tohse, N			Cloning of a functional splice variant of L-type calcium channel beta(2) subunit from rat heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNEL; EXPRESSION; ALPHA(1C); INACTIVATION; AORTA; CDNA	L-type Ca2+ channels are heteromultimeric and finely tuned by auxiliary subunits in different tissues and regions. Among auxiliary subunits, beta subunit has been shown to play important roles in many functional aspects of Ca2+ channel. Rat heart was reported to specifically express beta (2c) subunit. However, the slow inactivation rates of Ca2+ currents recorded from recombinant Ca (2+) channels with the beta (2a), subunit, and the reported inability to detect beta (2a), subunit in rabbit heart by reverse transcription-PCR analysis raise the possibility of the existence of other beta subunits. We cloned a splice variant of beta (2) subunit from rat heart, using rapid amplification of cDNA 5' ends. The splice variant is highly similar to human beta (2c), subunit that was cloned from human ventricle. Northern blot analysis detected the rat beta (2c), subunit abundantly in rat heart and brain. The deduced amino acid sequence of the beta (2c) subunit was different from that of the beta (2a), subunit only in the N-terminal region. When the beta (2c), subunit was expressed along with alpha (1c) and alpha (2)delta subunits in baby hamster kidney cells, the inactivation rates were comparable with those from native cardiac myocytes, although those with the beta (2a). subunit were slow. Taken together, these observations suggest that the beta (2c) subunit is a functional beta (2a), subunit expressed in heart and that the short N-terminal region plays a major role in modifying inactivation kinetics.	Sapporo Med Univ, Sch Med, Dept Cellular Physiol & Signal Transduct, Sapporo, Hokkaido 0608556, Japan; Hokkaido Univ, Sch Med, Dept Cardiovasc Med, Sapporo, Hokkaido 0600815, Japan; Sapporo Med Univ, Sch Med, Dept Pharmacol, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Hokkaido University; Sapporo Medical University	Yamada, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Cellular Physiol & Signal Transduct, Sapporo, Hokkaido 0608556, Japan.	yamaday@sapmed.ac.jp		Horio, Yoshiyuki/0000-0002-5021-5929				Allen TJA, 1998, PFLUG ARCH EUR J PHY, V436, P238, DOI 10.1007/s004240050628; Angelotti T, 1996, FEBS LETT, V397, P331, DOI 10.1016/S0014-5793(96)01205-7; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Cens T, 1999, FEBS LETT, V450, P17, DOI 10.1016/S0014-5793(99)00463-9; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; Ding S, 1999, J BIOCHEM, V125, P750, DOI 10.1093/oxfordjournals.jbchem.a022346; Haase H, 1996, J MOL MED-JMM, V74, P99; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; ISENBERG G, 1982, PFLUG ARCH EUR J PHY, V395, P6, DOI 10.1007/BF00584963; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Lacinova L, 2000, GEN PHYSIOL BIOPHYS, V19, P121; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; Randall AD, 1998, J MEMBRANE BIOL, V161, P207, DOI 10.1007/s002329900327; ROSENFELD MR, 1993, ANN NEUROL, V33, P113, DOI 10.1002/ana.410330126; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Sunagawa M, 2001, JPN J PHYSIOL, V51, P115, DOI 10.2170/jjphysiol.51.115; TOHSE N, 1990, AM J PHYSIOL, V258, pH1200, DOI 10.1152/ajpheart.1990.258.4.H1200; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Verschuuren JJ, 1998, NEUROLOGY, V50, P475, DOI 10.1212/WNL.50.2.475; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; Yamaguchi H, 2000, BIOCHEM BIOPH RES CO, V267, P156, DOI 10.1006/bbrc.1999.1926; Yamaguchi S, 2000, J BIOL CHEM, V275, P41504, DOI 10.1074/jbc.M007165200	32	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47163	47170		10.1074/jbc.M108049200	http://dx.doi.org/10.1074/jbc.M108049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11604404	hybrid			2022-12-25	WOS:000172768500067
J	Morris-Desbois, C; Rety, S; Ferro, M; Garin, J; Jalinot, P				Morris-Desbois, C; Rety, S; Ferro, M; Garin, J; Jalinot, P			The human protein HSPC021 interacts with Int-6 and is associated with eukaryotic translation initiation factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNCHBACK MESSENGER-RNA; MAMMARY-TUMOR VIRUS; RET FINGER PROTEIN; PML NUCLEAR-BODIES; FACTOR EIF3; IN-VIVO; SUBUNIT; BINDING; PUMILIO; DOMAIN	The Int-6 protein has been shown to be a subunit of eukaryotic translation initiation factor 3 (eIF3) and to play a role in the control of cell growth. By immunoprecipitation experiments and mass spectrometry analyses, we identified a human protein previously known as HSPC021 that is associated with Int-6. Exposure of Jurkat cells to the phosphatase inhibitor H2O2 triggers a marked phosphorylation on tyrosine of HSPC021. Several experiments were performed to evaluate whether this protein is associated with eIF3. It was observed that HSPC021 coelutes with Int-6 and eIF3 in gel filtration, coimmunoprecipitates with eIF3, and is incorporated into eIF3 both in rabbit reticulocyte lysates and in COS7 cells. A direct protein-protein interaction occurs between HSPC021 and Int-6, but the analysis of different mutants of HSPC021 indicated that a larger region of the protein is necessary for incorporation into eIF3 as compared with binding to Int-6. Taken together, our results establish that HSPC021 is tightly associated with the mammalian translation initiation factor eIF3. Analysis of the primary sequence of HSPC021 from different species revealed the presence of a tetratricopeptide repeat, a proteasome-COP9 (constitutive photomorphogenesis 9) signalosome-initiation factor 3 domain along with a Pumilio FBF repeat. These protein motifs are also present in subunits of eIF3, of the lid of the 26 S proteasome, and of the COP9 signalosome.	Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, UMR 5665, CNRS, F-69364 Lyon 07, France; Commissariat Energie Atom Grenoble, Lab Chim Prot, F-38054 Grenoble, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CEA	Jalinot, P (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, UMR 5665, CNRS, 46 Allee Italie, F-69364 Lyon 07, France.		Rety, Stephane/L-9870-2019; Morris, Christelle/M-8168-2014; FERRO, Myriam/O-6588-2014	Rety, Stephane/0000-0002-2089-6727; Morris, Christelle/0000-0003-1575-4609; FERRO, Myriam/0000-0002-4222-6847				Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BUBECK P, 1993, NUCLEIC ACIDS RES, V21, P3601, DOI 10.1093/nar/21.15.3601; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Cao TY, 1998, J CELL SCI, V111, P1319; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Edwards TA, 2001, CELL, V105, P281, DOI 10.1016/S0092-8674(01)00318-X; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Jin YJ, 1998, J IMMUNOL, V161, P1743; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Miyazaki S, 1999, GENE, V233, P241, DOI 10.1016/S0378-1119(99)00130-4; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Wreden C, 1997, DEVELOPMENT, V124, P3015; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370; Zamore PD, 1997, RNA, V3, P1421	39	25	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45988	45995		10.1074/jbc.M104966200	http://dx.doi.org/10.1074/jbc.M104966200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590142	hybrid			2022-12-25	WOS:000172573100068
J	Liu, LD; Komori, K; Ishino, S; Bocquier, AA; Cann, IKO; Kohda, D; Ishino, Y				Liu, LD; Komori, K; Ishino, S; Bocquier, AA; Cann, IKO; Kohda, D; Ishino, Y			The archaeal DNA primase - Biochemical characterization of the p41-p46 complex from Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILIC ARCHAEON; ESCHERICHIA-COLI; REPLICATION FORK; POLYMERASE; EXPRESSION; SEQUENCE; CLONING; GENE	We characterized the primase complex of the hyperthermophilic archaeon, Pyrococcus furiosus. The two proteins, Pfup41 and Pfup46, have similar sequences to the p48 and p58 subunits, respectively, of the eukaryotic DNA polymerase alpha -primase complex. Unlike previously reported primases, the Pfup41 preferentially utilizes deoxyribonucleotides for its de novo synthesis, and moreover, it synthesizes up to several kilobases in length in a template-dependent manner (Bocquier, A., Liu, L., Cann, I., Komori, K., Kohda, D., and Ishino, Y. (2001) Curr. Biol. 11, 452-456). The p41-p46 complex showed higher DNA binding activity than the catalytic p41 subunit alone. In addition, the amount of DNA synthesized by the p41-p46 complex was much more abundant and shorter in length than that by Pfup41 alone. The activity for RNA primer synthesis, which was not detected with Pfup41, was observed from the reaction using the p41-p46 complex in vitro. The in vitro replication of M13 single-stranded DNA by the P. furiosus proteins was stimulated by ATP. Observation of the labeled primers by using [gamma-P-32]ATP in the substrates suggests ATP as the preferable initiating nucleotide for the p41-p46 complex. These results show that the primer synthesis activity of Pfup41 is regulated by Pfup46, and the p41-p46 complex may function as the primase in the DNA replication machinery of P. furiosus, in a similar fashion to the eukaryotic polymerase alpha -primase complex.	Binomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; Binomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan		Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Osaka 5650874, Japan.		Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776; Ishino, Yoshizumi/0000-0001-9419-0826; Ishino, Sonoko/0000-0002-1833-1735				Arezi B, 1999, BIOCHEMISTRY-US, V38, P12899, DOI 10.1021/bi9908991; Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Bocquier AA, 2001, CURR BIOL, V11, P452, DOI 10.1016/S0960-9822(01)00119-1; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Copeland WC, 1997, PROTEIN EXPRES PURIF, V9, P1, DOI 10.1006/prep.1996.0665; Desogus G, 1999, NUCLEIC ACIDS RES, V27, P4444, DOI 10.1093/nar/27.22.4444; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Imamura M, 1995, BIOL PHARM BULL, V18, P1647; Ishino Y, 2001, METHOD ENZYMOL, V334, P249; Ishino Y, 1998, GENES GENET SYST, V73, P323, DOI 10.1266/ggs.73.323; Kirk BW, 1999, BIOCHEMISTRY-US, V38, P7727, DOI 10.1021/bi990247c; Komori K, 2000, PROTEIN ENG, V13, P41, DOI 10.1093/protein/13.1.41; Komori K, 2001, J BIOL CHEM, V276, P25654, DOI 10.1074/jbc.M102423200; Kornberg A., 1992, DNA REPLICATION; Leipe DD, 1999, NUCLEIC ACIDS RES, V27, P3389, DOI 10.1093/nar/27.17.3389; SHEAFF RJ, 1994, BIOCHEMISTRY-US, V33, P2247, DOI 10.1021/bi00174a035; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; UEMORI T, 1993, NUCLEIC ACIDS RES, V21, P259, DOI 10.1093/nar/21.2.259; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WANG TSF, 1996, DNA REPLICATION EUKA, P461; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054	27	61	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45484	45490		10.1074/jbc.M106391200	http://dx.doi.org/10.1074/jbc.M106391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584001	hybrid			2022-12-25	WOS:000172406700147
J	Peace, BE; Hughes, MJ; Degen, SJF; Waltz, SE				Peace, BE; Hughes, MJ; Degen, SJF; Waltz, SE			Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis	ONCOGENE			English	Article						Ron; Stk; hepatocyte growth factor-like protein; tumorigenesis; metastasis	MACROPHAGE-STIMULATING PROTEIN; RECEPTOR TYROSINE KINASE; HEPATOCYTE GROWTH-FACTOR; MET PROTOONCOGENE; C-KIT; PHOSPHATIDYLINOSITOL-3 KINASE; ACTIVATING MUTATIONS; RET PROTOONCOGENE; SOMATIC MUTATIONS; CATALYTIC DOMAIN	The receptor tyrosine kinase Ron is a member of the receptor family that includes the proto-oncogene Met and the avian oncogene Sea. The interaction of Ron with its ligand, known as hepatocyte growth factor-like protein (HGFL) or macrophage stimulating protein (MSP), induces crucial cellular responses including invasive growth, proliferation, cell scattering, and branching morphogenesis. Based on the homology and functional similarities between Met and Ron it was hypothesized that Ron may be important in tumor formation and metastasis. To test this hypothesis, wildtype mouse Ron and three mutant forms of Ron containing mutations similar to those found in the Met gene in human hereditary papillary renal carcinoma (HPRC), were expressed in NIH3T3 cells. A transformed phenotype was produced in cell lines expressing either wild-type Ron or the mutated Ron proteins. Further, these cell lines displayed oncogenic potential by exhibiting increased proliferation and constitutive phosphorylation of Ron. These cell lines were also tested for the ability to form solid tumors. Cells expressing wild-type Ron and the three proteins with single amino acid substitutions were highly tumorigenic in vivo. In a model of experimental metastasis, two of the cell lines with altered Ron protein formed highly aggressive tumors in the lungs. These results suggest that Ron may be an aggressive oncogene when either overexpressed or when activated by mutation.	Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Waltz, SE (corresponding author), Childrens Hosp Res Fdn, Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Waltz, Susan/0000-0003-3572-4642	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036888] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058182] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07752] Funding Source: Medline; NICHD NIH HHS [HD-36888] Funding Source: Medline; NIDDK NIH HHS [DK-58182, DK-47003] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Chen QY, 1997, HEPATOLOGY, V26, P59; Chen YQ, 1998, J IMMUNOL, V161, P4950; Cirafici AM, 1997, ENDOCRINOLOGY, V138, P1450, DOI 10.1210/en.138.4.1450; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LONGATI P, 1994, ONCOGENE, V9, P49; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mera A, 1999, J BIOL CHEM, V274, P15766, DOI 10.1074/jbc.274.22.15766; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Okino T, 1999, INT J ONCOL, V15, P709; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; QUANTIN B, 1995, DEV DYNAM, V204, P383, DOI 10.1002/aja.1002040405; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Waltz SE, 1997, J BIOL CHEM, V272, P30526, DOI 10.1074/jbc.272.48.30526; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	45	75	83	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6142	6151		10.1038/sj.onc.1204836	http://dx.doi.org/10.1038/sj.onc.1204836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593422				2022-12-25	WOS:000171206300005
J	Xie, SH; Wang, Y; Liu, JX; Sun, T; Wilson, MB; Smithgall, TE; Arlinghaus, RB				Xie, SH; Wang, Y; Liu, JX; Sun, T; Wilson, MB; Smithgall, TE; Arlinghaus, RB			Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation	ONCOGENE			English	Article						Jak2; Bcr-Abl; Philadelphia chromosome; chronic myelogenous leukemia	CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; MYELOID-LEUKEMIA; CELLS; KINASE; RECEPTOR; PATHWAY; HEMATOPOIESIS; ONCOPROTEIN	We have previously reported that the Jak2 tyrosine kinase but not Jak1 is tyrosine phosphorylated in the absence of IL-3 in Bcr-Abl positive M3.16 cells, which are rendered IL-3 independent by BCR-ABL gene expression. We have explored the involvement of Jak2 tyrosine phosphorylation in Ber-Abl oncogenic effects. Our results indicate that Jak2 became tyrosine-phosphorylated in a number of cell tines expressing Bcr-Abl, when maintained in medium lacking IL-3, whereas Bcr-Abl negative cells lacked Jak2 tyrosine phosphorylation. Jak2 was poorly tyrosine-phosphorylated in cells expressing the SH2 deletion mutant of Bcr-Abl compared to either wild-type Ber-Abl or its SH3 deletion mutant. Moreover, tyrosine phosphorylation of Jak2 by Bcr-Abl was inhibited by the Abl tyrosine kinase inhibitor, STI 571, in a dose-dependent manner. This inhibition of Bcr-Abl kinase by the drug did not interfere with the ability of Jak2 and Bcr-Abl to form a complex. Studies with deletion mutants of Ber-Abl indicated that the C-terminal domain of Abl within Bcr-Abl was involved in complex formation with Jak2. Similarly, GST-Abl pull-down assays confirmed the strong binding to Jak2 by the C-terminus of Abl. Jak2 peptide substrate studies indicated that the Bcr-Abl and Abl tyrosine kinases specifically phosphorylated Y1007 of Jak2 but only poorly phosphorylated Y1008. Phosphorylation of Y1007 of Jak2 is known to be critical for its tyrosine kinase activation. Tyrosine residue 1007 of Jak2 was phosphorylated in 32Dp210 cells as measured by Western blotting with a phosphotyrosine 1007 sequence-specific antibody. A kinase-inactive Jak2 mutant blocked the colony forming ability of K562 cells. Tumor formation of K562 cells in nude mice was similarly inhibited by this kinase-inactive Jak2 mutant. This inhibition was independent of Stat5 tyrosine phosphorylation. Furthermore, tyrosine-phosphorylated Jak2 was detected in blood cells from CML patients in blast crisis but not in a normal marrow sample. In summary, these findings provide strong evidence that the Jak2 tyrosine kinase is a critical factor in Bcr-Abl malignant transformation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.				NCI NIH HHS [CA 81398, CA 16672, CA 49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639, R01CA081398, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; GUO JQ, 1993, HEMATOL PATHOL, V7, P91; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Liu JX, 1996, CANCER RES, V56, P5120; LIU JX, 1993, ONCOGENE, V8, P101; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SIRARD C, 1994, BLOOD, V83, P1575; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TENHOEVE J, 1994, BLOOD, V84, P1731; Ward AC, 2000, BLOOD, V95, P19; Watanabe Sumiko, 1997, Leukemia (Basingstoke), V11, P76; WilsonRawls J, 1996, CANCER RES, V56, P3426; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828	29	110	113	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6188	6195		10.1038/sj.onc.1204834	http://dx.doi.org/10.1038/sj.onc.1204834			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593427				2022-12-25	WOS:000171206300010
J	David-Pfeuty, T; Nouvian-Dooghe, Y; Sirri, V; Roussel, P; Hernandez-Verdun, D				David-Pfeuty, T; Nouvian-Dooghe, Y; Sirri, V; Roussel, P; Hernandez-Verdun, D			Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells	ONCOGENE			English	Article						cyclin-dependent kinase 2; casein kinase II; wt p53; p21(WAFI CIPI); ribosomal RNA processing; untransformed and tumor-derived cells	CYCLIN-DEPENDENT KINASES; POLYMERASE-II TRANSCRIPTION; DNA-REPLICATION; S-PHASE; MAMMALIAN FIBROBLASTS; EPITHELIAL-CELLS; NUCLEAR-PROTEIN; PURINE ANALOGS; CDC28 MUTATION; CDK INHIBITORS	Two specific inhibitors of cyclin-dependent kinase 2 (Cdk2), roscovitine and olomoucine, have been shown recently to induce nuclear accumulation of wt p53 and nucleolar unravelling in interphase human untransformed IMR-90 and breast tumor-derived MCF-7 cells. Here, we show that the early response of MCF-7 cells to roscovitine is fully reversible since a rapid restoration of nucleolar organization followed by an induction of p21(WAF1/CIP1), a downregulation of nuclear wt p53 and normal cell cycle resumption occurs if the compound is removed after 4 h. Interestingly, similar reversible effects are also induced by the casein kinase II (CKII) inhibitor, 5,6-dichloro-1-beta -D-ribofuranosylbenzimidazole. Upon short-term treatment also, both compounds significantly, but reversibly, reduce the level of 45S precursor ribosomal RNA. Cells exposed to the two types of protein kinase inhibitors for longer times keep exhibiting altered nucleolar and wt p53 features, yet they strikingly differentiate in that most roscovitine-treated bells fail to ever accumulate high levels of p21(WAF1/CIP1) in contrast with DRB-treated ones. In both cases, however, the cells eventually fall into an irreversible state and die. Moreover, we found that constitutive overexpression of p21(WAF1/CIP1) alters the nucleolar unravelling process in the presence of DRB, but not of roscovitine, suggesting a role for this physiological Cdk inhibitor in the regulation of nucleolar function. Our data also support the notion that both roscovitine- and DRB-sensitive protein kinases, probably including Cdk2 and CKII, via their dual implication in the p53-Rb pathway and in ribosomal biogenesis, would participate in coupling cell growth with cell division.	Ctr Univ Orsay, CNRS, UMR 146, Inst Curie Rech, F-91405 Orsay, France; Inst Jacques Monod, UMR 7592, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	David-Pfeuty, T (corresponding author), Ctr Univ Orsay, CNRS, UMR 146, Inst Curie Rech, Batiment 110, F-91405 Orsay, France.	Therese.Pfeuty@curie.u-psud.fr						Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DavidPfeuty T, 1996, ONCOGENE, V13, P1447; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRANICK D, 1975, J CELL BIOL, V65, P418, DOI 10.1083/jcb.65.2.418; GRANICK D, 1975, J CELL BIOL, V65, P398, DOI 10.1083/jcb.65.2.398; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Le Panse S, 1999, J CELL SCI, V112, P2145; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1994, ONCOGENE, V9, P2261; Linke SP, 1997, CANCER RES, V57, P1171; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Maniatis T., 1982, MOL CLONING LAB MANU; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISHI K, 1994, J BIOL CHEM, V269, P6320; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Prives C, 1999, J PATHOL, V187, P112; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROUSSEL P, 1993, J CELL SCI, V104, P327; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; WILSON GN, 1982, AM J HUM GENET, V34, P32; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	81	50	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					5951	5963		10.1038/sj.onc.1204741	http://dx.doi.org/10.1038/sj.onc.1204741			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593402				2022-12-25	WOS:000171056300002
J	Martins, LM; Iaccarino, I; Tenev, T; Gschmeissner, S; Totty, NF; Lemoine, NR; Savopoulos, J; Gray, CW; Creasy, CL; Dingwall, C; Downward, J				Martins, LM; Iaccarino, I; Tenev, T; Gschmeissner, S; Totty, NF; Lemoine, NR; Savopoulos, J; Gray, CW; Creasy, CL; Dingwall, C; Downward, J			The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; SMAC/DIABLO; ACTIVATION; LOCALIZATION; PURIFICATION; INHIBITION; HTRA2; CELLS	The inhibitor-of-apoptosis proteins (IAPs) play a critical role in the regulation of apoptosis by binding and inhibiting caspases. Reaper family proteins and Smac/DIABLO use a conserved amino-terminal sequence to bind to IA,Ps in flies and mammals, respectively, blocking their ability to inhibit caspases and thus promoting apoptosis. Here we have identified the serine protease Omi/HtrA2 as a second mammalian XIAP-binding protein with a Reaper-like motif. This protease autoprocesses to form a protein with amino-terminal homology to Smac/DIABLO and Reaper family proteins. Full-length Omi/HtrA2 is localized to mitochondria but fails to interact with XIAP. Mitochondria also contain processed Omi/HtrA2, which, following apoptotic insult, translocates to the cytosol, where it interacts with XIAP. Overexpression of Omi/HtrA2 sensitizes cells to apoptosis, and its removal by RNA interference reduces cell death. Omi/HtrA2 thus extends the set of mammalian proteins with Reaper-like function that are released from the mitochondria during apoptosis.	Imperial Canc Res Fund, London WC2A 3PX, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Imperial Canc Res Fund,Mol Oncol Unit, London W12 0HS, England; Glaxo Smith Kline Pharmaceut, Harlow CM19 5AW, Essex, England; Glaxo Smith Kline Pharmaceut, King Of Prussia, PA 19406 USA	Cancer Research UK; Cancer Research UK; Imperial College London; GlaxoSmithKline; GlaxoSmithKline	Downward, J (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012; Iaccarino, Ingram/B-9086-2015	Iaccarino, Ingram/0000-0001-7324-993X; Tenev, Tencho/0000-0001-8762-1069; Downward, Julian/0000-0002-2331-4729				Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Rabouille C, 1999, METH MOL B, V117, P125; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Savopoulos JW, 2000, PROTEIN EXPRES PURIF, V19, P227, DOI 10.1006/prep.2000.1240; Silke J, 2001, J CELL SCI, V114, P1821; Silke J, 2000, CELL DEATH DIFFER, V7, P1275, DOI 10.1038/sj.cdd.4400790; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012	25	430	453	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					439	444		10.1074/jbc.M109784200	http://dx.doi.org/10.1074/jbc.M109784200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11602612	hybrid			2022-12-25	WOS:000173087900059
J	Fiaschi, T; Chiarugi, P; Buricchi, F; Giannoni, E; Taddei, ML; Talini, D; Cozzi, G; Zecchi-Orlandini, S; Raugei, G; Ramponi, G				Fiaschi, T; Chiarugi, P; Buricchi, F; Giannoni, E; Taddei, ML; Talini, D; Cozzi, G; Zecchi-Orlandini, S; Raugei, G; Ramponi, G			Low molecular weight protein-tyrosine phosphatase is involved in growth inhibition during cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; EXPRESSION; PHOSPHORYLATION; SRC; IDENTIFICATION; GENE	Low molecular weight protein-tyrosine phosphatase (LMW-PTP) is an enzyme involved in mitogenic signaling and cytoskeletal rearrangement after platelet-derived growth factor (PDGF) stimulation. Recently, we demonstrated that LMW-PTP is regulated by a redox mechanism involving the two cysteine residues of the catalytic site, which turn reversibly from reduced to oxidized state after PDGF stimulation. Since recent findings showed a decrease of intracellular reactive oxygen species in contact inhibited cells and a lower tyrosine phosphorylation level in dense cultures in comparison to sparse ones, we studied if the level of endogenous LMW-PTP is regulated by growth inhibition conditions, such as cell confluence and differentiation. Results show that both cell confluence and cell differentiation up-regulate LMW-PTP expression in C2C12 and PC12 cells. We demonstrate that during myogenesis LMW-PTP is regulated at translational level and that the protein accumulates at the plasma membrane. Furthermore, we showed that both myogenesis and cell-cell contact lead to a dramatical decrease of tyrosine phosphorylation level of PDGF receptor. In addition, we observed an increased association of the receptor with LMW-PTP during myogenesis. Herein, we demonstrate that myogenesis decreases the intracellular level of reactive oxygen species, as observed in dense cultures. As a consequence, LMW-PTP turns from oxidized to reduced form during muscle differentiation, increasing its activity in growth inhibition conditions such as differentiation. These data suggest that LMW-PTP plays a crucial role in physiological processes, which require cell growth arrest such as confluence and differentiation.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Florence, Dipartimento Anat Istol & Med Legale, I-50134 Florence, Italy	University of Florence; University of Florence	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@scibio.unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022	Chiarugi, Paola/0000-0001-7655-2969; Giannoni, Elisa/0000-0001-7136-1098; raugei, giovanni/0000-0003-1294-786X				Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; CHIARUGI P, 2001, 27 M FED EUR BIOCH S; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kong WH, 2000, AM J PHYSIOL-GASTR L, V279, pG613, DOI 10.1152/ajpgi.2000.279.3.G613; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kume T, 1996, J BIOL CHEM, V271, P30916, DOI 10.1074/jbc.271.48.30916; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; MABLONKAREUVENI Z, 1990, J CELL BIOL, V111, P1623; Magherini F, 1998, FEBS LETT, V437, P263, DOI 10.1016/S0014-5793(98)01241-1; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sorby M, 1996, J BIOL CHEM, V271, P10963; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; YablonkaReuveni Z, 1997, GROWTH FACTORS, V15, P1, DOI 10.3109/08977199709002109; YEE AS, 1998, FRONT BIOSCI, V3, P532	33	37	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49156	49163		10.1074/jbc.M107538200	http://dx.doi.org/10.1074/jbc.M107538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11595742	hybrid			2022-12-25	WOS:000173922100071
J	Derrien, A; Druey, KM				Derrien, A; Druey, KM			RGS16 function is regulated by epidermal growth factor receptor-mediated tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SIGNALING RGS; GTPASE-ACTIVATING PROTEINS; MAP KINASE; EXPRESSION; DOMAIN; G(I); SRC; PALMITOYLATION; FEATURES; CYSTEINE	G alpha (i)-coupled receptor stimulation results in epidermal growth factor receptor (EGFR) phosphorylation and MAPK activation. Regulators of G protein signaling (RGS proteins) inhibit G protein-dependent signal transduction by accelerating Ga. GTP hydrolysis, shortening the duration of G protein effector stimulation. RGS16 contains two conserved tyrosine residues in the RGS box, Tyr(168) and Tyr(177), which are predicted sites of phosphorylation. RGS16 underwent phosphorylation in response to m2 muscarinic receptor or EGFR stimulation in HEK 293T or COS-7 cells, which required EGFR kinase activity. Mutational analysis suggested that RGS16 was phosphorylated on both tyrosine residues (Tyr(168) much greater than Tyr(177)) after EGF stimulation. RGS16 co-immunoprecipitated with EGFR, and the interaction did not require EGFR activation. Purified EGFR phosphorylated only recombinant RGS16 wild-type or Y177F in vitro, implying that EGFR-mediated phosphorylation depended on residue Tyr(168). Phosphorylated RGS16 demonstrated enhanced GTPase accelerating (GAP) activity on G alpha (i). Mutation of Tyr(168) to phenylalanine resulted in a 30% diminution in RGS16 GAP activity but completely eliminated its ability to regulate Gi-mediated MAPK activation or adenylyl cyclase inhibition in HEK 293T cells. In contrast, mutation of Tyr(177) to phenylalanine had no effect on RGS16 GAP activity but also abolished its regulation of Gi-mediated signal transduction in these cells. These data suggest that tyrosine phosphorylation regulates RGS16 function and that EGFR may potentially inhibit G alpha (i)-dependent MAPK activation in a feedback loop by enhancing RGS16 activity through tyrosine phosphorylation.	NIH, Mol Signal Transduct Sect, Lab Allerg Dis, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA	Druey, KM (corresponding author), NIH, Mol Signal Transduct Sect, Lab Allerg Dis, 12441 Parklawn Dr, Rockville, MD 20852 USA.	kdruey@nih.gov						Beadling C, 1999, J IMMUNOL, V162, P2677; Benzing T, 2000, J BIOL CHEM, V275, P28167; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Gold SJ, 1997, J NEUROSCI, V17, P8024; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Ingi T, 1998, J NEUROSCI, V18, P7178; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P7063, DOI 10.1021/bi992760w; Nishizuka M, 2001, J BIOL CHEM, V276, P29625, DOI 10.1074/jbc.C100272200; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x	35	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48532	48538		10.1074/jbc.M108862200	http://dx.doi.org/10.1074/jbc.M108862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602604	hybrid			2022-12-25	WOS:000172927000107
J	Le, S; Connors, TJ; Maroney, AC				Le, S; Connors, TJ; Maroney, AC			c-Jun N-terminal kinase specifically phosphorylates p66(ShcA) at serine 36 in response to ultraviolet irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDUCED APOPTOSIS; CELL-DEATH; TYROSINE PHOSPHORYLATION; SYMPATHETIC NEURONS; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; GENE-EXPRESSION; CEP-1347 KT7515; SHC	Alice lacking expression of the p66 isoform of the ShcA adaptor protein (p66(ShcA)) are less susceptible to oxidative stress and have an extended life span. Specifically, phosphorylation of p66(ShcA) at serine 36 is critical for the cell death response elicited by oxidative damage. We sought to identify the kinase(s) responsible for this phosphorylation. Utilizing the SH-SY5Y human neuroblastoma cell model, it is demonstrated that p66(ShcA) is phosphorylated on serine/threonine residues in response to UV irradiation. Both c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinases are activated by UV irradiation, and we show that both are capable of phosphorylating serine 36 of p66(ShcA) in vitro. However, treatment of cells with a multiple lineage kinase inhibitor, CEP-1347, that blocks UV-induced JNK activation, but not p38, phosphatidylinositol 3-kinase, or MEK1 inhibitors, prevented p66(ShcA) phosphorylation in SH-SY5Y cells. Consistent with this finding, transfected activated JNK1, but not the kinase-dead JNK1, leads to phosphorylation of serine 36 of p66(ShcA) in Chinese hamster ovary cells. In conclusion, JNKs are the kinases that phosphorylate serine 36 of p66(ShcA) in response to UV irradiation in SH-SY5Y cells, and blocking p66(ShcA) phosphorylation by intervening in the JNK pathway may prevent cellular damage due to light-induced oxidative stress.	Cephalon Inc, W Chester, PA 19380 USA	Teva Pharmaceutical Industries; Cephalon Inc.	Maroney, AC (corresponding author), Cephalon Inc, 145 Brandywine Pkwy, W Chester, PA 19380 USA.	amaroney@cephalon.com						Albers DS, 2000, J NEURAL TRANSM-SUPP, P133; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Eilers A, 1998, J NEUROSCI, V18, P1713; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Garay M, 2000, BIOCHEM PHARMACOL, V59, P1033, DOI 10.1016/S0006-2952(99)00412-8; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harlow E., 1988, ANTIBODIES LAB MANUA; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hreniuk D, 2001, MOL PHARMACOL, V59, P867, DOI 10.1124/mol.59.4.867; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Kaneko M, 1997, J MED CHEM, V40, P1863, DOI 10.1021/jm970031d; Kang CD, 1998, NEUROSCI LETT, V256, P37, DOI 10.1016/S0304-3940(98)00751-4; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; MIEKLE K, 2000, PROG NEUROBIOL, V61, P45; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Robberecht W, 2000, J NEUROL, V247, P1; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; Salh Baljinder S., 2000, Molecular Cell Biology Research Communications, V4, P158, DOI 10.1006/mcbr.2001.0271; SCHLINGENSIEPEN KH, 1994, CELL MOL NEUROBIOL, V14, P487, DOI 10.1007/BF02088833; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MA, 1997, J NEUROSCI, V17, P2563; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Yang CPH, 2000, CANCER RES, V60, P5171; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zheng CF, 1997, GENE, V186, P55, DOI 10.1016/S0378-1119(96)00680-4	46	84	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48332	48336		10.1074/jbc.M106612200	http://dx.doi.org/10.1074/jbc.M106612200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11602589	hybrid			2022-12-25	WOS:000172927000080
J	Zeller, KI; Haggerty, TJ; Barrett, JF; Guo, QB; Wonsey, DR; Dang, CV				Zeller, KI; Haggerty, TJ; Barrett, JF; Guo, QB; Wonsey, DR; Dang, CV			Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; IN-VIVO; GENE SPECIFICITY; RESPONSIVE GENES; CELL-CYCLE; PROTEIN; GROWTH; IDENTIFICATION; BINDING; PROLIFERATION	The genetic program through which a specific transcription factor regulates a biological response is fundamental to our understanding how instructions in the genome are implemented. The emergence of DNA microarray technology for gene expression analysis has generated vast numbers of target genes resulting from specific transcription factor activity. We use the oncogenic transcription factor c-Myc as proof-of-principle that human genome sequence analysis and scanning of a specific gene by chromatin immunoprecipitation can be coupled to identify target transcription factor binding sequences. We focused on nucleophosmin, also known as B23, which was identified as a candidate Myc-responsive gene from a subtractive hybridization screen, and we found that sequences in intron 1, and not 5' sequences in the proximal promoter, are bound by c-Myc in vivo. Hence, a scanning chromatin immunoprecipitation (SChIP) strategy is useful in analyzing functional transcription factor-binding sites.	Program Human Genet & Mol Biol, Baltimore, MD 21205 USA; Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Dang, CV (corresponding author), Ross Res Bldg,Rm 1025,720 Rutland Ave, Baltimore, MD 21205 USA.		Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NATIONAL CANCER INSTITUTE [R01CA057341] Funding Source: NIH RePORTER; NCI NIH HHS [CA57341] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; GNOMON PE, 2001, P NATL ACAD SCI USA, V98, P6378; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Guo QM, 2000, CANCER RES, V60, P5922; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu HT, 1999, CANCER LETT, V144, P45, DOI 10.1016/S0304-3835(99)00184-6; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198	26	100	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48285	48291		10.1074/jbc.M108506200	http://dx.doi.org/10.1074/jbc.M108506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604407	hybrid			2022-12-25	WOS:000172927000074
J	Desnoyers, L; Arnott, D; Pennica, D				Desnoyers, L; Arnott, D; Pennica, D			WISP-1 binds to decorin and biglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; CHONDROITIN SULFATE PROTEOGLYCAN; IMMEDIATE-EARLY GENE; EXTRACELLULAR-MATRIX; MASS-SPECTROMETRY; TRANSGENIC MICE; CELL-SURFACE; FACTOR-BETA; EXPRESSION; PROTEINS	Wnt-1-induced secreted protein 1 (WISP-1) is a member of the CCN (connective tissue growth factor, Cyr61, NOV) family of growth factors. Structural and experimental evidence suggests that CCN family member activities are modulated by their interaction with sulfated glycoconjugates. To elucidate the mechanism of action for WISP-1, we characterized the specificity of its tissue and cellular interaction and identified binding factors. WISP-1 binding was restricted to the stroma of colon tumors and to cells with a fibroblastic phenotype. By using a solid phase assay, we showed that human skin fibroblast conditioned media contained WISP-1 binding factors. Competitive inhibition with different glycosaminoglycans and treatment with glycosaminoglycan lyases and proteases demonstrated that binding to the conditioned media was mediated by dermatan sulfate proteoglycans. Mass spectrometric analysis identified the isolated binding factors as decorin and biglycan. Decorin and biglycan interacted directly with WISP-1 and inhibited its binding to components in the conditioned media. Similarly, WISP-I interaction with human skin fibroblasts was inhibited by dermatan sulfate, decorin, and biglycan or by treatment of the cell surface with dermatan sulfate-specific lyases. Together these results demonstrate that decorin and biglycan are WISP-1 binding factors that can mediate and modulate its interaction with the surface of fibroblasts. We propose that this specific interaction plays a role in the regulation of WISP-1 function.	Genentech Inc, Dept Mol Oncol MS 50, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Desnoyers, L (corresponding author), Genentech Inc, Dept Mol Oncol MS 50, 1 DNA Way, San Francisco, CA 94080 USA.	desnoyer@gene.com						ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, J BIOL CHEM, V265, P11389; Arnott D, 1998, ELECTROPHORESIS, V19, P968, DOI 10.1002/elps.1150190612; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brown LF, 1999, CLIN CANCER RES, V5, P1041; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Chevalier G, 1998, AM J PATHOL, V152, P1563; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gatlin CL, 2000, ANAL CHEM, V72, P757, DOI 10.1021/ac991025n; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hocking AM, 1998, MATRIX BIOL, V17, P1; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HUNZELMANN N, 1995, J INVEST DERMATOL, V104, P509, DOI 10.1111/1523-1747.ep12605979; Iozzo R. V., 2000, PROTEOGLYCANS STRUCT, P1; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCOTT JE, 1993, DERMATAN SULFATE PRO, P81; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Steffen CL, 1998, GROWTH FACTORS, V15, P199, DOI 10.3109/08977199809002117; Szurdoki F, 2001, ANAL BIOCHEM, V291, P219, DOI 10.1006/abio.2001.5041; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; Xu LF, 2000, GENE DEV, V14, P585; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	51	94	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47599	47607		10.1074/jbc.M108339200	http://dx.doi.org/10.1074/jbc.M108339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598131	hybrid			2022-12-25	WOS:000172768500120
J	Gaughan, L; Brady, ME; Cook, S; Neal, DE; Robson, CN				Gaughan, L; Brady, ME; Cook, S; Neal, DE; Robson, CN			Tip60 is a co-activator specific for class I nuclear hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLASE COMPLEX; LIGAND-BINDING DOMAIN; ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; COACTIVATOR; ACETYLTRANSFERASE; PROTEIN; TRANSCRIPTION; CBP	The nuclear hormone receptor superfamily is composed of a group of hormone-dependent transcription factors that play prominent roles in homeostatic events in vertebrates. A prerequisite for steroid hormone receptor activity is the binding of co-activator molecules to the activation function-2 domain of the receptor. The LXXLL motif/nuclear receptor box, contained within a number of co-activator molecules, mediates the interaction with nuclear hormone receptors. Tip60 (Tat-interactive protein 60 kDa), previously shown to bind to and enhance androgen receptor (AR)-mediated transactivation, contains a single nuclear receptor box at its extreme C terminus. We demonstrate that unlike members of the p160 co-activator family that interact predominantly with the N terminus of the AR in an LXXLL motif-independent manner, the LXXLL motif of Tip60 is required and is sufficient for AR interaction. Furthermore, by using the mammalian two-hybrid system and transient transfection experiments, we show that Tip60 preferentially interacts with and up-regulates class I nuclear receptors, suggesting that Tip60 is a steroid hormone receptor-specific co-activator. We conclude that Tip60 may specifically regulate a subset of nuclear hormone receptors, giving an indication to how regulated nuclear receptor activation can be achieved.	Univ Newcastle Upon Tyne, Sch Med, Prostate Res Grp, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robson, CN (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Prostate Res Grp, Sch Surg Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086				Alen P, 1999, MOL CELL BIOL, V19, P6085; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gnanapragasam VJ, 2000, BJU INT, V86, P1001, DOI 10.1046/j.1464-410x.2000.00943.x; HARD T, 1993, ACCOUNTS CHEM RES, V26, P644; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Li DS, 1999, MOL CELL BIOL, V19, P7191; Ma H, 1999, MOL CELL BIOL, V19, P6164; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thompson J, 2001, MOL ENDOCRINOL, V15, P923, DOI 10.1210/me.15.6.923; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	44	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46841	46848		10.1074/jbc.M103710200	http://dx.doi.org/10.1074/jbc.M103710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591700	hybrid			2022-12-25	WOS:000172768500024
J	Grellier, P; Vendeville, S; Joyeau, R; Bastos, IMD; Drobecq, H; Frappier, F; Teixeira, ARL; Schrevel, J; Davioud-Charvet, E; Sergheraert, C; Santana, JM				Grellier, P; Vendeville, S; Joyeau, R; Bastos, IMD; Drobecq, H; Frappier, F; Teixeira, ARL; Schrevel, J; Davioud-Charvet, E; Sergheraert, C; Santana, JM			Trypanosoma cruzi prolyl oligopeptidase Tc80 is involved in nonphagocytic mammalian cell invasion by trypomastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN; CYSTEINE PROTEASE; ENDOPEPTIDASE; INHIBITORS; PROTEINASE; CLONING; IDENTIFICATION; PURIFICATION; EXPRESSION; ENZYME	Trypanosoma cruzi is an intracellular protozoan parasite able to invade a wide variety of mammalian cells. To have access to the target organs/cells, the parasite must cross the basal laminae and the extracellular matrix (ECM). We previously characterized an 80-kDa proteinase (Tc80) secreted by the infective trypomastigotes that hydrolyzes native collagens and might be involved in infection by degrading ECM components. Here, we present evidence indicating a role for Tc80 in the invasion of nonphagocytic cells. Tc80 was classified as a member of the prolyl oligopeptidase (POP) family of serine proteases and was also found to hydrolyze fibronectin. Selective inhibitors for POP Tc80 were synthesized that blocked parasite entry into cells. Blockage occurred when trypomastigotes were preincubated with irreversible inhibitors but not after host cell preincubation, and the blockage correlated with inhibition of POP Tc80 activity in treated parasites. These data and the enzyme location inside a vesicular compartment close to the flagellar pocket, a specialized domain in endocytosis/exocytosis, strongly suggest a role for POP Tc80 in the maturation of parasite protein(s) and/or, after secretion, in a local action on parasite or host cell/ECM components required for invasion.	Museum Natl Hist Nat, FR CNRS 63, Lab Biol Parasitaire, F-75231 Paris 05, France; Univ Lille 2, UMR CNRS 8525, Inst Biol Lille,Fac Pharm, Inst Pasteur, F-59024 Lille, France; Museum Natl Hist Nat, ESA CNRS 8041, Chim Lab, F-75231 Paris 05, France; Univ Brasilia, Dept Biol Celular & Patol, Lab Multidisciplinar Pesquisa Doenca Chagas, BR-70919970 Brasilia, DF, Brazil	Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Museum National d'Histoire Naturelle (MNHN); Universidade de Brasilia	Grellier, P (corresponding author), Museum Natl Hist Nat, FR CNRS 63, Lab Biol Parasitaire, 61 Rue Buffon, F-75231 Paris 05, France.	grellier@mnhn.fr	Santana, Jaime/H-5319-2013; Davioud-Charvet, Elisabeth/I-3805-2013; Schrevel, Joseph/AAG-7085-2020	Davioud-Charvet, Elisabeth/0000-0001-7026-4034; Bastos, Izabela/0000-0002-2785-4255; Drobecq, Herve/0000-0002-4081-1575				AVILA JL, 1979, EXP PARASITOL, V48, P27, DOI 10.1016/0014-4894(79)90051-1; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1; BONALDO MC, 1991, EXP PARASITOL, V73, P44, DOI 10.1016/0014-4894(91)90006-I; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; Buckner FS, 1996, ANTIMICROB AGENTS CH, V40, P2592, DOI 10.1128/AAC.40.11.2592; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Burleigh BA, 1997, J CELL BIOL, V136, P609, DOI 10.1083/jcb.136.3.609; BURLEIGH BA, 1995, J BIOL CHEM, V270, P5172, DOI 10.1074/jbc.270.10.5172; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; Caler EV, 2000, INFECT IMMUN, V68, P6602, DOI 10.1128/IAI.68.12.6602-6610.2000; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI; Demuth H U, 1990, J Enzyme Inhib, V3, P249, DOI 10.3109/14756369009030375; EDWARDS PD, 1992, J AM CHEM SOC, V114, P1854, DOI 10.1021/ja00031a046; Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725; Favoreto S, 1998, EXP PARASITOL, V89, P188, DOI 10.1006/expr.1998.4285; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Garcia MP, 1998, MOL BIOCHEM PARASIT, V91, P263, DOI 10.1016/S0166-6851(97)00205-3; Giordano R, 1999, J BIOL CHEM, V274, P3461, DOI 10.1074/jbc.274.6.3461; HARTH G, 1993, MOL BIOCHEM PARASIT, V58, P17, DOI 10.1016/0166-6851(93)90086-D; Higgins D G, 1994, Methods Mol Biol, V25, P307; Joyeau R, 2000, EUR J MED CHEM, V35, P257, DOI 10.1016/S0223-5234(00)00118-5; KANATANI A, 1993, J BIOCHEM, V113, P790, DOI 10.1093/oxfordjournals.jbchem.a124120; KOIDA M, 1976, J BIOL CHEM, V251, P7593; Li JR, 1996, J NEUROCHEM, V66, P2105; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; MORIYAMA A, 1988, J BIOCHEM, V104, P112, DOI 10.1093/oxfordjournals.jbchem.a122404; Morty RE, 1999, J BIOL CHEM, V274, P26149, DOI 10.1074/jbc.274.37.26149; Nobrega OT, 1998, MOL BIOCHEM PARASIT, V97, P235, DOI 10.1016/S0166-6851(98)00125-X; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; OUAISSI MA, 1986, SCIENCE, V234, P603, DOI 10.1126/science.3094145; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SANTANA JM, 1992, BIOCHEM BIOPH RES CO, V187, P1466, DOI 10.1016/0006-291X(92)90467-Y; Santana JM, 1997, BIOCHEM J, V325, P129, DOI 10.1042/bj3250129; Serveau C, 1996, BIOCHEM J, V313, P951, DOI 10.1042/bj3130951; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; VELGE P, 1988, PARASITOLOGY, V97, P255, DOI 10.1017/S0031182000058467; Vendeville S, 1999, CHEM PHARM BULL, V47, P194, DOI 10.1248/cpb.47.194; Vendeville S, 1999, BIOORG MED CHEM LETT, V9, P437, DOI 10.1016/S0960-894X(99)00003-7; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; Villalta F, 1998, BIOCHEM BIOPH RES CO, V249, P247, DOI 10.1006/bbrc.1998.9127; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; Yong V, 2000, MOL BIOCHEM PARASIT, V109, P47, DOI 10.1016/S0166-6851(00)00237-1; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730; YOSHIMOTO T, 1987, BIOCHIM BIOPHYS ACTA, V916, P29, DOI 10.1016/0167-4838(87)90207-X	52	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47078	47086		10.1074/jbc.M106017200	http://dx.doi.org/10.1074/jbc.M106017200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598112	hybrid			2022-12-25	WOS:000172768500055
J	Gruz, P; Pisani, FM; Shimizu, M; Yamada, M; Hayashi, I; Morikawa, K; Nohmi, T				Gruz, P; Pisani, FM; Shimizu, M; Yamada, M; Hayashi, I; Morikawa, K; Nohmi, T			Synthetic activity of Sso DNA polymerase Y1, an archaeal DinB-like DNA polymerase, is stimulated by processivity factors proliferating cell nuclear antigen and replication factor C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SULFOLOBUS-SOLFATARICUS; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; DOMAIN ORGANIZATION; GENE ENCODES; MUTAGENESIS; FAMILY; COMPLEX; BYPASS	DNA replication efficiency is dictated by DNA polymerases (pol) and their associated proteins. The recent discovery of DNA polymerase Y family (DinB/UmuC/RAD30/REV1 superfamily) raises a question of whether the DNA polymerase activities are modified by accessory proteins such as proliferating cell nuclear antigen (PCNA). In fact, the activity of DNA pol IV (DinB) of Escherichia coli is enhanced upon interaction with the beta subunit, the processivity factor of DNA pol III. Here, we report the activity of Sso DNA pol Y1 encoded by the dbh gene of the archaeon Sulfolobus solfataricus is greatly enhanced by the presence of PCNA and replication factor C (RFC). Sso pol Y1 per se was a distributive enzyme but a substantial increase in the processivity was observed on poly(dA)-oligo(dT) in the presence of PCNA (039p or 048p) and RFC. The length of the synthesized DNA product reached at least 200 nucleotides. Sso pol Y1 displayed a higher affinity for DNA compared with pol IV of E. coli, suggesting that the two DNA polymerases have distinct reason(s) to require the processivity factors for efficient DNA synthesis. The abilities of pol Y1 and pol IV to bypass DNA lesions and their sensitive sites to protease are also discussed.	Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, Tokyo 1588501, Japan; CNR, Ist Biochim Prot & Enzimol, I-80125 Naples, Italy; Biomol Engn Res Inst, Dept Struct Biol, Osaka 5650874, Japan	National Institute of Health Sciences - Japan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Nohmi, T (corresponding author), Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.		Pisani, Francesca M./AAX-4025-2020	Yamada, Masami/0000-0002-8758-3979				Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bridges B, 2000, BIOESSAYS, V22, P933; Bruck I, 1996, J BIOL CHEM, V271, P10767, DOI 10.1074/jbc.271.18.10767; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; De Felice M, 1999, J MOL BIOL, V291, P47, DOI 10.1006/jmbi.1999.2939; Edgell DR, 1997, J BACTERIOL, V179, P2632, DOI 10.1128/jb.179.8.2632-2640.1997; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Garcia PL, 2000, BACTERIAL STRESS RESPONSES, P369; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kim SR, 2001, MOL GENET GENOMICS, V266, P207; KORNBERG A, 1992, DNA REPLICATION, P169; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; Lasken RS, 1996, J BIOL CHEM, V271, P17692, DOI 10.1074/jbc.271.30.17692; Leipe DD, 1999, NUCLEIC ACIDS RES, V27, P3389, DOI 10.1093/nar/27.17.3389; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; PETIT MA, 1994, J BIOL CHEM, V269, P23824; Pisani FM, 1998, BIOCHEMISTRY-US, V37, P15005, DOI 10.1021/bi981127s; PISANI FM, 1992, NUCLEIC ACIDS RES, V20, P2711, DOI 10.1093/nar/20.11.2711; Pisani FM, 1998, EXTREMOPHILES, V2, P171, DOI 10.1007/s007920050057; Pisani FM, 1996, BIOCHEMISTRY-US, V35, P9158, DOI 10.1021/bi960446l; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; Sarov-Blat L, 1998, J BIOL CHEM, V273, P5520, DOI 10.1074/jbc.273.10.5520; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tissier A, 2000, GENE DEV, V14, P1642; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wagner J, 2000, J BACTERIOL, V182, P4587, DOI 10.1128/JB.182.16.4587-4595.2000; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wagner J, 2000, EMBO REP, V1, P484; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	51	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47394	47401		10.1074/jbc.M107213200	http://dx.doi.org/10.1074/jbc.M107213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581267	hybrid			2022-12-25	WOS:000172768500095
J	Smisterova, J; Wagenaar, A; Stuart, MCA; Polushkin, E; ten Brinke, G; Hulst, R; Engberts, JBFN; Hoekstra, D				Smisterova, J; Wagenaar, A; Stuart, MCA; Polushkin, E; ten Brinke, G; Hulst, R; Engberts, JBFN; Hoekstra, D			Molecular shape of the cationic lipid controls the structure of cationic lipid/dioleylphosphatidylethanolamine-DNA complexes and the efficiency of gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOSOME COMPLEXES; TRANSFECTION ACTIVITY; ELECTRON-MICROSCOPY; PLASMID DNA; MECHANISM; RELEASE; CELLS; AMPHIPHILES; PARTICLES; MEMBRANES	Pyridinium amphiphiles, abbreviated as SAINT, are highly efficient vectors for delivery of DNA into cells. Within a group of structurally related compounds that differ in transfection capacity, we have investigated the role of the shape and structure of the pyridinium molecule on the stability of bilayers formed from a given SAINT and dioleoylphosphatidylethanolamine (DOPE) and on the polymorphism of SAINT/DOPE-DNA complexes. Using electron microscopy and small angle x-ray scattering, a relationship was established between the structure, stability, and morphology of the lipoplexes and their transfection efficiency. The structure with the lowest ratio of the cross-sectional area occupied by polar over hydrophobic domains (SAINT-2) formed the most unstable bilayers when mixed with DOPE and tended to convert into the hexagonal structure. In SAINT-2-containing lipoplexes, a hexagonal topology was apparent, provided that DOPE was present and complex assembly occurred in 150 mM NaCl. If not, a lamellar phase was obtained, as for lipoplexes prepared from geometrically more balanced SAINT structures. The hexagonal topology strongly promotes transfection efficiency, whereas a strongly reduced activity is seen for complexes displaying the lamellar topology. We conclude that in the DOPE-containing complexes the molecular shape and the nonbilayer preferences of the cationic lipid control the topology of the lipoplex and thereby the transfection efficiency.	Univ Groningen, Fac Med Sci, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands; Biomade Technol Fdn, NL-9747 AG Groningen, Netherlands; Univ Groningen, Stratingh Inst, Phys Irgan Chem Unit, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biophys Chem, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Polymer Chem, NL-9747 AG Groningen, Netherlands; Dutch Polymer Inst, Polymer Chem Lab, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; Dutch Polymer Institute	Hoekstra, D (corresponding author), Univ Groningen, Fac Med Sci, Dept Membrane Cell Biol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	d.hoekstra@med.rug.nl	Stuart, Marc/B-6274-2008	Stuart, Marc/0000-0003-0667-6338				Balasubramaniam RP, 1996, GENE THER, V3, P163; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; Bennett MJ, 1997, J MED CHEM, V40, P4069, DOI 10.1021/jm970155q; Bhattacharya S, 1998, BIOCHEMISTRY-US, V37, P7764, DOI 10.1021/bi971772j; Blessing T, 1998, P NATL ACAD SCI USA, V95, P1427, DOI 10.1073/pnas.95.4.1427; Boukhnikachvili T, 1997, FEBS LETT, V409, P188, DOI 10.1016/S0014-5793(97)00505-X; Byk G, 1998, J MED CHEM, V41, P224, DOI 10.1021/jm9704964; Chesnoy S, 2000, ANNU REV BIOPH BIOM, V29, P27, DOI 10.1146/annurev.biophys.29.1.27; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; Gao X, 1995, GENE THER, V2, P710; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; Hagstrom JE, 1996, BBA-BIOMEMBRANES, V1284, P47, DOI 10.1016/0005-2736(96)00106-X; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; Hui SW, 1996, BIOPHYS J, V71, P590, DOI 10.1016/S0006-3495(96)79309-8; ISRAELACHVILI JN, 1975, BIOCHIM BIOPHYS ACTA, V389, P13, DOI 10.1016/0005-2736(75)90381-8; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; LabatMoleur F, 1996, GENE THER, V3, P1010; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; Lewis RNAH, 2000, BIOPHYS J, V79, P1455, DOI 10.1016/S0006-3495(00)76397-1; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Meekel AAP, 2000, EUR J ORG CHEM, V2000, P665; Miller AD, 1998, ANGEW CHEM INT EDIT, V37, P1769; Mui B, 2000, BBA-BIOMEMBRANES, V1467, P281, DOI 10.1016/S0005-2736(00)00226-1; Oberle V, 2000, BIOPHYS J, V79, P1447, DOI 10.1016/S0006-3495(00)76396-X; Pitard B, 1999, P NATL ACAD SCI USA, V96, P2621, DOI 10.1073/pnas.96.6.2621; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Regelin AE, 2000, BBA-BIOMEMBRANES, V1464, P151, DOI 10.1016/S0005-2736(00)00126-7; REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021; Ren T, 2000, GENE THER, V7, P764, DOI 10.1038/sj.gt.3301153; SMYTHTEMPLETON N, 1997, NAT BIOTECHNOL, V15, P647; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; VANDERWOUDE I, 1995, BBA-BIOMEMBRANES, V1240, P34, DOI 10.1016/0005-2736(95)00161-1; VanDerWoude I, 1997, P NATL ACAD SCI USA, V94, P1160, DOI 10.1073/pnas.94.4.1160; Wang JK, 1998, J MED CHEM, V41, P2207, DOI 10.1021/jm950802i; Wheeler JJ, 1999, GENE THER, V6, P271, DOI 10.1038/sj.gt.3300821; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; Yoshikawa Y, 1996, FEBS LETT, V396, P71, DOI 10.1016/0014-5793(96)01057-5	38	154	168	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47615	47622		10.1074/jbc.M106199200	http://dx.doi.org/10.1074/jbc.M106199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11583999	hybrid			2022-12-25	WOS:000172768500122
J	Van Dort, HM; Knowles, DW; Chasis, JA; Lee, G; Mohandas, N; Low, PS				Van Dort, HM; Knowles, DW; Chasis, JA; Lee, G; Mohandas, N; Low, PS			Analysis of integral membrane protein contributions to the deformability and stability of the human erythrocyte membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-BINDING; CELL DEFORMABILITY; ANION-EXCHANGER; BAND-3 PROTEIN; SPECTRIN; SKELETON; PHOSPHATIDYLSERINE; SPHEROCYTOSIS; TRANSMEMBRANE; DEFICIENCY	Three major hypotheses have been proposed to explain the role of membrane-spanning proteins in establishing/maintaining membrane stability. These hypotheses ascribe the essential contribution of integral membrane proteins to (i) their ability to anchor the membrane skeleton to the lipid bilayer, (ii) their capacity to bind and stabilize membrane lipids, and (iii) their ability to influence and regulate local membrane curvature. In an effort to test these hypotheses in greater detail, we have modified both the membrane skeletal and lipid binding interactions of band 3 (the major membrane-spanning and skeletal binding protein of the human erythrocyte membrane) and have examined the impact of these modifications on erythrocyte membrane morphology., deformability, and stability. The desired changes in membrane skeletal and protein-lipid interactions were induced by 1) reaction of the cells with 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS), an inhibitor of band 3-mediated anion transport that dissociates band 3 into dimers (increasing its surface area in contact with lipid) and severs band 3 linkages to the membrane skeleton; 2) a fragment of ankyrin that ruptures the same ankyrin-band 3 bridge to the membrane skeleton, but drives the band 3 subunit equilibrium toward the tetramer (i.e. decreasing the band 3 surface area in contact with lipid); and 3) an antibody to the ankyrin-binding site on band 3 that promotes the same changes in band 3 skeletal and lipid interactions as the ankyrin fragment. We observed that although DIDS induced echinocytic morphological changes in the treated erythrocytes, it had little impact on either membrane deformability or stability. In contrast, resealing of either the ankyrin fragment or anti-band 3 IgG into erythrocytes caused spontaneous membrane fragmentation and loss of deformability/stability. Because these and other new observations cannot all be reconciled with any single hypothesis on membrane stability, we suggest that more than one hypothesis may be operative and provide an explanation of how each might individually contribute to net membrane stability.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Low, PS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.			Low, Philip/0000-0001-9042-5528	NHLBI NIH HHS [HL 31579] Funding Source: Medline; NIDDK NIH HHS [DK 26263] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08296, GM 24417] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, R01DK026263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008296, R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BESSIS M, 1975, BLOOD CELLS, V1, P307; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; Chang SH, 2001, J BIOL CHEM, V276, P22223, DOI 10.1074/jbc.M100604200; COHEN AM, 1986, BLOOD, V68, P920; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; Discher DE, 1996, BIOPHYS J, V71, P1680, DOI 10.1016/S0006-3495(96)79424-9; DISCHER DE, 1994, SCIENCE, V266, P1032, DOI 10.1126/science.7973655; EVANS E, 1984, J CLIN INVEST, V73, P477, DOI 10.1172/JCI111234; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; GOLAN DE, 1986, J CELL BIOL, V103, P819, DOI 10.1083/jcb.103.3.819; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOW PS, 1991, BLOOD, V77, P1581; MAKSYMIW R, 1987, BIOCHEMISTRY-US, V26, P2983, DOI 10.1021/bi00385a005; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MOHANDAS N, 1983, SEMIN HEMATOL, V20, P225; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MORROW JS, 1997, HDB PHYSIOL 14, P485; NIGG EA, 1979, BIOCHEMISTRY-US, V18, P3457, DOI 10.1021/bi00583a004; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; REID ME, 1987, BLOOD, V69, P1068; RYBICKI AC, 1988, J CLIN INVEST, V81, P255, DOI 10.1172/JCI113303; Sinard J. H., 1994, Molecular Biology of the Cell, V5, p421A; Snyers L, 1997, EUR J CELL BIOL, V73, P281; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; TANNER MJA, 1976, BIOCHEM J, V153, P271, DOI 10.1042/bj1530271; Van Dort HM, 1998, J BIOL CHEM, V273, P14819, DOI 10.1074/jbc.273.24.14819; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; Yi SJ, 1997, BIOCHEMISTRY-US, V36, P9596, DOI 10.1021/bi9704966	37	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46968	46974		10.1074/jbc.M107855200	http://dx.doi.org/10.1074/jbc.M107855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595743	hybrid			2022-12-25	WOS:000172768500041
J	Bosoy, D; Lue, NF				Bosoy, D; Lue, NF			Functional analysis of conserved residues in the putative "finger" domain of telomerase reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; TEMPLATE RNA COMPONENT; TETRAHYMENA TELOMERASE; YEAST TELOMERASE; SACCHAROMYCES-CEREVISIAE; IN-VITRO; MAMMALIAN TELOMERASE; PROTEIN; COMPLEX; VIVO	Telomerase is a ribonucleoprotein reverse transcriptase (RT) responsible for the maintenance of one strand of telomere terminal repeats. The catalytic protein subunit of telomerase, known generically as telomerase reverse transcriptase (TERT), exhibits significant homology to RTs encoded by retroviruses and retroelements. The polymerization mechanisms of telomerase may therefore be similar to those of the "conventional" RTs. In this study, we explored the extent of mechanistic conservation by analyzing mutations of conserved residues within the putative "finger" domain of TERT. Previous analysis has implicated this domain of retroviral RTs in nucleotide and RNA binding and in processivity control. Our results demonstrate that residues conserved between TERT and human immunodeficiency virus-1 RT are more likely than TERT-specific residues to be required for enzyme activity. In addition, residues presumed to make direct contact with either the RNA or nucleotide substrate appear to be functionally more important. Furthermore, distinct biochemical defects can be observed for alterations in the putative RNA- and nucleotide-binding TERT residues in a manner that can be rationalized by their postulated mechanisms of action. This study thus supports a high degree of mechanistic conservation between telomerase and retroviral RTs and underscores the roles of distinct aspects of telomerase biochemistry in telomere length maintenance.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, William Randolph Hearst Microbiol Res Ctr, New York, NY 10021 USA	Cornell University	Lue, NF (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, William Randolph Hearst Microbiol Res Ctr, 1300 York Ave, New York, NY 10021 USA.		Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062631] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM62631-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bhattacharyya A, 1997, P NATL ACAD SCI USA, V94, P2823, DOI 10.1073/pnas.94.7.2823; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Eickbush TH, 1997, SCIENCE, V277, P911, DOI 10.1126/science.277.5328.911; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1495, DOI 10.1093/nar/26.6.1495; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1487, DOI 10.1093/nar/26.6.1487; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller MC, 2000, EMBO J, V19, P4412, DOI 10.1093/emboj/19.16.4412; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	49	36	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46305	46312		10.1074/jbc.M108168200	http://dx.doi.org/10.1074/jbc.M108168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581271	hybrid			2022-12-25	WOS:000172573100111
J	Vaiskunaite, R; Kozasa, T; Voyno-Yasenetskaya, TA				Vaiskunaite, R; Kozasa, T; Voyno-Yasenetskaya, TA			Interaction between the ga subunit of heterotrimeric G(12) protein and Hsp90 is required for G alpha(12) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; STRESS FIBER FORMATION; ALPHA-SUBUNIT; CRYSTAL-STRUCTURE; CHAPERONE SITES; G13 PROTEINS; P115 RHOGEF; PATHWAY; BINDING; KINASE	The G alpha subunit of G(12) protein, one of the heterotrimeric G proteins, regulates diverse and complex cellular responses by transducing signals from the cell surface, presumably involving more than one downstream effector. Yeast two-hybrid screening of a human testis cDNA library identified a large fragment of Hsp90 as a protein that interacted with G alpha (12). The interaction between Ga-12 and Hsp90 was further substantiated by a co-immunoprecipitation technique. We have determined that Hsp90 is not required for the interaction of Ga-12 with its binding partners, p115(RhoGEF) and the G beta subunit. Importantly, Hsp90 is required for G alpha (12)-induced serum response element activation, cytoskeletal changes, and mitogenic response. Closely related to G alpha (12), the G alpha (13) subunit did not interact with Hsp90 and did not require functional Hsp90 for serum response element activation. Thus, our results identify a novel signaling module of Ga-12 and Hsp90.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.				NIGMS NIH HHS [GM56159] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056159, R55GM056159] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Busconi L, 2000, J BIOL CHEM, V275, P1565, DOI 10.1074/jbc.275.3.1565; FINLEY RL, 1995, DNA CLONING, V2, P169; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; INANOBE A, 1994, J BIOCHEM, V115, P486, DOI 10.1093/oxfordjournals.jbchem.a124363; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Scheibel T, 1999, MOL MICROBIOL, V34, P701, DOI 10.1046/j.1365-2958.1999.01632.x; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Toby GG, 2001, METHODS, V24, P201, DOI 10.1006/meth.2001.1182; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	43	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46088	46093		10.1074/jbc.M108711200	http://dx.doi.org/10.1074/jbc.M108711200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11598136	hybrid			2022-12-25	WOS:000172573100081
J	Prall, OWJ; Carroll, JS; Sutherland, RL				Prall, OWJ; Carroll, JS; Sutherland, RL			A low abundance pool of nascent p21(WAF1/Cip1) is targeted by estrogen to activate cyclin E-Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; DEPENDENT KINASES; CDK INHIBITORS; PHASE-TRANSITION; D1 EXPRESSION; S-PHASE; C-MYC; P27(KIP1); RECEPTOR	Estrogens regulate cell proliferation in target tissues, including breast cancer by stimulating G(1)-S phase transition. Activation of cyclin E-Cdk2 through abrogation of the ability of p21(WAF1/Cip1) to bind to and inhibit cyclin-CDKs is a pivotal event in this process in MCF-7 breast cancer cells. A proposed mechanism is p21 sequestration into cyclin D1.Cdk4/6 complexes driven by estrogen-induced transcriptional activation of cyclin D1 gene expression. However, we now show that some E-2-induced cyclin E.Cdk2 activation occurs in the absence of increased cyclin D1 levels and requires decreased p21 protein synthesis. Both mechanisms operate in the absence of major changes in total p21 protein levels and instead target a low abundance subset of newly synthesized p21. E2-induced activation of cyclin E-Cdk2 is mimicked by targeted inhibition of nascent p21 expression by antisense p21 oligonucleotides. Cyclin E-Cdk2 activation is completely inhibited by a combination of antisense cyclin D1 oligonucleotide transfection and elimination of the decrease in nascent p21 by infection with adenoviral-p21. These findings strongly support a central role for p21 in the early phase of E-2-induced mitogenesis and highlight a major functional role for newly synthesized CDK inhibitory proteins.	St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008	Carroll, Jason/0000-0003-3643-0080				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Altucci L, 1996, ONCOGENE, V12, P2315; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FALCKPEDERSEN E, 1998, CELLS LAB MANUAL; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Geng Y, 1996, ONCOGENE, V12, P1173; GREENBERG ME, 1999, CURRENT PROTOCOLS MO; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KEYOMARSI K, 1994, CANCER RES, V54, P380; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Liu JB, 2000, ONCOGENE, V19, P661, DOI 10.1038/sj.onc.1203373; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; WIMMEL A, 1994, ONCOGENE, V9, P995; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	60	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45433	45442		10.1074/jbc.M104752200	http://dx.doi.org/10.1074/jbc.M104752200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581254	hybrid			2022-12-25	WOS:000172406700141
J	Bergoglio, V; Canitrot, Y; Hogarth, L; Minto, L; Howell, SB; Cazaux, C; Hoffmann, JS				Bergoglio, V; Canitrot, Y; Hogarth, L; Minto, L; Howell, SB; Cazaux, C; Hoffmann, JS			Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents	ONCOGENE			English	Article						DNA polymerase beta; cisplatin resistance; translesion synthesis; 6-thioguanine	ACQUIRED-RESISTANCE; REVERSE-TRANSCRIPTASE; BYPASS REPLICATION; MUTATOR PHENOTYPE; MISMATCH REPAIR; EXCISION-REPAIR; CANCER-CELLS; IN-VITRO; CISPLATIN; LINES	DNA polymerase beta, one of the most inaccurate DNA synthesizing enzymes, has been shown to confer genetic instability when up-regulated in cells, a situation found in several human cancers. Here, we demonstrated that enhanced activity and expression of this enzyme occur in the human ovarian tumor 2008/CI3*5.25 cells, which are resistant to the antitumor agent cisplatin and hypersensitive to 6-thioguanine. We found that translesion synthesis across platinated DNA crosslinks as well as increased incorporation into DNA of 6-thioguanine took place in the 2008/CI3*5.25 cells compared to the parental 2008 cells. Such features being molecular signatures of DNA polymerase beta, these findings suggest that deregulation of its expression in cancer cells may contribute to the modulation of the response to antitumor treatments and therefore to tumor progression.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France; CRU, Sch Med, LRF Mol Pharmacol Grp, Newcastle Upon Tyne, Tyne & Wear, England; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Newcastle University - UK; University of California System; University of California San Diego; University of California System; University of California San Diego	Cazaux, C (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.		Bergoglio, Valérie VB/P-1624-2014; Hoffmann, Jean-Sebastien/O-9183-2014	Bergoglio, Valérie VB/0000-0003-2773-3178; Hoffmann, Jean-Sebastien/0000-0003-2222-354X	NCI NIH HHS [CA 78648] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1996, CANCER RES, V56, P3087; ANDREWS PA, 1985, CANCER RES, V45, P6250; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; Bouayadi K, 1997, CANCER RES, V57, P110; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DIWAN BA, 1995, TOXICOL APPL PHARM, V132, P115, DOI 10.1006/taap.1995.1092; Gomi A, 1996, BIOCHEM BIOPH RES CO, V227, P558, DOI 10.1006/bbrc.1996.1545; GRINDEY GB, 1979, CANCER TREAT REV, V6, P19, DOI 10.1016/S0305-7372(79)80006-7; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; Johnson SW, 1997, CANCER RES, V57, P850; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kornberg A., 1992, DNA REPLICATION; MAMENTA EL, 1994, CANCER RES, V54, P3500; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; NELSON J, 1975, CANCER RES, P2872; OHNO Y, 1988, CANCER RES, V48, P1494; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PIL P, 1997, ENCY CANC, V1, P392; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Vaisman A, 1999, BIOCHEMISTRY-US, V38, P11026, DOI 10.1021/bi9909187; WARREN DJ, 1995, CANCER RES, V55, P1670; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	37	75	81	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6181	6187		10.1038/sj.onc.1204743	http://dx.doi.org/10.1038/sj.onc.1204743			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593426	Bronze			2022-12-25	WOS:000171206300009
J	Chan, HM; Smith, L; La Thangue, NB				Chan, HM; Smith, L; La Thangue, NB			Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein	ONCOGENE			English	Article						pRb; E2F; HDAC; LXCXE; tumour suppressor	CELL-CYCLE ARREST; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; BINDING-SITE; E2F SITE; IN-VIVO; E GENE; RB; DOMAIN; CHROMATIN	Cell cycle control by pRb requires the integrity of the pocket domain, which is a region necessary for interactions with a variety of proteins, including E2F and LXCXE-motif containing proteins. Through knowledge of the crystal structure of pRb we have prepared a panel of pRb mutant derivatives in which a cluster of lysine residues that demark the LXCXE peptide binding domain were systematically mutated. One of the mutant derivatives, Rb6A, exhibits significantly reduced LXCXE-dependent interactions with HPV E7, cyclinD1 and HDAC2, but retained LXCXE-independent binding to E2F. Consistent with these results, Rb6A could down-regulate E2F-1-dependent activation of different E2F responsive promoters, but was compromised in Rb-dependent repression. Most importantly, Rb6A retained wild-type growth arrest activity, and colony forming activity similar to wild-type pRb. It is compatible with these results that directly targeting HDAC2 to E2F responsive promoters as an E2F/HDAC hybrid protein failed to effect cell cycle arrest. These results suggest that LXCXE-dependent interactions are not essential for pRb to exert growth arrest.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Blvd, Glasgow G12 8QQ, Lanark, Scotland.				MRC [G9400953] Funding Source: UKRI; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALBERT L, 1999, MOL CELL BIOL, V19, P6632; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Goodman RH, 2000, GENE DEV, V14, P1553; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han JW, 2000, CANCER RES, V60, P6068; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	44	60	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6152	6163		10.1038/sj.onc.1204793	http://dx.doi.org/10.1038/sj.onc.1204793			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593423				2022-12-25	WOS:000171206300006
J	Fukuyama, T; Sueoka, E; Sugio, Y; Otsuka, T; Niho, Y; Akagi, K; Kozu, T				Fukuyama, T; Sueoka, E; Sugio, Y; Otsuka, T; Niho, Y; Akagi, K; Kozu, T			MTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent protein kinase in lymphocytes	ONCOGENE			English	Article						AKAP; AML1 (RUNX-1); lymphocyte; MTG8 (ETO); PKA RII alpha	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TRANSCRIPTION FACTOR; FUSION PARTNER; SIGNALING ENZYMES; MOLECULAR-BASIS; RUNT DOMAIN; AML1 GENE; T(8-21); ETO	AML1-MTG8 chimeric oncogene is generated in acute myelogenous leukemia with t(8;21), and seems to be responsible for the pathogenesis of the disease. However, the role of MTG8 is ambiguous. Here we found that MTG8 interacted with the regulatory subunit of type II cyclic AMP-dependent protein kinase (PKA RII alpha). The binding site of MTG8 was NHR3 domain, and that of RII alpha was the N-terminus for interacting with PKA anchoring proteins (AKAPs). NHR3 contains a putative alpha -amphipathic helix which is characteristic in binding of AKAPs with RII. Indirect immunofluorescence microscopy showed that MTG8 and RII alpha were overlapped at the centrosome-Golgi area in lymphocytes. These findings suggest that MTG8 may function as an AKAP at the Centrosome-Golgi area in lymphocytes.	Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan; Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Fac Med, Dept Med & Biosyst Sci, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kozu, T (corresponding author), Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan.		Kozu, Tomoko/R-3087-2019	Fukuyama, Tomofusa/0000-0002-0709-3188				Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; CARR DW, 1991, J BIOL CHEM, V266, P14188; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEINSTEIN PG, 1995, GENETICS, V140, P573; Fracchiolla NS, 1998, BLOOD, V92, P3481, DOI 10.1182/blood.V92.9.3481.splL6_3481_3484; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Keryer G, 1999, EXP CELL RES, V249, P131, DOI 10.1006/excr.1999.4447; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; KOZU T, 1993, BLOOD, V82, P1270; Le XF, 1998, EUR J HAEMATOL, V60, P217; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sueoka E, 1998, BRIT J HAEMATOL, V101, P737, DOI 10.1046/j.1365-2141.1998.00757.x; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3	48	45	47	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6225	6232		10.1038/sj.onc.1204794	http://dx.doi.org/10.1038/sj.onc.1204794			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593431				2022-12-25	WOS:000171206300014
J	Pervaiz, S; Cao, J; Chao, OSP; Chin, YY; Clement, MV				Pervaiz, S; Cao, J; Chao, OSP; Chin, YY; Clement, MV			Activation of the RacGTPase inhibits apoptosis in human tumor cells	ONCOGENE			English	Article						superoxide anion; NADPH oxidase; Ha-Ras; anti-cancer drugs	SIGNAL-TRANSDUCTION; SUPEROXIDE ANION; RAS; PROTEINS; FAMILY; GENE	The small GTP-binding protein Rac is a downstream effector of the oncogene product p21-ras. Rac is involved in actin polymerization, Jun kinase activation, and intracellular superoxide anion production, through distinct pathways in tumor cells. Here we investigated the role of activated Rac in the response of tumor cells to apoptosis triggered by anti-cancer drugs or the cell surface death receptor CD95. Using M14 melanoma cells stably transfected with a constitutively active form of Rac1, we show that activated Rac inhibits tumor cell response to apoptosis. The inhibitory effect of activated Rac on apoptotic signaling is mediated by the interaction of Rac with intracellular oxidase and the subsequent production of superoxide, which is supported by experiments performed with M14 and NIH3T3 cells transiently transfected with the loss-of-function mutants of Rac in an activated RacV12 background. Consistent with these findings, we also demonstrate that inhibition of the Rac pathway in the HaRas-expressing T24 bladder carcinoma cell line induces a decrease in superoxide anion concentration, and results in a significant increase in tumor cell sensitivity to apoptosis. These findings demonstrate the existence of a novel Rac-dependent survival pathway mediated by intracellular superoxide in tumor cells.	Natl Univ Singapore, Inst Med, Oncol Res Inst, Clin Res Ctr, Singapore 117597, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore; Natl Univ Singapore, Dept Physiol, Singapore 119260, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Clement, MV (corresponding author), Natl Univ Singapore, Inst Med, Oncol Res Inst, Clin Res Ctr, Block MD11,12-01, Singapore 117597, Singapore.		Pervaiz, Shazib/C-4188-2015					Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MUSLEH W, 1994, NEUROPHARMACOLOGY, V33, P929, DOI 10.1016/0028-3908(94)90191-0; Pervaiz S, 1998, CANCER LETT, V128, P11, DOI 10.1016/S0304-3835(98)00021-4; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; WALKER PR, 1991, CANCER RES, V51, P1078	28	107	119	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6263	6268		10.1038/sj.onc.1204840	http://dx.doi.org/10.1038/sj.onc.1204840			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593437				2022-12-25	WOS:000171206300020
J	Yokoyama, N; Miller, WT				Yokoyama, N; Miller, WT			Protein phosphatase 2A interacts with the Src kinase substrate p130(CAS)	ONCOGENE			English	Article						Src; PP2A; Cas; serine dephosphorylation	POLYOMAVIRUS MIDDLE-T; ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; V-SRC; SACCHAROMYCES-CEREVISIAE; CELL-TRANSFORMATION; COMPLEX-FORMATION; STABLE COMPLEXES; OKADAIC ACID; ANTIGEN	In this study, we report that the Src substrate Cas (p130 Crk-associated substrate) associates with protein phosphatase 2A (PP2A), a serine/threonine phosphatase. We investigated this interaction in cells expressing a temperature-sensitive mutant form of v-Src. v-Src activation (by shifting cells from the nonpermissive to the permissive temperature) led to an increase in the tyrosine phosphorylation of v-Src and Cas, as well as in the association between v-Src and Cas. v-Src has previously been shown to bind to PP2A and to phosphorylate the catalytic subunit of PP2A, resulting in inhibition of phosphatase activity. We found that the association between v-Src and PP2A decreased as cells were shifted to the permissive temperature. In contrast, the levels of PP2A that co-immunoprecipitated with Cas increased when v-Src was activated. We obtained similar results in pull-down experiments with immobilized Microcystin, a PP2A inhibitor. Serine/threonine phosphorylation of Cas has previously been shown to occur in a cell cycle regulated matter. Treatment of NIH3T3 cells with okadaic acid, a PP2A inhibitor, augments the serine/threonine phosphorylation of Cas that occurs at mitosis. Furthermore, PP2A dephosphorylates serine residues on Cas in vitro. Taken together, our results suggest that PP2A may be involved in the cell cycle-specific dephosphorylation of Cas.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA 58530, CA 28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, P01CA028146, R29CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chaudhuri Sadhan K., 1997, Indian Journal of Experimental Biology, V35, P1044; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Evans DRH, 2000, MOL GEN GENET, V264, P425; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; Glover HR, 1999, ONCOGENE, V18, P4364, DOI 10.1038/sj.onc.1202816; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ogris E, 1999, J VIROL, V73, P7390, DOI 10.1128/JVI.73.9.7390-7398.1999; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; YANAGIDA M, 1992, CIBA F SYMP, V170, P130; YOKOYAMA N, 1995, MOL CELL BIOCHEM, V148, P123, DOI 10.1007/BF00928149; Yokoyama N, 1999, FEBS LETT, V456, P403, DOI 10.1016/S0014-5793(99)00992-8; ZHENG B, 1991, J BIOL CHEM, V266, P10031	39	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6057	6065		10.1038/sj.onc.1204735	http://dx.doi.org/10.1038/sj.onc.1204735			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593413				2022-12-25	WOS:000171056300013
J	Zhang, SL; Lloyd, R; Bowden, G; Glickman, BW; de Boer, JG				Zhang, SL; Lloyd, R; Bowden, G; Glickman, BW; de Boer, JG			Msh2 DNA mismatch repair gene deficiency and the food-borne mutagen 2-amino-1-methyl-6-phenolimidazo [4,5-b] pyridine (PhIP) synergistically affect mutagenesis in mouse colon	ONCOGENE			English	Article						mismatch repair; dietary mutagen; mutational spectra; lacI; cancer	NONPOLYPOSIS COLORECTAL-CANCER; HETEROCYCLIC AMINES; TRANSGENIC MICE; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; MAMMALIAN-CELLS; MUTATION; LACI; RATS; SPECIFICITY; RODENTS	Msh2 deficiency and food-borne carcinogen PhIP have been implicated as genetic and environmental factors, respectively, in human colon carcinogenesis. It is not clear whether loss of one or both alleles of Msh2 gene increases the mutational sensitivity in colon when exposed to environmental carcinogens. In the current study, Msh2(+/-)/lacI and Msh2(-/-)/lacI double transgenic mice were treated with PhIP and mutations in the lacI gene were studied in the colon. The spontaneous mutation frequency (MF) is approximately eightfold higher in Msh2(-/-) mice than in Msh2(+/+) mice, while Msh2(+/-) mice display similar levels of spontaneous mutation as the Msh2 wild type mice. PhIP induced a significant increase in MF in all genotypes of mice. However, induced MF is much higher in Msh2-/- mice compared to Msh2(+/+) and Msh2(+/-) mice. Msh2(+/-) mice ;displayed an increased level of G:C >T:A transversions and -1 frameshifts upon PhIP treatment. In contrast, loss of both Msh2 alleles mainly results in increased frequency of G:C >A:T transitions when exposed to PhIP. These results suggest that a defect in mismatch repair may result in an enhanced sensitivity from exposure to a dietary carcinogen. It also provides insight into interaction between genetic and environmental factors in human carcinogenesis.	Univ Victoria, Dept Biol, Ctr Environm Hlth, Victoria, BC V8W 3N5, Canada	University of Victoria	de Boer, JG (corresponding author), Univ Victoria, Dept Biol, Ctr Environm Hlth, POB 1700, Victoria, BC V8W 3N5, Canada.							Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; CAROTHRS AM, 1994, CHEM RES TOXICOL, V7, P209, DOI 10.1021/tx00038a015; de Boer JG, 1998, GENETICS, V148, P1441; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; ENDO H, 1994, CANCER RES, V54, P3745; Erfle HL, 1996, ENVIRON MOL MUTAGEN, V28, P393; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081; Felton JS, 1997, MUTAT RES-FUND MOL M, V376, P37, DOI 10.1016/S0027-5107(97)00023-7; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FISHEL R, 1994, CELL, V77, P167; Fornasarig M, 2000, ONCOL REP, V7, P39; FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Glaab WE, 2000, CANCER RES, V60, P4921; Glaab WE, 1999, CARCINOGENESIS, V20, P391, DOI 10.1093/carcin/20.3.391; Godard V, 1999, ANN DERMATOL VENER, V126, P600; Gooderham NJ, 1997, MUTAT RES-FUND MOL M, V376, P53, DOI 10.1016/S0027-5107(97)00025-0; ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; Marra G, 1996, GASTROENTEROL CLIN N, V25, P755, DOI 10.1016/S0889-8553(05)70273-9; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Okonogi H, 1997, CARCINOGENESIS, V18, P745, DOI 10.1093/carcin/18.4.745; Okonogi H, 1997, MUTAT RES-GEN TOX EN, V395, P93, DOI 10.1016/S1383-5718(97)00146-0; Planck M, 2000, GENE CHROMOSOME CANC, V29, P33, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1004>3.0.CO;2-R; RADMAN M, 1985, BIOCHIMIE, V67, P745, DOI 10.1016/S0300-9084(85)80162-0; ROGERS BJ, 1995, MUTAT RES-FUND MOL M, V327, P57, DOI 10.1016/0027-5107(94)00081-F; Sorensen IK, 1997, CARCINOGENESIS, V18, P777, DOI 10.1093/carcin/18.4.777; Stuart GR, 2000, MUTAT RES-FUND MOL M, V452, P101, DOI 10.1016/S0027-5107(00)00058-0; Suri A, 1996, MUTAT RES-FUND MOL M, V372, P23, DOI 10.1016/S0027-5107(96)00105-4; TAKAHASHI S, 1991, JPN J CANCER RES, V82, P135, DOI 10.1111/j.1349-7006.1991.tb01819.x; Toft NJ, 1998, J PATHOL, V185, P123; TUDEK B, 1989, CANCER RES, V49, P1236; TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X; Zhang XB, 1996, CARCINOGENESIS, V17, P2259, DOI 10.1093/carcin/17.10.2259	47	16	16	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6066	6072		10.1038/sj.onc.1204730	http://dx.doi.org/10.1038/sj.onc.1204730			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593414				2022-12-25	WOS:000171056300014
J	Delhem, N; Sabile, A; Gajardo, R; Podevin, P; Abadie, A; Blaton, MA; Kremsdorf, D; Beretta, L; Brechot, C				Delhem, N; Sabile, A; Gajardo, R; Podevin, P; Abadie, A; Blaton, MA; Kremsdorf, D; Beretta, L; Brechot, C			Activation of the interferon-inducible protein kinase PKR by Hepatocellular carcinoma derived-Hepatitis C virus core protein	ONCOGENE			English	Article						HCV; core; PKR; eIF2 alpha; apoptosis	NF-KAPPA-B; SIGNAL-TRANSDUCTION; MEDIATED APOPTOSIS; NS5A PROTEIN; EXPRESSION; PATHWAY; CELLS; BINDS; PATHOGENESIS; REPLICATION	Hepatitis C virus (HCV) is a major etiological agent of chronic liver disease and hepatocellular carcinoma (HCC). We demonstrate herewith that HCV core proteins encoded by sequences isolated from HCC tumor tissues, but not those derived from their non-tumor counterparts in the same liver, co-localise in vitro and in vivo and co-immunoprecipitate with PKR in hepatocytic Huh7 cells. We show that this association in fact augments the autophosphorylation of PKR and the phosphorylation of the translation initiation factor eIF2 alpha, which are two markers of PKR activity. The present study therefore identifies a novel model of virus-cell interactions whereby a viral protein, the HCV core, activates PKR activity.	CHU Necker, INSERM, U370, Dept Liver Canc & Mol Virol, F-75015 Paris, France; Inst Curie, Dept Cytokines & Interferon, Paris, France; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Michigan System; University of Michigan	Brechot, C (corresponding author), CHU Necker, INSERM, U370, Dept Liver Canc & Mol Virol, 156 Rue Vaugirard, F-75015 Paris, France.		Kremsdorf, Dina/O-9797-2017	Laura, Beretta/0000-0002-2054-684X				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157; Gil J, 1999, MOL CELL BIOL, V19, P4653; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lee JH, 1997, J MED VIROL, V53, P245, DOI 10.1002/(SICI)1096-9071(199711)53:3<245::AID-JMV11>3.0.CO;2-G; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; Lu JF, 1999, J BIOL CHEM, V274, P32198, DOI 10.1074/jbc.274.45.32198; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Naganuma A, 2000, J VIROL, V74, P8744, DOI 10.1128/JVI.74.18.8744-8750.2000; Neddermann P, 1997, BIOL CHEM, V378, P469; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Podevin P, 2001, HEPATOLOGY, V33, P1503, DOI 10.1053/jhep.2001.24749; Polyak SJ, 1999, HEPATOLOGY, V29, P1262, DOI 10.1002/hep.510290438; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Sarrazin C, 1999, Z Gastroenterol, V37, P669; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Shimada A, 1998, CANCER RES, V58, P4434; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Shimotohno K, 1995, INTERVIROLOGY, V38, P162, DOI 10.1159/000150427; Song J, 1999, J GEN VIROL, V80, P879, DOI 10.1099/0022-1317-80-4-879; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	44	66	73	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5836	5845		10.1038/sj.onc.1204744	http://dx.doi.org/10.1038/sj.onc.1204744			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593389				2022-12-25	WOS:000171037200007
J	Scott, MGH; Benmerah, A; Muntaner, O; Marullo, S				Scott, MGH; Benmerah, A; Muntaner, O; Marullo, S			Recruitment of activated G protein-coupled receptors to pre-existing clathrin-coated pits in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; HORMONE-RECEPTOR; MEDIATED ENDOCYTOSIS; TRANSFERRIN RECEPTOR; ADAPTER; RESENSITIZATION; ASSOCIATION; VESICLES; EPS15	The process of clathrin-mediated endocytosis tightly regulates signaling of the superfamily of seven-transmembrane G protein-coupled receptors (GPCRs). A fundamental question in the cell biology of membrane receptor endocytosis is whether activated receptors can initiate the formation of clathrin-coated pits (CPs) or whether they are simply mobilized to pre-existing CPs. Here, using various approaches, including a dynamic assay to monitor the distribution of CPs and GPCR-beta-arrestin complexes in live HeLa cells, we demonstrate for the first time that activated GPCRs do not initiate the de novo formation of CPs but instead are targeted to pre-existing CPs.	Inst Cochin Genet Mol, Dept Cell Biol, F-75679 Paris 14, France; Hop Necker Enfants Malad, INSERM E9925, F-75730 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marullo, S (corresponding author), Inst Cochin Genet Mol, Dept Cell Biol, Pavillon Gustave Roussy, F-75679 Paris 14, France.		Scott, Mark/R-3521-2019; benmerah, alexandre/H-3742-2017; Marullo, Stefano/C-6142-2008	benmerah, alexandre/0000-0003-0188-8016; Marullo, Stefano/0000-0001-9604-9973; Scott, Mark G.H./0000-0002-1557-1856				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; CHAKRABARTI R, 1993, J CELL BIOL, V123, P79, DOI 10.1083/jcb.123.1.79; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; CORVERA S, 1989, J BIOL CHEM, V264, P12568; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; Drmota T, 1998, J BIOL CHEM, V273, P24000, DOI 10.1074/jbc.273.37.24000; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; Groarke DA, 2001, MOL PHARMACOL, V59, P375, DOI 10.1124/mol.59.2.375; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Marullo S, 1999, RECEPTOR CHANNEL, V6, P255; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; Petrou C, 1998, CELL SIGNAL, V10, P553, DOI 10.1016/S0898-6568(97)00190-3; PETROU CP, 1995, BIOCHEM J, V306, P107, DOI 10.1042/bj3060107; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Poupon V, 1999, J BIOL CHEM, V274, P19188, DOI 10.1074/jbc.274.27.19188; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; Santini F, 2000, J CELL SCI, V113, P2463; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Trejo J, 2000, J BIOL CHEM, V275, P31255, DOI 10.1074/jbc.M003770200; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Warren RA, 1997, J BIOL CHEM, V272, P2116; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	49	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 1	2002	277	5					3552	3559		10.1074/jbc.M106586200	http://dx.doi.org/10.1074/jbc.M106586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	518VF	11602587	hybrid			2022-12-25	WOS:000173688000066
J	Lane, S; Birse, C; Zhou, S; Matson, R; Liu, HP				Lane, S; Birse, C; Zhou, S; Matson, R; Liu, HP			DNA array studies demonstrate convergent regulation of virulence factors by Cph1, Cph2, and Efg1 in Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENTOUS-GROWTH; HYPHAL DEVELOPMENT; MORPHOLOGICAL DEVELOPMENT; PROTEINASE EXPRESSION; BINDING PROTEIN; MAP KINASE; GENE; TRANSCRIPTION; MORPHOGENESIS; CONTRIBUTES	Candida albicans, normally a human commensal, can cause fatal systemic infections under certain circumstances. Its unique ability to switch from yeast to hyphal growth in response to various environmental signals is inherent to its pathogenicity. Filamentation is regulated by multiple pathways including a Cph1-mediated mitogen-activated protein kinase pathway, an Efg1-mediated cAmP/PKA pathway, and a Cph2 pathway. To gain a general picture of how these various signaling pathways regulate differential gene expression during filamentation, we have constructed a partial C. albicans DNA array of 7,000 genes and used it to study the gene expression profiles using various mutants and growth conditions. By combining this novel technology with a new liquid medium in which cph1/cph1 is defective in filamentation, previously identified differentially expressed genes (ECE1, HWP1, HYR1, RBT1, SAPs5-6, and RBT4) are found to be regulated by all three pathways. In addition, two novel genes, DDR48 and YPL184, have been found to be differentially regulated during hyphal development and by all three pathways. This suggests that distinct filamentation signaling pathways converge to regulate a common set of differentially expressed genes. As one of the mechanisms for the observed convergence, we find that the transcription of a key regulator, TEC1, is regulated by Efg1 and Cph2. Importantly, most of the genes regulated by multiple filamentation pathways encode known virulence factors. Perhaps, C. albicans utilizes converging pathways to regulate its vital virulence factors to ensure its survival and pathogenicity in various host environments.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Beckman Coulter Inc, Ctr Adv Technol, Fullerton, CA 92834 USA	University of California System; University of California Irvine; Beckman Coulter Inc.	Liu, HP (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.	h4liu@uci.edu			NIGMS NIH HHS [GM55155] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055155] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey DA, 1996, J BACTERIOL, V178, P5353, DOI 10.1128/jb.178.18.5353-5360.1996; BIRSE CE, 1993, INFECT IMMUN, V61, P3648, DOI 10.1128/IAI.61.9.3648-3655.1993; Bockmuhl DP, 2001, GENETICS, V157, P1523; Braun BR, 2000, GENETICS, V156, P31; Braun BR, 2000, GENETICS, V155, P57; Braun BR, 1997, SCIENCE, V277, P105, DOI 10.1126/science.277.5322.105; Brown AJP, 1999, TRENDS MICROBIOL, V7, P333, DOI 10.1016/S0966-842X(99)01556-5; Brown D. H. Jr., 1999, Molecular Microbiology, V34, P651, DOI 10.1046/j.1365-2958.1999.01619.x; Bubert A, 1999, MOL GEN GENET, V261, P323, DOI 10.1007/s004380050973; Buckman J, 1998, BIOCHEMISTRY-US, V37, P14326, DOI 10.1021/bi981106y; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Csank C, 1998, INFECT IMMUN, V66, P2713, DOI 10.1128/IAI.66.6.2713-2721.1998; Davis D, 2000, MOL CELL BIOL, V20, P971, DOI 10.1128/MCB.20.3.971-978.2000; DELBRUCK S, 1993, MOL MICROBIOL, V10, P859, DOI 10.1111/j.1365-2958.1993.tb00956.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El Barkani A, 2000, MOL CELL BIOL, V20, P4635, DOI 10.1128/MCB.20.13.4635-4647.2000; FONZI WA, 1993, GENETICS, V134, P717; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; Hoyer LL, 1998, CURR GENET, V33, P451, DOI 10.1007/s002940050359; HUBE B, 1994, MOL MICROBIOL, V14, P87, DOI 10.1111/j.1365-2958.1994.tb01269.x; Kadosh D, 2001, MOL CELL BIOL, V21, P2496, DOI 10.1128/MCB.21.7.2496-2505.2001; Khalaf RA, 2001, GENETICS, V157, P1503; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; Lane S, 2001, MOL CELL BIOL, V21, P6418, DOI 10.1128/MCB.21.19.6418-6428.2001; Leberer E, 1997, CURR BIOL, V7, P539, DOI 10.1016/S0960-9822(06)00252-1; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; Leng P, 2001, J BACTERIOL, V183, P4090, DOI 10.1128/JB.183.13.4090-4093.2001; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Marcus SL, 2000, MICROBES INFECT, V2, P145, DOI 10.1016/S1286-4579(00)00273-2; MILLER KY, 1992, GENE DEV, V6, P1770, DOI 10.1101/gad.6.9.1770; Murad AMA, 2001, EMBO J, V20, P4742, DOI 10.1093/emboj/20.17.4742; Naglik JR, 1999, INFECT IMMUN, V67, P2482, DOI 10.1128/IAI.67.5.2482-2490.1999; Olson KA, 2000, MOL CELL BIOL, V20, P4199, DOI 10.1128/MCB.20.12.4199-4209.2000; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; Pi HW, 1997, MOL CELL BIOL, V17, P6410, DOI 10.1128/MCB.17.11.6410; Powderly WG, 1999, AIDS RES HUM RETROV, V15, P1405, DOI 10.1089/088922299309900; Ramon AM, 1999, J BACTERIOL, V181, P7524, DOI 10.1128/JB.181.24.7524-7530.1999; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Schaller M, 1999, MOL MICROBIOL, V34, P169, DOI 10.1046/j.1365-2958.1999.01590.x; Schroppel K, 2000, INFECT IMMUN, V68, P7159, DOI 10.1128/IAI.68.12.7159-7161.2000; Schweizer A, 2000, MOL MICROBIOL, V38, P435, DOI 10.1046/j.1365-2958.2000.02132.x; Sharkey LL, 1999, J BACTERIOL, V181, P5273, DOI 10.1128/JB.181.17.5273-5279.1999; Sonneborn A, 2000, MOL MICROBIOL, V35, P386, DOI 10.1046/j.1365-2958.2000.01705.x; Sonneborn A, 1999, INFECT IMMUN, V67, P4655, DOI 10.1128/IAI.67.9.4655-4660.1999; SRIKANTHA T, 1995, MOL GEN GENET, V246, P342, DOI 10.1007/BF00288607; Staab JF, 1998, YEAST, V14, P681, DOI 10.1002/(SICI)1097-0061(199805)14:7&lt;681::AID-YEA256&gt;3.0.CO;2-8; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999	53	172	194	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48988	48996		10.1074/jbc.M104484200	http://dx.doi.org/10.1074/jbc.M104484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11595734	hybrid			2022-12-25	WOS:000173922100050
J	Wilson, KA; Maerz, AL; Poumbourios, P				Wilson, KA; Maerz, AL; Poumbourios, P			Evidence that the transmembrane domain proximal region of the human T-cell leukemia virus type 1 fusion glycoprotein gp21 has distinct roles in the prefusion and fusion-activated states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED MEMBRANE-FUSION; MALTOSE-BINDING PROTEIN; DODECYL-SULFATE MICELLE; AMINO-TERMINAL REGION; INFLUENZA HEMAGGLUTININ; ENVELOPE GLYCOPROTEIN; IMMUNODEFICIENCY-VIRUS; SYNCYTIUM FORMATION; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE	To investigate the structural context of the fusion peptide region in human T-cell leukemia virus type 1 gp21, maltose-binding protein (MBP) was used as an N-terminal solubilization partner for the entire gp21 ectodomain (residues 313-445) and C-terminally truncated ectodomain fragments. The bacterial expression of the MBP/gp21 chimeras resulted in soluble trimers containing intramonomer disulfide bonds. Detergents blocked the proteolytic cleavage of fusion peptide residues in the NIBP/gp21-(313-425) chimera, indicating that the fusion peptide is available for interaction with detergent despite the presence of an N-terminal MBP domain. Limited proteolysis experiments indicated that the transmembrane domain proximal sequence Thr(425)-Ala(439) protects fusion peptide residues from chymotrypsin. MBP/gp21 chimera stability therefore depends on a functional interaction between N-terminal and transmembrane domain proximal regions in a gp21 helical hairpin structure. In addition, thermal aggregation experiments indicated that the Thr(425)-Ser(436) sequence confers stability to the fusion peptide-containing MBP/gp21 chimeras. The functional role of the transmembrane domain proximal sequence was assessed by alanine-scanning mutagenesis of the full-length envelope glycoprotein, with 11 of 12 single alanine substitutions resulting in 1.5- to 4.5-fold enhancements in cell-cell fusion activity. By contrast, single alanine substitutions in MBP/gp21 did not significantly alter chimera stability, indicating that multiple residues within the transmembrane domain proximal region and the fusion peptide and adjacent glycine-rich segment contribute to stability, thereby mitigating the potential effects of the substitutions. The fusion-enhancing effects of the substitutions are therefore likely to be caused by alteration of the prefusion complex. Our observations suggest that the function of the transmembrane domain proximal sequence in the prefusion envelope glycoprotein is distinct from its role in stabilizing the fusion peptide region in the fusion-activated helical hairpin conformation of gp21.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Poumbourios, P (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	apoum@ariel.ucs.unimelb.edu.au						ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chang DK, 2000, J BIOL CHEM, V275, P19150, DOI 10.1074/jbc.M907148199; Chang DK, 1999, J BIOL CHEM, V274, P5299, DOI 10.1074/jbc.274.9.5299; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; Chen J, 1998, BIOCHEMISTRY-US, V37, P13643, DOI 10.1021/bi981098l; Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; Colotto A, 1996, BIOCHEMISTRY-US, V35, P980, DOI 10.1021/bi951991+; Colotto A, 1997, BIOCHEMISTRY-US, V36, P7644, DOI 10.1021/bi970382u; Daenke S, 1999, J GEN VIROL, V80, P1429, DOI 10.1099/0022-1317-80-6-1429; Damico R, 2000, J VIROL, V74, P6469, DOI 10.1128/JVI.74.14.6469-6475.2000; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; Delamarre L, 1997, J VIROL, V71, P259, DOI 10.1128/JVI.71.1.259-266.1997; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; FAN N, 1992, J CLIN MICROBIOL, V30, P905, DOI 10.1128/JCM.30.4.905-910.1992; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Hildreth JEK, 1998, J VIROL, V72, P9544, DOI 10.1128/JVI.72.12.9544-9552.1998; Jassal SR, 2001, J VIROL, V75, P8317, DOI 10.1128/JVI.75.17.8317-8328.2001; Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; Maerz AL, 2000, J VIROL, V74, P6614, DOI 10.1128/JVI.74.14.6614-6621.2000; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Pique C, 2000, VIROLOGY, V276, P455, DOI 10.1006/viro.2000.0538; PIQUE C, 1992, J VIROL, V66, P906, DOI 10.1128/JVI.66.2.906-913.1992; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; Rosenberg JR, 1997, J VIROL, V71, P7180, DOI 10.1128/JVI.71.10.7180-7186.1997; Sagara Y, 1998, J VIROL, V72, P535, DOI 10.1128/JVI.72.1.535-541.1998; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	52	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49466	49475		10.1074/jbc.M108449200	http://dx.doi.org/10.1074/jbc.M108449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11595747	hybrid			2022-12-25	WOS:000173922100109
J	Evans, GJO; Wilkinson, MC; Graham, ME; Turner, KM; Chamberlain, LH; Burgoyne, RD; Morgan, A				Evans, GJO; Wilkinson, MC; Graham, ME; Turner, KM; Chamberlain, LH; Burgoyne, RD; Morgan, A			Phosphorylation of cysteine string protein by protein kinase A. Implications for the modulation of exocytosis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; SYNAPTOSOME-ASSOCIATED PROTEIN; II INHIBITOR KN-62; NEUROTRANSMITTER RELEASE; CALCIUM CHANNELS; CYCLIC-AMP; CATECHOLAMINE SECRETION; STRUCTURAL DETERMINANTS; REGULATED EXOCYTOSIS; CATALYTIC SUBUNIT	Cyclic AMP-dependent protein kinase (PKA) enhances regulated exocytosis in neurons and most other secretory cells. To explore the molecular basis of this effect, known exocytotic proteins were screened for PKA substrates. Both cysteine string protein (CSP) and soluble NSF attachment protein-a (a-SNAP) were phosphorylated by PKA in vitro, but immunoprecipitation of cellular a-SNAP failed to detect P-32 incorporation. In contrast, endogenous CSP was phosphorylated in synaptosomes, PC12 cells, and chromaffin cells. In-gel kinase assays confirmed PKA to be a cellular CSP kinase, with phosphorylation occurring on Ser(10). PYKA phosphorylation of CSP reduced its binding to syntaxin by 10-fold but had little effect on its interaction with HSC70 or G-protein subunits. Furthermore, an in vivo role for Ser(10) phosphorylation at a late stage of exocytosis is suggested by analysis of chromaffin cells transfected with wild type or non-phosphorylatable mutant CSP. We propose that PKA phosphorylation of CSP could modulate the exocytotic machinery, by selectively altering its availability for protein-protein interactions.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool; University of Liverpool	Morgan, A (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.		Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019; Morgan, Alan/AAI-8875-2020	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387; Morgan, Alan/0000-0002-0346-1289; Evans, Gareth John Owen/0000-0003-2573-7001; Wilkinson, Mark/0000-0003-3109-6888				AHNERTHILGER G, 1987, BIOCHEMISTRY-US, V26, P7842, DOI 10.1021/bi00398a046; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Bronk P, 2001, NEURON, V30, P475, DOI 10.1016/S0896-6273(01)00292-6; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; Chamberlain LH, 1998, MOL BIOL CELL, V9, P2259, DOI 10.1091/mbc.9.8.2259; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chamberlain LH, 2001, J CELL SCI, V114, P445; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cox ME, 1996, J NEUROCHEM, V66, P1103; Dawson-Scully K, 2000, J NEUROSCI, V20, P6039, DOI 10.1523/JNEUROSCI.20-16-06039.2000; Evans GJO, 1999, EUR J NEUROSCI, V11, P279, DOI 10.1046/j.1460-9568.1999.00427.x; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; Hilfiker S, 1999, J NEUROCHEM, V73, P921, DOI 10.1046/j.1471-4159.1999.0730921.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHT DE, 1988, J MEMBRANE BIOL, V104, P21, DOI 10.1007/BF01871899; KOOPMANN WR, 1990, BIOCHEM J, V265, P365, DOI 10.1042/bj2650365; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; LI GD, 1992, MOL PHARMACOL, V42, P489; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lonart G, 1998, J NEUROSCI, V18, P634; Machado JD, 2001, MOL PHARMACOL, V60, P514; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; MCFERRAN BW, 1996, J MOL ENDOCRINOL, V16, P2133; MORGAN A, 1992, BIOCHEM J, V286, P807, DOI 10.1042/bj2860807; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; Morgan A, 1995, ESSAYS BIOCHEM, V30, P77; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Murphy TV, 1999, EUR J PHARMACOL, V381, P77, DOI 10.1016/S0014-2999(99)00540-3; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; Nie ZP, 1999, J NEUROSCI, V19, P10270; OSULLIVAN AJ, 1992, BIOCHEM J, V287, P403, DOI 10.1042/bj2870403; Pellizzari R, 1996, J BIOL CHEM, V271, P20353, DOI 10.1074/jbc.271.34.20353; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pyle RA, 2000, J BIOL CHEM, V275, P17195, DOI 10.1074/jbc.M000674200; Ranjan R, 1998, J NEUROSCI, V18, P956; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; SCHWEITZER ES, 1995, J CELL SCI, V108, P2619; Scott CE, 1998, AM J PHYSIOL-CELL PH, V275, pC285, DOI 10.1152/ajpcell.1998.275.1.C285; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SMOLEN JE, 1990, BIOCHIM BIOPHYS ACTA, V1052, P133, DOI 10.1016/0167-4889(90)90068-O; Stahl B, 1999, EUR J CELL BIOL, V78, P375, DOI 10.1016/S0171-9335(99)80079-X; TAKUMA T, 1994, J BIOL CHEM, V269, P22124; Tandon A, 1998, NEURON, V21, P147, DOI 10.1016/S0896-6273(00)80522-X; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Umbach JA, 1998, J NEUROSCI, V18, P3233; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yawo H, 1999, J NEUROSCI, V19, P5293; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; Zhang H, 1999, J CELL SCI, V112, P1345; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	72	81	86	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47877	47885		10.1074/jbc.M108186200	http://dx.doi.org/10.1074/jbc.M108186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11604405	hybrid			2022-12-25	WOS:000172927000022
J	Logan-Smith, MJ; Lockyer, PJ; East, JM; Lee, AG				Logan-Smith, MJ; Lockyer, PJ; East, JM; Lee, AG			Curcumin, a molecule that inhibits the Ca2+-ATPase of sarcoplasmic reticulum but increases the rate of accumulation of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; INOSITOL 1,4,5-TRISPHOSPHATE; ADENOSINE-TRIPHOSPHATASE; CRYSTAL-STRUCTURE; ATP HYDROLYSIS; CA-2+ RELEASE; THAPSIGARGIN; VESICLES; MUSCLE; TRANSPORT	Curcumin, an important inhibitor of carcinogenesis, is an inhibitor of the ATPase activity of the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum (SR). Inhibition by curcumin is structurally specific, requiring the presence of a pair of -OH groups at the 4-position of the rings. Inhibition is not competitive with ATP. Unexpectedly, addition of curcumin to SR vesicles leads to an increase in the rate of accumulation of Ca2+, unlike other inhibitors of the Ca2+-ATPase that result in a reduced rate of accumulation. An increase in the rate of accumulation of Ca2+ is seen in the presence of phosphate ion, which lowers the concentration of free Ca2+ within the lumen of the SR, showing that the effect is not passive leak across the SR membrane. Rather, simulations suggest that the effect is to reduce the rate of slippage on the ATPase, a process in which a Ca2+ bound, phosphorylated intermediate releases its bound Ca2+ on the cytoplasmic rather than on the lumenal side of the membrane. The structural specificity of the effects of curcumin on ATPase activity and on Ca2+ accumulation is the same, and the apparent dissociation constants for the two effects are similar, suggesting that the two effects of curcumin could follow from binding to a single site on the ATPase.	Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Southampton; University of Bristol	Lee, AG (corresponding author), Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England.	agl@soton.ac.uk						ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANTONIU B, 1985, BIOCHIM BIOPHYS ACTA, V816, P9, DOI 10.1016/0005-2736(85)90387-6; BIGELOW DJ, 1987, J BIOL CHEM, V262, P13449; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; BROWN GR, 1994, BBA-BIOMEMBRANES, V1195, P252, DOI 10.1016/0005-2736(94)90264-X; CHAMBERLAIN BK, 1984, J BIOL CHEM, V259, P7547; CHRISTENSEN SB, 1993, FEBS LETT, V335, P345, DOI 10.1016/0014-5793(93)80416-R; Coll KE, 1999, BIOCHEMISTRY-US, V38, P2444, DOI 10.1021/bi9823028; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; de Meis L, 1998, BIOCHEM BIOPH RES CO, V243, P598, DOI 10.1006/bbrc.1997.8028; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, SARCOPLASMIC RETICUL, P1; DUGGAN PF, 1970, J GEN PHYSIOL, V56, P147, DOI 10.1085/jgp.56.2.147; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GODT RE, 1974, J GEN PHYSIOL, V63, P722, DOI 10.1085/jgp.63.6.722; GOULD GW, 1987, BIOCHEM J, V245, P739, DOI 10.1042/bj2450739; GOULD GW, 1987, J BIOL CHEM, V262, P7676; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P45, DOI 10.1016/0005-2736(87)90085-X; HARDWICKE PM, 1974, EUR J BIOCHEM, V42, P183; HASSELBACH W, 1974, MEMBRANE PROTEINS TR, P103; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1983, J BIOL CHEM, V258, P4804; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JONES OT, 1986, PESTIC BIOCHEM PHYS, V25, P420, DOI 10.1016/0048-3575(86)90017-9; KHAN YM, 1995, BIOCHEMISTRY-US, V34, P14385, DOI 10.1021/bi00044a015; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUTSCHABSKY L, 1986, CRYST RES TECHNOL, V21, P627, DOI 10.1002/crat.2170210513; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; Logan-Smith MJ, 2000, FASEB J, V14, pA1574; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; Manson MM, 2000, BIOCHEM SOC T, V28, P7, DOI 10.1042/bst0280007; MARTINEZAZORIN F, 1992, J BIOL CHEM, V267, P11923; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MATHIESON AM, 1968, ACTA CRYSTALL B-STRU, VB 24, P1456, DOI 10.1107/S0567740868004474; MCWHIRTER JM, 1987, BIOCHEM J, V245, P731, DOI 10.1042/bj2450731; MCWHIRTER JM, 1987, BIOCHEM J, V245, P713, DOI 10.1042/bj2450713; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELGUNOV VI, 1988, FEBS LETT, V227, P157, DOI 10.1016/0014-5793(88)80888-3; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P3091, DOI 10.1021/bi00464a028; MIKOS GJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P256, DOI 10.1016/0167-4889(87)90142-X; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; PAPP B, 1991, J BIOL CHEM, V266, P14593; PATIL AO, 1984, J CHEM SOC PERK T 2, P1107, DOI 10.1039/p29840001107; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAITO K, 1984, J BIOCHEM, V95, P1297, DOI 10.1093/oxfordjournals.jbchem.a134735; SCHERER NM, 1985, BIOCHEM BIOPH RES CO, V128, P1064, DOI 10.1016/0006-291X(85)91048-4; SOKOLOVE PM, 1986, FEBS LETT, V203, P121, DOI 10.1016/0014-5793(86)80726-8; STARLING AP, 1994, BIOCHEMISTRY-US, V33, P3023, DOI 10.1021/bi00176a035; STEFANOVA HI, 1991, BIOCHIM BIOPHYS ACTA, V1064, P321, DOI 10.1016/0005-2736(91)90318-3; STONER GD, 1995, J CELL BIOCHEM, P169; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WICTOME M, 1995, BIOCHEM J, V310, P859, DOI 10.1042/bj3100859; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; WICTOME M, 1994, BIOCHEM BIOPH RES CO, V199, P916, DOI 10.1006/bbrc.1994.1316; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397	64	76	92	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46905	46911		10.1074/jbc.M108778200	http://dx.doi.org/10.1074/jbc.M108778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592968	hybrid			2022-12-25	WOS:000172768500032
J	St John, RJ; Carpenter, JF; Balny, C; Randolph, TW				St John, RJ; Carpenter, JF; Balny, C; Randolph, TW			High pressure refolding of recombinant human growth hormone from insoluble aggregates - Structural transformations, kinetic barriers, and energetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH HYDROSTATIC-PRESSURE; PROTEIN AGGREGATION; CRYSTAL-STRUCTURE; DENATURATION; STATE; UREA; STABILIZATION; INTERMEDIATE; TEMPERATURE; DEPENDENCE	Two different types of insoluble, non-native aggregates of recombinant human growth hormone were formed by agitation in buffer or buffer containing 0.75 m guanidine HCl (GdnHCl) and characterized by infrared and second derivative UV spectroseopies. The degree of secondary structural perturbation was greater in the aggregates formed in 0.75 m GdnHCl. Both aggregate types were dissolved and refolded using high hydrostatic pressures in combination with either elevated temperature or non-denaturing levels of guanidine HCl or urea. The effects of a range of temperature, pressure, and chaotrope concentrations were tested and led to optimal conditions that approached 100%, yield of native protein. The aggregates formed in 0.75 m GdnHCl required higher concentrations of urea or GdnHCl, or higher temperature or pressure for a yield equivalent to that for aggregates formed in buffer alone. Investigation of the effects of pressure, temperature, and chaotrope on unfolding of rhGH documented that under conditions used for optimal high pressure disaggregation and refolding, the native state is greatly favored thermodynamically (e.g. 25 kJ/mol at 2000 bar and 0.75 m GdnHCl). Dissolution of aggregates under pressure is a kinetically limited process. Comparison of refolding yields in GdnHCl and urea solutions suggest that pressure effects on electrostatic interactions do not dominate pressure effects on disaggregation. We suggest that non-native hydrogen bonds between protein molecules within aggregates of recombinant human growth hormone are responsible for the rate-limiting kinetic barrier in pressure-induced disaggregation.	Univ Colorado, Dept Chem Engn, Ctr Engn, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA; INSERM, U128, IFR 24, F-34293 Montpellier 05, France	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Institut National de la Sante et de la Recherche Medicale (Inserm)	Randolph, TW (corresponding author), Univ Colorado, Dept Chem Engn, Ctr Engn, ECCH 111, Boulder, CO 80309 USA.	randolph@pressure.colorado.edu						ARAKAWA T, 1984, BIOCHEMISTRY-US, V23, P5924, DOI 10.1021/bi00320a005; BALNY C, 1993, FOOD REV INT, V9, P611, DOI 10.1080/87559129309540980; Bam NB, 1998, J PHARM SCI, V87, P1554, DOI 10.1021/js980175v; Bam NB, 1996, BIOTECHNOL PROGR, V12, P801, DOI 10.1021/bp960068b; Carpenter JF, 1999, METHOD ENZYMOL, V309, P236; Cioni P, 1996, J MOL BIOL, V263, P789, DOI 10.1006/jmbi.1996.0616; Clark ED, 2001, CURR OPIN BIOTECH, V12, P202, DOI 10.1016/S0958-1669(00)00200-7; Clark EDB, 1998, CURR OPIN BIOTECH, V9, P157; CLELAND JL, 1993, ACS SYM SER, V516, P151; CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEYOUNG LR, 1993, ACCOUNTS CHEM RES, V26, P614, DOI 10.1021/ar00036a002; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Dong AC, 1997, ARCH BIOCHEM BIOPHYS, V347, P213, DOI 10.1006/abbi.1997.0349; FIELDS GB, 1992, J PHYS CHEM-US, V96, P3974, DOI 10.1021/j100189a013; GEKKO K, 1989, J PHYS CHEM-US, V93, P426, DOI 10.1021/j100338a082; Gorovits BM, 1998, BIOCHEMISTRY-US, V37, P6132, DOI 10.1021/bi9730137; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; Gupta R, 1999, BIOCHEMISTRY-US, V38, P2471, DOI 10.1021/bi982078m; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; Kendrick BS, 1998, P NATL ACAD SCI USA, V95, P14142, DOI 10.1073/pnas.95.24.14142; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; Lange R, 1996, EUR BIOPHYS J BIOPHY, V24, P277; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LEACH SJ, 1960, J AM CHEM SOC, V82, P4790, DOI 10.1021/ja01503a008; LI TM, 1976, BIOCHEMISTRY-US, V15, P5571, DOI 10.1021/bi00670a023; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Mohana-Borges R, 1999, J BIOL CHEM, V274, P7732, DOI 10.1074/jbc.274.12.7732; MOORE WV, 1980, J CLIN ENDOCR METAB, V51, P691, DOI 10.1210/jcem-51-4-691; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; NOWICKI C, 1981, INT J PEPT PROT RES, V18, P52; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RATNER RE, 1990, DIABETES, V39, P728, DOI 10.2337/diabetes.39.6.728; Rick SW, 2000, J PHYS CHEM B, V104, P6884, DOI 10.1021/jp000841s; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; Rudolph R, 1995, PROTEIN ENG PRINCIPL, P283; Speed MA, 1997, BIOTECHNOL BIOENG, V54, P333; SPEED MA, 1995, PROTEIN SCI, V4, P900; St John RJ, 1999, P NATL ACAD SCI USA, V96, P13029, DOI 10.1073/pnas.96.23.13029; TANFORD C, 1964, J AM CHEM SOC, V86, P2050, DOI 10.1021/ja01064a028; THORNTON CA, 1993, ARCH NEUROL-CHICAGO, V50, P135, DOI 10.1001/archneur.1993.00540020013009; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; VANELDIK R, 1989, CHEM REV, V89, P549, DOI 10.1021/cr00093a005; Volkin DB, 1997, MOL BIOTECHNOL, V8, P105, DOI 10.1007/BF02752255; Webb JN, 2001, P NATL ACAD SCI USA, V98, P7259, DOI 10.1073/pnas.131194798; YANARI S, 1960, J BIOL CHEM, V235, P2818; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; Zhang ZY, 2001, BIOPHYS CHEM, V89, P145, DOI 10.1016/S0301-4622(00)00227-1; Zou Q, 1998, PROTEINS, V31, P107, DOI 10.1002/(SICI)1097-0134(19980501)31:2<107::AID-PROT1>3.0.CO;2-J	51	73	82	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46856	46863		10.1074/jbc.M107671200	http://dx.doi.org/10.1074/jbc.M107671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591710	hybrid			2022-12-25	WOS:000172768500026
J	Wakino, S; Kintscher, U; Liu, ZW; Kim, S; Yin, F; Ohba, M; Kuroki, T; Schonthal, AH; Hsueh, WA; Law, RE				Wakino, S; Kintscher, U; Liu, ZW; Kim, S; Yin, F; Ohba, M; Kuroki, T; Schonthal, AH; Hsueh, WA; Law, RE			Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase C delta pathway in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; CDK INHIBITORS; GROWTH; EXPRESSION; P27(KIP1); CYCLE; P21	The cyclin-dependent kinase inhibitor p21(Cip1) is upregulated in response to mitogenic stimulation in various cells. PPAR gamma ligands troglitazone (TRO, 10 muM) and rosiglitazone (RSG, 10 pm) attenuated the induction of p21(Cip1) protein by platelet-derived growth factor (PDGF) and insulin without affecting cognate mRNA levels in rat aortic smooth muscle cells (RASMC). The protein kinase C delta (PKC delta) inhibitor rottlerin also blocked the induction of p21(Cip1) protein, whereas the conventional PKC isotype inhibitor Go 6976 had no effect. Kinetic studies using the protein synthesis inhibitor cycloheximide showed that TRO, RSG, and rottlerin shortened the half-life of p21(Cip1) protein. TRO, RSG, and rottlerin inhibited PDGF-induced expression of p21(Cip1), but they did not affect insulin-induced expression of p21(Cip1). Both ligands inhibited PKC delta enzymatic activity in PDGF-stimulated RASMC but not in insulin-stimulated cells. Adenovirus-mediated overexpression of PKC delta rescued the down-regulation of p21(Cip1) expression both by TRO and RSG in PDGF-treated RASMC. These data suggested that the PKC delta pathway plays a critical role in PDGF-induced expression of p21(Cip1) in RASMC and may be the potential target for PPAR gamma ligand effects. Src kinase-dependent tyrosine phosphorylation of PKC delta was decreased substantially by TRO and RSG. Tyrosine phosphorylation and activation of c-Src in response to PDGF were unaffected by either PPAR gamma ligand. Protein-tyrosine-phosphatase inhibitors sodium orthovanadate and dephostatin prevented PPAR gamma ligand effects on PKC delta tyrosine phosphorylation and enzymatic activity. Both inhibitors also reversed PPAR gamma ligand effects on p21(Cip1) expression in PDGF-treated RASMC. PPAR gamma ligands enhanced protein-tyrosine-phosphatase activity in RASMC, which may be the mechanism for decreased PKC delta tyrosine phosphorylation and activity. PPAR gamma ligands regulate p21(Cip1) at a post-translational level by blocking PKC delta signaling and accelerating p21(Cip1) turnover.	Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA; Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo, Japan; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Showa University; University of Southern California	Law, RE (corresponding author), Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Hypertens, 142-8555,Warren Hall,2nd Floor,Suite 24-130,900 V, Los Angeles, CA 90095 USA.		Kuroki, Toshio/A-9500-2011; Schonthal, Axel/ABH-3846-2020	Kuroki, Toshio/0000-0001-6369-4351; Kintscher, Ulrich/0000-0001-7386-0990; Schonthal, Axel/0000-0003-0662-5653	NHLBI NIH HHS [HL 58328-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Assender JW, 1996, ACTA PHYSIOL SCAND, V157, P451, DOI 10.1046/j.1365-201X.1996.511285000.x; Balciunaite E, 2000, CURR BIOL, V10, P261, DOI 10.1016/S0960-9822(00)00358-4; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GOUNI BI, 2001, N-S ARCH PHARMACOL, V363, P215; Hanke H, 1996, CIRCULATION, V93, P202; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hsueh WA, 2001, DIABETES CARE, V24, P392, DOI 10.2337/diacare.24.2.392; Kanoh Y, 2000, J BIOL CHEM, V275, P16690, DOI 10.1074/jbc.M000287200; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Leng L, 1996, ARTERY, V22, P140; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LI Y, 1994, ONCOGENE, V9, P2261; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Rao GN, 1999, BBA-MOL CELL RES, V1448, P525, DOI 10.1016/S0167-4889(98)00149-9; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yasunari K, 1997, CIRC RES, V81, P953; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	44	69	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47650	47657		10.1074/jbc.M108719200	http://dx.doi.org/10.1074/jbc.M108719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598137	hybrid			2022-12-25	WOS:000172768500126
J	Gross, I; Bassit, B; Benezra, M; Licht, JD				Gross, I; Bassit, B; Benezra, M; Licht, JD			Mammalian Sprouty proteins inhibit cell growth and differentiation by preventing Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; DROSOPHILA SPROUTY; SIGNALING PATHWAY; KINASE ACTIVATION; PC12 CELLS; RECEPTOR; FGF; EXPRESSION; PATTERN; IDENTIFICATION	Sprouty was genetically identified as an antagonist of fibroblast growth factor signaling during tracheal branching in Drosophila. In this study, we provide a functional characterization of mammalian Sprouty1 and Sprouty2. Sprouty1 and Sprouty2 inhibited events downstream of multiple receptor tyrosine kinases and regulated both cell proliferation and differentiation. Using NIH3T3 cell lines conditionally expressing Sprouty1 or Sprouty2, we found that these proteins specifically inhibit the Ras/Raf/MAP kinase pathway by preventing Ras activation. In contrast, activation of the phosphatidylinositol 3-kinase pathway was not affected by Sprouty1 or Sprouty2. We further showed that Sprouty1 and Sprouty2 do no prevent the formation of a SNT.Grb2.Sos complex upon fibroblast growth factor stimulation, yet block Ras activation. Taken together, these results establish mammalian Sprouty proteins as important negative regulators of growth factor signaling and suggest that Sprouty proteins act downstream of the Grb2.Sos complex to selectively uncouple growth factor signals from Ras activation and the MAP Kinase pathway.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Gross, Isabelle/P-9859-2019; Licht, Jonathan/L-4239-2019; Gross, Isabelle/I-4972-2016	Gross, Isabelle/0000-0002-2783-8773; Gross, Isabelle/0000-0002-2783-8773; Licht, Jonathan/0000-0002-3942-1369	NCI NIH HHS [CA59998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Green DR, 2000, METHOD ENZYMOL, V322, P15; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kramer S, 1999, DEVELOPMENT, V126, P2515; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; Minowada G, 1999, DEVELOPMENT, V126, P4465; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Reich A, 1999, DEVELOPMENT, V126, P4139; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Taguchi A, 2000, GENETICS, V154, P1639; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Wang JK, 1996, ONCOGENE, V13, P721; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	36	215	221	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46460	46468		10.1074/jbc.M108234200	http://dx.doi.org/10.1074/jbc.M108234200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585837	hybrid			2022-12-25	WOS:000172573100131
J	Santaguida, M; Ding, QM; Berube, G; Truscott, M; Whyte, P; Nepveu, A				Santaguida, M; Ding, QM; Berube, G; Truscott, M; Whyte, P; Nepveu, A			Phosphorylation of the CCAAT displacement protein (CDP)/Cux transcription factor by cyclin A-cdk1 modulates its DNA binding activity in G(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUT HOMEODOMAIN PROTEIN; FACTOR HINF-D; DEPENDENT-KINASE INHIBITOR; HISTONE GENE PROMOTER; CELL-CYCLE; CDK INHIBITORS; DROSOPHILA-MELANOGASTER; DOCKING SITE; S-PHASE; A CDK2	Stable DNA binding by the mammalian CCAAT displacement protein (CDP)/Cux transcription factor was previously found to be up-regulated at the G(1)/S transition as the result of two events, dephosphorylation by the Cdc25A phosphatase and proteolytic processing, to generate an amino-truncated isoform of 110 kDa. In S phase, CDP/Cux was shown to interact with and repress the core promoter of the p21(WAF1) gene. Here we demonstrate that DNA binding by p110 CDP/Cux is down-modulated as cells progress into G(2). Accordingly, cyclin A-Cdk1 was found to bind to CDP/Cux and modulate its DNA binding activity in vitro and in vivo. Interaction with CDP/Cux required the presence of both cyclin A and a cyclin-dependent kinase (Cdk)-activating kinase-activated Cdk1 and involved the Cut homeodomain and a downstream Cy motif. Phosphorylation of serines 1237 and 1270 caused inhibition of DNA binding in vitro. In cotransfection studies, cyclin A-Cdk1 inhibited CDP/ Cux stable DNA binding and prevented repression of the p21(WAF1) reporter. In contrast, mutant CDP/Cux proteins in which serines 1237 and 1270 were replaced with alanines were not affected by cyclin A-Cdk1. In summary, our results suggest that the phosphorylation of CDP/ Cux by cyclin A-Cdk1 contributes to down-modulate CDP/Cux activity as cells progress into the G2 phase of the cell cycle.	McGill Univ, Hlth Ctr, Mol Oncol Grp, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McGill Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McGill Univ, Dept Oncol, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McGill University; McGill University; McMaster University; McGill University; McMaster University; McMaster University	Nepveu, A (corresponding author), 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		/AAB-8315-2020	Truscott, Mary/0000-0002-2324-6383				Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLTHUIS J, 1990, SCIENCE, V247, P1454, DOI 10.1126/science.2321007; JACK JW, 1985, CELL, V42, P869, DOI 10.1016/0092-8674(85)90283-1; KATO J, 1993, GENE DEV, V7, P331; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu F, 1999, MOL CELL BIOL, V19, P5113; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; LIU S, 1991, GENETICS, V127, P151; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Moon NS, 2001, MOL CELL BIOL, V21, P6332, DOI 10.1128/MCB.21.18.6332-6345.2001; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pattison S, 1997, J VIROL, V71, P2013, DOI 10.1128/JVI.71.3.2013-2022.1997; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; Stunkel W, 2000, J VIROL, V74, P2489, DOI 10.1128/JVI.74.6.2489-2501.2000; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VANDENENT FMI, 1994, J CELL PHYSIOL, V159, P515, DOI 10.1002/jcp.1041590316; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANWIJNEN AJ, 1989, J BIOL CHEM, V264, P15034; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; Wang ZY, 1999, MOL CELL BIOL, V19, P284; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	70	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45780	45790		10.1074/jbc.M107978200	http://dx.doi.org/10.1074/jbc.M107978200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584018	hybrid			2022-12-25	WOS:000172573100039
J	Warnmark, A; Wikstrom, A; Wright, APH; Gustafsson, JA; Hard, T				Warnmark, A; Wikstrom, A; Wright, APH; Gustafsson, JA; Hard, T			The N-terminal regions of estrogen receptor alpha and beta are unstructured in vitro and show different TBP binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION DOMAIN; HUMAN GLUCOCORTICOID RECEPTOR; KAPPA-B P65; TRANSACTIVATION DOMAIN; TATA-BOX; FUNCTIONAL-ANALYSIS; PROMOTER-CONTEXT; FUNCTION AF-1; PROTEIN; DNA	The N-terminal regions of the estrogen receptor ve (ER alpha -N) and beta (ER beta -N) were expressed and purified to homogeneity. Using NAM and circular dichroism spectroscopy, we conclude that both ER alpha -N and ER beta -N are unstructured in solution. The TATA box-binding protein (TBP) has been shown previously to interact with ERa-N in vitro and to potentiate ER-activated transcription. We used surface plasmon resonance and circular dichroism spectroscopy to confirm and further characterize the ER-N-TBP interaction. Our results show that the intrinsically unstructured ERa-N interacts with TBP, and suggest that structural changes are induced in ERa-N upon TBP interaction. Conformational changes upon target factor interaction have not previously been demonstrated for any N-terminal region of nuclear receptors. In addition, no binding of ER beta -N to TBP was detected. This difference in TBP binding could imply differential recruitment of target proteins by ERa-N and ER beta -N. The affinity of the ER alpha -N-TBP interaction was determined to be in the micromolar range (K-D = 10(-6) to 10(-5) m). Our results support models of TBP as a target protein for the N-terminal activation domain of ER alpha. Further, our results suggest that target proteins can induce and/or stabilize ordered structure in N-terminal regions of nuclear receptors upon interaction.	Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Royal Inst Technol, Dept Biotechnol, SE-10691 Stockholm, Sweden; Sodertorns Hogskola, Dept Nat Sci, SE-14104 Huddinge, Sweden	Karolinska Institutet; Royal Institute of Technology; Sodertorn University	Warnmark, A (corresponding author), Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden.		; Wright, Anthony/J-8187-2015	Hard, Torleif/0000-0001-9813-9913; Wright, Anthony/0000-0003-1029-9969				Alen P, 1999, MOL CELL BIOL, V19, P6085; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bhat RA, 1998, J STEROID BIOCHEM, V67, P233, DOI 10.1016/S0960-0760(98)00115-0; BIRNBAUMER M, 1983, J BIOL CHEM, V258, P7331; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Delaunay F, 2000, MOL PHARMACOL, V58, P584, DOI 10.1124/mol.58.3.584; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; Ford J, 1997, MOL ENDOCRINOL, V11, P1467, DOI 10.1210/me.11.10.1467; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hermann S, 2001, J BIOL CHEM, V276, P40127, DOI 10.1074/jbc.M103793200; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Metivier R, 2000, MOL ENDOCRINOL, V14, P1849, DOI 10.1210/me.14.11.1849; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4827; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605	50	101	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45939	45944		10.1074/jbc.M107875200	http://dx.doi.org/10.1074/jbc.M107875200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11595744	hybrid			2022-12-25	WOS:000172573100062
J	Angata, T; Hingorani, R; Varki, NM; Varki, A				Angata, T; Hingorani, R; Varki, NM; Varki, A			Cloning and characterization of a novel mouse Siglec, mSiglec-F - Differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; ACID-BINDING-SITE; MYELIN-ASSOCIATED GLYCOPROTEIN; MOLECULAR-CLONING; NEGATIVE REGULATOR; SIALIC ACIDS; IDENTIFICATION; SIALOADHESIN; RECEPTOR; CELLS	A novel mouse Siglec (mSiglec-F) belonging to the subfamily of Siglec-3-related Siglecs has been cloned and characterized. Unlike most human Siglec-3 (hSiglec-3)-related Siglecs with promiscuous linkage specificity, mSiglec-F shows a strong preference for alpha2-3-linked sialic acids. It is predominantly expressed in immature cells of the myelomonocytic lineage and in a subset of CD11b (Mac-1)-positive cells in some tissues. As with previously cloned Siglec-3-related mSiglecs, the lack of strong sequence similarity to a singular hSiglec made identification of the human ortholog difficult. We therefore conducted a comprehensive comparison of Siglecs between the human and mouse genomes. The mouse genome contains eight Siglec genes, whereas the human genome contains 11 Siglec genes and a Siglec-like gene. Although a one-to-one orthologous correspondence between human and mouse Siglecs 1, 2, and 4 is confirmed, the Siglec-3-related Siglecs showed marked differences between human and mouse. We found only four Siglec genes and two pseudogenes in the mouse chromosome 7 region syntenic to the Siglec-3-related gene cluster on human chromosome 19, which, in contrast, contains seven Siglec genes, a Siglec-like gene, and thirteen pseudogenes. Although analysis of gene maps and exon structures allows tentative assignments of mouse-human Siglec ortholog pairs, the possibility of unequal genetic recombination makes the assignments inconclusive. We therefore support a temporary lettered nomenclature for additional mouse Siglecs. Current information suggests that mSiglec-F is likely a hSiglec-5 ortholog. The previously reported mSiglec-3/CD33 and mSiglec-E/MIS are likely orthologs of hSiglec-3 and hSiglec-9, respectively. The other Siglec-3-like gene in the cluster (mSiglec-G) is probably a hSiglec-10 ortholog. Another mouse gene (mSiglec-H), without an apparent human ortholog, lies outside of the cluster. Thus, although some duplications of Siglec-3-related genes predated separation of the primate and rodent lineages (about 80-100 million years ago), this gene cluster underwent extensive duplications in the primate lineage thereafter.	Univ Calif San Diego, Sch Med 0687, Dept Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; BD Biosci Pharmingen, Res Immunocytometry, San Diego, CA 92121 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Sch Med 0687, Dept Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.	avarki@ucsd.edu			NHLBI NIH HHS [P01-HL57345] Funding Source: Medline; NIGMS NIH HHS [R37-GM32373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Biermann H, 1999, J LEUKOCYTE BIOL, V65, P217, DOI 10.1002/jlb.65.2.217; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Eichler EE, 1996, HUM MOL GENET, V5, P899, DOI 10.1093/hmg/5.7.899; FUJITA N, 1989, BIOCHEM BIOPH RES CO, V165, P1162, DOI 10.1016/0006-291X(89)92724-1; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Kim J, 2001, GENOMICS, V74, P129, DOI 10.1006/geno.2001.6521; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li W. H, 1997, MOL EVOLUTION; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Martini R, 1997, GLIA, V19, P298; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Munday J, 2001, BIOCHEM J, V355, P489, DOI 10.1042/0264-6021:3550489; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Page R.D.M., 1998, MOL EVOLUTION PHYLOG; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PEIPER SC, 1988, BLOOD, V72, P314; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; TCHILIAN EZ, 1994, BLOOD, V83, P3188; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Ulyanova T, 2001, J BIOL CHEM, V276, P14451, DOI 10.1074/jbc.M011650200; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Yu ZB, 2001, J BIOL CHEM, V276, P23816, DOI 10.1074/jbc.M102394200	42	79	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45128	45136		10.1074/jbc.M108573200	http://dx.doi.org/10.1074/jbc.M108573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579105	hybrid			2022-12-25	WOS:000172406700104
J	Robert, SJ; Zugaza, JL; Fischmeister, R; Gardier, AM; Lezoualc'h, F				Robert, SJ; Zugaza, JL; Fischmeister, R; Gardier, AM; Lezoualc'h, F			The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; KINASE-C; ALZHEIMERS-DISEASE; APP CLEAVAGE; ACTIVATION; RELEASE; EXPRESSION; ALPHA; CELLS; IDENTIFICATION	The serotonin 5-HT4 receptor has recently gained a lot of attention for its functional roles in central processes such as memory and cognition. In this study, we show that activation of the human 5-HT4 (h5-HT4) receptor stimulates the secretion of the non-amyloidogenic soluble form of the amyloid precursor protein (sAPP alpha). 5-HT enhanced the level of secreted sAPP alpha in a time- and dose-dependent manner in Chinese hamster ovary cells stably expressing the h5-HT4(e) receptor isoform. The increase was inhibited by the selective 5-HT4 receptor antagonist, GR113808. The 5-HT4 selective agonists, prucalopride and renzapride, also increased secreted sAPP alpha in IMR32 human neuroblastoma cells. The stimulatory effect of 5-HT was mimicked by forskolin, a direct activator of adenylyl cyclase, and 8-bromo-cAMP, a membrane-permeant cAMP analogue. On the contrary, inhibition of protein kinase A (PKA) by H89 potentiated the 5-HT-induced increase in both secreted and cellular sAPP alpha. This phenomenon involves a novel PKA-independent stimulatory process that overcomes a PKA-dependent inhibitory one. Finally, activation of the h5-HT4(e) receptor did not modify extracellular amyloid beta -protein in Chinese hamster ovary cells transfected with the human APP695. Given the neuroprotective and enhancing memory effects of sAPP alpha, our results may open a new avenue for the treatment of Alzheimer's disease.	Univ Paris Sud, Fac Pharm, INSERM,U446, Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France; Univ Paris Sud, Fac Pharm, INSERM,U461, Lab Neuropharmacol,UPRES EAD 2707, F-92296 Chatenay Malabry, France; Univ Paris Sud, Fac Pharm, Inst Sinalisat & Innovat Therapeut IFR 75ISIT, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Lezoualc'h, F (corresponding author), Univ Paris Sud, Fac Pharm, INSERM,U446, Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France.	Frank.Lezoualch@cep.u-psud.fr	Bustelo, Xose R./A-9526-2010; Lezoualc'h, Frank/E-5031-2016; Fischmeister, Rodolphe/L-6061-2018	Bustelo, Xose R./0000-0001-9398-6072; Fischmeister, Rodolphe/0000-0003-2086-9865; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bender E, 2000, J NEUROCHEM, V74, P478, DOI 10.1046/j.1471-4159.2000.740478.x; Blondel O, 1998, J NEUROCHEM, V70, P2252; Bonaventure P, 2000, SYNAPSE, V36, P35, DOI 10.1002/(SICI)1098-2396(200004)36:1<35::AID-SYN4>3.0.CO;2-Y; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Claeysen S, 1999, MOL PHARMACOL, V55, P910; CONSOLO S, 1994, NEUROREPORT, V5, P1230, DOI 10.1097/00001756-199406020-00018; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; De Strooper B, 2000, NATURE, V405, P627, DOI 10.1038/35015193; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; Efthimiopoulos S, 1996, J NEUROCHEM, V67, P872; EGLEN RM, 1995, TRENDS PHARMACOL SCI, V16, P391, DOI 10.1016/S0165-6147(00)89081-1; FAGNI L, 1992, BRIT J PHARMACOL, V105, P973, DOI 10.1111/j.1476-5381.1992.tb09087.x; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Gandy S, 1999, TRENDS ENDOCRIN MET, V10, P273, DOI 10.1016/S1043-2760(99)00166-6; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Jolly-Tornetta C, 1998, J BIOL CHEM, V273, P14015, DOI 10.1074/jbc.273.22.14015; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; Lee RKK, 1997, J NEUROCHEM, V68, P1830; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Lezoualc'h F, 2000, MOL ENDOCRINOL, V14, P147, DOI 10.1210/me.14.1.147; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Marambaud P, 1998, MOL MED, V4, P715, DOI 10.1007/BF03401766; Marambaud P, 1996, J NEUROCHEM, V67, P2616; Marchetti E, 2000, NEUROPHARMACOLOGY, V39, P2017, DOI 10.1016/S0028-3908(00)00038-1; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mialet J, 2000, BRIT J PHARMACOL, V129, P771, DOI 10.1038/sj.bjp.0703101; Mialet J, 2000, BRIT J PHARMACOL, V131, P827, DOI 10.1038/sj.bjp.0703641; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Racchi M, 1999, TRENDS PHARMACOL SCI, V20, P418, DOI 10.1016/S0165-6147(99)01380-2; REYNOLDS GP, 1995, BRIT J PHARMACOL, V114, P993, DOI 10.1111/j.1476-5381.1995.tb13303.x; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; Rossner S, 2000, EUR J NEUROSCI, V12, P3191, DOI 10.1046/j.1460-9568.2000.00211.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Xie EZ, 1996, GENOMICS, V35, P551, DOI 10.1006/geno.1996.0397; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	58	105	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44881	44888		10.1074/jbc.M109008200	http://dx.doi.org/10.1074/jbc.M109008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584021	hybrid, Green Submitted			2022-12-25	WOS:000172406700074
J	Ljungman, M; O'Hagan, HM; Paulsen, MT				Ljungman, M; O'Hagan, HM; Paulsen, MT			Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation	ONCOGENE			English	Article						RNA polymerase II; inhibitors; DNA damage; UV light; Xeroderma pigmentosum; Cockayne's syndrome	RNA-POLYMERASE-II; DAMAGE-INDUCED PHOSPHORYLATION; CARBOXYL-TERMINAL DOMAIN; LIGHT-INDUCED APOPTOSIS; RING-FINGER DOMAIN; DNA-DAMAGE; ULTRAVIOLET-RADIATION; NUCLEAR EXPORT; UV-RADIATION; CELL-CYCLE	Blockage of transcription has been shown to induce the tumor suppressor p53 in human cells. We here show that RNA synthesis inhibitors blocking the phosphorylation of the carboxyl terminal domain (CTD) of RNA polymerase II, such as DRB and H7, induced rapid nuclear accumulation of p53 proteins that were not phosphorylated at ser15 or acetylated at lys382. In contrast, agents that inhibit the elongation phase of transcription, such as UV light, camptothecin or actinomycin D, induced the accumulation of nuclear p53 proteins that were modified at both of these sites. Furthermore, using a panel of DNA repair-deficient cells we show that persistent DNA lesions in the transcribed strand of active genes are responsible for the induction of the ser15 and lys382 modifications following UV-irradiation. We conclude that inhibition of transcription is sufficient for the accumulation of p53 in the nucleus regardless of whether the ser15 site of p53 is phosphorylated or not. Importantly, blockage of the elongation phase of transcription triggers a distinct signaling pathway leading to p53 modifications on ser15 and lys382. We propose that the elongating RNA polymerase complex may act as a sensor of DNA damage and as an integrator of cellular stress signals.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ljungman, M (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, 4306 CCGC,150 E Med Ctr Dr, Ann Arbor, MI 48109 USA.			O'Hagan, Heather/0000-0001-9750-5088	NCI NIH HHS [CA 82376-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirose Y, 2000, GENE DEV, V14, P1415; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Ljungman M, 1996, CARCINOGENESIS, V17, P31, DOI 10.1093/carcin/17.1.31; Lu X, 1996, ONCOGENE, V13, P413; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Poele RHT, 1999, ONCOGENE, V18, P5765, DOI 10.1038/sj.onc.1202961; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883	56	54	54	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5964	5971		10.1038/sj.onc.1204734	http://dx.doi.org/10.1038/sj.onc.1204734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593403				2022-12-25	WOS:000171056300003
J	Riley, D; Carragher, N; Frame, MC; Wyke, JA				Riley, D; Carragher, N; Frame, MC; Wyke, JA			The mechanism of cell cycle regulation by v-Src	ONCOGENE			English	Article						v-Src; ERK; P13-K; p27; cell cycle	PROTEIN-KINASE KINASE; D-DEPENDENT KINASES; CDK INHIBITORS; EXPRESSION; P21; PHOSPHORYLATION; ONCOPROTEIN; BINDING; GENE; MITOGENESIS	The tyrosine kinase oncoprotein v-Src can overcome the requirements for serum growth factors and anchorage which restrain normal cell growth. Here we investigated the biochemical mechanisms whereby v-Src induces quiescent cells to enter S phase in the absence of serum mitogens. Activating a temperature sensitive v-Src in quiescent cells sequentially induced cyclins D1, E and A and also down regulated p27. We addressed whether p27 down regulation was required to activate cyclin D1/ CDK4/6 or cyclin E/CDK2 by engineering cells with inducible p27. Both S phase entry and activation of cyclin/CDKs were inhibited by over expression of p27. Using cells engineered with inducible p16 we showed that Cyclin D/CDK4/6 activity was required for v-Src to increase expression of cyclin A but not cyclin E. To determine which downstream kinases mediated these effects of v-Src we added pharmacological inhibitors of phosphatidylinositol 3-kinase (PI3-K), LY294002 or mitogen activated protein kinase kinase (MEK), U0126. PI3-K was required for v-Src to activate MEK and MEK was required for v-Src to increase expression of cyclins DI and E. However, the MEK inhibitor prevented p27 protein down regulation whereas the PI3K inhibitor did not. This was because reduced PI3-K activity lead to proteolytic degradation of p27.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Wyke, JA (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Carragher, Neil/0000-0001-5541-9747				Adachi M, 1997, BLOOD, V90, P126; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Botz J, 1996, MOL CELL BIOL, V16, P3401; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fotedar R, 1996, ONCOGENE, V12, P2155; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HALL M, 1995, ONCOGENE, V11, P1581; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lee KM, 1999, CURR BIOL, V9, P441, DOI 10.1016/S0960-9822(99)80194-8; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; Nishiwaki E, 2000, MOL CELL BIOL, V20, P7726, DOI 10.1128/MCB.20.20.7726-7734.2000; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225	47	41	45	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5941	5950		10.1038/sj.onc.1204826	http://dx.doi.org/10.1038/sj.onc.1204826			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593401				2022-12-25	WOS:000171056300001
